{
  "cells": [
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "peGMhp_M_rYk",
        "outputId": "40fea7e5-3023-4166-93ca-ce1cb10ddd92"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "File humira (1).pdf exists.\n"
          ]
        }
      ],
      "source": [
        "import os\n",
        "import requests\n",
        "\n",
        "# Get PDF document path\n",
        "pdf_path = \"humira (1).pdf\"\n",
        "\n",
        "# Download PDF\n",
        "if not os.path.exists(pdf_path):\n",
        "    print(\"[INFO] File doesn't exist, downloading...\")\n",
        "\n",
        "    # Enter the URL of the PDF\n",
        "    url = \"https://www.rxabbvie.com/pdf/humira.pdf\"\n",
        "\n",
        "    # The local filename to save the downloaded file\n",
        "    filename = pdf_path\n",
        "\n",
        "    # Send a GET request to the URL\n",
        "    response = requests.get(url)\n",
        "\n",
        "    # Check if the request was successful\n",
        "    if response.status_code == 200:\n",
        "        # Open the file and save it\n",
        "        with open(filename, \"wb\") as file:\n",
        "            file.write(response.content)\n",
        "        print(f\"[INFO] The file has been download and saved as {filename}\")\n",
        "    else:\n",
        "        print(f\"[INFO] Failed to download the file. Status code: {reponse.status_code}\")\n",
        "\n",
        "else:\n",
        "    print(f\"File {pdf_path} exists.\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "kDUiNOyHBRw7",
        "outputId": "5330baec-4a79-4978-85eb-f3e45217f35b"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: pymupdf in /usr/local/lib/python3.11/dist-packages (1.25.3)\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "[nltk_data] Downloading package punkt to /root/nltk_data...\n",
            "[nltk_data]   Package punkt is already up-to-date!\n",
            "[nltk_data] Downloading package stopwords to /root/nltk_data...\n",
            "[nltk_data]   Package stopwords is already up-to-date!\n",
            "[nltk_data] Downloading package wordnet to /root/nltk_data...\n",
            "[nltk_data]   Package wordnet is already up-to-date!\n",
            "[nltk_data] Downloading package punkt_tab to /root/nltk_data...\n",
            "[nltk_data]   Package punkt_tab is already up-to-date!\n"
          ]
        }
      ],
      "source": [
        "!pip install pymupdf\n",
        "import os\n",
        "import requests\n",
        "from tqdm.auto import tqdm\n",
        "import nltk\n",
        "from nltk.tokenize import sent_tokenize, word_tokenize\n",
        "from nltk.corpus import stopwords\n",
        "from nltk.stem import WordNetLemmatizer, PorterStemmer\n",
        "import spacy\n",
        "import json\n",
        "import fitz\n",
        "\n",
        "\n",
        "# Download necessary resources\n",
        "nltk.download(\"punkt\")\n",
        "nltk.download(\"stopwords\")\n",
        "nltk.download(\"wordnet\")\n",
        "nltk.download('punkt_tab') # Download the 'punkt_tab' data package\n",
        "\n",
        "# Initialize tools\n",
        "lemmatizer = WordNetLemmatizer()\n",
        "stemmer = PorterStemmer()\n",
        "stop_words = set(stopwords.words(\"english\"))\n",
        "nlp = spacy.load(\"en_core_web_sm\")\n",
        "\n",
        "def text_formatter(text: str) -> str:\n",
        "    \"\"\"Clean and format text.\"\"\"\n",
        "    return text.replace(\"\\n\", \" \").strip()\n",
        "\n",
        "def preprocess_text(text: str) -> dict:\n",
        "    \"\"\"Perform NLP preprocessing.\"\"\"\n",
        "    sentences = sent_tokenize(text)\n",
        "    processed_sentences = []\n",
        "\n",
        "    for sentence in sentences:\n",
        "        words = word_tokenize(sentence)\n",
        "        filtered_words = [word for word in words if word.lower() not in stop_words]\n",
        "        lemmatized_words = [lemmatizer.lemmatize(word) for word in filtered_words]\n",
        "        stemmed_words = [stemmer.stem(word) for word in lemmatized_words]\n",
        "        doc = nlp(\" \".join(stemmed_words))\n",
        "        dependencies = [(token.text, token.dep_) for token in doc]\n",
        "\n",
        "        processed_sentences.append({\n",
        "            \"original_sentence\": sentence,\n",
        "            \"tokens\": filtered_words,\n",
        "            \"lemmatized\": lemmatized_words,\n",
        "            \"stemmed\": stemmed_words,\n",
        "            \"dependencies\": dependencies,\n",
        "        })\n",
        "\n",
        "    return {\"sentences\": processed_sentences, \"text\": text}\n",
        "\n",
        "# Download PDF if not exists\n",
        "pdf_path = \"humira.pdf\"\n",
        "url = \"https://www.rxabbvie.com/pdf/humira.pdf\"\n",
        "\n",
        "if not os.path.exists(pdf_path):\n",
        "    print(\"[INFO] Downloading PDF...\")\n",
        "    response = requests.get(url)\n",
        "    if response.status_code == 200:\n",
        "        with open(pdf_path, \"wb\") as file:\n",
        "            file.write(response.content)\n",
        "        print(\"[INFO] PDF downloaded successfully.\")\n",
        "    else:\n",
        "        raise Exception(f\"Failed to download PDF. Status code: {response.status_code}\")\n",
        "\n",
        "# import fitz #This line is already present at the top of the file. Removing the duplicate import\n",
        "from tqdm import tqdm\n",
        "\n",
        "def open_and_read_pdf(pdf_path: str) -> list[dict]:\n",
        "    \"\"\"Read and preprocess PDF text with metadata.\"\"\"\n",
        "    try:\n",
        "        doc = fitz.open(pdf_path)  # Open the PDF\n",
        "    except Exception as e:\n",
        "        print(f\"Error opening PDF: {e}\")\n",
        "        return []\n",
        "\n",
        "    pages_and_texts = []\n",
        "\n",
        "    for page_number, page in tqdm(enumerate(doc, start=1), desc=\"Processing PDF\"):\n",
        "        text = page.get_text() or \"\"  # Get text or set to empty if none exists\n",
        "        processed_text = preprocess_text(text) if text else \"\"\n",
        "\n",
        "        pages_and_texts.append({\n",
        "            \"page_number\": page_number,\n",
        "            \"text\": text,\n",
        "            \"processed_text\": processed_text,\n",
        "            \"page_char_count\": len(text),\n",
        "            \"page_word_count\": len(text.split()),\n",
        "        })\n",
        "\n",
        "    return pages_and_texts\n",
        "\n",
        "# Ensure `pdf_path` is defined\n",
        "# pdf_"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 223
        },
        "id": "VYA672OoGGgr",
        "outputId": "6338a118-5454-4ae6-b7dd-c80b6838f22c"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "Processing PDF: 111it [00:23,  4.68it/s]\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "   page_number                                               text  \\\n",
              "0            1  HIGHLIGHTS OF PRESCRIBING INFORMATION \\nThese ...   \n",
              "1            2    \\n WARNINGS AND PRECAUTIONS  \\n• Serious inf...   \n",
              "2            3  FULL PRESCRIBING INFORMATION \\nWARNING: SERIOU...   \n",
              "3            4  blocker in combination with these other immuno...   \n",
              "4            5  will be closely monitored and have regular fol...   \n",
              "\n",
              "                                      processed_text  page_char_count  \\\n",
              "0  {'sentences': [{'original_sentence': 'HIGHLIGH...             6260   \n",
              "1  {'sentences': [{'original_sentence': '  \n",
              " WARN...             3879   \n",
              "2  {'sentences': [{'original_sentence': 'FULL PRE...             2712   \n",
              "3  {'sentences': [{'original_sentence': 'blocker ...             2053   \n",
              "4  {'sentences': [{'original_sentence': 'will be ...             2176   \n",
              "\n",
              "   page_word_count  \n",
              "0             1017  \n",
              "1              503  \n",
              "2              377  \n",
              "3              291  \n",
              "4              340  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-ee1e1e4a-baa3-4445-b3ac-588c4047a4d1\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>page_number</th>\n",
              "      <th>text</th>\n",
              "      <th>processed_text</th>\n",
              "      <th>page_char_count</th>\n",
              "      <th>page_word_count</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>1</td>\n",
              "      <td>HIGHLIGHTS OF PRESCRIBING INFORMATION \\nThese ...</td>\n",
              "      <td>{'sentences': [{'original_sentence': 'HIGHLIGH...</td>\n",
              "      <td>6260</td>\n",
              "      <td>1017</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>2</td>\n",
              "      <td>\\n WARNINGS AND PRECAUTIONS  \\n• Serious inf...</td>\n",
              "      <td>{'sentences': [{'original_sentence': '  \n",
              " WARN...</td>\n",
              "      <td>3879</td>\n",
              "      <td>503</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>3</td>\n",
              "      <td>FULL PRESCRIBING INFORMATION \\nWARNING: SERIOU...</td>\n",
              "      <td>{'sentences': [{'original_sentence': 'FULL PRE...</td>\n",
              "      <td>2712</td>\n",
              "      <td>377</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>4</td>\n",
              "      <td>blocker in combination with these other immuno...</td>\n",
              "      <td>{'sentences': [{'original_sentence': 'blocker ...</td>\n",
              "      <td>2053</td>\n",
              "      <td>291</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>5</td>\n",
              "      <td>will be closely monitored and have regular fol...</td>\n",
              "      <td>{'sentences': [{'original_sentence': 'will be ...</td>\n",
              "      <td>2176</td>\n",
              "      <td>340</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-ee1e1e4a-baa3-4445-b3ac-588c4047a4d1')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-ee1e1e4a-baa3-4445-b3ac-588c4047a4d1 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-ee1e1e4a-baa3-4445-b3ac-588c4047a4d1');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-313f0bb7-edbb-46e7-aa63-eb662cf3f75b\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-313f0bb7-edbb-46e7-aa63-eb662cf3f75b')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-313f0bb7-edbb-46e7-aa63-eb662cf3f75b button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "df",
              "summary": "{\n  \"name\": \"df\",\n  \"rows\": 111,\n  \"fields\": [\n    {\n      \"column\": \"page_number\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 32,\n        \"min\": 1,\n        \"max\": 111,\n        \"num_unique_values\": 111,\n        \"samples\": [\n          79,\n          11,\n          5\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"text\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 111,\n        \"samples\": [\n          \" \\nFigure N \\n \\n\\u2022 If you do not have a FDA-cleared sharps disposal container, you may use a household \\ncontainer that is:  \\n\\u25e6 made of a heavy-duty plastic,  \\n\\u25e6 can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to \\ncome out, \\n\\u25e6 upright and stable during use,  \\n\\u25e6 leak-resistant, and \\n\\u25e6 properly labeled to warn of hazardous waste inside the container. \\n\\u2022 When your sharps disposal container is almost full, you will need to follow your community \\nguidelines for the right way to dispose of your sharps disposal container. There may be state \\nor local laws about how you should throw away used needles and syringes. For more \\ninformation about safe sharps disposal, and for specific information about sharps disposal in \\nthe state that you live in, go to the FDA\\u2019s website at: http://www.fda.gov/safesharpsdisposal.  \\n\\u2022 For the safety and health of you and others, never re-use your HUMIRA Pens. \\n\\u2022 The used alcohol pads, cotton balls, dose trays and packaging may be placed in your \\nhousehold trash. \\n\\u2022 Do not dispose of your used sharps disposal container in your household trash \\nunless your community guidelines permit this. Do not recycle your used sharps \\ndisposal container.  \\n\\u2022 Always keep the sharps container out of the reach of children. \\n  \\nHow should I store HUMIRA? \\n\\u2022 Store HUMIRA in the refrigerator between 36\\u00baF to 46\\u00baF (2\\u00baC to 8\\u00baC). Store HUMIRA in the \\noriginal carton until use to protect it from light.  \\n\",\n          \"lymphoma and NMSC, were breast, colon, prostate, lung, and melanoma. The malignancies in \\nHUMIRA-treated patients in the controlled and uncontrolled portions of the studies were similar \\nin type and number to what would be expected in the general U.S. population according to the \\nSEER database (adjusted for age, gender, and race).1 \\nIn controlled trials of other TNF blockers in adult patients at higher risk for malignancies (i.e., \\npatients with COPD with a significant smoking history and cyclophosphamide-treated patients \\nwith Wegener\\u2019s granulomatosis), a greater portion of malignancies occurred in the TNF blocker \\ngroup compared to the control group.  \\nNon-Melanoma Skin Cancer \\nDuring the controlled portions of 39 global HUMIRA clinical trials in adult patients with RA, \\nPsA, AS, CD, UC, Ps, HS and UV, the rate (95% confidence interval) of NMSC was 0.8 (0.52, \\n1.09) per 100 patient-years among HUMIRA-treated patients and 0.2 (0.10, 0.59) per 100 \\npatient-years among control-treated patients. Examine all patients, and in particular patients with \\na medical history of prior prolonged immunosuppressant therapy or psoriasis patients with a \\nhistory of PUVA treatment for the presence of NMSC prior to and during treatment with \\nHUMIRA.  \\nLymphoma and Leukemia \\nIn the controlled portions of clinical trials of all the TNF-blockers in adults, more cases of \\nlymphoma have been observed among TNF-blocker-treated patients compared to control-treated \\npatients. In the controlled portions of 39 global HUMIRA clinical trials in adult patients with \\nRA, PsA, AS, CD, UC, Ps, HS and UV, 2 lymphomas occurred among 7973 HUMIRA-treated \\npatients versus 1 among 4848 control-treated patients. In 52 global controlled and uncontrolled \\nclinical trials of HUMIRA in adult patients with RA, PsA, AS, CD, UC, Ps, HS and UV with a \\nmedian duration of approximately 0.7 years, including 24,605 patients and over 40,215 patient-\\nyears of HUMIRA, the observed rate of lymphomas was approximately 0.11 per 100 patient-\\nyears. This is approximately 3-fold higher than expected in the general U.S. population \\naccording to the SEER database (adjusted for age, gender, and race).1 Rates of lymphoma in \\nclinical trials of HUMIRA cannot be compared to rates of lymphoma in clinical trials of other \\nTNF blockers and may not predict the rates observed in a broader patient population. Patients \\nwith RA and other chronic inflammatory diseases, particularly those with highly active disease \\nand/or chronic exposure to immunosuppressant therapies, may be at a higher risk (up to several \\nfold) than the general population for the development of lymphoma, even in the absence of TNF \\nblockers. Post-marketing cases of acute and chronic leukemia have been reported in association \\nwith TNF-blocker use in RA and other indications. Even in the absence of TNF-blocker therapy, \\npatients with RA may be at a higher risk (approximately 2-fold) than the general population for \\nthe development of leukemia.  \\nMalignancies in Pediatric Patients and Young Adults \\nMalignancies, some fatal, have been reported among children, adolescents, and young adults \\nwho received treatment with TNF-blockers (initiation of therapy \\u2264 18 years of age), of which \\nHUMIRA is a member. Approximately half the cases were lymphomas, including Hodgkin's and \\nnon-Hodgkin's lymphoma. The other cases represented a variety of different malignancies and \\nincluded rare malignancies usually associated with immunosuppression and malignancies that \\nare not usually observed in children and adolescents. The malignancies occurred after a median \\n\",\n          \"will be closely monitored and have regular follow-up visits with a physician [see Warnings and \\nPrecautions (5)].  \\n1.8 Hidradenitis Suppurativa \\nHUMIRA is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients \\n12 years of age and older.  \\n1.9 Uveitis \\nHUMIRA is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis \\nin adults and pediatric patients 2 years of age and older.  \\n2 DOSAGE AND ADMINISTRATION \\n2.1 Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis \\nThe recommended subcutaneous dosage of HUMIRA for adult patients with rheumatoid arthritis \\n(RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) is 40 mg administered every other \\nweek. Methotrexate (MTX), other non-biologic DMARDS, glucocorticoids, nonsteroidal anti-\\ninflammatory drugs (NSAIDs), and/or analgesics may be continued during treatment with \\nHUMIRA. In the treatment of RA, some patients not taking concomitant MTX may derive \\nadditional benefit from increasing the dosage of HUMIRA to 40 mg every week or 80 mg every \\nother week.  \\n2.2 Juvenile Idiopathic Arthritis or Pediatric Uveitis \\nThe recommended subcutaneous dosage of HUMIRA for patients 2 years of age and older with \\npolyarticular juvenile idiopathic arthritis (JIA) or pediatric uveitis is based on weight as shown \\nbelow. MTX, glucocorticoids, NSAIDs, and/or analgesics may be continued during treatment \\nwith HUMIRA.  \\n \\n  \\nPediatric Weight \\n(2 Years of Age and older) \\nRecommended Dosage \\n10 kg (22 lbs) to less than 15 kg (33 lbs) \\n10 mg every other week  \\n15 kg (33 lbs) to less than 30 kg (66 lbs) \\n20 mg every other week \\n30 kg (66 lbs) and greater \\n40 mg every other week \\n \\n  \\nHUMIRA has not been studied in patients with polyarticular JIA or pediatric uveitis less than 2 \\nyears of age or in patients with a weight below 10 kg.  \\n2.3 Crohn\\u2019s Disease \\nAdults \\nThe recommended subcutaneous dosage of HUMIRA for adult patients with Crohn\\u2019s disease \\n(CD) is 160 mg initially on Day 1 (given in one day or split over two consecutive days), \\nfollowed by 80 mg two weeks later (Day 15). Two weeks later (Day 29) begin a dosage of 40 mg \\n\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"processed_text\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"page_char_count\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 1139,\n        \"min\": 150,\n        \"max\": 6260,\n        \"num_unique_values\": 107,\n        \"samples\": [\n          1433,\n          3605,\n          2176\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"page_word_count\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 173,\n        \"min\": 26,\n        \"max\": 1017,\n        \"num_unique_values\": 97,\n        \"samples\": [\n          100,\n          343,\n          140\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 37
        }
      ],
      "source": [
        "import pandas as pd\n",
        "import fitz # Import fitz here\n",
        "\n",
        "# ... (include the open_and_read_pdf function here)\n",
        "\n",
        "# Call the function and assign the result to pages_and_texts\n",
        "pdf_path = \"humira (1).pdf\"  # Make sure this path is correct\n",
        "pages_and_texts = open_and_read_pdf(pdf_path)\n",
        "\n",
        "# Now create the DataFrame\n",
        "df = pd.DataFrame(pages_and_texts)\n",
        "df.head()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "y0X2s5nnGSIU"
      },
      "outputs": [],
      "source": []
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 300
        },
        "id": "Z-694s3bHCdl",
        "outputId": "5448479e-79bc-40df-a863-495af28617fe"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "       page_number  page_char_count  page_word_count\n",
              "count       111.00           111.00           111.00\n",
              "mean         56.00          1964.23           310.74\n",
              "std          32.19          1139.53           173.75\n",
              "min           1.00           150.00            26.00\n",
              "25%          28.50          1072.50           184.50\n",
              "50%          56.00          1957.00           291.00\n",
              "75%          83.50          2889.00           454.00\n",
              "max         111.00          6260.00          1017.00"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-132a117d-65c8-4b5b-8351-76a6f63933ea\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>page_number</th>\n",
              "      <th>page_char_count</th>\n",
              "      <th>page_word_count</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>count</th>\n",
              "      <td>111.00</td>\n",
              "      <td>111.00</td>\n",
              "      <td>111.00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>mean</th>\n",
              "      <td>56.00</td>\n",
              "      <td>1964.23</td>\n",
              "      <td>310.74</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>std</th>\n",
              "      <td>32.19</td>\n",
              "      <td>1139.53</td>\n",
              "      <td>173.75</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>min</th>\n",
              "      <td>1.00</td>\n",
              "      <td>150.00</td>\n",
              "      <td>26.00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>25%</th>\n",
              "      <td>28.50</td>\n",
              "      <td>1072.50</td>\n",
              "      <td>184.50</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>50%</th>\n",
              "      <td>56.00</td>\n",
              "      <td>1957.00</td>\n",
              "      <td>291.00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>75%</th>\n",
              "      <td>83.50</td>\n",
              "      <td>2889.00</td>\n",
              "      <td>454.00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>max</th>\n",
              "      <td>111.00</td>\n",
              "      <td>6260.00</td>\n",
              "      <td>1017.00</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-132a117d-65c8-4b5b-8351-76a6f63933ea')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-132a117d-65c8-4b5b-8351-76a6f63933ea button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-132a117d-65c8-4b5b-8351-76a6f63933ea');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-352c87e7-2eda-43b2-b331-a17a9cebf1b8\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-352c87e7-2eda-43b2-b331-a17a9cebf1b8')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-352c87e7-2eda-43b2-b331-a17a9cebf1b8 button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "summary": "{\n  \"name\": \"df\",\n  \"rows\": 8,\n  \"fields\": [\n    {\n      \"column\": \"page_number\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 39.70033121038521,\n        \"min\": 1.0,\n        \"max\": 111.0,\n        \"num_unique_values\": 6,\n        \"samples\": [\n          111.0,\n          56.0,\n          83.5\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"page_char_count\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 1982.2951681375375,\n        \"min\": 111.0,\n        \"max\": 6260.0,\n        \"num_unique_values\": 8,\n        \"samples\": [\n          1964.23,\n          1957.0,\n          111.0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"page_word_count\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 310.4259930407844,\n        \"min\": 26.0,\n        \"max\": 1017.0,\n        \"num_unique_values\": 8,\n        \"samples\": [\n          310.74,\n          291.0,\n          111.0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 38
        }
      ],
      "source": [
        "df.describe().round(2)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "r5N3l1QuguML",
        "outputId": "a74cf059-2210-4b36-eecf-0569a28fa305"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[This is a sentence., This another sentence., I like elephants.]"
            ]
          },
          "metadata": {},
          "execution_count": 39
        }
      ],
      "source": [
        "from spacy.lang.en import English\n",
        "\n",
        "nlp = English()\n",
        "\n",
        "# Add a sentencizer pipeline, see https://spacy.io/api/sentencizer\n",
        "nlp.add_pipe(\"sentencizer\")\n",
        "\n",
        "# Create document instance as an example\n",
        "doc = nlp(\"This is a sentence. This another sentence. I like elephants.\")\n",
        "assert len(list(doc.sents)) == 3\n",
        "\n",
        "# Print out our sentences split\n",
        "list(doc.sents)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "naa3G3LEgyfz",
        "outputId": "0b49b877-c262-49ab-9e95-0a5a12f87e82"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "{'page_number': 101,\n",
              " 'text': 'Figure H \\n \\nInject HUMIRA \\n12. Using a quick, dart-like motion, insert the needle into the squeezed skin at about a 45-\\ndegree angle. See Figure I.  \\n',\n",
              " 'processed_text': {'sentences': [{'original_sentence': 'Figure H \\n \\nInject HUMIRA \\n12.',\n",
              "    'tokens': ['Figure', 'H', 'Inject', 'HUMIRA', '12', '.'],\n",
              "    'lemmatized': ['Figure', 'H', 'Inject', 'HUMIRA', '12', '.'],\n",
              "    'stemmed': ['figur', 'h', 'inject', 'humira', '12', '.'],\n",
              "    'dependencies': [('figur', 'compound'),\n",
              "     ('h', 'compound'),\n",
              "     ('inject', 'compound'),\n",
              "     ('humira', 'ROOT'),\n",
              "     ('12', 'nummod'),\n",
              "     ('.', 'punct')]},\n",
              "   {'original_sentence': 'Using a quick, dart-like motion, insert the needle into the squeezed skin at about a 45-\\ndegree angle.',\n",
              "    'tokens': ['Using',\n",
              "     'quick',\n",
              "     ',',\n",
              "     'dart-like',\n",
              "     'motion',\n",
              "     ',',\n",
              "     'insert',\n",
              "     'needle',\n",
              "     'squeezed',\n",
              "     'skin',\n",
              "     '45-',\n",
              "     'degree',\n",
              "     'angle',\n",
              "     '.'],\n",
              "    'lemmatized': ['Using',\n",
              "     'quick',\n",
              "     ',',\n",
              "     'dart-like',\n",
              "     'motion',\n",
              "     ',',\n",
              "     'insert',\n",
              "     'needle',\n",
              "     'squeezed',\n",
              "     'skin',\n",
              "     '45-',\n",
              "     'degree',\n",
              "     'angle',\n",
              "     '.'],\n",
              "    'stemmed': ['use',\n",
              "     'quick',\n",
              "     ',',\n",
              "     'dart-lik',\n",
              "     'motion',\n",
              "     ',',\n",
              "     'insert',\n",
              "     'needl',\n",
              "     'squeez',\n",
              "     'skin',\n",
              "     '45-',\n",
              "     'degre',\n",
              "     'angl',\n",
              "     '.'],\n",
              "    'dependencies': [('use', 'ROOT'),\n",
              "     ('quick', 'amod'),\n",
              "     (',', 'punct'),\n",
              "     ('dart', 'compound'),\n",
              "     ('-', 'punct'),\n",
              "     ('lik', 'compound'),\n",
              "     ('motion', 'dobj'),\n",
              "     (',', 'punct'),\n",
              "     ('insert', 'nsubj'),\n",
              "     ('needl', 'conj'),\n",
              "     ('squeez', 'compound'),\n",
              "     ('skin', 'dobj'),\n",
              "     ('45-', 'meta'),\n",
              "     ('degre', 'npadvmod'),\n",
              "     ('angl', 'ROOT'),\n",
              "     ('.', 'punct')]},\n",
              "   {'original_sentence': 'See Figure I.',\n",
              "    'tokens': ['See', 'Figure', '.'],\n",
              "    'lemmatized': ['See', 'Figure', '.'],\n",
              "    'stemmed': ['see', 'figur', '.'],\n",
              "    'dependencies': [('see', 'ROOT'), ('figur', 'dobj'), ('.', 'punct')]}],\n",
              "  'text': 'Figure H \\n \\nInject HUMIRA \\n12. Using a quick, dart-like motion, insert the needle into the squeezed skin at about a 45-\\ndegree angle. See Figure I.  \\n'},\n",
              " 'page_char_count': 150,\n",
              " 'page_word_count': 26}"
            ]
          },
          "metadata": {},
          "execution_count": 40
        }
      ],
      "source": [
        "pages_and_texts[100]"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "MQMPl3rNg_L9",
        "outputId": "85262d58-38b2-41c1-fab9-946bb53ccf74"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            " 11%|█         | 12/111 [00:00<00:01, 51.76it/s]"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "{'page_number': 1, 'text': \"HIGHLIGHTS OF PRESCRIBING INFORMATION \\nThese highlights do not include all the information needed to use \\nHUMIRA safely and effectively. See full prescribing information for \\nHUMIRA. \\n \\nHUMIRA® (adalimumab) injection, for subcutaneous use \\nInitial U.S. Approval: 2002 \\n  \\nWARNING: SERIOUS INFECTIONS AND MALIGNANCY \\nSee full prescribing information for complete boxed warning. \\nSERIOUS INFECTIONS (5.1, 6.1): \\n• Increased risk of serious infections leading to hospitalization or \\ndeath, including tuberculosis (TB), bacterial sepsis, invasive \\nfungal infections (such as histoplasmosis), and infections due to \\nother opportunistic pathogens. \\n• Discontinue HUMIRA if a patient develops a serious infection or \\nsepsis during treatment. \\n• Perform test for latent TB; if positive, start treatment for TB \\nprior to starting HUMIRA. \\n• Monitor all patients for active TB during treatment, even if initial \\nlatent TB test is negative.  \\nMALIGNANCY (5.2): \\n• Lymphoma and other malignancies, some fatal, have been \\nreported in children and adolescent patients treated with TNF \\nblockers including HUMIRA. \\n• Post-marketing cases of hepatosplenic T-cell lymphoma \\n(HSTCL), a rare type of T-cell lymphoma, have occurred in \\nadolescent and young adults with inflammatory bowel disease \\ntreated with TNF blockers including HUMIRA.  \\n \\n INDICATIONS AND USAGE  \\nHUMIRA is a tumor necrosis factor (TNF) blocker indicated for:  \\n• Rheumatoid Arthritis (RA) (1.1): reducing signs and symptoms, inducing \\nmajor clinical response, inhibiting the progression of structural damage, and \\nimproving physical function in adult patients with moderately to severely \\nactive RA.  \\n• Juvenile Idiopathic Arthritis (JIA) (1.2): reducing signs and symptoms of \\nmoderately to severely active polyarticular JIA in patients 2 years of age \\nand older.  \\n• Psoriatic Arthritis (PsA) (1.3): reducing signs and symptoms, inhibiting \\nthe progression of structural damage, and improving physical function in \\nadult patients with active PsA.  \\n• Ankylosing Spondylitis (AS) (1.4): reducing signs and symptoms in adult \\npatients with active AS.  \\n• Crohn’s Disease (CD) (1.5): treatment of moderately to severely active \\nCrohn’s disease in adults and pediatric patients 6 years of age and older.  \\n• Ulcerative Colitis (UC) (1.6): treatment of moderately to severely active \\nulcerative colitis in adults and pediatric patients 5 years of age and older.  \\nLimitations of Use: Effectiveness has not been established in patients who \\nhave lost response to or were intolerant to TNF blockers. \\n• Plaque Psoriasis (Ps) (1.7): treatment of adult patients with moderate to \\nsevere chronic plaque psoriasis who are candidates for systemic therapy or \\nphototherapy, and when other systemic therapies are medically less \\nappropriate.  \\n• Hidradenitis Suppurativa (HS) (1.8): treatment of moderate to severe \\nhidradenitis suppurativa in patients 12 years of age and older.  \\n• Uveitis (UV) (1.9): treatment of non-infectious intermediate, posterior, and \\npanuveitis in adults and pediatric patients 2 years of age and older.  \\n  \\n DOSAGE AND ADMINISTRATION  \\n• Administer by subcutaneous injection (2) \\nRheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis (2.1): \\n• Adults:  40 mg every other week.  \\n• Some patients with RA not receiving methotrexate may benefit from \\nincreasing the dosage to 40 mg every week or 80 mg every other \\nweek. \\n \\n \\n \\n \\n \\n \\n \\n \\n \\nJuvenile Idiopathic Arthritis or Pediatric Uveitis (2.2):  \\nPediatric Weight \\n2 Years of Age and Older \\nRecommended Dosage \\n10 kg (22 lbs) to less than 15 kg (33 lbs) \\n10 mg every other week  \\n15 kg (33 lbs) to less than 30 kg (66 lbs) \\n20 mg every other week \\n30 kg (66 lbs) and greater \\n40 mg every other week  \\nCrohn's Disease (2.3): \\n• Adults:  160 mg on Day 1 (given in one day or split over two consecutive \\ndays); 80 mg on Day 15; and 40 mg every other week starting on Day 29.  \\n• Pediatric Patients 6 Years of Age and Older: \\nPediatric Weight \\n \\nRecommended Dosage \\nDays 1 and 15 \\nStarting on Day 29 \\n17 kg (37 lbs)  \\nto less than  \\n40 kg (88 lbs)  \\nDay 1:  80 mg  \\nDay 15: 40 mg  \\n20 mg every other week \\n40 kg (88 lbs)  \\nand greater \\nDay 1:  160 mg (single dose or  \\nsplit over two consecutive days)  \\nDay 15:  80 mg  \\n40 mg every other week \\nUlcerative Colitis (2.4): \\n• Adults:  160 mg on Day 1 (given in one day or split over two consecutive \\ndays), 80 mg on Day 15 and 40 mg every other week starting on Day 29. \\nDiscontinue in patients without evidence of clinical remission by eight \\nweeks (Day 57). \\n• Pediatric Patients 5 Years of Age and Older: \\nPediatric Weight \\n \\nRecommended Dosage \\nDays 1 through 15  \\nStarting on Day 29* \\n20 kg (44 lbs) \\nto less than  \\n40 kg (88 lbs) \\nDay 1:  80 mg  \\nDay 8:  40 mg  \\nDay 15: 40 mg  \\n40 mg every other week \\nor \\n20 mg every week \\n40 kg (88 lbs) and \\ngreater \\nDay 1: 160 mg (single dose or \\nsplit over two consecutive \\ndays)  \\nDay 8: 80 mg  \\nDay 15: 80 mg  \\n80 mg every other week \\nor \\n40 mg every week \\n* Continue the recommended pediatric dosage in patients who turn 18 years \\nof age and who are well-controlled on their HUMIRA regimen. \\nPlaque Psoriasis or Adult Uveitis (2.5): \\n• Adults: 80 mg initial dose, followed by 40 mg every other week starting one \\nweek after initial dose. \\nHidradenitis Suppurativa (2.6): \\n• Adults: \\no \\nDay 1: 160 mg (given in one day or split over two consecutive days) \\no \\nDay 15: 80 mg  \\no \\nDay 29 and subsequent doses: 40 mg every week or 80 mg every \\nother week \\n• Adolescents 12 years of age and older: \\nAdolescent \\nWeight \\nRecommended Dosage  \\n30 kg (66 lbs)  \\nto less than  \\n60 kg (132 lbs) \\nDay 1:  80 mg  \\nDay 8 and subsequent doses:  40 mg every other week \\n60 kg (132 lbs)  \\nand greater \\nDay 1:  160 mg (given in one day or split over two \\nconsecutive days) \\nDay 15:  80 mg  \\nDay 29 and subsequent doses:  40 mg every week or 80 \\nmg every other week \\n \\n DOSAGE FORMS AND STRENGTHS  \\nInjection:  \\n• Single-dose prefilled pen (HUMIRA Pen): 80 mg/0.8 mL, 40 mg/0.8 mL, \\nand 40 mg/0.4 mL (3) \\n• Single-dose prefilled glass syringe:  80 mg/0.8 mL, 40 mg/0.8 mL, 40 \\nmg/0.4 mL, 20 mg/0.4 mL, 20 mg/0.2 mL, 10 mg/0.2 mL, 10 mg/0.1 mL \\n(3) \\n• Single-dose glass vial for institutional use only: 40 mg/0.8 mL (3) \\n  \\n CONTRAINDICATIONS  \\nNone (4) \\n\", 'processed_text': {'sentences': [{'original_sentence': 'HIGHLIGHTS OF PRESCRIBING INFORMATION \\nThese highlights do not include all the information needed to use \\nHUMIRA safely and effectively.', 'tokens': ['HIGHLIGHTS', 'PRESCRIBING', 'INFORMATION', 'highlights', 'include', 'information', 'needed', 'use', 'HUMIRA', 'safely', 'effectively', '.'], 'lemmatized': ['HIGHLIGHTS', 'PRESCRIBING', 'INFORMATION', 'highlight', 'include', 'information', 'needed', 'use', 'HUMIRA', 'safely', 'effectively', '.'], 'stemmed': ['highlight', 'prescrib', 'inform', 'highlight', 'includ', 'inform', 'need', 'use', 'humira', 'safe', 'effect', '.'], 'dependencies': [('highlight', 'compound'), ('prescrib', 'nsubj'), ('inform', 'ROOT'), ('highlight', 'compound'), ('includ', 'compound'), ('inform', 'dobj'), ('need', 'compound'), ('use', 'nmod'), ('humira', 'nmod'), ('safe', 'amod'), ('effect', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'See full prescribing information for \\nHUMIRA.', 'tokens': ['See', 'full', 'prescribing', 'information', 'HUMIRA', '.'], 'lemmatized': ['See', 'full', 'prescribing', 'information', 'HUMIRA', '.'], 'stemmed': ['see', 'full', 'prescrib', 'inform', 'humira', '.'], 'dependencies': [('see', 'ROOT'), ('full', 'amod'), ('prescrib', 'compound'), ('inform', 'compound'), ('humira', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'HUMIRA® (adalimumab) injection, for subcutaneous use \\nInitial U.S. Approval: 2002 \\n  \\nWARNING: SERIOUS INFECTIONS AND MALIGNANCY \\nSee full prescribing information for complete boxed warning.', 'tokens': ['HUMIRA®', '(', 'adalimumab', ')', 'injection', ',', 'subcutaneous', 'use', 'Initial', 'U.S.', 'Approval', ':', '2002', 'WARNING', ':', 'SERIOUS', 'INFECTIONS', 'MALIGNANCY', 'See', 'full', 'prescribing', 'information', 'complete', 'boxed', 'warning', '.'], 'lemmatized': ['HUMIRA®', '(', 'adalimumab', ')', 'injection', ',', 'subcutaneous', 'use', 'Initial', 'U.S.', 'Approval', ':', '2002', 'WARNING', ':', 'SERIOUS', 'INFECTIONS', 'MALIGNANCY', 'See', 'full', 'prescribing', 'information', 'complete', 'boxed', 'warning', '.'], 'stemmed': ['humira®', '(', 'adalimumab', ')', 'inject', ',', 'subcutan', 'use', 'initi', 'u.s.', 'approv', ':', '2002', 'warn', ':', 'seriou', 'infect', 'malign', 'see', 'full', 'prescrib', 'inform', 'complet', 'box', 'warn', '.'], 'dependencies': [('humira', 'nmod'), ('®', 'nmod'), ('(', 'punct'), ('adalimumab', 'nmod'), (')', 'punct'), ('inject', 'compound'), (',', 'punct'), ('subcutan', 'amod'), ('use', 'compound'), ('initi', 'compound'), ('u.s', 'compound'), ('.', 'compound'), ('approv', 'nsubj'), (':', 'punct'), ('2002', 'appos'), ('warn', 'ROOT'), (':', 'punct'), ('seriou', 'compound'), ('infect', 'compound'), ('malign', 'nsubj'), ('see', 'ccomp'), ('full', 'amod'), ('prescrib', 'nsubj'), ('inform', 'compound'), ('complet', 'compound'), ('box', 'compound'), ('warn', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'SERIOUS INFECTIONS (5.1, 6.1): \\n• Increased risk of serious infections leading to hospitalization or \\ndeath, including tuberculosis (TB), bacterial sepsis, invasive \\nfungal infections (such as histoplasmosis), and infections due to \\nother opportunistic pathogens.', 'tokens': ['SERIOUS', 'INFECTIONS', '(', '5.1', ',', '6.1', ')', ':', '•', 'Increased', 'risk', 'serious', 'infections', 'leading', 'hospitalization', 'death', ',', 'including', 'tuberculosis', '(', 'TB', ')', ',', 'bacterial', 'sepsis', ',', 'invasive', 'fungal', 'infections', '(', 'histoplasmosis', ')', ',', 'infections', 'due', 'opportunistic', 'pathogens', '.'], 'lemmatized': ['SERIOUS', 'INFECTIONS', '(', '5.1', ',', '6.1', ')', ':', '•', 'Increased', 'risk', 'serious', 'infection', 'leading', 'hospitalization', 'death', ',', 'including', 'tuberculosis', '(', 'TB', ')', ',', 'bacterial', 'sepsis', ',', 'invasive', 'fungal', 'infection', '(', 'histoplasmosis', ')', ',', 'infection', 'due', 'opportunistic', 'pathogen', '.'], 'stemmed': ['seriou', 'infect', '(', '5.1', ',', '6.1', ')', ':', '•', 'increas', 'risk', 'seriou', 'infect', 'lead', 'hospit', 'death', ',', 'includ', 'tuberculosi', '(', 'tb', ')', ',', 'bacteri', 'sepsi', ',', 'invas', 'fungal', 'infect', '(', 'histoplasmosi', ')', ',', 'infect', 'due', 'opportunist', 'pathogen', '.'], 'dependencies': [('seriou', 'compound'), ('infect', 'ROOT'), ('(', 'punct'), ('5.1', 'appos'), (',', 'punct'), ('6.1', 'appos'), (')', 'punct'), (':', 'punct'), ('•', 'nummod'), ('increas', 'compound'), ('risk', 'compound'), ('seriou', 'nsubj'), ('infect', 'compound'), ('lead', 'compound'), ('hospit', 'compound'), ('death', 'appos'), (',', 'punct'), ('includ', 'compound'), ('tuberculosi', 'conj'), ('(', 'punct'), ('tb', 'parataxis'), (')', 'punct'), (',', 'punct'), ('bacteri', 'appos'), ('sepsi', 'dobj'), (',', 'punct'), ('invas', 'compound'), ('fungal', 'compound'), ('infect', 'conj'), ('(', 'punct'), ('histoplasmosi', 'appos'), (')', 'punct'), (',', 'punct'), ('infect', 'conj'), ('due', 'amod'), ('opportunist', 'compound'), ('pathogen', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• Discontinue HUMIRA if a patient develops a serious infection or \\nsepsis during treatment.', 'tokens': ['•', 'Discontinue', 'HUMIRA', 'patient', 'develops', 'serious', 'infection', 'sepsis', 'treatment', '.'], 'lemmatized': ['•', 'Discontinue', 'HUMIRA', 'patient', 'develops', 'serious', 'infection', 'sepsis', 'treatment', '.'], 'stemmed': ['•', 'discontinu', 'humira', 'patient', 'develop', 'seriou', 'infect', 'sepsi', 'treatment', '.'], 'dependencies': [('•', 'dep'), ('discontinu', 'compound'), ('humira', 'compound'), ('patient', 'nsubj'), ('develop', 'ROOT'), ('seriou', 'compound'), ('infect', 'compound'), ('sepsi', 'compound'), ('treatment', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• Perform test for latent TB; if positive, start treatment for TB \\nprior to starting HUMIRA.', 'tokens': ['•', 'Perform', 'test', 'latent', 'TB', ';', 'positive', ',', 'start', 'treatment', 'TB', 'prior', 'starting', 'HUMIRA', '.'], 'lemmatized': ['•', 'Perform', 'test', 'latent', 'TB', ';', 'positive', ',', 'start', 'treatment', 'TB', 'prior', 'starting', 'HUMIRA', '.'], 'stemmed': ['•', 'perform', 'test', 'latent', 'tb', ';', 'posit', ',', 'start', 'treatment', 'tb', 'prior', 'start', 'humira', '.'], 'dependencies': [('•', 'meta'), ('perform', 'ROOT'), ('test', 'compound'), ('latent', 'compound'), ('tb', 'dobj'), (';', 'punct'), ('posit', 'dep'), (',', 'punct'), ('start', 'dep'), ('treatment', 'dobj'), ('tb', 'prep'), ('prior', 'amod'), ('start', 'compound'), ('humira', 'pobj'), ('.', 'punct')]}, {'original_sentence': '• Monitor all patients for active TB during treatment, even if initial \\nlatent TB test is negative.', 'tokens': ['•', 'Monitor', 'patients', 'active', 'TB', 'treatment', ',', 'even', 'initial', 'latent', 'TB', 'test', 'negative', '.'], 'lemmatized': ['•', 'Monitor', 'patient', 'active', 'TB', 'treatment', ',', 'even', 'initial', 'latent', 'TB', 'test', 'negative', '.'], 'stemmed': ['•', 'monitor', 'patient', 'activ', 'tb', 'treatment', ',', 'even', 'initi', 'latent', 'tb', 'test', 'neg', '.'], 'dependencies': [('•', 'npadvmod'), ('monitor', 'ROOT'), ('patient', 'compound'), ('activ', 'dobj'), ('tb', 'prep'), ('treatment', 'pobj'), (',', 'punct'), ('even', 'advmod'), ('initi', 'compound'), ('latent', 'appos'), ('tb', 'compound'), ('test', 'compound'), ('neg', 'appos'), ('.', 'punct')]}, {'original_sentence': 'MALIGNANCY (5.2): \\n• Lymphoma and other malignancies, some fatal, have been \\nreported in children and adolescent patients treated with TNF \\nblockers including HUMIRA.', 'tokens': ['MALIGNANCY', '(', '5.2', ')', ':', '•', 'Lymphoma', 'malignancies', ',', 'fatal', ',', 'reported', 'children', 'adolescent', 'patients', 'treated', 'TNF', 'blockers', 'including', 'HUMIRA', '.'], 'lemmatized': ['MALIGNANCY', '(', '5.2', ')', ':', '•', 'Lymphoma', 'malignancy', ',', 'fatal', ',', 'reported', 'child', 'adolescent', 'patient', 'treated', 'TNF', 'blocker', 'including', 'HUMIRA', '.'], 'stemmed': ['malign', '(', '5.2', ')', ':', '•', 'lymphoma', 'malign', ',', 'fatal', ',', 'report', 'child', 'adolesc', 'patient', 'treat', 'tnf', 'blocker', 'includ', 'humira', '.'], 'dependencies': [('malign', 'ROOT'), ('(', 'punct'), ('5.2', 'appos'), (')', 'punct'), (':', 'punct'), ('•', 'nummod'), ('lymphoma', 'compound'), ('malign', 'appos'), (',', 'punct'), ('fatal', 'amod'), (',', 'punct'), ('report', 'compound'), ('child', 'compound'), ('adolesc', 'compound'), ('patient', 'compound'), ('treat', 'compound'), ('tnf', 'compound'), ('blocker', 'compound'), ('includ', 'compound'), ('humira', 'appos'), ('.', 'punct')]}, {'original_sentence': '• Post-marketing cases of hepatosplenic T-cell lymphoma \\n(HSTCL), a rare type of T-cell lymphoma, have occurred in \\nadolescent and young adults with inflammatory bowel disease \\ntreated with TNF blockers including HUMIRA.', 'tokens': ['•', 'Post-marketing', 'cases', 'hepatosplenic', 'T-cell', 'lymphoma', '(', 'HSTCL', ')', ',', 'rare', 'type', 'T-cell', 'lymphoma', ',', 'occurred', 'adolescent', 'young', 'adults', 'inflammatory', 'bowel', 'disease', 'treated', 'TNF', 'blockers', 'including', 'HUMIRA', '.'], 'lemmatized': ['•', 'Post-marketing', 'case', 'hepatosplenic', 'T-cell', 'lymphoma', '(', 'HSTCL', ')', ',', 'rare', 'type', 'T-cell', 'lymphoma', ',', 'occurred', 'adolescent', 'young', 'adult', 'inflammatory', 'bowel', 'disease', 'treated', 'TNF', 'blocker', 'including', 'HUMIRA', '.'], 'stemmed': ['•', 'post-market', 'case', 'hepatosplen', 't-cell', 'lymphoma', '(', 'hstcl', ')', ',', 'rare', 'type', 't-cell', 'lymphoma', ',', 'occur', 'adolesc', 'young', 'adult', 'inflammatori', 'bowel', 'diseas', 'treat', 'tnf', 'blocker', 'includ', 'humira', '.'], 'dependencies': [('•', 'nummod'), ('post', 'amod'), ('-', 'amod'), ('market', 'amod'), ('case', 'nsubj'), ('hepatosplen', 'amod'), ('t', 'compound'), ('-', 'punct'), ('cell', 'compound'), ('lymphoma', 'appos'), ('(', 'punct'), ('hstcl', 'appos'), (')', 'punct'), (',', 'punct'), ('rare', 'amod'), ('type', 'compound'), ('t', 'compound'), ('-', 'punct'), ('cell', 'compound'), ('lymphoma', 'appos'), (',', 'punct'), ('occur', 'ROOT'), ('adolesc', 'compound'), ('young', 'amod'), ('adult', 'compound'), ('inflammatori', 'compound'), ('bowel', 'compound'), ('diseas', 'dobj'), ('treat', 'advcl'), ('tnf', 'compound'), ('blocker', 'compound'), ('includ', 'compound'), ('humira', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'INDICATIONS AND USAGE  \\nHUMIRA is a tumor necrosis factor (TNF) blocker indicated for:  \\n• Rheumatoid Arthritis (RA) (1.1): reducing signs and symptoms, inducing \\nmajor clinical response, inhibiting the progression of structural damage, and \\nimproving physical function in adult patients with moderately to severely \\nactive RA.', 'tokens': ['INDICATIONS', 'USAGE', 'HUMIRA', 'tumor', 'necrosis', 'factor', '(', 'TNF', ')', 'blocker', 'indicated', ':', '•', 'Rheumatoid', 'Arthritis', '(', 'RA', ')', '(', '1.1', ')', ':', 'reducing', 'signs', 'symptoms', ',', 'inducing', 'major', 'clinical', 'response', ',', 'inhibiting', 'progression', 'structural', 'damage', ',', 'improving', 'physical', 'function', 'adult', 'patients', 'moderately', 'severely', 'active', 'RA', '.'], 'lemmatized': ['INDICATIONS', 'USAGE', 'HUMIRA', 'tumor', 'necrosis', 'factor', '(', 'TNF', ')', 'blocker', 'indicated', ':', '•', 'Rheumatoid', 'Arthritis', '(', 'RA', ')', '(', '1.1', ')', ':', 'reducing', 'sign', 'symptom', ',', 'inducing', 'major', 'clinical', 'response', ',', 'inhibiting', 'progression', 'structural', 'damage', ',', 'improving', 'physical', 'function', 'adult', 'patient', 'moderately', 'severely', 'active', 'RA', '.'], 'stemmed': ['indic', 'usag', 'humira', 'tumor', 'necrosi', 'factor', '(', 'tnf', ')', 'blocker', 'indic', ':', '•', 'rheumatoid', 'arthriti', '(', 'ra', ')', '(', '1.1', ')', ':', 'reduc', 'sign', 'symptom', ',', 'induc', 'major', 'clinic', 'respons', ',', 'inhibit', 'progress', 'structur', 'damag', ',', 'improv', 'physic', 'function', 'adult', 'patient', 'moder', 'sever', 'activ', 'ra', '.'], 'dependencies': [('indic', 'amod'), ('usag', 'amod'), ('humira', 'nmod'), ('tumor', 'nmod'), ('necrosi', 'compound'), ('factor', 'ROOT'), ('(', 'punct'), ('tnf', 'advmod'), (')', 'punct'), ('blocker', 'npadvmod'), ('indic', 'appos'), (':', 'punct'), ('•', 'punct'), ('rheumatoid', 'amod'), ('arthriti', 'appos'), ('(', 'punct'), ('ra', 'appos'), (')', 'punct'), ('(', 'punct'), ('1.1', 'ROOT'), (')', 'punct'), (':', 'punct'), ('reduc', 'compound'), ('sign', 'compound'), ('symptom', 'nsubj'), (',', 'punct'), ('induc', 'amod'), ('major', 'amod'), ('clinic', 'compound'), ('respons', 'conj'), (',', 'punct'), ('inhibit', 'compound'), ('progress', 'compound'), ('structur', 'nsubj'), ('damag', 'appos'), (',', 'punct'), ('improv', 'compound'), ('physic', 'compound'), ('function', 'compound'), ('adult', 'compound'), ('patient', 'compound'), ('moder', 'nsubj'), ('sever', 'ROOT'), ('activ', 'compound'), ('ra', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• Juvenile Idiopathic Arthritis (JIA) (1.2): reducing signs and symptoms of \\nmoderately to severely active polyarticular JIA in patients 2 years of age \\nand older.', 'tokens': ['•', 'Juvenile', 'Idiopathic', 'Arthritis', '(', 'JIA', ')', '(', '1.2', ')', ':', 'reducing', 'signs', 'symptoms', 'moderately', 'severely', 'active', 'polyarticular', 'JIA', 'patients', '2', 'years', 'age', 'older', '.'], 'lemmatized': ['•', 'Juvenile', 'Idiopathic', 'Arthritis', '(', 'JIA', ')', '(', '1.2', ')', ':', 'reducing', 'sign', 'symptom', 'moderately', 'severely', 'active', 'polyarticular', 'JIA', 'patient', '2', 'year', 'age', 'older', '.'], 'stemmed': ['•', 'juvenil', 'idiopath', 'arthriti', '(', 'jia', ')', '(', '1.2', ')', ':', 'reduc', 'sign', 'symptom', 'moder', 'sever', 'activ', 'polyarticular', 'jia', 'patient', '2', 'year', 'age', 'older', '.'], 'dependencies': [('•', 'nummod'), ('juvenil', 'amod'), ('idiopath', 'compound'), ('arthriti', 'ROOT'), ('(', 'punct'), ('jia', 'ROOT'), (')', 'punct'), ('(', 'punct'), ('1.2', 'ROOT'), (')', 'punct'), (':', 'punct'), ('reduc', 'compound'), ('sign', 'compound'), ('symptom', 'compound'), ('moder', 'nsubj'), ('sever', 'ROOT'), ('activ', 'nmod'), ('polyarticular', 'nmod'), ('jia', 'nmod'), ('patient', 'nmod'), ('2', 'nummod'), ('year', 'compound'), ('age', 'npadvmod'), ('older', 'ccomp'), ('.', 'punct')]}, {'original_sentence': '• Psoriatic Arthritis (PsA) (1.3): reducing signs and symptoms, inhibiting \\nthe progression of structural damage, and improving physical function in \\nadult patients with active PsA.', 'tokens': ['•', 'Psoriatic', 'Arthritis', '(', 'PsA', ')', '(', '1.3', ')', ':', 'reducing', 'signs', 'symptoms', ',', 'inhibiting', 'progression', 'structural', 'damage', ',', 'improving', 'physical', 'function', 'adult', 'patients', 'active', 'PsA', '.'], 'lemmatized': ['•', 'Psoriatic', 'Arthritis', '(', 'PsA', ')', '(', '1.3', ')', ':', 'reducing', 'sign', 'symptom', ',', 'inhibiting', 'progression', 'structural', 'damage', ',', 'improving', 'physical', 'function', 'adult', 'patient', 'active', 'PsA', '.'], 'stemmed': ['•', 'psoriat', 'arthriti', '(', 'psa', ')', '(', '1.3', ')', ':', 'reduc', 'sign', 'symptom', ',', 'inhibit', 'progress', 'structur', 'damag', ',', 'improv', 'physic', 'function', 'adult', 'patient', 'activ', 'psa', '.'], 'dependencies': [('•', 'nummod'), ('psoriat', 'compound'), ('arthriti', 'ROOT'), ('(', 'punct'), ('psa', 'parataxis'), (')', 'punct'), ('(', 'punct'), ('1.3', 'appos'), (')', 'punct'), (':', 'punct'), ('reduc', 'compound'), ('sign', 'compound'), ('symptom', 'dep'), (',', 'punct'), ('inhibit', 'compound'), ('progress', 'compound'), ('structur', 'nsubj'), ('damag', 'advcl'), (',', 'punct'), ('improv', 'compound'), ('physic', 'compound'), ('function', 'compound'), ('adult', 'compound'), ('patient', 'amod'), ('activ', 'compound'), ('psa', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• Ankylosing Spondylitis (AS) (1.4): reducing signs and symptoms in adult \\npatients with active AS.', 'tokens': ['•', 'Ankylosing', 'Spondylitis', '(', ')', '(', '1.4', ')', ':', 'reducing', 'signs', 'symptoms', 'adult', 'patients', 'active', '.'], 'lemmatized': ['•', 'Ankylosing', 'Spondylitis', '(', ')', '(', '1.4', ')', ':', 'reducing', 'sign', 'symptom', 'adult', 'patient', 'active', '.'], 'stemmed': ['•', 'ankylos', 'spondyl', '(', ')', '(', '1.4', ')', ':', 'reduc', 'sign', 'symptom', 'adult', 'patient', 'activ', '.'], 'dependencies': [('•', 'nummod'), ('ankylos', 'compound'), ('spondyl', 'ROOT'), ('(', 'punct'), (')', 'punct'), ('(', 'punct'), ('1.4', 'appos'), (')', 'punct'), (':', 'punct'), ('reduc', 'compound'), ('sign', 'compound'), ('symptom', 'compound'), ('adult', 'compound'), ('patient', 'compound'), ('activ', 'appos'), ('.', 'punct')]}, {'original_sentence': '• Crohn’s Disease (CD) (1.5): treatment of moderately to severely active \\nCrohn’s disease in adults and pediatric patients 6 years of age and older.', 'tokens': ['•', 'Crohn', '’', 'Disease', '(', 'CD', ')', '(', '1.5', ')', ':', 'treatment', 'moderately', 'severely', 'active', 'Crohn', '’', 'disease', 'adults', 'pediatric', 'patients', '6', 'years', 'age', 'older', '.'], 'lemmatized': ['•', 'Crohn', '’', 'Disease', '(', 'CD', ')', '(', '1.5', ')', ':', 'treatment', 'moderately', 'severely', 'active', 'Crohn', '’', 'disease', 'adult', 'pediatric', 'patient', '6', 'year', 'age', 'older', '.'], 'stemmed': ['•', 'crohn', '’', 'diseas', '(', 'cd', ')', '(', '1.5', ')', ':', 'treatment', 'moder', 'sever', 'activ', 'crohn', '’', 'diseas', 'adult', 'pediatr', 'patient', '6', 'year', 'age', 'older', '.'], 'dependencies': [('•', 'meta'), ('crohn', 'amod'), ('’', 'punct'), ('diseas', 'ROOT'), ('(', 'punct'), ('cd', 'appos'), (')', 'punct'), ('(', 'punct'), ('1.5', 'appos'), (')', 'punct'), (':', 'punct'), ('treatment', 'compound'), ('moder', 'nsubj'), ('sever', 'ROOT'), ('activ', 'compound'), ('crohn', 'dobj'), ('’', 'punct'), ('diseas', 'amod'), ('adult', 'nmod'), ('pediatr', 'amod'), ('patient', 'nmod'), ('6', 'nummod'), ('year', 'compound'), ('age', 'npadvmod'), ('older', 'ccomp'), ('.', 'punct')]}, {'original_sentence': '• Ulcerative Colitis (UC) (1.6): treatment of moderately to severely active \\nulcerative colitis in adults and pediatric patients 5 years of age and older.', 'tokens': ['•', 'Ulcerative', 'Colitis', '(', 'UC', ')', '(', '1.6', ')', ':', 'treatment', 'moderately', 'severely', 'active', 'ulcerative', 'colitis', 'adults', 'pediatric', 'patients', '5', 'years', 'age', 'older', '.'], 'lemmatized': ['•', 'Ulcerative', 'Colitis', '(', 'UC', ')', '(', '1.6', ')', ':', 'treatment', 'moderately', 'severely', 'active', 'ulcerative', 'colitis', 'adult', 'pediatric', 'patient', '5', 'year', 'age', 'older', '.'], 'stemmed': ['•', 'ulcer', 'coliti', '(', 'uc', ')', '(', '1.6', ')', ':', 'treatment', 'moder', 'sever', 'activ', 'ulcer', 'coliti', 'adult', 'pediatr', 'patient', '5', 'year', 'age', 'older', '.'], 'dependencies': [('•', 'nummod'), ('ulcer', 'compound'), ('coliti', 'dep'), ('(', 'punct'), ('uc', 'appos'), (')', 'punct'), ('(', 'punct'), ('1.6', 'appos'), (')', 'punct'), (':', 'punct'), ('treatment', 'compound'), ('moder', 'nsubj'), ('sever', 'ROOT'), ('activ', 'compound'), ('ulcer', 'dobj'), ('coliti', 'compound'), ('adult', 'nmod'), ('pediatr', 'amod'), ('patient', 'amod'), ('5', 'nummod'), ('year', 'compound'), ('age', 'npadvmod'), ('older', 'ccomp'), ('.', 'punct')]}, {'original_sentence': 'Limitations of Use: Effectiveness has not been established in patients who \\nhave lost response to or were intolerant to TNF blockers.', 'tokens': ['Limitations', 'Use', ':', 'Effectiveness', 'established', 'patients', 'lost', 'response', 'intolerant', 'TNF', 'blockers', '.'], 'lemmatized': ['Limitations', 'Use', ':', 'Effectiveness', 'established', 'patient', 'lost', 'response', 'intolerant', 'TNF', 'blocker', '.'], 'stemmed': ['limit', 'use', ':', 'effect', 'establish', 'patient', 'lost', 'respons', 'intoler', 'tnf', 'blocker', '.'], 'dependencies': [('limit', 'advcl'), ('use', 'dobj'), (':', 'punct'), ('effect', 'nsubj'), ('establish', 'ROOT'), ('patient', 'compound'), ('lost', 'amod'), ('respons', 'compound'), ('intoler', 'compound'), ('tnf', 'compound'), ('blocker', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• Plaque Psoriasis (Ps) (1.7): treatment of adult patients with moderate to \\nsevere chronic plaque psoriasis who are candidates for systemic therapy or \\nphototherapy, and when other systemic therapies are medically less \\nappropriate.', 'tokens': ['•', 'Plaque', 'Psoriasis', '(', 'Ps', ')', '(', '1.7', ')', ':', 'treatment', 'adult', 'patients', 'moderate', 'severe', 'chronic', 'plaque', 'psoriasis', 'candidates', 'systemic', 'therapy', 'phototherapy', ',', 'systemic', 'therapies', 'medically', 'less', 'appropriate', '.'], 'lemmatized': ['•', 'Plaque', 'Psoriasis', '(', 'Ps', ')', '(', '1.7', ')', ':', 'treatment', 'adult', 'patient', 'moderate', 'severe', 'chronic', 'plaque', 'psoriasis', 'candidate', 'systemic', 'therapy', 'phototherapy', ',', 'systemic', 'therapy', 'medically', 'less', 'appropriate', '.'], 'stemmed': ['•', 'plaqu', 'psoriasi', '(', 'ps', ')', '(', '1.7', ')', ':', 'treatment', 'adult', 'patient', 'moder', 'sever', 'chronic', 'plaqu', 'psoriasi', 'candid', 'system', 'therapi', 'phototherapi', ',', 'system', 'therapi', 'medic', 'less', 'appropri', '.'], 'dependencies': [('•', 'nummod'), ('plaqu', 'compound'), ('psoriasi', 'ROOT'), ('(', 'punct'), ('ps', 'appos'), (')', 'punct'), ('(', 'punct'), ('1.7', 'appos'), (')', 'punct'), (':', 'punct'), ('treatment', 'compound'), ('adult', 'compound'), ('patient', 'compound'), ('moder', 'nsubj'), ('sever', 'compound'), ('chronic', 'amod'), ('plaqu', 'compound'), ('psoriasi', 'compound'), ('candid', 'amod'), ('system', 'nsubj'), ('therapi', 'ccomp'), ('phototherapi', 'dobj'), (',', 'punct'), ('system', 'nsubj'), ('therapi', 'ROOT'), ('medic', 'npadvmod'), ('less', 'amod'), ('appropri', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• Hidradenitis Suppurativa (HS) (1.8): treatment of moderate to severe \\nhidradenitis suppurativa in patients 12 years of age and older.', 'tokens': ['•', 'Hidradenitis', 'Suppurativa', '(', 'HS', ')', '(', '1.8', ')', ':', 'treatment', 'moderate', 'severe', 'hidradenitis', 'suppurativa', 'patients', '12', 'years', 'age', 'older', '.'], 'lemmatized': ['•', 'Hidradenitis', 'Suppurativa', '(', 'HS', ')', '(', '1.8', ')', ':', 'treatment', 'moderate', 'severe', 'hidradenitis', 'suppurativa', 'patient', '12', 'year', 'age', 'older', '.'], 'stemmed': ['•', 'hidraden', 'suppurativa', '(', 'hs', ')', '(', '1.8', ')', ':', 'treatment', 'moder', 'sever', 'hidraden', 'suppurativa', 'patient', '12', 'year', 'age', 'older', '.'], 'dependencies': [('•', 'nummod'), ('hidraden', 'compound'), ('suppurativa', 'dep'), ('(', 'punct'), ('hs', 'appos'), (')', 'punct'), ('(', 'punct'), ('1.8', 'appos'), (')', 'punct'), (':', 'punct'), ('treatment', 'compound'), ('moder', 'nsubj'), ('sever', 'ROOT'), ('hidraden', 'compound'), ('suppurativa', 'compound'), ('patient', 'dobj'), ('12', 'nummod'), ('year', 'compound'), ('age', 'npadvmod'), ('older', 'amod'), ('.', 'punct')]}, {'original_sentence': '• Uveitis (UV) (1.9): treatment of non-infectious intermediate, posterior, and \\npanuveitis in adults and pediatric patients 2 years of age and older.', 'tokens': ['•', 'Uveitis', '(', 'UV', ')', '(', '1.9', ')', ':', 'treatment', 'non-infectious', 'intermediate', ',', 'posterior', ',', 'panuveitis', 'adults', 'pediatric', 'patients', '2', 'years', 'age', 'older', '.'], 'lemmatized': ['•', 'Uveitis', '(', 'UV', ')', '(', '1.9', ')', ':', 'treatment', 'non-infectious', 'intermediate', ',', 'posterior', ',', 'panuveitis', 'adult', 'pediatric', 'patient', '2', 'year', 'age', 'older', '.'], 'stemmed': ['•', 'uveiti', '(', 'uv', ')', '(', '1.9', ')', ':', 'treatment', 'non-infecti', 'intermedi', ',', 'posterior', ',', 'panuv', 'adult', 'pediatr', 'patient', '2', 'year', 'age', 'older', '.'], 'dependencies': [('•', 'nummod'), ('uveiti', 'ROOT'), ('(', 'punct'), ('uv', 'appos'), (')', 'punct'), ('(', 'punct'), ('1.9', 'appos'), (')', 'punct'), (':', 'punct'), ('treatment', 'nmod'), ('non', 'amod'), ('-', 'amod'), ('infecti', 'amod'), ('intermedi', 'amod'), (',', 'punct'), ('posterior', 'amod'), (',', 'punct'), ('panuv', 'nmod'), ('adult', 'nmod'), ('pediatr', 'amod'), ('patient', 'amod'), ('2', 'nummod'), ('year', 'compound'), ('age', 'ROOT'), ('older', 'amod'), ('.', 'punct')]}, {'original_sentence': 'DOSAGE AND ADMINISTRATION  \\n• Administer by subcutaneous injection (2) \\nRheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis (2.1): \\n• Adults:  40 mg every other week.', 'tokens': ['DOSAGE', 'ADMINISTRATION', '•', 'Administer', 'subcutaneous', 'injection', '(', '2', ')', 'Rheumatoid', 'Arthritis', ',', 'Psoriatic', 'Arthritis', ',', 'Ankylosing', 'Spondylitis', '(', '2.1', ')', ':', '•', 'Adults', ':', '40', 'mg', 'every', 'week', '.'], 'lemmatized': ['DOSAGE', 'ADMINISTRATION', '•', 'Administer', 'subcutaneous', 'injection', '(', '2', ')', 'Rheumatoid', 'Arthritis', ',', 'Psoriatic', 'Arthritis', ',', 'Ankylosing', 'Spondylitis', '(', '2.1', ')', ':', '•', 'Adults', ':', '40', 'mg', 'every', 'week', '.'], 'stemmed': ['dosag', 'administr', '•', 'administ', 'subcutan', 'inject', '(', '2', ')', 'rheumatoid', 'arthriti', ',', 'psoriat', 'arthriti', ',', 'ankylos', 'spondyl', '(', '2.1', ')', ':', '•', 'adult', ':', '40', 'mg', 'everi', 'week', '.'], 'dependencies': [('dosag', 'compound'), ('administr', 'nmod'), ('•', 'nummod'), ('administ', 'appos'), ('subcutan', 'compound'), ('inject', 'ROOT'), ('(', 'punct'), ('2', 'meta'), (')', 'punct'), ('rheumatoid', 'amod'), ('arthriti', 'appos'), (',', 'punct'), ('psoriat', 'compound'), ('arthriti', 'conj'), (',', 'punct'), ('ankylos', 'compound'), ('spondyl', 'conj'), ('(', 'punct'), ('2.1', 'appos'), (')', 'punct'), (':', 'punct'), ('•', 'nummod'), ('adult', 'appos'), (':', 'punct'), ('40', 'nummod'), ('mg', 'ROOT'), ('everi', 'amod'), ('week', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': '• Some patients with RA not receiving methotrexate may benefit from \\nincreasing the dosage to 40 mg every week or 80 mg every other \\nweek.', 'tokens': ['•', 'patients', 'RA', 'receiving', 'methotrexate', 'may', 'benefit', 'increasing', 'dosage', '40', 'mg', 'every', 'week', '80', 'mg', 'every', 'week', '.'], 'lemmatized': ['•', 'patient', 'RA', 'receiving', 'methotrexate', 'may', 'benefit', 'increasing', 'dosage', '40', 'mg', 'every', 'week', '80', 'mg', 'every', 'week', '.'], 'stemmed': ['•', 'patient', 'ra', 'receiv', 'methotrex', 'may', 'benefit', 'increas', 'dosag', '40', 'mg', 'everi', 'week', '80', 'mg', 'everi', 'week', '.'], 'dependencies': [('•', 'nummod'), ('patient', 'compound'), ('ra', 'compound'), ('receiv', 'compound'), ('methotrex', 'nsubj'), ('may', 'aux'), ('benefit', 'ROOT'), ('increas', 'dobj'), ('dosag', 'npadvmod'), ('40', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'npadvmod'), ('80', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': \"Juvenile Idiopathic Arthritis or Pediatric Uveitis (2.2):  \\nPediatric Weight \\n2 Years of Age and Older \\nRecommended Dosage \\n10 kg (22 lbs) to less than 15 kg (33 lbs) \\n10 mg every other week  \\n15 kg (33 lbs) to less than 30 kg (66 lbs) \\n20 mg every other week \\n30 kg (66 lbs) and greater \\n40 mg every other week  \\nCrohn's Disease (2.3): \\n• Adults:  160 mg on Day 1 (given in one day or split over two consecutive \\ndays); 80 mg on Day 15; and 40 mg every other week starting on Day 29.\", 'tokens': ['Juvenile', 'Idiopathic', 'Arthritis', 'Pediatric', 'Uveitis', '(', '2.2', ')', ':', 'Pediatric', 'Weight', '2', 'Years', 'Age', 'Older', 'Recommended', 'Dosage', '10', 'kg', '(', '22', 'lbs', ')', 'less', '15', 'kg', '(', '33', 'lbs', ')', '10', 'mg', 'every', 'week', '15', 'kg', '(', '33', 'lbs', ')', 'less', '30', 'kg', '(', '66', 'lbs', ')', '20', 'mg', 'every', 'week', '30', 'kg', '(', '66', 'lbs', ')', 'greater', '40', 'mg', 'every', 'week', 'Crohn', \"'s\", 'Disease', '(', '2.3', ')', ':', '•', 'Adults', ':', '160', 'mg', 'Day', '1', '(', 'given', 'one', 'day', 'split', 'two', 'consecutive', 'days', ')', ';', '80', 'mg', 'Day', '15', ';', '40', 'mg', 'every', 'week', 'starting', 'Day', '29', '.'], 'lemmatized': ['Juvenile', 'Idiopathic', 'Arthritis', 'Pediatric', 'Uveitis', '(', '2.2', ')', ':', 'Pediatric', 'Weight', '2', 'Years', 'Age', 'Older', 'Recommended', 'Dosage', '10', 'kg', '(', '22', 'lb', ')', 'less', '15', 'kg', '(', '33', 'lb', ')', '10', 'mg', 'every', 'week', '15', 'kg', '(', '33', 'lb', ')', 'less', '30', 'kg', '(', '66', 'lb', ')', '20', 'mg', 'every', 'week', '30', 'kg', '(', '66', 'lb', ')', 'greater', '40', 'mg', 'every', 'week', 'Crohn', \"'s\", 'Disease', '(', '2.3', ')', ':', '•', 'Adults', ':', '160', 'mg', 'Day', '1', '(', 'given', 'one', 'day', 'split', 'two', 'consecutive', 'day', ')', ';', '80', 'mg', 'Day', '15', ';', '40', 'mg', 'every', 'week', 'starting', 'Day', '29', '.'], 'stemmed': ['juvenil', 'idiopath', 'arthriti', 'pediatr', 'uveiti', '(', '2.2', ')', ':', 'pediatr', 'weight', '2', 'year', 'age', 'older', 'recommend', 'dosag', '10', 'kg', '(', '22', 'lb', ')', 'less', '15', 'kg', '(', '33', 'lb', ')', '10', 'mg', 'everi', 'week', '15', 'kg', '(', '33', 'lb', ')', 'less', '30', 'kg', '(', '66', 'lb', ')', '20', 'mg', 'everi', 'week', '30', 'kg', '(', '66', 'lb', ')', 'greater', '40', 'mg', 'everi', 'week', 'crohn', \"'s\", 'diseas', '(', '2.3', ')', ':', '•', 'adult', ':', '160', 'mg', 'day', '1', '(', 'given', 'one', 'day', 'split', 'two', 'consecut', 'day', ')', ';', '80', 'mg', 'day', '15', ';', '40', 'mg', 'everi', 'week', 'start', 'day', '29', '.'], 'dependencies': [('juvenil', 'amod'), ('idiopath', 'compound'), ('arthriti', 'compound'), ('pediatr', 'compound'), ('uveiti', 'nsubj'), ('(', 'punct'), ('2.2', 'appos'), (')', 'punct'), (':', 'punct'), ('pediatr', 'amod'), ('weight', 'nmod'), ('2', 'nummod'), ('year', 'compound'), ('age', 'nsubj'), ('older', 'amod'), ('recommend', 'ccomp'), ('dosag', 'dobj'), ('10', 'nummod'), ('kg', 'npadvmod'), ('(', 'punct'), ('22', 'nummod'), ('lb', 'appos'), (')', 'punct'), ('less', 'amod'), ('15', 'nummod'), ('kg', 'npadvmod'), ('(', 'punct'), ('33', 'nummod'), ('lb', 'appos'), (')', 'punct'), ('10', 'appos'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'pobj'), ('15', 'nummod'), ('kg', 'npadvmod'), ('(', 'punct'), ('33', 'nummod'), ('lb', 'appos'), (')', 'punct'), ('less', 'amod'), ('30', 'nummod'), ('kg', 'npadvmod'), ('(', 'punct'), ('66', 'nummod'), ('lb', 'appos'), (')', 'punct'), ('20', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'npadvmod'), ('30', 'nummod'), ('kg', 'npadvmod'), ('(', 'punct'), ('66', 'nummod'), ('lb', 'parataxis'), (')', 'punct'), ('greater', 'acomp'), ('40', 'nummod'), ('mg', 'nmod'), ('everi', 'amod'), ('week', 'compound'), ('crohn', 'poss'), (\"'s\", 'case'), ('diseas', 'dobj'), ('(', 'punct'), ('2.3', 'appos'), (')', 'punct'), (':', 'punct'), ('•', 'nummod'), ('adult', 'appos'), (':', 'punct'), ('160', 'nummod'), ('mg', 'nmod'), ('day', 'npadvmod'), ('1', 'nummod'), ('(', 'punct'), ('given', 'prep'), ('one', 'nummod'), ('day', 'npadvmod'), ('split', 'pcomp'), ('two', 'nummod'), ('consecut', 'compound'), ('day', 'npadvmod'), (')', 'punct'), (';', 'punct'), ('80', 'nummod'), ('mg', 'prep'), ('day', 'dep'), ('15', 'nummod'), (';', 'punct'), ('40', 'nummod'), ('mg', 'npadvmod'), ('everi', 'amod'), ('week', 'npadvmod'), ('start', 'ROOT'), ('day', 'npadvmod'), ('29', 'nummod'), ('.', 'punct')]}, {'original_sentence': '• Pediatric Patients 6 Years of Age and Older: \\nPediatric Weight \\n \\nRecommended Dosage \\nDays 1 and 15 \\nStarting on Day 29 \\n17 kg (37 lbs)  \\nto less than  \\n40 kg (88 lbs)  \\nDay 1:  80 mg  \\nDay 15: 40 mg  \\n20 mg every other week \\n40 kg (88 lbs)  \\nand greater \\nDay 1:  160 mg (single dose or  \\nsplit over two consecutive days)  \\nDay 15:  80 mg  \\n40 mg every other week \\nUlcerative Colitis (2.4): \\n• Adults:  160 mg on Day 1 (given in one day or split over two consecutive \\ndays), 80 mg on Day 15 and 40 mg every other week starting on Day 29.', 'tokens': ['•', 'Pediatric', 'Patients', '6', 'Years', 'Age', 'Older', ':', 'Pediatric', 'Weight', 'Recommended', 'Dosage', 'Days', '1', '15', 'Starting', 'Day', '29', '17', 'kg', '(', '37', 'lbs', ')', 'less', '40', 'kg', '(', '88', 'lbs', ')', 'Day', '1', ':', '80', 'mg', 'Day', '15', ':', '40', 'mg', '20', 'mg', 'every', 'week', '40', 'kg', '(', '88', 'lbs', ')', 'greater', 'Day', '1', ':', '160', 'mg', '(', 'single', 'dose', 'split', 'two', 'consecutive', 'days', ')', 'Day', '15', ':', '80', 'mg', '40', 'mg', 'every', 'week', 'Ulcerative', 'Colitis', '(', '2.4', ')', ':', '•', 'Adults', ':', '160', 'mg', 'Day', '1', '(', 'given', 'one', 'day', 'split', 'two', 'consecutive', 'days', ')', ',', '80', 'mg', 'Day', '15', '40', 'mg', 'every', 'week', 'starting', 'Day', '29', '.'], 'lemmatized': ['•', 'Pediatric', 'Patients', '6', 'Years', 'Age', 'Older', ':', 'Pediatric', 'Weight', 'Recommended', 'Dosage', 'Days', '1', '15', 'Starting', 'Day', '29', '17', 'kg', '(', '37', 'lb', ')', 'less', '40', 'kg', '(', '88', 'lb', ')', 'Day', '1', ':', '80', 'mg', 'Day', '15', ':', '40', 'mg', '20', 'mg', 'every', 'week', '40', 'kg', '(', '88', 'lb', ')', 'greater', 'Day', '1', ':', '160', 'mg', '(', 'single', 'dose', 'split', 'two', 'consecutive', 'day', ')', 'Day', '15', ':', '80', 'mg', '40', 'mg', 'every', 'week', 'Ulcerative', 'Colitis', '(', '2.4', ')', ':', '•', 'Adults', ':', '160', 'mg', 'Day', '1', '(', 'given', 'one', 'day', 'split', 'two', 'consecutive', 'day', ')', ',', '80', 'mg', 'Day', '15', '40', 'mg', 'every', 'week', 'starting', 'Day', '29', '.'], 'stemmed': ['•', 'pediatr', 'patient', '6', 'year', 'age', 'older', ':', 'pediatr', 'weight', 'recommend', 'dosag', 'day', '1', '15', 'start', 'day', '29', '17', 'kg', '(', '37', 'lb', ')', 'less', '40', 'kg', '(', '88', 'lb', ')', 'day', '1', ':', '80', 'mg', 'day', '15', ':', '40', 'mg', '20', 'mg', 'everi', 'week', '40', 'kg', '(', '88', 'lb', ')', 'greater', 'day', '1', ':', '160', 'mg', '(', 'singl', 'dose', 'split', 'two', 'consecut', 'day', ')', 'day', '15', ':', '80', 'mg', '40', 'mg', 'everi', 'week', 'ulcer', 'coliti', '(', '2.4', ')', ':', '•', 'adult', ':', '160', 'mg', 'day', '1', '(', 'given', 'one', 'day', 'split', 'two', 'consecut', 'day', ')', ',', '80', 'mg', 'day', '15', '40', 'mg', 'everi', 'week', 'start', 'day', '29', '.'], 'dependencies': [('•', 'meta'), ('pediatr', 'amod'), ('patient', 'dep'), ('6', 'nummod'), ('year', 'compound'), ('age', 'npadvmod'), ('older', 'amod'), (':', 'punct'), ('pediatr', 'amod'), ('weight', 'nsubj'), ('recommend', 'ROOT'), ('dosag', 'compound'), ('day', 'npadvmod'), ('1', 'compound'), ('15', 'nummod'), ('start', 'compound'), ('day', 'npadvmod'), ('29', 'compound'), ('17', 'nummod'), ('kg', 'appos'), ('(', 'punct'), ('37', 'nummod'), ('lb', 'appos'), (')', 'punct'), ('less', 'amod'), ('40', 'nummod'), ('kg', 'dobj'), ('(', 'punct'), ('88', 'nummod'), ('lb', 'appos'), (')', 'punct'), ('day', 'appos'), ('1', 'nummod'), (':', 'punct'), ('80', 'nummod'), ('mg', 'prep'), ('day', 'npadvmod'), ('15', 'nummod'), (':', 'punct'), ('40', 'quantmod'), ('mg', 'quantmod'), ('20', 'nummod'), ('mg', 'appos'), ('everi', 'amod'), ('week', 'npadvmod'), ('40', 'nummod'), ('kg', 'npadvmod'), ('(', 'punct'), ('88', 'nummod'), ('lb', 'appos'), (')', 'punct'), ('greater', 'amod'), ('day', 'npadvmod'), ('1', 'nummod'), (':', 'punct'), ('160', 'nummod'), ('mg', 'nsubj'), ('(', 'punct'), ('singl', 'compound'), ('dose', 'nsubj'), ('split', 'appos'), ('two', 'nummod'), ('consecut', 'compound'), ('day', 'npadvmod'), (')', 'punct'), ('day', 'npadvmod'), ('15', 'nummod'), (':', 'punct'), ('80', 'quantmod'), ('mg', 'quantmod'), ('40', 'nummod'), ('mg', 'nmod'), ('everi', 'amod'), ('week', 'compound'), ('ulcer', 'compound'), ('coliti', 'appos'), ('(', 'punct'), ('2.4', 'appos'), (')', 'punct'), (':', 'punct'), ('•', 'nummod'), ('adult', 'appos'), (':', 'punct'), ('160', 'nummod'), ('mg', 'nmod'), ('day', 'appos'), ('1', 'nummod'), ('(', 'punct'), ('given', 'prep'), ('one', 'nummod'), ('day', 'npadvmod'), ('split', 'pcomp'), ('two', 'nummod'), ('consecut', 'compound'), ('day', 'npadvmod'), (')', 'punct'), (',', 'punct'), ('80', 'nummod'), ('mg', 'prep'), ('day', 'npadvmod'), ('15', 'compound'), ('40', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'npadvmod'), ('start', 'ROOT'), ('day', 'npadvmod'), ('29', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Discontinue in patients without evidence of clinical remission by eight \\nweeks (Day 57).', 'tokens': ['Discontinue', 'patients', 'without', 'evidence', 'clinical', 'remission', 'eight', 'weeks', '(', 'Day', '57', ')', '.'], 'lemmatized': ['Discontinue', 'patient', 'without', 'evidence', 'clinical', 'remission', 'eight', 'week', '(', 'Day', '57', ')', '.'], 'stemmed': ['discontinu', 'patient', 'without', 'evid', 'clinic', 'remiss', 'eight', 'week', '(', 'day', '57', ')', '.'], 'dependencies': [('discontinu', 'amod'), ('patient', 'ROOT'), ('without', 'prep'), ('evid', 'compound'), ('clinic', 'compound'), ('remiss', 'pobj'), ('eight', 'nummod'), ('week', 'npadvmod'), ('(', 'punct'), ('day', 'appos'), ('57', 'nummod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': '• Pediatric Patients 5 Years of Age and Older: \\nPediatric Weight \\n \\nRecommended Dosage \\nDays 1 through 15  \\nStarting on Day 29* \\n20 kg (44 lbs) \\nto less than  \\n40 kg (88 lbs) \\nDay 1:  80 mg  \\nDay 8:  40 mg  \\nDay 15: 40 mg  \\n40 mg every other week \\nor \\n20 mg every week \\n40 kg (88 lbs) and \\ngreater \\nDay 1: 160 mg (single dose or \\nsplit over two consecutive \\ndays)  \\nDay 8: 80 mg  \\nDay 15: 80 mg  \\n80 mg every other week \\nor \\n40 mg every week \\n* Continue the recommended pediatric dosage in patients who turn 18 years \\nof age and who are well-controlled on their HUMIRA regimen.', 'tokens': ['•', 'Pediatric', 'Patients', '5', 'Years', 'Age', 'Older', ':', 'Pediatric', 'Weight', 'Recommended', 'Dosage', 'Days', '1', '15', 'Starting', 'Day', '29', '*', '20', 'kg', '(', '44', 'lbs', ')', 'less', '40', 'kg', '(', '88', 'lbs', ')', 'Day', '1', ':', '80', 'mg', 'Day', '8', ':', '40', 'mg', 'Day', '15', ':', '40', 'mg', '40', 'mg', 'every', 'week', '20', 'mg', 'every', 'week', '40', 'kg', '(', '88', 'lbs', ')', 'greater', 'Day', '1', ':', '160', 'mg', '(', 'single', 'dose', 'split', 'two', 'consecutive', 'days', ')', 'Day', '8', ':', '80', 'mg', 'Day', '15', ':', '80', 'mg', '80', 'mg', 'every', 'week', '40', 'mg', 'every', 'week', '*', 'Continue', 'recommended', 'pediatric', 'dosage', 'patients', 'turn', '18', 'years', 'age', 'well-controlled', 'HUMIRA', 'regimen', '.'], 'lemmatized': ['•', 'Pediatric', 'Patients', '5', 'Years', 'Age', 'Older', ':', 'Pediatric', 'Weight', 'Recommended', 'Dosage', 'Days', '1', '15', 'Starting', 'Day', '29', '*', '20', 'kg', '(', '44', 'lb', ')', 'less', '40', 'kg', '(', '88', 'lb', ')', 'Day', '1', ':', '80', 'mg', 'Day', '8', ':', '40', 'mg', 'Day', '15', ':', '40', 'mg', '40', 'mg', 'every', 'week', '20', 'mg', 'every', 'week', '40', 'kg', '(', '88', 'lb', ')', 'greater', 'Day', '1', ':', '160', 'mg', '(', 'single', 'dose', 'split', 'two', 'consecutive', 'day', ')', 'Day', '8', ':', '80', 'mg', 'Day', '15', ':', '80', 'mg', '80', 'mg', 'every', 'week', '40', 'mg', 'every', 'week', '*', 'Continue', 'recommended', 'pediatric', 'dosage', 'patient', 'turn', '18', 'year', 'age', 'well-controlled', 'HUMIRA', 'regimen', '.'], 'stemmed': ['•', 'pediatr', 'patient', '5', 'year', 'age', 'older', ':', 'pediatr', 'weight', 'recommend', 'dosag', 'day', '1', '15', 'start', 'day', '29', '*', '20', 'kg', '(', '44', 'lb', ')', 'less', '40', 'kg', '(', '88', 'lb', ')', 'day', '1', ':', '80', 'mg', 'day', '8', ':', '40', 'mg', 'day', '15', ':', '40', 'mg', '40', 'mg', 'everi', 'week', '20', 'mg', 'everi', 'week', '40', 'kg', '(', '88', 'lb', ')', 'greater', 'day', '1', ':', '160', 'mg', '(', 'singl', 'dose', 'split', 'two', 'consecut', 'day', ')', 'day', '8', ':', '80', 'mg', 'day', '15', ':', '80', 'mg', '80', 'mg', 'everi', 'week', '40', 'mg', 'everi', 'week', '*', 'continu', 'recommend', 'pediatr', 'dosag', 'patient', 'turn', '18', 'year', 'age', 'well-control', 'humira', 'regimen', '.'], 'dependencies': [('•', 'nummod'), ('pediatr', 'amod'), ('patient', 'amod'), ('5', 'nummod'), ('year', 'compound'), ('age', 'dep'), ('older', 'amod'), (':', 'punct'), ('pediatr', 'amod'), ('weight', 'nsubj'), ('recommend', 'ROOT'), ('dosag', 'compound'), ('day', 'npadvmod'), ('1', 'compound'), ('15', 'nummod'), ('start', 'compound'), ('day', 'npadvmod'), ('29', 'nummod'), ('*', 'punct'), ('20', 'nummod'), ('kg', 'appos'), ('(', 'punct'), ('44', 'nummod'), ('lb', 'appos'), (')', 'punct'), ('less', 'amod'), ('40', 'nummod'), ('kg', 'dobj'), ('(', 'punct'), ('88', 'nummod'), ('lb', 'appos'), (')', 'punct'), ('day', 'appos'), ('1', 'nummod'), (':', 'punct'), ('80', 'nummod'), ('mg', 'prep'), ('day', 'npadvmod'), ('8', 'nummod'), (':', 'punct'), ('40', 'prep'), ('mg', 'compound'), ('day', 'npadvmod'), ('15', 'nummod'), (':', 'punct'), ('40', 'quantmod'), ('mg', 'quantmod'), ('40', 'nummod'), ('mg', 'appos'), ('everi', 'amod'), ('week', 'npadvmod'), ('20', 'nummod'), ('mg', 'npadvmod'), ('everi', 'amod'), ('week', 'npadvmod'), ('40', 'nummod'), ('kg', 'appos'), ('(', 'punct'), ('88', 'nummod'), ('lb', 'parataxis'), (')', 'punct'), ('greater', 'amod'), ('day', 'npadvmod'), ('1', 'nummod'), (':', 'punct'), ('160', 'nummod'), ('mg', 'dep'), ('(', 'punct'), ('singl', 'compound'), ('dose', 'nsubj'), ('split', 'appos'), ('two', 'nummod'), ('consecut', 'compound'), ('day', 'npadvmod'), (')', 'punct'), ('day', 'appos'), ('8', 'nummod'), (':', 'punct'), ('80', 'appos'), ('mg', 'prep'), ('day', 'appos'), ('15', 'nummod'), (':', 'punct'), ('80', 'quantmod'), ('mg', 'quantmod'), ('80', 'nummod'), ('mg', 'npadvmod'), ('everi', 'amod'), ('week', 'appos'), ('40', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'npadvmod'), ('*', 'punct'), ('continu', 'nsubj'), ('recommend', 'conj'), ('pediatr', 'amod'), ('dosag', 'compound'), ('patient', 'compound'), ('turn', 'dobj'), ('18', 'nummod'), ('year', 'compound'), ('age', 'nmod'), ('well', 'amod'), ('-', 'punct'), ('control', 'compound'), ('humira', 'compound'), ('regimen', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Plaque Psoriasis or Adult Uveitis (2.5): \\n• Adults: 80 mg initial dose, followed by 40 mg every other week starting one \\nweek after initial dose.', 'tokens': ['Plaque', 'Psoriasis', 'Adult', 'Uveitis', '(', '2.5', ')', ':', '•', 'Adults', ':', '80', 'mg', 'initial', 'dose', ',', 'followed', '40', 'mg', 'every', 'week', 'starting', 'one', 'week', 'initial', 'dose', '.'], 'lemmatized': ['Plaque', 'Psoriasis', 'Adult', 'Uveitis', '(', '2.5', ')', ':', '•', 'Adults', ':', '80', 'mg', 'initial', 'dose', ',', 'followed', '40', 'mg', 'every', 'week', 'starting', 'one', 'week', 'initial', 'dose', '.'], 'stemmed': ['plaqu', 'psoriasi', 'adult', 'uveiti', '(', '2.5', ')', ':', '•', 'adult', ':', '80', 'mg', 'initi', 'dose', ',', 'follow', '40', 'mg', 'everi', 'week', 'start', 'one', 'week', 'initi', 'dose', '.'], 'dependencies': [('plaqu', 'ROOT'), ('psoriasi', 'compound'), ('adult', 'compound'), ('uveiti', 'dobj'), ('(', 'punct'), ('2.5', 'appos'), (')', 'punct'), (':', 'punct'), ('•', 'nummod'), ('adult', 'appos'), (':', 'punct'), ('80', 'nummod'), ('mg', 'compound'), ('initi', 'compound'), ('dose', 'appos'), (',', 'punct'), ('follow', 'conj'), ('40', 'nummod'), ('mg', 'dobj'), ('everi', 'amod'), ('week', 'npadvmod'), ('start', 'conj'), ('one', 'nummod'), ('week', 'compound'), ('initi', 'compound'), ('dose', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Hidradenitis Suppurativa (2.6): \\n• Adults: \\no \\nDay 1: 160 mg (given in one day or split over two consecutive days) \\no \\nDay 15: 80 mg  \\no \\nDay 29 and subsequent doses: 40 mg every week or 80 mg every \\nother week \\n• Adolescents 12 years of age and older: \\nAdolescent \\nWeight \\nRecommended Dosage  \\n30 kg (66 lbs)  \\nto less than  \\n60 kg (132 lbs) \\nDay 1:  80 mg  \\nDay 8 and subsequent doses:  40 mg every other week \\n60 kg (132 lbs)  \\nand greater \\nDay 1:  160 mg (given in one day or split over two \\nconsecutive days) \\nDay 15:  80 mg  \\nDay 29 and subsequent doses:  40 mg every week or 80 \\nmg every other week \\n \\n DOSAGE FORMS AND STRENGTHS  \\nInjection:  \\n• Single-dose prefilled pen (HUMIRA Pen): 80 mg/0.8 mL, 40 mg/0.8 mL, \\nand 40 mg/0.4 mL (3) \\n• Single-dose prefilled glass syringe:  80 mg/0.8 mL, 40 mg/0.8 mL, 40 \\nmg/0.4 mL, 20 mg/0.4 mL, 20 mg/0.2 mL, 10 mg/0.2 mL, 10 mg/0.1 mL \\n(3) \\n• Single-dose glass vial for institutional use only: 40 mg/0.8 mL (3) \\n  \\n CONTRAINDICATIONS  \\nNone (4)', 'tokens': ['Hidradenitis', 'Suppurativa', '(', '2.6', ')', ':', '•', 'Adults', ':', 'Day', '1', ':', '160', 'mg', '(', 'given', 'one', 'day', 'split', 'two', 'consecutive', 'days', ')', 'Day', '15', ':', '80', 'mg', 'Day', '29', 'subsequent', 'doses', ':', '40', 'mg', 'every', 'week', '80', 'mg', 'every', 'week', '•', 'Adolescents', '12', 'years', 'age', 'older', ':', 'Adolescent', 'Weight', 'Recommended', 'Dosage', '30', 'kg', '(', '66', 'lbs', ')', 'less', '60', 'kg', '(', '132', 'lbs', ')', 'Day', '1', ':', '80', 'mg', 'Day', '8', 'subsequent', 'doses', ':', '40', 'mg', 'every', 'week', '60', 'kg', '(', '132', 'lbs', ')', 'greater', 'Day', '1', ':', '160', 'mg', '(', 'given', 'one', 'day', 'split', 'two', 'consecutive', 'days', ')', 'Day', '15', ':', '80', 'mg', 'Day', '29', 'subsequent', 'doses', ':', '40', 'mg', 'every', 'week', '80', 'mg', 'every', 'week', 'DOSAGE', 'FORMS', 'STRENGTHS', 'Injection', ':', '•', 'Single-dose', 'prefilled', 'pen', '(', 'HUMIRA', 'Pen', ')', ':', '80', 'mg/0.8', 'mL', ',', '40', 'mg/0.8', 'mL', ',', '40', 'mg/0.4', 'mL', '(', '3', ')', '•', 'Single-dose', 'prefilled', 'glass', 'syringe', ':', '80', 'mg/0.8', 'mL', ',', '40', 'mg/0.8', 'mL', ',', '40', 'mg/0.4', 'mL', ',', '20', 'mg/0.4', 'mL', ',', '20', 'mg/0.2', 'mL', ',', '10', 'mg/0.2', 'mL', ',', '10', 'mg/0.1', 'mL', '(', '3', ')', '•', 'Single-dose', 'glass', 'vial', 'institutional', 'use', ':', '40', 'mg/0.8', 'mL', '(', '3', ')', 'CONTRAINDICATIONS', 'None', '(', '4', ')'], 'lemmatized': ['Hidradenitis', 'Suppurativa', '(', '2.6', ')', ':', '•', 'Adults', ':', 'Day', '1', ':', '160', 'mg', '(', 'given', 'one', 'day', 'split', 'two', 'consecutive', 'day', ')', 'Day', '15', ':', '80', 'mg', 'Day', '29', 'subsequent', 'dos', ':', '40', 'mg', 'every', 'week', '80', 'mg', 'every', 'week', '•', 'Adolescents', '12', 'year', 'age', 'older', ':', 'Adolescent', 'Weight', 'Recommended', 'Dosage', '30', 'kg', '(', '66', 'lb', ')', 'less', '60', 'kg', '(', '132', 'lb', ')', 'Day', '1', ':', '80', 'mg', 'Day', '8', 'subsequent', 'dos', ':', '40', 'mg', 'every', 'week', '60', 'kg', '(', '132', 'lb', ')', 'greater', 'Day', '1', ':', '160', 'mg', '(', 'given', 'one', 'day', 'split', 'two', 'consecutive', 'day', ')', 'Day', '15', ':', '80', 'mg', 'Day', '29', 'subsequent', 'dos', ':', '40', 'mg', 'every', 'week', '80', 'mg', 'every', 'week', 'DOSAGE', 'FORMS', 'STRENGTHS', 'Injection', ':', '•', 'Single-dose', 'prefilled', 'pen', '(', 'HUMIRA', 'Pen', ')', ':', '80', 'mg/0.8', 'mL', ',', '40', 'mg/0.8', 'mL', ',', '40', 'mg/0.4', 'mL', '(', '3', ')', '•', 'Single-dose', 'prefilled', 'glass', 'syringe', ':', '80', 'mg/0.8', 'mL', ',', '40', 'mg/0.8', 'mL', ',', '40', 'mg/0.4', 'mL', ',', '20', 'mg/0.4', 'mL', ',', '20', 'mg/0.2', 'mL', ',', '10', 'mg/0.2', 'mL', ',', '10', 'mg/0.1', 'mL', '(', '3', ')', '•', 'Single-dose', 'glass', 'vial', 'institutional', 'use', ':', '40', 'mg/0.8', 'mL', '(', '3', ')', 'CONTRAINDICATIONS', 'None', '(', '4', ')'], 'stemmed': ['hidraden', 'suppurativa', '(', '2.6', ')', ':', '•', 'adult', ':', 'day', '1', ':', '160', 'mg', '(', 'given', 'one', 'day', 'split', 'two', 'consecut', 'day', ')', 'day', '15', ':', '80', 'mg', 'day', '29', 'subsequ', 'do', ':', '40', 'mg', 'everi', 'week', '80', 'mg', 'everi', 'week', '•', 'adolesc', '12', 'year', 'age', 'older', ':', 'adolesc', 'weight', 'recommend', 'dosag', '30', 'kg', '(', '66', 'lb', ')', 'less', '60', 'kg', '(', '132', 'lb', ')', 'day', '1', ':', '80', 'mg', 'day', '8', 'subsequ', 'do', ':', '40', 'mg', 'everi', 'week', '60', 'kg', '(', '132', 'lb', ')', 'greater', 'day', '1', ':', '160', 'mg', '(', 'given', 'one', 'day', 'split', 'two', 'consecut', 'day', ')', 'day', '15', ':', '80', 'mg', 'day', '29', 'subsequ', 'do', ':', '40', 'mg', 'everi', 'week', '80', 'mg', 'everi', 'week', 'dosag', 'form', 'strength', 'inject', ':', '•', 'single-dos', 'prefil', 'pen', '(', 'humira', 'pen', ')', ':', '80', 'mg/0.8', 'ml', ',', '40', 'mg/0.8', 'ml', ',', '40', 'mg/0.4', 'ml', '(', '3', ')', '•', 'single-dos', 'prefil', 'glass', 'syring', ':', '80', 'mg/0.8', 'ml', ',', '40', 'mg/0.8', 'ml', ',', '40', 'mg/0.4', 'ml', ',', '20', 'mg/0.4', 'ml', ',', '20', 'mg/0.2', 'ml', ',', '10', 'mg/0.2', 'ml', ',', '10', 'mg/0.1', 'ml', '(', '3', ')', '•', 'single-dos', 'glass', 'vial', 'institut', 'use', ':', '40', 'mg/0.8', 'ml', '(', '3', ')', 'contraind', 'none', '(', '4', ')'], 'dependencies': [('hidraden', 'compound'), ('suppurativa', 'nsubj'), ('(', 'punct'), ('2.6', 'appos'), (')', 'punct'), (':', 'punct'), ('•', 'nummod'), ('adult', 'appos'), (':', 'punct'), ('day', 'dep'), ('1', 'nummod'), (':', 'punct'), ('160', 'nummod'), ('mg', 'appos'), ('(', 'punct'), ('given', 'prep'), ('one', 'nummod'), ('day', 'npadvmod'), ('split', 'pcomp'), ('two', 'nummod'), ('consecut', 'compound'), ('day', 'npadvmod'), (')', 'punct'), ('day', 'pobj'), ('15', 'nummod'), (':', 'punct'), ('80', 'nummod'), ('mg', 'prep'), ('day', 'appos'), ('29', 'nummod'), ('subsequ', 'appos'), ('do', 'ccomp'), (':', 'punct'), ('40', 'nummod'), ('mg', 'advmod'), ('everi', 'amod'), ('week', 'npadvmod'), ('80', 'nummod'), ('mg', 'nmod'), ('everi', 'amod'), ('week', 'npadvmod'), ('•', 'nummod'), ('adolesc', 'npadvmod'), ('12', 'nummod'), ('year', 'compound'), ('age', 'dobj'), ('older', 'amod'), (':', 'punct'), ('adolesc', 'compound'), ('weight', 'nsubj'), ('recommend', 'ROOT'), ('dosag', 'dobj'), ('30', 'nummod'), ('kg', 'npadvmod'), ('(', 'punct'), ('66', 'nummod'), ('lb', 'appos'), (')', 'punct'), ('less', 'amod'), ('60', 'nummod'), ('kg', 'npadvmod'), ('(', 'punct'), ('132', 'nummod'), ('lb', 'appos'), (')', 'punct'), ('day', 'appos'), ('1', 'nummod'), (':', 'punct'), ('80', 'nummod'), ('mg', 'prep'), ('day', 'nsubj'), ('8', 'nummod'), ('subsequ', 'appos'), ('do', 'prep'), (':', 'punct'), ('40', 'nummod'), ('mg', 'advmod'), ('everi', 'amod'), ('week', 'npadvmod'), ('60', 'nummod'), ('kg', 'appos'), ('(', 'punct'), ('132', 'nummod'), ('lb', 'parataxis'), (')', 'punct'), ('greater', 'amod'), ('day', 'npadvmod'), ('1', 'nummod'), (':', 'punct'), ('160', 'nummod'), ('mg', 'npadvmod'), ('(', 'punct'), ('given', 'prep'), ('one', 'nummod'), ('day', 'npadvmod'), ('split', 'pcomp'), ('two', 'nummod'), ('consecut', 'compound'), ('day', 'npadvmod'), (')', 'punct'), ('day', 'pobj'), ('15', 'nummod'), (':', 'punct'), ('80', 'nummod'), ('mg', 'prep'), ('day', 'npadvmod'), ('29', 'nummod'), ('subsequ', 'nsubj'), ('do', 'conj'), (':', 'punct'), ('40', 'nummod'), ('mg', 'advmod'), ('everi', 'amod'), ('week', 'npadvmod'), ('80', 'nummod'), ('mg', 'nmod'), ('everi', 'amod'), ('week', 'compound'), ('dosag', 'compound'), ('form', 'compound'), ('strength', 'nsubj'), ('inject', 'ccomp'), (':', 'punct'), ('•', 'nummod'), ('single', 'amod'), ('-', 'punct'), ('dos', 'compound'), ('prefil', 'compound'), ('pen', 'dobj'), ('(', 'punct'), ('humira', 'compound'), ('pen', 'appos'), (')', 'punct'), (':', 'punct'), ('80', 'nummod'), ('mg/0.8', 'dep'), ('ml', 'dep'), (',', 'punct'), ('40', 'nummod'), ('mg/0.8', 'quantmod'), ('ml', 'appos'), (',', 'punct'), ('40', 'nummod'), ('mg/0.4', 'dep'), ('ml', 'dep'), ('(', 'punct'), ('3', 'nummod'), (')', 'punct'), ('•', 'nummod'), ('single', 'amod'), ('-', 'punct'), ('dos', 'compound'), ('prefil', 'compound'), ('glass', 'compound'), ('syring', 'appos'), (':', 'punct'), ('80', 'nummod'), ('mg/0.8', 'dep'), ('ml', 'conj'), (',', 'punct'), ('40', 'nummod'), ('mg/0.8', 'quantmod'), ('ml', 'conj'), (',', 'punct'), ('40', 'nummod'), ('mg/0.4', 'dep'), ('ml', 'dep'), (',', 'punct'), ('20', 'nummod'), ('mg/0.4', 'punct'), ('ml', 'appos'), (',', 'punct'), ('20', 'nummod'), ('mg/0.2', 'appos'), ('ml', 'appos'), (',', 'punct'), ('10', 'nummod'), ('mg/0.2', 'appos'), ('ml', 'appos'), (',', 'punct'), ('10', 'nummod'), ('mg/0.1', 'npadvmod'), ('ml', 'nmod'), ('(', 'punct'), ('3', 'appos'), (')', 'punct'), ('•', 'nummod'), ('single', 'amod'), ('-', 'punct'), ('dos', 'compound'), ('glass', 'compound'), ('vial', 'compound'), ('institut', 'compound'), ('use', 'appos'), (':', 'punct'), ('40', 'nummod'), ('mg/0.8', 'dep'), ('ml', 'nsubj'), ('(', 'punct'), ('3', 'appos'), (')', 'punct'), ('contraind', 'prep'), ('none', 'dobj'), ('(', 'punct'), ('4', 'npadvmod'), (')', 'punct')]}], 'text': \"HIGHLIGHTS OF PRESCRIBING INFORMATION \\nThese highlights do not include all the information needed to use \\nHUMIRA safely and effectively. See full prescribing information for \\nHUMIRA. \\n \\nHUMIRA® (adalimumab) injection, for subcutaneous use \\nInitial U.S. Approval: 2002 \\n  \\nWARNING: SERIOUS INFECTIONS AND MALIGNANCY \\nSee full prescribing information for complete boxed warning. \\nSERIOUS INFECTIONS (5.1, 6.1): \\n• Increased risk of serious infections leading to hospitalization or \\ndeath, including tuberculosis (TB), bacterial sepsis, invasive \\nfungal infections (such as histoplasmosis), and infections due to \\nother opportunistic pathogens. \\n• Discontinue HUMIRA if a patient develops a serious infection or \\nsepsis during treatment. \\n• Perform test for latent TB; if positive, start treatment for TB \\nprior to starting HUMIRA. \\n• Monitor all patients for active TB during treatment, even if initial \\nlatent TB test is negative.  \\nMALIGNANCY (5.2): \\n• Lymphoma and other malignancies, some fatal, have been \\nreported in children and adolescent patients treated with TNF \\nblockers including HUMIRA. \\n• Post-marketing cases of hepatosplenic T-cell lymphoma \\n(HSTCL), a rare type of T-cell lymphoma, have occurred in \\nadolescent and young adults with inflammatory bowel disease \\ntreated with TNF blockers including HUMIRA.  \\n \\n INDICATIONS AND USAGE  \\nHUMIRA is a tumor necrosis factor (TNF) blocker indicated for:  \\n• Rheumatoid Arthritis (RA) (1.1): reducing signs and symptoms, inducing \\nmajor clinical response, inhibiting the progression of structural damage, and \\nimproving physical function in adult patients with moderately to severely \\nactive RA.  \\n• Juvenile Idiopathic Arthritis (JIA) (1.2): reducing signs and symptoms of \\nmoderately to severely active polyarticular JIA in patients 2 years of age \\nand older.  \\n• Psoriatic Arthritis (PsA) (1.3): reducing signs and symptoms, inhibiting \\nthe progression of structural damage, and improving physical function in \\nadult patients with active PsA.  \\n• Ankylosing Spondylitis (AS) (1.4): reducing signs and symptoms in adult \\npatients with active AS.  \\n• Crohn’s Disease (CD) (1.5): treatment of moderately to severely active \\nCrohn’s disease in adults and pediatric patients 6 years of age and older.  \\n• Ulcerative Colitis (UC) (1.6): treatment of moderately to severely active \\nulcerative colitis in adults and pediatric patients 5 years of age and older.  \\nLimitations of Use: Effectiveness has not been established in patients who \\nhave lost response to or were intolerant to TNF blockers. \\n• Plaque Psoriasis (Ps) (1.7): treatment of adult patients with moderate to \\nsevere chronic plaque psoriasis who are candidates for systemic therapy or \\nphototherapy, and when other systemic therapies are medically less \\nappropriate.  \\n• Hidradenitis Suppurativa (HS) (1.8): treatment of moderate to severe \\nhidradenitis suppurativa in patients 12 years of age and older.  \\n• Uveitis (UV) (1.9): treatment of non-infectious intermediate, posterior, and \\npanuveitis in adults and pediatric patients 2 years of age and older.  \\n  \\n DOSAGE AND ADMINISTRATION  \\n• Administer by subcutaneous injection (2) \\nRheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis (2.1): \\n• Adults:  40 mg every other week.  \\n• Some patients with RA not receiving methotrexate may benefit from \\nincreasing the dosage to 40 mg every week or 80 mg every other \\nweek. \\n \\n \\n \\n \\n \\n \\n \\n \\n \\nJuvenile Idiopathic Arthritis or Pediatric Uveitis (2.2):  \\nPediatric Weight \\n2 Years of Age and Older \\nRecommended Dosage \\n10 kg (22 lbs) to less than 15 kg (33 lbs) \\n10 mg every other week  \\n15 kg (33 lbs) to less than 30 kg (66 lbs) \\n20 mg every other week \\n30 kg (66 lbs) and greater \\n40 mg every other week  \\nCrohn's Disease (2.3): \\n• Adults:  160 mg on Day 1 (given in one day or split over two consecutive \\ndays); 80 mg on Day 15; and 40 mg every other week starting on Day 29.  \\n• Pediatric Patients 6 Years of Age and Older: \\nPediatric Weight \\n \\nRecommended Dosage \\nDays 1 and 15 \\nStarting on Day 29 \\n17 kg (37 lbs)  \\nto less than  \\n40 kg (88 lbs)  \\nDay 1:  80 mg  \\nDay 15: 40 mg  \\n20 mg every other week \\n40 kg (88 lbs)  \\nand greater \\nDay 1:  160 mg (single dose or  \\nsplit over two consecutive days)  \\nDay 15:  80 mg  \\n40 mg every other week \\nUlcerative Colitis (2.4): \\n• Adults:  160 mg on Day 1 (given in one day or split over two consecutive \\ndays), 80 mg on Day 15 and 40 mg every other week starting on Day 29. \\nDiscontinue in patients without evidence of clinical remission by eight \\nweeks (Day 57). \\n• Pediatric Patients 5 Years of Age and Older: \\nPediatric Weight \\n \\nRecommended Dosage \\nDays 1 through 15  \\nStarting on Day 29* \\n20 kg (44 lbs) \\nto less than  \\n40 kg (88 lbs) \\nDay 1:  80 mg  \\nDay 8:  40 mg  \\nDay 15: 40 mg  \\n40 mg every other week \\nor \\n20 mg every week \\n40 kg (88 lbs) and \\ngreater \\nDay 1: 160 mg (single dose or \\nsplit over two consecutive \\ndays)  \\nDay 8: 80 mg  \\nDay 15: 80 mg  \\n80 mg every other week \\nor \\n40 mg every week \\n* Continue the recommended pediatric dosage in patients who turn 18 years \\nof age and who are well-controlled on their HUMIRA regimen. \\nPlaque Psoriasis or Adult Uveitis (2.5): \\n• Adults: 80 mg initial dose, followed by 40 mg every other week starting one \\nweek after initial dose. \\nHidradenitis Suppurativa (2.6): \\n• Adults: \\no \\nDay 1: 160 mg (given in one day or split over two consecutive days) \\no \\nDay 15: 80 mg  \\no \\nDay 29 and subsequent doses: 40 mg every week or 80 mg every \\nother week \\n• Adolescents 12 years of age and older: \\nAdolescent \\nWeight \\nRecommended Dosage  \\n30 kg (66 lbs)  \\nto less than  \\n60 kg (132 lbs) \\nDay 1:  80 mg  \\nDay 8 and subsequent doses:  40 mg every other week \\n60 kg (132 lbs)  \\nand greater \\nDay 1:  160 mg (given in one day or split over two \\nconsecutive days) \\nDay 15:  80 mg  \\nDay 29 and subsequent doses:  40 mg every week or 80 \\nmg every other week \\n \\n DOSAGE FORMS AND STRENGTHS  \\nInjection:  \\n• Single-dose prefilled pen (HUMIRA Pen): 80 mg/0.8 mL, 40 mg/0.8 mL, \\nand 40 mg/0.4 mL (3) \\n• Single-dose prefilled glass syringe:  80 mg/0.8 mL, 40 mg/0.8 mL, 40 \\nmg/0.4 mL, 20 mg/0.4 mL, 20 mg/0.2 mL, 10 mg/0.2 mL, 10 mg/0.1 mL \\n(3) \\n• Single-dose glass vial for institutional use only: 40 mg/0.8 mL (3) \\n  \\n CONTRAINDICATIONS  \\nNone (4) \\n\"}, 'page_char_count': 6260, 'page_word_count': 1017, 'sentences': ['HIGHLIGHTS OF PRESCRIBING INFORMATION \\nThese highlights do not include all the information needed to use \\nHUMIRA safely and effectively.', 'See full prescribing information for \\nHUMIRA.', '\\n \\nHUMIRA® (adalimumab) injection, for subcutaneous use \\nInitial U.S. Approval: 2002 \\n  \\nWARNING: SERIOUS INFECTIONS AND MALIGNANCY \\nSee full prescribing information for complete boxed warning.', '\\nSERIOUS INFECTIONS (5.1, 6.1): \\n• Increased risk of serious infections leading to hospitalization or \\ndeath, including tuberculosis (TB), bacterial sepsis, invasive \\nfungal infections (such as histoplasmosis), and infections due to \\nother opportunistic pathogens.', '\\n• Discontinue HUMIRA if a patient develops a serious infection or \\nsepsis during treatment.', '\\n• Perform test for latent TB; if positive, start treatment for TB \\nprior to starting HUMIRA.', '\\n• Monitor all patients for active TB during treatment, even if initial \\nlatent TB test is negative.', ' \\nMALIGNANCY (5.2): \\n• Lymphoma and other malignancies, some fatal, have been \\nreported in children and adolescent patients treated with TNF \\nblockers including HUMIRA.', '\\n• Post-marketing cases of hepatosplenic T-cell lymphoma \\n(HSTCL), a rare type of T-cell lymphoma, have occurred in \\nadolescent and young adults with inflammatory bowel disease \\ntreated with TNF blockers including HUMIRA.', ' \\n \\n INDICATIONS AND USAGE  \\nHUMIRA is a tumor necrosis factor (TNF) blocker indicated for:  \\n• Rheumatoid Arthritis (RA) (1.1): reducing signs and symptoms, inducing \\nmajor clinical response, inhibiting the progression of structural damage, and \\nimproving physical function in adult patients with moderately to severely \\nactive RA.', ' \\n• Juvenile Idiopathic Arthritis (JIA) (1.2): reducing signs and symptoms of \\nmoderately to severely active polyarticular JIA in patients 2 years of age \\nand older.', ' \\n• Psoriatic Arthritis (PsA) (1.3): reducing signs and symptoms, inhibiting \\nthe progression of structural damage, and improving physical function in \\nadult patients with active PsA.  \\n• Ankylosing Spondylitis (AS) (1.4): reducing signs and symptoms in adult \\npatients with active AS.', ' \\n• Crohn’s Disease (CD) (1.5): treatment of moderately to severely active \\nCrohn’s disease in adults and pediatric patients 6 years of age and older.', ' \\n• Ulcerative Colitis (UC) (1.6): treatment of moderately to severely active \\nulcerative colitis in adults and pediatric patients 5 years of age and older.', ' \\nLimitations of Use: Effectiveness has not been established in patients who \\nhave lost response to or were intolerant to TNF blockers.', '\\n• Plaque Psoriasis (Ps) (1.7): treatment of adult patients with moderate to \\nsevere chronic plaque psoriasis who are candidates for systemic therapy or \\nphototherapy, and when other systemic therapies are medically less \\nappropriate.', ' \\n• Hidradenitis Suppurativa (HS) (1.8): treatment of moderate to severe \\nhidradenitis suppurativa in patients 12 years of age and older.', ' \\n• Uveitis (UV) (1.9): treatment of non-infectious intermediate, posterior, and \\npanuveitis in adults and pediatric patients 2 years of age and older.', ' \\n  \\n DOSAGE AND ADMINISTRATION  \\n• Administer by subcutaneous injection (2) \\nRheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis (2.1): \\n• Adults:  40 mg every other week.', ' \\n• Some patients with RA not receiving methotrexate may benefit from \\nincreasing the dosage to 40 mg every week or 80 mg every other \\nweek.', \"\\n \\n \\n \\n \\n \\n \\n \\n \\n \\nJuvenile Idiopathic Arthritis or Pediatric Uveitis (2.2):  \\nPediatric Weight \\n2 Years of Age and Older \\nRecommended Dosage \\n10 kg (22 lbs) to less than 15 kg (33 lbs) \\n10 mg every other week  \\n15 kg (33 lbs) to less than 30 kg (66 lbs) \\n20 mg every other week \\n30 kg (66 lbs) and greater \\n40 mg every other week  \\nCrohn's Disease (2.3): \\n• Adults:  160 mg on Day 1 (given in one day or split over two consecutive \\ndays); 80 mg on Day 15; and 40 mg every other week starting on Day 29.\", ' \\n• Pediatric Patients 6 Years of Age and Older: \\nPediatric Weight \\n \\nRecommended Dosage \\nDays 1 and 15 \\nStarting on Day 29 \\n17 kg (37 lbs)  \\nto less than  \\n40 kg (88 lbs)  \\nDay 1:  80 mg  \\nDay 15: 40 mg  \\n20 mg every other week \\n40 kg (88 lbs)  \\nand greater \\nDay 1:  160 mg (single dose or  \\nsplit over two consecutive days)  \\nDay 15:  80 mg  \\n40 mg every other week \\nUlcerative Colitis (2.4): \\n• Adults:  160 mg on Day 1 (given in one day or split over two consecutive \\ndays), 80 mg on Day 15 and 40 mg every other week starting on Day 29.', '\\nDiscontinue in patients without evidence of clinical remission by eight \\nweeks (Day 57).', '\\n• Pediatric Patients 5 Years of Age and Older: \\nPediatric Weight \\n \\nRecommended Dosage \\nDays 1 through 15  \\nStarting on Day 29* \\n20 kg (44 lbs) \\nto less than  \\n40 kg (88 lbs) \\nDay 1:  80 mg  \\nDay 8:  40 mg  \\nDay 15: 40 mg  \\n40 mg every other week \\nor \\n20 mg every week \\n40 kg (88 lbs) and \\ngreater \\nDay 1: 160 mg (single dose or \\nsplit over two consecutive \\ndays)  \\nDay 8: 80 mg  \\nDay 15: 80 mg  \\n80 mg every other week \\nor \\n40 mg every week \\n* Continue the recommended pediatric dosage in patients who turn 18 years \\nof age and who are well-controlled on their HUMIRA regimen.', '\\nPlaque Psoriasis or Adult Uveitis (2.5): \\n• Adults: 80 mg initial dose, followed by 40 mg every other week starting one \\nweek after initial dose.', '\\nHidradenitis Suppurativa (2.6): \\n• Adults: \\no \\nDay 1: 160 mg (given in one day or split over two consecutive days) \\no \\nDay 15: 80 mg  \\no \\nDay 29 and subsequent doses: 40 mg every week or 80 mg every \\nother week \\n• Adolescents 12 years of age and older: \\nAdolescent \\nWeight \\nRecommended Dosage  \\n30 kg (66 lbs)  \\nto less than  \\n60 kg (132 lbs) \\nDay 1:  80 mg  \\nDay 8 and subsequent doses:  40 mg every other week \\n60 kg (132 lbs)  \\nand greater \\nDay 1:  160 mg (given in one day or split over two \\nconsecutive days) \\nDay 15:  80 mg  \\nDay 29 and subsequent doses:  40 mg every week or 80 \\nmg every other week \\n \\n DOSAGE FORMS AND STRENGTHS  \\nInjection:  \\n• Single-dose prefilled pen (HUMIRA Pen): 80 mg/0.8 mL, 40 mg/0.8 mL, \\nand 40 mg/0.4 mL (3) \\n• Single-dose prefilled glass syringe:  80 mg/0.8 mL, 40 mg/0.8 mL, 40 \\nmg/0.4 mL, 20 mg/0.4 mL, 20 mg/0.2 mL, 10 mg/0.2 mL, 10 mg/0.1 mL \\n(3) \\n• Single-dose glass vial for institutional use only: 40 mg/0.8 mL (3) \\n  \\n CONTRAINDICATIONS  \\nNone (4) \\n'], 'page_sentence_count_spacy': 26}\n",
            "{'page_number': 2, 'text': '  \\n WARNINGS AND PRECAUTIONS  \\n• Serious infections: Do not start HUMIRA during an active infection. If an \\ninfection develops, monitor carefully, and stop HUMIRA if infection \\nbecomes serious. (5.1) \\n• Invasive fungal infections: For patients who develop a systemic illness on \\nHUMIRA, consider empiric antifungal therapy for those who reside or \\ntravel to regions where mycoses are endemic. (5.1) \\n• Malignancies: Incidence of malignancies was greater in HUMIRA-treated \\npatients than in controls (5.2) \\n• Anaphylaxis or serious hypersensitivity reactions may occur (5.3) \\n• Hepatitis B virus reactivation: Monitor HBV carriers during and several \\nmonths after therapy. If reactivation occurs, stop HUMIRA and begin anti-\\nviral therapy. (5.4) \\n• Demyelinating disease: Exacerbation or new onset, may occur. (5.5) \\n• Cytopenias, pancytopenia: Advise patients to seek immediate medical \\nattention if symptoms develop, and consider stopping HUMIRA. (5.6) \\n• Heart failure: Worsening or new onset, may occur. (5.8) \\n• Lupus-like syndrome: Stop HUMIRA if syndrome develops. (5.9) \\n  \\n ADVERSE REACTIONS  \\nMost common adverse reactions (>10%) are: infections (e.g. upper \\nrespiratory, sinusitis), injection site reactions, headache and rash. (6.1) \\n \\nTo report SUSPECTED ADVERSE REACTIONS, contact AbbVie Inc. \\nat 1-800-633-9110 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch \\n  \\n DRUG INTERACTIONS  \\n• Abatacept: Increased risk of serious infection. (5.1, 5.11, 7.2)  \\n• Anakinra: Increased risk of serious infection. (5.1, 5.7, 7.2)  \\n• Live vaccines: Avoid use with HUMIRA. (5.10, 7.3)  \\n \\nSee 17 for PATIENT COUNSELING INFORMATION and Medication \\nGuide. \\n \\nRevised: 2/2024 \\n \\n \\n \\nFULL PRESCRIBING INFORMATION: CONTENTS* \\n \\nWARNING: SERIOUS INFECTIONS AND MALIGNANCY \\n1 INDICATIONS AND USAGE \\n1.1 Rheumatoid Arthritis \\n1.2 Juvenile Idiopathic Arthritis \\n1.3 Psoriatic Arthritis \\n1.4 Ankylosing Spondylitis \\n1.5 Crohn’s Disease \\n1.6 Ulcerative Colitis  \\n1.7 Plaque Psoriasis \\n1.8 Hidradenitis Suppurativa \\n1.9 Uveitis \\n2 DOSAGE AND ADMINISTRATION \\n2.1 Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis \\n2.2 Juvenile Idiopathic Arthritis or Pediatric Uveitis \\n2.3 Crohn’s Disease \\n2.4  Ulcerative Colitis  \\n2.5 Plaque Psoriasis or Adult Uveitis \\n2.6 Hidradenitis Suppurativa \\n2.7 Monitoring to Assess Safety \\n2.8 General Considerations for Administration \\n3 DOSAGE FORMS AND STRENGTHS \\n4 CONTRAINDICATIONS \\n5 WARNINGS AND PRECAUTIONS  \\n5.1 Serious Infections \\n5.2 Malignancies \\n5.3 Hypersensitivity Reactions \\n5.4 Hepatitis B Virus Reactivation \\n5.5 Neurologic Reactions \\n5.6 Hematological Reactions \\n5.7 Increased Risk of Infection When Used with Anakinra \\n5.8 Heart Failure \\n5.9 Autoimmunity \\n5.10 Immunizations \\n5.11 Increased risk of Infection When Used with Abatacept \\n6 ADVERSE REACTIONS \\n6.1 Clinical Trials Experience \\n6.2 Immunogenicity \\n6.3 Postmarketing Experience \\n7 DRUG INTERACTIONS \\n7.1 Methotrexate \\n7.2 Biological Products  \\n7.3 Live Vaccines \\n7.4 Cytochrome P450 Substrates \\n8 USE IN SPECIFIC POPULATIONS \\n8.1 Pregnancy \\n8.2 Lactation \\n8.4 Pediatric Use \\n8.5 Geriatric Use \\n10 OVERDOSAGE \\n11 DESCRIPTION \\n12 CLINICAL PHARMACOLOGY \\n12.1 Mechanism of Action \\n12.2 Pharmacodynamics \\n12.3 Pharmacokinetics \\n13 NONCLINICAL TOXICOLOGY \\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility \\n14 CLINICAL STUDIES \\n14.1 Rheumatoid Arthritis \\n14.2 Juvenile Idiopathic Arthritis \\n14.3 Psoriatic Arthritis \\n14.4 Ankylosing Spondylitis \\n14.5 Adult Crohn’s Disease \\n14.6 Pediatric Crohn’s Disease  \\n14.7 Adult Ulcerative Colitis \\n14.8 Pediatric Ulcerative Colitis \\n14.9 Plaque Psoriasis \\n14.10 Hidradenitis Suppurativa \\n14.11 Adult Uveitis \\n14.12 Pediatric Uveitis \\n15 REFERENCES \\n16 HOW SUPPLIED/STORAGE AND HANDLING \\n17 PATIENT COUNSELING INFORMATION \\n \\n*Sections or subsections omitted from the full prescribing information are not \\nlisted.  \\n   \\n \\n', 'processed_text': {'sentences': [{'original_sentence': '  \\n WARNINGS AND PRECAUTIONS  \\n• Serious infections: Do not start HUMIRA during an active infection.', 'tokens': ['WARNINGS', 'PRECAUTIONS', '•', 'Serious', 'infections', ':', 'start', 'HUMIRA', 'active', 'infection', '.'], 'lemmatized': ['WARNINGS', 'PRECAUTIONS', '•', 'Serious', 'infection', ':', 'start', 'HUMIRA', 'active', 'infection', '.'], 'stemmed': ['warn', 'precaut', '•', 'seriou', 'infect', ':', 'start', 'humira', 'activ', 'infect', '.'], 'dependencies': [('warn', 'ROOT'), ('precaut', 'dative'), ('•', 'nummod'), ('seriou', 'compound'), ('infect', 'dobj'), (':', 'punct'), ('start', 'acl'), ('humira', 'compound'), ('activ', 'compound'), ('infect', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'If an \\ninfection develops, monitor carefully, and stop HUMIRA if infection \\nbecomes serious.', 'tokens': ['infection', 'develops', ',', 'monitor', 'carefully', ',', 'stop', 'HUMIRA', 'infection', 'becomes', 'serious', '.'], 'lemmatized': ['infection', 'develops', ',', 'monitor', 'carefully', ',', 'stop', 'HUMIRA', 'infection', 'becomes', 'serious', '.'], 'stemmed': ['infect', 'develop', ',', 'monitor', 'care', ',', 'stop', 'humira', 'infect', 'becom', 'seriou', '.'], 'dependencies': [('infect', 'advcl'), ('develop', 'xcomp'), (',', 'punct'), ('monitor', 'compound'), ('care', 'dobj'), (',', 'punct'), ('stop', 'ROOT'), ('humira', 'nsubj'), ('infect', 'ccomp'), ('becom', 'compound'), ('seriou', 'dobj'), ('.', 'punct')]}, {'original_sentence': '(5.1) \\n• Invasive fungal infections: For patients who develop a systemic illness on \\nHUMIRA, consider empiric antifungal therapy for those who reside or \\ntravel to regions where mycoses are endemic.', 'tokens': ['(', '5.1', ')', '•', 'Invasive', 'fungal', 'infections', ':', 'patients', 'develop', 'systemic', 'illness', 'HUMIRA', ',', 'consider', 'empiric', 'antifungal', 'therapy', 'reside', 'travel', 'regions', 'mycoses', 'endemic', '.'], 'lemmatized': ['(', '5.1', ')', '•', 'Invasive', 'fungal', 'infection', ':', 'patient', 'develop', 'systemic', 'illness', 'HUMIRA', ',', 'consider', 'empiric', 'antifungal', 'therapy', 'reside', 'travel', 'region', 'mycoses', 'endemic', '.'], 'stemmed': ['(', '5.1', ')', '•', 'invas', 'fungal', 'infect', ':', 'patient', 'develop', 'system', 'ill', 'humira', ',', 'consid', 'empir', 'antifung', 'therapi', 'resid', 'travel', 'region', 'mycos', 'endem', '.'], 'dependencies': [('(', 'punct'), ('5.1', 'nummod'), (')', 'punct'), ('•', 'nummod'), ('invas', 'compound'), ('fungal', 'compound'), ('infect', 'ROOT'), (':', 'punct'), ('patient', 'nsubj'), ('develop', 'acl'), ('system', 'nmod'), ('ill', 'amod'), ('humira', 'nmod'), (',', 'punct'), ('consid', 'amod'), ('empir', 'nmod'), ('antifung', 'amod'), ('therapi', 'amod'), ('resid', 'compound'), ('travel', 'compound'), ('region', 'compound'), ('mycos', 'compound'), ('endem', 'dobj'), ('.', 'punct')]}, {'original_sentence': '(5.1) \\n• Malignancies: Incidence of malignancies was greater in HUMIRA-treated \\npatients than in controls (5.2) \\n• Anaphylaxis or serious hypersensitivity reactions may occur (5.3) \\n• Hepatitis B virus reactivation: Monitor HBV carriers during and several \\nmonths after therapy.', 'tokens': ['(', '5.1', ')', '•', 'Malignancies', ':', 'Incidence', 'malignancies', 'greater', 'HUMIRA-treated', 'patients', 'controls', '(', '5.2', ')', '•', 'Anaphylaxis', 'serious', 'hypersensitivity', 'reactions', 'may', 'occur', '(', '5.3', ')', '•', 'Hepatitis', 'B', 'virus', 'reactivation', ':', 'Monitor', 'HBV', 'carriers', 'several', 'months', 'therapy', '.'], 'lemmatized': ['(', '5.1', ')', '•', 'Malignancies', ':', 'Incidence', 'malignancy', 'greater', 'HUMIRA-treated', 'patient', 'control', '(', '5.2', ')', '•', 'Anaphylaxis', 'serious', 'hypersensitivity', 'reaction', 'may', 'occur', '(', '5.3', ')', '•', 'Hepatitis', 'B', 'virus', 'reactivation', ':', 'Monitor', 'HBV', 'carrier', 'several', 'month', 'therapy', '.'], 'stemmed': ['(', '5.1', ')', '•', 'malign', ':', 'incid', 'malign', 'greater', 'humira-tr', 'patient', 'control', '(', '5.2', ')', '•', 'anaphylaxi', 'seriou', 'hypersensit', 'reaction', 'may', 'occur', '(', '5.3', ')', '•', 'hepat', 'b', 'viru', 'reactiv', ':', 'monitor', 'hbv', 'carrier', 'sever', 'month', 'therapi', '.'], 'dependencies': [('(', 'punct'), ('5.1', 'nummod'), (')', 'punct'), ('•', 'nummod'), ('malign', 'dep'), (':', 'punct'), ('incid', 'amod'), ('malign', 'nmod'), ('greater', 'amod'), ('humira', 'npadvmod'), ('-', 'punct'), ('tr', 'nmod'), ('patient', 'amod'), ('control', 'nsubj'), ('(', 'punct'), ('5.2', 'nmod'), (')', 'punct'), ('•', 'nmod'), ('anaphylaxi', 'amod'), ('seriou', 'compound'), ('hypersensit', 'compound'), ('reaction', 'appos'), ('may', 'aux'), ('occur', 'ROOT'), ('(', 'punct'), ('5.3', 'nummod'), (')', 'punct'), ('•', 'compound'), ('hepat', 'compound'), ('b', 'compound'), ('viru', 'compound'), ('reactiv', 'dobj'), (':', 'punct'), ('monitor', 'advcl'), ('hbv', 'compound'), ('carrier', 'dobj'), ('sever', 'compound'), ('month', 'npadvmod'), ('therapi', 'dep'), ('.', 'punct')]}, {'original_sentence': 'If reactivation occurs, stop HUMIRA and begin anti-\\nviral therapy.', 'tokens': ['reactivation', 'occurs', ',', 'stop', 'HUMIRA', 'begin', 'anti-', 'viral', 'therapy', '.'], 'lemmatized': ['reactivation', 'occurs', ',', 'stop', 'HUMIRA', 'begin', 'anti-', 'viral', 'therapy', '.'], 'stemmed': ['reactiv', 'occur', ',', 'stop', 'humira', 'begin', 'anti-', 'viral', 'therapi', '.'], 'dependencies': [('reactiv', 'nsubj'), ('occur', 'ccomp'), (',', 'punct'), ('stop', 'parataxis'), ('humira', 'dobj'), ('begin', 'ROOT'), ('anti-', 'dep'), ('viral', 'amod'), ('therapi', 'oprd'), ('.', 'punct')]}, {'original_sentence': '(5.4) \\n• Demyelinating disease: Exacerbation or new onset, may occur.', 'tokens': ['(', '5.4', ')', '•', 'Demyelinating', 'disease', ':', 'Exacerbation', 'new', 'onset', ',', 'may', 'occur', '.'], 'lemmatized': ['(', '5.4', ')', '•', 'Demyelinating', 'disease', ':', 'Exacerbation', 'new', 'onset', ',', 'may', 'occur', '.'], 'stemmed': ['(', '5.4', ')', '•', 'demyelin', 'diseas', ':', 'exacerb', 'new', 'onset', ',', 'may', 'occur', '.'], 'dependencies': [('(', 'punct'), ('5.4', 'nummod'), (')', 'punct'), ('•', 'nummod'), ('demyelin', 'compound'), ('diseas', 'nsubj'), (':', 'punct'), ('exacerb', 'amod'), ('new', 'amod'), ('onset', 'appos'), (',', 'punct'), ('may', 'aux'), ('occur', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '(5.5) \\n• Cytopenias, pancytopenia: Advise patients to seek immediate medical \\nattention if symptoms develop, and consider stopping HUMIRA.', 'tokens': ['(', '5.5', ')', '•', 'Cytopenias', ',', 'pancytopenia', ':', 'Advise', 'patients', 'seek', 'immediate', 'medical', 'attention', 'symptoms', 'develop', ',', 'consider', 'stopping', 'HUMIRA', '.'], 'lemmatized': ['(', '5.5', ')', '•', 'Cytopenias', ',', 'pancytopenia', ':', 'Advise', 'patient', 'seek', 'immediate', 'medical', 'attention', 'symptom', 'develop', ',', 'consider', 'stopping', 'HUMIRA', '.'], 'stemmed': ['(', '5.5', ')', '•', 'cytopenia', ',', 'pancytopenia', ':', 'advis', 'patient', 'seek', 'immedi', 'medic', 'attent', 'symptom', 'develop', ',', 'consid', 'stop', 'humira', '.'], 'dependencies': [('(', 'punct'), ('5.5', 'nummod'), (')', 'punct'), ('•', 'nummod'), ('cytopenia', 'nsubj'), (',', 'punct'), ('pancytopenia', 'ROOT'), (':', 'punct'), ('advis', 'nmod'), ('patient', 'amod'), ('seek', 'ccomp'), ('immedi', 'compound'), ('medic', 'compound'), ('attent', 'compound'), ('symptom', 'nsubj'), ('develop', 'ccomp'), (',', 'punct'), ('consid', 'advmod'), ('stop', 'appos'), ('humira', 'dobj'), ('.', 'punct')]}, {'original_sentence': '(5.6) \\n• Heart failure: Worsening or new onset, may occur.', 'tokens': ['(', '5.6', ')', '•', 'Heart', 'failure', ':', 'Worsening', 'new', 'onset', ',', 'may', 'occur', '.'], 'lemmatized': ['(', '5.6', ')', '•', 'Heart', 'failure', ':', 'Worsening', 'new', 'onset', ',', 'may', 'occur', '.'], 'stemmed': ['(', '5.6', ')', '•', 'heart', 'failur', ':', 'worsen', 'new', 'onset', ',', 'may', 'occur', '.'], 'dependencies': [('(', 'punct'), ('5.6', 'quantmod'), (')', 'punct'), ('•', 'nummod'), ('heart', 'compound'), ('failur', 'nsubj'), (':', 'punct'), ('worsen', 'ccomp'), ('new', 'amod'), ('onset', 'dobj'), (',', 'punct'), ('may', 'aux'), ('occur', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '(5.8) \\n• Lupus-like syndrome: Stop HUMIRA if syndrome develops.', 'tokens': ['(', '5.8', ')', '•', 'Lupus-like', 'syndrome', ':', 'Stop', 'HUMIRA', 'syndrome', 'develops', '.'], 'lemmatized': ['(', '5.8', ')', '•', 'Lupus-like', 'syndrome', ':', 'Stop', 'HUMIRA', 'syndrome', 'develops', '.'], 'stemmed': ['(', '5.8', ')', '•', 'lupus-lik', 'syndrom', ':', 'stop', 'humira', 'syndrom', 'develop', '.'], 'dependencies': [('(', 'punct'), ('5.8', 'nummod'), (')', 'punct'), ('•', 'nummod'), ('lupus', 'compound'), ('-', 'punct'), ('lik', 'compound'), ('syndrom', 'dep'), (':', 'punct'), ('stop', 'ROOT'), ('humira', 'nsubj'), ('syndrom', 'aux'), ('develop', 'ccomp'), ('.', 'punct')]}, {'original_sentence': '(5.9) \\n  \\n ADVERSE REACTIONS  \\nMost common adverse reactions (>10%) are: infections (e.g.', 'tokens': ['(', '5.9', ')', 'ADVERSE', 'REACTIONS', 'common', 'adverse', 'reactions', '(', '>', '10', '%', ')', ':', 'infections', '(', 'e.g', '.'], 'lemmatized': ['(', '5.9', ')', 'ADVERSE', 'REACTIONS', 'common', 'adverse', 'reaction', '(', '>', '10', '%', ')', ':', 'infection', '(', 'e.g', '.'], 'stemmed': ['(', '5.9', ')', 'advers', 'reaction', 'common', 'advers', 'reaction', '(', '>', '10', '%', ')', ':', 'infect', '(', 'e.g', '.'], 'dependencies': [('(', 'punct'), ('5.9', 'nummod'), (')', 'punct'), ('advers', 'nsubj'), ('reaction', 'ROOT'), ('common', 'amod'), ('advers', 'compound'), ('reaction', 'dobj'), ('(', 'punct'), ('>', 'nmod'), ('10', 'nummod'), ('%', 'appos'), (')', 'punct'), (':', 'punct'), ('infect', 'appos'), ('(', 'punct'), ('e.g', 'appos'), ('.', 'punct')]}, {'original_sentence': 'upper \\nrespiratory, sinusitis), injection site reactions, headache and rash.', 'tokens': ['upper', 'respiratory', ',', 'sinusitis', ')', ',', 'injection', 'site', 'reactions', ',', 'headache', 'rash', '.'], 'lemmatized': ['upper', 'respiratory', ',', 'sinusitis', ')', ',', 'injection', 'site', 'reaction', ',', 'headache', 'rash', '.'], 'stemmed': ['upper', 'respiratori', ',', 'sinus', ')', ',', 'inject', 'site', 'reaction', ',', 'headach', 'rash', '.'], 'dependencies': [('upper', 'amod'), ('respiratori', 'ROOT'), (',', 'punct'), ('sinus', 'appos'), (')', 'punct'), (',', 'punct'), ('inject', 'compound'), ('site', 'compound'), ('reaction', 'conj'), (',', 'punct'), ('headach', 'compound'), ('rash', 'conj'), ('.', 'punct')]}, {'original_sentence': '(6.1) \\n \\nTo report SUSPECTED ADVERSE REACTIONS, contact AbbVie Inc. \\nat 1-800-633-9110 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch \\n  \\n DRUG INTERACTIONS  \\n• Abatacept: Increased risk of serious infection.', 'tokens': ['(', '6.1', ')', 'report', 'SUSPECTED', 'ADVERSE', 'REACTIONS', ',', 'contact', 'AbbVie', 'Inc.', '1-800-633-9110', 'FDA', '1-800-FDA-1088', 'www.fda.gov/medwatch', 'DRUG', 'INTERACTIONS', '•', 'Abatacept', ':', 'Increased', 'risk', 'serious', 'infection', '.'], 'lemmatized': ['(', '6.1', ')', 'report', 'SUSPECTED', 'ADVERSE', 'REACTIONS', ',', 'contact', 'AbbVie', 'Inc.', '1-800-633-9110', 'FDA', '1-800-FDA-1088', 'www.fda.gov/medwatch', 'DRUG', 'INTERACTIONS', '•', 'Abatacept', ':', 'Increased', 'risk', 'serious', 'infection', '.'], 'stemmed': ['(', '6.1', ')', 'report', 'suspect', 'advers', 'reaction', ',', 'contact', 'abbvi', 'inc.', '1-800-633-9110', 'fda', '1-800-fda-1088', 'www.fda.gov/medwatch', 'drug', 'interact', '•', 'abatacept', ':', 'increas', 'risk', 'seriou', 'infect', '.'], 'dependencies': [('(', 'punct'), ('6.1', 'nummod'), (')', 'punct'), ('report', 'dep'), ('suspect', 'compound'), ('advers', 'compound'), ('reaction', 'dobj'), (',', 'punct'), ('contact', 'nsubj'), ('abbvi', 'compound'), ('inc', 'nsubj'), ('.', 'punct'), ('1', 'quantmod'), ('-', 'punct'), ('800', 'prep'), ('-', 'punct'), ('633', 'quantmod'), ('-', 'punct'), ('9110', 'nummod'), ('fda', 'nmod'), ('1', 'nummod'), ('-', 'punct'), ('800', 'nummod'), ('-', 'punct'), ('fda-1088', 'compound'), ('www.fda.gov/medwatch', 'compound'), ('drug', 'compound'), ('interact', 'nsubj'), ('•', 'appos'), ('abatacept', 'ROOT'), (':', 'punct'), ('increas', 'compound'), ('risk', 'compound'), ('seriou', 'compound'), ('infect', 'dobj'), ('.', 'punct')]}, {'original_sentence': '(5.1, 5.11, 7.2)  \\n• Anakinra: Increased risk of serious infection.', 'tokens': ['(', '5.1', ',', '5.11', ',', '7.2', ')', '•', 'Anakinra', ':', 'Increased', 'risk', 'serious', 'infection', '.'], 'lemmatized': ['(', '5.1', ',', '5.11', ',', '7.2', ')', '•', 'Anakinra', ':', 'Increased', 'risk', 'serious', 'infection', '.'], 'stemmed': ['(', '5.1', ',', '5.11', ',', '7.2', ')', '•', 'anakinra', ':', 'increas', 'risk', 'seriou', 'infect', '.'], 'dependencies': [('(', 'punct'), ('5.1', 'meta'), (',', 'punct'), ('5.11', 'npadvmod'), (',', 'punct'), ('7.2', 'npadvmod'), (')', 'punct'), ('•', 'nsubj'), ('anakinra', 'ROOT'), (':', 'punct'), ('increas', 'compound'), ('risk', 'compound'), ('seriou', 'compound'), ('infect', 'ccomp'), ('.', 'punct')]}, {'original_sentence': '(5.1, 5.7, 7.2)  \\n• Live vaccines: Avoid use with HUMIRA.', 'tokens': ['(', '5.1', ',', '5.7', ',', '7.2', ')', '•', 'Live', 'vaccines', ':', 'Avoid', 'use', 'HUMIRA', '.'], 'lemmatized': ['(', '5.1', ',', '5.7', ',', '7.2', ')', '•', 'Live', 'vaccine', ':', 'Avoid', 'use', 'HUMIRA', '.'], 'stemmed': ['(', '5.1', ',', '5.7', ',', '7.2', ')', '•', 'live', 'vaccin', ':', 'avoid', 'use', 'humira', '.'], 'dependencies': [('(', 'punct'), ('5.1', 'meta'), (',', 'punct'), ('5.7', 'npadvmod'), (',', 'punct'), ('7.2', 'npadvmod'), (')', 'punct'), ('•', 'nummod'), ('live', 'amod'), ('vaccin', 'dep'), (':', 'punct'), ('avoid', 'ROOT'), ('use', 'dobj'), ('humira', 'dobj'), ('.', 'punct')]}, {'original_sentence': '(5.10, 7.3)  \\n \\nSee 17 for PATIENT COUNSELING INFORMATION and Medication \\nGuide.', 'tokens': ['(', '5.10', ',', '7.3', ')', 'See', '17', 'PATIENT', 'COUNSELING', 'INFORMATION', 'Medication', 'Guide', '.'], 'lemmatized': ['(', '5.10', ',', '7.3', ')', 'See', '17', 'PATIENT', 'COUNSELING', 'INFORMATION', 'Medication', 'Guide', '.'], 'stemmed': ['(', '5.10', ',', '7.3', ')', 'see', '17', 'patient', 'counsel', 'inform', 'medic', 'guid', '.'], 'dependencies': [('(', 'punct'), ('5.10', 'nsubj'), (',', 'punct'), ('7.3', 'appos'), (')', 'punct'), ('see', 'ROOT'), ('17', 'nummod'), ('patient', 'amod'), ('counsel', 'nsubj'), ('inform', 'ccomp'), ('medic', 'compound'), ('guid', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Revised: 2/2024 \\n \\n \\n \\nFULL PRESCRIBING INFORMATION: CONTENTS* \\n \\nWARNING: SERIOUS INFECTIONS AND MALIGNANCY \\n1 INDICATIONS AND USAGE \\n1.1 Rheumatoid Arthritis \\n1.2 Juvenile Idiopathic Arthritis \\n1.3 Psoriatic Arthritis \\n1.4 Ankylosing Spondylitis \\n1.5 Crohn’s Disease \\n1.6 Ulcerative Colitis  \\n1.7 Plaque Psoriasis \\n1.8 Hidradenitis Suppurativa \\n1.9 Uveitis \\n2 DOSAGE AND ADMINISTRATION \\n2.1 Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis \\n2.2 Juvenile Idiopathic Arthritis or Pediatric Uveitis \\n2.3 Crohn’s Disease \\n2.4  Ulcerative Colitis  \\n2.5 Plaque Psoriasis or Adult Uveitis \\n2.6 Hidradenitis Suppurativa \\n2.7 Monitoring to Assess Safety \\n2.8 General Considerations for Administration \\n3 DOSAGE FORMS AND STRENGTHS \\n4 CONTRAINDICATIONS \\n5 WARNINGS AND PRECAUTIONS  \\n5.1 Serious Infections \\n5.2 Malignancies \\n5.3 Hypersensitivity Reactions \\n5.4 Hepatitis B Virus Reactivation \\n5.5 Neurologic Reactions \\n5.6 Hematological Reactions \\n5.7 Increased Risk of Infection When Used with Anakinra \\n5.8 Heart Failure \\n5.9 Autoimmunity \\n5.10 Immunizations \\n5.11 Increased risk of Infection When Used with Abatacept \\n6 ADVERSE REACTIONS \\n6.1 Clinical Trials Experience \\n6.2 Immunogenicity \\n6.3 Postmarketing Experience \\n7 DRUG INTERACTIONS \\n7.1 Methotrexate \\n7.2 Biological Products  \\n7.3 Live Vaccines \\n7.4 Cytochrome P450 Substrates \\n8 USE IN SPECIFIC POPULATIONS \\n8.1 Pregnancy \\n8.2 Lactation \\n8.4 Pediatric Use \\n8.5 Geriatric Use \\n10 OVERDOSAGE \\n11 DESCRIPTION \\n12 CLINICAL PHARMACOLOGY \\n12.1 Mechanism of Action \\n12.2 Pharmacodynamics \\n12.3 Pharmacokinetics \\n13 NONCLINICAL TOXICOLOGY \\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility \\n14 CLINICAL STUDIES \\n14.1 Rheumatoid Arthritis \\n14.2 Juvenile Idiopathic Arthritis \\n14.3 Psoriatic Arthritis \\n14.4 Ankylosing Spondylitis \\n14.5 Adult Crohn’s Disease \\n14.6 Pediatric Crohn’s Disease  \\n14.7 Adult Ulcerative Colitis \\n14.8 Pediatric Ulcerative Colitis \\n14.9 Plaque Psoriasis \\n14.10 Hidradenitis Suppurativa \\n14.11 Adult Uveitis \\n14.12 Pediatric Uveitis \\n15 REFERENCES \\n16 HOW SUPPLIED/STORAGE AND HANDLING \\n17 PATIENT COUNSELING INFORMATION \\n \\n*Sections or subsections omitted from the full prescribing information are not \\nlisted.', 'tokens': ['Revised', ':', '2/2024', 'FULL', 'PRESCRIBING', 'INFORMATION', ':', 'CONTENTS', '*', 'WARNING', ':', 'SERIOUS', 'INFECTIONS', 'MALIGNANCY', '1', 'INDICATIONS', 'USAGE', '1.1', 'Rheumatoid', 'Arthritis', '1.2', 'Juvenile', 'Idiopathic', 'Arthritis', '1.3', 'Psoriatic', 'Arthritis', '1.4', 'Ankylosing', 'Spondylitis', '1.5', 'Crohn', '’', 'Disease', '1.6', 'Ulcerative', 'Colitis', '1.7', 'Plaque', 'Psoriasis', '1.8', 'Hidradenitis', 'Suppurativa', '1.9', 'Uveitis', '2', 'DOSAGE', 'ADMINISTRATION', '2.1', 'Rheumatoid', 'Arthritis', ',', 'Psoriatic', 'Arthritis', ',', 'Ankylosing', 'Spondylitis', '2.2', 'Juvenile', 'Idiopathic', 'Arthritis', 'Pediatric', 'Uveitis', '2.3', 'Crohn', '’', 'Disease', '2.4', 'Ulcerative', 'Colitis', '2.5', 'Plaque', 'Psoriasis', 'Adult', 'Uveitis', '2.6', 'Hidradenitis', 'Suppurativa', '2.7', 'Monitoring', 'Assess', 'Safety', '2.8', 'General', 'Considerations', 'Administration', '3', 'DOSAGE', 'FORMS', 'STRENGTHS', '4', 'CONTRAINDICATIONS', '5', 'WARNINGS', 'PRECAUTIONS', '5.1', 'Serious', 'Infections', '5.2', 'Malignancies', '5.3', 'Hypersensitivity', 'Reactions', '5.4', 'Hepatitis', 'B', 'Virus', 'Reactivation', '5.5', 'Neurologic', 'Reactions', '5.6', 'Hematological', 'Reactions', '5.7', 'Increased', 'Risk', 'Infection', 'Used', 'Anakinra', '5.8', 'Heart', 'Failure', '5.9', 'Autoimmunity', '5.10', 'Immunizations', '5.11', 'Increased', 'risk', 'Infection', 'Used', 'Abatacept', '6', 'ADVERSE', 'REACTIONS', '6.1', 'Clinical', 'Trials', 'Experience', '6.2', 'Immunogenicity', '6.3', 'Postmarketing', 'Experience', '7', 'DRUG', 'INTERACTIONS', '7.1', 'Methotrexate', '7.2', 'Biological', 'Products', '7.3', 'Live', 'Vaccines', '7.4', 'Cytochrome', 'P450', 'Substrates', '8', 'USE', 'SPECIFIC', 'POPULATIONS', '8.1', 'Pregnancy', '8.2', 'Lactation', '8.4', 'Pediatric', 'Use', '8.5', 'Geriatric', 'Use', '10', 'OVERDOSAGE', '11', 'DESCRIPTION', '12', 'CLINICAL', 'PHARMACOLOGY', '12.1', 'Mechanism', 'Action', '12.2', 'Pharmacodynamics', '12.3', 'Pharmacokinetics', '13', 'NONCLINICAL', 'TOXICOLOGY', '13.1', 'Carcinogenesis', ',', 'Mutagenesis', ',', 'Impairment', 'Fertility', '14', 'CLINICAL', 'STUDIES', '14.1', 'Rheumatoid', 'Arthritis', '14.2', 'Juvenile', 'Idiopathic', 'Arthritis', '14.3', 'Psoriatic', 'Arthritis', '14.4', 'Ankylosing', 'Spondylitis', '14.5', 'Adult', 'Crohn', '’', 'Disease', '14.6', 'Pediatric', 'Crohn', '’', 'Disease', '14.7', 'Adult', 'Ulcerative', 'Colitis', '14.8', 'Pediatric', 'Ulcerative', 'Colitis', '14.9', 'Plaque', 'Psoriasis', '14.10', 'Hidradenitis', 'Suppurativa', '14.11', 'Adult', 'Uveitis', '14.12', 'Pediatric', 'Uveitis', '15', 'REFERENCES', '16', 'SUPPLIED/STORAGE', 'HANDLING', '17', 'PATIENT', 'COUNSELING', 'INFORMATION', '*', 'Sections', 'subsections', 'omitted', 'full', 'prescribing', 'information', 'listed', '.'], 'lemmatized': ['Revised', ':', '2/2024', 'FULL', 'PRESCRIBING', 'INFORMATION', ':', 'CONTENTS', '*', 'WARNING', ':', 'SERIOUS', 'INFECTIONS', 'MALIGNANCY', '1', 'INDICATIONS', 'USAGE', '1.1', 'Rheumatoid', 'Arthritis', '1.2', 'Juvenile', 'Idiopathic', 'Arthritis', '1.3', 'Psoriatic', 'Arthritis', '1.4', 'Ankylosing', 'Spondylitis', '1.5', 'Crohn', '’', 'Disease', '1.6', 'Ulcerative', 'Colitis', '1.7', 'Plaque', 'Psoriasis', '1.8', 'Hidradenitis', 'Suppurativa', '1.9', 'Uveitis', '2', 'DOSAGE', 'ADMINISTRATION', '2.1', 'Rheumatoid', 'Arthritis', ',', 'Psoriatic', 'Arthritis', ',', 'Ankylosing', 'Spondylitis', '2.2', 'Juvenile', 'Idiopathic', 'Arthritis', 'Pediatric', 'Uveitis', '2.3', 'Crohn', '’', 'Disease', '2.4', 'Ulcerative', 'Colitis', '2.5', 'Plaque', 'Psoriasis', 'Adult', 'Uveitis', '2.6', 'Hidradenitis', 'Suppurativa', '2.7', 'Monitoring', 'Assess', 'Safety', '2.8', 'General', 'Considerations', 'Administration', '3', 'DOSAGE', 'FORMS', 'STRENGTHS', '4', 'CONTRAINDICATIONS', '5', 'WARNINGS', 'PRECAUTIONS', '5.1', 'Serious', 'Infections', '5.2', 'Malignancies', '5.3', 'Hypersensitivity', 'Reactions', '5.4', 'Hepatitis', 'B', 'Virus', 'Reactivation', '5.5', 'Neurologic', 'Reactions', '5.6', 'Hematological', 'Reactions', '5.7', 'Increased', 'Risk', 'Infection', 'Used', 'Anakinra', '5.8', 'Heart', 'Failure', '5.9', 'Autoimmunity', '5.10', 'Immunizations', '5.11', 'Increased', 'risk', 'Infection', 'Used', 'Abatacept', '6', 'ADVERSE', 'REACTIONS', '6.1', 'Clinical', 'Trials', 'Experience', '6.2', 'Immunogenicity', '6.3', 'Postmarketing', 'Experience', '7', 'DRUG', 'INTERACTIONS', '7.1', 'Methotrexate', '7.2', 'Biological', 'Products', '7.3', 'Live', 'Vaccines', '7.4', 'Cytochrome', 'P450', 'Substrates', '8', 'USE', 'SPECIFIC', 'POPULATIONS', '8.1', 'Pregnancy', '8.2', 'Lactation', '8.4', 'Pediatric', 'Use', '8.5', 'Geriatric', 'Use', '10', 'OVERDOSAGE', '11', 'DESCRIPTION', '12', 'CLINICAL', 'PHARMACOLOGY', '12.1', 'Mechanism', 'Action', '12.2', 'Pharmacodynamics', '12.3', 'Pharmacokinetics', '13', 'NONCLINICAL', 'TOXICOLOGY', '13.1', 'Carcinogenesis', ',', 'Mutagenesis', ',', 'Impairment', 'Fertility', '14', 'CLINICAL', 'STUDIES', '14.1', 'Rheumatoid', 'Arthritis', '14.2', 'Juvenile', 'Idiopathic', 'Arthritis', '14.3', 'Psoriatic', 'Arthritis', '14.4', 'Ankylosing', 'Spondylitis', '14.5', 'Adult', 'Crohn', '’', 'Disease', '14.6', 'Pediatric', 'Crohn', '’', 'Disease', '14.7', 'Adult', 'Ulcerative', 'Colitis', '14.8', 'Pediatric', 'Ulcerative', 'Colitis', '14.9', 'Plaque', 'Psoriasis', '14.10', 'Hidradenitis', 'Suppurativa', '14.11', 'Adult', 'Uveitis', '14.12', 'Pediatric', 'Uveitis', '15', 'REFERENCES', '16', 'SUPPLIED/STORAGE', 'HANDLING', '17', 'PATIENT', 'COUNSELING', 'INFORMATION', '*', 'Sections', 'subsection', 'omitted', 'full', 'prescribing', 'information', 'listed', '.'], 'stemmed': ['revis', ':', '2/2024', 'full', 'prescrib', 'inform', ':', 'content', '*', 'warn', ':', 'seriou', 'infect', 'malign', '1', 'indic', 'usag', '1.1', 'rheumatoid', 'arthriti', '1.2', 'juvenil', 'idiopath', 'arthriti', '1.3', 'psoriat', 'arthriti', '1.4', 'ankylos', 'spondyl', '1.5', 'crohn', '’', 'diseas', '1.6', 'ulcer', 'coliti', '1.7', 'plaqu', 'psoriasi', '1.8', 'hidraden', 'suppurativa', '1.9', 'uveiti', '2', 'dosag', 'administr', '2.1', 'rheumatoid', 'arthriti', ',', 'psoriat', 'arthriti', ',', 'ankylos', 'spondyl', '2.2', 'juvenil', 'idiopath', 'arthriti', 'pediatr', 'uveiti', '2.3', 'crohn', '’', 'diseas', '2.4', 'ulcer', 'coliti', '2.5', 'plaqu', 'psoriasi', 'adult', 'uveiti', '2.6', 'hidraden', 'suppurativa', '2.7', 'monitor', 'assess', 'safeti', '2.8', 'gener', 'consider', 'administr', '3', 'dosag', 'form', 'strength', '4', 'contraind', '5', 'warn', 'precaut', '5.1', 'seriou', 'infect', '5.2', 'malign', '5.3', 'hypersensit', 'reaction', '5.4', 'hepat', 'b', 'viru', 'reactiv', '5.5', 'neurolog', 'reaction', '5.6', 'hematolog', 'reaction', '5.7', 'increas', 'risk', 'infect', 'use', 'anakinra', '5.8', 'heart', 'failur', '5.9', 'autoimmun', '5.10', 'immun', '5.11', 'increas', 'risk', 'infect', 'use', 'abatacept', '6', 'advers', 'reaction', '6.1', 'clinic', 'trial', 'experi', '6.2', 'immunogen', '6.3', 'postmarket', 'experi', '7', 'drug', 'interact', '7.1', 'methotrex', '7.2', 'biolog', 'product', '7.3', 'live', 'vaccin', '7.4', 'cytochrom', 'p450', 'substrat', '8', 'use', 'specif', 'popul', '8.1', 'pregnanc', '8.2', 'lactat', '8.4', 'pediatr', 'use', '8.5', 'geriatr', 'use', '10', 'overdosag', '11', 'descript', '12', 'clinic', 'pharmacolog', '12.1', 'mechan', 'action', '12.2', 'pharmacodynam', '12.3', 'pharmacokinet', '13', 'nonclin', 'toxicolog', '13.1', 'carcinogenesi', ',', 'mutagenesi', ',', 'impair', 'fertil', '14', 'clinic', 'studi', '14.1', 'rheumatoid', 'arthriti', '14.2', 'juvenil', 'idiopath', 'arthriti', '14.3', 'psoriat', 'arthriti', '14.4', 'ankylos', 'spondyl', '14.5', 'adult', 'crohn', '’', 'diseas', '14.6', 'pediatr', 'crohn', '’', 'diseas', '14.7', 'adult', 'ulcer', 'coliti', '14.8', 'pediatr', 'ulcer', 'coliti', '14.9', 'plaqu', 'psoriasi', '14.10', 'hidraden', 'suppurativa', '14.11', 'adult', 'uveiti', '14.12', 'pediatr', 'uveiti', '15', 'refer', '16', 'supplied/storag', 'handl', '17', 'patient', 'counsel', 'inform', '*', 'section', 'subsect', 'omit', 'full', 'prescrib', 'inform', 'list', '.'], 'dependencies': [('revis', 'dep'), (':', 'punct'), ('2/2024', 'nummod'), ('full', 'amod'), ('prescrib', 'compound'), ('inform', 'appos'), (':', 'punct'), ('content', 'appos'), ('*', 'punct'), ('warn', 'ROOT'), (':', 'punct'), ('seriou', 'npadvmod'), ('infect', 'ccomp'), ('malign', 'nmod'), ('1', 'nummod'), ('indic', 'amod'), ('usag', 'nmod'), ('1.1', 'nummod'), ('rheumatoid', 'amod'), ('arthriti', 'dobj'), ('1.2', 'nummod'), ('juvenil', 'nmod'), ('idiopath', 'nmod'), ('arthriti', 'compound'), ('1.3', 'nummod'), ('psoriat', 'compound'), ('arthriti', 'nmod'), ('1.4', 'nummod'), ('ankylos', 'compound'), ('spondyl', 'nmod'), ('1.5', 'nummod'), ('crohn', 'npadvmod'), ('’', 'punct'), ('diseas', 'ROOT'), ('1.6', 'nummod'), ('ulcer', 'npadvmod'), ('coliti', 'compound'), ('1.7', 'nummod'), ('plaqu', 'compound'), ('psoriasi', 'nmod'), ('1.8', 'nummod'), ('hidraden', 'compound'), ('suppurativa', 'nmod'), ('1.9', 'nummod'), ('uveiti', 'nmod'), ('2', 'nummod'), ('dosag', 'compound'), ('administr', 'appos'), ('2.1', 'nummod'), ('rheumatoid', 'amod'), ('arthriti', 'appos'), (',', 'punct'), ('psoriat', 'compound'), ('arthriti', 'appos'), (',', 'punct'), ('ankylos', 'compound'), ('spondyl', 'conj'), ('2.2', 'nummod'), ('juvenil', 'compound'), ('idiopath', 'compound'), ('arthriti', 'compound'), ('pediatr', 'nsubj'), ('uveiti', 'ROOT'), ('2.3', 'nummod'), ('crohn', 'nmod'), ('’', 'punct'), ('diseas', 'dobj'), ('2.4', 'nummod'), ('ulcer', 'npadvmod'), ('coliti', 'prep'), ('2.5', 'nummod'), ('plaqu', 'compound'), ('psoriasi', 'compound'), ('adult', 'compound'), ('uveiti', 'npadvmod'), ('2.6', 'nummod'), ('hidraden', 'nmod'), ('suppurativa', 'nmod'), ('2.7', 'nummod'), ('monitor', 'compound'), ('assess', 'compound'), ('safeti', 'appos'), ('2.8', 'nummod'), ('gener', 'nsubj'), ('consider', 'xcomp'), ('administr', 'nsubj'), ('3', 'nummod'), ('dosag', 'compound'), ('form', 'compound'), ('strength', 'ccomp'), ('4', 'nummod'), ('contraind', 'amod'), ('5', 'nummod'), ('warn', 'nmod'), ('precaut', 'dative'), ('5.1', 'nummod'), ('seriou', 'nsubj'), ('infect', 'ccomp'), ('5.2', 'nummod'), ('malign', 'nmod'), ('5.3', 'nummod'), ('hypersensit', 'compound'), ('reaction', 'dobj'), ('5.4', 'nummod'), ('hepat', 'compound'), ('b', 'compound'), ('viru', 'compound'), ('reactiv', 'appos'), ('5.5', 'nummod'), ('neurolog', 'nmod'), ('reaction', 'nmod'), ('5.6', 'nummod'), ('hematolog', 'compound'), ('reaction', 'appos'), ('5.7', 'nummod'), ('increas', 'compound'), ('risk', 'compound'), ('infect', 'compound'), ('use', 'nsubj'), ('anakinra', 'ccomp'), ('5.8', 'nummod'), ('heart', 'compound'), ('failur', 'nmod'), ('5.9', 'nummod'), ('autoimmun', 'amod'), ('5.10', 'nummod'), ('immun', 'nmod'), ('5.11', 'nummod'), ('increas', 'compound'), ('risk', 'compound'), ('infect', 'compound'), ('use', 'nsubj'), ('abatacept', 'ccomp'), ('6', 'nummod'), ('advers', 'compound'), ('reaction', 'xcomp'), ('6.1', 'nummod'), ('clinic', 'compound'), ('trial', 'dobj'), ('experi', 'acl'), ('6.2', 'nummod'), ('immunogen', 'nmod'), ('6.3', 'nummod'), ('postmarket', 'nmod'), ('experi', 'amod'), ('7', 'nummod'), ('drug', 'compound'), ('interact', 'dobj'), ('7.1', 'nummod'), ('methotrex', 'compound'), ('7.2', 'nummod'), ('biolog', 'compound'), ('product', 'appos'), ('7.3', 'nummod'), ('live', 'advmod'), ('vaccin', 'advcl'), ('7.4', 'nummod'), ('cytochrom', 'npadvmod'), ('p450', 'compound'), ('substrat', 'nsubj'), ('8', 'nummod'), ('use', 'nmod'), ('specif', 'compound'), ('popul', 'dobj'), ('8.1', 'nummod'), ('pregnanc', 'npadvmod'), ('8.2', 'nummod'), ('lactat', 'npadvmod'), ('8.4', 'nummod'), ('pediatr', 'advmod'), ('use', 'xcomp'), ('8.5', 'nummod'), ('geriatr', 'compound'), ('use', 'dobj'), ('10', 'nummod'), ('overdosag', 'amod'), ('11', 'nummod'), ('descript', 'nmod'), ('12', 'nummod'), ('clinic', 'compound'), ('pharmacolog', 'dobj'), ('12.1', 'nummod'), ('mechan', 'compound'), ('action', 'ROOT'), ('12.2', 'nummod'), ('pharmacodynam', 'appos'), ('12.3', 'nummod'), ('pharmacokinet', 'appos'), ('13', 'nummod'), ('nonclin', 'compound'), ('toxicolog', 'appos'), ('13.1', 'nummod'), ('carcinogenesi', 'appos'), (',', 'punct'), ('mutagenesi', 'conj'), (',', 'punct'), ('impair', 'nmod'), ('fertil', 'nmod'), ('14', 'nummod'), ('clinic', 'nmod'), ('studi', 'appos'), ('14.1', 'appos'), ('rheumatoid', 'nmod'), ('arthriti', 'npadvmod'), ('14.2', 'nummod'), ('juvenil', 'compound'), ('idiopath', 'compound'), ('arthriti', 'nmod'), ('14.3', 'nummod'), ('psoriat', 'compound'), ('arthriti', 'nmod'), ('14.4', 'nummod'), ('ankylos', 'npadvmod'), ('spondyl', 'appos'), ('14.5', 'nummod'), ('adult', 'compound'), ('crohn', 'appos'), ('’', 'punct'), ('diseas', 'nmod'), ('14.6', 'nummod'), ('pediatr', 'amod'), ('crohn', 'appos'), ('’', 'punct'), ('diseas', 'nsubj'), ('14.7', 'nummod'), ('adult', 'compound'), ('ulcer', 'npadvmod'), ('coliti', 'xcomp'), ('14.8', 'nummod'), ('pediatr', 'amod'), ('ulcer', 'npadvmod'), ('coliti', 'prep'), ('14.9', 'nummod'), ('plaqu', 'compound'), ('psoriasi', 'nmod'), ('14.10', 'nummod'), ('hidraden', 'nmod'), ('suppurativa', 'nmod'), ('14.11', 'nummod'), ('adult', 'compound'), ('uveiti', 'appos'), ('14.12', 'nummod'), ('pediatr', 'amod'), ('uveiti', 'conj'), ('15', 'nummod'), ('refer', 'nsubj'), ('16', 'nummod'), ('supplied', 'amod'), ('/', 'punct'), ('storag', 'compound'), ('handl', 'nmod'), ('17', 'nummod'), ('patient', 'amod'), ('counsel', 'compound'), ('inform', 'ROOT'), ('*', 'punct'), ('section', 'compound'), ('subsect', 'compound'), ('omit', 'dobj'), ('full', 'amod'), ('prescrib', 'compound'), ('inform', 'compound'), ('list', 'dobj'), ('.', 'punct')]}], 'text': '  \\n WARNINGS AND PRECAUTIONS  \\n• Serious infections: Do not start HUMIRA during an active infection. If an \\ninfection develops, monitor carefully, and stop HUMIRA if infection \\nbecomes serious. (5.1) \\n• Invasive fungal infections: For patients who develop a systemic illness on \\nHUMIRA, consider empiric antifungal therapy for those who reside or \\ntravel to regions where mycoses are endemic. (5.1) \\n• Malignancies: Incidence of malignancies was greater in HUMIRA-treated \\npatients than in controls (5.2) \\n• Anaphylaxis or serious hypersensitivity reactions may occur (5.3) \\n• Hepatitis B virus reactivation: Monitor HBV carriers during and several \\nmonths after therapy. If reactivation occurs, stop HUMIRA and begin anti-\\nviral therapy. (5.4) \\n• Demyelinating disease: Exacerbation or new onset, may occur. (5.5) \\n• Cytopenias, pancytopenia: Advise patients to seek immediate medical \\nattention if symptoms develop, and consider stopping HUMIRA. (5.6) \\n• Heart failure: Worsening or new onset, may occur. (5.8) \\n• Lupus-like syndrome: Stop HUMIRA if syndrome develops. (5.9) \\n  \\n ADVERSE REACTIONS  \\nMost common adverse reactions (>10%) are: infections (e.g. upper \\nrespiratory, sinusitis), injection site reactions, headache and rash. (6.1) \\n \\nTo report SUSPECTED ADVERSE REACTIONS, contact AbbVie Inc. \\nat 1-800-633-9110 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch \\n  \\n DRUG INTERACTIONS  \\n• Abatacept: Increased risk of serious infection. (5.1, 5.11, 7.2)  \\n• Anakinra: Increased risk of serious infection. (5.1, 5.7, 7.2)  \\n• Live vaccines: Avoid use with HUMIRA. (5.10, 7.3)  \\n \\nSee 17 for PATIENT COUNSELING INFORMATION and Medication \\nGuide. \\n \\nRevised: 2/2024 \\n \\n \\n \\nFULL PRESCRIBING INFORMATION: CONTENTS* \\n \\nWARNING: SERIOUS INFECTIONS AND MALIGNANCY \\n1 INDICATIONS AND USAGE \\n1.1 Rheumatoid Arthritis \\n1.2 Juvenile Idiopathic Arthritis \\n1.3 Psoriatic Arthritis \\n1.4 Ankylosing Spondylitis \\n1.5 Crohn’s Disease \\n1.6 Ulcerative Colitis  \\n1.7 Plaque Psoriasis \\n1.8 Hidradenitis Suppurativa \\n1.9 Uveitis \\n2 DOSAGE AND ADMINISTRATION \\n2.1 Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis \\n2.2 Juvenile Idiopathic Arthritis or Pediatric Uveitis \\n2.3 Crohn’s Disease \\n2.4  Ulcerative Colitis  \\n2.5 Plaque Psoriasis or Adult Uveitis \\n2.6 Hidradenitis Suppurativa \\n2.7 Monitoring to Assess Safety \\n2.8 General Considerations for Administration \\n3 DOSAGE FORMS AND STRENGTHS \\n4 CONTRAINDICATIONS \\n5 WARNINGS AND PRECAUTIONS  \\n5.1 Serious Infections \\n5.2 Malignancies \\n5.3 Hypersensitivity Reactions \\n5.4 Hepatitis B Virus Reactivation \\n5.5 Neurologic Reactions \\n5.6 Hematological Reactions \\n5.7 Increased Risk of Infection When Used with Anakinra \\n5.8 Heart Failure \\n5.9 Autoimmunity \\n5.10 Immunizations \\n5.11 Increased risk of Infection When Used with Abatacept \\n6 ADVERSE REACTIONS \\n6.1 Clinical Trials Experience \\n6.2 Immunogenicity \\n6.3 Postmarketing Experience \\n7 DRUG INTERACTIONS \\n7.1 Methotrexate \\n7.2 Biological Products  \\n7.3 Live Vaccines \\n7.4 Cytochrome P450 Substrates \\n8 USE IN SPECIFIC POPULATIONS \\n8.1 Pregnancy \\n8.2 Lactation \\n8.4 Pediatric Use \\n8.5 Geriatric Use \\n10 OVERDOSAGE \\n11 DESCRIPTION \\n12 CLINICAL PHARMACOLOGY \\n12.1 Mechanism of Action \\n12.2 Pharmacodynamics \\n12.3 Pharmacokinetics \\n13 NONCLINICAL TOXICOLOGY \\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility \\n14 CLINICAL STUDIES \\n14.1 Rheumatoid Arthritis \\n14.2 Juvenile Idiopathic Arthritis \\n14.3 Psoriatic Arthritis \\n14.4 Ankylosing Spondylitis \\n14.5 Adult Crohn’s Disease \\n14.6 Pediatric Crohn’s Disease  \\n14.7 Adult Ulcerative Colitis \\n14.8 Pediatric Ulcerative Colitis \\n14.9 Plaque Psoriasis \\n14.10 Hidradenitis Suppurativa \\n14.11 Adult Uveitis \\n14.12 Pediatric Uveitis \\n15 REFERENCES \\n16 HOW SUPPLIED/STORAGE AND HANDLING \\n17 PATIENT COUNSELING INFORMATION \\n \\n*Sections or subsections omitted from the full prescribing information are not \\nlisted.  \\n   \\n \\n'}, 'page_char_count': 3879, 'page_word_count': 503, 'sentences': ['  \\n WARNINGS AND PRECAUTIONS  \\n• Serious infections: Do not start HUMIRA during an active infection.', 'If an \\ninfection develops, monitor carefully, and stop HUMIRA if infection \\nbecomes serious. (', '5.1) \\n• Invasive fungal infections: For patients who develop a systemic illness on \\nHUMIRA, consider empiric antifungal therapy for those who reside or \\ntravel to regions where mycoses are endemic. (', '5.1) \\n• Malignancies: Incidence of malignancies was greater in HUMIRA-treated \\npatients than in controls (5.2) \\n• Anaphylaxis or serious hypersensitivity reactions may occur (5.3) \\n• Hepatitis B virus reactivation: Monitor HBV carriers during and several \\nmonths after therapy.', 'If reactivation occurs, stop HUMIRA and begin anti-\\nviral therapy. (', '5.4) \\n• Demyelinating disease: Exacerbation or new onset, may occur. (', '5.5) \\n• Cytopenias, pancytopenia: Advise patients to seek immediate medical \\nattention if symptoms develop, and consider stopping HUMIRA. (', '5.6) \\n• Heart failure: Worsening or new onset, may occur. (', '5.8) \\n• Lupus-like syndrome: Stop HUMIRA if syndrome develops. (', '5.9) \\n  \\n ADVERSE REACTIONS  \\nMost common adverse reactions (>10%) are: infections (e.g. upper \\nrespiratory, sinusitis), injection site reactions, headache and rash. (', '6.1) \\n \\nTo report SUSPECTED ADVERSE REACTIONS, contact AbbVie Inc. \\nat 1-800-633-9110 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch \\n  \\n DRUG INTERACTIONS  \\n• Abatacept: Increased risk of serious infection. (', '5.1, 5.11, 7.2)  \\n• Anakinra: Increased risk of serious infection. (', '5.1, 5.7, 7.2)  \\n• Live vaccines: Avoid use with HUMIRA. (', '5.10, 7.3)  \\n \\nSee 17 for PATIENT COUNSELING INFORMATION and Medication \\nGuide.', '\\n \\nRevised: 2/2024 \\n \\n \\n \\nFULL PRESCRIBING INFORMATION: CONTENTS* \\n \\nWARNING: SERIOUS INFECTIONS AND MALIGNANCY \\n1 INDICATIONS AND USAGE \\n1.1 Rheumatoid Arthritis \\n1.2 Juvenile Idiopathic Arthritis \\n1.3 Psoriatic Arthritis \\n1.4 Ankylosing Spondylitis \\n1.5 Crohn’s Disease \\n1.6 Ulcerative Colitis  \\n1.7 Plaque Psoriasis \\n1.8 Hidradenitis Suppurativa \\n1.9 Uveitis \\n2 DOSAGE AND ADMINISTRATION \\n2.1 Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis \\n2.2 Juvenile Idiopathic Arthritis or Pediatric Uveitis \\n2.3 Crohn’s Disease \\n2.4  Ulcerative Colitis  \\n2.5 Plaque Psoriasis or Adult Uveitis \\n2.6 Hidradenitis Suppurativa \\n2.7 Monitoring to Assess Safety \\n2.8 General Considerations for Administration \\n3 DOSAGE FORMS AND STRENGTHS \\n4 CONTRAINDICATIONS \\n5 WARNINGS AND PRECAUTIONS  \\n5.1 Serious Infections \\n5.2 Malignancies \\n5.3 Hypersensitivity Reactions \\n5.4 Hepatitis B Virus Reactivation \\n5.5 Neurologic Reactions \\n5.6 Hematological Reactions \\n5.7 Increased Risk of Infection When Used with Anakinra \\n5.8 Heart Failure \\n5.9 Autoimmunity \\n5.10 Immunizations \\n5.11 Increased risk of Infection When Used with Abatacept \\n6 ADVERSE REACTIONS \\n6.1 Clinical Trials Experience \\n6.2 Immunogenicity \\n6.3 Postmarketing Experience \\n7 DRUG INTERACTIONS \\n7.1 Methotrexate \\n7.2 Biological Products  \\n7.3 Live Vaccines \\n7.4 Cytochrome P450 Substrates \\n8 USE IN SPECIFIC POPULATIONS \\n8.1 Pregnancy \\n8.2 Lactation \\n8.4 Pediatric Use \\n8.5 Geriatric Use \\n10 OVERDOSAGE \\n11 DESCRIPTION \\n12 CLINICAL PHARMACOLOGY \\n12.1 Mechanism of Action \\n12.2 Pharmacodynamics \\n12.3 Pharmacokinetics \\n13 NONCLINICAL TOXICOLOGY \\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility \\n14 CLINICAL STUDIES \\n14.1 Rheumatoid Arthritis \\n14.2 Juvenile Idiopathic Arthritis \\n14.3 Psoriatic Arthritis \\n14.4 Ankylosing Spondylitis \\n14.5 Adult Crohn’s Disease \\n14.6 Pediatric Crohn’s Disease  \\n14.7 Adult Ulcerative Colitis \\n14.8 Pediatric Ulcerative Colitis \\n14.9 Plaque Psoriasis \\n14.10 Hidradenitis Suppurativa \\n14.11 Adult Uveitis \\n14.12 Pediatric Uveitis \\n15 REFERENCES \\n16 HOW SUPPLIED/STORAGE AND HANDLING \\n17 PATIENT COUNSELING INFORMATION \\n \\n*Sections or subsections omitted from the full prescribing information are not \\nlisted.', ' \\n   \\n \\n'], 'page_sentence_count_spacy': 16}\n",
            "{'page_number': 3, 'text': \"FULL PRESCRIBING INFORMATION \\nWARNING: SERIOUS INFECTIONS AND MALIGNANCY \\nSERIOUS INFECTIONS \\nPatients treated with HUMIRA are at increased risk for developing serious infections \\nthat may lead to hospitalization or death [see Warnings and Precautions (5.1)]. Most \\npatients who developed these infections were taking concomitant immunosuppressants \\nsuch as methotrexate or corticosteroids. \\nDiscontinue HUMIRA if a patient develops a serious infection or sepsis. \\nReported infections include: \\n• Active tuberculosis (TB), including reactivation of latent TB. Patients with TB \\nhave frequently presented with disseminated or extrapulmonary disease. Test \\npatients for latent TB before HUMIRA use and during therapy. Initiate \\ntreatment for latent TB prior to HUMIRA use. \\n• Invasive fungal infections, including histoplasmosis, coccidioidomycosis, \\ncandidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with \\nhistoplasmosis or other invasive fungal infections may present with disseminated, \\nrather than localized, disease. Antigen and antibody testing for histoplasmosis \\nmay be negative in some patients with active infection. Consider empiric anti-\\nfungal therapy in patients at risk for invasive fungal infections who develop \\nsevere systemic illness. \\n• Bacterial, viral and other infections due to opportunistic pathogens, including \\nLegionella and Listeria. \\n  \\nCarefully consider the risks and benefits of treatment with HUMIRA prior to initiating \\ntherapy in patients with chronic or recurrent infection. \\nMonitor patients closely for the development of signs and symptoms of infection during \\nand after treatment with HUMIRA, including the possible development of TB in \\npatients who tested negative for latent TB infection prior to initiating therapy [see \\nWarnings and Precautions (5.1) and Adverse Reactions (6.1)]. \\nMALIGNANCY \\nLymphoma and other malignancies, some fatal, have been reported in children and \\nadolescent patients treated with TNF blockers including HUMIRA [see Warnings and \\nPrecautions (5.2)]. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a \\nrare type of T-cell lymphoma, have been reported in patients treated with TNF blockers \\nincluding HUMIRA. These cases have had a very aggressive disease course and have \\nbeen fatal. The majority of reported TNF blocker cases have occurred in patients with \\nCrohn's disease or ulcerative colitis and the majority were in adolescent and young adult \\nmales. Almost all these patients had received treatment with azathioprine or 6-\\nmercaptopurine (6–MP) concomitantly with a TNF blocker at or prior to diagnosis. It is \\nuncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF \\n\", 'processed_text': {'sentences': [{'original_sentence': 'FULL PRESCRIBING INFORMATION \\nWARNING: SERIOUS INFECTIONS AND MALIGNANCY \\nSERIOUS INFECTIONS \\nPatients treated with HUMIRA are at increased risk for developing serious infections \\nthat may lead to hospitalization or death [see Warnings and Precautions (5.1)].', 'tokens': ['FULL', 'PRESCRIBING', 'INFORMATION', 'WARNING', ':', 'SERIOUS', 'INFECTIONS', 'MALIGNANCY', 'SERIOUS', 'INFECTIONS', 'Patients', 'treated', 'HUMIRA', 'increased', 'risk', 'developing', 'serious', 'infections', 'may', 'lead', 'hospitalization', 'death', '[', 'see', 'Warnings', 'Precautions', '(', '5.1', ')', ']', '.'], 'lemmatized': ['FULL', 'PRESCRIBING', 'INFORMATION', 'WARNING', ':', 'SERIOUS', 'INFECTIONS', 'MALIGNANCY', 'SERIOUS', 'INFECTIONS', 'Patients', 'treated', 'HUMIRA', 'increased', 'risk', 'developing', 'serious', 'infection', 'may', 'lead', 'hospitalization', 'death', '[', 'see', 'Warnings', 'Precautions', '(', '5.1', ')', ']', '.'], 'stemmed': ['full', 'prescrib', 'inform', 'warn', ':', 'seriou', 'infect', 'malign', 'seriou', 'infect', 'patient', 'treat', 'humira', 'increas', 'risk', 'develop', 'seriou', 'infect', 'may', 'lead', 'hospit', 'death', '[', 'see', 'warn', 'precaut', '(', '5.1', ')', ']', '.'], 'dependencies': [('full', 'amod'), ('prescrib', 'compound'), ('inform', 'nsubj'), ('warn', 'ROOT'), (':', 'punct'), ('seriou', 'npadvmod'), ('infect', 'compound'), ('malign', 'compound'), ('seriou', 'nsubj'), ('infect', 'compound'), ('patient', 'compound'), ('treat', 'compound'), ('humira', 'compound'), ('increas', 'compound'), ('risk', 'nsubj'), ('develop', 'ccomp'), ('seriou', 'compound'), ('infect', 'dobj'), ('may', 'aux'), ('lead', 'ccomp'), ('hospit', 'compound'), ('death', 'dobj'), ('[', 'punct'), ('see', 'parataxis'), ('warn', 'dep'), ('precaut', 'dobj'), ('(', 'punct'), ('5.1', 'dobj'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Most \\npatients who developed these infections were taking concomitant immunosuppressants \\nsuch as methotrexate or corticosteroids.', 'tokens': ['patients', 'developed', 'infections', 'taking', 'concomitant', 'immunosuppressants', 'methotrexate', 'corticosteroids', '.'], 'lemmatized': ['patient', 'developed', 'infection', 'taking', 'concomitant', 'immunosuppressant', 'methotrexate', 'corticosteroid', '.'], 'stemmed': ['patient', 'develop', 'infect', 'take', 'concomit', 'immunosuppress', 'methotrex', 'corticosteroid', '.'], 'dependencies': [('patient', 'nsubj'), ('develop', 'ROOT'), ('infect', 'amod'), ('take', 'compound'), ('concomit', 'compound'), ('immunosuppress', 'compound'), ('methotrex', 'compound'), ('corticosteroid', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Discontinue HUMIRA if a patient develops a serious infection or sepsis.', 'tokens': ['Discontinue', 'HUMIRA', 'patient', 'develops', 'serious', 'infection', 'sepsis', '.'], 'lemmatized': ['Discontinue', 'HUMIRA', 'patient', 'develops', 'serious', 'infection', 'sepsis', '.'], 'stemmed': ['discontinu', 'humira', 'patient', 'develop', 'seriou', 'infect', 'sepsi', '.'], 'dependencies': [('discontinu', 'compound'), ('humira', 'compound'), ('patient', 'nsubj'), ('develop', 'ROOT'), ('seriou', 'compound'), ('infect', 'compound'), ('sepsi', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Reported infections include: \\n• Active tuberculosis (TB), including reactivation of latent TB.', 'tokens': ['Reported', 'infections', 'include', ':', '•', 'Active', 'tuberculosis', '(', 'TB', ')', ',', 'including', 'reactivation', 'latent', 'TB', '.'], 'lemmatized': ['Reported', 'infection', 'include', ':', '•', 'Active', 'tuberculosis', '(', 'TB', ')', ',', 'including', 'reactivation', 'latent', 'TB', '.'], 'stemmed': ['report', 'infect', 'includ', ':', '•', 'activ', 'tuberculosi', '(', 'tb', ')', ',', 'includ', 'reactiv', 'latent', 'tb', '.'], 'dependencies': [('report', 'ROOT'), ('infect', 'compound'), ('includ', 'dobj'), (':', 'punct'), ('•', 'nummod'), ('activ', 'compound'), ('tuberculosi', 'dobj'), ('(', 'punct'), ('tb', 'appos'), (')', 'punct'), (',', 'punct'), ('includ', 'compound'), ('reactiv', 'compound'), ('latent', 'compound'), ('tb', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Patients with TB \\nhave frequently presented with disseminated or extrapulmonary disease.', 'tokens': ['Patients', 'TB', 'frequently', 'presented', 'disseminated', 'extrapulmonary', 'disease', '.'], 'lemmatized': ['Patients', 'TB', 'frequently', 'presented', 'disseminated', 'extrapulmonary', 'disease', '.'], 'stemmed': ['patient', 'tb', 'frequent', 'present', 'dissemin', 'extrapulmonari', 'diseas', '.'], 'dependencies': [('patient', 'ROOT'), ('tb', 'prep'), ('frequent', 'amod'), ('present', 'amod'), ('dissemin', 'compound'), ('extrapulmonari', 'compound'), ('diseas', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'Test \\npatients for latent TB before HUMIRA use and during therapy.', 'tokens': ['Test', 'patients', 'latent', 'TB', 'HUMIRA', 'use', 'therapy', '.'], 'lemmatized': ['Test', 'patient', 'latent', 'TB', 'HUMIRA', 'use', 'therapy', '.'], 'stemmed': ['test', 'patient', 'latent', 'tb', 'humira', 'use', 'therapi', '.'], 'dependencies': [('test', 'compound'), ('patient', 'compound'), ('latent', 'nsubj'), ('tb', 'prep'), ('humira', 'compound'), ('use', 'pobj'), ('therapi', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Initiate \\ntreatment for latent TB prior to HUMIRA use.', 'tokens': ['Initiate', 'treatment', 'latent', 'TB', 'prior', 'HUMIRA', 'use', '.'], 'lemmatized': ['Initiate', 'treatment', 'latent', 'TB', 'prior', 'HUMIRA', 'use', '.'], 'stemmed': ['initi', 'treatment', 'latent', 'tb', 'prior', 'humira', 'use', '.'], 'dependencies': [('initi', 'compound'), ('treatment', 'compound'), ('latent', 'ROOT'), ('tb', 'prep'), ('prior', 'amod'), ('humira', 'compound'), ('use', 'pobj'), ('.', 'punct')]}, {'original_sentence': '• Invasive fungal infections, including histoplasmosis, coccidioidomycosis, \\ncandidiasis, aspergillosis, blastomycosis, and pneumocystosis.', 'tokens': ['•', 'Invasive', 'fungal', 'infections', ',', 'including', 'histoplasmosis', ',', 'coccidioidomycosis', ',', 'candidiasis', ',', 'aspergillosis', ',', 'blastomycosis', ',', 'pneumocystosis', '.'], 'lemmatized': ['•', 'Invasive', 'fungal', 'infection', ',', 'including', 'histoplasmosis', ',', 'coccidioidomycosis', ',', 'candidiasis', ',', 'aspergillosis', ',', 'blastomycosis', ',', 'pneumocystosis', '.'], 'stemmed': ['•', 'invas', 'fungal', 'infect', ',', 'includ', 'histoplasmosi', ',', 'coccidioidomycosi', ',', 'candidiasi', ',', 'aspergillosi', ',', 'blastomycosi', ',', 'pneumocystosi', '.'], 'dependencies': [('•', 'nummod'), ('invas', 'compound'), ('fungal', 'compound'), ('infect', 'ROOT'), (',', 'punct'), ('includ', 'amod'), ('histoplasmosi', 'conj'), (',', 'punct'), ('coccidioidomycosi', 'conj'), (',', 'punct'), ('candidiasi', 'conj'), (',', 'punct'), ('aspergillosi', 'nmod'), (',', 'punct'), ('blastomycosi', 'conj'), (',', 'punct'), ('pneumocystosi', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Patients with \\nhistoplasmosis or other invasive fungal infections may present with disseminated, \\nrather than localized, disease.', 'tokens': ['Patients', 'histoplasmosis', 'invasive', 'fungal', 'infections', 'may', 'present', 'disseminated', ',', 'rather', 'localized', ',', 'disease', '.'], 'lemmatized': ['Patients', 'histoplasmosis', 'invasive', 'fungal', 'infection', 'may', 'present', 'disseminated', ',', 'rather', 'localized', ',', 'disease', '.'], 'stemmed': ['patient', 'histoplasmosi', 'invas', 'fungal', 'infect', 'may', 'present', 'dissemin', ',', 'rather', 'local', ',', 'diseas', '.'], 'dependencies': [('patient', 'amod'), ('histoplasmosi', 'compound'), ('invas', 'compound'), ('fungal', 'compound'), ('infect', 'nsubj'), ('may', 'aux'), ('present', 'ROOT'), ('dissemin', 'advmod'), (',', 'punct'), ('rather', 'advmod'), ('local', 'conj'), (',', 'punct'), ('diseas', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Antigen and antibody testing for histoplasmosis \\nmay be negative in some patients with active infection.', 'tokens': ['Antigen', 'antibody', 'testing', 'histoplasmosis', 'may', 'negative', 'patients', 'active', 'infection', '.'], 'lemmatized': ['Antigen', 'antibody', 'testing', 'histoplasmosis', 'may', 'negative', 'patient', 'active', 'infection', '.'], 'stemmed': ['antigen', 'antibodi', 'test', 'histoplasmosi', 'may', 'neg', 'patient', 'activ', 'infect', '.'], 'dependencies': [('antigen', 'compound'), ('antibodi', 'compound'), ('test', 'compound'), ('histoplasmosi', 'nsubj'), ('may', 'aux'), ('neg', 'ROOT'), ('patient', 'amod'), ('activ', 'compound'), ('infect', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Consider empiric anti-\\nfungal therapy in patients at risk for invasive fungal infections who develop \\nsevere systemic illness.', 'tokens': ['Consider', 'empiric', 'anti-', 'fungal', 'therapy', 'patients', 'risk', 'invasive', 'fungal', 'infections', 'develop', 'severe', 'systemic', 'illness', '.'], 'lemmatized': ['Consider', 'empiric', 'anti-', 'fungal', 'therapy', 'patient', 'risk', 'invasive', 'fungal', 'infection', 'develop', 'severe', 'systemic', 'illness', '.'], 'stemmed': ['consid', 'empir', 'anti-', 'fungal', 'therapi', 'patient', 'risk', 'invas', 'fungal', 'infect', 'develop', 'sever', 'system', 'ill', '.'], 'dependencies': [('consid', 'amod'), ('empir', 'ROOT'), ('anti-', 'dep'), ('fungal', 'nmod'), ('therapi', 'nmod'), ('patient', 'compound'), ('risk', 'compound'), ('invas', 'compound'), ('fungal', 'compound'), ('infect', 'nsubj'), ('develop', 'ROOT'), ('sever', 'amod'), ('system', 'dobj'), ('ill', 'amod'), ('.', 'punct')]}, {'original_sentence': '• Bacterial, viral and other infections due to opportunistic pathogens, including \\nLegionella and Listeria.', 'tokens': ['•', 'Bacterial', ',', 'viral', 'infections', 'due', 'opportunistic', 'pathogens', ',', 'including', 'Legionella', 'Listeria', '.'], 'lemmatized': ['•', 'Bacterial', ',', 'viral', 'infection', 'due', 'opportunistic', 'pathogen', ',', 'including', 'Legionella', 'Listeria', '.'], 'stemmed': ['•', 'bacteri', ',', 'viral', 'infect', 'due', 'opportunist', 'pathogen', ',', 'includ', 'legionella', 'listeria', '.'], 'dependencies': [('•', 'dep'), ('bacteri', 'nmod'), (',', 'punct'), ('viral', 'amod'), ('infect', 'nmod'), ('due', 'amod'), ('opportunist', 'compound'), ('pathogen', 'ROOT'), (',', 'punct'), ('includ', 'compound'), ('legionella', 'compound'), ('listeria', 'conj'), ('.', 'punct')]}, {'original_sentence': 'Carefully consider the risks and benefits of treatment with HUMIRA prior to initiating \\ntherapy in patients with chronic or recurrent infection.', 'tokens': ['Carefully', 'consider', 'risks', 'benefits', 'treatment', 'HUMIRA', 'prior', 'initiating', 'therapy', 'patients', 'chronic', 'recurrent', 'infection', '.'], 'lemmatized': ['Carefully', 'consider', 'risk', 'benefit', 'treatment', 'HUMIRA', 'prior', 'initiating', 'therapy', 'patient', 'chronic', 'recurrent', 'infection', '.'], 'stemmed': ['care', 'consid', 'risk', 'benefit', 'treatment', 'humira', 'prior', 'initi', 'therapi', 'patient', 'chronic', 'recurr', 'infect', '.'], 'dependencies': [('care', 'ROOT'), ('consid', 'amod'), ('risk', 'compound'), ('benefit', 'compound'), ('treatment', 'compound'), ('humira', 'dobj'), ('prior', 'amod'), ('initi', 'compound'), ('therapi', 'amod'), ('patient', 'nmod'), ('chronic', 'amod'), ('recurr', 'compound'), ('infect', 'oprd'), ('.', 'punct')]}, {'original_sentence': 'Monitor patients closely for the development of signs and symptoms of infection during \\nand after treatment with HUMIRA, including the possible development of TB in \\npatients who tested negative for latent TB infection prior to initiating therapy [see \\nWarnings and Precautions (5.1) and Adverse Reactions (6.1)].', 'tokens': ['Monitor', 'patients', 'closely', 'development', 'signs', 'symptoms', 'infection', 'treatment', 'HUMIRA', ',', 'including', 'possible', 'development', 'TB', 'patients', 'tested', 'negative', 'latent', 'TB', 'infection', 'prior', 'initiating', 'therapy', '[', 'see', 'Warnings', 'Precautions', '(', '5.1', ')', 'Adverse', 'Reactions', '(', '6.1', ')', ']', '.'], 'lemmatized': ['Monitor', 'patient', 'closely', 'development', 'sign', 'symptom', 'infection', 'treatment', 'HUMIRA', ',', 'including', 'possible', 'development', 'TB', 'patient', 'tested', 'negative', 'latent', 'TB', 'infection', 'prior', 'initiating', 'therapy', '[', 'see', 'Warnings', 'Precautions', '(', '5.1', ')', 'Adverse', 'Reactions', '(', '6.1', ')', ']', '.'], 'stemmed': ['monitor', 'patient', 'close', 'develop', 'sign', 'symptom', 'infect', 'treatment', 'humira', ',', 'includ', 'possibl', 'develop', 'tb', 'patient', 'test', 'neg', 'latent', 'tb', 'infect', 'prior', 'initi', 'therapi', '[', 'see', 'warn', 'precaut', '(', '5.1', ')', 'advers', 'reaction', '(', '6.1', ')', ']', '.'], 'dependencies': [('monitor', 'advcl'), ('patient', 'compound'), ('close', 'advmod'), ('develop', 'compound'), ('sign', 'compound'), ('symptom', 'compound'), ('infect', 'compound'), ('treatment', 'compound'), ('humira', 'dobj'), (',', 'punct'), ('includ', 'compound'), ('possibl', 'nsubj'), ('develop', 'ROOT'), ('tb', 'prep'), ('patient', 'amod'), ('test', 'compound'), ('neg', 'compound'), ('latent', 'pobj'), ('tb', 'nmod'), ('infect', 'advcl'), ('prior', 'amod'), ('initi', 'compound'), ('therapi', 'dobj'), ('[', 'punct'), ('see', 'parataxis'), ('warn', 'xcomp'), ('precaut', 'dobj'), ('(', 'punct'), ('5.1', 'nummod'), (')', 'punct'), ('advers', 'compound'), ('reaction', 'dobj'), ('(', 'punct'), ('6.1', 'appos'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': 'MALIGNANCY \\nLymphoma and other malignancies, some fatal, have been reported in children and \\nadolescent patients treated with TNF blockers including HUMIRA [see Warnings and \\nPrecautions (5.2)].', 'tokens': ['MALIGNANCY', 'Lymphoma', 'malignancies', ',', 'fatal', ',', 'reported', 'children', 'adolescent', 'patients', 'treated', 'TNF', 'blockers', 'including', 'HUMIRA', '[', 'see', 'Warnings', 'Precautions', '(', '5.2', ')', ']', '.'], 'lemmatized': ['MALIGNANCY', 'Lymphoma', 'malignancy', ',', 'fatal', ',', 'reported', 'child', 'adolescent', 'patient', 'treated', 'TNF', 'blocker', 'including', 'HUMIRA', '[', 'see', 'Warnings', 'Precautions', '(', '5.2', ')', ']', '.'], 'stemmed': ['malign', 'lymphoma', 'malign', ',', 'fatal', ',', 'report', 'child', 'adolesc', 'patient', 'treat', 'tnf', 'blocker', 'includ', 'humira', '[', 'see', 'warn', 'precaut', '(', '5.2', ')', ']', '.'], 'dependencies': [('malign', 'compound'), ('lymphoma', 'compound'), ('malign', 'nsubj'), (',', 'punct'), ('fatal', 'conj'), (',', 'punct'), ('report', 'compound'), ('child', 'compound'), ('adolesc', 'compound'), ('patient', 'compound'), ('treat', 'compound'), ('tnf', 'compound'), ('blocker', 'compound'), ('includ', 'compound'), ('humira', 'appos'), ('[', 'punct'), ('see', 'ROOT'), ('warn', 'dep'), ('precaut', 'dobj'), ('(', 'punct'), ('5.2', 'npadvmod'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a \\nrare type of T-cell lymphoma, have been reported in patients treated with TNF blockers \\nincluding HUMIRA.', 'tokens': ['Post-marketing', 'cases', 'hepatosplenic', 'T-cell', 'lymphoma', '(', 'HSTCL', ')', ',', 'rare', 'type', 'T-cell', 'lymphoma', ',', 'reported', 'patients', 'treated', 'TNF', 'blockers', 'including', 'HUMIRA', '.'], 'lemmatized': ['Post-marketing', 'case', 'hepatosplenic', 'T-cell', 'lymphoma', '(', 'HSTCL', ')', ',', 'rare', 'type', 'T-cell', 'lymphoma', ',', 'reported', 'patient', 'treated', 'TNF', 'blocker', 'including', 'HUMIRA', '.'], 'stemmed': ['post-market', 'case', 'hepatosplen', 't-cell', 'lymphoma', '(', 'hstcl', ')', ',', 'rare', 'type', 't-cell', 'lymphoma', ',', 'report', 'patient', 'treat', 'tnf', 'blocker', 'includ', 'humira', '.'], 'dependencies': [('post', 'amod'), ('-', 'amod'), ('market', 'amod'), ('case', 'nsubj'), ('hepatosplen', 'amod'), ('t', 'compound'), ('-', 'punct'), ('cell', 'compound'), ('lymphoma', 'nsubj'), ('(', 'punct'), ('hstcl', 'appos'), (')', 'punct'), (',', 'punct'), ('rare', 'amod'), ('type', 'compound'), ('t', 'compound'), ('-', 'punct'), ('cell', 'compound'), ('lymphoma', 'appos'), (',', 'punct'), ('report', 'ROOT'), ('patient', 'compound'), ('treat', 'compound'), ('tnf', 'compound'), ('blocker', 'compound'), ('includ', 'compound'), ('humira', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'These cases have had a very aggressive disease course and have \\nbeen fatal.', 'tokens': ['cases', 'aggressive', 'disease', 'course', 'fatal', '.'], 'lemmatized': ['case', 'aggressive', 'disease', 'course', 'fatal', '.'], 'stemmed': ['case', 'aggress', 'diseas', 'cours', 'fatal', '.'], 'dependencies': [('case', 'compound'), ('aggress', 'compound'), ('diseas', 'nsubj'), ('cours', 'ROOT'), ('fatal', 'dobj'), ('.', 'punct')]}, {'original_sentence': \"The majority of reported TNF blocker cases have occurred in patients with \\nCrohn's disease or ulcerative colitis and the majority were in adolescent and young adult \\nmales.\", 'tokens': ['majority', 'reported', 'TNF', 'blocker', 'cases', 'occurred', 'patients', 'Crohn', \"'s\", 'disease', 'ulcerative', 'colitis', 'majority', 'adolescent', 'young', 'adult', 'males', '.'], 'lemmatized': ['majority', 'reported', 'TNF', 'blocker', 'case', 'occurred', 'patient', 'Crohn', \"'s\", 'disease', 'ulcerative', 'colitis', 'majority', 'adolescent', 'young', 'adult', 'male', '.'], 'stemmed': ['major', 'report', 'tnf', 'blocker', 'case', 'occur', 'patient', 'crohn', \"'s\", 'diseas', 'ulcer', 'coliti', 'major', 'adolesc', 'young', 'adult', 'male', '.'], 'dependencies': [('major', 'amod'), ('report', 'compound'), ('tnf', 'compound'), ('blocker', 'compound'), ('case', 'nsubj'), ('occur', 'ROOT'), ('patient', 'compound'), ('crohn', 'poss'), (\"'s\", 'case'), ('diseas', 'compound'), ('ulcer', 'dobj'), ('coliti', 'nmod'), ('major', 'amod'), ('adolesc', 'nmod'), ('young', 'amod'), ('adult', 'compound'), ('male', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Almost all these patients had received treatment with azathioprine or 6-\\nmercaptopurine (6–MP) concomitantly with a TNF blocker at or prior to diagnosis.', 'tokens': ['Almost', 'patients', 'received', 'treatment', 'azathioprine', '6-', 'mercaptopurine', '(', '6–MP', ')', 'concomitantly', 'TNF', 'blocker', 'prior', 'diagnosis', '.'], 'lemmatized': ['Almost', 'patient', 'received', 'treatment', 'azathioprine', '6-', 'mercaptopurine', '(', '6–MP', ')', 'concomitantly', 'TNF', 'blocker', 'prior', 'diagnosis', '.'], 'stemmed': ['almost', 'patient', 'receiv', 'treatment', 'azathioprin', '6-', 'mercaptopurin', '(', '6–mp', ')', 'concomitantli', 'tnf', 'blocker', 'prior', 'diagnosi', '.'], 'dependencies': [('almost', 'advmod'), ('patient', 'amod'), ('receiv', 'compound'), ('treatment', 'compound'), ('azathioprin', 'ROOT'), ('6-', 'compound'), ('mercaptopurin', 'ROOT'), ('(', 'punct'), ('6', 'nummod'), ('–', 'punct'), ('mp', 'appos'), (')', 'punct'), ('concomitantli', 'compound'), ('tnf', 'compound'), ('blocker', 'appos'), ('prior', 'advmod'), ('diagnosi', 'appos'), ('.', 'punct')]}, {'original_sentence': 'It is \\nuncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF', 'tokens': ['uncertain', 'whether', 'occurrence', 'HSTCL', 'related', 'use', 'TNF', 'blocker', 'TNF'], 'lemmatized': ['uncertain', 'whether', 'occurrence', 'HSTCL', 'related', 'use', 'TNF', 'blocker', 'TNF'], 'stemmed': ['uncertain', 'whether', 'occurr', 'hstcl', 'relat', 'use', 'tnf', 'blocker', 'tnf'], 'dependencies': [('uncertain', 'ROOT'), ('whether', 'mark'), ('occurr', 'aux'), ('hstcl', 'compound'), ('relat', 'compound'), ('use', 'ccomp'), ('tnf', 'compound'), ('blocker', 'compound'), ('tnf', 'dobj')]}], 'text': \"FULL PRESCRIBING INFORMATION \\nWARNING: SERIOUS INFECTIONS AND MALIGNANCY \\nSERIOUS INFECTIONS \\nPatients treated with HUMIRA are at increased risk for developing serious infections \\nthat may lead to hospitalization or death [see Warnings and Precautions (5.1)]. Most \\npatients who developed these infections were taking concomitant immunosuppressants \\nsuch as methotrexate or corticosteroids. \\nDiscontinue HUMIRA if a patient develops a serious infection or sepsis. \\nReported infections include: \\n• Active tuberculosis (TB), including reactivation of latent TB. Patients with TB \\nhave frequently presented with disseminated or extrapulmonary disease. Test \\npatients for latent TB before HUMIRA use and during therapy. Initiate \\ntreatment for latent TB prior to HUMIRA use. \\n• Invasive fungal infections, including histoplasmosis, coccidioidomycosis, \\ncandidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with \\nhistoplasmosis or other invasive fungal infections may present with disseminated, \\nrather than localized, disease. Antigen and antibody testing for histoplasmosis \\nmay be negative in some patients with active infection. Consider empiric anti-\\nfungal therapy in patients at risk for invasive fungal infections who develop \\nsevere systemic illness. \\n• Bacterial, viral and other infections due to opportunistic pathogens, including \\nLegionella and Listeria. \\n  \\nCarefully consider the risks and benefits of treatment with HUMIRA prior to initiating \\ntherapy in patients with chronic or recurrent infection. \\nMonitor patients closely for the development of signs and symptoms of infection during \\nand after treatment with HUMIRA, including the possible development of TB in \\npatients who tested negative for latent TB infection prior to initiating therapy [see \\nWarnings and Precautions (5.1) and Adverse Reactions (6.1)]. \\nMALIGNANCY \\nLymphoma and other malignancies, some fatal, have been reported in children and \\nadolescent patients treated with TNF blockers including HUMIRA [see Warnings and \\nPrecautions (5.2)]. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a \\nrare type of T-cell lymphoma, have been reported in patients treated with TNF blockers \\nincluding HUMIRA. These cases have had a very aggressive disease course and have \\nbeen fatal. The majority of reported TNF blocker cases have occurred in patients with \\nCrohn's disease or ulcerative colitis and the majority were in adolescent and young adult \\nmales. Almost all these patients had received treatment with azathioprine or 6-\\nmercaptopurine (6–MP) concomitantly with a TNF blocker at or prior to diagnosis. It is \\nuncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF \\n\"}, 'page_char_count': 2712, 'page_word_count': 377, 'sentences': ['FULL PRESCRIBING INFORMATION \\nWARNING: SERIOUS INFECTIONS AND MALIGNANCY \\nSERIOUS INFECTIONS \\nPatients treated with HUMIRA are at increased risk for developing serious infections \\nthat may lead to hospitalization or death [see Warnings and Precautions (5.1)].', 'Most \\npatients who developed these infections were taking concomitant immunosuppressants \\nsuch as methotrexate or corticosteroids.', '\\nDiscontinue HUMIRA if a patient develops a serious infection or sepsis.', '\\nReported infections include: \\n• Active tuberculosis (TB), including reactivation of latent TB.', 'Patients with TB \\nhave frequently presented with disseminated or extrapulmonary disease.', 'Test \\npatients for latent TB before HUMIRA use and during therapy.', 'Initiate \\ntreatment for latent TB prior to HUMIRA use.', '\\n• Invasive fungal infections, including histoplasmosis, coccidioidomycosis, \\ncandidiasis, aspergillosis, blastomycosis, and pneumocystosis.', 'Patients with \\nhistoplasmosis or other invasive fungal infections may present with disseminated, \\nrather than localized, disease.', 'Antigen and antibody testing for histoplasmosis \\nmay be negative in some patients with active infection.', 'Consider empiric anti-\\nfungal therapy in patients at risk for invasive fungal infections who develop \\nsevere systemic illness.', '\\n• Bacterial, viral and other infections due to opportunistic pathogens, including \\nLegionella and Listeria.', '\\n  \\nCarefully consider the risks and benefits of treatment with HUMIRA prior to initiating \\ntherapy in patients with chronic or recurrent infection.', '\\nMonitor patients closely for the development of signs and symptoms of infection during \\nand after treatment with HUMIRA, including the possible development of TB in \\npatients who tested negative for latent TB infection prior to initiating therapy [see \\nWarnings and Precautions (5.1) and Adverse Reactions (6.1)].', '\\nMALIGNANCY \\nLymphoma and other malignancies, some fatal, have been reported in children and \\nadolescent patients treated with TNF blockers including HUMIRA [see Warnings and \\nPrecautions (5.2)].', 'Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a \\nrare type of T-cell lymphoma, have been reported in patients treated with TNF blockers \\nincluding HUMIRA.', 'These cases have had a very aggressive disease course and have \\nbeen fatal.', \"The majority of reported TNF blocker cases have occurred in patients with \\nCrohn's disease or ulcerative colitis and the majority were in adolescent and young adult \\nmales.\", 'Almost all these patients had received treatment with azathioprine or 6-\\nmercaptopurine (6–MP) concomitantly with a TNF blocker at or prior to diagnosis.', 'It is \\nuncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF \\n'], 'page_sentence_count_spacy': 20}\n",
            "{'page_number': 4, 'text': 'blocker in combination with these other immunosuppressants [see Warnings and \\nPrecautions (5.2)]. \\n1 INDICATIONS AND USAGE \\n1.1 Rheumatoid Arthritis \\nHUMIRA is indicated for reducing signs and symptoms, inducing major clinical response, \\ninhibiting the progression of structural damage, and improving physical function in adult patients \\nwith moderately to severely active rheumatoid arthritis. HUMIRA can be used alone or in \\ncombination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs \\n(DMARDs).  \\n1.2 Juvenile Idiopathic Arthritis \\nHUMIRA is indicated for reducing signs and symptoms of moderately to severely active \\npolyarticular juvenile idiopathic arthritis in patients 2 years of age and older. HUMIRA can be \\nused alone or in combination with methotrexate. \\n1.3 Psoriatic Arthritis \\nHUMIRA is indicated for reducing signs and symptoms, inhibiting the progression of structural \\ndamage, and improving physical function in adult patients with active psoriatic arthritis. \\nHUMIRA can be used alone or in combination with non-biologic DMARDs. \\n1.4 Ankylosing Spondylitis \\nHUMIRA is indicated for reducing signs and symptoms in adult patients with active ankylosing \\nspondylitis.  \\n1.5 Crohn’s Disease \\nHUMIRA is indicated for the treatment of moderately to severely active Crohn’s disease in \\nadults and pediatric patients 6 years of age and older.  \\n1.6 Ulcerative Colitis  \\nHUMIRA is indicated for the treatment of moderately to severely active ulcerative colitis in \\nadults and pediatric patients 5 years of age and older.  \\nLimitations of Use \\nThe effectiveness of HUMIRA has not been established in patients who have lost response to or \\nwere intolerant to TNF blockers [see Clinical Studies (14.7, 14.8)]. \\n1.7 Plaque Psoriasis \\nHUMIRA is indicated for the treatment of adult patients with moderate to severe chronic plaque \\npsoriasis who are candidates for systemic therapy or phototherapy, and when other systemic \\ntherapies are medically less appropriate. HUMIRA should only be administered to patients who \\n', 'processed_text': {'sentences': [{'original_sentence': 'blocker in combination with these other immunosuppressants [see Warnings and \\nPrecautions (5.2)].', 'tokens': ['blocker', 'combination', 'immunosuppressants', '[', 'see', 'Warnings', 'Precautions', '(', '5.2', ')', ']', '.'], 'lemmatized': ['blocker', 'combination', 'immunosuppressant', '[', 'see', 'Warnings', 'Precautions', '(', '5.2', ')', ']', '.'], 'stemmed': ['blocker', 'combin', 'immunosuppress', '[', 'see', 'warn', 'precaut', '(', '5.2', ')', ']', '.'], 'dependencies': [('blocker', 'compound'), ('combin', 'compound'), ('immunosuppress', 'nsubj'), ('[', 'punct'), ('see', 'ROOT'), ('warn', 'dep'), ('precaut', 'dobj'), ('(', 'punct'), ('5.2', 'npadvmod'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': '1 INDICATIONS AND USAGE \\n1.1 Rheumatoid Arthritis \\nHUMIRA is indicated for reducing signs and symptoms, inducing major clinical response, \\ninhibiting the progression of structural damage, and improving physical function in adult patients \\nwith moderately to severely active rheumatoid arthritis.', 'tokens': ['1', 'INDICATIONS', 'USAGE', '1.1', 'Rheumatoid', 'Arthritis', 'HUMIRA', 'indicated', 'reducing', 'signs', 'symptoms', ',', 'inducing', 'major', 'clinical', 'response', ',', 'inhibiting', 'progression', 'structural', 'damage', ',', 'improving', 'physical', 'function', 'adult', 'patients', 'moderately', 'severely', 'active', 'rheumatoid', 'arthritis', '.'], 'lemmatized': ['1', 'INDICATIONS', 'USAGE', '1.1', 'Rheumatoid', 'Arthritis', 'HUMIRA', 'indicated', 'reducing', 'sign', 'symptom', ',', 'inducing', 'major', 'clinical', 'response', ',', 'inhibiting', 'progression', 'structural', 'damage', ',', 'improving', 'physical', 'function', 'adult', 'patient', 'moderately', 'severely', 'active', 'rheumatoid', 'arthritis', '.'], 'stemmed': ['1', 'indic', 'usag', '1.1', 'rheumatoid', 'arthriti', 'humira', 'indic', 'reduc', 'sign', 'symptom', ',', 'induc', 'major', 'clinic', 'respons', ',', 'inhibit', 'progress', 'structur', 'damag', ',', 'improv', 'physic', 'function', 'adult', 'patient', 'moder', 'sever', 'activ', 'rheumatoid', 'arthriti', '.'], 'dependencies': [('1', 'nummod'), ('indic', 'amod'), ('usag', 'nmod'), ('1.1', 'nummod'), ('rheumatoid', 'amod'), ('arthriti', 'nmod'), ('humira', 'nmod'), ('indic', 'amod'), ('reduc', 'compound'), ('sign', 'compound'), ('symptom', 'npadvmod'), (',', 'punct'), ('induc', 'amod'), ('major', 'amod'), ('clinic', 'compound'), ('respons', 'appos'), (',', 'punct'), ('inhibit', 'compound'), ('progress', 'compound'), ('structur', 'nsubj'), ('damag', 'meta'), (',', 'punct'), ('improv', 'compound'), ('physic', 'compound'), ('function', 'compound'), ('adult', 'compound'), ('patient', 'compound'), ('moder', 'nsubj'), ('sever', 'ROOT'), ('activ', 'nmod'), ('rheumatoid', 'amod'), ('arthriti', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'HUMIRA can be used alone or in \\ncombination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs \\n(DMARDs).', 'tokens': ['HUMIRA', 'used', 'alone', 'combination', 'methotrexate', 'non-biologic', 'disease-modifying', 'anti-rheumatic', 'drugs', '(', 'DMARDs', ')', '.'], 'lemmatized': ['HUMIRA', 'used', 'alone', 'combination', 'methotrexate', 'non-biologic', 'disease-modifying', 'anti-rheumatic', 'drug', '(', 'DMARDs', ')', '.'], 'stemmed': ['humira', 'use', 'alon', 'combin', 'methotrex', 'non-biolog', 'disease-modifi', 'anti-rheumat', 'drug', '(', 'dmard', ')', '.'], 'dependencies': [('humira', 'nsubj'), ('use', 'ROOT'), ('alon', 'dobj'), ('combin', 'prep'), ('methotrex', 'amod'), ('non', 'amod'), ('-', 'amod'), ('biolog', 'amod'), ('disease', 'nmod'), ('-', 'punct'), ('modifi', 'nmod'), ('anti', 'amod'), ('-', 'amod'), ('rheumat', 'amod'), ('drug', 'pobj'), ('(', 'punct'), ('dmard', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': '1.2 Juvenile Idiopathic Arthritis \\nHUMIRA is indicated for reducing signs and symptoms of moderately to severely active \\npolyarticular juvenile idiopathic arthritis in patients 2 years of age and older.', 'tokens': ['1.2', 'Juvenile', 'Idiopathic', 'Arthritis', 'HUMIRA', 'indicated', 'reducing', 'signs', 'symptoms', 'moderately', 'severely', 'active', 'polyarticular', 'juvenile', 'idiopathic', 'arthritis', 'patients', '2', 'years', 'age', 'older', '.'], 'lemmatized': ['1.2', 'Juvenile', 'Idiopathic', 'Arthritis', 'HUMIRA', 'indicated', 'reducing', 'sign', 'symptom', 'moderately', 'severely', 'active', 'polyarticular', 'juvenile', 'idiopathic', 'arthritis', 'patient', '2', 'year', 'age', 'older', '.'], 'stemmed': ['1.2', 'juvenil', 'idiopath', 'arthriti', 'humira', 'indic', 'reduc', 'sign', 'symptom', 'moder', 'sever', 'activ', 'polyarticular', 'juvenil', 'idiopath', 'arthriti', 'patient', '2', 'year', 'age', 'older', '.'], 'dependencies': [('1.2', 'nummod'), ('juvenil', 'amod'), ('idiopath', 'compound'), ('arthriti', 'nmod'), ('humira', 'nmod'), ('indic', 'amod'), ('reduc', 'compound'), ('sign', 'compound'), ('symptom', 'compound'), ('moder', 'nsubj'), ('sever', 'ROOT'), ('activ', 'nmod'), ('polyarticular', 'amod'), ('juvenil', 'amod'), ('idiopath', 'compound'), ('arthriti', 'nsubj'), ('patient', 'ccomp'), ('2', 'nummod'), ('year', 'compound'), ('age', 'dobj'), ('older', 'advcl'), ('.', 'punct')]}, {'original_sentence': 'HUMIRA can be \\nused alone or in combination with methotrexate.', 'tokens': ['HUMIRA', 'used', 'alone', 'combination', 'methotrexate', '.'], 'lemmatized': ['HUMIRA', 'used', 'alone', 'combination', 'methotrexate', '.'], 'stemmed': ['humira', 'use', 'alon', 'combin', 'methotrex', '.'], 'dependencies': [('humira', 'nsubj'), ('use', 'ROOT'), ('alon', 'dobj'), ('combin', 'compound'), ('methotrex', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': '1.3 Psoriatic Arthritis \\nHUMIRA is indicated for reducing signs and symptoms, inhibiting the progression of structural \\ndamage, and improving physical function in adult patients with active psoriatic arthritis.', 'tokens': ['1.3', 'Psoriatic', 'Arthritis', 'HUMIRA', 'indicated', 'reducing', 'signs', 'symptoms', ',', 'inhibiting', 'progression', 'structural', 'damage', ',', 'improving', 'physical', 'function', 'adult', 'patients', 'active', 'psoriatic', 'arthritis', '.'], 'lemmatized': ['1.3', 'Psoriatic', 'Arthritis', 'HUMIRA', 'indicated', 'reducing', 'sign', 'symptom', ',', 'inhibiting', 'progression', 'structural', 'damage', ',', 'improving', 'physical', 'function', 'adult', 'patient', 'active', 'psoriatic', 'arthritis', '.'], 'stemmed': ['1.3', 'psoriat', 'arthriti', 'humira', 'indic', 'reduc', 'sign', 'symptom', ',', 'inhibit', 'progress', 'structur', 'damag', ',', 'improv', 'physic', 'function', 'adult', 'patient', 'activ', 'psoriat', 'arthriti', '.'], 'dependencies': [('1.3', 'nummod'), ('psoriat', 'compound'), ('arthriti', 'compound'), ('humira', 'nmod'), ('indic', 'amod'), ('reduc', 'compound'), ('sign', 'compound'), ('symptom', 'npadvmod'), (',', 'punct'), ('inhibit', 'compound'), ('progress', 'compound'), ('structur', 'nsubj'), ('damag', 'dep'), (',', 'punct'), ('improv', 'nmod'), ('physic', 'compound'), ('function', 'compound'), ('adult', 'compound'), ('patient', 'amod'), ('activ', 'compound'), ('psoriat', 'compound'), ('arthriti', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'HUMIRA can be used alone or in combination with non-biologic DMARDs.', 'tokens': ['HUMIRA', 'used', 'alone', 'combination', 'non-biologic', 'DMARDs', '.'], 'lemmatized': ['HUMIRA', 'used', 'alone', 'combination', 'non-biologic', 'DMARDs', '.'], 'stemmed': ['humira', 'use', 'alon', 'combin', 'non-biolog', 'dmard', '.'], 'dependencies': [('humira', 'nsubj'), ('use', 'ROOT'), ('alon', 'dobj'), ('combin', 'prep'), ('non', 'amod'), ('-', 'amod'), ('biolog', 'amod'), ('dmard', 'pobj'), ('.', 'punct')]}, {'original_sentence': '1.4 Ankylosing Spondylitis \\nHUMIRA is indicated for reducing signs and symptoms in adult patients with active ankylosing \\nspondylitis.', 'tokens': ['1.4', 'Ankylosing', 'Spondylitis', 'HUMIRA', 'indicated', 'reducing', 'signs', 'symptoms', 'adult', 'patients', 'active', 'ankylosing', 'spondylitis', '.'], 'lemmatized': ['1.4', 'Ankylosing', 'Spondylitis', 'HUMIRA', 'indicated', 'reducing', 'sign', 'symptom', 'adult', 'patient', 'active', 'ankylosing', 'spondylitis', '.'], 'stemmed': ['1.4', 'ankylos', 'spondyl', 'humira', 'indic', 'reduc', 'sign', 'symptom', 'adult', 'patient', 'activ', 'ankylos', 'spondyl', '.'], 'dependencies': [('1.4', 'nummod'), ('ankylos', 'nmod'), ('spondyl', 'nmod'), ('humira', 'nmod'), ('indic', 'nmod'), ('reduc', 'compound'), ('sign', 'compound'), ('symptom', 'compound'), ('adult', 'compound'), ('patient', 'compound'), ('activ', 'ROOT'), ('ankylos', 'compound'), ('spondyl', 'appos'), ('.', 'punct')]}, {'original_sentence': '1.5 Crohn’s Disease \\nHUMIRA is indicated for the treatment of moderately to severely active Crohn’s disease in \\nadults and pediatric patients 6 years of age and older.', 'tokens': ['1.5', 'Crohn', '’', 'Disease', 'HUMIRA', 'indicated', 'treatment', 'moderately', 'severely', 'active', 'Crohn', '’', 'disease', 'adults', 'pediatric', 'patients', '6', 'years', 'age', 'older', '.'], 'lemmatized': ['1.5', 'Crohn', '’', 'Disease', 'HUMIRA', 'indicated', 'treatment', 'moderately', 'severely', 'active', 'Crohn', '’', 'disease', 'adult', 'pediatric', 'patient', '6', 'year', 'age', 'older', '.'], 'stemmed': ['1.5', 'crohn', '’', 'diseas', 'humira', 'indic', 'treatment', 'moder', 'sever', 'activ', 'crohn', '’', 'diseas', 'adult', 'pediatr', 'patient', '6', 'year', 'age', 'older', '.'], 'dependencies': [('1.5', 'nummod'), ('crohn', 'nmod'), ('’', 'punct'), ('diseas', 'nsubj'), ('humira', 'compound'), ('indic', 'amod'), ('treatment', 'compound'), ('moder', 'nsubj'), ('sever', 'ROOT'), ('activ', 'compound'), ('crohn', 'dative'), ('’', 'punct'), ('diseas', 'amod'), ('adult', 'nmod'), ('pediatr', 'amod'), ('patient', 'nmod'), ('6', 'nummod'), ('year', 'compound'), ('age', 'npadvmod'), ('older', 'ccomp'), ('.', 'punct')]}, {'original_sentence': '1.6 Ulcerative Colitis  \\nHUMIRA is indicated for the treatment of moderately to severely active ulcerative colitis in \\nadults and pediatric patients 5 years of age and older.', 'tokens': ['1.6', 'Ulcerative', 'Colitis', 'HUMIRA', 'indicated', 'treatment', 'moderately', 'severely', 'active', 'ulcerative', 'colitis', 'adults', 'pediatric', 'patients', '5', 'years', 'age', 'older', '.'], 'lemmatized': ['1.6', 'Ulcerative', 'Colitis', 'HUMIRA', 'indicated', 'treatment', 'moderately', 'severely', 'active', 'ulcerative', 'colitis', 'adult', 'pediatric', 'patient', '5', 'year', 'age', 'older', '.'], 'stemmed': ['1.6', 'ulcer', 'coliti', 'humira', 'indic', 'treatment', 'moder', 'sever', 'activ', 'ulcer', 'coliti', 'adult', 'pediatr', 'patient', '5', 'year', 'age', 'older', '.'], 'dependencies': [('1.6', 'nummod'), ('ulcer', 'compound'), ('coliti', 'compound'), ('humira', 'nmod'), ('indic', 'amod'), ('treatment', 'compound'), ('moder', 'nsubj'), ('sever', 'ROOT'), ('activ', 'compound'), ('ulcer', 'dobj'), ('coliti', 'compound'), ('adult', 'nmod'), ('pediatr', 'amod'), ('patient', 'amod'), ('5', 'nummod'), ('year', 'compound'), ('age', 'npadvmod'), ('older', 'ccomp'), ('.', 'punct')]}, {'original_sentence': 'Limitations of Use \\nThe effectiveness of HUMIRA has not been established in patients who have lost response to or \\nwere intolerant to TNF blockers [see Clinical Studies (14.7, 14.8)].', 'tokens': ['Limitations', 'Use', 'effectiveness', 'HUMIRA', 'established', 'patients', 'lost', 'response', 'intolerant', 'TNF', 'blockers', '[', 'see', 'Clinical', 'Studies', '(', '14.7', ',', '14.8', ')', ']', '.'], 'lemmatized': ['Limitations', 'Use', 'effectiveness', 'HUMIRA', 'established', 'patient', 'lost', 'response', 'intolerant', 'TNF', 'blocker', '[', 'see', 'Clinical', 'Studies', '(', '14.7', ',', '14.8', ')', ']', '.'], 'stemmed': ['limit', 'use', 'effect', 'humira', 'establish', 'patient', 'lost', 'respons', 'intoler', 'tnf', 'blocker', '[', 'see', 'clinic', 'studi', '(', '14.7', ',', '14.8', ')', ']', '.'], 'dependencies': [('limit', 'ROOT'), ('use', 'compound'), ('effect', 'dobj'), ('humira', 'nsubj'), ('establish', 'conj'), ('patient', 'compound'), ('lost', 'amod'), ('respons', 'compound'), ('intoler', 'compound'), ('tnf', 'compound'), ('blocker', 'dobj'), ('[', 'punct'), ('see', 'conj'), ('clinic', 'compound'), ('studi', 'dobj'), ('(', 'punct'), ('14.7', 'nummod'), (',', 'punct'), ('14.8', 'appos'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': '1.7 Plaque Psoriasis \\nHUMIRA is indicated for the treatment of adult patients with moderate to severe chronic plaque \\npsoriasis who are candidates for systemic therapy or phototherapy, and when other systemic \\ntherapies are medically less appropriate.', 'tokens': ['1.7', 'Plaque', 'Psoriasis', 'HUMIRA', 'indicated', 'treatment', 'adult', 'patients', 'moderate', 'severe', 'chronic', 'plaque', 'psoriasis', 'candidates', 'systemic', 'therapy', 'phototherapy', ',', 'systemic', 'therapies', 'medically', 'less', 'appropriate', '.'], 'lemmatized': ['1.7', 'Plaque', 'Psoriasis', 'HUMIRA', 'indicated', 'treatment', 'adult', 'patient', 'moderate', 'severe', 'chronic', 'plaque', 'psoriasis', 'candidate', 'systemic', 'therapy', 'phototherapy', ',', 'systemic', 'therapy', 'medically', 'less', 'appropriate', '.'], 'stemmed': ['1.7', 'plaqu', 'psoriasi', 'humira', 'indic', 'treatment', 'adult', 'patient', 'moder', 'sever', 'chronic', 'plaqu', 'psoriasi', 'candid', 'system', 'therapi', 'phototherapi', ',', 'system', 'therapi', 'medic', 'less', 'appropri', '.'], 'dependencies': [('1.7', 'nummod'), ('plaqu', 'compound'), ('psoriasi', 'compound'), ('humira', 'nmod'), ('indic', 'amod'), ('treatment', 'compound'), ('adult', 'compound'), ('patient', 'compound'), ('moder', 'nsubj'), ('sever', 'compound'), ('chronic', 'amod'), ('plaqu', 'compound'), ('psoriasi', 'compound'), ('candid', 'amod'), ('system', 'nsubj'), ('therapi', 'ccomp'), ('phototherapi', 'dobj'), (',', 'punct'), ('system', 'nsubj'), ('therapi', 'ROOT'), ('medic', 'npadvmod'), ('less', 'amod'), ('appropri', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'HUMIRA should only be administered to patients who', 'tokens': ['HUMIRA', 'administered', 'patients'], 'lemmatized': ['HUMIRA', 'administered', 'patient'], 'stemmed': ['humira', 'administ', 'patient'], 'dependencies': [('humira', 'compound'), ('administ', 'compound'), ('patient', 'ROOT')]}], 'text': 'blocker in combination with these other immunosuppressants [see Warnings and \\nPrecautions (5.2)]. \\n1 INDICATIONS AND USAGE \\n1.1 Rheumatoid Arthritis \\nHUMIRA is indicated for reducing signs and symptoms, inducing major clinical response, \\ninhibiting the progression of structural damage, and improving physical function in adult patients \\nwith moderately to severely active rheumatoid arthritis. HUMIRA can be used alone or in \\ncombination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs \\n(DMARDs).  \\n1.2 Juvenile Idiopathic Arthritis \\nHUMIRA is indicated for reducing signs and symptoms of moderately to severely active \\npolyarticular juvenile idiopathic arthritis in patients 2 years of age and older. HUMIRA can be \\nused alone or in combination with methotrexate. \\n1.3 Psoriatic Arthritis \\nHUMIRA is indicated for reducing signs and symptoms, inhibiting the progression of structural \\ndamage, and improving physical function in adult patients with active psoriatic arthritis. \\nHUMIRA can be used alone or in combination with non-biologic DMARDs. \\n1.4 Ankylosing Spondylitis \\nHUMIRA is indicated for reducing signs and symptoms in adult patients with active ankylosing \\nspondylitis.  \\n1.5 Crohn’s Disease \\nHUMIRA is indicated for the treatment of moderately to severely active Crohn’s disease in \\nadults and pediatric patients 6 years of age and older.  \\n1.6 Ulcerative Colitis  \\nHUMIRA is indicated for the treatment of moderately to severely active ulcerative colitis in \\nadults and pediatric patients 5 years of age and older.  \\nLimitations of Use \\nThe effectiveness of HUMIRA has not been established in patients who have lost response to or \\nwere intolerant to TNF blockers [see Clinical Studies (14.7, 14.8)]. \\n1.7 Plaque Psoriasis \\nHUMIRA is indicated for the treatment of adult patients with moderate to severe chronic plaque \\npsoriasis who are candidates for systemic therapy or phototherapy, and when other systemic \\ntherapies are medically less appropriate. HUMIRA should only be administered to patients who \\n'}, 'page_char_count': 2053, 'page_word_count': 291, 'sentences': ['blocker in combination with these other immunosuppressants [see Warnings and \\nPrecautions (5.2)].', '\\n1 INDICATIONS AND USAGE \\n1.1 Rheumatoid Arthritis \\nHUMIRA is indicated for reducing signs and symptoms, inducing major clinical response, \\ninhibiting the progression of structural damage, and improving physical function in adult patients \\nwith moderately to severely active rheumatoid arthritis.', 'HUMIRA can be used alone or in \\ncombination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs \\n(DMARDs).', ' \\n1.2 Juvenile Idiopathic Arthritis \\nHUMIRA is indicated for reducing signs and symptoms of moderately to severely active \\npolyarticular juvenile idiopathic arthritis in patients 2 years of age and older.', 'HUMIRA can be \\nused alone or in combination with methotrexate.', '\\n1.3 Psoriatic Arthritis \\nHUMIRA is indicated for reducing signs and symptoms, inhibiting the progression of structural \\ndamage, and improving physical function in adult patients with active psoriatic arthritis.', '\\nHUMIRA can be used alone or in combination with non-biologic DMARDs.', '\\n1.4 Ankylosing Spondylitis \\nHUMIRA is indicated for reducing signs and symptoms in adult patients with active ankylosing \\nspondylitis.', ' \\n1.5 Crohn’s Disease \\nHUMIRA is indicated for the treatment of moderately to severely active Crohn’s disease in \\nadults and pediatric patients 6 years of age and older.', ' \\n1.6 Ulcerative Colitis  \\nHUMIRA is indicated for the treatment of moderately to severely active ulcerative colitis in \\nadults and pediatric patients 5 years of age and older.', ' \\nLimitations of Use \\nThe effectiveness of HUMIRA has not been established in patients who have lost response to or \\nwere intolerant to TNF blockers [see Clinical Studies (14.7, 14.8)].', '\\n1.7 Plaque Psoriasis \\nHUMIRA is indicated for the treatment of adult patients with moderate to severe chronic plaque \\npsoriasis who are candidates for systemic therapy or phototherapy, and when other systemic \\ntherapies are medically less appropriate.', 'HUMIRA should only be administered to patients who \\n'], 'page_sentence_count_spacy': 13}\n",
            "{'page_number': 5, 'text': 'will be closely monitored and have regular follow-up visits with a physician [see Warnings and \\nPrecautions (5)].  \\n1.8 Hidradenitis Suppurativa \\nHUMIRA is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients \\n12 years of age and older.  \\n1.9 Uveitis \\nHUMIRA is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis \\nin adults and pediatric patients 2 years of age and older.  \\n2 DOSAGE AND ADMINISTRATION \\n2.1 Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis \\nThe recommended subcutaneous dosage of HUMIRA for adult patients with rheumatoid arthritis \\n(RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) is 40 mg administered every other \\nweek. Methotrexate (MTX), other non-biologic DMARDS, glucocorticoids, nonsteroidal anti-\\ninflammatory drugs (NSAIDs), and/or analgesics may be continued during treatment with \\nHUMIRA. In the treatment of RA, some patients not taking concomitant MTX may derive \\nadditional benefit from increasing the dosage of HUMIRA to 40 mg every week or 80 mg every \\nother week.  \\n2.2 Juvenile Idiopathic Arthritis or Pediatric Uveitis \\nThe recommended subcutaneous dosage of HUMIRA for patients 2 years of age and older with \\npolyarticular juvenile idiopathic arthritis (JIA) or pediatric uveitis is based on weight as shown \\nbelow. MTX, glucocorticoids, NSAIDs, and/or analgesics may be continued during treatment \\nwith HUMIRA.  \\n \\n  \\nPediatric Weight \\n(2 Years of Age and older) \\nRecommended Dosage \\n10 kg (22 lbs) to less than 15 kg (33 lbs) \\n10 mg every other week  \\n15 kg (33 lbs) to less than 30 kg (66 lbs) \\n20 mg every other week \\n30 kg (66 lbs) and greater \\n40 mg every other week \\n \\n  \\nHUMIRA has not been studied in patients with polyarticular JIA or pediatric uveitis less than 2 \\nyears of age or in patients with a weight below 10 kg.  \\n2.3 Crohn’s Disease \\nAdults \\nThe recommended subcutaneous dosage of HUMIRA for adult patients with Crohn’s disease \\n(CD) is 160 mg initially on Day 1 (given in one day or split over two consecutive days), \\nfollowed by 80 mg two weeks later (Day 15). Two weeks later (Day 29) begin a dosage of 40 mg \\n', 'processed_text': {'sentences': [{'original_sentence': 'will be closely monitored and have regular follow-up visits with a physician [see Warnings and \\nPrecautions (5)].', 'tokens': ['closely', 'monitored', 'regular', 'follow-up', 'visits', 'physician', '[', 'see', 'Warnings', 'Precautions', '(', '5', ')', ']', '.'], 'lemmatized': ['closely', 'monitored', 'regular', 'follow-up', 'visit', 'physician', '[', 'see', 'Warnings', 'Precautions', '(', '5', ')', ']', '.'], 'stemmed': ['close', 'monitor', 'regular', 'follow-up', 'visit', 'physician', '[', 'see', 'warn', 'precaut', '(', '5', ')', ']', '.'], 'dependencies': [('close', 'advmod'), ('monitor', 'ROOT'), ('regular', 'amod'), ('follow', 'amod'), ('-', 'punct'), ('up', 'prt'), ('visit', 'compound'), ('physician', 'dobj'), ('[', 'punct'), ('see', 'parataxis'), ('warn', 'dep'), ('precaut', 'dobj'), ('(', 'punct'), ('5', 'dobj'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': '1.8 Hidradenitis Suppurativa \\nHUMIRA is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients \\n12 years of age and older.', 'tokens': ['1.8', 'Hidradenitis', 'Suppurativa', 'HUMIRA', 'indicated', 'treatment', 'moderate', 'severe', 'hidradenitis', 'suppurativa', 'patients', '12', 'years', 'age', 'older', '.'], 'lemmatized': ['1.8', 'Hidradenitis', 'Suppurativa', 'HUMIRA', 'indicated', 'treatment', 'moderate', 'severe', 'hidradenitis', 'suppurativa', 'patient', '12', 'year', 'age', 'older', '.'], 'stemmed': ['1.8', 'hidraden', 'suppurativa', 'humira', 'indic', 'treatment', 'moder', 'sever', 'hidraden', 'suppurativa', 'patient', '12', 'year', 'age', 'older', '.'], 'dependencies': [('1.8', 'nummod'), ('hidraden', 'nmod'), ('suppurativa', 'nmod'), ('humira', 'compound'), ('indic', 'amod'), ('treatment', 'compound'), ('moder', 'nsubj'), ('sever', 'ROOT'), ('hidraden', 'compound'), ('suppurativa', 'compound'), ('patient', 'dobj'), ('12', 'nummod'), ('year', 'compound'), ('age', 'npadvmod'), ('older', 'amod'), ('.', 'punct')]}, {'original_sentence': '1.9 Uveitis \\nHUMIRA is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis \\nin adults and pediatric patients 2 years of age and older.', 'tokens': ['1.9', 'Uveitis', 'HUMIRA', 'indicated', 'treatment', 'non-infectious', 'intermediate', ',', 'posterior', ',', 'panuveitis', 'adults', 'pediatric', 'patients', '2', 'years', 'age', 'older', '.'], 'lemmatized': ['1.9', 'Uveitis', 'HUMIRA', 'indicated', 'treatment', 'non-infectious', 'intermediate', ',', 'posterior', ',', 'panuveitis', 'adult', 'pediatric', 'patient', '2', 'year', 'age', 'older', '.'], 'stemmed': ['1.9', 'uveiti', 'humira', 'indic', 'treatment', 'non-infecti', 'intermedi', ',', 'posterior', ',', 'panuv', 'adult', 'pediatr', 'patient', '2', 'year', 'age', 'older', '.'], 'dependencies': [('1.9', 'nummod'), ('uveiti', 'nmod'), ('humira', 'nmod'), ('indic', 'amod'), ('treatment', 'nmod'), ('non', 'amod'), ('-', 'amod'), ('infecti', 'amod'), ('intermedi', 'amod'), (',', 'punct'), ('posterior', 'amod'), (',', 'punct'), ('panuv', 'nmod'), ('adult', 'nmod'), ('pediatr', 'amod'), ('patient', 'amod'), ('2', 'nummod'), ('year', 'compound'), ('age', 'npadvmod'), ('older', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '2 DOSAGE AND ADMINISTRATION \\n2.1 Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis \\nThe recommended subcutaneous dosage of HUMIRA for adult patients with rheumatoid arthritis \\n(RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) is 40 mg administered every other \\nweek.', 'tokens': ['2', 'DOSAGE', 'ADMINISTRATION', '2.1', 'Rheumatoid', 'Arthritis', ',', 'Psoriatic', 'Arthritis', ',', 'Ankylosing', 'Spondylitis', 'recommended', 'subcutaneous', 'dosage', 'HUMIRA', 'adult', 'patients', 'rheumatoid', 'arthritis', '(', 'RA', ')', ',', 'psoriatic', 'arthritis', '(', 'PsA', ')', ',', 'ankylosing', 'spondylitis', '(', ')', '40', 'mg', 'administered', 'every', 'week', '.'], 'lemmatized': ['2', 'DOSAGE', 'ADMINISTRATION', '2.1', 'Rheumatoid', 'Arthritis', ',', 'Psoriatic', 'Arthritis', ',', 'Ankylosing', 'Spondylitis', 'recommended', 'subcutaneous', 'dosage', 'HUMIRA', 'adult', 'patient', 'rheumatoid', 'arthritis', '(', 'RA', ')', ',', 'psoriatic', 'arthritis', '(', 'PsA', ')', ',', 'ankylosing', 'spondylitis', '(', ')', '40', 'mg', 'administered', 'every', 'week', '.'], 'stemmed': ['2', 'dosag', 'administr', '2.1', 'rheumatoid', 'arthriti', ',', 'psoriat', 'arthriti', ',', 'ankylos', 'spondyl', 'recommend', 'subcutan', 'dosag', 'humira', 'adult', 'patient', 'rheumatoid', 'arthriti', '(', 'ra', ')', ',', 'psoriat', 'arthriti', '(', 'psa', ')', ',', 'ankylos', 'spondyl', '(', ')', '40', 'mg', 'administ', 'everi', 'week', '.'], 'dependencies': [('2', 'nummod'), ('dosag', 'compound'), ('administr', 'nmod'), ('2.1', 'nummod'), ('rheumatoid', 'amod'), ('arthriti', 'dep'), (',', 'punct'), ('psoriat', 'compound'), ('arthriti', 'appos'), (',', 'punct'), ('ankylos', 'compound'), ('spondyl', 'nsubj'), ('recommend', 'ROOT'), ('subcutan', 'compound'), ('dosag', 'compound'), ('humira', 'compound'), ('adult', 'compound'), ('patient', 'dobj'), ('rheumatoid', 'compound'), ('arthriti', 'appos'), ('(', 'punct'), ('ra', 'appos'), (')', 'punct'), (',', 'punct'), ('psoriat', 'compound'), ('arthriti', 'appos'), ('(', 'punct'), ('psa', 'parataxis'), (')', 'punct'), (',', 'punct'), ('ankylos', 'compound'), ('spondyl', 'conj'), ('(', 'punct'), (')', 'punct'), ('40', 'appos'), ('mg', 'prep'), ('administ', 'pobj'), ('everi', 'amod'), ('week', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Methotrexate (MTX), other non-biologic DMARDS, glucocorticoids, nonsteroidal anti-\\ninflammatory drugs (NSAIDs), and/or analgesics may be continued during treatment with \\nHUMIRA.', 'tokens': ['Methotrexate', '(', 'MTX', ')', ',', 'non-biologic', 'DMARDS', ',', 'glucocorticoids', ',', 'nonsteroidal', 'anti-', 'inflammatory', 'drugs', '(', 'NSAIDs', ')', ',', 'and/or', 'analgesics', 'may', 'continued', 'treatment', 'HUMIRA', '.'], 'lemmatized': ['Methotrexate', '(', 'MTX', ')', ',', 'non-biologic', 'DMARDS', ',', 'glucocorticoid', ',', 'nonsteroidal', 'anti-', 'inflammatory', 'drug', '(', 'NSAIDs', ')', ',', 'and/or', 'analgesic', 'may', 'continued', 'treatment', 'HUMIRA', '.'], 'stemmed': ['methotrex', '(', 'mtx', ')', ',', 'non-biolog', 'dmard', ',', 'glucocorticoid', ',', 'nonsteroid', 'anti-', 'inflammatori', 'drug', '(', 'nsaid', ')', ',', 'and/or', 'analges', 'may', 'continu', 'treatment', 'humira', '.'], 'dependencies': [('methotrex', 'nsubj'), ('(', 'punct'), ('mtx', 'appos'), (')', 'punct'), (',', 'punct'), ('non', 'amod'), ('-', 'amod'), ('biolog', 'amod'), ('dmard', 'amod'), (',', 'punct'), ('glucocorticoid', 'amod'), (',', 'punct'), ('nonsteroid', 'compound'), ('anti-', 'compound'), ('inflammatori', 'compound'), ('drug', 'appos'), ('(', 'punct'), ('nsaid', 'parataxis'), (')', 'punct'), (',', 'punct'), ('and/or', 'cc'), ('analges', 'conj'), ('may', 'aux'), ('continu', 'ROOT'), ('treatment', 'compound'), ('humira', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'In the treatment of RA, some patients not taking concomitant MTX may derive \\nadditional benefit from increasing the dosage of HUMIRA to 40 mg every week or 80 mg every \\nother week.', 'tokens': ['treatment', 'RA', ',', 'patients', 'taking', 'concomitant', 'MTX', 'may', 'derive', 'additional', 'benefit', 'increasing', 'dosage', 'HUMIRA', '40', 'mg', 'every', 'week', '80', 'mg', 'every', 'week', '.'], 'lemmatized': ['treatment', 'RA', ',', 'patient', 'taking', 'concomitant', 'MTX', 'may', 'derive', 'additional', 'benefit', 'increasing', 'dosage', 'HUMIRA', '40', 'mg', 'every', 'week', '80', 'mg', 'every', 'week', '.'], 'stemmed': ['treatment', 'ra', ',', 'patient', 'take', 'concomit', 'mtx', 'may', 'deriv', 'addit', 'benefit', 'increas', 'dosag', 'humira', '40', 'mg', 'everi', 'week', '80', 'mg', 'everi', 'week', '.'], 'dependencies': [('treatment', 'compound'), ('ra', 'npadvmod'), (',', 'punct'), ('patient', 'nsubj'), ('take', 'nsubj'), ('concomit', 'dobj'), ('mtx', 'dobj'), ('may', 'aux'), ('deriv', 'ROOT'), ('addit', 'compound'), ('benefit', 'compound'), ('increas', 'compound'), ('dosag', 'compound'), ('humira', 'dobj'), ('40', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'ROOT'), ('80', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': '2.2 Juvenile Idiopathic Arthritis or Pediatric Uveitis \\nThe recommended subcutaneous dosage of HUMIRA for patients 2 years of age and older with \\npolyarticular juvenile idiopathic arthritis (JIA) or pediatric uveitis is based on weight as shown \\nbelow.', 'tokens': ['2.2', 'Juvenile', 'Idiopathic', 'Arthritis', 'Pediatric', 'Uveitis', 'recommended', 'subcutaneous', 'dosage', 'HUMIRA', 'patients', '2', 'years', 'age', 'older', 'polyarticular', 'juvenile', 'idiopathic', 'arthritis', '(', 'JIA', ')', 'pediatric', 'uveitis', 'based', 'weight', 'shown', '.'], 'lemmatized': ['2.2', 'Juvenile', 'Idiopathic', 'Arthritis', 'Pediatric', 'Uveitis', 'recommended', 'subcutaneous', 'dosage', 'HUMIRA', 'patient', '2', 'year', 'age', 'older', 'polyarticular', 'juvenile', 'idiopathic', 'arthritis', '(', 'JIA', ')', 'pediatric', 'uveitis', 'based', 'weight', 'shown', '.'], 'stemmed': ['2.2', 'juvenil', 'idiopath', 'arthriti', 'pediatr', 'uveiti', 'recommend', 'subcutan', 'dosag', 'humira', 'patient', '2', 'year', 'age', 'older', 'polyarticular', 'juvenil', 'idiopath', 'arthriti', '(', 'jia', ')', 'pediatr', 'uveiti', 'base', 'weight', 'shown', '.'], 'dependencies': [('2.2', 'nummod'), ('juvenil', 'amod'), ('idiopath', 'compound'), ('arthriti', 'compound'), ('pediatr', 'compound'), ('uveiti', 'nsubj'), ('recommend', 'ROOT'), ('subcutan', 'compound'), ('dosag', 'compound'), ('humira', 'compound'), ('patient', 'nmod'), ('2', 'nummod'), ('year', 'compound'), ('age', 'dobj'), ('older', 'amod'), ('polyarticular', 'amod'), ('juvenil', 'amod'), ('idiopath', 'compound'), ('arthriti', 'npadvmod'), ('(', 'punct'), ('jia', 'nmod'), (')', 'punct'), ('pediatr', 'amod'), ('uveiti', 'compound'), ('base', 'compound'), ('weight', 'nsubj'), ('shown', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'MTX, glucocorticoids, NSAIDs, and/or analgesics may be continued during treatment \\nwith HUMIRA.', 'tokens': ['MTX', ',', 'glucocorticoids', ',', 'NSAIDs', ',', 'and/or', 'analgesics', 'may', 'continued', 'treatment', 'HUMIRA', '.'], 'lemmatized': ['MTX', ',', 'glucocorticoid', ',', 'NSAIDs', ',', 'and/or', 'analgesic', 'may', 'continued', 'treatment', 'HUMIRA', '.'], 'stemmed': ['mtx', ',', 'glucocorticoid', ',', 'nsaid', ',', 'and/or', 'analges', 'may', 'continu', 'treatment', 'humira', '.'], 'dependencies': [('mtx', 'ROOT'), (',', 'punct'), ('glucocorticoid', 'amod'), (',', 'punct'), ('nsaid', 'nsubj'), (',', 'punct'), ('and/or', 'cc'), ('analges', 'conj'), ('may', 'aux'), ('continu', 'ccomp'), ('treatment', 'compound'), ('humira', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Pediatric Weight \\n(2 Years of Age and older) \\nRecommended Dosage \\n10 kg (22 lbs) to less than 15 kg (33 lbs) \\n10 mg every other week  \\n15 kg (33 lbs) to less than 30 kg (66 lbs) \\n20 mg every other week \\n30 kg (66 lbs) and greater \\n40 mg every other week \\n \\n  \\nHUMIRA has not been studied in patients with polyarticular JIA or pediatric uveitis less than 2 \\nyears of age or in patients with a weight below 10 kg.', 'tokens': ['Pediatric', 'Weight', '(', '2', 'Years', 'Age', 'older', ')', 'Recommended', 'Dosage', '10', 'kg', '(', '22', 'lbs', ')', 'less', '15', 'kg', '(', '33', 'lbs', ')', '10', 'mg', 'every', 'week', '15', 'kg', '(', '33', 'lbs', ')', 'less', '30', 'kg', '(', '66', 'lbs', ')', '20', 'mg', 'every', 'week', '30', 'kg', '(', '66', 'lbs', ')', 'greater', '40', 'mg', 'every', 'week', 'HUMIRA', 'studied', 'patients', 'polyarticular', 'JIA', 'pediatric', 'uveitis', 'less', '2', 'years', 'age', 'patients', 'weight', '10', 'kg', '.'], 'lemmatized': ['Pediatric', 'Weight', '(', '2', 'Years', 'Age', 'older', ')', 'Recommended', 'Dosage', '10', 'kg', '(', '22', 'lb', ')', 'less', '15', 'kg', '(', '33', 'lb', ')', '10', 'mg', 'every', 'week', '15', 'kg', '(', '33', 'lb', ')', 'less', '30', 'kg', '(', '66', 'lb', ')', '20', 'mg', 'every', 'week', '30', 'kg', '(', '66', 'lb', ')', 'greater', '40', 'mg', 'every', 'week', 'HUMIRA', 'studied', 'patient', 'polyarticular', 'JIA', 'pediatric', 'uveitis', 'less', '2', 'year', 'age', 'patient', 'weight', '10', 'kg', '.'], 'stemmed': ['pediatr', 'weight', '(', '2', 'year', 'age', 'older', ')', 'recommend', 'dosag', '10', 'kg', '(', '22', 'lb', ')', 'less', '15', 'kg', '(', '33', 'lb', ')', '10', 'mg', 'everi', 'week', '15', 'kg', '(', '33', 'lb', ')', 'less', '30', 'kg', '(', '66', 'lb', ')', '20', 'mg', 'everi', 'week', '30', 'kg', '(', '66', 'lb', ')', 'greater', '40', 'mg', 'everi', 'week', 'humira', 'studi', 'patient', 'polyarticular', 'jia', 'pediatr', 'uveiti', 'less', '2', 'year', 'age', 'patient', 'weight', '10', 'kg', '.'], 'dependencies': [('pediatr', 'amod'), ('weight', 'nsubj'), ('(', 'punct'), ('2', 'nummod'), ('year', 'compound'), ('age', 'nsubj'), ('older', 'amod'), (')', 'punct'), ('recommend', 'ROOT'), ('dosag', 'dobj'), ('10', 'nummod'), ('kg', 'npadvmod'), ('(', 'punct'), ('22', 'nummod'), ('lb', 'appos'), (')', 'punct'), ('less', 'amod'), ('15', 'nummod'), ('kg', 'npadvmod'), ('(', 'punct'), ('33', 'nummod'), ('lb', 'appos'), (')', 'punct'), ('10', 'appos'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'pobj'), ('15', 'nummod'), ('kg', 'npadvmod'), ('(', 'punct'), ('33', 'nummod'), ('lb', 'appos'), (')', 'punct'), ('less', 'amod'), ('30', 'nummod'), ('kg', 'npadvmod'), ('(', 'punct'), ('66', 'nummod'), ('lb', 'appos'), (')', 'punct'), ('20', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'npadvmod'), ('30', 'nummod'), ('kg', 'npadvmod'), ('(', 'punct'), ('66', 'nummod'), ('lb', 'parataxis'), (')', 'punct'), ('greater', 'acomp'), ('40', 'nummod'), ('mg', 'nmod'), ('everi', 'amod'), ('week', 'npadvmod'), ('humira', 'compound'), ('studi', 'nmod'), ('patient', 'nmod'), ('polyarticular', 'appos'), ('jia', 'nmod'), ('pediatr', 'compound'), ('uveiti', 'npadvmod'), ('less', 'amod'), ('2', 'nummod'), ('year', 'compound'), ('age', 'compound'), ('patient', 'compound'), ('weight', 'dobj'), ('10', 'nummod'), ('kg', 'appos'), ('.', 'punct')]}, {'original_sentence': '2.3 Crohn’s Disease \\nAdults \\nThe recommended subcutaneous dosage of HUMIRA for adult patients with Crohn’s disease \\n(CD) is 160 mg initially on Day 1 (given in one day or split over two consecutive days), \\nfollowed by 80 mg two weeks later (Day 15).', 'tokens': ['2.3', 'Crohn', '’', 'Disease', 'Adults', 'recommended', 'subcutaneous', 'dosage', 'HUMIRA', 'adult', 'patients', 'Crohn', '’', 'disease', '(', 'CD', ')', '160', 'mg', 'initially', 'Day', '1', '(', 'given', 'one', 'day', 'split', 'two', 'consecutive', 'days', ')', ',', 'followed', '80', 'mg', 'two', 'weeks', 'later', '(', 'Day', '15', ')', '.'], 'lemmatized': ['2.3', 'Crohn', '’', 'Disease', 'Adults', 'recommended', 'subcutaneous', 'dosage', 'HUMIRA', 'adult', 'patient', 'Crohn', '’', 'disease', '(', 'CD', ')', '160', 'mg', 'initially', 'Day', '1', '(', 'given', 'one', 'day', 'split', 'two', 'consecutive', 'day', ')', ',', 'followed', '80', 'mg', 'two', 'week', 'later', '(', 'Day', '15', ')', '.'], 'stemmed': ['2.3', 'crohn', '’', 'diseas', 'adult', 'recommend', 'subcutan', 'dosag', 'humira', 'adult', 'patient', 'crohn', '’', 'diseas', '(', 'cd', ')', '160', 'mg', 'initi', 'day', '1', '(', 'given', 'one', 'day', 'split', 'two', 'consecut', 'day', ')', ',', 'follow', '80', 'mg', 'two', 'week', 'later', '(', 'day', '15', ')', '.'], 'dependencies': [('2.3', 'nummod'), ('crohn', 'nsubj'), ('’', 'punct'), ('diseas', 'compound'), ('adult', 'nsubj'), ('recommend', 'ROOT'), ('subcutan', 'compound'), ('dosag', 'compound'), ('humira', 'compound'), ('adult', 'nmod'), ('patient', 'compound'), ('crohn', 'nmod'), ('’', 'punct'), ('diseas', 'dobj'), ('(', 'punct'), ('cd', 'appos'), (')', 'punct'), ('160', 'nummod'), ('mg', 'compound'), ('initi', 'appos'), ('day', 'npadvmod'), ('1', 'nummod'), ('(', 'punct'), ('given', 'prep'), ('one', 'nummod'), ('day', 'npadvmod'), ('split', 'pcomp'), ('two', 'nummod'), ('consecut', 'compound'), ('day', 'npadvmod'), (')', 'punct'), (',', 'punct'), ('follow', 'parataxis'), ('80', 'nummod'), ('mg', 'dobj'), ('two', 'nummod'), ('week', 'npadvmod'), ('later', 'advmod'), ('(', 'punct'), ('day', 'npadvmod'), ('15', 'nummod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Two weeks later (Day 29) begin a dosage of 40 mg', 'tokens': ['Two', 'weeks', 'later', '(', 'Day', '29', ')', 'begin', 'dosage', '40', 'mg'], 'lemmatized': ['Two', 'week', 'later', '(', 'Day', '29', ')', 'begin', 'dosage', '40', 'mg'], 'stemmed': ['two', 'week', 'later', '(', 'day', '29', ')', 'begin', 'dosag', '40', 'mg'], 'dependencies': [('two', 'nummod'), ('week', 'npadvmod'), ('later', 'advmod'), ('(', 'punct'), ('day', 'npadvmod'), ('29', 'nummod'), (')', 'punct'), ('begin', 'ROOT'), ('dosag', 'npadvmod'), ('40', 'nummod'), ('mg', 'prep')]}], 'text': 'will be closely monitored and have regular follow-up visits with a physician [see Warnings and \\nPrecautions (5)].  \\n1.8 Hidradenitis Suppurativa \\nHUMIRA is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients \\n12 years of age and older.  \\n1.9 Uveitis \\nHUMIRA is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis \\nin adults and pediatric patients 2 years of age and older.  \\n2 DOSAGE AND ADMINISTRATION \\n2.1 Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis \\nThe recommended subcutaneous dosage of HUMIRA for adult patients with rheumatoid arthritis \\n(RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) is 40 mg administered every other \\nweek. Methotrexate (MTX), other non-biologic DMARDS, glucocorticoids, nonsteroidal anti-\\ninflammatory drugs (NSAIDs), and/or analgesics may be continued during treatment with \\nHUMIRA. In the treatment of RA, some patients not taking concomitant MTX may derive \\nadditional benefit from increasing the dosage of HUMIRA to 40 mg every week or 80 mg every \\nother week.  \\n2.2 Juvenile Idiopathic Arthritis or Pediatric Uveitis \\nThe recommended subcutaneous dosage of HUMIRA for patients 2 years of age and older with \\npolyarticular juvenile idiopathic arthritis (JIA) or pediatric uveitis is based on weight as shown \\nbelow. MTX, glucocorticoids, NSAIDs, and/or analgesics may be continued during treatment \\nwith HUMIRA.  \\n \\n  \\nPediatric Weight \\n(2 Years of Age and older) \\nRecommended Dosage \\n10 kg (22 lbs) to less than 15 kg (33 lbs) \\n10 mg every other week  \\n15 kg (33 lbs) to less than 30 kg (66 lbs) \\n20 mg every other week \\n30 kg (66 lbs) and greater \\n40 mg every other week \\n \\n  \\nHUMIRA has not been studied in patients with polyarticular JIA or pediatric uveitis less than 2 \\nyears of age or in patients with a weight below 10 kg.  \\n2.3 Crohn’s Disease \\nAdults \\nThe recommended subcutaneous dosage of HUMIRA for adult patients with Crohn’s disease \\n(CD) is 160 mg initially on Day 1 (given in one day or split over two consecutive days), \\nfollowed by 80 mg two weeks later (Day 15). Two weeks later (Day 29) begin a dosage of 40 mg \\n'}, 'page_char_count': 2176, 'page_word_count': 340, 'sentences': ['will be closely monitored and have regular follow-up visits with a physician [see Warnings and \\nPrecautions (5)].', ' \\n1.8 Hidradenitis Suppurativa \\nHUMIRA is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients \\n12 years of age and older.', ' \\n1.9 Uveitis \\nHUMIRA is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis \\nin adults and pediatric patients 2 years of age and older.', ' \\n2 DOSAGE AND ADMINISTRATION \\n2.1 Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis \\nThe recommended subcutaneous dosage of HUMIRA for adult patients with rheumatoid arthritis \\n(RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) is 40 mg administered every other \\nweek.', 'Methotrexate (MTX), other non-biologic DMARDS, glucocorticoids, nonsteroidal anti-\\ninflammatory drugs (NSAIDs), and/or analgesics may be continued during treatment with \\nHUMIRA.', 'In the treatment of RA, some patients not taking concomitant MTX may derive \\nadditional benefit from increasing the dosage of HUMIRA to 40 mg every week or 80 mg every \\nother week.', ' \\n2.2 Juvenile Idiopathic Arthritis or Pediatric Uveitis \\nThe recommended subcutaneous dosage of HUMIRA for patients 2 years of age and older with \\npolyarticular juvenile idiopathic arthritis (JIA) or pediatric uveitis is based on weight as shown \\nbelow.', 'MTX, glucocorticoids, NSAIDs, and/or analgesics may be continued during treatment \\nwith HUMIRA.', ' \\n \\n  \\nPediatric Weight \\n(2 Years of Age and older) \\nRecommended Dosage \\n10 kg (22 lbs) to less than 15 kg (33 lbs) \\n10 mg every other week  \\n15 kg (33 lbs) to less than 30 kg (66 lbs) \\n20 mg every other week \\n30 kg (66 lbs) and greater \\n40 mg every other week \\n \\n  \\nHUMIRA has not been studied in patients with polyarticular JIA or pediatric uveitis less than 2 \\nyears of age or in patients with a weight below 10 kg.', ' \\n2.3 Crohn’s Disease \\nAdults \\nThe recommended subcutaneous dosage of HUMIRA for adult patients with Crohn’s disease \\n(CD) is 160 mg initially on Day 1 (given in one day or split over two consecutive days), \\nfollowed by 80 mg two weeks later (Day 15).', 'Two weeks later (Day 29) begin a dosage of 40 mg \\n'], 'page_sentence_count_spacy': 11}\n",
            "{'page_number': 6, 'text': 'every other week. Aminosalicylates and/or corticosteroids may be continued during treatment \\nwith HUMIRA. Azathioprine, 6-mercaptopurine (6-MP) [see Warnings and Precautions (5.2)] \\nor MTX may be continued during treatment with HUMIRA if necessary.  \\nPediatrics  \\nThe recommended subcutaneous dosage of HUMIRA for pediatric patients 6 years of age and \\nolder with Crohn’s disease (CD) is based on body weight as shown below:  \\n \\n  \\n \\nPediatric Weight \\n \\nRecommended Dosage \\nDays 1 through 15 \\nStarting on Day 29  \\n17 kg (37 lbs) to  \\nless than 40 kg (88 lbs)  \\nDay 1: 80 mg \\nDay 15: 40 mg \\n20 mg every other week \\n40 kg (88 lbs) and greater \\nDay 1: 160 mg (single dose or split \\nover two consecutive days) \\nDay 15: 80 mg \\n40 mg every other week \\n \\n  \\n2.4 Ulcerative Colitis  \\nAdults \\nThe recommended subcutaneous dosage of HUMIRA for adult patients with ulcerative colitis is \\n160 mg initially on Day 1 (given in one day or split over two consecutive days), followed by 80 \\nmg two weeks later (Day 15). Two weeks later (Day 29) continue with a dosage of 40 mg every \\nother week.  \\nDiscontinue HUMIRA in adult patients without evidence of clinical remission by eight weeks \\n(Day 57) of therapy. Aminosalicylates and/or corticosteroids may be continued during treatment \\nwith HUMIRA. Azathioprine and 6-mercaptopurine (6-MP) [see Warnings and Precautions \\n(5.2)] may be continued during treatment with HUMIRA if necessary.  \\nPediatrics \\nThe recommended subcutaneous dosage of HUMIRA for pediatric patients 5 years of age and \\nolder with ulcerative colitis is based on body weight as shown below: \\n \\nPediatric Weight \\nRecommended Dosage \\nDays 1 through 15 \\nStarting on Day 29* \\n20 kg (44 lbs) to  \\nless than 40 kg (88 lbs) \\nDay 1:  80 mg  \\nDay 8:  40 mg  \\nDay 15: 40 mg  \\n40 mg every other week \\nor \\n20 mg every week \\n40 kg (88 lbs) and greater \\nDay 1:  160 mg (single dose or \\nsplit over two consecutive days) \\nDay 8:  80 mg  \\nDay 15:  80 mg  \\n80 mg every other week \\nor \\n40 mg every week \\n* Continue the recommended pediatric dosage in patients who turn 18 years of age and who are well-controlled on \\ntheir HUMIRA regimen. \\n', 'processed_text': {'sentences': [{'original_sentence': 'every other week.', 'tokens': ['every', 'week', '.'], 'lemmatized': ['every', 'week', '.'], 'stemmed': ['everi', 'week', '.'], 'dependencies': [('everi', 'amod'), ('week', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Aminosalicylates and/or corticosteroids may be continued during treatment \\nwith HUMIRA.', 'tokens': ['Aminosalicylates', 'and/or', 'corticosteroids', 'may', 'continued', 'treatment', 'HUMIRA', '.'], 'lemmatized': ['Aminosalicylates', 'and/or', 'corticosteroid', 'may', 'continued', 'treatment', 'HUMIRA', '.'], 'stemmed': ['aminosalicyl', 'and/or', 'corticosteroid', 'may', 'continu', 'treatment', 'humira', '.'], 'dependencies': [('aminosalicyl', 'nsubj'), ('and/or', 'cc'), ('corticosteroid', 'conj'), ('may', 'aux'), ('continu', 'ROOT'), ('treatment', 'compound'), ('humira', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Azathioprine, 6-mercaptopurine (6-MP) [see Warnings and Precautions (5.2)] \\nor MTX may be continued during treatment with HUMIRA if necessary.', 'tokens': ['Azathioprine', ',', '6-mercaptopurine', '(', '6-MP', ')', '[', 'see', 'Warnings', 'Precautions', '(', '5.2', ')', ']', 'MTX', 'may', 'continued', 'treatment', 'HUMIRA', 'necessary', '.'], 'lemmatized': ['Azathioprine', ',', '6-mercaptopurine', '(', '6-MP', ')', '[', 'see', 'Warnings', 'Precautions', '(', '5.2', ')', ']', 'MTX', 'may', 'continued', 'treatment', 'HUMIRA', 'necessary', '.'], 'stemmed': ['azathioprin', ',', '6-mercaptopurin', '(', '6-mp', ')', '[', 'see', 'warn', 'precaut', '(', '5.2', ')', ']', 'mtx', 'may', 'continu', 'treatment', 'humira', 'necessari', '.'], 'dependencies': [('azathioprin', 'npadvmod'), (',', 'punct'), ('6', 'nummod'), ('-', 'punct'), ('mercaptopurin', 'ROOT'), ('(', 'punct'), ('6', 'nummod'), ('-', 'punct'), ('mp', 'appos'), (')', 'punct'), ('[', 'punct'), ('see', 'ROOT'), ('warn', 'dep'), ('precaut', 'dobj'), ('(', 'punct'), ('5.2', 'npadvmod'), (')', 'punct'), (']', 'punct'), ('mtx', 'ROOT'), ('may', 'aux'), ('continu', 'ccomp'), ('treatment', 'compound'), ('humira', 'compound'), ('necessari', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Pediatrics  \\nThe recommended subcutaneous dosage of HUMIRA for pediatric patients 6 years of age and \\nolder with Crohn’s disease (CD) is based on body weight as shown below:  \\n \\n  \\n \\nPediatric Weight \\n \\nRecommended Dosage \\nDays 1 through 15 \\nStarting on Day 29  \\n17 kg (37 lbs) to  \\nless than 40 kg (88 lbs)  \\nDay 1: 80 mg \\nDay 15: 40 mg \\n20 mg every other week \\n40 kg (88 lbs) and greater \\nDay 1: 160 mg (single dose or split \\nover two consecutive days) \\nDay 15: 80 mg \\n40 mg every other week \\n \\n  \\n2.4 Ulcerative Colitis  \\nAdults \\nThe recommended subcutaneous dosage of HUMIRA for adult patients with ulcerative colitis is \\n160 mg initially on Day 1 (given in one day or split over two consecutive days), followed by 80 \\nmg two weeks later (Day 15).', 'tokens': ['Pediatrics', 'recommended', 'subcutaneous', 'dosage', 'HUMIRA', 'pediatric', 'patients', '6', 'years', 'age', 'older', 'Crohn', '’', 'disease', '(', 'CD', ')', 'based', 'body', 'weight', 'shown', ':', 'Pediatric', 'Weight', 'Recommended', 'Dosage', 'Days', '1', '15', 'Starting', 'Day', '29', '17', 'kg', '(', '37', 'lbs', ')', 'less', '40', 'kg', '(', '88', 'lbs', ')', 'Day', '1', ':', '80', 'mg', 'Day', '15', ':', '40', 'mg', '20', 'mg', 'every', 'week', '40', 'kg', '(', '88', 'lbs', ')', 'greater', 'Day', '1', ':', '160', 'mg', '(', 'single', 'dose', 'split', 'two', 'consecutive', 'days', ')', 'Day', '15', ':', '80', 'mg', '40', 'mg', 'every', 'week', '2.4', 'Ulcerative', 'Colitis', 'Adults', 'recommended', 'subcutaneous', 'dosage', 'HUMIRA', 'adult', 'patients', 'ulcerative', 'colitis', '160', 'mg', 'initially', 'Day', '1', '(', 'given', 'one', 'day', 'split', 'two', 'consecutive', 'days', ')', ',', 'followed', '80', 'mg', 'two', 'weeks', 'later', '(', 'Day', '15', ')', '.'], 'lemmatized': ['Pediatrics', 'recommended', 'subcutaneous', 'dosage', 'HUMIRA', 'pediatric', 'patient', '6', 'year', 'age', 'older', 'Crohn', '’', 'disease', '(', 'CD', ')', 'based', 'body', 'weight', 'shown', ':', 'Pediatric', 'Weight', 'Recommended', 'Dosage', 'Days', '1', '15', 'Starting', 'Day', '29', '17', 'kg', '(', '37', 'lb', ')', 'less', '40', 'kg', '(', '88', 'lb', ')', 'Day', '1', ':', '80', 'mg', 'Day', '15', ':', '40', 'mg', '20', 'mg', 'every', 'week', '40', 'kg', '(', '88', 'lb', ')', 'greater', 'Day', '1', ':', '160', 'mg', '(', 'single', 'dose', 'split', 'two', 'consecutive', 'day', ')', 'Day', '15', ':', '80', 'mg', '40', 'mg', 'every', 'week', '2.4', 'Ulcerative', 'Colitis', 'Adults', 'recommended', 'subcutaneous', 'dosage', 'HUMIRA', 'adult', 'patient', 'ulcerative', 'colitis', '160', 'mg', 'initially', 'Day', '1', '(', 'given', 'one', 'day', 'split', 'two', 'consecutive', 'day', ')', ',', 'followed', '80', 'mg', 'two', 'week', 'later', '(', 'Day', '15', ')', '.'], 'stemmed': ['pediatr', 'recommend', 'subcutan', 'dosag', 'humira', 'pediatr', 'patient', '6', 'year', 'age', 'older', 'crohn', '’', 'diseas', '(', 'cd', ')', 'base', 'bodi', 'weight', 'shown', ':', 'pediatr', 'weight', 'recommend', 'dosag', 'day', '1', '15', 'start', 'day', '29', '17', 'kg', '(', '37', 'lb', ')', 'less', '40', 'kg', '(', '88', 'lb', ')', 'day', '1', ':', '80', 'mg', 'day', '15', ':', '40', 'mg', '20', 'mg', 'everi', 'week', '40', 'kg', '(', '88', 'lb', ')', 'greater', 'day', '1', ':', '160', 'mg', '(', 'singl', 'dose', 'split', 'two', 'consecut', 'day', ')', 'day', '15', ':', '80', 'mg', '40', 'mg', 'everi', 'week', '2.4', 'ulcer', 'coliti', 'adult', 'recommend', 'subcutan', 'dosag', 'humira', 'adult', 'patient', 'ulcer', 'coliti', '160', 'mg', 'initi', 'day', '1', '(', 'given', 'one', 'day', 'split', 'two', 'consecut', 'day', ')', ',', 'follow', '80', 'mg', 'two', 'week', 'later', '(', 'day', '15', ')', '.'], 'dependencies': [('pediatr', 'nsubj'), ('recommend', 'ROOT'), ('subcutan', 'compound'), ('dosag', 'nmod'), ('humira', 'nmod'), ('pediatr', 'nmod'), ('patient', 'dobj'), ('6', 'nummod'), ('year', 'compound'), ('age', 'appos'), ('older', 'amod'), ('crohn', 'nmod'), ('’', 'punct'), ('diseas', 'dobj'), ('(', 'punct'), ('cd', 'nmod'), (')', 'punct'), ('base', 'compound'), ('bodi', 'compound'), ('weight', 'appos'), ('shown', 'advcl'), (':', 'punct'), ('pediatr', 'amod'), ('weight', 'nsubj'), ('recommend', 'ccomp'), ('dosag', 'compound'), ('day', 'npadvmod'), ('1', 'compound'), ('15', 'nummod'), ('start', 'compound'), ('day', 'npadvmod'), ('29', 'compound'), ('17', 'nummod'), ('kg', 'appos'), ('(', 'punct'), ('37', 'nummod'), ('lb', 'appos'), (')', 'punct'), ('less', 'amod'), ('40', 'nummod'), ('kg', 'dobj'), ('(', 'punct'), ('88', 'nummod'), ('lb', 'appos'), (')', 'punct'), ('day', 'appos'), ('1', 'nummod'), (':', 'punct'), ('80', 'nummod'), ('mg', 'prep'), ('day', 'npadvmod'), ('15', 'nummod'), (':', 'punct'), ('40', 'quantmod'), ('mg', 'quantmod'), ('20', 'nummod'), ('mg', 'appos'), ('everi', 'amod'), ('week', 'npadvmod'), ('40', 'nummod'), ('kg', 'appos'), ('(', 'punct'), ('88', 'nummod'), ('lb', 'parataxis'), (')', 'punct'), ('greater', 'amod'), ('day', 'npadvmod'), ('1', 'nummod'), (':', 'punct'), ('160', 'nummod'), ('mg', 'nsubj'), ('(', 'punct'), ('singl', 'compound'), ('dose', 'nsubj'), ('split', 'ROOT'), ('two', 'nummod'), ('consecut', 'compound'), ('day', 'npadvmod'), (')', 'punct'), ('day', 'nsubj'), ('15', 'nummod'), (':', 'punct'), ('80', 'quantmod'), ('mg', 'quantmod'), ('40', 'nummod'), ('mg', 'npadvmod'), ('everi', 'amod'), ('week', 'npadvmod'), ('2.4', 'nummod'), ('ulcer', 'npadvmod'), ('coliti', 'compound'), ('adult', 'nsubj'), ('recommend', 'ROOT'), ('subcutan', 'compound'), ('dosag', 'compound'), ('humira', 'compound'), ('adult', 'compound'), ('patient', 'compound'), ('ulcer', 'dobj'), ('coliti', 'prep'), ('160', 'nummod'), ('mg', 'compound'), ('initi', 'compound'), ('day', 'npadvmod'), ('1', 'nummod'), ('(', 'punct'), ('given', 'prep'), ('one', 'nummod'), ('day', 'npadvmod'), ('split', 'pcomp'), ('two', 'nummod'), ('consecut', 'compound'), ('day', 'npadvmod'), (')', 'punct'), (',', 'punct'), ('follow', 'advcl'), ('80', 'nummod'), ('mg', 'dobj'), ('two', 'nummod'), ('week', 'npadvmod'), ('later', 'advmod'), ('(', 'punct'), ('day', 'npadvmod'), ('15', 'nummod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Two weeks later (Day 29) continue with a dosage of 40 mg every \\nother week.', 'tokens': ['Two', 'weeks', 'later', '(', 'Day', '29', ')', 'continue', 'dosage', '40', 'mg', 'every', 'week', '.'], 'lemmatized': ['Two', 'week', 'later', '(', 'Day', '29', ')', 'continue', 'dosage', '40', 'mg', 'every', 'week', '.'], 'stemmed': ['two', 'week', 'later', '(', 'day', '29', ')', 'continu', 'dosag', '40', 'mg', 'everi', 'week', '.'], 'dependencies': [('two', 'nummod'), ('week', 'npadvmod'), ('later', 'advmod'), ('(', 'punct'), ('day', 'nmod'), ('29', 'nummod'), (')', 'punct'), ('continu', 'compound'), ('dosag', 'ROOT'), ('40', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Discontinue HUMIRA in adult patients without evidence of clinical remission by eight weeks \\n(Day 57) of therapy.', 'tokens': ['Discontinue', 'HUMIRA', 'adult', 'patients', 'without', 'evidence', 'clinical', 'remission', 'eight', 'weeks', '(', 'Day', '57', ')', 'therapy', '.'], 'lemmatized': ['Discontinue', 'HUMIRA', 'adult', 'patient', 'without', 'evidence', 'clinical', 'remission', 'eight', 'week', '(', 'Day', '57', ')', 'therapy', '.'], 'stemmed': ['discontinu', 'humira', 'adult', 'patient', 'without', 'evid', 'clinic', 'remiss', 'eight', 'week', '(', 'day', '57', ')', 'therapi', '.'], 'dependencies': [('discontinu', 'compound'), ('humira', 'compound'), ('adult', 'compound'), ('patient', 'nsubj'), ('without', 'prep'), ('evid', 'compound'), ('clinic', 'compound'), ('remiss', 'pobj'), ('eight', 'nummod'), ('week', 'npadvmod'), ('(', 'punct'), ('day', 'npadvmod'), ('57', 'nummod'), (')', 'punct'), ('therapi', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Aminosalicylates and/or corticosteroids may be continued during treatment \\nwith HUMIRA.', 'tokens': ['Aminosalicylates', 'and/or', 'corticosteroids', 'may', 'continued', 'treatment', 'HUMIRA', '.'], 'lemmatized': ['Aminosalicylates', 'and/or', 'corticosteroid', 'may', 'continued', 'treatment', 'HUMIRA', '.'], 'stemmed': ['aminosalicyl', 'and/or', 'corticosteroid', 'may', 'continu', 'treatment', 'humira', '.'], 'dependencies': [('aminosalicyl', 'nsubj'), ('and/or', 'cc'), ('corticosteroid', 'conj'), ('may', 'aux'), ('continu', 'ROOT'), ('treatment', 'compound'), ('humira', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Azathioprine and 6-mercaptopurine (6-MP) [see Warnings and Precautions \\n(5.2)] may be continued during treatment with HUMIRA if necessary.', 'tokens': ['Azathioprine', '6-mercaptopurine', '(', '6-MP', ')', '[', 'see', 'Warnings', 'Precautions', '(', '5.2', ')', ']', 'may', 'continued', 'treatment', 'HUMIRA', 'necessary', '.'], 'lemmatized': ['Azathioprine', '6-mercaptopurine', '(', '6-MP', ')', '[', 'see', 'Warnings', 'Precautions', '(', '5.2', ')', ']', 'may', 'continued', 'treatment', 'HUMIRA', 'necessary', '.'], 'stemmed': ['azathioprin', '6-mercaptopurin', '(', '6-mp', ')', '[', 'see', 'warn', 'precaut', '(', '5.2', ')', ']', 'may', 'continu', 'treatment', 'humira', 'necessari', '.'], 'dependencies': [('azathioprin', 'ROOT'), ('6', 'nummod'), ('-', 'punct'), ('mercaptopurin', 'appos'), ('(', 'punct'), ('6', 'nummod'), ('-', 'punct'), ('mp', 'appos'), (')', 'punct'), ('[', 'punct'), ('see', 'ROOT'), ('warn', 'dep'), ('precaut', 'dobj'), ('(', 'punct'), ('5.2', 'npadvmod'), (')', 'punct'), (']', 'punct'), ('may', 'aux'), ('continu', 'ccomp'), ('treatment', 'compound'), ('humira', 'compound'), ('necessari', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Pediatrics \\nThe recommended subcutaneous dosage of HUMIRA for pediatric patients 5 years of age and \\nolder with ulcerative colitis is based on body weight as shown below: \\n \\nPediatric Weight \\nRecommended Dosage \\nDays 1 through 15 \\nStarting on Day 29* \\n20 kg (44 lbs) to  \\nless than 40 kg (88 lbs) \\nDay 1:  80 mg  \\nDay 8:  40 mg  \\nDay 15: 40 mg  \\n40 mg every other week \\nor \\n20 mg every week \\n40 kg (88 lbs) and greater \\nDay 1:  160 mg (single dose or \\nsplit over two consecutive days) \\nDay 8:  80 mg  \\nDay 15:  80 mg  \\n80 mg every other week \\nor \\n40 mg every week \\n* Continue the recommended pediatric dosage in patients who turn 18 years of age and who are well-controlled on \\ntheir HUMIRA regimen.', 'tokens': ['Pediatrics', 'recommended', 'subcutaneous', 'dosage', 'HUMIRA', 'pediatric', 'patients', '5', 'years', 'age', 'older', 'ulcerative', 'colitis', 'based', 'body', 'weight', 'shown', ':', 'Pediatric', 'Weight', 'Recommended', 'Dosage', 'Days', '1', '15', 'Starting', 'Day', '29', '*', '20', 'kg', '(', '44', 'lbs', ')', 'less', '40', 'kg', '(', '88', 'lbs', ')', 'Day', '1', ':', '80', 'mg', 'Day', '8', ':', '40', 'mg', 'Day', '15', ':', '40', 'mg', '40', 'mg', 'every', 'week', '20', 'mg', 'every', 'week', '40', 'kg', '(', '88', 'lbs', ')', 'greater', 'Day', '1', ':', '160', 'mg', '(', 'single', 'dose', 'split', 'two', 'consecutive', 'days', ')', 'Day', '8', ':', '80', 'mg', 'Day', '15', ':', '80', 'mg', '80', 'mg', 'every', 'week', '40', 'mg', 'every', 'week', '*', 'Continue', 'recommended', 'pediatric', 'dosage', 'patients', 'turn', '18', 'years', 'age', 'well-controlled', 'HUMIRA', 'regimen', '.'], 'lemmatized': ['Pediatrics', 'recommended', 'subcutaneous', 'dosage', 'HUMIRA', 'pediatric', 'patient', '5', 'year', 'age', 'older', 'ulcerative', 'colitis', 'based', 'body', 'weight', 'shown', ':', 'Pediatric', 'Weight', 'Recommended', 'Dosage', 'Days', '1', '15', 'Starting', 'Day', '29', '*', '20', 'kg', '(', '44', 'lb', ')', 'less', '40', 'kg', '(', '88', 'lb', ')', 'Day', '1', ':', '80', 'mg', 'Day', '8', ':', '40', 'mg', 'Day', '15', ':', '40', 'mg', '40', 'mg', 'every', 'week', '20', 'mg', 'every', 'week', '40', 'kg', '(', '88', 'lb', ')', 'greater', 'Day', '1', ':', '160', 'mg', '(', 'single', 'dose', 'split', 'two', 'consecutive', 'day', ')', 'Day', '8', ':', '80', 'mg', 'Day', '15', ':', '80', 'mg', '80', 'mg', 'every', 'week', '40', 'mg', 'every', 'week', '*', 'Continue', 'recommended', 'pediatric', 'dosage', 'patient', 'turn', '18', 'year', 'age', 'well-controlled', 'HUMIRA', 'regimen', '.'], 'stemmed': ['pediatr', 'recommend', 'subcutan', 'dosag', 'humira', 'pediatr', 'patient', '5', 'year', 'age', 'older', 'ulcer', 'coliti', 'base', 'bodi', 'weight', 'shown', ':', 'pediatr', 'weight', 'recommend', 'dosag', 'day', '1', '15', 'start', 'day', '29', '*', '20', 'kg', '(', '44', 'lb', ')', 'less', '40', 'kg', '(', '88', 'lb', ')', 'day', '1', ':', '80', 'mg', 'day', '8', ':', '40', 'mg', 'day', '15', ':', '40', 'mg', '40', 'mg', 'everi', 'week', '20', 'mg', 'everi', 'week', '40', 'kg', '(', '88', 'lb', ')', 'greater', 'day', '1', ':', '160', 'mg', '(', 'singl', 'dose', 'split', 'two', 'consecut', 'day', ')', 'day', '8', ':', '80', 'mg', 'day', '15', ':', '80', 'mg', '80', 'mg', 'everi', 'week', '40', 'mg', 'everi', 'week', '*', 'continu', 'recommend', 'pediatr', 'dosag', 'patient', 'turn', '18', 'year', 'age', 'well-control', 'humira', 'regimen', '.'], 'dependencies': [('pediatr', 'nsubj'), ('recommend', 'ROOT'), ('subcutan', 'compound'), ('dosag', 'nmod'), ('humira', 'nmod'), ('pediatr', 'advmod'), ('patient', 'dobj'), ('5', 'nummod'), ('year', 'compound'), ('age', 'appos'), ('older', 'amod'), ('ulcer', 'compound'), ('coliti', 'compound'), ('base', 'compound'), ('bodi', 'compound'), ('weight', 'nsubj'), ('shown', 'advcl'), (':', 'punct'), ('pediatr', 'amod'), ('weight', 'nsubj'), ('recommend', 'ccomp'), ('dosag', 'compound'), ('day', 'npadvmod'), ('1', 'compound'), ('15', 'nummod'), ('start', 'compound'), ('day', 'npadvmod'), ('29', 'nummod'), ('*', 'punct'), ('20', 'nummod'), ('kg', 'appos'), ('(', 'punct'), ('44', 'nummod'), ('lb', 'appos'), (')', 'punct'), ('less', 'amod'), ('40', 'nummod'), ('kg', 'dobj'), ('(', 'punct'), ('88', 'nummod'), ('lb', 'appos'), (')', 'punct'), ('day', 'appos'), ('1', 'nummod'), (':', 'punct'), ('80', 'nummod'), ('mg', 'prep'), ('day', 'npadvmod'), ('8', 'nummod'), (':', 'punct'), ('40', 'prep'), ('mg', 'compound'), ('day', 'npadvmod'), ('15', 'nummod'), (':', 'punct'), ('40', 'quantmod'), ('mg', 'quantmod'), ('40', 'nummod'), ('mg', 'appos'), ('everi', 'amod'), ('week', 'npadvmod'), ('20', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'npadvmod'), ('40', 'nummod'), ('kg', 'appos'), ('(', 'punct'), ('88', 'nummod'), ('lb', 'parataxis'), (')', 'punct'), ('greater', 'amod'), ('day', 'npadvmod'), ('1', 'nummod'), (':', 'punct'), ('160', 'nummod'), ('mg', 'nsubj'), ('(', 'punct'), ('singl', 'compound'), ('dose', 'nsubj'), ('split', 'ROOT'), ('two', 'nummod'), ('consecut', 'compound'), ('day', 'npadvmod'), (')', 'punct'), ('day', 'npadvmod'), ('8', 'nummod'), (':', 'punct'), ('80', 'nummod'), ('mg', 'prep'), ('day', 'npadvmod'), ('15', 'nummod'), (':', 'punct'), ('80', 'quantmod'), ('mg', 'quantmod'), ('80', 'nummod'), ('mg', 'npadvmod'), ('everi', 'amod'), ('week', 'npadvmod'), ('40', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'npadvmod'), ('*', 'punct'), ('continu', 'nsubj'), ('recommend', 'ROOT'), ('pediatr', 'amod'), ('dosag', 'compound'), ('patient', 'compound'), ('turn', 'dobj'), ('18', 'nummod'), ('year', 'compound'), ('age', 'nmod'), ('well', 'amod'), ('-', 'punct'), ('control', 'compound'), ('humira', 'compound'), ('regimen', 'dobj'), ('.', 'punct')]}], 'text': 'every other week. Aminosalicylates and/or corticosteroids may be continued during treatment \\nwith HUMIRA. Azathioprine, 6-mercaptopurine (6-MP) [see Warnings and Precautions (5.2)] \\nor MTX may be continued during treatment with HUMIRA if necessary.  \\nPediatrics  \\nThe recommended subcutaneous dosage of HUMIRA for pediatric patients 6 years of age and \\nolder with Crohn’s disease (CD) is based on body weight as shown below:  \\n \\n  \\n \\nPediatric Weight \\n \\nRecommended Dosage \\nDays 1 through 15 \\nStarting on Day 29  \\n17 kg (37 lbs) to  \\nless than 40 kg (88 lbs)  \\nDay 1: 80 mg \\nDay 15: 40 mg \\n20 mg every other week \\n40 kg (88 lbs) and greater \\nDay 1: 160 mg (single dose or split \\nover two consecutive days) \\nDay 15: 80 mg \\n40 mg every other week \\n \\n  \\n2.4 Ulcerative Colitis  \\nAdults \\nThe recommended subcutaneous dosage of HUMIRA for adult patients with ulcerative colitis is \\n160 mg initially on Day 1 (given in one day or split over two consecutive days), followed by 80 \\nmg two weeks later (Day 15). Two weeks later (Day 29) continue with a dosage of 40 mg every \\nother week.  \\nDiscontinue HUMIRA in adult patients without evidence of clinical remission by eight weeks \\n(Day 57) of therapy. Aminosalicylates and/or corticosteroids may be continued during treatment \\nwith HUMIRA. Azathioprine and 6-mercaptopurine (6-MP) [see Warnings and Precautions \\n(5.2)] may be continued during treatment with HUMIRA if necessary.  \\nPediatrics \\nThe recommended subcutaneous dosage of HUMIRA for pediatric patients 5 years of age and \\nolder with ulcerative colitis is based on body weight as shown below: \\n \\nPediatric Weight \\nRecommended Dosage \\nDays 1 through 15 \\nStarting on Day 29* \\n20 kg (44 lbs) to  \\nless than 40 kg (88 lbs) \\nDay 1:  80 mg  \\nDay 8:  40 mg  \\nDay 15: 40 mg  \\n40 mg every other week \\nor \\n20 mg every week \\n40 kg (88 lbs) and greater \\nDay 1:  160 mg (single dose or \\nsplit over two consecutive days) \\nDay 8:  80 mg  \\nDay 15:  80 mg  \\n80 mg every other week \\nor \\n40 mg every week \\n* Continue the recommended pediatric dosage in patients who turn 18 years of age and who are well-controlled on \\ntheir HUMIRA regimen. \\n'}, 'page_char_count': 2124, 'page_word_count': 355, 'sentences': ['every other week.', 'Aminosalicylates and/or corticosteroids may be continued during treatment \\nwith HUMIRA.', 'Azathioprine, 6-mercaptopurine (6-MP) [see Warnings and Precautions (5.2)] \\nor MTX may be continued during treatment with HUMIRA if necessary.', ' \\nPediatrics  \\nThe recommended subcutaneous dosage of HUMIRA for pediatric patients 6 years of age and \\nolder with Crohn’s disease (CD) is based on body weight as shown below:  \\n \\n  \\n \\nPediatric Weight \\n \\nRecommended Dosage \\nDays 1 through 15 \\nStarting on Day 29  \\n17 kg (37 lbs) to  \\nless than 40 kg (88 lbs)  \\nDay 1: 80 mg \\nDay 15: 40 mg \\n20 mg every other week \\n40 kg (88 lbs) and greater \\nDay 1: 160 mg (single dose or split \\nover two consecutive days) \\nDay 15: 80 mg \\n40 mg every other week \\n \\n  \\n2.4 Ulcerative Colitis  \\nAdults \\nThe recommended subcutaneous dosage of HUMIRA for adult patients with ulcerative colitis is \\n160 mg initially on Day 1 (given in one day or split over two consecutive days), followed by 80 \\nmg two weeks later (Day 15).', 'Two weeks later (Day 29) continue with a dosage of 40 mg every \\nother week.', ' \\nDiscontinue HUMIRA in adult patients without evidence of clinical remission by eight weeks \\n(Day 57) of therapy.', 'Aminosalicylates and/or corticosteroids may be continued during treatment \\nwith HUMIRA.', 'Azathioprine and 6-mercaptopurine (6-MP) [see Warnings and Precautions \\n(5.2)] may be continued during treatment with HUMIRA if necessary.', ' \\nPediatrics \\nThe recommended subcutaneous dosage of HUMIRA for pediatric patients 5 years of age and \\nolder with ulcerative colitis is based on body weight as shown below: \\n \\nPediatric Weight \\nRecommended Dosage \\nDays 1 through 15 \\nStarting on Day 29* \\n20 kg (44 lbs) to  \\nless than 40 kg (88 lbs) \\nDay 1:  80 mg  \\nDay 8:  40 mg  \\nDay 15: 40 mg  \\n40 mg every other week \\nor \\n20 mg every week \\n40 kg (88 lbs) and greater \\nDay 1:  160 mg (single dose or \\nsplit over two consecutive days) \\nDay 8:  80 mg  \\nDay 15:  80 mg  \\n80 mg every other week \\nor \\n40 mg every week \\n* Continue the recommended pediatric dosage in patients who turn 18 years of age and who are well-controlled on \\ntheir HUMIRA regimen.', '\\n'], 'page_sentence_count_spacy': 10}\n",
            "{'page_number': 7, 'text': '2.5 Plaque Psoriasis or Adult Uveitis \\nThe recommended subcutaneous dosage of HUMIRA for adult patients with plaque psoriasis \\n(Ps) or Uveitis (UV) is an initial dose of 80 mg, followed by 40 mg given every other week \\nstarting one week after the initial dose. The use of HUMIRA in moderate to severe chronic Ps \\nbeyond one year has not been evaluated in controlled clinical studies.  \\n2.6 Hidradenitis Suppurativa \\nAdults \\nThe recommended subcutaneous dosage of HUMIRA for adult patients with hidradenitis \\nsuppurativa (HS) is an initial dose of 160 mg (given in one day or split over two consecutive \\ndays), followed by 80 mg two weeks later (Day 15). Begin 40 mg weekly or 80 mg every other \\nweek dosing two weeks later (Day 29).  \\nAdolescents \\nThe recommended subcutaneous dosage of HUMIRA for adolescent patients 12 years of age and \\nolder weighing at least 30 kg with hidradenitis suppurativa (HS) is based on body weight as \\nshown below [see Use in Specific Populations (8.4) and Clinical Pharmacology (12.3)]:  \\n \\n  \\nBody Weight of Adolescent \\nPatients \\n(12 years of age and older) \\nRecommended Dosage  \\n30 kg (66 lbs) to less than 60 kg \\n(132 lbs) \\n• Day 1: 80 mg  \\n• Day 8 and subsequent doses: 40 mg every other week \\n60 kg (132 lbs) and greater \\n• Day 1: 160 mg (given in one day or split over two \\nconsecutive days); \\n• Day 15: 80 mg  \\n• Day 29 and subsequent doses:  40 mg every week or 80 mg \\nevery other week  \\n \\n  \\n2.7 Monitoring to Assess Safety \\nPrior to initiating HUMIRA and periodically during therapy, evaluate patients for active \\ntuberculosis and test for latent infection [see Warnings and Precautions (5.1)].  \\n2.8 General Considerations for Administration \\nHUMIRA is intended for use under the guidance and supervision of a physician. A patient may \\nself-inject HUMIRA or a caregiver may inject HUMIRA using either the HUMIRA Pen or \\nprefilled syringe if a physician determines that it is appropriate, and with medical follow-up, as \\nnecessary, after proper training in subcutaneous injection technique.  \\n HUMIRA can be taken out of the refrigerator for 15 to 30 minutes before injecting to allow the \\nliquid to come to room temperature. Do not remove the cap or cover while allowing it to reach \\nroom temperature. Carefully inspect the solution in the HUMIRA Pen, prefilled syringe, or \\nsingle-dose institutional use vial for particulate matter and discoloration prior to subcutaneous \\nadministration. If particulates and discolorations are noted, do not use the product. HUMIRA \\n', 'processed_text': {'sentences': [{'original_sentence': '2.5 Plaque Psoriasis or Adult Uveitis \\nThe recommended subcutaneous dosage of HUMIRA for adult patients with plaque psoriasis \\n(Ps) or Uveitis (UV) is an initial dose of 80 mg, followed by 40 mg given every other week \\nstarting one week after the initial dose.', 'tokens': ['2.5', 'Plaque', 'Psoriasis', 'Adult', 'Uveitis', 'recommended', 'subcutaneous', 'dosage', 'HUMIRA', 'adult', 'patients', 'plaque', 'psoriasis', '(', 'Ps', ')', 'Uveitis', '(', 'UV', ')', 'initial', 'dose', '80', 'mg', ',', 'followed', '40', 'mg', 'given', 'every', 'week', 'starting', 'one', 'week', 'initial', 'dose', '.'], 'lemmatized': ['2.5', 'Plaque', 'Psoriasis', 'Adult', 'Uveitis', 'recommended', 'subcutaneous', 'dosage', 'HUMIRA', 'adult', 'patient', 'plaque', 'psoriasis', '(', 'Ps', ')', 'Uveitis', '(', 'UV', ')', 'initial', 'dose', '80', 'mg', ',', 'followed', '40', 'mg', 'given', 'every', 'week', 'starting', 'one', 'week', 'initial', 'dose', '.'], 'stemmed': ['2.5', 'plaqu', 'psoriasi', 'adult', 'uveiti', 'recommend', 'subcutan', 'dosag', 'humira', 'adult', 'patient', 'plaqu', 'psoriasi', '(', 'ps', ')', 'uveiti', '(', 'uv', ')', 'initi', 'dose', '80', 'mg', ',', 'follow', '40', 'mg', 'given', 'everi', 'week', 'start', 'one', 'week', 'initi', 'dose', '.'], 'dependencies': [('2.5', 'nummod'), ('plaqu', 'compound'), ('psoriasi', 'compound'), ('adult', 'compound'), ('uveiti', 'nsubj'), ('recommend', 'ROOT'), ('subcutan', 'nmod'), ('dosag', 'compound'), ('humira', 'compound'), ('adult', 'compound'), ('patient', 'compound'), ('plaqu', 'compound'), ('psoriasi', 'dobj'), ('(', 'punct'), ('ps', 'nmod'), (')', 'punct'), ('uveiti', 'appos'), ('(', 'punct'), ('uv', 'parataxis'), (')', 'punct'), ('initi', 'nsubj'), ('dose', 'ccomp'), ('80', 'nummod'), ('mg', 'dobj'), (',', 'punct'), ('follow', 'conj'), ('40', 'nummod'), ('mg', 'dobj'), ('given', 'prep'), ('everi', 'amod'), ('week', 'pobj'), ('start', 'conj'), ('one', 'nummod'), ('week', 'compound'), ('initi', 'compound'), ('dose', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The use of HUMIRA in moderate to severe chronic Ps \\nbeyond one year has not been evaluated in controlled clinical studies.', 'tokens': ['use', 'HUMIRA', 'moderate', 'severe', 'chronic', 'Ps', 'beyond', 'one', 'year', 'evaluated', 'controlled', 'clinical', 'studies', '.'], 'lemmatized': ['use', 'HUMIRA', 'moderate', 'severe', 'chronic', 'Ps', 'beyond', 'one', 'year', 'evaluated', 'controlled', 'clinical', 'study', '.'], 'stemmed': ['use', 'humira', 'moder', 'sever', 'chronic', 'ps', 'beyond', 'one', 'year', 'evalu', 'control', 'clinic', 'studi', '.'], 'dependencies': [('use', 'ROOT'), ('humira', 'compound'), ('moder', 'compound'), ('sever', 'compound'), ('chronic', 'amod'), ('ps', 'dobj'), ('beyond', 'prep'), ('one', 'nummod'), ('year', 'compound'), ('evalu', 'compound'), ('control', 'compound'), ('clinic', 'compound'), ('studi', 'pobj'), ('.', 'punct')]}, {'original_sentence': '2.6 Hidradenitis Suppurativa \\nAdults \\nThe recommended subcutaneous dosage of HUMIRA for adult patients with hidradenitis \\nsuppurativa (HS) is an initial dose of 160 mg (given in one day or split over two consecutive \\ndays), followed by 80 mg two weeks later (Day 15).', 'tokens': ['2.6', 'Hidradenitis', 'Suppurativa', 'Adults', 'recommended', 'subcutaneous', 'dosage', 'HUMIRA', 'adult', 'patients', 'hidradenitis', 'suppurativa', '(', 'HS', ')', 'initial', 'dose', '160', 'mg', '(', 'given', 'one', 'day', 'split', 'two', 'consecutive', 'days', ')', ',', 'followed', '80', 'mg', 'two', 'weeks', 'later', '(', 'Day', '15', ')', '.'], 'lemmatized': ['2.6', 'Hidradenitis', 'Suppurativa', 'Adults', 'recommended', 'subcutaneous', 'dosage', 'HUMIRA', 'adult', 'patient', 'hidradenitis', 'suppurativa', '(', 'HS', ')', 'initial', 'dose', '160', 'mg', '(', 'given', 'one', 'day', 'split', 'two', 'consecutive', 'day', ')', ',', 'followed', '80', 'mg', 'two', 'week', 'later', '(', 'Day', '15', ')', '.'], 'stemmed': ['2.6', 'hidraden', 'suppurativa', 'adult', 'recommend', 'subcutan', 'dosag', 'humira', 'adult', 'patient', 'hidraden', 'suppurativa', '(', 'hs', ')', 'initi', 'dose', '160', 'mg', '(', 'given', 'one', 'day', 'split', 'two', 'consecut', 'day', ')', ',', 'follow', '80', 'mg', 'two', 'week', 'later', '(', 'day', '15', ')', '.'], 'dependencies': [('2.6', 'nummod'), ('hidraden', 'compound'), ('suppurativa', 'compound'), ('adult', 'nsubj'), ('recommend', 'ROOT'), ('subcutan', 'compound'), ('dosag', 'compound'), ('humira', 'compound'), ('adult', 'compound'), ('patient', 'compound'), ('hidraden', 'compound'), ('suppurativa', 'nmod'), ('(', 'punct'), ('hs', 'nmod'), (')', 'punct'), ('initi', 'nsubj'), ('dose', 'ccomp'), ('160', 'nummod'), ('mg', 'dobj'), ('(', 'punct'), ('given', 'prep'), ('one', 'nummod'), ('day', 'npadvmod'), ('split', 'pcomp'), ('two', 'nummod'), ('consecut', 'compound'), ('day', 'npadvmod'), (')', 'punct'), (',', 'punct'), ('follow', 'conj'), ('80', 'nummod'), ('mg', 'dobj'), ('two', 'nummod'), ('week', 'npadvmod'), ('later', 'advmod'), ('(', 'punct'), ('day', 'npadvmod'), ('15', 'nummod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Begin 40 mg weekly or 80 mg every other \\nweek dosing two weeks later (Day 29).', 'tokens': ['Begin', '40', 'mg', 'weekly', '80', 'mg', 'every', 'week', 'dosing', 'two', 'weeks', 'later', '(', 'Day', '29', ')', '.'], 'lemmatized': ['Begin', '40', 'mg', 'weekly', '80', 'mg', 'every', 'week', 'dosing', 'two', 'week', 'later', '(', 'Day', '29', ')', '.'], 'stemmed': ['begin', '40', 'mg', 'weekli', '80', 'mg', 'everi', 'week', 'dose', 'two', 'week', 'later', '(', 'day', '29', ')', '.'], 'dependencies': [('begin', 'ROOT'), ('40', 'nummod'), ('mg', 'compound'), ('weekli', 'dobj'), ('80', 'nummod'), ('mg', 'advmod'), ('everi', 'amod'), ('week', 'compound'), ('dose', 'conj'), ('two', 'nummod'), ('week', 'npadvmod'), ('later', 'advmod'), ('(', 'punct'), ('day', 'npadvmod'), ('29', 'nummod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Adolescents \\nThe recommended subcutaneous dosage of HUMIRA for adolescent patients 12 years of age and \\nolder weighing at least 30 kg with hidradenitis suppurativa (HS) is based on body weight as \\nshown below [see Use in Specific Populations (8.4) and Clinical Pharmacology (12.3)]:  \\n \\n  \\nBody Weight of Adolescent \\nPatients \\n(12 years of age and older) \\nRecommended Dosage  \\n30 kg (66 lbs) to less than 60 kg \\n(132 lbs) \\n• Day 1: 80 mg  \\n• Day 8 and subsequent doses: 40 mg every other week \\n60 kg (132 lbs) and greater \\n• Day 1: 160 mg (given in one day or split over two \\nconsecutive days); \\n• Day 15: 80 mg  \\n• Day 29 and subsequent doses:  40 mg every week or 80 mg \\nevery other week  \\n \\n  \\n2.7 Monitoring to Assess Safety \\nPrior to initiating HUMIRA and periodically during therapy, evaluate patients for active \\ntuberculosis and test for latent infection [see Warnings and Precautions (5.1)].', 'tokens': ['Adolescents', 'recommended', 'subcutaneous', 'dosage', 'HUMIRA', 'adolescent', 'patients', '12', 'years', 'age', 'older', 'weighing', 'least', '30', 'kg', 'hidradenitis', 'suppurativa', '(', 'HS', ')', 'based', 'body', 'weight', 'shown', '[', 'see', 'Use', 'Specific', 'Populations', '(', '8.4', ')', 'Clinical', 'Pharmacology', '(', '12.3', ')', ']', ':', 'Body', 'Weight', 'Adolescent', 'Patients', '(', '12', 'years', 'age', 'older', ')', 'Recommended', 'Dosage', '30', 'kg', '(', '66', 'lbs', ')', 'less', '60', 'kg', '(', '132', 'lbs', ')', '•', 'Day', '1', ':', '80', 'mg', '•', 'Day', '8', 'subsequent', 'doses', ':', '40', 'mg', 'every', 'week', '60', 'kg', '(', '132', 'lbs', ')', 'greater', '•', 'Day', '1', ':', '160', 'mg', '(', 'given', 'one', 'day', 'split', 'two', 'consecutive', 'days', ')', ';', '•', 'Day', '15', ':', '80', 'mg', '•', 'Day', '29', 'subsequent', 'doses', ':', '40', 'mg', 'every', 'week', '80', 'mg', 'every', 'week', '2.7', 'Monitoring', 'Assess', 'Safety', 'Prior', 'initiating', 'HUMIRA', 'periodically', 'therapy', ',', 'evaluate', 'patients', 'active', 'tuberculosis', 'test', 'latent', 'infection', '[', 'see', 'Warnings', 'Precautions', '(', '5.1', ')', ']', '.'], 'lemmatized': ['Adolescents', 'recommended', 'subcutaneous', 'dosage', 'HUMIRA', 'adolescent', 'patient', '12', 'year', 'age', 'older', 'weighing', 'least', '30', 'kg', 'hidradenitis', 'suppurativa', '(', 'HS', ')', 'based', 'body', 'weight', 'shown', '[', 'see', 'Use', 'Specific', 'Populations', '(', '8.4', ')', 'Clinical', 'Pharmacology', '(', '12.3', ')', ']', ':', 'Body', 'Weight', 'Adolescent', 'Patients', '(', '12', 'year', 'age', 'older', ')', 'Recommended', 'Dosage', '30', 'kg', '(', '66', 'lb', ')', 'less', '60', 'kg', '(', '132', 'lb', ')', '•', 'Day', '1', ':', '80', 'mg', '•', 'Day', '8', 'subsequent', 'dos', ':', '40', 'mg', 'every', 'week', '60', 'kg', '(', '132', 'lb', ')', 'greater', '•', 'Day', '1', ':', '160', 'mg', '(', 'given', 'one', 'day', 'split', 'two', 'consecutive', 'day', ')', ';', '•', 'Day', '15', ':', '80', 'mg', '•', 'Day', '29', 'subsequent', 'dos', ':', '40', 'mg', 'every', 'week', '80', 'mg', 'every', 'week', '2.7', 'Monitoring', 'Assess', 'Safety', 'Prior', 'initiating', 'HUMIRA', 'periodically', 'therapy', ',', 'evaluate', 'patient', 'active', 'tuberculosis', 'test', 'latent', 'infection', '[', 'see', 'Warnings', 'Precautions', '(', '5.1', ')', ']', '.'], 'stemmed': ['adolesc', 'recommend', 'subcutan', 'dosag', 'humira', 'adolesc', 'patient', '12', 'year', 'age', 'older', 'weigh', 'least', '30', 'kg', 'hidraden', 'suppurativa', '(', 'hs', ')', 'base', 'bodi', 'weight', 'shown', '[', 'see', 'use', 'specif', 'popul', '(', '8.4', ')', 'clinic', 'pharmacolog', '(', '12.3', ')', ']', ':', 'bodi', 'weight', 'adolesc', 'patient', '(', '12', 'year', 'age', 'older', ')', 'recommend', 'dosag', '30', 'kg', '(', '66', 'lb', ')', 'less', '60', 'kg', '(', '132', 'lb', ')', '•', 'day', '1', ':', '80', 'mg', '•', 'day', '8', 'subsequ', 'do', ':', '40', 'mg', 'everi', 'week', '60', 'kg', '(', '132', 'lb', ')', 'greater', '•', 'day', '1', ':', '160', 'mg', '(', 'given', 'one', 'day', 'split', 'two', 'consecut', 'day', ')', ';', '•', 'day', '15', ':', '80', 'mg', '•', 'day', '29', 'subsequ', 'do', ':', '40', 'mg', 'everi', 'week', '80', 'mg', 'everi', 'week', '2.7', 'monitor', 'assess', 'safeti', 'prior', 'initi', 'humira', 'period', 'therapi', ',', 'evalu', 'patient', 'activ', 'tuberculosi', 'test', 'latent', 'infect', '[', 'see', 'warn', 'precaut', '(', '5.1', ')', ']', '.'], 'dependencies': [('adolesc', 'npadvmod'), ('recommend', 'ROOT'), ('subcutan', 'compound'), ('dosag', 'compound'), ('humira', 'dobj'), ('adolesc', 'nsubj'), ('patient', 'ccomp'), ('12', 'nummod'), ('year', 'compound'), ('age', 'dobj'), ('older', 'amod'), ('weigh', 'npadvmod'), ('least', 'advmod'), ('30', 'nummod'), ('kg', 'compound'), ('hidraden', 'compound'), ('suppurativa', 'nmod'), ('(', 'punct'), ('hs', 'nmod'), (')', 'punct'), ('base', 'compound'), ('bodi', 'compound'), ('weight', 'npadvmod'), ('shown', 'acl'), ('[', 'punct'), ('see', 'parataxis'), ('use', 'compound'), ('specif', 'compound'), ('popul', 'dobj'), ('(', 'punct'), ('8.4', 'nummod'), (')', 'punct'), ('clinic', 'compound'), ('pharmacolog', 'appos'), ('(', 'punct'), ('12.3', 'appos'), (')', 'punct'), (']', 'punct'), (':', 'punct'), ('bodi', 'compound'), ('weight', 'compound'), ('adolesc', 'compound'), ('patient', 'nsubj'), ('(', 'punct'), ('12', 'nummod'), ('year', 'compound'), ('age', 'appos'), ('older', 'amod'), (')', 'punct'), ('recommend', 'ROOT'), ('dosag', 'dobj'), ('30', 'nummod'), ('kg', 'npadvmod'), ('(', 'punct'), ('66', 'nummod'), ('lb', 'appos'), (')', 'punct'), ('less', 'amod'), ('60', 'nummod'), ('kg', 'npadvmod'), ('(', 'punct'), ('132', 'nummod'), ('lb', 'appos'), (')', 'punct'), ('•', 'nummod'), ('day', 'appos'), ('1', 'nummod'), (':', 'punct'), ('80', 'quantmod'), ('mg', 'quantmod'), ('•', 'nummod'), ('day', 'appos'), ('8', 'nummod'), ('subsequ', 'nsubj'), ('do', 'conj'), (':', 'punct'), ('40', 'nummod'), ('mg', 'advmod'), ('everi', 'amod'), ('week', 'npadvmod'), ('60', 'nummod'), ('kg', 'npadvmod'), ('(', 'punct'), ('132', 'nummod'), ('lb', 'parataxis'), (')', 'punct'), ('greater', 'advmod'), ('•', 'nummod'), ('day', 'npadvmod'), ('1', 'nummod'), (':', 'punct'), ('160', 'nummod'), ('mg', 'nsubj'), ('(', 'punct'), ('given', 'prep'), ('one', 'nummod'), ('day', 'npadvmod'), ('split', 'pcomp'), ('two', 'nummod'), ('consecut', 'compound'), ('day', 'npadvmod'), (')', 'punct'), (';', 'punct'), ('•', 'nummod'), ('day', 'dep'), ('15', 'nummod'), (':', 'punct'), ('80', 'quantmod'), ('mg', 'quantmod'), ('•', 'nummod'), ('day', 'appos'), ('29', 'nummod'), ('subsequ', 'appos'), ('do', 'conj'), (':', 'punct'), ('40', 'nummod'), ('mg', 'advmod'), ('everi', 'amod'), ('week', 'npadvmod'), ('80', 'nummod'), ('mg', 'advmod'), ('everi', 'amod'), ('week', 'npadvmod'), ('2.7', 'nummod'), ('monitor', 'compound'), ('assess', 'compound'), ('safeti', 'appos'), ('prior', 'amod'), ('initi', 'compound'), ('humira', 'compound'), ('period', 'compound'), ('therapi', 'nmod'), (',', 'punct'), ('evalu', 'npadvmod'), ('patient', 'amod'), ('activ', 'compound'), ('tuberculosi', 'compound'), ('test', 'compound'), ('latent', 'compound'), ('infect', 'dobj'), ('[', 'punct'), ('see', 'parataxis'), ('warn', 'ccomp'), ('precaut', 'dobj'), ('(', 'punct'), ('5.1', 'appos'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': '2.8 General Considerations for Administration \\nHUMIRA is intended for use under the guidance and supervision of a physician.', 'tokens': ['2.8', 'General', 'Considerations', 'Administration', 'HUMIRA', 'intended', 'use', 'guidance', 'supervision', 'physician', '.'], 'lemmatized': ['2.8', 'General', 'Considerations', 'Administration', 'HUMIRA', 'intended', 'use', 'guidance', 'supervision', 'physician', '.'], 'stemmed': ['2.8', 'gener', 'consider', 'administr', 'humira', 'intend', 'use', 'guidanc', 'supervis', 'physician', '.'], 'dependencies': [('2.8', 'nummod'), ('gener', 'nsubj'), ('consider', 'ROOT'), ('administr', 'compound'), ('humira', 'nsubj'), ('intend', 'ccomp'), ('use', 'xcomp'), ('guidanc', 'compound'), ('supervis', 'compound'), ('physician', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'A patient may \\nself-inject HUMIRA or a caregiver may inject HUMIRA using either the HUMIRA Pen or \\nprefilled syringe if a physician determines that it is appropriate, and with medical follow-up, as \\nnecessary, after proper training in subcutaneous injection technique.', 'tokens': ['patient', 'may', 'self-inject', 'HUMIRA', 'caregiver', 'may', 'inject', 'HUMIRA', 'using', 'either', 'HUMIRA', 'Pen', 'prefilled', 'syringe', 'physician', 'determines', 'appropriate', ',', 'medical', 'follow-up', ',', 'necessary', ',', 'proper', 'training', 'subcutaneous', 'injection', 'technique', '.'], 'lemmatized': ['patient', 'may', 'self-inject', 'HUMIRA', 'caregiver', 'may', 'inject', 'HUMIRA', 'using', 'either', 'HUMIRA', 'Pen', 'prefilled', 'syringe', 'physician', 'determines', 'appropriate', ',', 'medical', 'follow-up', ',', 'necessary', ',', 'proper', 'training', 'subcutaneous', 'injection', 'technique', '.'], 'stemmed': ['patient', 'may', 'self-inject', 'humira', 'caregiv', 'may', 'inject', 'humira', 'use', 'either', 'humira', 'pen', 'prefil', 'syring', 'physician', 'determin', 'appropri', ',', 'medic', 'follow-up', ',', 'necessari', ',', 'proper', 'train', 'subcutan', 'inject', 'techniqu', '.'], 'dependencies': [('patient', 'nsubj'), ('may', 'aux'), ('self', 'compound'), ('-', 'punct'), ('inject', 'compound'), ('humira', 'compound'), ('caregiv', 'nsubj'), ('may', 'aux'), ('inject', 'ROOT'), ('humira', 'dobj'), ('use', 'dobj'), ('either', 'preconj'), ('humira', 'compound'), ('pen', 'compound'), ('prefil', 'compound'), ('syring', 'compound'), ('physician', 'compound'), ('determin', 'compound'), ('appropri', 'dobj'), (',', 'punct'), ('medic', 'amod'), ('follow', 'compound'), ('-', 'punct'), ('up', 'conj'), (',', 'punct'), ('necessari', 'conj'), (',', 'punct'), ('proper', 'amod'), ('train', 'conj'), ('subcutan', 'prep'), ('inject', 'compound'), ('techniqu', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'HUMIRA can be taken out of the refrigerator for 15 to 30 minutes before injecting to allow the \\nliquid to come to room temperature.', 'tokens': ['HUMIRA', 'taken', 'refrigerator', '15', '30', 'minutes', 'injecting', 'allow', 'liquid', 'come', 'room', 'temperature', '.'], 'lemmatized': ['HUMIRA', 'taken', 'refrigerator', '15', '30', 'minute', 'injecting', 'allow', 'liquid', 'come', 'room', 'temperature', '.'], 'stemmed': ['humira', 'taken', 'refriger', '15', '30', 'minut', 'inject', 'allow', 'liquid', 'come', 'room', 'temperatur', '.'], 'dependencies': [('humira', 'nsubj'), ('taken', 'ROOT'), ('refriger', 'dobj'), ('15', 'nummod'), ('30', 'nummod'), ('minut', 'compound'), ('inject', 'nsubj'), ('allow', 'conj'), ('liquid', 'compound'), ('come', 'compound'), ('room', 'compound'), ('temperatur', 'ccomp'), ('.', 'punct')]}, {'original_sentence': 'Do not remove the cap or cover while allowing it to reach \\nroom temperature.', 'tokens': ['remove', 'cap', 'cover', 'allowing', 'reach', 'room', 'temperature', '.'], 'lemmatized': ['remove', 'cap', 'cover', 'allowing', 'reach', 'room', 'temperature', '.'], 'stemmed': ['remov', 'cap', 'cover', 'allow', 'reach', 'room', 'temperatur', '.'], 'dependencies': [('remov', 'compound'), ('cap', 'compound'), ('cover', 'nsubj'), ('allow', 'ROOT'), ('reach', 'compound'), ('room', 'compound'), ('temperatur', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Carefully inspect the solution in the HUMIRA Pen, prefilled syringe, or \\nsingle-dose institutional use vial for particulate matter and discoloration prior to subcutaneous \\nadministration.', 'tokens': ['Carefully', 'inspect', 'solution', 'HUMIRA', 'Pen', ',', 'prefilled', 'syringe', ',', 'single-dose', 'institutional', 'use', 'vial', 'particulate', 'matter', 'discoloration', 'prior', 'subcutaneous', 'administration', '.'], 'lemmatized': ['Carefully', 'inspect', 'solution', 'HUMIRA', 'Pen', ',', 'prefilled', 'syringe', ',', 'single-dose', 'institutional', 'use', 'vial', 'particulate', 'matter', 'discoloration', 'prior', 'subcutaneous', 'administration', '.'], 'stemmed': ['care', 'inspect', 'solut', 'humira', 'pen', ',', 'prefil', 'syring', ',', 'single-dos', 'institut', 'use', 'vial', 'particul', 'matter', 'discolor', 'prior', 'subcutan', 'administr', '.'], 'dependencies': [('care', 'advcl'), ('inspect', 'compound'), ('solut', 'compound'), ('humira', 'compound'), ('pen', 'dobj'), (',', 'punct'), ('prefil', 'compound'), ('syring', 'npadvmod'), (',', 'punct'), ('single', 'amod'), ('-', 'punct'), ('dos', 'compound'), ('institut', 'nsubj'), ('use', 'ROOT'), ('vial', 'amod'), ('particul', 'dobj'), ('matter', 'xcomp'), ('discolor', 'nmod'), ('prior', 'advmod'), ('subcutan', 'compound'), ('administr', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'If particulates and discolorations are noted, do not use the product.', 'tokens': ['particulates', 'discolorations', 'noted', ',', 'use', 'product', '.'], 'lemmatized': ['particulate', 'discoloration', 'noted', ',', 'use', 'product', '.'], 'stemmed': ['particul', 'discolor', 'note', ',', 'use', 'product', '.'], 'dependencies': [('particul', 'compound'), ('discolor', 'compound'), ('note', 'nsubj'), (',', 'punct'), ('use', 'ROOT'), ('product', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'HUMIRA', 'tokens': ['HUMIRA'], 'lemmatized': ['HUMIRA'], 'stemmed': ['humira'], 'dependencies': [('humira', 'ROOT')]}], 'text': '2.5 Plaque Psoriasis or Adult Uveitis \\nThe recommended subcutaneous dosage of HUMIRA for adult patients with plaque psoriasis \\n(Ps) or Uveitis (UV) is an initial dose of 80 mg, followed by 40 mg given every other week \\nstarting one week after the initial dose. The use of HUMIRA in moderate to severe chronic Ps \\nbeyond one year has not been evaluated in controlled clinical studies.  \\n2.6 Hidradenitis Suppurativa \\nAdults \\nThe recommended subcutaneous dosage of HUMIRA for adult patients with hidradenitis \\nsuppurativa (HS) is an initial dose of 160 mg (given in one day or split over two consecutive \\ndays), followed by 80 mg two weeks later (Day 15). Begin 40 mg weekly or 80 mg every other \\nweek dosing two weeks later (Day 29).  \\nAdolescents \\nThe recommended subcutaneous dosage of HUMIRA for adolescent patients 12 years of age and \\nolder weighing at least 30 kg with hidradenitis suppurativa (HS) is based on body weight as \\nshown below [see Use in Specific Populations (8.4) and Clinical Pharmacology (12.3)]:  \\n \\n  \\nBody Weight of Adolescent \\nPatients \\n(12 years of age and older) \\nRecommended Dosage  \\n30 kg (66 lbs) to less than 60 kg \\n(132 lbs) \\n• Day 1: 80 mg  \\n• Day 8 and subsequent doses: 40 mg every other week \\n60 kg (132 lbs) and greater \\n• Day 1: 160 mg (given in one day or split over two \\nconsecutive days); \\n• Day 15: 80 mg  \\n• Day 29 and subsequent doses:  40 mg every week or 80 mg \\nevery other week  \\n \\n  \\n2.7 Monitoring to Assess Safety \\nPrior to initiating HUMIRA and periodically during therapy, evaluate patients for active \\ntuberculosis and test for latent infection [see Warnings and Precautions (5.1)].  \\n2.8 General Considerations for Administration \\nHUMIRA is intended for use under the guidance and supervision of a physician. A patient may \\nself-inject HUMIRA or a caregiver may inject HUMIRA using either the HUMIRA Pen or \\nprefilled syringe if a physician determines that it is appropriate, and with medical follow-up, as \\nnecessary, after proper training in subcutaneous injection technique.  \\n HUMIRA can be taken out of the refrigerator for 15 to 30 minutes before injecting to allow the \\nliquid to come to room temperature. Do not remove the cap or cover while allowing it to reach \\nroom temperature. Carefully inspect the solution in the HUMIRA Pen, prefilled syringe, or \\nsingle-dose institutional use vial for particulate matter and discoloration prior to subcutaneous \\nadministration. If particulates and discolorations are noted, do not use the product. HUMIRA \\n'}, 'page_char_count': 2510, 'page_word_count': 409, 'sentences': ['2.5 Plaque Psoriasis or Adult Uveitis \\nThe recommended subcutaneous dosage of HUMIRA for adult patients with plaque psoriasis \\n(Ps) or Uveitis (UV) is an initial dose of 80 mg, followed by 40 mg given every other week \\nstarting one week after the initial dose.', 'The use of HUMIRA in moderate to severe chronic Ps \\nbeyond one year has not been evaluated in controlled clinical studies.', ' \\n2.6 Hidradenitis Suppurativa \\nAdults \\nThe recommended subcutaneous dosage of HUMIRA for adult patients with hidradenitis \\nsuppurativa (HS) is an initial dose of 160 mg (given in one day or split over two consecutive \\ndays), followed by 80 mg two weeks later (Day 15).', 'Begin 40 mg weekly or 80 mg every other \\nweek dosing two weeks later (Day 29).', ' \\nAdolescents \\nThe recommended subcutaneous dosage of HUMIRA for adolescent patients 12 years of age and \\nolder weighing at least 30 kg with hidradenitis suppurativa (HS) is based on body weight as \\nshown below [see Use in Specific Populations (8.4) and Clinical Pharmacology (12.3)]:  \\n \\n  \\nBody Weight of Adolescent \\nPatients \\n(12 years of age and older) \\nRecommended Dosage  \\n30 kg (66 lbs) to less than 60 kg \\n(132 lbs) \\n• Day 1: 80 mg  \\n• Day 8 and subsequent doses: 40 mg every other week \\n60 kg (132 lbs) and greater \\n• Day 1: 160 mg (given in one day or split over two \\nconsecutive days); \\n• Day 15: 80 mg  \\n• Day 29 and subsequent doses:  40 mg every week or 80 mg \\nevery other week  \\n \\n  \\n2.7 Monitoring to Assess Safety \\nPrior to initiating HUMIRA and periodically during therapy, evaluate patients for active \\ntuberculosis and test for latent infection [see Warnings and Precautions (5.1)].', ' \\n2.8 General Considerations for Administration \\nHUMIRA is intended for use under the guidance and supervision of a physician.', 'A patient may \\nself-inject HUMIRA or a caregiver may inject HUMIRA using either the HUMIRA Pen or \\nprefilled syringe if a physician determines that it is appropriate, and with medical follow-up, as \\nnecessary, after proper training in subcutaneous injection technique.', ' \\n HUMIRA can be taken out of the refrigerator for 15 to 30 minutes before injecting to allow the \\nliquid to come to room temperature.', 'Do not remove the cap or cover while allowing it to reach \\nroom temperature.', 'Carefully inspect the solution in the HUMIRA Pen, prefilled syringe, or \\nsingle-dose institutional use vial for particulate matter and discoloration prior to subcutaneous \\nadministration.', 'If particulates and discolorations are noted, do not use the product.', 'HUMIRA \\n'], 'page_sentence_count_spacy': 12}\n",
            "{'page_number': 8, 'text': 'does not contain preservatives; therefore, discard unused portions of drug remaining from the \\nsyringe. NOTE: Instruct patients sensitive to latex not to handle the needle cover of the \\nHUMIRA 40 mg/0.8 mL Pen and 40 mg/0.8 mL, 20 mg/0.4 mL and 10 mg/0.2 mL prefilled \\nsyringe because it may contain natural rubber latex [see How Supplied/Storage and Handling \\n(16)].  \\nInstruct patients using the HUMIRA Pen or prefilled syringe to inject the full amount in the \\nsyringe, according to the directions provided in the Instructions for Use [see Instructions for \\nUse].  \\nInjections should occur at separate sites in the thigh or abdomen. Rotate injection sites and do \\nnot give injections into areas where the skin is tender, bruised, red or hard.  \\nIf a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the \\nregular scheduled time. \\nThe HUMIRA single-dose institutional use vial is for administration within an institutional \\nsetting only, such as a hospital, physician’s office or clinic. Withdraw the dose using a sterile \\nneedle and syringe and administer promptly by a healthcare provider within an institutional \\nsetting. Only administer one dose per vial. The vial does not contain preservatives; therefore, \\ndiscard unused portions.  \\n3 DOSAGE FORMS AND STRENGTHS \\nHUMIRA is a clear and colorless solution available as:  \\n• Pen (HUMIRA Pen) \\nInjection: 80 mg/0.8 mL in a single-dose pen. \\nInjection: 40 mg/0.8 mL in a single-dose pen.  \\nInjection: 40 mg/0.4 mL in a single-dose pen.  \\n  \\n• Prefilled Syringe \\nInjection: 80 mg/0.8 mL in a single-dose prefilled glass syringe. \\nInjection: 40 mg/0.8 mL in a single-dose prefilled glass syringe. \\nInjection: 40 mg/0.4 mL in a single-dose prefilled glass syringe. \\nInjection: 20 mg/0.4 mL in a single-dose prefilled glass syringe. \\nInjection: 20 mg/0.2 mL in a single-dose prefilled glass syringe. \\nInjection: 10 mg/0.2 mL in a single-dose prefilled glass syringe. \\nInjection: 10 mg/0.1 mL in a single-dose prefilled glass syringe.  \\n  \\n• Single-Dose Institutional Use Vial \\nInjection: 40 mg/0.8 mL in a single-dose, glass vial for institutional use only.  \\n  \\n4 CONTRAINDICATIONS \\nNone.  \\n', 'processed_text': {'sentences': [{'original_sentence': 'does not contain preservatives; therefore, discard unused portions of drug remaining from the \\nsyringe.', 'tokens': ['contain', 'preservatives', ';', 'therefore', ',', 'discard', 'unused', 'portions', 'drug', 'remaining', 'syringe', '.'], 'lemmatized': ['contain', 'preservative', ';', 'therefore', ',', 'discard', 'unused', 'portion', 'drug', 'remaining', 'syringe', '.'], 'stemmed': ['contain', 'preserv', ';', 'therefor', ',', 'discard', 'unus', 'portion', 'drug', 'remain', 'syring', '.'], 'dependencies': [('contain', 'ccomp'), ('preserv', 'dobj'), (';', 'punct'), ('therefor', 'advmod'), (',', 'punct'), ('discard', 'amod'), ('unus', 'amod'), ('portion', 'compound'), ('drug', 'nsubj'), ('remain', 'ROOT'), ('syring', 'acomp'), ('.', 'punct')]}, {'original_sentence': 'NOTE: Instruct patients sensitive to latex not to handle the needle cover of the \\nHUMIRA 40 mg/0.8 mL Pen and 40 mg/0.8 mL, 20 mg/0.4 mL and 10 mg/0.2 mL prefilled \\nsyringe because it may contain natural rubber latex [see How Supplied/Storage and Handling \\n(16)].', 'tokens': ['NOTE', ':', 'Instruct', 'patients', 'sensitive', 'latex', 'handle', 'needle', 'cover', 'HUMIRA', '40', 'mg/0.8', 'mL', 'Pen', '40', 'mg/0.8', 'mL', ',', '20', 'mg/0.4', 'mL', '10', 'mg/0.2', 'mL', 'prefilled', 'syringe', 'may', 'contain', 'natural', 'rubber', 'latex', '[', 'see', 'Supplied/Storage', 'Handling', '(', '16', ')', ']', '.'], 'lemmatized': ['NOTE', ':', 'Instruct', 'patient', 'sensitive', 'latex', 'handle', 'needle', 'cover', 'HUMIRA', '40', 'mg/0.8', 'mL', 'Pen', '40', 'mg/0.8', 'mL', ',', '20', 'mg/0.4', 'mL', '10', 'mg/0.2', 'mL', 'prefilled', 'syringe', 'may', 'contain', 'natural', 'rubber', 'latex', '[', 'see', 'Supplied/Storage', 'Handling', '(', '16', ')', ']', '.'], 'stemmed': ['note', ':', 'instruct', 'patient', 'sensit', 'latex', 'handl', 'needl', 'cover', 'humira', '40', 'mg/0.8', 'ml', 'pen', '40', 'mg/0.8', 'ml', ',', '20', 'mg/0.4', 'ml', '10', 'mg/0.2', 'ml', 'prefil', 'syring', 'may', 'contain', 'natur', 'rubber', 'latex', '[', 'see', 'supplied/storag', 'handl', '(', '16', ')', ']', '.'], 'dependencies': [('note', 'ROOT'), (':', 'punct'), ('instruct', 'ccomp'), ('patient', 'amod'), ('sensit', 'compound'), ('latex', 'compound'), ('handl', 'nsubj'), ('needl', 'ccomp'), ('cover', 'compound'), ('humira', 'dobj'), ('40', 'nummod'), ('mg/0.8', 'advmod'), ('ml', 'aux'), ('pen', 'ccomp'), ('40', 'nummod'), ('mg/0.8', 'dep'), ('ml', 'dobj'), (',', 'punct'), ('20', 'nummod'), ('mg/0.4', 'punct'), ('ml', 'npadvmod'), ('10', 'nummod'), ('mg/0.2', 'npadvmod'), ('ml', 'nmod'), ('prefil', 'compound'), ('syring', 'nsubj'), ('may', 'aux'), ('contain', 'ROOT'), ('natur', 'compound'), ('rubber', 'compound'), ('latex', 'dobj'), ('[', 'punct'), ('see', 'ROOT'), ('supplied', 'amod'), ('/', 'punct'), ('storag', 'compound'), ('handl', 'dobj'), ('(', 'punct'), ('16', 'appos'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Instruct patients using the HUMIRA Pen or prefilled syringe to inject the full amount in the \\nsyringe, according to the directions provided in the Instructions for Use [see Instructions for \\nUse].', 'tokens': ['Instruct', 'patients', 'using', 'HUMIRA', 'Pen', 'prefilled', 'syringe', 'inject', 'full', 'amount', 'syringe', ',', 'according', 'directions', 'provided', 'Instructions', 'Use', '[', 'see', 'Instructions', 'Use', ']', '.'], 'lemmatized': ['Instruct', 'patient', 'using', 'HUMIRA', 'Pen', 'prefilled', 'syringe', 'inject', 'full', 'amount', 'syringe', ',', 'according', 'direction', 'provided', 'Instructions', 'Use', '[', 'see', 'Instructions', 'Use', ']', '.'], 'stemmed': ['instruct', 'patient', 'use', 'humira', 'pen', 'prefil', 'syring', 'inject', 'full', 'amount', 'syring', ',', 'accord', 'direct', 'provid', 'instruct', 'use', '[', 'see', 'instruct', 'use', ']', '.'], 'dependencies': [('instruct', 'ROOT'), ('patient', 'amod'), ('use', 'compound'), ('humira', 'compound'), ('pen', 'compound'), ('prefil', 'nmod'), ('syring', 'compound'), ('inject', 'dobj'), ('full', 'amod'), ('amount', 'compound'), ('syring', 'dobj'), (',', 'punct'), ('accord', 'conj'), ('direct', 'amod'), ('provid', 'compound'), ('instruct', 'compound'), ('use', 'dobj'), ('[', 'punct'), ('see', 'parataxis'), ('instruct', 'compound'), ('use', 'dobj'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Injections should occur at separate sites in the thigh or abdomen.', 'tokens': ['Injections', 'occur', 'separate', 'sites', 'thigh', 'abdomen', '.'], 'lemmatized': ['Injections', 'occur', 'separate', 'site', 'thigh', 'abdomen', '.'], 'stemmed': ['inject', 'occur', 'separ', 'site', 'thigh', 'abdomen', '.'], 'dependencies': [('inject', 'nsubj'), ('occur', 'ROOT'), ('separ', 'compound'), ('site', 'compound'), ('thigh', 'compound'), ('abdomen', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Rotate injection sites and do \\nnot give injections into areas where the skin is tender, bruised, red or hard.', 'tokens': ['Rotate', 'injection', 'sites', 'give', 'injections', 'areas', 'skin', 'tender', ',', 'bruised', ',', 'red', 'hard', '.'], 'lemmatized': ['Rotate', 'injection', 'site', 'give', 'injection', 'area', 'skin', 'tender', ',', 'bruised', ',', 'red', 'hard', '.'], 'stemmed': ['rotat', 'inject', 'site', 'give', 'inject', 'area', 'skin', 'tender', ',', 'bruis', ',', 'red', 'hard', '.'], 'dependencies': [('rotat', 'ROOT'), ('inject', 'compound'), ('site', 'dobj'), ('give', 'ccomp'), ('inject', 'compound'), ('area', 'compound'), ('skin', 'compound'), ('tender', 'dobj'), (',', 'punct'), ('bruis', 'conj'), (',', 'punct'), ('red', 'conj'), ('hard', 'advmod'), ('.', 'punct')]}, {'original_sentence': 'If a dose is missed, administer the dose as soon as possible.', 'tokens': ['dose', 'missed', ',', 'administer', 'dose', 'soon', 'possible', '.'], 'lemmatized': ['dose', 'missed', ',', 'administer', 'dose', 'soon', 'possible', '.'], 'stemmed': ['dose', 'miss', ',', 'administ', 'dose', 'soon', 'possibl', '.'], 'dependencies': [('dose', 'compound'), ('miss', 'npadvmod'), (',', 'punct'), ('administ', 'nsubj'), ('dose', 'ROOT'), ('soon', 'advmod'), ('possibl', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Thereafter, resume dosing at the \\nregular scheduled time.', 'tokens': ['Thereafter', ',', 'resume', 'dosing', 'regular', 'scheduled', 'time', '.'], 'lemmatized': ['Thereafter', ',', 'resume', 'dosing', 'regular', 'scheduled', 'time', '.'], 'stemmed': ['thereaft', ',', 'resum', 'dose', 'regular', 'schedul', 'time', '.'], 'dependencies': [('thereaft', 'dep'), (',', 'punct'), ('resum', 'npadvmod'), ('dose', 'ROOT'), ('regular', 'amod'), ('schedul', 'compound'), ('time', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The HUMIRA single-dose institutional use vial is for administration within an institutional \\nsetting only, such as a hospital, physician’s office or clinic.', 'tokens': ['HUMIRA', 'single-dose', 'institutional', 'use', 'vial', 'administration', 'within', 'institutional', 'setting', ',', 'hospital', ',', 'physician', '’', 'office', 'clinic', '.'], 'lemmatized': ['HUMIRA', 'single-dose', 'institutional', 'use', 'vial', 'administration', 'within', 'institutional', 'setting', ',', 'hospital', ',', 'physician', '’', 'office', 'clinic', '.'], 'stemmed': ['humira', 'single-dos', 'institut', 'use', 'vial', 'administr', 'within', 'institut', 'set', ',', 'hospit', ',', 'physician', '’', 'offic', 'clinic', '.'], 'dependencies': [('humira', 'nmod'), ('single', 'amod'), ('-', 'punct'), ('dos', 'preconj'), ('institut', 'nsubj'), ('use', 'ROOT'), ('vial', 'amod'), ('administr', 'dobj'), ('within', 'prep'), ('institut', 'compound'), ('set', 'pobj'), (',', 'punct'), ('hospit', 'nmod'), (',', 'punct'), ('physician', 'nmod'), ('’', 'punct'), ('offic', 'amod'), ('clinic', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Withdraw the dose using a sterile \\nneedle and syringe and administer promptly by a healthcare provider within an institutional \\nsetting.', 'tokens': ['Withdraw', 'dose', 'using', 'sterile', 'needle', 'syringe', 'administer', 'promptly', 'healthcare', 'provider', 'within', 'institutional', 'setting', '.'], 'lemmatized': ['Withdraw', 'dose', 'using', 'sterile', 'needle', 'syringe', 'administer', 'promptly', 'healthcare', 'provider', 'within', 'institutional', 'setting', '.'], 'stemmed': ['withdraw', 'dose', 'use', 'steril', 'needl', 'syring', 'administ', 'promptli', 'healthcar', 'provid', 'within', 'institut', 'set', '.'], 'dependencies': [('withdraw', 'csubj'), ('dose', 'compound'), ('use', 'compound'), ('steril', 'dobj'), ('needl', 'ROOT'), ('syring', 'dobj'), ('administ', 'compound'), ('promptli', 'dobj'), ('healthcar', 'compound'), ('provid', 'dobj'), ('within', 'prep'), ('institut', 'compound'), ('set', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'Only administer one dose per vial.', 'tokens': ['administer', 'one', 'dose', 'per', 'vial', '.'], 'lemmatized': ['administer', 'one', 'dose', 'per', 'vial', '.'], 'stemmed': ['administ', 'one', 'dose', 'per', 'vial', '.'], 'dependencies': [('administ', 'ROOT'), ('one', 'nummod'), ('dose', 'dobj'), ('per', 'prep'), ('vial', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'The vial does not contain preservatives; therefore, \\ndiscard unused portions.', 'tokens': ['vial', 'contain', 'preservatives', ';', 'therefore', ',', 'discard', 'unused', 'portions', '.'], 'lemmatized': ['vial', 'contain', 'preservative', ';', 'therefore', ',', 'discard', 'unused', 'portion', '.'], 'stemmed': ['vial', 'contain', 'preserv', ';', 'therefor', ',', 'discard', 'unus', 'portion', '.'], 'dependencies': [('vial', 'amod'), ('contain', 'compound'), ('preserv', 'dep'), (';', 'punct'), ('therefor', 'nmod'), (',', 'punct'), ('discard', 'amod'), ('unus', 'amod'), ('portion', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '3 DOSAGE FORMS AND STRENGTHS \\nHUMIRA is a clear and colorless solution available as:  \\n• Pen (HUMIRA Pen) \\nInjection: 80 mg/0.8 mL in a single-dose pen.', 'tokens': ['3', 'DOSAGE', 'FORMS', 'STRENGTHS', 'HUMIRA', 'clear', 'colorless', 'solution', 'available', ':', '•', 'Pen', '(', 'HUMIRA', 'Pen', ')', 'Injection', ':', '80', 'mg/0.8', 'mL', 'single-dose', 'pen', '.'], 'lemmatized': ['3', 'DOSAGE', 'FORMS', 'STRENGTHS', 'HUMIRA', 'clear', 'colorless', 'solution', 'available', ':', '•', 'Pen', '(', 'HUMIRA', 'Pen', ')', 'Injection', ':', '80', 'mg/0.8', 'mL', 'single-dose', 'pen', '.'], 'stemmed': ['3', 'dosag', 'form', 'strength', 'humira', 'clear', 'colorless', 'solut', 'avail', ':', '•', 'pen', '(', 'humira', 'pen', ')', 'inject', ':', '80', 'mg/0.8', 'ml', 'single-dos', 'pen', '.'], 'dependencies': [('3', 'nummod'), ('dosag', 'compound'), ('form', 'compound'), ('strength', 'compound'), ('humira', 'compound'), ('clear', 'compound'), ('colorless', 'compound'), ('solut', 'compound'), ('avail', 'ROOT'), (':', 'punct'), ('•', 'nummod'), ('pen', 'nsubj'), ('(', 'punct'), ('humira', 'compound'), ('pen', 'appos'), (')', 'punct'), ('inject', 'ccomp'), (':', 'punct'), ('80', 'nummod'), ('mg/0.8', 'nsubj'), ('ml', 'appos'), ('single', 'amod'), ('-', 'punct'), ('dos', 'compound'), ('pen', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Injection: 40 mg/0.8 mL in a single-dose pen.', 'tokens': ['Injection', ':', '40', 'mg/0.8', 'mL', 'single-dose', 'pen', '.'], 'lemmatized': ['Injection', ':', '40', 'mg/0.8', 'mL', 'single-dose', 'pen', '.'], 'stemmed': ['inject', ':', '40', 'mg/0.8', 'ml', 'single-dos', 'pen', '.'], 'dependencies': [('inject', 'ROOT'), (':', 'punct'), ('40', 'nummod'), ('mg/0.8', 'quantmod'), ('ml', 'nmod'), ('single', 'amod'), ('-', 'punct'), ('dos', 'compound'), ('pen', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Injection: 40 mg/0.4 mL in a single-dose pen.', 'tokens': ['Injection', ':', '40', 'mg/0.4', 'mL', 'single-dose', 'pen', '.'], 'lemmatized': ['Injection', ':', '40', 'mg/0.4', 'mL', 'single-dose', 'pen', '.'], 'stemmed': ['inject', ':', '40', 'mg/0.4', 'ml', 'single-dos', 'pen', '.'], 'dependencies': [('inject', 'ROOT'), (':', 'punct'), ('40', 'nummod'), ('mg/0.4', 'appos'), ('ml', 'nmod'), ('single', 'amod'), ('-', 'punct'), ('dos', 'compound'), ('pen', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• Prefilled Syringe \\nInjection: 80 mg/0.8 mL in a single-dose prefilled glass syringe.', 'tokens': ['•', 'Prefilled', 'Syringe', 'Injection', ':', '80', 'mg/0.8', 'mL', 'single-dose', 'prefilled', 'glass', 'syringe', '.'], 'lemmatized': ['•', 'Prefilled', 'Syringe', 'Injection', ':', '80', 'mg/0.8', 'mL', 'single-dose', 'prefilled', 'glass', 'syringe', '.'], 'stemmed': ['•', 'prefil', 'syring', 'inject', ':', '80', 'mg/0.8', 'ml', 'single-dos', 'prefil', 'glass', 'syring', '.'], 'dependencies': [('•', 'nummod'), ('prefil', 'compound'), ('syring', 'compound'), ('inject', 'dep'), (':', 'punct'), ('80', 'nummod'), ('mg/0.8', 'dep'), ('ml', 'ROOT'), ('single', 'amod'), ('-', 'punct'), ('dos', 'compound'), ('prefil', 'compound'), ('glass', 'compound'), ('syring', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Injection: 40 mg/0.8 mL in a single-dose prefilled glass syringe.', 'tokens': ['Injection', ':', '40', 'mg/0.8', 'mL', 'single-dose', 'prefilled', 'glass', 'syringe', '.'], 'lemmatized': ['Injection', ':', '40', 'mg/0.8', 'mL', 'single-dose', 'prefilled', 'glass', 'syringe', '.'], 'stemmed': ['inject', ':', '40', 'mg/0.8', 'ml', 'single-dos', 'prefil', 'glass', 'syring', '.'], 'dependencies': [('inject', 'ROOT'), (':', 'punct'), ('40', 'nummod'), ('mg/0.8', 'quantmod'), ('ml', 'nmod'), ('single', 'amod'), ('-', 'punct'), ('dos', 'compound'), ('prefil', 'compound'), ('glass', 'compound'), ('syring', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Injection: 40 mg/0.4 mL in a single-dose prefilled glass syringe.', 'tokens': ['Injection', ':', '40', 'mg/0.4', 'mL', 'single-dose', 'prefilled', 'glass', 'syringe', '.'], 'lemmatized': ['Injection', ':', '40', 'mg/0.4', 'mL', 'single-dose', 'prefilled', 'glass', 'syringe', '.'], 'stemmed': ['inject', ':', '40', 'mg/0.4', 'ml', 'single-dos', 'prefil', 'glass', 'syring', '.'], 'dependencies': [('inject', 'ROOT'), (':', 'punct'), ('40', 'nummod'), ('mg/0.4', 'appos'), ('ml', 'nmod'), ('single', 'amod'), ('-', 'punct'), ('dos', 'compound'), ('prefil', 'compound'), ('glass', 'compound'), ('syring', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Injection: 20 mg/0.4 mL in a single-dose prefilled glass syringe.', 'tokens': ['Injection', ':', '20', 'mg/0.4', 'mL', 'single-dose', 'prefilled', 'glass', 'syringe', '.'], 'lemmatized': ['Injection', ':', '20', 'mg/0.4', 'mL', 'single-dose', 'prefilled', 'glass', 'syringe', '.'], 'stemmed': ['inject', ':', '20', 'mg/0.4', 'ml', 'single-dos', 'prefil', 'glass', 'syring', '.'], 'dependencies': [('inject', 'ROOT'), (':', 'punct'), ('20', 'nummod'), ('mg/0.4', 'dep'), ('ml', 'nmod'), ('single', 'amod'), ('-', 'punct'), ('dos', 'compound'), ('prefil', 'compound'), ('glass', 'compound'), ('syring', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Injection: 20 mg/0.2 mL in a single-dose prefilled glass syringe.', 'tokens': ['Injection', ':', '20', 'mg/0.2', 'mL', 'single-dose', 'prefilled', 'glass', 'syringe', '.'], 'lemmatized': ['Injection', ':', '20', 'mg/0.2', 'mL', 'single-dose', 'prefilled', 'glass', 'syringe', '.'], 'stemmed': ['inject', ':', '20', 'mg/0.2', 'ml', 'single-dos', 'prefil', 'glass', 'syring', '.'], 'dependencies': [('inject', 'ROOT'), (':', 'punct'), ('20', 'nummod'), ('mg/0.2', 'npadvmod'), ('ml', 'nmod'), ('single', 'amod'), ('-', 'punct'), ('dos', 'compound'), ('prefil', 'compound'), ('glass', 'compound'), ('syring', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Injection: 10 mg/0.2 mL in a single-dose prefilled glass syringe.', 'tokens': ['Injection', ':', '10', 'mg/0.2', 'mL', 'single-dose', 'prefilled', 'glass', 'syringe', '.'], 'lemmatized': ['Injection', ':', '10', 'mg/0.2', 'mL', 'single-dose', 'prefilled', 'glass', 'syringe', '.'], 'stemmed': ['inject', ':', '10', 'mg/0.2', 'ml', 'single-dos', 'prefil', 'glass', 'syring', '.'], 'dependencies': [('inject', 'ROOT'), (':', 'punct'), ('10', 'nummod'), ('mg/0.2', 'npadvmod'), ('ml', 'nmod'), ('single', 'amod'), ('-', 'punct'), ('dos', 'compound'), ('prefil', 'compound'), ('glass', 'compound'), ('syring', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Injection: 10 mg/0.1 mL in a single-dose prefilled glass syringe.', 'tokens': ['Injection', ':', '10', 'mg/0.1', 'mL', 'single-dose', 'prefilled', 'glass', 'syringe', '.'], 'lemmatized': ['Injection', ':', '10', 'mg/0.1', 'mL', 'single-dose', 'prefilled', 'glass', 'syringe', '.'], 'stemmed': ['inject', ':', '10', 'mg/0.1', 'ml', 'single-dos', 'prefil', 'glass', 'syring', '.'], 'dependencies': [('inject', 'ROOT'), (':', 'punct'), ('10', 'nummod'), ('mg/0.1', 'npadvmod'), ('ml', 'nmod'), ('single', 'amod'), ('-', 'punct'), ('dos', 'compound'), ('prefil', 'compound'), ('glass', 'compound'), ('syring', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• Single-Dose Institutional Use Vial \\nInjection: 40 mg/0.8 mL in a single-dose, glass vial for institutional use only.', 'tokens': ['•', 'Single-Dose', 'Institutional', 'Use', 'Vial', 'Injection', ':', '40', 'mg/0.8', 'mL', 'single-dose', ',', 'glass', 'vial', 'institutional', 'use', '.'], 'lemmatized': ['•', 'Single-Dose', 'Institutional', 'Use', 'Vial', 'Injection', ':', '40', 'mg/0.8', 'mL', 'single-dose', ',', 'glass', 'vial', 'institutional', 'use', '.'], 'stemmed': ['•', 'single-dos', 'institut', 'use', 'vial', 'inject', ':', '40', 'mg/0.8', 'ml', 'single-dos', ',', 'glass', 'vial', 'institut', 'use', '.'], 'dependencies': [('•', 'meta'), ('single', 'amod'), ('-', 'punct'), ('dos', 'compound'), ('institut', 'nsubj'), ('use', 'ccomp'), ('vial', 'amod'), ('inject', 'dobj'), (':', 'punct'), ('40', 'nummod'), ('mg/0.8', 'dep'), ('ml', 'nmod'), ('single', 'amod'), ('-', 'punct'), ('dos', 'dobj'), (',', 'punct'), ('glass', 'compound'), ('vial', 'amod'), ('institut', 'compound'), ('use', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '4 CONTRAINDICATIONS \\nNone.', 'tokens': ['4', 'CONTRAINDICATIONS', 'None', '.'], 'lemmatized': ['4', 'CONTRAINDICATIONS', 'None', '.'], 'stemmed': ['4', 'contraind', 'none', '.'], 'dependencies': [('4', 'nsubj'), ('contraind', 'ROOT'), ('none', 'dobj'), ('.', 'punct')]}], 'text': 'does not contain preservatives; therefore, discard unused portions of drug remaining from the \\nsyringe. NOTE: Instruct patients sensitive to latex not to handle the needle cover of the \\nHUMIRA 40 mg/0.8 mL Pen and 40 mg/0.8 mL, 20 mg/0.4 mL and 10 mg/0.2 mL prefilled \\nsyringe because it may contain natural rubber latex [see How Supplied/Storage and Handling \\n(16)].  \\nInstruct patients using the HUMIRA Pen or prefilled syringe to inject the full amount in the \\nsyringe, according to the directions provided in the Instructions for Use [see Instructions for \\nUse].  \\nInjections should occur at separate sites in the thigh or abdomen. Rotate injection sites and do \\nnot give injections into areas where the skin is tender, bruised, red or hard.  \\nIf a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the \\nregular scheduled time. \\nThe HUMIRA single-dose institutional use vial is for administration within an institutional \\nsetting only, such as a hospital, physician’s office or clinic. Withdraw the dose using a sterile \\nneedle and syringe and administer promptly by a healthcare provider within an institutional \\nsetting. Only administer one dose per vial. The vial does not contain preservatives; therefore, \\ndiscard unused portions.  \\n3 DOSAGE FORMS AND STRENGTHS \\nHUMIRA is a clear and colorless solution available as:  \\n• Pen (HUMIRA Pen) \\nInjection: 80 mg/0.8 mL in a single-dose pen. \\nInjection: 40 mg/0.8 mL in a single-dose pen.  \\nInjection: 40 mg/0.4 mL in a single-dose pen.  \\n  \\n• Prefilled Syringe \\nInjection: 80 mg/0.8 mL in a single-dose prefilled glass syringe. \\nInjection: 40 mg/0.8 mL in a single-dose prefilled glass syringe. \\nInjection: 40 mg/0.4 mL in a single-dose prefilled glass syringe. \\nInjection: 20 mg/0.4 mL in a single-dose prefilled glass syringe. \\nInjection: 20 mg/0.2 mL in a single-dose prefilled glass syringe. \\nInjection: 10 mg/0.2 mL in a single-dose prefilled glass syringe. \\nInjection: 10 mg/0.1 mL in a single-dose prefilled glass syringe.  \\n  \\n• Single-Dose Institutional Use Vial \\nInjection: 40 mg/0.8 mL in a single-dose, glass vial for institutional use only.  \\n  \\n4 CONTRAINDICATIONS \\nNone.  \\n'}, 'page_char_count': 2178, 'page_word_count': 334, 'sentences': ['does not contain preservatives; therefore, discard unused portions of drug remaining from the \\nsyringe.', 'NOTE: Instruct patients sensitive to latex not to handle the needle cover of the \\nHUMIRA 40 mg/0.8 mL Pen and 40 mg/0.8 mL, 20 mg/0.4 mL and 10 mg/0.2 mL prefilled \\nsyringe because it may contain natural rubber latex [see How Supplied/Storage and Handling \\n(16)].', ' \\nInstruct patients using the HUMIRA Pen or prefilled syringe to inject the full amount in the \\nsyringe, according to the directions provided in the Instructions for Use [see Instructions for \\nUse].', ' \\nInjections should occur at separate sites in the thigh or abdomen.', 'Rotate injection sites and do \\nnot give injections into areas where the skin is tender, bruised, red or hard.', ' \\nIf a dose is missed, administer the dose as soon as possible.', 'Thereafter, resume dosing at the \\nregular scheduled time.', '\\nThe HUMIRA single-dose institutional use vial is for administration within an institutional \\nsetting only, such as a hospital, physician’s office or clinic.', 'Withdraw the dose using a sterile \\nneedle and syringe and administer promptly by a healthcare provider within an institutional \\nsetting.', 'Only administer one dose per vial.', 'The vial does not contain preservatives; therefore, \\ndiscard unused portions.', ' \\n3 DOSAGE FORMS AND STRENGTHS \\nHUMIRA is a clear and colorless solution available as:  \\n• Pen (HUMIRA Pen) \\nInjection: 80 mg/0.8 mL in a single-dose pen.', '\\nInjection: 40 mg/0.8 mL in a single-dose pen.', ' \\nInjection: 40 mg/0.4 mL in a single-dose pen.', ' \\n  \\n• Prefilled Syringe \\nInjection: 80 mg/0.8 mL in a single-dose prefilled glass syringe.', '\\nInjection: 40 mg/0.8 mL in a single-dose prefilled glass syringe.', '\\nInjection: 40 mg/0.4 mL in a single-dose prefilled glass syringe.', '\\nInjection: 20 mg/0.4 mL in a single-dose prefilled glass syringe.', '\\nInjection: 20 mg/0.2 mL in a single-dose prefilled glass syringe.', '\\nInjection: 10 mg/0.2 mL in a single-dose prefilled glass syringe.', '\\nInjection: 10 mg/0.1 mL in a single-dose prefilled glass syringe.', ' \\n  \\n• Single-Dose Institutional Use Vial \\nInjection: 40 mg/0.8 mL in a single-dose, glass vial for institutional use only.', ' \\n  \\n4 CONTRAINDICATIONS \\nNone.', ' \\n'], 'page_sentence_count_spacy': 24}\n",
            "{'page_number': 9, 'text': '5 WARNINGS AND PRECAUTIONS  \\n5.1 Serious Infections \\nPatients treated with HUMIRA are at increased risk for developing serious infections involving \\nvarious organ systems and sites that may lead to hospitalization or death. Opportunistic \\ninfections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic \\npathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, \\nhistoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported \\nwith TNF blockers. Patients have frequently presented with disseminated rather than localized \\ndisease.  \\nThe concomitant use of a TNF blocker and abatacept or anakinra was associated with a higher \\nrisk of serious infections in patients with rheumatoid arthritis (RA); therefore, the concomitant \\nuse of HUMIRA and these biologic products is not recommended in the treatment of patients \\nwith RA [see Warnings and Precautions (5.7, 5.11) and Drug Interactions (7.2)].  \\nTreatment with HUMIRA should not be initiated in patients with an active infection, including \\nlocalized infections. Patients 65 years of age and older, patients with co-morbid conditions \\nand/or patients taking concomitant immunosuppressants (such as corticosteroids or \\nmethotrexate), may be at greater risk of infection. Consider the risks and benefits of treatment \\nprior to initiating therapy in patients:  \\n• with chronic or recurrent infection; \\n• who have been exposed to tuberculosis; \\n• with a history of an opportunistic infection; \\n• who have resided or traveled in areas of endemic tuberculosis or endemic mycoses, such as \\nhistoplasmosis, coccidioidomycosis, or blastomycosis; or  \\n• with underlying conditions that may predispose them to infection. \\n  \\nTuberculosis \\nCases of reactivation of tuberculosis and new onset tuberculosis infections have been reported in \\npatients receiving HUMIRA, including patients who have previously received treatment for \\nlatent or active tuberculosis. Reports included cases of pulmonary and extrapulmonary (i.e., \\ndisseminated) tuberculosis. Evaluate patients for tuberculosis risk factors and test for latent \\ninfection prior to initiating HUMIRA and periodically during therapy.  \\nTreatment of latent tuberculosis infection prior to therapy with TNF blocking agents has been \\nshown to reduce the risk of tuberculosis reactivation during therapy. Prior to initiating HUMIRA, \\nassess if treatment for latent tuberculosis is needed; and consider an induration of ≥ 5 mm a \\npositive tuberculin skin test result, even for patients previously vaccinated with Bacille Calmette-\\nGuerin (BCG).  \\nConsider anti-tuberculosis therapy prior to initiation of HUMIRA in patients with a past history \\nof latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, \\nand for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis \\ninfection. Despite prophylactic treatment for tuberculosis, cases of reactivated tuberculosis have \\noccurred in patients treated with HUMIRA. Consultation with a physician with expertise in the \\n', 'processed_text': {'sentences': [{'original_sentence': '5 WARNINGS AND PRECAUTIONS  \\n5.1 Serious Infections \\nPatients treated with HUMIRA are at increased risk for developing serious infections involving \\nvarious organ systems and sites that may lead to hospitalization or death.', 'tokens': ['5', 'WARNINGS', 'PRECAUTIONS', '5.1', 'Serious', 'Infections', 'Patients', 'treated', 'HUMIRA', 'increased', 'risk', 'developing', 'serious', 'infections', 'involving', 'various', 'organ', 'systems', 'sites', 'may', 'lead', 'hospitalization', 'death', '.'], 'lemmatized': ['5', 'WARNINGS', 'PRECAUTIONS', '5.1', 'Serious', 'Infections', 'Patients', 'treated', 'HUMIRA', 'increased', 'risk', 'developing', 'serious', 'infection', 'involving', 'various', 'organ', 'system', 'site', 'may', 'lead', 'hospitalization', 'death', '.'], 'stemmed': ['5', 'warn', 'precaut', '5.1', 'seriou', 'infect', 'patient', 'treat', 'humira', 'increas', 'risk', 'develop', 'seriou', 'infect', 'involv', 'variou', 'organ', 'system', 'site', 'may', 'lead', 'hospit', 'death', '.'], 'dependencies': [('5', 'meta'), ('warn', 'nmod'), ('precaut', 'nsubj'), ('5.1', 'nummod'), ('seriou', 'npadvmod'), ('infect', 'amod'), ('patient', 'compound'), ('treat', 'compound'), ('humira', 'compound'), ('increas', 'compound'), ('risk', 'nsubj'), ('develop', 'ROOT'), ('seriou', 'compound'), ('infect', 'compound'), ('involv', 'compound'), ('variou', 'compound'), ('organ', 'compound'), ('system', 'compound'), ('site', 'nsubj'), ('may', 'aux'), ('lead', 'ccomp'), ('hospit', 'compound'), ('death', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Opportunistic \\ninfections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic \\npathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, \\nhistoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported \\nwith TNF blockers.', 'tokens': ['Opportunistic', 'infections', 'due', 'bacterial', ',', 'mycobacterial', ',', 'invasive', 'fungal', ',', 'viral', ',', 'parasitic', ',', 'opportunistic', 'pathogens', 'including', 'aspergillosis', ',', 'blastomycosis', ',', 'candidiasis', ',', 'coccidioidomycosis', ',', 'histoplasmosis', ',', 'legionellosis', ',', 'listeriosis', ',', 'pneumocystosis', 'tuberculosis', 'reported', 'TNF', 'blockers', '.'], 'lemmatized': ['Opportunistic', 'infection', 'due', 'bacterial', ',', 'mycobacterial', ',', 'invasive', 'fungal', ',', 'viral', ',', 'parasitic', ',', 'opportunistic', 'pathogen', 'including', 'aspergillosis', ',', 'blastomycosis', ',', 'candidiasis', ',', 'coccidioidomycosis', ',', 'histoplasmosis', ',', 'legionellosis', ',', 'listeriosis', ',', 'pneumocystosis', 'tuberculosis', 'reported', 'TNF', 'blocker', '.'], 'stemmed': ['opportunist', 'infect', 'due', 'bacteri', ',', 'mycobacteri', ',', 'invas', 'fungal', ',', 'viral', ',', 'parasit', ',', 'opportunist', 'pathogen', 'includ', 'aspergillosi', ',', 'blastomycosi', ',', 'candidiasi', ',', 'coccidioidomycosi', ',', 'histoplasmosi', ',', 'legionellosi', ',', 'listeriosi', ',', 'pneumocystosi', 'tuberculosi', 'report', 'tnf', 'blocker', '.'], 'dependencies': [('opportunist', 'compound'), ('infect', 'ROOT'), ('due', 'amod'), ('bacteri', 'appos'), (',', 'punct'), ('mycobacteri', 'conj'), (',', 'punct'), ('invas', 'compound'), ('fungal', 'conj'), (',', 'punct'), ('viral', 'conj'), (',', 'punct'), ('parasit', 'conj'), (',', 'punct'), ('opportunist', 'compound'), ('pathogen', 'compound'), ('includ', 'compound'), ('aspergillosi', 'conj'), (',', 'punct'), ('blastomycosi', 'conj'), (',', 'punct'), ('candidiasi', 'conj'), (',', 'punct'), ('coccidioidomycosi', 'conj'), (',', 'punct'), ('histoplasmosi', 'conj'), (',', 'punct'), ('legionellosi', 'conj'), (',', 'punct'), ('listeriosi', 'conj'), (',', 'punct'), ('pneumocystosi', 'appos'), ('tuberculosi', 'nsubj'), ('report', 'relcl'), ('tnf', 'compound'), ('blocker', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Patients have frequently presented with disseminated rather than localized \\ndisease.', 'tokens': ['Patients', 'frequently', 'presented', 'disseminated', 'rather', 'localized', 'disease', '.'], 'lemmatized': ['Patients', 'frequently', 'presented', 'disseminated', 'rather', 'localized', 'disease', '.'], 'stemmed': ['patient', 'frequent', 'present', 'dissemin', 'rather', 'local', 'diseas', '.'], 'dependencies': [('patient', 'amod'), ('frequent', 'amod'), ('present', 'amod'), ('dissemin', 'nmod'), ('rather', 'advmod'), ('local', 'amod'), ('diseas', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'The concomitant use of a TNF blocker and abatacept or anakinra was associated with a higher \\nrisk of serious infections in patients with rheumatoid arthritis (RA); therefore, the concomitant \\nuse of HUMIRA and these biologic products is not recommended in the treatment of patients \\nwith RA [see Warnings and Precautions (5.7, 5.11) and Drug Interactions (7.2)].', 'tokens': ['concomitant', 'use', 'TNF', 'blocker', 'abatacept', 'anakinra', 'associated', 'higher', 'risk', 'serious', 'infections', 'patients', 'rheumatoid', 'arthritis', '(', 'RA', ')', ';', 'therefore', ',', 'concomitant', 'use', 'HUMIRA', 'biologic', 'products', 'recommended', 'treatment', 'patients', 'RA', '[', 'see', 'Warnings', 'Precautions', '(', '5.7', ',', '5.11', ')', 'Drug', 'Interactions', '(', '7.2', ')', ']', '.'], 'lemmatized': ['concomitant', 'use', 'TNF', 'blocker', 'abatacept', 'anakinra', 'associated', 'higher', 'risk', 'serious', 'infection', 'patient', 'rheumatoid', 'arthritis', '(', 'RA', ')', ';', 'therefore', ',', 'concomitant', 'use', 'HUMIRA', 'biologic', 'product', 'recommended', 'treatment', 'patient', 'RA', '[', 'see', 'Warnings', 'Precautions', '(', '5.7', ',', '5.11', ')', 'Drug', 'Interactions', '(', '7.2', ')', ']', '.'], 'stemmed': ['concomit', 'use', 'tnf', 'blocker', 'abatacept', 'anakinra', 'associ', 'higher', 'risk', 'seriou', 'infect', 'patient', 'rheumatoid', 'arthriti', '(', 'ra', ')', ';', 'therefor', ',', 'concomit', 'use', 'humira', 'biolog', 'product', 'recommend', 'treatment', 'patient', 'ra', '[', 'see', 'warn', 'precaut', '(', '5.7', ',', '5.11', ')', 'drug', 'interact', '(', '7.2', ')', ']', '.'], 'dependencies': [('concomit', 'compound'), ('use', 'dep'), ('tnf', 'compound'), ('blocker', 'compound'), ('abatacept', 'compound'), ('anakinra', 'compound'), ('associ', 'dobj'), ('higher', 'amod'), ('risk', 'compound'), ('seriou', 'nsubj'), ('infect', 'ccomp'), ('patient', 'compound'), ('rheumatoid', 'compound'), ('arthriti', 'dobj'), ('(', 'punct'), ('ra', 'npadvmod'), (')', 'punct'), (';', 'punct'), ('therefor', 'nsubj'), (',', 'punct'), ('concomit', 'compound'), ('use', 'compound'), ('humira', 'compound'), ('biolog', 'compound'), ('product', 'appos'), ('recommend', 'ROOT'), ('treatment', 'compound'), ('patient', 'dobj'), ('ra', 'punct'), ('[', 'punct'), ('see', 'ROOT'), ('warn', 'xcomp'), ('precaut', 'dobj'), ('(', 'punct'), ('5.7', 'nummod'), (',', 'punct'), ('5.11', 'npadvmod'), (')', 'punct'), ('drug', 'compound'), ('interact', 'npadvmod'), ('(', 'punct'), ('7.2', 'appos'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Treatment with HUMIRA should not be initiated in patients with an active infection, including \\nlocalized infections.', 'tokens': ['Treatment', 'HUMIRA', 'initiated', 'patients', 'active', 'infection', ',', 'including', 'localized', 'infections', '.'], 'lemmatized': ['Treatment', 'HUMIRA', 'initiated', 'patient', 'active', 'infection', ',', 'including', 'localized', 'infection', '.'], 'stemmed': ['treatment', 'humira', 'initi', 'patient', 'activ', 'infect', ',', 'includ', 'local', 'infect', '.'], 'dependencies': [('treatment', 'compound'), ('humira', 'compound'), ('initi', 'compound'), ('patient', 'amod'), ('activ', 'compound'), ('infect', 'ROOT'), (',', 'punct'), ('includ', 'amod'), ('local', 'amod'), ('infect', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Patients 65 years of age and older, patients with co-morbid conditions \\nand/or patients taking concomitant immunosuppressants (such as corticosteroids or \\nmethotrexate), may be at greater risk of infection.', 'tokens': ['Patients', '65', 'years', 'age', 'older', ',', 'patients', 'co-morbid', 'conditions', 'and/or', 'patients', 'taking', 'concomitant', 'immunosuppressants', '(', 'corticosteroids', 'methotrexate', ')', ',', 'may', 'greater', 'risk', 'infection', '.'], 'lemmatized': ['Patients', '65', 'year', 'age', 'older', ',', 'patient', 'co-morbid', 'condition', 'and/or', 'patient', 'taking', 'concomitant', 'immunosuppressant', '(', 'corticosteroid', 'methotrexate', ')', ',', 'may', 'greater', 'risk', 'infection', '.'], 'stemmed': ['patient', '65', 'year', 'age', 'older', ',', 'patient', 'co-morbid', 'condit', 'and/or', 'patient', 'take', 'concomit', 'immunosuppress', '(', 'corticosteroid', 'methotrex', ')', ',', 'may', 'greater', 'risk', 'infect', '.'], 'dependencies': [('patient', 'nsubj'), ('65', 'nummod'), ('year', 'compound'), ('age', 'npadvmod'), ('older', 'amod'), (',', 'punct'), ('patient', 'amod'), ('co', 'amod'), ('-', 'amod'), ('morbid', 'amod'), ('condit', 'dobj'), ('and/or', 'cc'), ('patient', 'conj'), ('take', 'ccomp'), ('concomit', 'compound'), ('immunosuppress', 'dobj'), ('(', 'punct'), ('corticosteroid', 'amod'), ('methotrex', 'appos'), (')', 'punct'), (',', 'punct'), ('may', 'aux'), ('greater', 'amod'), ('risk', 'nsubj'), ('infect', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Consider the risks and benefits of treatment \\nprior to initiating therapy in patients:  \\n• with chronic or recurrent infection; \\n• who have been exposed to tuberculosis; \\n• with a history of an opportunistic infection; \\n• who have resided or traveled in areas of endemic tuberculosis or endemic mycoses, such as \\nhistoplasmosis, coccidioidomycosis, or blastomycosis; or  \\n• with underlying conditions that may predispose them to infection.', 'tokens': ['Consider', 'risks', 'benefits', 'treatment', 'prior', 'initiating', 'therapy', 'patients', ':', '•', 'chronic', 'recurrent', 'infection', ';', '•', 'exposed', 'tuberculosis', ';', '•', 'history', 'opportunistic', 'infection', ';', '•', 'resided', 'traveled', 'areas', 'endemic', 'tuberculosis', 'endemic', 'mycoses', ',', 'histoplasmosis', ',', 'coccidioidomycosis', ',', 'blastomycosis', ';', '•', 'underlying', 'conditions', 'may', 'predispose', 'infection', '.'], 'lemmatized': ['Consider', 'risk', 'benefit', 'treatment', 'prior', 'initiating', 'therapy', 'patient', ':', '•', 'chronic', 'recurrent', 'infection', ';', '•', 'exposed', 'tuberculosis', ';', '•', 'history', 'opportunistic', 'infection', ';', '•', 'resided', 'traveled', 'area', 'endemic', 'tuberculosis', 'endemic', 'mycoses', ',', 'histoplasmosis', ',', 'coccidioidomycosis', ',', 'blastomycosis', ';', '•', 'underlying', 'condition', 'may', 'predispose', 'infection', '.'], 'stemmed': ['consid', 'risk', 'benefit', 'treatment', 'prior', 'initi', 'therapi', 'patient', ':', '•', 'chronic', 'recurr', 'infect', ';', '•', 'expos', 'tuberculosi', ';', '•', 'histori', 'opportunist', 'infect', ';', '•', 'resid', 'travel', 'area', 'endem', 'tuberculosi', 'endem', 'mycos', ',', 'histoplasmosi', ',', 'coccidioidomycosi', ',', 'blastomycosi', ';', '•', 'underli', 'condit', 'may', 'predispos', 'infect', '.'], 'dependencies': [('consid', 'amod'), ('risk', 'compound'), ('benefit', 'compound'), ('treatment', 'compound'), ('prior', 'amod'), ('initi', 'compound'), ('therapi', 'amod'), ('patient', 'nsubj'), (':', 'punct'), ('•', 'nummod'), ('chronic', 'amod'), ('recurr', 'compound'), ('infect', 'appos'), (';', 'punct'), ('•', 'nummod'), ('expos', 'compound'), ('tuberculosi', 'dep'), (';', 'punct'), ('•', 'cc'), ('histori', 'compound'), ('opportunist', 'compound'), ('infect', 'conj'), (';', 'punct'), ('•', 'nummod'), ('resid', 'compound'), ('travel', 'compound'), ('area', 'compound'), ('endem', 'compound'), ('tuberculosi', 'compound'), ('endem', 'compound'), ('mycos', 'conj'), (',', 'punct'), ('histoplasmosi', 'conj'), (',', 'punct'), ('coccidioidomycosi', 'conj'), (',', 'punct'), ('blastomycosi', 'conj'), (';', 'punct'), ('•', 'meta'), ('underli', 'amod'), ('condit', 'nsubj'), ('may', 'aux'), ('predispos', 'ROOT'), ('infect', 'xcomp'), ('.', 'punct')]}, {'original_sentence': 'Tuberculosis \\nCases of reactivation of tuberculosis and new onset tuberculosis infections have been reported in \\npatients receiving HUMIRA, including patients who have previously received treatment for \\nlatent or active tuberculosis.', 'tokens': ['Tuberculosis', 'Cases', 'reactivation', 'tuberculosis', 'new', 'onset', 'tuberculosis', 'infections', 'reported', 'patients', 'receiving', 'HUMIRA', ',', 'including', 'patients', 'previously', 'received', 'treatment', 'latent', 'active', 'tuberculosis', '.'], 'lemmatized': ['Tuberculosis', 'Cases', 'reactivation', 'tuberculosis', 'new', 'onset', 'tuberculosis', 'infection', 'reported', 'patient', 'receiving', 'HUMIRA', ',', 'including', 'patient', 'previously', 'received', 'treatment', 'latent', 'active', 'tuberculosis', '.'], 'stemmed': ['tuberculosi', 'case', 'reactiv', 'tuberculosi', 'new', 'onset', 'tuberculosi', 'infect', 'report', 'patient', 'receiv', 'humira', ',', 'includ', 'patient', 'previous', 'receiv', 'treatment', 'latent', 'activ', 'tuberculosi', '.'], 'dependencies': [('tuberculosi', 'compound'), ('case', 'compound'), ('reactiv', 'compound'), ('tuberculosi', 'dep'), ('new', 'amod'), ('onset', 'compound'), ('tuberculosi', 'compound'), ('infect', 'compound'), ('report', 'compound'), ('patient', 'compound'), ('receiv', 'compound'), ('humira', 'appos'), (',', 'punct'), ('includ', 'npadvmod'), ('patient', 'amod'), ('previous', 'amod'), ('receiv', 'compound'), ('treatment', 'compound'), ('latent', 'compound'), ('activ', 'compound'), ('tuberculosi', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Reports included cases of pulmonary and extrapulmonary (i.e., \\ndisseminated) tuberculosis.', 'tokens': ['Reports', 'included', 'cases', 'pulmonary', 'extrapulmonary', '(', 'i.e.', ',', 'disseminated', ')', 'tuberculosis', '.'], 'lemmatized': ['Reports', 'included', 'case', 'pulmonary', 'extrapulmonary', '(', 'i.e.', ',', 'disseminated', ')', 'tuberculosis', '.'], 'stemmed': ['report', 'includ', 'case', 'pulmonari', 'extrapulmonari', '(', 'i.e.', ',', 'dissemin', ')', 'tuberculosi', '.'], 'dependencies': [('report', 'ROOT'), ('includ', 'compound'), ('case', 'compound'), ('pulmonari', 'compound'), ('extrapulmonari', 'dobj'), ('(', 'punct'), ('i.e.', 'advmod'), (',', 'punct'), ('dissemin', 'parataxis'), (')', 'punct'), ('tuberculosi', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Evaluate patients for tuberculosis risk factors and test for latent \\ninfection prior to initiating HUMIRA and periodically during therapy.', 'tokens': ['Evaluate', 'patients', 'tuberculosis', 'risk', 'factors', 'test', 'latent', 'infection', 'prior', 'initiating', 'HUMIRA', 'periodically', 'therapy', '.'], 'lemmatized': ['Evaluate', 'patient', 'tuberculosis', 'risk', 'factor', 'test', 'latent', 'infection', 'prior', 'initiating', 'HUMIRA', 'periodically', 'therapy', '.'], 'stemmed': ['evalu', 'patient', 'tuberculosi', 'risk', 'factor', 'test', 'latent', 'infect', 'prior', 'initi', 'humira', 'period', 'therapi', '.'], 'dependencies': [('evalu', 'compound'), ('patient', 'compound'), ('tuberculosi', 'compound'), ('risk', 'compound'), ('factor', 'compound'), ('test', 'compound'), ('latent', 'nsubj'), ('infect', 'nsubj'), ('prior', 'amod'), ('initi', 'compound'), ('humira', 'compound'), ('period', 'nsubj'), ('therapi', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Treatment of latent tuberculosis infection prior to therapy with TNF blocking agents has been \\nshown to reduce the risk of tuberculosis reactivation during therapy.', 'tokens': ['Treatment', 'latent', 'tuberculosis', 'infection', 'prior', 'therapy', 'TNF', 'blocking', 'agents', 'shown', 'reduce', 'risk', 'tuberculosis', 'reactivation', 'therapy', '.'], 'lemmatized': ['Treatment', 'latent', 'tuberculosis', 'infection', 'prior', 'therapy', 'TNF', 'blocking', 'agent', 'shown', 'reduce', 'risk', 'tuberculosis', 'reactivation', 'therapy', '.'], 'stemmed': ['treatment', 'latent', 'tuberculosi', 'infect', 'prior', 'therapi', 'tnf', 'block', 'agent', 'shown', 'reduc', 'risk', 'tuberculosi', 'reactiv', 'therapi', '.'], 'dependencies': [('treatment', 'compound'), ('latent', 'compound'), ('tuberculosi', 'nsubj'), ('infect', 'ROOT'), ('prior', 'amod'), ('therapi', 'compound'), ('tnf', 'compound'), ('block', 'compound'), ('agent', 'nsubj'), ('shown', 'ccomp'), ('reduc', 'compound'), ('risk', 'compound'), ('tuberculosi', 'compound'), ('reactiv', 'compound'), ('therapi', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Prior to initiating HUMIRA, \\nassess if treatment for latent tuberculosis is needed; and consider an induration of ≥ 5 mm a \\npositive tuberculin skin test result, even for patients previously vaccinated with Bacille Calmette-\\nGuerin (BCG).', 'tokens': ['Prior', 'initiating', 'HUMIRA', ',', 'assess', 'treatment', 'latent', 'tuberculosis', 'needed', ';', 'consider', 'induration', '≥', '5', 'mm', 'positive', 'tuberculin', 'skin', 'test', 'result', ',', 'even', 'patients', 'previously', 'vaccinated', 'Bacille', 'Calmette-', 'Guerin', '(', 'BCG', ')', '.'], 'lemmatized': ['Prior', 'initiating', 'HUMIRA', ',', 'assess', 'treatment', 'latent', 'tuberculosis', 'needed', ';', 'consider', 'induration', '≥', '5', 'mm', 'positive', 'tuberculin', 'skin', 'test', 'result', ',', 'even', 'patient', 'previously', 'vaccinated', 'Bacille', 'Calmette-', 'Guerin', '(', 'BCG', ')', '.'], 'stemmed': ['prior', 'initi', 'humira', ',', 'assess', 'treatment', 'latent', 'tuberculosi', 'need', ';', 'consid', 'indur', '≥', '5', 'mm', 'posit', 'tuberculin', 'skin', 'test', 'result', ',', 'even', 'patient', 'previous', 'vaccin', 'bacil', 'calmette-', 'guerin', '(', 'bcg', ')', '.'], 'dependencies': [('prior', 'amod'), ('initi', 'compound'), ('humira', 'nsubj'), (',', 'punct'), ('assess', 'ccomp'), ('treatment', 'compound'), ('latent', 'dobj'), ('tuberculosi', 'nsubj'), ('need', 'ccomp'), (';', 'punct'), ('consid', 'advmod'), ('indur', 'ROOT'), ('≥', 'npadvmod'), ('5', 'nummod'), ('mm', 'compound'), ('posit', 'compound'), ('tuberculin', 'compound'), ('skin', 'compound'), ('test', 'compound'), ('result', 'dobj'), (',', 'punct'), ('even', 'advmod'), ('patient', 'advcl'), ('previous', 'amod'), ('vaccin', 'compound'), ('bacil', 'compound'), ('calmette-', 'compound'), ('guerin', 'dobj'), ('(', 'punct'), ('bcg', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Consider anti-tuberculosis therapy prior to initiation of HUMIRA in patients with a past history \\nof latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, \\nand for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis \\ninfection.', 'tokens': ['Consider', 'anti-tuberculosis', 'therapy', 'prior', 'initiation', 'HUMIRA', 'patients', 'past', 'history', 'latent', 'active', 'tuberculosis', 'adequate', 'course', 'treatment', 'confirmed', ',', 'patients', 'negative', 'test', 'latent', 'tuberculosis', 'risk', 'factors', 'tuberculosis', 'infection', '.'], 'lemmatized': ['Consider', 'anti-tuberculosis', 'therapy', 'prior', 'initiation', 'HUMIRA', 'patient', 'past', 'history', 'latent', 'active', 'tuberculosis', 'adequate', 'course', 'treatment', 'confirmed', ',', 'patient', 'negative', 'test', 'latent', 'tuberculosis', 'risk', 'factor', 'tuberculosis', 'infection', '.'], 'stemmed': ['consid', 'anti-tuberculosi', 'therapi', 'prior', 'initi', 'humira', 'patient', 'past', 'histori', 'latent', 'activ', 'tuberculosi', 'adequ', 'cours', 'treatment', 'confirm', ',', 'patient', 'neg', 'test', 'latent', 'tuberculosi', 'risk', 'factor', 'tuberculosi', 'infect', '.'], 'dependencies': [('consid', 'amod'), ('anti', 'amod'), ('-', 'amod'), ('tuberculosi', 'amod'), ('therapi', 'amod'), ('prior', 'amod'), ('initi', 'compound'), ('humira', 'compound'), ('patient', 'dep'), ('past', 'prep'), ('histori', 'compound'), ('latent', 'amod'), ('activ', 'compound'), ('tuberculosi', 'compound'), ('adequ', 'compound'), ('cours', 'compound'), ('treatment', 'compound'), ('confirm', 'pobj'), (',', 'punct'), ('patient', 'amod'), ('neg', 'compound'), ('test', 'compound'), ('latent', 'compound'), ('tuberculosi', 'compound'), ('risk', 'compound'), ('factor', 'compound'), ('tuberculosi', 'nsubj'), ('infect', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Despite prophylactic treatment for tuberculosis, cases of reactivated tuberculosis have \\noccurred in patients treated with HUMIRA.', 'tokens': ['Despite', 'prophylactic', 'treatment', 'tuberculosis', ',', 'cases', 'reactivated', 'tuberculosis', 'occurred', 'patients', 'treated', 'HUMIRA', '.'], 'lemmatized': ['Despite', 'prophylactic', 'treatment', 'tuberculosis', ',', 'case', 'reactivated', 'tuberculosis', 'occurred', 'patient', 'treated', 'HUMIRA', '.'], 'stemmed': ['despit', 'prophylact', 'treatment', 'tuberculosi', ',', 'case', 'reactiv', 'tuberculosi', 'occur', 'patient', 'treat', 'humira', '.'], 'dependencies': [('despit', 'compound'), ('prophylact', 'compound'), ('treatment', 'compound'), ('tuberculosi', 'nsubj'), (',', 'punct'), ('case', 'compound'), ('reactiv', 'compound'), ('tuberculosi', 'nsubj'), ('occur', 'ROOT'), ('patient', 'compound'), ('treat', 'compound'), ('humira', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Consultation with a physician with expertise in the', 'tokens': ['Consultation', 'physician', 'expertise'], 'lemmatized': ['Consultation', 'physician', 'expertise'], 'stemmed': ['consult', 'physician', 'expertis'], 'dependencies': [('consult', 'ROOT'), ('physician', 'compound'), ('expertis', 'dobj')]}], 'text': '5 WARNINGS AND PRECAUTIONS  \\n5.1 Serious Infections \\nPatients treated with HUMIRA are at increased risk for developing serious infections involving \\nvarious organ systems and sites that may lead to hospitalization or death. Opportunistic \\ninfections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic \\npathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, \\nhistoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported \\nwith TNF blockers. Patients have frequently presented with disseminated rather than localized \\ndisease.  \\nThe concomitant use of a TNF blocker and abatacept or anakinra was associated with a higher \\nrisk of serious infections in patients with rheumatoid arthritis (RA); therefore, the concomitant \\nuse of HUMIRA and these biologic products is not recommended in the treatment of patients \\nwith RA [see Warnings and Precautions (5.7, 5.11) and Drug Interactions (7.2)].  \\nTreatment with HUMIRA should not be initiated in patients with an active infection, including \\nlocalized infections. Patients 65 years of age and older, patients with co-morbid conditions \\nand/or patients taking concomitant immunosuppressants (such as corticosteroids or \\nmethotrexate), may be at greater risk of infection. Consider the risks and benefits of treatment \\nprior to initiating therapy in patients:  \\n• with chronic or recurrent infection; \\n• who have been exposed to tuberculosis; \\n• with a history of an opportunistic infection; \\n• who have resided or traveled in areas of endemic tuberculosis or endemic mycoses, such as \\nhistoplasmosis, coccidioidomycosis, or blastomycosis; or  \\n• with underlying conditions that may predispose them to infection. \\n  \\nTuberculosis \\nCases of reactivation of tuberculosis and new onset tuberculosis infections have been reported in \\npatients receiving HUMIRA, including patients who have previously received treatment for \\nlatent or active tuberculosis. Reports included cases of pulmonary and extrapulmonary (i.e., \\ndisseminated) tuberculosis. Evaluate patients for tuberculosis risk factors and test for latent \\ninfection prior to initiating HUMIRA and periodically during therapy.  \\nTreatment of latent tuberculosis infection prior to therapy with TNF blocking agents has been \\nshown to reduce the risk of tuberculosis reactivation during therapy. Prior to initiating HUMIRA, \\nassess if treatment for latent tuberculosis is needed; and consider an induration of ≥ 5 mm a \\npositive tuberculin skin test result, even for patients previously vaccinated with Bacille Calmette-\\nGuerin (BCG).  \\nConsider anti-tuberculosis therapy prior to initiation of HUMIRA in patients with a past history \\nof latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, \\nand for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis \\ninfection. Despite prophylactic treatment for tuberculosis, cases of reactivated tuberculosis have \\noccurred in patients treated with HUMIRA. Consultation with a physician with expertise in the \\n'}, 'page_char_count': 3125, 'page_word_count': 427, 'sentences': ['5 WARNINGS AND PRECAUTIONS  \\n5.1 Serious Infections \\nPatients treated with HUMIRA are at increased risk for developing serious infections involving \\nvarious organ systems and sites that may lead to hospitalization or death.', 'Opportunistic \\ninfections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic \\npathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, \\nhistoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported \\nwith TNF blockers.', 'Patients have frequently presented with disseminated rather than localized \\ndisease.', ' \\nThe concomitant use of a TNF blocker and abatacept or anakinra was associated with a higher \\nrisk of serious infections in patients with rheumatoid arthritis (RA); therefore, the concomitant \\nuse of HUMIRA and these biologic products is not recommended in the treatment of patients \\nwith RA [see Warnings and Precautions (5.7, 5.11) and Drug Interactions (7.2)].', ' \\nTreatment with HUMIRA should not be initiated in patients with an active infection, including \\nlocalized infections.', 'Patients 65 years of age and older, patients with co-morbid conditions \\nand/or patients taking concomitant immunosuppressants (such as corticosteroids or \\nmethotrexate), may be at greater risk of infection.', 'Consider the risks and benefits of treatment \\nprior to initiating therapy in patients:  \\n• with chronic or recurrent infection; \\n• who have been exposed to tuberculosis; \\n• with a history of an opportunistic infection; \\n• who have resided or traveled in areas of endemic tuberculosis or endemic mycoses, such as \\nhistoplasmosis, coccidioidomycosis, or blastomycosis; or  \\n• with underlying conditions that may predispose them to infection.', '\\n  \\nTuberculosis \\nCases of reactivation of tuberculosis and new onset tuberculosis infections have been reported in \\npatients receiving HUMIRA, including patients who have previously received treatment for \\nlatent or active tuberculosis.', 'Reports included cases of pulmonary and extrapulmonary (i.e., \\ndisseminated) tuberculosis.', 'Evaluate patients for tuberculosis risk factors and test for latent \\ninfection prior to initiating HUMIRA and periodically during therapy.', ' \\nTreatment of latent tuberculosis infection prior to therapy with TNF blocking agents has been \\nshown to reduce the risk of tuberculosis reactivation during therapy.', 'Prior to initiating HUMIRA, \\nassess if treatment for latent tuberculosis is needed; and consider an induration of ≥ 5 mm a \\npositive tuberculin skin test result, even for patients previously vaccinated with Bacille Calmette-\\nGuerin (BCG).', ' \\nConsider anti-tuberculosis therapy prior to initiation of HUMIRA in patients with a past history \\nof latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, \\nand for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis \\ninfection.', 'Despite prophylactic treatment for tuberculosis, cases of reactivated tuberculosis have \\noccurred in patients treated with HUMIRA.', 'Consultation with a physician with expertise in the \\n'], 'page_sentence_count_spacy': 15}\n",
            "{'page_number': 10, 'text': 'treatment of tuberculosis is recommended to aid in the decision whether initiating anti-\\ntuberculosis therapy is appropriate for an individual patient.  \\nStrongly consider tuberculosis in the differential diagnosis in patients who develop a new \\ninfection during HUMIRA treatment, especially in patients who have previously or recently \\ntraveled to countries with a high prevalence of tuberculosis, or who have had close contact with a \\nperson with active tuberculosis.  \\nMonitoring \\nClosely monitor patients for the development of signs and symptoms of infection during and \\nafter treatment with HUMIRA, including the development of tuberculosis in patients who tested \\nnegative for latent tuberculosis infection prior to initiating therapy. Tests for latent tuberculosis \\ninfection may also be falsely negative while on therapy with HUMIRA.  \\nDiscontinue HUMIRA if a patient develops a serious infection or sepsis. For a patient who \\ndevelops a new infection during treatment with HUMIRA, closely monitor them, perform a \\nprompt and complete diagnostic workup appropriate for an immunocompromised patient, and \\ninitiate appropriate antimicrobial therapy.  \\nInvasive Fungal Infections \\nIf patients develop a serious systemic illness and they reside or travel in regions where mycoses \\nare endemic, consider invasive fungal infection in the differential diagnosis. Antigen and \\nantibody testing for histoplasmosis may be negative in some patients with active infection. \\nConsider appropriate empiric antifungal therapy, taking into account both the risk for severe \\nfungal infection and the risks of antifungal therapy, while a diagnostic workup is being \\nperformed. To aid in the management of such patients, consider consultation with a physician \\nwith expertise in the diagnosis and treatment of invasive fungal infections.  \\n5.2 Malignancies \\nConsider the risks and benefits of TNF-blocker treatment including HUMIRA prior to initiating \\ntherapy in patients with a known malignancy other than a successfully treated non-melanoma \\nskin cancer (NMSC) or when considering continuing a TNF blocker in patients who develop a \\nmalignancy.  \\nMalignancies in Adults \\nIn the controlled portions of clinical trials of some TNF-blockers, including HUMIRA, more \\ncases of malignancies have been observed among TNF-blocker-treated adult patients compared \\nto control-treated adult patients. During the controlled portions of 39 global HUMIRA clinical \\ntrials in adult patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing \\nspondylitis (AS), Crohn’s disease (CD), ulcerative colitis (UC), plaque psoriasis (Ps), \\nhidradenitis suppurativa (HS) and uveitis (UV), malignancies, other than non-melanoma (basal \\ncell and squamous cell) skin cancer, were observed at a rate (95% confidence interval) of 0.7 \\n(0.48, 1.03) per 100 patient-years among 7973 HUMIRA-treated patients versus a rate of 0.7 \\n(0.41, 1.17) per 100 patient-years among 4848 control-treated patients (median duration of \\ntreatment of 4 months for HUMIRA-treated patients and 4 months for control-treated patients). \\nIn 52 global controlled and uncontrolled clinical trials of HUMIRA in adult patients with RA, \\nPsA, AS, CD, UC, Ps, HS and UV, the most frequently observed malignancies, other than \\n', 'processed_text': {'sentences': [{'original_sentence': 'treatment of tuberculosis is recommended to aid in the decision whether initiating anti-\\ntuberculosis therapy is appropriate for an individual patient.', 'tokens': ['treatment', 'tuberculosis', 'recommended', 'aid', 'decision', 'whether', 'initiating', 'anti-', 'tuberculosis', 'therapy', 'appropriate', 'individual', 'patient', '.'], 'lemmatized': ['treatment', 'tuberculosis', 'recommended', 'aid', 'decision', 'whether', 'initiating', 'anti-', 'tuberculosis', 'therapy', 'appropriate', 'individual', 'patient', '.'], 'stemmed': ['treatment', 'tuberculosi', 'recommend', 'aid', 'decis', 'whether', 'initi', 'anti-', 'tuberculosi', 'therapi', 'appropri', 'individu', 'patient', '.'], 'dependencies': [('treatment', 'compound'), ('tuberculosi', 'nsubj'), ('recommend', 'ROOT'), ('aid', 'compound'), ('decis', 'dobj'), ('whether', 'mark'), ('initi', 'compound'), ('anti-', 'compound'), ('tuberculosi', 'compound'), ('therapi', 'amod'), ('appropri', 'nsubj'), ('individu', 'compound'), ('patient', 'advcl'), ('.', 'punct')]}, {'original_sentence': 'Strongly consider tuberculosis in the differential diagnosis in patients who develop a new \\ninfection during HUMIRA treatment, especially in patients who have previously or recently \\ntraveled to countries with a high prevalence of tuberculosis, or who have had close contact with a \\nperson with active tuberculosis.', 'tokens': ['Strongly', 'consider', 'tuberculosis', 'differential', 'diagnosis', 'patients', 'develop', 'new', 'infection', 'HUMIRA', 'treatment', ',', 'especially', 'patients', 'previously', 'recently', 'traveled', 'countries', 'high', 'prevalence', 'tuberculosis', ',', 'close', 'contact', 'person', 'active', 'tuberculosis', '.'], 'lemmatized': ['Strongly', 'consider', 'tuberculosis', 'differential', 'diagnosis', 'patient', 'develop', 'new', 'infection', 'HUMIRA', 'treatment', ',', 'especially', 'patient', 'previously', 'recently', 'traveled', 'country', 'high', 'prevalence', 'tuberculosis', ',', 'close', 'contact', 'person', 'active', 'tuberculosis', '.'], 'stemmed': ['strongli', 'consid', 'tuberculosi', 'differenti', 'diagnosi', 'patient', 'develop', 'new', 'infect', 'humira', 'treatment', ',', 'especi', 'patient', 'previous', 'recent', 'travel', 'countri', 'high', 'preval', 'tuberculosi', ',', 'close', 'contact', 'person', 'activ', 'tuberculosi', '.'], 'dependencies': [('strongli', 'compound'), ('consid', 'nsubj'), ('tuberculosi', 'dep'), ('differenti', 'compound'), ('diagnosi', 'compound'), ('patient', 'nsubj'), ('develop', 'ROOT'), ('new', 'amod'), ('infect', 'compound'), ('humira', 'compound'), ('treatment', 'dobj'), (',', 'punct'), ('especi', 'conj'), ('patient', 'advmod'), ('previous', 'amod'), ('recent', 'amod'), ('travel', 'nmod'), ('countri', 'amod'), ('high', 'amod'), ('preval', 'compound'), ('tuberculosi', 'dobj'), (',', 'punct'), ('close', 'amod'), ('contact', 'compound'), ('person', 'compound'), ('activ', 'compound'), ('tuberculosi', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Monitoring \\nClosely monitor patients for the development of signs and symptoms of infection during and \\nafter treatment with HUMIRA, including the development of tuberculosis in patients who tested \\nnegative for latent tuberculosis infection prior to initiating therapy.', 'tokens': ['Monitoring', 'Closely', 'monitor', 'patients', 'development', 'signs', 'symptoms', 'infection', 'treatment', 'HUMIRA', ',', 'including', 'development', 'tuberculosis', 'patients', 'tested', 'negative', 'latent', 'tuberculosis', 'infection', 'prior', 'initiating', 'therapy', '.'], 'lemmatized': ['Monitoring', 'Closely', 'monitor', 'patient', 'development', 'sign', 'symptom', 'infection', 'treatment', 'HUMIRA', ',', 'including', 'development', 'tuberculosis', 'patient', 'tested', 'negative', 'latent', 'tuberculosis', 'infection', 'prior', 'initiating', 'therapy', '.'], 'stemmed': ['monitor', 'close', 'monitor', 'patient', 'develop', 'sign', 'symptom', 'infect', 'treatment', 'humira', ',', 'includ', 'develop', 'tuberculosi', 'patient', 'test', 'neg', 'latent', 'tuberculosi', 'infect', 'prior', 'initi', 'therapi', '.'], 'dependencies': [('monitor', 'ROOT'), ('close', 'amod'), ('monitor', 'compound'), ('patient', 'dobj'), ('develop', 'ccomp'), ('sign', 'compound'), ('symptom', 'compound'), ('infect', 'compound'), ('treatment', 'compound'), ('humira', 'dobj'), (',', 'punct'), ('includ', 'nsubj'), ('develop', 'conj'), ('tuberculosi', 'nmod'), ('patient', 'amod'), ('test', 'compound'), ('neg', 'compound'), ('latent', 'compound'), ('tuberculosi', 'nsubj'), ('infect', 'conj'), ('prior', 'amod'), ('initi', 'dobj'), ('therapi', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Tests for latent tuberculosis \\ninfection may also be falsely negative while on therapy with HUMIRA.', 'tokens': ['Tests', 'latent', 'tuberculosis', 'infection', 'may', 'also', 'falsely', 'negative', 'therapy', 'HUMIRA', '.'], 'lemmatized': ['Tests', 'latent', 'tuberculosis', 'infection', 'may', 'also', 'falsely', 'negative', 'therapy', 'HUMIRA', '.'], 'stemmed': ['test', 'latent', 'tuberculosi', 'infect', 'may', 'also', 'fals', 'neg', 'therapi', 'humira', '.'], 'dependencies': [('test', 'compound'), ('latent', 'compound'), ('tuberculosi', 'compound'), ('infect', 'nsubj'), ('may', 'aux'), ('also', 'advmod'), ('fals', 'ROOT'), ('neg', 'compound'), ('therapi', 'compound'), ('humira', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Discontinue HUMIRA if a patient develops a serious infection or sepsis.', 'tokens': ['Discontinue', 'HUMIRA', 'patient', 'develops', 'serious', 'infection', 'sepsis', '.'], 'lemmatized': ['Discontinue', 'HUMIRA', 'patient', 'develops', 'serious', 'infection', 'sepsis', '.'], 'stemmed': ['discontinu', 'humira', 'patient', 'develop', 'seriou', 'infect', 'sepsi', '.'], 'dependencies': [('discontinu', 'compound'), ('humira', 'compound'), ('patient', 'nsubj'), ('develop', 'ROOT'), ('seriou', 'compound'), ('infect', 'compound'), ('sepsi', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'For a patient who \\ndevelops a new infection during treatment with HUMIRA, closely monitor them, perform a \\nprompt and complete diagnostic workup appropriate for an immunocompromised patient, and \\ninitiate appropriate antimicrobial therapy.', 'tokens': ['patient', 'develops', 'new', 'infection', 'treatment', 'HUMIRA', ',', 'closely', 'monitor', ',', 'perform', 'prompt', 'complete', 'diagnostic', 'workup', 'appropriate', 'immunocompromised', 'patient', ',', 'initiate', 'appropriate', 'antimicrobial', 'therapy', '.'], 'lemmatized': ['patient', 'develops', 'new', 'infection', 'treatment', 'HUMIRA', ',', 'closely', 'monitor', ',', 'perform', 'prompt', 'complete', 'diagnostic', 'workup', 'appropriate', 'immunocompromised', 'patient', ',', 'initiate', 'appropriate', 'antimicrobial', 'therapy', '.'], 'stemmed': ['patient', 'develop', 'new', 'infect', 'treatment', 'humira', ',', 'close', 'monitor', ',', 'perform', 'prompt', 'complet', 'diagnost', 'workup', 'appropri', 'immunocompromis', 'patient', ',', 'initi', 'appropri', 'antimicrobi', 'therapi', '.'], 'dependencies': [('patient', 'nsubj'), ('develop', 'ccomp'), ('new', 'amod'), ('infect', 'amod'), ('treatment', 'compound'), ('humira', 'dobj'), (',', 'punct'), ('close', 'amod'), ('monitor', 'appos'), (',', 'punct'), ('perform', 'conj'), ('prompt', 'amod'), ('complet', 'compound'), ('diagnost', 'compound'), ('workup', 'compound'), ('appropri', 'compound'), ('immunocompromis', 'compound'), ('patient', 'dobj'), (',', 'punct'), ('initi', 'compound'), ('appropri', 'compound'), ('antimicrobi', 'nsubj'), ('therapi', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Invasive Fungal Infections \\nIf patients develop a serious systemic illness and they reside or travel in regions where mycoses \\nare endemic, consider invasive fungal infection in the differential diagnosis.', 'tokens': ['Invasive', 'Fungal', 'Infections', 'patients', 'develop', 'serious', 'systemic', 'illness', 'reside', 'travel', 'regions', 'mycoses', 'endemic', ',', 'consider', 'invasive', 'fungal', 'infection', 'differential', 'diagnosis', '.'], 'lemmatized': ['Invasive', 'Fungal', 'Infections', 'patient', 'develop', 'serious', 'systemic', 'illness', 'reside', 'travel', 'region', 'mycoses', 'endemic', ',', 'consider', 'invasive', 'fungal', 'infection', 'differential', 'diagnosis', '.'], 'stemmed': ['invas', 'fungal', 'infect', 'patient', 'develop', 'seriou', 'system', 'ill', 'resid', 'travel', 'region', 'mycos', 'endem', ',', 'consid', 'invas', 'fungal', 'infect', 'differenti', 'diagnosi', '.'], 'dependencies': [('invas', 'compound'), ('fungal', 'compound'), ('infect', 'compound'), ('patient', 'nsubj'), ('develop', 'ROOT'), ('seriou', 'compound'), ('system', 'dobj'), ('ill', 'amod'), ('resid', 'compound'), ('travel', 'compound'), ('region', 'compound'), ('mycos', 'compound'), ('endem', 'appos'), (',', 'punct'), ('consid', 'advmod'), ('invas', 'compound'), ('fungal', 'compound'), ('infect', 'compound'), ('differenti', 'compound'), ('diagnosi', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Antigen and \\nantibody testing for histoplasmosis may be negative in some patients with active infection.', 'tokens': ['Antigen', 'antibody', 'testing', 'histoplasmosis', 'may', 'negative', 'patients', 'active', 'infection', '.'], 'lemmatized': ['Antigen', 'antibody', 'testing', 'histoplasmosis', 'may', 'negative', 'patient', 'active', 'infection', '.'], 'stemmed': ['antigen', 'antibodi', 'test', 'histoplasmosi', 'may', 'neg', 'patient', 'activ', 'infect', '.'], 'dependencies': [('antigen', 'compound'), ('antibodi', 'compound'), ('test', 'compound'), ('histoplasmosi', 'nsubj'), ('may', 'aux'), ('neg', 'ROOT'), ('patient', 'amod'), ('activ', 'compound'), ('infect', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Consider appropriate empiric antifungal therapy, taking into account both the risk for severe \\nfungal infection and the risks of antifungal therapy, while a diagnostic workup is being \\nperformed.', 'tokens': ['Consider', 'appropriate', 'empiric', 'antifungal', 'therapy', ',', 'taking', 'account', 'risk', 'severe', 'fungal', 'infection', 'risks', 'antifungal', 'therapy', ',', 'diagnostic', 'workup', 'performed', '.'], 'lemmatized': ['Consider', 'appropriate', 'empiric', 'antifungal', 'therapy', ',', 'taking', 'account', 'risk', 'severe', 'fungal', 'infection', 'risk', 'antifungal', 'therapy', ',', 'diagnostic', 'workup', 'performed', '.'], 'stemmed': ['consid', 'appropri', 'empir', 'antifung', 'therapi', ',', 'take', 'account', 'risk', 'sever', 'fungal', 'infect', 'risk', 'antifung', 'therapi', ',', 'diagnost', 'workup', 'perform', '.'], 'dependencies': [('consid', 'amod'), ('appropri', 'compound'), ('empir', 'compound'), ('antifung', 'compound'), ('therapi', 'npadvmod'), (',', 'punct'), ('take', 'ccomp'), ('account', 'compound'), ('risk', 'compound'), ('sever', 'compound'), ('fungal', 'compound'), ('infect', 'compound'), ('risk', 'compound'), ('antifung', 'compound'), ('therapi', 'dobj'), (',', 'punct'), ('diagnost', 'compound'), ('workup', 'nsubj'), ('perform', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'To aid in the management of such patients, consider consultation with a physician \\nwith expertise in the diagnosis and treatment of invasive fungal infections.', 'tokens': ['aid', 'management', 'patients', ',', 'consider', 'consultation', 'physician', 'expertise', 'diagnosis', 'treatment', 'invasive', 'fungal', 'infections', '.'], 'lemmatized': ['aid', 'management', 'patient', ',', 'consider', 'consultation', 'physician', 'expertise', 'diagnosis', 'treatment', 'invasive', 'fungal', 'infection', '.'], 'stemmed': ['aid', 'manag', 'patient', ',', 'consid', 'consult', 'physician', 'expertis', 'diagnosi', 'treatment', 'invas', 'fungal', 'infect', '.'], 'dependencies': [('aid', 'compound'), ('manag', 'compound'), ('patient', 'npadvmod'), (',', 'punct'), ('consid', 'advmod'), ('consult', 'ROOT'), ('physician', 'compound'), ('expertis', 'nsubj'), ('diagnosi', 'dative'), ('treatment', 'compound'), ('invas', 'compound'), ('fungal', 'compound'), ('infect', 'dobj'), ('.', 'punct')]}, {'original_sentence': '5.2 Malignancies \\nConsider the risks and benefits of TNF-blocker treatment including HUMIRA prior to initiating \\ntherapy in patients with a known malignancy other than a successfully treated non-melanoma \\nskin cancer (NMSC) or when considering continuing a TNF blocker in patients who develop a \\nmalignancy.', 'tokens': ['5.2', 'Malignancies', 'Consider', 'risks', 'benefits', 'TNF-blocker', 'treatment', 'including', 'HUMIRA', 'prior', 'initiating', 'therapy', 'patients', 'known', 'malignancy', 'successfully', 'treated', 'non-melanoma', 'skin', 'cancer', '(', 'NMSC', ')', 'considering', 'continuing', 'TNF', 'blocker', 'patients', 'develop', 'malignancy', '.'], 'lemmatized': ['5.2', 'Malignancies', 'Consider', 'risk', 'benefit', 'TNF-blocker', 'treatment', 'including', 'HUMIRA', 'prior', 'initiating', 'therapy', 'patient', 'known', 'malignancy', 'successfully', 'treated', 'non-melanoma', 'skin', 'cancer', '(', 'NMSC', ')', 'considering', 'continuing', 'TNF', 'blocker', 'patient', 'develop', 'malignancy', '.'], 'stemmed': ['5.2', 'malign', 'consid', 'risk', 'benefit', 'tnf-blocker', 'treatment', 'includ', 'humira', 'prior', 'initi', 'therapi', 'patient', 'known', 'malign', 'success', 'treat', 'non-melanoma', 'skin', 'cancer', '(', 'nmsc', ')', 'consid', 'continu', 'tnf', 'blocker', 'patient', 'develop', 'malign', '.'], 'dependencies': [('5.2', 'nummod'), ('malign', 'nmod'), ('consid', 'amod'), ('risk', 'compound'), ('benefit', 'compound'), ('tnf', 'compound'), ('-', 'punct'), ('blocker', 'compound'), ('treatment', 'compound'), ('includ', 'compound'), ('humira', 'nsubj'), ('prior', 'amod'), ('initi', 'nmod'), ('therapi', 'amod'), ('patient', 'npadvmod'), ('known', 'amod'), ('malign', 'compound'), ('success', 'nsubj'), ('treat', 'ROOT'), ('non', 'amod'), ('-', 'amod'), ('melanoma', 'amod'), ('skin', 'compound'), ('cancer', 'dobj'), ('(', 'punct'), ('nmsc', 'nmod'), (')', 'punct'), ('consid', 'amod'), ('continu', 'compound'), ('tnf', 'compound'), ('blocker', 'compound'), ('patient', 'nsubj'), ('develop', 'relcl'), ('malign', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Malignancies in Adults \\nIn the controlled portions of clinical trials of some TNF-blockers, including HUMIRA, more \\ncases of malignancies have been observed among TNF-blocker-treated adult patients compared \\nto control-treated adult patients.', 'tokens': ['Malignancies', 'Adults', 'controlled', 'portions', 'clinical', 'trials', 'TNF-blockers', ',', 'including', 'HUMIRA', ',', 'cases', 'malignancies', 'observed', 'among', 'TNF-blocker-treated', 'adult', 'patients', 'compared', 'control-treated', 'adult', 'patients', '.'], 'lemmatized': ['Malignancies', 'Adults', 'controlled', 'portion', 'clinical', 'trial', 'TNF-blockers', ',', 'including', 'HUMIRA', ',', 'case', 'malignancy', 'observed', 'among', 'TNF-blocker-treated', 'adult', 'patient', 'compared', 'control-treated', 'adult', 'patient', '.'], 'stemmed': ['malign', 'adult', 'control', 'portion', 'clinic', 'trial', 'tnf-blocker', ',', 'includ', 'humira', ',', 'case', 'malign', 'observ', 'among', 'tnf-blocker-tr', 'adult', 'patient', 'compar', 'control-tr', 'adult', 'patient', '.'], 'dependencies': [('malign', 'compound'), ('adult', 'compound'), ('control', 'compound'), ('portion', 'compound'), ('clinic', 'compound'), ('trial', 'compound'), ('tnf', 'compound'), ('-', 'punct'), ('blocker', 'nmod'), (',', 'punct'), ('includ', 'compound'), ('humira', 'ROOT'), (',', 'punct'), ('case', 'compound'), ('malign', 'compound'), ('observ', 'appos'), ('among', 'prep'), ('tnf', 'compound'), ('-', 'punct'), ('blocker', 'nmod'), ('-', 'punct'), ('tr', 'prt'), ('adult', 'nmod'), ('patient', 'compound'), ('compar', 'compound'), ('control', 'compound'), ('-', 'punct'), ('tr', 'nummod'), ('adult', 'compound'), ('patient', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'During the controlled portions of 39 global HUMIRA clinical \\ntrials in adult patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing \\nspondylitis (AS), Crohn’s disease (CD), ulcerative colitis (UC), plaque psoriasis (Ps), \\nhidradenitis suppurativa (HS) and uveitis (UV), malignancies, other than non-melanoma (basal \\ncell and squamous cell) skin cancer, were observed at a rate (95% confidence interval) of 0.7 \\n(0.48, 1.03) per 100 patient-years among 7973 HUMIRA-treated patients versus a rate of 0.7 \\n(0.41, 1.17) per 100 patient-years among 4848 control-treated patients (median duration of \\ntreatment of 4 months for HUMIRA-treated patients and 4 months for control-treated patients).', 'tokens': ['controlled', 'portions', '39', 'global', 'HUMIRA', 'clinical', 'trials', 'adult', 'patients', 'rheumatoid', 'arthritis', '(', 'RA', ')', ',', 'psoriatic', 'arthritis', '(', 'PsA', ')', ',', 'ankylosing', 'spondylitis', '(', ')', ',', 'Crohn', '’', 'disease', '(', 'CD', ')', ',', 'ulcerative', 'colitis', '(', 'UC', ')', ',', 'plaque', 'psoriasis', '(', 'Ps', ')', ',', 'hidradenitis', 'suppurativa', '(', 'HS', ')', 'uveitis', '(', 'UV', ')', ',', 'malignancies', ',', 'non-melanoma', '(', 'basal', 'cell', 'squamous', 'cell', ')', 'skin', 'cancer', ',', 'observed', 'rate', '(', '95', '%', 'confidence', 'interval', ')', '0.7', '(', '0.48', ',', '1.03', ')', 'per', '100', 'patient-years', 'among', '7973', 'HUMIRA-treated', 'patients', 'versus', 'rate', '0.7', '(', '0.41', ',', '1.17', ')', 'per', '100', 'patient-years', 'among', '4848', 'control-treated', 'patients', '(', 'median', 'duration', 'treatment', '4', 'months', 'HUMIRA-treated', 'patients', '4', 'months', 'control-treated', 'patients', ')', '.'], 'lemmatized': ['controlled', 'portion', '39', 'global', 'HUMIRA', 'clinical', 'trial', 'adult', 'patient', 'rheumatoid', 'arthritis', '(', 'RA', ')', ',', 'psoriatic', 'arthritis', '(', 'PsA', ')', ',', 'ankylosing', 'spondylitis', '(', ')', ',', 'Crohn', '’', 'disease', '(', 'CD', ')', ',', 'ulcerative', 'colitis', '(', 'UC', ')', ',', 'plaque', 'psoriasis', '(', 'Ps', ')', ',', 'hidradenitis', 'suppurativa', '(', 'HS', ')', 'uveitis', '(', 'UV', ')', ',', 'malignancy', ',', 'non-melanoma', '(', 'basal', 'cell', 'squamous', 'cell', ')', 'skin', 'cancer', ',', 'observed', 'rate', '(', '95', '%', 'confidence', 'interval', ')', '0.7', '(', '0.48', ',', '1.03', ')', 'per', '100', 'patient-years', 'among', '7973', 'HUMIRA-treated', 'patient', 'versus', 'rate', '0.7', '(', '0.41', ',', '1.17', ')', 'per', '100', 'patient-years', 'among', '4848', 'control-treated', 'patient', '(', 'median', 'duration', 'treatment', '4', 'month', 'HUMIRA-treated', 'patient', '4', 'month', 'control-treated', 'patient', ')', '.'], 'stemmed': ['control', 'portion', '39', 'global', 'humira', 'clinic', 'trial', 'adult', 'patient', 'rheumatoid', 'arthriti', '(', 'ra', ')', ',', 'psoriat', 'arthriti', '(', 'psa', ')', ',', 'ankylos', 'spondyl', '(', ')', ',', 'crohn', '’', 'diseas', '(', 'cd', ')', ',', 'ulcer', 'coliti', '(', 'uc', ')', ',', 'plaqu', 'psoriasi', '(', 'ps', ')', ',', 'hidraden', 'suppurativa', '(', 'hs', ')', 'uveiti', '(', 'uv', ')', ',', 'malign', ',', 'non-melanoma', '(', 'basal', 'cell', 'squamou', 'cell', ')', 'skin', 'cancer', ',', 'observ', 'rate', '(', '95', '%', 'confid', 'interv', ')', '0.7', '(', '0.48', ',', '1.03', ')', 'per', '100', 'patient-year', 'among', '7973', 'humira-tr', 'patient', 'versu', 'rate', '0.7', '(', '0.41', ',', '1.17', ')', 'per', '100', 'patient-year', 'among', '4848', 'control-tr', 'patient', '(', 'median', 'durat', 'treatment', '4', 'month', 'humira-tr', 'patient', '4', 'month', 'control-tr', 'patient', ')', '.'], 'dependencies': [('control', 'compound'), ('portion', 'nsubj'), ('39', 'nummod'), ('global', 'amod'), ('humira', 'compound'), ('clinic', 'compound'), ('trial', 'compound'), ('adult', 'compound'), ('patient', 'nsubj'), ('rheumatoid', 'compound'), ('arthriti', 'appos'), ('(', 'punct'), ('ra', 'appos'), (')', 'punct'), (',', 'punct'), ('psoriat', 'compound'), ('arthriti', 'appos'), ('(', 'punct'), ('psa', 'parataxis'), (')', 'punct'), (',', 'punct'), ('ankylos', 'compound'), ('spondyl', 'conj'), ('(', 'punct'), (')', 'punct'), (',', 'punct'), ('crohn', 'amod'), ('’', 'punct'), ('diseas', 'appos'), ('(', 'punct'), ('cd', 'appos'), (')', 'punct'), (',', 'punct'), ('ulcer', 'compound'), ('coliti', 'conj'), ('(', 'punct'), ('uc', 'appos'), (')', 'punct'), (',', 'punct'), ('plaqu', 'ROOT'), ('psoriasi', 'dobj'), ('(', 'punct'), ('ps', 'appos'), (')', 'punct'), (',', 'punct'), ('hidraden', 'compound'), ('suppurativa', 'nmod'), ('(', 'punct'), ('hs', 'nmod'), (')', 'punct'), ('uveiti', 'conj'), ('(', 'punct'), ('uv', 'appos'), (')', 'punct'), (',', 'punct'), ('malign', 'conj'), (',', 'punct'), ('non', 'conj'), ('-', 'conj'), ('melanoma', 'conj'), ('(', 'punct'), ('basal', 'compound'), ('cell', 'compound'), ('squamou', 'compound'), ('cell', 'parataxis'), (')', 'punct'), ('skin', 'compound'), ('cancer', 'conj'), (',', 'punct'), ('observ', 'compound'), ('rate', 'conj'), ('(', 'punct'), ('95', 'nummod'), ('%', 'appos'), ('confid', 'compound'), ('interv', 'appos'), (')', 'punct'), ('0.7', 'ROOT'), ('(', 'punct'), ('0.48', 'nummod'), (',', 'punct'), ('1.03', 'npadvmod'), (')', 'punct'), ('per', 'ROOT'), ('100', 'nummod'), ('patient', 'compound'), ('-', 'punct'), ('year', 'pobj'), ('among', 'prep'), ('7973', 'nummod'), ('humira', 'npadvmod'), ('-', 'punct'), ('tr', 'nmod'), ('patient', 'amod'), ('versu', 'compound'), ('rate', 'pobj'), ('0.7', 'nummod'), ('(', 'punct'), ('0.41', 'appos'), (',', 'punct'), ('1.17', 'npadvmod'), (')', 'punct'), ('per', 'prep'), ('100', 'nummod'), ('patient', 'compound'), ('-', 'punct'), ('year', 'pobj'), ('among', 'prep'), ('4848', 'pobj'), ('control', 'compound'), ('-', 'punct'), ('tr', 'amod'), ('patient', 'pobj'), ('(', 'punct'), ('median', 'compound'), ('durat', 'compound'), ('treatment', 'appos'), ('4', 'nummod'), ('month', 'pobj'), ('humira', 'npadvmod'), ('-', 'punct'), ('tr', 'amod'), ('patient', 'amod'), ('4', 'nummod'), ('month', 'npadvmod'), ('control', 'compound'), ('-', 'punct'), ('tr', 'prep'), ('patient', 'pobj'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'In 52 global controlled and uncontrolled clinical trials of HUMIRA in adult patients with RA, \\nPsA, AS, CD, UC, Ps, HS and UV, the most frequently observed malignancies, other than', 'tokens': ['52', 'global', 'controlled', 'uncontrolled', 'clinical', 'trials', 'HUMIRA', 'adult', 'patients', 'RA', ',', 'PsA', ',', ',', 'CD', ',', 'UC', ',', 'Ps', ',', 'HS', 'UV', ',', 'frequently', 'observed', 'malignancies', ','], 'lemmatized': ['52', 'global', 'controlled', 'uncontrolled', 'clinical', 'trial', 'HUMIRA', 'adult', 'patient', 'RA', ',', 'PsA', ',', ',', 'CD', ',', 'UC', ',', 'Ps', ',', 'HS', 'UV', ',', 'frequently', 'observed', 'malignancy', ','], 'stemmed': ['52', 'global', 'control', 'uncontrol', 'clinic', 'trial', 'humira', 'adult', 'patient', 'ra', ',', 'psa', ',', ',', 'cd', ',', 'uc', ',', 'ps', ',', 'hs', 'uv', ',', 'frequent', 'observ', 'malign', ','], 'dependencies': [('52', 'nummod'), ('global', 'amod'), ('control', 'compound'), ('uncontrol', 'compound'), ('clinic', 'compound'), ('trial', 'compound'), ('humira', 'compound'), ('adult', 'compound'), ('patient', 'compound'), ('ra', 'npadvmod'), (',', 'punct'), ('psa', 'ROOT'), (',', 'punct'), (',', 'punct'), ('cd', 'npadvmod'), (',', 'punct'), ('uc', 'intj'), (',', 'punct'), ('ps', 'nmod'), (',', 'punct'), ('hs', 'compound'), ('uv', 'dep'), (',', 'punct'), ('frequent', 'amod'), ('observ', 'compound'), ('malign', 'conj'), (',', 'punct')]}], 'text': 'treatment of tuberculosis is recommended to aid in the decision whether initiating anti-\\ntuberculosis therapy is appropriate for an individual patient.  \\nStrongly consider tuberculosis in the differential diagnosis in patients who develop a new \\ninfection during HUMIRA treatment, especially in patients who have previously or recently \\ntraveled to countries with a high prevalence of tuberculosis, or who have had close contact with a \\nperson with active tuberculosis.  \\nMonitoring \\nClosely monitor patients for the development of signs and symptoms of infection during and \\nafter treatment with HUMIRA, including the development of tuberculosis in patients who tested \\nnegative for latent tuberculosis infection prior to initiating therapy. Tests for latent tuberculosis \\ninfection may also be falsely negative while on therapy with HUMIRA.  \\nDiscontinue HUMIRA if a patient develops a serious infection or sepsis. For a patient who \\ndevelops a new infection during treatment with HUMIRA, closely monitor them, perform a \\nprompt and complete diagnostic workup appropriate for an immunocompromised patient, and \\ninitiate appropriate antimicrobial therapy.  \\nInvasive Fungal Infections \\nIf patients develop a serious systemic illness and they reside or travel in regions where mycoses \\nare endemic, consider invasive fungal infection in the differential diagnosis. Antigen and \\nantibody testing for histoplasmosis may be negative in some patients with active infection. \\nConsider appropriate empiric antifungal therapy, taking into account both the risk for severe \\nfungal infection and the risks of antifungal therapy, while a diagnostic workup is being \\nperformed. To aid in the management of such patients, consider consultation with a physician \\nwith expertise in the diagnosis and treatment of invasive fungal infections.  \\n5.2 Malignancies \\nConsider the risks and benefits of TNF-blocker treatment including HUMIRA prior to initiating \\ntherapy in patients with a known malignancy other than a successfully treated non-melanoma \\nskin cancer (NMSC) or when considering continuing a TNF blocker in patients who develop a \\nmalignancy.  \\nMalignancies in Adults \\nIn the controlled portions of clinical trials of some TNF-blockers, including HUMIRA, more \\ncases of malignancies have been observed among TNF-blocker-treated adult patients compared \\nto control-treated adult patients. During the controlled portions of 39 global HUMIRA clinical \\ntrials in adult patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing \\nspondylitis (AS), Crohn’s disease (CD), ulcerative colitis (UC), plaque psoriasis (Ps), \\nhidradenitis suppurativa (HS) and uveitis (UV), malignancies, other than non-melanoma (basal \\ncell and squamous cell) skin cancer, were observed at a rate (95% confidence interval) of 0.7 \\n(0.48, 1.03) per 100 patient-years among 7973 HUMIRA-treated patients versus a rate of 0.7 \\n(0.41, 1.17) per 100 patient-years among 4848 control-treated patients (median duration of \\ntreatment of 4 months for HUMIRA-treated patients and 4 months for control-treated patients). \\nIn 52 global controlled and uncontrolled clinical trials of HUMIRA in adult patients with RA, \\nPsA, AS, CD, UC, Ps, HS and UV, the most frequently observed malignancies, other than \\n'}, 'page_char_count': 3278, 'page_word_count': 461, 'sentences': ['treatment of tuberculosis is recommended to aid in the decision whether initiating anti-\\ntuberculosis therapy is appropriate for an individual patient.', ' \\nStrongly consider tuberculosis in the differential diagnosis in patients who develop a new \\ninfection during HUMIRA treatment, especially in patients who have previously or recently \\ntraveled to countries with a high prevalence of tuberculosis, or who have had close contact with a \\nperson with active tuberculosis.', ' \\nMonitoring \\nClosely monitor patients for the development of signs and symptoms of infection during and \\nafter treatment with HUMIRA, including the development of tuberculosis in patients who tested \\nnegative for latent tuberculosis infection prior to initiating therapy.', 'Tests for latent tuberculosis \\ninfection may also be falsely negative while on therapy with HUMIRA.', ' \\nDiscontinue HUMIRA if a patient develops a serious infection or sepsis.', 'For a patient who \\ndevelops a new infection during treatment with HUMIRA, closely monitor them, perform a \\nprompt and complete diagnostic workup appropriate for an immunocompromised patient, and \\ninitiate appropriate antimicrobial therapy.', ' \\nInvasive Fungal Infections \\nIf patients develop a serious systemic illness and they reside or travel in regions where mycoses \\nare endemic, consider invasive fungal infection in the differential diagnosis.', 'Antigen and \\nantibody testing for histoplasmosis may be negative in some patients with active infection.', '\\nConsider appropriate empiric antifungal therapy, taking into account both the risk for severe \\nfungal infection and the risks of antifungal therapy, while a diagnostic workup is being \\nperformed.', 'To aid in the management of such patients, consider consultation with a physician \\nwith expertise in the diagnosis and treatment of invasive fungal infections.', ' \\n5.2 Malignancies \\nConsider the risks and benefits of TNF-blocker treatment including HUMIRA prior to initiating \\ntherapy in patients with a known malignancy other than a successfully treated non-melanoma \\nskin cancer (NMSC) or when considering continuing a TNF blocker in patients who develop a \\nmalignancy.', ' \\nMalignancies in Adults \\nIn the controlled portions of clinical trials of some TNF-blockers, including HUMIRA, more \\ncases of malignancies have been observed among TNF-blocker-treated adult patients compared \\nto control-treated adult patients.', 'During the controlled portions of 39 global HUMIRA clinical \\ntrials in adult patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing \\nspondylitis (AS), Crohn’s disease (CD), ulcerative colitis (UC), plaque psoriasis (Ps), \\nhidradenitis suppurativa (HS) and uveitis (UV), malignancies, other than non-melanoma (basal \\ncell and squamous cell) skin cancer, were observed at a rate (95% confidence interval) of 0.7 \\n(0.48, 1.03) per 100 patient-years among 7973 HUMIRA-treated patients versus a rate of 0.7 \\n(0.41, 1.17) per 100 patient-years among 4848 control-treated patients (median duration of \\ntreatment of 4 months for HUMIRA-treated patients and 4 months for control-treated patients).', '\\nIn 52 global controlled and uncontrolled clinical trials of HUMIRA in adult patients with RA, \\nPsA, AS, CD, UC, Ps, HS and UV, the most frequently observed malignancies, other than \\n'], 'page_sentence_count_spacy': 14}\n",
            "{'page_number': 11, 'text': \"lymphoma and NMSC, were breast, colon, prostate, lung, and melanoma. The malignancies in \\nHUMIRA-treated patients in the controlled and uncontrolled portions of the studies were similar \\nin type and number to what would be expected in the general U.S. population according to the \\nSEER database (adjusted for age, gender, and race).1 \\nIn controlled trials of other TNF blockers in adult patients at higher risk for malignancies (i.e., \\npatients with COPD with a significant smoking history and cyclophosphamide-treated patients \\nwith Wegener’s granulomatosis), a greater portion of malignancies occurred in the TNF blocker \\ngroup compared to the control group.  \\nNon-Melanoma Skin Cancer \\nDuring the controlled portions of 39 global HUMIRA clinical trials in adult patients with RA, \\nPsA, AS, CD, UC, Ps, HS and UV, the rate (95% confidence interval) of NMSC was 0.8 (0.52, \\n1.09) per 100 patient-years among HUMIRA-treated patients and 0.2 (0.10, 0.59) per 100 \\npatient-years among control-treated patients. Examine all patients, and in particular patients with \\na medical history of prior prolonged immunosuppressant therapy or psoriasis patients with a \\nhistory of PUVA treatment for the presence of NMSC prior to and during treatment with \\nHUMIRA.  \\nLymphoma and Leukemia \\nIn the controlled portions of clinical trials of all the TNF-blockers in adults, more cases of \\nlymphoma have been observed among TNF-blocker-treated patients compared to control-treated \\npatients. In the controlled portions of 39 global HUMIRA clinical trials in adult patients with \\nRA, PsA, AS, CD, UC, Ps, HS and UV, 2 lymphomas occurred among 7973 HUMIRA-treated \\npatients versus 1 among 4848 control-treated patients. In 52 global controlled and uncontrolled \\nclinical trials of HUMIRA in adult patients with RA, PsA, AS, CD, UC, Ps, HS and UV with a \\nmedian duration of approximately 0.7 years, including 24,605 patients and over 40,215 patient-\\nyears of HUMIRA, the observed rate of lymphomas was approximately 0.11 per 100 patient-\\nyears. This is approximately 3-fold higher than expected in the general U.S. population \\naccording to the SEER database (adjusted for age, gender, and race).1 Rates of lymphoma in \\nclinical trials of HUMIRA cannot be compared to rates of lymphoma in clinical trials of other \\nTNF blockers and may not predict the rates observed in a broader patient population. Patients \\nwith RA and other chronic inflammatory diseases, particularly those with highly active disease \\nand/or chronic exposure to immunosuppressant therapies, may be at a higher risk (up to several \\nfold) than the general population for the development of lymphoma, even in the absence of TNF \\nblockers. Post-marketing cases of acute and chronic leukemia have been reported in association \\nwith TNF-blocker use in RA and other indications. Even in the absence of TNF-blocker therapy, \\npatients with RA may be at a higher risk (approximately 2-fold) than the general population for \\nthe development of leukemia.  \\nMalignancies in Pediatric Patients and Young Adults \\nMalignancies, some fatal, have been reported among children, adolescents, and young adults \\nwho received treatment with TNF-blockers (initiation of therapy ≤ 18 years of age), of which \\nHUMIRA is a member. Approximately half the cases were lymphomas, including Hodgkin's and \\nnon-Hodgkin's lymphoma. The other cases represented a variety of different malignancies and \\nincluded rare malignancies usually associated with immunosuppression and malignancies that \\nare not usually observed in children and adolescents. The malignancies occurred after a median \\n\", 'processed_text': {'sentences': [{'original_sentence': 'lymphoma and NMSC, were breast, colon, prostate, lung, and melanoma.', 'tokens': ['lymphoma', 'NMSC', ',', 'breast', ',', 'colon', ',', 'prostate', ',', 'lung', ',', 'melanoma', '.'], 'lemmatized': ['lymphoma', 'NMSC', ',', 'breast', ',', 'colon', ',', 'prostate', ',', 'lung', ',', 'melanoma', '.'], 'stemmed': ['lymphoma', 'nmsc', ',', 'breast', ',', 'colon', ',', 'prostat', ',', 'lung', ',', 'melanoma', '.'], 'dependencies': [('lymphoma', 'ROOT'), ('nmsc', 'npadvmod'), (',', 'punct'), ('breast', 'conj'), (',', 'punct'), ('colon', 'conj'), (',', 'punct'), ('prostat', 'conj'), (',', 'punct'), ('lung', 'conj'), (',', 'punct'), ('melanoma', 'conj'), ('.', 'punct')]}, {'original_sentence': 'The malignancies in \\nHUMIRA-treated patients in the controlled and uncontrolled portions of the studies were similar \\nin type and number to what would be expected in the general U.S. population according to the \\nSEER database (adjusted for age, gender, and race).1 \\nIn controlled trials of other TNF blockers in adult patients at higher risk for malignancies (i.e., \\npatients with COPD with a significant smoking history and cyclophosphamide-treated patients \\nwith Wegener’s granulomatosis), a greater portion of malignancies occurred in the TNF blocker \\ngroup compared to the control group.', 'tokens': ['malignancies', 'HUMIRA-treated', 'patients', 'controlled', 'uncontrolled', 'portions', 'studies', 'similar', 'type', 'number', 'would', 'expected', 'general', 'U.S.', 'population', 'according', 'SEER', 'database', '(', 'adjusted', 'age', ',', 'gender', ',', 'race', ')', '.1', 'controlled', 'trials', 'TNF', 'blockers', 'adult', 'patients', 'higher', 'risk', 'malignancies', '(', 'i.e.', ',', 'patients', 'COPD', 'significant', 'smoking', 'history', 'cyclophosphamide-treated', 'patients', 'Wegener', '’', 'granulomatosis', ')', ',', 'greater', 'portion', 'malignancies', 'occurred', 'TNF', 'blocker', 'group', 'compared', 'control', 'group', '.'], 'lemmatized': ['malignancy', 'HUMIRA-treated', 'patient', 'controlled', 'uncontrolled', 'portion', 'study', 'similar', 'type', 'number', 'would', 'expected', 'general', 'U.S.', 'population', 'according', 'SEER', 'database', '(', 'adjusted', 'age', ',', 'gender', ',', 'race', ')', '.1', 'controlled', 'trial', 'TNF', 'blocker', 'adult', 'patient', 'higher', 'risk', 'malignancy', '(', 'i.e.', ',', 'patient', 'COPD', 'significant', 'smoking', 'history', 'cyclophosphamide-treated', 'patient', 'Wegener', '’', 'granulomatosis', ')', ',', 'greater', 'portion', 'malignancy', 'occurred', 'TNF', 'blocker', 'group', 'compared', 'control', 'group', '.'], 'stemmed': ['malign', 'humira-tr', 'patient', 'control', 'uncontrol', 'portion', 'studi', 'similar', 'type', 'number', 'would', 'expect', 'gener', 'u.s.', 'popul', 'accord', 'seer', 'databas', '(', 'adjust', 'age', ',', 'gender', ',', 'race', ')', '.1', 'control', 'trial', 'tnf', 'blocker', 'adult', 'patient', 'higher', 'risk', 'malign', '(', 'i.e.', ',', 'patient', 'copd', 'signific', 'smoke', 'histori', 'cyclophosphamide-tr', 'patient', 'wegen', '’', 'granulomatosi', ')', ',', 'greater', 'portion', 'malign', 'occur', 'tnf', 'blocker', 'group', 'compar', 'control', 'group', '.'], 'dependencies': [('malign', 'nmod'), ('humira', 'nmod'), ('-', 'punct'), ('tr', 'prep'), ('patient', 'amod'), ('control', 'compound'), ('uncontrol', 'compound'), ('portion', 'nsubj'), ('studi', 'nmod'), ('similar', 'amod'), ('type', 'compound'), ('number', 'appos'), ('would', 'aux'), ('expect', 'ROOT'), ('gener', 'compound'), ('u.s', 'compound'), ('.', 'compound'), ('popul', 'compound'), ('accord', 'compound'), ('seer', 'compound'), ('databas', 'nsubj'), ('(', 'punct'), ('adjust', 'ccomp'), ('age', 'dobj'), (',', 'punct'), ('gender', 'conj'), (',', 'punct'), ('race', 'conj'), (')', 'punct'), ('.1', 'compound'), ('control', 'compound'), ('trial', 'compound'), ('tnf', 'compound'), ('blocker', 'compound'), ('adult', 'compound'), ('patient', 'nmod'), ('higher', 'amod'), ('risk', 'compound'), ('malign', 'ROOT'), ('(', 'punct'), ('i.e.', 'amod'), (',', 'punct'), ('patient', 'amod'), ('copd', 'appos'), ('signific', 'compound'), ('smoke', 'appos'), ('histori', 'nmod'), ('cyclophosphamide', 'compound'), ('-', 'punct'), ('tr', 'cc'), ('patient', 'amod'), ('wegen', 'nmod'), ('’', 'punct'), ('granulomatosi', 'appos'), (')', 'punct'), (',', 'punct'), ('greater', 'amod'), ('portion', 'compound'), ('malign', 'nsubj'), ('occur', 'appos'), ('tnf', 'compound'), ('blocker', 'compound'), ('group', 'compound'), ('compar', 'compound'), ('control', 'compound'), ('group', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Non-Melanoma Skin Cancer \\nDuring the controlled portions of 39 global HUMIRA clinical trials in adult patients with RA, \\nPsA, AS, CD, UC, Ps, HS and UV, the rate (95% confidence interval) of NMSC was 0.8 (0.52, \\n1.09) per 100 patient-years among HUMIRA-treated patients and 0.2 (0.10, 0.59) per 100 \\npatient-years among control-treated patients.', 'tokens': ['Non-Melanoma', 'Skin', 'Cancer', 'controlled', 'portions', '39', 'global', 'HUMIRA', 'clinical', 'trials', 'adult', 'patients', 'RA', ',', 'PsA', ',', ',', 'CD', ',', 'UC', ',', 'Ps', ',', 'HS', 'UV', ',', 'rate', '(', '95', '%', 'confidence', 'interval', ')', 'NMSC', '0.8', '(', '0.52', ',', '1.09', ')', 'per', '100', 'patient-years', 'among', 'HUMIRA-treated', 'patients', '0.2', '(', '0.10', ',', '0.59', ')', 'per', '100', 'patient-years', 'among', 'control-treated', 'patients', '.'], 'lemmatized': ['Non-Melanoma', 'Skin', 'Cancer', 'controlled', 'portion', '39', 'global', 'HUMIRA', 'clinical', 'trial', 'adult', 'patient', 'RA', ',', 'PsA', ',', ',', 'CD', ',', 'UC', ',', 'Ps', ',', 'HS', 'UV', ',', 'rate', '(', '95', '%', 'confidence', 'interval', ')', 'NMSC', '0.8', '(', '0.52', ',', '1.09', ')', 'per', '100', 'patient-years', 'among', 'HUMIRA-treated', 'patient', '0.2', '(', '0.10', ',', '0.59', ')', 'per', '100', 'patient-years', 'among', 'control-treated', 'patient', '.'], 'stemmed': ['non-melanoma', 'skin', 'cancer', 'control', 'portion', '39', 'global', 'humira', 'clinic', 'trial', 'adult', 'patient', 'ra', ',', 'psa', ',', ',', 'cd', ',', 'uc', ',', 'ps', ',', 'hs', 'uv', ',', 'rate', '(', '95', '%', 'confid', 'interv', ')', 'nmsc', '0.8', '(', '0.52', ',', '1.09', ')', 'per', '100', 'patient-year', 'among', 'humira-tr', 'patient', '0.2', '(', '0.10', ',', '0.59', ')', 'per', '100', 'patient-year', 'among', 'control-tr', 'patient', '.'], 'dependencies': [('non', 'amod'), ('-', 'amod'), ('melanoma', 'amod'), ('skin', 'compound'), ('cancer', 'compound'), ('control', 'compound'), ('portion', 'ROOT'), ('39', 'nummod'), ('global', 'amod'), ('humira', 'compound'), ('clinic', 'compound'), ('trial', 'compound'), ('adult', 'compound'), ('patient', 'dobj'), ('ra', 'appos'), (',', 'punct'), ('psa', 'conj'), (',', 'punct'), (',', 'punct'), ('cd', 'appos'), (',', 'punct'), ('uc', 'intj'), (',', 'punct'), ('ps', 'nmod'), (',', 'punct'), ('hs', 'nmod'), ('uv', 'conj'), (',', 'punct'), ('rate', 'appos'), ('(', 'punct'), ('95', 'nummod'), ('%', 'appos'), ('confid', 'amod'), ('interv', 'appos'), (')', 'punct'), ('nmsc', 'ROOT'), ('0.8', 'nummod'), ('(', 'punct'), ('0.52', 'appos'), (',', 'punct'), ('1.09', 'npadvmod'), (')', 'punct'), ('per', 'prep'), ('100', 'nummod'), ('patient', 'compound'), ('-', 'punct'), ('year', 'pobj'), ('among', 'prep'), ('humira', 'compound'), ('-', 'punct'), ('tr', 'compound'), ('patient', 'pobj'), ('0.2', 'nummod'), ('(', 'punct'), ('0.10', 'appos'), (',', 'punct'), ('0.59', 'npadvmod'), (')', 'punct'), ('per', 'prep'), ('100', 'nummod'), ('patient', 'compound'), ('-', 'punct'), ('year', 'pobj'), ('among', 'prep'), ('control', 'compound'), ('-', 'punct'), ('tr', 'pobj'), ('patient', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'Examine all patients, and in particular patients with \\na medical history of prior prolonged immunosuppressant therapy or psoriasis patients with a \\nhistory of PUVA treatment for the presence of NMSC prior to and during treatment with \\nHUMIRA.', 'tokens': ['Examine', 'patients', ',', 'particular', 'patients', 'medical', 'history', 'prior', 'prolonged', 'immunosuppressant', 'therapy', 'psoriasis', 'patients', 'history', 'PUVA', 'treatment', 'presence', 'NMSC', 'prior', 'treatment', 'HUMIRA', '.'], 'lemmatized': ['Examine', 'patient', ',', 'particular', 'patient', 'medical', 'history', 'prior', 'prolonged', 'immunosuppressant', 'therapy', 'psoriasis', 'patient', 'history', 'PUVA', 'treatment', 'presence', 'NMSC', 'prior', 'treatment', 'HUMIRA', '.'], 'stemmed': ['examin', 'patient', ',', 'particular', 'patient', 'medic', 'histori', 'prior', 'prolong', 'immunosuppress', 'therapi', 'psoriasi', 'patient', 'histori', 'puva', 'treatment', 'presenc', 'nmsc', 'prior', 'treatment', 'humira', '.'], 'dependencies': [('examin', 'compound'), ('patient', 'nsubj'), (',', 'punct'), ('particular', 'amod'), ('patient', 'amod'), ('medic', 'compound'), ('histori', 'conj'), ('prior', 'prep'), ('prolong', 'amod'), ('immunosuppress', 'appos'), ('therapi', 'ROOT'), ('psoriasi', 'compound'), ('patient', 'nmod'), ('histori', 'compound'), ('puva', 'compound'), ('treatment', 'compound'), ('presenc', 'dobj'), ('nmsc', 'npadvmod'), ('prior', 'amod'), ('treatment', 'compound'), ('humira', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Lymphoma and Leukemia \\nIn the controlled portions of clinical trials of all the TNF-blockers in adults, more cases of \\nlymphoma have been observed among TNF-blocker-treated patients compared to control-treated \\npatients.', 'tokens': ['Lymphoma', 'Leukemia', 'controlled', 'portions', 'clinical', 'trials', 'TNF-blockers', 'adults', ',', 'cases', 'lymphoma', 'observed', 'among', 'TNF-blocker-treated', 'patients', 'compared', 'control-treated', 'patients', '.'], 'lemmatized': ['Lymphoma', 'Leukemia', 'controlled', 'portion', 'clinical', 'trial', 'TNF-blockers', 'adult', ',', 'case', 'lymphoma', 'observed', 'among', 'TNF-blocker-treated', 'patient', 'compared', 'control-treated', 'patient', '.'], 'stemmed': ['lymphoma', 'leukemia', 'control', 'portion', 'clinic', 'trial', 'tnf-blocker', 'adult', ',', 'case', 'lymphoma', 'observ', 'among', 'tnf-blocker-tr', 'patient', 'compar', 'control-tr', 'patient', '.'], 'dependencies': [('lymphoma', 'ROOT'), ('leukemia', 'compound'), ('control', 'compound'), ('portion', 'compound'), ('clinic', 'compound'), ('trial', 'compound'), ('tnf', 'compound'), ('-', 'punct'), ('blocker', 'compound'), ('adult', 'dobj'), (',', 'punct'), ('case', 'compound'), ('lymphoma', 'conj'), ('observ', 'dobj'), ('among', 'prep'), ('tnf', 'pobj'), ('-', 'punct'), ('blocker', 'dep'), ('-', 'punct'), ('tr', 'conj'), ('patient', 'amod'), ('compar', 'compound'), ('control', 'compound'), ('-', 'punct'), ('tr', 'pobj'), ('patient', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'In the controlled portions of 39 global HUMIRA clinical trials in adult patients with \\nRA, PsA, AS, CD, UC, Ps, HS and UV, 2 lymphomas occurred among 7973 HUMIRA-treated \\npatients versus 1 among 4848 control-treated patients.', 'tokens': ['controlled', 'portions', '39', 'global', 'HUMIRA', 'clinical', 'trials', 'adult', 'patients', 'RA', ',', 'PsA', ',', ',', 'CD', ',', 'UC', ',', 'Ps', ',', 'HS', 'UV', ',', '2', 'lymphomas', 'occurred', 'among', '7973', 'HUMIRA-treated', 'patients', 'versus', '1', 'among', '4848', 'control-treated', 'patients', '.'], 'lemmatized': ['controlled', 'portion', '39', 'global', 'HUMIRA', 'clinical', 'trial', 'adult', 'patient', 'RA', ',', 'PsA', ',', ',', 'CD', ',', 'UC', ',', 'Ps', ',', 'HS', 'UV', ',', '2', 'lymphoma', 'occurred', 'among', '7973', 'HUMIRA-treated', 'patient', 'versus', '1', 'among', '4848', 'control-treated', 'patient', '.'], 'stemmed': ['control', 'portion', '39', 'global', 'humira', 'clinic', 'trial', 'adult', 'patient', 'ra', ',', 'psa', ',', ',', 'cd', ',', 'uc', ',', 'ps', ',', 'hs', 'uv', ',', '2', 'lymphoma', 'occur', 'among', '7973', 'humira-tr', 'patient', 'versu', '1', 'among', '4848', 'control-tr', 'patient', '.'], 'dependencies': [('control', 'compound'), ('portion', 'nsubj'), ('39', 'nummod'), ('global', 'amod'), ('humira', 'compound'), ('clinic', 'compound'), ('trial', 'compound'), ('adult', 'compound'), ('patient', 'dobj'), ('ra', 'appos'), (',', 'punct'), ('psa', 'conj'), (',', 'punct'), (',', 'punct'), ('cd', 'appos'), (',', 'punct'), ('uc', 'intj'), (',', 'punct'), ('ps', 'conj'), (',', 'punct'), ('hs', 'compound'), ('uv', 'appos'), (',', 'punct'), ('2', 'nummod'), ('lymphoma', 'appos'), ('occur', 'ROOT'), ('among', 'prep'), ('7973', 'nummod'), ('humira', 'npadvmod'), ('-', 'punct'), ('tr', 'nmod'), ('patient', 'amod'), ('versu', 'pobj'), ('1', 'nummod'), ('among', 'prep'), ('4848', 'nummod'), ('control', 'compound'), ('-', 'punct'), ('tr', 'pobj'), ('patient', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'In 52 global controlled and uncontrolled \\nclinical trials of HUMIRA in adult patients with RA, PsA, AS, CD, UC, Ps, HS and UV with a \\nmedian duration of approximately 0.7 years, including 24,605 patients and over 40,215 patient-\\nyears of HUMIRA, the observed rate of lymphomas was approximately 0.11 per 100 patient-\\nyears.', 'tokens': ['52', 'global', 'controlled', 'uncontrolled', 'clinical', 'trials', 'HUMIRA', 'adult', 'patients', 'RA', ',', 'PsA', ',', ',', 'CD', ',', 'UC', ',', 'Ps', ',', 'HS', 'UV', 'median', 'duration', 'approximately', '0.7', 'years', ',', 'including', '24,605', 'patients', '40,215', 'patient-', 'years', 'HUMIRA', ',', 'observed', 'rate', 'lymphomas', 'approximately', '0.11', 'per', '100', 'patient-', 'years', '.'], 'lemmatized': ['52', 'global', 'controlled', 'uncontrolled', 'clinical', 'trial', 'HUMIRA', 'adult', 'patient', 'RA', ',', 'PsA', ',', ',', 'CD', ',', 'UC', ',', 'Ps', ',', 'HS', 'UV', 'median', 'duration', 'approximately', '0.7', 'year', ',', 'including', '24,605', 'patient', '40,215', 'patient-', 'year', 'HUMIRA', ',', 'observed', 'rate', 'lymphoma', 'approximately', '0.11', 'per', '100', 'patient-', 'year', '.'], 'stemmed': ['52', 'global', 'control', 'uncontrol', 'clinic', 'trial', 'humira', 'adult', 'patient', 'ra', ',', 'psa', ',', ',', 'cd', ',', 'uc', ',', 'ps', ',', 'hs', 'uv', 'median', 'durat', 'approxim', '0.7', 'year', ',', 'includ', '24,605', 'patient', '40,215', 'patient-', 'year', 'humira', ',', 'observ', 'rate', 'lymphoma', 'approxim', '0.11', 'per', '100', 'patient-', 'year', '.'], 'dependencies': [('52', 'nummod'), ('global', 'amod'), ('control', 'compound'), ('uncontrol', 'compound'), ('clinic', 'compound'), ('trial', 'compound'), ('humira', 'compound'), ('adult', 'compound'), ('patient', 'compound'), ('ra', 'npadvmod'), (',', 'punct'), ('psa', 'amod'), (',', 'punct'), (',', 'punct'), ('cd', 'npadvmod'), (',', 'punct'), ('uc', 'intj'), (',', 'punct'), ('ps', 'conj'), (',', 'punct'), ('hs', 'nmod'), ('uv', 'cc'), ('median', 'compound'), ('durat', 'compound'), ('approxim', 'conj'), ('0.7', 'nummod'), ('year', 'npadvmod'), (',', 'punct'), ('includ', 'conj'), ('24,605', 'nummod'), ('patient', 'dobj'), ('40,215', 'nummod'), ('patient-', 'compound'), ('year', 'npadvmod'), ('humira', 'appos'), (',', 'punct'), ('observ', 'compound'), ('rate', 'compound'), ('lymphoma', 'conj'), ('approxim', 'ROOT'), ('0.11', 'nummod'), ('per', 'prep'), ('100', 'nummod'), ('patient-', 'amod'), ('year', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'This is approximately 3-fold higher than expected in the general U.S. population \\naccording to the SEER database (adjusted for age, gender, and race).1 Rates of lymphoma in \\nclinical trials of HUMIRA cannot be compared to rates of lymphoma in clinical trials of other \\nTNF blockers and may not predict the rates observed in a broader patient population.', 'tokens': ['approximately', '3-fold', 'higher', 'expected', 'general', 'U.S.', 'population', 'according', 'SEER', 'database', '(', 'adjusted', 'age', ',', 'gender', ',', 'race', ')', '.1', 'Rates', 'lymphoma', 'clinical', 'trials', 'HUMIRA', 'compared', 'rates', 'lymphoma', 'clinical', 'trials', 'TNF', 'blockers', 'may', 'predict', 'rates', 'observed', 'broader', 'patient', 'population', '.'], 'lemmatized': ['approximately', '3-fold', 'higher', 'expected', 'general', 'U.S.', 'population', 'according', 'SEER', 'database', '(', 'adjusted', 'age', ',', 'gender', ',', 'race', ')', '.1', 'Rates', 'lymphoma', 'clinical', 'trial', 'HUMIRA', 'compared', 'rate', 'lymphoma', 'clinical', 'trial', 'TNF', 'blocker', 'may', 'predict', 'rate', 'observed', 'broader', 'patient', 'population', '.'], 'stemmed': ['approxim', '3-fold', 'higher', 'expect', 'gener', 'u.s.', 'popul', 'accord', 'seer', 'databas', '(', 'adjust', 'age', ',', 'gender', ',', 'race', ')', '.1', 'rate', 'lymphoma', 'clinic', 'trial', 'humira', 'compar', 'rate', 'lymphoma', 'clinic', 'trial', 'tnf', 'blocker', 'may', 'predict', 'rate', 'observ', 'broader', 'patient', 'popul', '.'], 'dependencies': [('approxim', 'nsubj'), ('3', 'nummod'), ('-', 'punct'), ('fold', 'appos'), ('higher', 'advmod'), ('expect', 'ROOT'), ('gener', 'compound'), ('u.s', 'compound'), ('.', 'compound'), ('popul', 'compound'), ('accord', 'compound'), ('seer', 'compound'), ('databas', 'nsubj'), ('(', 'punct'), ('adjust', 'ccomp'), ('age', 'dobj'), (',', 'punct'), ('gender', 'conj'), (',', 'punct'), ('race', 'conj'), (')', 'punct'), ('.1', 'compound'), ('rate', 'compound'), ('lymphoma', 'nmod'), ('clinic', 'compound'), ('trial', 'compound'), ('humira', 'compound'), ('compar', 'compound'), ('rate', 'nsubj'), ('lymphoma', 'compound'), ('clinic', 'compound'), ('trial', 'compound'), ('tnf', 'compound'), ('blocker', 'nsubj'), ('may', 'aux'), ('predict', 'ROOT'), ('rate', 'compound'), ('observ', 'npadvmod'), ('broader', 'amod'), ('patient', 'compound'), ('popul', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Patients \\nwith RA and other chronic inflammatory diseases, particularly those with highly active disease \\nand/or chronic exposure to immunosuppressant therapies, may be at a higher risk (up to several \\nfold) than the general population for the development of lymphoma, even in the absence of TNF \\nblockers.', 'tokens': ['Patients', 'RA', 'chronic', 'inflammatory', 'diseases', ',', 'particularly', 'highly', 'active', 'disease', 'and/or', 'chronic', 'exposure', 'immunosuppressant', 'therapies', ',', 'may', 'higher', 'risk', '(', 'several', 'fold', ')', 'general', 'population', 'development', 'lymphoma', ',', 'even', 'absence', 'TNF', 'blockers', '.'], 'lemmatized': ['Patients', 'RA', 'chronic', 'inflammatory', 'disease', ',', 'particularly', 'highly', 'active', 'disease', 'and/or', 'chronic', 'exposure', 'immunosuppressant', 'therapy', ',', 'may', 'higher', 'risk', '(', 'several', 'fold', ')', 'general', 'population', 'development', 'lymphoma', ',', 'even', 'absence', 'TNF', 'blocker', '.'], 'stemmed': ['patient', 'ra', 'chronic', 'inflammatori', 'diseas', ',', 'particularli', 'highli', 'activ', 'diseas', 'and/or', 'chronic', 'exposur', 'immunosuppress', 'therapi', ',', 'may', 'higher', 'risk', '(', 'sever', 'fold', ')', 'gener', 'popul', 'develop', 'lymphoma', ',', 'even', 'absenc', 'tnf', 'blocker', '.'], 'dependencies': [('patient', 'compound'), ('ra', 'compound'), ('chronic', 'compound'), ('inflammatori', 'compound'), ('diseas', 'ROOT'), (',', 'punct'), ('particularli', 'amod'), ('highli', 'compound'), ('activ', 'compound'), ('diseas', 'conj'), ('and/or', 'cc'), ('chronic', 'amod'), ('exposur', 'compound'), ('immunosuppress', 'compound'), ('therapi', 'conj'), (',', 'punct'), ('may', 'aux'), ('higher', 'amod'), ('risk', 'appos'), ('(', 'punct'), ('sever', 'amod'), ('fold', 'amod'), (')', 'punct'), ('gener', 'compound'), ('popul', 'nsubj'), ('develop', 'relcl'), ('lymphoma', 'dobj'), (',', 'punct'), ('even', 'advmod'), ('absenc', 'compound'), ('tnf', 'compound'), ('blocker', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Post-marketing cases of acute and chronic leukemia have been reported in association \\nwith TNF-blocker use in RA and other indications.', 'tokens': ['Post-marketing', 'cases', 'acute', 'chronic', 'leukemia', 'reported', 'association', 'TNF-blocker', 'use', 'RA', 'indications', '.'], 'lemmatized': ['Post-marketing', 'case', 'acute', 'chronic', 'leukemia', 'reported', 'association', 'TNF-blocker', 'use', 'RA', 'indication', '.'], 'stemmed': ['post-market', 'case', 'acut', 'chronic', 'leukemia', 'report', 'associ', 'tnf-blocker', 'use', 'ra', 'indic', '.'], 'dependencies': [('post', 'amod'), ('-', 'amod'), ('market', 'amod'), ('case', 'compound'), ('acut', 'compound'), ('chronic', 'compound'), ('leukemia', 'compound'), ('report', 'compound'), ('associ', 'compound'), ('tnf', 'compound'), ('-', 'punct'), ('blocker', 'nsubj'), ('use', 'compound'), ('ra', 'compound'), ('indic', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Even in the absence of TNF-blocker therapy, \\npatients with RA may be at a higher risk (approximately 2-fold) than the general population for \\nthe development of leukemia.', 'tokens': ['Even', 'absence', 'TNF-blocker', 'therapy', ',', 'patients', 'RA', 'may', 'higher', 'risk', '(', 'approximately', '2-fold', ')', 'general', 'population', 'development', 'leukemia', '.'], 'lemmatized': ['Even', 'absence', 'TNF-blocker', 'therapy', ',', 'patient', 'RA', 'may', 'higher', 'risk', '(', 'approximately', '2-fold', ')', 'general', 'population', 'development', 'leukemia', '.'], 'stemmed': ['even', 'absenc', 'tnf-blocker', 'therapi', ',', 'patient', 'ra', 'may', 'higher', 'risk', '(', 'approxim', '2-fold', ')', 'gener', 'popul', 'develop', 'leukemia', '.'], 'dependencies': [('even', 'advmod'), ('absenc', 'compound'), ('tnf', 'compound'), ('-', 'punct'), ('blocker', 'compound'), ('therapi', 'amod'), (',', 'punct'), ('patient', 'compound'), ('ra', 'nsubj'), ('may', 'aux'), ('higher', 'amod'), ('risk', 'ROOT'), ('(', 'punct'), ('approxim', 'nmod'), ('2', 'nummod'), ('-', 'amod'), ('fold', 'amod'), (')', 'punct'), ('gener', 'compound'), ('popul', 'nsubj'), ('develop', 'relcl'), ('leukemia', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Malignancies in Pediatric Patients and Young Adults \\nMalignancies, some fatal, have been reported among children, adolescents, and young adults \\nwho received treatment with TNF-blockers (initiation of therapy ≤ 18 years of age), of which \\nHUMIRA is a member.', 'tokens': ['Malignancies', 'Pediatric', 'Patients', 'Young', 'Adults', 'Malignancies', ',', 'fatal', ',', 'reported', 'among', 'children', ',', 'adolescents', ',', 'young', 'adults', 'received', 'treatment', 'TNF-blockers', '(', 'initiation', 'therapy', '≤', '18', 'years', 'age', ')', ',', 'HUMIRA', 'member', '.'], 'lemmatized': ['Malignancies', 'Pediatric', 'Patients', 'Young', 'Adults', 'Malignancies', ',', 'fatal', ',', 'reported', 'among', 'child', ',', 'adolescent', ',', 'young', 'adult', 'received', 'treatment', 'TNF-blockers', '(', 'initiation', 'therapy', '≤', '18', 'year', 'age', ')', ',', 'HUMIRA', 'member', '.'], 'stemmed': ['malign', 'pediatr', 'patient', 'young', 'adult', 'malign', ',', 'fatal', ',', 'report', 'among', 'child', ',', 'adolesc', ',', 'young', 'adult', 'receiv', 'treatment', 'tnf-blocker', '(', 'initi', 'therapi', '≤', '18', 'year', 'age', ')', ',', 'humira', 'member', '.'], 'dependencies': [('malign', 'nmod'), ('pediatr', 'amod'), ('patient', 'amod'), ('young', 'amod'), ('adult', 'compound'), ('malign', 'nsubj'), (',', 'punct'), ('fatal', 'amod'), (',', 'punct'), ('report', 'appos'), ('among', 'prep'), ('child', 'pobj'), (',', 'punct'), ('adolesc', 'intj'), (',', 'punct'), ('young', 'amod'), ('adult', 'compound'), ('receiv', 'compound'), ('treatment', 'compound'), ('tnf', 'compound'), ('-', 'punct'), ('blocker', 'conj'), ('(', 'punct'), ('initi', 'npadvmod'), ('therapi', 'ROOT'), ('≤', 'dobj'), ('18', 'nummod'), ('year', 'compound'), ('age', 'npadvmod'), (')', 'punct'), (',', 'punct'), ('humira', 'compound'), ('member', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': \"Approximately half the cases were lymphomas, including Hodgkin's and \\nnon-Hodgkin's lymphoma.\", 'tokens': ['Approximately', 'half', 'cases', 'lymphomas', ',', 'including', 'Hodgkin', \"'s\", 'non-Hodgkin', \"'s\", 'lymphoma', '.'], 'lemmatized': ['Approximately', 'half', 'case', 'lymphoma', ',', 'including', 'Hodgkin', \"'s\", 'non-Hodgkin', \"'s\", 'lymphoma', '.'], 'stemmed': ['approxim', 'half', 'case', 'lymphoma', ',', 'includ', 'hodgkin', \"'s\", 'non-hodgkin', \"'s\", 'lymphoma', '.'], 'dependencies': [('approxim', 'compound'), ('half', 'compound'), ('case', 'compound'), ('lymphoma', 'ROOT'), (',', 'punct'), ('includ', 'compound'), ('hodgkin', 'poss'), (\"'s\", 'case'), ('non', 'amod'), ('-', 'poss'), ('hodgkin', 'poss'), (\"'s\", 'case'), ('lymphoma', 'conj'), ('.', 'punct')]}, {'original_sentence': 'The other cases represented a variety of different malignancies and \\nincluded rare malignancies usually associated with immunosuppression and malignancies that \\nare not usually observed in children and adolescents.', 'tokens': ['cases', 'represented', 'variety', 'different', 'malignancies', 'included', 'rare', 'malignancies', 'usually', 'associated', 'immunosuppression', 'malignancies', 'usually', 'observed', 'children', 'adolescents', '.'], 'lemmatized': ['case', 'represented', 'variety', 'different', 'malignancy', 'included', 'rare', 'malignancy', 'usually', 'associated', 'immunosuppression', 'malignancy', 'usually', 'observed', 'child', 'adolescent', '.'], 'stemmed': ['case', 'repres', 'varieti', 'differ', 'malign', 'includ', 'rare', 'malign', 'usual', 'associ', 'immunosuppress', 'malign', 'usual', 'observ', 'child', 'adolesc', '.'], 'dependencies': [('case', 'nsubj'), ('repres', 'nsubj'), ('varieti', 'nsubj'), ('differ', 'ROOT'), ('malign', 'nmod'), ('includ', 'nmod'), ('rare', 'amod'), ('malign', 'nmod'), ('usual', 'amod'), ('associ', 'compound'), ('immunosuppress', 'nmod'), ('malign', 'nmod'), ('usual', 'amod'), ('observ', 'compound'), ('child', 'compound'), ('adolesc', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'The malignancies occurred after a median', 'tokens': ['malignancies', 'occurred', 'median'], 'lemmatized': ['malignancy', 'occurred', 'median'], 'stemmed': ['malign', 'occur', 'median'], 'dependencies': [('malign', 'nsubj'), ('occur', 'ROOT'), ('median', 'dobj')]}], 'text': \"lymphoma and NMSC, were breast, colon, prostate, lung, and melanoma. The malignancies in \\nHUMIRA-treated patients in the controlled and uncontrolled portions of the studies were similar \\nin type and number to what would be expected in the general U.S. population according to the \\nSEER database (adjusted for age, gender, and race).1 \\nIn controlled trials of other TNF blockers in adult patients at higher risk for malignancies (i.e., \\npatients with COPD with a significant smoking history and cyclophosphamide-treated patients \\nwith Wegener’s granulomatosis), a greater portion of malignancies occurred in the TNF blocker \\ngroup compared to the control group.  \\nNon-Melanoma Skin Cancer \\nDuring the controlled portions of 39 global HUMIRA clinical trials in adult patients with RA, \\nPsA, AS, CD, UC, Ps, HS and UV, the rate (95% confidence interval) of NMSC was 0.8 (0.52, \\n1.09) per 100 patient-years among HUMIRA-treated patients and 0.2 (0.10, 0.59) per 100 \\npatient-years among control-treated patients. Examine all patients, and in particular patients with \\na medical history of prior prolonged immunosuppressant therapy or psoriasis patients with a \\nhistory of PUVA treatment for the presence of NMSC prior to and during treatment with \\nHUMIRA.  \\nLymphoma and Leukemia \\nIn the controlled portions of clinical trials of all the TNF-blockers in adults, more cases of \\nlymphoma have been observed among TNF-blocker-treated patients compared to control-treated \\npatients. In the controlled portions of 39 global HUMIRA clinical trials in adult patients with \\nRA, PsA, AS, CD, UC, Ps, HS and UV, 2 lymphomas occurred among 7973 HUMIRA-treated \\npatients versus 1 among 4848 control-treated patients. In 52 global controlled and uncontrolled \\nclinical trials of HUMIRA in adult patients with RA, PsA, AS, CD, UC, Ps, HS and UV with a \\nmedian duration of approximately 0.7 years, including 24,605 patients and over 40,215 patient-\\nyears of HUMIRA, the observed rate of lymphomas was approximately 0.11 per 100 patient-\\nyears. This is approximately 3-fold higher than expected in the general U.S. population \\naccording to the SEER database (adjusted for age, gender, and race).1 Rates of lymphoma in \\nclinical trials of HUMIRA cannot be compared to rates of lymphoma in clinical trials of other \\nTNF blockers and may not predict the rates observed in a broader patient population. Patients \\nwith RA and other chronic inflammatory diseases, particularly those with highly active disease \\nand/or chronic exposure to immunosuppressant therapies, may be at a higher risk (up to several \\nfold) than the general population for the development of lymphoma, even in the absence of TNF \\nblockers. Post-marketing cases of acute and chronic leukemia have been reported in association \\nwith TNF-blocker use in RA and other indications. Even in the absence of TNF-blocker therapy, \\npatients with RA may be at a higher risk (approximately 2-fold) than the general population for \\nthe development of leukemia.  \\nMalignancies in Pediatric Patients and Young Adults \\nMalignancies, some fatal, have been reported among children, adolescents, and young adults \\nwho received treatment with TNF-blockers (initiation of therapy ≤ 18 years of age), of which \\nHUMIRA is a member. Approximately half the cases were lymphomas, including Hodgkin's and \\nnon-Hodgkin's lymphoma. The other cases represented a variety of different malignancies and \\nincluded rare malignancies usually associated with immunosuppression and malignancies that \\nare not usually observed in children and adolescents. The malignancies occurred after a median \\n\"}, 'page_char_count': 3605, 'page_word_count': 539, 'sentences': ['lymphoma and NMSC, were breast, colon, prostate, lung, and melanoma.', 'The malignancies in \\nHUMIRA-treated patients in the controlled and uncontrolled portions of the studies were similar \\nin type and number to what would be expected in the general U.S. population according to the \\nSEER database (adjusted for age, gender, and race).1 \\nIn controlled trials of other TNF blockers in adult patients at higher risk for malignancies (i.e., \\npatients with COPD with a significant smoking history and cyclophosphamide-treated patients \\nwith Wegener’s granulomatosis), a greater portion of malignancies occurred in the TNF blocker \\ngroup compared to the control group.', ' \\nNon-Melanoma Skin Cancer \\nDuring the controlled portions of 39 global HUMIRA clinical trials in adult patients with RA, \\nPsA, AS, CD, UC, Ps, HS and UV, the rate (95% confidence interval) of NMSC was 0.8 (0.52, \\n1.09) per 100 patient-years among HUMIRA-treated patients and 0.2 (0.10, 0.59) per 100 \\npatient-years among control-treated patients.', 'Examine all patients, and in particular patients with \\na medical history of prior prolonged immunosuppressant therapy or psoriasis patients with a \\nhistory of PUVA treatment for the presence of NMSC prior to and during treatment with \\nHUMIRA.', ' \\nLymphoma and Leukemia \\nIn the controlled portions of clinical trials of all the TNF-blockers in adults, more cases of \\nlymphoma have been observed among TNF-blocker-treated patients compared to control-treated \\npatients.', 'In the controlled portions of 39 global HUMIRA clinical trials in adult patients with \\nRA, PsA, AS, CD, UC, Ps, HS and UV, 2 lymphomas occurred among 7973 HUMIRA-treated \\npatients versus 1 among 4848 control-treated patients.', 'In 52 global controlled and uncontrolled \\nclinical trials of HUMIRA in adult patients with RA, PsA, AS, CD, UC, Ps, HS and UV with a \\nmedian duration of approximately 0.7 years, including 24,605 patients and over 40,215 patient-\\nyears of HUMIRA, the observed rate of lymphomas was approximately 0.11 per 100 patient-\\nyears.', 'This is approximately 3-fold higher than expected in the general U.S. population \\naccording to the SEER database (adjusted for age, gender, and race).1 Rates of lymphoma in \\nclinical trials of HUMIRA cannot be compared to rates of lymphoma in clinical trials of other \\nTNF blockers and may not predict the rates observed in a broader patient population.', 'Patients \\nwith RA and other chronic inflammatory diseases, particularly those with highly active disease \\nand/or chronic exposure to immunosuppressant therapies, may be at a higher risk (up to several \\nfold) than the general population for the development of lymphoma, even in the absence of TNF \\nblockers.', 'Post-marketing cases of acute and chronic leukemia have been reported in association \\nwith TNF-blocker use in RA and other indications.', 'Even in the absence of TNF-blocker therapy, \\npatients with RA may be at a higher risk (approximately 2-fold) than the general population for \\nthe development of leukemia.', ' \\nMalignancies in Pediatric Patients and Young Adults \\nMalignancies, some fatal, have been reported among children, adolescents, and young adults \\nwho received treatment with TNF-blockers (initiation of therapy ≤ 18 years of age), of which \\nHUMIRA is a member.', \"Approximately half the cases were lymphomas, including Hodgkin's and \\nnon-Hodgkin's lymphoma.\", 'The other cases represented a variety of different malignancies and \\nincluded rare malignancies usually associated with immunosuppression and malignancies that \\nare not usually observed in children and adolescents.', 'The malignancies occurred after a median \\n'], 'page_sentence_count_spacy': 15}\n",
            "{'page_number': 12, 'text': \"of 30 months of therapy (range 1 to 84 months). Most of the patients were receiving concomitant \\nimmunosuppressants. These cases were reported post-marketing and are derived from a variety \\nof sources including registries and spontaneous postmarketing reports.  \\nPostmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell \\nlymphoma, have been reported in patients treated with TNF blockers including HUMIRA. These \\ncases have had a very aggressive disease course and have been fatal. The majority of reported \\nTNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the \\nmajority were in adolescent and young adult males. Almost all of these patients had received \\ntreatment with the immunosuppressants azathioprine or 6-mercaptopurine (6–MP) concomitantly \\nwith a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is \\nrelated to use of a TNF blocker or a TNF blocker in combination with these other \\nimmunosuppressants. The potential risk with the combination of azathioprine or 6-\\nmercaptopurine and HUMIRA should be carefully considered.  \\n5.3 Hypersensitivity Reactions \\nAnaphylaxis and angioneurotic edema have been reported following HUMIRA administration. If \\nan anaphylactic or other serious allergic reaction occurs, immediately discontinue administration \\nof HUMIRA and institute appropriate therapy. In clinical trials of HUMIRA, hypersensitivity \\nreactions (e.g., rash, anaphylactoid reaction, fixed drug reaction, non-specified drug reaction, \\nurticaria) have been observed.  \\n5.4 Hepatitis B Virus Reactivation \\nUse of TNF blockers, including HUMIRA, may increase the risk of reactivation of hepatitis B \\nvirus (HBV) in patients who are chronic carriers of this virus. In some instances, HBV \\nreactivation occurring in conjunction with TNF blocker therapy has been fatal. The majority of \\nthese reports have occurred in patients concomitantly receiving other medications that suppress \\nthe immune system, which may also contribute to HBV reactivation. Evaluate patients at risk for \\nHBV infection for prior evidence of HBV infection before initiating TNF blocker therapy. \\nExercise caution in prescribing TNF blockers for patients identified as carriers of HBV. \\nAdequate data are not available on the safety or efficacy of treating patients who are carriers of \\nHBV with anti-viral therapy in conjunction with TNF blocker therapy to prevent HBV \\nreactivation. For patients who are carriers of HBV and require treatment with TNF blockers, \\nclosely monitor such patients for clinical and laboratory signs of active HBV infection \\nthroughout therapy and for several months following termination of therapy. In patients who \\ndevelop HBV reactivation, stop HUMIRA and initiate effective anti-viral therapy with \\nappropriate supportive treatment. The safety of resuming TNF blocker therapy after HBV \\nreactivation is controlled is not known. Therefore, exercise caution when considering resumption \\nof HUMIRA therapy in this situation and monitor patients closely.  \\n5.5 Neurologic Reactions \\nUse of TNF blocking agents, including HUMIRA, has been associated with rare cases of new \\nonset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous \\nsystem demyelinating disease, including multiple sclerosis (MS) and optic neuritis, and \\nperipheral demyelinating disease, including Guillain-Barré syndrome. Exercise caution in \\nconsidering the use of HUMIRA in patients with preexisting or recent-onset central or peripheral \\n\", 'processed_text': {'sentences': [{'original_sentence': 'of 30 months of therapy (range 1 to 84 months).', 'tokens': ['30', 'months', 'therapy', '(', 'range', '1', '84', 'months', ')', '.'], 'lemmatized': ['30', 'month', 'therapy', '(', 'range', '1', '84', 'month', ')', '.'], 'stemmed': ['30', 'month', 'therapi', '(', 'rang', '1', '84', 'month', ')', '.'], 'dependencies': [('30', 'nummod'), ('month', 'npadvmod'), ('therapi', 'ROOT'), ('(', 'punct'), ('rang', 'parataxis'), ('1', 'nummod'), ('84', 'nummod'), ('month', 'npadvmod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Most of the patients were receiving concomitant \\nimmunosuppressants.', 'tokens': ['patients', 'receiving', 'concomitant', 'immunosuppressants', '.'], 'lemmatized': ['patient', 'receiving', 'concomitant', 'immunosuppressant', '.'], 'stemmed': ['patient', 'receiv', 'concomit', 'immunosuppress', '.'], 'dependencies': [('patient', 'compound'), ('receiv', 'compound'), ('concomit', 'compound'), ('immunosuppress', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'These cases were reported post-marketing and are derived from a variety \\nof sources including registries and spontaneous postmarketing reports.', 'tokens': ['cases', 'reported', 'post-marketing', 'derived', 'variety', 'sources', 'including', 'registries', 'spontaneous', 'postmarketing', 'reports', '.'], 'lemmatized': ['case', 'reported', 'post-marketing', 'derived', 'variety', 'source', 'including', 'registry', 'spontaneous', 'postmarketing', 'report', '.'], 'stemmed': ['case', 'report', 'post-market', 'deriv', 'varieti', 'sourc', 'includ', 'registri', 'spontan', 'postmarket', 'report', '.'], 'dependencies': [('case', 'nsubj'), ('report', 'ROOT'), ('post', 'amod'), ('-', 'amod'), ('market', 'amod'), ('deriv', 'nsubj'), ('varieti', 'nmod'), ('sourc', 'compound'), ('includ', 'dobj'), ('registri', 'amod'), ('spontan', 'compound'), ('postmarket', 'compound'), ('report', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell \\nlymphoma, have been reported in patients treated with TNF blockers including HUMIRA.', 'tokens': ['Postmarketing', 'cases', 'hepatosplenic', 'T-cell', 'lymphoma', '(', 'HSTCL', ')', ',', 'rare', 'type', 'T-cell', 'lymphoma', ',', 'reported', 'patients', 'treated', 'TNF', 'blockers', 'including', 'HUMIRA', '.'], 'lemmatized': ['Postmarketing', 'case', 'hepatosplenic', 'T-cell', 'lymphoma', '(', 'HSTCL', ')', ',', 'rare', 'type', 'T-cell', 'lymphoma', ',', 'reported', 'patient', 'treated', 'TNF', 'blocker', 'including', 'HUMIRA', '.'], 'stemmed': ['postmarket', 'case', 'hepatosplen', 't-cell', 'lymphoma', '(', 'hstcl', ')', ',', 'rare', 'type', 't-cell', 'lymphoma', ',', 'report', 'patient', 'treat', 'tnf', 'blocker', 'includ', 'humira', '.'], 'dependencies': [('postmarket', 'compound'), ('case', 'nsubj'), ('hepatosplen', 'amod'), ('t', 'compound'), ('-', 'punct'), ('cell', 'compound'), ('lymphoma', 'nsubj'), ('(', 'punct'), ('hstcl', 'appos'), (')', 'punct'), (',', 'punct'), ('rare', 'amod'), ('type', 'compound'), ('t', 'compound'), ('-', 'punct'), ('cell', 'compound'), ('lymphoma', 'appos'), (',', 'punct'), ('report', 'ROOT'), ('patient', 'compound'), ('treat', 'compound'), ('tnf', 'compound'), ('blocker', 'compound'), ('includ', 'compound'), ('humira', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'These \\ncases have had a very aggressive disease course and have been fatal.', 'tokens': ['cases', 'aggressive', 'disease', 'course', 'fatal', '.'], 'lemmatized': ['case', 'aggressive', 'disease', 'course', 'fatal', '.'], 'stemmed': ['case', 'aggress', 'diseas', 'cours', 'fatal', '.'], 'dependencies': [('case', 'compound'), ('aggress', 'compound'), ('diseas', 'nsubj'), ('cours', 'ROOT'), ('fatal', 'dobj'), ('.', 'punct')]}, {'original_sentence': \"The majority of reported \\nTNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the \\nmajority were in adolescent and young adult males.\", 'tokens': ['majority', 'reported', 'TNF', 'blocker', 'cases', 'occurred', 'patients', 'Crohn', \"'s\", 'disease', 'ulcerative', 'colitis', 'majority', 'adolescent', 'young', 'adult', 'males', '.'], 'lemmatized': ['majority', 'reported', 'TNF', 'blocker', 'case', 'occurred', 'patient', 'Crohn', \"'s\", 'disease', 'ulcerative', 'colitis', 'majority', 'adolescent', 'young', 'adult', 'male', '.'], 'stemmed': ['major', 'report', 'tnf', 'blocker', 'case', 'occur', 'patient', 'crohn', \"'s\", 'diseas', 'ulcer', 'coliti', 'major', 'adolesc', 'young', 'adult', 'male', '.'], 'dependencies': [('major', 'amod'), ('report', 'compound'), ('tnf', 'compound'), ('blocker', 'compound'), ('case', 'nsubj'), ('occur', 'ROOT'), ('patient', 'compound'), ('crohn', 'poss'), (\"'s\", 'case'), ('diseas', 'compound'), ('ulcer', 'dobj'), ('coliti', 'nmod'), ('major', 'amod'), ('adolesc', 'nmod'), ('young', 'amod'), ('adult', 'compound'), ('male', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Almost all of these patients had received \\ntreatment with the immunosuppressants azathioprine or 6-mercaptopurine (6–MP) concomitantly \\nwith a TNF blocker at or prior to diagnosis.', 'tokens': ['Almost', 'patients', 'received', 'treatment', 'immunosuppressants', 'azathioprine', '6-mercaptopurine', '(', '6–MP', ')', 'concomitantly', 'TNF', 'blocker', 'prior', 'diagnosis', '.'], 'lemmatized': ['Almost', 'patient', 'received', 'treatment', 'immunosuppressant', 'azathioprine', '6-mercaptopurine', '(', '6–MP', ')', 'concomitantly', 'TNF', 'blocker', 'prior', 'diagnosis', '.'], 'stemmed': ['almost', 'patient', 'receiv', 'treatment', 'immunosuppress', 'azathioprin', '6-mercaptopurin', '(', '6–mp', ')', 'concomitantli', 'tnf', 'blocker', 'prior', 'diagnosi', '.'], 'dependencies': [('almost', 'advmod'), ('patient', 'amod'), ('receiv', 'compound'), ('treatment', 'compound'), ('immunosuppress', 'compound'), ('azathioprin', 'ROOT'), ('6', 'nummod'), ('-', 'punct'), ('mercaptopurin', 'appos'), ('(', 'punct'), ('6', 'nummod'), ('–', 'punct'), ('mp', 'nmod'), (')', 'punct'), ('concomitantli', 'compound'), ('tnf', 'compound'), ('blocker', 'appos'), ('prior', 'advmod'), ('diagnosi', 'appos'), ('.', 'punct')]}, {'original_sentence': 'It is uncertain whether the occurrence of HSTCL is \\nrelated to use of a TNF blocker or a TNF blocker in combination with these other \\nimmunosuppressants.', 'tokens': ['uncertain', 'whether', 'occurrence', 'HSTCL', 'related', 'use', 'TNF', 'blocker', 'TNF', 'blocker', 'combination', 'immunosuppressants', '.'], 'lemmatized': ['uncertain', 'whether', 'occurrence', 'HSTCL', 'related', 'use', 'TNF', 'blocker', 'TNF', 'blocker', 'combination', 'immunosuppressant', '.'], 'stemmed': ['uncertain', 'whether', 'occurr', 'hstcl', 'relat', 'use', 'tnf', 'blocker', 'tnf', 'blocker', 'combin', 'immunosuppress', '.'], 'dependencies': [('uncertain', 'ROOT'), ('whether', 'mark'), ('occurr', 'aux'), ('hstcl', 'compound'), ('relat', 'compound'), ('use', 'ccomp'), ('tnf', 'compound'), ('blocker', 'compound'), ('tnf', 'compound'), ('blocker', 'compound'), ('combin', 'compound'), ('immunosuppress', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The potential risk with the combination of azathioprine or 6-\\nmercaptopurine and HUMIRA should be carefully considered.', 'tokens': ['potential', 'risk', 'combination', 'azathioprine', '6-', 'mercaptopurine', 'HUMIRA', 'carefully', 'considered', '.'], 'lemmatized': ['potential', 'risk', 'combination', 'azathioprine', '6-', 'mercaptopurine', 'HUMIRA', 'carefully', 'considered', '.'], 'stemmed': ['potenti', 'risk', 'combin', 'azathioprin', '6-', 'mercaptopurin', 'humira', 'care', 'consid', '.'], 'dependencies': [('potenti', 'compound'), ('risk', 'compound'), ('combin', 'compound'), ('azathioprin', 'compound'), ('6-', 'meta'), ('mercaptopurin', 'compound'), ('humira', 'compound'), ('care', 'compound'), ('consid', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '5.3 Hypersensitivity Reactions \\nAnaphylaxis and angioneurotic edema have been reported following HUMIRA administration.', 'tokens': ['5.3', 'Hypersensitivity', 'Reactions', 'Anaphylaxis', 'angioneurotic', 'edema', 'reported', 'following', 'HUMIRA', 'administration', '.'], 'lemmatized': ['5.3', 'Hypersensitivity', 'Reactions', 'Anaphylaxis', 'angioneurotic', 'edema', 'reported', 'following', 'HUMIRA', 'administration', '.'], 'stemmed': ['5.3', 'hypersensit', 'reaction', 'anaphylaxi', 'angioneurot', 'edema', 'report', 'follow', 'humira', 'administr', '.'], 'dependencies': [('5.3', 'nummod'), ('hypersensit', 'compound'), ('reaction', 'compound'), ('anaphylaxi', 'amod'), ('angioneurot', 'compound'), ('edema', 'compound'), ('report', 'compound'), ('follow', 'compound'), ('humira', 'compound'), ('administr', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'If \\nan anaphylactic or other serious allergic reaction occurs, immediately discontinue administration \\nof HUMIRA and institute appropriate therapy.', 'tokens': ['anaphylactic', 'serious', 'allergic', 'reaction', 'occurs', ',', 'immediately', 'discontinue', 'administration', 'HUMIRA', 'institute', 'appropriate', 'therapy', '.'], 'lemmatized': ['anaphylactic', 'serious', 'allergic', 'reaction', 'occurs', ',', 'immediately', 'discontinue', 'administration', 'HUMIRA', 'institute', 'appropriate', 'therapy', '.'], 'stemmed': ['anaphylact', 'seriou', 'allerg', 'reaction', 'occur', ',', 'immedi', 'discontinu', 'administr', 'humira', 'institut', 'appropri', 'therapi', '.'], 'dependencies': [('anaphylact', 'compound'), ('seriou', 'compound'), ('allerg', 'compound'), ('reaction', 'nsubj'), ('occur', 'ccomp'), (',', 'punct'), ('immedi', 'compound'), ('discontinu', 'compound'), ('administr', 'compound'), ('humira', 'compound'), ('institut', 'compound'), ('appropri', 'nsubj'), ('therapi', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'In clinical trials of HUMIRA, hypersensitivity \\nreactions (e.g., rash, anaphylactoid reaction, fixed drug reaction, non-specified drug reaction, \\nurticaria) have been observed.', 'tokens': ['clinical', 'trials', 'HUMIRA', ',', 'hypersensitivity', 'reactions', '(', 'e.g.', ',', 'rash', ',', 'anaphylactoid', 'reaction', ',', 'fixed', 'drug', 'reaction', ',', 'non-specified', 'drug', 'reaction', ',', 'urticaria', ')', 'observed', '.'], 'lemmatized': ['clinical', 'trial', 'HUMIRA', ',', 'hypersensitivity', 'reaction', '(', 'e.g.', ',', 'rash', ',', 'anaphylactoid', 'reaction', ',', 'fixed', 'drug', 'reaction', ',', 'non-specified', 'drug', 'reaction', ',', 'urticaria', ')', 'observed', '.'], 'stemmed': ['clinic', 'trial', 'humira', ',', 'hypersensit', 'reaction', '(', 'e.g.', ',', 'rash', ',', 'anaphylactoid', 'reaction', ',', 'fix', 'drug', 'reaction', ',', 'non-specifi', 'drug', 'reaction', ',', 'urticaria', ')', 'observ', '.'], 'dependencies': [('clinic', 'compound'), ('trial', 'compound'), ('humira', 'nsubj'), (',', 'punct'), ('hypersensit', 'compound'), ('reaction', 'conj'), ('(', 'punct'), ('e.g.', 'advmod'), (',', 'punct'), ('rash', 'amod'), (',', 'punct'), ('anaphylactoid', 'amod'), ('reaction', 'appos'), (',', 'punct'), ('fix', 'nmod'), ('drug', 'compound'), ('reaction', 'dobj'), (',', 'punct'), ('non', 'amod'), ('-', 'amod'), ('specifi', 'amod'), ('drug', 'compound'), ('reaction', 'conj'), (',', 'punct'), ('urticaria', 'nmod'), (')', 'punct'), ('observ', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '5.4 Hepatitis B Virus Reactivation \\nUse of TNF blockers, including HUMIRA, may increase the risk of reactivation of hepatitis B \\nvirus (HBV) in patients who are chronic carriers of this virus.', 'tokens': ['5.4', 'Hepatitis', 'B', 'Virus', 'Reactivation', 'Use', 'TNF', 'blockers', ',', 'including', 'HUMIRA', ',', 'may', 'increase', 'risk', 'reactivation', 'hepatitis', 'B', 'virus', '(', 'HBV', ')', 'patients', 'chronic', 'carriers', 'virus', '.'], 'lemmatized': ['5.4', 'Hepatitis', 'B', 'Virus', 'Reactivation', 'Use', 'TNF', 'blocker', ',', 'including', 'HUMIRA', ',', 'may', 'increase', 'risk', 'reactivation', 'hepatitis', 'B', 'virus', '(', 'HBV', ')', 'patient', 'chronic', 'carrier', 'virus', '.'], 'stemmed': ['5.4', 'hepat', 'b', 'viru', 'reactiv', 'use', 'tnf', 'blocker', ',', 'includ', 'humira', ',', 'may', 'increas', 'risk', 'reactiv', 'hepat', 'b', 'viru', '(', 'hbv', ')', 'patient', 'chronic', 'carrier', 'viru', '.'], 'dependencies': [('5.4', 'nummod'), ('hepat', 'compound'), ('b', 'compound'), ('viru', 'compound'), ('reactiv', 'compound'), ('use', 'compound'), ('tnf', 'compound'), ('blocker', 'nsubj'), (',', 'punct'), ('includ', 'compound'), ('humira', 'appos'), (',', 'punct'), ('may', 'aux'), ('increas', 'ROOT'), ('risk', 'compound'), ('reactiv', 'compound'), ('hepat', 'compound'), ('b', 'compound'), ('viru', 'dobj'), ('(', 'punct'), ('hbv', 'appos'), (')', 'punct'), ('patient', 'amod'), ('chronic', 'amod'), ('carrier', 'compound'), ('viru', 'appos'), ('.', 'punct')]}, {'original_sentence': 'In some instances, HBV \\nreactivation occurring in conjunction with TNF blocker therapy has been fatal.', 'tokens': ['instances', ',', 'HBV', 'reactivation', 'occurring', 'conjunction', 'TNF', 'blocker', 'therapy', 'fatal', '.'], 'lemmatized': ['instance', ',', 'HBV', 'reactivation', 'occurring', 'conjunction', 'TNF', 'blocker', 'therapy', 'fatal', '.'], 'stemmed': ['instanc', ',', 'hbv', 'reactiv', 'occur', 'conjunct', 'tnf', 'blocker', 'therapi', 'fatal', '.'], 'dependencies': [('instanc', 'advcl'), (',', 'punct'), ('hbv', 'compound'), ('reactiv', 'nsubj'), ('occur', 'ROOT'), ('conjunct', 'compound'), ('tnf', 'compound'), ('blocker', 'compound'), ('therapi', 'compound'), ('fatal', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The majority of \\nthese reports have occurred in patients concomitantly receiving other medications that suppress \\nthe immune system, which may also contribute to HBV reactivation.', 'tokens': ['majority', 'reports', 'occurred', 'patients', 'concomitantly', 'receiving', 'medications', 'suppress', 'immune', 'system', ',', 'may', 'also', 'contribute', 'HBV', 'reactivation', '.'], 'lemmatized': ['majority', 'report', 'occurred', 'patient', 'concomitantly', 'receiving', 'medication', 'suppress', 'immune', 'system', ',', 'may', 'also', 'contribute', 'HBV', 'reactivation', '.'], 'stemmed': ['major', 'report', 'occur', 'patient', 'concomitantli', 'receiv', 'medic', 'suppress', 'immun', 'system', ',', 'may', 'also', 'contribut', 'hbv', 'reactiv', '.'], 'dependencies': [('major', 'amod'), ('report', 'nsubj'), ('occur', 'ccomp'), ('patient', 'amod'), ('concomitantli', 'compound'), ('receiv', 'compound'), ('medic', 'compound'), ('suppress', 'compound'), ('immun', 'compound'), ('system', 'dobj'), (',', 'punct'), ('may', 'aux'), ('also', 'advmod'), ('contribut', 'ROOT'), ('hbv', 'compound'), ('reactiv', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Evaluate patients at risk for \\nHBV infection for prior evidence of HBV infection before initiating TNF blocker therapy.', 'tokens': ['Evaluate', 'patients', 'risk', 'HBV', 'infection', 'prior', 'evidence', 'HBV', 'infection', 'initiating', 'TNF', 'blocker', 'therapy', '.'], 'lemmatized': ['Evaluate', 'patient', 'risk', 'HBV', 'infection', 'prior', 'evidence', 'HBV', 'infection', 'initiating', 'TNF', 'blocker', 'therapy', '.'], 'stemmed': ['evalu', 'patient', 'risk', 'hbv', 'infect', 'prior', 'evid', 'hbv', 'infect', 'initi', 'tnf', 'blocker', 'therapi', '.'], 'dependencies': [('evalu', 'compound'), ('patient', 'compound'), ('risk', 'compound'), ('hbv', 'nsubj'), ('infect', 'ROOT'), ('prior', 'amod'), ('evid', 'compound'), ('hbv', 'compound'), ('infect', 'compound'), ('initi', 'compound'), ('tnf', 'compound'), ('blocker', 'compound'), ('therapi', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Exercise caution in prescribing TNF blockers for patients identified as carriers of HBV.', 'tokens': ['Exercise', 'caution', 'prescribing', 'TNF', 'blockers', 'patients', 'identified', 'carriers', 'HBV', '.'], 'lemmatized': ['Exercise', 'caution', 'prescribing', 'TNF', 'blocker', 'patient', 'identified', 'carrier', 'HBV', '.'], 'stemmed': ['exercis', 'caution', 'prescrib', 'tnf', 'blocker', 'patient', 'identifi', 'carrier', 'hbv', '.'], 'dependencies': [('exercis', 'compound'), ('caution', 'compound'), ('prescrib', 'compound'), ('tnf', 'compound'), ('blocker', 'compound'), ('patient', 'compound'), ('identifi', 'compound'), ('carrier', 'compound'), ('hbv', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Adequate data are not available on the safety or efficacy of treating patients who are carriers of \\nHBV with anti-viral therapy in conjunction with TNF blocker therapy to prevent HBV \\nreactivation.', 'tokens': ['Adequate', 'data', 'available', 'safety', 'efficacy', 'treating', 'patients', 'carriers', 'HBV', 'anti-viral', 'therapy', 'conjunction', 'TNF', 'blocker', 'therapy', 'prevent', 'HBV', 'reactivation', '.'], 'lemmatized': ['Adequate', 'data', 'available', 'safety', 'efficacy', 'treating', 'patient', 'carrier', 'HBV', 'anti-viral', 'therapy', 'conjunction', 'TNF', 'blocker', 'therapy', 'prevent', 'HBV', 'reactivation', '.'], 'stemmed': ['adequ', 'data', 'avail', 'safeti', 'efficaci', 'treat', 'patient', 'carrier', 'hbv', 'anti-vir', 'therapi', 'conjunct', 'tnf', 'blocker', 'therapi', 'prevent', 'hbv', 'reactiv', '.'], 'dependencies': [('adequ', 'compound'), ('data', 'compound'), ('avail', 'compound'), ('safeti', 'compound'), ('efficaci', 'nsubj'), ('treat', 'compound'), ('patient', 'compound'), ('carrier', 'nsubj'), ('hbv', 'nsubj'), ('anti', 'nsubj'), ('-', 'nsubj'), ('vir', 'amod'), ('therapi', 'compound'), ('conjunct', 'compound'), ('tnf', 'compound'), ('blocker', 'nsubj'), ('therapi', 'nsubj'), ('prevent', 'ROOT'), ('hbv', 'compound'), ('reactiv', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'For patients who are carriers of HBV and require treatment with TNF blockers, \\nclosely monitor such patients for clinical and laboratory signs of active HBV infection \\nthroughout therapy and for several months following termination of therapy.', 'tokens': ['patients', 'carriers', 'HBV', 'require', 'treatment', 'TNF', 'blockers', ',', 'closely', 'monitor', 'patients', 'clinical', 'laboratory', 'signs', 'active', 'HBV', 'infection', 'throughout', 'therapy', 'several', 'months', 'following', 'termination', 'therapy', '.'], 'lemmatized': ['patient', 'carrier', 'HBV', 'require', 'treatment', 'TNF', 'blocker', ',', 'closely', 'monitor', 'patient', 'clinical', 'laboratory', 'sign', 'active', 'HBV', 'infection', 'throughout', 'therapy', 'several', 'month', 'following', 'termination', 'therapy', '.'], 'stemmed': ['patient', 'carrier', 'hbv', 'requir', 'treatment', 'tnf', 'blocker', ',', 'close', 'monitor', 'patient', 'clinic', 'laboratori', 'sign', 'activ', 'hbv', 'infect', 'throughout', 'therapi', 'sever', 'month', 'follow', 'termin', 'therapi', '.'], 'dependencies': [('patient', 'compound'), ('carrier', 'compound'), ('hbv', 'compound'), ('requir', 'compound'), ('treatment', 'compound'), ('tnf', 'compound'), ('blocker', 'npadvmod'), (',', 'punct'), ('close', 'amod'), ('monitor', 'compound'), ('patient', 'compound'), ('clinic', 'compound'), ('laboratori', 'compound'), ('sign', 'compound'), ('activ', 'compound'), ('hbv', 'compound'), ('infect', 'ROOT'), ('throughout', 'prep'), ('therapi', 'amod'), ('sever', 'compound'), ('month', 'compound'), ('follow', 'compound'), ('termin', 'compound'), ('therapi', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'In patients who \\ndevelop HBV reactivation, stop HUMIRA and initiate effective anti-viral therapy with \\nappropriate supportive treatment.', 'tokens': ['patients', 'develop', 'HBV', 'reactivation', ',', 'stop', 'HUMIRA', 'initiate', 'effective', 'anti-viral', 'therapy', 'appropriate', 'supportive', 'treatment', '.'], 'lemmatized': ['patient', 'develop', 'HBV', 'reactivation', ',', 'stop', 'HUMIRA', 'initiate', 'effective', 'anti-viral', 'therapy', 'appropriate', 'supportive', 'treatment', '.'], 'stemmed': ['patient', 'develop', 'hbv', 'reactiv', ',', 'stop', 'humira', 'initi', 'effect', 'anti-vir', 'therapi', 'appropri', 'support', 'treatment', '.'], 'dependencies': [('patient', 'nsubj'), ('develop', 'ROOT'), ('hbv', 'compound'), ('reactiv', 'dobj'), (',', 'punct'), ('stop', 'dep'), ('humira', 'compound'), ('initi', 'compound'), ('effect', 'ccomp'), ('anti', 'amod'), ('-', 'amod'), ('vir', 'amod'), ('therapi', 'compound'), ('appropri', 'compound'), ('support', 'compound'), ('treatment', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The safety of resuming TNF blocker therapy after HBV \\nreactivation is controlled is not known.', 'tokens': ['safety', 'resuming', 'TNF', 'blocker', 'therapy', 'HBV', 'reactivation', 'controlled', 'known', '.'], 'lemmatized': ['safety', 'resuming', 'TNF', 'blocker', 'therapy', 'HBV', 'reactivation', 'controlled', 'known', '.'], 'stemmed': ['safeti', 'resum', 'tnf', 'blocker', 'therapi', 'hbv', 'reactiv', 'control', 'known', '.'], 'dependencies': [('safeti', 'compound'), ('resum', 'ROOT'), ('tnf', 'compound'), ('blocker', 'compound'), ('therapi', 'compound'), ('hbv', 'compound'), ('reactiv', 'compound'), ('control', 'dobj'), ('known', 'acl'), ('.', 'punct')]}, {'original_sentence': 'Therefore, exercise caution when considering resumption \\nof HUMIRA therapy in this situation and monitor patients closely.', 'tokens': ['Therefore', ',', 'exercise', 'caution', 'considering', 'resumption', 'HUMIRA', 'therapy', 'situation', 'monitor', 'patients', 'closely', '.'], 'lemmatized': ['Therefore', ',', 'exercise', 'caution', 'considering', 'resumption', 'HUMIRA', 'therapy', 'situation', 'monitor', 'patient', 'closely', '.'], 'stemmed': ['therefor', ',', 'exercis', 'caution', 'consid', 'resumpt', 'humira', 'therapi', 'situat', 'monitor', 'patient', 'close', '.'], 'dependencies': [('therefor', 'ROOT'), (',', 'punct'), ('exercis', 'compound'), ('caution', 'compound'), ('consid', 'advmod'), ('resumpt', 'compound'), ('humira', 'compound'), ('therapi', 'compound'), ('situat', 'compound'), ('monitor', 'compound'), ('patient', 'pobj'), ('close', 'advmod'), ('.', 'punct')]}, {'original_sentence': '5.5 Neurologic Reactions \\nUse of TNF blocking agents, including HUMIRA, has been associated with rare cases of new \\nonset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous \\nsystem demyelinating disease, including multiple sclerosis (MS) and optic neuritis, and \\nperipheral demyelinating disease, including Guillain-Barré syndrome.', 'tokens': ['5.5', 'Neurologic', 'Reactions', 'Use', 'TNF', 'blocking', 'agents', ',', 'including', 'HUMIRA', ',', 'associated', 'rare', 'cases', 'new', 'onset', 'exacerbation', 'clinical', 'symptoms', 'and/or', 'radiographic', 'evidence', 'central', 'nervous', 'system', 'demyelinating', 'disease', ',', 'including', 'multiple', 'sclerosis', '(', 'MS', ')', 'optic', 'neuritis', ',', 'peripheral', 'demyelinating', 'disease', ',', 'including', 'Guillain-Barré', 'syndrome', '.'], 'lemmatized': ['5.5', 'Neurologic', 'Reactions', 'Use', 'TNF', 'blocking', 'agent', ',', 'including', 'HUMIRA', ',', 'associated', 'rare', 'case', 'new', 'onset', 'exacerbation', 'clinical', 'symptom', 'and/or', 'radiographic', 'evidence', 'central', 'nervous', 'system', 'demyelinating', 'disease', ',', 'including', 'multiple', 'sclerosis', '(', 'MS', ')', 'optic', 'neuritis', ',', 'peripheral', 'demyelinating', 'disease', ',', 'including', 'Guillain-Barré', 'syndrome', '.'], 'stemmed': ['5.5', 'neurolog', 'reaction', 'use', 'tnf', 'block', 'agent', ',', 'includ', 'humira', ',', 'associ', 'rare', 'case', 'new', 'onset', 'exacerb', 'clinic', 'symptom', 'and/or', 'radiograph', 'evid', 'central', 'nervou', 'system', 'demyelin', 'diseas', ',', 'includ', 'multipl', 'sclerosi', '(', 'ms', ')', 'optic', 'neuriti', ',', 'peripher', 'demyelin', 'diseas', ',', 'includ', 'guillain-barré', 'syndrom', '.'], 'dependencies': [('5.5', 'nummod'), ('neurolog', 'compound'), ('reaction', 'compound'), ('use', 'compound'), ('tnf', 'compound'), ('block', 'compound'), ('agent', 'nsubj'), (',', 'punct'), ('includ', 'compound'), ('humira', 'conj'), (',', 'punct'), ('associ', 'nmod'), ('rare', 'amod'), ('case', 'conj'), ('new', 'amod'), ('onset', 'nmod'), ('exacerb', 'amod'), ('clinic', 'compound'), ('symptom', 'nmod'), ('and/or', 'cc'), ('radiograph', 'compound'), ('evid', 'conj'), ('central', 'amod'), ('nervou', 'compound'), ('system', 'compound'), ('demyelin', 'compound'), ('diseas', 'conj'), (',', 'punct'), ('includ', 'compound'), ('multipl', 'compound'), ('sclerosi', 'nsubj'), ('(', 'punct'), ('ms', 'nmod'), (')', 'punct'), ('optic', 'amod'), ('neuriti', 'appos'), (',', 'punct'), ('peripher', 'ROOT'), ('demyelin', 'compound'), ('diseas', 'dobj'), (',', 'punct'), ('includ', 'amod'), ('guillain', 'compound'), ('-', 'punct'), ('barré', 'amod'), ('syndrom', 'conj'), ('.', 'punct')]}, {'original_sentence': 'Exercise caution in \\nconsidering the use of HUMIRA in patients with preexisting or recent-onset central or peripheral', 'tokens': ['Exercise', 'caution', 'considering', 'use', 'HUMIRA', 'patients', 'preexisting', 'recent-onset', 'central', 'peripheral'], 'lemmatized': ['Exercise', 'caution', 'considering', 'use', 'HUMIRA', 'patient', 'preexisting', 'recent-onset', 'central', 'peripheral'], 'stemmed': ['exercis', 'caution', 'consid', 'use', 'humira', 'patient', 'preexist', 'recent-onset', 'central', 'peripher'], 'dependencies': [('exercis', 'compound'), ('caution', 'nsubj'), ('consid', 'advmod'), ('use', 'ROOT'), ('humira', 'nmod'), ('patient', 'nmod'), ('preexist', 'nmod'), ('recent', 'amod'), ('-', 'punct'), ('onset', 'amod'), ('central', 'amod'), ('peripher', 'dobj')]}], 'text': \"of 30 months of therapy (range 1 to 84 months). Most of the patients were receiving concomitant \\nimmunosuppressants. These cases were reported post-marketing and are derived from a variety \\nof sources including registries and spontaneous postmarketing reports.  \\nPostmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell \\nlymphoma, have been reported in patients treated with TNF blockers including HUMIRA. These \\ncases have had a very aggressive disease course and have been fatal. The majority of reported \\nTNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the \\nmajority were in adolescent and young adult males. Almost all of these patients had received \\ntreatment with the immunosuppressants azathioprine or 6-mercaptopurine (6–MP) concomitantly \\nwith a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is \\nrelated to use of a TNF blocker or a TNF blocker in combination with these other \\nimmunosuppressants. The potential risk with the combination of azathioprine or 6-\\nmercaptopurine and HUMIRA should be carefully considered.  \\n5.3 Hypersensitivity Reactions \\nAnaphylaxis and angioneurotic edema have been reported following HUMIRA administration. If \\nan anaphylactic or other serious allergic reaction occurs, immediately discontinue administration \\nof HUMIRA and institute appropriate therapy. In clinical trials of HUMIRA, hypersensitivity \\nreactions (e.g., rash, anaphylactoid reaction, fixed drug reaction, non-specified drug reaction, \\nurticaria) have been observed.  \\n5.4 Hepatitis B Virus Reactivation \\nUse of TNF blockers, including HUMIRA, may increase the risk of reactivation of hepatitis B \\nvirus (HBV) in patients who are chronic carriers of this virus. In some instances, HBV \\nreactivation occurring in conjunction with TNF blocker therapy has been fatal. The majority of \\nthese reports have occurred in patients concomitantly receiving other medications that suppress \\nthe immune system, which may also contribute to HBV reactivation. Evaluate patients at risk for \\nHBV infection for prior evidence of HBV infection before initiating TNF blocker therapy. \\nExercise caution in prescribing TNF blockers for patients identified as carriers of HBV. \\nAdequate data are not available on the safety or efficacy of treating patients who are carriers of \\nHBV with anti-viral therapy in conjunction with TNF blocker therapy to prevent HBV \\nreactivation. For patients who are carriers of HBV and require treatment with TNF blockers, \\nclosely monitor such patients for clinical and laboratory signs of active HBV infection \\nthroughout therapy and for several months following termination of therapy. In patients who \\ndevelop HBV reactivation, stop HUMIRA and initiate effective anti-viral therapy with \\nappropriate supportive treatment. The safety of resuming TNF blocker therapy after HBV \\nreactivation is controlled is not known. Therefore, exercise caution when considering resumption \\nof HUMIRA therapy in this situation and monitor patients closely.  \\n5.5 Neurologic Reactions \\nUse of TNF blocking agents, including HUMIRA, has been associated with rare cases of new \\nonset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous \\nsystem demyelinating disease, including multiple sclerosis (MS) and optic neuritis, and \\nperipheral demyelinating disease, including Guillain-Barré syndrome. Exercise caution in \\nconsidering the use of HUMIRA in patients with preexisting or recent-onset central or peripheral \\n\"}, 'page_char_count': 3557, 'page_word_count': 502, 'sentences': ['of 30 months of therapy (range 1 to 84 months).', 'Most of the patients were receiving concomitant \\nimmunosuppressants.', 'These cases were reported post-marketing and are derived from a variety \\nof sources including registries and spontaneous postmarketing reports.', ' \\nPostmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell \\nlymphoma, have been reported in patients treated with TNF blockers including HUMIRA.', 'These \\ncases have had a very aggressive disease course and have been fatal.', \"The majority of reported \\nTNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the \\nmajority were in adolescent and young adult males.\", 'Almost all of these patients had received \\ntreatment with the immunosuppressants azathioprine or 6-mercaptopurine (6–MP) concomitantly \\nwith a TNF blocker at or prior to diagnosis.', 'It is uncertain whether the occurrence of HSTCL is \\nrelated to use of a TNF blocker or a TNF blocker in combination with these other \\nimmunosuppressants.', 'The potential risk with the combination of azathioprine or 6-\\nmercaptopurine and HUMIRA should be carefully considered.', ' \\n5.3 Hypersensitivity Reactions \\nAnaphylaxis and angioneurotic edema have been reported following HUMIRA administration.', 'If \\nan anaphylactic or other serious allergic reaction occurs, immediately discontinue administration \\nof HUMIRA and institute appropriate therapy.', 'In clinical trials of HUMIRA, hypersensitivity \\nreactions (e.g., rash, anaphylactoid reaction, fixed drug reaction, non-specified drug reaction, \\nurticaria) have been observed.', ' \\n5.4 Hepatitis B Virus Reactivation \\nUse of TNF blockers, including HUMIRA, may increase the risk of reactivation of hepatitis B \\nvirus (HBV) in patients who are chronic carriers of this virus.', 'In some instances, HBV \\nreactivation occurring in conjunction with TNF blocker therapy has been fatal.', 'The majority of \\nthese reports have occurred in patients concomitantly receiving other medications that suppress \\nthe immune system, which may also contribute to HBV reactivation.', 'Evaluate patients at risk for \\nHBV infection for prior evidence of HBV infection before initiating TNF blocker therapy.', '\\nExercise caution in prescribing TNF blockers for patients identified as carriers of HBV.', '\\nAdequate data are not available on the safety or efficacy of treating patients who are carriers of \\nHBV with anti-viral therapy in conjunction with TNF blocker therapy to prevent HBV \\nreactivation.', 'For patients who are carriers of HBV and require treatment with TNF blockers, \\nclosely monitor such patients for clinical and laboratory signs of active HBV infection \\nthroughout therapy and for several months following termination of therapy.', 'In patients who \\ndevelop HBV reactivation, stop HUMIRA and initiate effective anti-viral therapy with \\nappropriate supportive treatment.', 'The safety of resuming TNF blocker therapy after HBV \\nreactivation is controlled is not known.', 'Therefore, exercise caution when considering resumption \\nof HUMIRA therapy in this situation and monitor patients closely.', ' \\n5.5 Neurologic Reactions \\nUse of TNF blocking agents, including HUMIRA, has been associated with rare cases of new \\nonset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous \\nsystem demyelinating disease, including multiple sclerosis (MS) and optic neuritis, and \\nperipheral demyelinating disease, including Guillain-Barré syndrome.', 'Exercise caution in \\nconsidering the use of HUMIRA in patients with preexisting or recent-onset central or peripheral \\n'], 'page_sentence_count_spacy': 24}\n",
            "{'page_number': 13, 'text': 'nervous system demyelinating disorders; discontinuation of HUMIRA should be considered if \\nany of these disorders develop. There is a known association between intermediate uveitis and \\ncentral demyelinating disorders.  \\n5.6 Hematological Reactions \\nRare reports of pancytopenia including aplastic anemia have been reported with TNF blocking \\nagents. Adverse reactions of the hematologic system, including medically significant cytopenia \\n(e.g., thrombocytopenia, leukopenia) have been infrequently reported with HUMIRA. The causal \\nrelationship of these reports to HUMIRA remains unclear. Advise all patients to seek immediate \\nmedical attention if they develop signs and symptoms suggestive of blood dyscrasias or infection \\n(e.g., persistent fever, bruising, bleeding, pallor) while on HUMIRA. Consider discontinuation of \\nHUMIRA therapy in patients with confirmed significant hematologic abnormalities.  \\n5.7 Increased Risk of Infection when Used with Anakinra \\nConcurrent use of anakinra (an interleukin-1 antagonist) and another TNF-blocker, was \\nassociated with a greater proportion of serious infections and neutropenia and no added benefit \\ncompared with the TNF-blocker alone in patients with RA. Therefore, the combination of \\nHUMIRA and anakinra is not recommended [see Drug Interactions (7.2)]. \\n5.8 Heart Failure \\nCases of worsening congestive heart failure (CHF) and new onset CHF have been reported with \\nTNF blockers. Cases of worsening CHF have also been observed with HUMIRA. HUMIRA has \\nnot been formally studied in patients with CHF; however, in clinical trials of another TNF \\nblocker, a higher rate of serious CHF-related adverse reactions was observed. Exercise caution \\nwhen using HUMIRA in patients who have heart failure and monitor them carefully.  \\n5.9 Autoimmunity \\nTreatment with HUMIRA may result in the formation of autoantibodies and, rarely, in the \\ndevelopment of a lupus-like syndrome. If a patient develops symptoms suggestive of a lupus-like \\nsyndrome following treatment with HUMIRA, discontinue treatment [see Adverse Reactions \\n(6.1)].  \\n5.10 Immunizations \\nIn a placebo-controlled clinical trial of patients with RA, no difference was detected in anti-\\npneumococcal antibody response between HUMIRA and placebo treatment groups when the \\npneumococcal polysaccharide vaccine and influenza vaccine were administered concurrently \\nwith HUMIRA. Similar proportions of patients developed protective levels of anti-influenza \\nantibodies between HUMIRA and placebo treatment groups; however, titers in aggregate to \\ninfluenza antigens were moderately lower in patients receiving HUMIRA. The clinical \\nsignificance of this is unknown. Patients on HUMIRA may receive concurrent vaccinations, \\nexcept for live vaccines. No data are available on the secondary transmission of infection by live \\nvaccines in patients receiving HUMIRA.  \\n', 'processed_text': {'sentences': [{'original_sentence': 'nervous system demyelinating disorders; discontinuation of HUMIRA should be considered if \\nany of these disorders develop.', 'tokens': ['nervous', 'system', 'demyelinating', 'disorders', ';', 'discontinuation', 'HUMIRA', 'considered', 'disorders', 'develop', '.'], 'lemmatized': ['nervous', 'system', 'demyelinating', 'disorder', ';', 'discontinuation', 'HUMIRA', 'considered', 'disorder', 'develop', '.'], 'stemmed': ['nervou', 'system', 'demyelin', 'disord', ';', 'discontinu', 'humira', 'consid', 'disord', 'develop', '.'], 'dependencies': [('nervou', 'compound'), ('system', 'compound'), ('demyelin', 'compound'), ('disord', 'dep'), (';', 'punct'), ('discontinu', 'compound'), ('humira', 'compound'), ('consid', 'compound'), ('disord', 'nsubj'), ('develop', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'There is a known association between intermediate uveitis and \\ncentral demyelinating disorders.', 'tokens': ['known', 'association', 'intermediate', 'uveitis', 'central', 'demyelinating', 'disorders', '.'], 'lemmatized': ['known', 'association', 'intermediate', 'uveitis', 'central', 'demyelinating', 'disorder', '.'], 'stemmed': ['known', 'associ', 'intermedi', 'uveiti', 'central', 'demyelin', 'disord', '.'], 'dependencies': [('known', 'amod'), ('associ', 'nmod'), ('intermedi', 'compound'), ('uveiti', 'compound'), ('central', 'amod'), ('demyelin', 'compound'), ('disord', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '5.6 Hematological Reactions \\nRare reports of pancytopenia including aplastic anemia have been reported with TNF blocking \\nagents.', 'tokens': ['5.6', 'Hematological', 'Reactions', 'Rare', 'reports', 'pancytopenia', 'including', 'aplastic', 'anemia', 'reported', 'TNF', 'blocking', 'agents', '.'], 'lemmatized': ['5.6', 'Hematological', 'Reactions', 'Rare', 'report', 'pancytopenia', 'including', 'aplastic', 'anemia', 'reported', 'TNF', 'blocking', 'agent', '.'], 'stemmed': ['5.6', 'hematolog', 'reaction', 'rare', 'report', 'pancytopenia', 'includ', 'aplast', 'anemia', 'report', 'tnf', 'block', 'agent', '.'], 'dependencies': [('5.6', 'nummod'), ('hematolog', 'compound'), ('reaction', 'compound'), ('rare', 'amod'), ('report', 'ROOT'), ('pancytopenia', 'compound'), ('includ', 'compound'), ('aplast', 'compound'), ('anemia', 'compound'), ('report', 'compound'), ('tnf', 'compound'), ('block', 'compound'), ('agent', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Adverse reactions of the hematologic system, including medically significant cytopenia \\n(e.g., thrombocytopenia, leukopenia) have been infrequently reported with HUMIRA.', 'tokens': ['Adverse', 'reactions', 'hematologic', 'system', ',', 'including', 'medically', 'significant', 'cytopenia', '(', 'e.g.', ',', 'thrombocytopenia', ',', 'leukopenia', ')', 'infrequently', 'reported', 'HUMIRA', '.'], 'lemmatized': ['Adverse', 'reaction', 'hematologic', 'system', ',', 'including', 'medically', 'significant', 'cytopenia', '(', 'e.g.', ',', 'thrombocytopenia', ',', 'leukopenia', ')', 'infrequently', 'reported', 'HUMIRA', '.'], 'stemmed': ['advers', 'reaction', 'hematolog', 'system', ',', 'includ', 'medic', 'signific', 'cytopenia', '(', 'e.g.', ',', 'thrombocytopenia', ',', 'leukopenia', ')', 'infrequ', 'report', 'humira', '.'], 'dependencies': [('advers', 'compound'), ('reaction', 'compound'), ('hematolog', 'compound'), ('system', 'ROOT'), (',', 'punct'), ('includ', 'compound'), ('medic', 'compound'), ('signific', 'compound'), ('cytopenia', 'appos'), ('(', 'punct'), ('e.g.', 'advmod'), (',', 'punct'), ('thrombocytopenia', 'nmod'), (',', 'punct'), ('leukopenia', 'appos'), (')', 'punct'), ('infrequ', 'nsubj'), ('report', 'ROOT'), ('humira', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The causal \\nrelationship of these reports to HUMIRA remains unclear.', 'tokens': ['causal', 'relationship', 'reports', 'HUMIRA', 'remains', 'unclear', '.'], 'lemmatized': ['causal', 'relationship', 'report', 'HUMIRA', 'remains', 'unclear', '.'], 'stemmed': ['causal', 'relationship', 'report', 'humira', 'remain', 'unclear', '.'], 'dependencies': [('causal', 'compound'), ('relationship', 'compound'), ('report', 'compound'), ('humira', 'nsubj'), ('remain', 'ROOT'), ('unclear', 'acomp'), ('.', 'punct')]}, {'original_sentence': 'Advise all patients to seek immediate \\nmedical attention if they develop signs and symptoms suggestive of blood dyscrasias or infection \\n(e.g., persistent fever, bruising, bleeding, pallor) while on HUMIRA.', 'tokens': ['Advise', 'patients', 'seek', 'immediate', 'medical', 'attention', 'develop', 'signs', 'symptoms', 'suggestive', 'blood', 'dyscrasias', 'infection', '(', 'e.g.', ',', 'persistent', 'fever', ',', 'bruising', ',', 'bleeding', ',', 'pallor', ')', 'HUMIRA', '.'], 'lemmatized': ['Advise', 'patient', 'seek', 'immediate', 'medical', 'attention', 'develop', 'sign', 'symptom', 'suggestive', 'blood', 'dyscrasia', 'infection', '(', 'e.g.', ',', 'persistent', 'fever', ',', 'bruising', ',', 'bleeding', ',', 'pallor', ')', 'HUMIRA', '.'], 'stemmed': ['advis', 'patient', 'seek', 'immedi', 'medic', 'attent', 'develop', 'sign', 'symptom', 'suggest', 'blood', 'dyscrasia', 'infect', '(', 'e.g.', ',', 'persist', 'fever', ',', 'bruis', ',', 'bleed', ',', 'pallor', ')', 'humira', '.'], 'dependencies': [('advis', 'nmod'), ('patient', 'nsubj'), ('seek', 'nsubj'), ('immedi', 'compound'), ('medic', 'compound'), ('attent', 'nsubj'), ('develop', 'ccomp'), ('sign', 'compound'), ('symptom', 'dobj'), ('suggest', 'ROOT'), ('blood', 'compound'), ('dyscrasia', 'nsubj'), ('infect', 'ccomp'), ('(', 'punct'), ('e.g.', 'advmod'), (',', 'punct'), ('persist', 'amod'), ('fever', 'dobj'), (',', 'punct'), ('bruis', 'nmod'), (',', 'punct'), ('bleed', 'nmod'), (',', 'punct'), ('pallor', 'nmod'), (')', 'punct'), ('humira', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Consider discontinuation of \\nHUMIRA therapy in patients with confirmed significant hematologic abnormalities.', 'tokens': ['Consider', 'discontinuation', 'HUMIRA', 'therapy', 'patients', 'confirmed', 'significant', 'hematologic', 'abnormalities', '.'], 'lemmatized': ['Consider', 'discontinuation', 'HUMIRA', 'therapy', 'patient', 'confirmed', 'significant', 'hematologic', 'abnormality', '.'], 'stemmed': ['consid', 'discontinu', 'humira', 'therapi', 'patient', 'confirm', 'signific', 'hematolog', 'abnorm', '.'], 'dependencies': [('consid', 'advmod'), ('discontinu', 'compound'), ('humira', 'nmod'), ('therapi', 'compound'), ('patient', 'nsubj'), ('confirm', 'ROOT'), ('signific', 'amod'), ('hematolog', 'compound'), ('abnorm', 'dobj'), ('.', 'punct')]}, {'original_sentence': '5.7 Increased Risk of Infection when Used with Anakinra \\nConcurrent use of anakinra (an interleukin-1 antagonist) and another TNF-blocker, was \\nassociated with a greater proportion of serious infections and neutropenia and no added benefit \\ncompared with the TNF-blocker alone in patients with RA.', 'tokens': ['5.7', 'Increased', 'Risk', 'Infection', 'Used', 'Anakinra', 'Concurrent', 'use', 'anakinra', '(', 'interleukin-1', 'antagonist', ')', 'another', 'TNF-blocker', ',', 'associated', 'greater', 'proportion', 'serious', 'infections', 'neutropenia', 'added', 'benefit', 'compared', 'TNF-blocker', 'alone', 'patients', 'RA', '.'], 'lemmatized': ['5.7', 'Increased', 'Risk', 'Infection', 'Used', 'Anakinra', 'Concurrent', 'use', 'anakinra', '(', 'interleukin-1', 'antagonist', ')', 'another', 'TNF-blocker', ',', 'associated', 'greater', 'proportion', 'serious', 'infection', 'neutropenia', 'added', 'benefit', 'compared', 'TNF-blocker', 'alone', 'patient', 'RA', '.'], 'stemmed': ['5.7', 'increas', 'risk', 'infect', 'use', 'anakinra', 'concurr', 'use', 'anakinra', '(', 'interleukin-1', 'antagonist', ')', 'anoth', 'tnf-blocker', ',', 'associ', 'greater', 'proport', 'seriou', 'infect', 'neutropenia', 'ad', 'benefit', 'compar', 'tnf-blocker', 'alon', 'patient', 'ra', '.'], 'dependencies': [('5.7', 'nummod'), ('increas', 'compound'), ('risk', 'compound'), ('infect', 'compound'), ('use', 'compound'), ('anakinra', 'amod'), ('concurr', 'compound'), ('use', 'npadvmod'), ('anakinra', 'ROOT'), ('(', 'punct'), ('interleukin-1', 'compound'), ('antagonist', 'parataxis'), (')', 'punct'), ('anoth', 'npadvmod'), ('tnf', 'npadvmod'), ('-', 'npadvmod'), ('blocker', 'npadvmod'), (',', 'punct'), ('associ', 'nsubj'), ('greater', 'amod'), ('proport', 'compound'), ('seriou', 'nsubj'), ('infect', 'ccomp'), ('neutropenia', 'compound'), ('ad', 'compound'), ('benefit', 'compound'), ('compar', 'compound'), ('tnf', 'compound'), ('-', 'punct'), ('blocker', 'compound'), ('alon', 'compound'), ('patient', 'compound'), ('ra', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Therefore, the combination of \\nHUMIRA and anakinra is not recommended [see Drug Interactions (7.2)].', 'tokens': ['Therefore', ',', 'combination', 'HUMIRA', 'anakinra', 'recommended', '[', 'see', 'Drug', 'Interactions', '(', '7.2', ')', ']', '.'], 'lemmatized': ['Therefore', ',', 'combination', 'HUMIRA', 'anakinra', 'recommended', '[', 'see', 'Drug', 'Interactions', '(', '7.2', ')', ']', '.'], 'stemmed': ['therefor', ',', 'combin', 'humira', 'anakinra', 'recommend', '[', 'see', 'drug', 'interact', '(', '7.2', ')', ']', '.'], 'dependencies': [('therefor', 'nsubj'), (',', 'punct'), ('combin', 'compound'), ('humira', 'compound'), ('anakinra', 'compound'), ('recommend', 'pobj'), ('[', 'punct'), ('see', 'ROOT'), ('drug', 'compound'), ('interact', 'dobj'), ('(', 'punct'), ('7.2', 'appos'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': '5.8 Heart Failure \\nCases of worsening congestive heart failure (CHF) and new onset CHF have been reported with \\nTNF blockers.', 'tokens': ['5.8', 'Heart', 'Failure', 'Cases', 'worsening', 'congestive', 'heart', 'failure', '(', 'CHF', ')', 'new', 'onset', 'CHF', 'reported', 'TNF', 'blockers', '.'], 'lemmatized': ['5.8', 'Heart', 'Failure', 'Cases', 'worsening', 'congestive', 'heart', 'failure', '(', 'CHF', ')', 'new', 'onset', 'CHF', 'reported', 'TNF', 'blocker', '.'], 'stemmed': ['5.8', 'heart', 'failur', 'case', 'worsen', 'congest', 'heart', 'failur', '(', 'chf', ')', 'new', 'onset', 'chf', 'report', 'tnf', 'blocker', '.'], 'dependencies': [('5.8', 'nummod'), ('heart', 'compound'), ('failur', 'compound'), ('case', 'nsubj'), ('worsen', 'ROOT'), ('congest', 'compound'), ('heart', 'compound'), ('failur', 'dobj'), ('(', 'punct'), ('chf', 'appos'), (')', 'punct'), ('new', 'amod'), ('onset', 'compound'), ('chf', 'compound'), ('report', 'appos'), ('tnf', 'compound'), ('blocker', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Cases of worsening CHF have also been observed with HUMIRA.', 'tokens': ['Cases', 'worsening', 'CHF', 'also', 'observed', 'HUMIRA', '.'], 'lemmatized': ['Cases', 'worsening', 'CHF', 'also', 'observed', 'HUMIRA', '.'], 'stemmed': ['case', 'worsen', 'chf', 'also', 'observ', 'humira', '.'], 'dependencies': [('case', 'compound'), ('worsen', 'compound'), ('chf', 'nsubj'), ('also', 'advmod'), ('observ', 'ROOT'), ('humira', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'HUMIRA has \\nnot been formally studied in patients with CHF; however, in clinical trials of another TNF \\nblocker, a higher rate of serious CHF-related adverse reactions was observed.', 'tokens': ['HUMIRA', 'formally', 'studied', 'patients', 'CHF', ';', 'however', ',', 'clinical', 'trials', 'another', 'TNF', 'blocker', ',', 'higher', 'rate', 'serious', 'CHF-related', 'adverse', 'reactions', 'observed', '.'], 'lemmatized': ['HUMIRA', 'formally', 'studied', 'patient', 'CHF', ';', 'however', ',', 'clinical', 'trial', 'another', 'TNF', 'blocker', ',', 'higher', 'rate', 'serious', 'CHF-related', 'adverse', 'reaction', 'observed', '.'], 'stemmed': ['humira', 'formal', 'studi', 'patient', 'chf', ';', 'howev', ',', 'clinic', 'trial', 'anoth', 'tnf', 'blocker', ',', 'higher', 'rate', 'seriou', 'chf-relat', 'advers', 'reaction', 'observ', '.'], 'dependencies': [('humira', 'npadvmod'), ('formal', 'amod'), ('studi', 'compound'), ('patient', 'compound'), ('chf', 'ROOT'), (';', 'punct'), ('howev', 'nmod'), (',', 'punct'), ('clinic', 'compound'), ('trial', 'conj'), ('anoth', 'compound'), ('tnf', 'compound'), ('blocker', 'conj'), (',', 'punct'), ('higher', 'amod'), ('rate', 'compound'), ('seriou', 'compound'), ('chf', 'amod'), ('-', 'punct'), ('relat', 'compound'), ('advers', 'compound'), ('reaction', 'compound'), ('observ', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Exercise caution \\nwhen using HUMIRA in patients who have heart failure and monitor them carefully.', 'tokens': ['Exercise', 'caution', 'using', 'HUMIRA', 'patients', 'heart', 'failure', 'monitor', 'carefully', '.'], 'lemmatized': ['Exercise', 'caution', 'using', 'HUMIRA', 'patient', 'heart', 'failure', 'monitor', 'carefully', '.'], 'stemmed': ['exercis', 'caution', 'use', 'humira', 'patient', 'heart', 'failur', 'monitor', 'care', '.'], 'dependencies': [('exercis', 'compound'), ('caution', 'nsubj'), ('use', 'ROOT'), ('humira', 'compound'), ('patient', 'compound'), ('heart', 'compound'), ('failur', 'compound'), ('monitor', 'compound'), ('care', 'dobj'), ('.', 'punct')]}, {'original_sentence': '5.9 Autoimmunity \\nTreatment with HUMIRA may result in the formation of autoantibodies and, rarely, in the \\ndevelopment of a lupus-like syndrome.', 'tokens': ['5.9', 'Autoimmunity', 'Treatment', 'HUMIRA', 'may', 'result', 'formation', 'autoantibodies', ',', 'rarely', ',', 'development', 'lupus-like', 'syndrome', '.'], 'lemmatized': ['5.9', 'Autoimmunity', 'Treatment', 'HUMIRA', 'may', 'result', 'formation', 'autoantibody', ',', 'rarely', ',', 'development', 'lupus-like', 'syndrome', '.'], 'stemmed': ['5.9', 'autoimmun', 'treatment', 'humira', 'may', 'result', 'format', 'autoantibodi', ',', 'rare', ',', 'develop', 'lupus-lik', 'syndrom', '.'], 'dependencies': [('5.9', 'nummod'), ('autoimmun', 'amod'), ('treatment', 'compound'), ('humira', 'nsubj'), ('may', 'aux'), ('result', 'ROOT'), ('format', 'compound'), ('autoantibodi', 'nsubj'), (',', 'punct'), ('rare', 'amod'), (',', 'punct'), ('develop', 'ccomp'), ('lupus', 'compound'), ('-', 'punct'), ('lik', 'compound'), ('syndrom', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'If a patient develops symptoms suggestive of a lupus-like \\nsyndrome following treatment with HUMIRA, discontinue treatment [see Adverse Reactions \\n(6.1)].', 'tokens': ['patient', 'develops', 'symptoms', 'suggestive', 'lupus-like', 'syndrome', 'following', 'treatment', 'HUMIRA', ',', 'discontinue', 'treatment', '[', 'see', 'Adverse', 'Reactions', '(', '6.1', ')', ']', '.'], 'lemmatized': ['patient', 'develops', 'symptom', 'suggestive', 'lupus-like', 'syndrome', 'following', 'treatment', 'HUMIRA', ',', 'discontinue', 'treatment', '[', 'see', 'Adverse', 'Reactions', '(', '6.1', ')', ']', '.'], 'stemmed': ['patient', 'develop', 'symptom', 'suggest', 'lupus-lik', 'syndrom', 'follow', 'treatment', 'humira', ',', 'discontinu', 'treatment', '[', 'see', 'advers', 'reaction', '(', '6.1', ')', ']', '.'], 'dependencies': [('patient', 'nsubj'), ('develop', 'nsubj'), ('symptom', 'dobj'), ('suggest', 'ROOT'), ('lupus', 'compound'), ('-', 'punct'), ('lik', 'compound'), ('syndrom', 'compound'), ('follow', 'compound'), ('treatment', 'compound'), ('humira', 'nsubj'), (',', 'punct'), ('discontinu', 'compound'), ('treatment', 'conj'), ('[', 'punct'), ('see', 'parataxis'), ('advers', 'compound'), ('reaction', 'dobj'), ('(', 'punct'), ('6.1', 'appos'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': '5.10 Immunizations \\nIn a placebo-controlled clinical trial of patients with RA, no difference was detected in anti-\\npneumococcal antibody response between HUMIRA and placebo treatment groups when the \\npneumococcal polysaccharide vaccine and influenza vaccine were administered concurrently \\nwith HUMIRA.', 'tokens': ['5.10', 'Immunizations', 'placebo-controlled', 'clinical', 'trial', 'patients', 'RA', ',', 'difference', 'detected', 'anti-', 'pneumococcal', 'antibody', 'response', 'HUMIRA', 'placebo', 'treatment', 'groups', 'pneumococcal', 'polysaccharide', 'vaccine', 'influenza', 'vaccine', 'administered', 'concurrently', 'HUMIRA', '.'], 'lemmatized': ['5.10', 'Immunizations', 'placebo-controlled', 'clinical', 'trial', 'patient', 'RA', ',', 'difference', 'detected', 'anti-', 'pneumococcal', 'antibody', 'response', 'HUMIRA', 'placebo', 'treatment', 'group', 'pneumococcal', 'polysaccharide', 'vaccine', 'influenza', 'vaccine', 'administered', 'concurrently', 'HUMIRA', '.'], 'stemmed': ['5.10', 'immun', 'placebo-control', 'clinic', 'trial', 'patient', 'ra', ',', 'differ', 'detect', 'anti-', 'pneumococc', 'antibodi', 'respons', 'humira', 'placebo', 'treatment', 'group', 'pneumococc', 'polysaccharid', 'vaccin', 'influenza', 'vaccin', 'administ', 'concurr', 'humira', '.'], 'dependencies': [('5.10', 'nummod'), ('immun', 'compound'), ('placebo', 'compound'), ('-', 'punct'), ('control', 'compound'), ('clinic', 'compound'), ('trial', 'compound'), ('patient', 'nsubj'), ('ra', 'appos'), (',', 'punct'), ('differ', 'ROOT'), ('detect', 'xcomp'), ('anti-', 'compound'), ('pneumococc', 'dobj'), ('antibodi', 'nsubj'), ('respons', 'relcl'), ('humira', 'compound'), ('placebo', 'compound'), ('treatment', 'compound'), ('group', 'compound'), ('pneumococc', 'nsubj'), ('polysaccharid', 'compound'), ('vaccin', 'compound'), ('influenza', 'nsubj'), ('vaccin', 'advcl'), ('administ', 'compound'), ('concurr', 'compound'), ('humira', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Similar proportions of patients developed protective levels of anti-influenza \\nantibodies between HUMIRA and placebo treatment groups; however, titers in aggregate to \\ninfluenza antigens were moderately lower in patients receiving HUMIRA.', 'tokens': ['Similar', 'proportions', 'patients', 'developed', 'protective', 'levels', 'anti-influenza', 'antibodies', 'HUMIRA', 'placebo', 'treatment', 'groups', ';', 'however', ',', 'titers', 'aggregate', 'influenza', 'antigens', 'moderately', 'lower', 'patients', 'receiving', 'HUMIRA', '.'], 'lemmatized': ['Similar', 'proportion', 'patient', 'developed', 'protective', 'level', 'anti-influenza', 'antibody', 'HUMIRA', 'placebo', 'treatment', 'group', ';', 'however', ',', 'titer', 'aggregate', 'influenza', 'antigen', 'moderately', 'lower', 'patient', 'receiving', 'HUMIRA', '.'], 'stemmed': ['similar', 'proport', 'patient', 'develop', 'protect', 'level', 'anti-influenza', 'antibodi', 'humira', 'placebo', 'treatment', 'group', ';', 'howev', ',', 'titer', 'aggreg', 'influenza', 'antigen', 'moder', 'lower', 'patient', 'receiv', 'humira', '.'], 'dependencies': [('similar', 'amod'), ('proport', 'compound'), ('patient', 'nsubj'), ('develop', 'ROOT'), ('protect', 'amod'), ('level', 'nmod'), ('anti', 'amod'), ('-', 'amod'), ('influenza', 'amod'), ('antibodi', 'compound'), ('humira', 'compound'), ('placebo', 'compound'), ('treatment', 'compound'), ('group', 'dobj'), (';', 'punct'), ('howev', 'conj'), (',', 'punct'), ('titer', 'compound'), ('aggreg', 'compound'), ('influenza', 'compound'), ('antigen', 'compound'), ('moder', 'conj'), ('lower', 'amod'), ('patient', 'compound'), ('receiv', 'compound'), ('humira', 'appos'), ('.', 'punct')]}, {'original_sentence': 'The clinical \\nsignificance of this is unknown.', 'tokens': ['clinical', 'significance', 'unknown', '.'], 'lemmatized': ['clinical', 'significance', 'unknown', '.'], 'stemmed': ['clinic', 'signific', 'unknown', '.'], 'dependencies': [('clinic', 'compound'), ('signific', 'ROOT'), ('unknown', 'amod'), ('.', 'punct')]}, {'original_sentence': 'Patients on HUMIRA may receive concurrent vaccinations, \\nexcept for live vaccines.', 'tokens': ['Patients', 'HUMIRA', 'may', 'receive', 'concurrent', 'vaccinations', ',', 'except', 'live', 'vaccines', '.'], 'lemmatized': ['Patients', 'HUMIRA', 'may', 'receive', 'concurrent', 'vaccination', ',', 'except', 'live', 'vaccine', '.'], 'stemmed': ['patient', 'humira', 'may', 'receiv', 'concurr', 'vaccin', ',', 'except', 'live', 'vaccin', '.'], 'dependencies': [('patient', 'compound'), ('humira', 'nsubj'), ('may', 'aux'), ('receiv', 'ROOT'), ('concurr', 'dobj'), ('vaccin', 'dobj'), (',', 'punct'), ('except', 'prep'), ('live', 'amod'), ('vaccin', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'No data are available on the secondary transmission of infection by live \\nvaccines in patients receiving HUMIRA.', 'tokens': ['data', 'available', 'secondary', 'transmission', 'infection', 'live', 'vaccines', 'patients', 'receiving', 'HUMIRA', '.'], 'lemmatized': ['data', 'available', 'secondary', 'transmission', 'infection', 'live', 'vaccine', 'patient', 'receiving', 'HUMIRA', '.'], 'stemmed': ['data', 'avail', 'secondari', 'transmiss', 'infect', 'live', 'vaccin', 'patient', 'receiv', 'humira', '.'], 'dependencies': [('data', 'compound'), ('avail', 'compound'), ('secondari', 'compound'), ('transmiss', 'nsubj'), ('infect', 'ROOT'), ('live', 'advmod'), ('vaccin', 'dep'), ('patient', 'compound'), ('receiv', 'compound'), ('humira', 'dobj'), ('.', 'punct')]}], 'text': 'nervous system demyelinating disorders; discontinuation of HUMIRA should be considered if \\nany of these disorders develop. There is a known association between intermediate uveitis and \\ncentral demyelinating disorders.  \\n5.6 Hematological Reactions \\nRare reports of pancytopenia including aplastic anemia have been reported with TNF blocking \\nagents. Adverse reactions of the hematologic system, including medically significant cytopenia \\n(e.g., thrombocytopenia, leukopenia) have been infrequently reported with HUMIRA. The causal \\nrelationship of these reports to HUMIRA remains unclear. Advise all patients to seek immediate \\nmedical attention if they develop signs and symptoms suggestive of blood dyscrasias or infection \\n(e.g., persistent fever, bruising, bleeding, pallor) while on HUMIRA. Consider discontinuation of \\nHUMIRA therapy in patients with confirmed significant hematologic abnormalities.  \\n5.7 Increased Risk of Infection when Used with Anakinra \\nConcurrent use of anakinra (an interleukin-1 antagonist) and another TNF-blocker, was \\nassociated with a greater proportion of serious infections and neutropenia and no added benefit \\ncompared with the TNF-blocker alone in patients with RA. Therefore, the combination of \\nHUMIRA and anakinra is not recommended [see Drug Interactions (7.2)]. \\n5.8 Heart Failure \\nCases of worsening congestive heart failure (CHF) and new onset CHF have been reported with \\nTNF blockers. Cases of worsening CHF have also been observed with HUMIRA. HUMIRA has \\nnot been formally studied in patients with CHF; however, in clinical trials of another TNF \\nblocker, a higher rate of serious CHF-related adverse reactions was observed. Exercise caution \\nwhen using HUMIRA in patients who have heart failure and monitor them carefully.  \\n5.9 Autoimmunity \\nTreatment with HUMIRA may result in the formation of autoantibodies and, rarely, in the \\ndevelopment of a lupus-like syndrome. If a patient develops symptoms suggestive of a lupus-like \\nsyndrome following treatment with HUMIRA, discontinue treatment [see Adverse Reactions \\n(6.1)].  \\n5.10 Immunizations \\nIn a placebo-controlled clinical trial of patients with RA, no difference was detected in anti-\\npneumococcal antibody response between HUMIRA and placebo treatment groups when the \\npneumococcal polysaccharide vaccine and influenza vaccine were administered concurrently \\nwith HUMIRA. Similar proportions of patients developed protective levels of anti-influenza \\nantibodies between HUMIRA and placebo treatment groups; however, titers in aggregate to \\ninfluenza antigens were moderately lower in patients receiving HUMIRA. The clinical \\nsignificance of this is unknown. Patients on HUMIRA may receive concurrent vaccinations, \\nexcept for live vaccines. No data are available on the secondary transmission of infection by live \\nvaccines in patients receiving HUMIRA.  \\n'}, 'page_char_count': 2868, 'page_word_count': 390, 'sentences': ['nervous system demyelinating disorders; discontinuation of HUMIRA should be considered if \\nany of these disorders develop.', 'There is a known association between intermediate uveitis and \\ncentral demyelinating disorders.', ' \\n5.6 Hematological Reactions \\nRare reports of pancytopenia including aplastic anemia have been reported with TNF blocking \\nagents.', 'Adverse reactions of the hematologic system, including medically significant cytopenia \\n(e.g., thrombocytopenia, leukopenia) have been infrequently reported with HUMIRA.', 'The causal \\nrelationship of these reports to HUMIRA remains unclear.', 'Advise all patients to seek immediate \\nmedical attention if they develop signs and symptoms suggestive of blood dyscrasias or infection \\n(e.g., persistent fever, bruising, bleeding, pallor) while on HUMIRA.', 'Consider discontinuation of \\nHUMIRA therapy in patients with confirmed significant hematologic abnormalities.', ' \\n5.7 Increased Risk of Infection when Used with Anakinra \\nConcurrent use of anakinra (an interleukin-1 antagonist) and another TNF-blocker, was \\nassociated with a greater proportion of serious infections and neutropenia and no added benefit \\ncompared with the TNF-blocker alone in patients with RA.', 'Therefore, the combination of \\nHUMIRA and anakinra is not recommended [see Drug Interactions (7.2)].', '\\n5.8 Heart Failure \\nCases of worsening congestive heart failure (CHF) and new onset CHF have been reported with \\nTNF blockers.', 'Cases of worsening CHF have also been observed with HUMIRA.', 'HUMIRA has \\nnot been formally studied in patients with CHF; however, in clinical trials of another TNF \\nblocker, a higher rate of serious CHF-related adverse reactions was observed.', 'Exercise caution \\nwhen using HUMIRA in patients who have heart failure and monitor them carefully.', ' \\n5.9 Autoimmunity \\nTreatment with HUMIRA may result in the formation of autoantibodies and, rarely, in the \\ndevelopment of a lupus-like syndrome.', 'If a patient develops symptoms suggestive of a lupus-like \\nsyndrome following treatment with HUMIRA, discontinue treatment [see Adverse Reactions \\n(6.1)].', ' \\n5.10 Immunizations \\nIn a placebo-controlled clinical trial of patients with RA, no difference was detected in anti-\\npneumococcal antibody response between HUMIRA and placebo treatment groups when the \\npneumococcal polysaccharide vaccine and influenza vaccine were administered concurrently \\nwith HUMIRA.', 'Similar proportions of patients developed protective levels of anti-influenza \\nantibodies between HUMIRA and placebo treatment groups; however, titers in aggregate to \\ninfluenza antigens were moderately lower in patients receiving HUMIRA.', 'The clinical \\nsignificance of this is unknown.', 'Patients on HUMIRA may receive concurrent vaccinations, \\nexcept for live vaccines.', 'No data are available on the secondary transmission of infection by live \\nvaccines in patients receiving HUMIRA.', ' \\n'], 'page_sentence_count_spacy': 21}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            " 23%|██▎       | 26/111 [00:00<00:01, 59.13it/s]"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "{'page_number': 14, 'text': 'It is recommended that pediatric patients, if possible, be brought up to date with all \\nimmunizations in agreement with current immunization guidelines prior to initiating HUMIRA \\ntherapy. Patients on HUMIRA may receive concurrent vaccinations, except for live vaccines.  \\nThe safety of administering live or live-attenuated vaccines in infants exposed to HUMIRA in \\nutero is unknown. Risks and benefits should be considered prior to vaccinating (live or live-\\nattenuated) exposed infants [see Use in Specific Populations (8.1, 8.4)].  \\n5.11 Increased Risk of Infection When Used with Abatacept \\nIn controlled trials, the concurrent administration of TNF-blockers and abatacept was associated \\nwith a greater proportion of serious infections than the use of a TNF-blocker alone; the \\ncombination therapy, compared to the use of a TNF-blocker alone, has not demonstrated \\nimproved clinical benefit in the treatment of RA. Therefore, the combination of abatacept with \\nTNF-blockers including HUMIRA is not recommended [see Drug Interactions (7.2)].  \\n6 ADVERSE REACTIONS \\nThe following clinically significant adverse reactions are described elsewhere in the labeling:  \\n• Serious Infections [see Warnings and Precautions (5.1)] \\n• Malignancies [see Warnings and Precautions (5.2)] \\n• Hypersensitivity Reactions [see Warnings and Precautions (5.3)] \\n• Hepatitis B Virus Reactivation [see Warnings and Precautions (5.4)] \\n• Neurologic Reactions [see Warnings and Precautions (5.5)] \\n• Hematological Reactions [see Warnings and Precautions (5.6)] \\n• Heart Failure [see Warnings and Precautions (5.8)] \\n• Autoimmunity [see Warnings and Precautions (5.9)] \\n  \\n6.1 Clinical Trials Experience \\nBecause clinical trials are conducted under widely varying conditions, adverse reaction rates \\nobserved in the clinical trials of a drug cannot be directly compared to rates in the clinical trials \\nof another drug and may not reflect the rates observed in practice.  \\nThe most common adverse reaction with HUMIRA was injection site reactions. In placebo-\\ncontrolled trials, 20% of patients treated with HUMIRA developed injection site reactions \\n(erythema and/or itching, hemorrhage, pain or swelling), compared to 14% of patients receiving \\nplacebo. Most injection site reactions were described as mild and generally did not necessitate \\ndrug discontinuation.  \\nThe proportion of patients who discontinued treatment due to adverse reactions during the \\ndouble-blind, placebo-controlled portion of studies in patients with RA (i.e., Studies RA-I, RA-\\nII, RA-III and RA-IV) was 7% for patients taking HUMIRA and 4% for placebo-treated patients. \\nThe most common adverse reactions leading to discontinuation of HUMIRA in these RA studies \\nwere clinical flare reaction (0.7%), rash (0.3%) and pneumonia (0.3%).  \\nInfections \\n', 'processed_text': {'sentences': [{'original_sentence': 'It is recommended that pediatric patients, if possible, be brought up to date with all \\nimmunizations in agreement with current immunization guidelines prior to initiating HUMIRA \\ntherapy.', 'tokens': ['recommended', 'pediatric', 'patients', ',', 'possible', ',', 'brought', 'date', 'immunizations', 'agreement', 'current', 'immunization', 'guidelines', 'prior', 'initiating', 'HUMIRA', 'therapy', '.'], 'lemmatized': ['recommended', 'pediatric', 'patient', ',', 'possible', ',', 'brought', 'date', 'immunization', 'agreement', 'current', 'immunization', 'guideline', 'prior', 'initiating', 'HUMIRA', 'therapy', '.'], 'stemmed': ['recommend', 'pediatr', 'patient', ',', 'possibl', ',', 'brought', 'date', 'immun', 'agreement', 'current', 'immun', 'guidelin', 'prior', 'initi', 'humira', 'therapi', '.'], 'dependencies': [('recommend', 'ROOT'), ('pediatr', 'amod'), ('patient', 'dobj'), (',', 'punct'), ('possibl', 'intj'), (',', 'punct'), ('brought', 'conj'), ('date', 'compound'), ('immun', 'compound'), ('agreement', 'dative'), ('current', 'nmod'), ('immun', 'compound'), ('guidelin', 'appos'), ('prior', 'amod'), ('initi', 'compound'), ('humira', 'compound'), ('therapi', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Patients on HUMIRA may receive concurrent vaccinations, except for live vaccines.', 'tokens': ['Patients', 'HUMIRA', 'may', 'receive', 'concurrent', 'vaccinations', ',', 'except', 'live', 'vaccines', '.'], 'lemmatized': ['Patients', 'HUMIRA', 'may', 'receive', 'concurrent', 'vaccination', ',', 'except', 'live', 'vaccine', '.'], 'stemmed': ['patient', 'humira', 'may', 'receiv', 'concurr', 'vaccin', ',', 'except', 'live', 'vaccin', '.'], 'dependencies': [('patient', 'compound'), ('humira', 'nsubj'), ('may', 'aux'), ('receiv', 'ROOT'), ('concurr', 'dobj'), ('vaccin', 'dobj'), (',', 'punct'), ('except', 'prep'), ('live', 'amod'), ('vaccin', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'The safety of administering live or live-attenuated vaccines in infants exposed to HUMIRA in \\nutero is unknown.', 'tokens': ['safety', 'administering', 'live', 'live-attenuated', 'vaccines', 'infants', 'exposed', 'HUMIRA', 'utero', 'unknown', '.'], 'lemmatized': ['safety', 'administering', 'live', 'live-attenuated', 'vaccine', 'infant', 'exposed', 'HUMIRA', 'utero', 'unknown', '.'], 'stemmed': ['safeti', 'administ', 'live', 'live-attenu', 'vaccin', 'infant', 'expos', 'humira', 'utero', 'unknown', '.'], 'dependencies': [('safeti', 'compound'), ('administ', 'nsubj'), ('live', 'amod'), ('live', 'amod'), ('-', 'punct'), ('attenu', 'nsubj'), ('vaccin', 'compound'), ('infant', 'compound'), ('expos', 'compound'), ('humira', 'compound'), ('utero', 'compound'), ('unknown', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Risks and benefits should be considered prior to vaccinating (live or live-\\nattenuated) exposed infants [see Use in Specific Populations (8.1, 8.4)].', 'tokens': ['Risks', 'benefits', 'considered', 'prior', 'vaccinating', '(', 'live', 'live-', 'attenuated', ')', 'exposed', 'infants', '[', 'see', 'Use', 'Specific', 'Populations', '(', '8.1', ',', '8.4', ')', ']', '.'], 'lemmatized': ['Risks', 'benefit', 'considered', 'prior', 'vaccinating', '(', 'live', 'live-', 'attenuated', ')', 'exposed', 'infant', '[', 'see', 'Use', 'Specific', 'Populations', '(', '8.1', ',', '8.4', ')', ']', '.'], 'stemmed': ['risk', 'benefit', 'consid', 'prior', 'vaccin', '(', 'live', 'live-', 'attenu', ')', 'expos', 'infant', '[', 'see', 'use', 'specif', 'popul', '(', '8.1', ',', '8.4', ')', ']', '.'], 'dependencies': [('risk', 'compound'), ('benefit', 'ROOT'), ('consid', 'advmod'), ('prior', 'advmod'), ('vaccin', 'appos'), ('(', 'punct'), ('live', 'amod'), ('live-', 'dep'), ('attenu', 'dep'), (')', 'punct'), ('expos', 'compound'), ('infant', 'dobj'), ('[', 'punct'), ('see', 'parataxis'), ('use', 'compound'), ('specif', 'compound'), ('popul', 'dobj'), ('(', 'punct'), ('8.1', 'appos'), (',', 'punct'), ('8.4', 'npadvmod'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': '5.11 Increased Risk of Infection When Used with Abatacept \\nIn controlled trials, the concurrent administration of TNF-blockers and abatacept was associated \\nwith a greater proportion of serious infections than the use of a TNF-blocker alone; the \\ncombination therapy, compared to the use of a TNF-blocker alone, has not demonstrated \\nimproved clinical benefit in the treatment of RA.', 'tokens': ['5.11', 'Increased', 'Risk', 'Infection', 'Used', 'Abatacept', 'controlled', 'trials', ',', 'concurrent', 'administration', 'TNF-blockers', 'abatacept', 'associated', 'greater', 'proportion', 'serious', 'infections', 'use', 'TNF-blocker', 'alone', ';', 'combination', 'therapy', ',', 'compared', 'use', 'TNF-blocker', 'alone', ',', 'demonstrated', 'improved', 'clinical', 'benefit', 'treatment', 'RA', '.'], 'lemmatized': ['5.11', 'Increased', 'Risk', 'Infection', 'Used', 'Abatacept', 'controlled', 'trial', ',', 'concurrent', 'administration', 'TNF-blockers', 'abatacept', 'associated', 'greater', 'proportion', 'serious', 'infection', 'use', 'TNF-blocker', 'alone', ';', 'combination', 'therapy', ',', 'compared', 'use', 'TNF-blocker', 'alone', ',', 'demonstrated', 'improved', 'clinical', 'benefit', 'treatment', 'RA', '.'], 'stemmed': ['5.11', 'increas', 'risk', 'infect', 'use', 'abatacept', 'control', 'trial', ',', 'concurr', 'administr', 'tnf-blocker', 'abatacept', 'associ', 'greater', 'proport', 'seriou', 'infect', 'use', 'tnf-blocker', 'alon', ';', 'combin', 'therapi', ',', 'compar', 'use', 'tnf-blocker', 'alon', ',', 'demonstr', 'improv', 'clinic', 'benefit', 'treatment', 'ra', '.'], 'dependencies': [('5.11', 'nummod'), ('increas', 'compound'), ('risk', 'compound'), ('infect', 'compound'), ('use', 'compound'), ('abatacept', 'compound'), ('control', 'compound'), ('trial', 'nsubj'), (',', 'punct'), ('concurr', 'ccomp'), ('administr', 'compound'), ('tnf', 'compound'), ('-', 'punct'), ('blocker', 'compound'), ('abatacept', 'compound'), ('associ', 'dobj'), ('greater', 'amod'), ('proport', 'compound'), ('seriou', 'appos'), ('infect', 'ccomp'), ('use', 'compound'), ('tnf', 'compound'), ('-', 'punct'), ('blocker', 'compound'), ('alon', 'dobj'), (';', 'punct'), ('combin', 'compound'), ('therapi', 'dep'), (',', 'punct'), ('compar', 'compound'), ('use', 'compound'), ('tnf', 'compound'), ('-', 'punct'), ('blocker', 'compound'), ('alon', 'ROOT'), (',', 'punct'), ('demonstr', 'compound'), ('improv', 'compound'), ('clinic', 'compound'), ('benefit', 'compound'), ('treatment', 'compound'), ('ra', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Therefore, the combination of abatacept with \\nTNF-blockers including HUMIRA is not recommended [see Drug Interactions (7.2)].', 'tokens': ['Therefore', ',', 'combination', 'abatacept', 'TNF-blockers', 'including', 'HUMIRA', 'recommended', '[', 'see', 'Drug', 'Interactions', '(', '7.2', ')', ']', '.'], 'lemmatized': ['Therefore', ',', 'combination', 'abatacept', 'TNF-blockers', 'including', 'HUMIRA', 'recommended', '[', 'see', 'Drug', 'Interactions', '(', '7.2', ')', ']', '.'], 'stemmed': ['therefor', ',', 'combin', 'abatacept', 'tnf-blocker', 'includ', 'humira', 'recommend', '[', 'see', 'drug', 'interact', '(', '7.2', ')', ']', '.'], 'dependencies': [('therefor', 'intj'), (',', 'punct'), ('combin', 'compound'), ('abatacept', 'compound'), ('tnf', 'compound'), ('-', 'punct'), ('blocker', 'compound'), ('includ', 'compound'), ('humira', 'compound'), ('recommend', 'ROOT'), ('[', 'punct'), ('see', 'parataxis'), ('drug', 'compound'), ('interact', 'dobj'), ('(', 'punct'), ('7.2', 'appos'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': '6 ADVERSE REACTIONS \\nThe following clinically significant adverse reactions are described elsewhere in the labeling:  \\n• Serious Infections [see Warnings and Precautions (5.1)] \\n• Malignancies [see Warnings and Precautions (5.2)] \\n• Hypersensitivity Reactions [see Warnings and Precautions (5.3)] \\n• Hepatitis B Virus Reactivation [see Warnings and Precautions (5.4)] \\n• Neurologic Reactions [see Warnings and Precautions (5.5)] \\n• Hematological Reactions [see Warnings and Precautions (5.6)] \\n• Heart Failure [see Warnings and Precautions (5.8)] \\n• Autoimmunity [see Warnings and Precautions (5.9)] \\n  \\n6.1 Clinical Trials Experience \\nBecause clinical trials are conducted under widely varying conditions, adverse reaction rates \\nobserved in the clinical trials of a drug cannot be directly compared to rates in the clinical trials \\nof another drug and may not reflect the rates observed in practice.', 'tokens': ['6', 'ADVERSE', 'REACTIONS', 'following', 'clinically', 'significant', 'adverse', 'reactions', 'described', 'elsewhere', 'labeling', ':', '•', 'Serious', 'Infections', '[', 'see', 'Warnings', 'Precautions', '(', '5.1', ')', ']', '•', 'Malignancies', '[', 'see', 'Warnings', 'Precautions', '(', '5.2', ')', ']', '•', 'Hypersensitivity', 'Reactions', '[', 'see', 'Warnings', 'Precautions', '(', '5.3', ')', ']', '•', 'Hepatitis', 'B', 'Virus', 'Reactivation', '[', 'see', 'Warnings', 'Precautions', '(', '5.4', ')', ']', '•', 'Neurologic', 'Reactions', '[', 'see', 'Warnings', 'Precautions', '(', '5.5', ')', ']', '•', 'Hematological', 'Reactions', '[', 'see', 'Warnings', 'Precautions', '(', '5.6', ')', ']', '•', 'Heart', 'Failure', '[', 'see', 'Warnings', 'Precautions', '(', '5.8', ')', ']', '•', 'Autoimmunity', '[', 'see', 'Warnings', 'Precautions', '(', '5.9', ')', ']', '6.1', 'Clinical', 'Trials', 'Experience', 'clinical', 'trials', 'conducted', 'widely', 'varying', 'conditions', ',', 'adverse', 'reaction', 'rates', 'observed', 'clinical', 'trials', 'drug', 'directly', 'compared', 'rates', 'clinical', 'trials', 'another', 'drug', 'may', 'reflect', 'rates', 'observed', 'practice', '.'], 'lemmatized': ['6', 'ADVERSE', 'REACTIONS', 'following', 'clinically', 'significant', 'adverse', 'reaction', 'described', 'elsewhere', 'labeling', ':', '•', 'Serious', 'Infections', '[', 'see', 'Warnings', 'Precautions', '(', '5.1', ')', ']', '•', 'Malignancies', '[', 'see', 'Warnings', 'Precautions', '(', '5.2', ')', ']', '•', 'Hypersensitivity', 'Reactions', '[', 'see', 'Warnings', 'Precautions', '(', '5.3', ')', ']', '•', 'Hepatitis', 'B', 'Virus', 'Reactivation', '[', 'see', 'Warnings', 'Precautions', '(', '5.4', ')', ']', '•', 'Neurologic', 'Reactions', '[', 'see', 'Warnings', 'Precautions', '(', '5.5', ')', ']', '•', 'Hematological', 'Reactions', '[', 'see', 'Warnings', 'Precautions', '(', '5.6', ')', ']', '•', 'Heart', 'Failure', '[', 'see', 'Warnings', 'Precautions', '(', '5.8', ')', ']', '•', 'Autoimmunity', '[', 'see', 'Warnings', 'Precautions', '(', '5.9', ')', ']', '6.1', 'Clinical', 'Trials', 'Experience', 'clinical', 'trial', 'conducted', 'widely', 'varying', 'condition', ',', 'adverse', 'reaction', 'rate', 'observed', 'clinical', 'trial', 'drug', 'directly', 'compared', 'rate', 'clinical', 'trial', 'another', 'drug', 'may', 'reflect', 'rate', 'observed', 'practice', '.'], 'stemmed': ['6', 'advers', 'reaction', 'follow', 'clinic', 'signific', 'advers', 'reaction', 'describ', 'elsewher', 'label', ':', '•', 'seriou', 'infect', '[', 'see', 'warn', 'precaut', '(', '5.1', ')', ']', '•', 'malign', '[', 'see', 'warn', 'precaut', '(', '5.2', ')', ']', '•', 'hypersensit', 'reaction', '[', 'see', 'warn', 'precaut', '(', '5.3', ')', ']', '•', 'hepat', 'b', 'viru', 'reactiv', '[', 'see', 'warn', 'precaut', '(', '5.4', ')', ']', '•', 'neurolog', 'reaction', '[', 'see', 'warn', 'precaut', '(', '5.5', ')', ']', '•', 'hematolog', 'reaction', '[', 'see', 'warn', 'precaut', '(', '5.6', ')', ']', '•', 'heart', 'failur', '[', 'see', 'warn', 'precaut', '(', '5.8', ')', ']', '•', 'autoimmun', '[', 'see', 'warn', 'precaut', '(', '5.9', ')', ']', '6.1', 'clinic', 'trial', 'experi', 'clinic', 'trial', 'conduct', 'wide', 'vari', 'condit', ',', 'advers', 'reaction', 'rate', 'observ', 'clinic', 'trial', 'drug', 'directli', 'compar', 'rate', 'clinic', 'trial', 'anoth', 'drug', 'may', 'reflect', 'rate', 'observ', 'practic', '.'], 'dependencies': [('6', 'nummod'), ('advers', 'compound'), ('reaction', 'compound'), ('follow', 'compound'), ('clinic', 'nmod'), ('signific', 'compound'), ('advers', 'compound'), ('reaction', 'compound'), ('describ', 'compound'), ('elsewher', 'compound'), ('label', 'ROOT'), (':', 'punct'), ('•', 'nummod'), ('seriou', 'compound'), ('infect', 'nsubj'), ('[', 'punct'), ('see', 'parataxis'), ('warn', 'compound'), ('precaut', 'dobj'), ('(', 'punct'), ('5.1', 'nummod'), (')', 'punct'), (']', 'punct'), ('•', 'nummod'), ('malign', 'appos'), ('[', 'punct'), ('see', 'parataxis'), ('warn', 'xcomp'), ('precaut', 'dobj'), ('(', 'punct'), ('5.2', 'appos'), (')', 'punct'), (']', 'nmod'), ('•', 'nummod'), ('hypersensit', 'compound'), ('reaction', 'appos'), ('[', 'punct'), ('see', 'acl'), ('warn', 'xcomp'), ('precaut', 'dobj'), ('(', 'punct'), ('5.3', 'appos'), (')', 'punct'), (']', 'punct'), ('•', 'compound'), ('hepat', 'compound'), ('b', 'compound'), ('viru', 'compound'), ('reactiv', 'punct'), ('[', 'punct'), ('see', 'ROOT'), ('warn', 'ccomp'), ('precaut', 'dobj'), ('(', 'punct'), ('5.4', 'npadvmod'), (')', 'punct'), (']', 'dep'), ('•', 'nummod'), ('neurolog', 'compound'), ('reaction', 'ROOT'), ('[', 'punct'), ('see', 'parataxis'), ('warn', 'xcomp'), ('precaut', 'dobj'), ('(', 'punct'), ('5.5', 'appos'), (')', 'punct'), (']', 'punct'), ('•', 'nummod'), ('hematolog', 'compound'), ('reaction', 'appos'), ('[', 'punct'), ('see', 'acl'), ('warn', 'xcomp'), ('precaut', 'dobj'), ('(', 'punct'), ('5.6', 'npadvmod'), (')', 'punct'), (']', 'punct'), ('•', 'nummod'), ('heart', 'compound'), ('failur', 'nsubj'), ('[', 'punct'), ('see', 'ROOT'), ('warn', 'xcomp'), ('precaut', 'dobj'), ('(', 'punct'), ('5.8', 'npadvmod'), (')', 'punct'), (']', 'punct'), ('•', 'npadvmod'), ('autoimmun', 'amod'), ('[', 'punct'), ('see', 'parataxis'), ('warn', 'compound'), ('precaut', 'dobj'), ('(', 'punct'), ('5.9', 'appos'), (')', 'punct'), (']', 'punct'), ('6.1', 'nummod'), ('clinic', 'amod'), ('trial', 'nmod'), ('experi', 'amod'), ('clinic', 'compound'), ('trial', 'nsubj'), ('conduct', 'ccomp'), ('wide', 'amod'), ('vari', 'compound'), ('condit', 'dobj'), (',', 'punct'), ('advers', 'compound'), ('reaction', 'compound'), ('rate', 'compound'), ('observ', 'compound'), ('clinic', 'compound'), ('trial', 'compound'), ('drug', 'compound'), ('directli', 'compound'), ('compar', 'compound'), ('rate', 'compound'), ('clinic', 'compound'), ('trial', 'nmod'), ('anoth', 'advmod'), ('drug', 'nsubj'), ('may', 'aux'), ('reflect', 'ROOT'), ('rate', 'compound'), ('observ', 'compound'), ('practic', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The most common adverse reaction with HUMIRA was injection site reactions.', 'tokens': ['common', 'adverse', 'reaction', 'HUMIRA', 'injection', 'site', 'reactions', '.'], 'lemmatized': ['common', 'adverse', 'reaction', 'HUMIRA', 'injection', 'site', 'reaction', '.'], 'stemmed': ['common', 'advers', 'reaction', 'humira', 'inject', 'site', 'reaction', '.'], 'dependencies': [('common', 'amod'), ('advers', 'compound'), ('reaction', 'ROOT'), ('humira', 'compound'), ('inject', 'compound'), ('site', 'compound'), ('reaction', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'In placebo-\\ncontrolled trials, 20% of patients treated with HUMIRA developed injection site reactions \\n(erythema and/or itching, hemorrhage, pain or swelling), compared to 14% of patients receiving \\nplacebo.', 'tokens': ['placebo-', 'controlled', 'trials', ',', '20', '%', 'patients', 'treated', 'HUMIRA', 'developed', 'injection', 'site', 'reactions', '(', 'erythema', 'and/or', 'itching', ',', 'hemorrhage', ',', 'pain', 'swelling', ')', ',', 'compared', '14', '%', 'patients', 'receiving', 'placebo', '.'], 'lemmatized': ['placebo-', 'controlled', 'trial', ',', '20', '%', 'patient', 'treated', 'HUMIRA', 'developed', 'injection', 'site', 'reaction', '(', 'erythema', 'and/or', 'itching', ',', 'hemorrhage', ',', 'pain', 'swelling', ')', ',', 'compared', '14', '%', 'patient', 'receiving', 'placebo', '.'], 'stemmed': ['placebo-', 'control', 'trial', ',', '20', '%', 'patient', 'treat', 'humira', 'develop', 'inject', 'site', 'reaction', '(', 'erythema', 'and/or', 'itch', ',', 'hemorrhag', ',', 'pain', 'swell', ')', ',', 'compar', '14', '%', 'patient', 'receiv', 'placebo', '.'], 'dependencies': [('placebo-', 'compound'), ('control', 'compound'), ('trial', 'dep'), (',', 'punct'), ('20', 'nummod'), ('%', 'nmod'), ('patient', 'compound'), ('treat', 'compound'), ('humira', 'nsubj'), ('develop', 'ROOT'), ('inject', 'compound'), ('site', 'compound'), ('reaction', 'dobj'), ('(', 'punct'), ('erythema', 'appos'), ('and/or', 'cc'), ('itch', 'conj'), (',', 'punct'), ('hemorrhag', 'conj'), (',', 'punct'), ('pain', 'compound'), ('swell', 'conj'), (')', 'punct'), (',', 'punct'), ('compar', 'conj'), ('14', 'nummod'), ('%', 'nmod'), ('patient', 'compound'), ('receiv', 'compound'), ('placebo', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Most injection site reactions were described as mild and generally did not necessitate \\ndrug discontinuation.', 'tokens': ['injection', 'site', 'reactions', 'described', 'mild', 'generally', 'necessitate', 'drug', 'discontinuation', '.'], 'lemmatized': ['injection', 'site', 'reaction', 'described', 'mild', 'generally', 'necessitate', 'drug', 'discontinuation', '.'], 'stemmed': ['inject', 'site', 'reaction', 'describ', 'mild', 'gener', 'necessit', 'drug', 'discontinu', '.'], 'dependencies': [('inject', 'compound'), ('site', 'compound'), ('reaction', 'compound'), ('describ', 'ROOT'), ('mild', 'compound'), ('gener', 'compound'), ('necessit', 'compound'), ('drug', 'compound'), ('discontinu', 'appos'), ('.', 'punct')]}, {'original_sentence': 'The proportion of patients who discontinued treatment due to adverse reactions during the \\ndouble-blind, placebo-controlled portion of studies in patients with RA (i.e., Studies RA-I, RA-\\nII, RA-III and RA-IV) was 7% for patients taking HUMIRA and 4% for placebo-treated patients.', 'tokens': ['proportion', 'patients', 'discontinued', 'treatment', 'due', 'adverse', 'reactions', 'double-blind', ',', 'placebo-controlled', 'portion', 'studies', 'patients', 'RA', '(', 'i.e.', ',', 'Studies', 'RA-I', ',', 'RA-', 'II', ',', 'RA-III', 'RA-IV', ')', '7', '%', 'patients', 'taking', 'HUMIRA', '4', '%', 'placebo-treated', 'patients', '.'], 'lemmatized': ['proportion', 'patient', 'discontinued', 'treatment', 'due', 'adverse', 'reaction', 'double-blind', ',', 'placebo-controlled', 'portion', 'study', 'patient', 'RA', '(', 'i.e.', ',', 'Studies', 'RA-I', ',', 'RA-', 'II', ',', 'RA-III', 'RA-IV', ')', '7', '%', 'patient', 'taking', 'HUMIRA', '4', '%', 'placebo-treated', 'patient', '.'], 'stemmed': ['proport', 'patient', 'discontinu', 'treatment', 'due', 'advers', 'reaction', 'double-blind', ',', 'placebo-control', 'portion', 'studi', 'patient', 'ra', '(', 'i.e.', ',', 'studi', 'ra-i', ',', 'ra-', 'ii', ',', 'ra-iii', 'ra-iv', ')', '7', '%', 'patient', 'take', 'humira', '4', '%', 'placebo-tr', 'patient', '.'], 'dependencies': [('proport', 'compound'), ('patient', 'nmod'), ('discontinu', 'compound'), ('treatment', 'nmod'), ('due', 'amod'), ('advers', 'compound'), ('reaction', 'ROOT'), ('double', 'amod'), ('-', 'punct'), ('blind', 'amod'), (',', 'punct'), ('placebo', 'compound'), ('-', 'punct'), ('control', 'compound'), ('portion', 'dobj'), ('studi', 'compound'), ('patient', 'compound'), ('ra', 'appos'), ('(', 'punct'), ('i.e.', 'advmod'), (',', 'punct'), ('studi', 'compound'), ('ra', 'appos'), ('-', 'punct'), ('i', 'npadvmod'), (',', 'punct'), ('ra-', 'punct'), ('ii', 'nsubj'), (',', 'punct'), ('ra', 'compound'), ('-', 'punct'), ('iii', 'compound'), ('ra', 'compound'), ('-', 'punct'), ('iv', 'nmod'), (')', 'punct'), ('7', 'nummod'), ('%', 'compound'), ('patient', 'appos'), ('take', 'ROOT'), ('humira', 'dobj'), ('4', 'nummod'), ('%', 'compound'), ('placebo', 'compound'), ('-', 'punct'), ('tr', 'conj'), ('patient', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The most common adverse reactions leading to discontinuation of HUMIRA in these RA studies \\nwere clinical flare reaction (0.7%), rash (0.3%) and pneumonia (0.3%).', 'tokens': ['common', 'adverse', 'reactions', 'leading', 'discontinuation', 'HUMIRA', 'RA', 'studies', 'clinical', 'flare', 'reaction', '(', '0.7', '%', ')', ',', 'rash', '(', '0.3', '%', ')', 'pneumonia', '(', '0.3', '%', ')', '.'], 'lemmatized': ['common', 'adverse', 'reaction', 'leading', 'discontinuation', 'HUMIRA', 'RA', 'study', 'clinical', 'flare', 'reaction', '(', '0.7', '%', ')', ',', 'rash', '(', '0.3', '%', ')', 'pneumonia', '(', '0.3', '%', ')', '.'], 'stemmed': ['common', 'advers', 'reaction', 'lead', 'discontinu', 'humira', 'ra', 'studi', 'clinic', 'flare', 'reaction', '(', '0.7', '%', ')', ',', 'rash', '(', '0.3', '%', ')', 'pneumonia', '(', '0.3', '%', ')', '.'], 'dependencies': [('common', 'amod'), ('advers', 'compound'), ('reaction', 'nsubj'), ('lead', 'compound'), ('discontinu', 'compound'), ('humira', 'compound'), ('ra', 'compound'), ('studi', 'compound'), ('clinic', 'compound'), ('flare', 'compound'), ('reaction', 'dobj'), ('(', 'punct'), ('0.7', 'nummod'), ('%', 'appos'), (')', 'punct'), (',', 'punct'), ('rash', 'conj'), ('(', 'punct'), ('0.3', 'nummod'), ('%', 'appos'), (')', 'punct'), ('pneumonia', 'ROOT'), ('(', 'punct'), ('0.3', 'nummod'), ('%', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Infections', 'tokens': ['Infections'], 'lemmatized': ['Infections'], 'stemmed': ['infect'], 'dependencies': [('infect', 'ROOT')]}], 'text': 'It is recommended that pediatric patients, if possible, be brought up to date with all \\nimmunizations in agreement with current immunization guidelines prior to initiating HUMIRA \\ntherapy. Patients on HUMIRA may receive concurrent vaccinations, except for live vaccines.  \\nThe safety of administering live or live-attenuated vaccines in infants exposed to HUMIRA in \\nutero is unknown. Risks and benefits should be considered prior to vaccinating (live or live-\\nattenuated) exposed infants [see Use in Specific Populations (8.1, 8.4)].  \\n5.11 Increased Risk of Infection When Used with Abatacept \\nIn controlled trials, the concurrent administration of TNF-blockers and abatacept was associated \\nwith a greater proportion of serious infections than the use of a TNF-blocker alone; the \\ncombination therapy, compared to the use of a TNF-blocker alone, has not demonstrated \\nimproved clinical benefit in the treatment of RA. Therefore, the combination of abatacept with \\nTNF-blockers including HUMIRA is not recommended [see Drug Interactions (7.2)].  \\n6 ADVERSE REACTIONS \\nThe following clinically significant adverse reactions are described elsewhere in the labeling:  \\n• Serious Infections [see Warnings and Precautions (5.1)] \\n• Malignancies [see Warnings and Precautions (5.2)] \\n• Hypersensitivity Reactions [see Warnings and Precautions (5.3)] \\n• Hepatitis B Virus Reactivation [see Warnings and Precautions (5.4)] \\n• Neurologic Reactions [see Warnings and Precautions (5.5)] \\n• Hematological Reactions [see Warnings and Precautions (5.6)] \\n• Heart Failure [see Warnings and Precautions (5.8)] \\n• Autoimmunity [see Warnings and Precautions (5.9)] \\n  \\n6.1 Clinical Trials Experience \\nBecause clinical trials are conducted under widely varying conditions, adverse reaction rates \\nobserved in the clinical trials of a drug cannot be directly compared to rates in the clinical trials \\nof another drug and may not reflect the rates observed in practice.  \\nThe most common adverse reaction with HUMIRA was injection site reactions. In placebo-\\ncontrolled trials, 20% of patients treated with HUMIRA developed injection site reactions \\n(erythema and/or itching, hemorrhage, pain or swelling), compared to 14% of patients receiving \\nplacebo. Most injection site reactions were described as mild and generally did not necessitate \\ndrug discontinuation.  \\nThe proportion of patients who discontinued treatment due to adverse reactions during the \\ndouble-blind, placebo-controlled portion of studies in patients with RA (i.e., Studies RA-I, RA-\\nII, RA-III and RA-IV) was 7% for patients taking HUMIRA and 4% for placebo-treated patients. \\nThe most common adverse reactions leading to discontinuation of HUMIRA in these RA studies \\nwere clinical flare reaction (0.7%), rash (0.3%) and pneumonia (0.3%).  \\nInfections \\n'}, 'page_char_count': 2807, 'page_word_count': 395, 'sentences': ['It is recommended that pediatric patients, if possible, be brought up to date with all \\nimmunizations in agreement with current immunization guidelines prior to initiating HUMIRA \\ntherapy.', 'Patients on HUMIRA may receive concurrent vaccinations, except for live vaccines.', ' \\nThe safety of administering live or live-attenuated vaccines in infants exposed to HUMIRA in \\nutero is unknown.', 'Risks and benefits should be considered prior to vaccinating (live or live-\\nattenuated) exposed infants [see Use in Specific Populations (8.1, 8.4)].', ' \\n5.11 Increased Risk of Infection When Used with Abatacept \\nIn controlled trials, the concurrent administration of TNF-blockers and abatacept was associated \\nwith a greater proportion of serious infections than the use of a TNF-blocker alone; the \\ncombination therapy, compared to the use of a TNF-blocker alone, has not demonstrated \\nimproved clinical benefit in the treatment of RA.', 'Therefore, the combination of abatacept with \\nTNF-blockers including HUMIRA is not recommended [see Drug Interactions (7.2)].', ' \\n6 ADVERSE REACTIONS \\nThe following clinically significant adverse reactions are described elsewhere in the labeling:  \\n• Serious Infections [see Warnings and Precautions (5.1)] \\n• Malignancies [see Warnings and Precautions (5.2)] \\n• Hypersensitivity Reactions [see Warnings and Precautions (5.3)] \\n• Hepatitis B Virus Reactivation [see Warnings and Precautions (5.4)] \\n• Neurologic Reactions [see Warnings and Precautions (5.5)] \\n• Hematological Reactions [see Warnings and Precautions (5.6)] \\n• Heart Failure [see Warnings and Precautions (5.8)] \\n• Autoimmunity [see Warnings and Precautions (5.9)] \\n  \\n6.1 Clinical Trials Experience \\nBecause clinical trials are conducted under widely varying conditions, adverse reaction rates \\nobserved in the clinical trials of a drug cannot be directly compared to rates in the clinical trials \\nof another drug and may not reflect the rates observed in practice.', ' \\nThe most common adverse reaction with HUMIRA was injection site reactions.', 'In placebo-\\ncontrolled trials, 20% of patients treated with HUMIRA developed injection site reactions \\n(erythema and/or itching, hemorrhage, pain or swelling), compared to 14% of patients receiving \\nplacebo.', 'Most injection site reactions were described as mild and generally did not necessitate \\ndrug discontinuation.', ' \\nThe proportion of patients who discontinued treatment due to adverse reactions during the \\ndouble-blind, placebo-controlled portion of studies in patients with RA (i.e., Studies RA-I, RA-\\nII, RA-III and RA-IV) was 7% for patients taking HUMIRA and 4% for placebo-treated patients.', '\\nThe most common adverse reactions leading to discontinuation of HUMIRA in these RA studies \\nwere clinical flare reaction (0.7%), rash (0.3%) and pneumonia (0.3%).', ' \\nInfections \\n'], 'page_sentence_count_spacy': 13}\n",
            "{'page_number': 15, 'text': 'In the controlled portions of the 39 global HUMIRA clinical trials in adult patients with RA, \\nPsA, AS, CD, UC, Ps, HS and UV, the rate of serious infections was 4.3 per 100 patient-years in \\n7973 HUMIRA-treated patients versus a rate of 2.9 per 100 patient-years in 4848 control-treated \\npatients. Serious infections observed included pneumonia, septic arthritis, prosthetic and post-\\nsurgical infections, erysipelas, cellulitis, diverticulitis, and pyelonephritis [see Warnings and \\nPrecautions (5.1)].  \\nTuberculosis and Opportunistic Infections \\nIn 52 global controlled and uncontrolled clinical trials in RA, PsA, AS, CD, UC, Ps, HS and UV \\nthat included 24,605 HUMIRA-treated patients, the rate of reported active tuberculosis was 0.20 \\nper 100 patient-years and the rate of positive PPD conversion was 0.09 per 100 patient-years. In \\na subgroup of 10,113 U.S. and Canadian HUMIRA-treated patients, the rate of reported active \\nTB was 0.05 per 100 patient-years and the rate of positive PPD conversion was 0.07 per 100 \\npatient-years. These trials included reports of miliary, lymphatic, peritoneal, and pulmonary TB. \\nMost of the TB cases occurred within the first eight months after initiation of therapy and may \\nreflect recrudescence of latent disease. In these global clinical trials, cases of serious \\nopportunistic infections have been reported at an overall rate of 0.05 per 100 patient-years. Some \\ncases of serious opportunistic infections and TB have been fatal [see Warnings and Precautions \\n(5.1)].  \\nAutoantibodies \\nIn the rheumatoid arthritis controlled trials, 12% of patients treated with HUMIRA and 7% of \\nplacebo-treated patients that had negative baseline ANA titers developed positive titers at week \\n24. Two patients out of 3046 treated with HUMIRA developed clinical signs suggestive of new-\\nonset lupus-like syndrome. The patients improved following discontinuation of therapy. No \\npatients developed lupus nephritis or central nervous system symptoms. The impact of long-term \\ntreatment with HUMIRA on the development of autoimmune diseases is unknown.  \\nLiver Enzyme Elevations  \\nThere have been reports of severe hepatic reactions including acute liver failure in patients \\nreceiving TNF-blockers. In controlled Phase 3 trials of HUMIRA (40 mg SC every other week) \\nin patients with RA, PsA, and AS with control period duration ranging from 4 to 104 weeks, \\nALT elevations ≥ 3 x ULN occurred in 3.5% of HUMIRA-treated patients and 1.5% of control-\\ntreated patients. Since many of these patients in these trials were also taking medications that \\ncause liver enzyme elevations (e.g., NSAIDS, MTX), the relationship between HUMIRA and the \\nliver enzyme elevations is not clear. In a controlled Phase 3 trial of HUMIRA in patients with \\npolyarticular JIA who were 4 to 17 years, ALT elevations ≥ 3 x ULN occurred in 4.4% of \\nHUMIRA-treated patients and 1.5% of control-treated patients (ALT more common than AST); \\nliver enzyme test elevations were more frequent among those treated with the combination of \\nHUMIRA and MTX than those treated with HUMIRA alone. In general, these elevations did not \\nlead to discontinuation of HUMIRA treatment. No ALT elevations ≥ 3 x ULN occurred in the \\nopen-label study of HUMIRA in patients with polyarticular JIA who were 2 to <4 years.  \\nIn controlled Phase 3 trials of HUMIRA (initial doses of 160 mg and 80 mg, or 80 mg and 40 mg \\non Days 1 and 15, respectively, followed by 40 mg every other week) in adult patients with \\nCrohn’s Disease with a control period duration ranging from 4 to 52 weeks, ALT elevations ≥ 3 \\nx ULN occurred in 0.9% of HUMIRA-treated patients and 0.9% of control-treated patients. In \\n', 'processed_text': {'sentences': [{'original_sentence': 'In the controlled portions of the 39 global HUMIRA clinical trials in adult patients with RA, \\nPsA, AS, CD, UC, Ps, HS and UV, the rate of serious infections was 4.3 per 100 patient-years in \\n7973 HUMIRA-treated patients versus a rate of 2.9 per 100 patient-years in 4848 control-treated \\npatients.', 'tokens': ['controlled', 'portions', '39', 'global', 'HUMIRA', 'clinical', 'trials', 'adult', 'patients', 'RA', ',', 'PsA', ',', ',', 'CD', ',', 'UC', ',', 'Ps', ',', 'HS', 'UV', ',', 'rate', 'serious', 'infections', '4.3', 'per', '100', 'patient-years', '7973', 'HUMIRA-treated', 'patients', 'versus', 'rate', '2.9', 'per', '100', 'patient-years', '4848', 'control-treated', 'patients', '.'], 'lemmatized': ['controlled', 'portion', '39', 'global', 'HUMIRA', 'clinical', 'trial', 'adult', 'patient', 'RA', ',', 'PsA', ',', ',', 'CD', ',', 'UC', ',', 'Ps', ',', 'HS', 'UV', ',', 'rate', 'serious', 'infection', '4.3', 'per', '100', 'patient-years', '7973', 'HUMIRA-treated', 'patient', 'versus', 'rate', '2.9', 'per', '100', 'patient-years', '4848', 'control-treated', 'patient', '.'], 'stemmed': ['control', 'portion', '39', 'global', 'humira', 'clinic', 'trial', 'adult', 'patient', 'ra', ',', 'psa', ',', ',', 'cd', ',', 'uc', ',', 'ps', ',', 'hs', 'uv', ',', 'rate', 'seriou', 'infect', '4.3', 'per', '100', 'patient-year', '7973', 'humira-tr', 'patient', 'versu', 'rate', '2.9', 'per', '100', 'patient-year', '4848', 'control-tr', 'patient', '.'], 'dependencies': [('control', 'compound'), ('portion', 'nsubj'), ('39', 'nummod'), ('global', 'amod'), ('humira', 'compound'), ('clinic', 'compound'), ('trial', 'compound'), ('adult', 'compound'), ('patient', 'dobj'), ('ra', 'appos'), (',', 'punct'), ('psa', 'conj'), (',', 'punct'), (',', 'punct'), ('cd', 'appos'), (',', 'punct'), ('uc', 'intj'), (',', 'punct'), ('ps', 'conj'), (',', 'punct'), ('hs', 'compound'), ('uv', 'conj'), (',', 'punct'), ('rate', 'compound'), ('seriou', 'nsubj'), ('infect', 'ROOT'), ('4.3', 'dobj'), ('per', 'quantmod'), ('100', 'nummod'), ('patient', 'amod'), ('-', 'punct'), ('year', 'nmod'), ('7973', 'nummod'), ('humira', 'npadvmod'), ('-', 'punct'), ('tr', 'nmod'), ('patient', 'amod'), ('versu', 'compound'), ('rate', 'appos'), ('2.9', 'nummod'), ('per', 'prep'), ('100', 'pobj'), ('patient', 'amod'), ('-', 'punct'), ('year', 'nmod'), ('4848', 'nummod'), ('control', 'compound'), ('-', 'punct'), ('tr', 'pobj'), ('patient', 'conj'), ('.', 'punct')]}, {'original_sentence': 'Serious infections observed included pneumonia, septic arthritis, prosthetic and post-\\nsurgical infections, erysipelas, cellulitis, diverticulitis, and pyelonephritis [see Warnings and \\nPrecautions (5.1)].', 'tokens': ['Serious', 'infections', 'observed', 'included', 'pneumonia', ',', 'septic', 'arthritis', ',', 'prosthetic', 'post-', 'surgical', 'infections', ',', 'erysipelas', ',', 'cellulitis', ',', 'diverticulitis', ',', 'pyelonephritis', '[', 'see', 'Warnings', 'Precautions', '(', '5.1', ')', ']', '.'], 'lemmatized': ['Serious', 'infection', 'observed', 'included', 'pneumonia', ',', 'septic', 'arthritis', ',', 'prosthetic', 'post-', 'surgical', 'infection', ',', 'erysipelas', ',', 'cellulitis', ',', 'diverticulitis', ',', 'pyelonephritis', '[', 'see', 'Warnings', 'Precautions', '(', '5.1', ')', ']', '.'], 'stemmed': ['seriou', 'infect', 'observ', 'includ', 'pneumonia', ',', 'septic', 'arthriti', ',', 'prosthet', 'post-', 'surgic', 'infect', ',', 'erysipela', ',', 'cellul', ',', 'diverticul', ',', 'pyelonephr', '[', 'see', 'warn', 'precaut', '(', '5.1', ')', ']', '.'], 'dependencies': [('seriou', 'compound'), ('infect', 'compound'), ('observ', 'compound'), ('includ', 'compound'), ('pneumonia', 'nsubj'), (',', 'punct'), ('septic', 'amod'), ('arthriti', 'conj'), (',', 'punct'), ('prosthet', 'nmod'), ('post-', 'dep'), ('surgic', 'amod'), ('infect', 'conj'), (',', 'punct'), ('erysipela', 'conj'), (',', 'punct'), ('cellul', 'conj'), (',', 'punct'), ('diverticul', 'conj'), (',', 'punct'), ('pyelonephr', 'conj'), ('[', 'punct'), ('see', 'ROOT'), ('warn', 'dep'), ('precaut', 'dobj'), ('(', 'punct'), ('5.1', 'dobj'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Tuberculosis and Opportunistic Infections \\nIn 52 global controlled and uncontrolled clinical trials in RA, PsA, AS, CD, UC, Ps, HS and UV \\nthat included 24,605 HUMIRA-treated patients, the rate of reported active tuberculosis was 0.20 \\nper 100 patient-years and the rate of positive PPD conversion was 0.09 per 100 patient-years.', 'tokens': ['Tuberculosis', 'Opportunistic', 'Infections', '52', 'global', 'controlled', 'uncontrolled', 'clinical', 'trials', 'RA', ',', 'PsA', ',', ',', 'CD', ',', 'UC', ',', 'Ps', ',', 'HS', 'UV', 'included', '24,605', 'HUMIRA-treated', 'patients', ',', 'rate', 'reported', 'active', 'tuberculosis', '0.20', 'per', '100', 'patient-years', 'rate', 'positive', 'PPD', 'conversion', '0.09', 'per', '100', 'patient-years', '.'], 'lemmatized': ['Tuberculosis', 'Opportunistic', 'Infections', '52', 'global', 'controlled', 'uncontrolled', 'clinical', 'trial', 'RA', ',', 'PsA', ',', ',', 'CD', ',', 'UC', ',', 'Ps', ',', 'HS', 'UV', 'included', '24,605', 'HUMIRA-treated', 'patient', ',', 'rate', 'reported', 'active', 'tuberculosis', '0.20', 'per', '100', 'patient-years', 'rate', 'positive', 'PPD', 'conversion', '0.09', 'per', '100', 'patient-years', '.'], 'stemmed': ['tuberculosi', 'opportunist', 'infect', '52', 'global', 'control', 'uncontrol', 'clinic', 'trial', 'ra', ',', 'psa', ',', ',', 'cd', ',', 'uc', ',', 'ps', ',', 'hs', 'uv', 'includ', '24,605', 'humira-tr', 'patient', ',', 'rate', 'report', 'activ', 'tuberculosi', '0.20', 'per', '100', 'patient-year', 'rate', 'posit', 'ppd', 'convers', '0.09', 'per', '100', 'patient-year', '.'], 'dependencies': [('tuberculosi', 'compound'), ('opportunist', 'nsubj'), ('infect', 'ROOT'), ('52', 'nummod'), ('global', 'amod'), ('control', 'compound'), ('uncontrol', 'compound'), ('clinic', 'compound'), ('trial', 'compound'), ('ra', 'npadvmod'), (',', 'punct'), ('psa', 'parataxis'), (',', 'punct'), (',', 'punct'), ('cd', 'appos'), (',', 'punct'), ('uc', 'intj'), (',', 'punct'), ('ps', 'nmod'), (',', 'punct'), ('hs', 'nmod'), ('uv', 'advmod'), ('includ', 'dobj'), ('24,605', 'nummod'), ('humira', 'npadvmod'), ('-', 'punct'), ('tr', 'amod'), ('patient', 'nmod'), (',', 'punct'), ('rate', 'compound'), ('report', 'compound'), ('activ', 'compound'), ('tuberculosi', 'npadvmod'), ('0.20', 'nummod'), ('per', 'prep'), ('100', 'nummod'), ('patient', 'amod'), ('-', 'punct'), ('year', 'compound'), ('rate', 'compound'), ('posit', 'compound'), ('ppd', 'compound'), ('convers', 'pobj'), ('0.09', 'nummod'), ('per', 'prep'), ('100', 'nummod'), ('patient', 'compound'), ('-', 'punct'), ('year', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'In \\na subgroup of 10,113 U.S. and Canadian HUMIRA-treated patients, the rate of reported active \\nTB was 0.05 per 100 patient-years and the rate of positive PPD conversion was 0.07 per 100 \\npatient-years.', 'tokens': ['subgroup', '10,113', 'U.S.', 'Canadian', 'HUMIRA-treated', 'patients', ',', 'rate', 'reported', 'active', 'TB', '0.05', 'per', '100', 'patient-years', 'rate', 'positive', 'PPD', 'conversion', '0.07', 'per', '100', 'patient-years', '.'], 'lemmatized': ['subgroup', '10,113', 'U.S.', 'Canadian', 'HUMIRA-treated', 'patient', ',', 'rate', 'reported', 'active', 'TB', '0.05', 'per', '100', 'patient-years', 'rate', 'positive', 'PPD', 'conversion', '0.07', 'per', '100', 'patient-years', '.'], 'stemmed': ['subgroup', '10,113', 'u.s.', 'canadian', 'humira-tr', 'patient', ',', 'rate', 'report', 'activ', 'tb', '0.05', 'per', '100', 'patient-year', 'rate', 'posit', 'ppd', 'convers', '0.07', 'per', '100', 'patient-year', '.'], 'dependencies': [('subgroup', 'ROOT'), ('10,113', 'nummod'), ('u.s', 'nmod'), ('.', 'compound'), ('canadian', 'amod'), ('humira', 'compound'), ('-', 'punct'), ('tr', 'nummod'), ('patient', 'appos'), (',', 'punct'), ('rate', 'compound'), ('report', 'compound'), ('activ', 'npadvmod'), ('tb', 'prep'), ('0.05', 'pobj'), ('per', 'prep'), ('100', 'nummod'), ('patient', 'amod'), ('-', 'punct'), ('year', 'compound'), ('rate', 'compound'), ('posit', 'compound'), ('ppd', 'compound'), ('convers', 'pobj'), ('0.07', 'nummod'), ('per', 'prep'), ('100', 'nummod'), ('patient', 'compound'), ('-', 'punct'), ('year', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'These trials included reports of miliary, lymphatic, peritoneal, and pulmonary TB.', 'tokens': ['trials', 'included', 'reports', 'miliary', ',', 'lymphatic', ',', 'peritoneal', ',', 'pulmonary', 'TB', '.'], 'lemmatized': ['trial', 'included', 'report', 'miliary', ',', 'lymphatic', ',', 'peritoneal', ',', 'pulmonary', 'TB', '.'], 'stemmed': ['trial', 'includ', 'report', 'miliari', ',', 'lymphat', ',', 'periton', ',', 'pulmonari', 'tb', '.'], 'dependencies': [('trial', 'compound'), ('includ', 'nsubj'), ('report', 'ROOT'), ('miliari', 'dobj'), (',', 'punct'), ('lymphat', 'intj'), (',', 'punct'), ('periton', 'conj'), (',', 'punct'), ('pulmonari', 'compound'), ('tb', 'conj'), ('.', 'punct')]}, {'original_sentence': 'Most of the TB cases occurred within the first eight months after initiation of therapy and may \\nreflect recrudescence of latent disease.', 'tokens': ['TB', 'cases', 'occurred', 'within', 'first', 'eight', 'months', 'initiation', 'therapy', 'may', 'reflect', 'recrudescence', 'latent', 'disease', '.'], 'lemmatized': ['TB', 'case', 'occurred', 'within', 'first', 'eight', 'month', 'initiation', 'therapy', 'may', 'reflect', 'recrudescence', 'latent', 'disease', '.'], 'stemmed': ['tb', 'case', 'occur', 'within', 'first', 'eight', 'month', 'initi', 'therapi', 'may', 'reflect', 'recrudesc', 'latent', 'diseas', '.'], 'dependencies': [('tb', 'compound'), ('case', 'nsubj'), ('occur', 'ROOT'), ('within', 'prep'), ('first', 'amod'), ('eight', 'nummod'), ('month', 'compound'), ('initi', 'pobj'), ('therapi', 'npadvmod'), ('may', 'aux'), ('reflect', 'conj'), ('recrudesc', 'compound'), ('latent', 'compound'), ('diseas', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'In these global clinical trials, cases of serious \\nopportunistic infections have been reported at an overall rate of 0.05 per 100 patient-years.', 'tokens': ['global', 'clinical', 'trials', ',', 'cases', 'serious', 'opportunistic', 'infections', 'reported', 'overall', 'rate', '0.05', 'per', '100', 'patient-years', '.'], 'lemmatized': ['global', 'clinical', 'trial', ',', 'case', 'serious', 'opportunistic', 'infection', 'reported', 'overall', 'rate', '0.05', 'per', '100', 'patient-years', '.'], 'stemmed': ['global', 'clinic', 'trial', ',', 'case', 'seriou', 'opportunist', 'infect', 'report', 'overal', 'rate', '0.05', 'per', '100', 'patient-year', '.'], 'dependencies': [('global', 'amod'), ('clinic', 'compound'), ('trial', 'nsubj'), (',', 'punct'), ('case', 'compound'), ('seriou', 'compound'), ('opportunist', 'nmod'), ('infect', 'compound'), ('report', 'ROOT'), ('overal', 'amod'), ('rate', 'appos'), ('0.05', 'npadvmod'), ('per', 'prep'), ('100', 'nummod'), ('patient', 'compound'), ('-', 'punct'), ('year', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'Some \\ncases of serious opportunistic infections and TB have been fatal [see Warnings and Precautions \\n(5.1)].', 'tokens': ['cases', 'serious', 'opportunistic', 'infections', 'TB', 'fatal', '[', 'see', 'Warnings', 'Precautions', '(', '5.1', ')', ']', '.'], 'lemmatized': ['case', 'serious', 'opportunistic', 'infection', 'TB', 'fatal', '[', 'see', 'Warnings', 'Precautions', '(', '5.1', ')', ']', '.'], 'stemmed': ['case', 'seriou', 'opportunist', 'infect', 'tb', 'fatal', '[', 'see', 'warn', 'precaut', '(', '5.1', ')', ']', '.'], 'dependencies': [('case', 'compound'), ('seriou', 'compound'), ('opportunist', 'compound'), ('infect', 'nsubj'), ('tb', 'prep'), ('fatal', 'pobj'), ('[', 'punct'), ('see', 'ROOT'), ('warn', 'dep'), ('precaut', 'dobj'), ('(', 'punct'), ('5.1', 'npadvmod'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Autoantibodies \\nIn the rheumatoid arthritis controlled trials, 12% of patients treated with HUMIRA and 7% of \\nplacebo-treated patients that had negative baseline ANA titers developed positive titers at week \\n24.', 'tokens': ['Autoantibodies', 'rheumatoid', 'arthritis', 'controlled', 'trials', ',', '12', '%', 'patients', 'treated', 'HUMIRA', '7', '%', 'placebo-treated', 'patients', 'negative', 'baseline', 'ANA', 'titers', 'developed', 'positive', 'titers', 'week', '24', '.'], 'lemmatized': ['Autoantibodies', 'rheumatoid', 'arthritis', 'controlled', 'trial', ',', '12', '%', 'patient', 'treated', 'HUMIRA', '7', '%', 'placebo-treated', 'patient', 'negative', 'baseline', 'ANA', 'titer', 'developed', 'positive', 'titer', 'week', '24', '.'], 'stemmed': ['autoantibodi', 'rheumatoid', 'arthriti', 'control', 'trial', ',', '12', '%', 'patient', 'treat', 'humira', '7', '%', 'placebo-tr', 'patient', 'neg', 'baselin', 'ana', 'titer', 'develop', 'posit', 'titer', 'week', '24', '.'], 'dependencies': [('autoantibodi', 'nsubj'), ('rheumatoid', 'amod'), ('arthriti', 'compound'), ('control', 'compound'), ('trial', 'dobj'), (',', 'punct'), ('12', 'nummod'), ('%', 'compound'), ('patient', 'conj'), ('treat', 'compound'), ('humira', 'appos'), ('7', 'nummod'), ('%', 'compound'), ('placebo', 'compound'), ('-', 'punct'), ('tr', 'prep'), ('patient', 'amod'), ('neg', 'compound'), ('baselin', 'compound'), ('ana', 'compound'), ('titer', 'npadvmod'), ('develop', 'ROOT'), ('posit', 'compound'), ('titer', 'compound'), ('week', 'npadvmod'), ('24', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Two patients out of 3046 treated with HUMIRA developed clinical signs suggestive of new-\\nonset lupus-like syndrome.', 'tokens': ['Two', 'patients', '3046', 'treated', 'HUMIRA', 'developed', 'clinical', 'signs', 'suggestive', 'new-', 'onset', 'lupus-like', 'syndrome', '.'], 'lemmatized': ['Two', 'patient', '3046', 'treated', 'HUMIRA', 'developed', 'clinical', 'sign', 'suggestive', 'new-', 'onset', 'lupus-like', 'syndrome', '.'], 'stemmed': ['two', 'patient', '3046', 'treat', 'humira', 'develop', 'clinic', 'sign', 'suggest', 'new-', 'onset', 'lupus-lik', 'syndrom', '.'], 'dependencies': [('two', 'nummod'), ('patient', 'amod'), ('3046', 'nummod'), ('treat', 'compound'), ('humira', 'nsubj'), ('develop', 'ROOT'), ('clinic', 'compound'), ('sign', 'dobj'), ('suggest', 'conj'), ('new-', 'dep'), ('onset', 'compound'), ('lupus', 'compound'), ('-', 'punct'), ('lik', 'compound'), ('syndrom', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The patients improved following discontinuation of therapy.', 'tokens': ['patients', 'improved', 'following', 'discontinuation', 'therapy', '.'], 'lemmatized': ['patient', 'improved', 'following', 'discontinuation', 'therapy', '.'], 'stemmed': ['patient', 'improv', 'follow', 'discontinu', 'therapi', '.'], 'dependencies': [('patient', 'nsubj'), ('improv', 'advmod'), ('follow', 'ROOT'), ('discontinu', 'dobj'), ('therapi', 'oprd'), ('.', 'punct')]}, {'original_sentence': 'No \\npatients developed lupus nephritis or central nervous system symptoms.', 'tokens': ['patients', 'developed', 'lupus', 'nephritis', 'central', 'nervous', 'system', 'symptoms', '.'], 'lemmatized': ['patient', 'developed', 'lupus', 'nephritis', 'central', 'nervous', 'system', 'symptom', '.'], 'stemmed': ['patient', 'develop', 'lupu', 'nephriti', 'central', 'nervou', 'system', 'symptom', '.'], 'dependencies': [('patient', 'nsubj'), ('develop', 'ROOT'), ('lupu', 'amod'), ('nephriti', 'compound'), ('central', 'amod'), ('nervou', 'compound'), ('system', 'compound'), ('symptom', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The impact of long-term \\ntreatment with HUMIRA on the development of autoimmune diseases is unknown.', 'tokens': ['impact', 'long-term', 'treatment', 'HUMIRA', 'development', 'autoimmune', 'diseases', 'unknown', '.'], 'lemmatized': ['impact', 'long-term', 'treatment', 'HUMIRA', 'development', 'autoimmune', 'disease', 'unknown', '.'], 'stemmed': ['impact', 'long-term', 'treatment', 'humira', 'develop', 'autoimmun', 'diseas', 'unknown', '.'], 'dependencies': [('impact', 'ROOT'), ('long', 'amod'), ('-', 'punct'), ('term', 'compound'), ('treatment', 'compound'), ('humira', 'nsubj'), ('develop', 'ccomp'), ('autoimmun', 'amod'), ('diseas', 'dobj'), ('unknown', 'amod'), ('.', 'punct')]}, {'original_sentence': 'Liver Enzyme Elevations  \\nThere have been reports of severe hepatic reactions including acute liver failure in patients \\nreceiving TNF-blockers.', 'tokens': ['Liver', 'Enzyme', 'Elevations', 'reports', 'severe', 'hepatic', 'reactions', 'including', 'acute', 'liver', 'failure', 'patients', 'receiving', 'TNF-blockers', '.'], 'lemmatized': ['Liver', 'Enzyme', 'Elevations', 'report', 'severe', 'hepatic', 'reaction', 'including', 'acute', 'liver', 'failure', 'patient', 'receiving', 'TNF-blockers', '.'], 'stemmed': ['liver', 'enzym', 'elev', 'report', 'sever', 'hepat', 'reaction', 'includ', 'acut', 'liver', 'failur', 'patient', 'receiv', 'tnf-blocker', '.'], 'dependencies': [('liver', 'nsubj'), ('enzym', 'ROOT'), ('elev', 'compound'), ('report', 'dobj'), ('sever', 'advcl'), ('hepat', 'compound'), ('reaction', 'compound'), ('includ', 'compound'), ('acut', 'compound'), ('liver', 'compound'), ('failur', 'compound'), ('patient', 'compound'), ('receiv', 'compound'), ('tnf', 'dobj'), ('-', 'npadvmod'), ('blocker', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'In controlled Phase 3 trials of HUMIRA (40 mg SC every other week) \\nin patients with RA, PsA, and AS with control period duration ranging from 4 to 104 weeks, \\nALT elevations ≥ 3 x ULN occurred in 3.5% of HUMIRA-treated patients and 1.5% of control-\\ntreated patients.', 'tokens': ['controlled', 'Phase', '3', 'trials', 'HUMIRA', '(', '40', 'mg', 'SC', 'every', 'week', ')', 'patients', 'RA', ',', 'PsA', ',', 'control', 'period', 'duration', 'ranging', '4', '104', 'weeks', ',', 'ALT', 'elevations', '≥', '3', 'x', 'ULN', 'occurred', '3.5', '%', 'HUMIRA-treated', 'patients', '1.5', '%', 'control-', 'treated', 'patients', '.'], 'lemmatized': ['controlled', 'Phase', '3', 'trial', 'HUMIRA', '(', '40', 'mg', 'SC', 'every', 'week', ')', 'patient', 'RA', ',', 'PsA', ',', 'control', 'period', 'duration', 'ranging', '4', '104', 'week', ',', 'ALT', 'elevation', '≥', '3', 'x', 'ULN', 'occurred', '3.5', '%', 'HUMIRA-treated', 'patient', '1.5', '%', 'control-', 'treated', 'patient', '.'], 'stemmed': ['control', 'phase', '3', 'trial', 'humira', '(', '40', 'mg', 'sc', 'everi', 'week', ')', 'patient', 'ra', ',', 'psa', ',', 'control', 'period', 'durat', 'rang', '4', '104', 'week', ',', 'alt', 'elev', '≥', '3', 'x', 'uln', 'occur', '3.5', '%', 'humira-tr', 'patient', '1.5', '%', 'control-', 'treat', 'patient', '.'], 'dependencies': [('control', 'compound'), ('phase', 'nmod'), ('3', 'nummod'), ('trial', 'compound'), ('humira', 'dobj'), ('(', 'punct'), ('40', 'nummod'), ('mg', 'nmod'), ('sc', 'nmod'), ('everi', 'amod'), ('week', 'npadvmod'), (')', 'punct'), ('patient', 'compound'), ('ra', 'dep'), (',', 'punct'), ('psa', 'meta'), (',', 'punct'), ('control', 'compound'), ('period', 'compound'), ('durat', 'nsubj'), ('rang', 'nsubj'), ('4', 'nummod'), ('104', 'nummod'), ('week', 'npadvmod'), (',', 'punct'), ('alt', 'ROOT'), ('elev', 'dobj'), ('≥', 'npadvmod'), ('3', 'nummod'), ('x', 'punct'), ('uln', 'advmod'), ('occur', 'ccomp'), ('3.5', 'nummod'), ('%', 'npadvmod'), ('humira', 'npadvmod'), ('-', 'punct'), ('tr', 'nmod'), ('patient', 'amod'), ('1.5', 'nummod'), ('%', 'compound'), ('control-', 'compound'), ('treat', 'compound'), ('patient', 'oprd'), ('.', 'punct')]}, {'original_sentence': 'Since many of these patients in these trials were also taking medications that \\ncause liver enzyme elevations (e.g., NSAIDS, MTX), the relationship between HUMIRA and the \\nliver enzyme elevations is not clear.', 'tokens': ['Since', 'many', 'patients', 'trials', 'also', 'taking', 'medications', 'cause', 'liver', 'enzyme', 'elevations', '(', 'e.g.', ',', 'NSAIDS', ',', 'MTX', ')', ',', 'relationship', 'HUMIRA', 'liver', 'enzyme', 'elevations', 'clear', '.'], 'lemmatized': ['Since', 'many', 'patient', 'trial', 'also', 'taking', 'medication', 'cause', 'liver', 'enzyme', 'elevation', '(', 'e.g.', ',', 'NSAIDS', ',', 'MTX', ')', ',', 'relationship', 'HUMIRA', 'liver', 'enzyme', 'elevation', 'clear', '.'], 'stemmed': ['sinc', 'mani', 'patient', 'trial', 'also', 'take', 'medic', 'caus', 'liver', 'enzym', 'elev', '(', 'e.g.', ',', 'nsaid', ',', 'mtx', ')', ',', 'relationship', 'humira', 'liver', 'enzym', 'elev', 'clear', '.'], 'dependencies': [('sinc', 'compound'), ('mani', 'compound'), ('patient', 'compound'), ('trial', 'nsubj'), ('also', 'advmod'), ('take', 'ROOT'), ('medic', 'amod'), ('caus', 'compound'), ('liver', 'nsubj'), ('enzym', 'ccomp'), ('elev', 'dobj'), ('(', 'punct'), ('e.g.', 'advmod'), (',', 'punct'), ('nsaid', 'parataxis'), (',', 'punct'), ('mtx', 'conj'), (')', 'punct'), (',', 'punct'), ('relationship', 'compound'), ('humira', 'compound'), ('liver', 'nsubj'), ('enzym', 'conj'), ('elev', 'advmod'), ('clear', 'acomp'), ('.', 'punct')]}, {'original_sentence': 'In a controlled Phase 3 trial of HUMIRA in patients with \\npolyarticular JIA who were 4 to 17 years, ALT elevations ≥ 3 x ULN occurred in 4.4% of \\nHUMIRA-treated patients and 1.5% of control-treated patients (ALT more common than AST); \\nliver enzyme test elevations were more frequent among those treated with the combination of \\nHUMIRA and MTX than those treated with HUMIRA alone.', 'tokens': ['controlled', 'Phase', '3', 'trial', 'HUMIRA', 'patients', 'polyarticular', 'JIA', '4', '17', 'years', ',', 'ALT', 'elevations', '≥', '3', 'x', 'ULN', 'occurred', '4.4', '%', 'HUMIRA-treated', 'patients', '1.5', '%', 'control-treated', 'patients', '(', 'ALT', 'common', 'AST', ')', ';', 'liver', 'enzyme', 'test', 'elevations', 'frequent', 'among', 'treated', 'combination', 'HUMIRA', 'MTX', 'treated', 'HUMIRA', 'alone', '.'], 'lemmatized': ['controlled', 'Phase', '3', 'trial', 'HUMIRA', 'patient', 'polyarticular', 'JIA', '4', '17', 'year', ',', 'ALT', 'elevation', '≥', '3', 'x', 'ULN', 'occurred', '4.4', '%', 'HUMIRA-treated', 'patient', '1.5', '%', 'control-treated', 'patient', '(', 'ALT', 'common', 'AST', ')', ';', 'liver', 'enzyme', 'test', 'elevation', 'frequent', 'among', 'treated', 'combination', 'HUMIRA', 'MTX', 'treated', 'HUMIRA', 'alone', '.'], 'stemmed': ['control', 'phase', '3', 'trial', 'humira', 'patient', 'polyarticular', 'jia', '4', '17', 'year', ',', 'alt', 'elev', '≥', '3', 'x', 'uln', 'occur', '4.4', '%', 'humira-tr', 'patient', '1.5', '%', 'control-tr', 'patient', '(', 'alt', 'common', 'ast', ')', ';', 'liver', 'enzym', 'test', 'elev', 'frequent', 'among', 'treat', 'combin', 'humira', 'mtx', 'treat', 'humira', 'alon', '.'], 'dependencies': [('control', 'compound'), ('phase', 'nmod'), ('3', 'nummod'), ('trial', 'nsubj'), ('humira', 'nmod'), ('patient', 'nmod'), ('polyarticular', 'npadvmod'), ('jia', 'npadvmod'), ('4', 'nummod'), ('17', 'nummod'), ('year', 'npadvmod'), (',', 'punct'), ('alt', 'ROOT'), ('elev', 'dobj'), ('≥', 'npadvmod'), ('3', 'nummod'), ('x', 'punct'), ('uln', 'advmod'), ('occur', 'ccomp'), ('4.4', 'nummod'), ('%', 'npadvmod'), ('humira', 'npadvmod'), ('-', 'punct'), ('tr', 'nsubj'), ('patient', 'amod'), ('1.5', 'nummod'), ('%', 'npadvmod'), ('control', 'compound'), ('-', 'punct'), ('tr', 'xcomp'), ('patient', 'ccomp'), ('(', 'punct'), ('alt', 'parataxis'), ('common', 'amod'), ('ast', 'dobj'), (')', 'punct'), (';', 'punct'), ('liver', 'nsubj'), ('enzym', 'compound'), ('test', 'npadvmod'), ('elev', 'advmod'), ('frequent', 'amod'), ('among', 'prep'), ('treat', 'compound'), ('combin', 'compound'), ('humira', 'compound'), ('mtx', 'compound'), ('treat', 'compound'), ('humira', 'compound'), ('alon', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'In general, these elevations did not \\nlead to discontinuation of HUMIRA treatment.', 'tokens': ['general', ',', 'elevations', 'lead', 'discontinuation', 'HUMIRA', 'treatment', '.'], 'lemmatized': ['general', ',', 'elevation', 'lead', 'discontinuation', 'HUMIRA', 'treatment', '.'], 'stemmed': ['gener', ',', 'elev', 'lead', 'discontinu', 'humira', 'treatment', '.'], 'dependencies': [('gener', 'npadvmod'), (',', 'punct'), ('elev', 'nsubj'), ('lead', 'ROOT'), ('discontinu', 'compound'), ('humira', 'compound'), ('treatment', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'No ALT elevations ≥ 3 x ULN occurred in the \\nopen-label study of HUMIRA in patients with polyarticular JIA who were 2 to <4 years.', 'tokens': ['ALT', 'elevations', '≥', '3', 'x', 'ULN', 'occurred', 'open-label', 'study', 'HUMIRA', 'patients', 'polyarticular', 'JIA', '2', '<', '4', 'years', '.'], 'lemmatized': ['ALT', 'elevation', '≥', '3', 'x', 'ULN', 'occurred', 'open-label', 'study', 'HUMIRA', 'patient', 'polyarticular', 'JIA', '2', '<', '4', 'year', '.'], 'stemmed': ['alt', 'elev', '≥', '3', 'x', 'uln', 'occur', 'open-label', 'studi', 'humira', 'patient', 'polyarticular', 'jia', '2', '<', '4', 'year', '.'], 'dependencies': [('alt', 'ROOT'), ('elev', 'dobj'), ('≥', 'appos'), ('3', 'nummod'), ('x', 'punct'), ('uln', 'advmod'), ('occur', 'ccomp'), ('open', 'amod'), ('-', 'punct'), ('label', 'compound'), ('studi', 'compound'), ('humira', 'dobj'), ('patient', 'compound'), ('polyarticular', 'nmod'), ('jia', 'nmod'), ('2', 'nummod'), ('<', 'nmod'), ('4', 'nummod'), ('year', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'In controlled Phase 3 trials of HUMIRA (initial doses of 160 mg and 80 mg, or 80 mg and 40 mg \\non Days 1 and 15, respectively, followed by 40 mg every other week) in adult patients with \\nCrohn’s Disease with a control period duration ranging from 4 to 52 weeks, ALT elevations ≥ 3 \\nx ULN occurred in 0.9% of HUMIRA-treated patients and 0.9% of control-treated patients.', 'tokens': ['controlled', 'Phase', '3', 'trials', 'HUMIRA', '(', 'initial', 'doses', '160', 'mg', '80', 'mg', ',', '80', 'mg', '40', 'mg', 'Days', '1', '15', ',', 'respectively', ',', 'followed', '40', 'mg', 'every', 'week', ')', 'adult', 'patients', 'Crohn', '’', 'Disease', 'control', 'period', 'duration', 'ranging', '4', '52', 'weeks', ',', 'ALT', 'elevations', '≥', '3', 'x', 'ULN', 'occurred', '0.9', '%', 'HUMIRA-treated', 'patients', '0.9', '%', 'control-treated', 'patients', '.'], 'lemmatized': ['controlled', 'Phase', '3', 'trial', 'HUMIRA', '(', 'initial', 'dos', '160', 'mg', '80', 'mg', ',', '80', 'mg', '40', 'mg', 'Days', '1', '15', ',', 'respectively', ',', 'followed', '40', 'mg', 'every', 'week', ')', 'adult', 'patient', 'Crohn', '’', 'Disease', 'control', 'period', 'duration', 'ranging', '4', '52', 'week', ',', 'ALT', 'elevation', '≥', '3', 'x', 'ULN', 'occurred', '0.9', '%', 'HUMIRA-treated', 'patient', '0.9', '%', 'control-treated', 'patient', '.'], 'stemmed': ['control', 'phase', '3', 'trial', 'humira', '(', 'initi', 'do', '160', 'mg', '80', 'mg', ',', '80', 'mg', '40', 'mg', 'day', '1', '15', ',', 'respect', ',', 'follow', '40', 'mg', 'everi', 'week', ')', 'adult', 'patient', 'crohn', '’', 'diseas', 'control', 'period', 'durat', 'rang', '4', '52', 'week', ',', 'alt', 'elev', '≥', '3', 'x', 'uln', 'occur', '0.9', '%', 'humira-tr', 'patient', '0.9', '%', 'control-tr', 'patient', '.'], 'dependencies': [('control', 'compound'), ('phase', 'compound'), ('3', 'nummod'), ('trial', 'compound'), ('humira', 'nsubj'), ('(', 'punct'), ('initi', 'npadvmod'), ('do', 'aux'), ('160', 'nummod'), ('mg', 'quantmod'), ('80', 'nummod'), ('mg', 'dobj'), (',', 'punct'), ('80', 'quantmod'), ('mg', 'quantmod'), ('40', 'nummod'), ('mg', 'prep'), ('day', 'appos'), ('1', 'compound'), ('15', 'nummod'), (',', 'punct'), ('respect', 'appos'), (',', 'punct'), ('follow', 'conj'), ('40', 'dobj'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'npadvmod'), (')', 'punct'), ('adult', 'compound'), ('patient', 'compound'), ('crohn', 'poss'), ('’', 'punct'), ('diseas', 'compound'), ('control', 'compound'), ('period', 'compound'), ('durat', 'compound'), ('rang', 'dative'), ('4', 'nummod'), ('52', 'nummod'), ('week', 'npadvmod'), (',', 'punct'), ('alt', 'advcl'), ('elev', 'dobj'), ('≥', 'npadvmod'), ('3', 'nummod'), ('x', 'punct'), ('uln', 'advmod'), ('occur', 'ROOT'), ('0.9', 'nummod'), ('%', 'npadvmod'), ('humira', 'npadvmod'), ('-', 'punct'), ('tr', 'nsubj'), ('patient', 'conj'), ('0.9', 'nummod'), ('%', 'npadvmod'), ('control', 'compound'), ('-', 'punct'), ('tr', 'amod'), ('patient', 'conj'), ('.', 'punct')]}, {'original_sentence': 'In', 'tokens': [], 'lemmatized': [], 'stemmed': [], 'dependencies': []}], 'text': 'In the controlled portions of the 39 global HUMIRA clinical trials in adult patients with RA, \\nPsA, AS, CD, UC, Ps, HS and UV, the rate of serious infections was 4.3 per 100 patient-years in \\n7973 HUMIRA-treated patients versus a rate of 2.9 per 100 patient-years in 4848 control-treated \\npatients. Serious infections observed included pneumonia, septic arthritis, prosthetic and post-\\nsurgical infections, erysipelas, cellulitis, diverticulitis, and pyelonephritis [see Warnings and \\nPrecautions (5.1)].  \\nTuberculosis and Opportunistic Infections \\nIn 52 global controlled and uncontrolled clinical trials in RA, PsA, AS, CD, UC, Ps, HS and UV \\nthat included 24,605 HUMIRA-treated patients, the rate of reported active tuberculosis was 0.20 \\nper 100 patient-years and the rate of positive PPD conversion was 0.09 per 100 patient-years. In \\na subgroup of 10,113 U.S. and Canadian HUMIRA-treated patients, the rate of reported active \\nTB was 0.05 per 100 patient-years and the rate of positive PPD conversion was 0.07 per 100 \\npatient-years. These trials included reports of miliary, lymphatic, peritoneal, and pulmonary TB. \\nMost of the TB cases occurred within the first eight months after initiation of therapy and may \\nreflect recrudescence of latent disease. In these global clinical trials, cases of serious \\nopportunistic infections have been reported at an overall rate of 0.05 per 100 patient-years. Some \\ncases of serious opportunistic infections and TB have been fatal [see Warnings and Precautions \\n(5.1)].  \\nAutoantibodies \\nIn the rheumatoid arthritis controlled trials, 12% of patients treated with HUMIRA and 7% of \\nplacebo-treated patients that had negative baseline ANA titers developed positive titers at week \\n24. Two patients out of 3046 treated with HUMIRA developed clinical signs suggestive of new-\\nonset lupus-like syndrome. The patients improved following discontinuation of therapy. No \\npatients developed lupus nephritis or central nervous system symptoms. The impact of long-term \\ntreatment with HUMIRA on the development of autoimmune diseases is unknown.  \\nLiver Enzyme Elevations  \\nThere have been reports of severe hepatic reactions including acute liver failure in patients \\nreceiving TNF-blockers. In controlled Phase 3 trials of HUMIRA (40 mg SC every other week) \\nin patients with RA, PsA, and AS with control period duration ranging from 4 to 104 weeks, \\nALT elevations ≥ 3 x ULN occurred in 3.5% of HUMIRA-treated patients and 1.5% of control-\\ntreated patients. Since many of these patients in these trials were also taking medications that \\ncause liver enzyme elevations (e.g., NSAIDS, MTX), the relationship between HUMIRA and the \\nliver enzyme elevations is not clear. In a controlled Phase 3 trial of HUMIRA in patients with \\npolyarticular JIA who were 4 to 17 years, ALT elevations ≥ 3 x ULN occurred in 4.4% of \\nHUMIRA-treated patients and 1.5% of control-treated patients (ALT more common than AST); \\nliver enzyme test elevations were more frequent among those treated with the combination of \\nHUMIRA and MTX than those treated with HUMIRA alone. In general, these elevations did not \\nlead to discontinuation of HUMIRA treatment. No ALT elevations ≥ 3 x ULN occurred in the \\nopen-label study of HUMIRA in patients with polyarticular JIA who were 2 to <4 years.  \\nIn controlled Phase 3 trials of HUMIRA (initial doses of 160 mg and 80 mg, or 80 mg and 40 mg \\non Days 1 and 15, respectively, followed by 40 mg every other week) in adult patients with \\nCrohn’s Disease with a control period duration ranging from 4 to 52 weeks, ALT elevations ≥ 3 \\nx ULN occurred in 0.9% of HUMIRA-treated patients and 0.9% of control-treated patients. In \\n'}, 'page_char_count': 3681, 'page_word_count': 574, 'sentences': ['In the controlled portions of the 39 global HUMIRA clinical trials in adult patients with RA, \\nPsA, AS, CD, UC, Ps, HS and UV, the rate of serious infections was 4.3 per 100 patient-years in \\n7973 HUMIRA-treated patients versus a rate of 2.9 per 100 patient-years in 4848 control-treated \\npatients.', 'Serious infections observed included pneumonia, septic arthritis, prosthetic and post-\\nsurgical infections, erysipelas, cellulitis, diverticulitis, and pyelonephritis [see Warnings and \\nPrecautions (5.1)].', ' \\nTuberculosis and Opportunistic Infections \\nIn 52 global controlled and uncontrolled clinical trials in RA, PsA, AS, CD, UC, Ps, HS and UV \\nthat included 24,605 HUMIRA-treated patients, the rate of reported active tuberculosis was 0.20 \\nper 100 patient-years and the rate of positive PPD conversion was 0.09 per 100 patient-years.', 'In \\na subgroup of 10,113 U.S. and Canadian HUMIRA-treated patients, the rate of reported active \\nTB was 0.05 per 100 patient-years and the rate of positive PPD conversion was 0.07 per 100 \\npatient-years.', 'These trials included reports of miliary, lymphatic, peritoneal, and pulmonary TB.', '\\nMost of the TB cases occurred within the first eight months after initiation of therapy and may \\nreflect recrudescence of latent disease.', 'In these global clinical trials, cases of serious \\nopportunistic infections have been reported at an overall rate of 0.05 per 100 patient-years.', 'Some \\ncases of serious opportunistic infections and TB have been fatal [see Warnings and Precautions \\n(5.1)].', ' \\nAutoantibodies \\nIn the rheumatoid arthritis controlled trials, 12% of patients treated with HUMIRA and 7% of \\nplacebo-treated patients that had negative baseline ANA titers developed positive titers at week \\n24.', 'Two patients out of 3046 treated with HUMIRA developed clinical signs suggestive of new-\\nonset lupus-like syndrome.', 'The patients improved following discontinuation of therapy.', 'No \\npatients developed lupus nephritis or central nervous system symptoms.', 'The impact of long-term \\ntreatment with HUMIRA on the development of autoimmune diseases is unknown.', ' \\nLiver Enzyme Elevations  \\nThere have been reports of severe hepatic reactions including acute liver failure in patients \\nreceiving TNF-blockers.', 'In controlled Phase 3 trials of HUMIRA (40 mg SC every other week) \\nin patients with RA, PsA, and AS with control period duration ranging from 4 to 104 weeks, \\nALT elevations ≥ 3 x ULN occurred in 3.5% of HUMIRA-treated patients and 1.5% of control-\\ntreated patients.', 'Since many of these patients in these trials were also taking medications that \\ncause liver enzyme elevations (e.g., NSAIDS, MTX), the relationship between HUMIRA and the \\nliver enzyme elevations is not clear.', 'In a controlled Phase 3 trial of HUMIRA in patients with \\npolyarticular JIA who were 4 to 17 years, ALT elevations ≥ 3 x ULN occurred in 4.4% of \\nHUMIRA-treated patients and 1.5% of control-treated patients (ALT more common than AST); \\nliver enzyme test elevations were more frequent among those treated with the combination of \\nHUMIRA and MTX than those treated with HUMIRA alone.', 'In general, these elevations did not \\nlead to discontinuation of HUMIRA treatment.', 'No ALT elevations ≥ 3 x ULN occurred in the \\nopen-label study of HUMIRA in patients with polyarticular JIA who were 2 to <4 years.', ' \\nIn controlled Phase 3 trials of HUMIRA (initial doses of 160 mg and 80 mg, or 80 mg and 40 mg \\non Days 1 and 15, respectively, followed by 40 mg every other week) in adult patients with \\nCrohn’s Disease with a control period duration ranging from 4 to 52 weeks, ALT elevations ≥ 3 \\nx ULN occurred in 0.9% of HUMIRA-treated patients and 0.9% of control-treated patients.', 'In \\n'], 'page_sentence_count_spacy': 21}\n",
            "{'page_number': 16, 'text': 'the Phase 3 trial of HUMIRA in pediatric patients with Crohn’s disease which evaluated efficacy \\nand safety of two body weight based maintenance dose regimens following body weight based \\ninduction therapy up to 52 weeks of treatment, ALT elevations ≥ 3 x ULN occurred in 2.6% \\n(5/192) of patients, of whom 4 were receiving concomitant immunosuppressants at baseline; \\nnone of these patients discontinued due to abnormalities in ALT tests. In controlled Phase 3 trials \\nof HUMIRA (initial doses of 160 mg and 80 mg on Days 1 and 15 respectively, followed by 40 \\nmg every other week) in adult patients with UC with control period duration ranging from 1 to \\n52 weeks, ALT elevations ≥3 x ULN occurred in 1.5% of HUMIRA-treated patients and 1.0% of \\ncontrol-treated patients. In the controlled Phase 3 trial of HUMIRA in patients with pediatric \\nulcerative colitis (N=93), which evaluated efficacy and safety of a maintenance dose of 0.6 \\nmg/kg (maximum of 40 mg) every other week (N=31) and a maintenance dose of 0.6 mg/kg \\n(maximum of 40 mg) every week (N=32), following body weight based induction doses of 2.4 \\nmg/kg (maximum of 160 mg) at Week 0 and Week 1, and 1.2 mg/kg (maximum of 80 mg) at \\nWeek 2 (N=63), or an induction dose of 2.4 mg/kg (maximum of 160 mg) at Week 0, placebo at \\nWeek 1, and 1.2 mg/kg (maximum of 80 mg) at Week 2 (N=30), ALT elevations ≥ 3 X ULN \\noccurred in 1.1% (1/93) of patients. In controlled Phase 3 trials of HUMIRA (initial dose of 80 \\nmg then 40 mg every other week) in patients with Ps with control period duration ranging from \\n12 to 24 weeks, ALT elevations ≥ 3 x ULN occurred in 1.8% of HUMIRA-treated patients and \\n1.8% of control-treated patients. In controlled trials of HUMIRA (initial doses of 160 mg at \\nWeek 0 and 80 mg at Week 2, followed by 40 mg every week starting at Week 4), in subjects \\nwith HS with a control period duration ranging from 12 to 16 weeks, ALT elevations ≥ 3 x ULN \\noccurred in 0.3% of HUMIRA-treated subjects and 0.6% of control-treated subjects. In \\ncontrolled trials of HUMIRA (initial doses of 80 mg at Week 0 followed by 40 mg every other \\nweek starting at Week 1) in adult patients with uveitis with an exposure of 165.4 PYs and 119.8 \\nPYs in HUMIRA-treated and control-treated patients, respectively, ALT elevations ≥ 3 x ULN \\noccurred in 2.4% of HUMIRA-treated patients and 2.4% of control-treated patients.  \\nOther Adverse Reactions \\nRheumatoid Arthritis Clinical Studies \\nThe data described below reflect exposure to HUMIRA in 2468 patients, including 2073 exposed \\nfor 6 months, 1497 exposed for greater than one year and 1380 in adequate and well-controlled \\nstudies (Studies RA-I, RA-II, RA-III, and RA-IV). HUMIRA was studied primarily in placebo-\\ncontrolled trials and in long-term follow up studies for up to 36 months duration. The population \\nhad a mean age of 54 years, 77% were female, 91% were Caucasian and had moderately to \\nseverely active rheumatoid arthritis. Most patients received 40 mg HUMIRA every other week \\n[see Clinical Studies (14.1)].  \\nTable 1 summarizes reactions reported at a rate of at least 5% in patients treated with HUMIRA \\n40 mg every other week compared to placebo and with an incidence higher than placebo. In \\nStudy RA-III, the types and frequencies of adverse reactions in the second year open-label \\nextension were similar to those observed in the one-year double-blind portion.  \\n \\n \\n', 'processed_text': {'sentences': [{'original_sentence': 'the Phase 3 trial of HUMIRA in pediatric patients with Crohn’s disease which evaluated efficacy \\nand safety of two body weight based maintenance dose regimens following body weight based \\ninduction therapy up to 52 weeks of treatment, ALT elevations ≥ 3 x ULN occurred in 2.6% \\n(5/192) of patients, of whom 4 were receiving concomitant immunosuppressants at baseline; \\nnone of these patients discontinued due to abnormalities in ALT tests.', 'tokens': ['Phase', '3', 'trial', 'HUMIRA', 'pediatric', 'patients', 'Crohn', '’', 'disease', 'evaluated', 'efficacy', 'safety', 'two', 'body', 'weight', 'based', 'maintenance', 'dose', 'regimens', 'following', 'body', 'weight', 'based', 'induction', 'therapy', '52', 'weeks', 'treatment', ',', 'ALT', 'elevations', '≥', '3', 'x', 'ULN', 'occurred', '2.6', '%', '(', '5/192', ')', 'patients', ',', '4', 'receiving', 'concomitant', 'immunosuppressants', 'baseline', ';', 'none', 'patients', 'discontinued', 'due', 'abnormalities', 'ALT', 'tests', '.'], 'lemmatized': ['Phase', '3', 'trial', 'HUMIRA', 'pediatric', 'patient', 'Crohn', '’', 'disease', 'evaluated', 'efficacy', 'safety', 'two', 'body', 'weight', 'based', 'maintenance', 'dose', 'regimen', 'following', 'body', 'weight', 'based', 'induction', 'therapy', '52', 'week', 'treatment', ',', 'ALT', 'elevation', '≥', '3', 'x', 'ULN', 'occurred', '2.6', '%', '(', '5/192', ')', 'patient', ',', '4', 'receiving', 'concomitant', 'immunosuppressant', 'baseline', ';', 'none', 'patient', 'discontinued', 'due', 'abnormality', 'ALT', 'test', '.'], 'stemmed': ['phase', '3', 'trial', 'humira', 'pediatr', 'patient', 'crohn', '’', 'diseas', 'evalu', 'efficaci', 'safeti', 'two', 'bodi', 'weight', 'base', 'mainten', 'dose', 'regimen', 'follow', 'bodi', 'weight', 'base', 'induct', 'therapi', '52', 'week', 'treatment', ',', 'alt', 'elev', '≥', '3', 'x', 'uln', 'occur', '2.6', '%', '(', '5/192', ')', 'patient', ',', '4', 'receiv', 'concomit', 'immunosuppress', 'baselin', ';', 'none', 'patient', 'discontinu', 'due', 'abnorm', 'alt', 'test', '.'], 'dependencies': [('phase', 'nmod'), ('3', 'nummod'), ('trial', 'compound'), ('humira', 'nmod'), ('pediatr', 'compound'), ('patient', 'compound'), ('crohn', 'dobj'), ('’', 'punct'), ('diseas', 'compound'), ('evalu', 'compound'), ('efficaci', 'compound'), ('safeti', 'nmod'), ('two', 'nummod'), ('bodi', 'compound'), ('weight', 'compound'), ('base', 'appos'), ('mainten', 'compound'), ('dose', 'compound'), ('regimen', 'compound'), ('follow', 'compound'), ('bodi', 'compound'), ('weight', 'compound'), ('base', 'compound'), ('induct', 'nsubj'), ('therapi', 'ccomp'), ('52', 'nummod'), ('week', 'compound'), ('treatment', 'dobj'), (',', 'punct'), ('alt', 'conj'), ('elev', 'dobj'), ('≥', 'npadvmod'), ('3', 'nummod'), ('x', 'punct'), ('uln', 'advmod'), ('occur', 'advcl'), ('2.6', 'nummod'), ('%', 'npadvmod'), ('(', 'punct'), ('5/192', 'nummod'), (')', 'punct'), ('patient', 'appos'), (',', 'punct'), ('4', 'nummod'), ('receiv', 'compound'), ('concomit', 'compound'), ('immunosuppress', 'compound'), ('baselin', 'appos'), (';', 'punct'), ('none', 'npadvmod'), ('patient', 'amod'), ('discontinu', 'nsubj'), ('due', 'amod'), ('abnorm', 'ROOT'), ('alt', 'amod'), ('test', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'In controlled Phase 3 trials \\nof HUMIRA (initial doses of 160 mg and 80 mg on Days 1 and 15 respectively, followed by 40 \\nmg every other week) in adult patients with UC with control period duration ranging from 1 to \\n52 weeks, ALT elevations ≥3 x ULN occurred in 1.5% of HUMIRA-treated patients and 1.0% of \\ncontrol-treated patients.', 'tokens': ['controlled', 'Phase', '3', 'trials', 'HUMIRA', '(', 'initial', 'doses', '160', 'mg', '80', 'mg', 'Days', '1', '15', 'respectively', ',', 'followed', '40', 'mg', 'every', 'week', ')', 'adult', 'patients', 'UC', 'control', 'period', 'duration', 'ranging', '1', '52', 'weeks', ',', 'ALT', 'elevations', '≥3', 'x', 'ULN', 'occurred', '1.5', '%', 'HUMIRA-treated', 'patients', '1.0', '%', 'control-treated', 'patients', '.'], 'lemmatized': ['controlled', 'Phase', '3', 'trial', 'HUMIRA', '(', 'initial', 'dos', '160', 'mg', '80', 'mg', 'Days', '1', '15', 'respectively', ',', 'followed', '40', 'mg', 'every', 'week', ')', 'adult', 'patient', 'UC', 'control', 'period', 'duration', 'ranging', '1', '52', 'week', ',', 'ALT', 'elevation', '≥3', 'x', 'ULN', 'occurred', '1.5', '%', 'HUMIRA-treated', 'patient', '1.0', '%', 'control-treated', 'patient', '.'], 'stemmed': ['control', 'phase', '3', 'trial', 'humira', '(', 'initi', 'do', '160', 'mg', '80', 'mg', 'day', '1', '15', 'respect', ',', 'follow', '40', 'mg', 'everi', 'week', ')', 'adult', 'patient', 'uc', 'control', 'period', 'durat', 'rang', '1', '52', 'week', ',', 'alt', 'elev', '≥3', 'x', 'uln', 'occur', '1.5', '%', 'humira-tr', 'patient', '1.0', '%', 'control-tr', 'patient', '.'], 'dependencies': [('control', 'compound'), ('phase', 'compound'), ('3', 'nummod'), ('trial', 'compound'), ('humira', 'nsubj'), ('(', 'punct'), ('initi', 'npadvmod'), ('do', 'ROOT'), ('160', 'quantmod'), ('mg', 'quantmod'), ('80', 'dobj'), ('mg', 'nmod'), ('day', 'nmod'), ('1', 'compound'), ('15', 'nummod'), ('respect', 'dobj'), (',', 'punct'), ('follow', 'conj'), ('40', 'dobj'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'npadvmod'), (')', 'punct'), ('adult', 'compound'), ('patient', 'dobj'), ('uc', 'compound'), ('control', 'compound'), ('period', 'compound'), ('durat', 'compound'), ('rang', 'dep'), ('1', 'nummod'), ('52', 'nummod'), ('week', 'npadvmod'), (',', 'punct'), ('alt', 'advcl'), ('elev', 'dobj'), ('≥3', 'punct'), ('x', 'nsubj'), ('uln', 'advmod'), ('occur', 'ROOT'), ('1.5', 'nummod'), ('%', 'npadvmod'), ('humira', 'npadvmod'), ('-', 'punct'), ('tr', 'nsubj'), ('patient', 'amod'), ('1.0', 'nummod'), ('%', 'npadvmod'), ('control', 'compound'), ('-', 'punct'), ('tr', 'xcomp'), ('patient', 'oprd'), ('.', 'punct')]}, {'original_sentence': 'In the controlled Phase 3 trial of HUMIRA in patients with pediatric \\nulcerative colitis (N=93), which evaluated efficacy and safety of a maintenance dose of 0.6 \\nmg/kg (maximum of 40 mg) every other week (N=31) and a maintenance dose of 0.6 mg/kg \\n(maximum of 40 mg) every week (N=32), following body weight based induction doses of 2.4 \\nmg/kg (maximum of 160 mg) at Week 0 and Week 1, and 1.2 mg/kg (maximum of 80 mg) at \\nWeek 2 (N=63), or an induction dose of 2.4 mg/kg (maximum of 160 mg) at Week 0, placebo at \\nWeek 1, and 1.2 mg/kg (maximum of 80 mg) at Week 2 (N=30), ALT elevations ≥ 3 X ULN \\noccurred in 1.1% (1/93) of patients.', 'tokens': ['controlled', 'Phase', '3', 'trial', 'HUMIRA', 'patients', 'pediatric', 'ulcerative', 'colitis', '(', 'N=93', ')', ',', 'evaluated', 'efficacy', 'safety', 'maintenance', 'dose', '0.6', 'mg/kg', '(', 'maximum', '40', 'mg', ')', 'every', 'week', '(', 'N=31', ')', 'maintenance', 'dose', '0.6', 'mg/kg', '(', 'maximum', '40', 'mg', ')', 'every', 'week', '(', 'N=32', ')', ',', 'following', 'body', 'weight', 'based', 'induction', 'doses', '2.4', 'mg/kg', '(', 'maximum', '160', 'mg', ')', 'Week', '0', 'Week', '1', ',', '1.2', 'mg/kg', '(', 'maximum', '80', 'mg', ')', 'Week', '2', '(', 'N=63', ')', ',', 'induction', 'dose', '2.4', 'mg/kg', '(', 'maximum', '160', 'mg', ')', 'Week', '0', ',', 'placebo', 'Week', '1', ',', '1.2', 'mg/kg', '(', 'maximum', '80', 'mg', ')', 'Week', '2', '(', 'N=30', ')', ',', 'ALT', 'elevations', '≥', '3', 'X', 'ULN', 'occurred', '1.1', '%', '(', '1/93', ')', 'patients', '.'], 'lemmatized': ['controlled', 'Phase', '3', 'trial', 'HUMIRA', 'patient', 'pediatric', 'ulcerative', 'colitis', '(', 'N=93', ')', ',', 'evaluated', 'efficacy', 'safety', 'maintenance', 'dose', '0.6', 'mg/kg', '(', 'maximum', '40', 'mg', ')', 'every', 'week', '(', 'N=31', ')', 'maintenance', 'dose', '0.6', 'mg/kg', '(', 'maximum', '40', 'mg', ')', 'every', 'week', '(', 'N=32', ')', ',', 'following', 'body', 'weight', 'based', 'induction', 'dos', '2.4', 'mg/kg', '(', 'maximum', '160', 'mg', ')', 'Week', '0', 'Week', '1', ',', '1.2', 'mg/kg', '(', 'maximum', '80', 'mg', ')', 'Week', '2', '(', 'N=63', ')', ',', 'induction', 'dose', '2.4', 'mg/kg', '(', 'maximum', '160', 'mg', ')', 'Week', '0', ',', 'placebo', 'Week', '1', ',', '1.2', 'mg/kg', '(', 'maximum', '80', 'mg', ')', 'Week', '2', '(', 'N=30', ')', ',', 'ALT', 'elevation', '≥', '3', 'X', 'ULN', 'occurred', '1.1', '%', '(', '1/93', ')', 'patient', '.'], 'stemmed': ['control', 'phase', '3', 'trial', 'humira', 'patient', 'pediatr', 'ulcer', 'coliti', '(', 'n=93', ')', ',', 'evalu', 'efficaci', 'safeti', 'mainten', 'dose', '0.6', 'mg/kg', '(', 'maximum', '40', 'mg', ')', 'everi', 'week', '(', 'n=31', ')', 'mainten', 'dose', '0.6', 'mg/kg', '(', 'maximum', '40', 'mg', ')', 'everi', 'week', '(', 'n=32', ')', ',', 'follow', 'bodi', 'weight', 'base', 'induct', 'do', '2.4', 'mg/kg', '(', 'maximum', '160', 'mg', ')', 'week', '0', 'week', '1', ',', '1.2', 'mg/kg', '(', 'maximum', '80', 'mg', ')', 'week', '2', '(', 'n=63', ')', ',', 'induct', 'dose', '2.4', 'mg/kg', '(', 'maximum', '160', 'mg', ')', 'week', '0', ',', 'placebo', 'week', '1', ',', '1.2', 'mg/kg', '(', 'maximum', '80', 'mg', ')', 'week', '2', '(', 'n=30', ')', ',', 'alt', 'elev', '≥', '3', 'x', 'uln', 'occur', '1.1', '%', '(', '1/93', ')', 'patient', '.'], 'dependencies': [('control', 'compound'), ('phase', 'nsubj'), ('3', 'nummod'), ('trial', 'compound'), ('humira', 'nmod'), ('patient', 'nmod'), ('pediatr', 'amod'), ('ulcer', 'compound'), ('coliti', 'appos'), ('(', 'punct'), ('n=93', 'appos'), (')', 'punct'), (',', 'punct'), ('evalu', 'compound'), ('efficaci', 'appos'), ('safeti', 'compound'), ('mainten', 'conj'), ('dose', 'nsubj'), ('0.6', 'nummod'), ('mg', 'nmod'), ('/', 'punct'), ('kg', 'dobj'), ('(', 'punct'), ('maximum', 'dep'), ('40', 'nummod'), ('mg', 'dobj'), (')', 'punct'), ('everi', 'amod'), ('week', 'npadvmod'), ('(', 'punct'), ('n=31', 'npadvmod'), (')', 'punct'), ('mainten', 'compound'), ('dose', 'prep'), ('0.6', 'nummod'), ('mg', 'nmod'), ('/', 'punct'), ('kg', 'dobj'), ('(', 'punct'), ('maximum', 'amod'), ('40', 'nummod'), ('mg', 'dobj'), (')', 'punct'), ('everi', 'amod'), ('week', 'npadvmod'), ('(', 'punct'), ('n=32', 'appos'), (')', 'punct'), (',', 'punct'), ('follow', 'conj'), ('bodi', 'compound'), ('weight', 'compound'), ('base', 'compound'), ('induct', 'dobj'), ('do', 'ROOT'), ('2.4', 'nummod'), ('mg', 'nmod'), ('/', 'punct'), ('kg', 'dobj'), ('(', 'punct'), ('maximum', 'appos'), ('160', 'nummod'), ('mg', 'appos'), (')', 'punct'), ('week', 'npadvmod'), ('0', 'nummod'), ('week', 'npadvmod'), ('1', 'nummod'), (',', 'punct'), ('1.2', 'nummod'), ('mg', 'nmod'), ('/', 'punct'), ('kg', 'appos'), ('(', 'punct'), ('maximum', 'amod'), ('80', 'nummod'), ('mg', 'appos'), (')', 'punct'), ('week', 'appos'), ('2', 'nummod'), ('(', 'punct'), ('n=63', 'npadvmod'), (')', 'punct'), (',', 'punct'), ('induct', 'compound'), ('dose', 'dep'), ('2.4', 'nummod'), ('mg', 'nmod'), ('/', 'punct'), ('kg', 'dobj'), ('(', 'punct'), ('maximum', 'appos'), ('160', 'nummod'), ('mg', 'appos'), (')', 'punct'), ('week', 'npadvmod'), ('0', 'nummod'), (',', 'punct'), ('placebo', 'compound'), ('week', 'npadvmod'), ('1', 'nummod'), (',', 'punct'), ('1.2', 'nummod'), ('mg', 'nmod'), ('/', 'punct'), ('kg', 'appos'), ('(', 'punct'), ('maximum', 'amod'), ('80', 'nummod'), ('mg', 'nmod'), (')', 'punct'), ('week', 'npadvmod'), ('2', 'nummod'), ('(', 'punct'), ('n=30', 'appos'), (')', 'punct'), (',', 'punct'), ('alt', 'advcl'), ('elev', 'dobj'), ('≥', 'npadvmod'), ('3', 'nummod'), ('x', 'punct'), ('uln', 'advmod'), ('occur', 'ccomp'), ('1.1', 'nummod'), ('%', 'nmod'), ('(', 'punct'), ('1/93', 'nummod'), (')', 'punct'), ('patient', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'In controlled Phase 3 trials of HUMIRA (initial dose of 80 \\nmg then 40 mg every other week) in patients with Ps with control period duration ranging from \\n12 to 24 weeks, ALT elevations ≥ 3 x ULN occurred in 1.8% of HUMIRA-treated patients and \\n1.8% of control-treated patients.', 'tokens': ['controlled', 'Phase', '3', 'trials', 'HUMIRA', '(', 'initial', 'dose', '80', 'mg', '40', 'mg', 'every', 'week', ')', 'patients', 'Ps', 'control', 'period', 'duration', 'ranging', '12', '24', 'weeks', ',', 'ALT', 'elevations', '≥', '3', 'x', 'ULN', 'occurred', '1.8', '%', 'HUMIRA-treated', 'patients', '1.8', '%', 'control-treated', 'patients', '.'], 'lemmatized': ['controlled', 'Phase', '3', 'trial', 'HUMIRA', '(', 'initial', 'dose', '80', 'mg', '40', 'mg', 'every', 'week', ')', 'patient', 'Ps', 'control', 'period', 'duration', 'ranging', '12', '24', 'week', ',', 'ALT', 'elevation', '≥', '3', 'x', 'ULN', 'occurred', '1.8', '%', 'HUMIRA-treated', 'patient', '1.8', '%', 'control-treated', 'patient', '.'], 'stemmed': ['control', 'phase', '3', 'trial', 'humira', '(', 'initi', 'dose', '80', 'mg', '40', 'mg', 'everi', 'week', ')', 'patient', 'ps', 'control', 'period', 'durat', 'rang', '12', '24', 'week', ',', 'alt', 'elev', '≥', '3', 'x', 'uln', 'occur', '1.8', '%', 'humira-tr', 'patient', '1.8', '%', 'control-tr', 'patient', '.'], 'dependencies': [('control', 'compound'), ('phase', 'compound'), ('3', 'nummod'), ('trial', 'compound'), ('humira', 'nsubj'), ('(', 'punct'), ('initi', 'npadvmod'), ('dose', 'parataxis'), ('80', 'nummod'), ('mg', 'npadvmod'), ('40', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'npadvmod'), (')', 'punct'), ('patient', 'compound'), ('ps', 'compound'), ('control', 'compound'), ('period', 'compound'), ('durat', 'compound'), ('rang', 'conj'), ('12', 'nummod'), ('24', 'nummod'), ('week', 'npadvmod'), (',', 'punct'), ('alt', 'parataxis'), ('elev', 'dobj'), ('≥', 'npadvmod'), ('3', 'nummod'), ('x', 'punct'), ('uln', 'advmod'), ('occur', 'ROOT'), ('1.8', 'nummod'), ('%', 'npadvmod'), ('humira', 'npadvmod'), ('-', 'punct'), ('tr', 'nsubj'), ('patient', 'amod'), ('1.8', 'nummod'), ('%', 'compound'), ('control', 'compound'), ('-', 'punct'), ('tr', 'conj'), ('patient', 'amod'), ('.', 'punct')]}, {'original_sentence': 'In controlled trials of HUMIRA (initial doses of 160 mg at \\nWeek 0 and 80 mg at Week 2, followed by 40 mg every week starting at Week 4), in subjects \\nwith HS with a control period duration ranging from 12 to 16 weeks, ALT elevations ≥ 3 x ULN \\noccurred in 0.3% of HUMIRA-treated subjects and 0.6% of control-treated subjects.', 'tokens': ['controlled', 'trials', 'HUMIRA', '(', 'initial', 'doses', '160', 'mg', 'Week', '0', '80', 'mg', 'Week', '2', ',', 'followed', '40', 'mg', 'every', 'week', 'starting', 'Week', '4', ')', ',', 'subjects', 'HS', 'control', 'period', 'duration', 'ranging', '12', '16', 'weeks', ',', 'ALT', 'elevations', '≥', '3', 'x', 'ULN', 'occurred', '0.3', '%', 'HUMIRA-treated', 'subjects', '0.6', '%', 'control-treated', 'subjects', '.'], 'lemmatized': ['controlled', 'trial', 'HUMIRA', '(', 'initial', 'dos', '160', 'mg', 'Week', '0', '80', 'mg', 'Week', '2', ',', 'followed', '40', 'mg', 'every', 'week', 'starting', 'Week', '4', ')', ',', 'subject', 'HS', 'control', 'period', 'duration', 'ranging', '12', '16', 'week', ',', 'ALT', 'elevation', '≥', '3', 'x', 'ULN', 'occurred', '0.3', '%', 'HUMIRA-treated', 'subject', '0.6', '%', 'control-treated', 'subject', '.'], 'stemmed': ['control', 'trial', 'humira', '(', 'initi', 'do', '160', 'mg', 'week', '0', '80', 'mg', 'week', '2', ',', 'follow', '40', 'mg', 'everi', 'week', 'start', 'week', '4', ')', ',', 'subject', 'hs', 'control', 'period', 'durat', 'rang', '12', '16', 'week', ',', 'alt', 'elev', '≥', '3', 'x', 'uln', 'occur', '0.3', '%', 'humira-tr', 'subject', '0.6', '%', 'control-tr', 'subject', '.'], 'dependencies': [('control', 'compound'), ('trial', 'compound'), ('humira', 'nsubj'), ('(', 'punct'), ('initi', 'npadvmod'), ('do', 'aux'), ('160', 'dobj'), ('mg', 'prep'), ('week', 'pobj'), ('0', 'nummod'), ('80', 'nummod'), ('mg', 'prep'), ('week', 'pobj'), ('2', 'nummod'), (',', 'punct'), ('follow', 'conj'), ('40', 'nummod'), ('mg', 'nmod'), ('everi', 'amod'), ('week', 'npadvmod'), ('start', 'ccomp'), ('week', 'npadvmod'), ('4', 'nummod'), (')', 'punct'), (',', 'punct'), ('subject', 'conj'), ('hs', 'nmod'), ('control', 'compound'), ('period', 'compound'), ('durat', 'compound'), ('rang', 'npadvmod'), ('12', 'nummod'), ('16', 'nummod'), ('week', 'npadvmod'), (',', 'punct'), ('alt', 'conj'), ('elev', 'dobj'), ('≥', 'npadvmod'), ('3', 'nummod'), ('x', 'punct'), ('uln', 'advmod'), ('occur', 'ROOT'), ('0.3', 'nummod'), ('%', 'npadvmod'), ('humira', 'compound'), ('-', 'punct'), ('tr', 'nsubj'), ('subject', 'nmod'), ('0.6', 'nummod'), ('%', 'npadvmod'), ('control', 'compound'), ('-', 'punct'), ('tr', 'appos'), ('subject', 'oprd'), ('.', 'punct')]}, {'original_sentence': 'In \\ncontrolled trials of HUMIRA (initial doses of 80 mg at Week 0 followed by 40 mg every other \\nweek starting at Week 1) in adult patients with uveitis with an exposure of 165.4 PYs and 119.8 \\nPYs in HUMIRA-treated and control-treated patients, respectively, ALT elevations ≥ 3 x ULN \\noccurred in 2.4% of HUMIRA-treated patients and 2.4% of control-treated patients.', 'tokens': ['controlled', 'trials', 'HUMIRA', '(', 'initial', 'doses', '80', 'mg', 'Week', '0', 'followed', '40', 'mg', 'every', 'week', 'starting', 'Week', '1', ')', 'adult', 'patients', 'uveitis', 'exposure', '165.4', 'PYs', '119.8', 'PYs', 'HUMIRA-treated', 'control-treated', 'patients', ',', 'respectively', ',', 'ALT', 'elevations', '≥', '3', 'x', 'ULN', 'occurred', '2.4', '%', 'HUMIRA-treated', 'patients', '2.4', '%', 'control-treated', 'patients', '.'], 'lemmatized': ['controlled', 'trial', 'HUMIRA', '(', 'initial', 'dos', '80', 'mg', 'Week', '0', 'followed', '40', 'mg', 'every', 'week', 'starting', 'Week', '1', ')', 'adult', 'patient', 'uveitis', 'exposure', '165.4', 'PYs', '119.8', 'PYs', 'HUMIRA-treated', 'control-treated', 'patient', ',', 'respectively', ',', 'ALT', 'elevation', '≥', '3', 'x', 'ULN', 'occurred', '2.4', '%', 'HUMIRA-treated', 'patient', '2.4', '%', 'control-treated', 'patient', '.'], 'stemmed': ['control', 'trial', 'humira', '(', 'initi', 'do', '80', 'mg', 'week', '0', 'follow', '40', 'mg', 'everi', 'week', 'start', 'week', '1', ')', 'adult', 'patient', 'uveiti', 'exposur', '165.4', 'py', '119.8', 'py', 'humira-tr', 'control-tr', 'patient', ',', 'respect', ',', 'alt', 'elev', '≥', '3', 'x', 'uln', 'occur', '2.4', '%', 'humira-tr', 'patient', '2.4', '%', 'control-tr', 'patient', '.'], 'dependencies': [('control', 'compound'), ('trial', 'compound'), ('humira', 'nsubj'), ('(', 'punct'), ('initi', 'npadvmod'), ('do', 'ccomp'), ('80', 'dobj'), ('mg', 'prep'), ('week', 'pobj'), ('0', 'nummod'), ('follow', 'dobj'), ('40', 'nummod'), ('mg', 'nmod'), ('everi', 'amod'), ('week', 'npadvmod'), ('start', 'nmod'), ('week', 'npadvmod'), ('1', 'nummod'), (')', 'punct'), ('adult', 'compound'), ('patient', 'compound'), ('uveiti', 'compound'), ('exposur', 'npadvmod'), ('165.4', 'nummod'), ('py', 'npadvmod'), ('119.8', 'nummod'), ('py', 'compound'), ('humira', 'npadvmod'), ('-', 'punct'), ('tr', 'punct'), ('control', 'compound'), ('-', 'punct'), ('tr', 'amod'), ('patient', 'dobj'), (',', 'punct'), ('respect', 'conj'), (',', 'punct'), ('alt', 'ROOT'), ('elev', 'dobj'), ('≥', 'npadvmod'), ('3', 'nummod'), ('x', 'punct'), ('uln', 'advmod'), ('occur', 'ccomp'), ('2.4', 'nummod'), ('%', 'npadvmod'), ('humira', 'npadvmod'), ('-', 'punct'), ('tr', 'amod'), ('patient', 'amod'), ('2.4', 'nummod'), ('%', 'npadvmod'), ('control', 'compound'), ('-', 'punct'), ('tr', 'amod'), ('patient', 'oprd'), ('.', 'punct')]}, {'original_sentence': 'Other Adverse Reactions \\nRheumatoid Arthritis Clinical Studies \\nThe data described below reflect exposure to HUMIRA in 2468 patients, including 2073 exposed \\nfor 6 months, 1497 exposed for greater than one year and 1380 in adequate and well-controlled \\nstudies (Studies RA-I, RA-II, RA-III, and RA-IV).', 'tokens': ['Adverse', 'Reactions', 'Rheumatoid', 'Arthritis', 'Clinical', 'Studies', 'data', 'described', 'reflect', 'exposure', 'HUMIRA', '2468', 'patients', ',', 'including', '2073', 'exposed', '6', 'months', ',', '1497', 'exposed', 'greater', 'one', 'year', '1380', 'adequate', 'well-controlled', 'studies', '(', 'Studies', 'RA-I', ',', 'RA-II', ',', 'RA-III', ',', 'RA-IV', ')', '.'], 'lemmatized': ['Adverse', 'Reactions', 'Rheumatoid', 'Arthritis', 'Clinical', 'Studies', 'data', 'described', 'reflect', 'exposure', 'HUMIRA', '2468', 'patient', ',', 'including', '2073', 'exposed', '6', 'month', ',', '1497', 'exposed', 'greater', 'one', 'year', '1380', 'adequate', 'well-controlled', 'study', '(', 'Studies', 'RA-I', ',', 'RA-II', ',', 'RA-III', ',', 'RA-IV', ')', '.'], 'stemmed': ['advers', 'reaction', 'rheumatoid', 'arthriti', 'clinic', 'studi', 'data', 'describ', 'reflect', 'exposur', 'humira', '2468', 'patient', ',', 'includ', '2073', 'expos', '6', 'month', ',', '1497', 'expos', 'greater', 'one', 'year', '1380', 'adequ', 'well-control', 'studi', '(', 'studi', 'ra-i', ',', 'ra-ii', ',', 'ra-iii', ',', 'ra-iv', ')', '.'], 'dependencies': [('advers', 'nsubj'), ('reaction', 'ROOT'), ('rheumatoid', 'compound'), ('arthriti', 'compound'), ('clinic', 'compound'), ('studi', 'compound'), ('data', 'compound'), ('describ', 'nsubj'), ('reflect', 'ccomp'), ('exposur', 'compound'), ('humira', 'nmod'), ('2468', 'nummod'), ('patient', 'dobj'), (',', 'punct'), ('includ', 'conj'), ('2073', 'nummod'), ('expos', 'dobj'), ('6', 'nummod'), ('month', 'npadvmod'), (',', 'punct'), ('1497', 'nummod'), ('expos', 'npadvmod'), ('greater', 'amod'), ('one', 'nummod'), ('year', 'npadvmod'), ('1380', 'nummod'), ('adequ', 'compound'), ('well', 'compound'), ('-', 'punct'), ('control', 'compound'), ('studi', 'dobj'), ('(', 'punct'), ('studi', 'compound'), ('ra', 'appos'), ('-', 'punct'), ('i', 'conj'), (',', 'punct'), ('ra', 'compound'), ('-', 'punct'), ('ii', 'conj'), (',', 'punct'), ('ra', 'compound'), ('-', 'punct'), ('iii', 'conj'), (',', 'punct'), ('ra', 'compound'), ('-', 'punct'), ('iv', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'HUMIRA was studied primarily in placebo-\\ncontrolled trials and in long-term follow up studies for up to 36 months duration.', 'tokens': ['HUMIRA', 'studied', 'primarily', 'placebo-', 'controlled', 'trials', 'long-term', 'follow', 'studies', '36', 'months', 'duration', '.'], 'lemmatized': ['HUMIRA', 'studied', 'primarily', 'placebo-', 'controlled', 'trial', 'long-term', 'follow', 'study', '36', 'month', 'duration', '.'], 'stemmed': ['humira', 'studi', 'primarili', 'placebo-', 'control', 'trial', 'long-term', 'follow', 'studi', '36', 'month', 'durat', '.'], 'dependencies': [('humira', 'compound'), ('studi', 'nmod'), ('primarili', 'nmod'), ('placebo-', 'compound'), ('control', 'nmod'), ('trial', 'compound'), ('long', 'amod'), ('-', 'punct'), ('term', 'compound'), ('follow', 'compound'), ('studi', 'appos'), ('36', 'nummod'), ('month', 'compound'), ('durat', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'The population \\nhad a mean age of 54 years, 77% were female, 91% were Caucasian and had moderately to \\nseverely active rheumatoid arthritis.', 'tokens': ['population', 'mean', 'age', '54', 'years', ',', '77', '%', 'female', ',', '91', '%', 'Caucasian', 'moderately', 'severely', 'active', 'rheumatoid', 'arthritis', '.'], 'lemmatized': ['population', 'mean', 'age', '54', 'year', ',', '77', '%', 'female', ',', '91', '%', 'Caucasian', 'moderately', 'severely', 'active', 'rheumatoid', 'arthritis', '.'], 'stemmed': ['popul', 'mean', 'age', '54', 'year', ',', '77', '%', 'femal', ',', '91', '%', 'caucasian', 'moder', 'sever', 'activ', 'rheumatoid', 'arthriti', '.'], 'dependencies': [('popul', 'nsubj'), ('mean', 'parataxis'), ('age', 'nsubj'), ('54', 'nummod'), ('year', 'npadvmod'), (',', 'punct'), ('77', 'nummod'), ('%', 'compound'), ('femal', 'conj'), (',', 'punct'), ('91', 'nummod'), ('%', 'nmod'), ('caucasian', 'amod'), ('moder', 'appos'), ('sever', 'ROOT'), ('activ', 'nmod'), ('rheumatoid', 'amod'), ('arthriti', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Most patients received 40 mg HUMIRA every other week \\n[see Clinical Studies (14.1)].', 'tokens': ['patients', 'received', '40', 'mg', 'HUMIRA', 'every', 'week', '[', 'see', 'Clinical', 'Studies', '(', '14.1', ')', ']', '.'], 'lemmatized': ['patient', 'received', '40', 'mg', 'HUMIRA', 'every', 'week', '[', 'see', 'Clinical', 'Studies', '(', '14.1', ')', ']', '.'], 'stemmed': ['patient', 'receiv', '40', 'mg', 'humira', 'everi', 'week', '[', 'see', 'clinic', 'studi', '(', '14.1', ')', ']', '.'], 'dependencies': [('patient', 'compound'), ('receiv', 'nsubj'), ('40', 'nummod'), ('mg', 'prep'), ('humira', 'punct'), ('everi', 'compound'), ('week', 'npadvmod'), ('[', 'punct'), ('see', 'ROOT'), ('clinic', 'compound'), ('studi', 'npadvmod'), ('(', 'punct'), ('14.1', 'appos'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Table 1 summarizes reactions reported at a rate of at least 5% in patients treated with HUMIRA \\n40 mg every other week compared to placebo and with an incidence higher than placebo.', 'tokens': ['Table', '1', 'summarizes', 'reactions', 'reported', 'rate', 'least', '5', '%', 'patients', 'treated', 'HUMIRA', '40', 'mg', 'every', 'week', 'compared', 'placebo', 'incidence', 'higher', 'placebo', '.'], 'lemmatized': ['Table', '1', 'summarizes', 'reaction', 'reported', 'rate', 'least', '5', '%', 'patient', 'treated', 'HUMIRA', '40', 'mg', 'every', 'week', 'compared', 'placebo', 'incidence', 'higher', 'placebo', '.'], 'stemmed': ['tabl', '1', 'summar', 'reaction', 'report', 'rate', 'least', '5', '%', 'patient', 'treat', 'humira', '40', 'mg', 'everi', 'week', 'compar', 'placebo', 'incid', 'higher', 'placebo', '.'], 'dependencies': [('tabl', 'amod'), ('1', 'nummod'), ('summar', 'compound'), ('reaction', 'compound'), ('report', 'compound'), ('rate', 'dobj'), ('least', 'advmod'), ('5', 'nummod'), ('%', 'nmod'), ('patient', 'compound'), ('treat', 'compound'), ('humira', 'npadvmod'), ('40', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'compound'), ('compar', 'compound'), ('placebo', 'nsubj'), ('incid', 'amod'), ('higher', 'amod'), ('placebo', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'In \\nStudy RA-III, the types and frequencies of adverse reactions in the second year open-label \\nextension were similar to those observed in the one-year double-blind portion.', 'tokens': ['Study', 'RA-III', ',', 'types', 'frequencies', 'adverse', 'reactions', 'second', 'year', 'open-label', 'extension', 'similar', 'observed', 'one-year', 'double-blind', 'portion', '.'], 'lemmatized': ['Study', 'RA-III', ',', 'type', 'frequency', 'adverse', 'reaction', 'second', 'year', 'open-label', 'extension', 'similar', 'observed', 'one-year', 'double-blind', 'portion', '.'], 'stemmed': ['studi', 'ra-iii', ',', 'type', 'frequenc', 'advers', 'reaction', 'second', 'year', 'open-label', 'extens', 'similar', 'observ', 'one-year', 'double-blind', 'portion', '.'], 'dependencies': [('studi', 'compound'), ('ra', 'compound'), ('-', 'punct'), ('iii', 'nsubj'), (',', 'punct'), ('type', 'compound'), ('frequenc', 'compound'), ('advers', 'appos'), ('reaction', 'ROOT'), ('second', 'amod'), ('year', 'nmod'), ('open', 'amod'), ('-', 'punct'), ('label', 'compound'), ('extens', 'nmod'), ('similar', 'amod'), ('observ', 'nmod'), ('one', 'nummod'), ('-', 'punct'), ('year', 'nmod'), ('double', 'amod'), ('-', 'punct'), ('blind', 'amod'), ('portion', 'dobj'), ('.', 'punct')]}], 'text': 'the Phase 3 trial of HUMIRA in pediatric patients with Crohn’s disease which evaluated efficacy \\nand safety of two body weight based maintenance dose regimens following body weight based \\ninduction therapy up to 52 weeks of treatment, ALT elevations ≥ 3 x ULN occurred in 2.6% \\n(5/192) of patients, of whom 4 were receiving concomitant immunosuppressants at baseline; \\nnone of these patients discontinued due to abnormalities in ALT tests. In controlled Phase 3 trials \\nof HUMIRA (initial doses of 160 mg and 80 mg on Days 1 and 15 respectively, followed by 40 \\nmg every other week) in adult patients with UC with control period duration ranging from 1 to \\n52 weeks, ALT elevations ≥3 x ULN occurred in 1.5% of HUMIRA-treated patients and 1.0% of \\ncontrol-treated patients. In the controlled Phase 3 trial of HUMIRA in patients with pediatric \\nulcerative colitis (N=93), which evaluated efficacy and safety of a maintenance dose of 0.6 \\nmg/kg (maximum of 40 mg) every other week (N=31) and a maintenance dose of 0.6 mg/kg \\n(maximum of 40 mg) every week (N=32), following body weight based induction doses of 2.4 \\nmg/kg (maximum of 160 mg) at Week 0 and Week 1, and 1.2 mg/kg (maximum of 80 mg) at \\nWeek 2 (N=63), or an induction dose of 2.4 mg/kg (maximum of 160 mg) at Week 0, placebo at \\nWeek 1, and 1.2 mg/kg (maximum of 80 mg) at Week 2 (N=30), ALT elevations ≥ 3 X ULN \\noccurred in 1.1% (1/93) of patients. In controlled Phase 3 trials of HUMIRA (initial dose of 80 \\nmg then 40 mg every other week) in patients with Ps with control period duration ranging from \\n12 to 24 weeks, ALT elevations ≥ 3 x ULN occurred in 1.8% of HUMIRA-treated patients and \\n1.8% of control-treated patients. In controlled trials of HUMIRA (initial doses of 160 mg at \\nWeek 0 and 80 mg at Week 2, followed by 40 mg every week starting at Week 4), in subjects \\nwith HS with a control period duration ranging from 12 to 16 weeks, ALT elevations ≥ 3 x ULN \\noccurred in 0.3% of HUMIRA-treated subjects and 0.6% of control-treated subjects. In \\ncontrolled trials of HUMIRA (initial doses of 80 mg at Week 0 followed by 40 mg every other \\nweek starting at Week 1) in adult patients with uveitis with an exposure of 165.4 PYs and 119.8 \\nPYs in HUMIRA-treated and control-treated patients, respectively, ALT elevations ≥ 3 x ULN \\noccurred in 2.4% of HUMIRA-treated patients and 2.4% of control-treated patients.  \\nOther Adverse Reactions \\nRheumatoid Arthritis Clinical Studies \\nThe data described below reflect exposure to HUMIRA in 2468 patients, including 2073 exposed \\nfor 6 months, 1497 exposed for greater than one year and 1380 in adequate and well-controlled \\nstudies (Studies RA-I, RA-II, RA-III, and RA-IV). HUMIRA was studied primarily in placebo-\\ncontrolled trials and in long-term follow up studies for up to 36 months duration. The population \\nhad a mean age of 54 years, 77% were female, 91% were Caucasian and had moderately to \\nseverely active rheumatoid arthritis. Most patients received 40 mg HUMIRA every other week \\n[see Clinical Studies (14.1)].  \\nTable 1 summarizes reactions reported at a rate of at least 5% in patients treated with HUMIRA \\n40 mg every other week compared to placebo and with an incidence higher than placebo. In \\nStudy RA-III, the types and frequencies of adverse reactions in the second year open-label \\nextension were similar to those observed in the one-year double-blind portion.  \\n \\n \\n'}, 'page_char_count': 3406, 'page_word_count': 577, 'sentences': ['the Phase 3 trial of HUMIRA in pediatric patients with Crohn’s disease which evaluated efficacy \\nand safety of two body weight based maintenance dose regimens following body weight based \\ninduction therapy up to 52 weeks of treatment, ALT elevations ≥ 3 x ULN occurred in 2.6% \\n(5/192) of patients, of whom 4 were receiving concomitant immunosuppressants at baseline; \\nnone of these patients discontinued due to abnormalities in ALT tests.', 'In controlled Phase 3 trials \\nof HUMIRA (initial doses of 160 mg and 80 mg on Days 1 and 15 respectively, followed by 40 \\nmg every other week) in adult patients with UC with control period duration ranging from 1 to \\n52 weeks, ALT elevations ≥3 x ULN occurred in 1.5% of HUMIRA-treated patients and 1.0% of \\ncontrol-treated patients.', 'In the controlled Phase 3 trial of HUMIRA in patients with pediatric \\nulcerative colitis (N=93), which evaluated efficacy and safety of a maintenance dose of 0.6 \\nmg/kg (maximum of 40 mg) every other week (N=31) and a maintenance dose of 0.6 mg/kg \\n(maximum of 40 mg) every week (N=32), following body weight based induction doses of 2.4 \\nmg/kg (maximum of 160 mg) at Week 0 and Week 1, and 1.2 mg/kg (maximum of 80 mg) at \\nWeek 2 (N=63), or an induction dose of 2.4 mg/kg (maximum of 160 mg) at Week 0, placebo at \\nWeek 1, and 1.2 mg/kg (maximum of 80 mg) at Week 2 (N=30), ALT elevations ≥ 3 X ULN \\noccurred in 1.1% (1/93) of patients.', 'In controlled Phase 3 trials of HUMIRA (initial dose of 80 \\nmg then 40 mg every other week) in patients with Ps with control period duration ranging from \\n12 to 24 weeks, ALT elevations ≥ 3 x ULN occurred in 1.8% of HUMIRA-treated patients and \\n1.8% of control-treated patients.', 'In controlled trials of HUMIRA (initial doses of 160 mg at \\nWeek 0 and 80 mg at Week 2, followed by 40 mg every week starting at Week 4), in subjects \\nwith HS with a control period duration ranging from 12 to 16 weeks, ALT elevations ≥ 3 x ULN \\noccurred in 0.3% of HUMIRA-treated subjects and 0.6% of control-treated subjects.', 'In \\ncontrolled trials of HUMIRA (initial doses of 80 mg at Week 0 followed by 40 mg every other \\nweek starting at Week 1) in adult patients with uveitis with an exposure of 165.4 PYs and 119.8 \\nPYs in HUMIRA-treated and control-treated patients, respectively, ALT elevations ≥ 3 x ULN \\noccurred in 2.4% of HUMIRA-treated patients and 2.4% of control-treated patients.', ' \\nOther Adverse Reactions \\nRheumatoid Arthritis Clinical Studies \\nThe data described below reflect exposure to HUMIRA in 2468 patients, including 2073 exposed \\nfor 6 months, 1497 exposed for greater than one year and 1380 in adequate and well-controlled \\nstudies (Studies RA-I, RA-II, RA-III, and RA-IV).', 'HUMIRA was studied primarily in placebo-\\ncontrolled trials and in long-term follow up studies for up to 36 months duration.', 'The population \\nhad a mean age of 54 years, 77% were female, 91% were Caucasian and had moderately to \\nseverely active rheumatoid arthritis.', 'Most patients received 40 mg HUMIRA every other week \\n[see Clinical Studies (14.1)].', ' \\nTable 1 summarizes reactions reported at a rate of at least 5% in patients treated with HUMIRA \\n40 mg every other week compared to placebo and with an incidence higher than placebo.', 'In \\nStudy RA-III, the types and frequencies of adverse reactions in the second year open-label \\nextension were similar to those observed in the one-year double-blind portion.', ' \\n \\n \\n'], 'page_sentence_count_spacy': 13}\n",
            "{'page_number': 17, 'text': 'Table 1. Adverse Reactions Reported by ≥5% of Patients Treated with HUMIRA During \\nPlacebo-Controlled Period of Pooled RA Studies (Studies RA-I, RA-II, RA-III, and RA-IV)  \\n  \\nHUMIRA \\n40 mg subcutaneous \\nEvery Other Week  \\nPlacebo \\n  \\n(N=705) \\n(N=690) \\nAdverse Reaction (Preferred Term) \\n  \\n  \\n  Respiratory \\n  \\n  \\n     Upper respiratory infection \\n17% \\n13% \\n     Sinusitis \\n11% \\n9% \\n     Flu syndrome \\n7% \\n6% \\nGastrointestinal \\n  \\n  \\n     Nausea \\n9% \\n8% \\n     Abdominal pain \\n7% \\n4% \\nLaboratory Tests* \\n  \\n  \\n     Laboratory test abnormal \\n8% \\n7% \\n     Hypercholesterolemia \\n6% \\n4% \\n     Hyperlipidemia \\n7% \\n5% \\n     Hematuria \\n5% \\n4% \\n     Alkaline phosphatase increased \\n5% \\n3% \\nOther \\n  \\n  \\n     Headache \\n12% \\n8% \\n     Rash \\n12% \\n6% \\n     Accidental injury \\n10% \\n8% \\n     Injection site reaction ** \\n8% \\n1% \\n     Back pain \\n6% \\n4% \\n     Urinary tract infection \\n8% \\n5% \\n     Hypertension \\n5% \\n3% \\n*  Laboratory test abnormalities were reported as adverse reactions in European trials \\n** Does not include injection site erythema, itching, hemorrhage, pain or swelling  \\n \\n  \\nLess Common Adverse Reactions in Rheumatoid Arthritis Clinical Studies \\nOther infrequent serious adverse reactions that do not appear in the Warnings and Precautions or \\nAdverse Reaction sections that occurred at an incidence of less than 5% in HUMIRA-treated \\npatients in RA studies were:  \\nBody As A Whole: Pain in extremity, pelvic pain, surgery, thorax pain  \\n', 'processed_text': {'sentences': [{'original_sentence': 'Table 1.', 'tokens': ['Table', '1', '.'], 'lemmatized': ['Table', '1', '.'], 'stemmed': ['tabl', '1', '.'], 'dependencies': [('tabl', 'ROOT'), ('1', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Adverse Reactions Reported by ≥5% of Patients Treated with HUMIRA During \\nPlacebo-Controlled Period of Pooled RA Studies (Studies RA-I, RA-II, RA-III, and RA-IV)  \\n  \\nHUMIRA \\n40 mg subcutaneous \\nEvery Other Week  \\nPlacebo \\n  \\n(N=705) \\n(N=690) \\nAdverse Reaction (Preferred Term) \\n  \\n  \\n  Respiratory \\n  \\n  \\n     Upper respiratory infection \\n17% \\n13% \\n     Sinusitis \\n11% \\n9% \\n     Flu syndrome \\n7% \\n6% \\nGastrointestinal \\n  \\n  \\n     Nausea \\n9% \\n8% \\n     Abdominal pain \\n7% \\n4% \\nLaboratory Tests* \\n  \\n  \\n     Laboratory test abnormal \\n8% \\n7% \\n     Hypercholesterolemia \\n6% \\n4% \\n     Hyperlipidemia \\n7% \\n5% \\n     Hematuria \\n5% \\n4% \\n     Alkaline phosphatase increased \\n5% \\n3% \\nOther \\n  \\n  \\n     Headache \\n12% \\n8% \\n     Rash \\n12% \\n6% \\n     Accidental injury \\n10% \\n8% \\n     Injection site reaction ** \\n8% \\n1% \\n     Back pain \\n6% \\n4% \\n     Urinary tract infection \\n8% \\n5% \\n     Hypertension \\n5% \\n3% \\n*  Laboratory test abnormalities were reported as adverse reactions in European trials \\n** Does not include injection site erythema, itching, hemorrhage, pain or swelling  \\n \\n  \\nLess Common Adverse Reactions in Rheumatoid Arthritis Clinical Studies \\nOther infrequent serious adverse reactions that do not appear in the Warnings and Precautions or \\nAdverse Reaction sections that occurred at an incidence of less than 5% in HUMIRA-treated \\npatients in RA studies were:  \\nBody As A Whole: Pain in extremity, pelvic pain, surgery, thorax pain', 'tokens': ['Adverse', 'Reactions', 'Reported', '≥5', '%', 'Patients', 'Treated', 'HUMIRA', 'Placebo-Controlled', 'Period', 'Pooled', 'RA', 'Studies', '(', 'Studies', 'RA-I', ',', 'RA-II', ',', 'RA-III', ',', 'RA-IV', ')', 'HUMIRA', '40', 'mg', 'subcutaneous', 'Every', 'Week', 'Placebo', '(', 'N=705', ')', '(', 'N=690', ')', 'Adverse', 'Reaction', '(', 'Preferred', 'Term', ')', 'Respiratory', 'Upper', 'respiratory', 'infection', '17', '%', '13', '%', 'Sinusitis', '11', '%', '9', '%', 'Flu', 'syndrome', '7', '%', '6', '%', 'Gastrointestinal', 'Nausea', '9', '%', '8', '%', 'Abdominal', 'pain', '7', '%', '4', '%', 'Laboratory', 'Tests', '*', 'Laboratory', 'test', 'abnormal', '8', '%', '7', '%', 'Hypercholesterolemia', '6', '%', '4', '%', 'Hyperlipidemia', '7', '%', '5', '%', 'Hematuria', '5', '%', '4', '%', 'Alkaline', 'phosphatase', 'increased', '5', '%', '3', '%', 'Headache', '12', '%', '8', '%', 'Rash', '12', '%', '6', '%', 'Accidental', 'injury', '10', '%', '8', '%', 'Injection', 'site', 'reaction', '*', '*', '8', '%', '1', '%', 'Back', 'pain', '6', '%', '4', '%', 'Urinary', 'tract', 'infection', '8', '%', '5', '%', 'Hypertension', '5', '%', '3', '%', '*', 'Laboratory', 'test', 'abnormalities', 'reported', 'adverse', 'reactions', 'European', 'trials', '*', '*', 'include', 'injection', 'site', 'erythema', ',', 'itching', ',', 'hemorrhage', ',', 'pain', 'swelling', 'Less', 'Common', 'Adverse', 'Reactions', 'Rheumatoid', 'Arthritis', 'Clinical', 'Studies', 'infrequent', 'serious', 'adverse', 'reactions', 'appear', 'Warnings', 'Precautions', 'Adverse', 'Reaction', 'sections', 'occurred', 'incidence', 'less', '5', '%', 'HUMIRA-treated', 'patients', 'RA', 'studies', ':', 'Body', 'Whole', ':', 'Pain', 'extremity', ',', 'pelvic', 'pain', ',', 'surgery', ',', 'thorax', 'pain'], 'lemmatized': ['Adverse', 'Reactions', 'Reported', '≥5', '%', 'Patients', 'Treated', 'HUMIRA', 'Placebo-Controlled', 'Period', 'Pooled', 'RA', 'Studies', '(', 'Studies', 'RA-I', ',', 'RA-II', ',', 'RA-III', ',', 'RA-IV', ')', 'HUMIRA', '40', 'mg', 'subcutaneous', 'Every', 'Week', 'Placebo', '(', 'N=705', ')', '(', 'N=690', ')', 'Adverse', 'Reaction', '(', 'Preferred', 'Term', ')', 'Respiratory', 'Upper', 'respiratory', 'infection', '17', '%', '13', '%', 'Sinusitis', '11', '%', '9', '%', 'Flu', 'syndrome', '7', '%', '6', '%', 'Gastrointestinal', 'Nausea', '9', '%', '8', '%', 'Abdominal', 'pain', '7', '%', '4', '%', 'Laboratory', 'Tests', '*', 'Laboratory', 'test', 'abnormal', '8', '%', '7', '%', 'Hypercholesterolemia', '6', '%', '4', '%', 'Hyperlipidemia', '7', '%', '5', '%', 'Hematuria', '5', '%', '4', '%', 'Alkaline', 'phosphatase', 'increased', '5', '%', '3', '%', 'Headache', '12', '%', '8', '%', 'Rash', '12', '%', '6', '%', 'Accidental', 'injury', '10', '%', '8', '%', 'Injection', 'site', 'reaction', '*', '*', '8', '%', '1', '%', 'Back', 'pain', '6', '%', '4', '%', 'Urinary', 'tract', 'infection', '8', '%', '5', '%', 'Hypertension', '5', '%', '3', '%', '*', 'Laboratory', 'test', 'abnormality', 'reported', 'adverse', 'reaction', 'European', 'trial', '*', '*', 'include', 'injection', 'site', 'erythema', ',', 'itching', ',', 'hemorrhage', ',', 'pain', 'swelling', 'Less', 'Common', 'Adverse', 'Reactions', 'Rheumatoid', 'Arthritis', 'Clinical', 'Studies', 'infrequent', 'serious', 'adverse', 'reaction', 'appear', 'Warnings', 'Precautions', 'Adverse', 'Reaction', 'section', 'occurred', 'incidence', 'less', '5', '%', 'HUMIRA-treated', 'patient', 'RA', 'study', ':', 'Body', 'Whole', ':', 'Pain', 'extremity', ',', 'pelvic', 'pain', ',', 'surgery', ',', 'thorax', 'pain'], 'stemmed': ['advers', 'reaction', 'report', '≥5', '%', 'patient', 'treat', 'humira', 'placebo-control', 'period', 'pool', 'ra', 'studi', '(', 'studi', 'ra-i', ',', 'ra-ii', ',', 'ra-iii', ',', 'ra-iv', ')', 'humira', '40', 'mg', 'subcutan', 'everi', 'week', 'placebo', '(', 'n=705', ')', '(', 'n=690', ')', 'advers', 'reaction', '(', 'prefer', 'term', ')', 'respiratori', 'upper', 'respiratori', 'infect', '17', '%', '13', '%', 'sinus', '11', '%', '9', '%', 'flu', 'syndrom', '7', '%', '6', '%', 'gastrointestin', 'nausea', '9', '%', '8', '%', 'abdomin', 'pain', '7', '%', '4', '%', 'laboratori', 'test', '*', 'laboratori', 'test', 'abnorm', '8', '%', '7', '%', 'hypercholesterolemia', '6', '%', '4', '%', 'hyperlipidemia', '7', '%', '5', '%', 'hematuria', '5', '%', '4', '%', 'alkalin', 'phosphatas', 'increas', '5', '%', '3', '%', 'headach', '12', '%', '8', '%', 'rash', '12', '%', '6', '%', 'accident', 'injuri', '10', '%', '8', '%', 'inject', 'site', 'reaction', '*', '*', '8', '%', '1', '%', 'back', 'pain', '6', '%', '4', '%', 'urinari', 'tract', 'infect', '8', '%', '5', '%', 'hypertens', '5', '%', '3', '%', '*', 'laboratori', 'test', 'abnorm', 'report', 'advers', 'reaction', 'european', 'trial', '*', '*', 'includ', 'inject', 'site', 'erythema', ',', 'itch', ',', 'hemorrhag', ',', 'pain', 'swell', 'less', 'common', 'advers', 'reaction', 'rheumatoid', 'arthriti', 'clinic', 'studi', 'infrequ', 'seriou', 'advers', 'reaction', 'appear', 'warn', 'precaut', 'advers', 'reaction', 'section', 'occur', 'incid', 'less', '5', '%', 'humira-tr', 'patient', 'ra', 'studi', ':', 'bodi', 'whole', ':', 'pain', 'extrem', ',', 'pelvic', 'pain', ',', 'surgeri', ',', 'thorax', 'pain'], 'dependencies': [('advers', 'compound'), ('reaction', 'compound'), ('report', 'ROOT'), ('≥5', 'nummod'), ('%', 'compound'), ('patient', 'compound'), ('treat', 'compound'), ('humira', 'compound'), ('placebo', 'compound'), ('-', 'punct'), ('control', 'compound'), ('period', 'compound'), ('pool', 'appos'), ('ra', 'compound'), ('studi', 'appos'), ('(', 'punct'), ('studi', 'meta'), ('ra', 'nmod'), ('-', 'punct'), ('i', 'appos'), (',', 'punct'), ('ra', 'compound'), ('-', 'punct'), ('ii', 'appos'), (',', 'punct'), ('ra', 'compound'), ('-', 'punct'), ('iii', 'conj'), (',', 'punct'), ('ra', 'compound'), ('-', 'punct'), ('iv', 'appos'), (')', 'punct'), ('humira', 'appos'), ('40', 'nummod'), ('mg', 'prep'), ('subcutan', 'pobj'), ('everi', 'compound'), ('week', 'compound'), ('placebo', 'npadvmod'), ('(', 'punct'), ('n=705', 'appos'), (')', 'punct'), ('(', 'punct'), ('n=690', 'nmod'), (')', 'punct'), ('advers', 'compound'), ('reaction', 'meta'), ('(', 'punct'), ('prefer', 'acl'), ('term', 'dobj'), (')', 'punct'), ('respiratori', 'ROOT'), ('upper', 'amod'), ('respiratori', 'dobj'), ('infect', 'conj'), ('17', 'nummod'), ('%', 'npadvmod'), ('13', 'nummod'), ('%', 'compound'), ('sinus', 'appos'), ('11', 'nummod'), ('%', 'nmod'), ('9', 'nummod'), ('%', 'compound'), ('flu', 'npadvmod'), ('syndrom', 'prep'), ('7', 'nummod'), ('%', 'npadvmod'), ('6', 'nummod'), ('%', 'compound'), ('gastrointestin', 'nsubj'), ('nausea', 'ROOT'), ('9', 'nummod'), ('%', 'npadvmod'), ('8', 'nummod'), ('%', 'compound'), ('abdomin', 'compound'), ('pain', 'appos'), ('7', 'nummod'), ('%', 'npadvmod'), ('4', 'nummod'), ('%', 'compound'), ('laboratori', 'compound'), ('test', 'appos'), ('*', 'punct'), ('laboratori', 'compound'), ('test', 'nsubj'), ('abnorm', 'ROOT'), ('8', 'nummod'), ('%', 'npadvmod'), ('7', 'nummod'), ('%', 'compound'), ('hypercholesterolemia', 'npadvmod'), ('6', 'nummod'), ('%', 'appos'), ('4', 'nummod'), ('%', 'compound'), ('hyperlipidemia', 'npadvmod'), ('7', 'nummod'), ('%', 'npadvmod'), ('5', 'nummod'), ('%', 'appos'), ('hematuria', 'npadvmod'), ('5', 'nummod'), ('%', 'appos'), ('4', 'nummod'), ('%', 'appos'), ('alkalin', 'nsubj'), ('phosphatas', 'conj'), ('increas', 'dobj'), ('5', 'nummod'), ('%', 'npadvmod'), ('3', 'nummod'), ('%', 'compound'), ('headach', 'appos'), ('12', 'nummod'), ('%', 'npadvmod'), ('8', 'nummod'), ('%', 'appos'), ('rash', 'conj'), ('12', 'nummod'), ('%', 'npadvmod'), ('6', 'nummod'), ('%', 'compound'), ('accident', 'compound'), ('injuri', 'appos'), ('10', 'nummod'), ('%', 'npadvmod'), ('8', 'nummod'), ('%', 'appos'), ('inject', 'compound'), ('site', 'compound'), ('reaction', 'appos'), ('*', 'punct'), ('*', 'punct'), ('8', 'nummod'), ('%', 'npadvmod'), ('1', 'nummod'), ('%', 'appos'), ('back', 'compound'), ('pain', 'appos'), ('6', 'nummod'), ('%', 'nmod'), ('4', 'nummod'), ('%', 'nmod'), ('urinari', 'amod'), ('tract', 'nsubj'), ('infect', 'ROOT'), ('8', 'nummod'), ('%', 'npadvmod'), ('5', 'nummod'), ('%', 'compound'), ('hypertens', 'appos'), ('5', 'nummod'), ('%', 'appos'), ('3', 'nummod'), ('%', 'appos'), ('*', 'punct'), ('laboratori', 'compound'), ('test', 'compound'), ('abnorm', 'compound'), ('report', 'compound'), ('advers', 'nsubj'), ('reaction', 'compound'), ('european', 'amod'), ('trial', 'dobj'), ('*', 'punct'), ('*', 'punct'), ('includ', 'compound'), ('inject', 'compound'), ('site', 'compound'), ('erythema', 'dobj'), (',', 'punct'), ('itch', 'conj'), (',', 'punct'), ('hemorrhag', 'conj'), (',', 'punct'), ('pain', 'npadvmod'), ('swell', 'conj'), ('less', 'amod'), ('common', 'amod'), ('advers', 'dobj'), ('reaction', 'nsubj'), ('rheumatoid', 'compound'), ('arthriti', 'compound'), ('clinic', 'compound'), ('studi', 'compound'), ('infrequ', 'compound'), ('seriou', 'compound'), ('advers', 'compound'), ('reaction', 'dobj'), ('appear', 'ROOT'), ('warn', 'xcomp'), ('precaut', 'compound'), ('advers', 'compound'), ('reaction', 'compound'), ('section', 'dobj'), ('occur', 'ccomp'), ('incid', 'acomp'), ('less', 'advmod'), ('5', 'nummod'), ('%', 'npadvmod'), ('humira', 'compound'), ('-', 'punct'), ('tr', 'compound'), ('patient', 'appos'), ('ra', 'compound'), ('studi', 'appos'), (':', 'punct'), ('bodi', 'compound'), ('whole', 'dep'), (':', 'punct'), ('pain', 'compound'), ('extrem', 'appos'), (',', 'punct'), ('pelvic', 'amod'), ('pain', 'conj'), (',', 'punct'), ('surgeri', 'conj'), (',', 'punct'), ('thorax', 'compound'), ('pain', 'conj')]}], 'text': 'Table 1. Adverse Reactions Reported by ≥5% of Patients Treated with HUMIRA During \\nPlacebo-Controlled Period of Pooled RA Studies (Studies RA-I, RA-II, RA-III, and RA-IV)  \\n  \\nHUMIRA \\n40 mg subcutaneous \\nEvery Other Week  \\nPlacebo \\n  \\n(N=705) \\n(N=690) \\nAdverse Reaction (Preferred Term) \\n  \\n  \\n  Respiratory \\n  \\n  \\n     Upper respiratory infection \\n17% \\n13% \\n     Sinusitis \\n11% \\n9% \\n     Flu syndrome \\n7% \\n6% \\nGastrointestinal \\n  \\n  \\n     Nausea \\n9% \\n8% \\n     Abdominal pain \\n7% \\n4% \\nLaboratory Tests* \\n  \\n  \\n     Laboratory test abnormal \\n8% \\n7% \\n     Hypercholesterolemia \\n6% \\n4% \\n     Hyperlipidemia \\n7% \\n5% \\n     Hematuria \\n5% \\n4% \\n     Alkaline phosphatase increased \\n5% \\n3% \\nOther \\n  \\n  \\n     Headache \\n12% \\n8% \\n     Rash \\n12% \\n6% \\n     Accidental injury \\n10% \\n8% \\n     Injection site reaction ** \\n8% \\n1% \\n     Back pain \\n6% \\n4% \\n     Urinary tract infection \\n8% \\n5% \\n     Hypertension \\n5% \\n3% \\n*  Laboratory test abnormalities were reported as adverse reactions in European trials \\n** Does not include injection site erythema, itching, hemorrhage, pain or swelling  \\n \\n  \\nLess Common Adverse Reactions in Rheumatoid Arthritis Clinical Studies \\nOther infrequent serious adverse reactions that do not appear in the Warnings and Precautions or \\nAdverse Reaction sections that occurred at an incidence of less than 5% in HUMIRA-treated \\npatients in RA studies were:  \\nBody As A Whole: Pain in extremity, pelvic pain, surgery, thorax pain  \\n'}, 'page_char_count': 1444, 'page_word_count': 189, 'sentences': ['Table 1.', 'Adverse Reactions Reported by ≥5% of Patients Treated with HUMIRA During \\nPlacebo-Controlled Period of Pooled RA Studies (Studies RA-I, RA-II, RA-III, and RA-IV)  \\n  \\nHUMIRA \\n40 mg subcutaneous \\nEvery Other Week  \\nPlacebo \\n  \\n(N=705) \\n(N=690) \\nAdverse Reaction (Preferred Term) \\n  \\n  \\n  Respiratory \\n  \\n  \\n     Upper respiratory infection \\n17% \\n13% \\n     Sinusitis \\n11% \\n9% \\n     Flu syndrome \\n7% \\n6% \\nGastrointestinal \\n  \\n  \\n     Nausea \\n9% \\n8% \\n     Abdominal pain \\n7% \\n4% \\nLaboratory Tests* \\n  \\n  \\n     Laboratory test abnormal \\n8% \\n7% \\n     Hypercholesterolemia \\n6% \\n4% \\n     Hyperlipidemia \\n7% \\n5% \\n     Hematuria \\n5% \\n4% \\n     Alkaline phosphatase increased \\n5% \\n3% \\nOther \\n  \\n  \\n     Headache \\n12% \\n8% \\n     Rash \\n12% \\n6% \\n     Accidental injury \\n10% \\n8% \\n     Injection site reaction ** \\n8% \\n1% \\n     Back pain \\n6% \\n4% \\n     Urinary tract infection \\n8% \\n5% \\n     Hypertension \\n5% \\n3% \\n*  Laboratory test abnormalities were reported as adverse reactions in European trials \\n** Does not include injection site erythema, itching, hemorrhage, pain or swelling  \\n \\n  \\nLess Common Adverse Reactions in Rheumatoid Arthritis Clinical Studies \\nOther infrequent serious adverse reactions that do not appear in the Warnings and Precautions or \\nAdverse Reaction sections that occurred at an incidence of less than 5% in HUMIRA-treated \\npatients in RA studies were:  \\nBody As A Whole: Pain in extremity, pelvic pain, surgery, thorax pain  \\n'], 'page_sentence_count_spacy': 2}\n",
            "{'page_number': 18, 'text': 'Cardiovascular System: Arrhythmia, atrial fibrillation, chest pain, coronary artery disorder, heart \\narrest, hypertensive encephalopathy, myocardial infarct, palpitation, pericardial effusion, \\npericarditis, syncope, tachycardia  \\nDigestive System: Cholecystitis, cholelithiasis, esophagitis, gastroenteritis, gastrointestinal \\nhemorrhage, hepatic necrosis, vomiting  \\nEndocrine System: Parathyroid disorder  \\nHemic And Lymphatic System: Agranulocytosis, polycythemia  \\nMetabolic And Nutritional Disorders: Dehydration, healing abnormal, ketosis, paraproteinemia, \\nperipheral edema  \\nMusculo-Skeletal System: Arthritis, bone disorder, bone fracture (not spontaneous), bone \\nnecrosis, joint disorder, muscle cramps, myasthenia, pyogenic arthritis, synovitis, tendon \\ndisorder  \\nNeoplasia: Adenoma  \\nNervous System: Confusion, paresthesia, subdural hematoma, tremor  \\nRespiratory System: Asthma, bronchospasm, dyspnea, lung function decreased, pleural effusion  \\nSpecial Senses: Cataract  \\nThrombosis: Thrombosis leg  \\nUrogenital System: Cystitis, kidney calculus, menstrual disorder  \\nJuvenile Idiopathic Arthritis Clinical Studies \\nIn general, the adverse reactions in the HUMIRA-treated patients in the polyarticular juvenile \\nidiopathic arthritis (JIA) trials (Studies JIA-I and JIA-II) [see Clinical Studies (14.2)] were \\nsimilar in frequency and type to those seen in adult patients [see Warnings and Precautions (5), \\nAdverse Reactions (6)]. Important findings and differences from adults are discussed in the \\nfollowing paragraphs.  \\nIn Study JIA-I, HUMIRA was studied in 171 patients who were 4 to 17 years of age, with \\npolyarticular JIA. Severe adverse reactions reported in the study included neutropenia, \\nstreptococcal pharyngitis, increased aminotransferases, herpes zoster, myositis, metrorrhagia, \\nand appendicitis. Serious infections were observed in 4% of patients within approximately 2 \\nyears of initiation of treatment with HUMIRA and included cases of herpes simplex, pneumonia, \\nurinary tract infection, pharyngitis, and herpes zoster.  \\nIn Study JIA-I, 45% of patients experienced an infection while receiving HUMIRA with or \\nwithout concomitant MTX in the first 16 weeks of treatment. The types of infections reported in \\nHUMIRA-treated patients were generally similar to those commonly seen in polyarticular JIA \\npatients who are not treated with TNF blockers. Upon initiation of treatment, the most common \\nadverse reactions occurring in this patient population treated with HUMIRA were injection site \\npain and injection site reaction (19% and 16%, respectively). A less commonly reported adverse \\nevent in patients receiving HUMIRA was granuloma annulare which did not lead to \\ndiscontinuation of HUMIRA treatment.  \\n', 'processed_text': {'sentences': [{'original_sentence': 'Cardiovascular System: Arrhythmia, atrial fibrillation, chest pain, coronary artery disorder, heart \\narrest, hypertensive encephalopathy, myocardial infarct, palpitation, pericardial effusion, \\npericarditis, syncope, tachycardia  \\nDigestive System: Cholecystitis, cholelithiasis, esophagitis, gastroenteritis, gastrointestinal \\nhemorrhage, hepatic necrosis, vomiting  \\nEndocrine System: Parathyroid disorder  \\nHemic And Lymphatic System: Agranulocytosis, polycythemia  \\nMetabolic And Nutritional Disorders: Dehydration, healing abnormal, ketosis, paraproteinemia, \\nperipheral edema  \\nMusculo-Skeletal System: Arthritis, bone disorder, bone fracture (not spontaneous), bone \\nnecrosis, joint disorder, muscle cramps, myasthenia, pyogenic arthritis, synovitis, tendon \\ndisorder  \\nNeoplasia: Adenoma  \\nNervous System: Confusion, paresthesia, subdural hematoma, tremor  \\nRespiratory System: Asthma, bronchospasm, dyspnea, lung function decreased, pleural effusion  \\nSpecial Senses: Cataract  \\nThrombosis: Thrombosis leg  \\nUrogenital System: Cystitis, kidney calculus, menstrual disorder  \\nJuvenile Idiopathic Arthritis Clinical Studies \\nIn general, the adverse reactions in the HUMIRA-treated patients in the polyarticular juvenile \\nidiopathic arthritis (JIA) trials (Studies JIA-I and JIA-II) [see Clinical Studies (14.2)] were \\nsimilar in frequency and type to those seen in adult patients [see Warnings and Precautions (5), \\nAdverse Reactions (6)].', 'tokens': ['Cardiovascular', 'System', ':', 'Arrhythmia', ',', 'atrial', 'fibrillation', ',', 'chest', 'pain', ',', 'coronary', 'artery', 'disorder', ',', 'heart', 'arrest', ',', 'hypertensive', 'encephalopathy', ',', 'myocardial', 'infarct', ',', 'palpitation', ',', 'pericardial', 'effusion', ',', 'pericarditis', ',', 'syncope', ',', 'tachycardia', 'Digestive', 'System', ':', 'Cholecystitis', ',', 'cholelithiasis', ',', 'esophagitis', ',', 'gastroenteritis', ',', 'gastrointestinal', 'hemorrhage', ',', 'hepatic', 'necrosis', ',', 'vomiting', 'Endocrine', 'System', ':', 'Parathyroid', 'disorder', 'Hemic', 'Lymphatic', 'System', ':', 'Agranulocytosis', ',', 'polycythemia', 'Metabolic', 'Nutritional', 'Disorders', ':', 'Dehydration', ',', 'healing', 'abnormal', ',', 'ketosis', ',', 'paraproteinemia', ',', 'peripheral', 'edema', 'Musculo-Skeletal', 'System', ':', 'Arthritis', ',', 'bone', 'disorder', ',', 'bone', 'fracture', '(', 'spontaneous', ')', ',', 'bone', 'necrosis', ',', 'joint', 'disorder', ',', 'muscle', 'cramps', ',', 'myasthenia', ',', 'pyogenic', 'arthritis', ',', 'synovitis', ',', 'tendon', 'disorder', 'Neoplasia', ':', 'Adenoma', 'Nervous', 'System', ':', 'Confusion', ',', 'paresthesia', ',', 'subdural', 'hematoma', ',', 'tremor', 'Respiratory', 'System', ':', 'Asthma', ',', 'bronchospasm', ',', 'dyspnea', ',', 'lung', 'function', 'decreased', ',', 'pleural', 'effusion', 'Special', 'Senses', ':', 'Cataract', 'Thrombosis', ':', 'Thrombosis', 'leg', 'Urogenital', 'System', ':', 'Cystitis', ',', 'kidney', 'calculus', ',', 'menstrual', 'disorder', 'Juvenile', 'Idiopathic', 'Arthritis', 'Clinical', 'Studies', 'general', ',', 'adverse', 'reactions', 'HUMIRA-treated', 'patients', 'polyarticular', 'juvenile', 'idiopathic', 'arthritis', '(', 'JIA', ')', 'trials', '(', 'Studies', 'JIA-I', 'JIA-II', ')', '[', 'see', 'Clinical', 'Studies', '(', '14.2', ')', ']', 'similar', 'frequency', 'type', 'seen', 'adult', 'patients', '[', 'see', 'Warnings', 'Precautions', '(', '5', ')', ',', 'Adverse', 'Reactions', '(', '6', ')', ']', '.'], 'lemmatized': ['Cardiovascular', 'System', ':', 'Arrhythmia', ',', 'atrial', 'fibrillation', ',', 'chest', 'pain', ',', 'coronary', 'artery', 'disorder', ',', 'heart', 'arrest', ',', 'hypertensive', 'encephalopathy', ',', 'myocardial', 'infarct', ',', 'palpitation', ',', 'pericardial', 'effusion', ',', 'pericarditis', ',', 'syncope', ',', 'tachycardia', 'Digestive', 'System', ':', 'Cholecystitis', ',', 'cholelithiasis', ',', 'esophagitis', ',', 'gastroenteritis', ',', 'gastrointestinal', 'hemorrhage', ',', 'hepatic', 'necrosis', ',', 'vomiting', 'Endocrine', 'System', ':', 'Parathyroid', 'disorder', 'Hemic', 'Lymphatic', 'System', ':', 'Agranulocytosis', ',', 'polycythemia', 'Metabolic', 'Nutritional', 'Disorders', ':', 'Dehydration', ',', 'healing', 'abnormal', ',', 'ketosis', ',', 'paraproteinemia', ',', 'peripheral', 'edema', 'Musculo-Skeletal', 'System', ':', 'Arthritis', ',', 'bone', 'disorder', ',', 'bone', 'fracture', '(', 'spontaneous', ')', ',', 'bone', 'necrosis', ',', 'joint', 'disorder', ',', 'muscle', 'cramp', ',', 'myasthenia', ',', 'pyogenic', 'arthritis', ',', 'synovitis', ',', 'tendon', 'disorder', 'Neoplasia', ':', 'Adenoma', 'Nervous', 'System', ':', 'Confusion', ',', 'paresthesia', ',', 'subdural', 'hematoma', ',', 'tremor', 'Respiratory', 'System', ':', 'Asthma', ',', 'bronchospasm', ',', 'dyspnea', ',', 'lung', 'function', 'decreased', ',', 'pleural', 'effusion', 'Special', 'Senses', ':', 'Cataract', 'Thrombosis', ':', 'Thrombosis', 'leg', 'Urogenital', 'System', ':', 'Cystitis', ',', 'kidney', 'calculus', ',', 'menstrual', 'disorder', 'Juvenile', 'Idiopathic', 'Arthritis', 'Clinical', 'Studies', 'general', ',', 'adverse', 'reaction', 'HUMIRA-treated', 'patient', 'polyarticular', 'juvenile', 'idiopathic', 'arthritis', '(', 'JIA', ')', 'trial', '(', 'Studies', 'JIA-I', 'JIA-II', ')', '[', 'see', 'Clinical', 'Studies', '(', '14.2', ')', ']', 'similar', 'frequency', 'type', 'seen', 'adult', 'patient', '[', 'see', 'Warnings', 'Precautions', '(', '5', ')', ',', 'Adverse', 'Reactions', '(', '6', ')', ']', '.'], 'stemmed': ['cardiovascular', 'system', ':', 'arrhythmia', ',', 'atrial', 'fibril', ',', 'chest', 'pain', ',', 'coronari', 'arteri', 'disord', ',', 'heart', 'arrest', ',', 'hypertens', 'encephalopathi', ',', 'myocardi', 'infarct', ',', 'palpit', ',', 'pericardi', 'effus', ',', 'pericard', ',', 'syncop', ',', 'tachycardia', 'digest', 'system', ':', 'cholecyst', ',', 'cholelithiasi', ',', 'esophag', ',', 'gastroenter', ',', 'gastrointestin', 'hemorrhag', ',', 'hepat', 'necrosi', ',', 'vomit', 'endocrin', 'system', ':', 'parathyroid', 'disord', 'hemic', 'lymphat', 'system', ':', 'agranulocytosi', ',', 'polycythemia', 'metabol', 'nutrit', 'disord', ':', 'dehydr', ',', 'heal', 'abnorm', ',', 'ketosi', ',', 'paraproteinemia', ',', 'peripher', 'edema', 'musculo-skelet', 'system', ':', 'arthriti', ',', 'bone', 'disord', ',', 'bone', 'fractur', '(', 'spontan', ')', ',', 'bone', 'necrosi', ',', 'joint', 'disord', ',', 'muscl', 'cramp', ',', 'myasthenia', ',', 'pyogen', 'arthriti', ',', 'synov', ',', 'tendon', 'disord', 'neoplasia', ':', 'adenoma', 'nervou', 'system', ':', 'confus', ',', 'paresthesia', ',', 'subdur', 'hematoma', ',', 'tremor', 'respiratori', 'system', ':', 'asthma', ',', 'bronchospasm', ',', 'dyspnea', ',', 'lung', 'function', 'decreas', ',', 'pleural', 'effus', 'special', 'sens', ':', 'cataract', 'thrombosi', ':', 'thrombosi', 'leg', 'urogenit', 'system', ':', 'cystiti', ',', 'kidney', 'calculu', ',', 'menstrual', 'disord', 'juvenil', 'idiopath', 'arthriti', 'clinic', 'studi', 'gener', ',', 'advers', 'reaction', 'humira-tr', 'patient', 'polyarticular', 'juvenil', 'idiopath', 'arthriti', '(', 'jia', ')', 'trial', '(', 'studi', 'jia-i', 'jia-ii', ')', '[', 'see', 'clinic', 'studi', '(', '14.2', ')', ']', 'similar', 'frequenc', 'type', 'seen', 'adult', 'patient', '[', 'see', 'warn', 'precaut', '(', '5', ')', ',', 'advers', 'reaction', '(', '6', ')', ']', '.'], 'dependencies': [('cardiovascular', 'amod'), ('system', 'nsubj'), (':', 'punct'), ('arrhythmia', 'appos'), (',', 'punct'), ('atrial', 'amod'), ('fibril', 'conj'), (',', 'punct'), ('chest', 'compound'), ('pain', 'conj'), (',', 'punct'), ('coronari', 'compound'), ('arteri', 'compound'), ('disord', 'conj'), (',', 'punct'), ('heart', 'compound'), ('arrest', 'conj'), (',', 'punct'), ('hypertens', 'compound'), ('encephalopathi', 'conj'), (',', 'punct'), ('myocardi', 'compound'), ('infarct', 'conj'), (',', 'punct'), ('palpit', 'conj'), (',', 'punct'), ('pericardi', 'compound'), ('effus', 'conj'), (',', 'punct'), ('pericard', 'conj'), (',', 'punct'), ('syncop', 'conj'), (',', 'punct'), ('tachycardia', 'compound'), ('digest', 'compound'), ('system', 'appos'), (':', 'punct'), ('cholecyst', 'appos'), (',', 'punct'), ('cholelithiasi', 'conj'), (',', 'punct'), ('esophag', 'conj'), (',', 'punct'), ('gastroenter', 'conj'), (',', 'punct'), ('gastrointestin', 'compound'), ('hemorrhag', 'conj'), (',', 'punct'), ('hepat', 'compound'), ('necrosi', 'appos'), (',', 'punct'), ('vomit', 'ROOT'), ('endocrin', 'compound'), ('system', 'dobj'), (':', 'punct'), ('parathyroid', 'amod'), ('disord', 'compound'), ('hemic', 'compound'), ('lymphat', 'compound'), ('system', 'appos'), (':', 'punct'), ('agranulocytosi', 'appos'), (',', 'punct'), ('polycythemia', 'compound'), ('metabol', 'compound'), ('nutrit', 'compound'), ('disord', 'meta'), (':', 'punct'), ('dehydr', 'advmod'), (',', 'punct'), ('heal', 'conj'), ('abnorm', 'dobj'), (',', 'punct'), ('ketosi', 'conj'), (',', 'punct'), ('paraproteinemia', 'conj'), (',', 'punct'), ('peripher', 'compound'), ('edema', 'compound'), ('musculo', 'amod'), ('-', 'punct'), ('skelet', 'compound'), ('system', 'dobj'), (':', 'punct'), ('arthriti', 'conj'), (',', 'punct'), ('bone', 'compound'), ('disord', 'conj'), (',', 'punct'), ('bone', 'compound'), ('fractur', 'meta'), ('(', 'punct'), ('spontan', 'appos'), (')', 'punct'), (',', 'punct'), ('bone', 'compound'), ('necrosi', 'conj'), (',', 'punct'), ('joint', 'amod'), ('disord', 'appos'), (',', 'punct'), ('muscl', 'compound'), ('cramp', 'conj'), (',', 'punct'), ('myasthenia', 'conj'), (',', 'punct'), ('pyogen', 'compound'), ('arthriti', 'conj'), (',', 'punct'), ('synov', 'conj'), (',', 'punct'), ('tendon', 'compound'), ('disord', 'compound'), ('neoplasia', 'appos'), (':', 'punct'), ('adenoma', 'amod'), ('nervou', 'compound'), ('system', 'dep'), (':', 'punct'), ('confus', 'appos'), (',', 'punct'), ('paresthesia', 'conj'), (',', 'punct'), ('subdur', 'amod'), ('hematoma', 'conj'), (',', 'punct'), ('tremor', 'compound'), ('respiratori', 'compound'), ('system', 'conj'), (':', 'punct'), ('asthma', 'conj'), (',', 'punct'), ('bronchospasm', 'conj'), (',', 'punct'), ('dyspnea', 'conj'), (',', 'punct'), ('lung', 'compound'), ('function', 'compound'), ('decreas', 'conj'), (',', 'punct'), ('pleural', 'amod'), ('effus', 'nmod'), ('special', 'amod'), ('sens', 'appos'), (':', 'punct'), ('cataract', 'conj'), ('thrombosi', 'dobj'), (':', 'punct'), ('thrombosi', 'compound'), ('leg', 'compound'), ('urogenit', 'compound'), ('system', 'dep'), (':', 'punct'), ('cystiti', 'advmod'), (',', 'punct'), ('kidney', 'nsubj'), ('calculu', 'ROOT'), (',', 'punct'), ('menstrual', 'amod'), ('disord', 'compound'), ('juvenil', 'compound'), ('idiopath', 'compound'), ('arthriti', 'compound'), ('clinic', 'compound'), ('studi', 'compound'), ('gener', 'npadvmod'), (',', 'punct'), ('advers', 'nsubj'), ('reaction', 'conj'), ('humira', 'npadvmod'), ('-', 'punct'), ('tr', 'nmod'), ('patient', 'amod'), ('polyarticular', 'amod'), ('juvenil', 'amod'), ('idiopath', 'compound'), ('arthriti', 'nmod'), ('(', 'punct'), ('jia', 'nmod'), (')', 'punct'), ('trial', 'dobj'), ('(', 'punct'), ('studi', 'compound'), ('jia', 'nmod'), ('-', 'punct'), ('i', 'nmod'), ('jia', 'compound'), ('-', 'punct'), ('ii', 'appos'), (')', 'punct'), ('[', 'punct'), ('see', 'ROOT'), ('clinic', 'compound'), ('studi', 'npadvmod'), ('(', 'punct'), ('14.2', 'appos'), (')', 'punct'), (']', 'punct'), ('similar', 'amod'), ('frequenc', 'compound'), ('type', 'nsubj'), ('seen', 'acl'), ('adult', 'compound'), ('patient', 'dobj'), ('[', 'punct'), ('see', 'ccomp'), ('warn', 'dep'), ('precaut', 'dobj'), ('(', 'punct'), ('5', 'dobj'), (')', 'punct'), (',', 'punct'), ('advers', 'compound'), ('reaction', 'dobj'), ('(', 'punct'), ('6', 'appos'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Important findings and differences from adults are discussed in the \\nfollowing paragraphs.', 'tokens': ['Important', 'findings', 'differences', 'adults', 'discussed', 'following', 'paragraphs', '.'], 'lemmatized': ['Important', 'finding', 'difference', 'adult', 'discussed', 'following', 'paragraph', '.'], 'stemmed': ['import', 'find', 'differ', 'adult', 'discuss', 'follow', 'paragraph', '.'], 'dependencies': [('import', 'compound'), ('find', 'nsubj'), ('differ', 'ROOT'), ('adult', 'compound'), ('discuss', 'compound'), ('follow', 'compound'), ('paragraph', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'In Study JIA-I, HUMIRA was studied in 171 patients who were 4 to 17 years of age, with \\npolyarticular JIA.', 'tokens': ['Study', 'JIA-I', ',', 'HUMIRA', 'studied', '171', 'patients', '4', '17', 'years', 'age', ',', 'polyarticular', 'JIA', '.'], 'lemmatized': ['Study', 'JIA-I', ',', 'HUMIRA', 'studied', '171', 'patient', '4', '17', 'year', 'age', ',', 'polyarticular', 'JIA', '.'], 'stemmed': ['studi', 'jia-i', ',', 'humira', 'studi', '171', 'patient', '4', '17', 'year', 'age', ',', 'polyarticular', 'jia', '.'], 'dependencies': [('studi', 'compound'), ('jia', 'compound'), ('-', 'punct'), ('i', 'ROOT'), (',', 'punct'), ('humira', 'compound'), ('studi', 'npadvmod'), ('171', 'nummod'), ('patient', 'appos'), ('4', 'compound'), ('17', 'nummod'), ('year', 'compound'), ('age', 'npadvmod'), (',', 'punct'), ('polyarticular', 'compound'), ('jia', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Severe adverse reactions reported in the study included neutropenia, \\nstreptococcal pharyngitis, increased aminotransferases, herpes zoster, myositis, metrorrhagia, \\nand appendicitis.', 'tokens': ['Severe', 'adverse', 'reactions', 'reported', 'study', 'included', 'neutropenia', ',', 'streptococcal', 'pharyngitis', ',', 'increased', 'aminotransferases', ',', 'herpes', 'zoster', ',', 'myositis', ',', 'metrorrhagia', ',', 'appendicitis', '.'], 'lemmatized': ['Severe', 'adverse', 'reaction', 'reported', 'study', 'included', 'neutropenia', ',', 'streptococcal', 'pharyngitis', ',', 'increased', 'aminotransferase', ',', 'herpes', 'zoster', ',', 'myositis', ',', 'metrorrhagia', ',', 'appendicitis', '.'], 'stemmed': ['sever', 'advers', 'reaction', 'report', 'studi', 'includ', 'neutropenia', ',', 'streptococc', 'pharyng', ',', 'increas', 'aminotransferas', ',', 'herp', 'zoster', ',', 'myositi', ',', 'metrorrhagia', ',', 'append', '.'], 'dependencies': [('sever', 'amod'), ('advers', 'compound'), ('reaction', 'compound'), ('report', 'compound'), ('studi', 'compound'), ('includ', 'compound'), ('neutropenia', 'ROOT'), (',', 'punct'), ('streptococc', 'compound'), ('pharyng', 'conj'), (',', 'punct'), ('increas', 'compound'), ('aminotransferas', 'conj'), (',', 'punct'), ('herp', 'compound'), ('zoster', 'conj'), (',', 'punct'), ('myositi', 'conj'), (',', 'punct'), ('metrorrhagia', 'conj'), (',', 'punct'), ('append', 'conj'), ('.', 'punct')]}, {'original_sentence': 'Serious infections were observed in 4% of patients within approximately 2 \\nyears of initiation of treatment with HUMIRA and included cases of herpes simplex, pneumonia, \\nurinary tract infection, pharyngitis, and herpes zoster.', 'tokens': ['Serious', 'infections', 'observed', '4', '%', 'patients', 'within', 'approximately', '2', 'years', 'initiation', 'treatment', 'HUMIRA', 'included', 'cases', 'herpes', 'simplex', ',', 'pneumonia', ',', 'urinary', 'tract', 'infection', ',', 'pharyngitis', ',', 'herpes', 'zoster', '.'], 'lemmatized': ['Serious', 'infection', 'observed', '4', '%', 'patient', 'within', 'approximately', '2', 'year', 'initiation', 'treatment', 'HUMIRA', 'included', 'case', 'herpes', 'simplex', ',', 'pneumonia', ',', 'urinary', 'tract', 'infection', ',', 'pharyngitis', ',', 'herpes', 'zoster', '.'], 'stemmed': ['seriou', 'infect', 'observ', '4', '%', 'patient', 'within', 'approxim', '2', 'year', 'initi', 'treatment', 'humira', 'includ', 'case', 'herp', 'simplex', ',', 'pneumonia', ',', 'urinari', 'tract', 'infect', ',', 'pharyng', ',', 'herp', 'zoster', '.'], 'dependencies': [('seriou', 'npadvmod'), ('infect', 'ROOT'), ('observ', 'nmod'), ('4', 'nummod'), ('%', 'compound'), ('patient', 'dobj'), ('within', 'prep'), ('approxim', 'compound'), ('2', 'nummod'), ('year', 'compound'), ('initi', 'compound'), ('treatment', 'compound'), ('humira', 'compound'), ('includ', 'compound'), ('case', 'compound'), ('herp', 'compound'), ('simplex', 'pobj'), (',', 'punct'), ('pneumonia', 'conj'), (',', 'punct'), ('urinari', 'amod'), ('tract', 'compound'), ('infect', 'conj'), (',', 'punct'), ('pharyng', 'conj'), (',', 'punct'), ('herp', 'compound'), ('zoster', 'conj'), ('.', 'punct')]}, {'original_sentence': 'In Study JIA-I, 45% of patients experienced an infection while receiving HUMIRA with or \\nwithout concomitant MTX in the first 16 weeks of treatment.', 'tokens': ['Study', 'JIA-I', ',', '45', '%', 'patients', 'experienced', 'infection', 'receiving', 'HUMIRA', 'without', 'concomitant', 'MTX', 'first', '16', 'weeks', 'treatment', '.'], 'lemmatized': ['Study', 'JIA-I', ',', '45', '%', 'patient', 'experienced', 'infection', 'receiving', 'HUMIRA', 'without', 'concomitant', 'MTX', 'first', '16', 'week', 'treatment', '.'], 'stemmed': ['studi', 'jia-i', ',', '45', '%', 'patient', 'experienc', 'infect', 'receiv', 'humira', 'without', 'concomit', 'mtx', 'first', '16', 'week', 'treatment', '.'], 'dependencies': [('studi', 'compound'), ('jia', 'nsubj'), ('-', 'punct'), ('i', 'appos'), (',', 'punct'), ('45', 'nummod'), ('%', 'npadvmod'), ('patient', 'compound'), ('experienc', 'compound'), ('infect', 'compound'), ('receiv', 'compound'), ('humira', 'nsubj'), ('without', 'prep'), ('concomit', 'pobj'), ('mtx', 'ROOT'), ('first', 'amod'), ('16', 'nummod'), ('week', 'compound'), ('treatment', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The types of infections reported in \\nHUMIRA-treated patients were generally similar to those commonly seen in polyarticular JIA \\npatients who are not treated with TNF blockers.', 'tokens': ['types', 'infections', 'reported', 'HUMIRA-treated', 'patients', 'generally', 'similar', 'commonly', 'seen', 'polyarticular', 'JIA', 'patients', 'treated', 'TNF', 'blockers', '.'], 'lemmatized': ['type', 'infection', 'reported', 'HUMIRA-treated', 'patient', 'generally', 'similar', 'commonly', 'seen', 'polyarticular', 'JIA', 'patient', 'treated', 'TNF', 'blocker', '.'], 'stemmed': ['type', 'infect', 'report', 'humira-tr', 'patient', 'gener', 'similar', 'commonli', 'seen', 'polyarticular', 'jia', 'patient', 'treat', 'tnf', 'blocker', '.'], 'dependencies': [('type', 'compound'), ('infect', 'compound'), ('report', 'compound'), ('humira', 'compound'), ('-', 'punct'), ('tr', 'nmod'), ('patient', 'compound'), ('gener', 'nmod'), ('similar', 'amod'), ('commonli', 'ROOT'), ('seen', 'acl'), ('polyarticular', 'amod'), ('jia', 'compound'), ('patient', 'compound'), ('treat', 'compound'), ('tnf', 'compound'), ('blocker', 'oprd'), ('.', 'punct')]}, {'original_sentence': 'Upon initiation of treatment, the most common \\nadverse reactions occurring in this patient population treated with HUMIRA were injection site \\npain and injection site reaction (19% and 16%, respectively).', 'tokens': ['Upon', 'initiation', 'treatment', ',', 'common', 'adverse', 'reactions', 'occurring', 'patient', 'population', 'treated', 'HUMIRA', 'injection', 'site', 'pain', 'injection', 'site', 'reaction', '(', '19', '%', '16', '%', ',', 'respectively', ')', '.'], 'lemmatized': ['Upon', 'initiation', 'treatment', ',', 'common', 'adverse', 'reaction', 'occurring', 'patient', 'population', 'treated', 'HUMIRA', 'injection', 'site', 'pain', 'injection', 'site', 'reaction', '(', '19', '%', '16', '%', ',', 'respectively', ')', '.'], 'stemmed': ['upon', 'initi', 'treatment', ',', 'common', 'advers', 'reaction', 'occur', 'patient', 'popul', 'treat', 'humira', 'inject', 'site', 'pain', 'inject', 'site', 'reaction', '(', '19', '%', '16', '%', ',', 'respect', ')', '.'], 'dependencies': [('upon', 'prep'), ('initi', 'compound'), ('treatment', 'pobj'), (',', 'punct'), ('common', 'amod'), ('advers', 'compound'), ('reaction', 'nsubj'), ('occur', 'ROOT'), ('patient', 'compound'), ('popul', 'dobj'), ('treat', 'dep'), ('humira', 'compound'), ('inject', 'compound'), ('site', 'compound'), ('pain', 'compound'), ('inject', 'compound'), ('site', 'compound'), ('reaction', 'dobj'), ('(', 'punct'), ('19', 'nummod'), ('%', 'appos'), ('16', 'nummod'), ('%', 'appos'), (',', 'punct'), ('respect', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'A less commonly reported adverse \\nevent in patients receiving HUMIRA was granuloma annulare which did not lead to \\ndiscontinuation of HUMIRA treatment.', 'tokens': ['less', 'commonly', 'reported', 'adverse', 'event', 'patients', 'receiving', 'HUMIRA', 'granuloma', 'annulare', 'lead', 'discontinuation', 'HUMIRA', 'treatment', '.'], 'lemmatized': ['less', 'commonly', 'reported', 'adverse', 'event', 'patient', 'receiving', 'HUMIRA', 'granuloma', 'annulare', 'lead', 'discontinuation', 'HUMIRA', 'treatment', '.'], 'stemmed': ['less', 'commonli', 'report', 'advers', 'event', 'patient', 'receiv', 'humira', 'granuloma', 'annular', 'lead', 'discontinu', 'humira', 'treatment', '.'], 'dependencies': [('less', 'amod'), ('commonli', 'compound'), ('report', 'compound'), ('advers', 'compound'), ('event', 'compound'), ('patient', 'compound'), ('receiv', 'compound'), ('humira', 'compound'), ('granuloma', 'nmod'), ('annular', 'amod'), ('lead', 'compound'), ('discontinu', 'compound'), ('humira', 'compound'), ('treatment', 'ROOT'), ('.', 'punct')]}], 'text': 'Cardiovascular System: Arrhythmia, atrial fibrillation, chest pain, coronary artery disorder, heart \\narrest, hypertensive encephalopathy, myocardial infarct, palpitation, pericardial effusion, \\npericarditis, syncope, tachycardia  \\nDigestive System: Cholecystitis, cholelithiasis, esophagitis, gastroenteritis, gastrointestinal \\nhemorrhage, hepatic necrosis, vomiting  \\nEndocrine System: Parathyroid disorder  \\nHemic And Lymphatic System: Agranulocytosis, polycythemia  \\nMetabolic And Nutritional Disorders: Dehydration, healing abnormal, ketosis, paraproteinemia, \\nperipheral edema  \\nMusculo-Skeletal System: Arthritis, bone disorder, bone fracture (not spontaneous), bone \\nnecrosis, joint disorder, muscle cramps, myasthenia, pyogenic arthritis, synovitis, tendon \\ndisorder  \\nNeoplasia: Adenoma  \\nNervous System: Confusion, paresthesia, subdural hematoma, tremor  \\nRespiratory System: Asthma, bronchospasm, dyspnea, lung function decreased, pleural effusion  \\nSpecial Senses: Cataract  \\nThrombosis: Thrombosis leg  \\nUrogenital System: Cystitis, kidney calculus, menstrual disorder  \\nJuvenile Idiopathic Arthritis Clinical Studies \\nIn general, the adverse reactions in the HUMIRA-treated patients in the polyarticular juvenile \\nidiopathic arthritis (JIA) trials (Studies JIA-I and JIA-II) [see Clinical Studies (14.2)] were \\nsimilar in frequency and type to those seen in adult patients [see Warnings and Precautions (5), \\nAdverse Reactions (6)]. Important findings and differences from adults are discussed in the \\nfollowing paragraphs.  \\nIn Study JIA-I, HUMIRA was studied in 171 patients who were 4 to 17 years of age, with \\npolyarticular JIA. Severe adverse reactions reported in the study included neutropenia, \\nstreptococcal pharyngitis, increased aminotransferases, herpes zoster, myositis, metrorrhagia, \\nand appendicitis. Serious infections were observed in 4% of patients within approximately 2 \\nyears of initiation of treatment with HUMIRA and included cases of herpes simplex, pneumonia, \\nurinary tract infection, pharyngitis, and herpes zoster.  \\nIn Study JIA-I, 45% of patients experienced an infection while receiving HUMIRA with or \\nwithout concomitant MTX in the first 16 weeks of treatment. The types of infections reported in \\nHUMIRA-treated patients were generally similar to those commonly seen in polyarticular JIA \\npatients who are not treated with TNF blockers. Upon initiation of treatment, the most common \\nadverse reactions occurring in this patient population treated with HUMIRA were injection site \\npain and injection site reaction (19% and 16%, respectively). A less commonly reported adverse \\nevent in patients receiving HUMIRA was granuloma annulare which did not lead to \\ndiscontinuation of HUMIRA treatment.  \\n'}, 'page_char_count': 2745, 'page_word_count': 341, 'sentences': ['Cardiovascular System: Arrhythmia, atrial fibrillation, chest pain, coronary artery disorder, heart \\narrest, hypertensive encephalopathy, myocardial infarct, palpitation, pericardial effusion, \\npericarditis, syncope, tachycardia  \\nDigestive System: Cholecystitis, cholelithiasis, esophagitis, gastroenteritis, gastrointestinal \\nhemorrhage, hepatic necrosis, vomiting  \\nEndocrine System: Parathyroid disorder  \\nHemic And Lymphatic System: Agranulocytosis, polycythemia  \\nMetabolic And Nutritional Disorders: Dehydration, healing abnormal, ketosis, paraproteinemia, \\nperipheral edema  \\nMusculo-Skeletal System: Arthritis, bone disorder, bone fracture (not spontaneous), bone \\nnecrosis, joint disorder, muscle cramps, myasthenia, pyogenic arthritis, synovitis, tendon \\ndisorder  \\nNeoplasia: Adenoma  \\nNervous System: Confusion, paresthesia, subdural hematoma, tremor  \\nRespiratory System: Asthma, bronchospasm, dyspnea, lung function decreased, pleural effusion  \\nSpecial Senses: Cataract  \\nThrombosis: Thrombosis leg  \\nUrogenital System: Cystitis, kidney calculus, menstrual disorder  \\nJuvenile Idiopathic Arthritis Clinical Studies \\nIn general, the adverse reactions in the HUMIRA-treated patients in the polyarticular juvenile \\nidiopathic arthritis (JIA) trials (Studies JIA-I and JIA-II) [see Clinical Studies (14.2)] were \\nsimilar in frequency and type to those seen in adult patients [see Warnings and Precautions (5), \\nAdverse Reactions (6)].', 'Important findings and differences from adults are discussed in the \\nfollowing paragraphs.', ' \\nIn Study JIA-I, HUMIRA was studied in 171 patients who were 4 to 17 years of age, with \\npolyarticular JIA.', 'Severe adverse reactions reported in the study included neutropenia, \\nstreptococcal pharyngitis, increased aminotransferases, herpes zoster, myositis, metrorrhagia, \\nand appendicitis.', 'Serious infections were observed in 4% of patients within approximately 2 \\nyears of initiation of treatment with HUMIRA and included cases of herpes simplex, pneumonia, \\nurinary tract infection, pharyngitis, and herpes zoster.', ' \\nIn Study JIA-I, 45% of patients experienced an infection while receiving HUMIRA with or \\nwithout concomitant MTX in the first 16 weeks of treatment.', 'The types of infections reported in \\nHUMIRA-treated patients were generally similar to those commonly seen in polyarticular JIA \\npatients who are not treated with TNF blockers.', 'Upon initiation of treatment, the most common \\nadverse reactions occurring in this patient population treated with HUMIRA were injection site \\npain and injection site reaction (19% and 16%, respectively).', 'A less commonly reported adverse \\nevent in patients receiving HUMIRA was granuloma annulare which did not lead to \\ndiscontinuation of HUMIRA treatment.', ' \\n'], 'page_sentence_count_spacy': 10}\n",
            "{'page_number': 19, 'text': 'In the first 48 weeks of treatment in Study JIA-I, non-serious hypersensitivity reactions were \\nseen in approximately 6% of patients and included primarily localized allergic hypersensitivity \\nreactions and allergic rash.  \\nIn Study JIA-I, 10% of patients treated with HUMIRA who had negative baseline anti-dsDNA \\nantibodies developed positive titers after 48 weeks of treatment. No patient developed clinical \\nsigns of autoimmunity during the clinical trial.  \\nApproximately 15% of patients treated with HUMIRA developed mild-to-moderate elevations of \\ncreatine phosphokinase (CPK) in Study JIA-I. Elevations exceeding 5 times the upper limit of \\nnormal were observed in several patients. CPK concentrations decreased or returned to normal in \\nall patients. Most patients were able to continue HUMIRA without interruption.  \\nIn Study JIA-II, HUMIRA was studied in 32 patients who were 2 to <4 years of age or 4 years of \\nage and older weighing <15 kg with polyarticular JIA. The safety profile for this patient \\npopulation was similar to the safety profile seen in patients 4 to 17 years of age with \\npolyarticular JIA.  \\nIn Study JIA-II, 78% of patients experienced an infection while receiving HUMIRA. These \\nincluded nasopharyngitis, bronchitis, upper respiratory tract infection, otitis media, and were \\nmostly mild to moderate in severity. Serious infections were observed in 9% of patients \\nreceiving HUMIRA in the study and included dental caries, rotavirus gastroenteritis, and \\nvaricella.  \\nIn Study JIA-II, non-serious allergic reactions were observed in 6% of patients and included \\nintermittent urticaria and rash, which were all mild in severity.  \\nPsoriatic Arthritis and Ankylosing Spondylitis Clinical Studies \\nHUMIRA has been studied in 395 patients with psoriatic arthritis (PsA) in two placebo-\\ncontrolled trials and in an open label study and in 393 patients with ankylosing spondylitis (AS) \\nin two placebo-controlled studies [see Clinical Studies (14.3, 14.4)]. The safety profile for \\npatients with PsA and AS treated with HUMIRA 40 mg every other week was similar to the \\nsafety profile seen in patients with RA, HUMIRA Studies RA-I through IV.  \\nCrohn’s Disease Clinical Studies \\nAdults:  The safety profile of HUMIRA in 1478 adult patients with Crohn’s disease from four \\nplacebo-controlled and two open-label extension studies [see Clinical Studies (14.5)] was similar \\nto the safety profile seen in patients with RA.  \\nPediatric Patients 6 Years to 17 Years:  The safety profile of HUMIRA in 192 pediatric patients \\nfrom one double-blind study (Study PCD-I) and one open-label extension study [see Clinical \\nStudies (14.6)] was similar to the safety profile seen in adult patients with Crohn’s disease.  \\nDuring the 4-week open label induction phase of Study PCD-I, the most common adverse \\nreactions occurring in the pediatric population treated with HUMIRA were injection site pain \\nand injection site reaction (6% and 5%, respectively).  \\nA total of 67% of children experienced an infection while receiving HUMIRA in Study PCD-I. \\nThese included upper respiratory tract infection and nasopharyngitis.  \\n', 'processed_text': {'sentences': [{'original_sentence': 'In the first 48 weeks of treatment in Study JIA-I, non-serious hypersensitivity reactions were \\nseen in approximately 6% of patients and included primarily localized allergic hypersensitivity \\nreactions and allergic rash.', 'tokens': ['first', '48', 'weeks', 'treatment', 'Study', 'JIA-I', ',', 'non-serious', 'hypersensitivity', 'reactions', 'seen', 'approximately', '6', '%', 'patients', 'included', 'primarily', 'localized', 'allergic', 'hypersensitivity', 'reactions', 'allergic', 'rash', '.'], 'lemmatized': ['first', '48', 'week', 'treatment', 'Study', 'JIA-I', ',', 'non-serious', 'hypersensitivity', 'reaction', 'seen', 'approximately', '6', '%', 'patient', 'included', 'primarily', 'localized', 'allergic', 'hypersensitivity', 'reaction', 'allergic', 'rash', '.'], 'stemmed': ['first', '48', 'week', 'treatment', 'studi', 'jia-i', ',', 'non-seri', 'hypersensit', 'reaction', 'seen', 'approxim', '6', '%', 'patient', 'includ', 'primarili', 'local', 'allerg', 'hypersensit', 'reaction', 'allerg', 'rash', '.'], 'dependencies': [('first', 'amod'), ('48', 'nummod'), ('week', 'compound'), ('treatment', 'npadvmod'), ('studi', 'npadvmod'), ('jia', 'npadvmod'), ('-', 'punct'), ('i', 'appos'), (',', 'punct'), ('non', 'amod'), ('-', 'amod'), ('seri', 'amod'), ('hypersensit', 'compound'), ('reaction', 'appos'), ('seen', 'acl'), ('approxim', 'nsubj'), ('6', 'nummod'), ('%', 'nmod'), ('patient', 'amod'), ('includ', 'nmod'), ('primarili', 'amod'), ('local', 'amod'), ('allerg', 'compound'), ('hypersensit', 'compound'), ('reaction', 'compound'), ('allerg', 'nsubj'), ('rash', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'In Study JIA-I, 10% of patients treated with HUMIRA who had negative baseline anti-dsDNA \\nantibodies developed positive titers after 48 weeks of treatment.', 'tokens': ['Study', 'JIA-I', ',', '10', '%', 'patients', 'treated', 'HUMIRA', 'negative', 'baseline', 'anti-dsDNA', 'antibodies', 'developed', 'positive', 'titers', '48', 'weeks', 'treatment', '.'], 'lemmatized': ['Study', 'JIA-I', ',', '10', '%', 'patient', 'treated', 'HUMIRA', 'negative', 'baseline', 'anti-dsDNA', 'antibody', 'developed', 'positive', 'titer', '48', 'week', 'treatment', '.'], 'stemmed': ['studi', 'jia-i', ',', '10', '%', 'patient', 'treat', 'humira', 'neg', 'baselin', 'anti-dsdna', 'antibodi', 'develop', 'posit', 'titer', '48', 'week', 'treatment', '.'], 'dependencies': [('studi', 'compound'), ('jia', 'nsubj'), ('-', 'punct'), ('i', 'appos'), (',', 'punct'), ('10', 'nummod'), ('%', 'npadvmod'), ('patient', 'compound'), ('treat', 'compound'), ('humira', 'nmod'), ('neg', 'compound'), ('baselin', 'nmod'), ('anti', 'amod'), ('-', 'amod'), ('dsdna', 'amod'), ('antibodi', 'nsubj'), ('develop', 'ROOT'), ('posit', 'compound'), ('titer', 'nmod'), ('48', 'nummod'), ('week', 'compound'), ('treatment', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'No patient developed clinical \\nsigns of autoimmunity during the clinical trial.', 'tokens': ['patient', 'developed', 'clinical', 'signs', 'autoimmunity', 'clinical', 'trial', '.'], 'lemmatized': ['patient', 'developed', 'clinical', 'sign', 'autoimmunity', 'clinical', 'trial', '.'], 'stemmed': ['patient', 'develop', 'clinic', 'sign', 'autoimmun', 'clinic', 'trial', '.'], 'dependencies': [('patient', 'nsubj'), ('develop', 'ROOT'), ('clinic', 'compound'), ('sign', 'nmod'), ('autoimmun', 'amod'), ('clinic', 'compound'), ('trial', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Approximately 15% of patients treated with HUMIRA developed mild-to-moderate elevations of \\ncreatine phosphokinase (CPK) in Study JIA-I.', 'tokens': ['Approximately', '15', '%', 'patients', 'treated', 'HUMIRA', 'developed', 'mild-to-moderate', 'elevations', 'creatine', 'phosphokinase', '(', 'CPK', ')', 'Study', 'JIA-I', '.'], 'lemmatized': ['Approximately', '15', '%', 'patient', 'treated', 'HUMIRA', 'developed', 'mild-to-moderate', 'elevation', 'creatine', 'phosphokinase', '(', 'CPK', ')', 'Study', 'JIA-I', '.'], 'stemmed': ['approxim', '15', '%', 'patient', 'treat', 'humira', 'develop', 'mild-to-moder', 'elev', 'creatin', 'phosphokinas', '(', 'cpk', ')', 'studi', 'jia-i', '.'], 'dependencies': [('approxim', 'nsubj'), ('15', 'nummod'), ('%', 'nmod'), ('patient', 'compound'), ('treat', 'compound'), ('humira', 'dobj'), ('develop', 'ROOT'), ('mild', 'amod'), ('-', 'punct'), ('to', 'prep'), ('-', 'punct'), ('moder', 'pobj'), ('elev', 'compound'), ('creatin', 'compound'), ('phosphokinas', 'dobj'), ('(', 'punct'), ('cpk', 'appos'), (')', 'punct'), ('studi', 'appos'), ('jia', 'npadvmod'), ('-', 'punct'), ('i', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Elevations exceeding 5 times the upper limit of \\nnormal were observed in several patients.', 'tokens': ['Elevations', 'exceeding', '5', 'times', 'upper', 'limit', 'normal', 'observed', 'several', 'patients', '.'], 'lemmatized': ['Elevations', 'exceeding', '5', 'time', 'upper', 'limit', 'normal', 'observed', 'several', 'patient', '.'], 'stemmed': ['elev', 'exceed', '5', 'time', 'upper', 'limit', 'normal', 'observ', 'sever', 'patient', '.'], 'dependencies': [('elev', 'nsubj'), ('exceed', 'ROOT'), ('5', 'nummod'), ('time', 'nmod'), ('upper', 'amod'), ('limit', 'dobj'), ('normal', 'amod'), ('observ', 'compound'), ('sever', 'compound'), ('patient', 'appos'), ('.', 'punct')]}, {'original_sentence': 'CPK concentrations decreased or returned to normal in \\nall patients.', 'tokens': ['CPK', 'concentrations', 'decreased', 'returned', 'normal', 'patients', '.'], 'lemmatized': ['CPK', 'concentration', 'decreased', 'returned', 'normal', 'patient', '.'], 'stemmed': ['cpk', 'concentr', 'decreas', 'return', 'normal', 'patient', '.'], 'dependencies': [('cpk', 'nsubj'), ('concentr', 'ROOT'), ('decreas', 'nsubj'), ('return', 'ccomp'), ('normal', 'amod'), ('patient', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Most patients were able to continue HUMIRA without interruption.', 'tokens': ['patients', 'able', 'continue', 'HUMIRA', 'without', 'interruption', '.'], 'lemmatized': ['patient', 'able', 'continue', 'HUMIRA', 'without', 'interruption', '.'], 'stemmed': ['patient', 'abl', 'continu', 'humira', 'without', 'interrupt', '.'], 'dependencies': [('patient', 'compound'), ('abl', 'compound'), ('continu', 'compound'), ('humira', 'ROOT'), ('without', 'prep'), ('interrupt', 'amod'), ('.', 'punct')]}, {'original_sentence': 'In Study JIA-II, HUMIRA was studied in 32 patients who were 2 to <4 years of age or 4 years of \\nage and older weighing <15 kg with polyarticular JIA.', 'tokens': ['Study', 'JIA-II', ',', 'HUMIRA', 'studied', '32', 'patients', '2', '<', '4', 'years', 'age', '4', 'years', 'age', 'older', 'weighing', '<', '15', 'kg', 'polyarticular', 'JIA', '.'], 'lemmatized': ['Study', 'JIA-II', ',', 'HUMIRA', 'studied', '32', 'patient', '2', '<', '4', 'year', 'age', '4', 'year', 'age', 'older', 'weighing', '<', '15', 'kg', 'polyarticular', 'JIA', '.'], 'stemmed': ['studi', 'jia-ii', ',', 'humira', 'studi', '32', 'patient', '2', '<', '4', 'year', 'age', '4', 'year', 'age', 'older', 'weigh', '<', '15', 'kg', 'polyarticular', 'jia', '.'], 'dependencies': [('studi', 'compound'), ('jia', 'compound'), ('-', 'punct'), ('ii', 'dep'), (',', 'punct'), ('humira', 'compound'), ('studi', 'npadvmod'), ('32', 'nummod'), ('patient', 'nmod'), ('2', 'nummod'), ('<', 'dep'), ('4', 'nummod'), ('year', 'compound'), ('age', 'nmod'), ('4', 'nummod'), ('year', 'compound'), ('age', 'ROOT'), ('older', 'amod'), ('weigh', 'nmod'), ('<', 'nmod'), ('15', 'nummod'), ('kg', 'appos'), ('polyarticular', 'compound'), ('jia', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'The safety profile for this patient \\npopulation was similar to the safety profile seen in patients 4 to 17 years of age with \\npolyarticular JIA.', 'tokens': ['safety', 'profile', 'patient', 'population', 'similar', 'safety', 'profile', 'seen', 'patients', '4', '17', 'years', 'age', 'polyarticular', 'JIA', '.'], 'lemmatized': ['safety', 'profile', 'patient', 'population', 'similar', 'safety', 'profile', 'seen', 'patient', '4', '17', 'year', 'age', 'polyarticular', 'JIA', '.'], 'stemmed': ['safeti', 'profil', 'patient', 'popul', 'similar', 'safeti', 'profil', 'seen', 'patient', '4', '17', 'year', 'age', 'polyarticular', 'jia', '.'], 'dependencies': [('safeti', 'compound'), ('profil', 'compound'), ('patient', 'compound'), ('popul', 'nsubj'), ('similar', 'amod'), ('safeti', 'compound'), ('profil', 'nsubj'), ('seen', 'ROOT'), ('patient', 'oprd'), ('4', 'compound'), ('17', 'nummod'), ('year', 'compound'), ('age', 'compound'), ('polyarticular', 'compound'), ('jia', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'In Study JIA-II, 78% of patients experienced an infection while receiving HUMIRA.', 'tokens': ['Study', 'JIA-II', ',', '78', '%', 'patients', 'experienced', 'infection', 'receiving', 'HUMIRA', '.'], 'lemmatized': ['Study', 'JIA-II', ',', '78', '%', 'patient', 'experienced', 'infection', 'receiving', 'HUMIRA', '.'], 'stemmed': ['studi', 'jia-ii', ',', '78', '%', 'patient', 'experienc', 'infect', 'receiv', 'humira', '.'], 'dependencies': [('studi', 'compound'), ('jia', 'compound'), ('-', 'punct'), ('ii', 'dep'), (',', 'punct'), ('78', 'nummod'), ('%', 'npadvmod'), ('patient', 'compound'), ('experienc', 'compound'), ('infect', 'compound'), ('receiv', 'compound'), ('humira', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'These \\nincluded nasopharyngitis, bronchitis, upper respiratory tract infection, otitis media, and were \\nmostly mild to moderate in severity.', 'tokens': ['included', 'nasopharyngitis', ',', 'bronchitis', ',', 'upper', 'respiratory', 'tract', 'infection', ',', 'otitis', 'media', ',', 'mostly', 'mild', 'moderate', 'severity', '.'], 'lemmatized': ['included', 'nasopharyngitis', ',', 'bronchitis', ',', 'upper', 'respiratory', 'tract', 'infection', ',', 'otitis', 'medium', ',', 'mostly', 'mild', 'moderate', 'severity', '.'], 'stemmed': ['includ', 'nasopharyng', ',', 'bronchiti', ',', 'upper', 'respiratori', 'tract', 'infect', ',', 'otiti', 'medium', ',', 'mostli', 'mild', 'moder', 'sever', '.'], 'dependencies': [('includ', 'compound'), ('nasopharyng', 'dep'), (',', 'punct'), ('bronchiti', 'appos'), (',', 'punct'), ('upper', 'amod'), ('respiratori', 'compound'), ('tract', 'nsubj'), ('infect', 'ccomp'), (',', 'punct'), ('otiti', 'compound'), ('medium', 'npadvmod'), (',', 'punct'), ('mostli', 'amod'), ('mild', 'amod'), ('moder', 'nsubj'), ('sever', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Serious infections were observed in 9% of patients \\nreceiving HUMIRA in the study and included dental caries, rotavirus gastroenteritis, and \\nvaricella.', 'tokens': ['Serious', 'infections', 'observed', '9', '%', 'patients', 'receiving', 'HUMIRA', 'study', 'included', 'dental', 'caries', ',', 'rotavirus', 'gastroenteritis', ',', 'varicella', '.'], 'lemmatized': ['Serious', 'infection', 'observed', '9', '%', 'patient', 'receiving', 'HUMIRA', 'study', 'included', 'dental', 'caries', ',', 'rotavirus', 'gastroenteritis', ',', 'varicella', '.'], 'stemmed': ['seriou', 'infect', 'observ', '9', '%', 'patient', 'receiv', 'humira', 'studi', 'includ', 'dental', 'cari', ',', 'rotaviru', 'gastroenter', ',', 'varicella', '.'], 'dependencies': [('seriou', 'npadvmod'), ('infect', 'ROOT'), ('observ', 'nmod'), ('9', 'nummod'), ('%', 'compound'), ('patient', 'compound'), ('receiv', 'compound'), ('humira', 'compound'), ('studi', 'compound'), ('includ', 'compound'), ('dental', 'compound'), ('cari', 'dobj'), (',', 'punct'), ('rotaviru', 'compound'), ('gastroenter', 'conj'), (',', 'punct'), ('varicella', 'conj'), ('.', 'punct')]}, {'original_sentence': 'In Study JIA-II, non-serious allergic reactions were observed in 6% of patients and included \\nintermittent urticaria and rash, which were all mild in severity.', 'tokens': ['Study', 'JIA-II', ',', 'non-serious', 'allergic', 'reactions', 'observed', '6', '%', 'patients', 'included', 'intermittent', 'urticaria', 'rash', ',', 'mild', 'severity', '.'], 'lemmatized': ['Study', 'JIA-II', ',', 'non-serious', 'allergic', 'reaction', 'observed', '6', '%', 'patient', 'included', 'intermittent', 'urticaria', 'rash', ',', 'mild', 'severity', '.'], 'stemmed': ['studi', 'jia-ii', ',', 'non-seri', 'allerg', 'reaction', 'observ', '6', '%', 'patient', 'includ', 'intermitt', 'urticaria', 'rash', ',', 'mild', 'sever', '.'], 'dependencies': [('studi', 'compound'), ('jia', 'compound'), ('-', 'punct'), ('ii', 'nmod'), (',', 'punct'), ('non', 'amod'), ('-', 'amod'), ('seri', 'amod'), ('allerg', 'compound'), ('reaction', 'nsubj'), ('observ', 'ROOT'), ('6', 'nummod'), ('%', 'compound'), ('patient', 'compound'), ('includ', 'nsubj'), ('intermitt', 'conj'), ('urticaria', 'compound'), ('rash', 'dobj'), (',', 'punct'), ('mild', 'amod'), ('sever', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Psoriatic Arthritis and Ankylosing Spondylitis Clinical Studies \\nHUMIRA has been studied in 395 patients with psoriatic arthritis (PsA) in two placebo-\\ncontrolled trials and in an open label study and in 393 patients with ankylosing spondylitis (AS) \\nin two placebo-controlled studies [see Clinical Studies (14.3, 14.4)].', 'tokens': ['Psoriatic', 'Arthritis', 'Ankylosing', 'Spondylitis', 'Clinical', 'Studies', 'HUMIRA', 'studied', '395', 'patients', 'psoriatic', 'arthritis', '(', 'PsA', ')', 'two', 'placebo-', 'controlled', 'trials', 'open', 'label', 'study', '393', 'patients', 'ankylosing', 'spondylitis', '(', ')', 'two', 'placebo-controlled', 'studies', '[', 'see', 'Clinical', 'Studies', '(', '14.3', ',', '14.4', ')', ']', '.'], 'lemmatized': ['Psoriatic', 'Arthritis', 'Ankylosing', 'Spondylitis', 'Clinical', 'Studies', 'HUMIRA', 'studied', '395', 'patient', 'psoriatic', 'arthritis', '(', 'PsA', ')', 'two', 'placebo-', 'controlled', 'trial', 'open', 'label', 'study', '393', 'patient', 'ankylosing', 'spondylitis', '(', ')', 'two', 'placebo-controlled', 'study', '[', 'see', 'Clinical', 'Studies', '(', '14.3', ',', '14.4', ')', ']', '.'], 'stemmed': ['psoriat', 'arthriti', 'ankylos', 'spondyl', 'clinic', 'studi', 'humira', 'studi', '395', 'patient', 'psoriat', 'arthriti', '(', 'psa', ')', 'two', 'placebo-', 'control', 'trial', 'open', 'label', 'studi', '393', 'patient', 'ankylos', 'spondyl', '(', ')', 'two', 'placebo-control', 'studi', '[', 'see', 'clinic', 'studi', '(', '14.3', ',', '14.4', ')', ']', '.'], 'dependencies': [('psoriat', 'compound'), ('arthriti', 'nsubj'), ('ankylos', 'ROOT'), ('spondyl', 'compound'), ('clinic', 'nmod'), ('studi', 'nmod'), ('humira', 'nmod'), ('studi', 'npadvmod'), ('395', 'nummod'), ('patient', 'compound'), ('psoriat', 'compound'), ('arthriti', 'npadvmod'), ('(', 'punct'), ('psa', 'parataxis'), (')', 'punct'), ('two', 'nummod'), ('placebo-', 'nmod'), ('control', 'nmod'), ('trial', 'nmod'), ('open', 'amod'), ('label', 'npadvmod'), ('studi', 'appos'), ('393', 'nummod'), ('patient', 'compound'), ('ankylos', 'compound'), ('spondyl', 'npadvmod'), ('(', 'punct'), (')', 'punct'), ('two', 'nummod'), ('placebo', 'compound'), ('-', 'punct'), ('control', 'compound'), ('studi', 'appos'), ('[', 'punct'), ('see', 'ROOT'), ('clinic', 'compound'), ('studi', 'dobj'), ('(', 'punct'), ('14.3', 'appos'), (',', 'punct'), ('14.4', 'appos'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': 'The safety profile for \\npatients with PsA and AS treated with HUMIRA 40 mg every other week was similar to the \\nsafety profile seen in patients with RA, HUMIRA Studies RA-I through IV.', 'tokens': ['safety', 'profile', 'patients', 'PsA', 'treated', 'HUMIRA', '40', 'mg', 'every', 'week', 'similar', 'safety', 'profile', 'seen', 'patients', 'RA', ',', 'HUMIRA', 'Studies', 'RA-I', 'IV', '.'], 'lemmatized': ['safety', 'profile', 'patient', 'PsA', 'treated', 'HUMIRA', '40', 'mg', 'every', 'week', 'similar', 'safety', 'profile', 'seen', 'patient', 'RA', ',', 'HUMIRA', 'Studies', 'RA-I', 'IV', '.'], 'stemmed': ['safeti', 'profil', 'patient', 'psa', 'treat', 'humira', '40', 'mg', 'everi', 'week', 'similar', 'safeti', 'profil', 'seen', 'patient', 'ra', ',', 'humira', 'studi', 'ra-i', 'iv', '.'], 'dependencies': [('safeti', 'compound'), ('profil', 'compound'), ('patient', 'compound'), ('psa', 'compound'), ('treat', 'compound'), ('humira', 'ROOT'), ('40', 'nummod'), ('mg', 'nmod'), ('everi', 'amod'), ('week', 'appos'), ('similar', 'amod'), ('safeti', 'compound'), ('profil', 'nsubj'), ('seen', 'relcl'), ('patient', 'compound'), ('ra', 'dobj'), (',', 'punct'), ('humira', 'npadvmod'), ('studi', 'npadvmod'), ('ra', 'npadvmod'), ('-', 'punct'), ('i', 'prep'), ('iv', 'dep'), ('.', 'punct')]}, {'original_sentence': 'Crohn’s Disease Clinical Studies \\nAdults:  The safety profile of HUMIRA in 1478 adult patients with Crohn’s disease from four \\nplacebo-controlled and two open-label extension studies [see Clinical Studies (14.5)] was similar \\nto the safety profile seen in patients with RA.', 'tokens': ['Crohn', '’', 'Disease', 'Clinical', 'Studies', 'Adults', ':', 'safety', 'profile', 'HUMIRA', '1478', 'adult', 'patients', 'Crohn', '’', 'disease', 'four', 'placebo-controlled', 'two', 'open-label', 'extension', 'studies', '[', 'see', 'Clinical', 'Studies', '(', '14.5', ')', ']', 'similar', 'safety', 'profile', 'seen', 'patients', 'RA', '.'], 'lemmatized': ['Crohn', '’', 'Disease', 'Clinical', 'Studies', 'Adults', ':', 'safety', 'profile', 'HUMIRA', '1478', 'adult', 'patient', 'Crohn', '’', 'disease', 'four', 'placebo-controlled', 'two', 'open-label', 'extension', 'study', '[', 'see', 'Clinical', 'Studies', '(', '14.5', ')', ']', 'similar', 'safety', 'profile', 'seen', 'patient', 'RA', '.'], 'stemmed': ['crohn', '’', 'diseas', 'clinic', 'studi', 'adult', ':', 'safeti', 'profil', 'humira', '1478', 'adult', 'patient', 'crohn', '’', 'diseas', 'four', 'placebo-control', 'two', 'open-label', 'extens', 'studi', '[', 'see', 'clinic', 'studi', '(', '14.5', ')', ']', 'similar', 'safeti', 'profil', 'seen', 'patient', 'ra', '.'], 'dependencies': [('crohn', 'nmod'), ('’', 'punct'), ('diseas', 'compound'), ('clinic', 'compound'), ('studi', 'compound'), ('adult', 'nmod'), (':', 'punct'), ('safeti', 'compound'), ('profil', 'compound'), ('humira', 'compound'), ('1478', 'nummod'), ('adult', 'compound'), ('patient', 'compound'), ('crohn', 'dobj'), ('’', 'punct'), ('diseas', 'ROOT'), ('four', 'nummod'), ('placebo', 'compound'), ('-', 'punct'), ('control', 'compound'), ('two', 'nummod'), ('open', 'amod'), ('-', 'punct'), ('label', 'compound'), ('extens', 'compound'), ('studi', 'punct'), ('[', 'punct'), ('see', 'ROOT'), ('clinic', 'compound'), ('studi', 'dobj'), ('(', 'punct'), ('14.5', 'appos'), (')', 'punct'), (']', 'punct'), ('similar', 'amod'), ('safeti', 'compound'), ('profil', 'nsubj'), ('seen', 'ccomp'), ('patient', 'dobj'), ('ra', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Pediatric Patients 6 Years to 17 Years:  The safety profile of HUMIRA in 192 pediatric patients \\nfrom one double-blind study (Study PCD-I) and one open-label extension study [see Clinical \\nStudies (14.6)] was similar to the safety profile seen in adult patients with Crohn’s disease.', 'tokens': ['Pediatric', 'Patients', '6', 'Years', '17', 'Years', ':', 'safety', 'profile', 'HUMIRA', '192', 'pediatric', 'patients', 'one', 'double-blind', 'study', '(', 'Study', 'PCD-I', ')', 'one', 'open-label', 'extension', 'study', '[', 'see', 'Clinical', 'Studies', '(', '14.6', ')', ']', 'similar', 'safety', 'profile', 'seen', 'adult', 'patients', 'Crohn', '’', 'disease', '.'], 'lemmatized': ['Pediatric', 'Patients', '6', 'Years', '17', 'Years', ':', 'safety', 'profile', 'HUMIRA', '192', 'pediatric', 'patient', 'one', 'double-blind', 'study', '(', 'Study', 'PCD-I', ')', 'one', 'open-label', 'extension', 'study', '[', 'see', 'Clinical', 'Studies', '(', '14.6', ')', ']', 'similar', 'safety', 'profile', 'seen', 'adult', 'patient', 'Crohn', '’', 'disease', '.'], 'stemmed': ['pediatr', 'patient', '6', 'year', '17', 'year', ':', 'safeti', 'profil', 'humira', '192', 'pediatr', 'patient', 'one', 'double-blind', 'studi', '(', 'studi', 'pcd-i', ')', 'one', 'open-label', 'extens', 'studi', '[', 'see', 'clinic', 'studi', '(', '14.6', ')', ']', 'similar', 'safeti', 'profil', 'seen', 'adult', 'patient', 'crohn', '’', 'diseas', '.'], 'dependencies': [('pediatr', 'amod'), ('patient', 'nsubj'), ('6', 'nummod'), ('year', 'npadvmod'), ('17', 'nummod'), ('year', 'npadvmod'), (':', 'punct'), ('safeti', 'compound'), ('profil', 'compound'), ('humira', 'appos'), ('192', 'nummod'), ('pediatr', 'amod'), ('patient', 'appos'), ('one', 'nummod'), ('double', 'amod'), ('-', 'punct'), ('blind', 'amod'), ('studi', 'appos'), ('(', 'punct'), ('studi', 'npadvmod'), ('pcd', 'npadvmod'), ('-', 'punct'), ('i', 'appos'), (')', 'punct'), ('one', 'nummod'), ('open', 'amod'), ('-', 'punct'), ('label', 'compound'), ('extens', 'compound'), ('studi', 'appos'), ('[', 'punct'), ('see', 'ROOT'), ('clinic', 'compound'), ('studi', 'npadvmod'), ('(', 'punct'), ('14.6', 'appos'), (')', 'punct'), (']', 'punct'), ('similar', 'amod'), ('safeti', 'compound'), ('profil', 'nsubj'), ('seen', 'ccomp'), ('adult', 'compound'), ('patient', 'compound'), ('crohn', 'nmod'), ('’', 'punct'), ('diseas', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'During the 4-week open label induction phase of Study PCD-I, the most common adverse \\nreactions occurring in the pediatric population treated with HUMIRA were injection site pain \\nand injection site reaction (6% and 5%, respectively).', 'tokens': ['4-week', 'open', 'label', 'induction', 'phase', 'Study', 'PCD-I', ',', 'common', 'adverse', 'reactions', 'occurring', 'pediatric', 'population', 'treated', 'HUMIRA', 'injection', 'site', 'pain', 'injection', 'site', 'reaction', '(', '6', '%', '5', '%', ',', 'respectively', ')', '.'], 'lemmatized': ['4-week', 'open', 'label', 'induction', 'phase', 'Study', 'PCD-I', ',', 'common', 'adverse', 'reaction', 'occurring', 'pediatric', 'population', 'treated', 'HUMIRA', 'injection', 'site', 'pain', 'injection', 'site', 'reaction', '(', '6', '%', '5', '%', ',', 'respectively', ')', '.'], 'stemmed': ['4-week', 'open', 'label', 'induct', 'phase', 'studi', 'pcd-i', ',', 'common', 'advers', 'reaction', 'occur', 'pediatr', 'popul', 'treat', 'humira', 'inject', 'site', 'pain', 'inject', 'site', 'reaction', '(', '6', '%', '5', '%', ',', 'respect', ')', '.'], 'dependencies': [('4', 'nummod'), ('-', 'punct'), ('week', 'nmod'), ('open', 'amod'), ('label', 'compound'), ('induct', 'compound'), ('phase', 'nmod'), ('studi', 'compound'), ('pcd', 'nmod'), ('-', 'punct'), ('i', 'appos'), (',', 'punct'), ('common', 'amod'), ('advers', 'compound'), ('reaction', 'nsubj'), ('occur', 'ROOT'), ('pediatr', 'compound'), ('popul', 'nsubj'), ('treat', 'ccomp'), ('humira', 'compound'), ('inject', 'compound'), ('site', 'compound'), ('pain', 'compound'), ('inject', 'compound'), ('site', 'compound'), ('reaction', 'dobj'), ('(', 'punct'), ('6', 'nummod'), ('%', 'npadvmod'), ('5', 'nummod'), ('%', 'appos'), (',', 'punct'), ('respect', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'A total of 67% of children experienced an infection while receiving HUMIRA in Study PCD-I.', 'tokens': ['total', '67', '%', 'children', 'experienced', 'infection', 'receiving', 'HUMIRA', 'Study', 'PCD-I', '.'], 'lemmatized': ['total', '67', '%', 'child', 'experienced', 'infection', 'receiving', 'HUMIRA', 'Study', 'PCD-I', '.'], 'stemmed': ['total', '67', '%', 'child', 'experienc', 'infect', 'receiv', 'humira', 'studi', 'pcd-i', '.'], 'dependencies': [('total', 'ROOT'), ('67', 'nummod'), ('%', 'compound'), ('child', 'compound'), ('experienc', 'compound'), ('infect', 'compound'), ('receiv', 'compound'), ('humira', 'compound'), ('studi', 'npadvmod'), ('pcd', 'npadvmod'), ('-', 'punct'), ('i', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'These included upper respiratory tract infection and nasopharyngitis.', 'tokens': ['included', 'upper', 'respiratory', 'tract', 'infection', 'nasopharyngitis', '.'], 'lemmatized': ['included', 'upper', 'respiratory', 'tract', 'infection', 'nasopharyngitis', '.'], 'stemmed': ['includ', 'upper', 'respiratori', 'tract', 'infect', 'nasopharyng', '.'], 'dependencies': [('includ', 'amod'), ('upper', 'amod'), ('respiratori', 'compound'), ('tract', 'nsubj'), ('infect', 'ROOT'), ('nasopharyng', 'dobj'), ('.', 'punct')]}], 'text': 'In the first 48 weeks of treatment in Study JIA-I, non-serious hypersensitivity reactions were \\nseen in approximately 6% of patients and included primarily localized allergic hypersensitivity \\nreactions and allergic rash.  \\nIn Study JIA-I, 10% of patients treated with HUMIRA who had negative baseline anti-dsDNA \\nantibodies developed positive titers after 48 weeks of treatment. No patient developed clinical \\nsigns of autoimmunity during the clinical trial.  \\nApproximately 15% of patients treated with HUMIRA developed mild-to-moderate elevations of \\ncreatine phosphokinase (CPK) in Study JIA-I. Elevations exceeding 5 times the upper limit of \\nnormal were observed in several patients. CPK concentrations decreased or returned to normal in \\nall patients. Most patients were able to continue HUMIRA without interruption.  \\nIn Study JIA-II, HUMIRA was studied in 32 patients who were 2 to <4 years of age or 4 years of \\nage and older weighing <15 kg with polyarticular JIA. The safety profile for this patient \\npopulation was similar to the safety profile seen in patients 4 to 17 years of age with \\npolyarticular JIA.  \\nIn Study JIA-II, 78% of patients experienced an infection while receiving HUMIRA. These \\nincluded nasopharyngitis, bronchitis, upper respiratory tract infection, otitis media, and were \\nmostly mild to moderate in severity. Serious infections were observed in 9% of patients \\nreceiving HUMIRA in the study and included dental caries, rotavirus gastroenteritis, and \\nvaricella.  \\nIn Study JIA-II, non-serious allergic reactions were observed in 6% of patients and included \\nintermittent urticaria and rash, which were all mild in severity.  \\nPsoriatic Arthritis and Ankylosing Spondylitis Clinical Studies \\nHUMIRA has been studied in 395 patients with psoriatic arthritis (PsA) in two placebo-\\ncontrolled trials and in an open label study and in 393 patients with ankylosing spondylitis (AS) \\nin two placebo-controlled studies [see Clinical Studies (14.3, 14.4)]. The safety profile for \\npatients with PsA and AS treated with HUMIRA 40 mg every other week was similar to the \\nsafety profile seen in patients with RA, HUMIRA Studies RA-I through IV.  \\nCrohn’s Disease Clinical Studies \\nAdults:  The safety profile of HUMIRA in 1478 adult patients with Crohn’s disease from four \\nplacebo-controlled and two open-label extension studies [see Clinical Studies (14.5)] was similar \\nto the safety profile seen in patients with RA.  \\nPediatric Patients 6 Years to 17 Years:  The safety profile of HUMIRA in 192 pediatric patients \\nfrom one double-blind study (Study PCD-I) and one open-label extension study [see Clinical \\nStudies (14.6)] was similar to the safety profile seen in adult patients with Crohn’s disease.  \\nDuring the 4-week open label induction phase of Study PCD-I, the most common adverse \\nreactions occurring in the pediatric population treated with HUMIRA were injection site pain \\nand injection site reaction (6% and 5%, respectively).  \\nA total of 67% of children experienced an infection while receiving HUMIRA in Study PCD-I. \\nThese included upper respiratory tract infection and nasopharyngitis.  \\n'}, 'page_char_count': 3135, 'page_word_count': 465, 'sentences': ['In the first 48 weeks of treatment in Study JIA-I, non-serious hypersensitivity reactions were \\nseen in approximately 6% of patients and included primarily localized allergic hypersensitivity \\nreactions and allergic rash.', ' \\nIn Study JIA-I, 10% of patients treated with HUMIRA who had negative baseline anti-dsDNA \\nantibodies developed positive titers after 48 weeks of treatment.', 'No patient developed clinical \\nsigns of autoimmunity during the clinical trial.', ' \\nApproximately 15% of patients treated with HUMIRA developed mild-to-moderate elevations of \\ncreatine phosphokinase (CPK) in Study JIA-I. Elevations exceeding 5 times the upper limit of \\nnormal were observed in several patients.', 'CPK concentrations decreased or returned to normal in \\nall patients.', 'Most patients were able to continue HUMIRA without interruption.', ' \\nIn Study JIA-II, HUMIRA was studied in 32 patients who were 2 to <4 years of age or 4 years of \\nage and older weighing <15 kg with polyarticular JIA.', 'The safety profile for this patient \\npopulation was similar to the safety profile seen in patients 4 to 17 years of age with \\npolyarticular JIA.', ' \\nIn Study JIA-II, 78% of patients experienced an infection while receiving HUMIRA.', 'These \\nincluded nasopharyngitis, bronchitis, upper respiratory tract infection, otitis media, and were \\nmostly mild to moderate in severity.', 'Serious infections were observed in 9% of patients \\nreceiving HUMIRA in the study and included dental caries, rotavirus gastroenteritis, and \\nvaricella.', ' \\nIn Study JIA-II, non-serious allergic reactions were observed in 6% of patients and included \\nintermittent urticaria and rash, which were all mild in severity.', ' \\nPsoriatic Arthritis and Ankylosing Spondylitis Clinical Studies \\nHUMIRA has been studied in 395 patients with psoriatic arthritis (PsA) in two placebo-\\ncontrolled trials and in an open label study and in 393 patients with ankylosing spondylitis (AS) \\nin two placebo-controlled studies [see Clinical Studies (14.3, 14.4)].', 'The safety profile for \\npatients with PsA and AS treated with HUMIRA 40 mg every other week was similar to the \\nsafety profile seen in patients with RA, HUMIRA Studies RA-I through IV.', ' \\nCrohn’s Disease Clinical Studies \\nAdults:  The safety profile of HUMIRA in 1478 adult patients with Crohn’s disease from four \\nplacebo-controlled and two open-label extension studies [see Clinical Studies (14.5)] was similar \\nto the safety profile seen in patients with RA.', ' \\nPediatric Patients 6 Years to 17 Years:  The safety profile of HUMIRA in 192 pediatric patients \\nfrom one double-blind study (Study PCD-I) and one open-label extension study [see Clinical \\nStudies (14.6)] was similar to the safety profile seen in adult patients with Crohn’s disease.', ' \\nDuring the 4-week open label induction phase of Study PCD-I, the most common adverse \\nreactions occurring in the pediatric population treated with HUMIRA were injection site pain \\nand injection site reaction (6% and 5%, respectively).', ' \\nA total of 67% of children experienced an infection while receiving HUMIRA in Study PCD-I. \\nThese included upper respiratory tract infection and nasopharyngitis.', ' \\n'], 'page_sentence_count_spacy': 19}\n",
            "{'page_number': 20, 'text': 'A total of 5% of children experienced a serious infection while receiving HUMIRA in Study \\nPCD-I. These included viral infection, device related sepsis (catheter), gastroenteritis, H1N1 \\ninfluenza, and disseminated histoplasmosis.  \\nIn Study PCD-I, allergic reactions were observed in 5% of children which were all non-serious \\nand were primarily localized reactions.  \\nUlcerative Colitis Clinical Studies \\nAdults: The safety profile of HUMIRA in 1010 adult patients with ulcerative colitis (UC) from \\ntwo placebo-controlled studies and one open-label extension study [see Clinical Studies (14.7)] \\nwas similar to the safety profile seen in patients with RA. \\nPediatric Patients 5 Years to 17 Years:  The safety profile of HUMIRA in 93 pediatric patients \\nwith ulcerative colitis from one double-blind study and one open-label extension study [see \\nClinical Studies (14.8)] was similar to the safety profile seen in adult patients with ulcerative \\ncolitis. \\nPlaque Psoriasis Clinical Studies \\nHUMIRA has been studied in 1696 subjects with plaque psoriasis (Ps) in placebo-controlled and \\nopen-label extension studies [see Clinical Studies (14.9)]. The safety profile for subjects with Ps \\ntreated with HUMIRA was similar to the safety profile seen in subjects with RA with the \\nfollowing exceptions. In the placebo-controlled portions of the clinical trials in Ps subjects, \\nHUMIRA-treated subjects had a higher incidence of arthralgia when compared to controls (3% \\nvs. 1%).  \\nHidradenitis Suppurativa Clinical Studies \\nHUMIRA has been studied in 727 subjects with hidradenitis suppurativa (HS) in three placebo-\\ncontrolled studies and one open-label extension study [see Clinical Studies (14.10)]. The safety \\nprofile for subjects with HS treated with HUMIRA weekly was consistent with the known safety \\nprofile of HUMIRA.  \\nFlare of HS, defined as ≥25% increase from baseline in abscesses and inflammatory nodule \\ncounts and with a minimum of 2 additional lesions, was documented in 22 (22%) of the 100 \\nsubjects who were withdrawn from HUMIRA treatment following the primary efficacy \\ntimepoint in two studies.  \\nUveitis Clinical Studies \\nHUMIRA has been studied in 464 adult patients with uveitis (UV) in placebo-controlled and \\nopen-label extension studies and in 90 pediatric patients with uveitis (Study PUV-I) [see Clinical \\nStudies (14.11, 14.12)] . The safety profile for patients with UV treated with HUMIRA was \\nsimilar to the safety profile seen in patients with RA.  \\n6.2 Immunogenicity \\nAs with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody \\nformation is highly dependent on the sensitivity and specificity of the assay. Additionally, the \\nobserved incidence of antibody (including neutralizing antibody) positivity in an assay may be \\ninfluenced by several factors including assay methodology, sample handling, timing of sample \\n', 'processed_text': {'sentences': [{'original_sentence': 'A total of 5% of children experienced a serious infection while receiving HUMIRA in Study \\nPCD-I.', 'tokens': ['total', '5', '%', 'children', 'experienced', 'serious', 'infection', 'receiving', 'HUMIRA', 'Study', 'PCD-I', '.'], 'lemmatized': ['total', '5', '%', 'child', 'experienced', 'serious', 'infection', 'receiving', 'HUMIRA', 'Study', 'PCD-I', '.'], 'stemmed': ['total', '5', '%', 'child', 'experienc', 'seriou', 'infect', 'receiv', 'humira', 'studi', 'pcd-i', '.'], 'dependencies': [('total', 'ROOT'), ('5', 'nummod'), ('%', 'compound'), ('child', 'compound'), ('experienc', 'compound'), ('seriou', 'compound'), ('infect', 'compound'), ('receiv', 'compound'), ('humira', 'compound'), ('studi', 'npadvmod'), ('pcd', 'npadvmod'), ('-', 'punct'), ('i', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'These included viral infection, device related sepsis (catheter), gastroenteritis, H1N1 \\ninfluenza, and disseminated histoplasmosis.', 'tokens': ['included', 'viral', 'infection', ',', 'device', 'related', 'sepsis', '(', 'catheter', ')', ',', 'gastroenteritis', ',', 'H1N1', 'influenza', ',', 'disseminated', 'histoplasmosis', '.'], 'lemmatized': ['included', 'viral', 'infection', ',', 'device', 'related', 'sepsis', '(', 'catheter', ')', ',', 'gastroenteritis', ',', 'H1N1', 'influenza', ',', 'disseminated', 'histoplasmosis', '.'], 'stemmed': ['includ', 'viral', 'infect', ',', 'devic', 'relat', 'sepsi', '(', 'cathet', ')', ',', 'gastroenter', ',', 'h1n1', 'influenza', ',', 'dissemin', 'histoplasmosi', '.'], 'dependencies': [('includ', 'amod'), ('viral', 'amod'), ('infect', 'ROOT'), (',', 'punct'), ('devic', 'compound'), ('relat', 'compound'), ('sepsi', 'appos'), ('(', 'punct'), ('cathet', 'appos'), (')', 'punct'), (',', 'punct'), ('gastroenter', 'conj'), (',', 'punct'), ('h1n1', 'compound'), ('influenza', 'conj'), (',', 'punct'), ('dissemin', 'amod'), ('histoplasmosi', 'conj'), ('.', 'punct')]}, {'original_sentence': 'In Study PCD-I, allergic reactions were observed in 5% of children which were all non-serious \\nand were primarily localized reactions.', 'tokens': ['Study', 'PCD-I', ',', 'allergic', 'reactions', 'observed', '5', '%', 'children', 'non-serious', 'primarily', 'localized', 'reactions', '.'], 'lemmatized': ['Study', 'PCD-I', ',', 'allergic', 'reaction', 'observed', '5', '%', 'child', 'non-serious', 'primarily', 'localized', 'reaction', '.'], 'stemmed': ['studi', 'pcd-i', ',', 'allerg', 'reaction', 'observ', '5', '%', 'child', 'non-seri', 'primarili', 'local', 'reaction', '.'], 'dependencies': [('studi', 'compound'), ('pcd', 'nmod'), ('-', 'punct'), ('i', 'appos'), (',', 'punct'), ('allerg', 'compound'), ('reaction', 'appos'), ('observ', 'nmod'), ('5', 'nummod'), ('%', 'compound'), ('child', 'nmod'), ('non', 'amod'), ('-', 'amod'), ('seri', 'amod'), ('primarili', 'amod'), ('local', 'amod'), ('reaction', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Ulcerative Colitis Clinical Studies \\nAdults: The safety profile of HUMIRA in 1010 adult patients with ulcerative colitis (UC) from \\ntwo placebo-controlled studies and one open-label extension study [see Clinical Studies (14.7)] \\nwas similar to the safety profile seen in patients with RA.', 'tokens': ['Ulcerative', 'Colitis', 'Clinical', 'Studies', 'Adults', ':', 'safety', 'profile', 'HUMIRA', '1010', 'adult', 'patients', 'ulcerative', 'colitis', '(', 'UC', ')', 'two', 'placebo-controlled', 'studies', 'one', 'open-label', 'extension', 'study', '[', 'see', 'Clinical', 'Studies', '(', '14.7', ')', ']', 'similar', 'safety', 'profile', 'seen', 'patients', 'RA', '.'], 'lemmatized': ['Ulcerative', 'Colitis', 'Clinical', 'Studies', 'Adults', ':', 'safety', 'profile', 'HUMIRA', '1010', 'adult', 'patient', 'ulcerative', 'colitis', '(', 'UC', ')', 'two', 'placebo-controlled', 'study', 'one', 'open-label', 'extension', 'study', '[', 'see', 'Clinical', 'Studies', '(', '14.7', ')', ']', 'similar', 'safety', 'profile', 'seen', 'patient', 'RA', '.'], 'stemmed': ['ulcer', 'coliti', 'clinic', 'studi', 'adult', ':', 'safeti', 'profil', 'humira', '1010', 'adult', 'patient', 'ulcer', 'coliti', '(', 'uc', ')', 'two', 'placebo-control', 'studi', 'one', 'open-label', 'extens', 'studi', '[', 'see', 'clinic', 'studi', '(', '14.7', ')', ']', 'similar', 'safeti', 'profil', 'seen', 'patient', 'ra', '.'], 'dependencies': [('ulcer', 'compound'), ('coliti', 'compound'), ('clinic', 'compound'), ('studi', 'compound'), ('adult', 'ROOT'), (':', 'punct'), ('safeti', 'compound'), ('profil', 'compound'), ('humira', 'compound'), ('1010', 'nummod'), ('adult', 'compound'), ('patient', 'compound'), ('ulcer', 'compound'), ('coliti', 'appos'), ('(', 'punct'), ('uc', 'appos'), (')', 'punct'), ('two', 'nummod'), ('placebo', 'compound'), ('-', 'punct'), ('control', 'compound'), ('studi', 'punct'), ('one', 'nummod'), ('open', 'amod'), ('-', 'punct'), ('label', 'compound'), ('extens', 'compound'), ('studi', 'appos'), ('[', 'punct'), ('see', 'ROOT'), ('clinic', 'compound'), ('studi', 'dobj'), ('(', 'punct'), ('14.7', 'appos'), (')', 'punct'), (']', 'punct'), ('similar', 'amod'), ('safeti', 'compound'), ('profil', 'nsubj'), ('seen', 'ccomp'), ('patient', 'dobj'), ('ra', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Pediatric Patients 5 Years to 17 Years:  The safety profile of HUMIRA in 93 pediatric patients \\nwith ulcerative colitis from one double-blind study and one open-label extension study [see \\nClinical Studies (14.8)] was similar to the safety profile seen in adult patients with ulcerative \\ncolitis.', 'tokens': ['Pediatric', 'Patients', '5', 'Years', '17', 'Years', ':', 'safety', 'profile', 'HUMIRA', '93', 'pediatric', 'patients', 'ulcerative', 'colitis', 'one', 'double-blind', 'study', 'one', 'open-label', 'extension', 'study', '[', 'see', 'Clinical', 'Studies', '(', '14.8', ')', ']', 'similar', 'safety', 'profile', 'seen', 'adult', 'patients', 'ulcerative', 'colitis', '.'], 'lemmatized': ['Pediatric', 'Patients', '5', 'Years', '17', 'Years', ':', 'safety', 'profile', 'HUMIRA', '93', 'pediatric', 'patient', 'ulcerative', 'colitis', 'one', 'double-blind', 'study', 'one', 'open-label', 'extension', 'study', '[', 'see', 'Clinical', 'Studies', '(', '14.8', ')', ']', 'similar', 'safety', 'profile', 'seen', 'adult', 'patient', 'ulcerative', 'colitis', '.'], 'stemmed': ['pediatr', 'patient', '5', 'year', '17', 'year', ':', 'safeti', 'profil', 'humira', '93', 'pediatr', 'patient', 'ulcer', 'coliti', 'one', 'double-blind', 'studi', 'one', 'open-label', 'extens', 'studi', '[', 'see', 'clinic', 'studi', '(', '14.8', ')', ']', 'similar', 'safeti', 'profil', 'seen', 'adult', 'patient', 'ulcer', 'coliti', '.'], 'dependencies': [('pediatr', 'amod'), ('patient', 'nsubj'), ('5', 'nummod'), ('year', 'npadvmod'), ('17', 'nummod'), ('year', 'npadvmod'), (':', 'punct'), ('safeti', 'compound'), ('profil', 'compound'), ('humira', 'appos'), ('93', 'nummod'), ('pediatr', 'amod'), ('patient', 'compound'), ('ulcer', 'npadvmod'), ('coliti', 'npadvmod'), ('one', 'nummod'), ('double', 'amod'), ('-', 'punct'), ('blind', 'nmod'), ('studi', 'pobj'), ('one', 'nummod'), ('open', 'amod'), ('-', 'punct'), ('label', 'compound'), ('extens', 'compound'), ('studi', 'appos'), ('[', 'punct'), ('see', 'ROOT'), ('clinic', 'compound'), ('studi', 'npadvmod'), ('(', 'punct'), ('14.8', 'appos'), (')', 'punct'), (']', 'punct'), ('similar', 'amod'), ('safeti', 'compound'), ('profil', 'nsubj'), ('seen', 'ccomp'), ('adult', 'compound'), ('patient', 'compound'), ('ulcer', 'compound'), ('coliti', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Plaque Psoriasis Clinical Studies \\nHUMIRA has been studied in 1696 subjects with plaque psoriasis (Ps) in placebo-controlled and \\nopen-label extension studies [see Clinical Studies (14.9)].', 'tokens': ['Plaque', 'Psoriasis', 'Clinical', 'Studies', 'HUMIRA', 'studied', '1696', 'subjects', 'plaque', 'psoriasis', '(', 'Ps', ')', 'placebo-controlled', 'open-label', 'extension', 'studies', '[', 'see', 'Clinical', 'Studies', '(', '14.9', ')', ']', '.'], 'lemmatized': ['Plaque', 'Psoriasis', 'Clinical', 'Studies', 'HUMIRA', 'studied', '1696', 'subject', 'plaque', 'psoriasis', '(', 'Ps', ')', 'placebo-controlled', 'open-label', 'extension', 'study', '[', 'see', 'Clinical', 'Studies', '(', '14.9', ')', ']', '.'], 'stemmed': ['plaqu', 'psoriasi', 'clinic', 'studi', 'humira', 'studi', '1696', 'subject', 'plaqu', 'psoriasi', '(', 'ps', ')', 'placebo-control', 'open-label', 'extens', 'studi', '[', 'see', 'clinic', 'studi', '(', '14.9', ')', ']', '.'], 'dependencies': [('plaqu', 'ROOT'), ('psoriasi', 'compound'), ('clinic', 'nmod'), ('studi', 'compound'), ('humira', 'appos'), ('studi', 'npadvmod'), ('1696', 'nummod'), ('subject', 'compound'), ('plaqu', 'compound'), ('psoriasi', 'dobj'), ('(', 'punct'), ('ps', 'nmod'), (')', 'punct'), ('placebo', 'nmod'), ('-', 'punct'), ('control', 'compound'), ('open', 'amod'), ('-', 'punct'), ('label', 'compound'), ('extens', 'compound'), ('studi', 'npadvmod'), ('[', 'punct'), ('see', 'ROOT'), ('clinic', 'compound'), ('studi', 'dobj'), ('(', 'punct'), ('14.9', 'appos'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': 'The safety profile for subjects with Ps \\ntreated with HUMIRA was similar to the safety profile seen in subjects with RA with the \\nfollowing exceptions.', 'tokens': ['safety', 'profile', 'subjects', 'Ps', 'treated', 'HUMIRA', 'similar', 'safety', 'profile', 'seen', 'subjects', 'RA', 'following', 'exceptions', '.'], 'lemmatized': ['safety', 'profile', 'subject', 'Ps', 'treated', 'HUMIRA', 'similar', 'safety', 'profile', 'seen', 'subject', 'RA', 'following', 'exception', '.'], 'stemmed': ['safeti', 'profil', 'subject', 'ps', 'treat', 'humira', 'similar', 'safeti', 'profil', 'seen', 'subject', 'ra', 'follow', 'except', '.'], 'dependencies': [('safeti', 'compound'), ('profil', 'compound'), ('subject', 'compound'), ('ps', 'nmod'), ('treat', 'compound'), ('humira', 'nmod'), ('similar', 'amod'), ('safeti', 'compound'), ('profil', 'nsubj'), ('seen', 'ROOT'), ('subject', 'dobj'), ('ra', 'compound'), ('follow', 'dobj'), ('except', 'prep'), ('.', 'punct')]}, {'original_sentence': 'In the placebo-controlled portions of the clinical trials in Ps subjects, \\nHUMIRA-treated subjects had a higher incidence of arthralgia when compared to controls (3% \\nvs. 1%).', 'tokens': ['placebo-controlled', 'portions', 'clinical', 'trials', 'Ps', 'subjects', ',', 'HUMIRA-treated', 'subjects', 'higher', 'incidence', 'arthralgia', 'compared', 'controls', '(', '3', '%', 'vs.', '1', '%', ')', '.'], 'lemmatized': ['placebo-controlled', 'portion', 'clinical', 'trial', 'Ps', 'subject', ',', 'HUMIRA-treated', 'subject', 'higher', 'incidence', 'arthralgia', 'compared', 'control', '(', '3', '%', 'vs.', '1', '%', ')', '.'], 'stemmed': ['placebo-control', 'portion', 'clinic', 'trial', 'ps', 'subject', ',', 'humira-tr', 'subject', 'higher', 'incid', 'arthralgia', 'compar', 'control', '(', '3', '%', 'vs.', '1', '%', ')', '.'], 'dependencies': [('placebo', 'compound'), ('-', 'punct'), ('control', 'compound'), ('portion', 'compound'), ('clinic', 'compound'), ('trial', 'compound'), ('ps', 'compound'), ('subject', 'amod'), (',', 'punct'), ('humira', 'compound'), ('-', 'punct'), ('tr', 'amod'), ('subject', 'nmod'), ('higher', 'amod'), ('incid', 'amod'), ('arthralgia', 'compound'), ('compar', 'compound'), ('control', 'ROOT'), ('(', 'punct'), ('3', 'nummod'), ('%', 'appos'), ('vs.', 'prep'), ('1', 'nummod'), ('%', 'pobj'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Hidradenitis Suppurativa Clinical Studies \\nHUMIRA has been studied in 727 subjects with hidradenitis suppurativa (HS) in three placebo-\\ncontrolled studies and one open-label extension study [see Clinical Studies (14.10)].', 'tokens': ['Hidradenitis', 'Suppurativa', 'Clinical', 'Studies', 'HUMIRA', 'studied', '727', 'subjects', 'hidradenitis', 'suppurativa', '(', 'HS', ')', 'three', 'placebo-', 'controlled', 'studies', 'one', 'open-label', 'extension', 'study', '[', 'see', 'Clinical', 'Studies', '(', '14.10', ')', ']', '.'], 'lemmatized': ['Hidradenitis', 'Suppurativa', 'Clinical', 'Studies', 'HUMIRA', 'studied', '727', 'subject', 'hidradenitis', 'suppurativa', '(', 'HS', ')', 'three', 'placebo-', 'controlled', 'study', 'one', 'open-label', 'extension', 'study', '[', 'see', 'Clinical', 'Studies', '(', '14.10', ')', ']', '.'], 'stemmed': ['hidraden', 'suppurativa', 'clinic', 'studi', 'humira', 'studi', '727', 'subject', 'hidraden', 'suppurativa', '(', 'hs', ')', 'three', 'placebo-', 'control', 'studi', 'one', 'open-label', 'extens', 'studi', '[', 'see', 'clinic', 'studi', '(', '14.10', ')', ']', '.'], 'dependencies': [('hidraden', 'compound'), ('suppurativa', 'compound'), ('clinic', 'compound'), ('studi', 'compound'), ('humira', 'compound'), ('studi', 'nmod'), ('727', 'nummod'), ('subject', 'compound'), ('hidraden', 'compound'), ('suppurativa', 'ROOT'), ('(', 'punct'), ('hs', 'appos'), (')', 'punct'), ('three', 'nummod'), ('placebo-', 'compound'), ('control', 'compound'), ('studi', 'appos'), ('one', 'nummod'), ('open', 'amod'), ('-', 'punct'), ('label', 'compound'), ('extens', 'compound'), ('studi', 'nsubj'), ('[', 'punct'), ('see', 'ROOT'), ('clinic', 'compound'), ('studi', 'dobj'), ('(', 'punct'), ('14.10', 'appos'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': 'The safety \\nprofile for subjects with HS treated with HUMIRA weekly was consistent with the known safety \\nprofile of HUMIRA.', 'tokens': ['safety', 'profile', 'subjects', 'HS', 'treated', 'HUMIRA', 'weekly', 'consistent', 'known', 'safety', 'profile', 'HUMIRA', '.'], 'lemmatized': ['safety', 'profile', 'subject', 'HS', 'treated', 'HUMIRA', 'weekly', 'consistent', 'known', 'safety', 'profile', 'HUMIRA', '.'], 'stemmed': ['safeti', 'profil', 'subject', 'hs', 'treat', 'humira', 'weekli', 'consist', 'known', 'safeti', 'profil', 'humira', '.'], 'dependencies': [('safeti', 'compound'), ('profil', 'nsubj'), ('subject', 'amod'), ('hs', 'nmod'), ('treat', 'compound'), ('humira', 'compound'), ('weekli', 'nsubj'), ('consist', 'ROOT'), ('known', 'amod'), ('safeti', 'compound'), ('profil', 'compound'), ('humira', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Flare of HS, defined as ≥25% increase from baseline in abscesses and inflammatory nodule \\ncounts and with a minimum of 2 additional lesions, was documented in 22 (22%) of the 100 \\nsubjects who were withdrawn from HUMIRA treatment following the primary efficacy \\ntimepoint in two studies.', 'tokens': ['Flare', 'HS', ',', 'defined', '≥25', '%', 'increase', 'baseline', 'abscesses', 'inflammatory', 'nodule', 'counts', 'minimum', '2', 'additional', 'lesions', ',', 'documented', '22', '(', '22', '%', ')', '100', 'subjects', 'withdrawn', 'HUMIRA', 'treatment', 'following', 'primary', 'efficacy', 'timepoint', 'two', 'studies', '.'], 'lemmatized': ['Flare', 'HS', ',', 'defined', '≥25', '%', 'increase', 'baseline', 'abscess', 'inflammatory', 'nodule', 'count', 'minimum', '2', 'additional', 'lesion', ',', 'documented', '22', '(', '22', '%', ')', '100', 'subject', 'withdrawn', 'HUMIRA', 'treatment', 'following', 'primary', 'efficacy', 'timepoint', 'two', 'study', '.'], 'stemmed': ['flare', 'hs', ',', 'defin', '≥25', '%', 'increas', 'baselin', 'abscess', 'inflammatori', 'nodul', 'count', 'minimum', '2', 'addit', 'lesion', ',', 'document', '22', '(', '22', '%', ')', '100', 'subject', 'withdrawn', 'humira', 'treatment', 'follow', 'primari', 'efficaci', 'timepoint', 'two', 'studi', '.'], 'dependencies': [('flare', 'advcl'), ('hs', 'dobj'), (',', 'punct'), ('defin', 'advmod'), ('≥25', 'nummod'), ('%', 'compound'), ('increas', 'compound'), ('baselin', 'compound'), ('abscess', 'compound'), ('inflammatori', 'dobj'), ('nodul', 'nsubj'), ('count', 'ROOT'), ('minimum', 'amod'), ('2', 'nummod'), ('addit', 'compound'), ('lesion', 'dobj'), (',', 'punct'), ('document', 'appos'), ('22', 'nummod'), ('(', 'punct'), ('22', 'nummod'), ('%', 'dep'), (')', 'punct'), ('100', 'nummod'), ('subject', 'npadvmod'), ('withdrawn', 'amod'), ('humira', 'compound'), ('treatment', 'compound'), ('follow', 'compound'), ('primari', 'compound'), ('efficaci', 'nsubj'), ('timepoint', 'conj'), ('two', 'nummod'), ('studi', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Uveitis Clinical Studies \\nHUMIRA has been studied in 464 adult patients with uveitis (UV) in placebo-controlled and \\nopen-label extension studies and in 90 pediatric patients with uveitis (Study PUV-I) [see Clinical \\nStudies (14.11, 14.12)] .', 'tokens': ['Uveitis', 'Clinical', 'Studies', 'HUMIRA', 'studied', '464', 'adult', 'patients', 'uveitis', '(', 'UV', ')', 'placebo-controlled', 'open-label', 'extension', 'studies', '90', 'pediatric', 'patients', 'uveitis', '(', 'Study', 'PUV-I', ')', '[', 'see', 'Clinical', 'Studies', '(', '14.11', ',', '14.12', ')', ']', '.'], 'lemmatized': ['Uveitis', 'Clinical', 'Studies', 'HUMIRA', 'studied', '464', 'adult', 'patient', 'uveitis', '(', 'UV', ')', 'placebo-controlled', 'open-label', 'extension', 'study', '90', 'pediatric', 'patient', 'uveitis', '(', 'Study', 'PUV-I', ')', '[', 'see', 'Clinical', 'Studies', '(', '14.11', ',', '14.12', ')', ']', '.'], 'stemmed': ['uveiti', 'clinic', 'studi', 'humira', 'studi', '464', 'adult', 'patient', 'uveiti', '(', 'uv', ')', 'placebo-control', 'open-label', 'extens', 'studi', '90', 'pediatr', 'patient', 'uveiti', '(', 'studi', 'puv-i', ')', '[', 'see', 'clinic', 'studi', '(', '14.11', ',', '14.12', ')', ']', '.'], 'dependencies': [('uveiti', 'compound'), ('clinic', 'compound'), ('studi', 'compound'), ('humira', 'compound'), ('studi', 'ROOT'), ('464', 'nummod'), ('adult', 'compound'), ('patient', 'compound'), ('uveiti', 'appos'), ('(', 'punct'), ('uv', 'appos'), (')', 'punct'), ('placebo', 'nmod'), ('-', 'punct'), ('control', 'compound'), ('open', 'amod'), ('-', 'punct'), ('label', 'compound'), ('extens', 'appos'), ('studi', 'appos'), ('90', 'nummod'), ('pediatr', 'amod'), ('patient', 'compound'), ('uveiti', 'appos'), ('(', 'punct'), ('studi', 'compound'), ('puv', 'compound'), ('-', 'punct'), ('i', 'appos'), (')', 'punct'), ('[', 'punct'), ('see', 'ROOT'), ('clinic', 'compound'), ('studi', 'dobj'), ('(', 'punct'), ('14.11', 'appos'), (',', 'punct'), ('14.12', 'npadvmod'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': 'The safety profile for patients with UV treated with HUMIRA was \\nsimilar to the safety profile seen in patients with RA.', 'tokens': ['safety', 'profile', 'patients', 'UV', 'treated', 'HUMIRA', 'similar', 'safety', 'profile', 'seen', 'patients', 'RA', '.'], 'lemmatized': ['safety', 'profile', 'patient', 'UV', 'treated', 'HUMIRA', 'similar', 'safety', 'profile', 'seen', 'patient', 'RA', '.'], 'stemmed': ['safeti', 'profil', 'patient', 'uv', 'treat', 'humira', 'similar', 'safeti', 'profil', 'seen', 'patient', 'ra', '.'], 'dependencies': [('safeti', 'compound'), ('profil', 'nmod'), ('patient', 'nmod'), ('uv', 'nmod'), ('treat', 'compound'), ('humira', 'nmod'), ('similar', 'amod'), ('safeti', 'compound'), ('profil', 'nsubj'), ('seen', 'ROOT'), ('patient', 'dobj'), ('ra', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': '6.2 Immunogenicity \\nAs with all therapeutic proteins, there is potential for immunogenicity.', 'tokens': ['6.2', 'Immunogenicity', 'therapeutic', 'proteins', ',', 'potential', 'immunogenicity', '.'], 'lemmatized': ['6.2', 'Immunogenicity', 'therapeutic', 'protein', ',', 'potential', 'immunogenicity', '.'], 'stemmed': ['6.2', 'immunogen', 'therapeut', 'protein', ',', 'potenti', 'immunogen', '.'], 'dependencies': [('6.2', 'nummod'), ('immunogen', 'compound'), ('therapeut', 'compound'), ('protein', 'ROOT'), (',', 'punct'), ('potenti', 'compound'), ('immunogen', 'appos'), ('.', 'punct')]}, {'original_sentence': 'The detection of antibody \\nformation is highly dependent on the sensitivity and specificity of the assay.', 'tokens': ['detection', 'antibody', 'formation', 'highly', 'dependent', 'sensitivity', 'specificity', 'assay', '.'], 'lemmatized': ['detection', 'antibody', 'formation', 'highly', 'dependent', 'sensitivity', 'specificity', 'assay', '.'], 'stemmed': ['detect', 'antibodi', 'format', 'highli', 'depend', 'sensit', 'specif', 'assay', '.'], 'dependencies': [('detect', 'ROOT'), ('antibodi', 'amod'), ('format', 'compound'), ('highli', 'nsubj'), ('depend', 'ccomp'), ('sensit', 'compound'), ('specif', 'nsubj'), ('assay', 'ccomp'), ('.', 'punct')]}, {'original_sentence': 'Additionally, the \\nobserved incidence of antibody (including neutralizing antibody) positivity in an assay may be \\ninfluenced by several factors including assay methodology, sample handling, timing of sample', 'tokens': ['Additionally', ',', 'observed', 'incidence', 'antibody', '(', 'including', 'neutralizing', 'antibody', ')', 'positivity', 'assay', 'may', 'influenced', 'several', 'factors', 'including', 'assay', 'methodology', ',', 'sample', 'handling', ',', 'timing', 'sample'], 'lemmatized': ['Additionally', ',', 'observed', 'incidence', 'antibody', '(', 'including', 'neutralizing', 'antibody', ')', 'positivity', 'assay', 'may', 'influenced', 'several', 'factor', 'including', 'assay', 'methodology', ',', 'sample', 'handling', ',', 'timing', 'sample'], 'stemmed': ['addit', ',', 'observ', 'incid', 'antibodi', '(', 'includ', 'neutral', 'antibodi', ')', 'posit', 'assay', 'may', 'influenc', 'sever', 'factor', 'includ', 'assay', 'methodolog', ',', 'sampl', 'handl', ',', 'time', 'sampl'], 'dependencies': [('addit', 'dep'), (',', 'punct'), ('observ', 'compound'), ('incid', 'amod'), ('antibodi', 'ROOT'), ('(', 'punct'), ('includ', 'amod'), ('neutral', 'amod'), ('antibodi', 'appos'), (')', 'punct'), ('posit', 'compound'), ('assay', 'ROOT'), ('may', 'aux'), ('influenc', 'amod'), ('sever', 'compound'), ('factor', 'compound'), ('includ', 'compound'), ('assay', 'compound'), ('methodolog', 'dobj'), (',', 'punct'), ('sampl', 'compound'), ('handl', 'conj'), (',', 'punct'), ('time', 'compound'), ('sampl', 'conj')]}], 'text': 'A total of 5% of children experienced a serious infection while receiving HUMIRA in Study \\nPCD-I. These included viral infection, device related sepsis (catheter), gastroenteritis, H1N1 \\ninfluenza, and disseminated histoplasmosis.  \\nIn Study PCD-I, allergic reactions were observed in 5% of children which were all non-serious \\nand were primarily localized reactions.  \\nUlcerative Colitis Clinical Studies \\nAdults: The safety profile of HUMIRA in 1010 adult patients with ulcerative colitis (UC) from \\ntwo placebo-controlled studies and one open-label extension study [see Clinical Studies (14.7)] \\nwas similar to the safety profile seen in patients with RA. \\nPediatric Patients 5 Years to 17 Years:  The safety profile of HUMIRA in 93 pediatric patients \\nwith ulcerative colitis from one double-blind study and one open-label extension study [see \\nClinical Studies (14.8)] was similar to the safety profile seen in adult patients with ulcerative \\ncolitis. \\nPlaque Psoriasis Clinical Studies \\nHUMIRA has been studied in 1696 subjects with plaque psoriasis (Ps) in placebo-controlled and \\nopen-label extension studies [see Clinical Studies (14.9)]. The safety profile for subjects with Ps \\ntreated with HUMIRA was similar to the safety profile seen in subjects with RA with the \\nfollowing exceptions. In the placebo-controlled portions of the clinical trials in Ps subjects, \\nHUMIRA-treated subjects had a higher incidence of arthralgia when compared to controls (3% \\nvs. 1%).  \\nHidradenitis Suppurativa Clinical Studies \\nHUMIRA has been studied in 727 subjects with hidradenitis suppurativa (HS) in three placebo-\\ncontrolled studies and one open-label extension study [see Clinical Studies (14.10)]. The safety \\nprofile for subjects with HS treated with HUMIRA weekly was consistent with the known safety \\nprofile of HUMIRA.  \\nFlare of HS, defined as ≥25% increase from baseline in abscesses and inflammatory nodule \\ncounts and with a minimum of 2 additional lesions, was documented in 22 (22%) of the 100 \\nsubjects who were withdrawn from HUMIRA treatment following the primary efficacy \\ntimepoint in two studies.  \\nUveitis Clinical Studies \\nHUMIRA has been studied in 464 adult patients with uveitis (UV) in placebo-controlled and \\nopen-label extension studies and in 90 pediatric patients with uveitis (Study PUV-I) [see Clinical \\nStudies (14.11, 14.12)] . The safety profile for patients with UV treated with HUMIRA was \\nsimilar to the safety profile seen in patients with RA.  \\n6.2 Immunogenicity \\nAs with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody \\nformation is highly dependent on the sensitivity and specificity of the assay. Additionally, the \\nobserved incidence of antibody (including neutralizing antibody) positivity in an assay may be \\ninfluenced by several factors including assay methodology, sample handling, timing of sample \\n'}, 'page_char_count': 2891, 'page_word_count': 419, 'sentences': ['A total of 5% of children experienced a serious infection while receiving HUMIRA in Study \\nPCD-I. These included viral infection, device related sepsis (catheter), gastroenteritis, H1N1 \\ninfluenza, and disseminated histoplasmosis.', ' \\nIn Study PCD-I, allergic reactions were observed in 5% of children which were all non-serious \\nand were primarily localized reactions.', ' \\nUlcerative Colitis Clinical Studies \\nAdults: The safety profile of HUMIRA in 1010 adult patients with ulcerative colitis (UC) from \\ntwo placebo-controlled studies and one open-label extension study [see Clinical Studies (14.7)] \\nwas similar to the safety profile seen in patients with RA.', '\\nPediatric Patients 5 Years to 17 Years:  The safety profile of HUMIRA in 93 pediatric patients \\nwith ulcerative colitis from one double-blind study and one open-label extension study [see \\nClinical Studies (14.8)] was similar to the safety profile seen in adult patients with ulcerative \\ncolitis.', '\\nPlaque Psoriasis Clinical Studies \\nHUMIRA has been studied in 1696 subjects with plaque psoriasis (Ps) in placebo-controlled and \\nopen-label extension studies [see Clinical Studies (14.9)].', 'The safety profile for subjects with Ps \\ntreated with HUMIRA was similar to the safety profile seen in subjects with RA with the \\nfollowing exceptions.', 'In the placebo-controlled portions of the clinical trials in Ps subjects, \\nHUMIRA-treated subjects had a higher incidence of arthralgia when compared to controls (3% \\nvs. 1%).', ' \\nHidradenitis Suppurativa Clinical Studies \\nHUMIRA has been studied in 727 subjects with hidradenitis suppurativa (HS) in three placebo-\\ncontrolled studies and one open-label extension study [see Clinical Studies (14.10)].', 'The safety \\nprofile for subjects with HS treated with HUMIRA weekly was consistent with the known safety \\nprofile of HUMIRA.', ' \\nFlare of HS, defined as ≥25% increase from baseline in abscesses and inflammatory nodule \\ncounts and with a minimum of 2 additional lesions, was documented in 22 (22%) of the 100 \\nsubjects who were withdrawn from HUMIRA treatment following the primary efficacy \\ntimepoint in two studies.', ' \\nUveitis Clinical Studies \\nHUMIRA has been studied in 464 adult patients with uveitis (UV) in placebo-controlled and \\nopen-label extension studies and in 90 pediatric patients with uveitis (Study PUV-I) [see Clinical \\nStudies (14.11, 14.12)] .', 'The safety profile for patients with UV treated with HUMIRA was \\nsimilar to the safety profile seen in patients with RA.', ' \\n6.2 Immunogenicity \\nAs with all therapeutic proteins, there is potential for immunogenicity.', 'The detection of antibody \\nformation is highly dependent on the sensitivity and specificity of the assay.', 'Additionally, the \\nobserved incidence of antibody (including neutralizing antibody) positivity in an assay may be \\ninfluenced by several factors including assay methodology, sample handling, timing of sample \\n'], 'page_sentence_count_spacy': 15}\n",
            "{'page_number': 21, 'text': 'collection, concomitant medications, and underlying disease. For these reasons, comparison of \\nthe incidence of antibodies in the studies described below with the incidence of antibodies in \\nother studies or to other adalimumab products may be misleading. \\n \\nThere are two assays that have been used to measure anti-adalimumab antibodies. With the \\nELISA, antibodies to adalimumab could be detected only when serum adalimumab \\nconcentrations were < 2 mcg/mL. The ECL assay can detect anti-adalimumab antibody titers \\nindependent of adalimumab concentrations in the serum samples. The incidence of anti-\\nadalimumab antibody (AAA) development in patients treated with HUMIRA are presented in \\nTable 2. \\n \\nTable 2: Anti-Adalimumab Antibody Development Determined by ELISA and ECL Assay \\nin Patients Treated with HUMIRA \\nIndications \\nStudy \\nDuration \\nAnti-Adalimumab Antibody \\nIncidence by ELISA (n/N) \\nAnti-Adalimumab \\nAntibody \\nIncidence by ECL \\nAssay (n/N) \\nIn all patients \\nwho received \\nadalimumab  \\nIn patients \\nwith serum \\nadalimumab \\nconcentrations \\n< 2 mcg/mL  \\n \\nRheumatoid Arthritisa \\n \\n6 to 12 \\nmonths \\n5% (58/1062) \\nNR \\nNA \\nJuvenile \\nIdiopathic \\nArthritis \\n(JIA) \\n4 to 17 years of \\nageb \\n48 weeks \\n16% (27/171) \\nNR \\nNA \\n2 to 4 years of \\nage or ≥ 4 years \\nof age and \\nweighing < 15 \\nkg \\n24 weeks \\n7% (1/15)c \\nNR \\nNA \\nPsoriatic Arthritisd \\n48 weekse 13% (24/178) \\nNR \\nNA \\nAnkylosing Spondylitis  \\n24 weeks \\n9% (16/185) \\nNR \\nNA \\nAdult Crohn’s Disease  \\n56 weeks \\n3% (7/269) \\n8% (7/86) \\nNA \\nPediatric Crohn’s Disease  \\n52 weeks \\n3% (6/182) \\n10% (6/58) \\nNA \\nAdult Ulcerative Colitis  \\n52 weeks \\n5% (19/360) \\n21% (19/92) \\nNA \\nPediatric Ulcerative Colitis \\n52 weeks \\n3% (3/100) \\n13% (3/23) \\n33% (33/100)i \\nPlaque Psoriasisf \\nUp to 52 \\nweeksg \\n8% (77/920) \\n21% (77/372) \\nNA \\nHidradenitis Suppurativa  \\n36 weeks \\n7% (30/461) \\n28% (58/207)h 61% (272/445)j \\nNon-infectious Uveitis  \\n52 weeks \\n5% (12/249) \\n21% (12/57) \\n40% (99/249)k \\nn: number of patients with anti-adalimumab antibody; NR: not reported; NA: Not applicable (not \\nperformed) \\na In patients receiving concomitant methotrexate (MTX), the incidence of anti-adalimumab antibody was \\n1% compared to 12% with HUMIRA monotherapy  \\n', 'processed_text': {'sentences': [{'original_sentence': 'collection, concomitant medications, and underlying disease.', 'tokens': ['collection', ',', 'concomitant', 'medications', ',', 'underlying', 'disease', '.'], 'lemmatized': ['collection', ',', 'concomitant', 'medication', ',', 'underlying', 'disease', '.'], 'stemmed': ['collect', ',', 'concomit', 'medic', ',', 'underli', 'diseas', '.'], 'dependencies': [('collect', 'ROOT'), (',', 'punct'), ('concomit', 'compound'), ('medic', 'npadvmod'), (',', 'punct'), ('underli', 'amod'), ('diseas', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'For these reasons, comparison of \\nthe incidence of antibodies in the studies described below with the incidence of antibodies in \\nother studies or to other adalimumab products may be misleading.', 'tokens': ['reasons', ',', 'comparison', 'incidence', 'antibodies', 'studies', 'described', 'incidence', 'antibodies', 'studies', 'adalimumab', 'products', 'may', 'misleading', '.'], 'lemmatized': ['reason', ',', 'comparison', 'incidence', 'antibody', 'study', 'described', 'incidence', 'antibody', 'study', 'adalimumab', 'product', 'may', 'misleading', '.'], 'stemmed': ['reason', ',', 'comparison', 'incid', 'antibodi', 'studi', 'describ', 'incid', 'antibodi', 'studi', 'adalimumab', 'product', 'may', 'mislead', '.'], 'dependencies': [('reason', 'nsubj'), (',', 'punct'), ('comparison', 'compound'), ('incid', 'amod'), ('antibodi', 'compound'), ('studi', 'compound'), ('describ', 'compound'), ('incid', 'appos'), ('antibodi', 'npadvmod'), ('studi', 'compound'), ('adalimumab', 'compound'), ('product', 'nsubj'), ('may', 'aux'), ('mislead', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'There are two assays that have been used to measure anti-adalimumab antibodies.', 'tokens': ['two', 'assays', 'used', 'measure', 'anti-adalimumab', 'antibodies', '.'], 'lemmatized': ['two', 'assay', 'used', 'measure', 'anti-adalimumab', 'antibody', '.'], 'stemmed': ['two', 'assay', 'use', 'measur', 'anti-adalimumab', 'antibodi', '.'], 'dependencies': [('two', 'nummod'), ('assay', 'amod'), ('use', 'ROOT'), ('measur', 'nmod'), ('anti', 'amod'), ('-', 'amod'), ('adalimumab', 'amod'), ('antibodi', 'appos'), ('.', 'punct')]}, {'original_sentence': 'With the \\nELISA, antibodies to adalimumab could be detected only when serum adalimumab \\nconcentrations were < 2 mcg/mL.', 'tokens': ['ELISA', ',', 'antibodies', 'adalimumab', 'could', 'detected', 'serum', 'adalimumab', 'concentrations', '<', '2', 'mcg/mL', '.'], 'lemmatized': ['ELISA', ',', 'antibody', 'adalimumab', 'could', 'detected', 'serum', 'adalimumab', 'concentration', '<', '2', 'mcg/mL', '.'], 'stemmed': ['elisa', ',', 'antibodi', 'adalimumab', 'could', 'detect', 'serum', 'adalimumab', 'concentr', '<', '2', 'mcg/ml', '.'], 'dependencies': [('elisa', 'advcl'), (',', 'punct'), ('antibodi', 'compound'), ('adalimumab', 'nsubj'), ('could', 'aux'), ('detect', 'ROOT'), ('serum', 'compound'), ('adalimumab', 'compound'), ('concentr', 'dobj'), ('<', 'dep'), ('2', 'nummod'), ('mcg', 'nmod'), ('/', 'punct'), ('ml', 'appos'), ('.', 'punct')]}, {'original_sentence': 'The ECL assay can detect anti-adalimumab antibody titers \\nindependent of adalimumab concentrations in the serum samples.', 'tokens': ['ECL', 'assay', 'detect', 'anti-adalimumab', 'antibody', 'titers', 'independent', 'adalimumab', 'concentrations', 'serum', 'samples', '.'], 'lemmatized': ['ECL', 'assay', 'detect', 'anti-adalimumab', 'antibody', 'titer', 'independent', 'adalimumab', 'concentration', 'serum', 'sample', '.'], 'stemmed': ['ecl', 'assay', 'detect', 'anti-adalimumab', 'antibodi', 'titer', 'independ', 'adalimumab', 'concentr', 'serum', 'sampl', '.'], 'dependencies': [('ecl', 'nsubj'), ('assay', 'pobj'), ('detect', 'ROOT'), ('anti', 'amod'), ('-', 'amod'), ('adalimumab', 'amod'), ('antibodi', 'amod'), ('titer', 'dobj'), ('independ', 'compound'), ('adalimumab', 'compound'), ('concentr', 'dobj'), ('serum', 'compound'), ('sampl', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The incidence of anti-\\nadalimumab antibody (AAA) development in patients treated with HUMIRA are presented in \\nTable 2.', 'tokens': ['incidence', 'anti-', 'adalimumab', 'antibody', '(', 'AAA', ')', 'development', 'patients', 'treated', 'HUMIRA', 'presented', 'Table', '2', '.'], 'lemmatized': ['incidence', 'anti-', 'adalimumab', 'antibody', '(', 'AAA', ')', 'development', 'patient', 'treated', 'HUMIRA', 'presented', 'Table', '2', '.'], 'stemmed': ['incid', 'anti-', 'adalimumab', 'antibodi', '(', 'aaa', ')', 'develop', 'patient', 'treat', 'humira', 'present', 'tabl', '2', '.'], 'dependencies': [('incid', 'amod'), ('anti-', 'compound'), ('adalimumab', 'compound'), ('antibodi', 'nsubj'), ('(', 'punct'), ('aaa', 'appos'), (')', 'punct'), ('develop', 'ROOT'), ('patient', 'compound'), ('treat', 'compound'), ('humira', 'dobj'), ('present', 'advcl'), ('tabl', 'npadvmod'), ('2', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Table 2: Anti-Adalimumab Antibody Development Determined by ELISA and ECL Assay \\nin Patients Treated with HUMIRA \\nIndications \\nStudy \\nDuration \\nAnti-Adalimumab Antibody \\nIncidence by ELISA (n/N) \\nAnti-Adalimumab \\nAntibody \\nIncidence by ECL \\nAssay (n/N) \\nIn all patients \\nwho received \\nadalimumab  \\nIn patients \\nwith serum \\nadalimumab \\nconcentrations \\n< 2 mcg/mL  \\n \\nRheumatoid Arthritisa \\n \\n6 to 12 \\nmonths \\n5% (58/1062) \\nNR \\nNA \\nJuvenile \\nIdiopathic \\nArthritis \\n(JIA) \\n4 to 17 years of \\nageb \\n48 weeks \\n16% (27/171) \\nNR \\nNA \\n2 to 4 years of \\nage or ≥ 4 years \\nof age and \\nweighing < 15 \\nkg \\n24 weeks \\n7% (1/15)c \\nNR \\nNA \\nPsoriatic Arthritisd \\n48 weekse 13% (24/178) \\nNR \\nNA \\nAnkylosing Spondylitis  \\n24 weeks \\n9% (16/185) \\nNR \\nNA \\nAdult Crohn’s Disease  \\n56 weeks \\n3% (7/269) \\n8% (7/86) \\nNA \\nPediatric Crohn’s Disease  \\n52 weeks \\n3% (6/182) \\n10% (6/58) \\nNA \\nAdult Ulcerative Colitis  \\n52 weeks \\n5% (19/360) \\n21% (19/92) \\nNA \\nPediatric Ulcerative Colitis \\n52 weeks \\n3% (3/100) \\n13% (3/23) \\n33% (33/100)i \\nPlaque Psoriasisf \\nUp to 52 \\nweeksg \\n8% (77/920) \\n21% (77/372) \\nNA \\nHidradenitis Suppurativa  \\n36 weeks \\n7% (30/461) \\n28% (58/207)h 61% (272/445)j \\nNon-infectious Uveitis  \\n52 weeks \\n5% (12/249) \\n21% (12/57) \\n40% (99/249)k \\nn: number of patients with anti-adalimumab antibody; NR: not reported; NA: Not applicable (not \\nperformed) \\na In patients receiving concomitant methotrexate (MTX), the incidence of anti-adalimumab antibody was \\n1% compared to 12% with HUMIRA monotherapy', 'tokens': ['Table', '2', ':', 'Anti-Adalimumab', 'Antibody', 'Development', 'Determined', 'ELISA', 'ECL', 'Assay', 'Patients', 'Treated', 'HUMIRA', 'Indications', 'Study', 'Duration', 'Anti-Adalimumab', 'Antibody', 'Incidence', 'ELISA', '(', 'n/N', ')', 'Anti-Adalimumab', 'Antibody', 'Incidence', 'ECL', 'Assay', '(', 'n/N', ')', 'patients', 'received', 'adalimumab', 'patients', 'serum', 'adalimumab', 'concentrations', '<', '2', 'mcg/mL', 'Rheumatoid', 'Arthritisa', '6', '12', 'months', '5', '%', '(', '58/1062', ')', 'NR', 'NA', 'Juvenile', 'Idiopathic', 'Arthritis', '(', 'JIA', ')', '4', '17', 'years', 'ageb', '48', 'weeks', '16', '%', '(', '27/171', ')', 'NR', 'NA', '2', '4', 'years', 'age', '≥', '4', 'years', 'age', 'weighing', '<', '15', 'kg', '24', 'weeks', '7', '%', '(', '1/15', ')', 'c', 'NR', 'NA', 'Psoriatic', 'Arthritisd', '48', 'weekse', '13', '%', '(', '24/178', ')', 'NR', 'NA', 'Ankylosing', 'Spondylitis', '24', 'weeks', '9', '%', '(', '16/185', ')', 'NR', 'NA', 'Adult', 'Crohn', '’', 'Disease', '56', 'weeks', '3', '%', '(', '7/269', ')', '8', '%', '(', '7/86', ')', 'NA', 'Pediatric', 'Crohn', '’', 'Disease', '52', 'weeks', '3', '%', '(', '6/182', ')', '10', '%', '(', '6/58', ')', 'NA', 'Adult', 'Ulcerative', 'Colitis', '52', 'weeks', '5', '%', '(', '19/360', ')', '21', '%', '(', '19/92', ')', 'NA', 'Pediatric', 'Ulcerative', 'Colitis', '52', 'weeks', '3', '%', '(', '3/100', ')', '13', '%', '(', '3/23', ')', '33', '%', '(', '33/100', ')', 'Plaque', 'Psoriasisf', '52', 'weeksg', '8', '%', '(', '77/920', ')', '21', '%', '(', '77/372', ')', 'NA', 'Hidradenitis', 'Suppurativa', '36', 'weeks', '7', '%', '(', '30/461', ')', '28', '%', '(', '58/207', ')', 'h', '61', '%', '(', '272/445', ')', 'j', 'Non-infectious', 'Uveitis', '52', 'weeks', '5', '%', '(', '12/249', ')', '21', '%', '(', '12/57', ')', '40', '%', '(', '99/249', ')', 'k', 'n', ':', 'number', 'patients', 'anti-adalimumab', 'antibody', ';', 'NR', ':', 'reported', ';', 'NA', ':', 'applicable', '(', 'performed', ')', 'patients', 'receiving', 'concomitant', 'methotrexate', '(', 'MTX', ')', ',', 'incidence', 'anti-adalimumab', 'antibody', '1', '%', 'compared', '12', '%', 'HUMIRA', 'monotherapy'], 'lemmatized': ['Table', '2', ':', 'Anti-Adalimumab', 'Antibody', 'Development', 'Determined', 'ELISA', 'ECL', 'Assay', 'Patients', 'Treated', 'HUMIRA', 'Indications', 'Study', 'Duration', 'Anti-Adalimumab', 'Antibody', 'Incidence', 'ELISA', '(', 'n/N', ')', 'Anti-Adalimumab', 'Antibody', 'Incidence', 'ECL', 'Assay', '(', 'n/N', ')', 'patient', 'received', 'adalimumab', 'patient', 'serum', 'adalimumab', 'concentration', '<', '2', 'mcg/mL', 'Rheumatoid', 'Arthritisa', '6', '12', 'month', '5', '%', '(', '58/1062', ')', 'NR', 'NA', 'Juvenile', 'Idiopathic', 'Arthritis', '(', 'JIA', ')', '4', '17', 'year', 'ageb', '48', 'week', '16', '%', '(', '27/171', ')', 'NR', 'NA', '2', '4', 'year', 'age', '≥', '4', 'year', 'age', 'weighing', '<', '15', 'kg', '24', 'week', '7', '%', '(', '1/15', ')', 'c', 'NR', 'NA', 'Psoriatic', 'Arthritisd', '48', 'weekse', '13', '%', '(', '24/178', ')', 'NR', 'NA', 'Ankylosing', 'Spondylitis', '24', 'week', '9', '%', '(', '16/185', ')', 'NR', 'NA', 'Adult', 'Crohn', '’', 'Disease', '56', 'week', '3', '%', '(', '7/269', ')', '8', '%', '(', '7/86', ')', 'NA', 'Pediatric', 'Crohn', '’', 'Disease', '52', 'week', '3', '%', '(', '6/182', ')', '10', '%', '(', '6/58', ')', 'NA', 'Adult', 'Ulcerative', 'Colitis', '52', 'week', '5', '%', '(', '19/360', ')', '21', '%', '(', '19/92', ')', 'NA', 'Pediatric', 'Ulcerative', 'Colitis', '52', 'week', '3', '%', '(', '3/100', ')', '13', '%', '(', '3/23', ')', '33', '%', '(', '33/100', ')', 'Plaque', 'Psoriasisf', '52', 'weeksg', '8', '%', '(', '77/920', ')', '21', '%', '(', '77/372', ')', 'NA', 'Hidradenitis', 'Suppurativa', '36', 'week', '7', '%', '(', '30/461', ')', '28', '%', '(', '58/207', ')', 'h', '61', '%', '(', '272/445', ')', 'j', 'Non-infectious', 'Uveitis', '52', 'week', '5', '%', '(', '12/249', ')', '21', '%', '(', '12/57', ')', '40', '%', '(', '99/249', ')', 'k', 'n', ':', 'number', 'patient', 'anti-adalimumab', 'antibody', ';', 'NR', ':', 'reported', ';', 'NA', ':', 'applicable', '(', 'performed', ')', 'patient', 'receiving', 'concomitant', 'methotrexate', '(', 'MTX', ')', ',', 'incidence', 'anti-adalimumab', 'antibody', '1', '%', 'compared', '12', '%', 'HUMIRA', 'monotherapy'], 'stemmed': ['tabl', '2', ':', 'anti-adalimumab', 'antibodi', 'develop', 'determin', 'elisa', 'ecl', 'assay', 'patient', 'treat', 'humira', 'indic', 'studi', 'durat', 'anti-adalimumab', 'antibodi', 'incid', 'elisa', '(', 'n/n', ')', 'anti-adalimumab', 'antibodi', 'incid', 'ecl', 'assay', '(', 'n/n', ')', 'patient', 'receiv', 'adalimumab', 'patient', 'serum', 'adalimumab', 'concentr', '<', '2', 'mcg/ml', 'rheumatoid', 'arthritisa', '6', '12', 'month', '5', '%', '(', '58/1062', ')', 'nr', 'na', 'juvenil', 'idiopath', 'arthriti', '(', 'jia', ')', '4', '17', 'year', 'ageb', '48', 'week', '16', '%', '(', '27/171', ')', 'nr', 'na', '2', '4', 'year', 'age', '≥', '4', 'year', 'age', 'weigh', '<', '15', 'kg', '24', 'week', '7', '%', '(', '1/15', ')', 'c', 'nr', 'na', 'psoriat', 'arthritisd', '48', 'weeks', '13', '%', '(', '24/178', ')', 'nr', 'na', 'ankylos', 'spondyl', '24', 'week', '9', '%', '(', '16/185', ')', 'nr', 'na', 'adult', 'crohn', '’', 'diseas', '56', 'week', '3', '%', '(', '7/269', ')', '8', '%', '(', '7/86', ')', 'na', 'pediatr', 'crohn', '’', 'diseas', '52', 'week', '3', '%', '(', '6/182', ')', '10', '%', '(', '6/58', ')', 'na', 'adult', 'ulcer', 'coliti', '52', 'week', '5', '%', '(', '19/360', ')', '21', '%', '(', '19/92', ')', 'na', 'pediatr', 'ulcer', 'coliti', '52', 'week', '3', '%', '(', '3/100', ')', '13', '%', '(', '3/23', ')', '33', '%', '(', '33/100', ')', 'plaqu', 'psoriasisf', '52', 'weeksg', '8', '%', '(', '77/920', ')', '21', '%', '(', '77/372', ')', 'na', 'hidraden', 'suppurativa', '36', 'week', '7', '%', '(', '30/461', ')', '28', '%', '(', '58/207', ')', 'h', '61', '%', '(', '272/445', ')', 'j', 'non-infecti', 'uveiti', '52', 'week', '5', '%', '(', '12/249', ')', '21', '%', '(', '12/57', ')', '40', '%', '(', '99/249', ')', 'k', 'n', ':', 'number', 'patient', 'anti-adalimumab', 'antibodi', ';', 'nr', ':', 'report', ';', 'na', ':', 'applic', '(', 'perform', ')', 'patient', 'receiv', 'concomit', 'methotrex', '(', 'mtx', ')', ',', 'incid', 'anti-adalimumab', 'antibodi', '1', '%', 'compar', '12', '%', 'humira', 'monotherapi'], 'dependencies': [('tabl', 'advcl'), ('2', 'nummod'), (':', 'punct'), ('anti', 'amod'), ('-', 'amod'), ('adalimumab', 'amod'), ('antibodi', 'nsubj'), ('develop', 'ROOT'), ('determin', 'compound'), ('elisa', 'dobj'), ('ecl', 'nmod'), ('assay', 'compound'), ('patient', 'compound'), ('treat', 'compound'), ('humira', 'nmod'), ('indic', 'amod'), ('studi', 'compound'), ('durat', 'nmod'), ('anti', 'amod'), ('-', 'amod'), ('adalimumab', 'amod'), ('antibodi', 'amod'), ('incid', 'amod'), ('elisa', 'conj'), ('(', 'punct'), ('n', 'cc'), ('/', 'punct'), ('n', 'conj'), (')', 'punct'), ('anti', 'amod'), ('-', 'amod'), ('adalimumab', 'amod'), ('antibodi', 'amod'), ('incid', 'appos'), ('ecl', 'nmod'), ('assay', 'nmod'), ('(', 'punct'), ('n', 'cc'), ('/', 'punct'), ('n', 'conj'), (')', 'punct'), ('patient', 'compound'), ('receiv', 'compound'), ('adalimumab', 'compound'), ('patient', 'compound'), ('serum', 'compound'), ('adalimumab', 'compound'), ('concentr', 'nsubj'), ('<', 'dep'), ('2', 'nummod'), ('mcg', 'nmod'), ('/', 'punct'), ('ml', 'nsubj'), ('rheumatoid', 'advcl'), ('arthritisa', 'dobj'), ('6', 'nummod'), ('12', 'nummod'), ('month', 'npadvmod'), ('5', 'nummod'), ('%', 'appos'), ('(', 'punct'), ('58/1062', 'appos'), (')', 'punct'), ('nr', 'advmod'), ('na', 'ROOT'), ('juvenil', 'amod'), ('idiopath', 'compound'), ('arthriti', 'pobj'), ('(', 'punct'), ('jia', 'nmod'), (')', 'punct'), ('4', 'compound'), ('17', 'nummod'), ('year', 'compound'), ('ageb', 'ROOT'), ('48', 'nummod'), ('week', 'npadvmod'), ('16', 'nummod'), ('%', 'appos'), ('(', 'punct'), ('27/171', 'appos'), (')', 'punct'), ('nr', 'ROOT'), ('na', 'prep'), ('2', 'nummod'), ('4', 'nummod'), ('year', 'pobj'), ('age', 'compound'), ('≥', 'nummod'), ('4', 'nummod'), ('year', 'compound'), ('age', 'compound'), ('weigh', 'compound'), ('<', 'dep'), ('15', 'nummod'), ('kg', 'npadvmod'), ('24', 'nummod'), ('week', 'npadvmod'), ('7', 'nummod'), ('%', 'appos'), ('(', 'punct'), ('1/15', 'appos'), (')', 'punct'), ('c', 'ROOT'), ('nr', 'intj'), ('na', 'ROOT'), ('psoriat', 'compound'), ('arthritisd', 'pobj'), ('48', 'nummod'), ('weeks', 'npadvmod'), ('13', 'nummod'), ('%', 'appos'), ('(', 'punct'), ('24/178', 'appos'), (')', 'punct'), ('nr', 'ROOT'), ('na', 'prep'), ('ankylos', 'compound'), ('spondyl', 'pobj'), ('24', 'nummod'), ('week', 'appos'), ('9', 'nummod'), ('%', 'appos'), ('(', 'punct'), ('16/185', 'appos'), (')', 'punct'), ('nr', 'dep'), ('na', 'aux'), ('adult', 'compound'), ('crohn', 'nmod'), ('’', 'punct'), ('diseas', 'nmod'), ('56', 'nummod'), ('week', 'npadvmod'), ('3', 'nummod'), ('%', 'appos'), ('(', 'punct'), ('7/269', 'appos'), (')', 'punct'), ('8', 'nummod'), ('%', 'appos'), ('(', 'punct'), ('7/86', 'appos'), (')', 'punct'), ('na', 'prep'), ('pediatr', 'amod'), ('crohn', 'pobj'), ('’', 'punct'), ('diseas', 'pobj'), ('52', 'nummod'), ('week', 'npadvmod'), ('3', 'nummod'), ('%', 'appos'), ('(', 'punct'), ('6/182', 'appos'), (')', 'punct'), ('10', 'nummod'), ('%', 'appos'), ('(', 'punct'), ('6/58', 'appos'), (')', 'punct'), ('na', 'prep'), ('adult', 'compound'), ('ulcer', 'compound'), ('coliti', 'pobj'), ('52', 'nummod'), ('week', 'npadvmod'), ('5', 'nummod'), ('%', 'appos'), ('(', 'punct'), ('19/360', 'appos'), (')', 'punct'), ('21', 'nummod'), ('%', 'appos'), ('(', 'punct'), ('19/92', 'appos'), (')', 'punct'), ('na', 'prep'), ('pediatr', 'amod'), ('ulcer', 'compound'), ('coliti', 'pobj'), ('52', 'nummod'), ('week', 'npadvmod'), ('3', 'nummod'), ('%', 'appos'), ('(', 'punct'), ('3/100', 'appos'), (')', 'punct'), ('13', 'nummod'), ('%', 'appos'), ('(', 'punct'), ('3/23', 'appos'), (')', 'punct'), ('33', 'nummod'), ('%', 'nsubj'), ('(', 'punct'), ('33/100', 'appos'), (')', 'punct'), ('plaqu', 'nmod'), ('psoriasisf', 'dobj'), ('52', 'nummod'), ('weeksg', 'ccomp'), ('8', 'nummod'), ('%', 'npadvmod'), ('(', 'punct'), ('77/920', 'appos'), (')', 'punct'), ('21', 'nummod'), ('%', 'appos'), ('(', 'punct'), ('77/372', 'appos'), (')', 'punct'), ('na', 'aux'), ('hidraden', 'advcl'), ('suppurativa', 'dobj'), ('36', 'nummod'), ('week', 'npadvmod'), ('7', 'nummod'), ('%', 'appos'), ('(', 'punct'), ('30/461', 'appos'), (')', 'punct'), ('28', 'nummod'), ('%', 'appos'), ('(', 'punct'), ('58/207', 'appos'), (')', 'punct'), ('h', 'ROOT'), ('61', 'nummod'), ('%', 'appos'), ('(', 'punct'), ('272/445', 'appos'), (')', 'punct'), ('j', 'nmod'), ('non', 'amod'), ('-', 'amod'), ('infecti', 'amod'), ('uveiti', 'ROOT'), ('52', 'nummod'), ('week', 'npadvmod'), ('5', 'nummod'), ('%', 'appos'), ('(', 'punct'), ('12/249', 'nmod'), (')', 'punct'), ('21', 'nummod'), ('%', 'appos'), ('(', 'punct'), ('12/57', 'appos'), (')', 'punct'), ('40', 'nummod'), ('%', 'appos'), ('(', 'punct'), ('99/249', 'appos'), (')', 'punct'), ('k', 'ROOT'), ('n', 'nummod'), (':', 'punct'), ('number', 'nmod'), ('patient', 'amod'), ('anti', 'amod'), ('-', 'amod'), ('adalimumab', 'amod'), ('antibodi', 'ROOT'), (';', 'punct'), ('nr', 'intj'), (':', 'punct'), ('report', 'ccomp'), (';', 'punct'), ('na', 'aux'), (':', 'punct'), ('applic', 'nmod'), ('(', 'punct'), ('perform', 'appos'), (')', 'punct'), ('patient', 'compound'), ('receiv', 'compound'), ('concomit', 'compound'), ('methotrex', 'appos'), ('(', 'punct'), ('mtx', 'parataxis'), (')', 'punct'), (',', 'punct'), ('incid', 'amod'), ('anti', 'amod'), ('-', 'amod'), ('adalimumab', 'amod'), ('antibodi', 'nmod'), ('1', 'nummod'), ('%', 'compound'), ('compar', 'appos'), ('12', 'nummod'), ('%', 'appos'), ('humira', 'compound'), ('monotherapi', 'appos')]}], 'text': 'collection, concomitant medications, and underlying disease. For these reasons, comparison of \\nthe incidence of antibodies in the studies described below with the incidence of antibodies in \\nother studies or to other adalimumab products may be misleading. \\n \\nThere are two assays that have been used to measure anti-adalimumab antibodies. With the \\nELISA, antibodies to adalimumab could be detected only when serum adalimumab \\nconcentrations were < 2 mcg/mL. The ECL assay can detect anti-adalimumab antibody titers \\nindependent of adalimumab concentrations in the serum samples. The incidence of anti-\\nadalimumab antibody (AAA) development in patients treated with HUMIRA are presented in \\nTable 2. \\n \\nTable 2: Anti-Adalimumab Antibody Development Determined by ELISA and ECL Assay \\nin Patients Treated with HUMIRA \\nIndications \\nStudy \\nDuration \\nAnti-Adalimumab Antibody \\nIncidence by ELISA (n/N) \\nAnti-Adalimumab \\nAntibody \\nIncidence by ECL \\nAssay (n/N) \\nIn all patients \\nwho received \\nadalimumab  \\nIn patients \\nwith serum \\nadalimumab \\nconcentrations \\n< 2 mcg/mL  \\n \\nRheumatoid Arthritisa \\n \\n6 to 12 \\nmonths \\n5% (58/1062) \\nNR \\nNA \\nJuvenile \\nIdiopathic \\nArthritis \\n(JIA) \\n4 to 17 years of \\nageb \\n48 weeks \\n16% (27/171) \\nNR \\nNA \\n2 to 4 years of \\nage or ≥ 4 years \\nof age and \\nweighing < 15 \\nkg \\n24 weeks \\n7% (1/15)c \\nNR \\nNA \\nPsoriatic Arthritisd \\n48 weekse 13% (24/178) \\nNR \\nNA \\nAnkylosing Spondylitis  \\n24 weeks \\n9% (16/185) \\nNR \\nNA \\nAdult Crohn’s Disease  \\n56 weeks \\n3% (7/269) \\n8% (7/86) \\nNA \\nPediatric Crohn’s Disease  \\n52 weeks \\n3% (6/182) \\n10% (6/58) \\nNA \\nAdult Ulcerative Colitis  \\n52 weeks \\n5% (19/360) \\n21% (19/92) \\nNA \\nPediatric Ulcerative Colitis \\n52 weeks \\n3% (3/100) \\n13% (3/23) \\n33% (33/100)i \\nPlaque Psoriasisf \\nUp to 52 \\nweeksg \\n8% (77/920) \\n21% (77/372) \\nNA \\nHidradenitis Suppurativa  \\n36 weeks \\n7% (30/461) \\n28% (58/207)h 61% (272/445)j \\nNon-infectious Uveitis  \\n52 weeks \\n5% (12/249) \\n21% (12/57) \\n40% (99/249)k \\nn: number of patients with anti-adalimumab antibody; NR: not reported; NA: Not applicable (not \\nperformed) \\na In patients receiving concomitant methotrexate (MTX), the incidence of anti-adalimumab antibody was \\n1% compared to 12% with HUMIRA monotherapy  \\n'}, 'page_char_count': 2188, 'page_word_count': 319, 'sentences': ['collection, concomitant medications, and underlying disease.', 'For these reasons, comparison of \\nthe incidence of antibodies in the studies described below with the incidence of antibodies in \\nother studies or to other adalimumab products may be misleading.', '\\n \\nThere are two assays that have been used to measure anti-adalimumab antibodies.', 'With the \\nELISA, antibodies to adalimumab could be detected only when serum adalimumab \\nconcentrations were < 2 mcg/mL. The ECL assay can detect anti-adalimumab antibody titers \\nindependent of adalimumab concentrations in the serum samples.', 'The incidence of anti-\\nadalimumab antibody (AAA) development in patients treated with HUMIRA are presented in \\nTable 2.', '\\n \\nTable 2: Anti-Adalimumab Antibody Development Determined by ELISA and ECL Assay \\nin Patients Treated with HUMIRA \\nIndications \\nStudy \\nDuration \\nAnti-Adalimumab Antibody \\nIncidence by ELISA (n/N) \\nAnti-Adalimumab \\nAntibody \\nIncidence by ECL \\nAssay (n/N) \\nIn all patients \\nwho received \\nadalimumab  \\nIn patients \\nwith serum \\nadalimumab \\nconcentrations \\n< 2 mcg/mL  \\n \\nRheumatoid Arthritisa \\n \\n6 to 12 \\nmonths \\n5% (58/1062) \\nNR \\nNA \\nJuvenile \\nIdiopathic \\nArthritis \\n(JIA) \\n4 to 17 years of \\nageb \\n48 weeks \\n16% (27/171) \\nNR \\nNA \\n2 to 4 years of \\nage or ≥ 4 years \\nof age and \\nweighing < 15 \\nkg \\n24 weeks \\n7% (1/15)c \\nNR \\nNA \\nPsoriatic Arthritisd \\n48 weekse 13% (24/178) \\nNR \\nNA \\nAnkylosing Spondylitis  \\n24 weeks \\n9% (16/185) \\nNR \\nNA \\nAdult Crohn’s Disease  \\n56 weeks \\n3% (7/269) \\n8% (7/86) \\nNA \\nPediatric Crohn’s Disease  \\n52 weeks \\n3% (6/182) \\n10% (6/58) \\nNA \\nAdult Ulcerative Colitis  \\n52 weeks \\n5% (19/360) \\n21% (19/92) \\nNA \\nPediatric Ulcerative Colitis \\n52 weeks \\n3% (3/100) \\n13% (3/23) \\n33% (33/100)i \\nPlaque Psoriasisf \\nUp to 52 \\nweeksg \\n8% (77/920) \\n21% (77/372) \\nNA \\nHidradenitis Suppurativa  \\n36 weeks \\n7% (30/461) \\n28% (58/207)h 61% (272/445)j \\nNon-infectious Uveitis  \\n52 weeks \\n5% (12/249) \\n21% (12/57) \\n40% (99/249)k \\nn: number of patients with anti-adalimumab antibody; NR: not reported; NA: Not applicable (not \\nperformed) \\na In patients receiving concomitant methotrexate (MTX), the incidence of anti-adalimumab antibody was \\n1% compared to 12% with HUMIRA monotherapy  \\n'], 'page_sentence_count_spacy': 6}\n",
            "{'page_number': 22, 'text': 'b In patients receiving concomitant MTX, the incidence of anti-adalimumab antibody was 6% compared \\nto 26% with HUMIRA monotherapy  \\nc This patient received concomitant MTX \\nd In patients receiving concomitant MTX, the incidence of antibody development was 7% compared to \\n1% in RA \\ne Subjects enrolled after completing 2 previous studies of 24 weeks or 12 weeks of treatments. \\nf In plaque psoriasis patients who were on HUMIRA monotherapy and subsequently withdrawn from the \\ntreatment, the rate of antibodies to adalimumab after retreatment was similar to the rate observed prior to \\nwithdrawal \\ng One 12-week Phase 2 study and one 52-week Phase 3 study \\nh Among subjects in the 2 Phase 3 studies who stopped HUMIRA treatment for up to 24 weeks and in \\nwhom adalimumab serum levels subsequently declined to <2 mcg/mL (approximately 22% of total \\nsubjects studied) \\ni No apparent association between antibody development and safety was observed. The association of \\nantibody development and efficacy outcome was not assessed due to limited number of subjects in each \\ntreatment group stratified by anti-adalimumab antibody titer. \\nj No apparent association between antibody development and safety was observed \\nk No correlation of antibody development to safety or efficacy outcomes was observed   \\n \\nRheumatoid Arthritis and Psoriatic Arthritis: Patients in Studies RA-I, RA-II, and RA-III were \\ntested at multiple time points for antibodies to adalimumab using the ELISA during the 6- to 12-\\nmonth period. No apparent correlation of antibody development to adverse reactions was \\nobserved. With monotherapy, patients receiving every other week dosing may develop \\nantibodies more frequently than those receiving weekly dosing. In patients receiving the \\nrecommended dosage of 40 mg every other week as monotherapy, the ACR 20 response was \\nlower among antibody-positive patients than among antibody-negative patients. The long-term \\nimmunogenicity of HUMIRA is unknown.  \\n6.3 Postmarketing Experience \\nThe following adverse reactions have been identified during post-approval use of HUMIRA. \\nBecause these reactions are reported voluntarily from a population of uncertain size, it is not \\nalways possible to reliably estimate their frequency or establish a causal relationship to \\nHUMIRA exposure.  \\nGastrointestinal disorders: Diverticulitis, large bowel perforations including perforations \\nassociated with diverticulitis and appendiceal perforations associated with appendicitis, \\npancreatitis  \\nGeneral disorders and administration site conditions: Pyrexia  \\nHepato-biliary disorders: Liver failure, hepatitis  \\nImmune system disorders: Sarcoidosis  \\nNeoplasms benign, malignant and unspecified (including cysts and polyps): Merkel Cell \\nCarcinoma (neuroendocrine carcinoma of the skin)  \\nNervous system disorders: Demyelinating disorders (e.g., optic neuritis, Guillain-Barré \\nsyndrome), cerebrovascular accident  \\n', 'processed_text': {'sentences': [{'original_sentence': 'b In patients receiving concomitant MTX, the incidence of anti-adalimumab antibody was 6% compared \\nto 26% with HUMIRA monotherapy  \\nc This patient received concomitant MTX \\nd In patients receiving concomitant MTX, the incidence of antibody development was 7% compared to \\n1% in RA \\ne Subjects enrolled after completing 2 previous studies of 24 weeks or 12 weeks of treatments.', 'tokens': ['b', 'patients', 'receiving', 'concomitant', 'MTX', ',', 'incidence', 'anti-adalimumab', 'antibody', '6', '%', 'compared', '26', '%', 'HUMIRA', 'monotherapy', 'c', 'patient', 'received', 'concomitant', 'MTX', 'patients', 'receiving', 'concomitant', 'MTX', ',', 'incidence', 'antibody', 'development', '7', '%', 'compared', '1', '%', 'RA', 'e', 'Subjects', 'enrolled', 'completing', '2', 'previous', 'studies', '24', 'weeks', '12', 'weeks', 'treatments', '.'], 'lemmatized': ['b', 'patient', 'receiving', 'concomitant', 'MTX', ',', 'incidence', 'anti-adalimumab', 'antibody', '6', '%', 'compared', '26', '%', 'HUMIRA', 'monotherapy', 'c', 'patient', 'received', 'concomitant', 'MTX', 'patient', 'receiving', 'concomitant', 'MTX', ',', 'incidence', 'antibody', 'development', '7', '%', 'compared', '1', '%', 'RA', 'e', 'Subjects', 'enrolled', 'completing', '2', 'previous', 'study', '24', 'week', '12', 'week', 'treatment', '.'], 'stemmed': ['b', 'patient', 'receiv', 'concomit', 'mtx', ',', 'incid', 'anti-adalimumab', 'antibodi', '6', '%', 'compar', '26', '%', 'humira', 'monotherapi', 'c', 'patient', 'receiv', 'concomit', 'mtx', 'patient', 'receiv', 'concomit', 'mtx', ',', 'incid', 'antibodi', 'develop', '7', '%', 'compar', '1', '%', 'ra', 'e', 'subject', 'enrol', 'complet', '2', 'previou', 'studi', '24', 'week', '12', 'week', 'treatment', '.'], 'dependencies': [('b', 'meta'), ('patient', 'compound'), ('receiv', 'compound'), ('concomit', 'compound'), ('mtx', 'nsubj'), (',', 'punct'), ('incid', 'amod'), ('anti', 'amod'), ('-', 'amod'), ('adalimumab', 'amod'), ('antibodi', 'nmod'), ('6', 'nummod'), ('%', 'compound'), ('compar', 'appos'), ('26', 'nummod'), ('%', 'npadvmod'), ('humira', 'compound'), ('monotherapi', 'appos'), ('c', 'compound'), ('patient', 'compound'), ('receiv', 'compound'), ('concomit', 'nsubj'), ('mtx', 'ccomp'), ('patient', 'compound'), ('receiv', 'compound'), ('concomit', 'compound'), ('mtx', 'dobj'), (',', 'punct'), ('incid', 'amod'), ('antibodi', 'nsubj'), ('develop', 'ROOT'), ('7', 'nummod'), ('%', 'compound'), ('compar', 'dobj'), ('1', 'nummod'), ('%', 'appos'), ('ra', 'compound'), ('e', 'compound'), ('subject', 'compound'), ('enrol', 'appos'), ('complet', 'conj'), ('2', 'nummod'), ('previou', 'compound'), ('studi', 'npadvmod'), ('24', 'nummod'), ('week', 'nmod'), ('12', 'nummod'), ('week', 'compound'), ('treatment', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'f In plaque psoriasis patients who were on HUMIRA monotherapy and subsequently withdrawn from the \\ntreatment, the rate of antibodies to adalimumab after retreatment was similar to the rate observed prior to \\nwithdrawal \\ng One 12-week Phase 2 study and one 52-week Phase 3 study \\nh Among subjects in the 2 Phase 3 studies who stopped HUMIRA treatment for up to 24 weeks and in \\nwhom adalimumab serum levels subsequently declined to <2 mcg/mL (approximately 22% of total \\nsubjects studied) \\ni No apparent association between antibody development and safety was observed.', 'tokens': ['f', 'plaque', 'psoriasis', 'patients', 'HUMIRA', 'monotherapy', 'subsequently', 'withdrawn', 'treatment', ',', 'rate', 'antibodies', 'adalimumab', 'retreatment', 'similar', 'rate', 'observed', 'prior', 'withdrawal', 'g', 'One', '12-week', 'Phase', '2', 'study', 'one', '52-week', 'Phase', '3', 'study', 'h', 'Among', 'subjects', '2', 'Phase', '3', 'studies', 'stopped', 'HUMIRA', 'treatment', '24', 'weeks', 'adalimumab', 'serum', 'levels', 'subsequently', 'declined', '<', '2', 'mcg/mL', '(', 'approximately', '22', '%', 'total', 'subjects', 'studied', ')', 'apparent', 'association', 'antibody', 'development', 'safety', 'observed', '.'], 'lemmatized': ['f', 'plaque', 'psoriasis', 'patient', 'HUMIRA', 'monotherapy', 'subsequently', 'withdrawn', 'treatment', ',', 'rate', 'antibody', 'adalimumab', 'retreatment', 'similar', 'rate', 'observed', 'prior', 'withdrawal', 'g', 'One', '12-week', 'Phase', '2', 'study', 'one', '52-week', 'Phase', '3', 'study', 'h', 'Among', 'subject', '2', 'Phase', '3', 'study', 'stopped', 'HUMIRA', 'treatment', '24', 'week', 'adalimumab', 'serum', 'level', 'subsequently', 'declined', '<', '2', 'mcg/mL', '(', 'approximately', '22', '%', 'total', 'subject', 'studied', ')', 'apparent', 'association', 'antibody', 'development', 'safety', 'observed', '.'], 'stemmed': ['f', 'plaqu', 'psoriasi', 'patient', 'humira', 'monotherapi', 'subsequ', 'withdrawn', 'treatment', ',', 'rate', 'antibodi', 'adalimumab', 'retreat', 'similar', 'rate', 'observ', 'prior', 'withdraw', 'g', 'one', '12-week', 'phase', '2', 'studi', 'one', '52-week', 'phase', '3', 'studi', 'h', 'among', 'subject', '2', 'phase', '3', 'studi', 'stop', 'humira', 'treatment', '24', 'week', 'adalimumab', 'serum', 'level', 'subsequ', 'declin', '<', '2', 'mcg/ml', '(', 'approxim', '22', '%', 'total', 'subject', 'studi', ')', 'appar', 'associ', 'antibodi', 'develop', 'safeti', 'observ', '.'], 'dependencies': [('f', 'nsubj'), ('plaqu', 'ROOT'), ('psoriasi', 'compound'), ('patient', 'compound'), ('humira', 'compound'), ('monotherapi', 'compound'), ('subsequ', 'nsubj'), ('withdrawn', 'ccomp'), ('treatment', 'dobj'), (',', 'punct'), ('rate', 'conj'), ('antibodi', 'compound'), ('adalimumab', 'nmod'), ('retreat', 'nmod'), ('similar', 'amod'), ('rate', 'compound'), ('observ', 'dobj'), ('prior', 'advmod'), ('withdraw', 'advcl'), ('g', 'dobj'), ('one', 'nummod'), ('12', 'nummod'), ('-', 'punct'), ('week', 'compound'), ('phase', 'dobj'), ('2', 'nummod'), ('studi', 'npadvmod'), ('one', 'nummod'), ('52', 'nummod'), ('-', 'punct'), ('week', 'compound'), ('phase', 'appos'), ('3', 'nummod'), ('studi', 'compound'), ('h', 'appos'), ('among', 'prep'), ('subject', 'amod'), ('2', 'nummod'), ('phase', 'pobj'), ('3', 'nummod'), ('studi', 'amod'), ('stop', 'appos'), ('humira', 'compound'), ('treatment', 'dobj'), ('24', 'nummod'), ('week', 'compound'), ('adalimumab', 'compound'), ('serum', 'compound'), ('level', 'compound'), ('subsequ', 'compound'), ('declin', 'appos'), ('<', 'dep'), ('2', 'nummod'), ('mcg', 'nmod'), ('/', 'punct'), ('ml', 'nsubj'), ('(', 'punct'), ('approxim', 'appos'), ('22', 'nummod'), ('%', 'npadvmod'), ('total', 'amod'), ('subject', 'nmod'), ('studi', 'appos'), (')', 'punct'), ('appar', 'compound'), ('associ', 'compound'), ('antibodi', 'nsubj'), ('develop', 'ROOT'), ('safeti', 'compound'), ('observ', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The association of \\nantibody development and efficacy outcome was not assessed due to limited number of subjects in each \\ntreatment group stratified by anti-adalimumab antibody titer.', 'tokens': ['association', 'antibody', 'development', 'efficacy', 'outcome', 'assessed', 'due', 'limited', 'number', 'subjects', 'treatment', 'group', 'stratified', 'anti-adalimumab', 'antibody', 'titer', '.'], 'lemmatized': ['association', 'antibody', 'development', 'efficacy', 'outcome', 'assessed', 'due', 'limited', 'number', 'subject', 'treatment', 'group', 'stratified', 'anti-adalimumab', 'antibody', 'titer', '.'], 'stemmed': ['associ', 'antibodi', 'develop', 'efficaci', 'outcom', 'assess', 'due', 'limit', 'number', 'subject', 'treatment', 'group', 'stratifi', 'anti-adalimumab', 'antibodi', 'titer', '.'], 'dependencies': [('associ', 'compound'), ('antibodi', 'nsubj'), ('develop', 'ROOT'), ('efficaci', 'compound'), ('outcom', 'compound'), ('assess', 'compound'), ('due', 'amod'), ('limit', 'compound'), ('number', 'compound'), ('subject', 'compound'), ('treatment', 'compound'), ('group', 'compound'), ('stratifi', 'nmod'), ('anti', 'amod'), ('-', 'amod'), ('adalimumab', 'amod'), ('antibodi', 'amod'), ('titer', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'j No apparent association between antibody development and safety was observed \\nk No correlation of antibody development to safety or efficacy outcomes was observed   \\n \\nRheumatoid Arthritis and Psoriatic Arthritis: Patients in Studies RA-I, RA-II, and RA-III were \\ntested at multiple time points for antibodies to adalimumab using the ELISA during the 6- to 12-\\nmonth period.', 'tokens': ['j', 'apparent', 'association', 'antibody', 'development', 'safety', 'observed', 'k', 'correlation', 'antibody', 'development', 'safety', 'efficacy', 'outcomes', 'observed', 'Rheumatoid', 'Arthritis', 'Psoriatic', 'Arthritis', ':', 'Patients', 'Studies', 'RA-I', ',', 'RA-II', ',', 'RA-III', 'tested', 'multiple', 'time', 'points', 'antibodies', 'adalimumab', 'using', 'ELISA', '6-', '12-', 'month', 'period', '.'], 'lemmatized': ['j', 'apparent', 'association', 'antibody', 'development', 'safety', 'observed', 'k', 'correlation', 'antibody', 'development', 'safety', 'efficacy', 'outcome', 'observed', 'Rheumatoid', 'Arthritis', 'Psoriatic', 'Arthritis', ':', 'Patients', 'Studies', 'RA-I', ',', 'RA-II', ',', 'RA-III', 'tested', 'multiple', 'time', 'point', 'antibody', 'adalimumab', 'using', 'ELISA', '6-', '12-', 'month', 'period', '.'], 'stemmed': ['j', 'appar', 'associ', 'antibodi', 'develop', 'safeti', 'observ', 'k', 'correl', 'antibodi', 'develop', 'safeti', 'efficaci', 'outcom', 'observ', 'rheumatoid', 'arthriti', 'psoriat', 'arthriti', ':', 'patient', 'studi', 'ra-i', ',', 'ra-ii', ',', 'ra-iii', 'test', 'multipl', 'time', 'point', 'antibodi', 'adalimumab', 'use', 'elisa', '6-', '12-', 'month', 'period', '.'], 'dependencies': [('j', 'compound'), ('appar', 'compound'), ('associ', 'nsubj'), ('antibodi', 'npadvmod'), ('develop', 'ROOT'), ('safeti', 'compound'), ('observ', 'compound'), ('k', 'compound'), ('correl', 'compound'), ('antibodi', 'nsubj'), ('develop', 'ccomp'), ('safeti', 'compound'), ('efficaci', 'compound'), ('outcom', 'compound'), ('observ', 'compound'), ('rheumatoid', 'compound'), ('arthriti', 'compound'), ('psoriat', 'compound'), ('arthriti', 'dobj'), (':', 'punct'), ('patient', 'nmod'), ('studi', 'npadvmod'), ('ra', 'npadvmod'), ('-', 'punct'), ('i', 'dobj'), (',', 'punct'), ('ra', 'compound'), ('-', 'punct'), ('ii', 'appos'), (',', 'punct'), ('ra', 'compound'), ('-', 'punct'), ('iii', 'compound'), ('test', 'compound'), ('multipl', 'appos'), ('time', 'compound'), ('point', 'appos'), ('antibodi', 'amod'), ('adalimumab', 'compound'), ('use', 'compound'), ('elisa', 'ROOT'), ('6-', 'nmod'), ('12-', 'nummod'), ('month', 'compound'), ('period', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'No apparent correlation of antibody development to adverse reactions was \\nobserved.', 'tokens': ['apparent', 'correlation', 'antibody', 'development', 'adverse', 'reactions', 'observed', '.'], 'lemmatized': ['apparent', 'correlation', 'antibody', 'development', 'adverse', 'reaction', 'observed', '.'], 'stemmed': ['appar', 'correl', 'antibodi', 'develop', 'advers', 'reaction', 'observ', '.'], 'dependencies': [('appar', 'compound'), ('correl', 'compound'), ('antibodi', 'nsubj'), ('develop', 'ROOT'), ('advers', 'compound'), ('reaction', 'compound'), ('observ', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'With monotherapy, patients receiving every other week dosing may develop \\nantibodies more frequently than those receiving weekly dosing.', 'tokens': ['monotherapy', ',', 'patients', 'receiving', 'every', 'week', 'dosing', 'may', 'develop', 'antibodies', 'frequently', 'receiving', 'weekly', 'dosing', '.'], 'lemmatized': ['monotherapy', ',', 'patient', 'receiving', 'every', 'week', 'dosing', 'may', 'develop', 'antibody', 'frequently', 'receiving', 'weekly', 'dosing', '.'], 'stemmed': ['monotherapi', ',', 'patient', 'receiv', 'everi', 'week', 'dose', 'may', 'develop', 'antibodi', 'frequent', 'receiv', 'weekli', 'dose', '.'], 'dependencies': [('monotherapi', 'nsubj'), (',', 'punct'), ('patient', 'amod'), ('receiv', 'compound'), ('everi', 'compound'), ('week', 'compound'), ('dose', 'npadvmod'), ('may', 'aux'), ('develop', 'ROOT'), ('antibodi', 'amod'), ('frequent', 'amod'), ('receiv', 'compound'), ('weekli', 'compound'), ('dose', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'In patients receiving the \\nrecommended dosage of 40 mg every other week as monotherapy, the ACR 20 response was \\nlower among antibody-positive patients than among antibody-negative patients.', 'tokens': ['patients', 'receiving', 'recommended', 'dosage', '40', 'mg', 'every', 'week', 'monotherapy', ',', 'ACR', '20', 'response', 'lower', 'among', 'antibody-positive', 'patients', 'among', 'antibody-negative', 'patients', '.'], 'lemmatized': ['patient', 'receiving', 'recommended', 'dosage', '40', 'mg', 'every', 'week', 'monotherapy', ',', 'ACR', '20', 'response', 'lower', 'among', 'antibody-positive', 'patient', 'among', 'antibody-negative', 'patient', '.'], 'stemmed': ['patient', 'receiv', 'recommend', 'dosag', '40', 'mg', 'everi', 'week', 'monotherapi', ',', 'acr', '20', 'respons', 'lower', 'among', 'antibody-posit', 'patient', 'among', 'antibody-neg', 'patient', '.'], 'dependencies': [('patient', 'compound'), ('receiv', 'nsubj'), ('recommend', 'ROOT'), ('dosag', 'dobj'), ('40', 'nummod'), ('mg', 'nmod'), ('everi', 'amod'), ('week', 'compound'), ('monotherapi', 'npadvmod'), (',', 'punct'), ('acr', 'prep'), ('20', 'nummod'), ('respons', 'npadvmod'), ('lower', 'amod'), ('among', 'prep'), ('antibody', 'compound'), ('-', 'punct'), ('posit', 'compound'), ('patient', 'pobj'), ('among', 'prep'), ('antibody', 'compound'), ('-', 'punct'), ('neg', 'compound'), ('patient', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'The long-term \\nimmunogenicity of HUMIRA is unknown.', 'tokens': ['long-term', 'immunogenicity', 'HUMIRA', 'unknown', '.'], 'lemmatized': ['long-term', 'immunogenicity', 'HUMIRA', 'unknown', '.'], 'stemmed': ['long-term', 'immunogen', 'humira', 'unknown', '.'], 'dependencies': [('long', 'amod'), ('-', 'punct'), ('term', 'compound'), ('immunogen', 'compound'), ('humira', 'npadvmod'), ('unknown', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '6.3 Postmarketing Experience \\nThe following adverse reactions have been identified during post-approval use of HUMIRA.', 'tokens': ['6.3', 'Postmarketing', 'Experience', 'following', 'adverse', 'reactions', 'identified', 'post-approval', 'use', 'HUMIRA', '.'], 'lemmatized': ['6.3', 'Postmarketing', 'Experience', 'following', 'adverse', 'reaction', 'identified', 'post-approval', 'use', 'HUMIRA', '.'], 'stemmed': ['6.3', 'postmarket', 'experi', 'follow', 'advers', 'reaction', 'identifi', 'post-approv', 'use', 'humira', '.'], 'dependencies': [('6.3', 'nummod'), ('postmarket', 'nmod'), ('experi', 'amod'), ('follow', 'compound'), ('advers', 'compound'), ('reaction', 'ROOT'), ('identifi', 'compound'), ('post', 'amod'), ('-', 'amod'), ('approv', 'amod'), ('use', 'compound'), ('humira', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Because these reactions are reported voluntarily from a population of uncertain size, it is not \\nalways possible to reliably estimate their frequency or establish a causal relationship to \\nHUMIRA exposure.', 'tokens': ['reactions', 'reported', 'voluntarily', 'population', 'uncertain', 'size', ',', 'always', 'possible', 'reliably', 'estimate', 'frequency', 'establish', 'causal', 'relationship', 'HUMIRA', 'exposure', '.'], 'lemmatized': ['reaction', 'reported', 'voluntarily', 'population', 'uncertain', 'size', ',', 'always', 'possible', 'reliably', 'estimate', 'frequency', 'establish', 'causal', 'relationship', 'HUMIRA', 'exposure', '.'], 'stemmed': ['reaction', 'report', 'voluntarili', 'popul', 'uncertain', 'size', ',', 'alway', 'possibl', 'reliabl', 'estim', 'frequenc', 'establish', 'causal', 'relationship', 'humira', 'exposur', '.'], 'dependencies': [('reaction', 'compound'), ('report', 'compound'), ('voluntarili', 'compound'), ('popul', 'nmod'), ('uncertain', 'compound'), ('size', 'ROOT'), (',', 'punct'), ('alway', 'compound'), ('possibl', 'nsubj'), ('reliabl', 'nmod'), ('estim', 'compound'), ('frequenc', 'dobj'), ('establish', 'compound'), ('causal', 'compound'), ('relationship', 'compound'), ('humira', 'compound'), ('exposur', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Gastrointestinal disorders: Diverticulitis, large bowel perforations including perforations \\nassociated with diverticulitis and appendiceal perforations associated with appendicitis, \\npancreatitis  \\nGeneral disorders and administration site conditions: Pyrexia  \\nHepato-biliary disorders: Liver failure, hepatitis  \\nImmune system disorders: Sarcoidosis  \\nNeoplasms benign, malignant and unspecified (including cysts and polyps): Merkel Cell \\nCarcinoma (neuroendocrine carcinoma of the skin)  \\nNervous system disorders: Demyelinating disorders (e.g., optic neuritis, Guillain-Barré \\nsyndrome), cerebrovascular accident', 'tokens': ['Gastrointestinal', 'disorders', ':', 'Diverticulitis', ',', 'large', 'bowel', 'perforations', 'including', 'perforations', 'associated', 'diverticulitis', 'appendiceal', 'perforations', 'associated', 'appendicitis', ',', 'pancreatitis', 'General', 'disorders', 'administration', 'site', 'conditions', ':', 'Pyrexia', 'Hepato-biliary', 'disorders', ':', 'Liver', 'failure', ',', 'hepatitis', 'Immune', 'system', 'disorders', ':', 'Sarcoidosis', 'Neoplasms', 'benign', ',', 'malignant', 'unspecified', '(', 'including', 'cysts', 'polyps', ')', ':', 'Merkel', 'Cell', 'Carcinoma', '(', 'neuroendocrine', 'carcinoma', 'skin', ')', 'Nervous', 'system', 'disorders', ':', 'Demyelinating', 'disorders', '(', 'e.g.', ',', 'optic', 'neuritis', ',', 'Guillain-Barré', 'syndrome', ')', ',', 'cerebrovascular', 'accident'], 'lemmatized': ['Gastrointestinal', 'disorder', ':', 'Diverticulitis', ',', 'large', 'bowel', 'perforation', 'including', 'perforation', 'associated', 'diverticulitis', 'appendiceal', 'perforation', 'associated', 'appendicitis', ',', 'pancreatitis', 'General', 'disorder', 'administration', 'site', 'condition', ':', 'Pyrexia', 'Hepato-biliary', 'disorder', ':', 'Liver', 'failure', ',', 'hepatitis', 'Immune', 'system', 'disorder', ':', 'Sarcoidosis', 'Neoplasms', 'benign', ',', 'malignant', 'unspecified', '(', 'including', 'cyst', 'polyp', ')', ':', 'Merkel', 'Cell', 'Carcinoma', '(', 'neuroendocrine', 'carcinoma', 'skin', ')', 'Nervous', 'system', 'disorder', ':', 'Demyelinating', 'disorder', '(', 'e.g.', ',', 'optic', 'neuritis', ',', 'Guillain-Barré', 'syndrome', ')', ',', 'cerebrovascular', 'accident'], 'stemmed': ['gastrointestin', 'disord', ':', 'diverticul', ',', 'larg', 'bowel', 'perfor', 'includ', 'perfor', 'associ', 'diverticul', 'appendic', 'perfor', 'associ', 'append', ',', 'pancreat', 'gener', 'disord', 'administr', 'site', 'condit', ':', 'pyrexia', 'hepato-biliari', 'disord', ':', 'liver', 'failur', ',', 'hepat', 'immun', 'system', 'disord', ':', 'sarcoidosi', 'neoplasm', 'benign', ',', 'malign', 'unspecifi', '(', 'includ', 'cyst', 'polyp', ')', ':', 'merkel', 'cell', 'carcinoma', '(', 'neuroendocrin', 'carcinoma', 'skin', ')', 'nervou', 'system', 'disord', ':', 'demyelin', 'disord', '(', 'e.g.', ',', 'optic', 'neuriti', ',', 'guillain-barré', 'syndrom', ')', ',', 'cerebrovascular', 'accid'], 'dependencies': [('gastrointestin', 'compound'), ('disord', 'ROOT'), (':', 'punct'), ('diverticul', 'nmod'), (',', 'punct'), ('larg', 'compound'), ('bowel', 'conj'), ('perfor', 'compound'), ('includ', 'appos'), ('perfor', 'prep'), ('associ', 'compound'), ('diverticul', 'compound'), ('appendic', 'appos'), ('perfor', 'prep'), ('associ', 'compound'), ('append', 'pobj'), (',', 'punct'), ('pancreat', 'compound'), ('gener', 'compound'), ('disord', 'compound'), ('administr', 'compound'), ('site', 'compound'), ('condit', 'appos'), (':', 'punct'), ('pyrexia', 'compound'), ('hepato', 'compound'), ('-', 'punct'), ('biliari', 'compound'), ('disord', 'appos'), (':', 'punct'), ('liver', 'compound'), ('failur', 'appos'), (',', 'punct'), ('hepat', 'compound'), ('immun', 'compound'), ('system', 'compound'), ('disord', 'appos'), (':', 'punct'), ('sarcoidosi', 'amod'), ('neoplasm', 'compound'), ('benign', 'appos'), (',', 'punct'), ('malign', 'compound'), ('unspecifi', 'nsubj'), ('(', 'punct'), ('includ', 'compound'), ('cyst', 'compound'), ('polyp', 'appos'), (')', 'punct'), (':', 'punct'), ('merkel', 'compound'), ('cell', 'compound'), ('carcinoma', 'appos'), ('(', 'punct'), ('neuroendocrin', 'compound'), ('carcinoma', 'compound'), ('skin', 'parataxis'), (')', 'punct'), ('nervou', 'ROOT'), ('system', 'compound'), ('disord', 'dobj'), (':', 'punct'), ('demyelin', 'compound'), ('disord', 'ROOT'), ('(', 'punct'), ('e.g.', 'advmod'), (',', 'punct'), ('optic', 'amod'), ('neuriti', 'appos'), (',', 'punct'), ('guillain', 'compound'), ('-', 'punct'), ('barré', 'amod'), ('syndrom', 'conj'), (')', 'punct'), (',', 'punct'), ('cerebrovascular', 'amod'), ('accid', 'appos')]}], 'text': 'b In patients receiving concomitant MTX, the incidence of anti-adalimumab antibody was 6% compared \\nto 26% with HUMIRA monotherapy  \\nc This patient received concomitant MTX \\nd In patients receiving concomitant MTX, the incidence of antibody development was 7% compared to \\n1% in RA \\ne Subjects enrolled after completing 2 previous studies of 24 weeks or 12 weeks of treatments. \\nf In plaque psoriasis patients who were on HUMIRA monotherapy and subsequently withdrawn from the \\ntreatment, the rate of antibodies to adalimumab after retreatment was similar to the rate observed prior to \\nwithdrawal \\ng One 12-week Phase 2 study and one 52-week Phase 3 study \\nh Among subjects in the 2 Phase 3 studies who stopped HUMIRA treatment for up to 24 weeks and in \\nwhom adalimumab serum levels subsequently declined to <2 mcg/mL (approximately 22% of total \\nsubjects studied) \\ni No apparent association between antibody development and safety was observed. The association of \\nantibody development and efficacy outcome was not assessed due to limited number of subjects in each \\ntreatment group stratified by anti-adalimumab antibody titer. \\nj No apparent association between antibody development and safety was observed \\nk No correlation of antibody development to safety or efficacy outcomes was observed   \\n \\nRheumatoid Arthritis and Psoriatic Arthritis: Patients in Studies RA-I, RA-II, and RA-III were \\ntested at multiple time points for antibodies to adalimumab using the ELISA during the 6- to 12-\\nmonth period. No apparent correlation of antibody development to adverse reactions was \\nobserved. With monotherapy, patients receiving every other week dosing may develop \\nantibodies more frequently than those receiving weekly dosing. In patients receiving the \\nrecommended dosage of 40 mg every other week as monotherapy, the ACR 20 response was \\nlower among antibody-positive patients than among antibody-negative patients. The long-term \\nimmunogenicity of HUMIRA is unknown.  \\n6.3 Postmarketing Experience \\nThe following adverse reactions have been identified during post-approval use of HUMIRA. \\nBecause these reactions are reported voluntarily from a population of uncertain size, it is not \\nalways possible to reliably estimate their frequency or establish a causal relationship to \\nHUMIRA exposure.  \\nGastrointestinal disorders: Diverticulitis, large bowel perforations including perforations \\nassociated with diverticulitis and appendiceal perforations associated with appendicitis, \\npancreatitis  \\nGeneral disorders and administration site conditions: Pyrexia  \\nHepato-biliary disorders: Liver failure, hepatitis  \\nImmune system disorders: Sarcoidosis  \\nNeoplasms benign, malignant and unspecified (including cysts and polyps): Merkel Cell \\nCarcinoma (neuroendocrine carcinoma of the skin)  \\nNervous system disorders: Demyelinating disorders (e.g., optic neuritis, Guillain-Barré \\nsyndrome), cerebrovascular accident  \\n'}, 'page_char_count': 2924, 'page_word_count': 403, 'sentences': ['b In patients receiving concomitant MTX, the incidence of anti-adalimumab antibody was 6% compared \\nto 26% with HUMIRA monotherapy  \\nc This patient received concomitant MTX \\nd In patients receiving concomitant MTX, the incidence of antibody development was 7% compared to \\n1% in RA \\ne Subjects enrolled after completing 2 previous studies of 24 weeks or 12 weeks of treatments.', '\\nf In plaque psoriasis patients who were on HUMIRA monotherapy and subsequently withdrawn from the \\ntreatment, the rate of antibodies to adalimumab after retreatment was similar to the rate observed prior to \\nwithdrawal \\ng One 12-week Phase 2 study and one 52-week Phase 3 study \\nh Among subjects in the 2 Phase 3 studies who stopped HUMIRA treatment for up to 24 weeks and in \\nwhom adalimumab serum levels subsequently declined to <2 mcg/mL (approximately 22% of total \\nsubjects studied) \\ni No apparent association between antibody development and safety was observed.', 'The association of \\nantibody development and efficacy outcome was not assessed due to limited number of subjects in each \\ntreatment group stratified by anti-adalimumab antibody titer.', '\\nj No apparent association between antibody development and safety was observed \\nk No correlation of antibody development to safety or efficacy outcomes was observed   \\n \\nRheumatoid Arthritis and Psoriatic Arthritis: Patients in Studies RA-I, RA-II, and RA-III were \\ntested at multiple time points for antibodies to adalimumab using the ELISA during the 6- to 12-\\nmonth period.', 'No apparent correlation of antibody development to adverse reactions was \\nobserved.', 'With monotherapy, patients receiving every other week dosing may develop \\nantibodies more frequently than those receiving weekly dosing.', 'In patients receiving the \\nrecommended dosage of 40 mg every other week as monotherapy, the ACR 20 response was \\nlower among antibody-positive patients than among antibody-negative patients.', 'The long-term \\nimmunogenicity of HUMIRA is unknown.', ' \\n6.3 Postmarketing Experience \\nThe following adverse reactions have been identified during post-approval use of HUMIRA.', '\\nBecause these reactions are reported voluntarily from a population of uncertain size, it is not \\nalways possible to reliably estimate their frequency or establish a causal relationship to \\nHUMIRA exposure.', ' \\nGastrointestinal disorders: Diverticulitis, large bowel perforations including perforations \\nassociated with diverticulitis and appendiceal perforations associated with appendicitis, \\npancreatitis  \\nGeneral disorders and administration site conditions: Pyrexia  \\nHepato-biliary disorders: Liver failure, hepatitis  \\nImmune system disorders: Sarcoidosis  \\nNeoplasms benign, malignant and unspecified (including cysts and polyps): Merkel Cell \\nCarcinoma (neuroendocrine carcinoma of the skin)  \\nNervous system disorders: Demyelinating disorders (e.g., optic neuritis, Guillain-Barré \\nsyndrome), cerebrovascular accident  \\n'], 'page_sentence_count_spacy': 11}\n",
            "{'page_number': 23, 'text': 'Respiratory disorders: Interstitial lung disease, including pulmonary fibrosis, pulmonary \\nembolism  \\nSkin reactions: Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, new or \\nworsening psoriasis (all sub-types including pustular and palmoplantar), alopecia, lichenoid skin \\nreaction  \\nVascular disorders: Systemic vasculitis, deep vein thrombosis  \\n7 DRUG INTERACTIONS \\n7.1 Methotrexate \\nHUMIRA has been studied in rheumatoid arthritis (RA) patients taking concomitant \\nmethotrexate (MTX). Although MTX reduced the apparent adalimumab clearance, the data do \\nnot suggest the need for dose adjustment of either HUMIRA or MTX [see Clinical \\nPharmacology (12.3)].  \\n7.2 Biological Products  \\nIn clinical studies in patients with RA, an increased risk of serious infections has been observed \\nwith the combination of TNF blockers with anakinra or abatacept, with no added benefit; \\ntherefore, use of HUMIRA with abatacept or anakinra is not recommended in patients with RA \\n[see Warnings and Precautions (5.7, 5.11)]. A higher rate of serious infections has also been \\nobserved in patients with RA treated with rituximab who received subsequent treatment with a \\nTNF blocker. There is insufficient information regarding the concomitant use of HUMIRA and \\nother biologic products for the treatment of RA, PsA, AS, CD, UC, Ps, HS and UV. Concomitant \\nadministration of HUMIRA with other biologic DMARDS (e.g., anakinra and abatacept) or other \\nTNF blockers is not recommended based upon the possible increased risk for infections and \\nother potential pharmacological interactions.  \\n7.3 Live Vaccines \\nAvoid the use of live vaccines with HUMIRA [see Warnings and Precautions (5.10)].  \\n7.4 Cytochrome P450 Substrates \\nThe formation of CYP450 enzymes may be suppressed by increased concentrations of cytokines \\n(e.g., TNFα, IL-6) during chronic inflammation. It is possible for a molecule that antagonizes \\ncytokine activity, such as adalimumab, to influence the formation of CYP450 enzymes. Upon \\ninitiation or discontinuation of HUMIRA in patients being treated with CYP450 substrates with a \\nnarrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., \\ncyclosporine or theophylline) is recommended and the individual dose of the drug product may \\nbe adjusted as needed.  \\n', 'processed_text': {'sentences': [{'original_sentence': 'Respiratory disorders: Interstitial lung disease, including pulmonary fibrosis, pulmonary \\nembolism  \\nSkin reactions: Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, new or \\nworsening psoriasis (all sub-types including pustular and palmoplantar), alopecia, lichenoid skin \\nreaction  \\nVascular disorders: Systemic vasculitis, deep vein thrombosis  \\n7 DRUG INTERACTIONS \\n7.1 Methotrexate \\nHUMIRA has been studied in rheumatoid arthritis (RA) patients taking concomitant \\nmethotrexate (MTX).', 'tokens': ['Respiratory', 'disorders', ':', 'Interstitial', 'lung', 'disease', ',', 'including', 'pulmonary', 'fibrosis', ',', 'pulmonary', 'embolism', 'Skin', 'reactions', ':', 'Stevens', 'Johnson', 'Syndrome', ',', 'cutaneous', 'vasculitis', ',', 'erythema', 'multiforme', ',', 'new', 'worsening', 'psoriasis', '(', 'sub-types', 'including', 'pustular', 'palmoplantar', ')', ',', 'alopecia', ',', 'lichenoid', 'skin', 'reaction', 'Vascular', 'disorders', ':', 'Systemic', 'vasculitis', ',', 'deep', 'vein', 'thrombosis', '7', 'DRUG', 'INTERACTIONS', '7.1', 'Methotrexate', 'HUMIRA', 'studied', 'rheumatoid', 'arthritis', '(', 'RA', ')', 'patients', 'taking', 'concomitant', 'methotrexate', '(', 'MTX', ')', '.'], 'lemmatized': ['Respiratory', 'disorder', ':', 'Interstitial', 'lung', 'disease', ',', 'including', 'pulmonary', 'fibrosis', ',', 'pulmonary', 'embolism', 'Skin', 'reaction', ':', 'Stevens', 'Johnson', 'Syndrome', ',', 'cutaneous', 'vasculitis', ',', 'erythema', 'multiforme', ',', 'new', 'worsening', 'psoriasis', '(', 'sub-types', 'including', 'pustular', 'palmoplantar', ')', ',', 'alopecia', ',', 'lichenoid', 'skin', 'reaction', 'Vascular', 'disorder', ':', 'Systemic', 'vasculitis', ',', 'deep', 'vein', 'thrombosis', '7', 'DRUG', 'INTERACTIONS', '7.1', 'Methotrexate', 'HUMIRA', 'studied', 'rheumatoid', 'arthritis', '(', 'RA', ')', 'patient', 'taking', 'concomitant', 'methotrexate', '(', 'MTX', ')', '.'], 'stemmed': ['respiratori', 'disord', ':', 'interstiti', 'lung', 'diseas', ',', 'includ', 'pulmonari', 'fibrosi', ',', 'pulmonari', 'embol', 'skin', 'reaction', ':', 'steven', 'johnson', 'syndrom', ',', 'cutan', 'vascul', ',', 'erythema', 'multiform', ',', 'new', 'worsen', 'psoriasi', '(', 'sub-typ', 'includ', 'pustular', 'palmoplantar', ')', ',', 'alopecia', ',', 'lichenoid', 'skin', 'reaction', 'vascular', 'disord', ':', 'system', 'vascul', ',', 'deep', 'vein', 'thrombosi', '7', 'drug', 'interact', '7.1', 'methotrex', 'humira', 'studi', 'rheumatoid', 'arthriti', '(', 'ra', ')', 'patient', 'take', 'concomit', 'methotrex', '(', 'mtx', ')', '.'], 'dependencies': [('respiratori', 'compound'), ('disord', 'ROOT'), (':', 'punct'), ('interstiti', 'compound'), ('lung', 'compound'), ('diseas', 'dep'), (',', 'punct'), ('includ', 'amod'), ('pulmonari', 'compound'), ('fibrosi', 'conj'), (',', 'punct'), ('pulmonari', 'compound'), ('embol', 'compound'), ('skin', 'compound'), ('reaction', 'conj'), (':', 'punct'), ('steven', 'compound'), ('johnson', 'compound'), ('syndrom', 'nsubj'), (',', 'punct'), ('cutan', 'compound'), ('vascul', 'appos'), (',', 'punct'), ('erythema', 'compound'), ('multiform', 'conj'), (',', 'punct'), ('new', 'amod'), ('worsen', 'compound'), ('psoriasi', 'conj'), ('(', 'punct'), ('sub', 'appos'), ('-', 'amod'), ('typ', 'amod'), ('includ', 'nmod'), ('pustular', 'amod'), ('palmoplantar', 'appos'), (')', 'punct'), (',', 'punct'), ('alopecia', 'conj'), (',', 'punct'), ('lichenoid', 'compound'), ('skin', 'compound'), ('reaction', 'nmod'), ('vascular', 'amod'), ('disord', 'conj'), (':', 'punct'), ('system', 'compound'), ('vascul', 'conj'), (',', 'punct'), ('deep', 'amod'), ('vein', 'nmod'), ('thrombosi', 'nmod'), ('7', 'nummod'), ('drug', 'compound'), ('interact', 'conj'), ('7.1', 'nummod'), ('methotrex', 'compound'), ('humira', 'compound'), ('studi', 'compound'), ('rheumatoid', 'compound'), ('arthriti', 'nmod'), ('(', 'punct'), ('ra', 'nmod'), (')', 'punct'), ('patient', 'appos'), ('take', 'ROOT'), ('concomit', 'compound'), ('methotrex', 'dobj'), ('(', 'punct'), ('mtx', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Although MTX reduced the apparent adalimumab clearance, the data do \\nnot suggest the need for dose adjustment of either HUMIRA or MTX [see Clinical \\nPharmacology (12.3)].', 'tokens': ['Although', 'MTX', 'reduced', 'apparent', 'adalimumab', 'clearance', ',', 'data', 'suggest', 'need', 'dose', 'adjustment', 'either', 'HUMIRA', 'MTX', '[', 'see', 'Clinical', 'Pharmacology', '(', '12.3', ')', ']', '.'], 'lemmatized': ['Although', 'MTX', 'reduced', 'apparent', 'adalimumab', 'clearance', ',', 'data', 'suggest', 'need', 'dose', 'adjustment', 'either', 'HUMIRA', 'MTX', '[', 'see', 'Clinical', 'Pharmacology', '(', '12.3', ')', ']', '.'], 'stemmed': ['although', 'mtx', 'reduc', 'appar', 'adalimumab', 'clearanc', ',', 'data', 'suggest', 'need', 'dose', 'adjust', 'either', 'humira', 'mtx', '[', 'see', 'clinic', 'pharmacolog', '(', '12.3', ')', ']', '.'], 'dependencies': [('although', 'mark'), ('mtx', 'compound'), ('reduc', 'compound'), ('appar', 'compound'), ('adalimumab', 'compound'), ('clearanc', 'nsubj'), (',', 'punct'), ('data', 'nsubj'), ('suggest', 'parataxis'), ('need', 'compound'), ('dose', 'nsubj'), ('adjust', 'advcl'), ('either', 'preconj'), ('humira', 'compound'), ('mtx', 'dobj'), ('[', 'punct'), ('see', 'ROOT'), ('clinic', 'compound'), ('pharmacolog', 'dobj'), ('(', 'punct'), ('12.3', 'appos'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': '7.2 Biological Products  \\nIn clinical studies in patients with RA, an increased risk of serious infections has been observed \\nwith the combination of TNF blockers with anakinra or abatacept, with no added benefit; \\ntherefore, use of HUMIRA with abatacept or anakinra is not recommended in patients with RA \\n[see Warnings and Precautions (5.7, 5.11)].', 'tokens': ['7.2', 'Biological', 'Products', 'clinical', 'studies', 'patients', 'RA', ',', 'increased', 'risk', 'serious', 'infections', 'observed', 'combination', 'TNF', 'blockers', 'anakinra', 'abatacept', ',', 'added', 'benefit', ';', 'therefore', ',', 'use', 'HUMIRA', 'abatacept', 'anakinra', 'recommended', 'patients', 'RA', '[', 'see', 'Warnings', 'Precautions', '(', '5.7', ',', '5.11', ')', ']', '.'], 'lemmatized': ['7.2', 'Biological', 'Products', 'clinical', 'study', 'patient', 'RA', ',', 'increased', 'risk', 'serious', 'infection', 'observed', 'combination', 'TNF', 'blocker', 'anakinra', 'abatacept', ',', 'added', 'benefit', ';', 'therefore', ',', 'use', 'HUMIRA', 'abatacept', 'anakinra', 'recommended', 'patient', 'RA', '[', 'see', 'Warnings', 'Precautions', '(', '5.7', ',', '5.11', ')', ']', '.'], 'stemmed': ['7.2', 'biolog', 'product', 'clinic', 'studi', 'patient', 'ra', ',', 'increas', 'risk', 'seriou', 'infect', 'observ', 'combin', 'tnf', 'blocker', 'anakinra', 'abatacept', ',', 'ad', 'benefit', ';', 'therefor', ',', 'use', 'humira', 'abatacept', 'anakinra', 'recommend', 'patient', 'ra', '[', 'see', 'warn', 'precaut', '(', '5.7', ',', '5.11', ')', ']', '.'], 'dependencies': [('7.2', 'nummod'), ('biolog', 'compound'), ('product', 'compound'), ('clinic', 'compound'), ('studi', 'compound'), ('patient', 'compound'), ('ra', 'dep'), (',', 'punct'), ('increas', 'compound'), ('risk', 'compound'), ('seriou', 'compound'), ('infect', 'compound'), ('observ', 'compound'), ('combin', 'compound'), ('tnf', 'compound'), ('blocker', 'compound'), ('anakinra', 'nsubj'), ('abatacept', 'nsubj'), (',', 'punct'), ('ad', 'compound'), ('benefit', 'appos'), (';', 'punct'), ('therefor', 'appos'), (',', 'punct'), ('use', 'conj'), ('humira', 'compound'), ('abatacept', 'compound'), ('anakinra', 'xcomp'), ('recommend', 'ROOT'), ('patient', 'compound'), ('ra', 'dobj'), ('[', 'punct'), ('see', 'ROOT'), ('warn', 'xcomp'), ('precaut', 'dobj'), ('(', 'punct'), ('5.7', 'npadvmod'), (',', 'punct'), ('5.11', 'npadvmod'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': 'A higher rate of serious infections has also been \\nobserved in patients with RA treated with rituximab who received subsequent treatment with a \\nTNF blocker.', 'tokens': ['higher', 'rate', 'serious', 'infections', 'also', 'observed', 'patients', 'RA', 'treated', 'rituximab', 'received', 'subsequent', 'treatment', 'TNF', 'blocker', '.'], 'lemmatized': ['higher', 'rate', 'serious', 'infection', 'also', 'observed', 'patient', 'RA', 'treated', 'rituximab', 'received', 'subsequent', 'treatment', 'TNF', 'blocker', '.'], 'stemmed': ['higher', 'rate', 'seriou', 'infect', 'also', 'observ', 'patient', 'ra', 'treat', 'rituximab', 'receiv', 'subsequ', 'treatment', 'tnf', 'blocker', '.'], 'dependencies': [('higher', 'amod'), ('rate', 'compound'), ('seriou', 'compound'), ('infect', 'ROOT'), ('also', 'advmod'), ('observ', 'compound'), ('patient', 'compound'), ('ra', 'compound'), ('treat', 'compound'), ('rituximab', 'compound'), ('receiv', 'compound'), ('subsequ', 'compound'), ('treatment', 'compound'), ('tnf', 'compound'), ('blocker', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'There is insufficient information regarding the concomitant use of HUMIRA and \\nother biologic products for the treatment of RA, PsA, AS, CD, UC, Ps, HS and UV.', 'tokens': ['insufficient', 'information', 'regarding', 'concomitant', 'use', 'HUMIRA', 'biologic', 'products', 'treatment', 'RA', ',', 'PsA', ',', ',', 'CD', ',', 'UC', ',', 'Ps', ',', 'HS', 'UV', '.'], 'lemmatized': ['insufficient', 'information', 'regarding', 'concomitant', 'use', 'HUMIRA', 'biologic', 'product', 'treatment', 'RA', ',', 'PsA', ',', ',', 'CD', ',', 'UC', ',', 'Ps', ',', 'HS', 'UV', '.'], 'stemmed': ['insuffici', 'inform', 'regard', 'concomit', 'use', 'humira', 'biolog', 'product', 'treatment', 'ra', ',', 'psa', ',', ',', 'cd', ',', 'uc', ',', 'ps', ',', 'hs', 'uv', '.'], 'dependencies': [('insuffici', 'compound'), ('inform', 'ROOT'), ('regard', 'compound'), ('concomit', 'compound'), ('use', 'dobj'), ('humira', 'compound'), ('biolog', 'compound'), ('product', 'compound'), ('treatment', 'compound'), ('ra', 'npadvmod'), (',', 'punct'), ('psa', 'conj'), (',', 'punct'), (',', 'punct'), ('cd', 'npadvmod'), (',', 'punct'), ('uc', 'intj'), (',', 'punct'), ('ps', 'nmod'), (',', 'punct'), ('hs', 'appos'), ('uv', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Concomitant \\nadministration of HUMIRA with other biologic DMARDS (e.g., anakinra and abatacept) or other \\nTNF blockers is not recommended based upon the possible increased risk for infections and \\nother potential pharmacological interactions.', 'tokens': ['Concomitant', 'administration', 'HUMIRA', 'biologic', 'DMARDS', '(', 'e.g.', ',', 'anakinra', 'abatacept', ')', 'TNF', 'blockers', 'recommended', 'based', 'upon', 'possible', 'increased', 'risk', 'infections', 'potential', 'pharmacological', 'interactions', '.'], 'lemmatized': ['Concomitant', 'administration', 'HUMIRA', 'biologic', 'DMARDS', '(', 'e.g.', ',', 'anakinra', 'abatacept', ')', 'TNF', 'blocker', 'recommended', 'based', 'upon', 'possible', 'increased', 'risk', 'infection', 'potential', 'pharmacological', 'interaction', '.'], 'stemmed': ['concomit', 'administr', 'humira', 'biolog', 'dmard', '(', 'e.g.', ',', 'anakinra', 'abatacept', ')', 'tnf', 'blocker', 'recommend', 'base', 'upon', 'possibl', 'increas', 'risk', 'infect', 'potenti', 'pharmacolog', 'interact', '.'], 'dependencies': [('concomit', 'compound'), ('administr', 'compound'), ('humira', 'compound'), ('biolog', 'compound'), ('dmard', 'nsubj'), ('(', 'punct'), ('e.g.', 'advmod'), (',', 'punct'), ('anakinra', 'appos'), ('abatacept', 'dobj'), (')', 'punct'), ('tnf', 'compound'), ('blocker', 'nsubj'), ('recommend', 'ROOT'), ('base', 'dobj'), ('upon', 'prep'), ('possibl', 'compound'), ('increas', 'compound'), ('risk', 'pobj'), ('infect', 'advcl'), ('potenti', 'compound'), ('pharmacolog', 'compound'), ('interact', 'dobj'), ('.', 'punct')]}, {'original_sentence': '7.3 Live Vaccines \\nAvoid the use of live vaccines with HUMIRA [see Warnings and Precautions (5.10)].', 'tokens': ['7.3', 'Live', 'Vaccines', 'Avoid', 'use', 'live', 'vaccines', 'HUMIRA', '[', 'see', 'Warnings', 'Precautions', '(', '5.10', ')', ']', '.'], 'lemmatized': ['7.3', 'Live', 'Vaccines', 'Avoid', 'use', 'live', 'vaccine', 'HUMIRA', '[', 'see', 'Warnings', 'Precautions', '(', '5.10', ')', ']', '.'], 'stemmed': ['7.3', 'live', 'vaccin', 'avoid', 'use', 'live', 'vaccin', 'humira', '[', 'see', 'warn', 'precaut', '(', '5.10', ')', ']', '.'], 'dependencies': [('7.3', 'nummod'), ('live', 'amod'), ('vaccin', 'nsubj'), ('avoid', 'amod'), ('use', 'dobj'), ('live', 'advmod'), ('vaccin', 'compound'), ('humira', 'nsubj'), ('[', 'punct'), ('see', 'ROOT'), ('warn', 'xcomp'), ('precaut', 'dobj'), ('(', 'punct'), ('5.10', 'npadvmod'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': '7.4 Cytochrome P450 Substrates \\nThe formation of CYP450 enzymes may be suppressed by increased concentrations of cytokines \\n(e.g., TNFα, IL-6) during chronic inflammation.', 'tokens': ['7.4', 'Cytochrome', 'P450', 'Substrates', 'formation', 'CYP450', 'enzymes', 'may', 'suppressed', 'increased', 'concentrations', 'cytokines', '(', 'e.g.', ',', 'TNFα', ',', 'IL-6', ')', 'chronic', 'inflammation', '.'], 'lemmatized': ['7.4', 'Cytochrome', 'P450', 'Substrates', 'formation', 'CYP450', 'enzyme', 'may', 'suppressed', 'increased', 'concentration', 'cytokine', '(', 'e.g.', ',', 'TNFα', ',', 'IL-6', ')', 'chronic', 'inflammation', '.'], 'stemmed': ['7.4', 'cytochrom', 'p450', 'substrat', 'format', 'cyp450', 'enzym', 'may', 'suppress', 'increas', 'concentr', 'cytokin', '(', 'e.g.', ',', 'tnfα', ',', 'il-6', ')', 'chronic', 'inflamm', '.'], 'dependencies': [('7.4', 'nummod'), ('cytochrom', 'nsubj'), ('p450', 'compound'), ('substrat', 'amod'), ('format', 'compound'), ('cyp450', 'nsubj'), ('enzym', 'relcl'), ('may', 'aux'), ('suppress', 'ROOT'), ('increas', 'compound'), ('concentr', 'compound'), ('cytokin', 'dobj'), ('(', 'punct'), ('e.g.', 'meta'), (',', 'punct'), ('tnfα', 'npadvmod'), (',', 'punct'), ('il-6', 'conj'), (')', 'punct'), ('chronic', 'amod'), ('inflamm', 'appos'), ('.', 'punct')]}, {'original_sentence': 'It is possible for a molecule that antagonizes \\ncytokine activity, such as adalimumab, to influence the formation of CYP450 enzymes.', 'tokens': ['possible', 'molecule', 'antagonizes', 'cytokine', 'activity', ',', 'adalimumab', ',', 'influence', 'formation', 'CYP450', 'enzymes', '.'], 'lemmatized': ['possible', 'molecule', 'antagonizes', 'cytokine', 'activity', ',', 'adalimumab', ',', 'influence', 'formation', 'CYP450', 'enzyme', '.'], 'stemmed': ['possibl', 'molecul', 'antagon', 'cytokin', 'activ', ',', 'adalimumab', ',', 'influenc', 'format', 'cyp450', 'enzym', '.'], 'dependencies': [('possibl', 'compound'), ('molecul', 'compound'), ('antagon', 'compound'), ('cytokin', 'compound'), ('activ', 'nsubj'), (',', 'punct'), ('adalimumab', 'conj'), (',', 'punct'), ('influenc', 'amod'), ('format', 'conj'), ('cyp450', 'nsubj'), ('enzym', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Upon \\ninitiation or discontinuation of HUMIRA in patients being treated with CYP450 substrates with a \\nnarrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., \\ncyclosporine or theophylline) is recommended and the individual dose of the drug product may \\nbe adjusted as needed.', 'tokens': ['Upon', 'initiation', 'discontinuation', 'HUMIRA', 'patients', 'treated', 'CYP450', 'substrates', 'narrow', 'therapeutic', 'index', ',', 'monitoring', 'effect', '(', 'e.g.', ',', 'warfarin', ')', 'drug', 'concentration', '(', 'e.g.', ',', 'cyclosporine', 'theophylline', ')', 'recommended', 'individual', 'dose', 'drug', 'product', 'may', 'adjusted', 'needed', '.'], 'lemmatized': ['Upon', 'initiation', 'discontinuation', 'HUMIRA', 'patient', 'treated', 'CYP450', 'substrate', 'narrow', 'therapeutic', 'index', ',', 'monitoring', 'effect', '(', 'e.g.', ',', 'warfarin', ')', 'drug', 'concentration', '(', 'e.g.', ',', 'cyclosporine', 'theophylline', ')', 'recommended', 'individual', 'dose', 'drug', 'product', 'may', 'adjusted', 'needed', '.'], 'stemmed': ['upon', 'initi', 'discontinu', 'humira', 'patient', 'treat', 'cyp450', 'substrat', 'narrow', 'therapeut', 'index', ',', 'monitor', 'effect', '(', 'e.g.', ',', 'warfarin', ')', 'drug', 'concentr', '(', 'e.g.', ',', 'cyclosporin', 'theophyllin', ')', 'recommend', 'individu', 'dose', 'drug', 'product', 'may', 'adjust', 'need', '.'], 'dependencies': [('upon', 'prep'), ('initi', 'pobj'), ('discontinu', 'compound'), ('humira', 'compound'), ('patient', 'compound'), ('treat', 'compound'), ('cyp450', 'nmod'), ('substrat', 'compound'), ('narrow', 'amod'), ('therapeut', 'compound'), ('index', 'dobj'), (',', 'punct'), ('monitor', 'meta'), ('effect', 'dobj'), ('(', 'punct'), ('e.g.', 'advmod'), (',', 'punct'), ('warfarin', 'npadvmod'), (')', 'punct'), ('drug', 'compound'), ('concentr', 'nsubj'), ('(', 'punct'), ('e.g.', 'advmod'), (',', 'punct'), ('cyclosporin', 'compound'), ('theophyllin', 'appos'), (')', 'punct'), ('recommend', 'ROOT'), ('individu', 'compound'), ('dose', 'compound'), ('drug', 'compound'), ('product', 'nsubj'), ('may', 'aux'), ('adjust', 'ccomp'), ('need', 'dobj'), ('.', 'punct')]}], 'text': 'Respiratory disorders: Interstitial lung disease, including pulmonary fibrosis, pulmonary \\nembolism  \\nSkin reactions: Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, new or \\nworsening psoriasis (all sub-types including pustular and palmoplantar), alopecia, lichenoid skin \\nreaction  \\nVascular disorders: Systemic vasculitis, deep vein thrombosis  \\n7 DRUG INTERACTIONS \\n7.1 Methotrexate \\nHUMIRA has been studied in rheumatoid arthritis (RA) patients taking concomitant \\nmethotrexate (MTX). Although MTX reduced the apparent adalimumab clearance, the data do \\nnot suggest the need for dose adjustment of either HUMIRA or MTX [see Clinical \\nPharmacology (12.3)].  \\n7.2 Biological Products  \\nIn clinical studies in patients with RA, an increased risk of serious infections has been observed \\nwith the combination of TNF blockers with anakinra or abatacept, with no added benefit; \\ntherefore, use of HUMIRA with abatacept or anakinra is not recommended in patients with RA \\n[see Warnings and Precautions (5.7, 5.11)]. A higher rate of serious infections has also been \\nobserved in patients with RA treated with rituximab who received subsequent treatment with a \\nTNF blocker. There is insufficient information regarding the concomitant use of HUMIRA and \\nother biologic products for the treatment of RA, PsA, AS, CD, UC, Ps, HS and UV. Concomitant \\nadministration of HUMIRA with other biologic DMARDS (e.g., anakinra and abatacept) or other \\nTNF blockers is not recommended based upon the possible increased risk for infections and \\nother potential pharmacological interactions.  \\n7.3 Live Vaccines \\nAvoid the use of live vaccines with HUMIRA [see Warnings and Precautions (5.10)].  \\n7.4 Cytochrome P450 Substrates \\nThe formation of CYP450 enzymes may be suppressed by increased concentrations of cytokines \\n(e.g., TNFα, IL-6) during chronic inflammation. It is possible for a molecule that antagonizes \\ncytokine activity, such as adalimumab, to influence the formation of CYP450 enzymes. Upon \\ninitiation or discontinuation of HUMIRA in patients being treated with CYP450 substrates with a \\nnarrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., \\ncyclosporine or theophylline) is recommended and the individual dose of the drug product may \\nbe adjusted as needed.  \\n'}, 'page_char_count': 2325, 'page_word_count': 327, 'sentences': ['Respiratory disorders: Interstitial lung disease, including pulmonary fibrosis, pulmonary \\nembolism  \\nSkin reactions: Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, new or \\nworsening psoriasis (all sub-types including pustular and palmoplantar), alopecia, lichenoid skin \\nreaction  \\nVascular disorders: Systemic vasculitis, deep vein thrombosis  \\n7 DRUG INTERACTIONS \\n7.1 Methotrexate \\nHUMIRA has been studied in rheumatoid arthritis (RA) patients taking concomitant \\nmethotrexate (MTX).', 'Although MTX reduced the apparent adalimumab clearance, the data do \\nnot suggest the need for dose adjustment of either HUMIRA or MTX [see Clinical \\nPharmacology (12.3)].', ' \\n7.2 Biological Products  \\nIn clinical studies in patients with RA, an increased risk of serious infections has been observed \\nwith the combination of TNF blockers with anakinra or abatacept, with no added benefit; \\ntherefore, use of HUMIRA with abatacept or anakinra is not recommended in patients with RA \\n[see Warnings and Precautions (5.7, 5.11)].', 'A higher rate of serious infections has also been \\nobserved in patients with RA treated with rituximab who received subsequent treatment with a \\nTNF blocker.', 'There is insufficient information regarding the concomitant use of HUMIRA and \\nother biologic products for the treatment of RA, PsA, AS, CD, UC, Ps, HS and UV.', 'Concomitant \\nadministration of HUMIRA with other biologic DMARDS (e.g., anakinra and abatacept) or other \\nTNF blockers is not recommended based upon the possible increased risk for infections and \\nother potential pharmacological interactions.', ' \\n7.3 Live Vaccines \\nAvoid the use of live vaccines with HUMIRA [see Warnings and Precautions (5.10)].', ' \\n7.4 Cytochrome P450 Substrates \\nThe formation of CYP450 enzymes may be suppressed by increased concentrations of cytokines \\n(e.g., TNFα, IL-6) during chronic inflammation.', 'It is possible for a molecule that antagonizes \\ncytokine activity, such as adalimumab, to influence the formation of CYP450 enzymes.', 'Upon \\ninitiation or discontinuation of HUMIRA in patients being treated with CYP450 substrates with a \\nnarrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., \\ncyclosporine or theophylline) is recommended and the individual dose of the drug product may \\nbe adjusted as needed.', ' \\n'], 'page_sentence_count_spacy': 11}\n",
            "{'page_number': 24, 'text': '8 USE IN SPECIFIC POPULATIONS \\n8.1 Pregnancy \\nRisk Summary \\nAvailable studies with use of adalimumab during pregnancy do not reliably establish an \\nassociation between adalimumab and major birth defects. Clinical data are available from the \\nOrganization of Teratology Information Specialists (OTIS)/MotherToBaby HUMIRA Pregnancy \\nRegistry in pregnant women with rheumatoid arthritis (RA) or Crohn’s disease (CD). Registry \\nresults showed a rate of 10% for major birth defects with first trimester use of adalimumab in \\npregnant women with RA or CD and a rate of 7.5% for major birth defects in the disease-\\nmatched comparison cohort. The lack of pattern of major birth defects is reassuring and \\ndifferences between exposure groups may have impacted the occurrence of birth defects (see \\nData).  \\nAdalimumab is actively transferred across the placenta during the third trimester of pregnancy \\nand may affect immune response in the in-utero exposed infant (see Clinical Considerations). In \\nan embryo-fetal perinatal development study conducted in cynomolgus monkeys, no fetal harm \\nor malformations were observed with intravenous administration of adalimumab during \\norganogenesis and later in gestation, at doses that produced exposures up to approximately 373 \\ntimes the maximum recommended human dose (MRHD) of 40 mg subcutaneous without \\nmethotrexate (see Data).  \\nThe estimated background risk of major birth defects and miscarriage for the indicated \\npopulations is unknown. All pregnancies have a background risk of birth defect, loss, or other \\nadverse outcomes. In the U.S. general population, the estimated background risk of major birth \\ndefects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.  \\nClinical Considerations \\nDisease-associated maternal and embryo/fetal risk \\nPublished data suggest that the risk of adverse pregnancy outcomes in women with RA or \\ninflammatory bowel disease (IBD) is associated with increased disease activity. Adverse \\npregnancy outcomes include preterm delivery (before 37 weeks of gestation), low birth weight \\n(less than 2500 g) infants, and small for gestational age at birth.  \\nFetal/Neonatal Adverse Reactions \\nMonoclonal antibodies are increasingly transported across the placenta as pregnancy progresses, \\nwith the largest amount transferred during the third trimester (see Data). Risks and benefits \\nshould be considered prior to administering live or live-attenuated vaccines to infants exposed to \\nHUMIRA in utero [see Use in Specific Populations (8.4)].  \\nData \\nHuman Data \\nA prospective cohort pregnancy exposure registry conducted by OTIS/MotherToBaby in the \\nU.S. and Canada between 2004 and 2016 compared the risk of major birth defects in live-born \\n', 'processed_text': {'sentences': [{'original_sentence': '8 USE IN SPECIFIC POPULATIONS \\n8.1 Pregnancy \\nRisk Summary \\nAvailable studies with use of adalimumab during pregnancy do not reliably establish an \\nassociation between adalimumab and major birth defects.', 'tokens': ['8', 'USE', 'SPECIFIC', 'POPULATIONS', '8.1', 'Pregnancy', 'Risk', 'Summary', 'Available', 'studies', 'use', 'adalimumab', 'pregnancy', 'reliably', 'establish', 'association', 'adalimumab', 'major', 'birth', 'defects', '.'], 'lemmatized': ['8', 'USE', 'SPECIFIC', 'POPULATIONS', '8.1', 'Pregnancy', 'Risk', 'Summary', 'Available', 'study', 'use', 'adalimumab', 'pregnancy', 'reliably', 'establish', 'association', 'adalimumab', 'major', 'birth', 'defect', '.'], 'stemmed': ['8', 'use', 'specif', 'popul', '8.1', 'pregnanc', 'risk', 'summari', 'avail', 'studi', 'use', 'adalimumab', 'pregnanc', 'reliabl', 'establish', 'associ', 'adalimumab', 'major', 'birth', 'defect', '.'], 'dependencies': [('8', 'nummod'), ('use', 'nsubj'), ('specif', 'compound'), ('popul', 'dobj'), ('8.1', 'nummod'), ('pregnanc', 'compound'), ('risk', 'compound'), ('summari', 'compound'), ('avail', 'compound'), ('studi', 'nsubj'), ('use', 'ROOT'), ('adalimumab', 'compound'), ('pregnanc', 'compound'), ('reliabl', 'amod'), ('establish', 'compound'), ('associ', 'compound'), ('adalimumab', 'nmod'), ('major', 'amod'), ('birth', 'compound'), ('defect', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Clinical data are available from the \\nOrganization of Teratology Information Specialists (OTIS)/MotherToBaby HUMIRA Pregnancy \\nRegistry in pregnant women with rheumatoid arthritis (RA) or Crohn’s disease (CD).', 'tokens': ['Clinical', 'data', 'available', 'Organization', 'Teratology', 'Information', 'Specialists', '(', 'OTIS', ')', '/MotherToBaby', 'HUMIRA', 'Pregnancy', 'Registry', 'pregnant', 'women', 'rheumatoid', 'arthritis', '(', 'RA', ')', 'Crohn', '’', 'disease', '(', 'CD', ')', '.'], 'lemmatized': ['Clinical', 'data', 'available', 'Organization', 'Teratology', 'Information', 'Specialists', '(', 'OTIS', ')', '/MotherToBaby', 'HUMIRA', 'Pregnancy', 'Registry', 'pregnant', 'woman', 'rheumatoid', 'arthritis', '(', 'RA', ')', 'Crohn', '’', 'disease', '(', 'CD', ')', '.'], 'stemmed': ['clinic', 'data', 'avail', 'organ', 'teratolog', 'inform', 'specialist', '(', 'oti', ')', '/mothertobabi', 'humira', 'pregnanc', 'registri', 'pregnant', 'woman', 'rheumatoid', 'arthriti', '(', 'ra', ')', 'crohn', '’', 'diseas', '(', 'cd', ')', '.'], 'dependencies': [('clinic', 'compound'), ('data', 'compound'), ('avail', 'compound'), ('organ', 'compound'), ('teratolog', 'compound'), ('inform', 'ROOT'), ('specialist', 'dobj'), ('(', 'punct'), ('oti', 'appos'), (')', 'punct'), ('/mothertobabi', 'punct'), ('humira', 'compound'), ('pregnanc', 'nsubj'), ('registri', 'amod'), ('pregnant', 'amod'), ('woman', 'nsubj'), ('rheumatoid', 'compound'), ('arthriti', 'appos'), ('(', 'punct'), ('ra', 'appos'), (')', 'punct'), ('crohn', 'ROOT'), ('’', 'punct'), ('diseas', 'dobj'), ('(', 'punct'), ('cd', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Registry \\nresults showed a rate of 10% for major birth defects with first trimester use of adalimumab in \\npregnant women with RA or CD and a rate of 7.5% for major birth defects in the disease-\\nmatched comparison cohort.', 'tokens': ['Registry', 'results', 'showed', 'rate', '10', '%', 'major', 'birth', 'defects', 'first', 'trimester', 'use', 'adalimumab', 'pregnant', 'women', 'RA', 'CD', 'rate', '7.5', '%', 'major', 'birth', 'defects', 'disease-', 'matched', 'comparison', 'cohort', '.'], 'lemmatized': ['Registry', 'result', 'showed', 'rate', '10', '%', 'major', 'birth', 'defect', 'first', 'trimester', 'use', 'adalimumab', 'pregnant', 'woman', 'RA', 'CD', 'rate', '7.5', '%', 'major', 'birth', 'defect', 'disease-', 'matched', 'comparison', 'cohort', '.'], 'stemmed': ['registri', 'result', 'show', 'rate', '10', '%', 'major', 'birth', 'defect', 'first', 'trimest', 'use', 'adalimumab', 'pregnant', 'woman', 'ra', 'cd', 'rate', '7.5', '%', 'major', 'birth', 'defect', 'disease-', 'match', 'comparison', 'cohort', '.'], 'dependencies': [('registri', 'amod'), ('result', 'compound'), ('show', 'compound'), ('rate', 'nsubj'), ('10', 'nummod'), ('%', 'npadvmod'), ('major', 'amod'), ('birth', 'nsubj'), ('defect', 'ROOT'), ('first', 'amod'), ('trimest', 'amod'), ('use', 'compound'), ('adalimumab', 'nmod'), ('pregnant', 'amod'), ('woman', 'dobj'), ('ra', 'compound'), ('cd', 'appos'), ('rate', 'conj'), ('7.5', 'nummod'), ('%', 'npadvmod'), ('major', 'amod'), ('birth', 'nsubj'), ('defect', 'amod'), ('disease-', 'dobj'), ('match', 'compound'), ('comparison', 'compound'), ('cohort', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The lack of pattern of major birth defects is reassuring and \\ndifferences between exposure groups may have impacted the occurrence of birth defects (see \\nData).', 'tokens': ['lack', 'pattern', 'major', 'birth', 'defects', 'reassuring', 'differences', 'exposure', 'groups', 'may', 'impacted', 'occurrence', 'birth', 'defects', '(', 'see', 'Data', ')', '.'], 'lemmatized': ['lack', 'pattern', 'major', 'birth', 'defect', 'reassuring', 'difference', 'exposure', 'group', 'may', 'impacted', 'occurrence', 'birth', 'defect', '(', 'see', 'Data', ')', '.'], 'stemmed': ['lack', 'pattern', 'major', 'birth', 'defect', 'reassur', 'differ', 'exposur', 'group', 'may', 'impact', 'occurr', 'birth', 'defect', '(', 'see', 'data', ')', '.'], 'dependencies': [('lack', 'compound'), ('pattern', 'nsubj'), ('major', 'amod'), ('birth', 'compound'), ('defect', 'compound'), ('reassur', 'appos'), ('differ', 'ROOT'), ('exposur', 'compound'), ('group', 'nsubj'), ('may', 'aux'), ('impact', 'ccomp'), ('occurr', 'compound'), ('birth', 'compound'), ('defect', 'dobj'), ('(', 'punct'), ('see', 'parataxis'), ('data', 'dobj'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Adalimumab is actively transferred across the placenta during the third trimester of pregnancy \\nand may affect immune response in the in-utero exposed infant (see Clinical Considerations).', 'tokens': ['Adalimumab', 'actively', 'transferred', 'across', 'placenta', 'third', 'trimester', 'pregnancy', 'may', 'affect', 'immune', 'response', 'in-utero', 'exposed', 'infant', '(', 'see', 'Clinical', 'Considerations', ')', '.'], 'lemmatized': ['Adalimumab', 'actively', 'transferred', 'across', 'placenta', 'third', 'trimester', 'pregnancy', 'may', 'affect', 'immune', 'response', 'in-utero', 'exposed', 'infant', '(', 'see', 'Clinical', 'Considerations', ')', '.'], 'stemmed': ['adalimumab', 'activ', 'transfer', 'across', 'placenta', 'third', 'trimest', 'pregnanc', 'may', 'affect', 'immun', 'respons', 'in-utero', 'expos', 'infant', '(', 'see', 'clinic', 'consider', ')', '.'], 'dependencies': [('adalimumab', 'amod'), ('activ', 'compound'), ('transfer', 'nsubj'), ('across', 'prep'), ('placenta', 'nmod'), ('third', 'amod'), ('trimest', 'compound'), ('pregnanc', 'pobj'), ('may', 'aux'), ('affect', 'ROOT'), ('immun', 'amod'), ('respons', 'dobj'), ('in', 'nmod'), ('-', 'punct'), ('utero', 'pobj'), ('expos', 'compound'), ('infant', 'dobj'), ('(', 'punct'), ('see', 'parataxis'), ('clinic', 'nsubj'), ('consider', 'ccomp'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'In \\nan embryo-fetal perinatal development study conducted in cynomolgus monkeys, no fetal harm \\nor malformations were observed with intravenous administration of adalimumab during \\norganogenesis and later in gestation, at doses that produced exposures up to approximately 373 \\ntimes the maximum recommended human dose (MRHD) of 40 mg subcutaneous without \\nmethotrexate (see Data).', 'tokens': ['embryo-fetal', 'perinatal', 'development', 'study', 'conducted', 'cynomolgus', 'monkeys', ',', 'fetal', 'harm', 'malformations', 'observed', 'intravenous', 'administration', 'adalimumab', 'organogenesis', 'later', 'gestation', ',', 'doses', 'produced', 'exposures', 'approximately', '373', 'times', 'maximum', 'recommended', 'human', 'dose', '(', 'MRHD', ')', '40', 'mg', 'subcutaneous', 'without', 'methotrexate', '(', 'see', 'Data', ')', '.'], 'lemmatized': ['embryo-fetal', 'perinatal', 'development', 'study', 'conducted', 'cynomolgus', 'monkey', ',', 'fetal', 'harm', 'malformation', 'observed', 'intravenous', 'administration', 'adalimumab', 'organogenesis', 'later', 'gestation', ',', 'dos', 'produced', 'exposure', 'approximately', '373', 'time', 'maximum', 'recommended', 'human', 'dose', '(', 'MRHD', ')', '40', 'mg', 'subcutaneous', 'without', 'methotrexate', '(', 'see', 'Data', ')', '.'], 'stemmed': ['embryo-fet', 'perinat', 'develop', 'studi', 'conduct', 'cynomolgu', 'monkey', ',', 'fetal', 'harm', 'malform', 'observ', 'intraven', 'administr', 'adalimumab', 'organogenesi', 'later', 'gestat', ',', 'do', 'produc', 'exposur', 'approxim', '373', 'time', 'maximum', 'recommend', 'human', 'dose', '(', 'mrhd', ')', '40', 'mg', 'subcutan', 'without', 'methotrex', '(', 'see', 'data', ')', '.'], 'dependencies': [('embryo', 'compound'), ('-', 'punct'), ('fet', 'amod'), ('perinat', 'nsubj'), ('develop', 'ROOT'), ('studi', 'amod'), ('conduct', 'compound'), ('cynomolgu', 'compound'), ('monkey', 'dobj'), (',', 'punct'), ('fetal', 'amod'), ('harm', 'compound'), ('malform', 'compound'), ('observ', 'compound'), ('intraven', 'compound'), ('administr', 'compound'), ('adalimumab', 'compound'), ('organogenesi', 'nsubj'), ('later', 'advmod'), ('gestat', 'conj'), (',', 'punct'), ('do', 'aux'), ('produc', 'compound'), ('exposur', 'nsubj'), ('approxim', 'conj'), ('373', 'nummod'), ('time', 'npadvmod'), ('maximum', 'nsubj'), ('recommend', 'compound'), ('human', 'compound'), ('dose', 'dobj'), ('(', 'punct'), ('mrhd', 'appos'), (')', 'punct'), ('40', 'nummod'), ('mg', 'npadvmod'), ('subcutan', 'ROOT'), ('without', 'prep'), ('methotrex', 'pobj'), ('(', 'punct'), ('see', 'parataxis'), ('data', 'dobj'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'The estimated background risk of major birth defects and miscarriage for the indicated \\npopulations is unknown.', 'tokens': ['estimated', 'background', 'risk', 'major', 'birth', 'defects', 'miscarriage', 'indicated', 'populations', 'unknown', '.'], 'lemmatized': ['estimated', 'background', 'risk', 'major', 'birth', 'defect', 'miscarriage', 'indicated', 'population', 'unknown', '.'], 'stemmed': ['estim', 'background', 'risk', 'major', 'birth', 'defect', 'miscarriag', 'indic', 'popul', 'unknown', '.'], 'dependencies': [('estim', 'compound'), ('background', 'compound'), ('risk', 'ROOT'), ('major', 'amod'), ('birth', 'nsubj'), ('defect', 'appos'), ('miscarriag', 'nmod'), ('indic', 'amod'), ('popul', 'dobj'), ('unknown', 'amod'), ('.', 'punct')]}, {'original_sentence': 'All pregnancies have a background risk of birth defect, loss, or other \\nadverse outcomes.', 'tokens': ['pregnancies', 'background', 'risk', 'birth', 'defect', ',', 'loss', ',', 'adverse', 'outcomes', '.'], 'lemmatized': ['pregnancy', 'background', 'risk', 'birth', 'defect', ',', 'loss', ',', 'adverse', 'outcome', '.'], 'stemmed': ['pregnanc', 'background', 'risk', 'birth', 'defect', ',', 'loss', ',', 'advers', 'outcom', '.'], 'dependencies': [('pregnanc', 'compound'), ('background', 'compound'), ('risk', 'compound'), ('birth', 'compound'), ('defect', 'ROOT'), (',', 'punct'), ('loss', 'nmod'), (',', 'punct'), ('advers', 'compound'), ('outcom', 'appos'), ('.', 'punct')]}, {'original_sentence': 'In the U.S. general population, the estimated background risk of major birth \\ndefects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.', 'tokens': ['U.S.', 'general', 'population', ',', 'estimated', 'background', 'risk', 'major', 'birth', 'defects', 'miscarriage', 'clinically', 'recognized', 'pregnancies', '2-4', '%', '15-20', '%', ',', 'respectively', '.'], 'lemmatized': ['U.S.', 'general', 'population', ',', 'estimated', 'background', 'risk', 'major', 'birth', 'defect', 'miscarriage', 'clinically', 'recognized', 'pregnancy', '2-4', '%', '15-20', '%', ',', 'respectively', '.'], 'stemmed': ['u.s.', 'gener', 'popul', ',', 'estim', 'background', 'risk', 'major', 'birth', 'defect', 'miscarriag', 'clinic', 'recogn', 'pregnanc', '2-4', '%', '15-20', '%', ',', 'respect', '.'], 'dependencies': [('u.s', 'compound'), ('.', 'compound'), ('gener', 'compound'), ('popul', 'nsubj'), (',', 'punct'), ('estim', 'compound'), ('background', 'compound'), ('risk', 'nmod'), ('major', 'amod'), ('birth', 'compound'), ('defect', 'compound'), ('miscarriag', 'compound'), ('clinic', 'appos'), ('recogn', 'ROOT'), ('pregnanc', 'npadvmod'), ('2', 'npadvmod'), ('-', 'punct'), ('4', 'nummod'), ('%', 'prep'), ('15', 'nummod'), ('-', 'punct'), ('20', 'nummod'), ('%', 'appos'), (',', 'punct'), ('respect', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Clinical Considerations \\nDisease-associated maternal and embryo/fetal risk \\nPublished data suggest that the risk of adverse pregnancy outcomes in women with RA or \\ninflammatory bowel disease (IBD) is associated with increased disease activity.', 'tokens': ['Clinical', 'Considerations', 'Disease-associated', 'maternal', 'embryo/fetal', 'risk', 'Published', 'data', 'suggest', 'risk', 'adverse', 'pregnancy', 'outcomes', 'women', 'RA', 'inflammatory', 'bowel', 'disease', '(', 'IBD', ')', 'associated', 'increased', 'disease', 'activity', '.'], 'lemmatized': ['Clinical', 'Considerations', 'Disease-associated', 'maternal', 'embryo/fetal', 'risk', 'Published', 'data', 'suggest', 'risk', 'adverse', 'pregnancy', 'outcome', 'woman', 'RA', 'inflammatory', 'bowel', 'disease', '(', 'IBD', ')', 'associated', 'increased', 'disease', 'activity', '.'], 'stemmed': ['clinic', 'consider', 'disease-associ', 'matern', 'embryo/fet', 'risk', 'publish', 'data', 'suggest', 'risk', 'advers', 'pregnanc', 'outcom', 'woman', 'ra', 'inflammatori', 'bowel', 'diseas', '(', 'ibd', ')', 'associ', 'increas', 'diseas', 'activ', '.'], 'dependencies': [('clinic', 'nsubj'), ('consider', 'ROOT'), ('disease', 'compound'), ('-', 'punct'), ('associ', 'compound'), ('matern', 'nmod'), ('embryo', 'nsubj'), ('/', 'punct'), ('fet', 'amod'), ('risk', 'compound'), ('publish', 'compound'), ('data', 'nsubj'), ('suggest', 'ccomp'), ('risk', 'compound'), ('advers', 'compound'), ('pregnanc', 'compound'), ('outcom', 'compound'), ('woman', 'compound'), ('ra', 'nsubj'), ('inflammatori', 'ccomp'), ('bowel', 'compound'), ('diseas', 'dobj'), ('(', 'punct'), ('ibd', 'appos'), (')', 'punct'), ('associ', 'nsubj'), ('increas', 'ROOT'), ('diseas', 'compound'), ('activ', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Adverse \\npregnancy outcomes include preterm delivery (before 37 weeks of gestation), low birth weight \\n(less than 2500 g) infants, and small for gestational age at birth.', 'tokens': ['Adverse', 'pregnancy', 'outcomes', 'include', 'preterm', 'delivery', '(', '37', 'weeks', 'gestation', ')', ',', 'low', 'birth', 'weight', '(', 'less', '2500', 'g', ')', 'infants', ',', 'small', 'gestational', 'age', 'birth', '.'], 'lemmatized': ['Adverse', 'pregnancy', 'outcome', 'include', 'preterm', 'delivery', '(', '37', 'week', 'gestation', ')', ',', 'low', 'birth', 'weight', '(', 'less', '2500', 'g', ')', 'infant', ',', 'small', 'gestational', 'age', 'birth', '.'], 'stemmed': ['advers', 'pregnanc', 'outcom', 'includ', 'preterm', 'deliveri', '(', '37', 'week', 'gestat', ')', ',', 'low', 'birth', 'weight', '(', 'less', '2500', 'g', ')', 'infant', ',', 'small', 'gestat', 'age', 'birth', '.'], 'dependencies': [('advers', 'compound'), ('pregnanc', 'compound'), ('outcom', 'compound'), ('includ', 'compound'), ('preterm', 'compound'), ('deliveri', 'ROOT'), ('(', 'punct'), ('37', 'nummod'), ('week', 'compound'), ('gestat', 'parataxis'), (')', 'punct'), (',', 'punct'), ('low', 'amod'), ('birth', 'compound'), ('weight', 'nmod'), ('(', 'punct'), ('less', 'amod'), ('2500', 'nummod'), ('g', 'nmod'), (')', 'punct'), ('infant', 'nmod'), (',', 'punct'), ('small', 'amod'), ('gestat', 'compound'), ('age', 'compound'), ('birth', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Fetal/Neonatal Adverse Reactions \\nMonoclonal antibodies are increasingly transported across the placenta as pregnancy progresses, \\nwith the largest amount transferred during the third trimester (see Data).', 'tokens': ['Fetal/Neonatal', 'Adverse', 'Reactions', 'Monoclonal', 'antibodies', 'increasingly', 'transported', 'across', 'placenta', 'pregnancy', 'progresses', ',', 'largest', 'amount', 'transferred', 'third', 'trimester', '(', 'see', 'Data', ')', '.'], 'lemmatized': ['Fetal/Neonatal', 'Adverse', 'Reactions', 'Monoclonal', 'antibody', 'increasingly', 'transported', 'across', 'placenta', 'pregnancy', 'progress', ',', 'largest', 'amount', 'transferred', 'third', 'trimester', '(', 'see', 'Data', ')', '.'], 'stemmed': ['fetal/neonat', 'advers', 'reaction', 'monoclon', 'antibodi', 'increasingli', 'transport', 'across', 'placenta', 'pregnanc', 'progress', ',', 'largest', 'amount', 'transfer', 'third', 'trimest', '(', 'see', 'data', ')', '.'], 'dependencies': [('fetal', 'amod'), ('/', 'punct'), ('neonat', 'amod'), ('advers', 'compound'), ('reaction', 'compound'), ('monoclon', 'compound'), ('antibodi', 'compound'), ('increasingli', 'compound'), ('transport', 'ROOT'), ('across', 'prep'), ('placenta', 'compound'), ('pregnanc', 'compound'), ('progress', 'pobj'), (',', 'punct'), ('largest', 'amod'), ('amount', 'nmod'), ('transfer', 'nmod'), ('third', 'amod'), ('trimest', 'conj'), ('(', 'punct'), ('see', 'parataxis'), ('data', 'dobj'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Risks and benefits \\nshould be considered prior to administering live or live-attenuated vaccines to infants exposed to \\nHUMIRA in utero [see Use in Specific Populations (8.4)].', 'tokens': ['Risks', 'benefits', 'considered', 'prior', 'administering', 'live', 'live-attenuated', 'vaccines', 'infants', 'exposed', 'HUMIRA', 'utero', '[', 'see', 'Use', 'Specific', 'Populations', '(', '8.4', ')', ']', '.'], 'lemmatized': ['Risks', 'benefit', 'considered', 'prior', 'administering', 'live', 'live-attenuated', 'vaccine', 'infant', 'exposed', 'HUMIRA', 'utero', '[', 'see', 'Use', 'Specific', 'Populations', '(', '8.4', ')', ']', '.'], 'stemmed': ['risk', 'benefit', 'consid', 'prior', 'administ', 'live', 'live-attenu', 'vaccin', 'infant', 'expos', 'humira', 'utero', '[', 'see', 'use', 'specif', 'popul', '(', '8.4', ')', ']', '.'], 'dependencies': [('risk', 'compound'), ('benefit', 'ROOT'), ('consid', 'advmod'), ('prior', 'advmod'), ('administ', 'amod'), ('live', 'amod'), ('live', 'amod'), ('-', 'punct'), ('attenu', 'nmod'), ('vaccin', 'dep'), ('infant', 'compound'), ('expos', 'compound'), ('humira', 'compound'), ('utero', 'appos'), ('[', 'punct'), ('see', 'ROOT'), ('use', 'dobj'), ('specif', 'compound'), ('popul', 'dobj'), ('(', 'punct'), ('8.4', 'appos'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Data \\nHuman Data \\nA prospective cohort pregnancy exposure registry conducted by OTIS/MotherToBaby in the \\nU.S. and Canada between 2004 and 2016 compared the risk of major birth defects in live-born', 'tokens': ['Data', 'Human', 'Data', 'prospective', 'cohort', 'pregnancy', 'exposure', 'registry', 'conducted', 'OTIS/MotherToBaby', 'U.S.', 'Canada', '2004', '2016', 'compared', 'risk', 'major', 'birth', 'defects', 'live-born'], 'lemmatized': ['Data', 'Human', 'Data', 'prospective', 'cohort', 'pregnancy', 'exposure', 'registry', 'conducted', 'OTIS/MotherToBaby', 'U.S.', 'Canada', '2004', '2016', 'compared', 'risk', 'major', 'birth', 'defect', 'live-born'], 'stemmed': ['data', 'human', 'data', 'prospect', 'cohort', 'pregnanc', 'exposur', 'registri', 'conduct', 'otis/mothertobabi', 'u.s.', 'canada', '2004', '2016', 'compar', 'risk', 'major', 'birth', 'defect', 'live-born'], 'dependencies': [('data', 'compound'), ('human', 'amod'), ('data', 'compound'), ('prospect', 'compound'), ('cohort', 'compound'), ('pregnanc', 'compound'), ('exposur', 'nsubj'), ('registri', 'amod'), ('conduct', 'compound'), ('otis', 'nmod'), ('/', 'punct'), ('mothertobabi', 'nmod'), ('u.s', 'compound'), ('.', 'compound'), ('canada', 'nmod'), ('2004', 'nummod'), ('2016', 'nummod'), ('compar', 'compound'), ('risk', 'nsubj'), ('major', 'amod'), ('birth', 'appos'), ('defect', 'ROOT'), ('live', 'advmod'), ('-', 'punct'), ('born', 'advcl')]}], 'text': '8 USE IN SPECIFIC POPULATIONS \\n8.1 Pregnancy \\nRisk Summary \\nAvailable studies with use of adalimumab during pregnancy do not reliably establish an \\nassociation between adalimumab and major birth defects. Clinical data are available from the \\nOrganization of Teratology Information Specialists (OTIS)/MotherToBaby HUMIRA Pregnancy \\nRegistry in pregnant women with rheumatoid arthritis (RA) or Crohn’s disease (CD). Registry \\nresults showed a rate of 10% for major birth defects with first trimester use of adalimumab in \\npregnant women with RA or CD and a rate of 7.5% for major birth defects in the disease-\\nmatched comparison cohort. The lack of pattern of major birth defects is reassuring and \\ndifferences between exposure groups may have impacted the occurrence of birth defects (see \\nData).  \\nAdalimumab is actively transferred across the placenta during the third trimester of pregnancy \\nand may affect immune response in the in-utero exposed infant (see Clinical Considerations). In \\nan embryo-fetal perinatal development study conducted in cynomolgus monkeys, no fetal harm \\nor malformations were observed with intravenous administration of adalimumab during \\norganogenesis and later in gestation, at doses that produced exposures up to approximately 373 \\ntimes the maximum recommended human dose (MRHD) of 40 mg subcutaneous without \\nmethotrexate (see Data).  \\nThe estimated background risk of major birth defects and miscarriage for the indicated \\npopulations is unknown. All pregnancies have a background risk of birth defect, loss, or other \\nadverse outcomes. In the U.S. general population, the estimated background risk of major birth \\ndefects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.  \\nClinical Considerations \\nDisease-associated maternal and embryo/fetal risk \\nPublished data suggest that the risk of adverse pregnancy outcomes in women with RA or \\ninflammatory bowel disease (IBD) is associated with increased disease activity. Adverse \\npregnancy outcomes include preterm delivery (before 37 weeks of gestation), low birth weight \\n(less than 2500 g) infants, and small for gestational age at birth.  \\nFetal/Neonatal Adverse Reactions \\nMonoclonal antibodies are increasingly transported across the placenta as pregnancy progresses, \\nwith the largest amount transferred during the third trimester (see Data). Risks and benefits \\nshould be considered prior to administering live or live-attenuated vaccines to infants exposed to \\nHUMIRA in utero [see Use in Specific Populations (8.4)].  \\nData \\nHuman Data \\nA prospective cohort pregnancy exposure registry conducted by OTIS/MotherToBaby in the \\nU.S. and Canada between 2004 and 2016 compared the risk of major birth defects in live-born \\n'}, 'page_char_count': 2748, 'page_word_count': 390, 'sentences': ['8 USE IN SPECIFIC POPULATIONS \\n8.1 Pregnancy \\nRisk Summary \\nAvailable studies with use of adalimumab during pregnancy do not reliably establish an \\nassociation between adalimumab and major birth defects.', 'Clinical data are available from the \\nOrganization of Teratology Information Specialists (OTIS)/MotherToBaby HUMIRA Pregnancy \\nRegistry in pregnant women with rheumatoid arthritis (RA) or Crohn’s disease (CD).', 'Registry \\nresults showed a rate of 10% for major birth defects with first trimester use of adalimumab in \\npregnant women with RA or CD and a rate of 7.5% for major birth defects in the disease-\\nmatched comparison cohort.', 'The lack of pattern of major birth defects is reassuring and \\ndifferences between exposure groups may have impacted the occurrence of birth defects (see \\nData).', ' \\nAdalimumab is actively transferred across the placenta during the third trimester of pregnancy \\nand may affect immune response in the in-utero exposed infant (see Clinical Considerations).', 'In \\nan embryo-fetal perinatal development study conducted in cynomolgus monkeys, no fetal harm \\nor malformations were observed with intravenous administration of adalimumab during \\norganogenesis and later in gestation, at doses that produced exposures up to approximately 373 \\ntimes the maximum recommended human dose (MRHD) of 40 mg subcutaneous without \\nmethotrexate (see Data).', ' \\nThe estimated background risk of major birth defects and miscarriage for the indicated \\npopulations is unknown.', 'All pregnancies have a background risk of birth defect, loss, or other \\nadverse outcomes.', 'In the U.S. general population, the estimated background risk of major birth \\ndefects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.', ' \\nClinical Considerations \\nDisease-associated maternal and embryo/fetal risk \\nPublished data suggest that the risk of adverse pregnancy outcomes in women with RA or \\ninflammatory bowel disease (IBD) is associated with increased disease activity.', 'Adverse \\npregnancy outcomes include preterm delivery (before 37 weeks of gestation), low birth weight \\n(less than 2500 g) infants, and small for gestational age at birth.', ' \\nFetal/Neonatal Adverse Reactions \\nMonoclonal antibodies are increasingly transported across the placenta as pregnancy progresses, \\nwith the largest amount transferred during the third trimester (see Data).', 'Risks and benefits \\nshould be considered prior to administering live or live-attenuated vaccines to infants exposed to \\nHUMIRA in utero [see Use in Specific Populations (8.4)].', ' \\nData \\nHuman Data \\nA prospective cohort pregnancy exposure registry conducted by OTIS/MotherToBaby in the \\nU.S. and Canada between 2004 and 2016 compared the risk of major birth defects in live-born \\n'], 'page_sentence_count_spacy': 14}\n",
            "{'page_number': 25, 'text': 'infants of 221 women (69 RA, 152 CD) treated with adalimumab during the first trimester and \\n106 women (74 RA, 32 CD) not treated with adalimumab.  \\nThe proportion of major birth defects among live-born infants in the adalimumab-treated and \\nuntreated cohorts was 10% (8.7% RA, 10.5% CD) and 7.5% (6.8% RA, 9.4% CD), respectively. \\nThe lack of pattern of major birth defects is reassuring and differences between exposure groups \\nmay have impacted the occurrence of birth defects. This study cannot reliably establish whether \\nthere is an association between adalimumab and major birth defects because of methodological \\nlimitations of the registry, including small sample size, the voluntary nature of the study, and the \\nnon-randomized design.  \\nIn an independent clinical study conducted in ten pregnant women with IBD treated with \\nHUMIRA, adalimumab concentrations were measured in maternal serum as well as in cord \\nblood (n=10) and infant serum (n=8) on the day of birth. The last dose of HUMIRA was given \\nbetween 1 and 56 days prior to delivery. Adalimumab concentrations were 0.16-19.7 µg/mL in \\ncord blood, 4.28-17.7 µg/mL in infant serum, and 0-16.1 µg/mL in maternal serum. In all but one \\ncase, the cord blood concentration of adalimumab was higher than the maternal serum \\nconcentration, suggesting adalimumab actively crosses the placenta. In addition, one infant had \\nserum concentrations at each of the following: 6 weeks (1.94 µg/mL), 7 weeks (1.31 µg/mL), 8 \\nweeks (0.93 µg/mL), and 11 weeks (0.53 µg/mL), suggesting adalimumab can be detected in the \\nserum of infants exposed in utero for at least 3 months from birth.  \\nAnimal Data \\nIn an embryo-fetal perinatal development study, pregnant cynomolgus monkeys received \\nadalimumab from gestation days 20 to 97 at doses that produced exposures up to 373 times that \\nachieved with the MRHD without methotrexate (on an AUC basis with maternal IV doses up to \\n100 mg/kg/week). Adalimumab did not elicit harm to the fetuses or malformations.  \\n8.2 Lactation \\nRisk Summary \\nLimited data from case reports in the published literature describe the presence of adalimumab in \\nhuman milk at infant doses of 0.1% to 1% of the maternal serum concentration. Published data \\nsuggest that the systemic exposure to a breastfed infant is expected to be low because \\nadalimumab is a large molecule and is degraded in the gastrointestinal tract. However, the effects \\nof local exposure in the gastrointestinal tract are unknown. There are no reports of adverse \\neffects of adalimumab on the breastfed infant and no effects on milk production. The \\ndevelopmental and health benefits of breastfeeding should be considered along with the mother’s \\nclinical need for HUMIRA and any potential adverse effects on the breastfed child from \\nHUMIRA or from the underlying maternal condition.  \\n8.4 Pediatric Use \\nThe safety and effectiveness of HUMIRA have been established for:  \\n• reducing signs and symptoms of moderately to severely active polyarticular JIA in \\npediatric patients 2 years of age and older.  \\n• the treatment of moderately to severely active Crohn’s disease in pediatric patients 6 \\nyears of age and older. \\n', 'processed_text': {'sentences': [{'original_sentence': 'infants of 221 women (69 RA, 152 CD) treated with adalimumab during the first trimester and \\n106 women (74 RA, 32 CD) not treated with adalimumab.', 'tokens': ['infants', '221', 'women', '(', '69', 'RA', ',', '152', 'CD', ')', 'treated', 'adalimumab', 'first', 'trimester', '106', 'women', '(', '74', 'RA', ',', '32', 'CD', ')', 'treated', 'adalimumab', '.'], 'lemmatized': ['infant', '221', 'woman', '(', '69', 'RA', ',', '152', 'CD', ')', 'treated', 'adalimumab', 'first', 'trimester', '106', 'woman', '(', '74', 'RA', ',', '32', 'CD', ')', 'treated', 'adalimumab', '.'], 'stemmed': ['infant', '221', 'woman', '(', '69', 'ra', ',', '152', 'cd', ')', 'treat', 'adalimumab', 'first', 'trimest', '106', 'woman', '(', '74', 'ra', ',', '32', 'cd', ')', 'treat', 'adalimumab', '.'], 'dependencies': [('infant', 'nmod'), ('221', 'nummod'), ('woman', 'nsubj'), ('(', 'punct'), ('69', 'nummod'), ('ra', 'appos'), (',', 'punct'), ('152', 'nummod'), ('cd', 'appos'), (')', 'punct'), ('treat', 'ROOT'), ('adalimumab', 'nmod'), ('first', 'advmod'), ('trimest', 'amod'), ('106', 'nummod'), ('woman', 'dobj'), ('(', 'punct'), ('74', 'nummod'), ('ra', 'nsubj'), (',', 'punct'), ('32', 'nummod'), ('cd', 'appos'), (')', 'punct'), ('treat', 'relcl'), ('adalimumab', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The proportion of major birth defects among live-born infants in the adalimumab-treated and \\nuntreated cohorts was 10% (8.7% RA, 10.5% CD) and 7.5% (6.8% RA, 9.4% CD), respectively.', 'tokens': ['proportion', 'major', 'birth', 'defects', 'among', 'live-born', 'infants', 'adalimumab-treated', 'untreated', 'cohorts', '10', '%', '(', '8.7', '%', 'RA', ',', '10.5', '%', 'CD', ')', '7.5', '%', '(', '6.8', '%', 'RA', ',', '9.4', '%', 'CD', ')', ',', 'respectively', '.'], 'lemmatized': ['proportion', 'major', 'birth', 'defect', 'among', 'live-born', 'infant', 'adalimumab-treated', 'untreated', 'cohort', '10', '%', '(', '8.7', '%', 'RA', ',', '10.5', '%', 'CD', ')', '7.5', '%', '(', '6.8', '%', 'RA', ',', '9.4', '%', 'CD', ')', ',', 'respectively', '.'], 'stemmed': ['proport', 'major', 'birth', 'defect', 'among', 'live-born', 'infant', 'adalimumab-tr', 'untreat', 'cohort', '10', '%', '(', '8.7', '%', 'ra', ',', '10.5', '%', 'cd', ')', '7.5', '%', '(', '6.8', '%', 'ra', ',', '9.4', '%', 'cd', ')', ',', 'respect', '.'], 'dependencies': [('proport', 'nmod'), ('major', 'amod'), ('birth', 'compound'), ('defect', 'ROOT'), ('among', 'prep'), ('live', 'advmod'), ('-', 'punct'), ('born', 'amod'), ('infant', 'compound'), ('adalimumab', 'npadvmod'), ('-', 'punct'), ('tr', 'nmod'), ('untreat', 'amod'), ('cohort', 'pobj'), ('10', 'nummod'), ('%', 'npadvmod'), ('(', 'punct'), ('8.7', 'nummod'), ('%', 'appos'), ('ra', 'appos'), (',', 'punct'), ('10.5', 'nummod'), ('%', 'compound'), ('cd', 'appos'), (')', 'punct'), ('7.5', 'nummod'), ('%', 'appos'), ('(', 'punct'), ('6.8', 'nummod'), ('%', 'compound'), ('ra', 'appos'), (',', 'punct'), ('9.4', 'nummod'), ('%', 'compound'), ('cd', 'appos'), (')', 'punct'), (',', 'punct'), ('respect', 'appos'), ('.', 'punct')]}, {'original_sentence': 'The lack of pattern of major birth defects is reassuring and differences between exposure groups \\nmay have impacted the occurrence of birth defects.', 'tokens': ['lack', 'pattern', 'major', 'birth', 'defects', 'reassuring', 'differences', 'exposure', 'groups', 'may', 'impacted', 'occurrence', 'birth', 'defects', '.'], 'lemmatized': ['lack', 'pattern', 'major', 'birth', 'defect', 'reassuring', 'difference', 'exposure', 'group', 'may', 'impacted', 'occurrence', 'birth', 'defect', '.'], 'stemmed': ['lack', 'pattern', 'major', 'birth', 'defect', 'reassur', 'differ', 'exposur', 'group', 'may', 'impact', 'occurr', 'birth', 'defect', '.'], 'dependencies': [('lack', 'compound'), ('pattern', 'nsubj'), ('major', 'amod'), ('birth', 'compound'), ('defect', 'compound'), ('reassur', 'appos'), ('differ', 'ROOT'), ('exposur', 'compound'), ('group', 'nsubj'), ('may', 'aux'), ('impact', 'ccomp'), ('occurr', 'compound'), ('birth', 'compound'), ('defect', 'ccomp'), ('.', 'punct')]}, {'original_sentence': 'This study cannot reliably establish whether \\nthere is an association between adalimumab and major birth defects because of methodological \\nlimitations of the registry, including small sample size, the voluntary nature of the study, and the \\nnon-randomized design.', 'tokens': ['study', 'reliably', 'establish', 'whether', 'association', 'adalimumab', 'major', 'birth', 'defects', 'methodological', 'limitations', 'registry', ',', 'including', 'small', 'sample', 'size', ',', 'voluntary', 'nature', 'study', ',', 'non-randomized', 'design', '.'], 'lemmatized': ['study', 'reliably', 'establish', 'whether', 'association', 'adalimumab', 'major', 'birth', 'defect', 'methodological', 'limitation', 'registry', ',', 'including', 'small', 'sample', 'size', ',', 'voluntary', 'nature', 'study', ',', 'non-randomized', 'design', '.'], 'stemmed': ['studi', 'reliabl', 'establish', 'whether', 'associ', 'adalimumab', 'major', 'birth', 'defect', 'methodolog', 'limit', 'registri', ',', 'includ', 'small', 'sampl', 'size', ',', 'voluntari', 'natur', 'studi', ',', 'non-random', 'design', '.'], 'dependencies': [('studi', 'dep'), ('reliabl', 'amod'), ('establish', 'ROOT'), ('whether', 'mark'), ('associ', 'compound'), ('adalimumab', 'nmod'), ('major', 'amod'), ('birth', 'compound'), ('defect', 'compound'), ('methodolog', 'compound'), ('limit', 'nsubj'), ('registri', 'advcl'), (',', 'punct'), ('includ', 'amod'), ('small', 'amod'), ('sampl', 'compound'), ('size', 'nmod'), (',', 'punct'), ('voluntari', 'compound'), ('natur', 'compound'), ('studi', 'npadvmod'), (',', 'punct'), ('non', 'amod'), ('-', 'amod'), ('random', 'amod'), ('design', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'In an independent clinical study conducted in ten pregnant women with IBD treated with \\nHUMIRA, adalimumab concentrations were measured in maternal serum as well as in cord \\nblood (n=10) and infant serum (n=8) on the day of birth.', 'tokens': ['independent', 'clinical', 'study', 'conducted', 'ten', 'pregnant', 'women', 'IBD', 'treated', 'HUMIRA', ',', 'adalimumab', 'concentrations', 'measured', 'maternal', 'serum', 'well', 'cord', 'blood', '(', 'n=10', ')', 'infant', 'serum', '(', 'n=8', ')', 'day', 'birth', '.'], 'lemmatized': ['independent', 'clinical', 'study', 'conducted', 'ten', 'pregnant', 'woman', 'IBD', 'treated', 'HUMIRA', ',', 'adalimumab', 'concentration', 'measured', 'maternal', 'serum', 'well', 'cord', 'blood', '(', 'n=10', ')', 'infant', 'serum', '(', 'n=8', ')', 'day', 'birth', '.'], 'stemmed': ['independ', 'clinic', 'studi', 'conduct', 'ten', 'pregnant', 'woman', 'ibd', 'treat', 'humira', ',', 'adalimumab', 'concentr', 'measur', 'matern', 'serum', 'well', 'cord', 'blood', '(', 'n=10', ')', 'infant', 'serum', '(', 'n=8', ')', 'day', 'birth', '.'], 'dependencies': [('independ', 'compound'), ('clinic', 'compound'), ('studi', 'nsubj'), ('conduct', 'ROOT'), ('ten', 'nummod'), ('pregnant', 'amod'), ('woman', 'compound'), ('ibd', 'compound'), ('treat', 'compound'), ('humira', 'dobj'), (',', 'punct'), ('adalimumab', 'compound'), ('concentr', 'compound'), ('measur', 'compound'), ('matern', 'compound'), ('serum', 'conj'), ('well', 'intj'), ('cord', 'compound'), ('blood', 'npadvmod'), ('(', 'punct'), ('n=10', 'nmod'), (')', 'punct'), ('infant', 'compound'), ('serum', 'parataxis'), ('(', 'punct'), ('n=8', 'appos'), (')', 'punct'), ('day', 'compound'), ('birth', 'appos'), ('.', 'punct')]}, {'original_sentence': 'The last dose of HUMIRA was given \\nbetween 1 and 56 days prior to delivery.', 'tokens': ['last', 'dose', 'HUMIRA', 'given', '1', '56', 'days', 'prior', 'delivery', '.'], 'lemmatized': ['last', 'dose', 'HUMIRA', 'given', '1', '56', 'day', 'prior', 'delivery', '.'], 'stemmed': ['last', 'dose', 'humira', 'given', '1', '56', 'day', 'prior', 'deliveri', '.'], 'dependencies': [('last', 'amod'), ('dose', 'compound'), ('humira', 'nsubj'), ('given', 'ROOT'), ('1', 'nummod'), ('56', 'nummod'), ('day', 'npadvmod'), ('prior', 'advmod'), ('deliveri', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Adalimumab concentrations were 0.16-19.7 µg/mL in \\ncord blood, 4.28-17.7 µg/mL in infant serum, and 0-16.1 µg/mL in maternal serum.', 'tokens': ['Adalimumab', 'concentrations', '0.16-19.7', 'µg/mL', 'cord', 'blood', ',', '4.28-17.7', 'µg/mL', 'infant', 'serum', ',', '0-16.1', 'µg/mL', 'maternal', 'serum', '.'], 'lemmatized': ['Adalimumab', 'concentration', '0.16-19.7', 'µg/mL', 'cord', 'blood', ',', '4.28-17.7', 'µg/mL', 'infant', 'serum', ',', '0-16.1', 'µg/mL', 'maternal', 'serum', '.'], 'stemmed': ['adalimumab', 'concentr', '0.16-19.7', 'µg/ml', 'cord', 'blood', ',', '4.28-17.7', 'µg/ml', 'infant', 'serum', ',', '0-16.1', 'µg/ml', 'matern', 'serum', '.'], 'dependencies': [('adalimumab', 'compound'), ('concentr', 'ROOT'), ('0.16', 'npadvmod'), ('-', 'punct'), ('19.7', 'nummod'), ('µg', 'nmod'), ('/', 'punct'), ('ml', 'compound'), ('cord', 'compound'), ('blood', 'prep'), (',', 'punct'), ('4.28', 'nummod'), ('-', 'punct'), ('17.7', 'nummod'), ('µg', 'nmod'), ('/', 'punct'), ('ml', 'compound'), ('infant', 'compound'), ('serum', 'appos'), (',', 'punct'), ('0', 'appos'), ('-', 'punct'), ('16.1', 'nummod'), ('µg', 'nmod'), ('/', 'punct'), ('ml', 'advmod'), ('matern', 'compound'), ('serum', 'prep'), ('.', 'punct')]}, {'original_sentence': 'In all but one \\ncase, the cord blood concentration of adalimumab was higher than the maternal serum \\nconcentration, suggesting adalimumab actively crosses the placenta.', 'tokens': ['one', 'case', ',', 'cord', 'blood', 'concentration', 'adalimumab', 'higher', 'maternal', 'serum', 'concentration', ',', 'suggesting', 'adalimumab', 'actively', 'crosses', 'placenta', '.'], 'lemmatized': ['one', 'case', ',', 'cord', 'blood', 'concentration', 'adalimumab', 'higher', 'maternal', 'serum', 'concentration', ',', 'suggesting', 'adalimumab', 'actively', 'cross', 'placenta', '.'], 'stemmed': ['one', 'case', ',', 'cord', 'blood', 'concentr', 'adalimumab', 'higher', 'matern', 'serum', 'concentr', ',', 'suggest', 'adalimumab', 'activ', 'cross', 'placenta', '.'], 'dependencies': [('one', 'nummod'), ('case', 'npadvmod'), (',', 'punct'), ('cord', 'compound'), ('blood', 'nsubj'), ('concentr', 'ccomp'), ('adalimumab', 'advmod'), ('higher', 'amod'), ('matern', 'compound'), ('serum', 'compound'), ('concentr', 'dobj'), (',', 'punct'), ('suggest', 'ROOT'), ('adalimumab', 'compound'), ('activ', 'compound'), ('cross', 'compound'), ('placenta', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'In addition, one infant had \\nserum concentrations at each of the following: 6 weeks (1.94 µg/mL), 7 weeks (1.31 µg/mL), 8 \\nweeks (0.93 µg/mL), and 11 weeks (0.53 µg/mL), suggesting adalimumab can be detected in the \\nserum of infants exposed in utero for at least 3 months from birth.', 'tokens': ['addition', ',', 'one', 'infant', 'serum', 'concentrations', 'following', ':', '6', 'weeks', '(', '1.94', 'µg/mL', ')', ',', '7', 'weeks', '(', '1.31', 'µg/mL', ')', ',', '8', 'weeks', '(', '0.93', 'µg/mL', ')', ',', '11', 'weeks', '(', '0.53', 'µg/mL', ')', ',', 'suggesting', 'adalimumab', 'detected', 'serum', 'infants', 'exposed', 'utero', 'least', '3', 'months', 'birth', '.'], 'lemmatized': ['addition', ',', 'one', 'infant', 'serum', 'concentration', 'following', ':', '6', 'week', '(', '1.94', 'µg/mL', ')', ',', '7', 'week', '(', '1.31', 'µg/mL', ')', ',', '8', 'week', '(', '0.93', 'µg/mL', ')', ',', '11', 'week', '(', '0.53', 'µg/mL', ')', ',', 'suggesting', 'adalimumab', 'detected', 'serum', 'infant', 'exposed', 'utero', 'least', '3', 'month', 'birth', '.'], 'stemmed': ['addit', ',', 'one', 'infant', 'serum', 'concentr', 'follow', ':', '6', 'week', '(', '1.94', 'µg/ml', ')', ',', '7', 'week', '(', '1.31', 'µg/ml', ')', ',', '8', 'week', '(', '0.93', 'µg/ml', ')', ',', '11', 'week', '(', '0.53', 'µg/ml', ')', ',', 'suggest', 'adalimumab', 'detect', 'serum', 'infant', 'expos', 'utero', 'least', '3', 'month', 'birth', '.'], 'dependencies': [('addit', 'dep'), (',', 'punct'), ('one', 'nummod'), ('infant', 'compound'), ('serum', 'compound'), ('concentr', 'nsubj'), ('follow', 'ccomp'), (':', 'punct'), ('6', 'nummod'), ('week', 'npadvmod'), ('(', 'punct'), ('1.94', 'nummod'), ('µg', 'nmod'), ('/', 'punct'), ('ml', 'appos'), (')', 'punct'), (',', 'punct'), ('7', 'nummod'), ('week', 'appos'), ('(', 'punct'), ('1.31', 'nummod'), ('µg', 'nmod'), ('/', 'punct'), ('ml', 'appos'), (')', 'punct'), (',', 'punct'), ('8', 'nummod'), ('week', 'appos'), ('(', 'punct'), ('0.93', 'nummod'), ('µg', 'nmod'), ('/', 'punct'), ('ml', 'appos'), (')', 'punct'), (',', 'punct'), ('11', 'nummod'), ('week', 'npadvmod'), ('(', 'punct'), ('0.53', 'nummod'), ('µg', 'prep'), ('/', 'punct'), ('ml', 'appos'), (')', 'punct'), (',', 'punct'), ('suggest', 'ROOT'), ('adalimumab', 'nsubj'), ('detect', 'ccomp'), ('serum', 'compound'), ('infant', 'compound'), ('expos', 'compound'), ('utero', 'nmod'), ('least', 'advmod'), ('3', 'nummod'), ('month', 'compound'), ('birth', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Animal Data \\nIn an embryo-fetal perinatal development study, pregnant cynomolgus monkeys received \\nadalimumab from gestation days 20 to 97 at doses that produced exposures up to 373 times that \\nachieved with the MRHD without methotrexate (on an AUC basis with maternal IV doses up to \\n100 mg/kg/week).', 'tokens': ['Animal', 'Data', 'embryo-fetal', 'perinatal', 'development', 'study', ',', 'pregnant', 'cynomolgus', 'monkeys', 'received', 'adalimumab', 'gestation', 'days', '20', '97', 'doses', 'produced', 'exposures', '373', 'times', 'achieved', 'MRHD', 'without', 'methotrexate', '(', 'AUC', 'basis', 'maternal', 'IV', 'doses', '100', 'mg/kg/week', ')', '.'], 'lemmatized': ['Animal', 'Data', 'embryo-fetal', 'perinatal', 'development', 'study', ',', 'pregnant', 'cynomolgus', 'monkey', 'received', 'adalimumab', 'gestation', 'day', '20', '97', 'dos', 'produced', 'exposure', '373', 'time', 'achieved', 'MRHD', 'without', 'methotrexate', '(', 'AUC', 'basis', 'maternal', 'IV', 'dos', '100', 'mg/kg/week', ')', '.'], 'stemmed': ['anim', 'data', 'embryo-fet', 'perinat', 'develop', 'studi', ',', 'pregnant', 'cynomolgu', 'monkey', 'receiv', 'adalimumab', 'gestat', 'day', '20', '97', 'do', 'produc', 'exposur', '373', 'time', 'achiev', 'mrhd', 'without', 'methotrex', '(', 'auc', 'basi', 'matern', 'iv', 'do', '100', 'mg/kg/week', ')', '.'], 'dependencies': [('anim', 'compound'), ('data', 'nmod'), ('embryo', 'compound'), ('-', 'punct'), ('fet', 'amod'), ('perinat', 'nsubj'), ('develop', 'ROOT'), ('studi', 'dobj'), (',', 'punct'), ('pregnant', 'amod'), ('cynomolgu', 'compound'), ('monkey', 'compound'), ('receiv', 'compound'), ('adalimumab', 'compound'), ('gestat', 'compound'), ('day', 'nmod'), ('20', 'nummod'), ('97', 'npadvmod'), ('do', 'compound'), ('produc', 'compound'), ('exposur', 'conj'), ('373', 'nummod'), ('time', 'npadvmod'), ('achiev', 'prep'), ('mrhd', 'dobj'), ('without', 'prep'), ('methotrex', 'pobj'), ('(', 'punct'), ('auc', 'compound'), ('basi', 'compound'), ('matern', 'appos'), ('iv', 'nsubj'), ('do', 'conj'), ('100', 'nummod'), ('mg', 'nmod'), ('/', 'punct'), ('kg', 'nmod'), ('/', 'punct'), ('week', 'npadvmod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Adalimumab did not elicit harm to the fetuses or malformations.', 'tokens': ['Adalimumab', 'elicit', 'harm', 'fetuses', 'malformations', '.'], 'lemmatized': ['Adalimumab', 'elicit', 'harm', 'fetus', 'malformation', '.'], 'stemmed': ['adalimumab', 'elicit', 'harm', 'fetu', 'malform', '.'], 'dependencies': [('adalimumab', 'compound'), ('elicit', 'amod'), ('harm', 'compound'), ('fetu', 'compound'), ('malform', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '8.2 Lactation \\nRisk Summary \\nLimited data from case reports in the published literature describe the presence of adalimumab in \\nhuman milk at infant doses of 0.1% to 1% of the maternal serum concentration.', 'tokens': ['8.2', 'Lactation', 'Risk', 'Summary', 'Limited', 'data', 'case', 'reports', 'published', 'literature', 'describe', 'presence', 'adalimumab', 'human', 'milk', 'infant', 'doses', '0.1', '%', '1', '%', 'maternal', 'serum', 'concentration', '.'], 'lemmatized': ['8.2', 'Lactation', 'Risk', 'Summary', 'Limited', 'data', 'case', 'report', 'published', 'literature', 'describe', 'presence', 'adalimumab', 'human', 'milk', 'infant', 'dos', '0.1', '%', '1', '%', 'maternal', 'serum', 'concentration', '.'], 'stemmed': ['8.2', 'lactat', 'risk', 'summari', 'limit', 'data', 'case', 'report', 'publish', 'literatur', 'describ', 'presenc', 'adalimumab', 'human', 'milk', 'infant', 'do', '0.1', '%', '1', '%', 'matern', 'serum', 'concentr', '.'], 'dependencies': [('8.2', 'nummod'), ('lactat', 'nmod'), ('risk', 'compound'), ('summari', 'amod'), ('limit', 'compound'), ('data', 'compound'), ('case', 'compound'), ('report', 'nsubj'), ('publish', 'ROOT'), ('literatur', 'compound'), ('describ', 'compound'), ('presenc', 'compound'), ('adalimumab', 'compound'), ('human', 'amod'), ('milk', 'compound'), ('infant', 'dobj'), ('do', 'conj'), ('0.1', 'nummod'), ('%', 'nmod'), ('1', 'nummod'), ('%', 'compound'), ('matern', 'compound'), ('serum', 'compound'), ('concentr', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Published data \\nsuggest that the systemic exposure to a breastfed infant is expected to be low because \\nadalimumab is a large molecule and is degraded in the gastrointestinal tract.', 'tokens': ['Published', 'data', 'suggest', 'systemic', 'exposure', 'breastfed', 'infant', 'expected', 'low', 'adalimumab', 'large', 'molecule', 'degraded', 'gastrointestinal', 'tract', '.'], 'lemmatized': ['Published', 'data', 'suggest', 'systemic', 'exposure', 'breastfed', 'infant', 'expected', 'low', 'adalimumab', 'large', 'molecule', 'degraded', 'gastrointestinal', 'tract', '.'], 'stemmed': ['publish', 'data', 'suggest', 'system', 'exposur', 'breastf', 'infant', 'expect', 'low', 'adalimumab', 'larg', 'molecul', 'degrad', 'gastrointestin', 'tract', '.'], 'dependencies': [('publish', 'advcl'), ('data', 'dobj'), ('suggest', 'ROOT'), ('system', 'compound'), ('exposur', 'compound'), ('breastf', 'compound'), ('infant', 'nsubj'), ('expect', 'ccomp'), ('low', 'amod'), ('adalimumab', 'compound'), ('larg', 'compound'), ('molecul', 'compound'), ('degrad', 'compound'), ('gastrointestin', 'compound'), ('tract', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'However, the effects \\nof local exposure in the gastrointestinal tract are unknown.', 'tokens': ['However', ',', 'effects', 'local', 'exposure', 'gastrointestinal', 'tract', 'unknown', '.'], 'lemmatized': ['However', ',', 'effect', 'local', 'exposure', 'gastrointestinal', 'tract', 'unknown', '.'], 'stemmed': ['howev', ',', 'effect', 'local', 'exposur', 'gastrointestin', 'tract', 'unknown', '.'], 'dependencies': [('howev', 'nsubj'), (',', 'punct'), ('effect', 'appos'), ('local', 'amod'), ('exposur', 'compound'), ('gastrointestin', 'compound'), ('tract', 'dobj'), ('unknown', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'There are no reports of adverse \\neffects of adalimumab on the breastfed infant and no effects on milk production.', 'tokens': ['reports', 'adverse', 'effects', 'adalimumab', 'breastfed', 'infant', 'effects', 'milk', 'production', '.'], 'lemmatized': ['report', 'adverse', 'effect', 'adalimumab', 'breastfed', 'infant', 'effect', 'milk', 'production', '.'], 'stemmed': ['report', 'advers', 'effect', 'adalimumab', 'breastf', 'infant', 'effect', 'milk', 'product', '.'], 'dependencies': [('report', 'compound'), ('advers', 'nsubj'), ('effect', 'ROOT'), ('adalimumab', 'compound'), ('breastf', 'compound'), ('infant', 'compound'), ('effect', 'compound'), ('milk', 'compound'), ('product', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The \\ndevelopmental and health benefits of breastfeeding should be considered along with the mother’s \\nclinical need for HUMIRA and any potential adverse effects on the breastfed child from \\nHUMIRA or from the underlying maternal condition.', 'tokens': ['developmental', 'health', 'benefits', 'breastfeeding', 'considered', 'along', 'mother', '’', 'clinical', 'need', 'HUMIRA', 'potential', 'adverse', 'effects', 'breastfed', 'child', 'HUMIRA', 'underlying', 'maternal', 'condition', '.'], 'lemmatized': ['developmental', 'health', 'benefit', 'breastfeeding', 'considered', 'along', 'mother', '’', 'clinical', 'need', 'HUMIRA', 'potential', 'adverse', 'effect', 'breastfed', 'child', 'HUMIRA', 'underlying', 'maternal', 'condition', '.'], 'stemmed': ['development', 'health', 'benefit', 'breastfeed', 'consid', 'along', 'mother', '’', 'clinic', 'need', 'humira', 'potenti', 'advers', 'effect', 'breastf', 'child', 'humira', 'underli', 'matern', 'condit', '.'], 'dependencies': [('development', 'compound'), ('health', 'compound'), ('benefit', 'nsubj'), ('breastfeed', 'ROOT'), ('consid', 'dobj'), ('along', 'prep'), ('mother', 'nmod'), ('’', 'punct'), ('clinic', 'pobj'), ('need', 'dep'), ('humira', 'compound'), ('potenti', 'compound'), ('advers', 'nsubj'), ('effect', 'ccomp'), ('breastf', 'compound'), ('child', 'compound'), ('humira', 'dobj'), ('underli', 'amod'), ('matern', 'compound'), ('condit', 'dobj'), ('.', 'punct')]}, {'original_sentence': '8.4 Pediatric Use \\nThe safety and effectiveness of HUMIRA have been established for:  \\n• reducing signs and symptoms of moderately to severely active polyarticular JIA in \\npediatric patients 2 years of age and older.', 'tokens': ['8.4', 'Pediatric', 'Use', 'safety', 'effectiveness', 'HUMIRA', 'established', ':', '•', 'reducing', 'signs', 'symptoms', 'moderately', 'severely', 'active', 'polyarticular', 'JIA', 'pediatric', 'patients', '2', 'years', 'age', 'older', '.'], 'lemmatized': ['8.4', 'Pediatric', 'Use', 'safety', 'effectiveness', 'HUMIRA', 'established', ':', '•', 'reducing', 'sign', 'symptom', 'moderately', 'severely', 'active', 'polyarticular', 'JIA', 'pediatric', 'patient', '2', 'year', 'age', 'older', '.'], 'stemmed': ['8.4', 'pediatr', 'use', 'safeti', 'effect', 'humira', 'establish', ':', '•', 'reduc', 'sign', 'symptom', 'moder', 'sever', 'activ', 'polyarticular', 'jia', 'pediatr', 'patient', '2', 'year', 'age', 'older', '.'], 'dependencies': [('8.4', 'meta'), ('pediatr', 'amod'), ('use', 'nsubj'), ('safeti', 'compound'), ('effect', 'compound'), ('humira', 'dobj'), ('establish', 'ROOT'), (':', 'punct'), ('•', 'meta'), ('reduc', 'compound'), ('sign', 'compound'), ('symptom', 'compound'), ('moder', 'nsubj'), ('sever', 'ccomp'), ('activ', 'nmod'), ('polyarticular', 'nmod'), ('jia', 'nmod'), ('pediatr', 'amod'), ('patient', 'nmod'), ('2', 'nummod'), ('year', 'compound'), ('age', 'npadvmod'), ('older', 'ccomp'), ('.', 'punct')]}, {'original_sentence': '• the treatment of moderately to severely active Crohn’s disease in pediatric patients 6 \\nyears of age and older.', 'tokens': ['•', 'treatment', 'moderately', 'severely', 'active', 'Crohn', '’', 'disease', 'pediatric', 'patients', '6', 'years', 'age', 'older', '.'], 'lemmatized': ['•', 'treatment', 'moderately', 'severely', 'active', 'Crohn', '’', 'disease', 'pediatric', 'patient', '6', 'year', 'age', 'older', '.'], 'stemmed': ['•', 'treatment', 'moder', 'sever', 'activ', 'crohn', '’', 'diseas', 'pediatr', 'patient', '6', 'year', 'age', 'older', '.'], 'dependencies': [('•', 'nummod'), ('treatment', 'compound'), ('moder', 'nsubj'), ('sever', 'ROOT'), ('activ', 'compound'), ('crohn', 'dobj'), ('’', 'punct'), ('diseas', 'nmod'), ('pediatr', 'amod'), ('patient', 'advcl'), ('6', 'nummod'), ('year', 'compound'), ('age', 'appos'), ('older', 'amod'), ('.', 'punct')]}], 'text': 'infants of 221 women (69 RA, 152 CD) treated with adalimumab during the first trimester and \\n106 women (74 RA, 32 CD) not treated with adalimumab.  \\nThe proportion of major birth defects among live-born infants in the adalimumab-treated and \\nuntreated cohorts was 10% (8.7% RA, 10.5% CD) and 7.5% (6.8% RA, 9.4% CD), respectively. \\nThe lack of pattern of major birth defects is reassuring and differences between exposure groups \\nmay have impacted the occurrence of birth defects. This study cannot reliably establish whether \\nthere is an association between adalimumab and major birth defects because of methodological \\nlimitations of the registry, including small sample size, the voluntary nature of the study, and the \\nnon-randomized design.  \\nIn an independent clinical study conducted in ten pregnant women with IBD treated with \\nHUMIRA, adalimumab concentrations were measured in maternal serum as well as in cord \\nblood (n=10) and infant serum (n=8) on the day of birth. The last dose of HUMIRA was given \\nbetween 1 and 56 days prior to delivery. Adalimumab concentrations were 0.16-19.7 µg/mL in \\ncord blood, 4.28-17.7 µg/mL in infant serum, and 0-16.1 µg/mL in maternal serum. In all but one \\ncase, the cord blood concentration of adalimumab was higher than the maternal serum \\nconcentration, suggesting adalimumab actively crosses the placenta. In addition, one infant had \\nserum concentrations at each of the following: 6 weeks (1.94 µg/mL), 7 weeks (1.31 µg/mL), 8 \\nweeks (0.93 µg/mL), and 11 weeks (0.53 µg/mL), suggesting adalimumab can be detected in the \\nserum of infants exposed in utero for at least 3 months from birth.  \\nAnimal Data \\nIn an embryo-fetal perinatal development study, pregnant cynomolgus monkeys received \\nadalimumab from gestation days 20 to 97 at doses that produced exposures up to 373 times that \\nachieved with the MRHD without methotrexate (on an AUC basis with maternal IV doses up to \\n100 mg/kg/week). Adalimumab did not elicit harm to the fetuses or malformations.  \\n8.2 Lactation \\nRisk Summary \\nLimited data from case reports in the published literature describe the presence of adalimumab in \\nhuman milk at infant doses of 0.1% to 1% of the maternal serum concentration. Published data \\nsuggest that the systemic exposure to a breastfed infant is expected to be low because \\nadalimumab is a large molecule and is degraded in the gastrointestinal tract. However, the effects \\nof local exposure in the gastrointestinal tract are unknown. There are no reports of adverse \\neffects of adalimumab on the breastfed infant and no effects on milk production. The \\ndevelopmental and health benefits of breastfeeding should be considered along with the mother’s \\nclinical need for HUMIRA and any potential adverse effects on the breastfed child from \\nHUMIRA or from the underlying maternal condition.  \\n8.4 Pediatric Use \\nThe safety and effectiveness of HUMIRA have been established for:  \\n• reducing signs and symptoms of moderately to severely active polyarticular JIA in \\npediatric patients 2 years of age and older.  \\n• the treatment of moderately to severely active Crohn’s disease in pediatric patients 6 \\nyears of age and older. \\n'}, 'page_char_count': 3171, 'page_word_count': 497, 'sentences': ['infants of 221 women (69 RA, 152 CD) treated with adalimumab during the first trimester and \\n106 women (74 RA, 32 CD) not treated with adalimumab.', ' \\nThe proportion of major birth defects among live-born infants in the adalimumab-treated and \\nuntreated cohorts was 10% (8.7% RA, 10.5% CD) and 7.5% (6.8% RA, 9.4% CD), respectively.', '\\nThe lack of pattern of major birth defects is reassuring and differences between exposure groups \\nmay have impacted the occurrence of birth defects.', 'This study cannot reliably establish whether \\nthere is an association between adalimumab and major birth defects because of methodological \\nlimitations of the registry, including small sample size, the voluntary nature of the study, and the \\nnon-randomized design.', ' \\nIn an independent clinical study conducted in ten pregnant women with IBD treated with \\nHUMIRA, adalimumab concentrations were measured in maternal serum as well as in cord \\nblood (n=10) and infant serum (n=8) on the day of birth.', 'The last dose of HUMIRA was given \\nbetween 1 and 56 days prior to delivery.', 'Adalimumab concentrations were 0.16-19.7 µg/mL in \\ncord blood, 4.28-17.7 µg/mL in infant serum, and 0-16.1 µg/mL in maternal serum.', 'In all but one \\ncase, the cord blood concentration of adalimumab was higher than the maternal serum \\nconcentration, suggesting adalimumab actively crosses the placenta.', 'In addition, one infant had \\nserum concentrations at each of the following: 6 weeks (1.94 µg/mL), 7 weeks (1.31 µg/mL), 8 \\nweeks (0.93 µg/mL), and 11 weeks (0.53 µg/mL), suggesting adalimumab can be detected in the \\nserum of infants exposed in utero for at least 3 months from birth.', ' \\nAnimal Data \\nIn an embryo-fetal perinatal development study, pregnant cynomolgus monkeys received \\nadalimumab from gestation days 20 to 97 at doses that produced exposures up to 373 times that \\nachieved with the MRHD without methotrexate (on an AUC basis with maternal IV doses up to \\n100 mg/kg/week).', 'Adalimumab did not elicit harm to the fetuses or malformations.', ' \\n8.2 Lactation \\nRisk Summary \\nLimited data from case reports in the published literature describe the presence of adalimumab in \\nhuman milk at infant doses of 0.1% to 1% of the maternal serum concentration.', 'Published data \\nsuggest that the systemic exposure to a breastfed infant is expected to be low because \\nadalimumab is a large molecule and is degraded in the gastrointestinal tract.', 'However, the effects \\nof local exposure in the gastrointestinal tract are unknown.', 'There are no reports of adverse \\neffects of adalimumab on the breastfed infant and no effects on milk production.', 'The \\ndevelopmental and health benefits of breastfeeding should be considered along with the mother’s \\nclinical need for HUMIRA and any potential adverse effects on the breastfed child from \\nHUMIRA or from the underlying maternal condition.', ' \\n8.4 Pediatric Use \\nThe safety and effectiveness of HUMIRA have been established for:  \\n• reducing signs and symptoms of moderately to severely active polyarticular JIA in \\npediatric patients 2 years of age and older.', ' \\n• the treatment of moderately to severely active Crohn’s disease in pediatric patients 6 \\nyears of age and older.', '\\n'], 'page_sentence_count_spacy': 19}\n",
            "{'page_number': 26, 'text': '• the treatment of moderately to severely active ulcerative colitis in pediatric patients 5 \\nyears of age and older. \\n• the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age \\nand older.  \\n• the treatment of non-infectious intermediate, posterior, and panuveitis in pediatric \\npatients 2 years of age and older. \\nDue to its inhibition of TNFα, HUMIRA administered during pregnancy could affect immune \\nresponse in the in utero-exposed newborn and infant. Data from eight infants exposed to \\nHUMIRA in utero suggest adalimumab crosses the placenta [see Use in Specific Populations \\n(8.1)]. The clinical significance of elevated adalimumab concentrations in infants is unknown. \\nThe safety of administering live or live-attenuated vaccines in exposed infants is unknown. Risks \\nand benefits should be considered prior to vaccinating (live or live-attenuated) exposed infants.  \\nPost-marketing cases of lymphoma, including hepatosplenic T-cell lymphoma and other \\nmalignancies, some fatal, have been reported among children, adolescents, and young adults who \\nreceived treatment with TNF-blockers including HUMIRA [see Warnings and Precautions \\n(5.2)].  \\nJuvenile Idiopathic Arthritis \\nIn Study JIA-I, HUMIRA was shown to reduce signs and symptoms of active polyarticular JIA \\nin patients 4 to 17 years of age [see Clinical Studies (14.2)]. In Study JIA-II, the safety profile \\nfor patients 2 to <4 years of age was similar to the safety profile for patients 4 to 17 years of age \\nwith polyarticular JIA [see Adverse Reactions (6.1)]. HUMIRA has not been studied in patients \\nwith polyarticular JIA less than 2 years of age or in patients with a weight below 10 kg.  \\nThe safety of HUMIRA in patients in the polyarticular JIA trials was generally similar to that \\nobserved in adults with certain exceptions [see Adverse Reactions (6.1)].  \\nThe safety and effectiveness of HUMIRA have not been established in pediatric patients with \\nJIA less than 2 years of age. \\nPediatric Crohn’s Disease \\nThe safety and effectiveness of HUMIRA for the treatment of moderately to severely active \\nCrohn’s disease have been established in pediatric patients 6 years of age and older. Use of \\nHUMIRA for this indication is supported by evidence from adequate and well-controlled studies \\nin adults with additional data from a randomized, double-blind, 52-week clinical study of two \\ndose concentrations of HUMIRA in 192 pediatric patients (6 years to 17 years of age) [see \\nAdverse Reactions (6.1), Clinical Pharmacology (12.2, 12.3), Clinical Studies (14.6)]. The \\nadverse reaction profile in patients 6 years to 17 years of age was similar to adults.  \\nThe safety and effectiveness of HUMIRA have not been established in pediatric patients with \\nCrohn’s disease less than 6 years of age.  \\nPediatric Ulcerative Colitis \\nThe safety and effectiveness of HUMIRA for the treatment of moderately to severely active \\nulcerative colitis have been established in pediatric patients 5 years of age and older.  Use of \\nHUMIRA for this indication is supported by evidence from adequate and well-controlled studies \\nin adults with additional data from a randomized, double-blind, 52-week clinical study of two \\n', 'processed_text': {'sentences': [{'original_sentence': '• the treatment of moderately to severely active ulcerative colitis in pediatric patients 5 \\nyears of age and older.', 'tokens': ['•', 'treatment', 'moderately', 'severely', 'active', 'ulcerative', 'colitis', 'pediatric', 'patients', '5', 'years', 'age', 'older', '.'], 'lemmatized': ['•', 'treatment', 'moderately', 'severely', 'active', 'ulcerative', 'colitis', 'pediatric', 'patient', '5', 'year', 'age', 'older', '.'], 'stemmed': ['•', 'treatment', 'moder', 'sever', 'activ', 'ulcer', 'coliti', 'pediatr', 'patient', '5', 'year', 'age', 'older', '.'], 'dependencies': [('•', 'nummod'), ('treatment', 'compound'), ('moder', 'nsubj'), ('sever', 'ROOT'), ('activ', 'compound'), ('ulcer', 'dobj'), ('coliti', 'nmod'), ('pediatr', 'advmod'), ('patient', 'ccomp'), ('5', 'nummod'), ('year', 'compound'), ('age', 'dobj'), ('older', 'advmod'), ('.', 'punct')]}, {'original_sentence': '• the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age \\nand older.', 'tokens': ['•', 'treatment', 'moderate', 'severe', 'hidradenitis', 'suppurativa', 'patients', '12', 'years', 'age', 'older', '.'], 'lemmatized': ['•', 'treatment', 'moderate', 'severe', 'hidradenitis', 'suppurativa', 'patient', '12', 'year', 'age', 'older', '.'], 'stemmed': ['•', 'treatment', 'moder', 'sever', 'hidraden', 'suppurativa', 'patient', '12', 'year', 'age', 'older', '.'], 'dependencies': [('•', 'nummod'), ('treatment', 'compound'), ('moder', 'nsubj'), ('sever', 'ROOT'), ('hidraden', 'compound'), ('suppurativa', 'compound'), ('patient', 'dobj'), ('12', 'nummod'), ('year', 'compound'), ('age', 'npadvmod'), ('older', 'amod'), ('.', 'punct')]}, {'original_sentence': '• the treatment of non-infectious intermediate, posterior, and panuveitis in pediatric \\npatients 2 years of age and older.', 'tokens': ['•', 'treatment', 'non-infectious', 'intermediate', ',', 'posterior', ',', 'panuveitis', 'pediatric', 'patients', '2', 'years', 'age', 'older', '.'], 'lemmatized': ['•', 'treatment', 'non-infectious', 'intermediate', ',', 'posterior', ',', 'panuveitis', 'pediatric', 'patient', '2', 'year', 'age', 'older', '.'], 'stemmed': ['•', 'treatment', 'non-infecti', 'intermedi', ',', 'posterior', ',', 'panuv', 'pediatr', 'patient', '2', 'year', 'age', 'older', '.'], 'dependencies': [('•', 'nummod'), ('treatment', 'dep'), ('non', 'amod'), ('-', 'amod'), ('infecti', 'amod'), ('intermedi', 'amod'), (',', 'punct'), ('posterior', 'intj'), (',', 'punct'), ('panuv', 'nmod'), ('pediatr', 'amod'), ('patient', 'ROOT'), ('2', 'nummod'), ('year', 'compound'), ('age', 'dobj'), ('older', 'amod'), ('.', 'punct')]}, {'original_sentence': 'Due to its inhibition of TNFα, HUMIRA administered during pregnancy could affect immune \\nresponse in the in utero-exposed newborn and infant.', 'tokens': ['Due', 'inhibition', 'TNFα', ',', 'HUMIRA', 'administered', 'pregnancy', 'could', 'affect', 'immune', 'response', 'utero-exposed', 'newborn', 'infant', '.'], 'lemmatized': ['Due', 'inhibition', 'TNFα', ',', 'HUMIRA', 'administered', 'pregnancy', 'could', 'affect', 'immune', 'response', 'utero-exposed', 'newborn', 'infant', '.'], 'stemmed': ['due', 'inhibit', 'tnfα', ',', 'humira', 'administ', 'pregnanc', 'could', 'affect', 'immun', 'respons', 'utero-expos', 'newborn', 'infant', '.'], 'dependencies': [('due', 'amod'), ('inhibit', 'compound'), ('tnfα', 'nsubj'), (',', 'punct'), ('humira', 'compound'), ('administ', 'compound'), ('pregnanc', 'nsubj'), ('could', 'aux'), ('affect', 'ROOT'), ('immun', 'compound'), ('respons', 'nmod'), ('utero', 'amod'), ('-', 'punct'), ('expos', 'nmod'), ('newborn', 'amod'), ('infant', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Data from eight infants exposed to \\nHUMIRA in utero suggest adalimumab crosses the placenta [see Use in Specific Populations \\n(8.1)].', 'tokens': ['Data', 'eight', 'infants', 'exposed', 'HUMIRA', 'utero', 'suggest', 'adalimumab', 'crosses', 'placenta', '[', 'see', 'Use', 'Specific', 'Populations', '(', '8.1', ')', ']', '.'], 'lemmatized': ['Data', 'eight', 'infant', 'exposed', 'HUMIRA', 'utero', 'suggest', 'adalimumab', 'cross', 'placenta', '[', 'see', 'Use', 'Specific', 'Populations', '(', '8.1', ')', ']', '.'], 'stemmed': ['data', 'eight', 'infant', 'expos', 'humira', 'utero', 'suggest', 'adalimumab', 'cross', 'placenta', '[', 'see', 'use', 'specif', 'popul', '(', '8.1', ')', ']', '.'], 'dependencies': [('data', 'nsubj'), ('eight', 'nummod'), ('infant', 'compound'), ('expos', 'compound'), ('humira', 'compound'), ('utero', 'appos'), ('suggest', 'ROOT'), ('adalimumab', 'compound'), ('cross', 'compound'), ('placenta', 'dobj'), ('[', 'punct'), ('see', 'parataxis'), ('use', 'compound'), ('specif', 'compound'), ('popul', 'dobj'), ('(', 'punct'), ('8.1', 'appos'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': 'The clinical significance of elevated adalimumab concentrations in infants is unknown.', 'tokens': ['clinical', 'significance', 'elevated', 'adalimumab', 'concentrations', 'infants', 'unknown', '.'], 'lemmatized': ['clinical', 'significance', 'elevated', 'adalimumab', 'concentration', 'infant', 'unknown', '.'], 'stemmed': ['clinic', 'signific', 'elev', 'adalimumab', 'concentr', 'infant', 'unknown', '.'], 'dependencies': [('clinic', 'compound'), ('signific', 'nmod'), ('elev', 'advmod'), ('adalimumab', 'nsubj'), ('concentr', 'compound'), ('infant', 'compound'), ('unknown', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'The safety of administering live or live-attenuated vaccines in exposed infants is unknown.', 'tokens': ['safety', 'administering', 'live', 'live-attenuated', 'vaccines', 'exposed', 'infants', 'unknown', '.'], 'lemmatized': ['safety', 'administering', 'live', 'live-attenuated', 'vaccine', 'exposed', 'infant', 'unknown', '.'], 'stemmed': ['safeti', 'administ', 'live', 'live-attenu', 'vaccin', 'expos', 'infant', 'unknown', '.'], 'dependencies': [('safeti', 'compound'), ('administ', 'nsubj'), ('live', 'amod'), ('live', 'amod'), ('-', 'punct'), ('attenu', 'nmod'), ('vaccin', 'compound'), ('expos', 'compound'), ('infant', 'compound'), ('unknown', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Risks \\nand benefits should be considered prior to vaccinating (live or live-attenuated) exposed infants.', 'tokens': ['Risks', 'benefits', 'considered', 'prior', 'vaccinating', '(', 'live', 'live-attenuated', ')', 'exposed', 'infants', '.'], 'lemmatized': ['Risks', 'benefit', 'considered', 'prior', 'vaccinating', '(', 'live', 'live-attenuated', ')', 'exposed', 'infant', '.'], 'stemmed': ['risk', 'benefit', 'consid', 'prior', 'vaccin', '(', 'live', 'live-attenu', ')', 'expos', 'infant', '.'], 'dependencies': [('risk', 'compound'), ('benefit', 'ROOT'), ('consid', 'advmod'), ('prior', 'advmod'), ('vaccin', 'appos'), ('(', 'punct'), ('live', 'amod'), ('live', 'amod'), ('-', 'punct'), ('attenu', 'dep'), (')', 'punct'), ('expos', 'compound'), ('infant', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Post-marketing cases of lymphoma, including hepatosplenic T-cell lymphoma and other \\nmalignancies, some fatal, have been reported among children, adolescents, and young adults who \\nreceived treatment with TNF-blockers including HUMIRA [see Warnings and Precautions \\n(5.2)].', 'tokens': ['Post-marketing', 'cases', 'lymphoma', ',', 'including', 'hepatosplenic', 'T-cell', 'lymphoma', 'malignancies', ',', 'fatal', ',', 'reported', 'among', 'children', ',', 'adolescents', ',', 'young', 'adults', 'received', 'treatment', 'TNF-blockers', 'including', 'HUMIRA', '[', 'see', 'Warnings', 'Precautions', '(', '5.2', ')', ']', '.'], 'lemmatized': ['Post-marketing', 'case', 'lymphoma', ',', 'including', 'hepatosplenic', 'T-cell', 'lymphoma', 'malignancy', ',', 'fatal', ',', 'reported', 'among', 'child', ',', 'adolescent', ',', 'young', 'adult', 'received', 'treatment', 'TNF-blockers', 'including', 'HUMIRA', '[', 'see', 'Warnings', 'Precautions', '(', '5.2', ')', ']', '.'], 'stemmed': ['post-market', 'case', 'lymphoma', ',', 'includ', 'hepatosplen', 't-cell', 'lymphoma', 'malign', ',', 'fatal', ',', 'report', 'among', 'child', ',', 'adolesc', ',', 'young', 'adult', 'receiv', 'treatment', 'tnf-blocker', 'includ', 'humira', '[', 'see', 'warn', 'precaut', '(', '5.2', ')', ']', '.'], 'dependencies': [('post', 'amod'), ('-', 'amod'), ('market', 'amod'), ('case', 'compound'), ('lymphoma', 'ROOT'), (',', 'punct'), ('includ', 'conj'), ('hepatosplen', 'compound'), ('t', 'compound'), ('-', 'punct'), ('cell', 'compound'), ('lymphoma', 'compound'), ('malign', 'dobj'), (',', 'punct'), ('fatal', 'amod'), (',', 'punct'), ('report', 'conj'), ('among', 'prep'), ('child', 'pobj'), (',', 'punct'), ('adolesc', 'npadvmod'), (',', 'punct'), ('young', 'amod'), ('adult', 'compound'), ('receiv', 'compound'), ('treatment', 'compound'), ('tnf', 'compound'), ('-', 'punct'), ('blocker', 'compound'), ('includ', 'compound'), ('humira', 'conj'), ('[', 'punct'), ('see', 'parataxis'), ('warn', 'xcomp'), ('precaut', 'dobj'), ('(', 'punct'), ('5.2', 'appos'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Juvenile Idiopathic Arthritis \\nIn Study JIA-I, HUMIRA was shown to reduce signs and symptoms of active polyarticular JIA \\nin patients 4 to 17 years of age [see Clinical Studies (14.2)].', 'tokens': ['Juvenile', 'Idiopathic', 'Arthritis', 'Study', 'JIA-I', ',', 'HUMIRA', 'shown', 'reduce', 'signs', 'symptoms', 'active', 'polyarticular', 'JIA', 'patients', '4', '17', 'years', 'age', '[', 'see', 'Clinical', 'Studies', '(', '14.2', ')', ']', '.'], 'lemmatized': ['Juvenile', 'Idiopathic', 'Arthritis', 'Study', 'JIA-I', ',', 'HUMIRA', 'shown', 'reduce', 'sign', 'symptom', 'active', 'polyarticular', 'JIA', 'patient', '4', '17', 'year', 'age', '[', 'see', 'Clinical', 'Studies', '(', '14.2', ')', ']', '.'], 'stemmed': ['juvenil', 'idiopath', 'arthriti', 'studi', 'jia-i', ',', 'humira', 'shown', 'reduc', 'sign', 'symptom', 'activ', 'polyarticular', 'jia', 'patient', '4', '17', 'year', 'age', '[', 'see', 'clinic', 'studi', '(', '14.2', ')', ']', '.'], 'dependencies': [('juvenil', 'compound'), ('idiopath', 'compound'), ('arthriti', 'compound'), ('studi', 'compound'), ('jia', 'compound'), ('-', 'punct'), ('i', 'nsubj'), (',', 'punct'), ('humira', 'appos'), ('shown', 'ROOT'), ('reduc', 'compound'), ('sign', 'compound'), ('symptom', 'compound'), ('activ', 'nmod'), ('polyarticular', 'appos'), ('jia', 'compound'), ('patient', 'nmod'), ('4', 'compound'), ('17', 'nummod'), ('year', 'compound'), ('age', 'dobj'), ('[', 'punct'), ('see', 'parataxis'), ('clinic', 'compound'), ('studi', 'npadvmod'), ('(', 'punct'), ('14.2', 'appos'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': 'In Study JIA-II, the safety profile \\nfor patients 2 to <4 years of age was similar to the safety profile for patients 4 to 17 years of age \\nwith polyarticular JIA [see Adverse Reactions (6.1)].', 'tokens': ['Study', 'JIA-II', ',', 'safety', 'profile', 'patients', '2', '<', '4', 'years', 'age', 'similar', 'safety', 'profile', 'patients', '4', '17', 'years', 'age', 'polyarticular', 'JIA', '[', 'see', 'Adverse', 'Reactions', '(', '6.1', ')', ']', '.'], 'lemmatized': ['Study', 'JIA-II', ',', 'safety', 'profile', 'patient', '2', '<', '4', 'year', 'age', 'similar', 'safety', 'profile', 'patient', '4', '17', 'year', 'age', 'polyarticular', 'JIA', '[', 'see', 'Adverse', 'Reactions', '(', '6.1', ')', ']', '.'], 'stemmed': ['studi', 'jia-ii', ',', 'safeti', 'profil', 'patient', '2', '<', '4', 'year', 'age', 'similar', 'safeti', 'profil', 'patient', '4', '17', 'year', 'age', 'polyarticular', 'jia', '[', 'see', 'advers', 'reaction', '(', '6.1', ')', ']', '.'], 'dependencies': [('studi', 'compound'), ('jia', 'compound'), ('-', 'punct'), ('ii', 'dep'), (',', 'punct'), ('safeti', 'compound'), ('profil', 'npadvmod'), ('patient', 'nsubj'), ('2', 'nummod'), ('<', 'dep'), ('4', 'nummod'), ('year', 'compound'), ('age', 'nmod'), ('similar', 'amod'), ('safeti', 'compound'), ('profil', 'dobj'), ('patient', 'ROOT'), ('4', 'compound'), ('17', 'nummod'), ('year', 'compound'), ('age', 'compound'), ('polyarticular', 'npadvmod'), ('jia', 'punct'), ('[', 'punct'), ('see', 'ROOT'), ('advers', 'compound'), ('reaction', 'dobj'), ('(', 'punct'), ('6.1', 'appos'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': 'HUMIRA has not been studied in patients \\nwith polyarticular JIA less than 2 years of age or in patients with a weight below 10 kg.', 'tokens': ['HUMIRA', 'studied', 'patients', 'polyarticular', 'JIA', 'less', '2', 'years', 'age', 'patients', 'weight', '10', 'kg', '.'], 'lemmatized': ['HUMIRA', 'studied', 'patient', 'polyarticular', 'JIA', 'less', '2', 'year', 'age', 'patient', 'weight', '10', 'kg', '.'], 'stemmed': ['humira', 'studi', 'patient', 'polyarticular', 'jia', 'less', '2', 'year', 'age', 'patient', 'weight', '10', 'kg', '.'], 'dependencies': [('humira', 'compound'), ('studi', 'compound'), ('patient', 'compound'), ('polyarticular', 'compound'), ('jia', 'ROOT'), ('less', 'amod'), ('2', 'nummod'), ('year', 'compound'), ('age', 'compound'), ('patient', 'compound'), ('weight', 'appos'), ('10', 'nummod'), ('kg', 'appos'), ('.', 'punct')]}, {'original_sentence': 'The safety of HUMIRA in patients in the polyarticular JIA trials was generally similar to that \\nobserved in adults with certain exceptions [see Adverse Reactions (6.1)].', 'tokens': ['safety', 'HUMIRA', 'patients', 'polyarticular', 'JIA', 'trials', 'generally', 'similar', 'observed', 'adults', 'certain', 'exceptions', '[', 'see', 'Adverse', 'Reactions', '(', '6.1', ')', ']', '.'], 'lemmatized': ['safety', 'HUMIRA', 'patient', 'polyarticular', 'JIA', 'trial', 'generally', 'similar', 'observed', 'adult', 'certain', 'exception', '[', 'see', 'Adverse', 'Reactions', '(', '6.1', ')', ']', '.'], 'stemmed': ['safeti', 'humira', 'patient', 'polyarticular', 'jia', 'trial', 'gener', 'similar', 'observ', 'adult', 'certain', 'except', '[', 'see', 'advers', 'reaction', '(', '6.1', ')', ']', '.'], 'dependencies': [('safeti', 'compound'), ('humira', 'nmod'), ('patient', 'nmod'), ('polyarticular', 'nmod'), ('jia', 'compound'), ('trial', 'compound'), ('gener', 'nmod'), ('similar', 'amod'), ('observ', 'compound'), ('adult', 'ROOT'), ('certain', 'amod'), ('except', 'prep'), ('[', 'punct'), ('see', 'pcomp'), ('advers', 'compound'), ('reaction', 'dobj'), ('(', 'punct'), ('6.1', 'appos'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': 'The safety and effectiveness of HUMIRA have not been established in pediatric patients with \\nJIA less than 2 years of age.', 'tokens': ['safety', 'effectiveness', 'HUMIRA', 'established', 'pediatric', 'patients', 'JIA', 'less', '2', 'years', 'age', '.'], 'lemmatized': ['safety', 'effectiveness', 'HUMIRA', 'established', 'pediatric', 'patient', 'JIA', 'less', '2', 'year', 'age', '.'], 'stemmed': ['safeti', 'effect', 'humira', 'establish', 'pediatr', 'patient', 'jia', 'less', '2', 'year', 'age', '.'], 'dependencies': [('safeti', 'compound'), ('effect', 'compound'), ('humira', 'nsubj'), ('establish', 'ROOT'), ('pediatr', 'amod'), ('patient', 'dobj'), ('jia', 'npadvmod'), ('less', 'advmod'), ('2', 'nummod'), ('year', 'compound'), ('age', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Pediatric Crohn’s Disease \\nThe safety and effectiveness of HUMIRA for the treatment of moderately to severely active \\nCrohn’s disease have been established in pediatric patients 6 years of age and older.', 'tokens': ['Pediatric', 'Crohn', '’', 'Disease', 'safety', 'effectiveness', 'HUMIRA', 'treatment', 'moderately', 'severely', 'active', 'Crohn', '’', 'disease', 'established', 'pediatric', 'patients', '6', 'years', 'age', 'older', '.'], 'lemmatized': ['Pediatric', 'Crohn', '’', 'Disease', 'safety', 'effectiveness', 'HUMIRA', 'treatment', 'moderately', 'severely', 'active', 'Crohn', '’', 'disease', 'established', 'pediatric', 'patient', '6', 'year', 'age', 'older', '.'], 'stemmed': ['pediatr', 'crohn', '’', 'diseas', 'safeti', 'effect', 'humira', 'treatment', 'moder', 'sever', 'activ', 'crohn', '’', 'diseas', 'establish', 'pediatr', 'patient', '6', 'year', 'age', 'older', '.'], 'dependencies': [('pediatr', 'amod'), ('crohn', 'nsubj'), ('’', 'punct'), ('diseas', 'compound'), ('safeti', 'compound'), ('effect', 'compound'), ('humira', 'compound'), ('treatment', 'compound'), ('moder', 'nsubj'), ('sever', 'ROOT'), ('activ', 'compound'), ('crohn', 'dobj'), ('’', 'punct'), ('diseas', 'nsubj'), ('establish', 'ccomp'), ('pediatr', 'amod'), ('patient', 'nmod'), ('6', 'nummod'), ('year', 'compound'), ('age', 'npadvmod'), ('older', 'acomp'), ('.', 'punct')]}, {'original_sentence': 'Use of \\nHUMIRA for this indication is supported by evidence from adequate and well-controlled studies \\nin adults with additional data from a randomized, double-blind, 52-week clinical study of two \\ndose concentrations of HUMIRA in 192 pediatric patients (6 years to 17 years of age) [see \\nAdverse Reactions (6.1), Clinical Pharmacology (12.2, 12.3), Clinical Studies (14.6)].', 'tokens': ['Use', 'HUMIRA', 'indication', 'supported', 'evidence', 'adequate', 'well-controlled', 'studies', 'adults', 'additional', 'data', 'randomized', ',', 'double-blind', ',', '52-week', 'clinical', 'study', 'two', 'dose', 'concentrations', 'HUMIRA', '192', 'pediatric', 'patients', '(', '6', 'years', '17', 'years', 'age', ')', '[', 'see', 'Adverse', 'Reactions', '(', '6.1', ')', ',', 'Clinical', 'Pharmacology', '(', '12.2', ',', '12.3', ')', ',', 'Clinical', 'Studies', '(', '14.6', ')', ']', '.'], 'lemmatized': ['Use', 'HUMIRA', 'indication', 'supported', 'evidence', 'adequate', 'well-controlled', 'study', 'adult', 'additional', 'data', 'randomized', ',', 'double-blind', ',', '52-week', 'clinical', 'study', 'two', 'dose', 'concentration', 'HUMIRA', '192', 'pediatric', 'patient', '(', '6', 'year', '17', 'year', 'age', ')', '[', 'see', 'Adverse', 'Reactions', '(', '6.1', ')', ',', 'Clinical', 'Pharmacology', '(', '12.2', ',', '12.3', ')', ',', 'Clinical', 'Studies', '(', '14.6', ')', ']', '.'], 'stemmed': ['use', 'humira', 'indic', 'support', 'evid', 'adequ', 'well-control', 'studi', 'adult', 'addit', 'data', 'random', ',', 'double-blind', ',', '52-week', 'clinic', 'studi', 'two', 'dose', 'concentr', 'humira', '192', 'pediatr', 'patient', '(', '6', 'year', '17', 'year', 'age', ')', '[', 'see', 'advers', 'reaction', '(', '6.1', ')', ',', 'clinic', 'pharmacolog', '(', '12.2', ',', '12.3', ')', ',', 'clinic', 'studi', '(', '14.6', ')', ']', '.'], 'dependencies': [('use', 'ROOT'), ('humira', 'nmod'), ('indic', 'amod'), ('support', 'compound'), ('evid', 'nmod'), ('adequ', 'nmod'), ('well', 'advmod'), ('-', 'punct'), ('control', 'compound'), ('studi', 'amod'), ('adult', 'compound'), ('addit', 'compound'), ('data', 'dobj'), ('random', 'amod'), (',', 'punct'), ('double', 'amod'), ('-', 'punct'), ('blind', 'amod'), (',', 'punct'), ('52', 'nummod'), ('-', 'punct'), ('week', 'compound'), ('clinic', 'nmod'), ('studi', 'appos'), ('two', 'nummod'), ('dose', 'compound'), ('concentr', 'appos'), ('humira', 'appos'), ('192', 'nummod'), ('pediatr', 'amod'), ('patient', 'appos'), ('(', 'punct'), ('6', 'nummod'), ('year', 'npadvmod'), ('17', 'nummod'), ('year', 'compound'), ('age', 'appos'), (')', 'punct'), ('[', 'punct'), ('see', 'ROOT'), ('advers', 'compound'), ('reaction', 'dobj'), ('(', 'punct'), ('6.1', 'appos'), (')', 'punct'), (',', 'punct'), ('clinic', 'compound'), ('pharmacolog', 'conj'), ('(', 'punct'), ('12.2', 'nummod'), (',', 'punct'), ('12.3', 'appos'), (')', 'punct'), (',', 'punct'), ('clinic', 'compound'), ('studi', 'conj'), ('(', 'punct'), ('14.6', 'appos'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': 'The \\nadverse reaction profile in patients 6 years to 17 years of age was similar to adults.', 'tokens': ['adverse', 'reaction', 'profile', 'patients', '6', 'years', '17', 'years', 'age', 'similar', 'adults', '.'], 'lemmatized': ['adverse', 'reaction', 'profile', 'patient', '6', 'year', '17', 'year', 'age', 'similar', 'adult', '.'], 'stemmed': ['advers', 'reaction', 'profil', 'patient', '6', 'year', '17', 'year', 'age', 'similar', 'adult', '.'], 'dependencies': [('advers', 'compound'), ('reaction', 'compound'), ('profil', 'compound'), ('patient', 'ROOT'), ('6', 'nummod'), ('year', 'nmod'), ('17', 'nummod'), ('year', 'compound'), ('age', 'nmod'), ('similar', 'amod'), ('adult', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The safety and effectiveness of HUMIRA have not been established in pediatric patients with \\nCrohn’s disease less than 6 years of age.', 'tokens': ['safety', 'effectiveness', 'HUMIRA', 'established', 'pediatric', 'patients', 'Crohn', '’', 'disease', 'less', '6', 'years', 'age', '.'], 'lemmatized': ['safety', 'effectiveness', 'HUMIRA', 'established', 'pediatric', 'patient', 'Crohn', '’', 'disease', 'less', '6', 'year', 'age', '.'], 'stemmed': ['safeti', 'effect', 'humira', 'establish', 'pediatr', 'patient', 'crohn', '’', 'diseas', 'less', '6', 'year', 'age', '.'], 'dependencies': [('safeti', 'compound'), ('effect', 'compound'), ('humira', 'nsubj'), ('establish', 'ROOT'), ('pediatr', 'amod'), ('patient', 'compound'), ('crohn', 'nmod'), ('’', 'punct'), ('diseas', 'dobj'), ('less', 'amod'), ('6', 'nummod'), ('year', 'compound'), ('age', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Pediatric Ulcerative Colitis \\nThe safety and effectiveness of HUMIRA for the treatment of moderately to severely active \\nulcerative colitis have been established in pediatric patients 5 years of age and older.', 'tokens': ['Pediatric', 'Ulcerative', 'Colitis', 'safety', 'effectiveness', 'HUMIRA', 'treatment', 'moderately', 'severely', 'active', 'ulcerative', 'colitis', 'established', 'pediatric', 'patients', '5', 'years', 'age', 'older', '.'], 'lemmatized': ['Pediatric', 'Ulcerative', 'Colitis', 'safety', 'effectiveness', 'HUMIRA', 'treatment', 'moderately', 'severely', 'active', 'ulcerative', 'colitis', 'established', 'pediatric', 'patient', '5', 'year', 'age', 'older', '.'], 'stemmed': ['pediatr', 'ulcer', 'coliti', 'safeti', 'effect', 'humira', 'treatment', 'moder', 'sever', 'activ', 'ulcer', 'coliti', 'establish', 'pediatr', 'patient', '5', 'year', 'age', 'older', '.'], 'dependencies': [('pediatr', 'amod'), ('ulcer', 'compound'), ('coliti', 'compound'), ('safeti', 'compound'), ('effect', 'compound'), ('humira', 'compound'), ('treatment', 'compound'), ('moder', 'nsubj'), ('sever', 'ROOT'), ('activ', 'compound'), ('ulcer', 'dobj'), ('coliti', 'nsubj'), ('establish', 'ccomp'), ('pediatr', 'amod'), ('patient', 'amod'), ('5', 'nummod'), ('year', 'compound'), ('age', 'npadvmod'), ('older', 'acomp'), ('.', 'punct')]}, {'original_sentence': 'Use of \\nHUMIRA for this indication is supported by evidence from adequate and well-controlled studies \\nin adults with additional data from a randomized, double-blind, 52-week clinical study of two', 'tokens': ['Use', 'HUMIRA', 'indication', 'supported', 'evidence', 'adequate', 'well-controlled', 'studies', 'adults', 'additional', 'data', 'randomized', ',', 'double-blind', ',', '52-week', 'clinical', 'study', 'two'], 'lemmatized': ['Use', 'HUMIRA', 'indication', 'supported', 'evidence', 'adequate', 'well-controlled', 'study', 'adult', 'additional', 'data', 'randomized', ',', 'double-blind', ',', '52-week', 'clinical', 'study', 'two'], 'stemmed': ['use', 'humira', 'indic', 'support', 'evid', 'adequ', 'well-control', 'studi', 'adult', 'addit', 'data', 'random', ',', 'double-blind', ',', '52-week', 'clinic', 'studi', 'two'], 'dependencies': [('use', 'ROOT'), ('humira', 'nmod'), ('indic', 'amod'), ('support', 'compound'), ('evid', 'nmod'), ('adequ', 'nmod'), ('well', 'advmod'), ('-', 'punct'), ('control', 'compound'), ('studi', 'amod'), ('adult', 'compound'), ('addit', 'compound'), ('data', 'dobj'), ('random', 'amod'), (',', 'punct'), ('double', 'amod'), ('-', 'punct'), ('blind', 'amod'), (',', 'punct'), ('52', 'nummod'), ('-', 'punct'), ('week', 'compound'), ('clinic', 'compound'), ('studi', 'appos'), ('two', 'npadvmod')]}], 'text': '• the treatment of moderately to severely active ulcerative colitis in pediatric patients 5 \\nyears of age and older. \\n• the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age \\nand older.  \\n• the treatment of non-infectious intermediate, posterior, and panuveitis in pediatric \\npatients 2 years of age and older. \\nDue to its inhibition of TNFα, HUMIRA administered during pregnancy could affect immune \\nresponse in the in utero-exposed newborn and infant. Data from eight infants exposed to \\nHUMIRA in utero suggest adalimumab crosses the placenta [see Use in Specific Populations \\n(8.1)]. The clinical significance of elevated adalimumab concentrations in infants is unknown. \\nThe safety of administering live or live-attenuated vaccines in exposed infants is unknown. Risks \\nand benefits should be considered prior to vaccinating (live or live-attenuated) exposed infants.  \\nPost-marketing cases of lymphoma, including hepatosplenic T-cell lymphoma and other \\nmalignancies, some fatal, have been reported among children, adolescents, and young adults who \\nreceived treatment with TNF-blockers including HUMIRA [see Warnings and Precautions \\n(5.2)].  \\nJuvenile Idiopathic Arthritis \\nIn Study JIA-I, HUMIRA was shown to reduce signs and symptoms of active polyarticular JIA \\nin patients 4 to 17 years of age [see Clinical Studies (14.2)]. In Study JIA-II, the safety profile \\nfor patients 2 to <4 years of age was similar to the safety profile for patients 4 to 17 years of age \\nwith polyarticular JIA [see Adverse Reactions (6.1)]. HUMIRA has not been studied in patients \\nwith polyarticular JIA less than 2 years of age or in patients with a weight below 10 kg.  \\nThe safety of HUMIRA in patients in the polyarticular JIA trials was generally similar to that \\nobserved in adults with certain exceptions [see Adverse Reactions (6.1)].  \\nThe safety and effectiveness of HUMIRA have not been established in pediatric patients with \\nJIA less than 2 years of age. \\nPediatric Crohn’s Disease \\nThe safety and effectiveness of HUMIRA for the treatment of moderately to severely active \\nCrohn’s disease have been established in pediatric patients 6 years of age and older. Use of \\nHUMIRA for this indication is supported by evidence from adequate and well-controlled studies \\nin adults with additional data from a randomized, double-blind, 52-week clinical study of two \\ndose concentrations of HUMIRA in 192 pediatric patients (6 years to 17 years of age) [see \\nAdverse Reactions (6.1), Clinical Pharmacology (12.2, 12.3), Clinical Studies (14.6)]. The \\nadverse reaction profile in patients 6 years to 17 years of age was similar to adults.  \\nThe safety and effectiveness of HUMIRA have not been established in pediatric patients with \\nCrohn’s disease less than 6 years of age.  \\nPediatric Ulcerative Colitis \\nThe safety and effectiveness of HUMIRA for the treatment of moderately to severely active \\nulcerative colitis have been established in pediatric patients 5 years of age and older.  Use of \\nHUMIRA for this indication is supported by evidence from adequate and well-controlled studies \\nin adults with additional data from a randomized, double-blind, 52-week clinical study of two \\n'}, 'page_char_count': 3215, 'page_word_count': 489, 'sentences': ['• the treatment of moderately to severely active ulcerative colitis in pediatric patients 5 \\nyears of age and older.', '\\n• the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age \\nand older.', ' \\n• the treatment of non-infectious intermediate, posterior, and panuveitis in pediatric \\npatients 2 years of age and older.', '\\nDue to its inhibition of TNFα, HUMIRA administered during pregnancy could affect immune \\nresponse in the in utero-exposed newborn and infant.', 'Data from eight infants exposed to \\nHUMIRA in utero suggest adalimumab crosses the placenta [see Use in Specific Populations \\n(8.1)].', 'The clinical significance of elevated adalimumab concentrations in infants is unknown.', '\\nThe safety of administering live or live-attenuated vaccines in exposed infants is unknown.', 'Risks \\nand benefits should be considered prior to vaccinating (live or live-attenuated) exposed infants.', ' \\nPost-marketing cases of lymphoma, including hepatosplenic T-cell lymphoma and other \\nmalignancies, some fatal, have been reported among children, adolescents, and young adults who \\nreceived treatment with TNF-blockers including HUMIRA [see Warnings and Precautions \\n(5.2)].', ' \\nJuvenile Idiopathic Arthritis \\nIn Study JIA-I, HUMIRA was shown to reduce signs and symptoms of active polyarticular JIA \\nin patients 4 to 17 years of age [see Clinical Studies (14.2)].', 'In Study JIA-II, the safety profile \\nfor patients 2 to <4 years of age was similar to the safety profile for patients 4 to 17 years of age \\nwith polyarticular JIA [see Adverse Reactions (6.1)].', 'HUMIRA has not been studied in patients \\nwith polyarticular JIA less than 2 years of age or in patients with a weight below 10 kg.', ' \\nThe safety of HUMIRA in patients in the polyarticular JIA trials was generally similar to that \\nobserved in adults with certain exceptions [see Adverse Reactions (6.1)].', ' \\nThe safety and effectiveness of HUMIRA have not been established in pediatric patients with \\nJIA less than 2 years of age.', '\\nPediatric Crohn’s Disease \\nThe safety and effectiveness of HUMIRA for the treatment of moderately to severely active \\nCrohn’s disease have been established in pediatric patients 6 years of age and older.', 'Use of \\nHUMIRA for this indication is supported by evidence from adequate and well-controlled studies \\nin adults with additional data from a randomized, double-blind, 52-week clinical study of two \\ndose concentrations of HUMIRA in 192 pediatric patients (6 years to 17 years of age) [see \\nAdverse Reactions (6.1), Clinical Pharmacology (12.2, 12.3), Clinical Studies (14.6)].', 'The \\nadverse reaction profile in patients 6 years to 17 years of age was similar to adults.', ' \\nThe safety and effectiveness of HUMIRA have not been established in pediatric patients with \\nCrohn’s disease less than 6 years of age.', ' \\nPediatric Ulcerative Colitis \\nThe safety and effectiveness of HUMIRA for the treatment of moderately to severely active \\nulcerative colitis have been established in pediatric patients 5 years of age and older.', ' Use of \\nHUMIRA for this indication is supported by evidence from adequate and well-controlled studies \\nin adults with additional data from a randomized, double-blind, 52-week clinical study of two \\n'], 'page_sentence_count_spacy': 20}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "\r 30%|██▉       | 33/111 [00:00<00:01, 54.55it/s]"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "{'page_number': 27, 'text': 'dose concentrations of HUMIRA in 93 pediatric patients (5 years to 17 years of age) [see \\nAdverse Reactions (6.1), Clinical Pharmacology (12.3), Clinical Studies (14.8)]. The adverse \\nreaction profile in patients 5 years to 17 years of age was similar to adults.  \\nThe effectiveness of HUMIRA has not been established in patients who have lost response or \\nwere intolerant to TNF blockers. \\nThe safety and effectiveness of HUMIRA have not been established in pediatric patients with \\nulcerative colitis less than 5 years of age. \\nPediatric Uveitis \\nThe safety and effectiveness of HUMIRA for the treatment of non-infectious uveitis have been \\nestablished in pediatric patients 2 years of age and older. The use of HUMIRA is supported by \\nevidence from adequate and well-controlled studies of HUMIRA in adults and a 2:1 randomized, \\ncontrolled clinical study in 90 pediatric patients [see Clinical Studies (14.12)]. The safety and \\neffectiveness of HUMIRA have not been established in pediatric patients with uveitis less than 2 \\nyears of age.  \\nHidradenitis Suppurativa \\nUse of HUMIRA in pediatric patients 12 years of age and older for HS is supported by evidence \\nfrom adequate and well-controlled studies of HUMIRA in adult HS patients. Additional \\npopulation pharmacokinetic modeling and simulation predicted that weight-based dosing of \\nHUMIRA in pediatric patients 12 years of age and older can provide generally similar exposure \\nto adult HS patients. The course of HS is sufficiently similar in adult and adolescent patients to \\nallow extrapolation of data from adult to adolescent patients. The recommended dosage in \\npediatric patients 12 years of age or older is based on body weight [see Dosage and \\nAdministration (2.6), Clinical Pharmacology (12.3), and Clinical Studies (14.10)].  \\nThe safety and effectiveness of HUMIRA have not been established in patients less than 12 years \\nof age with HS.  \\n8.5 Geriatric Use \\nA total of 519 RA patients 65 years of age and older, including 107 patients 75 years of age and \\nolder, received HUMIRA in clinical studies RA-I through IV. No overall difference in \\neffectiveness was observed between these patients and younger patients. The frequency of \\nserious infection and malignancy among HUMIRA treated patients 65 years of age and older was \\nhigher than for those less than 65 years of age. Consider the benefits and risks of HUMIRA in \\npatients 65 years of age and older.  In patients treated with HUMIRA, closely monitor for the \\ndevelopment of infection or malignancy [see Warnings and Precautions (5.1, 5.2)].  \\n10 OVERDOSAGE \\nDoses up to 10 mg/kg have been administered to patients in clinical trials without evidence of \\ndose-limiting toxicities. In case of overdosage, it is recommended that the patient be monitored \\nfor any signs or symptoms of adverse reactions or effects and appropriate symptomatic treatment \\ninstituted immediately.  \\n', 'processed_text': {'sentences': [{'original_sentence': 'dose concentrations of HUMIRA in 93 pediatric patients (5 years to 17 years of age) [see \\nAdverse Reactions (6.1), Clinical Pharmacology (12.3), Clinical Studies (14.8)].', 'tokens': ['dose', 'concentrations', 'HUMIRA', '93', 'pediatric', 'patients', '(', '5', 'years', '17', 'years', 'age', ')', '[', 'see', 'Adverse', 'Reactions', '(', '6.1', ')', ',', 'Clinical', 'Pharmacology', '(', '12.3', ')', ',', 'Clinical', 'Studies', '(', '14.8', ')', ']', '.'], 'lemmatized': ['dose', 'concentration', 'HUMIRA', '93', 'pediatric', 'patient', '(', '5', 'year', '17', 'year', 'age', ')', '[', 'see', 'Adverse', 'Reactions', '(', '6.1', ')', ',', 'Clinical', 'Pharmacology', '(', '12.3', ')', ',', 'Clinical', 'Studies', '(', '14.8', ')', ']', '.'], 'stemmed': ['dose', 'concentr', 'humira', '93', 'pediatr', 'patient', '(', '5', 'year', '17', 'year', 'age', ')', '[', 'see', 'advers', 'reaction', '(', '6.1', ')', ',', 'clinic', 'pharmacolog', '(', '12.3', ')', ',', 'clinic', 'studi', '(', '14.8', ')', ']', '.'], 'dependencies': [('dose', 'compound'), ('concentr', 'nsubj'), ('humira', 'ROOT'), ('93', 'nummod'), ('pediatr', 'amod'), ('patient', 'appos'), ('(', 'punct'), ('5', 'nummod'), ('year', 'npadvmod'), ('17', 'nummod'), ('year', 'compound'), ('age', 'appos'), (')', 'punct'), ('[', 'punct'), ('see', 'ROOT'), ('advers', 'compound'), ('reaction', 'dobj'), ('(', 'punct'), ('6.1', 'appos'), (')', 'punct'), (',', 'punct'), ('clinic', 'compound'), ('pharmacolog', 'conj'), ('(', 'punct'), ('12.3', 'appos'), (')', 'punct'), (',', 'punct'), ('clinic', 'compound'), ('studi', 'conj'), ('(', 'punct'), ('14.8', 'appos'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': 'The adverse \\nreaction profile in patients 5 years to 17 years of age was similar to adults.', 'tokens': ['adverse', 'reaction', 'profile', 'patients', '5', 'years', '17', 'years', 'age', 'similar', 'adults', '.'], 'lemmatized': ['adverse', 'reaction', 'profile', 'patient', '5', 'year', '17', 'year', 'age', 'similar', 'adult', '.'], 'stemmed': ['advers', 'reaction', 'profil', 'patient', '5', 'year', '17', 'year', 'age', 'similar', 'adult', '.'], 'dependencies': [('advers', 'compound'), ('reaction', 'compound'), ('profil', 'nsubj'), ('patient', 'ROOT'), ('5', 'nummod'), ('year', 'nmod'), ('17', 'nummod'), ('year', 'compound'), ('age', 'nmod'), ('similar', 'amod'), ('adult', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The effectiveness of HUMIRA has not been established in patients who have lost response or \\nwere intolerant to TNF blockers.', 'tokens': ['effectiveness', 'HUMIRA', 'established', 'patients', 'lost', 'response', 'intolerant', 'TNF', 'blockers', '.'], 'lemmatized': ['effectiveness', 'HUMIRA', 'established', 'patient', 'lost', 'response', 'intolerant', 'TNF', 'blocker', '.'], 'stemmed': ['effect', 'humira', 'establish', 'patient', 'lost', 'respons', 'intoler', 'tnf', 'blocker', '.'], 'dependencies': [('effect', 'compound'), ('humira', 'nsubj'), ('establish', 'ROOT'), ('patient', 'compound'), ('lost', 'amod'), ('respons', 'compound'), ('intoler', 'compound'), ('tnf', 'compound'), ('blocker', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The safety and effectiveness of HUMIRA have not been established in pediatric patients with \\nulcerative colitis less than 5 years of age.', 'tokens': ['safety', 'effectiveness', 'HUMIRA', 'established', 'pediatric', 'patients', 'ulcerative', 'colitis', 'less', '5', 'years', 'age', '.'], 'lemmatized': ['safety', 'effectiveness', 'HUMIRA', 'established', 'pediatric', 'patient', 'ulcerative', 'colitis', 'less', '5', 'year', 'age', '.'], 'stemmed': ['safeti', 'effect', 'humira', 'establish', 'pediatr', 'patient', 'ulcer', 'coliti', 'less', '5', 'year', 'age', '.'], 'dependencies': [('safeti', 'compound'), ('effect', 'compound'), ('humira', 'nsubj'), ('establish', 'ROOT'), ('pediatr', 'amod'), ('patient', 'compound'), ('ulcer', 'dobj'), ('coliti', 'dobj'), ('less', 'amod'), ('5', 'nummod'), ('year', 'compound'), ('age', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Pediatric Uveitis \\nThe safety and effectiveness of HUMIRA for the treatment of non-infectious uveitis have been \\nestablished in pediatric patients 2 years of age and older.', 'tokens': ['Pediatric', 'Uveitis', 'safety', 'effectiveness', 'HUMIRA', 'treatment', 'non-infectious', 'uveitis', 'established', 'pediatric', 'patients', '2', 'years', 'age', 'older', '.'], 'lemmatized': ['Pediatric', 'Uveitis', 'safety', 'effectiveness', 'HUMIRA', 'treatment', 'non-infectious', 'uveitis', 'established', 'pediatric', 'patient', '2', 'year', 'age', 'older', '.'], 'stemmed': ['pediatr', 'uveiti', 'safeti', 'effect', 'humira', 'treatment', 'non-infecti', 'uveiti', 'establish', 'pediatr', 'patient', '2', 'year', 'age', 'older', '.'], 'dependencies': [('pediatr', 'amod'), ('uveiti', 'compound'), ('safeti', 'compound'), ('effect', 'compound'), ('humira', 'compound'), ('treatment', 'nmod'), ('non', 'amod'), ('-', 'amod'), ('infecti', 'amod'), ('uveiti', 'nsubj'), ('establish', 'ROOT'), ('pediatr', 'amod'), ('patient', 'nmod'), ('2', 'nummod'), ('year', 'compound'), ('age', 'npadvmod'), ('older', 'acomp'), ('.', 'punct')]}, {'original_sentence': 'The use of HUMIRA is supported by \\nevidence from adequate and well-controlled studies of HUMIRA in adults and a 2:1 randomized, \\ncontrolled clinical study in 90 pediatric patients [see Clinical Studies (14.12)].', 'tokens': ['use', 'HUMIRA', 'supported', 'evidence', 'adequate', 'well-controlled', 'studies', 'HUMIRA', 'adults', '2:1', 'randomized', ',', 'controlled', 'clinical', 'study', '90', 'pediatric', 'patients', '[', 'see', 'Clinical', 'Studies', '(', '14.12', ')', ']', '.'], 'lemmatized': ['use', 'HUMIRA', 'supported', 'evidence', 'adequate', 'well-controlled', 'study', 'HUMIRA', 'adult', '2:1', 'randomized', ',', 'controlled', 'clinical', 'study', '90', 'pediatric', 'patient', '[', 'see', 'Clinical', 'Studies', '(', '14.12', ')', ']', '.'], 'stemmed': ['use', 'humira', 'support', 'evid', 'adequ', 'well-control', 'studi', 'humira', 'adult', '2:1', 'random', ',', 'control', 'clinic', 'studi', '90', 'pediatr', 'patient', '[', 'see', 'clinic', 'studi', '(', '14.12', ')', ']', '.'], 'dependencies': [('use', 'ROOT'), ('humira', 'compound'), ('support', 'compound'), ('evid', 'nmod'), ('adequ', 'nmod'), ('well', 'compound'), ('-', 'punct'), ('control', 'compound'), ('studi', 'compound'), ('humira', 'compound'), ('adult', 'dobj'), ('2:1', 'npadvmod'), ('random', 'amod'), (',', 'punct'), ('control', 'compound'), ('clinic', 'dobj'), ('studi', 'npadvmod'), ('90', 'nummod'), ('pediatr', 'amod'), ('patient', 'dobj'), ('[', 'punct'), ('see', 'parataxis'), ('clinic', 'compound'), ('studi', 'dobj'), ('(', 'punct'), ('14.12', 'appos'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': 'The safety and \\neffectiveness of HUMIRA have not been established in pediatric patients with uveitis less than 2 \\nyears of age.', 'tokens': ['safety', 'effectiveness', 'HUMIRA', 'established', 'pediatric', 'patients', 'uveitis', 'less', '2', 'years', 'age', '.'], 'lemmatized': ['safety', 'effectiveness', 'HUMIRA', 'established', 'pediatric', 'patient', 'uveitis', 'less', '2', 'year', 'age', '.'], 'stemmed': ['safeti', 'effect', 'humira', 'establish', 'pediatr', 'patient', 'uveiti', 'less', '2', 'year', 'age', '.'], 'dependencies': [('safeti', 'compound'), ('effect', 'compound'), ('humira', 'nsubj'), ('establish', 'ROOT'), ('pediatr', 'amod'), ('patient', 'compound'), ('uveiti', 'dobj'), ('less', 'amod'), ('2', 'nummod'), ('year', 'compound'), ('age', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Hidradenitis Suppurativa \\nUse of HUMIRA in pediatric patients 12 years of age and older for HS is supported by evidence \\nfrom adequate and well-controlled studies of HUMIRA in adult HS patients.', 'tokens': ['Hidradenitis', 'Suppurativa', 'Use', 'HUMIRA', 'pediatric', 'patients', '12', 'years', 'age', 'older', 'HS', 'supported', 'evidence', 'adequate', 'well-controlled', 'studies', 'HUMIRA', 'adult', 'HS', 'patients', '.'], 'lemmatized': ['Hidradenitis', 'Suppurativa', 'Use', 'HUMIRA', 'pediatric', 'patient', '12', 'year', 'age', 'older', 'HS', 'supported', 'evidence', 'adequate', 'well-controlled', 'study', 'HUMIRA', 'adult', 'HS', 'patient', '.'], 'stemmed': ['hidraden', 'suppurativa', 'use', 'humira', 'pediatr', 'patient', '12', 'year', 'age', 'older', 'hs', 'support', 'evid', 'adequ', 'well-control', 'studi', 'humira', 'adult', 'hs', 'patient', '.'], 'dependencies': [('hidraden', 'compound'), ('suppurativa', 'compound'), ('use', 'dep'), ('humira', 'nmod'), ('pediatr', 'compound'), ('patient', 'ROOT'), ('12', 'nummod'), ('year', 'compound'), ('age', 'npadvmod'), ('older', 'amod'), ('hs', 'compound'), ('support', 'compound'), ('evid', 'nmod'), ('adequ', 'nmod'), ('well', 'amod'), ('-', 'punct'), ('control', 'nmod'), ('studi', 'compound'), ('humira', 'nmod'), ('adult', 'compound'), ('hs', 'compound'), ('patient', 'oprd'), ('.', 'punct')]}, {'original_sentence': 'Additional \\npopulation pharmacokinetic modeling and simulation predicted that weight-based dosing of \\nHUMIRA in pediatric patients 12 years of age and older can provide generally similar exposure \\nto adult HS patients.', 'tokens': ['Additional', 'population', 'pharmacokinetic', 'modeling', 'simulation', 'predicted', 'weight-based', 'dosing', 'HUMIRA', 'pediatric', 'patients', '12', 'years', 'age', 'older', 'provide', 'generally', 'similar', 'exposure', 'adult', 'HS', 'patients', '.'], 'lemmatized': ['Additional', 'population', 'pharmacokinetic', 'modeling', 'simulation', 'predicted', 'weight-based', 'dosing', 'HUMIRA', 'pediatric', 'patient', '12', 'year', 'age', 'older', 'provide', 'generally', 'similar', 'exposure', 'adult', 'HS', 'patient', '.'], 'stemmed': ['addit', 'popul', 'pharmacokinet', 'model', 'simul', 'predict', 'weight-bas', 'dose', 'humira', 'pediatr', 'patient', '12', 'year', 'age', 'older', 'provid', 'gener', 'similar', 'exposur', 'adult', 'hs', 'patient', '.'], 'dependencies': [('addit', 'compound'), ('popul', 'compound'), ('pharmacokinet', 'compound'), ('model', 'compound'), ('simul', 'nsubj'), ('predict', 'ROOT'), ('weight', 'compound'), ('-', 'punct'), ('bas', 'compound'), ('dose', 'compound'), ('humira', 'compound'), ('pediatr', 'compound'), ('patient', 'dobj'), ('12', 'nummod'), ('year', 'compound'), ('age', 'npadvmod'), ('older', 'amod'), ('provid', 'compound'), ('gener', 'compound'), ('similar', 'amod'), ('exposur', 'compound'), ('adult', 'compound'), ('hs', 'compound'), ('patient', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The course of HS is sufficiently similar in adult and adolescent patients to \\nallow extrapolation of data from adult to adolescent patients.', 'tokens': ['course', 'HS', 'sufficiently', 'similar', 'adult', 'adolescent', 'patients', 'allow', 'extrapolation', 'data', 'adult', 'adolescent', 'patients', '.'], 'lemmatized': ['course', 'HS', 'sufficiently', 'similar', 'adult', 'adolescent', 'patient', 'allow', 'extrapolation', 'data', 'adult', 'adolescent', 'patient', '.'], 'stemmed': ['cours', 'hs', 'suffici', 'similar', 'adult', 'adolesc', 'patient', 'allow', 'extrapol', 'data', 'adult', 'adolesc', 'patient', '.'], 'dependencies': [('cours', 'nsubj'), ('hs', 'nmod'), ('suffici', 'appos'), ('similar', 'amod'), ('adult', 'compound'), ('adolesc', 'compound'), ('patient', 'npadvmod'), ('allow', 'ROOT'), ('extrapol', 'compound'), ('data', 'compound'), ('adult', 'compound'), ('adolesc', 'compound'), ('patient', 'ccomp'), ('.', 'punct')]}, {'original_sentence': 'The recommended dosage in \\npediatric patients 12 years of age or older is based on body weight [see Dosage and \\nAdministration (2.6), Clinical Pharmacology (12.3), and Clinical Studies (14.10)].', 'tokens': ['recommended', 'dosage', 'pediatric', 'patients', '12', 'years', 'age', 'older', 'based', 'body', 'weight', '[', 'see', 'Dosage', 'Administration', '(', '2.6', ')', ',', 'Clinical', 'Pharmacology', '(', '12.3', ')', ',', 'Clinical', 'Studies', '(', '14.10', ')', ']', '.'], 'lemmatized': ['recommended', 'dosage', 'pediatric', 'patient', '12', 'year', 'age', 'older', 'based', 'body', 'weight', '[', 'see', 'Dosage', 'Administration', '(', '2.6', ')', ',', 'Clinical', 'Pharmacology', '(', '12.3', ')', ',', 'Clinical', 'Studies', '(', '14.10', ')', ']', '.'], 'stemmed': ['recommend', 'dosag', 'pediatr', 'patient', '12', 'year', 'age', 'older', 'base', 'bodi', 'weight', '[', 'see', 'dosag', 'administr', '(', '2.6', ')', ',', 'clinic', 'pharmacolog', '(', '12.3', ')', ',', 'clinic', 'studi', '(', '14.10', ')', ']', '.'], 'dependencies': [('recommend', 'ROOT'), ('dosag', 'nmod'), ('pediatr', 'amod'), ('patient', 'dobj'), ('12', 'nummod'), ('year', 'compound'), ('age', 'nmod'), ('older', 'amod'), ('base', 'compound'), ('bodi', 'compound'), ('weight', 'npadvmod'), ('[', 'punct'), ('see', 'parataxis'), ('dosag', 'compound'), ('administr', 'dobj'), ('(', 'punct'), ('2.6', 'appos'), (')', 'punct'), (',', 'punct'), ('clinic', 'compound'), ('pharmacolog', 'conj'), ('(', 'punct'), ('12.3', 'appos'), (')', 'punct'), (',', 'punct'), ('clinic', 'compound'), ('studi', 'conj'), ('(', 'punct'), ('14.10', 'appos'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': 'The safety and effectiveness of HUMIRA have not been established in patients less than 12 years \\nof age with HS.', 'tokens': ['safety', 'effectiveness', 'HUMIRA', 'established', 'patients', 'less', '12', 'years', 'age', 'HS', '.'], 'lemmatized': ['safety', 'effectiveness', 'HUMIRA', 'established', 'patient', 'less', '12', 'year', 'age', 'HS', '.'], 'stemmed': ['safeti', 'effect', 'humira', 'establish', 'patient', 'less', '12', 'year', 'age', 'hs', '.'], 'dependencies': [('safeti', 'compound'), ('effect', 'compound'), ('humira', 'nsubj'), ('establish', 'ROOT'), ('patient', 'dobj'), ('less', 'amod'), ('12', 'nummod'), ('year', 'compound'), ('age', 'npadvmod'), ('hs', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': '8.5 Geriatric Use \\nA total of 519 RA patients 65 years of age and older, including 107 patients 75 years of age and \\nolder, received HUMIRA in clinical studies RA-I through IV.', 'tokens': ['8.5', 'Geriatric', 'Use', 'total', '519', 'RA', 'patients', '65', 'years', 'age', 'older', ',', 'including', '107', 'patients', '75', 'years', 'age', 'older', ',', 'received', 'HUMIRA', 'clinical', 'studies', 'RA-I', 'IV', '.'], 'lemmatized': ['8.5', 'Geriatric', 'Use', 'total', '519', 'RA', 'patient', '65', 'year', 'age', 'older', ',', 'including', '107', 'patient', '75', 'year', 'age', 'older', ',', 'received', 'HUMIRA', 'clinical', 'study', 'RA-I', 'IV', '.'], 'stemmed': ['8.5', 'geriatr', 'use', 'total', '519', 'ra', 'patient', '65', 'year', 'age', 'older', ',', 'includ', '107', 'patient', '75', 'year', 'age', 'older', ',', 'receiv', 'humira', 'clinic', 'studi', 'ra-i', 'iv', '.'], 'dependencies': [('8.5', 'nummod'), ('geriatr', 'compound'), ('use', 'ROOT'), ('total', 'amod'), ('519', 'nummod'), ('ra', 'compound'), ('patient', 'amod'), ('65', 'nummod'), ('year', 'compound'), ('age', 'npadvmod'), ('older', 'amod'), (',', 'punct'), ('includ', 'conj'), ('107', 'nummod'), ('patient', 'dobj'), ('75', 'nummod'), ('year', 'compound'), ('age', 'dobj'), ('older', 'amod'), (',', 'punct'), ('receiv', 'compound'), ('humira', 'compound'), ('clinic', 'compound'), ('studi', 'npadvmod'), ('ra', 'npadvmod'), ('-', 'punct'), ('i', 'appos'), ('iv', 'advmod'), ('.', 'punct')]}, {'original_sentence': 'No overall difference in \\neffectiveness was observed between these patients and younger patients.', 'tokens': ['overall', 'difference', 'effectiveness', 'observed', 'patients', 'younger', 'patients', '.'], 'lemmatized': ['overall', 'difference', 'effectiveness', 'observed', 'patient', 'younger', 'patient', '.'], 'stemmed': ['overal', 'differ', 'effect', 'observ', 'patient', 'younger', 'patient', '.'], 'dependencies': [('overal', 'nsubj'), ('differ', 'ROOT'), ('effect', 'compound'), ('observ', 'compound'), ('patient', 'nmod'), ('younger', 'amod'), ('patient', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The frequency of \\nserious infection and malignancy among HUMIRA treated patients 65 years of age and older was \\nhigher than for those less than 65 years of age.', 'tokens': ['frequency', 'serious', 'infection', 'malignancy', 'among', 'HUMIRA', 'treated', 'patients', '65', 'years', 'age', 'older', 'higher', 'less', '65', 'years', 'age', '.'], 'lemmatized': ['frequency', 'serious', 'infection', 'malignancy', 'among', 'HUMIRA', 'treated', 'patient', '65', 'year', 'age', 'older', 'higher', 'less', '65', 'year', 'age', '.'], 'stemmed': ['frequenc', 'seriou', 'infect', 'malign', 'among', 'humira', 'treat', 'patient', '65', 'year', 'age', 'older', 'higher', 'less', '65', 'year', 'age', '.'], 'dependencies': [('frequenc', 'compound'), ('seriou', 'npadvmod'), ('infect', 'compound'), ('malign', 'nsubj'), ('among', 'prep'), ('humira', 'nmod'), ('treat', 'compound'), ('patient', 'pobj'), ('65', 'nummod'), ('year', 'compound'), ('age', 'dep'), ('older', 'amod'), ('higher', 'advmod'), ('less', 'amod'), ('65', 'nummod'), ('year', 'compound'), ('age', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Consider the benefits and risks of HUMIRA in \\npatients 65 years of age and older.', 'tokens': ['Consider', 'benefits', 'risks', 'HUMIRA', 'patients', '65', 'years', 'age', 'older', '.'], 'lemmatized': ['Consider', 'benefit', 'risk', 'HUMIRA', 'patient', '65', 'year', 'age', 'older', '.'], 'stemmed': ['consid', 'benefit', 'risk', 'humira', 'patient', '65', 'year', 'age', 'older', '.'], 'dependencies': [('consid', 'advmod'), ('benefit', 'ROOT'), ('risk', 'compound'), ('humira', 'compound'), ('patient', 'dobj'), ('65', 'nummod'), ('year', 'compound'), ('age', 'npadvmod'), ('older', 'acomp'), ('.', 'punct')]}, {'original_sentence': 'In patients treated with HUMIRA, closely monitor for the \\ndevelopment of infection or malignancy [see Warnings and Precautions (5.1, 5.2)].', 'tokens': ['patients', 'treated', 'HUMIRA', ',', 'closely', 'monitor', 'development', 'infection', 'malignancy', '[', 'see', 'Warnings', 'Precautions', '(', '5.1', ',', '5.2', ')', ']', '.'], 'lemmatized': ['patient', 'treated', 'HUMIRA', ',', 'closely', 'monitor', 'development', 'infection', 'malignancy', '[', 'see', 'Warnings', 'Precautions', '(', '5.1', ',', '5.2', ')', ']', '.'], 'stemmed': ['patient', 'treat', 'humira', ',', 'close', 'monitor', 'develop', 'infect', 'malign', '[', 'see', 'warn', 'precaut', '(', '5.1', ',', '5.2', ')', ']', '.'], 'dependencies': [('patient', 'compound'), ('treat', 'compound'), ('humira', 'npadvmod'), (',', 'punct'), ('close', 'amod'), ('monitor', 'nsubj'), ('develop', 'ROOT'), ('infect', 'amod'), ('malign', 'dobj'), ('[', 'punct'), ('see', 'parataxis'), ('warn', 'compound'), ('precaut', 'dobj'), ('(', 'punct'), ('5.1', 'appos'), (',', 'punct'), ('5.2', 'npadvmod'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': '10 OVERDOSAGE \\nDoses up to 10 mg/kg have been administered to patients in clinical trials without evidence of \\ndose-limiting toxicities.', 'tokens': ['10', 'OVERDOSAGE', 'Doses', '10', 'mg/kg', 'administered', 'patients', 'clinical', 'trials', 'without', 'evidence', 'dose-limiting', 'toxicities', '.'], 'lemmatized': ['10', 'OVERDOSAGE', 'Doses', '10', 'mg/kg', 'administered', 'patient', 'clinical', 'trial', 'without', 'evidence', 'dose-limiting', 'toxicity', '.'], 'stemmed': ['10', 'overdosag', 'dose', '10', 'mg/kg', 'administ', 'patient', 'clinic', 'trial', 'without', 'evid', 'dose-limit', 'toxic', '.'], 'dependencies': [('10', 'nummod'), ('overdosag', 'amod'), ('dose', 'nmod'), ('10', 'nummod'), ('mg', 'nmod'), ('/', 'punct'), ('kg', 'npadvmod'), ('administ', 'nmod'), ('patient', 'amod'), ('clinic', 'compound'), ('trial', 'ROOT'), ('without', 'prep'), ('evid', 'compound'), ('dose', 'compound'), ('-', 'punct'), ('limit', 'compound'), ('toxic', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'In case of overdosage, it is recommended that the patient be monitored \\nfor any signs or symptoms of adverse reactions or effects and appropriate symptomatic treatment \\ninstituted immediately.', 'tokens': ['case', 'overdosage', ',', 'recommended', 'patient', 'monitored', 'signs', 'symptoms', 'adverse', 'reactions', 'effects', 'appropriate', 'symptomatic', 'treatment', 'instituted', 'immediately', '.'], 'lemmatized': ['case', 'overdosage', ',', 'recommended', 'patient', 'monitored', 'sign', 'symptom', 'adverse', 'reaction', 'effect', 'appropriate', 'symptomatic', 'treatment', 'instituted', 'immediately', '.'], 'stemmed': ['case', 'overdosag', ',', 'recommend', 'patient', 'monitor', 'sign', 'symptom', 'advers', 'reaction', 'effect', 'appropri', 'symptomat', 'treatment', 'institut', 'immedi', '.'], 'dependencies': [('case', 'nsubj'), ('overdosag', 'amod'), (',', 'punct'), ('recommend', 'ROOT'), ('patient', 'compound'), ('monitor', 'compound'), ('sign', 'compound'), ('symptom', 'compound'), ('advers', 'compound'), ('reaction', 'compound'), ('effect', 'compound'), ('appropri', 'compound'), ('symptomat', 'compound'), ('treatment', 'compound'), ('institut', 'compound'), ('immedi', 'dobj'), ('.', 'punct')]}], 'text': 'dose concentrations of HUMIRA in 93 pediatric patients (5 years to 17 years of age) [see \\nAdverse Reactions (6.1), Clinical Pharmacology (12.3), Clinical Studies (14.8)]. The adverse \\nreaction profile in patients 5 years to 17 years of age was similar to adults.  \\nThe effectiveness of HUMIRA has not been established in patients who have lost response or \\nwere intolerant to TNF blockers. \\nThe safety and effectiveness of HUMIRA have not been established in pediatric patients with \\nulcerative colitis less than 5 years of age. \\nPediatric Uveitis \\nThe safety and effectiveness of HUMIRA for the treatment of non-infectious uveitis have been \\nestablished in pediatric patients 2 years of age and older. The use of HUMIRA is supported by \\nevidence from adequate and well-controlled studies of HUMIRA in adults and a 2:1 randomized, \\ncontrolled clinical study in 90 pediatric patients [see Clinical Studies (14.12)]. The safety and \\neffectiveness of HUMIRA have not been established in pediatric patients with uveitis less than 2 \\nyears of age.  \\nHidradenitis Suppurativa \\nUse of HUMIRA in pediatric patients 12 years of age and older for HS is supported by evidence \\nfrom adequate and well-controlled studies of HUMIRA in adult HS patients. Additional \\npopulation pharmacokinetic modeling and simulation predicted that weight-based dosing of \\nHUMIRA in pediatric patients 12 years of age and older can provide generally similar exposure \\nto adult HS patients. The course of HS is sufficiently similar in adult and adolescent patients to \\nallow extrapolation of data from adult to adolescent patients. The recommended dosage in \\npediatric patients 12 years of age or older is based on body weight [see Dosage and \\nAdministration (2.6), Clinical Pharmacology (12.3), and Clinical Studies (14.10)].  \\nThe safety and effectiveness of HUMIRA have not been established in patients less than 12 years \\nof age with HS.  \\n8.5 Geriatric Use \\nA total of 519 RA patients 65 years of age and older, including 107 patients 75 years of age and \\nolder, received HUMIRA in clinical studies RA-I through IV. No overall difference in \\neffectiveness was observed between these patients and younger patients. The frequency of \\nserious infection and malignancy among HUMIRA treated patients 65 years of age and older was \\nhigher than for those less than 65 years of age. Consider the benefits and risks of HUMIRA in \\npatients 65 years of age and older.  In patients treated with HUMIRA, closely monitor for the \\ndevelopment of infection or malignancy [see Warnings and Precautions (5.1, 5.2)].  \\n10 OVERDOSAGE \\nDoses up to 10 mg/kg have been administered to patients in clinical trials without evidence of \\ndose-limiting toxicities. In case of overdosage, it is recommended that the patient be monitored \\nfor any signs or symptoms of adverse reactions or effects and appropriate symptomatic treatment \\ninstituted immediately.  \\n'}, 'page_char_count': 2905, 'page_word_count': 451, 'sentences': ['dose concentrations of HUMIRA in 93 pediatric patients (5 years to 17 years of age) [see \\nAdverse Reactions (6.1), Clinical Pharmacology (12.3), Clinical Studies (14.8)].', 'The adverse \\nreaction profile in patients 5 years to 17 years of age was similar to adults.', ' \\nThe effectiveness of HUMIRA has not been established in patients who have lost response or \\nwere intolerant to TNF blockers.', '\\nThe safety and effectiveness of HUMIRA have not been established in pediatric patients with \\nulcerative colitis less than 5 years of age.', '\\nPediatric Uveitis \\nThe safety and effectiveness of HUMIRA for the treatment of non-infectious uveitis have been \\nestablished in pediatric patients 2 years of age and older.', 'The use of HUMIRA is supported by \\nevidence from adequate and well-controlled studies of HUMIRA in adults and a 2:1 randomized, \\ncontrolled clinical study in 90 pediatric patients [see Clinical Studies (14.12)].', 'The safety and \\neffectiveness of HUMIRA have not been established in pediatric patients with uveitis less than 2 \\nyears of age.', ' \\nHidradenitis Suppurativa \\nUse of HUMIRA in pediatric patients 12 years of age and older for HS is supported by evidence \\nfrom adequate and well-controlled studies of HUMIRA in adult HS patients.', 'Additional \\npopulation pharmacokinetic modeling and simulation predicted that weight-based dosing of \\nHUMIRA in pediatric patients 12 years of age and older can provide generally similar exposure \\nto adult HS patients.', 'The course of HS is sufficiently similar in adult and adolescent patients to \\nallow extrapolation of data from adult to adolescent patients.', 'The recommended dosage in \\npediatric patients 12 years of age or older is based on body weight [see Dosage and \\nAdministration (2.6), Clinical Pharmacology (12.3), and Clinical Studies (14.10)].', ' \\nThe safety and effectiveness of HUMIRA have not been established in patients less than 12 years \\nof age with HS.', ' \\n8.5 Geriatric Use \\nA total of 519 RA patients 65 years of age and older, including 107 patients 75 years of age and \\nolder, received HUMIRA in clinical studies RA-I through IV.', 'No overall difference in \\neffectiveness was observed between these patients and younger patients.', 'The frequency of \\nserious infection and malignancy among HUMIRA treated patients 65 years of age and older was \\nhigher than for those less than 65 years of age.', 'Consider the benefits and risks of HUMIRA in \\npatients 65 years of age and older.', ' In patients treated with HUMIRA, closely monitor for the \\ndevelopment of infection or malignancy [see Warnings and Precautions (5.1, 5.2)].', ' \\n10 OVERDOSAGE \\nDoses up to 10 mg/kg have been administered to patients in clinical trials without evidence of \\ndose-limiting toxicities.', 'In case of overdosage, it is recommended that the patient be monitored \\nfor any signs or symptoms of adverse reactions or effects and appropriate symptomatic treatment \\ninstituted immediately.', ' \\n'], 'page_sentence_count_spacy': 20}\n",
            "{'page_number': 28, 'text': '11 DESCRIPTION \\nAdalimumab is a tumor necrosis factor blocker. Adalimumab is a recombinant human IgG1 \\nmonoclonal antibody created using phage display technology resulting in an antibody with \\nhuman derived heavy and light chain variable regions and human IgG1:k constant regions. \\nAdalimumab is produced by recombinant DNA technology in a mammalian cell (Chinese \\nHamster Ovary (CHO)) expression system and is purified by a process that includes specific \\nviral inactivation and removal steps. It consists of 1330 amino acids and has a molecular weight \\nof approximately 148 kilodaltons.  \\nHUMIRA (adalimumab) injection is supplied as a sterile, preservative-free solution for \\nsubcutaneous administration. The drug product is supplied as either a single-dose, prefilled pen \\n(HUMIRA Pen), as a single-dose, 1 mL prefilled glass syringe, or as a single-dose institutional \\nuse vial. Enclosed within the pen is a single-dose, 1 mL prefilled glass syringe. The solution of \\nHUMIRA is clear and colorless, with a pH of about 5.2.  \\nEach 80 mg/0.8 mL prefilled syringe or prefilled pen delivers 0.8 mL (80 mg) of drug product. \\nEach 0.8 mL of HUMIRA contains adalimumab (80 mg), mannitol (33.6 mg), polysorbate 80 \\n(0.8 mg), and Water for Injection, USP.  \\nEach 40 mg/0.4 mL prefilled syringe or prefilled pen delivers 0.4 mL (40 mg) of drug product. \\nEach 0.4 mL of HUMIRA contains adalimumab (40 mg), mannitol (16.8 mg), polysorbate 80 \\n(0.4 mg), and Water for Injection, USP.  \\nEach 40 mg/0.8 mL prefilled syringe, prefilled pen, or single-dose institutional use vial delivers \\n0.8 mL (40 mg) of drug product. Each 0.8 mL of HUMIRA contains adalimumab (40 mg), citric \\nacid monohydrate (1.04 mg), dibasic sodium phosphate dihydrate (1.22 mg), mannitol (9.6 mg), \\nmonobasic sodium phosphate dihydrate (0.69 mg), polysorbate 80 (0.8 mg), sodium chloride \\n(4.93 mg), sodium citrate (0.24 mg) and Water for Injection, USP. Sodium hydroxide is added as \\nnecessary to adjust pH.  \\nEach 20 mg/0.2 mL prefilled syringe delivers 0.2 mL (20 mg) of drug product. Each 0.2 mL of \\nHUMIRA contains adalimumab (20 mg), mannitol (8.4 mg), polysorbate 80 (0.2 mg), and Water \\nfor Injection, USP.  \\nEach 20 mg/0.4 mL prefilled syringe delivers 0.4 mL (20 mg) of drug product. Each 0.4 mL of \\nHUMIRA contains adalimumab (20 mg), citric acid monohydrate (0.52 mg), dibasic sodium \\nphosphate dihydrate (0.61 mg), mannitol (4.8 mg), monobasic sodium phosphate dihydrate (0.34 \\nmg), polysorbate 80 (0.4 mg), sodium chloride (2.47 mg), sodium citrate (0.12 mg) and Water \\nfor Injection, USP. Sodium hydroxide is added as necessary to adjust pH.  \\nEach 10 mg/0.1 mL prefilled syringe delivers 0.1 mL (10 mg) of drug product. Each 0.1 mL of \\nHUMIRA contains adalimumab (10 mg), mannitol (4.2 mg), polysorbate 80 (0.1 mg), and Water \\nfor Injection, USP.  \\nEach 10 mg/0.2 mL prefilled syringe delivers 0.2 mL (10 mg) of drug product. Each 0.2 mL of \\nHUMIRA contains adalimumab (10 mg), citric acid monohydrate (0.26 mg), dibasic sodium \\nphosphate dihydrate (0.31 mg), mannitol (2.4 mg), monobasic sodium phosphate dihydrate (0.17 \\nmg), polysorbate 80 (0.2 mg), sodium chloride (1.23 mg), sodium citrate (0.06 mg) and Water \\nfor Injection, USP. Sodium hydroxide is added as necessary to adjust pH.  \\n', 'processed_text': {'sentences': [{'original_sentence': '11 DESCRIPTION \\nAdalimumab is a tumor necrosis factor blocker.', 'tokens': ['11', 'DESCRIPTION', 'Adalimumab', 'tumor', 'necrosis', 'factor', 'blocker', '.'], 'lemmatized': ['11', 'DESCRIPTION', 'Adalimumab', 'tumor', 'necrosis', 'factor', 'blocker', '.'], 'stemmed': ['11', 'descript', 'adalimumab', 'tumor', 'necrosi', 'factor', 'blocker', '.'], 'dependencies': [('11', 'nummod'), ('descript', 'compound'), ('adalimumab', 'compound'), ('tumor', 'compound'), ('necrosi', 'compound'), ('factor', 'compound'), ('blocker', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Adalimumab is a recombinant human IgG1 \\nmonoclonal antibody created using phage display technology resulting in an antibody with \\nhuman derived heavy and light chain variable regions and human IgG1:k constant regions.', 'tokens': ['Adalimumab', 'recombinant', 'human', 'IgG1', 'monoclonal', 'antibody', 'created', 'using', 'phage', 'display', 'technology', 'resulting', 'antibody', 'human', 'derived', 'heavy', 'light', 'chain', 'variable', 'regions', 'human', 'IgG1', ':', 'k', 'constant', 'regions', '.'], 'lemmatized': ['Adalimumab', 'recombinant', 'human', 'IgG1', 'monoclonal', 'antibody', 'created', 'using', 'phage', 'display', 'technology', 'resulting', 'antibody', 'human', 'derived', 'heavy', 'light', 'chain', 'variable', 'region', 'human', 'IgG1', ':', 'k', 'constant', 'region', '.'], 'stemmed': ['adalimumab', 'recombin', 'human', 'igg1', 'monoclon', 'antibodi', 'creat', 'use', 'phage', 'display', 'technolog', 'result', 'antibodi', 'human', 'deriv', 'heavi', 'light', 'chain', 'variabl', 'region', 'human', 'igg1', ':', 'k', 'constant', 'region', '.'], 'dependencies': [('adalimumab', 'compound'), ('recombin', 'nsubj'), ('human', 'compound'), ('igg1', 'compound'), ('monoclon', 'appos'), ('antibodi', 'compound'), ('creat', 'compound'), ('use', 'compound'), ('phage', 'compound'), ('display', 'compound'), ('technolog', 'compound'), ('result', 'ROOT'), ('antibodi', 'appos'), ('human', 'nmod'), ('deriv', 'amod'), ('heavi', 'nmod'), ('light', 'compound'), ('chain', 'compound'), ('variabl', 'compound'), ('region', 'nmod'), ('human', 'amod'), ('igg1', 'dep'), (':', 'punct'), ('k', 'nmod'), ('constant', 'amod'), ('region', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Adalimumab is produced by recombinant DNA technology in a mammalian cell (Chinese \\nHamster Ovary (CHO)) expression system and is purified by a process that includes specific \\nviral inactivation and removal steps.', 'tokens': ['Adalimumab', 'produced', 'recombinant', 'DNA', 'technology', 'mammalian', 'cell', '(', 'Chinese', 'Hamster', 'Ovary', '(', 'CHO', ')', ')', 'expression', 'system', 'purified', 'process', 'includes', 'specific', 'viral', 'inactivation', 'removal', 'steps', '.'], 'lemmatized': ['Adalimumab', 'produced', 'recombinant', 'DNA', 'technology', 'mammalian', 'cell', '(', 'Chinese', 'Hamster', 'Ovary', '(', 'CHO', ')', ')', 'expression', 'system', 'purified', 'process', 'includes', 'specific', 'viral', 'inactivation', 'removal', 'step', '.'], 'stemmed': ['adalimumab', 'produc', 'recombin', 'dna', 'technolog', 'mammalian', 'cell', '(', 'chines', 'hamster', 'ovari', '(', 'cho', ')', ')', 'express', 'system', 'purifi', 'process', 'includ', 'specif', 'viral', 'inactiv', 'remov', 'step', '.'], 'dependencies': [('adalimumab', 'compound'), ('produc', 'compound'), ('recombin', 'compound'), ('dna', 'nsubj'), ('technolog', 'compound'), ('mammalian', 'compound'), ('cell', 'nsubj'), ('(', 'punct'), ('chines', 'compound'), ('hamster', 'compound'), ('ovari', 'appos'), ('(', 'punct'), ('cho', 'appos'), (')', 'punct'), (')', 'punct'), ('express', 'ROOT'), ('system', 'compound'), ('purifi', 'compound'), ('process', 'dobj'), ('includ', 'compound'), ('specif', 'compound'), ('viral', 'amod'), ('inactiv', 'compound'), ('remov', 'compound'), ('step', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'It consists of 1330 amino acids and has a molecular weight \\nof approximately 148 kilodaltons.', 'tokens': ['consists', '1330', 'amino', 'acids', 'molecular', 'weight', 'approximately', '148', 'kilodaltons', '.'], 'lemmatized': ['consists', '1330', 'amino', 'acid', 'molecular', 'weight', 'approximately', '148', 'kilodaltons', '.'], 'stemmed': ['consist', '1330', 'amino', 'acid', 'molecular', 'weight', 'approxim', '148', 'kilodalton', '.'], 'dependencies': [('consist', 'ROOT'), ('1330', 'nummod'), ('amino', 'nmod'), ('acid', 'nmod'), ('molecular', 'amod'), ('weight', 'compound'), ('approxim', 'nmod'), ('148', 'nummod'), ('kilodalton', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'HUMIRA (adalimumab) injection is supplied as a sterile, preservative-free solution for \\nsubcutaneous administration.', 'tokens': ['HUMIRA', '(', 'adalimumab', ')', 'injection', 'supplied', 'sterile', ',', 'preservative-free', 'solution', 'subcutaneous', 'administration', '.'], 'lemmatized': ['HUMIRA', '(', 'adalimumab', ')', 'injection', 'supplied', 'sterile', ',', 'preservative-free', 'solution', 'subcutaneous', 'administration', '.'], 'stemmed': ['humira', '(', 'adalimumab', ')', 'inject', 'suppli', 'steril', ',', 'preservative-fre', 'solut', 'subcutan', 'administr', '.'], 'dependencies': [('humira', 'nmod'), ('(', 'punct'), ('adalimumab', 'appos'), (')', 'punct'), ('inject', 'compound'), ('suppli', 'compound'), ('steril', 'ROOT'), (',', 'punct'), ('preservative', 'amod'), ('-', 'punct'), ('fre', 'amod'), ('solut', 'amod'), ('subcutan', 'compound'), ('administr', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'The drug product is supplied as either a single-dose, prefilled pen \\n(HUMIRA Pen), as a single-dose, 1 mL prefilled glass syringe, or as a single-dose institutional \\nuse vial.', 'tokens': ['drug', 'product', 'supplied', 'either', 'single-dose', ',', 'prefilled', 'pen', '(', 'HUMIRA', 'Pen', ')', ',', 'single-dose', ',', '1', 'mL', 'prefilled', 'glass', 'syringe', ',', 'single-dose', 'institutional', 'use', 'vial', '.'], 'lemmatized': ['drug', 'product', 'supplied', 'either', 'single-dose', ',', 'prefilled', 'pen', '(', 'HUMIRA', 'Pen', ')', ',', 'single-dose', ',', '1', 'mL', 'prefilled', 'glass', 'syringe', ',', 'single-dose', 'institutional', 'use', 'vial', '.'], 'stemmed': ['drug', 'product', 'suppli', 'either', 'single-dos', ',', 'prefil', 'pen', '(', 'humira', 'pen', ')', ',', 'single-dos', ',', '1', 'ml', 'prefil', 'glass', 'syring', ',', 'single-dos', 'institut', 'use', 'vial', '.'], 'dependencies': [('drug', 'compound'), ('product', 'compound'), ('suppli', 'ROOT'), ('either', 'preconj'), ('single', 'amod'), ('-', 'punct'), ('dos', 'appos'), (',', 'punct'), ('prefil', 'compound'), ('pen', 'conj'), ('(', 'punct'), ('humira', 'compound'), ('pen', 'appos'), (')', 'punct'), (',', 'punct'), ('single', 'amod'), ('-', 'punct'), ('dos', 'dep'), (',', 'punct'), ('1', 'nummod'), ('ml', 'nmod'), ('prefil', 'compound'), ('glass', 'compound'), ('syring', 'appos'), (',', 'punct'), ('single', 'amod'), ('-', 'punct'), ('dos', 'compound'), ('institut', 'nsubj'), ('use', 'conj'), ('vial', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Enclosed within the pen is a single-dose, 1 mL prefilled glass syringe.', 'tokens': ['Enclosed', 'within', 'pen', 'single-dose', ',', '1', 'mL', 'prefilled', 'glass', 'syringe', '.'], 'lemmatized': ['Enclosed', 'within', 'pen', 'single-dose', ',', '1', 'mL', 'prefilled', 'glass', 'syringe', '.'], 'stemmed': ['enclos', 'within', 'pen', 'single-dos', ',', '1', 'ml', 'prefil', 'glass', 'syring', '.'], 'dependencies': [('enclos', 'dep'), ('within', 'prep'), ('pen', 'nmod'), ('single', 'amod'), ('-', 'punct'), ('dos', 'pobj'), (',', 'punct'), ('1', 'nummod'), ('ml', 'npadvmod'), ('prefil', 'compound'), ('glass', 'compound'), ('syring', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'The solution of \\nHUMIRA is clear and colorless, with a pH of about 5.2.', 'tokens': ['solution', 'HUMIRA', 'clear', 'colorless', ',', 'pH', '5.2', '.'], 'lemmatized': ['solution', 'HUMIRA', 'clear', 'colorless', ',', 'pH', '5.2', '.'], 'stemmed': ['solut', 'humira', 'clear', 'colorless', ',', 'ph', '5.2', '.'], 'dependencies': [('solut', 'compound'), ('humira', 'compound'), ('clear', 'compound'), ('colorless', 'nsubj'), (',', 'punct'), ('ph', 'ROOT'), ('5.2', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Each 80 mg/0.8 mL prefilled syringe or prefilled pen delivers 0.8 mL (80 mg) of drug product.', 'tokens': ['80', 'mg/0.8', 'mL', 'prefilled', 'syringe', 'prefilled', 'pen', 'delivers', '0.8', 'mL', '(', '80', 'mg', ')', 'drug', 'product', '.'], 'lemmatized': ['80', 'mg/0.8', 'mL', 'prefilled', 'syringe', 'prefilled', 'pen', 'delivers', '0.8', 'mL', '(', '80', 'mg', ')', 'drug', 'product', '.'], 'stemmed': ['80', 'mg/0.8', 'ml', 'prefil', 'syring', 'prefil', 'pen', 'deliv', '0.8', 'ml', '(', '80', 'mg', ')', 'drug', 'product', '.'], 'dependencies': [('80', 'nummod'), ('mg/0.8', 'nsubj'), ('ml', 'aux'), ('prefil', 'ROOT'), ('syring', 'compound'), ('prefil', 'compound'), ('pen', 'compound'), ('deliv', 'dobj'), ('0.8', 'nummod'), ('ml', 'dep'), ('(', 'punct'), ('80', 'nummod'), ('mg', 'nmod'), (')', 'punct'), ('drug', 'compound'), ('product', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Each 0.8 mL of HUMIRA contains adalimumab (80 mg), mannitol (33.6 mg), polysorbate 80 \\n(0.8 mg), and Water for Injection, USP.', 'tokens': ['0.8', 'mL', 'HUMIRA', 'contains', 'adalimumab', '(', '80', 'mg', ')', ',', 'mannitol', '(', '33.6', 'mg', ')', ',', 'polysorbate', '80', '(', '0.8', 'mg', ')', ',', 'Water', 'Injection', ',', 'USP', '.'], 'lemmatized': ['0.8', 'mL', 'HUMIRA', 'contains', 'adalimumab', '(', '80', 'mg', ')', ',', 'mannitol', '(', '33.6', 'mg', ')', ',', 'polysorbate', '80', '(', '0.8', 'mg', ')', ',', 'Water', 'Injection', ',', 'USP', '.'], 'stemmed': ['0.8', 'ml', 'humira', 'contain', 'adalimumab', '(', '80', 'mg', ')', ',', 'mannitol', '(', '33.6', 'mg', ')', ',', 'polysorb', '80', '(', '0.8', 'mg', ')', ',', 'water', 'inject', ',', 'usp', '.'], 'dependencies': [('0.8', 'nummod'), ('ml', 'dep'), ('humira', 'nsubj'), ('contain', 'ROOT'), ('adalimumab', 'dobj'), ('(', 'punct'), ('80', 'nummod'), ('mg', 'parataxis'), (')', 'punct'), (',', 'punct'), ('mannitol', 'nsubj'), ('(', 'punct'), ('33.6', 'nummod'), ('mg', 'appos'), (')', 'punct'), (',', 'punct'), ('polysorb', 'conj'), ('80', 'dobj'), ('(', 'punct'), ('0.8', 'nummod'), ('mg', 'dobj'), (')', 'punct'), (',', 'punct'), ('water', 'compound'), ('inject', 'conj'), (',', 'punct'), ('usp', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Each 40 mg/0.4 mL prefilled syringe or prefilled pen delivers 0.4 mL (40 mg) of drug product.', 'tokens': ['40', 'mg/0.4', 'mL', 'prefilled', 'syringe', 'prefilled', 'pen', 'delivers', '0.4', 'mL', '(', '40', 'mg', ')', 'drug', 'product', '.'], 'lemmatized': ['40', 'mg/0.4', 'mL', 'prefilled', 'syringe', 'prefilled', 'pen', 'delivers', '0.4', 'mL', '(', '40', 'mg', ')', 'drug', 'product', '.'], 'stemmed': ['40', 'mg/0.4', 'ml', 'prefil', 'syring', 'prefil', 'pen', 'deliv', '0.4', 'ml', '(', '40', 'mg', ')', 'drug', 'product', '.'], 'dependencies': [('40', 'meta'), ('mg/0.4', 'appos'), ('ml', 'aux'), ('prefil', 'ROOT'), ('syring', 'compound'), ('prefil', 'compound'), ('pen', 'compound'), ('deliv', 'dobj'), ('0.4', 'nummod'), ('ml', 'npadvmod'), ('(', 'punct'), ('40', 'nummod'), ('mg', 'nmod'), (')', 'punct'), ('drug', 'compound'), ('product', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Each 0.4 mL of HUMIRA contains adalimumab (40 mg), mannitol (16.8 mg), polysorbate 80 \\n(0.4 mg), and Water for Injection, USP.', 'tokens': ['0.4', 'mL', 'HUMIRA', 'contains', 'adalimumab', '(', '40', 'mg', ')', ',', 'mannitol', '(', '16.8', 'mg', ')', ',', 'polysorbate', '80', '(', '0.4', 'mg', ')', ',', 'Water', 'Injection', ',', 'USP', '.'], 'lemmatized': ['0.4', 'mL', 'HUMIRA', 'contains', 'adalimumab', '(', '40', 'mg', ')', ',', 'mannitol', '(', '16.8', 'mg', ')', ',', 'polysorbate', '80', '(', '0.4', 'mg', ')', ',', 'Water', 'Injection', ',', 'USP', '.'], 'stemmed': ['0.4', 'ml', 'humira', 'contain', 'adalimumab', '(', '40', 'mg', ')', ',', 'mannitol', '(', '16.8', 'mg', ')', ',', 'polysorb', '80', '(', '0.4', 'mg', ')', ',', 'water', 'inject', ',', 'usp', '.'], 'dependencies': [('0.4', 'nummod'), ('ml', 'compound'), ('humira', 'nsubj'), ('contain', 'ROOT'), ('adalimumab', 'dobj'), ('(', 'punct'), ('40', 'nummod'), ('mg', 'parataxis'), (')', 'punct'), (',', 'punct'), ('mannitol', 'nsubj'), ('(', 'punct'), ('16.8', 'nummod'), ('mg', 'parataxis'), (')', 'punct'), (',', 'punct'), ('polysorb', 'conj'), ('80', 'dobj'), ('(', 'punct'), ('0.4', 'nummod'), ('mg', 'dobj'), (')', 'punct'), (',', 'punct'), ('water', 'compound'), ('inject', 'conj'), (',', 'punct'), ('usp', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Each 40 mg/0.8 mL prefilled syringe, prefilled pen, or single-dose institutional use vial delivers \\n0.8 mL (40 mg) of drug product.', 'tokens': ['40', 'mg/0.8', 'mL', 'prefilled', 'syringe', ',', 'prefilled', 'pen', ',', 'single-dose', 'institutional', 'use', 'vial', 'delivers', '0.8', 'mL', '(', '40', 'mg', ')', 'drug', 'product', '.'], 'lemmatized': ['40', 'mg/0.8', 'mL', 'prefilled', 'syringe', ',', 'prefilled', 'pen', ',', 'single-dose', 'institutional', 'use', 'vial', 'delivers', '0.8', 'mL', '(', '40', 'mg', ')', 'drug', 'product', '.'], 'stemmed': ['40', 'mg/0.8', 'ml', 'prefil', 'syring', ',', 'prefil', 'pen', ',', 'single-dos', 'institut', 'use', 'vial', 'deliv', '0.8', 'ml', '(', '40', 'mg', ')', 'drug', 'product', '.'], 'dependencies': [('40', 'nummod'), ('mg/0.8', 'dep'), ('ml', 'aux'), ('prefil', 'ROOT'), ('syring', 'dobj'), (',', 'punct'), ('prefil', 'compound'), ('pen', 'conj'), (',', 'punct'), ('single', 'amod'), ('-', 'punct'), ('dos', 'compound'), ('institut', 'nsubj'), ('use', 'conj'), ('vial', 'amod'), ('deliv', 'dobj'), ('0.8', 'nummod'), ('ml', 'nmod'), ('(', 'punct'), ('40', 'nummod'), ('mg', 'nmod'), (')', 'punct'), ('drug', 'compound'), ('product', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Each 0.8 mL of HUMIRA contains adalimumab (40 mg), citric \\nacid monohydrate (1.04 mg), dibasic sodium phosphate dihydrate (1.22 mg), mannitol (9.6 mg), \\nmonobasic sodium phosphate dihydrate (0.69 mg), polysorbate 80 (0.8 mg), sodium chloride \\n(4.93 mg), sodium citrate (0.24 mg) and Water for Injection, USP.', 'tokens': ['0.8', 'mL', 'HUMIRA', 'contains', 'adalimumab', '(', '40', 'mg', ')', ',', 'citric', 'acid', 'monohydrate', '(', '1.04', 'mg', ')', ',', 'dibasic', 'sodium', 'phosphate', 'dihydrate', '(', '1.22', 'mg', ')', ',', 'mannitol', '(', '9.6', 'mg', ')', ',', 'monobasic', 'sodium', 'phosphate', 'dihydrate', '(', '0.69', 'mg', ')', ',', 'polysorbate', '80', '(', '0.8', 'mg', ')', ',', 'sodium', 'chloride', '(', '4.93', 'mg', ')', ',', 'sodium', 'citrate', '(', '0.24', 'mg', ')', 'Water', 'Injection', ',', 'USP', '.'], 'lemmatized': ['0.8', 'mL', 'HUMIRA', 'contains', 'adalimumab', '(', '40', 'mg', ')', ',', 'citric', 'acid', 'monohydrate', '(', '1.04', 'mg', ')', ',', 'dibasic', 'sodium', 'phosphate', 'dihydrate', '(', '1.22', 'mg', ')', ',', 'mannitol', '(', '9.6', 'mg', ')', ',', 'monobasic', 'sodium', 'phosphate', 'dihydrate', '(', '0.69', 'mg', ')', ',', 'polysorbate', '80', '(', '0.8', 'mg', ')', ',', 'sodium', 'chloride', '(', '4.93', 'mg', ')', ',', 'sodium', 'citrate', '(', '0.24', 'mg', ')', 'Water', 'Injection', ',', 'USP', '.'], 'stemmed': ['0.8', 'ml', 'humira', 'contain', 'adalimumab', '(', '40', 'mg', ')', ',', 'citric', 'acid', 'monohydr', '(', '1.04', 'mg', ')', ',', 'dibas', 'sodium', 'phosphat', 'dihydr', '(', '1.22', 'mg', ')', ',', 'mannitol', '(', '9.6', 'mg', ')', ',', 'monobas', 'sodium', 'phosphat', 'dihydr', '(', '0.69', 'mg', ')', ',', 'polysorb', '80', '(', '0.8', 'mg', ')', ',', 'sodium', 'chlorid', '(', '4.93', 'mg', ')', ',', 'sodium', 'citrat', '(', '0.24', 'mg', ')', 'water', 'inject', ',', 'usp', '.'], 'dependencies': [('0.8', 'nummod'), ('ml', 'dep'), ('humira', 'nsubj'), ('contain', 'ROOT'), ('adalimumab', 'dobj'), ('(', 'punct'), ('40', 'nummod'), ('mg', 'parataxis'), (')', 'punct'), (',', 'punct'), ('citric', 'compound'), ('acid', 'compound'), ('monohydr', 'npadvmod'), ('(', 'punct'), ('1.04', 'nummod'), ('mg', 'appos'), (')', 'punct'), (',', 'punct'), ('dibas', 'compound'), ('sodium', 'compound'), ('phosphat', 'ROOT'), ('dihydr', 'intj'), ('(', 'punct'), ('1.22', 'nummod'), ('mg', 'parataxis'), (')', 'punct'), (',', 'punct'), ('mannitol', 'appos'), ('(', 'punct'), ('9.6', 'nummod'), ('mg', 'parataxis'), (')', 'punct'), (',', 'punct'), ('monobas', 'compound'), ('sodium', 'compound'), ('phosphat', 'compound'), ('dihydr', 'ROOT'), ('(', 'punct'), ('0.69', 'nummod'), ('mg', 'parataxis'), (')', 'punct'), (',', 'punct'), ('polysorb', 'conj'), ('80', 'nummod'), ('(', 'punct'), ('0.8', 'nummod'), ('mg', 'dep'), (')', 'punct'), (',', 'punct'), ('sodium', 'compound'), ('chlorid', 'appos'), ('(', 'punct'), ('4.93', 'nummod'), ('mg', 'parataxis'), (')', 'punct'), (',', 'punct'), ('sodium', 'compound'), ('citrat', 'conj'), ('(', 'punct'), ('0.24', 'nummod'), ('mg', 'appos'), (')', 'punct'), ('water', 'compound'), ('inject', 'appos'), (',', 'punct'), ('usp', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Sodium hydroxide is added as \\nnecessary to adjust pH.', 'tokens': ['Sodium', 'hydroxide', 'added', 'necessary', 'adjust', 'pH', '.'], 'lemmatized': ['Sodium', 'hydroxide', 'added', 'necessary', 'adjust', 'pH', '.'], 'stemmed': ['sodium', 'hydroxid', 'ad', 'necessari', 'adjust', 'ph', '.'], 'dependencies': [('sodium', 'compound'), ('hydroxid', 'amod'), ('ad', 'compound'), ('necessari', 'nsubj'), ('adjust', 'ROOT'), ('ph', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Each 20 mg/0.2 mL prefilled syringe delivers 0.2 mL (20 mg) of drug product.', 'tokens': ['20', 'mg/0.2', 'mL', 'prefilled', 'syringe', 'delivers', '0.2', 'mL', '(', '20', 'mg', ')', 'drug', 'product', '.'], 'lemmatized': ['20', 'mg/0.2', 'mL', 'prefilled', 'syringe', 'delivers', '0.2', 'mL', '(', '20', 'mg', ')', 'drug', 'product', '.'], 'stemmed': ['20', 'mg/0.2', 'ml', 'prefil', 'syring', 'deliv', '0.2', 'ml', '(', '20', 'mg', ')', 'drug', 'product', '.'], 'dependencies': [('20', 'meta'), ('mg/0.2', 'npadvmod'), ('ml', 'dep'), ('prefil', 'dep'), ('syring', 'compound'), ('deliv', 'dobj'), ('0.2', 'nummod'), ('ml', 'ROOT'), ('(', 'punct'), ('20', 'nummod'), ('mg', 'nmod'), (')', 'punct'), ('drug', 'compound'), ('product', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Each 0.2 mL of \\nHUMIRA contains adalimumab (20 mg), mannitol (8.4 mg), polysorbate 80 (0.2 mg), and Water \\nfor Injection, USP.', 'tokens': ['0.2', 'mL', 'HUMIRA', 'contains', 'adalimumab', '(', '20', 'mg', ')', ',', 'mannitol', '(', '8.4', 'mg', ')', ',', 'polysorbate', '80', '(', '0.2', 'mg', ')', ',', 'Water', 'Injection', ',', 'USP', '.'], 'lemmatized': ['0.2', 'mL', 'HUMIRA', 'contains', 'adalimumab', '(', '20', 'mg', ')', ',', 'mannitol', '(', '8.4', 'mg', ')', ',', 'polysorbate', '80', '(', '0.2', 'mg', ')', ',', 'Water', 'Injection', ',', 'USP', '.'], 'stemmed': ['0.2', 'ml', 'humira', 'contain', 'adalimumab', '(', '20', 'mg', ')', ',', 'mannitol', '(', '8.4', 'mg', ')', ',', 'polysorb', '80', '(', '0.2', 'mg', ')', ',', 'water', 'inject', ',', 'usp', '.'], 'dependencies': [('0.2', 'nummod'), ('ml', 'compound'), ('humira', 'nsubj'), ('contain', 'ROOT'), ('adalimumab', 'dobj'), ('(', 'punct'), ('20', 'nummod'), ('mg', 'appos'), (')', 'punct'), (',', 'punct'), ('mannitol', 'npadvmod'), ('(', 'punct'), ('8.4', 'nummod'), ('mg', 'appos'), (')', 'punct'), (',', 'punct'), ('polysorb', 'dep'), ('80', 'dobj'), ('(', 'punct'), ('0.2', 'nummod'), ('mg', 'dep'), (')', 'punct'), (',', 'punct'), ('water', 'compound'), ('inject', 'conj'), (',', 'punct'), ('usp', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Each 20 mg/0.4 mL prefilled syringe delivers 0.4 mL (20 mg) of drug product.', 'tokens': ['20', 'mg/0.4', 'mL', 'prefilled', 'syringe', 'delivers', '0.4', 'mL', '(', '20', 'mg', ')', 'drug', 'product', '.'], 'lemmatized': ['20', 'mg/0.4', 'mL', 'prefilled', 'syringe', 'delivers', '0.4', 'mL', '(', '20', 'mg', ')', 'drug', 'product', '.'], 'stemmed': ['20', 'mg/0.4', 'ml', 'prefil', 'syring', 'deliv', '0.4', 'ml', '(', '20', 'mg', ')', 'drug', 'product', '.'], 'dependencies': [('20', 'dep'), ('mg/0.4', 'appos'), ('ml', 'aux'), ('prefil', 'ROOT'), ('syring', 'compound'), ('deliv', 'dobj'), ('0.4', 'nummod'), ('ml', 'npadvmod'), ('(', 'punct'), ('20', 'nummod'), ('mg', 'appos'), (')', 'punct'), ('drug', 'compound'), ('product', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Each 0.4 mL of \\nHUMIRA contains adalimumab (20 mg), citric acid monohydrate (0.52 mg), dibasic sodium \\nphosphate dihydrate (0.61 mg), mannitol (4.8 mg), monobasic sodium phosphate dihydrate (0.34 \\nmg), polysorbate 80 (0.4 mg), sodium chloride (2.47 mg), sodium citrate (0.12 mg) and Water \\nfor Injection, USP.', 'tokens': ['0.4', 'mL', 'HUMIRA', 'contains', 'adalimumab', '(', '20', 'mg', ')', ',', 'citric', 'acid', 'monohydrate', '(', '0.52', 'mg', ')', ',', 'dibasic', 'sodium', 'phosphate', 'dihydrate', '(', '0.61', 'mg', ')', ',', 'mannitol', '(', '4.8', 'mg', ')', ',', 'monobasic', 'sodium', 'phosphate', 'dihydrate', '(', '0.34', 'mg', ')', ',', 'polysorbate', '80', '(', '0.4', 'mg', ')', ',', 'sodium', 'chloride', '(', '2.47', 'mg', ')', ',', 'sodium', 'citrate', '(', '0.12', 'mg', ')', 'Water', 'Injection', ',', 'USP', '.'], 'lemmatized': ['0.4', 'mL', 'HUMIRA', 'contains', 'adalimumab', '(', '20', 'mg', ')', ',', 'citric', 'acid', 'monohydrate', '(', '0.52', 'mg', ')', ',', 'dibasic', 'sodium', 'phosphate', 'dihydrate', '(', '0.61', 'mg', ')', ',', 'mannitol', '(', '4.8', 'mg', ')', ',', 'monobasic', 'sodium', 'phosphate', 'dihydrate', '(', '0.34', 'mg', ')', ',', 'polysorbate', '80', '(', '0.4', 'mg', ')', ',', 'sodium', 'chloride', '(', '2.47', 'mg', ')', ',', 'sodium', 'citrate', '(', '0.12', 'mg', ')', 'Water', 'Injection', ',', 'USP', '.'], 'stemmed': ['0.4', 'ml', 'humira', 'contain', 'adalimumab', '(', '20', 'mg', ')', ',', 'citric', 'acid', 'monohydr', '(', '0.52', 'mg', ')', ',', 'dibas', 'sodium', 'phosphat', 'dihydr', '(', '0.61', 'mg', ')', ',', 'mannitol', '(', '4.8', 'mg', ')', ',', 'monobas', 'sodium', 'phosphat', 'dihydr', '(', '0.34', 'mg', ')', ',', 'polysorb', '80', '(', '0.4', 'mg', ')', ',', 'sodium', 'chlorid', '(', '2.47', 'mg', ')', ',', 'sodium', 'citrat', '(', '0.12', 'mg', ')', 'water', 'inject', ',', 'usp', '.'], 'dependencies': [('0.4', 'nummod'), ('ml', 'compound'), ('humira', 'nsubj'), ('contain', 'ROOT'), ('adalimumab', 'dobj'), ('(', 'punct'), ('20', 'nummod'), ('mg', 'parataxis'), (')', 'punct'), (',', 'punct'), ('citric', 'compound'), ('acid', 'compound'), ('monohydr', 'npadvmod'), ('(', 'punct'), ('0.52', 'nummod'), ('mg', 'appos'), (')', 'punct'), (',', 'punct'), ('dibas', 'compound'), ('sodium', 'compound'), ('phosphat', 'ROOT'), ('dihydr', 'dep'), ('(', 'punct'), ('0.61', 'nummod'), ('mg', 'intj'), (')', 'punct'), (',', 'punct'), ('mannitol', 'npadvmod'), ('(', 'punct'), ('4.8', 'nummod'), ('mg', 'appos'), (')', 'punct'), (',', 'punct'), ('monobas', 'compound'), ('sodium', 'compound'), ('phosphat', 'nsubj'), ('dihydr', 'dep'), ('(', 'punct'), ('0.34', 'nummod'), ('mg', 'intj'), (')', 'punct'), (',', 'punct'), ('polysorb', 'ROOT'), ('80', 'npadvmod'), ('(', 'punct'), ('0.4', 'nummod'), ('mg', 'dobj'), (')', 'punct'), (',', 'punct'), ('sodium', 'dep'), ('chlorid', 'amod'), ('(', 'punct'), ('2.47', 'nummod'), ('mg', 'npadvmod'), (')', 'punct'), (',', 'punct'), ('sodium', 'compound'), ('citrat', 'npadvmod'), ('(', 'punct'), ('0.12', 'nummod'), ('mg', 'appos'), (')', 'punct'), ('water', 'compound'), ('inject', 'appos'), (',', 'punct'), ('usp', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Sodium hydroxide is added as necessary to adjust pH.', 'tokens': ['Sodium', 'hydroxide', 'added', 'necessary', 'adjust', 'pH', '.'], 'lemmatized': ['Sodium', 'hydroxide', 'added', 'necessary', 'adjust', 'pH', '.'], 'stemmed': ['sodium', 'hydroxid', 'ad', 'necessari', 'adjust', 'ph', '.'], 'dependencies': [('sodium', 'compound'), ('hydroxid', 'amod'), ('ad', 'compound'), ('necessari', 'nsubj'), ('adjust', 'ROOT'), ('ph', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Each 10 mg/0.1 mL prefilled syringe delivers 0.1 mL (10 mg) of drug product.', 'tokens': ['10', 'mg/0.1', 'mL', 'prefilled', 'syringe', 'delivers', '0.1', 'mL', '(', '10', 'mg', ')', 'drug', 'product', '.'], 'lemmatized': ['10', 'mg/0.1', 'mL', 'prefilled', 'syringe', 'delivers', '0.1', 'mL', '(', '10', 'mg', ')', 'drug', 'product', '.'], 'stemmed': ['10', 'mg/0.1', 'ml', 'prefil', 'syring', 'deliv', '0.1', 'ml', '(', '10', 'mg', ')', 'drug', 'product', '.'], 'dependencies': [('10', 'meta'), ('mg/0.1', 'npadvmod'), ('ml', 'compound'), ('prefil', 'compound'), ('syring', 'compound'), ('deliv', 'dep'), ('0.1', 'nummod'), ('ml', 'nmod'), ('(', 'punct'), ('10', 'nummod'), ('mg', 'nmod'), (')', 'punct'), ('drug', 'compound'), ('product', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Each 0.1 mL of \\nHUMIRA contains adalimumab (10 mg), mannitol (4.2 mg), polysorbate 80 (0.1 mg), and Water \\nfor Injection, USP.', 'tokens': ['0.1', 'mL', 'HUMIRA', 'contains', 'adalimumab', '(', '10', 'mg', ')', ',', 'mannitol', '(', '4.2', 'mg', ')', ',', 'polysorbate', '80', '(', '0.1', 'mg', ')', ',', 'Water', 'Injection', ',', 'USP', '.'], 'lemmatized': ['0.1', 'mL', 'HUMIRA', 'contains', 'adalimumab', '(', '10', 'mg', ')', ',', 'mannitol', '(', '4.2', 'mg', ')', ',', 'polysorbate', '80', '(', '0.1', 'mg', ')', ',', 'Water', 'Injection', ',', 'USP', '.'], 'stemmed': ['0.1', 'ml', 'humira', 'contain', 'adalimumab', '(', '10', 'mg', ')', ',', 'mannitol', '(', '4.2', 'mg', ')', ',', 'polysorb', '80', '(', '0.1', 'mg', ')', ',', 'water', 'inject', ',', 'usp', '.'], 'dependencies': [('0.1', 'nummod'), ('ml', 'nsubj'), ('humira', 'appos'), ('contain', 'ROOT'), ('adalimumab', 'dobj'), ('(', 'punct'), ('10', 'nummod'), ('mg', 'appos'), (')', 'punct'), (',', 'punct'), ('mannitol', 'npadvmod'), ('(', 'punct'), ('4.2', 'nummod'), ('mg', 'appos'), (')', 'punct'), (',', 'punct'), ('polysorb', 'dep'), ('80', 'dobj'), ('(', 'punct'), ('0.1', 'nummod'), ('mg', 'dep'), (')', 'punct'), (',', 'punct'), ('water', 'compound'), ('inject', 'npadvmod'), (',', 'punct'), ('usp', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Each 10 mg/0.2 mL prefilled syringe delivers 0.2 mL (10 mg) of drug product.', 'tokens': ['10', 'mg/0.2', 'mL', 'prefilled', 'syringe', 'delivers', '0.2', 'mL', '(', '10', 'mg', ')', 'drug', 'product', '.'], 'lemmatized': ['10', 'mg/0.2', 'mL', 'prefilled', 'syringe', 'delivers', '0.2', 'mL', '(', '10', 'mg', ')', 'drug', 'product', '.'], 'stemmed': ['10', 'mg/0.2', 'ml', 'prefil', 'syring', 'deliv', '0.2', 'ml', '(', '10', 'mg', ')', 'drug', 'product', '.'], 'dependencies': [('10', 'meta'), ('mg/0.2', 'npadvmod'), ('ml', 'dep'), ('prefil', 'dep'), ('syring', 'compound'), ('deliv', 'dobj'), ('0.2', 'nummod'), ('ml', 'ROOT'), ('(', 'punct'), ('10', 'nummod'), ('mg', 'nmod'), (')', 'punct'), ('drug', 'compound'), ('product', 'parataxis'), ('.', 'punct')]}, {'original_sentence': 'Each 0.2 mL of \\nHUMIRA contains adalimumab (10 mg), citric acid monohydrate (0.26 mg), dibasic sodium \\nphosphate dihydrate (0.31 mg), mannitol (2.4 mg), monobasic sodium phosphate dihydrate (0.17 \\nmg), polysorbate 80 (0.2 mg), sodium chloride (1.23 mg), sodium citrate (0.06 mg) and Water \\nfor Injection, USP.', 'tokens': ['0.2', 'mL', 'HUMIRA', 'contains', 'adalimumab', '(', '10', 'mg', ')', ',', 'citric', 'acid', 'monohydrate', '(', '0.26', 'mg', ')', ',', 'dibasic', 'sodium', 'phosphate', 'dihydrate', '(', '0.31', 'mg', ')', ',', 'mannitol', '(', '2.4', 'mg', ')', ',', 'monobasic', 'sodium', 'phosphate', 'dihydrate', '(', '0.17', 'mg', ')', ',', 'polysorbate', '80', '(', '0.2', 'mg', ')', ',', 'sodium', 'chloride', '(', '1.23', 'mg', ')', ',', 'sodium', 'citrate', '(', '0.06', 'mg', ')', 'Water', 'Injection', ',', 'USP', '.'], 'lemmatized': ['0.2', 'mL', 'HUMIRA', 'contains', 'adalimumab', '(', '10', 'mg', ')', ',', 'citric', 'acid', 'monohydrate', '(', '0.26', 'mg', ')', ',', 'dibasic', 'sodium', 'phosphate', 'dihydrate', '(', '0.31', 'mg', ')', ',', 'mannitol', '(', '2.4', 'mg', ')', ',', 'monobasic', 'sodium', 'phosphate', 'dihydrate', '(', '0.17', 'mg', ')', ',', 'polysorbate', '80', '(', '0.2', 'mg', ')', ',', 'sodium', 'chloride', '(', '1.23', 'mg', ')', ',', 'sodium', 'citrate', '(', '0.06', 'mg', ')', 'Water', 'Injection', ',', 'USP', '.'], 'stemmed': ['0.2', 'ml', 'humira', 'contain', 'adalimumab', '(', '10', 'mg', ')', ',', 'citric', 'acid', 'monohydr', '(', '0.26', 'mg', ')', ',', 'dibas', 'sodium', 'phosphat', 'dihydr', '(', '0.31', 'mg', ')', ',', 'mannitol', '(', '2.4', 'mg', ')', ',', 'monobas', 'sodium', 'phosphat', 'dihydr', '(', '0.17', 'mg', ')', ',', 'polysorb', '80', '(', '0.2', 'mg', ')', ',', 'sodium', 'chlorid', '(', '1.23', 'mg', ')', ',', 'sodium', 'citrat', '(', '0.06', 'mg', ')', 'water', 'inject', ',', 'usp', '.'], 'dependencies': [('0.2', 'nummod'), ('ml', 'compound'), ('humira', 'nsubj'), ('contain', 'ROOT'), ('adalimumab', 'dobj'), ('(', 'punct'), ('10', 'nummod'), ('mg', 'appos'), (')', 'punct'), (',', 'punct'), ('citric', 'compound'), ('acid', 'compound'), ('monohydr', 'npadvmod'), ('(', 'punct'), ('0.26', 'nummod'), ('mg', 'appos'), (')', 'punct'), (',', 'punct'), ('dibas', 'compound'), ('sodium', 'compound'), ('phosphat', 'nsubj'), ('dihydr', 'dep'), ('(', 'punct'), ('0.31', 'nummod'), ('mg', 'intj'), (')', 'punct'), (',', 'punct'), ('mannitol', 'npadvmod'), ('(', 'punct'), ('2.4', 'nummod'), ('mg', 'appos'), (')', 'punct'), (',', 'punct'), ('monobas', 'compound'), ('sodium', 'compound'), ('phosphat', 'compound'), ('dihydr', 'advmod'), ('(', 'punct'), ('0.17', 'nummod'), ('mg', 'parataxis'), (')', 'punct'), (',', 'punct'), ('polysorb', 'ROOT'), ('80', 'dobj'), ('(', 'punct'), ('0.2', 'nummod'), ('mg', 'dobj'), (')', 'punct'), (',', 'punct'), ('sodium', 'compound'), ('chlorid', 'conj'), ('(', 'punct'), ('1.23', 'nummod'), ('mg', 'appos'), (')', 'punct'), (',', 'punct'), ('sodium', 'compound'), ('citrat', 'npadvmod'), ('(', 'punct'), ('0.06', 'nummod'), ('mg', 'parataxis'), (')', 'punct'), ('water', 'compound'), ('inject', 'conj'), (',', 'punct'), ('usp', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Sodium hydroxide is added as necessary to adjust pH.', 'tokens': ['Sodium', 'hydroxide', 'added', 'necessary', 'adjust', 'pH', '.'], 'lemmatized': ['Sodium', 'hydroxide', 'added', 'necessary', 'adjust', 'pH', '.'], 'stemmed': ['sodium', 'hydroxid', 'ad', 'necessari', 'adjust', 'ph', '.'], 'dependencies': [('sodium', 'compound'), ('hydroxid', 'amod'), ('ad', 'compound'), ('necessari', 'nsubj'), ('adjust', 'ROOT'), ('ph', 'dobj'), ('.', 'punct')]}], 'text': '11 DESCRIPTION \\nAdalimumab is a tumor necrosis factor blocker. Adalimumab is a recombinant human IgG1 \\nmonoclonal antibody created using phage display technology resulting in an antibody with \\nhuman derived heavy and light chain variable regions and human IgG1:k constant regions. \\nAdalimumab is produced by recombinant DNA technology in a mammalian cell (Chinese \\nHamster Ovary (CHO)) expression system and is purified by a process that includes specific \\nviral inactivation and removal steps. It consists of 1330 amino acids and has a molecular weight \\nof approximately 148 kilodaltons.  \\nHUMIRA (adalimumab) injection is supplied as a sterile, preservative-free solution for \\nsubcutaneous administration. The drug product is supplied as either a single-dose, prefilled pen \\n(HUMIRA Pen), as a single-dose, 1 mL prefilled glass syringe, or as a single-dose institutional \\nuse vial. Enclosed within the pen is a single-dose, 1 mL prefilled glass syringe. The solution of \\nHUMIRA is clear and colorless, with a pH of about 5.2.  \\nEach 80 mg/0.8 mL prefilled syringe or prefilled pen delivers 0.8 mL (80 mg) of drug product. \\nEach 0.8 mL of HUMIRA contains adalimumab (80 mg), mannitol (33.6 mg), polysorbate 80 \\n(0.8 mg), and Water for Injection, USP.  \\nEach 40 mg/0.4 mL prefilled syringe or prefilled pen delivers 0.4 mL (40 mg) of drug product. \\nEach 0.4 mL of HUMIRA contains adalimumab (40 mg), mannitol (16.8 mg), polysorbate 80 \\n(0.4 mg), and Water for Injection, USP.  \\nEach 40 mg/0.8 mL prefilled syringe, prefilled pen, or single-dose institutional use vial delivers \\n0.8 mL (40 mg) of drug product. Each 0.8 mL of HUMIRA contains adalimumab (40 mg), citric \\nacid monohydrate (1.04 mg), dibasic sodium phosphate dihydrate (1.22 mg), mannitol (9.6 mg), \\nmonobasic sodium phosphate dihydrate (0.69 mg), polysorbate 80 (0.8 mg), sodium chloride \\n(4.93 mg), sodium citrate (0.24 mg) and Water for Injection, USP. Sodium hydroxide is added as \\nnecessary to adjust pH.  \\nEach 20 mg/0.2 mL prefilled syringe delivers 0.2 mL (20 mg) of drug product. Each 0.2 mL of \\nHUMIRA contains adalimumab (20 mg), mannitol (8.4 mg), polysorbate 80 (0.2 mg), and Water \\nfor Injection, USP.  \\nEach 20 mg/0.4 mL prefilled syringe delivers 0.4 mL (20 mg) of drug product. Each 0.4 mL of \\nHUMIRA contains adalimumab (20 mg), citric acid monohydrate (0.52 mg), dibasic sodium \\nphosphate dihydrate (0.61 mg), mannitol (4.8 mg), monobasic sodium phosphate dihydrate (0.34 \\nmg), polysorbate 80 (0.4 mg), sodium chloride (2.47 mg), sodium citrate (0.12 mg) and Water \\nfor Injection, USP. Sodium hydroxide is added as necessary to adjust pH.  \\nEach 10 mg/0.1 mL prefilled syringe delivers 0.1 mL (10 mg) of drug product. Each 0.1 mL of \\nHUMIRA contains adalimumab (10 mg), mannitol (4.2 mg), polysorbate 80 (0.1 mg), and Water \\nfor Injection, USP.  \\nEach 10 mg/0.2 mL prefilled syringe delivers 0.2 mL (10 mg) of drug product. Each 0.2 mL of \\nHUMIRA contains adalimumab (10 mg), citric acid monohydrate (0.26 mg), dibasic sodium \\nphosphate dihydrate (0.31 mg), mannitol (2.4 mg), monobasic sodium phosphate dihydrate (0.17 \\nmg), polysorbate 80 (0.2 mg), sodium chloride (1.23 mg), sodium citrate (0.06 mg) and Water \\nfor Injection, USP. Sodium hydroxide is added as necessary to adjust pH.  \\n'}, 'page_char_count': 3271, 'page_word_count': 513, 'sentences': ['11 DESCRIPTION \\nAdalimumab is a tumor necrosis factor blocker.', 'Adalimumab is a recombinant human IgG1 \\nmonoclonal antibody created using phage display technology resulting in an antibody with \\nhuman derived heavy and light chain variable regions and human IgG1:k constant regions.', '\\nAdalimumab is produced by recombinant DNA technology in a mammalian cell (Chinese \\nHamster Ovary (CHO)) expression system and is purified by a process that includes specific \\nviral inactivation and removal steps.', 'It consists of 1330 amino acids and has a molecular weight \\nof approximately 148 kilodaltons.', ' \\nHUMIRA (adalimumab) injection is supplied as a sterile, preservative-free solution for \\nsubcutaneous administration.', 'The drug product is supplied as either a single-dose, prefilled pen \\n(HUMIRA Pen), as a single-dose, 1 mL prefilled glass syringe, or as a single-dose institutional \\nuse vial.', 'Enclosed within the pen is a single-dose, 1 mL prefilled glass syringe.', 'The solution of \\nHUMIRA is clear and colorless, with a pH of about 5.2.', ' \\nEach 80 mg/0.8 mL prefilled syringe or prefilled pen delivers 0.8 mL (80 mg) of drug product.', '\\nEach 0.8 mL of HUMIRA contains adalimumab (80 mg), mannitol (33.6 mg), polysorbate 80 \\n(0.8 mg), and Water for Injection, USP.', ' \\nEach 40 mg/0.4 mL prefilled syringe or prefilled pen delivers 0.4 mL (40 mg) of drug product.', '\\nEach 0.4 mL of HUMIRA contains adalimumab (40 mg), mannitol (16.8 mg), polysorbate 80 \\n(0.4 mg), and Water for Injection, USP.', ' \\nEach 40 mg/0.8 mL prefilled syringe, prefilled pen, or single-dose institutional use vial delivers \\n0.8 mL (40 mg) of drug product.', 'Each 0.8 mL of HUMIRA contains adalimumab (40 mg), citric \\nacid monohydrate (1.04 mg), dibasic sodium phosphate dihydrate (1.22 mg), mannitol (9.6 mg), \\nmonobasic sodium phosphate dihydrate (0.69 mg), polysorbate 80 (0.8 mg), sodium chloride \\n(4.93 mg), sodium citrate (0.24 mg) and Water for Injection, USP.', 'Sodium hydroxide is added as \\nnecessary to adjust pH.  \\nEach 20 mg/0.2 mL prefilled syringe delivers 0.2 mL (20 mg) of drug product.', 'Each 0.2 mL of \\nHUMIRA contains adalimumab (20 mg), mannitol (8.4 mg), polysorbate 80 (0.2 mg), and Water \\nfor Injection, USP.', ' \\nEach 20 mg/0.4 mL prefilled syringe delivers 0.4 mL (20 mg) of drug product.', 'Each 0.4 mL of \\nHUMIRA contains adalimumab (20 mg), citric acid monohydrate (0.52 mg), dibasic sodium \\nphosphate dihydrate (0.61 mg), mannitol (4.8 mg), monobasic sodium phosphate dihydrate (0.34 \\nmg), polysorbate 80 (0.4 mg), sodium chloride (2.47 mg), sodium citrate (0.12 mg) and Water \\nfor Injection, USP.', 'Sodium hydroxide is added as necessary to adjust pH.  \\nEach 10 mg/0.1 mL prefilled syringe delivers 0.1 mL (10 mg) of drug product.', 'Each 0.1 mL of \\nHUMIRA contains adalimumab (10 mg), mannitol (4.2 mg), polysorbate 80 (0.1 mg), and Water \\nfor Injection, USP.', ' \\nEach 10 mg/0.2 mL prefilled syringe delivers 0.2 mL (10 mg) of drug product.', 'Each 0.2 mL of \\nHUMIRA contains adalimumab (10 mg), citric acid monohydrate (0.26 mg), dibasic sodium \\nphosphate dihydrate (0.31 mg), mannitol (2.4 mg), monobasic sodium phosphate dihydrate (0.17 \\nmg), polysorbate 80 (0.2 mg), sodium chloride (1.23 mg), sodium citrate (0.06 mg) and Water \\nfor Injection, USP.', 'Sodium hydroxide is added as necessary to adjust pH.  \\n'], 'page_sentence_count_spacy': 23}\n",
            "{'page_number': 29, 'text': '12 CLINICAL PHARMACOLOGY \\n12.1 Mechanism of Action \\nAdalimumab binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell \\nsurface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the \\npresence of complement. Adalimumab does not bind or inactivate lymphotoxin (TNF-beta). TNF \\nis a naturally occurring cytokine that is involved in normal inflammatory and immune responses. \\nElevated concentrations of TNF are found in the synovial fluid of patients with RA, JIA, PsA, \\nand AS and play an important role in both the pathologic inflammation and the joint destruction \\nthat are hallmarks of these diseases. Increased concentrations of TNF are also found in psoriasis \\nplaques. In Ps, treatment with HUMIRA may reduce the epidermal thickness and infiltration of \\ninflammatory cells. The relationship between these pharmacodynamic activities and the \\nmechanism(s) by which HUMIRA exerts its clinical effects is unknown.  \\nAdalimumab also modulates biological responses that are induced or regulated by TNF, \\nincluding changes in the concentrations of adhesion molecules responsible for leukocyte \\nmigration (ELAM-1, VCAM-1, and ICAM-1 with an IC50 of 1-2 X 10-10M).  \\n12.2 Pharmacodynamics \\nAfter treatment with HUMIRA, a decrease in concentrations of acute phase reactants of \\ninflammation (C-reactive protein [CRP] and erythrocyte sedimentation rate [ESR]) and serum \\ncytokines (IL-6) was observed compared to baseline in patients with rheumatoid arthritis. A \\ndecrease in CRP concentrations was also observed in patients with Crohn’s disease, ulcerative \\ncolitis and hidradenitis suppurativa. Serum concentrations of matrix metalloproteinases (MMP-1 \\nand MMP-3) that produce tissue remodeling responsible for cartilage destruction were also \\ndecreased after HUMIRA administration.  \\nFor pediatric patients 5 years to 17 years with ulcerative colitis, the recommended dosage of \\nHUMIRA is based on modeled dose/exposure-efficacy relationships and pharmacokinetic data. \\nThere are no anticipated clinically relevant differences in efficacy between the studied higher \\ndosage administered in the clinical trial (Weeks 0 to 52 in Study PUC-I) [see Clinical Studies \\n(14.8)] and the recommended dosage [see Dosage and Administration (2.4)].  \\n12.3 Pharmacokinetics \\nThe pharmacokinetics of adalimumab were linear over the dose range of 0.5 to 10 mg/kg \\nfollowing administration of a single intravenous dose (HUMIRA is not approved for intravenous \\nuse). Following 20, 40, and 80 mg every other week and every week subcutaneous \\nadministration, adalimumab mean serum trough concentrations at steady state increased \\napproximately proportionally with dose in RA patients. The mean terminal half-life was \\napproximately 2 weeks, ranging from 10 to 20 days across studies. Healthy subjects and patients \\nwith RA displayed similar adalimumab pharmacokinetics.  \\nAdalimumab exposure in patients treated with 80 mg every other week is estimated to be \\ncomparable with that in patients treated with 40 mg every week. \\n', 'processed_text': {'sentences': [{'original_sentence': '12 CLINICAL PHARMACOLOGY \\n12.1 Mechanism of Action \\nAdalimumab binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell \\nsurface TNF receptors.', 'tokens': ['12', 'CLINICAL', 'PHARMACOLOGY', '12.1', 'Mechanism', 'Action', 'Adalimumab', 'binds', 'specifically', 'TNF-alpha', 'blocks', 'interaction', 'p55', 'p75', 'cell', 'surface', 'TNF', 'receptors', '.'], 'lemmatized': ['12', 'CLINICAL', 'PHARMACOLOGY', '12.1', 'Mechanism', 'Action', 'Adalimumab', 'bind', 'specifically', 'TNF-alpha', 'block', 'interaction', 'p55', 'p75', 'cell', 'surface', 'TNF', 'receptor', '.'], 'stemmed': ['12', 'clinic', 'pharmacolog', '12.1', 'mechan', 'action', 'adalimumab', 'bind', 'specif', 'tnf-alpha', 'block', 'interact', 'p55', 'p75', 'cell', 'surfac', 'tnf', 'receptor', '.'], 'dependencies': [('12', 'nummod'), ('clinic', 'nmod'), ('pharmacolog', 'nsubj'), ('12.1', 'nummod'), ('mechan', 'compound'), ('action', 'compound'), ('adalimumab', 'compound'), ('bind', 'appos'), ('specif', 'compound'), ('tnf', 'compound'), ('-', 'punct'), ('alpha', 'compound'), ('block', 'appos'), ('interact', 'ROOT'), ('p55', 'amod'), ('p75', 'amod'), ('cell', 'compound'), ('surfac', 'compound'), ('tnf', 'compound'), ('receptor', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Adalimumab also lyses surface TNF expressing cells in vitro in the \\npresence of complement.', 'tokens': ['Adalimumab', 'also', 'lyses', 'surface', 'TNF', 'expressing', 'cells', 'vitro', 'presence', 'complement', '.'], 'lemmatized': ['Adalimumab', 'also', 'lysis', 'surface', 'TNF', 'expressing', 'cell', 'vitro', 'presence', 'complement', '.'], 'stemmed': ['adalimumab', 'also', 'lysi', 'surfac', 'tnf', 'express', 'cell', 'vitro', 'presenc', 'complement', '.'], 'dependencies': [('adalimumab', 'nsubj'), ('also', 'advmod'), ('lysi', 'compound'), ('surfac', 'compound'), ('tnf', 'npadvmod'), ('express', 'ROOT'), ('cell', 'compound'), ('vitro', 'compound'), ('presenc', 'compound'), ('complement', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Adalimumab does not bind or inactivate lymphotoxin (TNF-beta).', 'tokens': ['Adalimumab', 'bind', 'inactivate', 'lymphotoxin', '(', 'TNF-beta', ')', '.'], 'lemmatized': ['Adalimumab', 'bind', 'inactivate', 'lymphotoxin', '(', 'TNF-beta', ')', '.'], 'stemmed': ['adalimumab', 'bind', 'inactiv', 'lymphotoxin', '(', 'tnf-beta', ')', '.'], 'dependencies': [('adalimumab', 'compound'), ('bind', 'compound'), ('inactiv', 'compound'), ('lymphotoxin', 'ROOT'), ('(', 'punct'), ('tnf', 'appos'), ('-', 'appos'), ('beta', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'TNF \\nis a naturally occurring cytokine that is involved in normal inflammatory and immune responses.', 'tokens': ['TNF', 'naturally', 'occurring', 'cytokine', 'involved', 'normal', 'inflammatory', 'immune', 'responses', '.'], 'lemmatized': ['TNF', 'naturally', 'occurring', 'cytokine', 'involved', 'normal', 'inflammatory', 'immune', 'response', '.'], 'stemmed': ['tnf', 'natur', 'occur', 'cytokin', 'involv', 'normal', 'inflammatori', 'immun', 'respons', '.'], 'dependencies': [('tnf', 'npadvmod'), ('natur', 'nsubj'), ('occur', 'ROOT'), ('cytokin', 'nsubj'), ('involv', 'ccomp'), ('normal', 'amod'), ('inflammatori', 'compound'), ('immun', 'compound'), ('respons', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Elevated concentrations of TNF are found in the synovial fluid of patients with RA, JIA, PsA, \\nand AS and play an important role in both the pathologic inflammation and the joint destruction \\nthat are hallmarks of these diseases.', 'tokens': ['Elevated', 'concentrations', 'TNF', 'found', 'synovial', 'fluid', 'patients', 'RA', ',', 'JIA', ',', 'PsA', ',', 'play', 'important', 'role', 'pathologic', 'inflammation', 'joint', 'destruction', 'hallmarks', 'diseases', '.'], 'lemmatized': ['Elevated', 'concentration', 'TNF', 'found', 'synovial', 'fluid', 'patient', 'RA', ',', 'JIA', ',', 'PsA', ',', 'play', 'important', 'role', 'pathologic', 'inflammation', 'joint', 'destruction', 'hallmark', 'disease', '.'], 'stemmed': ['elev', 'concentr', 'tnf', 'found', 'synovi', 'fluid', 'patient', 'ra', ',', 'jia', ',', 'psa', ',', 'play', 'import', 'role', 'patholog', 'inflamm', 'joint', 'destruct', 'hallmark', 'diseas', '.'], 'dependencies': [('elev', 'compound'), ('concentr', 'nsubj'), ('tnf', 'appos'), ('found', 'ROOT'), ('synovi', 'compound'), ('fluid', 'amod'), ('patient', 'nsubj'), ('ra', 'appos'), (',', 'punct'), ('jia', 'nsubj'), (',', 'punct'), ('psa', 'conj'), (',', 'punct'), ('play', 'ccomp'), ('import', 'compound'), ('role', 'compound'), ('patholog', 'dobj'), ('inflamm', 'nmod'), ('joint', 'amod'), ('destruct', 'nsubj'), ('hallmark', 'compound'), ('diseas', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Increased concentrations of TNF are also found in psoriasis \\nplaques.', 'tokens': ['Increased', 'concentrations', 'TNF', 'also', 'found', 'psoriasis', 'plaques', '.'], 'lemmatized': ['Increased', 'concentration', 'TNF', 'also', 'found', 'psoriasis', 'plaque', '.'], 'stemmed': ['increas', 'concentr', 'tnf', 'also', 'found', 'psoriasi', 'plaqu', '.'], 'dependencies': [('increas', 'compound'), ('concentr', 'nsubj'), ('tnf', 'appos'), ('also', 'advmod'), ('found', 'ROOT'), ('psoriasi', 'compound'), ('plaqu', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'In Ps, treatment with HUMIRA may reduce the epidermal thickness and infiltration of \\ninflammatory cells.', 'tokens': ['Ps', ',', 'treatment', 'HUMIRA', 'may', 'reduce', 'epidermal', 'thickness', 'infiltration', 'inflammatory', 'cells', '.'], 'lemmatized': ['Ps', ',', 'treatment', 'HUMIRA', 'may', 'reduce', 'epidermal', 'thickness', 'infiltration', 'inflammatory', 'cell', '.'], 'stemmed': ['ps', ',', 'treatment', 'humira', 'may', 'reduc', 'epiderm', 'thick', 'infiltr', 'inflammatori', 'cell', '.'], 'dependencies': [('ps', 'npadvmod'), (',', 'punct'), ('treatment', 'compound'), ('humira', 'nsubj'), ('may', 'aux'), ('reduc', 'ROOT'), ('epiderm', 'compound'), ('thick', 'amod'), ('infiltr', 'compound'), ('inflammatori', 'compound'), ('cell', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The relationship between these pharmacodynamic activities and the \\nmechanism(s) by which HUMIRA exerts its clinical effects is unknown.', 'tokens': ['relationship', 'pharmacodynamic', 'activities', 'mechanism', '(', ')', 'HUMIRA', 'exerts', 'clinical', 'effects', 'unknown', '.'], 'lemmatized': ['relationship', 'pharmacodynamic', 'activity', 'mechanism', '(', ')', 'HUMIRA', 'exerts', 'clinical', 'effect', 'unknown', '.'], 'stemmed': ['relationship', 'pharmacodynam', 'activ', 'mechan', '(', ')', 'humira', 'exert', 'clinic', 'effect', 'unknown', '.'], 'dependencies': [('relationship', 'compound'), ('pharmacodynam', 'compound'), ('activ', 'compound'), ('mechan', 'ROOT'), ('(', 'punct'), (')', 'punct'), ('humira', 'nsubj'), ('exert', 'parataxis'), ('clinic', 'compound'), ('effect', 'dobj'), ('unknown', 'amod'), ('.', 'punct')]}, {'original_sentence': 'Adalimumab also modulates biological responses that are induced or regulated by TNF, \\nincluding changes in the concentrations of adhesion molecules responsible for leukocyte \\nmigration (ELAM-1, VCAM-1, and ICAM-1 with an IC50 of 1-2 X 10-10M).', 'tokens': ['Adalimumab', 'also', 'modulates', 'biological', 'responses', 'induced', 'regulated', 'TNF', ',', 'including', 'changes', 'concentrations', 'adhesion', 'molecules', 'responsible', 'leukocyte', 'migration', '(', 'ELAM-1', ',', 'VCAM-1', ',', 'ICAM-1', 'IC50', '1-2', 'X', '10-10M', ')', '.'], 'lemmatized': ['Adalimumab', 'also', 'modulates', 'biological', 'response', 'induced', 'regulated', 'TNF', ',', 'including', 'change', 'concentration', 'adhesion', 'molecule', 'responsible', 'leukocyte', 'migration', '(', 'ELAM-1', ',', 'VCAM-1', ',', 'ICAM-1', 'IC50', '1-2', 'X', '10-10M', ')', '.'], 'stemmed': ['adalimumab', 'also', 'modul', 'biolog', 'respons', 'induc', 'regul', 'tnf', ',', 'includ', 'chang', 'concentr', 'adhes', 'molecul', 'respons', 'leukocyt', 'migrat', '(', 'elam-1', ',', 'vcam-1', ',', 'icam-1', 'ic50', '1-2', 'x', '10-10m', ')', '.'], 'dependencies': [('adalimumab', 'nsubj'), ('also', 'advmod'), ('modul', 'ccomp'), ('biolog', 'compound'), ('respons', 'compound'), ('induc', 'compound'), ('regul', 'compound'), ('tnf', 'dobj'), (',', 'punct'), ('includ', 'compound'), ('chang', 'compound'), ('concentr', 'nsubj'), ('adhes', 'ROOT'), ('molecul', 'compound'), ('respons', 'compound'), ('leukocyt', 'compound'), ('migrat', 'dobj'), ('(', 'punct'), ('elam-1', 'appos'), (',', 'punct'), ('vcam-1', 'conj'), (',', 'punct'), ('icam-1', 'punct'), ('ic50', 'ROOT'), ('1', 'nummod'), ('-', 'punct'), ('2', 'nummod'), ('x', 'punct'), ('10', 'npadvmod'), ('-', 'punct'), ('10', 'prep'), ('m', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': '12.2 Pharmacodynamics \\nAfter treatment with HUMIRA, a decrease in concentrations of acute phase reactants of \\ninflammation (C-reactive protein [CRP] and erythrocyte sedimentation rate [ESR]) and serum \\ncytokines (IL-6) was observed compared to baseline in patients with rheumatoid arthritis.', 'tokens': ['12.2', 'Pharmacodynamics', 'treatment', 'HUMIRA', ',', 'decrease', 'concentrations', 'acute', 'phase', 'reactants', 'inflammation', '(', 'C-reactive', 'protein', '[', 'CRP', ']', 'erythrocyte', 'sedimentation', 'rate', '[', 'ESR', ']', ')', 'serum', 'cytokines', '(', 'IL-6', ')', 'observed', 'compared', 'baseline', 'patients', 'rheumatoid', 'arthritis', '.'], 'lemmatized': ['12.2', 'Pharmacodynamics', 'treatment', 'HUMIRA', ',', 'decrease', 'concentration', 'acute', 'phase', 'reactant', 'inflammation', '(', 'C-reactive', 'protein', '[', 'CRP', ']', 'erythrocyte', 'sedimentation', 'rate', '[', 'ESR', ']', ')', 'serum', 'cytokine', '(', 'IL-6', ')', 'observed', 'compared', 'baseline', 'patient', 'rheumatoid', 'arthritis', '.'], 'stemmed': ['12.2', 'pharmacodynam', 'treatment', 'humira', ',', 'decreas', 'concentr', 'acut', 'phase', 'reactant', 'inflamm', '(', 'c-reactiv', 'protein', '[', 'crp', ']', 'erythrocyt', 'sediment', 'rate', '[', 'esr', ']', ')', 'serum', 'cytokin', '(', 'il-6', ')', 'observ', 'compar', 'baselin', 'patient', 'rheumatoid', 'arthriti', '.'], 'dependencies': [('12.2', 'nummod'), ('pharmacodynam', 'compound'), ('treatment', 'compound'), ('humira', 'dep'), (',', 'punct'), ('decreas', 'nsubj'), ('concentr', 'ROOT'), ('acut', 'compound'), ('phase', 'dobj'), ('reactant', 'amod'), ('inflamm', 'appos'), ('(', 'punct'), ('c', 'compound'), ('-', 'punct'), ('reactiv', 'compound'), ('protein', 'appos'), ('[', 'punct'), ('crp', 'dep'), (']', 'dep'), ('erythrocyt', 'ROOT'), ('sediment', 'compound'), ('rate', 'dobj'), ('[', 'punct'), ('esr', 'appos'), (']', 'punct'), (')', 'punct'), ('serum', 'compound'), ('cytokin', 'nmod'), ('(', 'punct'), ('il-6', 'appos'), (')', 'punct'), ('observ', 'compound'), ('compar', 'compound'), ('baselin', 'compound'), ('patient', 'ROOT'), ('rheumatoid', 'compound'), ('arthriti', 'appos'), ('.', 'punct')]}, {'original_sentence': 'A \\ndecrease in CRP concentrations was also observed in patients with Crohn’s disease, ulcerative \\ncolitis and hidradenitis suppurativa.', 'tokens': ['decrease', 'CRP', 'concentrations', 'also', 'observed', 'patients', 'Crohn', '’', 'disease', ',', 'ulcerative', 'colitis', 'hidradenitis', 'suppurativa', '.'], 'lemmatized': ['decrease', 'CRP', 'concentration', 'also', 'observed', 'patient', 'Crohn', '’', 'disease', ',', 'ulcerative', 'colitis', 'hidradenitis', 'suppurativa', '.'], 'stemmed': ['decreas', 'crp', 'concentr', 'also', 'observ', 'patient', 'crohn', '’', 'diseas', ',', 'ulcer', 'coliti', 'hidraden', 'suppurativa', '.'], 'dependencies': [('decreas', 'compound'), ('crp', 'compound'), ('concentr', 'nsubj'), ('also', 'advmod'), ('observ', 'ROOT'), ('patient', 'compound'), ('crohn', 'nmod'), ('’', 'punct'), ('diseas', 'dobj'), (',', 'punct'), ('ulcer', 'compound'), ('coliti', 'compound'), ('hidraden', 'compound'), ('suppurativa', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Serum concentrations of matrix metalloproteinases (MMP-1 \\nand MMP-3) that produce tissue remodeling responsible for cartilage destruction were also \\ndecreased after HUMIRA administration.', 'tokens': ['Serum', 'concentrations', 'matrix', 'metalloproteinases', '(', 'MMP-1', 'MMP-3', ')', 'produce', 'tissue', 'remodeling', 'responsible', 'cartilage', 'destruction', 'also', 'decreased', 'HUMIRA', 'administration', '.'], 'lemmatized': ['Serum', 'concentration', 'matrix', 'metalloproteinases', '(', 'MMP-1', 'MMP-3', ')', 'produce', 'tissue', 'remodeling', 'responsible', 'cartilage', 'destruction', 'also', 'decreased', 'HUMIRA', 'administration', '.'], 'stemmed': ['serum', 'concentr', 'matrix', 'metalloproteinas', '(', 'mmp-1', 'mmp-3', ')', 'produc', 'tissu', 'remodel', 'respons', 'cartilag', 'destruct', 'also', 'decreas', 'humira', 'administr', '.'], 'dependencies': [('serum', 'nsubj'), ('concentr', 'ROOT'), ('matrix', 'compound'), ('metalloproteinas', 'dobj'), ('(', 'punct'), ('mmp-1', 'appos'), ('mmp-3', 'npadvmod'), (')', 'punct'), ('produc', 'compound'), ('tissu', 'compound'), ('remodel', 'compound'), ('respons', 'compound'), ('cartilag', 'compound'), ('destruct', 'nsubj'), ('also', 'advmod'), ('decreas', 'ROOT'), ('humira', 'compound'), ('administr', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'For pediatric patients 5 years to 17 years with ulcerative colitis, the recommended dosage of \\nHUMIRA is based on modeled dose/exposure-efficacy relationships and pharmacokinetic data.', 'tokens': ['pediatric', 'patients', '5', 'years', '17', 'years', 'ulcerative', 'colitis', ',', 'recommended', 'dosage', 'HUMIRA', 'based', 'modeled', 'dose/exposure-efficacy', 'relationships', 'pharmacokinetic', 'data', '.'], 'lemmatized': ['pediatric', 'patient', '5', 'year', '17', 'year', 'ulcerative', 'colitis', ',', 'recommended', 'dosage', 'HUMIRA', 'based', 'modeled', 'dose/exposure-efficacy', 'relationship', 'pharmacokinetic', 'data', '.'], 'stemmed': ['pediatr', 'patient', '5', 'year', '17', 'year', 'ulcer', 'coliti', ',', 'recommend', 'dosag', 'humira', 'base', 'model', 'dose/exposure-efficaci', 'relationship', 'pharmacokinet', 'data', '.'], 'dependencies': [('pediatr', 'amod'), ('patient', 'nsubj'), ('5', 'nummod'), ('year', 'npadvmod'), ('17', 'nummod'), ('year', 'compound'), ('ulcer', 'compound'), ('coliti', 'appos'), (',', 'punct'), ('recommend', 'ROOT'), ('dosag', 'nmod'), ('humira', 'compound'), ('base', 'compound'), ('model', 'compound'), ('dose', 'amod'), ('/', 'punct'), ('exposure', 'compound'), ('-', 'punct'), ('efficaci', 'compound'), ('relationship', 'compound'), ('pharmacokinet', 'compound'), ('data', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'There are no anticipated clinically relevant differences in efficacy between the studied higher \\ndosage administered in the clinical trial (Weeks 0 to 52 in Study PUC-I) [see Clinical Studies \\n(14.8)] and the recommended dosage [see Dosage and Administration (2.4)].', 'tokens': ['anticipated', 'clinically', 'relevant', 'differences', 'efficacy', 'studied', 'higher', 'dosage', 'administered', 'clinical', 'trial', '(', 'Weeks', '0', '52', 'Study', 'PUC-I', ')', '[', 'see', 'Clinical', 'Studies', '(', '14.8', ')', ']', 'recommended', 'dosage', '[', 'see', 'Dosage', 'Administration', '(', '2.4', ')', ']', '.'], 'lemmatized': ['anticipated', 'clinically', 'relevant', 'difference', 'efficacy', 'studied', 'higher', 'dosage', 'administered', 'clinical', 'trial', '(', 'Weeks', '0', '52', 'Study', 'PUC-I', ')', '[', 'see', 'Clinical', 'Studies', '(', '14.8', ')', ']', 'recommended', 'dosage', '[', 'see', 'Dosage', 'Administration', '(', '2.4', ')', ']', '.'], 'stemmed': ['anticip', 'clinic', 'relev', 'differ', 'efficaci', 'studi', 'higher', 'dosag', 'administ', 'clinic', 'trial', '(', 'week', '0', '52', 'studi', 'puc-i', ')', '[', 'see', 'clinic', 'studi', '(', '14.8', ')', ']', 'recommend', 'dosag', '[', 'see', 'dosag', 'administr', '(', '2.4', ')', ']', '.'], 'dependencies': [('anticip', 'compound'), ('clinic', 'compound'), ('relev', 'nsubj'), ('differ', 'ROOT'), ('efficaci', 'compound'), ('studi', 'compound'), ('higher', 'amod'), ('dosag', 'nmod'), ('administ', 'compound'), ('clinic', 'compound'), ('trial', 'dobj'), ('(', 'punct'), ('week', 'npadvmod'), ('0', 'nummod'), ('52', 'nummod'), ('studi', 'compound'), ('puc', 'compound'), ('-', 'punct'), ('i', 'appos'), (')', 'punct'), ('[', 'punct'), ('see', 'ROOT'), ('clinic', 'compound'), ('studi', 'npadvmod'), ('(', 'punct'), ('14.8', 'appos'), (')', 'punct'), (']', 'punct'), ('recommend', 'ccomp'), ('dosag', 'dobj'), ('[', 'punct'), ('see', 'parataxis'), ('dosag', 'compound'), ('administr', 'dobj'), ('(', 'punct'), ('2.4', 'appos'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': '12.3 Pharmacokinetics \\nThe pharmacokinetics of adalimumab were linear over the dose range of 0.5 to 10 mg/kg \\nfollowing administration of a single intravenous dose (HUMIRA is not approved for intravenous \\nuse).', 'tokens': ['12.3', 'Pharmacokinetics', 'pharmacokinetics', 'adalimumab', 'linear', 'dose', 'range', '0.5', '10', 'mg/kg', 'following', 'administration', 'single', 'intravenous', 'dose', '(', 'HUMIRA', 'approved', 'intravenous', 'use', ')', '.'], 'lemmatized': ['12.3', 'Pharmacokinetics', 'pharmacokinetics', 'adalimumab', 'linear', 'dose', 'range', '0.5', '10', 'mg/kg', 'following', 'administration', 'single', 'intravenous', 'dose', '(', 'HUMIRA', 'approved', 'intravenous', 'use', ')', '.'], 'stemmed': ['12.3', 'pharmacokinet', 'pharmacokinet', 'adalimumab', 'linear', 'dose', 'rang', '0.5', '10', 'mg/kg', 'follow', 'administr', 'singl', 'intraven', 'dose', '(', 'humira', 'approv', 'intraven', 'use', ')', '.'], 'dependencies': [('12.3', 'nummod'), ('pharmacokinet', 'compound'), ('pharmacokinet', 'compound'), ('adalimumab', 'compound'), ('linear', 'compound'), ('dose', 'compound'), ('rang', 'nsubj'), ('0.5', 'nummod'), ('10', 'npadvmod'), ('mg', 'nmod'), ('/', 'punct'), ('kg', 'compound'), ('follow', 'ROOT'), ('administr', 'compound'), ('singl', 'compound'), ('intraven', 'compound'), ('dose', 'dobj'), ('(', 'punct'), ('humira', 'npadvmod'), ('approv', 'compound'), ('intraven', 'compound'), ('use', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Following 20, 40, and 80 mg every other week and every week subcutaneous \\nadministration, adalimumab mean serum trough concentrations at steady state increased \\napproximately proportionally with dose in RA patients.', 'tokens': ['Following', '20', ',', '40', ',', '80', 'mg', 'every', 'week', 'every', 'week', 'subcutaneous', 'administration', ',', 'adalimumab', 'mean', 'serum', 'trough', 'concentrations', 'steady', 'state', 'increased', 'approximately', 'proportionally', 'dose', 'RA', 'patients', '.'], 'lemmatized': ['Following', '20', ',', '40', ',', '80', 'mg', 'every', 'week', 'every', 'week', 'subcutaneous', 'administration', ',', 'adalimumab', 'mean', 'serum', 'trough', 'concentration', 'steady', 'state', 'increased', 'approximately', 'proportionally', 'dose', 'RA', 'patient', '.'], 'stemmed': ['follow', '20', ',', '40', ',', '80', 'mg', 'everi', 'week', 'everi', 'week', 'subcutan', 'administr', ',', 'adalimumab', 'mean', 'serum', 'trough', 'concentr', 'steadi', 'state', 'increas', 'approxim', 'proport', 'dose', 'ra', 'patient', '.'], 'dependencies': [('follow', 'ROOT'), ('20', 'dobj'), (',', 'punct'), ('40', 'npadvmod'), (',', 'punct'), ('80', 'nummod'), ('mg', 'advmod'), ('everi', 'amod'), ('week', 'npadvmod'), ('everi', 'amod'), ('week', 'npadvmod'), ('subcutan', 'compound'), ('administr', 'appos'), (',', 'punct'), ('adalimumab', 'compound'), ('mean', 'parataxis'), ('serum', 'compound'), ('trough', 'nsubj'), ('concentr', 'conj'), ('steadi', 'compound'), ('state', 'compound'), ('increas', 'compound'), ('approxim', 'compound'), ('proport', 'compound'), ('dose', 'compound'), ('ra', 'compound'), ('patient', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The mean terminal half-life was \\napproximately 2 weeks, ranging from 10 to 20 days across studies.', 'tokens': ['mean', 'terminal', 'half-life', 'approximately', '2', 'weeks', ',', 'ranging', '10', '20', 'days', 'across', 'studies', '.'], 'lemmatized': ['mean', 'terminal', 'half-life', 'approximately', '2', 'week', ',', 'ranging', '10', '20', 'day', 'across', 'study', '.'], 'stemmed': ['mean', 'termin', 'half-lif', 'approxim', '2', 'week', ',', 'rang', '10', '20', 'day', 'across', 'studi', '.'], 'dependencies': [('mean', 'parataxis'), ('termin', 'nmod'), ('half', 'amod'), ('-', 'punct'), ('lif', 'compound'), ('approxim', 'dobj'), ('2', 'nummod'), ('week', 'npadvmod'), (',', 'punct'), ('rang', 'ROOT'), ('10', 'nummod'), ('20', 'nummod'), ('day', 'npadvmod'), ('across', 'prep'), ('studi', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'Healthy subjects and patients \\nwith RA displayed similar adalimumab pharmacokinetics.', 'tokens': ['Healthy', 'subjects', 'patients', 'RA', 'displayed', 'similar', 'adalimumab', 'pharmacokinetics', '.'], 'lemmatized': ['Healthy', 'subject', 'patient', 'RA', 'displayed', 'similar', 'adalimumab', 'pharmacokinetics', '.'], 'stemmed': ['healthi', 'subject', 'patient', 'ra', 'display', 'similar', 'adalimumab', 'pharmacokinet', '.'], 'dependencies': [('healthi', 'amod'), ('subject', 'compound'), ('patient', 'compound'), ('ra', 'nsubj'), ('display', 'ROOT'), ('similar', 'amod'), ('adalimumab', 'compound'), ('pharmacokinet', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Adalimumab exposure in patients treated with 80 mg every other week is estimated to be \\ncomparable with that in patients treated with 40 mg every week.', 'tokens': ['Adalimumab', 'exposure', 'patients', 'treated', '80', 'mg', 'every', 'week', 'estimated', 'comparable', 'patients', 'treated', '40', 'mg', 'every', 'week', '.'], 'lemmatized': ['Adalimumab', 'exposure', 'patient', 'treated', '80', 'mg', 'every', 'week', 'estimated', 'comparable', 'patient', 'treated', '40', 'mg', 'every', 'week', '.'], 'stemmed': ['adalimumab', 'exposur', 'patient', 'treat', '80', 'mg', 'everi', 'week', 'estim', 'compar', 'patient', 'treat', '40', 'mg', 'everi', 'week', '.'], 'dependencies': [('adalimumab', 'compound'), ('exposur', 'compound'), ('patient', 'nsubj'), ('treat', 'ROOT'), ('80', 'nummod'), ('mg', 'nmod'), ('everi', 'amod'), ('week', 'npadvmod'), ('estim', 'compound'), ('compar', 'compound'), ('patient', 'nsubj'), ('treat', 'conj'), ('40', 'npadvmod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'npadvmod'), ('.', 'punct')]}], 'text': '12 CLINICAL PHARMACOLOGY \\n12.1 Mechanism of Action \\nAdalimumab binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell \\nsurface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the \\npresence of complement. Adalimumab does not bind or inactivate lymphotoxin (TNF-beta). TNF \\nis a naturally occurring cytokine that is involved in normal inflammatory and immune responses. \\nElevated concentrations of TNF are found in the synovial fluid of patients with RA, JIA, PsA, \\nand AS and play an important role in both the pathologic inflammation and the joint destruction \\nthat are hallmarks of these diseases. Increased concentrations of TNF are also found in psoriasis \\nplaques. In Ps, treatment with HUMIRA may reduce the epidermal thickness and infiltration of \\ninflammatory cells. The relationship between these pharmacodynamic activities and the \\nmechanism(s) by which HUMIRA exerts its clinical effects is unknown.  \\nAdalimumab also modulates biological responses that are induced or regulated by TNF, \\nincluding changes in the concentrations of adhesion molecules responsible for leukocyte \\nmigration (ELAM-1, VCAM-1, and ICAM-1 with an IC50 of 1-2 X 10-10M).  \\n12.2 Pharmacodynamics \\nAfter treatment with HUMIRA, a decrease in concentrations of acute phase reactants of \\ninflammation (C-reactive protein [CRP] and erythrocyte sedimentation rate [ESR]) and serum \\ncytokines (IL-6) was observed compared to baseline in patients with rheumatoid arthritis. A \\ndecrease in CRP concentrations was also observed in patients with Crohn’s disease, ulcerative \\ncolitis and hidradenitis suppurativa. Serum concentrations of matrix metalloproteinases (MMP-1 \\nand MMP-3) that produce tissue remodeling responsible for cartilage destruction were also \\ndecreased after HUMIRA administration.  \\nFor pediatric patients 5 years to 17 years with ulcerative colitis, the recommended dosage of \\nHUMIRA is based on modeled dose/exposure-efficacy relationships and pharmacokinetic data. \\nThere are no anticipated clinically relevant differences in efficacy between the studied higher \\ndosage administered in the clinical trial (Weeks 0 to 52 in Study PUC-I) [see Clinical Studies \\n(14.8)] and the recommended dosage [see Dosage and Administration (2.4)].  \\n12.3 Pharmacokinetics \\nThe pharmacokinetics of adalimumab were linear over the dose range of 0.5 to 10 mg/kg \\nfollowing administration of a single intravenous dose (HUMIRA is not approved for intravenous \\nuse). Following 20, 40, and 80 mg every other week and every week subcutaneous \\nadministration, adalimumab mean serum trough concentrations at steady state increased \\napproximately proportionally with dose in RA patients. The mean terminal half-life was \\napproximately 2 weeks, ranging from 10 to 20 days across studies. Healthy subjects and patients \\nwith RA displayed similar adalimumab pharmacokinetics.  \\nAdalimumab exposure in patients treated with 80 mg every other week is estimated to be \\ncomparable with that in patients treated with 40 mg every week. \\n'}, 'page_char_count': 3058, 'page_word_count': 433, 'sentences': ['12 CLINICAL PHARMACOLOGY \\n12.1 Mechanism of Action \\nAdalimumab binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell \\nsurface TNF receptors.', 'Adalimumab also lyses surface TNF expressing cells in vitro in the \\npresence of complement.', 'Adalimumab does not bind or inactivate lymphotoxin (TNF-beta).', 'TNF \\nis a naturally occurring cytokine that is involved in normal inflammatory and immune responses.', '\\nElevated concentrations of TNF are found in the synovial fluid of patients with RA, JIA, PsA, \\nand AS and play an important role in both the pathologic inflammation and the joint destruction \\nthat are hallmarks of these diseases.', 'Increased concentrations of TNF are also found in psoriasis \\nplaques.', 'In Ps, treatment with HUMIRA may reduce the epidermal thickness and infiltration of \\ninflammatory cells.', 'The relationship between these pharmacodynamic activities and the \\nmechanism(s) by which HUMIRA exerts its clinical effects is unknown.', ' \\nAdalimumab also modulates biological responses that are induced or regulated by TNF, \\nincluding changes in the concentrations of adhesion molecules responsible for leukocyte \\nmigration (ELAM-1, VCAM-1, and ICAM-1 with an IC50 of 1-2 X 10-10M).', ' \\n12.2 Pharmacodynamics \\nAfter treatment with HUMIRA, a decrease in concentrations of acute phase reactants of \\ninflammation (C-reactive protein [CRP] and erythrocyte sedimentation rate [ESR]) and serum \\ncytokines (IL-6) was observed compared to baseline in patients with rheumatoid arthritis.', 'A \\ndecrease in CRP concentrations was also observed in patients with Crohn’s disease, ulcerative \\ncolitis and hidradenitis suppurativa.', 'Serum concentrations of matrix metalloproteinases (MMP-1 \\nand MMP-3) that produce tissue remodeling responsible for cartilage destruction were also \\ndecreased after HUMIRA administration.', ' \\nFor pediatric patients 5 years to 17 years with ulcerative colitis, the recommended dosage of \\nHUMIRA is based on modeled dose/exposure-efficacy relationships and pharmacokinetic data.', '\\nThere are no anticipated clinically relevant differences in efficacy between the studied higher \\ndosage administered in the clinical trial (Weeks 0 to 52 in Study PUC-I) [see Clinical Studies \\n(14.8)] and the recommended dosage [see Dosage and Administration (2.4)].', ' \\n12.3 Pharmacokinetics \\nThe pharmacokinetics of adalimumab were linear over the dose range of 0.5 to 10 mg/kg \\nfollowing administration of a single intravenous dose (HUMIRA is not approved for intravenous \\nuse).', 'Following 20, 40, and 80 mg every other week and every week subcutaneous \\nadministration, adalimumab mean serum trough concentrations at steady state increased \\napproximately proportionally with dose in RA patients.', 'The mean terminal half-life was \\napproximately 2 weeks, ranging from 10 to 20 days across studies.', 'Healthy subjects and patients \\nwith RA displayed similar adalimumab pharmacokinetics.', ' \\nAdalimumab exposure in patients treated with 80 mg every other week is estimated to be \\ncomparable with that in patients treated with 40 mg every week.', '\\n'], 'page_sentence_count_spacy': 20}\n",
            "{'page_number': 30, 'text': 'Absorption \\nThe average absolute bioavailability of adalimumab following a single 40 mg subcutaneous dose \\nwas 64%. The mean time to reach the maximum concentration was 5.5 days (131 ± 56 hours) \\nand the maximum serum concentration was 4.7 ± 1.6 mcg/mL in healthy subjects following a \\nsingle 40 mg subcutaneous administration of HUMIRA.   \\nDistribution \\nThe distribution volume (Vss) ranged from 4.7 to 6.0 L following intravenous administration of \\ndoses ranging from 0.25 to 10 mg/kg in RA patients. \\nElimination \\nThe single dose pharmacokinetics of adalimumab in RA patients were determined in several \\nstudies with intravenous doses ranging from 0.25 to 10 mg/kg. The systemic clearance of \\nadalimumab is approximately 12 mL/hr. In long-term studies with dosing more than two years, \\nthere was no evidence of changes in clearance over time in RA patients.  \\nPatient Population \\nRheumatoid Arthritis and Ankylosing Spondylitis: In patients receiving 40 mg HUMIRA every \\nother week, adalimumab mean steady-state trough concentrations were approximately 5 mcg/mL \\nand 8 to 9 mcg/mL, without and with MTX concomitant treatment, respectively. Adalimumab \\nconcentrations in the synovial fluid from five rheumatoid arthritis patients ranged from 31 to \\n96% of those in serum. The pharmacokinetics of adalimumab in patients with AS were similar to \\nthose in patients with RA. \\nPsoriatic Arthritis: In patients receiving 40 mg every other week, adalimumab mean steady-state \\ntrough concentrations were 6 to 10 mcg/mL and 8.5 to 12 mcg/mL, without and with MTX \\nconcomitant treatment, respectively.  \\nPlaque Psoriasis: Adalimumab mean steady-state trough concentration was approximately 5 to 6 \\nmcg/mL during HUMIRA 40 mg every other week treatment.  \\nAdult Uveitis: Adalimumab mean steady concentration was approximately 8 to 10 mcg/mL \\nduring HUMIRA 40 mg every other week treatment. \\nAdult Hidradenitis Suppurativa: Adalimumab trough concentrations were approximately 7 to 8 \\nmcg/mL at Week 2 and Week 4, respectively, after receiving 160 mg on Week 0 followed by 80 \\nmg on Week 2.  Mean steady-state trough concentrations at Week 12 through Week 36 were \\napproximately 7 to 11 mcg/mL during HUMIRA 40 mg every week treatment.  \\nAdult Crohn’s Disease: Adalimumab mean trough concentrations were approximately 12 \\nmcg/mL at Week 2 and Week 4 after receiving 160 mg on Week 0 followed by 80 mg on Week \\n2. Mean steady-state trough concentrations were 7 mcg/mL at Week 24 and Week 56 during \\nHUMIRA 40 mg every other week treatment.  \\nAdult Ulcerative Colitis: Adalimumab mean trough concentrations were approximately 12 \\nmcg/mL at Week 2 and Week 4 after receiving 160 mg on Week 0 followed by 80 mg on Week \\n2. Mean steady-state trough concentrations were approximately 8 mcg/mL and 15 mcg/mL at \\nWeek 52 after receiving a dose of HUMIRA 40 mg every other week and 40 mg every week, \\nrespectively.  \\n', 'processed_text': {'sentences': [{'original_sentence': 'Absorption \\nThe average absolute bioavailability of adalimumab following a single 40 mg subcutaneous dose \\nwas 64%.', 'tokens': ['Absorption', 'average', 'absolute', 'bioavailability', 'adalimumab', 'following', 'single', '40', 'mg', 'subcutaneous', 'dose', '64', '%', '.'], 'lemmatized': ['Absorption', 'average', 'absolute', 'bioavailability', 'adalimumab', 'following', 'single', '40', 'mg', 'subcutaneous', 'dose', '64', '%', '.'], 'stemmed': ['absorpt', 'averag', 'absolut', 'bioavail', 'adalimumab', 'follow', 'singl', '40', 'mg', 'subcutan', 'dose', '64', '%', '.'], 'dependencies': [('absorpt', 'compound'), ('averag', 'nsubj'), ('absolut', 'compound'), ('bioavail', 'compound'), ('adalimumab', 'compound'), ('follow', 'npadvmod'), ('singl', 'ROOT'), ('40', 'nummod'), ('mg', 'cc'), ('subcutan', 'npadvmod'), ('dose', 'conj'), ('64', 'nummod'), ('%', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The mean time to reach the maximum concentration was 5.5 days (131 ± 56 hours) \\nand the maximum serum concentration was 4.7 ± 1.6 mcg/mL in healthy subjects following a \\nsingle 40 mg subcutaneous administration of HUMIRA.', 'tokens': ['mean', 'time', 'reach', 'maximum', 'concentration', '5.5', 'days', '(', '131', '±', '56', 'hours', ')', 'maximum', 'serum', 'concentration', '4.7', '±', '1.6', 'mcg/mL', 'healthy', 'subjects', 'following', 'single', '40', 'mg', 'subcutaneous', 'administration', 'HUMIRA', '.'], 'lemmatized': ['mean', 'time', 'reach', 'maximum', 'concentration', '5.5', 'day', '(', '131', '±', '56', 'hour', ')', 'maximum', 'serum', 'concentration', '4.7', '±', '1.6', 'mcg/mL', 'healthy', 'subject', 'following', 'single', '40', 'mg', 'subcutaneous', 'administration', 'HUMIRA', '.'], 'stemmed': ['mean', 'time', 'reach', 'maximum', 'concentr', '5.5', 'day', '(', '131', '±', '56', 'hour', ')', 'maximum', 'serum', 'concentr', '4.7', '±', '1.6', 'mcg/ml', 'healthi', 'subject', 'follow', 'singl', '40', 'mg', 'subcutan', 'administr', 'humira', '.'], 'dependencies': [('mean', 'parataxis'), ('time', 'nsubj'), ('reach', 'advcl'), ('maximum', 'amod'), ('concentr', 'dobj'), ('5.5', 'nummod'), ('day', 'npadvmod'), ('(', 'punct'), ('131', 'nummod'), ('±', 'nmod'), ('56', 'nummod'), ('hour', 'appos'), (')', 'punct'), ('maximum', 'amod'), ('serum', 'nsubj'), ('concentr', 'nsubj'), ('4.7', 'dobj'), ('±', 'npadvmod'), ('1.6', 'nummod'), ('mcg', 'nmod'), ('/', 'punct'), ('ml', 'appos'), ('healthi', 'advmod'), ('subject', 'advmod'), ('follow', 'conj'), ('singl', 'ROOT'), ('40', 'nummod'), ('mg', 'npadvmod'), ('subcutan', 'compound'), ('administr', 'compound'), ('humira', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Distribution \\nThe distribution volume (Vss) ranged from 4.7 to 6.0 L following intravenous administration of \\ndoses ranging from 0.25 to 10 mg/kg in RA patients.', 'tokens': ['Distribution', 'distribution', 'volume', '(', 'Vss', ')', 'ranged', '4.7', '6.0', 'L', 'following', 'intravenous', 'administration', 'doses', 'ranging', '0.25', '10', 'mg/kg', 'RA', 'patients', '.'], 'lemmatized': ['Distribution', 'distribution', 'volume', '(', 'Vss', ')', 'ranged', '4.7', '6.0', 'L', 'following', 'intravenous', 'administration', 'dos', 'ranging', '0.25', '10', 'mg/kg', 'RA', 'patient', '.'], 'stemmed': ['distribut', 'distribut', 'volum', '(', 'vss', ')', 'rang', '4.7', '6.0', 'l', 'follow', 'intraven', 'administr', 'do', 'rang', '0.25', '10', 'mg/kg', 'ra', 'patient', '.'], 'dependencies': [('distribut', 'nmod'), ('distribut', 'compound'), ('volum', 'nsubj'), ('(', 'punct'), ('vss', 'appos'), (')', 'punct'), ('rang', 'ROOT'), ('4.7', 'compound'), ('6.0', 'nummod'), ('l', 'compound'), ('follow', 'dobj'), ('intraven', 'compound'), ('administr', 'npadvmod'), ('do', 'aux'), ('rang', 'conj'), ('0.25', 'npadvmod'), ('10', 'nummod'), ('mg', 'nmod'), ('/', 'punct'), ('kg', 'compound'), ('ra', 'compound'), ('patient', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Elimination \\nThe single dose pharmacokinetics of adalimumab in RA patients were determined in several \\nstudies with intravenous doses ranging from 0.25 to 10 mg/kg.', 'tokens': ['Elimination', 'single', 'dose', 'pharmacokinetics', 'adalimumab', 'RA', 'patients', 'determined', 'several', 'studies', 'intravenous', 'doses', 'ranging', '0.25', '10', 'mg/kg', '.'], 'lemmatized': ['Elimination', 'single', 'dose', 'pharmacokinetics', 'adalimumab', 'RA', 'patient', 'determined', 'several', 'study', 'intravenous', 'dos', 'ranging', '0.25', '10', 'mg/kg', '.'], 'stemmed': ['elimin', 'singl', 'dose', 'pharmacokinet', 'adalimumab', 'ra', 'patient', 'determin', 'sever', 'studi', 'intraven', 'do', 'rang', '0.25', '10', 'mg/kg', '.'], 'dependencies': [('elimin', 'dep'), ('singl', 'det'), ('dose', 'compound'), ('pharmacokinet', 'compound'), ('adalimumab', 'compound'), ('ra', 'compound'), ('patient', 'compound'), ('determin', 'dobj'), ('sever', 'compound'), ('studi', 'compound'), ('intraven', 'nsubj'), ('do', 'aux'), ('rang', 'ROOT'), ('0.25', 'npadvmod'), ('10', 'nummod'), ('mg', 'nmod'), ('/', 'punct'), ('kg', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'The systemic clearance of \\nadalimumab is approximately 12 mL/hr.', 'tokens': ['systemic', 'clearance', 'adalimumab', 'approximately', '12', 'mL/hr', '.'], 'lemmatized': ['systemic', 'clearance', 'adalimumab', 'approximately', '12', 'mL/hr', '.'], 'stemmed': ['system', 'clearanc', 'adalimumab', 'approxim', '12', 'ml/hr', '.'], 'dependencies': [('system', 'compound'), ('clearanc', 'compound'), ('adalimumab', 'compound'), ('approxim', 'ROOT'), ('12', 'nummod'), ('ml', 'nmod'), ('/', 'punct'), ('hr', 'appos'), ('.', 'punct')]}, {'original_sentence': 'In long-term studies with dosing more than two years, \\nthere was no evidence of changes in clearance over time in RA patients.', 'tokens': ['long-term', 'studies', 'dosing', 'two', 'years', ',', 'evidence', 'changes', 'clearance', 'time', 'RA', 'patients', '.'], 'lemmatized': ['long-term', 'study', 'dosing', 'two', 'year', ',', 'evidence', 'change', 'clearance', 'time', 'RA', 'patient', '.'], 'stemmed': ['long-term', 'studi', 'dose', 'two', 'year', ',', 'evid', 'chang', 'clearanc', 'time', 'ra', 'patient', '.'], 'dependencies': [('long', 'amod'), ('-', 'punct'), ('term', 'compound'), ('studi', 'compound'), ('dose', 'ROOT'), ('two', 'nummod'), ('year', 'npadvmod'), (',', 'punct'), ('evid', 'compound'), ('chang', 'compound'), ('clearanc', 'compound'), ('time', 'compound'), ('ra', 'compound'), ('patient', 'conj'), ('.', 'punct')]}, {'original_sentence': 'Patient Population \\nRheumatoid Arthritis and Ankylosing Spondylitis: In patients receiving 40 mg HUMIRA every \\nother week, adalimumab mean steady-state trough concentrations were approximately 5 mcg/mL \\nand 8 to 9 mcg/mL, without and with MTX concomitant treatment, respectively.', 'tokens': ['Patient', 'Population', 'Rheumatoid', 'Arthritis', 'Ankylosing', 'Spondylitis', ':', 'patients', 'receiving', '40', 'mg', 'HUMIRA', 'every', 'week', ',', 'adalimumab', 'mean', 'steady-state', 'trough', 'concentrations', 'approximately', '5', 'mcg/mL', '8', '9', 'mcg/mL', ',', 'without', 'MTX', 'concomitant', 'treatment', ',', 'respectively', '.'], 'lemmatized': ['Patient', 'Population', 'Rheumatoid', 'Arthritis', 'Ankylosing', 'Spondylitis', ':', 'patient', 'receiving', '40', 'mg', 'HUMIRA', 'every', 'week', ',', 'adalimumab', 'mean', 'steady-state', 'trough', 'concentration', 'approximately', '5', 'mcg/mL', '8', '9', 'mcg/mL', ',', 'without', 'MTX', 'concomitant', 'treatment', ',', 'respectively', '.'], 'stemmed': ['patient', 'popul', 'rheumatoid', 'arthriti', 'ankylos', 'spondyl', ':', 'patient', 'receiv', '40', 'mg', 'humira', 'everi', 'week', ',', 'adalimumab', 'mean', 'steady-st', 'trough', 'concentr', 'approxim', '5', 'mcg/ml', '8', '9', 'mcg/ml', ',', 'without', 'mtx', 'concomit', 'treatment', ',', 'respect', '.'], 'dependencies': [('patient', 'compound'), ('popul', 'compound'), ('rheumatoid', 'compound'), ('arthriti', 'appos'), ('ankylos', 'nsubj'), ('spondyl', 'npadvmod'), (':', 'punct'), ('patient', 'compound'), ('receiv', 'appos'), ('40', 'nummod'), ('mg', 'prep'), ('humira', 'npadvmod'), ('everi', 'compound'), ('week', 'npadvmod'), (',', 'punct'), ('adalimumab', 'nsubj'), ('mean', 'amod'), ('steady', 'amod'), ('-', 'punct'), ('st', 'compound'), ('trough', 'compound'), ('concentr', 'nsubj'), ('approxim', 'ROOT'), ('5', 'nummod'), ('mcg', 'nmod'), ('/', 'punct'), ('ml', 'dobj'), ('8', 'nummod'), ('9', 'nummod'), ('mcg', 'nmod'), ('/', 'punct'), ('ml', 'npadvmod'), (',', 'punct'), ('without', 'prep'), ('mtx', 'pcomp'), ('concomit', 'compound'), ('treatment', 'dobj'), (',', 'punct'), ('respect', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'Adalimumab \\nconcentrations in the synovial fluid from five rheumatoid arthritis patients ranged from 31 to \\n96% of those in serum.', 'tokens': ['Adalimumab', 'concentrations', 'synovial', 'fluid', 'five', 'rheumatoid', 'arthritis', 'patients', 'ranged', '31', '96', '%', 'serum', '.'], 'lemmatized': ['Adalimumab', 'concentration', 'synovial', 'fluid', 'five', 'rheumatoid', 'arthritis', 'patient', 'ranged', '31', '96', '%', 'serum', '.'], 'stemmed': ['adalimumab', 'concentr', 'synovi', 'fluid', 'five', 'rheumatoid', 'arthriti', 'patient', 'rang', '31', '96', '%', 'serum', '.'], 'dependencies': [('adalimumab', 'compound'), ('concentr', 'compound'), ('synovi', 'compound'), ('fluid', 'amod'), ('five', 'nummod'), ('rheumatoid', 'amod'), ('arthriti', 'compound'), ('patient', 'nsubj'), ('rang', 'ROOT'), ('31', 'nummod'), ('96', 'nummod'), ('%', 'compound'), ('serum', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The pharmacokinetics of adalimumab in patients with AS were similar to \\nthose in patients with RA.', 'tokens': ['pharmacokinetics', 'adalimumab', 'patients', 'similar', 'patients', 'RA', '.'], 'lemmatized': ['pharmacokinetics', 'adalimumab', 'patient', 'similar', 'patient', 'RA', '.'], 'stemmed': ['pharmacokinet', 'adalimumab', 'patient', 'similar', 'patient', 'ra', '.'], 'dependencies': [('pharmacokinet', 'compound'), ('adalimumab', 'compound'), ('patient', 'ROOT'), ('similar', 'amod'), ('patient', 'dobj'), ('ra', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Psoriatic Arthritis: In patients receiving 40 mg every other week, adalimumab mean steady-state \\ntrough concentrations were 6 to 10 mcg/mL and 8.5 to 12 mcg/mL, without and with MTX \\nconcomitant treatment, respectively.', 'tokens': ['Psoriatic', 'Arthritis', ':', 'patients', 'receiving', '40', 'mg', 'every', 'week', ',', 'adalimumab', 'mean', 'steady-state', 'trough', 'concentrations', '6', '10', 'mcg/mL', '8.5', '12', 'mcg/mL', ',', 'without', 'MTX', 'concomitant', 'treatment', ',', 'respectively', '.'], 'lemmatized': ['Psoriatic', 'Arthritis', ':', 'patient', 'receiving', '40', 'mg', 'every', 'week', ',', 'adalimumab', 'mean', 'steady-state', 'trough', 'concentration', '6', '10', 'mcg/mL', '8.5', '12', 'mcg/mL', ',', 'without', 'MTX', 'concomitant', 'treatment', ',', 'respectively', '.'], 'stemmed': ['psoriat', 'arthriti', ':', 'patient', 'receiv', '40', 'mg', 'everi', 'week', ',', 'adalimumab', 'mean', 'steady-st', 'trough', 'concentr', '6', '10', 'mcg/ml', '8.5', '12', 'mcg/ml', ',', 'without', 'mtx', 'concomit', 'treatment', ',', 'respect', '.'], 'dependencies': [('psoriat', 'compound'), ('arthriti', 'dep'), (':', 'punct'), ('patient', 'compound'), ('receiv', 'ROOT'), ('40', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'npadvmod'), (',', 'punct'), ('adalimumab', 'nsubj'), ('mean', 'amod'), ('steady', 'amod'), ('-', 'punct'), ('st', 'compound'), ('trough', 'compound'), ('concentr', 'conj'), ('6', 'npadvmod'), ('10', 'nummod'), ('mcg', 'nmod'), ('/', 'punct'), ('ml', 'appos'), ('8.5', 'compound'), ('12', 'nummod'), ('mcg', 'nmod'), ('/', 'punct'), ('ml', 'appos'), (',', 'punct'), ('without', 'prep'), ('mtx', 'pcomp'), ('concomit', 'compound'), ('treatment', 'dobj'), (',', 'punct'), ('respect', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'Plaque Psoriasis: Adalimumab mean steady-state trough concentration was approximately 5 to 6 \\nmcg/mL during HUMIRA 40 mg every other week treatment.', 'tokens': ['Plaque', 'Psoriasis', ':', 'Adalimumab', 'mean', 'steady-state', 'trough', 'concentration', 'approximately', '5', '6', 'mcg/mL', 'HUMIRA', '40', 'mg', 'every', 'week', 'treatment', '.'], 'lemmatized': ['Plaque', 'Psoriasis', ':', 'Adalimumab', 'mean', 'steady-state', 'trough', 'concentration', 'approximately', '5', '6', 'mcg/mL', 'HUMIRA', '40', 'mg', 'every', 'week', 'treatment', '.'], 'stemmed': ['plaqu', 'psoriasi', ':', 'adalimumab', 'mean', 'steady-st', 'trough', 'concentr', 'approxim', '5', '6', 'mcg/ml', 'humira', '40', 'mg', 'everi', 'week', 'treatment', '.'], 'dependencies': [('plaqu', 'ccomp'), ('psoriasi', 'dobj'), (':', 'punct'), ('adalimumab', 'nsubj'), ('mean', 'ROOT'), ('steady', 'amod'), ('-', 'punct'), ('st', 'compound'), ('trough', 'compound'), ('concentr', 'nsubj'), ('approxim', 'ccomp'), ('5', 'nummod'), ('6', 'nummod'), ('mcg', 'nmod'), ('/', 'punct'), ('ml', 'compound'), ('humira', 'appos'), ('40', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'compound'), ('treatment', 'conj'), ('.', 'punct')]}, {'original_sentence': 'Adult Uveitis: Adalimumab mean steady concentration was approximately 8 to 10 mcg/mL \\nduring HUMIRA 40 mg every other week treatment.', 'tokens': ['Adult', 'Uveitis', ':', 'Adalimumab', 'mean', 'steady', 'concentration', 'approximately', '8', '10', 'mcg/mL', 'HUMIRA', '40', 'mg', 'every', 'week', 'treatment', '.'], 'lemmatized': ['Adult', 'Uveitis', ':', 'Adalimumab', 'mean', 'steady', 'concentration', 'approximately', '8', '10', 'mcg/mL', 'HUMIRA', '40', 'mg', 'every', 'week', 'treatment', '.'], 'stemmed': ['adult', 'uveiti', ':', 'adalimumab', 'mean', 'steadi', 'concentr', 'approxim', '8', '10', 'mcg/ml', 'humira', '40', 'mg', 'everi', 'week', 'treatment', '.'], 'dependencies': [('adult', 'compound'), ('uveiti', 'dep'), (':', 'punct'), ('adalimumab', 'compound'), ('mean', 'compound'), ('steadi', 'compound'), ('concentr', 'ROOT'), ('approxim', 'dobj'), ('8', 'nummod'), ('10', 'nummod'), ('mcg', 'nmod'), ('/', 'punct'), ('ml', 'npadvmod'), ('humira', 'appos'), ('40', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'compound'), ('treatment', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Adult Hidradenitis Suppurativa: Adalimumab trough concentrations were approximately 7 to 8 \\nmcg/mL at Week 2 and Week 4, respectively, after receiving 160 mg on Week 0 followed by 80 \\nmg on Week 2.', 'tokens': ['Adult', 'Hidradenitis', 'Suppurativa', ':', 'Adalimumab', 'trough', 'concentrations', 'approximately', '7', '8', 'mcg/mL', 'Week', '2', 'Week', '4', ',', 'respectively', ',', 'receiving', '160', 'mg', 'Week', '0', 'followed', '80', 'mg', 'Week', '2', '.'], 'lemmatized': ['Adult', 'Hidradenitis', 'Suppurativa', ':', 'Adalimumab', 'trough', 'concentration', 'approximately', '7', '8', 'mcg/mL', 'Week', '2', 'Week', '4', ',', 'respectively', ',', 'receiving', '160', 'mg', 'Week', '0', 'followed', '80', 'mg', 'Week', '2', '.'], 'stemmed': ['adult', 'hidraden', 'suppurativa', ':', 'adalimumab', 'trough', 'concentr', 'approxim', '7', '8', 'mcg/ml', 'week', '2', 'week', '4', ',', 'respect', ',', 'receiv', '160', 'mg', 'week', '0', 'follow', '80', 'mg', 'week', '2', '.'], 'dependencies': [('adult', 'compound'), ('hidraden', 'compound'), ('suppurativa', 'dep'), (':', 'punct'), ('adalimumab', 'compound'), ('trough', 'nsubj'), ('concentr', 'ROOT'), ('approxim', 'compound'), ('7', 'nummod'), ('8', 'nummod'), ('mcg', 'nmod'), ('/', 'punct'), ('ml', 'compound'), ('week', 'npadvmod'), ('2', 'nummod'), ('week', 'npadvmod'), ('4', 'nummod'), (',', 'punct'), ('respect', 'appos'), (',', 'punct'), ('receiv', 'conj'), ('160', 'nummod'), ('mg', 'prep'), ('week', 'pobj'), ('0', 'nummod'), ('follow', 'conj'), ('80', 'nummod'), ('mg', 'amod'), ('week', 'npadvmod'), ('2', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Mean steady-state trough concentrations at Week 12 through Week 36 were \\napproximately 7 to 11 mcg/mL during HUMIRA 40 mg every week treatment.', 'tokens': ['Mean', 'steady-state', 'trough', 'concentrations', 'Week', '12', 'Week', '36', 'approximately', '7', '11', 'mcg/mL', 'HUMIRA', '40', 'mg', 'every', 'week', 'treatment', '.'], 'lemmatized': ['Mean', 'steady-state', 'trough', 'concentration', 'Week', '12', 'Week', '36', 'approximately', '7', '11', 'mcg/mL', 'HUMIRA', '40', 'mg', 'every', 'week', 'treatment', '.'], 'stemmed': ['mean', 'steady-st', 'trough', 'concentr', 'week', '12', 'week', '36', 'approxim', '7', '11', 'mcg/ml', 'humira', '40', 'mg', 'everi', 'week', 'treatment', '.'], 'dependencies': [('mean', 'ROOT'), ('steady', 'amod'), ('-', 'punct'), ('st', 'compound'), ('trough', 'compound'), ('concentr', 'dobj'), ('week', 'npadvmod'), ('12', 'nummod'), ('week', 'nmod'), ('36', 'nummod'), ('approxim', 'nmod'), ('7', 'nummod'), ('11', 'nummod'), ('mcg', 'nmod'), ('/', 'punct'), ('ml', 'appos'), ('humira', 'npadvmod'), ('40', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'compound'), ('treatment', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Adult Crohn’s Disease: Adalimumab mean trough concentrations were approximately 12 \\nmcg/mL at Week 2 and Week 4 after receiving 160 mg on Week 0 followed by 80 mg on Week \\n2.', 'tokens': ['Adult', 'Crohn', '’', 'Disease', ':', 'Adalimumab', 'mean', 'trough', 'concentrations', 'approximately', '12', 'mcg/mL', 'Week', '2', 'Week', '4', 'receiving', '160', 'mg', 'Week', '0', 'followed', '80', 'mg', 'Week', '2', '.'], 'lemmatized': ['Adult', 'Crohn', '’', 'Disease', ':', 'Adalimumab', 'mean', 'trough', 'concentration', 'approximately', '12', 'mcg/mL', 'Week', '2', 'Week', '4', 'receiving', '160', 'mg', 'Week', '0', 'followed', '80', 'mg', 'Week', '2', '.'], 'stemmed': ['adult', 'crohn', '’', 'diseas', ':', 'adalimumab', 'mean', 'trough', 'concentr', 'approxim', '12', 'mcg/ml', 'week', '2', 'week', '4', 'receiv', '160', 'mg', 'week', '0', 'follow', '80', 'mg', 'week', '2', '.'], 'dependencies': [('adult', 'compound'), ('crohn', 'nmod'), ('’', 'punct'), ('diseas', 'ROOT'), (':', 'punct'), ('adalimumab', 'compound'), ('mean', 'compound'), ('trough', 'compound'), ('concentr', 'nsubj'), ('approxim', 'acl'), ('12', 'nummod'), ('mcg', 'nmod'), ('/', 'punct'), ('ml', 'dobj'), ('week', 'npadvmod'), ('2', 'nummod'), ('week', 'npadvmod'), ('4', 'nummod'), ('receiv', 'npadvmod'), ('160', 'nummod'), ('mg', 'aux'), ('week', 'npadvmod'), ('0', 'nummod'), ('follow', 'appos'), ('80', 'dobj'), ('mg', 'amod'), ('week', 'npadvmod'), ('2', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Mean steady-state trough concentrations were 7 mcg/mL at Week 24 and Week 56 during \\nHUMIRA 40 mg every other week treatment.', 'tokens': ['Mean', 'steady-state', 'trough', 'concentrations', '7', 'mcg/mL', 'Week', '24', 'Week', '56', 'HUMIRA', '40', 'mg', 'every', 'week', 'treatment', '.'], 'lemmatized': ['Mean', 'steady-state', 'trough', 'concentration', '7', 'mcg/mL', 'Week', '24', 'Week', '56', 'HUMIRA', '40', 'mg', 'every', 'week', 'treatment', '.'], 'stemmed': ['mean', 'steady-st', 'trough', 'concentr', '7', 'mcg/ml', 'week', '24', 'week', '56', 'humira', '40', 'mg', 'everi', 'week', 'treatment', '.'], 'dependencies': [('mean', 'ROOT'), ('steady', 'amod'), ('-', 'punct'), ('st', 'compound'), ('trough', 'nsubj'), ('concentr', 'ccomp'), ('7', 'nummod'), ('mcg', 'nmod'), ('/', 'punct'), ('ml', 'compound'), ('week', 'npadvmod'), ('24', 'nummod'), ('week', 'nmod'), ('56', 'nummod'), ('humira', 'npadvmod'), ('40', 'nummod'), ('mg', 'nmod'), ('everi', 'amod'), ('week', 'compound'), ('treatment', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Adult Ulcerative Colitis: Adalimumab mean trough concentrations were approximately 12 \\nmcg/mL at Week 2 and Week 4 after receiving 160 mg on Week 0 followed by 80 mg on Week \\n2.', 'tokens': ['Adult', 'Ulcerative', 'Colitis', ':', 'Adalimumab', 'mean', 'trough', 'concentrations', 'approximately', '12', 'mcg/mL', 'Week', '2', 'Week', '4', 'receiving', '160', 'mg', 'Week', '0', 'followed', '80', 'mg', 'Week', '2', '.'], 'lemmatized': ['Adult', 'Ulcerative', 'Colitis', ':', 'Adalimumab', 'mean', 'trough', 'concentration', 'approximately', '12', 'mcg/mL', 'Week', '2', 'Week', '4', 'receiving', '160', 'mg', 'Week', '0', 'followed', '80', 'mg', 'Week', '2', '.'], 'stemmed': ['adult', 'ulcer', 'coliti', ':', 'adalimumab', 'mean', 'trough', 'concentr', 'approxim', '12', 'mcg/ml', 'week', '2', 'week', '4', 'receiv', '160', 'mg', 'week', '0', 'follow', '80', 'mg', 'week', '2', '.'], 'dependencies': [('adult', 'compound'), ('ulcer', 'compound'), ('coliti', 'dep'), (':', 'punct'), ('adalimumab', 'compound'), ('mean', 'compound'), ('trough', 'compound'), ('concentr', 'nsubj'), ('approxim', 'ROOT'), ('12', 'nummod'), ('mcg', 'nmod'), ('/', 'punct'), ('ml', 'dobj'), ('week', 'npadvmod'), ('2', 'nummod'), ('week', 'npadvmod'), ('4', 'nummod'), ('receiv', 'npadvmod'), ('160', 'nummod'), ('mg', 'aux'), ('week', 'npadvmod'), ('0', 'nummod'), ('follow', 'prep'), ('80', 'dobj'), ('mg', 'amod'), ('week', 'npadvmod'), ('2', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Mean steady-state trough concentrations were approximately 8 mcg/mL and 15 mcg/mL at \\nWeek 52 after receiving a dose of HUMIRA 40 mg every other week and 40 mg every week, \\nrespectively.', 'tokens': ['Mean', 'steady-state', 'trough', 'concentrations', 'approximately', '8', 'mcg/mL', '15', 'mcg/mL', 'Week', '52', 'receiving', 'dose', 'HUMIRA', '40', 'mg', 'every', 'week', '40', 'mg', 'every', 'week', ',', 'respectively', '.'], 'lemmatized': ['Mean', 'steady-state', 'trough', 'concentration', 'approximately', '8', 'mcg/mL', '15', 'mcg/mL', 'Week', '52', 'receiving', 'dose', 'HUMIRA', '40', 'mg', 'every', 'week', '40', 'mg', 'every', 'week', ',', 'respectively', '.'], 'stemmed': ['mean', 'steady-st', 'trough', 'concentr', 'approxim', '8', 'mcg/ml', '15', 'mcg/ml', 'week', '52', 'receiv', 'dose', 'humira', '40', 'mg', 'everi', 'week', '40', 'mg', 'everi', 'week', ',', 'respect', '.'], 'dependencies': [('mean', 'ROOT'), ('steady', 'amod'), ('-', 'punct'), ('st', 'compound'), ('trough', 'compound'), ('concentr', 'nsubj'), ('approxim', 'ccomp'), ('8', 'nummod'), ('mcg', 'nmod'), ('/', 'punct'), ('ml', 'nsubj'), ('15', 'nummod'), ('mcg', 'nmod'), ('/', 'punct'), ('ml', 'compound'), ('week', 'npadvmod'), ('52', 'nummod'), ('receiv', 'compound'), ('dose', 'compound'), ('humira', 'appos'), ('40', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'npadvmod'), ('40', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'pobj'), (',', 'punct'), ('respect', 'conj'), ('.', 'punct')]}], 'text': 'Absorption \\nThe average absolute bioavailability of adalimumab following a single 40 mg subcutaneous dose \\nwas 64%. The mean time to reach the maximum concentration was 5.5 days (131 ± 56 hours) \\nand the maximum serum concentration was 4.7 ± 1.6 mcg/mL in healthy subjects following a \\nsingle 40 mg subcutaneous administration of HUMIRA.   \\nDistribution \\nThe distribution volume (Vss) ranged from 4.7 to 6.0 L following intravenous administration of \\ndoses ranging from 0.25 to 10 mg/kg in RA patients. \\nElimination \\nThe single dose pharmacokinetics of adalimumab in RA patients were determined in several \\nstudies with intravenous doses ranging from 0.25 to 10 mg/kg. The systemic clearance of \\nadalimumab is approximately 12 mL/hr. In long-term studies with dosing more than two years, \\nthere was no evidence of changes in clearance over time in RA patients.  \\nPatient Population \\nRheumatoid Arthritis and Ankylosing Spondylitis: In patients receiving 40 mg HUMIRA every \\nother week, adalimumab mean steady-state trough concentrations were approximately 5 mcg/mL \\nand 8 to 9 mcg/mL, without and with MTX concomitant treatment, respectively. Adalimumab \\nconcentrations in the synovial fluid from five rheumatoid arthritis patients ranged from 31 to \\n96% of those in serum. The pharmacokinetics of adalimumab in patients with AS were similar to \\nthose in patients with RA. \\nPsoriatic Arthritis: In patients receiving 40 mg every other week, adalimumab mean steady-state \\ntrough concentrations were 6 to 10 mcg/mL and 8.5 to 12 mcg/mL, without and with MTX \\nconcomitant treatment, respectively.  \\nPlaque Psoriasis: Adalimumab mean steady-state trough concentration was approximately 5 to 6 \\nmcg/mL during HUMIRA 40 mg every other week treatment.  \\nAdult Uveitis: Adalimumab mean steady concentration was approximately 8 to 10 mcg/mL \\nduring HUMIRA 40 mg every other week treatment. \\nAdult Hidradenitis Suppurativa: Adalimumab trough concentrations were approximately 7 to 8 \\nmcg/mL at Week 2 and Week 4, respectively, after receiving 160 mg on Week 0 followed by 80 \\nmg on Week 2.  Mean steady-state trough concentrations at Week 12 through Week 36 were \\napproximately 7 to 11 mcg/mL during HUMIRA 40 mg every week treatment.  \\nAdult Crohn’s Disease: Adalimumab mean trough concentrations were approximately 12 \\nmcg/mL at Week 2 and Week 4 after receiving 160 mg on Week 0 followed by 80 mg on Week \\n2. Mean steady-state trough concentrations were 7 mcg/mL at Week 24 and Week 56 during \\nHUMIRA 40 mg every other week treatment.  \\nAdult Ulcerative Colitis: Adalimumab mean trough concentrations were approximately 12 \\nmcg/mL at Week 2 and Week 4 after receiving 160 mg on Week 0 followed by 80 mg on Week \\n2. Mean steady-state trough concentrations were approximately 8 mcg/mL and 15 mcg/mL at \\nWeek 52 after receiving a dose of HUMIRA 40 mg every other week and 40 mg every week, \\nrespectively.  \\n'}, 'page_char_count': 2897, 'page_word_count': 449, 'sentences': ['Absorption \\nThe average absolute bioavailability of adalimumab following a single 40 mg subcutaneous dose \\nwas 64%.', 'The mean time to reach the maximum concentration was 5.5 days (131 ± 56 hours) \\nand the maximum serum concentration was 4.7 ± 1.6 mcg/mL in healthy subjects following a \\nsingle 40 mg subcutaneous administration of HUMIRA.', '  \\nDistribution \\nThe distribution volume (Vss) ranged from 4.7 to 6.0 L following intravenous administration of \\ndoses ranging from 0.25 to 10 mg/kg in RA patients.', '\\nElimination \\nThe single dose pharmacokinetics of adalimumab in RA patients were determined in several \\nstudies with intravenous doses ranging from 0.25 to 10 mg/kg.', 'The systemic clearance of \\nadalimumab is approximately 12 mL/hr.', 'In long-term studies with dosing more than two years, \\nthere was no evidence of changes in clearance over time in RA patients.', ' \\nPatient Population \\nRheumatoid Arthritis and Ankylosing Spondylitis: In patients receiving 40 mg HUMIRA every \\nother week, adalimumab mean steady-state trough concentrations were approximately 5 mcg/mL \\nand 8 to 9 mcg/mL, without and with MTX concomitant treatment, respectively.', 'Adalimumab \\nconcentrations in the synovial fluid from five rheumatoid arthritis patients ranged from 31 to \\n96% of those in serum.', 'The pharmacokinetics of adalimumab in patients with AS were similar to \\nthose in patients with RA.', '\\nPsoriatic Arthritis: In patients receiving 40 mg every other week, adalimumab mean steady-state \\ntrough concentrations were 6 to 10 mcg/mL and 8.5 to 12 mcg/mL, without and with MTX \\nconcomitant treatment, respectively.', ' \\nPlaque Psoriasis: Adalimumab mean steady-state trough concentration was approximately 5 to 6 \\nmcg/mL during HUMIRA 40 mg every other week treatment.', ' \\nAdult Uveitis: Adalimumab mean steady concentration was approximately 8 to 10 mcg/mL \\nduring HUMIRA 40 mg every other week treatment.', '\\nAdult Hidradenitis Suppurativa: Adalimumab trough concentrations were approximately 7 to 8 \\nmcg/mL at Week 2 and Week 4, respectively, after receiving 160 mg on Week 0 followed by 80 \\nmg on Week 2.', ' Mean steady-state trough concentrations at Week 12 through Week 36 were \\napproximately 7 to 11 mcg/mL during HUMIRA 40 mg every week treatment.', ' \\nAdult Crohn’s Disease: Adalimumab mean trough concentrations were approximately 12 \\nmcg/mL at Week 2 and Week 4 after receiving 160 mg on Week 0 followed by 80 mg on Week \\n2.', 'Mean steady-state trough concentrations were 7 mcg/mL at Week 24 and Week 56 during \\nHUMIRA 40 mg every other week treatment.', ' \\nAdult Ulcerative Colitis: Adalimumab mean trough concentrations were approximately 12 \\nmcg/mL at Week 2 and Week 4 after receiving 160 mg on Week 0 followed by 80 mg on Week \\n2.', 'Mean steady-state trough concentrations were approximately 8 mcg/mL and 15 mcg/mL at \\nWeek 52 after receiving a dose of HUMIRA 40 mg every other week and 40 mg every week, \\nrespectively.', ' \\n'], 'page_sentence_count_spacy': 19}\n",
            "{'page_number': 31, 'text': \"Anti-Drug Antibody Effects on Pharmacokinetics  \\nRheumatoid Arthritis: A trend toward higher apparent clearance of adalimumab in the presence \\nof anti-adalimumab antibodies was identified.  \\nPediatric Ulcerative Colitis: Antibodies to adalimumab by ECL assay were associated with \\nreduced serum adalimumab concentrations in pediatric patients with moderately to severely \\nactive ulcerative colitis. \\nHidradenitis Suppurativa: In subjects with moderate to severe HS, antibodies to adalimumab \\nwere associated with reduced serum adalimumab concentrations. In general, the extent of \\nreduction in serum adalimumab concentrations is greater with increasing titers of antibodies to \\nadalimumab.  \\nSpecific Populations \\nGeriatric Patients: A lower clearance with increasing age was observed in patients with RA aged \\n40 to >75 years. \\nPediatric Patients: \\nJuvenile Idiopathic Arthritis:  \\n• 4 years to 17 years of age: The adalimumab mean steady-state trough concentrations were \\n6.8 mcg/mL and 10.9 mcg/mL in patients weighing <30 kg receiving 20 mg HUMIRA \\nsubcutaneously every other week as monotherapy or with concomitant MTX, respectively. \\nThe adalimumab mean steady-state trough concentrations were 6.6 mcg/mL and 8.1 \\nmcg/mL in patients weighing ≥30 kg receiving 40 mg HUMIRA subcutaneously every \\nother week as monotherapy or with MTX concomitant treatment, respectively.  \\n• 2 years to <4 years of age or 4 years of age and older weighing <15 kg: The adalimumab \\nmean steady-state trough adalimumab concentrations were 6.0 mcg/mL and 7.9 mcg/mL in \\npatients receiving HUMIRA subcutaneously every other week as monotherapy or with \\nMTX concomitant treatment, respectively. \\nPediatric Hidradenitis Suppurativa: Adalimumab concentrations in adolescent patients with HS \\nreceiving the recommended dosage regimens are predicted to be similar to those observed in \\nadult subjects with HS based on population pharmacokinetic modeling and simulation. \\nPediatric Crohn's Disease: Adalimumab mean ± SD concentrations were 15.7±6.5 mcg/mL at \\nWeek 4 following 160 mg at Week 0 and 80 mg at Week 2, and 10.5±6.0 mcg/mL at Week 52 \\nfollowing 40 mg every other week dosing in patients weighing ≥ 40 kg. Adalimumab mean ± SD \\nconcentrations were 10.6±6.1 mcg/mL at Week 4 following dosing 80 mg at Week 0 and 40 mg \\nat Week 2, and 6.9±3.6 mcg/mL at Week 52 following 20 mg every other week dosing in \\npatients weighing < 40 kg. \\nPediatric Ulcerative Colitis: The adalimumab mean steady-state trough concentration was \\n5.0±3.3 mcg/mL at Week 52 following subcutaneous administration of 0.6 mg/kg (maximum of \\n40 mg) every other week in pediatric UC patients 5 years to 17 years of age. In patients who \\nreceived 0.6 mg/kg (maximum of 40 mg) every week, the mean steady-state trough \\nconcentration was 15.7±5.6 mcg/mL at Week 52 in pediatric UC patients 5 years to 17 years of \\nage. \\n\", 'processed_text': {'sentences': [{'original_sentence': 'Anti-Drug Antibody Effects on Pharmacokinetics  \\nRheumatoid Arthritis: A trend toward higher apparent clearance of adalimumab in the presence \\nof anti-adalimumab antibodies was identified.', 'tokens': ['Anti-Drug', 'Antibody', 'Effects', 'Pharmacokinetics', 'Rheumatoid', 'Arthritis', ':', 'trend', 'toward', 'higher', 'apparent', 'clearance', 'adalimumab', 'presence', 'anti-adalimumab', 'antibodies', 'identified', '.'], 'lemmatized': ['Anti-Drug', 'Antibody', 'Effects', 'Pharmacokinetics', 'Rheumatoid', 'Arthritis', ':', 'trend', 'toward', 'higher', 'apparent', 'clearance', 'adalimumab', 'presence', 'anti-adalimumab', 'antibody', 'identified', '.'], 'stemmed': ['anti-drug', 'antibodi', 'effect', 'pharmacokinet', 'rheumatoid', 'arthriti', ':', 'trend', 'toward', 'higher', 'appar', 'clearanc', 'adalimumab', 'presenc', 'anti-adalimumab', 'antibodi', 'identifi', '.'], 'dependencies': [('anti', 'amod'), ('-', 'amod'), ('drug', 'amod'), ('antibodi', 'amod'), ('effect', 'compound'), ('pharmacokinet', 'compound'), ('rheumatoid', 'compound'), ('arthriti', 'dep'), (':', 'punct'), ('trend', 'ROOT'), ('toward', 'prep'), ('higher', 'amod'), ('appar', 'compound'), ('clearanc', 'compound'), ('adalimumab', 'compound'), ('presenc', 'amod'), ('anti', 'amod'), ('-', 'amod'), ('adalimumab', 'amod'), ('antibodi', 'amod'), ('identifi', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'Pediatric Ulcerative Colitis: Antibodies to adalimumab by ECL assay were associated with \\nreduced serum adalimumab concentrations in pediatric patients with moderately to severely \\nactive ulcerative colitis.', 'tokens': ['Pediatric', 'Ulcerative', 'Colitis', ':', 'Antibodies', 'adalimumab', 'ECL', 'assay', 'associated', 'reduced', 'serum', 'adalimumab', 'concentrations', 'pediatric', 'patients', 'moderately', 'severely', 'active', 'ulcerative', 'colitis', '.'], 'lemmatized': ['Pediatric', 'Ulcerative', 'Colitis', ':', 'Antibodies', 'adalimumab', 'ECL', 'assay', 'associated', 'reduced', 'serum', 'adalimumab', 'concentration', 'pediatric', 'patient', 'moderately', 'severely', 'active', 'ulcerative', 'colitis', '.'], 'stemmed': ['pediatr', 'ulcer', 'coliti', ':', 'antibodi', 'adalimumab', 'ecl', 'assay', 'associ', 'reduc', 'serum', 'adalimumab', 'concentr', 'pediatr', 'patient', 'moder', 'sever', 'activ', 'ulcer', 'coliti', '.'], 'dependencies': [('pediatr', 'amod'), ('ulcer', 'compound'), ('coliti', 'dep'), (':', 'punct'), ('antibodi', 'amod'), ('adalimumab', 'compound'), ('ecl', 'compound'), ('assay', 'compound'), ('associ', 'compound'), ('reduc', 'compound'), ('serum', 'nmod'), ('adalimumab', 'compound'), ('concentr', 'appos'), ('pediatr', 'amod'), ('patient', 'compound'), ('moder', 'nsubj'), ('sever', 'ROOT'), ('activ', 'compound'), ('ulcer', 'compound'), ('coliti', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Hidradenitis Suppurativa: In subjects with moderate to severe HS, antibodies to adalimumab \\nwere associated with reduced serum adalimumab concentrations.', 'tokens': ['Hidradenitis', 'Suppurativa', ':', 'subjects', 'moderate', 'severe', 'HS', ',', 'antibodies', 'adalimumab', 'associated', 'reduced', 'serum', 'adalimumab', 'concentrations', '.'], 'lemmatized': ['Hidradenitis', 'Suppurativa', ':', 'subject', 'moderate', 'severe', 'HS', ',', 'antibody', 'adalimumab', 'associated', 'reduced', 'serum', 'adalimumab', 'concentration', '.'], 'stemmed': ['hidraden', 'suppurativa', ':', 'subject', 'moder', 'sever', 'hs', ',', 'antibodi', 'adalimumab', 'associ', 'reduc', 'serum', 'adalimumab', 'concentr', '.'], 'dependencies': [('hidraden', 'compound'), ('suppurativa', 'dep'), (':', 'punct'), ('subject', 'compound'), ('moder', 'nsubj'), ('sever', 'parataxis'), ('hs', 'dobj'), (',', 'punct'), ('antibodi', 'amod'), ('adalimumab', 'compound'), ('associ', 'nsubj'), ('reduc', 'ROOT'), ('serum', 'compound'), ('adalimumab', 'compound'), ('concentr', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'In general, the extent of \\nreduction in serum adalimumab concentrations is greater with increasing titers of antibodies to \\nadalimumab.', 'tokens': ['general', ',', 'extent', 'reduction', 'serum', 'adalimumab', 'concentrations', 'greater', 'increasing', 'titers', 'antibodies', 'adalimumab', '.'], 'lemmatized': ['general', ',', 'extent', 'reduction', 'serum', 'adalimumab', 'concentration', 'greater', 'increasing', 'titer', 'antibody', 'adalimumab', '.'], 'stemmed': ['gener', ',', 'extent', 'reduct', 'serum', 'adalimumab', 'concentr', 'greater', 'increas', 'titer', 'antibodi', 'adalimumab', '.'], 'dependencies': [('gener', 'dep'), (',', 'punct'), ('extent', 'compound'), ('reduct', 'compound'), ('serum', 'compound'), ('adalimumab', 'nsubj'), ('concentr', 'ROOT'), ('greater', 'amod'), ('increas', 'compound'), ('titer', 'compound'), ('antibodi', 'compound'), ('adalimumab', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Specific Populations \\nGeriatric Patients: A lower clearance with increasing age was observed in patients with RA aged \\n40 to >75 years.', 'tokens': ['Specific', 'Populations', 'Geriatric', 'Patients', ':', 'lower', 'clearance', 'increasing', 'age', 'observed', 'patients', 'RA', 'aged', '40', '>', '75', 'years', '.'], 'lemmatized': ['Specific', 'Populations', 'Geriatric', 'Patients', ':', 'lower', 'clearance', 'increasing', 'age', 'observed', 'patient', 'RA', 'aged', '40', '>', '75', 'year', '.'], 'stemmed': ['specif', 'popul', 'geriatr', 'patient', ':', 'lower', 'clearanc', 'increas', 'age', 'observ', 'patient', 'ra', 'age', '40', '>', '75', 'year', '.'], 'dependencies': [('specif', 'compound'), ('popul', 'nsubj'), ('geriatr', 'compound'), ('patient', 'ROOT'), (':', 'punct'), ('lower', 'amod'), ('clearanc', 'compound'), ('increas', 'compound'), ('age', 'compound'), ('observ', 'compound'), ('patient', 'compound'), ('ra', 'compound'), ('age', 'appos'), ('40', 'nummod'), ('>', 'punct'), ('75', 'nummod'), ('year', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Pediatric Patients: \\nJuvenile Idiopathic Arthritis:  \\n• 4 years to 17 years of age: The adalimumab mean steady-state trough concentrations were \\n6.8 mcg/mL and 10.9 mcg/mL in patients weighing <30 kg receiving 20 mg HUMIRA \\nsubcutaneously every other week as monotherapy or with concomitant MTX, respectively.', 'tokens': ['Pediatric', 'Patients', ':', 'Juvenile', 'Idiopathic', 'Arthritis', ':', '•', '4', 'years', '17', 'years', 'age', ':', 'adalimumab', 'mean', 'steady-state', 'trough', 'concentrations', '6.8', 'mcg/mL', '10.9', 'mcg/mL', 'patients', 'weighing', '<', '30', 'kg', 'receiving', '20', 'mg', 'HUMIRA', 'subcutaneously', 'every', 'week', 'monotherapy', 'concomitant', 'MTX', ',', 'respectively', '.'], 'lemmatized': ['Pediatric', 'Patients', ':', 'Juvenile', 'Idiopathic', 'Arthritis', ':', '•', '4', 'year', '17', 'year', 'age', ':', 'adalimumab', 'mean', 'steady-state', 'trough', 'concentration', '6.8', 'mcg/mL', '10.9', 'mcg/mL', 'patient', 'weighing', '<', '30', 'kg', 'receiving', '20', 'mg', 'HUMIRA', 'subcutaneously', 'every', 'week', 'monotherapy', 'concomitant', 'MTX', ',', 'respectively', '.'], 'stemmed': ['pediatr', 'patient', ':', 'juvenil', 'idiopath', 'arthriti', ':', '•', '4', 'year', '17', 'year', 'age', ':', 'adalimumab', 'mean', 'steady-st', 'trough', 'concentr', '6.8', 'mcg/ml', '10.9', 'mcg/ml', 'patient', 'weigh', '<', '30', 'kg', 'receiv', '20', 'mg', 'humira', 'subcutan', 'everi', 'week', 'monotherapi', 'concomit', 'mtx', ',', 'respect', '.'], 'dependencies': [('pediatr', 'amod'), ('patient', 'dep'), (':', 'punct'), ('juvenil', 'amod'), ('idiopath', 'compound'), ('arthriti', 'dep'), (':', 'punct'), ('•', 'appos'), ('4', 'nummod'), ('year', 'npadvmod'), ('17', 'nummod'), ('year', 'compound'), ('age', 'appos'), (':', 'punct'), ('adalimumab', 'nsubj'), ('mean', 'parataxis'), ('steady', 'amod'), ('-', 'punct'), ('st', 'compound'), ('trough', 'nsubj'), ('concentr', 'ROOT'), ('6.8', 'nummod'), ('mcg', 'nmod'), ('/', 'punct'), ('ml', 'nmod'), ('10.9', 'nummod'), ('mcg', 'nmod'), ('/', 'punct'), ('ml', 'nmod'), ('patient', 'compound'), ('weigh', 'nmod'), ('<', 'dep'), ('30', 'nummod'), ('kg', 'compound'), ('receiv', 'dobj'), ('20', 'nummod'), ('mg', 'prep'), ('humira', 'nsubj'), ('subcutan', 'conj'), ('everi', 'compound'), ('week', 'compound'), ('monotherapi', 'compound'), ('concomit', 'compound'), ('mtx', 'dobj'), (',', 'punct'), ('respect', 'appos'), ('.', 'punct')]}, {'original_sentence': 'The adalimumab mean steady-state trough concentrations were 6.6 mcg/mL and 8.1 \\nmcg/mL in patients weighing ≥30 kg receiving 40 mg HUMIRA subcutaneously every \\nother week as monotherapy or with MTX concomitant treatment, respectively.', 'tokens': ['adalimumab', 'mean', 'steady-state', 'trough', 'concentrations', '6.6', 'mcg/mL', '8.1', 'mcg/mL', 'patients', 'weighing', '≥30', 'kg', 'receiving', '40', 'mg', 'HUMIRA', 'subcutaneously', 'every', 'week', 'monotherapy', 'MTX', 'concomitant', 'treatment', ',', 'respectively', '.'], 'lemmatized': ['adalimumab', 'mean', 'steady-state', 'trough', 'concentration', '6.6', 'mcg/mL', '8.1', 'mcg/mL', 'patient', 'weighing', '≥30', 'kg', 'receiving', '40', 'mg', 'HUMIRA', 'subcutaneously', 'every', 'week', 'monotherapy', 'MTX', 'concomitant', 'treatment', ',', 'respectively', '.'], 'stemmed': ['adalimumab', 'mean', 'steady-st', 'trough', 'concentr', '6.6', 'mcg/ml', '8.1', 'mcg/ml', 'patient', 'weigh', '≥30', 'kg', 'receiv', '40', 'mg', 'humira', 'subcutan', 'everi', 'week', 'monotherapi', 'mtx', 'concomit', 'treatment', ',', 'respect', '.'], 'dependencies': [('adalimumab', 'nsubj'), ('mean', 'parataxis'), ('steady', 'amod'), ('-', 'punct'), ('st', 'compound'), ('trough', 'nsubj'), ('concentr', 'ROOT'), ('6.6', 'nummod'), ('mcg', 'nmod'), ('/', 'punct'), ('ml', 'npadvmod'), ('8.1', 'nummod'), ('mcg', 'nmod'), ('/', 'punct'), ('ml', 'nmod'), ('patient', 'compound'), ('weigh', 'punct'), ('≥30', 'punct'), ('kg', 'compound'), ('receiv', 'dep'), ('40', 'nummod'), ('mg', 'prep'), ('humira', 'nsubj'), ('subcutan', 'ROOT'), ('everi', 'compound'), ('week', 'compound'), ('monotherapi', 'compound'), ('mtx', 'compound'), ('concomit', 'compound'), ('treatment', 'dobj'), (',', 'punct'), ('respect', 'appos'), ('.', 'punct')]}, {'original_sentence': '• 2 years to <4 years of age or 4 years of age and older weighing <15 kg: The adalimumab \\nmean steady-state trough adalimumab concentrations were 6.0 mcg/mL and 7.9 mcg/mL in \\npatients receiving HUMIRA subcutaneously every other week as monotherapy or with \\nMTX concomitant treatment, respectively.', 'tokens': ['•', '2', 'years', '<', '4', 'years', 'age', '4', 'years', 'age', 'older', 'weighing', '<', '15', 'kg', ':', 'adalimumab', 'mean', 'steady-state', 'trough', 'adalimumab', 'concentrations', '6.0', 'mcg/mL', '7.9', 'mcg/mL', 'patients', 'receiving', 'HUMIRA', 'subcutaneously', 'every', 'week', 'monotherapy', 'MTX', 'concomitant', 'treatment', ',', 'respectively', '.'], 'lemmatized': ['•', '2', 'year', '<', '4', 'year', 'age', '4', 'year', 'age', 'older', 'weighing', '<', '15', 'kg', ':', 'adalimumab', 'mean', 'steady-state', 'trough', 'adalimumab', 'concentration', '6.0', 'mcg/mL', '7.9', 'mcg/mL', 'patient', 'receiving', 'HUMIRA', 'subcutaneously', 'every', 'week', 'monotherapy', 'MTX', 'concomitant', 'treatment', ',', 'respectively', '.'], 'stemmed': ['•', '2', 'year', '<', '4', 'year', 'age', '4', 'year', 'age', 'older', 'weigh', '<', '15', 'kg', ':', 'adalimumab', 'mean', 'steady-st', 'trough', 'adalimumab', 'concentr', '6.0', 'mcg/ml', '7.9', 'mcg/ml', 'patient', 'receiv', 'humira', 'subcutan', 'everi', 'week', 'monotherapi', 'mtx', 'concomit', 'treatment', ',', 'respect', '.'], 'dependencies': [('•', 'nummod'), ('2', 'nummod'), ('year', 'npadvmod'), ('<', 'dep'), ('4', 'nummod'), ('year', 'compound'), ('age', 'nmod'), ('4', 'nummod'), ('year', 'compound'), ('age', 'dep'), ('older', 'amod'), ('weigh', 'npadvmod'), ('<', 'dep'), ('15', 'nummod'), ('kg', 'appos'), (':', 'punct'), ('adalimumab', 'nsubj'), ('mean', 'parataxis'), ('steady', 'amod'), ('-', 'punct'), ('st', 'compound'), ('trough', 'compound'), ('adalimumab', 'nsubj'), ('concentr', 'dative'), ('6.0', 'nummod'), ('mcg', 'nmod'), ('/', 'punct'), ('ml', 'nmod'), ('7.9', 'nummod'), ('mcg', 'nmod'), ('/', 'punct'), ('ml', 'nmod'), ('patient', 'compound'), ('receiv', 'compound'), ('humira', 'nsubj'), ('subcutan', 'ROOT'), ('everi', 'compound'), ('week', 'compound'), ('monotherapi', 'compound'), ('mtx', 'compound'), ('concomit', 'compound'), ('treatment', 'dobj'), (',', 'punct'), ('respect', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Pediatric Hidradenitis Suppurativa: Adalimumab concentrations in adolescent patients with HS \\nreceiving the recommended dosage regimens are predicted to be similar to those observed in \\nadult subjects with HS based on population pharmacokinetic modeling and simulation.', 'tokens': ['Pediatric', 'Hidradenitis', 'Suppurativa', ':', 'Adalimumab', 'concentrations', 'adolescent', 'patients', 'HS', 'receiving', 'recommended', 'dosage', 'regimens', 'predicted', 'similar', 'observed', 'adult', 'subjects', 'HS', 'based', 'population', 'pharmacokinetic', 'modeling', 'simulation', '.'], 'lemmatized': ['Pediatric', 'Hidradenitis', 'Suppurativa', ':', 'Adalimumab', 'concentration', 'adolescent', 'patient', 'HS', 'receiving', 'recommended', 'dosage', 'regimen', 'predicted', 'similar', 'observed', 'adult', 'subject', 'HS', 'based', 'population', 'pharmacokinetic', 'modeling', 'simulation', '.'], 'stemmed': ['pediatr', 'hidraden', 'suppurativa', ':', 'adalimumab', 'concentr', 'adolesc', 'patient', 'hs', 'receiv', 'recommend', 'dosag', 'regimen', 'predict', 'similar', 'observ', 'adult', 'subject', 'hs', 'base', 'popul', 'pharmacokinet', 'model', 'simul', '.'], 'dependencies': [('pediatr', 'compound'), ('hidraden', 'compound'), ('suppurativa', 'dep'), (':', 'punct'), ('adalimumab', 'compound'), ('concentr', 'compound'), ('adolesc', 'advmod'), ('patient', 'compound'), ('hs', 'compound'), ('receiv', 'nsubj'), ('recommend', 'ROOT'), ('dosag', 'compound'), ('regimen', 'dobj'), ('predict', 'ccomp'), ('similar', 'amod'), ('observ', 'compound'), ('adult', 'nmod'), ('subject', 'amod'), ('hs', 'nmod'), ('base', 'compound'), ('popul', 'compound'), ('pharmacokinet', 'compound'), ('model', 'nsubj'), ('simul', 'ccomp'), ('.', 'punct')]}, {'original_sentence': \"Pediatric Crohn's Disease: Adalimumab mean ± SD concentrations were 15.7±6.5 mcg/mL at \\nWeek 4 following 160 mg at Week 0 and 80 mg at Week 2, and 10.5±6.0 mcg/mL at Week 52 \\nfollowing 40 mg every other week dosing in patients weighing ≥ 40 kg.\", 'tokens': ['Pediatric', 'Crohn', \"'s\", 'Disease', ':', 'Adalimumab', 'mean', '±', 'SD', 'concentrations', '15.7±6.5', 'mcg/mL', 'Week', '4', 'following', '160', 'mg', 'Week', '0', '80', 'mg', 'Week', '2', ',', '10.5±6.0', 'mcg/mL', 'Week', '52', 'following', '40', 'mg', 'every', 'week', 'dosing', 'patients', 'weighing', '≥', '40', 'kg', '.'], 'lemmatized': ['Pediatric', 'Crohn', \"'s\", 'Disease', ':', 'Adalimumab', 'mean', '±', 'SD', 'concentration', '15.7±6.5', 'mcg/mL', 'Week', '4', 'following', '160', 'mg', 'Week', '0', '80', 'mg', 'Week', '2', ',', '10.5±6.0', 'mcg/mL', 'Week', '52', 'following', '40', 'mg', 'every', 'week', 'dosing', 'patient', 'weighing', '≥', '40', 'kg', '.'], 'stemmed': ['pediatr', 'crohn', \"'s\", 'diseas', ':', 'adalimumab', 'mean', '±', 'sd', 'concentr', '15.7±6.5', 'mcg/ml', 'week', '4', 'follow', '160', 'mg', 'week', '0', '80', 'mg', 'week', '2', ',', '10.5±6.0', 'mcg/ml', 'week', '52', 'follow', '40', 'mg', 'everi', 'week', 'dose', 'patient', 'weigh', '≥', '40', 'kg', '.'], 'dependencies': [('pediatr', 'amod'), ('crohn', 'poss'), (\"'s\", 'case'), ('diseas', 'dep'), (':', 'punct'), ('adalimumab', 'compound'), ('mean', 'npadvmod'), ('±', 'compound'), ('sd', 'nsubj'), ('concentr', 'ROOT'), ('15.7±6.5', 'nummod'), ('mcg', 'nmod'), ('/', 'punct'), ('ml', 'dobj'), ('week', 'npadvmod'), ('4', 'nummod'), ('follow', 'conj'), ('160', 'nummod'), ('mg', 'prep'), ('week', 'pobj'), ('0', 'nummod'), ('80', 'nummod'), ('mg', 'prep'), ('week', 'pobj'), ('2', 'nummod'), (',', 'punct'), ('10.5±6.0', 'nummod'), ('mcg', 'nmod'), ('/', 'punct'), ('ml', 'compound'), ('week', 'npadvmod'), ('52', 'nummod'), ('follow', 'appos'), ('40', 'nummod'), ('mg', 'nmod'), ('everi', 'amod'), ('week', 'npadvmod'), ('dose', 'compound'), ('patient', 'compound'), ('weigh', 'compound'), ('≥', 'appos'), ('40', 'nummod'), ('kg', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Adalimumab mean ± SD \\nconcentrations were 10.6±6.1 mcg/mL at Week 4 following dosing 80 mg at Week 0 and 40 mg \\nat Week 2, and 6.9±3.6 mcg/mL at Week 52 following 20 mg every other week dosing in \\npatients weighing < 40 kg.', 'tokens': ['Adalimumab', 'mean', '±', 'SD', 'concentrations', '10.6±6.1', 'mcg/mL', 'Week', '4', 'following', 'dosing', '80', 'mg', 'Week', '0', '40', 'mg', 'Week', '2', ',', '6.9±3.6', 'mcg/mL', 'Week', '52', 'following', '20', 'mg', 'every', 'week', 'dosing', 'patients', 'weighing', '<', '40', 'kg', '.'], 'lemmatized': ['Adalimumab', 'mean', '±', 'SD', 'concentration', '10.6±6.1', 'mcg/mL', 'Week', '4', 'following', 'dosing', '80', 'mg', 'Week', '0', '40', 'mg', 'Week', '2', ',', '6.9±3.6', 'mcg/mL', 'Week', '52', 'following', '20', 'mg', 'every', 'week', 'dosing', 'patient', 'weighing', '<', '40', 'kg', '.'], 'stemmed': ['adalimumab', 'mean', '±', 'sd', 'concentr', '10.6±6.1', 'mcg/ml', 'week', '4', 'follow', 'dose', '80', 'mg', 'week', '0', '40', 'mg', 'week', '2', ',', '6.9±3.6', 'mcg/ml', 'week', '52', 'follow', '20', 'mg', 'everi', 'week', 'dose', 'patient', 'weigh', '<', '40', 'kg', '.'], 'dependencies': [('adalimumab', 'compound'), ('mean', 'npadvmod'), ('±', 'compound'), ('sd', 'nsubj'), ('concentr', 'ROOT'), ('10.6±6.1', 'nummod'), ('mcg', 'nmod'), ('/', 'punct'), ('ml', 'compound'), ('week', 'npadvmod'), ('4', 'nummod'), ('follow', 'compound'), ('dose', 'appos'), ('80', 'nummod'), ('mg', 'compound'), ('week', 'pobj'), ('0', 'nummod'), ('40', 'nummod'), ('mg', 'prep'), ('week', 'pobj'), ('2', 'nummod'), (',', 'punct'), ('6.9±3.6', 'nummod'), ('mcg', 'nmod'), ('/', 'punct'), ('ml', 'compound'), ('week', 'npadvmod'), ('52', 'nummod'), ('follow', 'appos'), ('20', 'nummod'), ('mg', 'nmod'), ('everi', 'amod'), ('week', 'compound'), ('dose', 'compound'), ('patient', 'compound'), ('weigh', 'npadvmod'), ('<', 'dep'), ('40', 'nummod'), ('kg', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Pediatric Ulcerative Colitis: The adalimumab mean steady-state trough concentration was \\n5.0±3.3 mcg/mL at Week 52 following subcutaneous administration of 0.6 mg/kg (maximum of \\n40 mg) every other week in pediatric UC patients 5 years to 17 years of age.', 'tokens': ['Pediatric', 'Ulcerative', 'Colitis', ':', 'adalimumab', 'mean', 'steady-state', 'trough', 'concentration', '5.0±3.3', 'mcg/mL', 'Week', '52', 'following', 'subcutaneous', 'administration', '0.6', 'mg/kg', '(', 'maximum', '40', 'mg', ')', 'every', 'week', 'pediatric', 'UC', 'patients', '5', 'years', '17', 'years', 'age', '.'], 'lemmatized': ['Pediatric', 'Ulcerative', 'Colitis', ':', 'adalimumab', 'mean', 'steady-state', 'trough', 'concentration', '5.0±3.3', 'mcg/mL', 'Week', '52', 'following', 'subcutaneous', 'administration', '0.6', 'mg/kg', '(', 'maximum', '40', 'mg', ')', 'every', 'week', 'pediatric', 'UC', 'patient', '5', 'year', '17', 'year', 'age', '.'], 'stemmed': ['pediatr', 'ulcer', 'coliti', ':', 'adalimumab', 'mean', 'steady-st', 'trough', 'concentr', '5.0±3.3', 'mcg/ml', 'week', '52', 'follow', 'subcutan', 'administr', '0.6', 'mg/kg', '(', 'maximum', '40', 'mg', ')', 'everi', 'week', 'pediatr', 'uc', 'patient', '5', 'year', '17', 'year', 'age', '.'], 'dependencies': [('pediatr', 'amod'), ('ulcer', 'compound'), ('coliti', 'dep'), (':', 'punct'), ('adalimumab', 'nsubj'), ('mean', 'parataxis'), ('steady', 'amod'), ('-', 'punct'), ('st', 'compound'), ('trough', 'nsubj'), ('concentr', 'dep'), ('5.0±3.3', 'dobj'), ('mcg', 'nmod'), ('/', 'punct'), ('ml', 'compound'), ('week', 'npadvmod'), ('52', 'nummod'), ('follow', 'ROOT'), ('subcutan', 'compound'), ('administr', 'dobj'), ('0.6', 'nummod'), ('mg', 'nmod'), ('/', 'punct'), ('kg', 'npadvmod'), ('(', 'punct'), ('maximum', 'parataxis'), ('40', 'nummod'), ('mg', 'prep'), (')', 'punct'), ('everi', 'amod'), ('week', 'compound'), ('pediatr', 'ROOT'), ('uc', 'advmod'), ('patient', 'amod'), ('5', 'nummod'), ('year', 'nmod'), ('17', 'nummod'), ('year', 'compound'), ('age', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'In patients who \\nreceived 0.6 mg/kg (maximum of 40 mg) every week, the mean steady-state trough \\nconcentration was 15.7±5.6 mcg/mL at Week 52 in pediatric UC patients 5 years to 17 years of \\nage.', 'tokens': ['patients', 'received', '0.6', 'mg/kg', '(', 'maximum', '40', 'mg', ')', 'every', 'week', ',', 'mean', 'steady-state', 'trough', 'concentration', '15.7±5.6', 'mcg/mL', 'Week', '52', 'pediatric', 'UC', 'patients', '5', 'years', '17', 'years', 'age', '.'], 'lemmatized': ['patient', 'received', '0.6', 'mg/kg', '(', 'maximum', '40', 'mg', ')', 'every', 'week', ',', 'mean', 'steady-state', 'trough', 'concentration', '15.7±5.6', 'mcg/mL', 'Week', '52', 'pediatric', 'UC', 'patient', '5', 'year', '17', 'year', 'age', '.'], 'stemmed': ['patient', 'receiv', '0.6', 'mg/kg', '(', 'maximum', '40', 'mg', ')', 'everi', 'week', ',', 'mean', 'steady-st', 'trough', 'concentr', '15.7±5.6', 'mcg/ml', 'week', '52', 'pediatr', 'uc', 'patient', '5', 'year', '17', 'year', 'age', '.'], 'dependencies': [('patient', 'compound'), ('receiv', 'ROOT'), ('0.6', 'nummod'), ('mg', 'nmod'), ('/', 'punct'), ('kg', 'appos'), ('(', 'punct'), ('maximum', 'amod'), ('40', 'nummod'), ('mg', 'appos'), (')', 'punct'), ('everi', 'amod'), ('week', 'npadvmod'), (',', 'punct'), ('mean', 'amod'), ('steady', 'amod'), ('-', 'punct'), ('st', 'compound'), ('trough', 'compound'), ('concentr', 'conj'), ('15.7±5.6', 'compound'), ('mcg', 'nmod'), ('/', 'punct'), ('ml', 'compound'), ('week', 'pobj'), ('52', 'nummod'), ('pediatr', 'amod'), ('uc', 'advmod'), ('patient', 'appos'), ('5', 'nummod'), ('year', 'ROOT'), ('17', 'nummod'), ('year', 'compound'), ('age', 'npadvmod'), ('.', 'punct')]}], 'text': \"Anti-Drug Antibody Effects on Pharmacokinetics  \\nRheumatoid Arthritis: A trend toward higher apparent clearance of adalimumab in the presence \\nof anti-adalimumab antibodies was identified.  \\nPediatric Ulcerative Colitis: Antibodies to adalimumab by ECL assay were associated with \\nreduced serum adalimumab concentrations in pediatric patients with moderately to severely \\nactive ulcerative colitis. \\nHidradenitis Suppurativa: In subjects with moderate to severe HS, antibodies to adalimumab \\nwere associated with reduced serum adalimumab concentrations. In general, the extent of \\nreduction in serum adalimumab concentrations is greater with increasing titers of antibodies to \\nadalimumab.  \\nSpecific Populations \\nGeriatric Patients: A lower clearance with increasing age was observed in patients with RA aged \\n40 to >75 years. \\nPediatric Patients: \\nJuvenile Idiopathic Arthritis:  \\n• 4 years to 17 years of age: The adalimumab mean steady-state trough concentrations were \\n6.8 mcg/mL and 10.9 mcg/mL in patients weighing <30 kg receiving 20 mg HUMIRA \\nsubcutaneously every other week as monotherapy or with concomitant MTX, respectively. \\nThe adalimumab mean steady-state trough concentrations were 6.6 mcg/mL and 8.1 \\nmcg/mL in patients weighing ≥30 kg receiving 40 mg HUMIRA subcutaneously every \\nother week as monotherapy or with MTX concomitant treatment, respectively.  \\n• 2 years to <4 years of age or 4 years of age and older weighing <15 kg: The adalimumab \\nmean steady-state trough adalimumab concentrations were 6.0 mcg/mL and 7.9 mcg/mL in \\npatients receiving HUMIRA subcutaneously every other week as monotherapy or with \\nMTX concomitant treatment, respectively. \\nPediatric Hidradenitis Suppurativa: Adalimumab concentrations in adolescent patients with HS \\nreceiving the recommended dosage regimens are predicted to be similar to those observed in \\nadult subjects with HS based on population pharmacokinetic modeling and simulation. \\nPediatric Crohn's Disease: Adalimumab mean ± SD concentrations were 15.7±6.5 mcg/mL at \\nWeek 4 following 160 mg at Week 0 and 80 mg at Week 2, and 10.5±6.0 mcg/mL at Week 52 \\nfollowing 40 mg every other week dosing in patients weighing ≥ 40 kg. Adalimumab mean ± SD \\nconcentrations were 10.6±6.1 mcg/mL at Week 4 following dosing 80 mg at Week 0 and 40 mg \\nat Week 2, and 6.9±3.6 mcg/mL at Week 52 following 20 mg every other week dosing in \\npatients weighing < 40 kg. \\nPediatric Ulcerative Colitis: The adalimumab mean steady-state trough concentration was \\n5.0±3.3 mcg/mL at Week 52 following subcutaneous administration of 0.6 mg/kg (maximum of \\n40 mg) every other week in pediatric UC patients 5 years to 17 years of age. In patients who \\nreceived 0.6 mg/kg (maximum of 40 mg) every week, the mean steady-state trough \\nconcentration was 15.7±5.6 mcg/mL at Week 52 in pediatric UC patients 5 years to 17 years of \\nage. \\n\"}, 'page_char_count': 2871, 'page_word_count': 429, 'sentences': ['Anti-Drug Antibody Effects on Pharmacokinetics  \\nRheumatoid Arthritis: A trend toward higher apparent clearance of adalimumab in the presence \\nof anti-adalimumab antibodies was identified.', ' \\nPediatric Ulcerative Colitis: Antibodies to adalimumab by ECL assay were associated with \\nreduced serum adalimumab concentrations in pediatric patients with moderately to severely \\nactive ulcerative colitis.', '\\nHidradenitis Suppurativa: In subjects with moderate to severe HS, antibodies to adalimumab \\nwere associated with reduced serum adalimumab concentrations.', 'In general, the extent of \\nreduction in serum adalimumab concentrations is greater with increasing titers of antibodies to \\nadalimumab.', ' \\nSpecific Populations \\nGeriatric Patients: A lower clearance with increasing age was observed in patients with RA aged \\n40 to >75 years.', '\\nPediatric Patients: \\nJuvenile Idiopathic Arthritis:  \\n• 4 years to 17 years of age: The adalimumab mean steady-state trough concentrations were \\n6.8 mcg/mL and 10.9 mcg/mL in patients weighing <30 kg receiving 20 mg HUMIRA \\nsubcutaneously every other week as monotherapy or with concomitant MTX, respectively.', '\\nThe adalimumab mean steady-state trough concentrations were 6.6 mcg/mL and 8.1 \\nmcg/mL in patients weighing ≥30 kg receiving 40 mg HUMIRA subcutaneously every \\nother week as monotherapy or with MTX concomitant treatment, respectively.', ' \\n• 2 years to <4 years of age or 4 years of age and older weighing <15 kg: The adalimumab \\nmean steady-state trough adalimumab concentrations were 6.0 mcg/mL and 7.9 mcg/mL in \\npatients receiving HUMIRA subcutaneously every other week as monotherapy or with \\nMTX concomitant treatment, respectively.', '\\nPediatric Hidradenitis Suppurativa: Adalimumab concentrations in adolescent patients with HS \\nreceiving the recommended dosage regimens are predicted to be similar to those observed in \\nadult subjects with HS based on population pharmacokinetic modeling and simulation.', \"\\nPediatric Crohn's Disease: Adalimumab mean ± SD concentrations were 15.7±6.5 mcg/mL at \\nWeek 4 following 160 mg at Week 0 and 80 mg at Week 2, and 10.5±6.0 mcg/mL at Week 52 \\nfollowing 40 mg every other week dosing in patients weighing ≥ 40 kg.\", 'Adalimumab mean ± SD \\nconcentrations were 10.6±6.1 mcg/mL at Week 4 following dosing 80 mg at Week 0 and 40 mg \\nat Week 2, and 6.9±3.6 mcg/mL at Week 52 following 20 mg every other week dosing in \\npatients weighing < 40 kg.', '\\nPediatric Ulcerative Colitis: The adalimumab mean steady-state trough concentration was \\n5.0±3.3 mcg/mL at Week 52 following subcutaneous administration of 0.6 mg/kg (maximum of \\n40 mg) every other week in pediatric UC patients 5 years to 17 years of age.', 'In patients who \\nreceived 0.6 mg/kg (maximum of 40 mg) every week, the mean steady-state trough \\nconcentration was 15.7±5.6 mcg/mL at Week 52 in pediatric UC patients 5 years to 17 years of \\nage.', '\\n'], 'page_sentence_count_spacy': 14}\n",
            "{'page_number': 32, 'text': 'Male and Female Patients:  No gender-related pharmacokinetic differences were observed after \\ncorrection for a patient’s body weight. Healthy subjects and patients with rheumatoid arthritis \\ndisplayed similar adalimumab pharmacokinetics. \\nPatients with Renal or Hepatic Impairment: No pharmacokinetic data are available in patients \\nwith hepatic or renal impairment.  \\nRheumatoid factor or CRP concentrations: Minor increases in apparent clearance were predicted \\nin RA patients receiving doses lower than the recommended dose and in RA patients with high \\nrheumatoid factor or CRP concentrations. These increases are not likely to be clinically \\nimportant.  \\nDrug Interaction Studies: \\nMethotrexate: MTX reduced adalimumab apparent clearance after single and multiple dosing by \\n29% and 44% respectively, in patients with RA [see Drug Interactions (7.1)]. \\n13 NONCLINICAL TOXICOLOGY \\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility \\nLong-term animal studies of HUMIRA have not been conducted to evaluate the carcinogenic \\npotential or its effect on fertility.  \\n14 CLINICAL STUDIES \\n14.1 Rheumatoid Arthritis \\nThe efficacy and safety of HUMIRA were assessed in five randomized, double-blind studies in \\npatients ≥18 years of age with active rheumatoid arthritis (RA) diagnosed according to American \\nCollege of Rheumatology (ACR) criteria. Patients had at least 6 swollen and 9 tender joints. \\nHUMIRA was administered subcutaneously in combination with methotrexate (MTX) (12.5 to \\n25 mg, Studies RA-I, RA-III and RA-V) or as monotherapy (Studies RA-II and RA-V) or with \\nother disease-modifying anti-rheumatic drugs (DMARDs) (Study RA-IV).  \\nStudy RA-I evaluated 271 patients who had failed therapy with at least one but no more than \\nfour DMARDs and had inadequate response to MTX. Doses of 20, 40 or 80 mg of HUMIRA or \\nplacebo were given every other week for 24 weeks.  \\nStudy RA-II evaluated 544 patients who had failed therapy with at least one DMARD. Doses of \\nplacebo, 20 or 40 mg of HUMIRA were given as monotherapy every other week or weekly for \\n26 weeks.  \\nStudy RA-III evaluated 619 patients who had an inadequate response to MTX. Patients received \\nplacebo, 40 mg of HUMIRA every other week with placebo injections on alternate weeks, or 20 \\nmg of HUMIRA weekly for up to 52 weeks. Study RA-III had an additional primary endpoint at \\n52 weeks of inhibition of disease progression (as detected by X-ray results). Upon completion of \\nthe first 52 weeks, 457 patients enrolled in an open-label extension phase in which 40 mg of \\nHUMIRA was administered every other week for up to 5 years.  \\n', 'processed_text': {'sentences': [{'original_sentence': 'Male and Female Patients:  No gender-related pharmacokinetic differences were observed after \\ncorrection for a patient’s body weight.', 'tokens': ['Male', 'Female', 'Patients', ':', 'gender-related', 'pharmacokinetic', 'differences', 'observed', 'correction', 'patient', '’', 'body', 'weight', '.'], 'lemmatized': ['Male', 'Female', 'Patients', ':', 'gender-related', 'pharmacokinetic', 'difference', 'observed', 'correction', 'patient', '’', 'body', 'weight', '.'], 'stemmed': ['male', 'femal', 'patient', ':', 'gender-rel', 'pharmacokinet', 'differ', 'observ', 'correct', 'patient', '’', 'bodi', 'weight', '.'], 'dependencies': [('male', 'amod'), ('femal', 'amod'), ('patient', 'nsubj'), (':', 'punct'), ('gender', 'compound'), ('-', 'punct'), ('rel', 'compound'), ('pharmacokinet', 'appos'), ('differ', 'ROOT'), ('observ', 'nmod'), ('correct', 'amod'), ('patient', 'nmod'), ('’', 'punct'), ('bodi', 'compound'), ('weight', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Healthy subjects and patients with rheumatoid arthritis \\ndisplayed similar adalimumab pharmacokinetics.', 'tokens': ['Healthy', 'subjects', 'patients', 'rheumatoid', 'arthritis', 'displayed', 'similar', 'adalimumab', 'pharmacokinetics', '.'], 'lemmatized': ['Healthy', 'subject', 'patient', 'rheumatoid', 'arthritis', 'displayed', 'similar', 'adalimumab', 'pharmacokinetics', '.'], 'stemmed': ['healthi', 'subject', 'patient', 'rheumatoid', 'arthriti', 'display', 'similar', 'adalimumab', 'pharmacokinet', '.'], 'dependencies': [('healthi', 'amod'), ('subject', 'amod'), ('patient', 'amod'), ('rheumatoid', 'compound'), ('arthriti', 'nsubj'), ('display', 'ROOT'), ('similar', 'amod'), ('adalimumab', 'compound'), ('pharmacokinet', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Patients with Renal or Hepatic Impairment: No pharmacokinetic data are available in patients \\nwith hepatic or renal impairment.', 'tokens': ['Patients', 'Renal', 'Hepatic', 'Impairment', ':', 'pharmacokinetic', 'data', 'available', 'patients', 'hepatic', 'renal', 'impairment', '.'], 'lemmatized': ['Patients', 'Renal', 'Hepatic', 'Impairment', ':', 'pharmacokinetic', 'data', 'available', 'patient', 'hepatic', 'renal', 'impairment', '.'], 'stemmed': ['patient', 'renal', 'hepat', 'impair', ':', 'pharmacokinet', 'data', 'avail', 'patient', 'hepat', 'renal', 'impair', '.'], 'dependencies': [('patient', 'compound'), ('renal', 'amod'), ('hepat', 'compound'), ('impair', 'dep'), (':', 'punct'), ('pharmacokinet', 'compound'), ('data', 'nsubj'), ('avail', 'ROOT'), ('patient', 'compound'), ('hepat', 'nmod'), ('renal', 'amod'), ('impair', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Rheumatoid factor or CRP concentrations: Minor increases in apparent clearance were predicted \\nin RA patients receiving doses lower than the recommended dose and in RA patients with high \\nrheumatoid factor or CRP concentrations.', 'tokens': ['Rheumatoid', 'factor', 'CRP', 'concentrations', ':', 'Minor', 'increases', 'apparent', 'clearance', 'predicted', 'RA', 'patients', 'receiving', 'doses', 'lower', 'recommended', 'dose', 'RA', 'patients', 'high', 'rheumatoid', 'factor', 'CRP', 'concentrations', '.'], 'lemmatized': ['Rheumatoid', 'factor', 'CRP', 'concentration', ':', 'Minor', 'increase', 'apparent', 'clearance', 'predicted', 'RA', 'patient', 'receiving', 'dos', 'lower', 'recommended', 'dose', 'RA', 'patient', 'high', 'rheumatoid', 'factor', 'CRP', 'concentration', '.'], 'stemmed': ['rheumatoid', 'factor', 'crp', 'concentr', ':', 'minor', 'increas', 'appar', 'clearanc', 'predict', 'ra', 'patient', 'receiv', 'do', 'lower', 'recommend', 'dose', 'ra', 'patient', 'high', 'rheumatoid', 'factor', 'crp', 'concentr', '.'], 'dependencies': [('rheumatoid', 'amod'), ('factor', 'compound'), ('crp', 'compound'), ('concentr', 'dep'), (':', 'punct'), ('minor', 'amod'), ('increas', 'compound'), ('appar', 'compound'), ('clearanc', 'nsubj'), ('predict', 'ROOT'), ('ra', 'compound'), ('patient', 'compound'), ('receiv', 'nsubj'), ('do', 'aux'), ('lower', 'amod'), ('recommend', 'ccomp'), ('dose', 'compound'), ('ra', 'compound'), ('patient', 'amod'), ('high', 'amod'), ('rheumatoid', 'amod'), ('factor', 'compound'), ('crp', 'compound'), ('concentr', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'These increases are not likely to be clinically \\nimportant.', 'tokens': ['increases', 'likely', 'clinically', 'important', '.'], 'lemmatized': ['increase', 'likely', 'clinically', 'important', '.'], 'stemmed': ['increas', 'like', 'clinic', 'import', '.'], 'dependencies': [('increas', 'ROOT'), ('like', 'prep'), ('clinic', 'compound'), ('import', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'Drug Interaction Studies: \\nMethotrexate: MTX reduced adalimumab apparent clearance after single and multiple dosing by \\n29% and 44% respectively, in patients with RA [see Drug Interactions (7.1)].', 'tokens': ['Drug', 'Interaction', 'Studies', ':', 'Methotrexate', ':', 'MTX', 'reduced', 'adalimumab', 'apparent', 'clearance', 'single', 'multiple', 'dosing', '29', '%', '44', '%', 'respectively', ',', 'patients', 'RA', '[', 'see', 'Drug', 'Interactions', '(', '7.1', ')', ']', '.'], 'lemmatized': ['Drug', 'Interaction', 'Studies', ':', 'Methotrexate', ':', 'MTX', 'reduced', 'adalimumab', 'apparent', 'clearance', 'single', 'multiple', 'dosing', '29', '%', '44', '%', 'respectively', ',', 'patient', 'RA', '[', 'see', 'Drug', 'Interactions', '(', '7.1', ')', ']', '.'], 'stemmed': ['drug', 'interact', 'studi', ':', 'methotrex', ':', 'mtx', 'reduc', 'adalimumab', 'appar', 'clearanc', 'singl', 'multipl', 'dose', '29', '%', '44', '%', 'respect', ',', 'patient', 'ra', '[', 'see', 'drug', 'interact', '(', '7.1', ')', ']', '.'], 'dependencies': [('drug', 'compound'), ('interact', 'compound'), ('studi', 'dep'), (':', 'punct'), ('methotrex', 'nmod'), (':', 'punct'), ('mtx', 'ROOT'), ('reduc', 'compound'), ('adalimumab', 'compound'), ('appar', 'compound'), ('clearanc', 'compound'), ('singl', 'compound'), ('multipl', 'nsubj'), ('dose', 'ccomp'), ('29', 'nummod'), ('%', 'dobj'), ('44', 'nummod'), ('%', 'compound'), ('respect', 'appos'), (',', 'punct'), ('patient', 'compound'), ('ra', 'npadvmod'), ('[', 'punct'), ('see', 'ROOT'), ('drug', 'compound'), ('interact', 'dobj'), ('(', 'punct'), ('7.1', 'appos'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': '13 NONCLINICAL TOXICOLOGY \\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility \\nLong-term animal studies of HUMIRA have not been conducted to evaluate the carcinogenic \\npotential or its effect on fertility.', 'tokens': ['13', 'NONCLINICAL', 'TOXICOLOGY', '13.1', 'Carcinogenesis', ',', 'Mutagenesis', ',', 'Impairment', 'Fertility', 'Long-term', 'animal', 'studies', 'HUMIRA', 'conducted', 'evaluate', 'carcinogenic', 'potential', 'effect', 'fertility', '.'], 'lemmatized': ['13', 'NONCLINICAL', 'TOXICOLOGY', '13.1', 'Carcinogenesis', ',', 'Mutagenesis', ',', 'Impairment', 'Fertility', 'Long-term', 'animal', 'study', 'HUMIRA', 'conducted', 'evaluate', 'carcinogenic', 'potential', 'effect', 'fertility', '.'], 'stemmed': ['13', 'nonclin', 'toxicolog', '13.1', 'carcinogenesi', ',', 'mutagenesi', ',', 'impair', 'fertil', 'long-term', 'anim', 'studi', 'humira', 'conduct', 'evalu', 'carcinogen', 'potenti', 'effect', 'fertil', '.'], 'dependencies': [('13', 'nummod'), ('nonclin', 'compound'), ('toxicolog', 'npadvmod'), ('13.1', 'nummod'), ('carcinogenesi', 'appos'), (',', 'punct'), ('mutagenesi', 'conj'), (',', 'punct'), ('impair', 'ROOT'), ('fertil', 'nmod'), ('long', 'amod'), ('-', 'punct'), ('term', 'compound'), ('anim', 'compound'), ('studi', 'compound'), ('humira', 'compound'), ('conduct', 'compound'), ('evalu', 'compound'), ('carcinogen', 'compound'), ('potenti', 'compound'), ('effect', 'compound'), ('fertil', 'dobj'), ('.', 'punct')]}, {'original_sentence': '14 CLINICAL STUDIES \\n14.1 Rheumatoid Arthritis \\nThe efficacy and safety of HUMIRA were assessed in five randomized, double-blind studies in \\npatients ≥18 years of age with active rheumatoid arthritis (RA) diagnosed according to American \\nCollege of Rheumatology (ACR) criteria.', 'tokens': ['14', 'CLINICAL', 'STUDIES', '14.1', 'Rheumatoid', 'Arthritis', 'efficacy', 'safety', 'HUMIRA', 'assessed', 'five', 'randomized', ',', 'double-blind', 'studies', 'patients', '≥18', 'years', 'age', 'active', 'rheumatoid', 'arthritis', '(', 'RA', ')', 'diagnosed', 'according', 'American', 'College', 'Rheumatology', '(', 'ACR', ')', 'criteria', '.'], 'lemmatized': ['14', 'CLINICAL', 'STUDIES', '14.1', 'Rheumatoid', 'Arthritis', 'efficacy', 'safety', 'HUMIRA', 'assessed', 'five', 'randomized', ',', 'double-blind', 'study', 'patient', '≥18', 'year', 'age', 'active', 'rheumatoid', 'arthritis', '(', 'RA', ')', 'diagnosed', 'according', 'American', 'College', 'Rheumatology', '(', 'ACR', ')', 'criterion', '.'], 'stemmed': ['14', 'clinic', 'studi', '14.1', 'rheumatoid', 'arthriti', 'efficaci', 'safeti', 'humira', 'assess', 'five', 'random', ',', 'double-blind', 'studi', 'patient', '≥18', 'year', 'age', 'activ', 'rheumatoid', 'arthriti', '(', 'ra', ')', 'diagnos', 'accord', 'american', 'colleg', 'rheumatolog', '(', 'acr', ')', 'criterion', '.'], 'dependencies': [('14', 'nummod'), ('clinic', 'nmod'), ('studi', 'nmod'), ('14.1', 'nummod'), ('rheumatoid', 'compound'), ('arthriti', 'compound'), ('efficaci', 'compound'), ('safeti', 'compound'), ('humira', 'nsubj'), ('assess', 'ROOT'), ('five', 'nummod'), ('random', 'amod'), (',', 'punct'), ('double', 'amod'), ('-', 'punct'), ('blind', 'amod'), ('studi', 'amod'), ('patient', 'dobj'), ('≥18', 'poss'), ('year', 'compound'), ('age', 'compound'), ('activ', 'appos'), ('rheumatoid', 'compound'), ('arthriti', 'appos'), ('(', 'punct'), ('ra', 'appos'), (')', 'punct'), ('diagnos', 'amod'), ('accord', 'compound'), ('american', 'compound'), ('colleg', 'compound'), ('rheumatolog', 'npadvmod'), ('(', 'punct'), ('acr', 'nmod'), (')', 'punct'), ('criterion', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Patients had at least 6 swollen and 9 tender joints.', 'tokens': ['Patients', 'least', '6', 'swollen', '9', 'tender', 'joints', '.'], 'lemmatized': ['Patients', 'least', '6', 'swollen', '9', 'tender', 'joint', '.'], 'stemmed': ['patient', 'least', '6', 'swollen', '9', 'tender', 'joint', '.'], 'dependencies': [('patient', 'ROOT'), ('least', 'advmod'), ('6', 'nummod'), ('swollen', 'amod'), ('9', 'nummod'), ('tender', 'compound'), ('joint', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'HUMIRA was administered subcutaneously in combination with methotrexate (MTX) (12.5 to \\n25 mg, Studies RA-I, RA-III and RA-V) or as monotherapy (Studies RA-II and RA-V) or with \\nother disease-modifying anti-rheumatic drugs (DMARDs) (Study RA-IV).', 'tokens': ['HUMIRA', 'administered', 'subcutaneously', 'combination', 'methotrexate', '(', 'MTX', ')', '(', '12.5', '25', 'mg', ',', 'Studies', 'RA-I', ',', 'RA-III', 'RA-V', ')', 'monotherapy', '(', 'Studies', 'RA-II', 'RA-V', ')', 'disease-modifying', 'anti-rheumatic', 'drugs', '(', 'DMARDs', ')', '(', 'Study', 'RA-IV', ')', '.'], 'lemmatized': ['HUMIRA', 'administered', 'subcutaneously', 'combination', 'methotrexate', '(', 'MTX', ')', '(', '12.5', '25', 'mg', ',', 'Studies', 'RA-I', ',', 'RA-III', 'RA-V', ')', 'monotherapy', '(', 'Studies', 'RA-II', 'RA-V', ')', 'disease-modifying', 'anti-rheumatic', 'drug', '(', 'DMARDs', ')', '(', 'Study', 'RA-IV', ')', '.'], 'stemmed': ['humira', 'administ', 'subcutan', 'combin', 'methotrex', '(', 'mtx', ')', '(', '12.5', '25', 'mg', ',', 'studi', 'ra-i', ',', 'ra-iii', 'ra-v', ')', 'monotherapi', '(', 'studi', 'ra-ii', 'ra-v', ')', 'disease-modifi', 'anti-rheumat', 'drug', '(', 'dmard', ')', '(', 'studi', 'ra-iv', ')', '.'], 'dependencies': [('humira', 'compound'), ('administ', 'nsubj'), ('subcutan', 'nmod'), ('combin', 'prep'), ('methotrex', 'pobj'), ('(', 'punct'), ('mtx', 'appos'), (')', 'punct'), ('(', 'punct'), ('12.5', 'nummod'), ('25', 'nummod'), ('mg', 'nmod'), (',', 'punct'), ('studi', 'npadvmod'), ('ra', 'npadvmod'), ('-', 'punct'), ('i', 'appos'), (',', 'punct'), ('ra', 'nmod'), ('-', 'punct'), ('iii', 'punct'), ('ra', 'compound'), ('-', 'punct'), ('v', 'conj'), (')', 'punct'), ('monotherapi', 'ROOT'), ('(', 'punct'), ('studi', 'compound'), ('ra', 'compound'), ('-', 'punct'), ('ii', 'compound'), ('ra', 'nmod'), ('-', 'punct'), ('v', 'prep'), (')', 'punct'), ('disease', 'compound'), ('-', 'punct'), ('modifi', 'nmod'), ('anti', 'amod'), ('-', 'amod'), ('rheumat', 'amod'), ('drug', 'appos'), ('(', 'punct'), ('dmard', 'appos'), (')', 'punct'), ('(', 'punct'), ('studi', 'compound'), ('ra', 'compound'), ('-', 'punct'), ('iv', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Study RA-I evaluated 271 patients who had failed therapy with at least one but no more than \\nfour DMARDs and had inadequate response to MTX.', 'tokens': ['Study', 'RA-I', 'evaluated', '271', 'patients', 'failed', 'therapy', 'least', 'one', 'four', 'DMARDs', 'inadequate', 'response', 'MTX', '.'], 'lemmatized': ['Study', 'RA-I', 'evaluated', '271', 'patient', 'failed', 'therapy', 'least', 'one', 'four', 'DMARDs', 'inadequate', 'response', 'MTX', '.'], 'stemmed': ['studi', 'ra-i', 'evalu', '271', 'patient', 'fail', 'therapi', 'least', 'one', 'four', 'dmard', 'inadequ', 'respons', 'mtx', '.'], 'dependencies': [('studi', 'compound'), ('ra', 'compound'), ('-', 'punct'), ('i', 'nsubj'), ('evalu', 'ROOT'), ('271', 'nummod'), ('patient', 'amod'), ('fail', 'dobj'), ('therapi', 'dep'), ('least', 'advmod'), ('one', 'compound'), ('four', 'nummod'), ('dmard', 'compound'), ('inadequ', 'compound'), ('respons', 'nsubj'), ('mtx', 'ccomp'), ('.', 'punct')]}, {'original_sentence': 'Doses of 20, 40 or 80 mg of HUMIRA or \\nplacebo were given every other week for 24 weeks.', 'tokens': ['Doses', '20', ',', '40', '80', 'mg', 'HUMIRA', 'placebo', 'given', 'every', 'week', '24', 'weeks', '.'], 'lemmatized': ['Doses', '20', ',', '40', '80', 'mg', 'HUMIRA', 'placebo', 'given', 'every', 'week', '24', 'week', '.'], 'stemmed': ['dose', '20', ',', '40', '80', 'mg', 'humira', 'placebo', 'given', 'everi', 'week', '24', 'week', '.'], 'dependencies': [('dose', 'ROOT'), ('20', 'dobj'), (',', 'punct'), ('40', 'compound'), ('80', 'nummod'), ('mg', 'nmod'), ('humira', 'compound'), ('placebo', 'npadvmod'), ('given', 'acl'), ('everi', 'amod'), ('week', 'pobj'), ('24', 'nummod'), ('week', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Study RA-II evaluated 544 patients who had failed therapy with at least one DMARD.', 'tokens': ['Study', 'RA-II', 'evaluated', '544', 'patients', 'failed', 'therapy', 'least', 'one', 'DMARD', '.'], 'lemmatized': ['Study', 'RA-II', 'evaluated', '544', 'patient', 'failed', 'therapy', 'least', 'one', 'DMARD', '.'], 'stemmed': ['studi', 'ra-ii', 'evalu', '544', 'patient', 'fail', 'therapi', 'least', 'one', 'dmard', '.'], 'dependencies': [('studi', 'compound'), ('ra', 'compound'), ('-', 'punct'), ('ii', 'compound'), ('evalu', 'nmod'), ('544', 'nummod'), ('patient', 'amod'), ('fail', 'nsubj'), ('therapi', 'ROOT'), ('least', 'advmod'), ('one', 'nummod'), ('dmard', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Doses of \\nplacebo, 20 or 40 mg of HUMIRA were given as monotherapy every other week or weekly for \\n26 weeks.', 'tokens': ['Doses', 'placebo', ',', '20', '40', 'mg', 'HUMIRA', 'given', 'monotherapy', 'every', 'week', 'weekly', '26', 'weeks', '.'], 'lemmatized': ['Doses', 'placebo', ',', '20', '40', 'mg', 'HUMIRA', 'given', 'monotherapy', 'every', 'week', 'weekly', '26', 'week', '.'], 'stemmed': ['dose', 'placebo', ',', '20', '40', 'mg', 'humira', 'given', 'monotherapi', 'everi', 'week', 'weekli', '26', 'week', '.'], 'dependencies': [('dose', 'ROOT'), ('placebo', 'dobj'), (',', 'punct'), ('20', 'compound'), ('40', 'npadvmod'), ('mg', 'prep'), ('humira', 'dobj'), ('given', 'prep'), ('monotherapi', 'nmod'), ('everi', 'amod'), ('week', 'compound'), ('weekli', 'pobj'), ('26', 'nummod'), ('week', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Study RA-III evaluated 619 patients who had an inadequate response to MTX.', 'tokens': ['Study', 'RA-III', 'evaluated', '619', 'patients', 'inadequate', 'response', 'MTX', '.'], 'lemmatized': ['Study', 'RA-III', 'evaluated', '619', 'patient', 'inadequate', 'response', 'MTX', '.'], 'stemmed': ['studi', 'ra-iii', 'evalu', '619', 'patient', 'inadequ', 'respons', 'mtx', '.'], 'dependencies': [('studi', 'compound'), ('ra', 'compound'), ('-', 'punct'), ('iii', 'compound'), ('evalu', 'dep'), ('619', 'nummod'), ('patient', 'appos'), ('inadequ', 'compound'), ('respons', 'nsubj'), ('mtx', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Patients received \\nplacebo, 40 mg of HUMIRA every other week with placebo injections on alternate weeks, or 20 \\nmg of HUMIRA weekly for up to 52 weeks.', 'tokens': ['Patients', 'received', 'placebo', ',', '40', 'mg', 'HUMIRA', 'every', 'week', 'placebo', 'injections', 'alternate', 'weeks', ',', '20', 'mg', 'HUMIRA', 'weekly', '52', 'weeks', '.'], 'lemmatized': ['Patients', 'received', 'placebo', ',', '40', 'mg', 'HUMIRA', 'every', 'week', 'placebo', 'injection', 'alternate', 'week', ',', '20', 'mg', 'HUMIRA', 'weekly', '52', 'week', '.'], 'stemmed': ['patient', 'receiv', 'placebo', ',', '40', 'mg', 'humira', 'everi', 'week', 'placebo', 'inject', 'altern', 'week', ',', '20', 'mg', 'humira', 'weekli', '52', 'week', '.'], 'dependencies': [('patient', 'compound'), ('receiv', 'compound'), ('placebo', 'ROOT'), (',', 'punct'), ('40', 'nummod'), ('mg', 'prep'), ('humira', 'compound'), ('everi', 'compound'), ('week', 'compound'), ('placebo', 'compound'), ('inject', 'pobj'), ('altern', 'amod'), ('week', 'npadvmod'), (',', 'punct'), ('20', 'nummod'), ('mg', 'nmod'), ('humira', 'compound'), ('weekli', 'appos'), ('52', 'nummod'), ('week', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Study RA-III had an additional primary endpoint at \\n52 weeks of inhibition of disease progression (as detected by X-ray results).', 'tokens': ['Study', 'RA-III', 'additional', 'primary', 'endpoint', '52', 'weeks', 'inhibition', 'disease', 'progression', '(', 'detected', 'X-ray', 'results', ')', '.'], 'lemmatized': ['Study', 'RA-III', 'additional', 'primary', 'endpoint', '52', 'week', 'inhibition', 'disease', 'progression', '(', 'detected', 'X-ray', 'result', ')', '.'], 'stemmed': ['studi', 'ra-iii', 'addit', 'primari', 'endpoint', '52', 'week', 'inhibit', 'diseas', 'progress', '(', 'detect', 'x-ray', 'result', ')', '.'], 'dependencies': [('studi', 'compound'), ('ra', 'compound'), ('-', 'punct'), ('iii', 'compound'), ('addit', 'compound'), ('primari', 'nsubj'), ('endpoint', 'ROOT'), ('52', 'nummod'), ('week', 'compound'), ('inhibit', 'dobj'), ('diseas', 'amod'), ('progress', 'appos'), ('(', 'punct'), ('detect', 'parataxis'), ('x', 'compound'), ('-', 'compound'), ('ray', 'compound'), ('result', 'dobj'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Upon completion of \\nthe first 52 weeks, 457 patients enrolled in an open-label extension phase in which 40 mg of \\nHUMIRA was administered every other week for up to 5 years.', 'tokens': ['Upon', 'completion', 'first', '52', 'weeks', ',', '457', 'patients', 'enrolled', 'open-label', 'extension', 'phase', '40', 'mg', 'HUMIRA', 'administered', 'every', 'week', '5', 'years', '.'], 'lemmatized': ['Upon', 'completion', 'first', '52', 'week', ',', '457', 'patient', 'enrolled', 'open-label', 'extension', 'phase', '40', 'mg', 'HUMIRA', 'administered', 'every', 'week', '5', 'year', '.'], 'stemmed': ['upon', 'complet', 'first', '52', 'week', ',', '457', 'patient', 'enrol', 'open-label', 'extens', 'phase', '40', 'mg', 'humira', 'administ', 'everi', 'week', '5', 'year', '.'], 'dependencies': [('upon', 'prep'), ('complet', 'pobj'), ('first', 'advmod'), ('52', 'nummod'), ('week', 'npadvmod'), (',', 'punct'), ('457', 'nummod'), ('patient', 'nsubj'), ('enrol', 'ROOT'), ('open', 'amod'), ('-', 'punct'), ('label', 'compound'), ('extens', 'compound'), ('phase', 'dobj'), ('40', 'nummod'), ('mg', 'prep'), ('humira', 'compound'), ('administ', 'appos'), ('everi', 'amod'), ('week', 'nmod'), ('5', 'nummod'), ('year', 'npadvmod'), ('.', 'punct')]}], 'text': 'Male and Female Patients:  No gender-related pharmacokinetic differences were observed after \\ncorrection for a patient’s body weight. Healthy subjects and patients with rheumatoid arthritis \\ndisplayed similar adalimumab pharmacokinetics. \\nPatients with Renal or Hepatic Impairment: No pharmacokinetic data are available in patients \\nwith hepatic or renal impairment.  \\nRheumatoid factor or CRP concentrations: Minor increases in apparent clearance were predicted \\nin RA patients receiving doses lower than the recommended dose and in RA patients with high \\nrheumatoid factor or CRP concentrations. These increases are not likely to be clinically \\nimportant.  \\nDrug Interaction Studies: \\nMethotrexate: MTX reduced adalimumab apparent clearance after single and multiple dosing by \\n29% and 44% respectively, in patients with RA [see Drug Interactions (7.1)]. \\n13 NONCLINICAL TOXICOLOGY \\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility \\nLong-term animal studies of HUMIRA have not been conducted to evaluate the carcinogenic \\npotential or its effect on fertility.  \\n14 CLINICAL STUDIES \\n14.1 Rheumatoid Arthritis \\nThe efficacy and safety of HUMIRA were assessed in five randomized, double-blind studies in \\npatients ≥18 years of age with active rheumatoid arthritis (RA) diagnosed according to American \\nCollege of Rheumatology (ACR) criteria. Patients had at least 6 swollen and 9 tender joints. \\nHUMIRA was administered subcutaneously in combination with methotrexate (MTX) (12.5 to \\n25 mg, Studies RA-I, RA-III and RA-V) or as monotherapy (Studies RA-II and RA-V) or with \\nother disease-modifying anti-rheumatic drugs (DMARDs) (Study RA-IV).  \\nStudy RA-I evaluated 271 patients who had failed therapy with at least one but no more than \\nfour DMARDs and had inadequate response to MTX. Doses of 20, 40 or 80 mg of HUMIRA or \\nplacebo were given every other week for 24 weeks.  \\nStudy RA-II evaluated 544 patients who had failed therapy with at least one DMARD. Doses of \\nplacebo, 20 or 40 mg of HUMIRA were given as monotherapy every other week or weekly for \\n26 weeks.  \\nStudy RA-III evaluated 619 patients who had an inadequate response to MTX. Patients received \\nplacebo, 40 mg of HUMIRA every other week with placebo injections on alternate weeks, or 20 \\nmg of HUMIRA weekly for up to 52 weeks. Study RA-III had an additional primary endpoint at \\n52 weeks of inhibition of disease progression (as detected by X-ray results). Upon completion of \\nthe first 52 weeks, 457 patients enrolled in an open-label extension phase in which 40 mg of \\nHUMIRA was administered every other week for up to 5 years.  \\n'}, 'page_char_count': 2613, 'page_word_count': 395, 'sentences': ['Male and Female Patients:  No gender-related pharmacokinetic differences were observed after \\ncorrection for a patient’s body weight.', 'Healthy subjects and patients with rheumatoid arthritis \\ndisplayed similar adalimumab pharmacokinetics.', '\\nPatients with Renal or Hepatic Impairment: No pharmacokinetic data are available in patients \\nwith hepatic or renal impairment.', ' \\nRheumatoid factor or CRP concentrations: Minor increases in apparent clearance were predicted \\nin RA patients receiving doses lower than the recommended dose and in RA patients with high \\nrheumatoid factor or CRP concentrations.', 'These increases are not likely to be clinically \\nimportant.', ' \\nDrug Interaction Studies: \\nMethotrexate: MTX reduced adalimumab apparent clearance after single and multiple dosing by \\n29% and 44% respectively, in patients with RA [see Drug Interactions (7.1)].', '\\n13 NONCLINICAL TOXICOLOGY \\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility \\nLong-term animal studies of HUMIRA have not been conducted to evaluate the carcinogenic \\npotential or its effect on fertility.', ' \\n14 CLINICAL STUDIES \\n14.1 Rheumatoid Arthritis \\nThe efficacy and safety of HUMIRA were assessed in five randomized, double-blind studies in \\npatients ≥18 years of age with active rheumatoid arthritis (RA) diagnosed according to American \\nCollege of Rheumatology (ACR) criteria.', 'Patients had at least 6 swollen and 9 tender joints.', '\\nHUMIRA was administered subcutaneously in combination with methotrexate (MTX) (12.5 to \\n25 mg, Studies RA-I, RA-III and RA-V) or as monotherapy (Studies RA-II and RA-V) or with \\nother disease-modifying anti-rheumatic drugs (DMARDs) (Study RA-IV).', ' \\nStudy RA-I evaluated 271 patients who had failed therapy with at least one but no more than \\nfour DMARDs and had inadequate response to MTX.', 'Doses of 20, 40 or 80 mg of HUMIRA or \\nplacebo were given every other week for 24 weeks.', ' \\nStudy RA-II evaluated 544 patients who had failed therapy with at least one DMARD.', 'Doses of \\nplacebo, 20 or 40 mg of HUMIRA were given as monotherapy every other week or weekly for \\n26 weeks.', ' \\nStudy RA-III evaluated 619 patients who had an inadequate response to MTX.', 'Patients received \\nplacebo, 40 mg of HUMIRA every other week with placebo injections on alternate weeks, or 20 \\nmg of HUMIRA weekly for up to 52 weeks.', 'Study RA-III had an additional primary endpoint at \\n52 weeks of inhibition of disease progression (as detected by X-ray results).', 'Upon completion of \\nthe first 52 weeks, 457 patients enrolled in an open-label extension phase in which 40 mg of \\nHUMIRA was administered every other week for up to 5 years.', ' \\n'], 'page_sentence_count_spacy': 19}\n",
            "{'page_number': 33, 'text': 'Study RA-IV assessed safety in 636 patients who were either DMARD-naive or were permitted \\nto remain on their pre-existing rheumatologic therapy provided that therapy was stable for a \\nminimum of 28 days. Patients were randomized to 40 mg of HUMIRA or placebo every other \\nweek for 24 weeks.  \\nStudy RA-V evaluated 799 patients with moderately to severely active RA of less than 3 years \\nduration who were ≥18 years old and MTX naïve. Patients were randomized to receive either \\nMTX (optimized to 20 mg/week by week 8), HUMIRA 40 mg every other week or \\nHUMIRA/MTX combination therapy for 104 weeks. Patients were evaluated for signs and \\nsymptoms, and for radiographic progression of joint damage. The median disease duration \\namong patients enrolled in the study was 5 months. The median MTX dose achieved was 20 mg.  \\nClinical Response \\nThe percent of HUMIRA treated patients achieving ACR 20, 50 and 70 responses in Studies RA-\\nII and III are shown in Table 3.  \\n \\n  \\nTable 3. ACR Responses in Studies RA-II and RA-III (Percent of Patients) \\n  \\nStudy RA-II \\nMonotherapy \\n(26 weeks) \\nStudy RA-III \\nMethotrexate Combination \\n(24 and 52 weeks) \\nResponse \\nPlacebo \\nHUMIRA \\nHUMIRA \\nPlacebo/MTX \\nHUMIRA/MTX \\n  \\n  \\n40 mg every  \\n40 mg weekly   \\n40 mg every \\n  \\n  \\n other week   \\n  \\nother week \\n  \\nN=110 \\nN=113 \\nN=103 \\nN=200 \\nN=207 \\nACR20 \\n  \\n  \\n  \\n  \\n  \\nMonth 6 \\n19% \\n46%* \\n53%* \\n30% \\n63%* \\nMonth 12 \\nNA \\nNA \\nNA \\n24% \\n59%* \\nACR50 \\n  \\n  \\n  \\n  \\n  \\nMonth 6 \\n8% \\n22%* \\n35%* \\n10% \\n39%* \\nMonth 12 \\nNA \\nNA \\nNA \\n10% \\n42%* \\nACR70 \\n  \\n  \\n  \\n  \\n  \\nMonth 6 \\n2% \\n12%* \\n18%* \\n3% \\n21%* \\nMonth 12 \\nNA \\nNA \\nNA \\n5% \\n23%* \\n* p<0.01, HUMIRA vs. placebo  \\nThe results of Study RA-I were similar to Study RA-III; patients receiving HUMIRA 40 mg \\nevery other week in Study RA-I also achieved ACR 20, 50 and 70 response rates of 65%, 52% \\nand 24%, respectively, compared to placebo responses of 13%, 7% and 3% respectively, at 6 \\nmonths (p<0.01).  \\nThe results of the components of the ACR response criteria for Studies RA-II and RA-III are \\nshown in Table 4. ACR response rates and improvement in all components of ACR response \\nwere maintained to week 104. Over the 2 years in Study RA-III, 20% of HUMIRA patients \\nreceiving 40 mg every other week achieved a major clinical response, defined as maintenance of \\nan ACR 70 response over a 6-month period. ACR responses were maintained in similar \\n', 'processed_text': {'sentences': [{'original_sentence': 'Study RA-IV assessed safety in 636 patients who were either DMARD-naive or were permitted \\nto remain on their pre-existing rheumatologic therapy provided that therapy was stable for a \\nminimum of 28 days.', 'tokens': ['Study', 'RA-IV', 'assessed', 'safety', '636', 'patients', 'either', 'DMARD-naive', 'permitted', 'remain', 'pre-existing', 'rheumatologic', 'therapy', 'provided', 'therapy', 'stable', 'minimum', '28', 'days', '.'], 'lemmatized': ['Study', 'RA-IV', 'assessed', 'safety', '636', 'patient', 'either', 'DMARD-naive', 'permitted', 'remain', 'pre-existing', 'rheumatologic', 'therapy', 'provided', 'therapy', 'stable', 'minimum', '28', 'day', '.'], 'stemmed': ['studi', 'ra-iv', 'assess', 'safeti', '636', 'patient', 'either', 'dmard-naiv', 'permit', 'remain', 'pre-exist', 'rheumatolog', 'therapi', 'provid', 'therapi', 'stabl', 'minimum', '28', 'day', '.'], 'dependencies': [('studi', 'compound'), ('ra', 'compound'), ('-', 'punct'), ('iv', 'compound'), ('assess', 'compound'), ('safeti', 'nsubj'), ('636', 'nummod'), ('patient', 'nsubj'), ('either', 'preconj'), ('dmard', 'compound'), ('-', 'punct'), ('naiv', 'compound'), ('permit', 'nsubj'), ('remain', 'ROOT'), ('pre', 'amod'), ('-', 'amod'), ('exist', 'amod'), ('rheumatolog', 'compound'), ('therapi', 'compound'), ('provid', 'compound'), ('therapi', 'ccomp'), ('stabl', 'amod'), ('minimum', 'amod'), ('28', 'nummod'), ('day', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Patients were randomized to 40 mg of HUMIRA or placebo every other \\nweek for 24 weeks.', 'tokens': ['Patients', 'randomized', '40', 'mg', 'HUMIRA', 'placebo', 'every', 'week', '24', 'weeks', '.'], 'lemmatized': ['Patients', 'randomized', '40', 'mg', 'HUMIRA', 'placebo', 'every', 'week', '24', 'week', '.'], 'stemmed': ['patient', 'random', '40', 'mg', 'humira', 'placebo', 'everi', 'week', '24', 'week', '.'], 'dependencies': [('patient', 'ROOT'), ('random', 'amod'), ('40', 'nummod'), ('mg', 'prep'), ('humira', 'compound'), ('placebo', 'npadvmod'), ('everi', 'compound'), ('week', 'npadvmod'), ('24', 'nummod'), ('week', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Study RA-V evaluated 799 patients with moderately to severely active RA of less than 3 years \\nduration who were ≥18 years old and MTX naïve.', 'tokens': ['Study', 'RA-V', 'evaluated', '799', 'patients', 'moderately', 'severely', 'active', 'RA', 'less', '3', 'years', 'duration', '≥18', 'years', 'old', 'MTX', 'naïve', '.'], 'lemmatized': ['Study', 'RA-V', 'evaluated', '799', 'patient', 'moderately', 'severely', 'active', 'RA', 'less', '3', 'year', 'duration', '≥18', 'year', 'old', 'MTX', 'naïve', '.'], 'stemmed': ['studi', 'ra-v', 'evalu', '799', 'patient', 'moder', 'sever', 'activ', 'ra', 'less', '3', 'year', 'durat', '≥18', 'year', 'old', 'mtx', 'naïv', '.'], 'dependencies': [('studi', 'compound'), ('ra', 'nmod'), ('-', 'punct'), ('v', 'prep'), ('evalu', 'nmod'), ('799', 'nummod'), ('patient', 'compound'), ('moder', 'nsubj'), ('sever', 'ROOT'), ('activ', 'compound'), ('ra', 'dative'), ('less', 'amod'), ('3', 'nummod'), ('year', 'npadvmod'), ('durat', 'nmod'), ('≥18', 'nummod'), ('year', 'npadvmod'), ('old', 'amod'), ('mtx', 'compound'), ('naïv', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Patients were randomized to receive either \\nMTX (optimized to 20 mg/week by week 8), HUMIRA 40 mg every other week or \\nHUMIRA/MTX combination therapy for 104 weeks.', 'tokens': ['Patients', 'randomized', 'receive', 'either', 'MTX', '(', 'optimized', '20', 'mg/week', 'week', '8', ')', ',', 'HUMIRA', '40', 'mg', 'every', 'week', 'HUMIRA/MTX', 'combination', 'therapy', '104', 'weeks', '.'], 'lemmatized': ['Patients', 'randomized', 'receive', 'either', 'MTX', '(', 'optimized', '20', 'mg/week', 'week', '8', ')', ',', 'HUMIRA', '40', 'mg', 'every', 'week', 'HUMIRA/MTX', 'combination', 'therapy', '104', 'week', '.'], 'stemmed': ['patient', 'random', 'receiv', 'either', 'mtx', '(', 'optim', '20', 'mg/week', 'week', '8', ')', ',', 'humira', '40', 'mg', 'everi', 'week', 'humira/mtx', 'combin', 'therapi', '104', 'week', '.'], 'dependencies': [('patient', 'amod'), ('random', 'amod'), ('receiv', 'nsubj'), ('either', 'preconj'), ('mtx', 'ROOT'), ('(', 'punct'), ('optim', 'parataxis'), ('20', 'nummod'), ('mg', 'nmod'), ('/', 'punct'), ('week', 'compound'), ('week', 'npadvmod'), ('8', 'nummod'), (')', 'punct'), (',', 'punct'), ('humira', 'npadvmod'), ('40', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'compound'), ('humira', 'nmod'), ('/', 'punct'), ('mtx', 'compound'), ('combin', 'nsubj'), ('therapi', 'npadvmod'), ('104', 'nummod'), ('week', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Patients were evaluated for signs and \\nsymptoms, and for radiographic progression of joint damage.', 'tokens': ['Patients', 'evaluated', 'signs', 'symptoms', ',', 'radiographic', 'progression', 'joint', 'damage', '.'], 'lemmatized': ['Patients', 'evaluated', 'sign', 'symptom', ',', 'radiographic', 'progression', 'joint', 'damage', '.'], 'stemmed': ['patient', 'evalu', 'sign', 'symptom', ',', 'radiograph', 'progress', 'joint', 'damag', '.'], 'dependencies': [('patient', 'compound'), ('evalu', 'compound'), ('sign', 'compound'), ('symptom', 'dep'), (',', 'punct'), ('radiograph', 'amod'), ('progress', 'compound'), ('joint', 'amod'), ('damag', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'The median disease duration \\namong patients enrolled in the study was 5 months.', 'tokens': ['median', 'disease', 'duration', 'among', 'patients', 'enrolled', 'study', '5', 'months', '.'], 'lemmatized': ['median', 'disease', 'duration', 'among', 'patient', 'enrolled', 'study', '5', 'month', '.'], 'stemmed': ['median', 'diseas', 'durat', 'among', 'patient', 'enrol', 'studi', '5', 'month', '.'], 'dependencies': [('median', 'compound'), ('diseas', 'compound'), ('durat', 'ROOT'), ('among', 'prep'), ('patient', 'compound'), ('enrol', 'pobj'), ('studi', 'npadvmod'), ('5', 'nummod'), ('month', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'The median MTX dose achieved was 20 mg.  \\nClinical Response \\nThe percent of HUMIRA treated patients achieving ACR 20, 50 and 70 responses in Studies RA-\\nII and III are shown in Table 3.', 'tokens': ['median', 'MTX', 'dose', 'achieved', '20', 'mg.', 'Clinical', 'Response', 'percent', 'HUMIRA', 'treated', 'patients', 'achieving', 'ACR', '20', ',', '50', '70', 'responses', 'Studies', 'RA-', 'II', 'III', 'shown', 'Table', '3', '.'], 'lemmatized': ['median', 'MTX', 'dose', 'achieved', '20', 'mg.', 'Clinical', 'Response', 'percent', 'HUMIRA', 'treated', 'patient', 'achieving', 'ACR', '20', ',', '50', '70', 'response', 'Studies', 'RA-', 'II', 'III', 'shown', 'Table', '3', '.'], 'stemmed': ['median', 'mtx', 'dose', 'achiev', '20', 'mg.', 'clinic', 'respons', 'percent', 'humira', 'treat', 'patient', 'achiev', 'acr', '20', ',', '50', '70', 'respons', 'studi', 'ra-', 'ii', 'iii', 'shown', 'tabl', '3', '.'], 'dependencies': [('median', 'compound'), ('mtx', 'npadvmod'), ('dose', 'compound'), ('achiev', 'dobj'), ('20', 'nummod'), ('mg', 'compound'), ('.', 'compound'), ('clinic', 'compound'), ('respons', 'compound'), ('percent', 'npadvmod'), ('humira', 'nsubj'), ('treat', 'ccomp'), ('patient', 'compound'), ('achiev', 'dobj'), ('acr', 'prep'), ('20', 'pobj'), (',', 'punct'), ('50', 'compound'), ('70', 'nummod'), ('respons', 'compound'), ('studi', 'compound'), ('ra-', 'compound'), ('ii', 'compound'), ('iii', 'nsubj'), ('shown', 'ROOT'), ('tabl', 'dobj'), ('3', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Table 3.', 'tokens': ['Table', '3', '.'], 'lemmatized': ['Table', '3', '.'], 'stemmed': ['tabl', '3', '.'], 'dependencies': [('tabl', 'ROOT'), ('3', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'ACR Responses in Studies RA-II and RA-III (Percent of Patients) \\n  \\nStudy RA-II \\nMonotherapy \\n(26 weeks) \\nStudy RA-III \\nMethotrexate Combination \\n(24 and 52 weeks) \\nResponse \\nPlacebo \\nHUMIRA \\nHUMIRA \\nPlacebo/MTX \\nHUMIRA/MTX \\n  \\n  \\n40 mg every  \\n40 mg weekly   \\n40 mg every \\n  \\n  \\n other week   \\n  \\nother week \\n  \\nN=110 \\nN=113 \\nN=103 \\nN=200 \\nN=207 \\nACR20 \\n  \\n  \\n  \\n  \\n  \\nMonth 6 \\n19% \\n46%* \\n53%* \\n30% \\n63%* \\nMonth 12 \\nNA \\nNA \\nNA \\n24% \\n59%* \\nACR50 \\n  \\n  \\n  \\n  \\n  \\nMonth 6 \\n8% \\n22%* \\n35%* \\n10% \\n39%* \\nMonth 12 \\nNA \\nNA \\nNA \\n10% \\n42%* \\nACR70 \\n  \\n  \\n  \\n  \\n  \\nMonth 6 \\n2% \\n12%* \\n18%* \\n3% \\n21%* \\nMonth 12 \\nNA \\nNA \\nNA \\n5% \\n23%* \\n* p<0.01, HUMIRA vs. placebo  \\nThe results of Study RA-I were similar to Study RA-III; patients receiving HUMIRA 40 mg \\nevery other week in Study RA-I also achieved ACR 20, 50 and 70 response rates of 65%, 52% \\nand 24%, respectively, compared to placebo responses of 13%, 7% and 3% respectively, at 6 \\nmonths (p<0.01).', 'tokens': ['ACR', 'Responses', 'Studies', 'RA-II', 'RA-III', '(', 'Percent', 'Patients', ')', 'Study', 'RA-II', 'Monotherapy', '(', '26', 'weeks', ')', 'Study', 'RA-III', 'Methotrexate', 'Combination', '(', '24', '52', 'weeks', ')', 'Response', 'Placebo', 'HUMIRA', 'HUMIRA', 'Placebo/MTX', 'HUMIRA/MTX', '40', 'mg', 'every', '40', 'mg', 'weekly', '40', 'mg', 'every', 'week', 'week', 'N=110', 'N=113', 'N=103', 'N=200', 'N=207', 'ACR20', 'Month', '6', '19', '%', '46', '%', '*', '53', '%', '*', '30', '%', '63', '%', '*', 'Month', '12', 'NA', 'NA', 'NA', '24', '%', '59', '%', '*', 'ACR50', 'Month', '6', '8', '%', '22', '%', '*', '35', '%', '*', '10', '%', '39', '%', '*', 'Month', '12', 'NA', 'NA', 'NA', '10', '%', '42', '%', '*', 'ACR70', 'Month', '6', '2', '%', '12', '%', '*', '18', '%', '*', '3', '%', '21', '%', '*', 'Month', '12', 'NA', 'NA', 'NA', '5', '%', '23', '%', '*', '*', 'p', '<', '0.01', ',', 'HUMIRA', 'vs.', 'placebo', 'results', 'Study', 'RA-I', 'similar', 'Study', 'RA-III', ';', 'patients', 'receiving', 'HUMIRA', '40', 'mg', 'every', 'week', 'Study', 'RA-I', 'also', 'achieved', 'ACR', '20', ',', '50', '70', 'response', 'rates', '65', '%', ',', '52', '%', '24', '%', ',', 'respectively', ',', 'compared', 'placebo', 'responses', '13', '%', ',', '7', '%', '3', '%', 'respectively', ',', '6', 'months', '(', 'p', '<', '0.01', ')', '.'], 'lemmatized': ['ACR', 'Responses', 'Studies', 'RA-II', 'RA-III', '(', 'Percent', 'Patients', ')', 'Study', 'RA-II', 'Monotherapy', '(', '26', 'week', ')', 'Study', 'RA-III', 'Methotrexate', 'Combination', '(', '24', '52', 'week', ')', 'Response', 'Placebo', 'HUMIRA', 'HUMIRA', 'Placebo/MTX', 'HUMIRA/MTX', '40', 'mg', 'every', '40', 'mg', 'weekly', '40', 'mg', 'every', 'week', 'week', 'N=110', 'N=113', 'N=103', 'N=200', 'N=207', 'ACR20', 'Month', '6', '19', '%', '46', '%', '*', '53', '%', '*', '30', '%', '63', '%', '*', 'Month', '12', 'NA', 'NA', 'NA', '24', '%', '59', '%', '*', 'ACR50', 'Month', '6', '8', '%', '22', '%', '*', '35', '%', '*', '10', '%', '39', '%', '*', 'Month', '12', 'NA', 'NA', 'NA', '10', '%', '42', '%', '*', 'ACR70', 'Month', '6', '2', '%', '12', '%', '*', '18', '%', '*', '3', '%', '21', '%', '*', 'Month', '12', 'NA', 'NA', 'NA', '5', '%', '23', '%', '*', '*', 'p', '<', '0.01', ',', 'HUMIRA', 'vs.', 'placebo', 'result', 'Study', 'RA-I', 'similar', 'Study', 'RA-III', ';', 'patient', 'receiving', 'HUMIRA', '40', 'mg', 'every', 'week', 'Study', 'RA-I', 'also', 'achieved', 'ACR', '20', ',', '50', '70', 'response', 'rate', '65', '%', ',', '52', '%', '24', '%', ',', 'respectively', ',', 'compared', 'placebo', 'response', '13', '%', ',', '7', '%', '3', '%', 'respectively', ',', '6', 'month', '(', 'p', '<', '0.01', ')', '.'], 'stemmed': ['acr', 'respons', 'studi', 'ra-ii', 'ra-iii', '(', 'percent', 'patient', ')', 'studi', 'ra-ii', 'monotherapi', '(', '26', 'week', ')', 'studi', 'ra-iii', 'methotrex', 'combin', '(', '24', '52', 'week', ')', 'respons', 'placebo', 'humira', 'humira', 'placebo/mtx', 'humira/mtx', '40', 'mg', 'everi', '40', 'mg', 'weekli', '40', 'mg', 'everi', 'week', 'week', 'n=110', 'n=113', 'n=103', 'n=200', 'n=207', 'acr20', 'month', '6', '19', '%', '46', '%', '*', '53', '%', '*', '30', '%', '63', '%', '*', 'month', '12', 'na', 'na', 'na', '24', '%', '59', '%', '*', 'acr50', 'month', '6', '8', '%', '22', '%', '*', '35', '%', '*', '10', '%', '39', '%', '*', 'month', '12', 'na', 'na', 'na', '10', '%', '42', '%', '*', 'acr70', 'month', '6', '2', '%', '12', '%', '*', '18', '%', '*', '3', '%', '21', '%', '*', 'month', '12', 'na', 'na', 'na', '5', '%', '23', '%', '*', '*', 'p', '<', '0.01', ',', 'humira', 'vs.', 'placebo', 'result', 'studi', 'ra-i', 'similar', 'studi', 'ra-iii', ';', 'patient', 'receiv', 'humira', '40', 'mg', 'everi', 'week', 'studi', 'ra-i', 'also', 'achiev', 'acr', '20', ',', '50', '70', 'respons', 'rate', '65', '%', ',', '52', '%', '24', '%', ',', 'respect', ',', 'compar', 'placebo', 'respons', '13', '%', ',', '7', '%', '3', '%', 'respect', ',', '6', 'month', '(', 'p', '<', '0.01', ')', '.'], 'dependencies': [('acr', 'ROOT'), ('respons', 'pobj'), ('studi', 'compound'), ('ra', 'compound'), ('-', 'punct'), ('ii', 'compound'), ('ra', 'compound'), ('-', 'punct'), ('iii', 'appos'), ('(', 'punct'), ('percent', 'npadvmod'), ('patient', 'appos'), (')', 'punct'), ('studi', 'compound'), ('ra', 'compound'), ('-', 'punct'), ('ii', 'compound'), ('monotherapi', 'ROOT'), ('(', 'punct'), ('26', 'nummod'), ('week', 'appos'), (')', 'punct'), ('studi', 'compound'), ('ra', 'compound'), ('-', 'punct'), ('iii', 'punct'), ('methotrex', 'amod'), ('combin', 'nsubj'), ('(', 'punct'), ('24', 'nummod'), ('52', 'nummod'), ('week', 'appos'), (')', 'punct'), ('respons', 'compound'), ('placebo', 'compound'), ('humira', 'compound'), ('humira', 'nsubj'), ('placebo', 'nmod'), ('/', 'punct'), ('mtx', 'compound'), ('humira', 'nmod'), ('/', 'punct'), ('mtx', 'ROOT'), ('40', 'nummod'), ('mg', 'npadvmod'), ('everi', 'dep'), ('40', 'nummod'), ('mg', 'compound'), ('weekli', 'npadvmod'), ('40', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'compound'), ('week', 'npadvmod'), ('n=110', 'compound'), ('n=113', 'compound'), ('n=103', 'amod'), ('n=200', 'compound'), ('n=207', 'dobj'), ('acr20', 'compound'), ('month', 'npadvmod'), ('6', 'nummod'), ('19', 'nummod'), ('%', 'appos'), ('46', 'nummod'), ('%', 'appos'), ('*', 'punct'), ('53', 'nummod'), ('%', 'ROOT'), ('*', 'punct'), ('30', 'nummod'), ('%', 'ROOT'), ('63', 'nummod'), ('%', 'appos'), ('*', 'punct'), ('month', 'npadvmod'), ('12', 'quantmod'), ('na', 'quantmod'), ('na', 'quantmod'), ('na', 'quantmod'), ('24', 'nummod'), ('%', 'appos'), ('59', 'nummod'), ('%', 'appos'), ('*', 'punct'), ('acr50', 'amod'), ('month', 'appos'), ('6', 'nummod'), ('8', 'nummod'), ('%', 'appos'), ('22', 'nummod'), ('%', 'appos'), ('*', 'ROOT'), ('35', 'nummod'), ('%', 'appos'), ('*', 'punct'), ('10', 'nummod'), ('%', 'ROOT'), ('39', 'nummod'), ('%', 'appos'), ('*', 'punct'), ('month', 'appos'), ('12', 'quantmod'), ('na', 'quantmod'), ('na', 'quantmod'), ('na', 'quantmod'), ('10', 'nummod'), ('%', 'appos'), ('42', 'nummod'), ('%', 'appos'), ('*', 'punct'), ('acr70', 'cc'), ('month', 'conj'), ('6', 'compound'), ('2', 'nummod'), ('%', 'appos'), ('12', 'nummod'), ('%', 'appos'), ('*', 'ROOT'), ('18', 'nummod'), ('%', 'ROOT'), ('*', 'punct'), ('3', 'nummod'), ('%', 'ROOT'), ('21', 'nummod'), ('%', 'appos'), ('*', 'punct'), ('month', 'npadvmod'), ('12', 'quantmod'), ('na', 'quantmod'), ('na', 'quantmod'), ('na', 'quantmod'), ('5', 'nummod'), ('%', 'appos'), ('23', 'nummod'), ('%', 'appos'), ('*', 'ROOT'), ('*', 'ROOT'), ('p', 'npadvmod'), ('<', 'dep'), ('0.01', 'nummod'), (',', 'punct'), ('humira', 'nsubj'), ('vs.', 'prep'), ('placebo', 'pobj'), ('result', 'compound'), ('studi', 'compound'), ('ra', 'compound'), ('-', 'punct'), ('i', 'ROOT'), ('similar', 'amod'), ('studi', 'compound'), ('ra', 'compound'), ('-', 'punct'), ('iii', 'appos'), (';', 'punct'), ('patient', 'compound'), ('receiv', 'compound'), ('humira', 'appos'), ('40', 'nummod'), ('mg', 'npadvmod'), ('everi', 'amod'), ('week', 'pobj'), ('studi', 'npadvmod'), ('ra', 'npadvmod'), ('-', 'pobj'), ('i', 'pobj'), ('also', 'advmod'), ('achiev', 'parataxis'), ('acr', 'dobj'), ('20', 'nummod'), (',', 'punct'), ('50', 'compound'), ('70', 'nummod'), ('respons', 'compound'), ('rate', 'ROOT'), ('65', 'nummod'), ('%', 'appos'), (',', 'punct'), ('52', 'nummod'), ('%', 'appos'), ('24', 'nummod'), ('%', 'appos'), (',', 'punct'), ('respect', 'conj'), (',', 'punct'), ('compar', 'compound'), ('placebo', 'compound'), ('respons', 'appos'), ('13', 'nummod'), ('%', 'appos'), (',', 'punct'), ('7', 'nummod'), ('%', 'appos'), ('3', 'nummod'), ('%', 'compound'), ('respect', 'conj'), (',', 'punct'), ('6', 'nummod'), ('month', 'appos'), ('(', 'punct'), ('p', 'appos'), ('<', 'dep'), ('0.01', 'nummod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'The results of the components of the ACR response criteria for Studies RA-II and RA-III are \\nshown in Table 4.', 'tokens': ['results', 'components', 'ACR', 'response', 'criteria', 'Studies', 'RA-II', 'RA-III', 'shown', 'Table', '4', '.'], 'lemmatized': ['result', 'component', 'ACR', 'response', 'criterion', 'Studies', 'RA-II', 'RA-III', 'shown', 'Table', '4', '.'], 'stemmed': ['result', 'compon', 'acr', 'respons', 'criterion', 'studi', 'ra-ii', 'ra-iii', 'shown', 'tabl', '4', '.'], 'dependencies': [('result', 'ROOT'), ('compon', 'xcomp'), ('acr', 'prep'), ('respons', 'compound'), ('criterion', 'compound'), ('studi', 'compound'), ('ra', 'compound'), ('-', 'punct'), ('ii', 'compound'), ('ra', 'compound'), ('-', 'punct'), ('iii', 'nsubj'), ('shown', 'amod'), ('tabl', 'npadvmod'), ('4', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'ACR response rates and improvement in all components of ACR response \\nwere maintained to week 104.', 'tokens': ['ACR', 'response', 'rates', 'improvement', 'components', 'ACR', 'response', 'maintained', 'week', '104', '.'], 'lemmatized': ['ACR', 'response', 'rate', 'improvement', 'component', 'ACR', 'response', 'maintained', 'week', '104', '.'], 'stemmed': ['acr', 'respons', 'rate', 'improv', 'compon', 'acr', 'respons', 'maintain', 'week', '104', '.'], 'dependencies': [('acr', 'prep'), ('respons', 'compound'), ('rate', 'pobj'), ('improv', 'advmod'), ('compon', 'ROOT'), ('acr', 'compound'), ('respons', 'nsubj'), ('maintain', 'ccomp'), ('week', 'npadvmod'), ('104', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Over the 2 years in Study RA-III, 20% of HUMIRA patients \\nreceiving 40 mg every other week achieved a major clinical response, defined as maintenance of \\nan ACR 70 response over a 6-month period.', 'tokens': ['2', 'years', 'Study', 'RA-III', ',', '20', '%', 'HUMIRA', 'patients', 'receiving', '40', 'mg', 'every', 'week', 'achieved', 'major', 'clinical', 'response', ',', 'defined', 'maintenance', 'ACR', '70', 'response', '6-month', 'period', '.'], 'lemmatized': ['2', 'year', 'Study', 'RA-III', ',', '20', '%', 'HUMIRA', 'patient', 'receiving', '40', 'mg', 'every', 'week', 'achieved', 'major', 'clinical', 'response', ',', 'defined', 'maintenance', 'ACR', '70', 'response', '6-month', 'period', '.'], 'stemmed': ['2', 'year', 'studi', 'ra-iii', ',', '20', '%', 'humira', 'patient', 'receiv', '40', 'mg', 'everi', 'week', 'achiev', 'major', 'clinic', 'respons', ',', 'defin', 'mainten', 'acr', '70', 'respons', '6-month', 'period', '.'], 'dependencies': [('2', 'nummod'), ('year', 'compound'), ('studi', 'compound'), ('ra', 'compound'), ('-', 'punct'), ('iii', 'nmod'), (',', 'punct'), ('20', 'nummod'), ('%', 'nmod'), ('humira', 'compound'), ('patient', 'compound'), ('receiv', 'appos'), ('40', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'appos'), ('achiev', 'appos'), ('major', 'amod'), ('clinic', 'compound'), ('respons', 'dep'), (',', 'punct'), ('defin', 'advmod'), ('mainten', 'ROOT'), ('acr', 'prep'), ('70', 'nummod'), ('respons', 'nmod'), ('6', 'nummod'), ('-', 'punct'), ('month', 'compound'), ('period', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'ACR responses were maintained in similar', 'tokens': ['ACR', 'responses', 'maintained', 'similar'], 'lemmatized': ['ACR', 'response', 'maintained', 'similar'], 'stemmed': ['acr', 'respons', 'maintain', 'similar'], 'dependencies': [('acr', 'prep'), ('respons', 'nsubj'), ('maintain', 'ROOT'), ('similar', 'acomp')]}], 'text': 'Study RA-IV assessed safety in 636 patients who were either DMARD-naive or were permitted \\nto remain on their pre-existing rheumatologic therapy provided that therapy was stable for a \\nminimum of 28 days. Patients were randomized to 40 mg of HUMIRA or placebo every other \\nweek for 24 weeks.  \\nStudy RA-V evaluated 799 patients with moderately to severely active RA of less than 3 years \\nduration who were ≥18 years old and MTX naïve. Patients were randomized to receive either \\nMTX (optimized to 20 mg/week by week 8), HUMIRA 40 mg every other week or \\nHUMIRA/MTX combination therapy for 104 weeks. Patients were evaluated for signs and \\nsymptoms, and for radiographic progression of joint damage. The median disease duration \\namong patients enrolled in the study was 5 months. The median MTX dose achieved was 20 mg.  \\nClinical Response \\nThe percent of HUMIRA treated patients achieving ACR 20, 50 and 70 responses in Studies RA-\\nII and III are shown in Table 3.  \\n \\n  \\nTable 3. ACR Responses in Studies RA-II and RA-III (Percent of Patients) \\n  \\nStudy RA-II \\nMonotherapy \\n(26 weeks) \\nStudy RA-III \\nMethotrexate Combination \\n(24 and 52 weeks) \\nResponse \\nPlacebo \\nHUMIRA \\nHUMIRA \\nPlacebo/MTX \\nHUMIRA/MTX \\n  \\n  \\n40 mg every  \\n40 mg weekly   \\n40 mg every \\n  \\n  \\n other week   \\n  \\nother week \\n  \\nN=110 \\nN=113 \\nN=103 \\nN=200 \\nN=207 \\nACR20 \\n  \\n  \\n  \\n  \\n  \\nMonth 6 \\n19% \\n46%* \\n53%* \\n30% \\n63%* \\nMonth 12 \\nNA \\nNA \\nNA \\n24% \\n59%* \\nACR50 \\n  \\n  \\n  \\n  \\n  \\nMonth 6 \\n8% \\n22%* \\n35%* \\n10% \\n39%* \\nMonth 12 \\nNA \\nNA \\nNA \\n10% \\n42%* \\nACR70 \\n  \\n  \\n  \\n  \\n  \\nMonth 6 \\n2% \\n12%* \\n18%* \\n3% \\n21%* \\nMonth 12 \\nNA \\nNA \\nNA \\n5% \\n23%* \\n* p<0.01, HUMIRA vs. placebo  \\nThe results of Study RA-I were similar to Study RA-III; patients receiving HUMIRA 40 mg \\nevery other week in Study RA-I also achieved ACR 20, 50 and 70 response rates of 65%, 52% \\nand 24%, respectively, compared to placebo responses of 13%, 7% and 3% respectively, at 6 \\nmonths (p<0.01).  \\nThe results of the components of the ACR response criteria for Studies RA-II and RA-III are \\nshown in Table 4. ACR response rates and improvement in all components of ACR response \\nwere maintained to week 104. Over the 2 years in Study RA-III, 20% of HUMIRA patients \\nreceiving 40 mg every other week achieved a major clinical response, defined as maintenance of \\nan ACR 70 response over a 6-month period. ACR responses were maintained in similar \\n'}, 'page_char_count': 2370, 'page_word_count': 386, 'sentences': ['Study RA-IV assessed safety in 636 patients who were either DMARD-naive or were permitted \\nto remain on their pre-existing rheumatologic therapy provided that therapy was stable for a \\nminimum of 28 days.', 'Patients were randomized to 40 mg of HUMIRA or placebo every other \\nweek for 24 weeks.', ' \\nStudy RA-V evaluated 799 patients with moderately to severely active RA of less than 3 years \\nduration who were ≥18 years old and MTX naïve.', 'Patients were randomized to receive either \\nMTX (optimized to 20 mg/week by week 8), HUMIRA 40 mg every other week or \\nHUMIRA/MTX combination therapy for 104 weeks.', 'Patients were evaluated for signs and \\nsymptoms, and for radiographic progression of joint damage.', 'The median disease duration \\namong patients enrolled in the study was 5 months.', 'The median MTX dose achieved was 20 mg.', ' \\nClinical Response \\nThe percent of HUMIRA treated patients achieving ACR 20, 50 and 70 responses in Studies RA-\\nII and III are shown in Table 3.', ' \\n \\n  \\nTable 3.', 'ACR Responses in Studies RA-II and RA-III (Percent of Patients) \\n  \\nStudy RA-II \\nMonotherapy \\n(26 weeks) \\nStudy RA-III \\nMethotrexate Combination \\n(24 and 52 weeks) \\nResponse \\nPlacebo \\nHUMIRA \\nHUMIRA \\nPlacebo/MTX \\nHUMIRA/MTX \\n  \\n  \\n40 mg every  \\n40 mg weekly   \\n40 mg every \\n  \\n  \\n other week   \\n  \\nother week \\n  \\nN=110 \\nN=113 \\nN=103 \\nN=200 \\nN=207 \\nACR20 \\n  \\n  \\n  \\n  \\n  \\nMonth 6 \\n19% \\n46%* \\n53%* \\n30% \\n63%* \\nMonth 12 \\nNA \\nNA \\nNA \\n24% \\n59%* \\nACR50 \\n  \\n  \\n  \\n  \\n  \\nMonth 6 \\n8% \\n22%* \\n35%* \\n10% \\n39%* \\nMonth 12 \\nNA \\nNA \\nNA \\n10% \\n42%* \\nACR70 \\n  \\n  \\n  \\n  \\n  \\nMonth 6 \\n2% \\n12%* \\n18%* \\n3% \\n21%* \\nMonth 12 \\nNA \\nNA \\nNA \\n5% \\n23%* \\n* p<0.01, HUMIRA vs. placebo  \\nThe results of Study RA-I were similar to Study RA-III; patients receiving HUMIRA 40 mg \\nevery other week in Study RA-I also achieved ACR 20, 50 and 70 response rates of 65%, 52% \\nand 24%, respectively, compared to placebo responses of 13%, 7% and 3% respectively, at 6 \\nmonths (p<0.01).', ' \\nThe results of the components of the ACR response criteria for Studies RA-II and RA-III are \\nshown in Table 4.', 'ACR response rates and improvement in all components of ACR response \\nwere maintained to week 104.', 'Over the 2 years in Study RA-III, 20% of HUMIRA patients \\nreceiving 40 mg every other week achieved a major clinical response, defined as maintenance of \\nan ACR 70 response over a 6-month period.', 'ACR responses were maintained in similar \\n'], 'page_sentence_count_spacy': 14}\n",
            "{'page_number': 34, 'text': 'proportions of patients for up to 5 years with continuous HUMIRA treatment in the open-label \\nportion of Study RA-III.  \\n \\n  \\nTable 4. Components of ACR Response in Studies RA-II and RA-III \\n  \\nStudy RA-II \\nStudy RA-III \\nParameter (median) \\nPlacebo \\nN=110 \\nHUMIRAa \\nN=113 \\nPlacebo/MTX \\nN=200 \\nHUMIRAa/MTX  \\nN=207 \\n  \\nBaseline Wk \\n26 \\nBaseline Wk \\n26 \\nBaseline Wk 24 Baseline \\nWk 24 \\nNumber of tender \\njoints (0-68) \\n35 \\n26 \\n31 \\n16* \\n26 \\n15 \\n24 \\n8* \\nNumber of swollen \\njoints (0-66) \\n19 \\n16 \\n18 \\n10* \\n17 \\n11 \\n18 \\n5* \\nPhysician global \\nassessmentb \\n7.0 \\n6.1 \\n6.6 \\n3.7* \\n6.3 \\n3.5 \\n6.5 \\n2.0* \\nPatient global \\nassessmentb \\n7.5 \\n6.3 \\n7.5 \\n4.5* \\n5.4 \\n3.9 \\n5.2 \\n2.0* \\nPainb \\n7.3 \\n6.1 \\n7.3 \\n4.1* \\n6.0 \\n3.8 \\n5.8 \\n2.1* \\nDisability index \\n(HAQ)c \\n2.0 \\n1.9 \\n1.9 \\n1.5* \\n1.5 \\n1.3 \\n1.5 \\n0.8* \\nCRP (mg/dL) \\n3.9 \\n4.3 \\n4.6 \\n1.8* \\n1.0 \\n0.9 \\n1.0 \\n0.4* \\na 40 mg HUMIRA administered every other week \\nb Visual analogue scale; 0 = best, 10 = worst \\nc Disability Index of the Health Assessment Questionnaire; 0 = best, 3 = worst, measures the \\npatient’s ability to perform the following: dress/groom, arise, eat, walk, reach, grip, maintain \\nhygiene, and maintain daily activity \\n* p<0.001, HUMIRA vs. placebo, based on mean change from baseline  \\nThe time course of ACR 20 response for Study RA-III is shown in Figure 1.  \\nIn Study RA-III, 85% of patients with ACR 20 responses at week 24 maintained the response at \\n52 weeks. The time course of ACR 20 response for Study RA-I and Study RA-II were similar.  \\n', 'processed_text': {'sentences': [{'original_sentence': 'proportions of patients for up to 5 years with continuous HUMIRA treatment in the open-label \\nportion of Study RA-III.', 'tokens': ['proportions', 'patients', '5', 'years', 'continuous', 'HUMIRA', 'treatment', 'open-label', 'portion', 'Study', 'RA-III', '.'], 'lemmatized': ['proportion', 'patient', '5', 'year', 'continuous', 'HUMIRA', 'treatment', 'open-label', 'portion', 'Study', 'RA-III', '.'], 'stemmed': ['proport', 'patient', '5', 'year', 'continu', 'humira', 'treatment', 'open-label', 'portion', 'studi', 'ra-iii', '.'], 'dependencies': [('proport', 'compound'), ('patient', 'amod'), ('5', 'nummod'), ('year', 'compound'), ('continu', 'nmod'), ('humira', 'nmod'), ('treatment', 'nmod'), ('open', 'amod'), ('-', 'punct'), ('label', 'compound'), ('portion', 'ROOT'), ('studi', 'compound'), ('ra', 'compound'), ('-', 'punct'), ('iii', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Table 4.', 'tokens': ['Table', '4', '.'], 'lemmatized': ['Table', '4', '.'], 'stemmed': ['tabl', '4', '.'], 'dependencies': [('tabl', 'ROOT'), ('4', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Components of ACR Response in Studies RA-II and RA-III \\n  \\nStudy RA-II \\nStudy RA-III \\nParameter (median) \\nPlacebo \\nN=110 \\nHUMIRAa \\nN=113 \\nPlacebo/MTX \\nN=200 \\nHUMIRAa/MTX  \\nN=207 \\n  \\nBaseline Wk \\n26 \\nBaseline Wk \\n26 \\nBaseline Wk 24 Baseline \\nWk 24 \\nNumber of tender \\njoints (0-68) \\n35 \\n26 \\n31 \\n16* \\n26 \\n15 \\n24 \\n8* \\nNumber of swollen \\njoints (0-66) \\n19 \\n16 \\n18 \\n10* \\n17 \\n11 \\n18 \\n5* \\nPhysician global \\nassessmentb \\n7.0 \\n6.1 \\n6.6 \\n3.7* \\n6.3 \\n3.5 \\n6.5 \\n2.0* \\nPatient global \\nassessmentb \\n7.5 \\n6.3 \\n7.5 \\n4.5* \\n5.4 \\n3.9 \\n5.2 \\n2.0* \\nPainb \\n7.3 \\n6.1 \\n7.3 \\n4.1* \\n6.0 \\n3.8 \\n5.8 \\n2.1* \\nDisability index \\n(HAQ)c \\n2.0 \\n1.9 \\n1.9 \\n1.5* \\n1.5 \\n1.3 \\n1.5 \\n0.8* \\nCRP (mg/dL) \\n3.9 \\n4.3 \\n4.6 \\n1.8* \\n1.0 \\n0.9 \\n1.0 \\n0.4* \\na 40 mg HUMIRA administered every other week \\nb Visual analogue scale; 0 = best, 10 = worst \\nc Disability Index of the Health Assessment Questionnaire; 0 = best, 3 = worst, measures the \\npatient’s ability to perform the following: dress/groom, arise, eat, walk, reach, grip, maintain \\nhygiene, and maintain daily activity \\n* p<0.001, HUMIRA vs. placebo, based on mean change from baseline  \\nThe time course of ACR 20 response for Study RA-III is shown in Figure 1.', 'tokens': ['Components', 'ACR', 'Response', 'Studies', 'RA-II', 'RA-III', 'Study', 'RA-II', 'Study', 'RA-III', 'Parameter', '(', 'median', ')', 'Placebo', 'N=110', 'HUMIRAa', 'N=113', 'Placebo/MTX', 'N=200', 'HUMIRAa/MTX', 'N=207', 'Baseline', 'Wk', '26', 'Baseline', 'Wk', '26', 'Baseline', 'Wk', '24', 'Baseline', 'Wk', '24', 'Number', 'tender', 'joints', '(', '0-68', ')', '35', '26', '31', '16', '*', '26', '15', '24', '8', '*', 'Number', 'swollen', 'joints', '(', '0-66', ')', '19', '16', '18', '10', '*', '17', '11', '18', '5', '*', 'Physician', 'global', 'assessmentb', '7.0', '6.1', '6.6', '3.7', '*', '6.3', '3.5', '6.5', '2.0', '*', 'Patient', 'global', 'assessmentb', '7.5', '6.3', '7.5', '4.5', '*', '5.4', '3.9', '5.2', '2.0', '*', 'Painb', '7.3', '6.1', '7.3', '4.1', '*', '6.0', '3.8', '5.8', '2.1', '*', 'Disability', 'index', '(', 'HAQ', ')', 'c', '2.0', '1.9', '1.9', '1.5', '*', '1.5', '1.3', '1.5', '0.8', '*', 'CRP', '(', 'mg/dL', ')', '3.9', '4.3', '4.6', '1.8', '*', '1.0', '0.9', '1.0', '0.4', '*', '40', 'mg', 'HUMIRA', 'administered', 'every', 'week', 'b', 'Visual', 'analogue', 'scale', ';', '0', '=', 'best', ',', '10', '=', 'worst', 'c', 'Disability', 'Index', 'Health', 'Assessment', 'Questionnaire', ';', '0', '=', 'best', ',', '3', '=', 'worst', ',', 'measures', 'patient', '’', 'ability', 'perform', 'following', ':', 'dress/groom', ',', 'arise', ',', 'eat', ',', 'walk', ',', 'reach', ',', 'grip', ',', 'maintain', 'hygiene', ',', 'maintain', 'daily', 'activity', '*', 'p', '<', '0.001', ',', 'HUMIRA', 'vs.', 'placebo', ',', 'based', 'mean', 'change', 'baseline', 'time', 'course', 'ACR', '20', 'response', 'Study', 'RA-III', 'shown', 'Figure', '1', '.'], 'lemmatized': ['Components', 'ACR', 'Response', 'Studies', 'RA-II', 'RA-III', 'Study', 'RA-II', 'Study', 'RA-III', 'Parameter', '(', 'median', ')', 'Placebo', 'N=110', 'HUMIRAa', 'N=113', 'Placebo/MTX', 'N=200', 'HUMIRAa/MTX', 'N=207', 'Baseline', 'Wk', '26', 'Baseline', 'Wk', '26', 'Baseline', 'Wk', '24', 'Baseline', 'Wk', '24', 'Number', 'tender', 'joint', '(', '0-68', ')', '35', '26', '31', '16', '*', '26', '15', '24', '8', '*', 'Number', 'swollen', 'joint', '(', '0-66', ')', '19', '16', '18', '10', '*', '17', '11', '18', '5', '*', 'Physician', 'global', 'assessmentb', '7.0', '6.1', '6.6', '3.7', '*', '6.3', '3.5', '6.5', '2.0', '*', 'Patient', 'global', 'assessmentb', '7.5', '6.3', '7.5', '4.5', '*', '5.4', '3.9', '5.2', '2.0', '*', 'Painb', '7.3', '6.1', '7.3', '4.1', '*', '6.0', '3.8', '5.8', '2.1', '*', 'Disability', 'index', '(', 'HAQ', ')', 'c', '2.0', '1.9', '1.9', '1.5', '*', '1.5', '1.3', '1.5', '0.8', '*', 'CRP', '(', 'mg/dL', ')', '3.9', '4.3', '4.6', '1.8', '*', '1.0', '0.9', '1.0', '0.4', '*', '40', 'mg', 'HUMIRA', 'administered', 'every', 'week', 'b', 'Visual', 'analogue', 'scale', ';', '0', '=', 'best', ',', '10', '=', 'worst', 'c', 'Disability', 'Index', 'Health', 'Assessment', 'Questionnaire', ';', '0', '=', 'best', ',', '3', '=', 'worst', ',', 'measure', 'patient', '’', 'ability', 'perform', 'following', ':', 'dress/groom', ',', 'arise', ',', 'eat', ',', 'walk', ',', 'reach', ',', 'grip', ',', 'maintain', 'hygiene', ',', 'maintain', 'daily', 'activity', '*', 'p', '<', '0.001', ',', 'HUMIRA', 'vs.', 'placebo', ',', 'based', 'mean', 'change', 'baseline', 'time', 'course', 'ACR', '20', 'response', 'Study', 'RA-III', 'shown', 'Figure', '1', '.'], 'stemmed': ['compon', 'acr', 'respons', 'studi', 'ra-ii', 'ra-iii', 'studi', 'ra-ii', 'studi', 'ra-iii', 'paramet', '(', 'median', ')', 'placebo', 'n=110', 'humiraa', 'n=113', 'placebo/mtx', 'n=200', 'humiraa/mtx', 'n=207', 'baselin', 'wk', '26', 'baselin', 'wk', '26', 'baselin', 'wk', '24', 'baselin', 'wk', '24', 'number', 'tender', 'joint', '(', '0-68', ')', '35', '26', '31', '16', '*', '26', '15', '24', '8', '*', 'number', 'swollen', 'joint', '(', '0-66', ')', '19', '16', '18', '10', '*', '17', '11', '18', '5', '*', 'physician', 'global', 'assessmentb', '7.0', '6.1', '6.6', '3.7', '*', '6.3', '3.5', '6.5', '2.0', '*', 'patient', 'global', 'assessmentb', '7.5', '6.3', '7.5', '4.5', '*', '5.4', '3.9', '5.2', '2.0', '*', 'painb', '7.3', '6.1', '7.3', '4.1', '*', '6.0', '3.8', '5.8', '2.1', '*', 'disabl', 'index', '(', 'haq', ')', 'c', '2.0', '1.9', '1.9', '1.5', '*', '1.5', '1.3', '1.5', '0.8', '*', 'crp', '(', 'mg/dl', ')', '3.9', '4.3', '4.6', '1.8', '*', '1.0', '0.9', '1.0', '0.4', '*', '40', 'mg', 'humira', 'administ', 'everi', 'week', 'b', 'visual', 'analogu', 'scale', ';', '0', '=', 'best', ',', '10', '=', 'worst', 'c', 'disabl', 'index', 'health', 'assess', 'questionnair', ';', '0', '=', 'best', ',', '3', '=', 'worst', ',', 'measur', 'patient', '’', 'abil', 'perform', 'follow', ':', 'dress/groom', ',', 'aris', ',', 'eat', ',', 'walk', ',', 'reach', ',', 'grip', ',', 'maintain', 'hygien', ',', 'maintain', 'daili', 'activ', '*', 'p', '<', '0.001', ',', 'humira', 'vs.', 'placebo', ',', 'base', 'mean', 'chang', 'baselin', 'time', 'cours', 'acr', '20', 'respons', 'studi', 'ra-iii', 'shown', 'figur', '1', '.'], 'dependencies': [('compon', 'ROOT'), ('acr', 'prt'), ('respons', 'dobj'), ('studi', 'compound'), ('ra', 'compound'), ('-', 'punct'), ('ii', 'npadvmod'), ('ra', 'compound'), ('-', 'punct'), ('iii', 'npadvmod'), ('studi', 'compound'), ('ra', 'compound'), ('-', 'punct'), ('ii', 'compound'), ('studi', 'compound'), ('ra', 'compound'), ('-', 'punct'), ('iii', 'compound'), ('paramet', 'dobj'), ('(', 'punct'), ('median', 'appos'), (')', 'punct'), ('placebo', 'compound'), ('n=110', 'compound'), ('humiraa', 'compound'), ('n=113', 'compound'), ('placebo', 'nsubj'), ('/', 'punct'), ('mtx', 'ccomp'), ('n=200', 'compound'), ('humiraa', 'nmod'), ('/', 'punct'), ('mtx', 'compound'), ('n=207', 'compound'), ('baselin', 'dobj'), ('wk', 'prep'), ('26', 'nummod'), ('baselin', 'npadvmod'), ('wk', 'prep'), ('26', 'nummod'), ('baselin', 'dobj'), ('wk', 'prep'), ('24', 'nummod'), ('baselin', 'npadvmod'), ('wk', 'nmod'), ('24', 'nummod'), ('number', 'compound'), ('tender', 'compound'), ('joint', 'dobj'), ('(', 'punct'), ('0', 'appos'), ('-', 'punct'), ('68', 'prep'), (')', 'punct'), ('35', 'nummod'), ('26', 'nummod'), ('31', 'npadvmod'), ('16', 'npadvmod'), ('*', 'punct'), ('26', 'dobj'), ('15', 'npadvmod'), ('24', 'nummod'), ('8', 'nummod'), ('*', 'punct'), ('number', 'npadvmod'), ('swollen', 'amod'), ('joint', 'dobj'), ('(', 'punct'), ('0', 'appos'), ('-', 'punct'), ('66', 'prep'), (')', 'punct'), ('19', 'nummod'), ('16', 'nummod'), ('18', 'npadvmod'), ('10', 'nummod'), ('*', 'punct'), ('17', 'nummod'), ('11', 'nummod'), ('18', 'compound'), ('5', 'nummod'), ('*', 'appos'), ('physician', 'nmod'), ('global', 'compound'), ('assessmentb', 'dobj'), ('7.0', 'quantmod'), ('6.1', 'compound'), ('6.6', 'compound'), ('3.7', 'nummod'), ('*', 'punct'), ('6.3', 'quantmod'), ('3.5', 'compound'), ('6.5', 'nummod'), ('2.0', 'appos'), ('*', 'quantmod'), ('patient', 'amod'), ('global', 'amod'), ('assessmentb', 'dobj'), ('7.5', 'compound'), ('6.3', 'compound'), ('7.5', 'compound'), ('4.5', 'npadvmod'), ('*', 'punct'), ('5.4', 'compound'), ('3.9', 'compound'), ('5.2', 'compound'), ('2.0', 'appos'), ('*', 'punct'), ('painb', 'ccomp'), ('7.3', 'quantmod'), ('6.1', 'compound'), ('7.3', 'compound'), ('4.1', 'nummod'), ('*', 'punct'), ('6.0', 'quantmod'), ('3.8', 'compound'), ('5.8', 'compound'), ('2.1', 'appos'), ('*', 'punct'), ('disabl', 'compound'), ('index', 'nmod'), ('(', 'punct'), ('haq', 'appos'), (')', 'punct'), ('c', 'ROOT'), ('2.0', 'quantmod'), ('1.9', 'npadvmod'), ('1.9', 'compound'), ('1.5', 'nummod'), ('*', 'punct'), ('1.5', 'compound'), ('1.3', 'compound'), ('1.5', 'compound'), ('0.8', 'appos'), ('*', 'punct'), ('crp', 'nmod'), ('(', 'punct'), ('mg', 'nmod'), ('/', 'punct'), ('dl', 'appos'), (')', 'punct'), ('3.9', 'nummod'), ('4.3', 'compound'), ('4.6', 'compound'), ('1.8', 'nummod'), ('*', 'punct'), ('1.0', 'nummod'), ('0.9', 'npadvmod'), ('1.0', 'nummod'), ('0.4', 'npadvmod'), ('*', 'punct'), ('40', 'quantmod'), ('mg', 'prep'), ('humira', 'compound'), ('administ', 'appos'), ('everi', 'compound'), ('week', 'compound'), ('b', 'prep'), ('visual', 'amod'), ('analogu', 'amod'), ('scale', 'nsubj'), (';', 'punct'), ('0', 'punct'), ('=', 'nmod'), ('best', 'advmod'), (',', 'punct'), ('10', 'npadvmod'), ('=', 'prep'), ('worst', 'punct'), ('c', 'npadvmod'), ('disabl', 'compound'), ('index', 'compound'), ('health', 'compound'), ('assess', 'compound'), ('questionnair', 'nsubj'), (';', 'punct'), ('0', 'punct'), ('=', 'dep'), ('best', 'advmod'), (',', 'punct'), ('3', 'nummod'), ('=', 'nmod'), ('worst', 'amod'), (',', 'punct'), ('measur', 'compound'), ('patient', 'nsubj'), ('’', 'punct'), ('abil', 'nsubj'), ('perform', 'ROOT'), ('follow', 'dobj'), (':', 'punct'), ('dress', 'nmod'), ('/', 'punct'), ('groom', 'nsubj'), (',', 'punct'), ('aris', 'conj'), (',', 'punct'), ('eat', 'conj'), (',', 'punct'), ('walk', 'conj'), (',', 'punct'), ('reach', 'conj'), (',', 'punct'), ('grip', 'conj'), (',', 'punct'), ('maintain', 'dep'), ('hygien', 'dobj'), (',', 'punct'), ('maintain', 'conj'), ('daili', 'compound'), ('activ', 'dobj'), ('*', 'npadvmod'), ('p', 'nmod'), ('<', 'nmod'), ('0.001', 'npadvmod'), (',', 'punct'), ('humira', 'npadvmod'), ('vs.', 'prep'), ('placebo', 'pobj'), (',', 'punct'), ('base', 'compound'), ('mean', 'compound'), ('chang', 'compound'), ('baselin', 'compound'), ('time', 'compound'), ('cours', 'conj'), ('acr', 'prep'), ('20', 'nummod'), ('respons', 'pobj'), ('studi', 'compound'), ('ra', 'compound'), ('-', 'punct'), ('iii', 'punct'), ('shown', 'amod'), ('figur', 'dobj'), ('1', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'In Study RA-III, 85% of patients with ACR 20 responses at week 24 maintained the response at \\n52 weeks.', 'tokens': ['Study', 'RA-III', ',', '85', '%', 'patients', 'ACR', '20', 'responses', 'week', '24', 'maintained', 'response', '52', 'weeks', '.'], 'lemmatized': ['Study', 'RA-III', ',', '85', '%', 'patient', 'ACR', '20', 'response', 'week', '24', 'maintained', 'response', '52', 'week', '.'], 'stemmed': ['studi', 'ra-iii', ',', '85', '%', 'patient', 'acr', '20', 'respons', 'week', '24', 'maintain', 'respons', '52', 'week', '.'], 'dependencies': [('studi', 'compound'), ('ra', 'compound'), ('-', 'punct'), ('iii', 'nsubj'), (',', 'punct'), ('85', 'nummod'), ('%', 'compound'), ('patient', 'appos'), ('acr', 'prep'), ('20', 'nummod'), ('respons', 'compound'), ('week', 'pobj'), ('24', 'nummod'), ('maintain', 'ROOT'), ('respons', 'dobj'), ('52', 'nummod'), ('week', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'The time course of ACR 20 response for Study RA-I and Study RA-II were similar.', 'tokens': ['time', 'course', 'ACR', '20', 'response', 'Study', 'RA-I', 'Study', 'RA-II', 'similar', '.'], 'lemmatized': ['time', 'course', 'ACR', '20', 'response', 'Study', 'RA-I', 'Study', 'RA-II', 'similar', '.'], 'stemmed': ['time', 'cours', 'acr', '20', 'respons', 'studi', 'ra-i', 'studi', 'ra-ii', 'similar', '.'], 'dependencies': [('time', 'nsubj'), ('cours', 'ROOT'), ('acr', 'prep'), ('20', 'nummod'), ('respons', 'nsubj'), ('studi', 'compound'), ('ra', 'compound'), ('-', 'punct'), ('i', 'appos'), ('studi', 'compound'), ('ra', 'compound'), ('-', 'punct'), ('ii', 'nsubj'), ('similar', 'ccomp'), ('.', 'punct')]}], 'text': 'proportions of patients for up to 5 years with continuous HUMIRA treatment in the open-label \\nportion of Study RA-III.  \\n \\n  \\nTable 4. Components of ACR Response in Studies RA-II and RA-III \\n  \\nStudy RA-II \\nStudy RA-III \\nParameter (median) \\nPlacebo \\nN=110 \\nHUMIRAa \\nN=113 \\nPlacebo/MTX \\nN=200 \\nHUMIRAa/MTX  \\nN=207 \\n  \\nBaseline Wk \\n26 \\nBaseline Wk \\n26 \\nBaseline Wk 24 Baseline \\nWk 24 \\nNumber of tender \\njoints (0-68) \\n35 \\n26 \\n31 \\n16* \\n26 \\n15 \\n24 \\n8* \\nNumber of swollen \\njoints (0-66) \\n19 \\n16 \\n18 \\n10* \\n17 \\n11 \\n18 \\n5* \\nPhysician global \\nassessmentb \\n7.0 \\n6.1 \\n6.6 \\n3.7* \\n6.3 \\n3.5 \\n6.5 \\n2.0* \\nPatient global \\nassessmentb \\n7.5 \\n6.3 \\n7.5 \\n4.5* \\n5.4 \\n3.9 \\n5.2 \\n2.0* \\nPainb \\n7.3 \\n6.1 \\n7.3 \\n4.1* \\n6.0 \\n3.8 \\n5.8 \\n2.1* \\nDisability index \\n(HAQ)c \\n2.0 \\n1.9 \\n1.9 \\n1.5* \\n1.5 \\n1.3 \\n1.5 \\n0.8* \\nCRP (mg/dL) \\n3.9 \\n4.3 \\n4.6 \\n1.8* \\n1.0 \\n0.9 \\n1.0 \\n0.4* \\na 40 mg HUMIRA administered every other week \\nb Visual analogue scale; 0 = best, 10 = worst \\nc Disability Index of the Health Assessment Questionnaire; 0 = best, 3 = worst, measures the \\npatient’s ability to perform the following: dress/groom, arise, eat, walk, reach, grip, maintain \\nhygiene, and maintain daily activity \\n* p<0.001, HUMIRA vs. placebo, based on mean change from baseline  \\nThe time course of ACR 20 response for Study RA-III is shown in Figure 1.  \\nIn Study RA-III, 85% of patients with ACR 20 responses at week 24 maintained the response at \\n52 weeks. The time course of ACR 20 response for Study RA-I and Study RA-II were similar.  \\n'}, 'page_char_count': 1485, 'page_word_count': 246, 'sentences': ['proportions of patients for up to 5 years with continuous HUMIRA treatment in the open-label \\nportion of Study RA-III.', ' \\n \\n  \\nTable 4.', 'Components of ACR Response in Studies RA-II and RA-III \\n  \\nStudy RA-II \\nStudy RA-III \\nParameter (median) \\nPlacebo \\nN=110 \\nHUMIRAa \\nN=113 \\nPlacebo/MTX \\nN=200 \\nHUMIRAa/MTX  \\nN=207 \\n  \\nBaseline Wk \\n26 \\nBaseline Wk \\n26 \\nBaseline Wk 24 Baseline \\nWk 24 \\nNumber of tender \\njoints (0-68) \\n35 \\n26 \\n31 \\n16* \\n26 \\n15 \\n24 \\n8* \\nNumber of swollen \\njoints (0-66) \\n19 \\n16 \\n18 \\n10* \\n17 \\n11 \\n18 \\n5* \\nPhysician global \\nassessmentb \\n7.0 \\n6.1 \\n6.6 \\n3.7* \\n6.3 \\n3.5 \\n6.5 \\n2.0* \\nPatient global \\nassessmentb \\n7.5 \\n6.3 \\n7.5 \\n4.5* \\n5.4 \\n3.9 \\n5.2 \\n2.0* \\nPainb \\n7.3 \\n6.1 \\n7.3 \\n4.1* \\n6.0 \\n3.8 \\n5.8 \\n2.1* \\nDisability index \\n(HAQ)c \\n2.0 \\n1.9 \\n1.9 \\n1.5* \\n1.5 \\n1.3 \\n1.5 \\n0.8* \\nCRP (mg/dL) \\n3.9 \\n4.3 \\n4.6 \\n1.8* \\n1.0 \\n0.9 \\n1.0 \\n0.4* \\na 40 mg HUMIRA administered every other week \\nb Visual analogue scale; 0 = best, 10 = worst \\nc Disability Index of the Health Assessment Questionnaire; 0 = best, 3 = worst, measures the \\npatient’s ability to perform the following: dress/groom, arise, eat, walk, reach, grip, maintain \\nhygiene, and maintain daily activity \\n* p<0.001, HUMIRA vs. placebo, based on mean change from baseline  \\nThe time course of ACR 20 response for Study RA-III is shown in Figure 1.', ' \\nIn Study RA-III, 85% of patients with ACR 20 responses at week 24 maintained the response at \\n52 weeks.', 'The time course of ACR 20 response for Study RA-I and Study RA-II were similar.', ' \\n'], 'page_sentence_count_spacy': 6}\n",
            "{'page_number': 35, 'text': 'Figure 1. Study RA-III ACR 20 Responses over 52 Weeks \\n \\nIn Study RA-IV, 53% of patients treated with HUMIRA 40 mg every other week plus standard \\nof care had an ACR 20 response at week 24 compared to 35% on placebo plus standard of care \\n(p<0.001). No unique adverse reactions related to the combination of HUMIRA (adalimumab) \\nand other DMARDs were observed.  \\nIn Study RA-V with MTX naïve patients with recent onset RA, the combination treatment with \\nHUMIRA plus MTX led to greater percentages of patients achieving ACR responses than either \\nMTX monotherapy or HUMIRA monotherapy at Week 52 and responses were sustained at \\nWeek 104 (see Table 5).  \\nTable 5. ACR Response in Study RA-V (Percent of Patients) \\nResponse \\nMTXb \\nN=257 \\nHUMIRAc \\nN=274 \\nHUMIRA/MTX \\nN=268 \\nACR20 \\n    Week 52 \\n    Week 104  \\n \\n63% \\n56%  \\n \\n54% \\n49%  \\n \\n73% \\n69%  \\nACR50 \\n    Week 52 \\n    Week 104  \\n \\n46% \\n43%  \\n \\n41% \\n37%  \\n \\n62% \\n59%  \\nACR70 \\n    Week 52 \\n    Week 104  \\n \\n27% \\n28%  \\n \\n26% \\n28%  \\n \\n46% \\n47%  \\nMajor Clinical Response a \\n28% \\n25% \\n49% \\na Major clinical response is defined as achieving an ACR70 response for a continuous six month \\nperiod \\nb p<0.05, HUMIRA/MTX vs. MTX for ACR 20 \\np<0.001, HUMIRA/MTX vs. MTX for ACR 50 and 70, and Major Clinical Response \\nc p<0.001, HUMIRA/MTX vs. HUMIRA  \\n', 'processed_text': {'sentences': [{'original_sentence': 'Figure 1.', 'tokens': ['Figure', '1', '.'], 'lemmatized': ['Figure', '1', '.'], 'stemmed': ['figur', '1', '.'], 'dependencies': [('figur', 'ROOT'), ('1', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Study RA-III ACR 20 Responses over 52 Weeks \\n \\nIn Study RA-IV, 53% of patients treated with HUMIRA 40 mg every other week plus standard \\nof care had an ACR 20 response at week 24 compared to 35% on placebo plus standard of care \\n(p<0.001).', 'tokens': ['Study', 'RA-III', 'ACR', '20', 'Responses', '52', 'Weeks', 'Study', 'RA-IV', ',', '53', '%', 'patients', 'treated', 'HUMIRA', '40', 'mg', 'every', 'week', 'plus', 'standard', 'care', 'ACR', '20', 'response', 'week', '24', 'compared', '35', '%', 'placebo', 'plus', 'standard', 'care', '(', 'p', '<', '0.001', ')', '.'], 'lemmatized': ['Study', 'RA-III', 'ACR', '20', 'Responses', '52', 'Weeks', 'Study', 'RA-IV', ',', '53', '%', 'patient', 'treated', 'HUMIRA', '40', 'mg', 'every', 'week', 'plus', 'standard', 'care', 'ACR', '20', 'response', 'week', '24', 'compared', '35', '%', 'placebo', 'plus', 'standard', 'care', '(', 'p', '<', '0.001', ')', '.'], 'stemmed': ['studi', 'ra-iii', 'acr', '20', 'respons', '52', 'week', 'studi', 'ra-iv', ',', '53', '%', 'patient', 'treat', 'humira', '40', 'mg', 'everi', 'week', 'plu', 'standard', 'care', 'acr', '20', 'respons', 'week', '24', 'compar', '35', '%', 'placebo', 'plu', 'standard', 'care', '(', 'p', '<', '0.001', ')', '.'], 'dependencies': [('studi', 'compound'), ('ra', 'compound'), ('-', 'punct'), ('iii', 'nmod'), ('acr', 'nmod'), ('20', 'nummod'), ('respons', 'ROOT'), ('52', 'nummod'), ('week', 'npadvmod'), ('studi', 'compound'), ('ra', 'compound'), ('-', 'punct'), ('iv', 'nmod'), (',', 'punct'), ('53', 'nummod'), ('%', 'npadvmod'), ('patient', 'compound'), ('treat', 'compound'), ('humira', 'appos'), ('40', 'nummod'), ('mg', 'nmod'), ('everi', 'amod'), ('week', 'npadvmod'), ('plu', 'compound'), ('standard', 'compound'), ('care', 'appos'), ('acr', 'prep'), ('20', 'nummod'), ('respons', 'pobj'), ('week', 'npadvmod'), ('24', 'nummod'), ('compar', 'appos'), ('35', 'nummod'), ('%', 'compound'), ('placebo', 'compound'), ('plu', 'compound'), ('standard', 'compound'), ('care', 'conj'), ('(', 'punct'), ('p', 'appos'), ('<', 'dep'), ('0.001', 'nummod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'No unique adverse reactions related to the combination of HUMIRA (adalimumab) \\nand other DMARDs were observed.', 'tokens': ['unique', 'adverse', 'reactions', 'related', 'combination', 'HUMIRA', '(', 'adalimumab', ')', 'DMARDs', 'observed', '.'], 'lemmatized': ['unique', 'adverse', 'reaction', 'related', 'combination', 'HUMIRA', '(', 'adalimumab', ')', 'DMARDs', 'observed', '.'], 'stemmed': ['uniqu', 'advers', 'reaction', 'relat', 'combin', 'humira', '(', 'adalimumab', ')', 'dmard', 'observ', '.'], 'dependencies': [('uniqu', 'compound'), ('advers', 'compound'), ('reaction', 'compound'), ('relat', 'ROOT'), ('combin', 'compound'), ('humira', 'appos'), ('(', 'punct'), ('adalimumab', 'nmod'), (')', 'punct'), ('dmard', 'compound'), ('observ', 'appos'), ('.', 'punct')]}, {'original_sentence': 'In Study RA-V with MTX naïve patients with recent onset RA, the combination treatment with \\nHUMIRA plus MTX led to greater percentages of patients achieving ACR responses than either \\nMTX monotherapy or HUMIRA monotherapy at Week 52 and responses were sustained at \\nWeek 104 (see Table 5).', 'tokens': ['Study', 'RA-V', 'MTX', 'naïve', 'patients', 'recent', 'onset', 'RA', ',', 'combination', 'treatment', 'HUMIRA', 'plus', 'MTX', 'led', 'greater', 'percentages', 'patients', 'achieving', 'ACR', 'responses', 'either', 'MTX', 'monotherapy', 'HUMIRA', 'monotherapy', 'Week', '52', 'responses', 'sustained', 'Week', '104', '(', 'see', 'Table', '5', ')', '.'], 'lemmatized': ['Study', 'RA-V', 'MTX', 'naïve', 'patient', 'recent', 'onset', 'RA', ',', 'combination', 'treatment', 'HUMIRA', 'plus', 'MTX', 'led', 'greater', 'percentage', 'patient', 'achieving', 'ACR', 'response', 'either', 'MTX', 'monotherapy', 'HUMIRA', 'monotherapy', 'Week', '52', 'response', 'sustained', 'Week', '104', '(', 'see', 'Table', '5', ')', '.'], 'stemmed': ['studi', 'ra-v', 'mtx', 'naïv', 'patient', 'recent', 'onset', 'ra', ',', 'combin', 'treatment', 'humira', 'plu', 'mtx', 'led', 'greater', 'percentag', 'patient', 'achiev', 'acr', 'respons', 'either', 'mtx', 'monotherapi', 'humira', 'monotherapi', 'week', '52', 'respons', 'sustain', 'week', '104', '(', 'see', 'tabl', '5', ')', '.'], 'dependencies': [('studi', 'compound'), ('ra', 'nmod'), ('-', 'punct'), ('v', 'prep'), ('mtx', 'compound'), ('naïv', 'compound'), ('patient', 'dep'), ('recent', 'amod'), ('onset', 'compound'), ('ra', 'dobj'), (',', 'punct'), ('combin', 'nmod'), ('treatment', 'pobj'), ('humira', 'compound'), ('plu', 'compound'), ('mtx', 'nsubj'), ('led', 'ROOT'), ('greater', 'amod'), ('percentag', 'compound'), ('patient', 'compound'), ('achiev', 'dobj'), ('acr', 'prep'), ('respons', 'pobj'), ('either', 'preconj'), ('mtx', 'npadvmod'), ('monotherapi', 'compound'), ('humira', 'compound'), ('monotherapi', 'compound'), ('week', 'npadvmod'), ('52', 'nummod'), ('respons', 'nsubj'), ('sustain', 'advcl'), ('week', 'npadvmod'), ('104', 'nummod'), ('(', 'punct'), ('see', 'parataxis'), ('tabl', 'dobj'), ('5', 'nummod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Table 5.', 'tokens': ['Table', '5', '.'], 'lemmatized': ['Table', '5', '.'], 'stemmed': ['tabl', '5', '.'], 'dependencies': [('tabl', 'ROOT'), ('5', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'ACR Response in Study RA-V (Percent of Patients) \\nResponse \\nMTXb \\nN=257 \\nHUMIRAc \\nN=274 \\nHUMIRA/MTX \\nN=268 \\nACR20 \\n    Week 52 \\n    Week 104  \\n \\n63% \\n56%  \\n \\n54% \\n49%  \\n \\n73% \\n69%  \\nACR50 \\n    Week 52 \\n    Week 104  \\n \\n46% \\n43%  \\n \\n41% \\n37%  \\n \\n62% \\n59%  \\nACR70 \\n    Week 52 \\n    Week 104  \\n \\n27% \\n28%  \\n \\n26% \\n28%  \\n \\n46% \\n47%  \\nMajor Clinical Response a \\n28% \\n25% \\n49% \\na Major clinical response is defined as achieving an ACR70 response for a continuous six month \\nperiod \\nb p<0.05, HUMIRA/MTX vs. MTX for ACR 20 \\np<0.001, HUMIRA/MTX vs. MTX for ACR 50 and 70, and Major Clinical Response \\nc p<0.001, HUMIRA/MTX vs. HUMIRA', 'tokens': ['ACR', 'Response', 'Study', 'RA-V', '(', 'Percent', 'Patients', ')', 'Response', 'MTXb', 'N=257', 'HUMIRAc', 'N=274', 'HUMIRA/MTX', 'N=268', 'ACR20', 'Week', '52', 'Week', '104', '63', '%', '56', '%', '54', '%', '49', '%', '73', '%', '69', '%', 'ACR50', 'Week', '52', 'Week', '104', '46', '%', '43', '%', '41', '%', '37', '%', '62', '%', '59', '%', 'ACR70', 'Week', '52', 'Week', '104', '27', '%', '28', '%', '26', '%', '28', '%', '46', '%', '47', '%', 'Major', 'Clinical', 'Response', '28', '%', '25', '%', '49', '%', 'Major', 'clinical', 'response', 'defined', 'achieving', 'ACR70', 'response', 'continuous', 'six', 'month', 'period', 'b', 'p', '<', '0.05', ',', 'HUMIRA/MTX', 'vs.', 'MTX', 'ACR', '20', 'p', '<', '0.001', ',', 'HUMIRA/MTX', 'vs.', 'MTX', 'ACR', '50', '70', ',', 'Major', 'Clinical', 'Response', 'c', 'p', '<', '0.001', ',', 'HUMIRA/MTX', 'vs.', 'HUMIRA'], 'lemmatized': ['ACR', 'Response', 'Study', 'RA-V', '(', 'Percent', 'Patients', ')', 'Response', 'MTXb', 'N=257', 'HUMIRAc', 'N=274', 'HUMIRA/MTX', 'N=268', 'ACR20', 'Week', '52', 'Week', '104', '63', '%', '56', '%', '54', '%', '49', '%', '73', '%', '69', '%', 'ACR50', 'Week', '52', 'Week', '104', '46', '%', '43', '%', '41', '%', '37', '%', '62', '%', '59', '%', 'ACR70', 'Week', '52', 'Week', '104', '27', '%', '28', '%', '26', '%', '28', '%', '46', '%', '47', '%', 'Major', 'Clinical', 'Response', '28', '%', '25', '%', '49', '%', 'Major', 'clinical', 'response', 'defined', 'achieving', 'ACR70', 'response', 'continuous', 'six', 'month', 'period', 'b', 'p', '<', '0.05', ',', 'HUMIRA/MTX', 'vs.', 'MTX', 'ACR', '20', 'p', '<', '0.001', ',', 'HUMIRA/MTX', 'vs.', 'MTX', 'ACR', '50', '70', ',', 'Major', 'Clinical', 'Response', 'c', 'p', '<', '0.001', ',', 'HUMIRA/MTX', 'vs.', 'HUMIRA'], 'stemmed': ['acr', 'respons', 'studi', 'ra-v', '(', 'percent', 'patient', ')', 'respons', 'mtxb', 'n=257', 'humirac', 'n=274', 'humira/mtx', 'n=268', 'acr20', 'week', '52', 'week', '104', '63', '%', '56', '%', '54', '%', '49', '%', '73', '%', '69', '%', 'acr50', 'week', '52', 'week', '104', '46', '%', '43', '%', '41', '%', '37', '%', '62', '%', '59', '%', 'acr70', 'week', '52', 'week', '104', '27', '%', '28', '%', '26', '%', '28', '%', '46', '%', '47', '%', 'major', 'clinic', 'respons', '28', '%', '25', '%', '49', '%', 'major', 'clinic', 'respons', 'defin', 'achiev', 'acr70', 'respons', 'continu', 'six', 'month', 'period', 'b', 'p', '<', '0.05', ',', 'humira/mtx', 'vs.', 'mtx', 'acr', '20', 'p', '<', '0.001', ',', 'humira/mtx', 'vs.', 'mtx', 'acr', '50', '70', ',', 'major', 'clinic', 'respons', 'c', 'p', '<', '0.001', ',', 'humira/mtx', 'vs.', 'humira'], 'dependencies': [('acr', 'prep'), ('respons', 'pobj'), ('studi', 'compound'), ('ra', 'appos'), ('-', 'punct'), ('v', 'prep'), ('(', 'punct'), ('percent', 'npadvmod'), ('patient', 'parataxis'), (')', 'punct'), ('respons', 'nsubj'), ('mtxb', 'dep'), ('n=257', 'nsubj'), ('humirac', 'ccomp'), ('n=274', 'nummod'), ('humira', 'nmod'), ('/', 'punct'), ('mtx', 'compound'), ('n=268', 'dobj'), ('acr20', 'compound'), ('week', 'npadvmod'), ('52', 'nummod'), ('week', 'appos'), ('104', 'nummod'), ('63', 'nummod'), ('%', 'appos'), ('56', 'nummod'), ('%', 'appos'), ('54', 'nummod'), ('%', 'appos'), ('49', 'nummod'), ('%', 'appos'), ('73', 'nummod'), ('%', 'appos'), ('69', 'nummod'), ('%', 'appos'), ('acr50', 'amod'), ('week', 'appos'), ('52', 'nummod'), ('week', 'appos'), ('104', 'compound'), ('46', 'nummod'), ('%', 'appos'), ('43', 'nummod'), ('%', 'appos'), ('41', 'nummod'), ('%', 'appos'), ('37', 'nummod'), ('%', 'appos'), ('62', 'nummod'), ('%', 'appos'), ('59', 'nummod'), ('%', 'appos'), ('acr70', 'cc'), ('week', 'pobj'), ('52', 'nummod'), ('week', 'appos'), ('104', 'compound'), ('27', 'nummod'), ('%', 'appos'), ('28', 'nummod'), ('%', 'appos'), ('26', 'nummod'), ('%', 'appos'), ('28', 'nummod'), ('%', 'appos'), ('46', 'nummod'), ('%', 'appos'), ('47', 'nummod'), ('%', 'appos'), ('major', 'amod'), ('clinic', 'compound'), ('respons', 'appos'), ('28', 'nummod'), ('%', 'appos'), ('25', 'nummod'), ('%', 'appos'), ('49', 'nummod'), ('%', 'appos'), ('major', 'amod'), ('clinic', 'compound'), ('respons', 'compound'), ('defin', 'advmod'), ('achiev', 'appos'), ('acr70', 'cc'), ('respons', 'compound'), ('continu', 'conj'), ('six', 'nummod'), ('month', 'compound'), ('period', 'npadvmod'), ('b', 'compound'), ('p', 'nmod'), ('<', 'nmod'), ('0.05', 'nummod'), (',', 'punct'), ('humira', 'nmod'), ('/', 'punct'), ('mtx', 'dep'), ('vs.', 'prep'), ('mtx', 'pobj'), ('acr', 'prep'), ('20', 'nummod'), ('p', 'pobj'), ('<', 'dep'), ('0.001', 'nummod'), (',', 'punct'), ('humira', 'nmod'), ('/', 'punct'), ('mtx', 'advcl'), ('vs.', 'prep'), ('mtx', 'pobj'), ('acr', 'prep'), ('50', 'compound'), ('70', 'pobj'), (',', 'punct'), ('major', 'amod'), ('clinic', 'compound'), ('respons', 'nmod'), ('c', 'compound'), ('p', 'nmod'), ('<', 'nmod'), ('0.001', 'appos'), (',', 'punct'), ('humira', 'nmod'), ('/', 'punct'), ('mtx', 'ROOT'), ('vs.', 'prep'), ('humira', 'pobj')]}], 'text': 'Figure 1. Study RA-III ACR 20 Responses over 52 Weeks \\n \\nIn Study RA-IV, 53% of patients treated with HUMIRA 40 mg every other week plus standard \\nof care had an ACR 20 response at week 24 compared to 35% on placebo plus standard of care \\n(p<0.001). No unique adverse reactions related to the combination of HUMIRA (adalimumab) \\nand other DMARDs were observed.  \\nIn Study RA-V with MTX naïve patients with recent onset RA, the combination treatment with \\nHUMIRA plus MTX led to greater percentages of patients achieving ACR responses than either \\nMTX monotherapy or HUMIRA monotherapy at Week 52 and responses were sustained at \\nWeek 104 (see Table 5).  \\nTable 5. ACR Response in Study RA-V (Percent of Patients) \\nResponse \\nMTXb \\nN=257 \\nHUMIRAc \\nN=274 \\nHUMIRA/MTX \\nN=268 \\nACR20 \\n    Week 52 \\n    Week 104  \\n \\n63% \\n56%  \\n \\n54% \\n49%  \\n \\n73% \\n69%  \\nACR50 \\n    Week 52 \\n    Week 104  \\n \\n46% \\n43%  \\n \\n41% \\n37%  \\n \\n62% \\n59%  \\nACR70 \\n    Week 52 \\n    Week 104  \\n \\n27% \\n28%  \\n \\n26% \\n28%  \\n \\n46% \\n47%  \\nMajor Clinical Response a \\n28% \\n25% \\n49% \\na Major clinical response is defined as achieving an ACR70 response for a continuous six month \\nperiod \\nb p<0.05, HUMIRA/MTX vs. MTX for ACR 20 \\np<0.001, HUMIRA/MTX vs. MTX for ACR 50 and 70, and Major Clinical Response \\nc p<0.001, HUMIRA/MTX vs. HUMIRA  \\n'}, 'page_char_count': 1292, 'page_word_count': 209, 'sentences': ['Figure 1.', 'Study RA-III ACR 20 Responses over 52 Weeks \\n \\nIn Study RA-IV, 53% of patients treated with HUMIRA 40 mg every other week plus standard \\nof care had an ACR 20 response at week 24 compared to 35% on placebo plus standard of care \\n(p<0.001).', 'No unique adverse reactions related to the combination of HUMIRA (adalimumab) \\nand other DMARDs were observed.', ' \\nIn Study RA-V with MTX naïve patients with recent onset RA, the combination treatment with \\nHUMIRA plus MTX led to greater percentages of patients achieving ACR responses than either \\nMTX monotherapy or HUMIRA monotherapy at Week 52 and responses were sustained at \\nWeek 104 (see Table 5).', ' \\nTable 5.', 'ACR Response in Study RA-V (Percent of Patients) \\nResponse \\nMTXb \\nN=257 \\nHUMIRAc \\nN=274 \\nHUMIRA/MTX \\nN=268 \\nACR20 \\n    Week 52 \\n    Week 104  \\n \\n63% \\n56%  \\n \\n54% \\n49%  \\n \\n73% \\n69%  \\nACR50 \\n    Week 52 \\n    Week 104  \\n \\n46% \\n43%  \\n \\n41% \\n37%  \\n \\n62% \\n59%  \\nACR70 \\n    Week 52 \\n    Week 104  \\n \\n27% \\n28%  \\n \\n26% \\n28%  \\n \\n46% \\n47%  \\nMajor Clinical Response a \\n28% \\n25% \\n49% \\na Major clinical response is defined as achieving an ACR70 response for a continuous six month \\nperiod \\nb p<0.05, HUMIRA/MTX vs. MTX for ACR 20 \\np<0.001, HUMIRA/MTX vs. MTX for ACR 50 and 70, and Major Clinical Response \\nc p<0.001, HUMIRA/MTX vs. HUMIRA  \\n'], 'page_sentence_count_spacy': 6}\n",
            "{'page_number': 36, 'text': 'At Week 52, all individual components of the ACR response criteria for Study RA-V improved \\nin the HUMIRA/MTX group and improvements were maintained to Week 104.  \\nRadiographic Response \\nIn Study RA-III, structural joint damage was assessed radiographically and expressed as change \\nin Total Sharp Score (TSS) and its components, the erosion score and Joint Space Narrowing \\n(JSN) score, at month 12 compared to baseline. At baseline, the median TSS was approximately \\n55 in the placebo and 40 mg every other week groups. The results are shown in Table 6. \\nHUMIRA/MTX treated patients demonstrated less radiographic progression than patients \\nreceiving MTX alone at 52 weeks.  \\nTable 6. Radiographic Mean Changes Over 12 Months in Study RA-III \\n  \\nPlacebo/MTX HUMIRA/MTX \\n40 mg every \\nother week  \\nPlacebo/MTX- \\nHUMIRA/MTX (95% Confidence \\nInterval*)  \\nP-value** \\nTotal Sharp score \\n2.7 \\n0.1 \\n2.6 (1.4, 3.8) \\n<0.001 \\nErosion score \\n1.6 \\n0.0 \\n1.6 (0.9, 2.2) \\n<0.001 \\nJSN score \\n1.0 \\n0.1 \\n0.9 (0.3, 1.4) \\n0.002 \\n*95% confidence intervals for the differences in change scores between MTX and HUMIRA.  \\n**Based on rank analysis  \\nIn the open-label extension of Study RA-III, 77% of the original patients treated with any dose of \\nHUMIRA were evaluated radiographically at 2 years. Patients maintained inhibition of structural \\ndamage, as measured by the TSS. Fifty-four percent had no progression of structural damage as \\ndefined by a change in the TSS of zero or less. Fifty-five percent (55%) of patients originally \\ntreated with 40 mg HUMIRA every other week have been evaluated radiographically at 5 years. \\nPatients had continued inhibition of structural damage with 50% showing no progression of \\nstructural damage defined by a change in the TSS of zero or less.  \\nIn Study RA-V, structural joint damage was assessed as in Study RA-III. Greater inhibition of \\nradiographic progression, as assessed by changes in TSS, erosion score and JSN was observed in \\nthe HUMIRA/MTX combination group as compared to either the MTX or HUMIRA \\nmonotherapy group at Week 52 as well as at Week 104 (see Table 7).  \\nTable 7.  Radiographic Mean Change* in Study RA-V \\n  \\n  \\nMTXa \\nN=257 \\nHUMIRAa,b \\nN=274 \\nHUMIRA/MTX \\nN=268 \\n52 Weeks \\nTotal Sharp score \\n5.7 (4.2, 7.3) \\n3.0 (1.7, 4.3) \\n1.3 (0.5, 2.1) \\n  \\nErosion score \\n3.7 (2.7, 4.8) \\n1.7 (1.0, 2.4) \\n0.8 (0.4, 1.2) \\n  \\nJSN score \\n2.0 (1.2, 2.8) \\n1.3 (0.5, 2.1) \\n0.5 (0.0, 1.0) \\n104 Weeks \\nTotal Sharp score \\n10.4 (7.7, 13.2) \\n5.5 (3.6, 7.4) \\n1.9 (0.9, 2.9) \\n  \\nErosion score \\n6.4 (4.6, 8.2) \\n3.0 (2.0, 4.0) \\n1.0 (0.4, 1.6) \\n  \\nJSN score \\n4.1 (2.7, 5.4) \\n2.6 (1.5, 3.7) \\n0.9 (0.3, 1.5) \\n', 'processed_text': {'sentences': [{'original_sentence': 'At Week 52, all individual components of the ACR response criteria for Study RA-V improved \\nin the HUMIRA/MTX group and improvements were maintained to Week 104.', 'tokens': ['Week', '52', ',', 'individual', 'components', 'ACR', 'response', 'criteria', 'Study', 'RA-V', 'improved', 'HUMIRA/MTX', 'group', 'improvements', 'maintained', 'Week', '104', '.'], 'lemmatized': ['Week', '52', ',', 'individual', 'component', 'ACR', 'response', 'criterion', 'Study', 'RA-V', 'improved', 'HUMIRA/MTX', 'group', 'improvement', 'maintained', 'Week', '104', '.'], 'stemmed': ['week', '52', ',', 'individu', 'compon', 'acr', 'respons', 'criterion', 'studi', 'ra-v', 'improv', 'humira/mtx', 'group', 'improv', 'maintain', 'week', '104', '.'], 'dependencies': [('week', 'npadvmod'), ('52', 'nummod'), (',', 'punct'), ('individu', 'amod'), ('compon', 'nsubj'), ('acr', 'prt'), ('respons', 'compound'), ('criterion', 'appos'), ('studi', 'compound'), ('ra', 'appos'), ('-', 'punct'), ('v', 'prep'), ('improv', 'compound'), ('humira', 'nmod'), ('/', 'punct'), ('mtx', 'compound'), ('group', 'appos'), ('improv', 'advmod'), ('maintain', 'ROOT'), ('week', 'npadvmod'), ('104', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Radiographic Response \\nIn Study RA-III, structural joint damage was assessed radiographically and expressed as change \\nin Total Sharp Score (TSS) and its components, the erosion score and Joint Space Narrowing \\n(JSN) score, at month 12 compared to baseline.', 'tokens': ['Radiographic', 'Response', 'Study', 'RA-III', ',', 'structural', 'joint', 'damage', 'assessed', 'radiographically', 'expressed', 'change', 'Total', 'Sharp', 'Score', '(', 'TSS', ')', 'components', ',', 'erosion', 'score', 'Joint', 'Space', 'Narrowing', '(', 'JSN', ')', 'score', ',', 'month', '12', 'compared', 'baseline', '.'], 'lemmatized': ['Radiographic', 'Response', 'Study', 'RA-III', ',', 'structural', 'joint', 'damage', 'assessed', 'radiographically', 'expressed', 'change', 'Total', 'Sharp', 'Score', '(', 'TSS', ')', 'component', ',', 'erosion', 'score', 'Joint', 'Space', 'Narrowing', '(', 'JSN', ')', 'score', ',', 'month', '12', 'compared', 'baseline', '.'], 'stemmed': ['radiograph', 'respons', 'studi', 'ra-iii', ',', 'structur', 'joint', 'damag', 'assess', 'radiograph', 'express', 'chang', 'total', 'sharp', 'score', '(', 'tss', ')', 'compon', ',', 'eros', 'score', 'joint', 'space', 'narrow', '(', 'jsn', ')', 'score', ',', 'month', '12', 'compar', 'baselin', '.'], 'dependencies': [('radiograph', 'compound'), ('respons', 'ccomp'), ('studi', 'compound'), ('ra', 'compound'), ('-', 'punct'), ('iii', 'appos'), (',', 'punct'), ('structur', 'nmod'), ('joint', 'amod'), ('damag', 'compound'), ('assess', 'compound'), ('radiograph', 'compound'), ('express', 'compound'), ('chang', 'compound'), ('total', 'amod'), ('sharp', 'amod'), ('score', 'appos'), ('(', 'punct'), ('tss', 'appos'), (')', 'punct'), ('compon', 'appos'), (',', 'punct'), ('eros', 'nsubj'), ('score', 'ROOT'), ('joint', 'amod'), ('space', 'npadvmod'), ('narrow', 'amod'), ('(', 'punct'), ('jsn', 'nmod'), (')', 'punct'), ('score', 'dobj'), (',', 'punct'), ('month', 'nmod'), ('12', 'nummod'), ('compar', 'compound'), ('baselin', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'At baseline, the median TSS was approximately \\n55 in the placebo and 40 mg every other week groups.', 'tokens': ['baseline', ',', 'median', 'TSS', 'approximately', '55', 'placebo', '40', 'mg', 'every', 'week', 'groups', '.'], 'lemmatized': ['baseline', ',', 'median', 'TSS', 'approximately', '55', 'placebo', '40', 'mg', 'every', 'week', 'group', '.'], 'stemmed': ['baselin', ',', 'median', 'tss', 'approxim', '55', 'placebo', '40', 'mg', 'everi', 'week', 'group', '.'], 'dependencies': [('baselin', 'ROOT'), (',', 'punct'), ('median', 'compound'), ('tss', 'compound'), ('approxim', 'nmod'), ('55', 'nummod'), ('placebo', 'nmod'), ('40', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'compound'), ('group', 'appos'), ('.', 'punct')]}, {'original_sentence': 'The results are shown in Table 6.', 'tokens': ['results', 'shown', 'Table', '6', '.'], 'lemmatized': ['result', 'shown', 'Table', '6', '.'], 'stemmed': ['result', 'shown', 'tabl', '6', '.'], 'dependencies': [('result', 'nsubj'), ('shown', 'ROOT'), ('tabl', 'dobj'), ('6', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'HUMIRA/MTX treated patients demonstrated less radiographic progression than patients \\nreceiving MTX alone at 52 weeks.', 'tokens': ['HUMIRA/MTX', 'treated', 'patients', 'demonstrated', 'less', 'radiographic', 'progression', 'patients', 'receiving', 'MTX', 'alone', '52', 'weeks', '.'], 'lemmatized': ['HUMIRA/MTX', 'treated', 'patient', 'demonstrated', 'less', 'radiographic', 'progression', 'patient', 'receiving', 'MTX', 'alone', '52', 'week', '.'], 'stemmed': ['humira/mtx', 'treat', 'patient', 'demonstr', 'less', 'radiograph', 'progress', 'patient', 'receiv', 'mtx', 'alon', '52', 'week', '.'], 'dependencies': [('humira', 'nmod'), ('/', 'punct'), ('mtx', 'nmod'), ('treat', 'compound'), ('patient', 'compound'), ('demonstr', 'nmod'), ('less', 'amod'), ('radiograph', 'compound'), ('progress', 'appos'), ('patient', 'compound'), ('receiv', 'compound'), ('mtx', 'compound'), ('alon', 'ROOT'), ('52', 'nummod'), ('week', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Table 6.', 'tokens': ['Table', '6', '.'], 'lemmatized': ['Table', '6', '.'], 'stemmed': ['tabl', '6', '.'], 'dependencies': [('tabl', 'ROOT'), ('6', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Radiographic Mean Changes Over 12 Months in Study RA-III \\n  \\nPlacebo/MTX HUMIRA/MTX \\n40 mg every \\nother week  \\nPlacebo/MTX- \\nHUMIRA/MTX (95% Confidence \\nInterval*)  \\nP-value** \\nTotal Sharp score \\n2.7 \\n0.1 \\n2.6 (1.4, 3.8) \\n<0.001 \\nErosion score \\n1.6 \\n0.0 \\n1.6 (0.9, 2.2) \\n<0.001 \\nJSN score \\n1.0 \\n0.1 \\n0.9 (0.3, 1.4) \\n0.002 \\n*95% confidence intervals for the differences in change scores between MTX and HUMIRA.', 'tokens': ['Radiographic', 'Mean', 'Changes', '12', 'Months', 'Study', 'RA-III', 'Placebo/MTX', 'HUMIRA/MTX', '40', 'mg', 'every', 'week', 'Placebo/MTX-', 'HUMIRA/MTX', '(', '95', '%', 'Confidence', 'Interval', '*', ')', 'P-value', '*', '*', 'Total', 'Sharp', 'score', '2.7', '0.1', '2.6', '(', '1.4', ',', '3.8', ')', '<', '0.001', 'Erosion', 'score', '1.6', '0.0', '1.6', '(', '0.9', ',', '2.2', ')', '<', '0.001', 'JSN', 'score', '1.0', '0.1', '0.9', '(', '0.3', ',', '1.4', ')', '0.002', '*', '95', '%', 'confidence', 'intervals', 'differences', 'change', 'scores', 'MTX', 'HUMIRA', '.'], 'lemmatized': ['Radiographic', 'Mean', 'Changes', '12', 'Months', 'Study', 'RA-III', 'Placebo/MTX', 'HUMIRA/MTX', '40', 'mg', 'every', 'week', 'Placebo/MTX-', 'HUMIRA/MTX', '(', '95', '%', 'Confidence', 'Interval', '*', ')', 'P-value', '*', '*', 'Total', 'Sharp', 'score', '2.7', '0.1', '2.6', '(', '1.4', ',', '3.8', ')', '<', '0.001', 'Erosion', 'score', '1.6', '0.0', '1.6', '(', '0.9', ',', '2.2', ')', '<', '0.001', 'JSN', 'score', '1.0', '0.1', '0.9', '(', '0.3', ',', '1.4', ')', '0.002', '*', '95', '%', 'confidence', 'interval', 'difference', 'change', 'score', 'MTX', 'HUMIRA', '.'], 'stemmed': ['radiograph', 'mean', 'chang', '12', 'month', 'studi', 'ra-iii', 'placebo/mtx', 'humira/mtx', '40', 'mg', 'everi', 'week', 'placebo/mtx-', 'humira/mtx', '(', '95', '%', 'confid', 'interv', '*', ')', 'p-valu', '*', '*', 'total', 'sharp', 'score', '2.7', '0.1', '2.6', '(', '1.4', ',', '3.8', ')', '<', '0.001', 'eros', 'score', '1.6', '0.0', '1.6', '(', '0.9', ',', '2.2', ')', '<', '0.001', 'jsn', 'score', '1.0', '0.1', '0.9', '(', '0.3', ',', '1.4', ')', '0.002', '*', '95', '%', 'confid', 'interv', 'differ', 'chang', 'score', 'mtx', 'humira', '.'], 'dependencies': [('radiograph', 'compound'), ('mean', 'compound'), ('chang', 'ROOT'), ('12', 'nummod'), ('month', 'npadvmod'), ('studi', 'compound'), ('ra', 'compound'), ('-', 'punct'), ('iii', 'nsubj'), ('placebo', 'nmod'), ('/', 'punct'), ('mtx', 'compound'), ('humira', 'nmod'), ('/', 'punct'), ('mtx', 'ROOT'), ('40', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'compound'), ('placebo', 'nmod'), ('/', 'punct'), ('mtx-', 'punct'), ('humira', 'nmod'), ('/', 'punct'), ('mtx', 'nmod'), ('(', 'punct'), ('95', 'nummod'), ('%', 'appos'), ('confid', 'amod'), ('interv', 'dep'), ('*', 'punct'), (')', 'punct'), ('p', 'compound'), ('-', 'punct'), ('valu', 'ROOT'), ('*', 'punct'), ('*', 'punct'), ('total', 'amod'), ('sharp', 'amod'), ('score', 'ROOT'), ('2.7', 'compound'), ('0.1', 'nummod'), ('2.6', 'npadvmod'), ('(', 'punct'), ('1.4', 'appos'), (',', 'punct'), ('3.8', 'appos'), (')', 'punct'), ('<', 'nmod'), ('0.001', 'nummod'), ('eros', 'compound'), ('score', 'ROOT'), ('1.6', 'compound'), ('0.0', 'compound'), ('1.6', 'npadvmod'), ('(', 'punct'), ('0.9', 'appos'), (',', 'punct'), ('2.2', 'appos'), (')', 'punct'), ('<', 'nmod'), ('0.001', 'nummod'), ('jsn', 'compound'), ('score', 'conj'), ('1.0', 'compound'), ('0.1', 'nummod'), ('0.9', 'npadvmod'), ('(', 'punct'), ('0.3', 'appos'), (',', 'punct'), ('1.4', 'npadvmod'), (')', 'punct'), ('0.002', 'npadvmod'), ('*', 'punct'), ('95', 'nummod'), ('%', 'nsubj'), ('confid', 'amod'), ('interv', 'nsubj'), ('differ', 'ROOT'), ('chang', 'compound'), ('score', 'nsubj'), ('mtx', 'ccomp'), ('humira', 'dobj'), ('.', 'punct')]}, {'original_sentence': '**Based on rank analysis  \\nIn the open-label extension of Study RA-III, 77% of the original patients treated with any dose of \\nHUMIRA were evaluated radiographically at 2 years.', 'tokens': ['*', '*', 'Based', 'rank', 'analysis', 'open-label', 'extension', 'Study', 'RA-III', ',', '77', '%', 'original', 'patients', 'treated', 'dose', 'HUMIRA', 'evaluated', 'radiographically', '2', 'years', '.'], 'lemmatized': ['*', '*', 'Based', 'rank', 'analysis', 'open-label', 'extension', 'Study', 'RA-III', ',', '77', '%', 'original', 'patient', 'treated', 'dose', 'HUMIRA', 'evaluated', 'radiographically', '2', 'year', '.'], 'stemmed': ['*', '*', 'base', 'rank', 'analysi', 'open-label', 'extens', 'studi', 'ra-iii', ',', '77', '%', 'origin', 'patient', 'treat', 'dose', 'humira', 'evalu', 'radiograph', '2', 'year', '.'], 'dependencies': [('*', 'punct'), ('*', 'punct'), ('base', 'compound'), ('rank', 'nmod'), ('analysi', 'compound'), ('open', 'amod'), ('-', 'punct'), ('label', 'compound'), ('extens', 'ROOT'), ('studi', 'compound'), ('ra', 'compound'), ('-', 'punct'), ('iii', 'appos'), (',', 'punct'), ('77', 'nummod'), ('%', 'compound'), ('origin', 'compound'), ('patient', 'compound'), ('treat', 'compound'), ('dose', 'compound'), ('humira', 'compound'), ('evalu', 'compound'), ('radiograph', 'appos'), ('2', 'nummod'), ('year', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Patients maintained inhibition of structural \\ndamage, as measured by the TSS.', 'tokens': ['Patients', 'maintained', 'inhibition', 'structural', 'damage', ',', 'measured', 'TSS', '.'], 'lemmatized': ['Patients', 'maintained', 'inhibition', 'structural', 'damage', ',', 'measured', 'TSS', '.'], 'stemmed': ['patient', 'maintain', 'inhibit', 'structur', 'damag', ',', 'measur', 'tss', '.'], 'dependencies': [('patient', 'nsubj'), ('maintain', 'ROOT'), ('inhibit', 'compound'), ('structur', 'dobj'), ('damag', 'acl'), (',', 'punct'), ('measur', 'compound'), ('tss', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Fifty-four percent had no progression of structural damage as \\ndefined by a change in the TSS of zero or less.', 'tokens': ['Fifty-four', 'percent', 'progression', 'structural', 'damage', 'defined', 'change', 'TSS', 'zero', 'less', '.'], 'lemmatized': ['Fifty-four', 'percent', 'progression', 'structural', 'damage', 'defined', 'change', 'TSS', 'zero', 'less', '.'], 'stemmed': ['fifty-four', 'percent', 'progress', 'structur', 'damag', 'defin', 'chang', 'tss', 'zero', 'less', '.'], 'dependencies': [('fifty', 'compound'), ('-', 'punct'), ('four', 'nummod'), ('percent', 'compound'), ('progress', 'compound'), ('structur', 'nsubj'), ('damag', 'dep'), ('defin', 'compound'), ('chang', 'compound'), ('tss', 'ROOT'), ('zero', 'nummod'), ('less', 'advmod'), ('.', 'punct')]}, {'original_sentence': 'Fifty-five percent (55%) of patients originally \\ntreated with 40 mg HUMIRA every other week have been evaluated radiographically at 5 years.', 'tokens': ['Fifty-five', 'percent', '(', '55', '%', ')', 'patients', 'originally', 'treated', '40', 'mg', 'HUMIRA', 'every', 'week', 'evaluated', 'radiographically', '5', 'years', '.'], 'lemmatized': ['Fifty-five', 'percent', '(', '55', '%', ')', 'patient', 'originally', 'treated', '40', 'mg', 'HUMIRA', 'every', 'week', 'evaluated', 'radiographically', '5', 'year', '.'], 'stemmed': ['fifty-f', 'percent', '(', '55', '%', ')', 'patient', 'origin', 'treat', '40', 'mg', 'humira', 'everi', 'week', 'evalu', 'radiograph', '5', 'year', '.'], 'dependencies': [('fifty', 'compound'), ('-', 'punct'), ('f', 'compound'), ('percent', 'nsubj'), ('(', 'punct'), ('55', 'nummod'), ('%', 'appos'), (')', 'punct'), ('patient', 'amod'), ('origin', 'nsubj'), ('treat', 'ROOT'), ('40', 'npadvmod'), ('mg', 'prep'), ('humira', 'nmod'), ('everi', 'compound'), ('week', 'compound'), ('evalu', 'compound'), ('radiograph', 'pobj'), ('5', 'nummod'), ('year', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Patients had continued inhibition of structural damage with 50% showing no progression of \\nstructural damage defined by a change in the TSS of zero or less.', 'tokens': ['Patients', 'continued', 'inhibition', 'structural', 'damage', '50', '%', 'showing', 'progression', 'structural', 'damage', 'defined', 'change', 'TSS', 'zero', 'less', '.'], 'lemmatized': ['Patients', 'continued', 'inhibition', 'structural', 'damage', '50', '%', 'showing', 'progression', 'structural', 'damage', 'defined', 'change', 'TSS', 'zero', 'less', '.'], 'stemmed': ['patient', 'continu', 'inhibit', 'structur', 'damag', '50', '%', 'show', 'progress', 'structur', 'damag', 'defin', 'chang', 'tss', 'zero', 'less', '.'], 'dependencies': [('patient', 'compound'), ('continu', 'compound'), ('inhibit', 'compound'), ('structur', 'nsubj'), ('damag', 'ROOT'), ('50', 'nummod'), ('%', 'compound'), ('show', 'compound'), ('progress', 'compound'), ('structur', 'nsubj'), ('damag', 'compound'), ('defin', 'compound'), ('chang', 'compound'), ('tss', 'ccomp'), ('zero', 'dobj'), ('less', 'advmod'), ('.', 'punct')]}, {'original_sentence': 'In Study RA-V, structural joint damage was assessed as in Study RA-III.', 'tokens': ['Study', 'RA-V', ',', 'structural', 'joint', 'damage', 'assessed', 'Study', 'RA-III', '.'], 'lemmatized': ['Study', 'RA-V', ',', 'structural', 'joint', 'damage', 'assessed', 'Study', 'RA-III', '.'], 'stemmed': ['studi', 'ra-v', ',', 'structur', 'joint', 'damag', 'assess', 'studi', 'ra-iii', '.'], 'dependencies': [('studi', 'compound'), ('ra', 'compound'), ('-', 'punct'), ('v', 'ROOT'), (',', 'punct'), ('structur', 'nmod'), ('joint', 'amod'), ('damag', 'compound'), ('assess', 'compound'), ('studi', 'compound'), ('ra', 'compound'), ('-', 'punct'), ('iii', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Greater inhibition of \\nradiographic progression, as assessed by changes in TSS, erosion score and JSN was observed in \\nthe HUMIRA/MTX combination group as compared to either the MTX or HUMIRA \\nmonotherapy group at Week 52 as well as at Week 104 (see Table 7).', 'tokens': ['Greater', 'inhibition', 'radiographic', 'progression', ',', 'assessed', 'changes', 'TSS', ',', 'erosion', 'score', 'JSN', 'observed', 'HUMIRA/MTX', 'combination', 'group', 'compared', 'either', 'MTX', 'HUMIRA', 'monotherapy', 'group', 'Week', '52', 'well', 'Week', '104', '(', 'see', 'Table', '7', ')', '.'], 'lemmatized': ['Greater', 'inhibition', 'radiographic', 'progression', ',', 'assessed', 'change', 'TSS', ',', 'erosion', 'score', 'JSN', 'observed', 'HUMIRA/MTX', 'combination', 'group', 'compared', 'either', 'MTX', 'HUMIRA', 'monotherapy', 'group', 'Week', '52', 'well', 'Week', '104', '(', 'see', 'Table', '7', ')', '.'], 'stemmed': ['greater', 'inhibit', 'radiograph', 'progress', ',', 'assess', 'chang', 'tss', ',', 'eros', 'score', 'jsn', 'observ', 'humira/mtx', 'combin', 'group', 'compar', 'either', 'mtx', 'humira', 'monotherapi', 'group', 'week', '52', 'well', 'week', '104', '(', 'see', 'tabl', '7', ')', '.'], 'dependencies': [('greater', 'amod'), ('inhibit', 'compound'), ('radiograph', 'compound'), ('progress', 'nsubj'), (',', 'punct'), ('assess', 'ROOT'), ('chang', 'compound'), ('tss', 'dobj'), (',', 'punct'), ('eros', 'compound'), ('score', 'compound'), ('jsn', 'compound'), ('observ', 'nmod'), ('humira', 'nmod'), ('/', 'punct'), ('mtx', 'compound'), ('combin', 'compound'), ('group', 'compound'), ('compar', 'dobj'), ('either', 'preconj'), ('mtx', 'compound'), ('humira', 'compound'), ('monotherapi', 'compound'), ('group', 'compound'), ('week', 'npadvmod'), ('52', 'nummod'), ('well', 'compound'), ('week', 'npadvmod'), ('104', 'ROOT'), ('(', 'punct'), ('see', 'parataxis'), ('tabl', 'dobj'), ('7', 'nummod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Table 7.', 'tokens': ['Table', '7', '.'], 'lemmatized': ['Table', '7', '.'], 'stemmed': ['tabl', '7', '.'], 'dependencies': [('tabl', 'ROOT'), ('7', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Radiographic Mean Change* in Study RA-V \\n  \\n  \\nMTXa \\nN=257 \\nHUMIRAa,b \\nN=274 \\nHUMIRA/MTX \\nN=268 \\n52 Weeks \\nTotal Sharp score \\n5.7 (4.2, 7.3) \\n3.0 (1.7, 4.3) \\n1.3 (0.5, 2.1) \\n  \\nErosion score \\n3.7 (2.7, 4.8) \\n1.7 (1.0, 2.4) \\n0.8 (0.4, 1.2) \\n  \\nJSN score \\n2.0 (1.2, 2.8) \\n1.3 (0.5, 2.1) \\n0.5 (0.0, 1.0) \\n104 Weeks \\nTotal Sharp score \\n10.4 (7.7, 13.2) \\n5.5 (3.6, 7.4) \\n1.9 (0.9, 2.9) \\n  \\nErosion score \\n6.4 (4.6, 8.2) \\n3.0 (2.0, 4.0) \\n1.0 (0.4, 1.6) \\n  \\nJSN score \\n4.1 (2.7, 5.4) \\n2.6 (1.5, 3.7) \\n0.9 (0.3, 1.5)', 'tokens': ['Radiographic', 'Mean', 'Change', '*', 'Study', 'RA-V', 'MTXa', 'N=257', 'HUMIRAa', ',', 'b', 'N=274', 'HUMIRA/MTX', 'N=268', '52', 'Weeks', 'Total', 'Sharp', 'score', '5.7', '(', '4.2', ',', '7.3', ')', '3.0', '(', '1.7', ',', '4.3', ')', '1.3', '(', '0.5', ',', '2.1', ')', 'Erosion', 'score', '3.7', '(', '2.7', ',', '4.8', ')', '1.7', '(', '1.0', ',', '2.4', ')', '0.8', '(', '0.4', ',', '1.2', ')', 'JSN', 'score', '2.0', '(', '1.2', ',', '2.8', ')', '1.3', '(', '0.5', ',', '2.1', ')', '0.5', '(', '0.0', ',', '1.0', ')', '104', 'Weeks', 'Total', 'Sharp', 'score', '10.4', '(', '7.7', ',', '13.2', ')', '5.5', '(', '3.6', ',', '7.4', ')', '1.9', '(', '0.9', ',', '2.9', ')', 'Erosion', 'score', '6.4', '(', '4.6', ',', '8.2', ')', '3.0', '(', '2.0', ',', '4.0', ')', '1.0', '(', '0.4', ',', '1.6', ')', 'JSN', 'score', '4.1', '(', '2.7', ',', '5.4', ')', '2.6', '(', '1.5', ',', '3.7', ')', '0.9', '(', '0.3', ',', '1.5', ')'], 'lemmatized': ['Radiographic', 'Mean', 'Change', '*', 'Study', 'RA-V', 'MTXa', 'N=257', 'HUMIRAa', ',', 'b', 'N=274', 'HUMIRA/MTX', 'N=268', '52', 'Weeks', 'Total', 'Sharp', 'score', '5.7', '(', '4.2', ',', '7.3', ')', '3.0', '(', '1.7', ',', '4.3', ')', '1.3', '(', '0.5', ',', '2.1', ')', 'Erosion', 'score', '3.7', '(', '2.7', ',', '4.8', ')', '1.7', '(', '1.0', ',', '2.4', ')', '0.8', '(', '0.4', ',', '1.2', ')', 'JSN', 'score', '2.0', '(', '1.2', ',', '2.8', ')', '1.3', '(', '0.5', ',', '2.1', ')', '0.5', '(', '0.0', ',', '1.0', ')', '104', 'Weeks', 'Total', 'Sharp', 'score', '10.4', '(', '7.7', ',', '13.2', ')', '5.5', '(', '3.6', ',', '7.4', ')', '1.9', '(', '0.9', ',', '2.9', ')', 'Erosion', 'score', '6.4', '(', '4.6', ',', '8.2', ')', '3.0', '(', '2.0', ',', '4.0', ')', '1.0', '(', '0.4', ',', '1.6', ')', 'JSN', 'score', '4.1', '(', '2.7', ',', '5.4', ')', '2.6', '(', '1.5', ',', '3.7', ')', '0.9', '(', '0.3', ',', '1.5', ')'], 'stemmed': ['radiograph', 'mean', 'chang', '*', 'studi', 'ra-v', 'mtxa', 'n=257', 'humiraa', ',', 'b', 'n=274', 'humira/mtx', 'n=268', '52', 'week', 'total', 'sharp', 'score', '5.7', '(', '4.2', ',', '7.3', ')', '3.0', '(', '1.7', ',', '4.3', ')', '1.3', '(', '0.5', ',', '2.1', ')', 'eros', 'score', '3.7', '(', '2.7', ',', '4.8', ')', '1.7', '(', '1.0', ',', '2.4', ')', '0.8', '(', '0.4', ',', '1.2', ')', 'jsn', 'score', '2.0', '(', '1.2', ',', '2.8', ')', '1.3', '(', '0.5', ',', '2.1', ')', '0.5', '(', '0.0', ',', '1.0', ')', '104', 'week', 'total', 'sharp', 'score', '10.4', '(', '7.7', ',', '13.2', ')', '5.5', '(', '3.6', ',', '7.4', ')', '1.9', '(', '0.9', ',', '2.9', ')', 'eros', 'score', '6.4', '(', '4.6', ',', '8.2', ')', '3.0', '(', '2.0', ',', '4.0', ')', '1.0', '(', '0.4', ',', '1.6', ')', 'jsn', 'score', '4.1', '(', '2.7', ',', '5.4', ')', '2.6', '(', '1.5', ',', '3.7', ')', '0.9', '(', '0.3', ',', '1.5', ')'], 'dependencies': [('radiograph', 'compound'), ('mean', 'compound'), ('chang', 'ROOT'), ('*', 'punct'), ('studi', 'compound'), ('ra', 'nmod'), ('-', 'punct'), ('v', 'prep'), ('mtxa', 'amod'), ('n=257', 'nsubj'), ('humiraa', 'nsubj'), (',', 'punct'), ('b', 'quantmod'), ('n=274', 'nummod'), ('humira', 'nmod'), ('/', 'punct'), ('mtx', 'compound'), ('n=268', 'appos'), ('52', 'nummod'), ('week', 'npadvmod'), ('total', 'amod'), ('sharp', 'amod'), ('score', 'npadvmod'), ('5.7', 'nummod'), ('(', 'punct'), ('4.2', 'appos'), (',', 'punct'), ('7.3', 'npadvmod'), (')', 'punct'), ('3.0', 'prep'), ('(', 'punct'), ('1.7', 'appos'), (',', 'punct'), ('4.3', 'npadvmod'), (')', 'punct'), ('1.3', 'prep'), ('(', 'punct'), ('0.5', 'appos'), (',', 'punct'), ('2.1', 'npadvmod'), (')', 'punct'), ('eros', 'ROOT'), ('score', 'dobj'), ('3.7', 'nummod'), ('(', 'punct'), ('2.7', 'appos'), (',', 'punct'), ('4.8', 'npadvmod'), (')', 'punct'), ('1.7', 'meta'), ('(', 'punct'), ('1.0', 'nummod'), (',', 'punct'), ('2.4', 'npadvmod'), (')', 'punct'), ('0.8', 'prep'), ('(', 'punct'), ('0.4', 'appos'), (',', 'punct'), ('1.2', 'appos'), (')', 'punct'), ('jsn', 'compound'), ('score', 'nsubj'), ('2.0', 'nummod'), ('(', 'punct'), ('1.2', 'appos'), (',', 'punct'), ('2.8', 'appos'), (')', 'punct'), ('1.3', 'nummod'), ('(', 'punct'), ('0.5', 'appos'), (',', 'punct'), ('2.1', 'npadvmod'), (')', 'punct'), ('0.5', 'nummod'), ('(', 'punct'), ('0.0', 'nummod'), (',', 'punct'), ('1.0', 'npadvmod'), (')', 'punct'), ('104', 'nummod'), ('week', 'nmod'), ('total', 'amod'), ('sharp', 'amod'), ('score', 'appos'), ('10.4', 'nummod'), ('(', 'punct'), ('7.7', 'appos'), (',', 'punct'), ('13.2', 'npadvmod'), (')', 'punct'), ('5.5', 'npadvmod'), ('(', 'punct'), ('3.6', 'npadvmod'), (',', 'punct'), ('7.4', 'appos'), (')', 'punct'), ('1.9', 'nummod'), ('(', 'punct'), ('0.9', 'meta'), (',', 'punct'), ('2.9', 'npadvmod'), (')', 'punct'), ('eros', 'compound'), ('score', 'ROOT'), ('6.4', 'nummod'), ('(', 'punct'), ('4.6', 'appos'), (',', 'punct'), ('8.2', 'npadvmod'), (')', 'punct'), ('3.0', 'appos'), ('(', 'punct'), ('2.0', 'appos'), (',', 'punct'), ('4.0', 'npadvmod'), (')', 'punct'), ('1.0', 'appos'), ('(', 'punct'), ('0.4', 'npadvmod'), (',', 'punct'), ('1.6', 'appos'), (')', 'punct'), ('jsn', 'compound'), ('score', 'ROOT'), ('4.1', 'nummod'), ('(', 'punct'), ('2.7', 'appos'), (',', 'punct'), ('5.4', 'appos'), (')', 'punct'), ('2.6', 'prep'), ('(', 'punct'), ('1.5', 'appos'), (',', 'punct'), ('3.7', 'nummod'), (')', 'punct'), ('0.9', 'appos'), ('(', 'punct'), ('0.3', 'appos'), (',', 'punct'), ('1.5', 'appos'), (')', 'punct')]}], 'text': 'At Week 52, all individual components of the ACR response criteria for Study RA-V improved \\nin the HUMIRA/MTX group and improvements were maintained to Week 104.  \\nRadiographic Response \\nIn Study RA-III, structural joint damage was assessed radiographically and expressed as change \\nin Total Sharp Score (TSS) and its components, the erosion score and Joint Space Narrowing \\n(JSN) score, at month 12 compared to baseline. At baseline, the median TSS was approximately \\n55 in the placebo and 40 mg every other week groups. The results are shown in Table 6. \\nHUMIRA/MTX treated patients demonstrated less radiographic progression than patients \\nreceiving MTX alone at 52 weeks.  \\nTable 6. Radiographic Mean Changes Over 12 Months in Study RA-III \\n  \\nPlacebo/MTX HUMIRA/MTX \\n40 mg every \\nother week  \\nPlacebo/MTX- \\nHUMIRA/MTX (95% Confidence \\nInterval*)  \\nP-value** \\nTotal Sharp score \\n2.7 \\n0.1 \\n2.6 (1.4, 3.8) \\n<0.001 \\nErosion score \\n1.6 \\n0.0 \\n1.6 (0.9, 2.2) \\n<0.001 \\nJSN score \\n1.0 \\n0.1 \\n0.9 (0.3, 1.4) \\n0.002 \\n*95% confidence intervals for the differences in change scores between MTX and HUMIRA.  \\n**Based on rank analysis  \\nIn the open-label extension of Study RA-III, 77% of the original patients treated with any dose of \\nHUMIRA were evaluated radiographically at 2 years. Patients maintained inhibition of structural \\ndamage, as measured by the TSS. Fifty-four percent had no progression of structural damage as \\ndefined by a change in the TSS of zero or less. Fifty-five percent (55%) of patients originally \\ntreated with 40 mg HUMIRA every other week have been evaluated radiographically at 5 years. \\nPatients had continued inhibition of structural damage with 50% showing no progression of \\nstructural damage defined by a change in the TSS of zero or less.  \\nIn Study RA-V, structural joint damage was assessed as in Study RA-III. Greater inhibition of \\nradiographic progression, as assessed by changes in TSS, erosion score and JSN was observed in \\nthe HUMIRA/MTX combination group as compared to either the MTX or HUMIRA \\nmonotherapy group at Week 52 as well as at Week 104 (see Table 7).  \\nTable 7.  Radiographic Mean Change* in Study RA-V \\n  \\n  \\nMTXa \\nN=257 \\nHUMIRAa,b \\nN=274 \\nHUMIRA/MTX \\nN=268 \\n52 Weeks \\nTotal Sharp score \\n5.7 (4.2, 7.3) \\n3.0 (1.7, 4.3) \\n1.3 (0.5, 2.1) \\n  \\nErosion score \\n3.7 (2.7, 4.8) \\n1.7 (1.0, 2.4) \\n0.8 (0.4, 1.2) \\n  \\nJSN score \\n2.0 (1.2, 2.8) \\n1.3 (0.5, 2.1) \\n0.5 (0.0, 1.0) \\n104 Weeks \\nTotal Sharp score \\n10.4 (7.7, 13.2) \\n5.5 (3.6, 7.4) \\n1.9 (0.9, 2.9) \\n  \\nErosion score \\n6.4 (4.6, 8.2) \\n3.0 (2.0, 4.0) \\n1.0 (0.4, 1.6) \\n  \\nJSN score \\n4.1 (2.7, 5.4) \\n2.6 (1.5, 3.7) \\n0.9 (0.3, 1.5) \\n'}, 'page_char_count': 2621, 'page_word_count': 414, 'sentences': ['At Week 52, all individual components of the ACR response criteria for Study RA-V improved \\nin the HUMIRA/MTX group and improvements were maintained to Week 104.', ' \\nRadiographic Response \\nIn Study RA-III, structural joint damage was assessed radiographically and expressed as change \\nin Total Sharp Score (TSS) and its components, the erosion score and Joint Space Narrowing \\n(JSN) score, at month 12 compared to baseline.', 'At baseline, the median TSS was approximately \\n55 in the placebo and 40 mg every other week groups.', 'The results are shown in Table 6.', '\\nHUMIRA/MTX treated patients demonstrated less radiographic progression than patients \\nreceiving MTX alone at 52 weeks.', ' \\nTable 6.', 'Radiographic Mean Changes Over 12 Months in Study RA-III \\n  \\nPlacebo/MTX HUMIRA/MTX \\n40 mg every \\nother week  \\nPlacebo/MTX- \\nHUMIRA/MTX (95% Confidence \\nInterval*)  \\nP-value** \\nTotal Sharp score \\n2.7 \\n0.1 \\n2.6 (1.4, 3.8) \\n<0.001 \\nErosion score \\n1.6 \\n0.0 \\n1.6 (0.9, 2.2) \\n<0.001 \\nJSN score \\n1.0 \\n0.1 \\n0.9 (0.3, 1.4) \\n0.002 \\n*95% confidence intervals for the differences in change scores between MTX and HUMIRA.', ' \\n**Based on rank analysis  \\nIn the open-label extension of Study RA-III, 77% of the original patients treated with any dose of \\nHUMIRA were evaluated radiographically at 2 years.', 'Patients maintained inhibition of structural \\ndamage, as measured by the TSS.', 'Fifty-four percent had no progression of structural damage as \\ndefined by a change in the TSS of zero or less.', 'Fifty-five percent (55%) of patients originally \\ntreated with 40 mg HUMIRA every other week have been evaluated radiographically at 5 years.', '\\nPatients had continued inhibition of structural damage with 50% showing no progression of \\nstructural damage defined by a change in the TSS of zero or less.', ' \\nIn Study RA-V, structural joint damage was assessed as in Study RA-III.', 'Greater inhibition of \\nradiographic progression, as assessed by changes in TSS, erosion score and JSN was observed in \\nthe HUMIRA/MTX combination group as compared to either the MTX or HUMIRA \\nmonotherapy group at Week 52 as well as at Week 104 (see Table 7).', ' \\nTable 7.', ' Radiographic Mean Change* in Study RA-V \\n  \\n  \\nMTXa \\nN=257 \\nHUMIRAa,b \\nN=274 \\nHUMIRA/MTX \\nN=268 \\n52 Weeks \\nTotal Sharp score \\n5.7 (4.2, 7.3) \\n3.0 (1.7, 4.3) \\n1.3 (0.5, 2.1) \\n  \\nErosion score \\n3.7 (2.7, 4.8) \\n1.7 (1.0, 2.4) \\n0.8 (0.4, 1.2) \\n  \\nJSN score \\n2.0 (1.2, 2.8) \\n1.3 (0.5, 2.1) \\n0.5 (0.0, 1.0) \\n104 Weeks \\nTotal Sharp score \\n10.4 (7.7, 13.2) \\n5.5 (3.6, 7.4) \\n1.9 (0.9, 2.9) \\n  \\nErosion score \\n6.4 (4.6, 8.2) \\n3.0 (2.0, 4.0) \\n1.0 (0.4, 1.6) \\n  \\nJSN score \\n4.1 (2.7, 5.4) \\n2.6 (1.5, 3.7) \\n0.9 (0.3, 1.5) \\n'], 'page_sentence_count_spacy': 16}\n",
            "{'page_number': 37, 'text': '*  mean (95% confidence interval) \\na  p<0.001, HUMIRA/MTX vs. MTX at 52 and 104 weeks and for HUMIRA/MTX vs. \\nHUMIRA at 104 weeks \\nb  p<0.01, for HUMIRA/MTX vs. HUMIRA at 52 weeks  \\n \\n  \\nPhysical Function Response \\nIn studies RA-I through IV, HUMIRA showed significantly greater improvement than placebo in \\nthe disability index of Health Assessment Questionnaire (HAQ-DI) from baseline to the end of \\nstudy, and significantly greater improvement than placebo in the health-outcomes as assessed by \\nThe Short Form Health Survey (SF 36). Improvement was seen in both the Physical Component \\nSummary (PCS) and the Mental Component Summary (MCS).  \\nIn Study RA-III, the mean (95% CI) improvement in HAQ-DI from baseline at week 52 was \\n0.60 (0.55, 0.65) for the HUMIRA patients and 0.25 (0.17, 0.33) for placebo/MTX (p<0.001) \\npatients. Sixty-three percent of HUMIRA-treated patients achieved a 0.5 or greater improvement \\nin HAQ-DI at week 52 in the double-blind portion of the study. Eighty-two percent of these \\npatients maintained that improvement through week 104 and a similar proportion of patients \\nmaintained this response through week 260 (5 years) of open-label treatment. Mean \\nimprovement in the SF-36 was maintained through the end of measurement at week 156 (3 \\nyears).  \\nIn Study RA-V, the HAQ-DI and the physical component of the SF-36 showed greater \\nimprovement (p<0.001) for the HUMIRA/MTX combination therapy group versus either the \\nMTX monotherapy or the HUMIRA monotherapy group at Week 52, which was maintained \\nthrough Week 104.  \\n14.2 Juvenile Idiopathic Arthritis \\nThe safety and efficacy of HUMIRA was assessed in two studies (Studies JIA-I and JIA-II) in \\npatients with active polyarticular juvenile idiopathic arthritis (JIA).  \\nStudy JIA-I \\nThe safety and efficacy of HUMIRA were assessed in a multicenter, randomized, withdrawal, \\ndouble-blind, parallel-group study in 171 patients who were 4 to 17 years of age with \\npolyarticular JIA. In the study, the patients were stratified into two groups: MTX-treated or non-\\nMTX-treated. All patients had to show signs of active moderate or severe disease despite \\nprevious treatment with NSAIDs, analgesics, corticosteroids, or DMARDS. Patients who \\nreceived prior treatment with any biologic DMARDS were excluded from the study.  \\nThe study included four phases: an open-label lead in phase (OL-LI; 16 weeks), a double-blind \\nrandomized withdrawal phase (DB; 32 weeks), an open-label extension phase (OLE-BSA; up to \\n136 weeks), and an open-label fixed dose phase (OLE-FD; 16 weeks). In the first three phases of \\nthe study, HUMIRA was administered based on body surface area at a dose of 24 mg/m2 up to a \\nmaximum total body dose of 40 mg subcutaneously (SC) every other week. In the OLE-FD \\nphase, the patients were treated with 20 mg of HUMIRA SC every other week if their weight \\nwas less than 30 kg and with 40 mg of HUMIRA SC every other week if their weight was 30 kg \\nor greater. Patients remained on stable doses of NSAIDs and or prednisone (≤0.2 mg/kg/day or \\n10 mg/day maximum).  \\n', 'processed_text': {'sentences': [{'original_sentence': '*  mean (95% confidence interval) \\na  p<0.001, HUMIRA/MTX vs. MTX at 52 and 104 weeks and for HUMIRA/MTX vs. \\nHUMIRA at 104 weeks \\nb  p<0.01, for HUMIRA/MTX vs. HUMIRA at 52 weeks  \\n \\n  \\nPhysical Function Response \\nIn studies RA-I through IV, HUMIRA showed significantly greater improvement than placebo in \\nthe disability index of Health Assessment Questionnaire (HAQ-DI) from baseline to the end of \\nstudy, and significantly greater improvement than placebo in the health-outcomes as assessed by \\nThe Short Form Health Survey (SF 36).', 'tokens': ['*', 'mean', '(', '95', '%', 'confidence', 'interval', ')', 'p', '<', '0.001', ',', 'HUMIRA/MTX', 'vs.', 'MTX', '52', '104', 'weeks', 'HUMIRA/MTX', 'vs.', 'HUMIRA', '104', 'weeks', 'b', 'p', '<', '0.01', ',', 'HUMIRA/MTX', 'vs.', 'HUMIRA', '52', 'weeks', 'Physical', 'Function', 'Response', 'studies', 'RA-I', 'IV', ',', 'HUMIRA', 'showed', 'significantly', 'greater', 'improvement', 'placebo', 'disability', 'index', 'Health', 'Assessment', 'Questionnaire', '(', 'HAQ-DI', ')', 'baseline', 'end', 'study', ',', 'significantly', 'greater', 'improvement', 'placebo', 'health-outcomes', 'assessed', 'Short', 'Form', 'Health', 'Survey', '(', 'SF', '36', ')', '.'], 'lemmatized': ['*', 'mean', '(', '95', '%', 'confidence', 'interval', ')', 'p', '<', '0.001', ',', 'HUMIRA/MTX', 'vs.', 'MTX', '52', '104', 'week', 'HUMIRA/MTX', 'vs.', 'HUMIRA', '104', 'week', 'b', 'p', '<', '0.01', ',', 'HUMIRA/MTX', 'vs.', 'HUMIRA', '52', 'week', 'Physical', 'Function', 'Response', 'study', 'RA-I', 'IV', ',', 'HUMIRA', 'showed', 'significantly', 'greater', 'improvement', 'placebo', 'disability', 'index', 'Health', 'Assessment', 'Questionnaire', '(', 'HAQ-DI', ')', 'baseline', 'end', 'study', ',', 'significantly', 'greater', 'improvement', 'placebo', 'health-outcomes', 'assessed', 'Short', 'Form', 'Health', 'Survey', '(', 'SF', '36', ')', '.'], 'stemmed': ['*', 'mean', '(', '95', '%', 'confid', 'interv', ')', 'p', '<', '0.001', ',', 'humira/mtx', 'vs.', 'mtx', '52', '104', 'week', 'humira/mtx', 'vs.', 'humira', '104', 'week', 'b', 'p', '<', '0.01', ',', 'humira/mtx', 'vs.', 'humira', '52', 'week', 'physic', 'function', 'respons', 'studi', 'ra-i', 'iv', ',', 'humira', 'show', 'significantli', 'greater', 'improv', 'placebo', 'disabl', 'index', 'health', 'assess', 'questionnair', '(', 'haq-di', ')', 'baselin', 'end', 'studi', ',', 'significantli', 'greater', 'improv', 'placebo', 'health-outcom', 'assess', 'short', 'form', 'health', 'survey', '(', 'sf', '36', ')', '.'], 'dependencies': [('*', 'punct'), ('mean', 'intj'), ('(', 'punct'), ('95', 'nummod'), ('%', 'ROOT'), ('confid', 'amod'), ('interv', 'appos'), (')', 'punct'), ('p', 'nmod'), ('<', 'dep'), ('0.001', 'nummod'), (',', 'punct'), ('humira', 'nmod'), ('/', 'punct'), ('mtx', 'ROOT'), ('vs.', 'prep'), ('mtx', 'pobj'), ('52', 'nummod'), ('104', 'nummod'), ('week', 'nmod'), ('humira', 'nmod'), ('/', 'punct'), ('mtx', 'npadvmod'), ('vs.', 'prep'), ('humira', 'pobj'), ('104', 'nummod'), ('week', 'npadvmod'), ('b', 'compound'), ('p', 'npadvmod'), ('<', 'appos'), ('0.01', 'nummod'), (',', 'punct'), ('humira', 'nmod'), ('/', 'punct'), ('mtx', 'nmod'), ('vs.', 'prep'), ('humira', 'pobj'), ('52', 'nummod'), ('week', 'compound'), ('physic', 'amod'), ('function', 'compound'), ('respons', 'nsubj'), ('studi', 'compound'), ('ra', 'appos'), ('-', 'punct'), ('i', 'punct'), ('iv', 'appos'), (',', 'punct'), ('humira', 'nsubj'), ('show', 'ROOT'), ('significantli', 'dobj'), ('greater', 'amod'), ('improv', 'amod'), ('placebo', 'compound'), ('disabl', 'compound'), ('index', 'compound'), ('health', 'compound'), ('assess', 'compound'), ('questionnair', 'dobj'), ('(', 'punct'), ('haq', 'compound'), ('-', 'punct'), ('di', 'appos'), (')', 'punct'), ('baselin', 'compound'), ('end', 'conj'), ('studi', 'npadvmod'), (',', 'punct'), ('significantli', 'nmod'), ('greater', 'amod'), ('improv', 'compound'), ('placebo', 'compound'), ('health', 'compound'), ('-', 'punct'), ('outcom', 'compound'), ('assess', 'nmod'), ('short', 'amod'), ('form', 'compound'), ('health', 'compound'), ('survey', 'ROOT'), ('(', 'punct'), ('sf', 'appos'), ('36', 'nummod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Improvement was seen in both the Physical Component \\nSummary (PCS) and the Mental Component Summary (MCS).', 'tokens': ['Improvement', 'seen', 'Physical', 'Component', 'Summary', '(', 'PCS', ')', 'Mental', 'Component', 'Summary', '(', 'MCS', ')', '.'], 'lemmatized': ['Improvement', 'seen', 'Physical', 'Component', 'Summary', '(', 'PCS', ')', 'Mental', 'Component', 'Summary', '(', 'MCS', ')', '.'], 'stemmed': ['improv', 'seen', 'physic', 'compon', 'summari', '(', 'pc', ')', 'mental', 'compon', 'summari', '(', 'mc', ')', '.'], 'dependencies': [('improv', 'advmod'), ('seen', 'ROOT'), ('physic', 'nsubj'), ('compon', 'nsubj'), ('summari', 'dobj'), ('(', 'punct'), ('pc', 'appos'), (')', 'punct'), ('mental', 'amod'), ('compon', 'compound'), ('summari', 'conj'), ('(', 'punct'), ('mc', 'parataxis'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'In Study RA-III, the mean (95% CI) improvement in HAQ-DI from baseline at week 52 was \\n0.60 (0.55, 0.65) for the HUMIRA patients and 0.25 (0.17, 0.33) for placebo/MTX (p<0.001) \\npatients.', 'tokens': ['Study', 'RA-III', ',', 'mean', '(', '95', '%', 'CI', ')', 'improvement', 'HAQ-DI', 'baseline', 'week', '52', '0.60', '(', '0.55', ',', '0.65', ')', 'HUMIRA', 'patients', '0.25', '(', '0.17', ',', '0.33', ')', 'placebo/MTX', '(', 'p', '<', '0.001', ')', 'patients', '.'], 'lemmatized': ['Study', 'RA-III', ',', 'mean', '(', '95', '%', 'CI', ')', 'improvement', 'HAQ-DI', 'baseline', 'week', '52', '0.60', '(', '0.55', ',', '0.65', ')', 'HUMIRA', 'patient', '0.25', '(', '0.17', ',', '0.33', ')', 'placebo/MTX', '(', 'p', '<', '0.001', ')', 'patient', '.'], 'stemmed': ['studi', 'ra-iii', ',', 'mean', '(', '95', '%', 'ci', ')', 'improv', 'haq-di', 'baselin', 'week', '52', '0.60', '(', '0.55', ',', '0.65', ')', 'humira', 'patient', '0.25', '(', '0.17', ',', '0.33', ')', 'placebo/mtx', '(', 'p', '<', '0.001', ')', 'patient', '.'], 'dependencies': [('studi', 'compound'), ('ra', 'compound'), ('-', 'punct'), ('iii', 'nsubj'), (',', 'punct'), ('mean', 'ROOT'), ('(', 'punct'), ('95', 'nummod'), ('%', 'appos'), ('ci', 'appos'), (')', 'punct'), ('improv', 'compound'), ('haq', 'compound'), ('-', 'punct'), ('di', 'ROOT'), ('baselin', 'compound'), ('week', 'npadvmod'), ('52', 'compound'), ('0.60', 'appos'), ('(', 'punct'), ('0.55', 'appos'), (',', 'punct'), ('0.65', 'advmod'), (')', 'punct'), ('humira', 'compound'), ('patient', 'ROOT'), ('0.25', 'nummod'), ('(', 'punct'), ('0.17', 'appos'), (',', 'punct'), ('0.33', 'npadvmod'), (')', 'punct'), ('placebo', 'nmod'), ('/', 'punct'), ('mtx', 'nmod'), ('(', 'punct'), ('p', 'nmod'), ('<', 'nmod'), ('0.001', 'nummod'), (')', 'punct'), ('patient', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Sixty-three percent of HUMIRA-treated patients achieved a 0.5 or greater improvement \\nin HAQ-DI at week 52 in the double-blind portion of the study.', 'tokens': ['Sixty-three', 'percent', 'HUMIRA-treated', 'patients', 'achieved', '0.5', 'greater', 'improvement', 'HAQ-DI', 'week', '52', 'double-blind', 'portion', 'study', '.'], 'lemmatized': ['Sixty-three', 'percent', 'HUMIRA-treated', 'patient', 'achieved', '0.5', 'greater', 'improvement', 'HAQ-DI', 'week', '52', 'double-blind', 'portion', 'study', '.'], 'stemmed': ['sixty-thre', 'percent', 'humira-tr', 'patient', 'achiev', '0.5', 'greater', 'improv', 'haq-di', 'week', '52', 'double-blind', 'portion', 'studi', '.'], 'dependencies': [('sixty', 'compound'), ('-', 'punct'), ('thre', 'compound'), ('percent', 'ROOT'), ('humira', 'npadvmod'), ('-', 'punct'), ('tr', 'nmod'), ('patient', 'compound'), ('achiev', 'appos'), ('0.5', 'nummod'), ('greater', 'amod'), ('improv', 'amod'), ('haq', 'compound'), ('-', 'punct'), ('di', 'nmod'), ('week', 'appos'), ('52', 'nummod'), ('double', 'amod'), ('-', 'punct'), ('blind', 'amod'), ('portion', 'compound'), ('studi', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Eighty-two percent of these \\npatients maintained that improvement through week 104 and a similar proportion of patients \\nmaintained this response through week 260 (5 years) of open-label treatment.', 'tokens': ['Eighty-two', 'percent', 'patients', 'maintained', 'improvement', 'week', '104', 'similar', 'proportion', 'patients', 'maintained', 'response', 'week', '260', '(', '5', 'years', ')', 'open-label', 'treatment', '.'], 'lemmatized': ['Eighty-two', 'percent', 'patient', 'maintained', 'improvement', 'week', '104', 'similar', 'proportion', 'patient', 'maintained', 'response', 'week', '260', '(', '5', 'year', ')', 'open-label', 'treatment', '.'], 'stemmed': ['eighty-two', 'percent', 'patient', 'maintain', 'improv', 'week', '104', 'similar', 'proport', 'patient', 'maintain', 'respons', 'week', '260', '(', '5', 'year', ')', 'open-label', 'treatment', '.'], 'dependencies': [('eighty', 'compound'), ('-', 'punct'), ('two', 'nummod'), ('percent', 'compound'), ('patient', 'nsubj'), ('maintain', 'ROOT'), ('improv', 'amod'), ('week', 'npadvmod'), ('104', 'nummod'), ('similar', 'amod'), ('proport', 'compound'), ('patient', 'nsubj'), ('maintain', 'ccomp'), ('respons', 'dobj'), ('week', 'npadvmod'), ('260', 'nummod'), ('(', 'punct'), ('5', 'nummod'), ('year', 'appos'), (')', 'punct'), ('open', 'amod'), ('-', 'punct'), ('label', 'compound'), ('treatment', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Mean \\nimprovement in the SF-36 was maintained through the end of measurement at week 156 (3 \\nyears).', 'tokens': ['Mean', 'improvement', 'SF-36', 'maintained', 'end', 'measurement', 'week', '156', '(', '3', 'years', ')', '.'], 'lemmatized': ['Mean', 'improvement', 'SF-36', 'maintained', 'end', 'measurement', 'week', '156', '(', '3', 'year', ')', '.'], 'stemmed': ['mean', 'improv', 'sf-36', 'maintain', 'end', 'measur', 'week', '156', '(', '3', 'year', ')', '.'], 'dependencies': [('mean', 'ROOT'), ('improv', 'amod'), ('sf-36', 'nsubj'), ('maintain', 'ROOT'), ('end', 'compound'), ('measur', 'compound'), ('week', 'npadvmod'), ('156', 'nummod'), ('(', 'punct'), ('3', 'nummod'), ('year', 'npadvmod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'In Study RA-V, the HAQ-DI and the physical component of the SF-36 showed greater \\nimprovement (p<0.001) for the HUMIRA/MTX combination therapy group versus either the \\nMTX monotherapy or the HUMIRA monotherapy group at Week 52, which was maintained \\nthrough Week 104.', 'tokens': ['Study', 'RA-V', ',', 'HAQ-DI', 'physical', 'component', 'SF-36', 'showed', 'greater', 'improvement', '(', 'p', '<', '0.001', ')', 'HUMIRA/MTX', 'combination', 'therapy', 'group', 'versus', 'either', 'MTX', 'monotherapy', 'HUMIRA', 'monotherapy', 'group', 'Week', '52', ',', 'maintained', 'Week', '104', '.'], 'lemmatized': ['Study', 'RA-V', ',', 'HAQ-DI', 'physical', 'component', 'SF-36', 'showed', 'greater', 'improvement', '(', 'p', '<', '0.001', ')', 'HUMIRA/MTX', 'combination', 'therapy', 'group', 'versus', 'either', 'MTX', 'monotherapy', 'HUMIRA', 'monotherapy', 'group', 'Week', '52', ',', 'maintained', 'Week', '104', '.'], 'stemmed': ['studi', 'ra-v', ',', 'haq-di', 'physic', 'compon', 'sf-36', 'show', 'greater', 'improv', '(', 'p', '<', '0.001', ')', 'humira/mtx', 'combin', 'therapi', 'group', 'versu', 'either', 'mtx', 'monotherapi', 'humira', 'monotherapi', 'group', 'week', '52', ',', 'maintain', 'week', '104', '.'], 'dependencies': [('studi', 'compound'), ('ra', 'compound'), ('-', 'punct'), ('v', 'dep'), (',', 'punct'), ('haq', 'amod'), ('-', 'punct'), ('di', 'amod'), ('physic', 'amod'), ('compon', 'npadvmod'), ('sf-36', 'punct'), ('show', 'ROOT'), ('greater', 'amod'), ('improv', 'dobj'), ('(', 'punct'), ('p', 'nmod'), ('<', 'nmod'), ('0.001', 'dep'), (')', 'punct'), ('humira', 'nmod'), ('/', 'punct'), ('mtx', 'compound'), ('combin', 'compound'), ('therapi', 'compound'), ('group', 'compound'), ('versu', 'nsubj'), ('either', 'preconj'), ('mtx', 'ROOT'), ('monotherapi', 'compound'), ('humira', 'compound'), ('monotherapi', 'compound'), ('group', 'compound'), ('week', 'npadvmod'), ('52', 'nummod'), (',', 'punct'), ('maintain', 'conj'), ('week', 'npadvmod'), ('104', 'nummod'), ('.', 'punct')]}, {'original_sentence': '14.2 Juvenile Idiopathic Arthritis \\nThe safety and efficacy of HUMIRA was assessed in two studies (Studies JIA-I and JIA-II) in \\npatients with active polyarticular juvenile idiopathic arthritis (JIA).', 'tokens': ['14.2', 'Juvenile', 'Idiopathic', 'Arthritis', 'safety', 'efficacy', 'HUMIRA', 'assessed', 'two', 'studies', '(', 'Studies', 'JIA-I', 'JIA-II', ')', 'patients', 'active', 'polyarticular', 'juvenile', 'idiopathic', 'arthritis', '(', 'JIA', ')', '.'], 'lemmatized': ['14.2', 'Juvenile', 'Idiopathic', 'Arthritis', 'safety', 'efficacy', 'HUMIRA', 'assessed', 'two', 'study', '(', 'Studies', 'JIA-I', 'JIA-II', ')', 'patient', 'active', 'polyarticular', 'juvenile', 'idiopathic', 'arthritis', '(', 'JIA', ')', '.'], 'stemmed': ['14.2', 'juvenil', 'idiopath', 'arthriti', 'safeti', 'efficaci', 'humira', 'assess', 'two', 'studi', '(', 'studi', 'jia-i', 'jia-ii', ')', 'patient', 'activ', 'polyarticular', 'juvenil', 'idiopath', 'arthriti', '(', 'jia', ')', '.'], 'dependencies': [('14.2', 'nummod'), ('juvenil', 'compound'), ('idiopath', 'compound'), ('arthriti', 'compound'), ('safeti', 'compound'), ('efficaci', 'compound'), ('humira', 'nsubj'), ('assess', 'ROOT'), ('two', 'nummod'), ('studi', 'dobj'), ('(', 'punct'), ('studi', 'compound'), ('jia', 'nmod'), ('-', 'punct'), ('i', 'nmod'), ('jia', 'compound'), ('-', 'punct'), ('ii', 'appos'), (')', 'punct'), ('patient', 'nmod'), ('activ', 'nmod'), ('polyarticular', 'amod'), ('juvenil', 'amod'), ('idiopath', 'compound'), ('arthriti', 'appos'), ('(', 'punct'), ('jia', 'ROOT'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Study JIA-I \\nThe safety and efficacy of HUMIRA were assessed in a multicenter, randomized, withdrawal, \\ndouble-blind, parallel-group study in 171 patients who were 4 to 17 years of age with \\npolyarticular JIA.', 'tokens': ['Study', 'JIA-I', 'safety', 'efficacy', 'HUMIRA', 'assessed', 'multicenter', ',', 'randomized', ',', 'withdrawal', ',', 'double-blind', ',', 'parallel-group', 'study', '171', 'patients', '4', '17', 'years', 'age', 'polyarticular', 'JIA', '.'], 'lemmatized': ['Study', 'JIA-I', 'safety', 'efficacy', 'HUMIRA', 'assessed', 'multicenter', ',', 'randomized', ',', 'withdrawal', ',', 'double-blind', ',', 'parallel-group', 'study', '171', 'patient', '4', '17', 'year', 'age', 'polyarticular', 'JIA', '.'], 'stemmed': ['studi', 'jia-i', 'safeti', 'efficaci', 'humira', 'assess', 'multicent', ',', 'random', ',', 'withdraw', ',', 'double-blind', ',', 'parallel-group', 'studi', '171', 'patient', '4', '17', 'year', 'age', 'polyarticular', 'jia', '.'], 'dependencies': [('studi', 'compound'), ('jia', 'compound'), ('-', 'punct'), ('i', 'compound'), ('safeti', 'compound'), ('efficaci', 'compound'), ('humira', 'compound'), ('assess', 'compound'), ('multicent', 'ROOT'), (',', 'punct'), ('random', 'amod'), (',', 'punct'), ('withdraw', 'conj'), (',', 'punct'), ('double', 'amod'), ('-', 'punct'), ('blind', 'conj'), (',', 'punct'), ('parallel', 'amod'), ('-', 'punct'), ('group', 'compound'), ('studi', 'npadvmod'), ('171', 'nummod'), ('patient', 'appos'), ('4', 'compound'), ('17', 'nummod'), ('year', 'compound'), ('age', 'npadvmod'), ('polyarticular', 'compound'), ('jia', 'appos'), ('.', 'punct')]}, {'original_sentence': 'In the study, the patients were stratified into two groups: MTX-treated or non-\\nMTX-treated.', 'tokens': ['study', ',', 'patients', 'stratified', 'two', 'groups', ':', 'MTX-treated', 'non-', 'MTX-treated', '.'], 'lemmatized': ['study', ',', 'patient', 'stratified', 'two', 'group', ':', 'MTX-treated', 'non-', 'MTX-treated', '.'], 'stemmed': ['studi', ',', 'patient', 'stratifi', 'two', 'group', ':', 'mtx-treat', 'non-', 'mtx-treat', '.'], 'dependencies': [('studi', 'npadvmod'), (',', 'punct'), ('patient', 'amod'), ('stratifi', 'nmod'), ('two', 'nummod'), ('group', 'ROOT'), (':', 'punct'), ('mtx', 'compound'), ('-', 'punct'), ('treat', 'compound'), ('non-', 'amod'), ('mtx', 'compound'), ('-', 'punct'), ('treat', 'appos'), ('.', 'punct')]}, {'original_sentence': 'All patients had to show signs of active moderate or severe disease despite \\nprevious treatment with NSAIDs, analgesics, corticosteroids, or DMARDS.', 'tokens': ['patients', 'show', 'signs', 'active', 'moderate', 'severe', 'disease', 'despite', 'previous', 'treatment', 'NSAIDs', ',', 'analgesics', ',', 'corticosteroids', ',', 'DMARDS', '.'], 'lemmatized': ['patient', 'show', 'sign', 'active', 'moderate', 'severe', 'disease', 'despite', 'previous', 'treatment', 'NSAIDs', ',', 'analgesic', ',', 'corticosteroid', ',', 'DMARDS', '.'], 'stemmed': ['patient', 'show', 'sign', 'activ', 'moder', 'sever', 'diseas', 'despit', 'previou', 'treatment', 'nsaid', ',', 'analges', ',', 'corticosteroid', ',', 'dmard', '.'], 'dependencies': [('patient', 'compound'), ('show', 'nsubj'), ('sign', 'compound'), ('activ', 'compound'), ('moder', 'nsubj'), ('sever', 'ROOT'), ('diseas', 'compound'), ('despit', 'compound'), ('previou', 'compound'), ('treatment', 'nsubj'), ('nsaid', 'advcl'), (',', 'punct'), ('analges', 'conj'), (',', 'punct'), ('corticosteroid', 'amod'), (',', 'punct'), ('dmard', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Patients who \\nreceived prior treatment with any biologic DMARDS were excluded from the study.', 'tokens': ['Patients', 'received', 'prior', 'treatment', 'biologic', 'DMARDS', 'excluded', 'study', '.'], 'lemmatized': ['Patients', 'received', 'prior', 'treatment', 'biologic', 'DMARDS', 'excluded', 'study', '.'], 'stemmed': ['patient', 'receiv', 'prior', 'treatment', 'biolog', 'dmard', 'exclud', 'studi', '.'], 'dependencies': [('patient', 'compound'), ('receiv', 'compound'), ('prior', 'amod'), ('treatment', 'compound'), ('biolog', 'compound'), ('dmard', 'compound'), ('exclud', 'compound'), ('studi', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'The study included four phases: an open-label lead in phase (OL-LI; 16 weeks), a double-blind \\nrandomized withdrawal phase (DB; 32 weeks), an open-label extension phase (OLE-BSA; up to \\n136 weeks), and an open-label fixed dose phase (OLE-FD; 16 weeks).', 'tokens': ['study', 'included', 'four', 'phases', ':', 'open-label', 'lead', 'phase', '(', 'OL-LI', ';', '16', 'weeks', ')', ',', 'double-blind', 'randomized', 'withdrawal', 'phase', '(', 'DB', ';', '32', 'weeks', ')', ',', 'open-label', 'extension', 'phase', '(', 'OLE-BSA', ';', '136', 'weeks', ')', ',', 'open-label', 'fixed', 'dose', 'phase', '(', 'OLE-FD', ';', '16', 'weeks', ')', '.'], 'lemmatized': ['study', 'included', 'four', 'phase', ':', 'open-label', 'lead', 'phase', '(', 'OL-LI', ';', '16', 'week', ')', ',', 'double-blind', 'randomized', 'withdrawal', 'phase', '(', 'DB', ';', '32', 'week', ')', ',', 'open-label', 'extension', 'phase', '(', 'OLE-BSA', ';', '136', 'week', ')', ',', 'open-label', 'fixed', 'dose', 'phase', '(', 'OLE-FD', ';', '16', 'week', ')', '.'], 'stemmed': ['studi', 'includ', 'four', 'phase', ':', 'open-label', 'lead', 'phase', '(', 'ol-li', ';', '16', 'week', ')', ',', 'double-blind', 'random', 'withdraw', 'phase', '(', 'db', ';', '32', 'week', ')', ',', 'open-label', 'extens', 'phase', '(', 'ole-bsa', ';', '136', 'week', ')', ',', 'open-label', 'fix', 'dose', 'phase', '(', 'ole-fd', ';', '16', 'week', ')', '.'], 'dependencies': [('studi', 'nsubj'), ('includ', 'ROOT'), ('four', 'nummod'), ('phase', 'dobj'), (':', 'punct'), ('open', 'amod'), ('-', 'punct'), ('label', 'compound'), ('lead', 'compound'), ('phase', 'appos'), ('(', 'punct'), ('ol', 'compound'), ('-', 'punct'), ('li', 'appos'), (';', 'punct'), ('16', 'nummod'), ('week', 'appos'), (')', 'punct'), (',', 'punct'), ('double', 'amod'), ('-', 'punct'), ('blind', 'amod'), ('random', 'amod'), ('withdraw', 'compound'), ('phase', 'npadvmod'), ('(', 'punct'), ('db', 'appos'), (';', 'punct'), ('32', 'nummod'), ('week', 'appos'), (')', 'punct'), (',', 'punct'), ('open', 'amod'), ('-', 'punct'), ('label', 'compound'), ('extens', 'compound'), ('phase', 'npadvmod'), ('(', 'punct'), ('ole', 'compound'), ('-', 'punct'), ('bsa', 'appos'), (';', 'punct'), ('136', 'nummod'), ('week', 'npadvmod'), (')', 'punct'), (',', 'punct'), ('open', 'amod'), ('-', 'punct'), ('label', 'compound'), ('fix', 'compound'), ('dose', 'compound'), ('phase', 'npadvmod'), ('(', 'punct'), ('ole', 'compound'), ('-', 'punct'), ('fd', 'appos'), (';', 'punct'), ('16', 'nummod'), ('week', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'In the first three phases of \\nthe study, HUMIRA was administered based on body surface area at a dose of 24 mg/m2 up to a \\nmaximum total body dose of 40 mg subcutaneously (SC) every other week.', 'tokens': ['first', 'three', 'phases', 'study', ',', 'HUMIRA', 'administered', 'based', 'body', 'surface', 'area', 'dose', '24', 'mg/m2', 'maximum', 'total', 'body', 'dose', '40', 'mg', 'subcutaneously', '(', 'SC', ')', 'every', 'week', '.'], 'lemmatized': ['first', 'three', 'phase', 'study', ',', 'HUMIRA', 'administered', 'based', 'body', 'surface', 'area', 'dose', '24', 'mg/m2', 'maximum', 'total', 'body', 'dose', '40', 'mg', 'subcutaneously', '(', 'SC', ')', 'every', 'week', '.'], 'stemmed': ['first', 'three', 'phase', 'studi', ',', 'humira', 'administ', 'base', 'bodi', 'surfac', 'area', 'dose', '24', 'mg/m2', 'maximum', 'total', 'bodi', 'dose', '40', 'mg', 'subcutan', '(', 'sc', ')', 'everi', 'week', '.'], 'dependencies': [('first', 'advmod'), ('three', 'nummod'), ('phase', 'npadvmod'), ('studi', 'appos'), (',', 'punct'), ('humira', 'compound'), ('administ', 'compound'), ('base', 'compound'), ('bodi', 'compound'), ('surfac', 'compound'), ('area', 'nsubj'), ('dose', 'ROOT'), ('24', 'nummod'), ('mg', 'nmod'), ('/', 'punct'), ('m2', 'amod'), ('maximum', 'amod'), ('total', 'amod'), ('bodi', 'nsubj'), ('dose', 'ccomp'), ('40', 'dobj'), ('mg', 'advmod'), ('subcutan', 'amod'), ('(', 'punct'), ('sc', 'appos'), (')', 'punct'), ('everi', 'amod'), ('week', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'In the OLE-FD \\nphase, the patients were treated with 20 mg of HUMIRA SC every other week if their weight \\nwas less than 30 kg and with 40 mg of HUMIRA SC every other week if their weight was 30 kg \\nor greater.', 'tokens': ['OLE-FD', 'phase', ',', 'patients', 'treated', '20', 'mg', 'HUMIRA', 'SC', 'every', 'week', 'weight', 'less', '30', 'kg', '40', 'mg', 'HUMIRA', 'SC', 'every', 'week', 'weight', '30', 'kg', 'greater', '.'], 'lemmatized': ['OLE-FD', 'phase', ',', 'patient', 'treated', '20', 'mg', 'HUMIRA', 'SC', 'every', 'week', 'weight', 'less', '30', 'kg', '40', 'mg', 'HUMIRA', 'SC', 'every', 'week', 'weight', '30', 'kg', 'greater', '.'], 'stemmed': ['ole-fd', 'phase', ',', 'patient', 'treat', '20', 'mg', 'humira', 'sc', 'everi', 'week', 'weight', 'less', '30', 'kg', '40', 'mg', 'humira', 'sc', 'everi', 'week', 'weight', '30', 'kg', 'greater', '.'], 'dependencies': [('ole', 'amod'), ('-', 'punct'), ('fd', 'compound'), ('phase', 'npadvmod'), (',', 'punct'), ('patient', 'compound'), ('treat', 'ROOT'), ('20', 'nummod'), ('mg', 'nmod'), ('humira', 'compound'), ('sc', 'compound'), ('everi', 'amod'), ('week', 'compound'), ('weight', 'npadvmod'), ('less', 'amod'), ('30', 'nummod'), ('kg', 'npadvmod'), ('40', 'nummod'), ('mg', 'nmod'), ('humira', 'compound'), ('sc', 'nmod'), ('everi', 'compound'), ('week', 'compound'), ('weight', 'npadvmod'), ('30', 'nummod'), ('kg', 'npadvmod'), ('greater', 'amod'), ('.', 'punct')]}, {'original_sentence': 'Patients remained on stable doses of NSAIDs and or prednisone (≤0.2 mg/kg/day or \\n10 mg/day maximum).', 'tokens': ['Patients', 'remained', 'stable', 'doses', 'NSAIDs', 'prednisone', '(', '≤0.2', 'mg/kg/day', '10', 'mg/day', 'maximum', ')', '.'], 'lemmatized': ['Patients', 'remained', 'stable', 'dos', 'NSAIDs', 'prednisone', '(', '≤0.2', 'mg/kg/day', '10', 'mg/day', 'maximum', ')', '.'], 'stemmed': ['patient', 'remain', 'stabl', 'do', 'nsaid', 'prednison', '(', '≤0.2', 'mg/kg/day', '10', 'mg/day', 'maximum', ')', '.'], 'dependencies': [('patient', 'nsubj'), ('remain', 'ROOT'), ('stabl', 'acomp'), ('do', 'aux'), ('nsaid', 'ccomp'), ('prednison', 'dobj'), ('(', 'punct'), ('≤0.2', 'nmod'), ('mg', 'nmod'), ('/', 'punct'), ('kg', 'nmod'), ('/', 'punct'), ('day', 'npadvmod'), ('10', 'nummod'), ('mg', 'nmod'), ('/', 'punct'), ('day', 'compound'), ('maximum', 'appos'), (')', 'punct'), ('.', 'punct')]}], 'text': '*  mean (95% confidence interval) \\na  p<0.001, HUMIRA/MTX vs. MTX at 52 and 104 weeks and for HUMIRA/MTX vs. \\nHUMIRA at 104 weeks \\nb  p<0.01, for HUMIRA/MTX vs. HUMIRA at 52 weeks  \\n \\n  \\nPhysical Function Response \\nIn studies RA-I through IV, HUMIRA showed significantly greater improvement than placebo in \\nthe disability index of Health Assessment Questionnaire (HAQ-DI) from baseline to the end of \\nstudy, and significantly greater improvement than placebo in the health-outcomes as assessed by \\nThe Short Form Health Survey (SF 36). Improvement was seen in both the Physical Component \\nSummary (PCS) and the Mental Component Summary (MCS).  \\nIn Study RA-III, the mean (95% CI) improvement in HAQ-DI from baseline at week 52 was \\n0.60 (0.55, 0.65) for the HUMIRA patients and 0.25 (0.17, 0.33) for placebo/MTX (p<0.001) \\npatients. Sixty-three percent of HUMIRA-treated patients achieved a 0.5 or greater improvement \\nin HAQ-DI at week 52 in the double-blind portion of the study. Eighty-two percent of these \\npatients maintained that improvement through week 104 and a similar proportion of patients \\nmaintained this response through week 260 (5 years) of open-label treatment. Mean \\nimprovement in the SF-36 was maintained through the end of measurement at week 156 (3 \\nyears).  \\nIn Study RA-V, the HAQ-DI and the physical component of the SF-36 showed greater \\nimprovement (p<0.001) for the HUMIRA/MTX combination therapy group versus either the \\nMTX monotherapy or the HUMIRA monotherapy group at Week 52, which was maintained \\nthrough Week 104.  \\n14.2 Juvenile Idiopathic Arthritis \\nThe safety and efficacy of HUMIRA was assessed in two studies (Studies JIA-I and JIA-II) in \\npatients with active polyarticular juvenile idiopathic arthritis (JIA).  \\nStudy JIA-I \\nThe safety and efficacy of HUMIRA were assessed in a multicenter, randomized, withdrawal, \\ndouble-blind, parallel-group study in 171 patients who were 4 to 17 years of age with \\npolyarticular JIA. In the study, the patients were stratified into two groups: MTX-treated or non-\\nMTX-treated. All patients had to show signs of active moderate or severe disease despite \\nprevious treatment with NSAIDs, analgesics, corticosteroids, or DMARDS. Patients who \\nreceived prior treatment with any biologic DMARDS were excluded from the study.  \\nThe study included four phases: an open-label lead in phase (OL-LI; 16 weeks), a double-blind \\nrandomized withdrawal phase (DB; 32 weeks), an open-label extension phase (OLE-BSA; up to \\n136 weeks), and an open-label fixed dose phase (OLE-FD; 16 weeks). In the first three phases of \\nthe study, HUMIRA was administered based on body surface area at a dose of 24 mg/m2 up to a \\nmaximum total body dose of 40 mg subcutaneously (SC) every other week. In the OLE-FD \\nphase, the patients were treated with 20 mg of HUMIRA SC every other week if their weight \\nwas less than 30 kg and with 40 mg of HUMIRA SC every other week if their weight was 30 kg \\nor greater. Patients remained on stable doses of NSAIDs and or prednisone (≤0.2 mg/kg/day or \\n10 mg/day maximum).  \\n'}, 'page_char_count': 3066, 'page_word_count': 482, 'sentences': ['*  mean (95% confidence interval) \\na  p<0.001, HUMIRA/MTX vs. MTX at 52 and 104 weeks and for HUMIRA/MTX vs. \\nHUMIRA at 104 weeks \\nb  p<0.01, for HUMIRA/MTX vs. HUMIRA at 52 weeks  \\n \\n  \\nPhysical Function Response \\nIn studies RA-I through IV, HUMIRA showed significantly greater improvement than placebo in \\nthe disability index of Health Assessment Questionnaire (HAQ-DI) from baseline to the end of \\nstudy, and significantly greater improvement than placebo in the health-outcomes as assessed by \\nThe Short Form Health Survey (SF 36).', 'Improvement was seen in both the Physical Component \\nSummary (PCS) and the Mental Component Summary (MCS).', ' \\nIn Study RA-III, the mean (95% CI) improvement in HAQ-DI from baseline at week 52 was \\n0.60 (0.55, 0.65) for the HUMIRA patients and 0.25 (0.17, 0.33) for placebo/MTX (p<0.001) \\npatients.', 'Sixty-three percent of HUMIRA-treated patients achieved a 0.5 or greater improvement \\nin HAQ-DI at week 52 in the double-blind portion of the study.', 'Eighty-two percent of these \\npatients maintained that improvement through week 104 and a similar proportion of patients \\nmaintained this response through week 260 (5 years) of open-label treatment.', 'Mean \\nimprovement in the SF-36 was maintained through the end of measurement at week 156 (3 \\nyears).', ' \\nIn Study RA-V, the HAQ-DI and the physical component of the SF-36 showed greater \\nimprovement (p<0.001) for the HUMIRA/MTX combination therapy group versus either the \\nMTX monotherapy or the HUMIRA monotherapy group at Week 52, which was maintained \\nthrough Week 104.', ' \\n14.2 Juvenile Idiopathic Arthritis \\nThe safety and efficacy of HUMIRA was assessed in two studies (Studies JIA-I and JIA-II) in \\npatients with active polyarticular juvenile idiopathic arthritis (JIA).', ' \\nStudy JIA-I \\nThe safety and efficacy of HUMIRA were assessed in a multicenter, randomized, withdrawal, \\ndouble-blind, parallel-group study in 171 patients who were 4 to 17 years of age with \\npolyarticular JIA.', 'In the study, the patients were stratified into two groups: MTX-treated or non-\\nMTX-treated.', 'All patients had to show signs of active moderate or severe disease despite \\nprevious treatment with NSAIDs, analgesics, corticosteroids, or DMARDS.', 'Patients who \\nreceived prior treatment with any biologic DMARDS were excluded from the study.', ' \\nThe study included four phases: an open-label lead in phase (OL-LI; 16 weeks), a double-blind \\nrandomized withdrawal phase (DB; 32 weeks), an open-label extension phase (OLE-BSA; up to \\n136 weeks), and an open-label fixed dose phase (OLE-FD; 16 weeks).', 'In the first three phases of \\nthe study, HUMIRA was administered based on body surface area at a dose of 24 mg/m2 up to a \\nmaximum total body dose of 40 mg subcutaneously (SC) every other week.', 'In the OLE-FD \\nphase, the patients were treated with 20 mg of HUMIRA SC every other week if their weight \\nwas less than 30 kg and with 40 mg of HUMIRA SC every other week if their weight was 30 kg \\nor greater.', 'Patients remained on stable doses of NSAIDs and or prednisone (≤0.2 mg/kg/day or \\n10 mg/day maximum).', ' \\n'], 'page_sentence_count_spacy': 17}\n",
            "{'page_number': 38, 'text': 'Patients demonstrating a Pediatric ACR 30 response at the end of OL-LI phase were randomized \\ninto the double blind (DB) phase of the study and received either HUMIRA or placebo every \\nother week for 32 weeks or until disease flare. Disease flare was defined as a worsening of ≥30% \\nfrom baseline in ≥3 of 6 Pediatric ACR core criteria, ≥2 active joints, and improvement of >30% \\nin no more than 1 of the 6 criteria. After 32 weeks or at the time of disease flare during the DB \\nphase, patients were treated in the open-label extension phase based on the BSA regimen (OLE-\\nBSA), before converting to a fixed dose regimen based on body weight (OLE-FD phase).  \\nStudy JIA-I Clinical Response \\nAt the end of the 16-week OL-LI phase, 94% of the patients in the MTX stratum and 74% of the \\npatients in the non-MTX stratum were Pediatric ACR 30 responders. In the DB phase \\nsignificantly fewer patients who received HUMIRA experienced disease flare compared to \\nplacebo, both without MTX (43% vs. 71%) and with MTX (37% vs. 65%). More patients treated \\nwith HUMIRA continued to show pediatric ACR 30/50/70 responses at Week 48 compared to \\npatients treated with placebo. Pediatric ACR responses were maintained for up to two years in \\nthe OLE phase in patients who received HUMIRA throughout the study.  \\nStudy JIA-II \\nHUMIRA was assessed in an open-label, multicenter study in 32 patients who were 2 to <4 years \\nof age or 4 years of age and older weighing <15 kg with moderately to severely active \\npolyarticular JIA. Most patients (97%) received at least 24 weeks of HUMIRA treatment dosed \\n24 mg/m2 up to a maximum of 20 mg every other week as a single SC injection up to a \\nmaximum of 120 weeks duration. During the study, most patients used concomitant MTX, with \\nfewer reporting use of corticosteroids or NSAIDs. The primary objective of the study was \\nevaluation of safety [see Adverse Reactions (6.1)].  \\n14.3 Psoriatic Arthritis \\nThe safety and efficacy of HUMIRA was assessed in two randomized, double-blind, placebo \\ncontrolled studies in 413 patients with psoriatic arthritis (PsA). Upon completion of both studies, \\n383 patients enrolled in an open-label extension study, in which 40 mg HUMIRA was \\nadministered every other week.  \\nStudy PsA-I enrolled 313 adult patients with moderately to severely active PsA (>3 swollen and \\n>3 tender joints) who had an inadequate response to NSAID therapy in one of the following \\nforms: (1) distal interphalangeal (DIP) involvement (N=23); (2) polyarticular arthritis (absence \\nof rheumatoid nodules and presence of plaque psoriasis) (N=210); (3) arthritis mutilans (N=1); \\n(4) asymmetric PsA (N=77); or (5) AS-like (N=2). Patients on MTX therapy (158 of 313 \\npatients) at enrollment (stable dose of ≤30 mg/week for >1 month) could continue MTX at the \\nsame dose. Doses of HUMIRA 40 mg or placebo every other week were administered during the \\n24-week double-blind period of the study.  \\nCompared to placebo, treatment with HUMIRA resulted in improvements in the measures of \\ndisease activity (see Tables 8 and 9). Among patients with PsA who received HUMIRA, the \\nclinical responses were apparent in some patients at the time of the first visit (two weeks) and \\nwere maintained up to 88 weeks in the ongoing open-label study. Similar responses were seen in \\npatients with each of the subtypes of psoriatic arthritis, although few patients were enrolled with \\n', 'processed_text': {'sentences': [{'original_sentence': 'Patients demonstrating a Pediatric ACR 30 response at the end of OL-LI phase were randomized \\ninto the double blind (DB) phase of the study and received either HUMIRA or placebo every \\nother week for 32 weeks or until disease flare.', 'tokens': ['Patients', 'demonstrating', 'Pediatric', 'ACR', '30', 'response', 'end', 'OL-LI', 'phase', 'randomized', 'double', 'blind', '(', 'DB', ')', 'phase', 'study', 'received', 'either', 'HUMIRA', 'placebo', 'every', 'week', '32', 'weeks', 'disease', 'flare', '.'], 'lemmatized': ['Patients', 'demonstrating', 'Pediatric', 'ACR', '30', 'response', 'end', 'OL-LI', 'phase', 'randomized', 'double', 'blind', '(', 'DB', ')', 'phase', 'study', 'received', 'either', 'HUMIRA', 'placebo', 'every', 'week', '32', 'week', 'disease', 'flare', '.'], 'stemmed': ['patient', 'demonstr', 'pediatr', 'acr', '30', 'respons', 'end', 'ol-li', 'phase', 'random', 'doubl', 'blind', '(', 'db', ')', 'phase', 'studi', 'receiv', 'either', 'humira', 'placebo', 'everi', 'week', '32', 'week', 'diseas', 'flare', '.'], 'dependencies': [('patient', 'compound'), ('demonstr', 'compound'), ('pediatr', 'ROOT'), ('acr', 'prep'), ('30', 'nummod'), ('respons', 'compound'), ('end', 'pobj'), ('ol', 'compound'), ('-', 'punct'), ('li', 'compound'), ('phase', 'dobj'), ('random', 'amod'), ('doubl', 'nsubj'), ('blind', 'amod'), ('(', 'punct'), ('db', 'appos'), (')', 'punct'), ('phase', 'ROOT'), ('studi', 'compound'), ('receiv', 'dobj'), ('either', 'preconj'), ('humira', 'compound'), ('placebo', 'nmod'), ('everi', 'compound'), ('week', 'npadvmod'), ('32', 'nummod'), ('week', 'npadvmod'), ('diseas', 'nsubj'), ('flare', 'conj'), ('.', 'punct')]}, {'original_sentence': 'Disease flare was defined as a worsening of ≥30% \\nfrom baseline in ≥3 of 6 Pediatric ACR core criteria, ≥2 active joints, and improvement of >30% \\nin no more than 1 of the 6 criteria.', 'tokens': ['Disease', 'flare', 'defined', 'worsening', '≥30', '%', 'baseline', '≥3', '6', 'Pediatric', 'ACR', 'core', 'criteria', ',', '≥2', 'active', 'joints', ',', 'improvement', '>', '30', '%', '1', '6', 'criteria', '.'], 'lemmatized': ['Disease', 'flare', 'defined', 'worsening', '≥30', '%', 'baseline', '≥3', '6', 'Pediatric', 'ACR', 'core', 'criterion', ',', '≥2', 'active', 'joint', ',', 'improvement', '>', '30', '%', '1', '6', 'criterion', '.'], 'stemmed': ['diseas', 'flare', 'defin', 'worsen', '≥30', '%', 'baselin', '≥3', '6', 'pediatr', 'acr', 'core', 'criterion', ',', '≥2', 'activ', 'joint', ',', 'improv', '>', '30', '%', '1', '6', 'criterion', '.'], 'dependencies': [('diseas', 'nsubj'), ('flare', 'dep'), ('defin', 'npadvmod'), ('worsen', 'ROOT'), ('≥30', 'intj'), ('%', 'intj'), ('baselin', 'npadvmod'), ('≥3', 'punct'), ('6', 'nummod'), ('pediatr', 'amod'), ('acr', 'nmod'), ('core', 'compound'), ('criterion', 'dobj'), (',', 'punct'), ('≥2', 'punct'), ('activ', 'compound'), ('joint', 'ROOT'), (',', 'punct'), ('improv', 'intj'), ('>', 'dep'), ('30', 'nummod'), ('%', 'appos'), ('1', 'quantmod'), ('6', 'nummod'), ('criterion', 'appos'), ('.', 'punct')]}, {'original_sentence': 'After 32 weeks or at the time of disease flare during the DB \\nphase, patients were treated in the open-label extension phase based on the BSA regimen (OLE-\\nBSA), before converting to a fixed dose regimen based on body weight (OLE-FD phase).', 'tokens': ['32', 'weeks', 'time', 'disease', 'flare', 'DB', 'phase', ',', 'patients', 'treated', 'open-label', 'extension', 'phase', 'based', 'BSA', 'regimen', '(', 'OLE-', 'BSA', ')', ',', 'converting', 'fixed', 'dose', 'regimen', 'based', 'body', 'weight', '(', 'OLE-FD', 'phase', ')', '.'], 'lemmatized': ['32', 'week', 'time', 'disease', 'flare', 'DB', 'phase', ',', 'patient', 'treated', 'open-label', 'extension', 'phase', 'based', 'BSA', 'regimen', '(', 'OLE-', 'BSA', ')', ',', 'converting', 'fixed', 'dose', 'regimen', 'based', 'body', 'weight', '(', 'OLE-FD', 'phase', ')', '.'], 'stemmed': ['32', 'week', 'time', 'diseas', 'flare', 'db', 'phase', ',', 'patient', 'treat', 'open-label', 'extens', 'phase', 'base', 'bsa', 'regimen', '(', 'ole-', 'bsa', ')', ',', 'convert', 'fix', 'dose', 'regimen', 'base', 'bodi', 'weight', '(', 'ole-fd', 'phase', ')', '.'], 'dependencies': [('32', 'nummod'), ('week', 'compound'), ('time', 'npadvmod'), ('diseas', 'nsubj'), ('flare', 'advcl'), ('db', 'nmod'), ('phase', 'dobj'), (',', 'punct'), ('patient', 'amod'), ('treat', 'advcl'), ('open', 'amod'), ('-', 'punct'), ('label', 'compound'), ('extens', 'compound'), ('phase', 'compound'), ('base', 'compound'), ('bsa', 'compound'), ('regimen', 'dobj'), ('(', 'punct'), ('ole-', 'compound'), ('bsa', 'appos'), (')', 'punct'), (',', 'punct'), ('convert', 'ROOT'), ('fix', 'compound'), ('dose', 'compound'), ('regimen', 'compound'), ('base', 'compound'), ('bodi', 'compound'), ('weight', 'dobj'), ('(', 'punct'), ('ole', 'amod'), ('-', 'punct'), ('fd', 'compound'), ('phase', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Study JIA-I Clinical Response \\nAt the end of the 16-week OL-LI phase, 94% of the patients in the MTX stratum and 74% of the \\npatients in the non-MTX stratum were Pediatric ACR 30 responders.', 'tokens': ['Study', 'JIA-I', 'Clinical', 'Response', 'end', '16-week', 'OL-LI', 'phase', ',', '94', '%', 'patients', 'MTX', 'stratum', '74', '%', 'patients', 'non-MTX', 'stratum', 'Pediatric', 'ACR', '30', 'responders', '.'], 'lemmatized': ['Study', 'JIA-I', 'Clinical', 'Response', 'end', '16-week', 'OL-LI', 'phase', ',', '94', '%', 'patient', 'MTX', 'stratum', '74', '%', 'patient', 'non-MTX', 'stratum', 'Pediatric', 'ACR', '30', 'responder', '.'], 'stemmed': ['studi', 'jia-i', 'clinic', 'respons', 'end', '16-week', 'ol-li', 'phase', ',', '94', '%', 'patient', 'mtx', 'stratum', '74', '%', 'patient', 'non-mtx', 'stratum', 'pediatr', 'acr', '30', 'respond', '.'], 'dependencies': [('studi', 'nmod'), ('jia', 'compound'), ('-', 'punct'), ('i', 'appos'), ('clinic', 'compound'), ('respons', 'nsubj'), ('end', 'ROOT'), ('16', 'nummod'), ('-', 'punct'), ('week', 'compound'), ('ol', 'compound'), ('-', 'punct'), ('li', 'compound'), ('phase', 'dobj'), (',', 'punct'), ('94', 'nummod'), ('%', 'npadvmod'), ('patient', 'compound'), ('mtx', 'compound'), ('stratum', 'compound'), ('74', 'nummod'), ('%', 'npadvmod'), ('patient', 'nmod'), ('non', 'amod'), ('-', 'amod'), ('mtx', 'amod'), ('stratum', 'compound'), ('pediatr', 'appos'), ('acr', 'prep'), ('30', 'nummod'), ('respond', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'In the DB phase \\nsignificantly fewer patients who received HUMIRA experienced disease flare compared to \\nplacebo, both without MTX (43% vs. 71%) and with MTX (37% vs. 65%).', 'tokens': ['DB', 'phase', 'significantly', 'fewer', 'patients', 'received', 'HUMIRA', 'experienced', 'disease', 'flare', 'compared', 'placebo', ',', 'without', 'MTX', '(', '43', '%', 'vs.', '71', '%', ')', 'MTX', '(', '37', '%', 'vs.', '65', '%', ')', '.'], 'lemmatized': ['DB', 'phase', 'significantly', 'fewer', 'patient', 'received', 'HUMIRA', 'experienced', 'disease', 'flare', 'compared', 'placebo', ',', 'without', 'MTX', '(', '43', '%', 'vs.', '71', '%', ')', 'MTX', '(', '37', '%', 'vs.', '65', '%', ')', '.'], 'stemmed': ['db', 'phase', 'significantli', 'fewer', 'patient', 'receiv', 'humira', 'experienc', 'diseas', 'flare', 'compar', 'placebo', ',', 'without', 'mtx', '(', '43', '%', 'vs.', '71', '%', ')', 'mtx', '(', '37', '%', 'vs.', '65', '%', ')', '.'], 'dependencies': [('db', 'nsubj'), ('phase', 'compound'), ('significantli', 'dobj'), ('fewer', 'amod'), ('patient', 'compound'), ('receiv', 'dobj'), ('humira', 'nmod'), ('experienc', 'nmod'), ('diseas', 'appos'), ('flare', 'compound'), ('compar', 'compound'), ('placebo', 'npadvmod'), (',', 'punct'), ('without', 'prep'), ('mtx', 'pobj'), ('(', 'punct'), ('43', 'nummod'), ('%', 'appos'), ('vs.', 'prep'), ('71', 'nummod'), ('%', 'pobj'), (')', 'punct'), ('mtx', 'ROOT'), ('(', 'punct'), ('37', 'nummod'), ('%', 'appos'), ('vs.', 'prep'), ('65', 'nummod'), ('%', 'pobj'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'More patients treated \\nwith HUMIRA continued to show pediatric ACR 30/50/70 responses at Week 48 compared to \\npatients treated with placebo.', 'tokens': ['patients', 'treated', 'HUMIRA', 'continued', 'show', 'pediatric', 'ACR', '30/50/70', 'responses', 'Week', '48', 'compared', 'patients', 'treated', 'placebo', '.'], 'lemmatized': ['patient', 'treated', 'HUMIRA', 'continued', 'show', 'pediatric', 'ACR', '30/50/70', 'response', 'Week', '48', 'compared', 'patient', 'treated', 'placebo', '.'], 'stemmed': ['patient', 'treat', 'humira', 'continu', 'show', 'pediatr', 'acr', '30/50/70', 'respons', 'week', '48', 'compar', 'patient', 'treat', 'placebo', '.'], 'dependencies': [('patient', 'compound'), ('treat', 'compound'), ('humira', 'compound'), ('continu', 'nsubj'), ('show', 'ROOT'), ('pediatr', 'dobj'), ('acr', 'prep'), ('30/50/70', 'compound'), ('respons', 'compound'), ('week', 'nmod'), ('48', 'nummod'), ('compar', 'compound'), ('patient', 'compound'), ('treat', 'compound'), ('placebo', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Pediatric ACR responses were maintained for up to two years in \\nthe OLE phase in patients who received HUMIRA throughout the study.', 'tokens': ['Pediatric', 'ACR', 'responses', 'maintained', 'two', 'years', 'OLE', 'phase', 'patients', 'received', 'HUMIRA', 'throughout', 'study', '.'], 'lemmatized': ['Pediatric', 'ACR', 'response', 'maintained', 'two', 'year', 'OLE', 'phase', 'patient', 'received', 'HUMIRA', 'throughout', 'study', '.'], 'stemmed': ['pediatr', 'acr', 'respons', 'maintain', 'two', 'year', 'ole', 'phase', 'patient', 'receiv', 'humira', 'throughout', 'studi', '.'], 'dependencies': [('pediatr', 'advmod'), ('acr', 'nmod'), ('respons', 'nsubj'), ('maintain', 'ROOT'), ('two', 'nummod'), ('year', 'nmod'), ('ole', 'amod'), ('phase', 'compound'), ('patient', 'compound'), ('receiv', 'compound'), ('humira', 'dobj'), ('throughout', 'prep'), ('studi', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'Study JIA-II \\nHUMIRA was assessed in an open-label, multicenter study in 32 patients who were 2 to <4 years \\nof age or 4 years of age and older weighing <15 kg with moderately to severely active \\npolyarticular JIA.', 'tokens': ['Study', 'JIA-II', 'HUMIRA', 'assessed', 'open-label', ',', 'multicenter', 'study', '32', 'patients', '2', '<', '4', 'years', 'age', '4', 'years', 'age', 'older', 'weighing', '<', '15', 'kg', 'moderately', 'severely', 'active', 'polyarticular', 'JIA', '.'], 'lemmatized': ['Study', 'JIA-II', 'HUMIRA', 'assessed', 'open-label', ',', 'multicenter', 'study', '32', 'patient', '2', '<', '4', 'year', 'age', '4', 'year', 'age', 'older', 'weighing', '<', '15', 'kg', 'moderately', 'severely', 'active', 'polyarticular', 'JIA', '.'], 'stemmed': ['studi', 'jia-ii', 'humira', 'assess', 'open-label', ',', 'multicent', 'studi', '32', 'patient', '2', '<', '4', 'year', 'age', '4', 'year', 'age', 'older', 'weigh', '<', '15', 'kg', 'moder', 'sever', 'activ', 'polyarticular', 'jia', '.'], 'dependencies': [('studi', 'compound'), ('jia', 'compound'), ('-', 'punct'), ('ii', 'compound'), ('humira', 'nsubj'), ('assess', 'ROOT'), ('open', 'amod'), ('-', 'punct'), ('label', 'dobj'), (',', 'punct'), ('multicent', 'conj'), ('studi', 'npadvmod'), ('32', 'nummod'), ('patient', 'npadvmod'), ('2', 'quantmod'), ('<', 'dep'), ('4', 'nummod'), ('year', 'compound'), ('age', 'nmod'), ('4', 'nummod'), ('year', 'compound'), ('age', 'npadvmod'), ('older', 'amod'), ('weigh', 'nmod'), ('<', 'dep'), ('15', 'nummod'), ('kg', 'appos'), ('moder', 'nsubj'), ('sever', 'ROOT'), ('activ', 'nmod'), ('polyarticular', 'compound'), ('jia', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Most patients (97%) received at least 24 weeks of HUMIRA treatment dosed \\n24 mg/m2 up to a maximum of 20 mg every other week as a single SC injection up to a \\nmaximum of 120 weeks duration.', 'tokens': ['patients', '(', '97', '%', ')', 'received', 'least', '24', 'weeks', 'HUMIRA', 'treatment', 'dosed', '24', 'mg/m2', 'maximum', '20', 'mg', 'every', 'week', 'single', 'SC', 'injection', 'maximum', '120', 'weeks', 'duration', '.'], 'lemmatized': ['patient', '(', '97', '%', ')', 'received', 'least', '24', 'week', 'HUMIRA', 'treatment', 'dosed', '24', 'mg/m2', 'maximum', '20', 'mg', 'every', 'week', 'single', 'SC', 'injection', 'maximum', '120', 'week', 'duration', '.'], 'stemmed': ['patient', '(', '97', '%', ')', 'receiv', 'least', '24', 'week', 'humira', 'treatment', 'dose', '24', 'mg/m2', 'maximum', '20', 'mg', 'everi', 'week', 'singl', 'sc', 'inject', 'maximum', '120', 'week', 'durat', '.'], 'dependencies': [('patient', 'nsubj'), ('(', 'punct'), ('97', 'nummod'), ('%', 'appos'), (')', 'punct'), ('receiv', 'appos'), ('least', 'advmod'), ('24', 'nummod'), ('week', 'npadvmod'), ('humira', 'compound'), ('treatment', 'compound'), ('dose', 'conj'), ('24', 'nummod'), ('mg', 'nmod'), ('/', 'punct'), ('m2', 'dobj'), ('maximum', 'ROOT'), ('20', 'nummod'), ('mg', 'npadvmod'), ('everi', 'nummod'), ('week', 'npadvmod'), ('singl', 'nmod'), ('sc', 'compound'), ('inject', 'compound'), ('maximum', 'amod'), ('120', 'nummod'), ('week', 'compound'), ('durat', 'nsubj'), ('.', 'punct')]}, {'original_sentence': 'During the study, most patients used concomitant MTX, with \\nfewer reporting use of corticosteroids or NSAIDs.', 'tokens': ['study', ',', 'patients', 'used', 'concomitant', 'MTX', ',', 'fewer', 'reporting', 'use', 'corticosteroids', 'NSAIDs', '.'], 'lemmatized': ['study', ',', 'patient', 'used', 'concomitant', 'MTX', ',', 'fewer', 'reporting', 'use', 'corticosteroid', 'NSAIDs', '.'], 'stemmed': ['studi', ',', 'patient', 'use', 'concomit', 'mtx', ',', 'fewer', 'report', 'use', 'corticosteroid', 'nsaid', '.'], 'dependencies': [('studi', 'npadvmod'), (',', 'punct'), ('patient', 'amod'), ('use', 'compound'), ('concomit', 'compound'), ('mtx', 'advcl'), (',', 'punct'), ('fewer', 'amod'), ('report', 'nsubj'), ('use', 'ROOT'), ('corticosteroid', 'amod'), ('nsaid', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The primary objective of the study was \\nevaluation of safety [see Adverse Reactions (6.1)].', 'tokens': ['primary', 'objective', 'study', 'evaluation', 'safety', '[', 'see', 'Adverse', 'Reactions', '(', '6.1', ')', ']', '.'], 'lemmatized': ['primary', 'objective', 'study', 'evaluation', 'safety', '[', 'see', 'Adverse', 'Reactions', '(', '6.1', ')', ']', '.'], 'stemmed': ['primari', 'object', 'studi', 'evalu', 'safeti', '[', 'see', 'advers', 'reaction', '(', '6.1', ')', ']', '.'], 'dependencies': [('primari', 'compound'), ('object', 'compound'), ('studi', 'compound'), ('evalu', 'compound'), ('safeti', 'nsubj'), ('[', 'punct'), ('see', 'ROOT'), ('advers', 'compound'), ('reaction', 'dobj'), ('(', 'punct'), ('6.1', 'appos'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': '14.3 Psoriatic Arthritis \\nThe safety and efficacy of HUMIRA was assessed in two randomized, double-blind, placebo \\ncontrolled studies in 413 patients with psoriatic arthritis (PsA).', 'tokens': ['14.3', 'Psoriatic', 'Arthritis', 'safety', 'efficacy', 'HUMIRA', 'assessed', 'two', 'randomized', ',', 'double-blind', ',', 'placebo', 'controlled', 'studies', '413', 'patients', 'psoriatic', 'arthritis', '(', 'PsA', ')', '.'], 'lemmatized': ['14.3', 'Psoriatic', 'Arthritis', 'safety', 'efficacy', 'HUMIRA', 'assessed', 'two', 'randomized', ',', 'double-blind', ',', 'placebo', 'controlled', 'study', '413', 'patient', 'psoriatic', 'arthritis', '(', 'PsA', ')', '.'], 'stemmed': ['14.3', 'psoriat', 'arthriti', 'safeti', 'efficaci', 'humira', 'assess', 'two', 'random', ',', 'double-blind', ',', 'placebo', 'control', 'studi', '413', 'patient', 'psoriat', 'arthriti', '(', 'psa', ')', '.'], 'dependencies': [('14.3', 'nummod'), ('psoriat', 'compound'), ('arthriti', 'compound'), ('safeti', 'compound'), ('efficaci', 'compound'), ('humira', 'nsubj'), ('assess', 'ROOT'), ('two', 'nummod'), ('random', 'amod'), (',', 'punct'), ('double', 'amod'), ('-', 'punct'), ('blind', 'dobj'), (',', 'punct'), ('placebo', 'compound'), ('control', 'compound'), ('studi', 'compound'), ('413', 'nummod'), ('patient', 'compound'), ('psoriat', 'compound'), ('arthriti', 'npadvmod'), ('(', 'punct'), ('psa', 'ROOT'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Upon completion of both studies, \\n383 patients enrolled in an open-label extension study, in which 40 mg HUMIRA was \\nadministered every other week.', 'tokens': ['Upon', 'completion', 'studies', ',', '383', 'patients', 'enrolled', 'open-label', 'extension', 'study', ',', '40', 'mg', 'HUMIRA', 'administered', 'every', 'week', '.'], 'lemmatized': ['Upon', 'completion', 'study', ',', '383', 'patient', 'enrolled', 'open-label', 'extension', 'study', ',', '40', 'mg', 'HUMIRA', 'administered', 'every', 'week', '.'], 'stemmed': ['upon', 'complet', 'studi', ',', '383', 'patient', 'enrol', 'open-label', 'extens', 'studi', ',', '40', 'mg', 'humira', 'administ', 'everi', 'week', '.'], 'dependencies': [('upon', 'prep'), ('complet', 'compound'), ('studi', 'pobj'), (',', 'punct'), ('383', 'nummod'), ('patient', 'nsubj'), ('enrol', 'ROOT'), ('open', 'amod'), ('-', 'punct'), ('label', 'compound'), ('extens', 'compound'), ('studi', 'npadvmod'), (',', 'punct'), ('40', 'nummod'), ('mg', 'prep'), ('humira', 'compound'), ('administ', 'appos'), ('everi', 'amod'), ('week', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Study PsA-I enrolled 313 adult patients with moderately to severely active PsA (>3 swollen and \\n>3 tender joints) who had an inadequate response to NSAID therapy in one of the following \\nforms: (1) distal interphalangeal (DIP) involvement (N=23); (2) polyarticular arthritis (absence \\nof rheumatoid nodules and presence of plaque psoriasis) (N=210); (3) arthritis mutilans (N=1); \\n(4) asymmetric PsA (N=77); or (5) AS-like (N=2).', 'tokens': ['Study', 'PsA-I', 'enrolled', '313', 'adult', 'patients', 'moderately', 'severely', 'active', 'PsA', '(', '>', '3', 'swollen', '>', '3', 'tender', 'joints', ')', 'inadequate', 'response', 'NSAID', 'therapy', 'one', 'following', 'forms', ':', '(', '1', ')', 'distal', 'interphalangeal', '(', 'DIP', ')', 'involvement', '(', 'N=23', ')', ';', '(', '2', ')', 'polyarticular', 'arthritis', '(', 'absence', 'rheumatoid', 'nodules', 'presence', 'plaque', 'psoriasis', ')', '(', 'N=210', ')', ';', '(', '3', ')', 'arthritis', 'mutilans', '(', 'N=1', ')', ';', '(', '4', ')', 'asymmetric', 'PsA', '(', 'N=77', ')', ';', '(', '5', ')', 'AS-like', '(', 'N=2', ')', '.'], 'lemmatized': ['Study', 'PsA-I', 'enrolled', '313', 'adult', 'patient', 'moderately', 'severely', 'active', 'PsA', '(', '>', '3', 'swollen', '>', '3', 'tender', 'joint', ')', 'inadequate', 'response', 'NSAID', 'therapy', 'one', 'following', 'form', ':', '(', '1', ')', 'distal', 'interphalangeal', '(', 'DIP', ')', 'involvement', '(', 'N=23', ')', ';', '(', '2', ')', 'polyarticular', 'arthritis', '(', 'absence', 'rheumatoid', 'nodule', 'presence', 'plaque', 'psoriasis', ')', '(', 'N=210', ')', ';', '(', '3', ')', 'arthritis', 'mutilans', '(', 'N=1', ')', ';', '(', '4', ')', 'asymmetric', 'PsA', '(', 'N=77', ')', ';', '(', '5', ')', 'AS-like', '(', 'N=2', ')', '.'], 'stemmed': ['studi', 'psa-i', 'enrol', '313', 'adult', 'patient', 'moder', 'sever', 'activ', 'psa', '(', '>', '3', 'swollen', '>', '3', 'tender', 'joint', ')', 'inadequ', 'respons', 'nsaid', 'therapi', 'one', 'follow', 'form', ':', '(', '1', ')', 'distal', 'interphalang', '(', 'dip', ')', 'involv', '(', 'n=23', ')', ';', '(', '2', ')', 'polyarticular', 'arthriti', '(', 'absenc', 'rheumatoid', 'nodul', 'presenc', 'plaqu', 'psoriasi', ')', '(', 'n=210', ')', ';', '(', '3', ')', 'arthriti', 'mutilan', '(', 'n=1', ')', ';', '(', '4', ')', 'asymmetr', 'psa', '(', 'n=77', ')', ';', '(', '5', ')', 'as-lik', '(', 'n=2', ')', '.'], 'dependencies': [('studi', 'npadvmod'), ('psa', 'compound'), ('-', 'punct'), ('i', 'nsubj'), ('enrol', 'ccomp'), ('313', 'nummod'), ('adult', 'compound'), ('patient', 'compound'), ('moder', 'nsubj'), ('sever', 'ccomp'), ('activ', 'nmod'), ('psa', 'nmod'), ('(', 'punct'), ('>', 'nmod'), ('3', 'nsubj'), ('swollen', 'nmod'), ('>', 'nmod'), ('3', 'nummod'), ('tender', 'compound'), ('joint', 'dobj'), (')', 'punct'), ('inadequ', 'compound'), ('respons', 'compound'), ('nsaid', 'nsubj'), ('therapi', 'ROOT'), ('one', 'nummod'), ('follow', 'compound'), ('form', 'dobj'), (':', 'punct'), ('(', 'punct'), ('1', 'nummod'), (')', 'punct'), ('distal', 'amod'), ('interphalang', 'nsubj'), ('(', 'punct'), ('dip', 'appos'), (')', 'punct'), ('involv', 'appos'), ('(', 'punct'), ('n=23', 'npadvmod'), (')', 'punct'), (';', 'punct'), ('(', 'punct'), ('2', 'meta'), (')', 'punct'), ('polyarticular', 'conj'), ('arthriti', 'dobj'), ('(', 'punct'), ('absenc', 'npadvmod'), ('rheumatoid', 'acl'), ('nodul', 'nmod'), ('presenc', 'compound'), ('plaqu', 'compound'), ('psoriasi', 'dobj'), (')', 'punct'), ('(', 'punct'), ('n=210', 'appos'), (')', 'punct'), (';', 'punct'), ('(', 'punct'), ('3', 'meta'), (')', 'punct'), ('arthriti', 'compound'), ('mutilan', 'dep'), ('(', 'punct'), ('n=1', 'appos'), (')', 'punct'), (';', 'punct'), ('(', 'punct'), ('4', 'meta'), (')', 'punct'), ('asymmetr', 'compound'), ('psa', 'appos'), ('(', 'punct'), ('n=77', 'npadvmod'), (')', 'punct'), (';', 'punct'), ('(', 'punct'), ('5', 'conj'), (')', 'punct'), ('as', 'prep'), ('-', 'punct'), ('lik', 'pobj'), ('(', 'punct'), ('n=2', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Patients on MTX therapy (158 of 313 \\npatients) at enrollment (stable dose of ≤30 mg/week for >1 month) could continue MTX at the \\nsame dose.', 'tokens': ['Patients', 'MTX', 'therapy', '(', '158', '313', 'patients', ')', 'enrollment', '(', 'stable', 'dose', '≤30', 'mg/week', '>', '1', 'month', ')', 'could', 'continue', 'MTX', 'dose', '.'], 'lemmatized': ['Patients', 'MTX', 'therapy', '(', '158', '313', 'patient', ')', 'enrollment', '(', 'stable', 'dose', '≤30', 'mg/week', '>', '1', 'month', ')', 'could', 'continue', 'MTX', 'dose', '.'], 'stemmed': ['patient', 'mtx', 'therapi', '(', '158', '313', 'patient', ')', 'enrol', '(', 'stabl', 'dose', '≤30', 'mg/week', '>', '1', 'month', ')', 'could', 'continu', 'mtx', 'dose', '.'], 'dependencies': [('patient', 'compound'), ('mtx', 'compound'), ('therapi', 'nsubj'), ('(', 'punct'), ('158', 'nummod'), ('313', 'nummod'), ('patient', 'nmod'), (')', 'punct'), ('enrol', 'appos'), ('(', 'punct'), ('stabl', 'prep'), ('dose', 'compound'), ('≤30', 'nmod'), ('mg', 'nmod'), ('/', 'punct'), ('week', 'npadvmod'), ('>', 'dep'), ('1', 'nummod'), ('month', 'npadvmod'), (')', 'punct'), ('could', 'aux'), ('continu', 'ROOT'), ('mtx', 'compound'), ('dose', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Doses of HUMIRA 40 mg or placebo every other week were administered during the \\n24-week double-blind period of the study.', 'tokens': ['Doses', 'HUMIRA', '40', 'mg', 'placebo', 'every', 'week', 'administered', '24-week', 'double-blind', 'period', 'study', '.'], 'lemmatized': ['Doses', 'HUMIRA', '40', 'mg', 'placebo', 'every', 'week', 'administered', '24-week', 'double-blind', 'period', 'study', '.'], 'stemmed': ['dose', 'humira', '40', 'mg', 'placebo', 'everi', 'week', 'administ', '24-week', 'double-blind', 'period', 'studi', '.'], 'dependencies': [('dose', 'ROOT'), ('humira', 'dobj'), ('40', 'nummod'), ('mg', 'prep'), ('placebo', 'pobj'), ('everi', 'amod'), ('week', 'npadvmod'), ('administ', 'dobj'), ('24', 'nummod'), ('-', 'punct'), ('week', 'nmod'), ('double', 'amod'), ('-', 'punct'), ('blind', 'amod'), ('period', 'compound'), ('studi', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Compared to placebo, treatment with HUMIRA resulted in improvements in the measures of \\ndisease activity (see Tables 8 and 9).', 'tokens': ['Compared', 'placebo', ',', 'treatment', 'HUMIRA', 'resulted', 'improvements', 'measures', 'disease', 'activity', '(', 'see', 'Tables', '8', '9', ')', '.'], 'lemmatized': ['Compared', 'placebo', ',', 'treatment', 'HUMIRA', 'resulted', 'improvement', 'measure', 'disease', 'activity', '(', 'see', 'Tables', '8', '9', ')', '.'], 'stemmed': ['compar', 'placebo', ',', 'treatment', 'humira', 'result', 'improv', 'measur', 'diseas', 'activ', '(', 'see', 'tabl', '8', '9', ')', '.'], 'dependencies': [('compar', 'compound'), ('placebo', 'dep'), (',', 'punct'), ('treatment', 'compound'), ('humira', 'nsubj'), ('result', 'compound'), ('improv', 'compound'), ('measur', 'compound'), ('diseas', 'compound'), ('activ', 'ROOT'), ('(', 'punct'), ('see', 'parataxis'), ('tabl', 'dobj'), ('8', 'compound'), ('9', 'nummod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Among patients with PsA who received HUMIRA, the \\nclinical responses were apparent in some patients at the time of the first visit (two weeks) and \\nwere maintained up to 88 weeks in the ongoing open-label study.', 'tokens': ['Among', 'patients', 'PsA', 'received', 'HUMIRA', ',', 'clinical', 'responses', 'apparent', 'patients', 'time', 'first', 'visit', '(', 'two', 'weeks', ')', 'maintained', '88', 'weeks', 'ongoing', 'open-label', 'study', '.'], 'lemmatized': ['Among', 'patient', 'PsA', 'received', 'HUMIRA', ',', 'clinical', 'response', 'apparent', 'patient', 'time', 'first', 'visit', '(', 'two', 'week', ')', 'maintained', '88', 'week', 'ongoing', 'open-label', 'study', '.'], 'stemmed': ['among', 'patient', 'psa', 'receiv', 'humira', ',', 'clinic', 'respons', 'appar', 'patient', 'time', 'first', 'visit', '(', 'two', 'week', ')', 'maintain', '88', 'week', 'ongo', 'open-label', 'studi', '.'], 'dependencies': [('among', 'prep'), ('patient', 'amod'), ('psa', 'compound'), ('receiv', 'compound'), ('humira', 'pobj'), (',', 'punct'), ('clinic', 'compound'), ('respons', 'nsubj'), ('appar', 'nsubj'), ('patient', 'compound'), ('time', 'nmod'), ('first', 'amod'), ('visit', 'nsubj'), ('(', 'punct'), ('two', 'nummod'), ('week', 'appos'), (')', 'punct'), ('maintain', 'ROOT'), ('88', 'nummod'), ('week', 'npadvmod'), ('ongo', 'compound'), ('open', 'amod'), ('-', 'punct'), ('label', 'compound'), ('studi', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Similar responses were seen in \\npatients with each of the subtypes of psoriatic arthritis, although few patients were enrolled with', 'tokens': ['Similar', 'responses', 'seen', 'patients', 'subtypes', 'psoriatic', 'arthritis', ',', 'although', 'patients', 'enrolled'], 'lemmatized': ['Similar', 'response', 'seen', 'patient', 'subtypes', 'psoriatic', 'arthritis', ',', 'although', 'patient', 'enrolled'], 'stemmed': ['similar', 'respons', 'seen', 'patient', 'subtyp', 'psoriat', 'arthriti', ',', 'although', 'patient', 'enrol'], 'dependencies': [('similar', 'amod'), ('respons', 'ROOT'), ('seen', 'acl'), ('patient', 'amod'), ('subtyp', 'compound'), ('psoriat', 'compound'), ('arthriti', 'dobj'), (',', 'punct'), ('although', 'mark'), ('patient', 'compound'), ('enrol', 'advcl')]}], 'text': 'Patients demonstrating a Pediatric ACR 30 response at the end of OL-LI phase were randomized \\ninto the double blind (DB) phase of the study and received either HUMIRA or placebo every \\nother week for 32 weeks or until disease flare. Disease flare was defined as a worsening of ≥30% \\nfrom baseline in ≥3 of 6 Pediatric ACR core criteria, ≥2 active joints, and improvement of >30% \\nin no more than 1 of the 6 criteria. After 32 weeks or at the time of disease flare during the DB \\nphase, patients were treated in the open-label extension phase based on the BSA regimen (OLE-\\nBSA), before converting to a fixed dose regimen based on body weight (OLE-FD phase).  \\nStudy JIA-I Clinical Response \\nAt the end of the 16-week OL-LI phase, 94% of the patients in the MTX stratum and 74% of the \\npatients in the non-MTX stratum were Pediatric ACR 30 responders. In the DB phase \\nsignificantly fewer patients who received HUMIRA experienced disease flare compared to \\nplacebo, both without MTX (43% vs. 71%) and with MTX (37% vs. 65%). More patients treated \\nwith HUMIRA continued to show pediatric ACR 30/50/70 responses at Week 48 compared to \\npatients treated with placebo. Pediatric ACR responses were maintained for up to two years in \\nthe OLE phase in patients who received HUMIRA throughout the study.  \\nStudy JIA-II \\nHUMIRA was assessed in an open-label, multicenter study in 32 patients who were 2 to <4 years \\nof age or 4 years of age and older weighing <15 kg with moderately to severely active \\npolyarticular JIA. Most patients (97%) received at least 24 weeks of HUMIRA treatment dosed \\n24 mg/m2 up to a maximum of 20 mg every other week as a single SC injection up to a \\nmaximum of 120 weeks duration. During the study, most patients used concomitant MTX, with \\nfewer reporting use of corticosteroids or NSAIDs. The primary objective of the study was \\nevaluation of safety [see Adverse Reactions (6.1)].  \\n14.3 Psoriatic Arthritis \\nThe safety and efficacy of HUMIRA was assessed in two randomized, double-blind, placebo \\ncontrolled studies in 413 patients with psoriatic arthritis (PsA). Upon completion of both studies, \\n383 patients enrolled in an open-label extension study, in which 40 mg HUMIRA was \\nadministered every other week.  \\nStudy PsA-I enrolled 313 adult patients with moderately to severely active PsA (>3 swollen and \\n>3 tender joints) who had an inadequate response to NSAID therapy in one of the following \\nforms: (1) distal interphalangeal (DIP) involvement (N=23); (2) polyarticular arthritis (absence \\nof rheumatoid nodules and presence of plaque psoriasis) (N=210); (3) arthritis mutilans (N=1); \\n(4) asymmetric PsA (N=77); or (5) AS-like (N=2). Patients on MTX therapy (158 of 313 \\npatients) at enrollment (stable dose of ≤30 mg/week for >1 month) could continue MTX at the \\nsame dose. Doses of HUMIRA 40 mg or placebo every other week were administered during the \\n24-week double-blind period of the study.  \\nCompared to placebo, treatment with HUMIRA resulted in improvements in the measures of \\ndisease activity (see Tables 8 and 9). Among patients with PsA who received HUMIRA, the \\nclinical responses were apparent in some patients at the time of the first visit (two weeks) and \\nwere maintained up to 88 weeks in the ongoing open-label study. Similar responses were seen in \\npatients with each of the subtypes of psoriatic arthritis, although few patients were enrolled with \\n'}, 'page_char_count': 3407, 'page_word_count': 559, 'sentences': ['Patients demonstrating a Pediatric ACR 30 response at the end of OL-LI phase were randomized \\ninto the double blind (DB) phase of the study and received either HUMIRA or placebo every \\nother week for 32 weeks or until disease flare.', 'Disease flare was defined as a worsening of ≥30% \\nfrom baseline in ≥3 of 6 Pediatric ACR core criteria, ≥2 active joints, and improvement of >30% \\nin no more than 1 of the 6 criteria.', 'After 32 weeks or at the time of disease flare during the DB \\nphase, patients were treated in the open-label extension phase based on the BSA regimen (OLE-\\nBSA), before converting to a fixed dose regimen based on body weight (OLE-FD phase).', ' \\nStudy JIA-I Clinical Response \\nAt the end of the 16-week OL-LI phase, 94% of the patients in the MTX stratum and 74% of the \\npatients in the non-MTX stratum were Pediatric ACR 30 responders.', 'In the DB phase \\nsignificantly fewer patients who received HUMIRA experienced disease flare compared to \\nplacebo, both without MTX (43% vs. 71%) and with MTX (37% vs. 65%).', 'More patients treated \\nwith HUMIRA continued to show pediatric ACR 30/50/70 responses at Week 48 compared to \\npatients treated with placebo.', 'Pediatric ACR responses were maintained for up to two years in \\nthe OLE phase in patients who received HUMIRA throughout the study.', ' \\nStudy JIA-II \\nHUMIRA was assessed in an open-label, multicenter study in 32 patients who were 2 to <4 years \\nof age or 4 years of age and older weighing <15 kg with moderately to severely active \\npolyarticular JIA.', 'Most patients (97%) received at least 24 weeks of HUMIRA treatment dosed \\n24 mg/m2 up to a maximum of 20 mg every other week as a single SC injection up to a \\nmaximum of 120 weeks duration.', 'During the study, most patients used concomitant MTX, with \\nfewer reporting use of corticosteroids or NSAIDs.', 'The primary objective of the study was \\nevaluation of safety [see Adverse Reactions (6.1)].', ' \\n14.3 Psoriatic Arthritis \\nThe safety and efficacy of HUMIRA was assessed in two randomized, double-blind, placebo \\ncontrolled studies in 413 patients with psoriatic arthritis (PsA).', 'Upon completion of both studies, \\n383 patients enrolled in an open-label extension study, in which 40 mg HUMIRA was \\nadministered every other week.', ' \\nStudy PsA-I enrolled 313 adult patients with moderately to severely active PsA (>3 swollen and \\n>3 tender joints) who had an inadequate response to NSAID therapy in one of the following \\nforms: (1) distal interphalangeal (DIP) involvement (N=23); (2) polyarticular arthritis (absence \\nof rheumatoid nodules and presence of plaque psoriasis) (N=210); (3) arthritis mutilans (N=1); \\n(4) asymmetric PsA (N=77); or (5) AS-like (N=2).', 'Patients on MTX therapy (158 of 313 \\npatients) at enrollment (stable dose of ≤30 mg/week for >1 month) could continue MTX at the \\nsame dose.', 'Doses of HUMIRA 40 mg or placebo every other week were administered during the \\n24-week double-blind period of the study.', ' \\nCompared to placebo, treatment with HUMIRA resulted in improvements in the measures of \\ndisease activity (see Tables 8 and 9).', 'Among patients with PsA who received HUMIRA, the \\nclinical responses were apparent in some patients at the time of the first visit (two weeks) and \\nwere maintained up to 88 weeks in the ongoing open-label study.', 'Similar responses were seen in \\npatients with each of the subtypes of psoriatic arthritis, although few patients were enrolled with \\n'], 'page_sentence_count_spacy': 19}\n",
            "{'page_number': 39, 'text': 'the arthritis mutilans and ankylosing spondylitis-like subtypes. Responses were similar in \\npatients who were or were not receiving concomitant MTX therapy at baseline.  \\nPatients with psoriatic involvement of at least three percent body surface area (BSA) were \\nevaluated for Psoriatic Area and Severity Index (PASI) responses. At 24 weeks, the proportions \\nof patients achieving a 75% or 90% improvement in the PASI were 59% and 42% respectively, \\nin the HUMIRA group (N=69), compared to 1% and 0% respectively, in the placebo group \\n(N=69) (p<0.001). PASI responses were apparent in some patients at the time of the first visit \\n(two weeks). Responses were similar in patients who were or were not receiving concomitant \\nMTX therapy at baseline.  \\nTable 8. ACR Response in Study PsA-I (Percent of Patients) \\n  \\nPlacebo \\nN=162  \\nHUMIRA* \\nN=151  \\nACR20 \\n    Week 12 \\n    Week 24  \\n \\n14% \\n15%  \\n \\n58% \\n57%  \\nACR50 \\n    Week 12 \\n    Week 24  \\n \\n4% \\n6%  \\n \\n36% \\n39%  \\nACR70 \\n    Week 12 \\n    Week 24  \\n \\n1% \\n1%  \\n \\n20% \\n23%  \\n*  p<0.001 for all comparisons between HUMIRA and placebo \\n \\nTable 9. Components of Disease Activity in Study PsA-I \\n  \\nPlacebo \\nN=162  \\nHUMIRA* \\nN=151  \\nParameter: median \\nBaseline \\n24 weeks \\nBaseline \\n24 weeks \\nNumber of tender jointsa \\n23.0 \\n17.0 \\n20.0 \\n5.0 \\nNumber of swollen jointsb \\n11.0 \\n9.0 \\n11.0 \\n3.0 \\nPhysician global assessmentc \\n53.0 \\n49.0 \\n55.0 \\n16.0 \\nPatient global assessmentc \\n49.5 \\n49.0 \\n48.0 \\n20.0 \\nPainc \\n49.0 \\n49.0 \\n54.0 \\n20.0 \\nDisability index (HAQ) d \\n1.0 \\n0.9 \\n1.0 \\n0.4 \\nCRP (mg/dL)e \\n0.8 \\n0.7 \\n0.8 \\n0.2 \\n*  p<0.001 for HUMIRA vs. placebo comparisons based on median changes \\na  Scale 0-78 \\nb  Scale 0-76 \\nc  Visual analog scale; 0=best, 100=worst \\nd  Disability Index of the Health Assessment Questionnaire; 0=best, 3=worst; measures the \\npatient’s ability to perform the following: dress/groom, arise, eat, walk, reach, grip, maintain \\nhygiene, and maintain daily activity. \\ne  Normal range: 0-0.287 mg/dL  \\n', 'processed_text': {'sentences': [{'original_sentence': 'the arthritis mutilans and ankylosing spondylitis-like subtypes.', 'tokens': ['arthritis', 'mutilans', 'ankylosing', 'spondylitis-like', 'subtypes', '.'], 'lemmatized': ['arthritis', 'mutilans', 'ankylosing', 'spondylitis-like', 'subtypes', '.'], 'stemmed': ['arthriti', 'mutilan', 'ankylos', 'spondylitis-lik', 'subtyp', '.'], 'dependencies': [('arthriti', 'compound'), ('mutilan', 'ROOT'), ('ankylos', 'compound'), ('spondylitis', 'compound'), ('-', 'punct'), ('lik', 'compound'), ('subtyp', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Responses were similar in \\npatients who were or were not receiving concomitant MTX therapy at baseline.', 'tokens': ['Responses', 'similar', 'patients', 'receiving', 'concomitant', 'MTX', 'therapy', 'baseline', '.'], 'lemmatized': ['Responses', 'similar', 'patient', 'receiving', 'concomitant', 'MTX', 'therapy', 'baseline', '.'], 'stemmed': ['respons', 'similar', 'patient', 'receiv', 'concomit', 'mtx', 'therapi', 'baselin', '.'], 'dependencies': [('respons', 'ROOT'), ('similar', 'amod'), ('patient', 'compound'), ('receiv', 'compound'), ('concomit', 'nsubj'), ('mtx', 'dobj'), ('therapi', 'compound'), ('baselin', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Patients with psoriatic involvement of at least three percent body surface area (BSA) were \\nevaluated for Psoriatic Area and Severity Index (PASI) responses.', 'tokens': ['Patients', 'psoriatic', 'involvement', 'least', 'three', 'percent', 'body', 'surface', 'area', '(', 'BSA', ')', 'evaluated', 'Psoriatic', 'Area', 'Severity', 'Index', '(', 'PASI', ')', 'responses', '.'], 'lemmatized': ['Patients', 'psoriatic', 'involvement', 'least', 'three', 'percent', 'body', 'surface', 'area', '(', 'BSA', ')', 'evaluated', 'Psoriatic', 'Area', 'Severity', 'Index', '(', 'PASI', ')', 'response', '.'], 'stemmed': ['patient', 'psoriat', 'involv', 'least', 'three', 'percent', 'bodi', 'surfac', 'area', '(', 'bsa', ')', 'evalu', 'psoriat', 'area', 'sever', 'index', '(', 'pasi', ')', 'respons', '.'], 'dependencies': [('patient', 'compound'), ('psoriat', 'nsubj'), ('involv', 'ROOT'), ('least', 'advmod'), ('three', 'nummod'), ('percent', 'compound'), ('bodi', 'compound'), ('surfac', 'compound'), ('area', 'dobj'), ('(', 'punct'), ('bsa', 'appos'), (')', 'punct'), ('evalu', 'compound'), ('psoriat', 'compound'), ('area', 'compound'), ('sever', 'compound'), ('index', 'nmod'), ('(', 'punct'), ('pasi', 'nmod'), (')', 'punct'), ('respons', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'At 24 weeks, the proportions \\nof patients achieving a 75% or 90% improvement in the PASI were 59% and 42% respectively, \\nin the HUMIRA group (N=69), compared to 1% and 0% respectively, in the placebo group \\n(N=69) (p<0.001).', 'tokens': ['24', 'weeks', ',', 'proportions', 'patients', 'achieving', '75', '%', '90', '%', 'improvement', 'PASI', '59', '%', '42', '%', 'respectively', ',', 'HUMIRA', 'group', '(', 'N=69', ')', ',', 'compared', '1', '%', '0', '%', 'respectively', ',', 'placebo', 'group', '(', 'N=69', ')', '(', 'p', '<', '0.001', ')', '.'], 'lemmatized': ['24', 'week', ',', 'proportion', 'patient', 'achieving', '75', '%', '90', '%', 'improvement', 'PASI', '59', '%', '42', '%', 'respectively', ',', 'HUMIRA', 'group', '(', 'N=69', ')', ',', 'compared', '1', '%', '0', '%', 'respectively', ',', 'placebo', 'group', '(', 'N=69', ')', '(', 'p', '<', '0.001', ')', '.'], 'stemmed': ['24', 'week', ',', 'proport', 'patient', 'achiev', '75', '%', '90', '%', 'improv', 'pasi', '59', '%', '42', '%', 'respect', ',', 'humira', 'group', '(', 'n=69', ')', ',', 'compar', '1', '%', '0', '%', 'respect', ',', 'placebo', 'group', '(', 'n=69', ')', '(', 'p', '<', '0.001', ')', '.'], 'dependencies': [('24', 'nummod'), ('week', 'npadvmod'), (',', 'punct'), ('proport', 'compound'), ('patient', 'compound'), ('achiev', 'ROOT'), ('75', 'nummod'), ('%', 'appos'), ('90', 'nummod'), ('%', 'npadvmod'), ('improv', 'advmod'), ('pasi', 'punct'), ('59', 'nummod'), ('%', 'appos'), ('42', 'nummod'), ('%', 'compound'), ('respect', 'appos'), (',', 'punct'), ('humira', 'compound'), ('group', 'appos'), ('(', 'punct'), ('n=69', 'appos'), (')', 'punct'), (',', 'punct'), ('compar', 'appos'), ('1', 'nummod'), ('%', 'npadvmod'), ('0', 'nummod'), ('%', 'compound'), ('respect', 'appos'), (',', 'punct'), ('placebo', 'compound'), ('group', 'appos'), ('(', 'punct'), ('n=69', 'appos'), (')', 'punct'), ('(', 'punct'), ('p', 'appos'), ('<', 'dep'), ('0.001', 'nummod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'PASI responses were apparent in some patients at the time of the first visit \\n(two weeks).', 'tokens': ['PASI', 'responses', 'apparent', 'patients', 'time', 'first', 'visit', '(', 'two', 'weeks', ')', '.'], 'lemmatized': ['PASI', 'response', 'apparent', 'patient', 'time', 'first', 'visit', '(', 'two', 'week', ')', '.'], 'stemmed': ['pasi', 'respons', 'appar', 'patient', 'time', 'first', 'visit', '(', 'two', 'week', ')', '.'], 'dependencies': [('pasi', 'compound'), ('respons', 'nsubj'), ('appar', 'ROOT'), ('patient', 'amod'), ('time', 'nmod'), ('first', 'amod'), ('visit', 'dobj'), ('(', 'punct'), ('two', 'nummod'), ('week', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Responses were similar in patients who were or were not receiving concomitant \\nMTX therapy at baseline.', 'tokens': ['Responses', 'similar', 'patients', 'receiving', 'concomitant', 'MTX', 'therapy', 'baseline', '.'], 'lemmatized': ['Responses', 'similar', 'patient', 'receiving', 'concomitant', 'MTX', 'therapy', 'baseline', '.'], 'stemmed': ['respons', 'similar', 'patient', 'receiv', 'concomit', 'mtx', 'therapi', 'baselin', '.'], 'dependencies': [('respons', 'ROOT'), ('similar', 'amod'), ('patient', 'compound'), ('receiv', 'compound'), ('concomit', 'nsubj'), ('mtx', 'dobj'), ('therapi', 'compound'), ('baselin', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Table 8.', 'tokens': ['Table', '8', '.'], 'lemmatized': ['Table', '8', '.'], 'stemmed': ['tabl', '8', '.'], 'dependencies': [('tabl', 'ROOT'), ('8', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'ACR Response in Study PsA-I (Percent of Patients) \\n  \\nPlacebo \\nN=162  \\nHUMIRA* \\nN=151  \\nACR20 \\n    Week 12 \\n    Week 24  \\n \\n14% \\n15%  \\n \\n58% \\n57%  \\nACR50 \\n    Week 12 \\n    Week 24  \\n \\n4% \\n6%  \\n \\n36% \\n39%  \\nACR70 \\n    Week 12 \\n    Week 24  \\n \\n1% \\n1%  \\n \\n20% \\n23%  \\n*  p<0.001 for all comparisons between HUMIRA and placebo \\n \\nTable 9.', 'tokens': ['ACR', 'Response', 'Study', 'PsA-I', '(', 'Percent', 'Patients', ')', 'Placebo', 'N=162', 'HUMIRA', '*', 'N=151', 'ACR20', 'Week', '12', 'Week', '24', '14', '%', '15', '%', '58', '%', '57', '%', 'ACR50', 'Week', '12', 'Week', '24', '4', '%', '6', '%', '36', '%', '39', '%', 'ACR70', 'Week', '12', 'Week', '24', '1', '%', '1', '%', '20', '%', '23', '%', '*', 'p', '<', '0.001', 'comparisons', 'HUMIRA', 'placebo', 'Table', '9', '.'], 'lemmatized': ['ACR', 'Response', 'Study', 'PsA-I', '(', 'Percent', 'Patients', ')', 'Placebo', 'N=162', 'HUMIRA', '*', 'N=151', 'ACR20', 'Week', '12', 'Week', '24', '14', '%', '15', '%', '58', '%', '57', '%', 'ACR50', 'Week', '12', 'Week', '24', '4', '%', '6', '%', '36', '%', '39', '%', 'ACR70', 'Week', '12', 'Week', '24', '1', '%', '1', '%', '20', '%', '23', '%', '*', 'p', '<', '0.001', 'comparison', 'HUMIRA', 'placebo', 'Table', '9', '.'], 'stemmed': ['acr', 'respons', 'studi', 'psa-i', '(', 'percent', 'patient', ')', 'placebo', 'n=162', 'humira', '*', 'n=151', 'acr20', 'week', '12', 'week', '24', '14', '%', '15', '%', '58', '%', '57', '%', 'acr50', 'week', '12', 'week', '24', '4', '%', '6', '%', '36', '%', '39', '%', 'acr70', 'week', '12', 'week', '24', '1', '%', '1', '%', '20', '%', '23', '%', '*', 'p', '<', '0.001', 'comparison', 'humira', 'placebo', 'tabl', '9', '.'], 'dependencies': [('acr', 'ROOT'), ('respons', 'pobj'), ('studi', 'conj'), ('psa', 'compound'), ('-', 'punct'), ('i', 'appos'), ('(', 'punct'), ('percent', 'npadvmod'), ('patient', 'preconj'), (')', 'punct'), ('placebo', 'compound'), ('n=162', 'dep'), ('humira', 'nmod'), ('*', 'punct'), ('n=151', 'compound'), ('acr20', 'compound'), ('week', 'ROOT'), ('12', 'nummod'), ('week', 'appos'), ('24', 'nummod'), ('14', 'nummod'), ('%', 'appos'), ('15', 'nummod'), ('%', 'appos'), ('58', 'nummod'), ('%', 'appos'), ('57', 'nummod'), ('%', 'appos'), ('acr50', 'amod'), ('week', 'appos'), ('12', 'nummod'), ('week', 'appos'), ('24', 'nummod'), ('4', 'nummod'), ('%', 'appos'), ('6', 'nummod'), ('%', 'appos'), ('36', 'nummod'), ('%', 'appos'), ('39', 'nummod'), ('%', 'appos'), ('acr70', 'cc'), ('week', 'conj'), ('12', 'nummod'), ('week', 'npadvmod'), ('24', 'nummod'), ('1', 'nummod'), ('%', 'appos'), ('1', 'nummod'), ('%', 'appos'), ('20', 'nummod'), ('%', 'appos'), ('23', 'nummod'), ('%', 'appos'), ('*', 'punct'), ('p', 'nmod'), ('<', 'nmod'), ('0.001', 'nummod'), ('comparison', 'compound'), ('humira', 'compound'), ('placebo', 'compound'), ('tabl', 'ROOT'), ('9', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Components of Disease Activity in Study PsA-I \\n  \\nPlacebo \\nN=162  \\nHUMIRA* \\nN=151  \\nParameter: median \\nBaseline \\n24 weeks \\nBaseline \\n24 weeks \\nNumber of tender jointsa \\n23.0 \\n17.0 \\n20.0 \\n5.0 \\nNumber of swollen jointsb \\n11.0 \\n9.0 \\n11.0 \\n3.0 \\nPhysician global assessmentc \\n53.0 \\n49.0 \\n55.0 \\n16.0 \\nPatient global assessmentc \\n49.5 \\n49.0 \\n48.0 \\n20.0 \\nPainc \\n49.0 \\n49.0 \\n54.0 \\n20.0 \\nDisability index (HAQ) d \\n1.0 \\n0.9 \\n1.0 \\n0.4 \\nCRP (mg/dL)e \\n0.8 \\n0.7 \\n0.8 \\n0.2 \\n*  p<0.001 for HUMIRA vs. placebo comparisons based on median changes \\na  Scale 0-78 \\nb  Scale 0-76 \\nc  Visual analog scale; 0=best, 100=worst \\nd  Disability Index of the Health Assessment Questionnaire; 0=best, 3=worst; measures the \\npatient’s ability to perform the following: dress/groom, arise, eat, walk, reach, grip, maintain \\nhygiene, and maintain daily activity.', 'tokens': ['Components', 'Disease', 'Activity', 'Study', 'PsA-I', 'Placebo', 'N=162', 'HUMIRA', '*', 'N=151', 'Parameter', ':', 'median', 'Baseline', '24', 'weeks', 'Baseline', '24', 'weeks', 'Number', 'tender', 'jointsa', '23.0', '17.0', '20.0', '5.0', 'Number', 'swollen', 'jointsb', '11.0', '9.0', '11.0', '3.0', 'Physician', 'global', 'assessmentc', '53.0', '49.0', '55.0', '16.0', 'Patient', 'global', 'assessmentc', '49.5', '49.0', '48.0', '20.0', 'Painc', '49.0', '49.0', '54.0', '20.0', 'Disability', 'index', '(', 'HAQ', ')', '1.0', '0.9', '1.0', '0.4', 'CRP', '(', 'mg/dL', ')', 'e', '0.8', '0.7', '0.8', '0.2', '*', 'p', '<', '0.001', 'HUMIRA', 'vs.', 'placebo', 'comparisons', 'based', 'median', 'changes', 'Scale', '0-78', 'b', 'Scale', '0-76', 'c', 'Visual', 'analog', 'scale', ';', '0=best', ',', '100=worst', 'Disability', 'Index', 'Health', 'Assessment', 'Questionnaire', ';', '0=best', ',', '3=worst', ';', 'measures', 'patient', '’', 'ability', 'perform', 'following', ':', 'dress/groom', ',', 'arise', ',', 'eat', ',', 'walk', ',', 'reach', ',', 'grip', ',', 'maintain', 'hygiene', ',', 'maintain', 'daily', 'activity', '.'], 'lemmatized': ['Components', 'Disease', 'Activity', 'Study', 'PsA-I', 'Placebo', 'N=162', 'HUMIRA', '*', 'N=151', 'Parameter', ':', 'median', 'Baseline', '24', 'week', 'Baseline', '24', 'week', 'Number', 'tender', 'jointsa', '23.0', '17.0', '20.0', '5.0', 'Number', 'swollen', 'jointsb', '11.0', '9.0', '11.0', '3.0', 'Physician', 'global', 'assessmentc', '53.0', '49.0', '55.0', '16.0', 'Patient', 'global', 'assessmentc', '49.5', '49.0', '48.0', '20.0', 'Painc', '49.0', '49.0', '54.0', '20.0', 'Disability', 'index', '(', 'HAQ', ')', '1.0', '0.9', '1.0', '0.4', 'CRP', '(', 'mg/dL', ')', 'e', '0.8', '0.7', '0.8', '0.2', '*', 'p', '<', '0.001', 'HUMIRA', 'vs.', 'placebo', 'comparison', 'based', 'median', 'change', 'Scale', '0-78', 'b', 'Scale', '0-76', 'c', 'Visual', 'analog', 'scale', ';', '0=best', ',', '100=worst', 'Disability', 'Index', 'Health', 'Assessment', 'Questionnaire', ';', '0=best', ',', '3=worst', ';', 'measure', 'patient', '’', 'ability', 'perform', 'following', ':', 'dress/groom', ',', 'arise', ',', 'eat', ',', 'walk', ',', 'reach', ',', 'grip', ',', 'maintain', 'hygiene', ',', 'maintain', 'daily', 'activity', '.'], 'stemmed': ['compon', 'diseas', 'activ', 'studi', 'psa-i', 'placebo', 'n=162', 'humira', '*', 'n=151', 'paramet', ':', 'median', 'baselin', '24', 'week', 'baselin', '24', 'week', 'number', 'tender', 'jointsa', '23.0', '17.0', '20.0', '5.0', 'number', 'swollen', 'jointsb', '11.0', '9.0', '11.0', '3.0', 'physician', 'global', 'assessmentc', '53.0', '49.0', '55.0', '16.0', 'patient', 'global', 'assessmentc', '49.5', '49.0', '48.0', '20.0', 'painc', '49.0', '49.0', '54.0', '20.0', 'disabl', 'index', '(', 'haq', ')', '1.0', '0.9', '1.0', '0.4', 'crp', '(', 'mg/dl', ')', 'e', '0.8', '0.7', '0.8', '0.2', '*', 'p', '<', '0.001', 'humira', 'vs.', 'placebo', 'comparison', 'base', 'median', 'chang', 'scale', '0-78', 'b', 'scale', '0-76', 'c', 'visual', 'analog', 'scale', ';', '0=best', ',', '100=worst', 'disabl', 'index', 'health', 'assess', 'questionnair', ';', '0=best', ',', '3=worst', ';', 'measur', 'patient', '’', 'abil', 'perform', 'follow', ':', 'dress/groom', ',', 'aris', ',', 'eat', ',', 'walk', ',', 'reach', ',', 'grip', ',', 'maintain', 'hygien', ',', 'maintain', 'daili', 'activ', '.'], 'dependencies': [('compon', 'ROOT'), ('diseas', 'dobj'), ('activ', 'compound'), ('studi', 'nmod'), ('psa', 'nmod'), ('-', 'punct'), ('i', 'dobj'), ('placebo', 'compound'), ('n=162', 'npadvmod'), ('humira', 'dobj'), ('*', 'punct'), ('n=151', 'compound'), ('paramet', 'dobj'), (':', 'punct'), ('median', 'amod'), ('baselin', 'nmod'), ('24', 'nummod'), ('week', 'compound'), ('baselin', 'npadvmod'), ('24', 'nummod'), ('week', 'compound'), ('number', 'compound'), ('tender', 'compound'), ('jointsa', 'appos'), ('23.0', 'nummod'), ('17.0', 'nummod'), ('20.0', 'compound'), ('5.0', 'nummod'), ('number', 'npadvmod'), ('swollen', 'compound'), ('jointsb', 'npadvmod'), ('11.0', 'nummod'), ('9.0', 'compound'), ('11.0', 'compound'), ('3.0', 'nummod'), ('physician', 'nmod'), ('global', 'amod'), ('assessmentc', 'appos'), ('53.0', 'quantmod'), ('49.0', 'compound'), ('55.0', 'compound'), ('16.0', 'nummod'), ('patient', 'nmod'), ('global', 'amod'), ('assessmentc', 'appos'), ('49.5', 'nummod'), ('49.0', 'nummod'), ('48.0', 'compound'), ('20.0', 'nummod'), ('painc', 'appos'), ('49.0', 'compound'), ('49.0', 'compound'), ('54.0', 'nummod'), ('20.0', 'nummod'), ('disabl', 'compound'), ('index', 'appos'), ('(', 'punct'), ('haq', 'nmod'), (')', 'punct'), ('1.0', 'nummod'), ('0.9', 'nummod'), ('1.0', 'compound'), ('0.4', 'nummod'), ('crp', 'nmod'), ('(', 'punct'), ('mg', 'nmod'), ('/', 'punct'), ('dl', 'nmod'), (')', 'punct'), ('e', 'appos'), ('0.8', 'nummod'), ('0.7', 'compound'), ('0.8', 'compound'), ('0.2', 'npadvmod'), ('*', 'punct'), ('p', 'nmod'), ('<', 'dep'), ('0.001', 'nummod'), ('humira', 'nsubj'), ('vs.', 'prep'), ('placebo', 'compound'), ('comparison', 'compound'), ('base', 'compound'), ('median', 'compound'), ('chang', 'pobj'), ('scale', 'nsubj'), ('0', 'npadvmod'), ('-', 'punct'), ('78', 'compound'), ('b', 'prep'), ('scale', 'dobj'), ('0', 'npadvmod'), ('-', 'punct'), ('76', 'prep'), ('c', 'nmod'), ('visual', 'amod'), ('analog', 'compound'), ('scale', 'appos'), (';', 'punct'), ('0', 'nummod'), ('=', 'punct'), ('best', 'amod'), (',', 'punct'), ('100', 'nummod'), ('=', 'punct'), ('worst', 'amod'), ('disabl', 'compound'), ('index', 'compound'), ('health', 'compound'), ('assess', 'compound'), ('questionnair', 'appos'), (';', 'punct'), ('0', 'nummod'), ('=', 'punct'), ('best', 'conj'), (',', 'punct'), ('3', 'nummod'), ('=', 'npadvmod'), ('worst', 'amod'), (';', 'punct'), ('measur', 'compound'), ('patient', 'nmod'), ('’', 'punct'), ('abil', 'nsubj'), ('perform', 'ROOT'), ('follow', 'dobj'), (':', 'punct'), ('dress', 'nmod'), ('/', 'punct'), ('groom', 'nsubj'), (',', 'punct'), ('aris', 'conj'), (',', 'punct'), ('eat', 'conj'), (',', 'punct'), ('walk', 'conj'), (',', 'punct'), ('reach', 'conj'), (',', 'punct'), ('grip', 'conj'), (',', 'punct'), ('maintain', 'dep'), ('hygien', 'dobj'), (',', 'punct'), ('maintain', 'conj'), ('daili', 'compound'), ('activ', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'e  Normal range: 0-0.287 mg/dL', 'tokens': ['e', 'Normal', 'range', ':', '0-0.287', 'mg/dL'], 'lemmatized': ['e', 'Normal', 'range', ':', '0-0.287', 'mg/dL'], 'stemmed': ['e', 'normal', 'rang', ':', '0-0.287', 'mg/dl'], 'dependencies': [('e', 'compound'), ('normal', 'amod'), ('rang', 'ROOT'), (':', 'punct'), ('0', 'appos'), ('-', 'punct'), ('0.287', 'nummod'), ('mg', 'nmod'), ('/', 'punct'), ('dl', 'appos')]}], 'text': 'the arthritis mutilans and ankylosing spondylitis-like subtypes. Responses were similar in \\npatients who were or were not receiving concomitant MTX therapy at baseline.  \\nPatients with psoriatic involvement of at least three percent body surface area (BSA) were \\nevaluated for Psoriatic Area and Severity Index (PASI) responses. At 24 weeks, the proportions \\nof patients achieving a 75% or 90% improvement in the PASI were 59% and 42% respectively, \\nin the HUMIRA group (N=69), compared to 1% and 0% respectively, in the placebo group \\n(N=69) (p<0.001). PASI responses were apparent in some patients at the time of the first visit \\n(two weeks). Responses were similar in patients who were or were not receiving concomitant \\nMTX therapy at baseline.  \\nTable 8. ACR Response in Study PsA-I (Percent of Patients) \\n  \\nPlacebo \\nN=162  \\nHUMIRA* \\nN=151  \\nACR20 \\n    Week 12 \\n    Week 24  \\n \\n14% \\n15%  \\n \\n58% \\n57%  \\nACR50 \\n    Week 12 \\n    Week 24  \\n \\n4% \\n6%  \\n \\n36% \\n39%  \\nACR70 \\n    Week 12 \\n    Week 24  \\n \\n1% \\n1%  \\n \\n20% \\n23%  \\n*  p<0.001 for all comparisons between HUMIRA and placebo \\n \\nTable 9. Components of Disease Activity in Study PsA-I \\n  \\nPlacebo \\nN=162  \\nHUMIRA* \\nN=151  \\nParameter: median \\nBaseline \\n24 weeks \\nBaseline \\n24 weeks \\nNumber of tender jointsa \\n23.0 \\n17.0 \\n20.0 \\n5.0 \\nNumber of swollen jointsb \\n11.0 \\n9.0 \\n11.0 \\n3.0 \\nPhysician global assessmentc \\n53.0 \\n49.0 \\n55.0 \\n16.0 \\nPatient global assessmentc \\n49.5 \\n49.0 \\n48.0 \\n20.0 \\nPainc \\n49.0 \\n49.0 \\n54.0 \\n20.0 \\nDisability index (HAQ) d \\n1.0 \\n0.9 \\n1.0 \\n0.4 \\nCRP (mg/dL)e \\n0.8 \\n0.7 \\n0.8 \\n0.2 \\n*  p<0.001 for HUMIRA vs. placebo comparisons based on median changes \\na  Scale 0-78 \\nb  Scale 0-76 \\nc  Visual analog scale; 0=best, 100=worst \\nd  Disability Index of the Health Assessment Questionnaire; 0=best, 3=worst; measures the \\npatient’s ability to perform the following: dress/groom, arise, eat, walk, reach, grip, maintain \\nhygiene, and maintain daily activity. \\ne  Normal range: 0-0.287 mg/dL  \\n'}, 'page_char_count': 1957, 'page_word_count': 294, 'sentences': ['the arthritis mutilans and ankylosing spondylitis-like subtypes.', 'Responses were similar in \\npatients who were or were not receiving concomitant MTX therapy at baseline.', ' \\nPatients with psoriatic involvement of at least three percent body surface area (BSA) were \\nevaluated for Psoriatic Area and Severity Index (PASI) responses.', 'At 24 weeks, the proportions \\nof patients achieving a 75% or 90% improvement in the PASI were 59% and 42% respectively, \\nin the HUMIRA group (N=69), compared to 1% and 0% respectively, in the placebo group \\n(N=69) (p<0.001).', 'PASI responses were apparent in some patients at the time of the first visit \\n(two weeks).', 'Responses were similar in patients who were or were not receiving concomitant \\nMTX therapy at baseline.', ' \\nTable 8.', 'ACR Response in Study PsA-I (Percent of Patients) \\n  \\nPlacebo \\nN=162  \\nHUMIRA* \\nN=151  \\nACR20 \\n    Week 12 \\n    Week 24  \\n \\n14% \\n15%  \\n \\n58% \\n57%  \\nACR50 \\n    Week 12 \\n    Week 24  \\n \\n4% \\n6%  \\n \\n36% \\n39%  \\nACR70 \\n    Week 12 \\n    Week 24  \\n \\n1% \\n1%  \\n \\n20% \\n23%  \\n*  p<0.001 for all comparisons between HUMIRA and placebo \\n \\nTable 9.', 'Components of Disease Activity in Study PsA-I \\n  \\nPlacebo \\nN=162  \\nHUMIRA* \\nN=151  \\nParameter: median \\nBaseline \\n24 weeks \\nBaseline \\n24 weeks \\nNumber of tender jointsa \\n23.0 \\n17.0 \\n20.0 \\n5.0 \\nNumber of swollen jointsb \\n11.0 \\n9.0 \\n11.0 \\n3.0 \\nPhysician global assessmentc \\n53.0 \\n49.0 \\n55.0 \\n16.0 \\nPatient global assessmentc \\n49.5 \\n49.0 \\n48.0 \\n20.0 \\nPainc \\n49.0 \\n49.0 \\n54.0 \\n20.0 \\nDisability index (HAQ) d \\n1.0 \\n0.9 \\n1.0 \\n0.4 \\nCRP (mg/dL)e \\n0.8 \\n0.7 \\n0.8 \\n0.2 \\n*  p<0.001 for HUMIRA vs. placebo comparisons based on median changes \\na  Scale 0-78 \\nb  Scale 0-76 \\nc  Visual analog scale; 0=best, 100=worst \\nd  Disability Index of the Health Assessment Questionnaire; 0=best, 3=worst; measures the \\npatient’s ability to perform the following: dress/groom, arise, eat, walk, reach, grip, maintain \\nhygiene, and maintain daily activity.', '\\ne  Normal range: 0-0.287 mg/dL  \\n'], 'page_sentence_count_spacy': 10}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            " 43%|████▎     | 48/111 [00:00<00:01, 58.50it/s]"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "{'page_number': 40, 'text': 'Similar results were seen in an additional, 12-week study in 100 patients with moderate to severe \\npsoriatic arthritis who had suboptimal response to DMARD therapy as manifested by ≥3 tender \\njoints and ≥3 swollen joints at enrollment.  \\nRadiographic Response \\nRadiographic changes were assessed in the PsA studies. Radiographs of hands, wrists, and feet \\nwere obtained at baseline and Week 24 during the double-blind period when patients were on \\nHUMIRA or placebo and at Week 48 when all patients were on open-label HUMIRA. A \\nmodified Total Sharp Score (mTSS), which included distal interphalangeal joints (i.e., not \\nidentical to the TSS used for rheumatoid arthritis), was used by readers blinded to treatment \\ngroup to assess the radiographs.  \\nHUMIRA-treated patients demonstrated greater inhibition of radiographic progression compared \\nto placebo-treated patients and this effect was maintained at 48 weeks (see Table 10).  \\nTable 10. Change in Modified Total Sharp Score in Psoriatic Arthritis \\n \\nPlacebo \\nN=141 \\nHUMIRA \\nN=133 \\n \\nWeek 24 \\nWeek 24 \\nWeek 48 \\nBaseline mean \\n22.1 \\n23.4 \\n23.4 \\nMean Change ± SD \\n0.9 ± 3.1 \\n-0.1 ± 1.7 \\n-0.2 ± 4.9* \\n* <0.001 for the difference between HUMIRA, Week 48 and Placebo, Week 24 (primary \\nanalysis) \\n \\n  \\nPhysical Function Response \\nIn Study PsA-I, physical function and disability were assessed using the HAQ Disability Index \\n(HAQ-DI) and the SF-36 Health Survey. Patients treated with 40 mg of HUMIRA every other \\nweek showed greater improvement from baseline in the HAQ-DI score (mean decreases of 47% \\nand 49% at Weeks 12 and 24 respectively) in comparison to placebo (mean decreases of 1% and \\n3% at Weeks 12 and 24 respectively). At Weeks 12 and 24, patients treated with HUMIRA \\nshowed greater improvement from baseline in the SF-36 Physical Component Summary score \\ncompared to patients treated with placebo, and no worsening in the SF-36 Mental Component \\nSummary score. Improvement in physical function based on the HAQ-DI was maintained for up \\nto 84 weeks through the open-label portion of the study.  \\n14.4 Ankylosing Spondylitis \\nThe safety and efficacy of HUMIRA 40 mg every other week was assessed in 315 adult patients \\nin a randomized, 24 week double-blind, placebo-controlled study in patients with active \\nankylosing spondylitis (AS) who had an inadequate response to glucocorticoids, NSAIDs, \\nanalgesics, methotrexate or sulfasalazine. Active AS was defined as patients who fulfilled at \\nleast two of the following three criteria: (1) a Bath AS disease activity index (BASDAI) score ≥4 \\ncm, (2) a visual analog score (VAS) for total back pain ≥ 40 mm, and (3) morning stiffness \\n≥ 1 hour. The blinded period was followed by an open-label period during which patients \\nreceived HUMIRA 40 mg every other week subcutaneously for up to an additional 28 weeks.  \\nImprovement in measures of disease activity was first observed at Week 2 and maintained \\nthrough 24 weeks as shown in Figure 2 and Table 11.  \\n', 'processed_text': {'sentences': [{'original_sentence': 'Similar results were seen in an additional, 12-week study in 100 patients with moderate to severe \\npsoriatic arthritis who had suboptimal response to DMARD therapy as manifested by ≥3 tender \\njoints and ≥3 swollen joints at enrollment.', 'tokens': ['Similar', 'results', 'seen', 'additional', ',', '12-week', 'study', '100', 'patients', 'moderate', 'severe', 'psoriatic', 'arthritis', 'suboptimal', 'response', 'DMARD', 'therapy', 'manifested', '≥3', 'tender', 'joints', '≥3', 'swollen', 'joints', 'enrollment', '.'], 'lemmatized': ['Similar', 'result', 'seen', 'additional', ',', '12-week', 'study', '100', 'patient', 'moderate', 'severe', 'psoriatic', 'arthritis', 'suboptimal', 'response', 'DMARD', 'therapy', 'manifested', '≥3', 'tender', 'joint', '≥3', 'swollen', 'joint', 'enrollment', '.'], 'stemmed': ['similar', 'result', 'seen', 'addit', ',', '12-week', 'studi', '100', 'patient', 'moder', 'sever', 'psoriat', 'arthriti', 'suboptim', 'respons', 'dmard', 'therapi', 'manifest', '≥3', 'tender', 'joint', '≥3', 'swollen', 'joint', 'enrol', '.'], 'dependencies': [('similar', 'amod'), ('result', 'nsubj'), ('seen', 'acl'), ('addit', 'dobj'), (',', 'punct'), ('12', 'nummod'), ('-', 'punct'), ('week', 'nmod'), ('studi', 'nmod'), ('100', 'nummod'), ('patient', 'amod'), ('moder', 'nsubj'), ('sever', 'ROOT'), ('psoriat', 'compound'), ('arthriti', 'dobj'), ('suboptim', 'compound'), ('respons', 'compound'), ('dmard', 'nmod'), ('therapi', 'nmod'), ('manifest', 'nmod'), ('≥3', 'punct'), ('tender', 'nmod'), ('joint', 'compound'), ('≥3', 'nmod'), ('swollen', 'amod'), ('joint', 'amod'), ('enrol', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Radiographic Response \\nRadiographic changes were assessed in the PsA studies.', 'tokens': ['Radiographic', 'Response', 'Radiographic', 'changes', 'assessed', 'PsA', 'studies', '.'], 'lemmatized': ['Radiographic', 'Response', 'Radiographic', 'change', 'assessed', 'PsA', 'study', '.'], 'stemmed': ['radiograph', 'respons', 'radiograph', 'chang', 'assess', 'psa', 'studi', '.'], 'dependencies': [('radiograph', 'compound'), ('respons', 'compound'), ('radiograph', 'compound'), ('chang', 'nsubj'), ('assess', 'ROOT'), ('psa', 'compound'), ('studi', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Radiographs of hands, wrists, and feet \\nwere obtained at baseline and Week 24 during the double-blind period when patients were on \\nHUMIRA or placebo and at Week 48 when all patients were on open-label HUMIRA.', 'tokens': ['Radiographs', 'hands', ',', 'wrists', ',', 'feet', 'obtained', 'baseline', 'Week', '24', 'double-blind', 'period', 'patients', 'HUMIRA', 'placebo', 'Week', '48', 'patients', 'open-label', 'HUMIRA', '.'], 'lemmatized': ['Radiographs', 'hand', ',', 'wrist', ',', 'foot', 'obtained', 'baseline', 'Week', '24', 'double-blind', 'period', 'patient', 'HUMIRA', 'placebo', 'Week', '48', 'patient', 'open-label', 'HUMIRA', '.'], 'stemmed': ['radiograph', 'hand', ',', 'wrist', ',', 'foot', 'obtain', 'baselin', 'week', '24', 'double-blind', 'period', 'patient', 'humira', 'placebo', 'week', '48', 'patient', 'open-label', 'humira', '.'], 'dependencies': [('radiograph', 'compound'), ('hand', 'ROOT'), (',', 'punct'), ('wrist', 'appos'), (',', 'punct'), ('foot', 'compound'), ('obtain', 'appos'), ('baselin', 'compound'), ('week', 'npadvmod'), ('24', 'nummod'), ('double', 'amod'), ('-', 'punct'), ('blind', 'amod'), ('period', 'compound'), ('patient', 'amod'), ('humira', 'compound'), ('placebo', 'compound'), ('week', 'appos'), ('48', 'nummod'), ('patient', 'amod'), ('open', 'amod'), ('-', 'punct'), ('label', 'compound'), ('humira', 'appos'), ('.', 'punct')]}, {'original_sentence': 'A \\nmodified Total Sharp Score (mTSS), which included distal interphalangeal joints (i.e., not \\nidentical to the TSS used for rheumatoid arthritis), was used by readers blinded to treatment \\ngroup to assess the radiographs.', 'tokens': ['modified', 'Total', 'Sharp', 'Score', '(', 'mTSS', ')', ',', 'included', 'distal', 'interphalangeal', 'joints', '(', 'i.e.', ',', 'identical', 'TSS', 'used', 'rheumatoid', 'arthritis', ')', ',', 'used', 'readers', 'blinded', 'treatment', 'group', 'assess', 'radiographs', '.'], 'lemmatized': ['modified', 'Total', 'Sharp', 'Score', '(', 'mTSS', ')', ',', 'included', 'distal', 'interphalangeal', 'joint', '(', 'i.e.', ',', 'identical', 'TSS', 'used', 'rheumatoid', 'arthritis', ')', ',', 'used', 'reader', 'blinded', 'treatment', 'group', 'assess', 'radiograph', '.'], 'stemmed': ['modifi', 'total', 'sharp', 'score', '(', 'mtss', ')', ',', 'includ', 'distal', 'interphalang', 'joint', '(', 'i.e.', ',', 'ident', 'tss', 'use', 'rheumatoid', 'arthriti', ')', ',', 'use', 'reader', 'blind', 'treatment', 'group', 'assess', 'radiograph', '.'], 'dependencies': [('modifi', 'compound'), ('total', 'amod'), ('sharp', 'amod'), ('score', 'nsubj'), ('(', 'punct'), ('mtss', 'appos'), (')', 'punct'), (',', 'punct'), ('includ', 'nmod'), ('distal', 'amod'), ('interphalang', 'compound'), ('joint', 'appos'), ('(', 'punct'), ('i.e.', 'advmod'), (',', 'punct'), ('ident', 'compound'), ('tss', 'nsubj'), ('use', 'parataxis'), ('rheumatoid', 'amod'), ('arthriti', 'dobj'), (')', 'punct'), (',', 'punct'), ('use', 'ROOT'), ('reader', 'compound'), ('blind', 'compound'), ('treatment', 'compound'), ('group', 'compound'), ('assess', 'compound'), ('radiograph', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'HUMIRA-treated patients demonstrated greater inhibition of radiographic progression compared \\nto placebo-treated patients and this effect was maintained at 48 weeks (see Table 10).', 'tokens': ['HUMIRA-treated', 'patients', 'demonstrated', 'greater', 'inhibition', 'radiographic', 'progression', 'compared', 'placebo-treated', 'patients', 'effect', 'maintained', '48', 'weeks', '(', 'see', 'Table', '10', ')', '.'], 'lemmatized': ['HUMIRA-treated', 'patient', 'demonstrated', 'greater', 'inhibition', 'radiographic', 'progression', 'compared', 'placebo-treated', 'patient', 'effect', 'maintained', '48', 'week', '(', 'see', 'Table', '10', ')', '.'], 'stemmed': ['humira-tr', 'patient', 'demonstr', 'greater', 'inhibit', 'radiograph', 'progress', 'compar', 'placebo-tr', 'patient', 'effect', 'maintain', '48', 'week', '(', 'see', 'tabl', '10', ')', '.'], 'dependencies': [('humira', 'npadvmod'), ('-', 'punct'), ('tr', 'amod'), ('patient', 'amod'), ('demonstr', 'nmod'), ('greater', 'amod'), ('inhibit', 'nmod'), ('radiograph', 'amod'), ('progress', 'compound'), ('compar', 'compound'), ('placebo', 'compound'), ('-', 'punct'), ('tr', 'dep'), ('patient', 'amod'), ('effect', 'nsubj'), ('maintain', 'ROOT'), ('48', 'nummod'), ('week', 'dobj'), ('(', 'punct'), ('see', 'parataxis'), ('tabl', 'dobj'), ('10', 'nummod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Table 10.', 'tokens': ['Table', '10', '.'], 'lemmatized': ['Table', '10', '.'], 'stemmed': ['tabl', '10', '.'], 'dependencies': [('tabl', 'ROOT'), ('10', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Change in Modified Total Sharp Score in Psoriatic Arthritis \\n \\nPlacebo \\nN=141 \\nHUMIRA \\nN=133 \\n \\nWeek 24 \\nWeek 24 \\nWeek 48 \\nBaseline mean \\n22.1 \\n23.4 \\n23.4 \\nMean Change ± SD \\n0.9 ± 3.1 \\n-0.1 ± 1.7 \\n-0.2 ± 4.9* \\n* <0.001 for the difference between HUMIRA, Week 48 and Placebo, Week 24 (primary \\nanalysis) \\n \\n  \\nPhysical Function Response \\nIn Study PsA-I, physical function and disability were assessed using the HAQ Disability Index \\n(HAQ-DI) and the SF-36 Health Survey.', 'tokens': ['Change', 'Modified', 'Total', 'Sharp', 'Score', 'Psoriatic', 'Arthritis', 'Placebo', 'N=141', 'HUMIRA', 'N=133', 'Week', '24', 'Week', '24', 'Week', '48', 'Baseline', 'mean', '22.1', '23.4', '23.4', 'Mean', 'Change', '±', 'SD', '0.9', '±', '3.1', '-0.1', '±', '1.7', '-0.2', '±', '4.9', '*', '*', '<', '0.001', 'difference', 'HUMIRA', ',', 'Week', '48', 'Placebo', ',', 'Week', '24', '(', 'primary', 'analysis', ')', 'Physical', 'Function', 'Response', 'Study', 'PsA-I', ',', 'physical', 'function', 'disability', 'assessed', 'using', 'HAQ', 'Disability', 'Index', '(', 'HAQ-DI', ')', 'SF-36', 'Health', 'Survey', '.'], 'lemmatized': ['Change', 'Modified', 'Total', 'Sharp', 'Score', 'Psoriatic', 'Arthritis', 'Placebo', 'N=141', 'HUMIRA', 'N=133', 'Week', '24', 'Week', '24', 'Week', '48', 'Baseline', 'mean', '22.1', '23.4', '23.4', 'Mean', 'Change', '±', 'SD', '0.9', '±', '3.1', '-0.1', '±', '1.7', '-0.2', '±', '4.9', '*', '*', '<', '0.001', 'difference', 'HUMIRA', ',', 'Week', '48', 'Placebo', ',', 'Week', '24', '(', 'primary', 'analysis', ')', 'Physical', 'Function', 'Response', 'Study', 'PsA-I', ',', 'physical', 'function', 'disability', 'assessed', 'using', 'HAQ', 'Disability', 'Index', '(', 'HAQ-DI', ')', 'SF-36', 'Health', 'Survey', '.'], 'stemmed': ['chang', 'modifi', 'total', 'sharp', 'score', 'psoriat', 'arthriti', 'placebo', 'n=141', 'humira', 'n=133', 'week', '24', 'week', '24', 'week', '48', 'baselin', 'mean', '22.1', '23.4', '23.4', 'mean', 'chang', '±', 'sd', '0.9', '±', '3.1', '-0.1', '±', '1.7', '-0.2', '±', '4.9', '*', '*', '<', '0.001', 'differ', 'humira', ',', 'week', '48', 'placebo', ',', 'week', '24', '(', 'primari', 'analysi', ')', 'physic', 'function', 'respons', 'studi', 'psa-i', ',', 'physic', 'function', 'disabl', 'assess', 'use', 'haq', 'disabl', 'index', '(', 'haq-di', ')', 'sf-36', 'health', 'survey', '.'], 'dependencies': [('chang', 'compound'), ('modifi', 'nsubj'), ('total', 'ROOT'), ('sharp', 'amod'), ('score', 'compound'), ('psoriat', 'compound'), ('arthriti', 'compound'), ('placebo', 'compound'), ('n=141', 'compound'), ('humira', 'compound'), ('n=133', 'compound'), ('week', 'npadvmod'), ('24', 'nummod'), ('week', 'npadvmod'), ('24', 'nummod'), ('week', 'npadvmod'), ('48', 'nummod'), ('baselin', 'compound'), ('mean', 'dep'), ('22.1', 'compound'), ('23.4', 'compound'), ('23.4', 'nummod'), ('mean', 'compound'), ('chang', 'compound'), ('±', 'appos'), ('sd', 'prep'), ('0.9', 'nummod'), ('±', 'pobj'), ('3.1', 'nummod'), ('-0.1', 'nmod'), ('±', 'npadvmod'), ('1.7', 'nummod'), ('-0.2', 'appos'), ('±', 'npadvmod'), ('4.9', 'nummod'), ('*', 'ROOT'), ('*', 'nmod'), ('<', 'nmod'), ('0.001', 'meta'), ('differ', 'ROOT'), ('humira', 'dobj'), (',', 'punct'), ('week', 'npadvmod'), ('48', 'nummod'), ('placebo', 'appos'), (',', 'punct'), ('week', 'npadvmod'), ('24', 'nummod'), ('(', 'punct'), ('primari', 'nmod'), ('analysi', 'nmod'), (')', 'punct'), ('physic', 'amod'), ('function', 'compound'), ('respons', 'dep'), ('studi', 'nmod'), ('psa', 'appos'), ('-', 'punct'), ('i', 'dobj'), (',', 'punct'), ('physic', 'amod'), ('function', 'compound'), ('disabl', 'compound'), ('assess', 'compound'), ('use', 'compound'), ('haq', 'compound'), ('disabl', 'compound'), ('index', 'dobj'), ('(', 'punct'), ('haq', 'compound'), ('-', 'punct'), ('di', 'appos'), (')', 'punct'), ('sf-36', 'appos'), ('health', 'compound'), ('survey', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Patients treated with 40 mg of HUMIRA every other \\nweek showed greater improvement from baseline in the HAQ-DI score (mean decreases of 47% \\nand 49% at Weeks 12 and 24 respectively) in comparison to placebo (mean decreases of 1% and \\n3% at Weeks 12 and 24 respectively).', 'tokens': ['Patients', 'treated', '40', 'mg', 'HUMIRA', 'every', 'week', 'showed', 'greater', 'improvement', 'baseline', 'HAQ-DI', 'score', '(', 'mean', 'decreases', '47', '%', '49', '%', 'Weeks', '12', '24', 'respectively', ')', 'comparison', 'placebo', '(', 'mean', 'decreases', '1', '%', '3', '%', 'Weeks', '12', '24', 'respectively', ')', '.'], 'lemmatized': ['Patients', 'treated', '40', 'mg', 'HUMIRA', 'every', 'week', 'showed', 'greater', 'improvement', 'baseline', 'HAQ-DI', 'score', '(', 'mean', 'decrease', '47', '%', '49', '%', 'Weeks', '12', '24', 'respectively', ')', 'comparison', 'placebo', '(', 'mean', 'decrease', '1', '%', '3', '%', 'Weeks', '12', '24', 'respectively', ')', '.'], 'stemmed': ['patient', 'treat', '40', 'mg', 'humira', 'everi', 'week', 'show', 'greater', 'improv', 'baselin', 'haq-di', 'score', '(', 'mean', 'decreas', '47', '%', '49', '%', 'week', '12', '24', 'respect', ')', 'comparison', 'placebo', '(', 'mean', 'decreas', '1', '%', '3', '%', 'week', '12', '24', 'respect', ')', '.'], 'dependencies': [('patient', 'compound'), ('treat', 'nsubj'), ('40', 'npadvmod'), ('mg', 'prep'), ('humira', 'nmod'), ('everi', 'compound'), ('week', 'npadvmod'), ('show', 'ROOT'), ('greater', 'amod'), ('improv', 'amod'), ('baselin', 'compound'), ('haq', 'compound'), ('-', 'punct'), ('di', 'compound'), ('score', 'dobj'), ('(', 'punct'), ('mean', 'npadvmod'), ('decreas', 'parataxis'), ('47', 'nummod'), ('%', 'dobj'), ('49', 'nummod'), ('%', 'compound'), ('week', 'npadvmod'), ('12', 'nummod'), ('24', 'nummod'), ('respect', 'appos'), (')', 'punct'), ('comparison', 'compound'), ('placebo', 'npadvmod'), ('(', 'punct'), ('mean', 'parataxis'), ('decreas', 'relcl'), ('1', 'nummod'), ('%', 'npadvmod'), ('3', 'nummod'), ('%', 'compound'), ('week', 'appos'), ('12', 'nummod'), ('24', 'nummod'), ('respect', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'At Weeks 12 and 24, patients treated with HUMIRA \\nshowed greater improvement from baseline in the SF-36 Physical Component Summary score \\ncompared to patients treated with placebo, and no worsening in the SF-36 Mental Component \\nSummary score.', 'tokens': ['Weeks', '12', '24', ',', 'patients', 'treated', 'HUMIRA', 'showed', 'greater', 'improvement', 'baseline', 'SF-36', 'Physical', 'Component', 'Summary', 'score', 'compared', 'patients', 'treated', 'placebo', ',', 'worsening', 'SF-36', 'Mental', 'Component', 'Summary', 'score', '.'], 'lemmatized': ['Weeks', '12', '24', ',', 'patient', 'treated', 'HUMIRA', 'showed', 'greater', 'improvement', 'baseline', 'SF-36', 'Physical', 'Component', 'Summary', 'score', 'compared', 'patient', 'treated', 'placebo', ',', 'worsening', 'SF-36', 'Mental', 'Component', 'Summary', 'score', '.'], 'stemmed': ['week', '12', '24', ',', 'patient', 'treat', 'humira', 'show', 'greater', 'improv', 'baselin', 'sf-36', 'physic', 'compon', 'summari', 'score', 'compar', 'patient', 'treat', 'placebo', ',', 'worsen', 'sf-36', 'mental', 'compon', 'summari', 'score', '.'], 'dependencies': [('week', 'npadvmod'), ('12', 'nummod'), ('24', 'nummod'), (',', 'punct'), ('patient', 'amod'), ('treat', 'compound'), ('humira', 'nsubj'), ('show', 'ROOT'), ('greater', 'amod'), ('improv', 'amod'), ('baselin', 'dobj'), ('sf-36', 'dep'), ('physic', 'nsubj'), ('compon', 'ROOT'), ('summari', 'amod'), ('score', 'compound'), ('compar', 'compound'), ('patient', 'compound'), ('treat', 'compound'), ('placebo', 'dobj'), (',', 'punct'), ('worsen', 'conj'), ('sf-36', 'punct'), ('mental', 'amod'), ('compon', 'compound'), ('summari', 'amod'), ('score', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Improvement in physical function based on the HAQ-DI was maintained for up \\nto 84 weeks through the open-label portion of the study.', 'tokens': ['Improvement', 'physical', 'function', 'based', 'HAQ-DI', 'maintained', '84', 'weeks', 'open-label', 'portion', 'study', '.'], 'lemmatized': ['Improvement', 'physical', 'function', 'based', 'HAQ-DI', 'maintained', '84', 'week', 'open-label', 'portion', 'study', '.'], 'stemmed': ['improv', 'physic', 'function', 'base', 'haq-di', 'maintain', '84', 'week', 'open-label', 'portion', 'studi', '.'], 'dependencies': [('improv', 'compound'), ('physic', 'compound'), ('function', 'compound'), ('base', 'compound'), ('haq', 'compound'), ('-', 'punct'), ('di', 'nsubj'), ('maintain', 'ROOT'), ('84', 'nummod'), ('week', 'nmod'), ('open', 'amod'), ('-', 'punct'), ('label', 'compound'), ('portion', 'compound'), ('studi', 'dobj'), ('.', 'punct')]}, {'original_sentence': '14.4 Ankylosing Spondylitis \\nThe safety and efficacy of HUMIRA 40 mg every other week was assessed in 315 adult patients \\nin a randomized, 24 week double-blind, placebo-controlled study in patients with active \\nankylosing spondylitis (AS) who had an inadequate response to glucocorticoids, NSAIDs, \\nanalgesics, methotrexate or sulfasalazine.', 'tokens': ['14.4', 'Ankylosing', 'Spondylitis', 'safety', 'efficacy', 'HUMIRA', '40', 'mg', 'every', 'week', 'assessed', '315', 'adult', 'patients', 'randomized', ',', '24', 'week', 'double-blind', ',', 'placebo-controlled', 'study', 'patients', 'active', 'ankylosing', 'spondylitis', '(', ')', 'inadequate', 'response', 'glucocorticoids', ',', 'NSAIDs', ',', 'analgesics', ',', 'methotrexate', 'sulfasalazine', '.'], 'lemmatized': ['14.4', 'Ankylosing', 'Spondylitis', 'safety', 'efficacy', 'HUMIRA', '40', 'mg', 'every', 'week', 'assessed', '315', 'adult', 'patient', 'randomized', ',', '24', 'week', 'double-blind', ',', 'placebo-controlled', 'study', 'patient', 'active', 'ankylosing', 'spondylitis', '(', ')', 'inadequate', 'response', 'glucocorticoid', ',', 'NSAIDs', ',', 'analgesic', ',', 'methotrexate', 'sulfasalazine', '.'], 'stemmed': ['14.4', 'ankylos', 'spondyl', 'safeti', 'efficaci', 'humira', '40', 'mg', 'everi', 'week', 'assess', '315', 'adult', 'patient', 'random', ',', '24', 'week', 'double-blind', ',', 'placebo-control', 'studi', 'patient', 'activ', 'ankylos', 'spondyl', '(', ')', 'inadequ', 'respons', 'glucocorticoid', ',', 'nsaid', ',', 'analges', ',', 'methotrex', 'sulfasalazin', '.'], 'dependencies': [('14.4', 'nummod'), ('ankylos', 'compound'), ('spondyl', 'compound'), ('safeti', 'compound'), ('efficaci', 'compound'), ('humira', 'nsubj'), ('40', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'npadvmod'), ('assess', 'ROOT'), ('315', 'nummod'), ('adult', 'compound'), ('patient', 'dobj'), ('random', 'amod'), (',', 'punct'), ('24', 'nummod'), ('week', 'npadvmod'), ('double', 'amod'), ('-', 'punct'), ('blind', 'conj'), (',', 'punct'), ('placebo', 'compound'), ('-', 'punct'), ('control', 'nmod'), ('studi', 'amod'), ('patient', 'compound'), ('activ', 'appos'), ('ankylos', 'compound'), ('spondyl', 'appos'), ('(', 'punct'), (')', 'punct'), ('inadequ', 'compound'), ('respons', 'nsubj'), ('glucocorticoid', 'amod'), (',', 'punct'), ('nsaid', 'conj'), (',', 'punct'), ('analges', 'conj'), (',', 'punct'), ('methotrex', 'amod'), ('sulfasalazin', 'conj'), ('.', 'punct')]}, {'original_sentence': 'Active AS was defined as patients who fulfilled at \\nleast two of the following three criteria: (1) a Bath AS disease activity index (BASDAI) score ≥4 \\ncm, (2) a visual analog score (VAS) for total back pain ≥ 40 mm, and (3) morning stiffness \\n≥ 1 hour.', 'tokens': ['Active', 'defined', 'patients', 'fulfilled', 'least', 'two', 'following', 'three', 'criteria', ':', '(', '1', ')', 'Bath', 'disease', 'activity', 'index', '(', 'BASDAI', ')', 'score', '≥4', 'cm', ',', '(', '2', ')', 'visual', 'analog', 'score', '(', 'VAS', ')', 'total', 'back', 'pain', '≥', '40', 'mm', ',', '(', '3', ')', 'morning', 'stiffness', '≥', '1', 'hour', '.'], 'lemmatized': ['Active', 'defined', 'patient', 'fulfilled', 'least', 'two', 'following', 'three', 'criterion', ':', '(', '1', ')', 'Bath', 'disease', 'activity', 'index', '(', 'BASDAI', ')', 'score', '≥4', 'cm', ',', '(', '2', ')', 'visual', 'analog', 'score', '(', 'VAS', ')', 'total', 'back', 'pain', '≥', '40', 'mm', ',', '(', '3', ')', 'morning', 'stiffness', '≥', '1', 'hour', '.'], 'stemmed': ['activ', 'defin', 'patient', 'fulfil', 'least', 'two', 'follow', 'three', 'criterion', ':', '(', '1', ')', 'bath', 'diseas', 'activ', 'index', '(', 'basdai', ')', 'score', '≥4', 'cm', ',', '(', '2', ')', 'visual', 'analog', 'score', '(', 'va', ')', 'total', 'back', 'pain', '≥', '40', 'mm', ',', '(', '3', ')', 'morn', 'stiff', '≥', '1', 'hour', '.'], 'dependencies': [('activ', 'nmod'), ('defin', 'compound'), ('patient', 'nmod'), ('fulfil', 'npadvmod'), ('least', 'advmod'), ('two', 'nummod'), ('follow', 'dep'), ('three', 'nummod'), ('criterion', 'ROOT'), (':', 'punct'), ('(', 'punct'), ('1', 'meta'), (')', 'punct'), ('bath', 'compound'), ('diseas', 'nmod'), ('activ', 'compound'), ('index', 'nmod'), ('(', 'punct'), ('basdai', 'nmod'), (')', 'punct'), ('score', 'appos'), ('≥4', 'compound'), ('cm', 'dep'), (',', 'punct'), ('(', 'punct'), ('2', 'nummod'), (')', 'punct'), ('visual', 'amod'), ('analog', 'compound'), ('score', 'nsubj'), ('(', 'punct'), ('va', 'appos'), (')', 'punct'), ('total', 'ROOT'), ('back', 'amod'), ('pain', 'compound'), ('≥', 'dobj'), ('40', 'nummod'), ('mm', 'appos'), (',', 'punct'), ('(', 'punct'), ('3', 'meta'), (')', 'punct'), ('morn', 'parataxis'), ('stiff', 'amod'), ('≥', 'dobj'), ('1', 'nummod'), ('hour', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'The blinded period was followed by an open-label period during which patients \\nreceived HUMIRA 40 mg every other week subcutaneously for up to an additional 28 weeks.', 'tokens': ['blinded', 'period', 'followed', 'open-label', 'period', 'patients', 'received', 'HUMIRA', '40', 'mg', 'every', 'week', 'subcutaneously', 'additional', '28', 'weeks', '.'], 'lemmatized': ['blinded', 'period', 'followed', 'open-label', 'period', 'patient', 'received', 'HUMIRA', '40', 'mg', 'every', 'week', 'subcutaneously', 'additional', '28', 'week', '.'], 'stemmed': ['blind', 'period', 'follow', 'open-label', 'period', 'patient', 'receiv', 'humira', '40', 'mg', 'everi', 'week', 'subcutan', 'addit', '28', 'week', '.'], 'dependencies': [('blind', 'amod'), ('period', 'nsubj'), ('follow', 'nmod'), ('open', 'amod'), ('-', 'punct'), ('label', 'compound'), ('period', 'nmod'), ('patient', 'compound'), ('receiv', 'compound'), ('humira', 'ROOT'), ('40', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'npadvmod'), ('subcutan', 'amod'), ('addit', 'appos'), ('28', 'nummod'), ('week', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Improvement in measures of disease activity was first observed at Week 2 and maintained \\nthrough 24 weeks as shown in Figure 2 and Table 11.', 'tokens': ['Improvement', 'measures', 'disease', 'activity', 'first', 'observed', 'Week', '2', 'maintained', '24', 'weeks', 'shown', 'Figure', '2', 'Table', '11', '.'], 'lemmatized': ['Improvement', 'measure', 'disease', 'activity', 'first', 'observed', 'Week', '2', 'maintained', '24', 'week', 'shown', 'Figure', '2', 'Table', '11', '.'], 'stemmed': ['improv', 'measur', 'diseas', 'activ', 'first', 'observ', 'week', '2', 'maintain', '24', 'week', 'shown', 'figur', '2', 'tabl', '11', '.'], 'dependencies': [('improv', 'compound'), ('measur', 'compound'), ('diseas', 'compound'), ('activ', 'nsubj'), ('first', 'amod'), ('observ', 'compound'), ('week', 'npadvmod'), ('2', 'nummod'), ('maintain', 'ROOT'), ('24', 'nummod'), ('week', 'npadvmod'), ('shown', 'ccomp'), ('figur', 'dobj'), ('2', 'nummod'), ('tabl', 'ccomp'), ('11', 'nummod'), ('.', 'punct')]}], 'text': 'Similar results were seen in an additional, 12-week study in 100 patients with moderate to severe \\npsoriatic arthritis who had suboptimal response to DMARD therapy as manifested by ≥3 tender \\njoints and ≥3 swollen joints at enrollment.  \\nRadiographic Response \\nRadiographic changes were assessed in the PsA studies. Radiographs of hands, wrists, and feet \\nwere obtained at baseline and Week 24 during the double-blind period when patients were on \\nHUMIRA or placebo and at Week 48 when all patients were on open-label HUMIRA. A \\nmodified Total Sharp Score (mTSS), which included distal interphalangeal joints (i.e., not \\nidentical to the TSS used for rheumatoid arthritis), was used by readers blinded to treatment \\ngroup to assess the radiographs.  \\nHUMIRA-treated patients demonstrated greater inhibition of radiographic progression compared \\nto placebo-treated patients and this effect was maintained at 48 weeks (see Table 10).  \\nTable 10. Change in Modified Total Sharp Score in Psoriatic Arthritis \\n \\nPlacebo \\nN=141 \\nHUMIRA \\nN=133 \\n \\nWeek 24 \\nWeek 24 \\nWeek 48 \\nBaseline mean \\n22.1 \\n23.4 \\n23.4 \\nMean Change ± SD \\n0.9 ± 3.1 \\n-0.1 ± 1.7 \\n-0.2 ± 4.9* \\n* <0.001 for the difference between HUMIRA, Week 48 and Placebo, Week 24 (primary \\nanalysis) \\n \\n  \\nPhysical Function Response \\nIn Study PsA-I, physical function and disability were assessed using the HAQ Disability Index \\n(HAQ-DI) and the SF-36 Health Survey. Patients treated with 40 mg of HUMIRA every other \\nweek showed greater improvement from baseline in the HAQ-DI score (mean decreases of 47% \\nand 49% at Weeks 12 and 24 respectively) in comparison to placebo (mean decreases of 1% and \\n3% at Weeks 12 and 24 respectively). At Weeks 12 and 24, patients treated with HUMIRA \\nshowed greater improvement from baseline in the SF-36 Physical Component Summary score \\ncompared to patients treated with placebo, and no worsening in the SF-36 Mental Component \\nSummary score. Improvement in physical function based on the HAQ-DI was maintained for up \\nto 84 weeks through the open-label portion of the study.  \\n14.4 Ankylosing Spondylitis \\nThe safety and efficacy of HUMIRA 40 mg every other week was assessed in 315 adult patients \\nin a randomized, 24 week double-blind, placebo-controlled study in patients with active \\nankylosing spondylitis (AS) who had an inadequate response to glucocorticoids, NSAIDs, \\nanalgesics, methotrexate or sulfasalazine. Active AS was defined as patients who fulfilled at \\nleast two of the following three criteria: (1) a Bath AS disease activity index (BASDAI) score ≥4 \\ncm, (2) a visual analog score (VAS) for total back pain ≥ 40 mm, and (3) morning stiffness \\n≥ 1 hour. The blinded period was followed by an open-label period during which patients \\nreceived HUMIRA 40 mg every other week subcutaneously for up to an additional 28 weeks.  \\nImprovement in measures of disease activity was first observed at Week 2 and maintained \\nthrough 24 weeks as shown in Figure 2 and Table 11.  \\n'}, 'page_char_count': 2971, 'page_word_count': 467, 'sentences': ['Similar results were seen in an additional, 12-week study in 100 patients with moderate to severe \\npsoriatic arthritis who had suboptimal response to DMARD therapy as manifested by ≥3 tender \\njoints and ≥3 swollen joints at enrollment.', ' \\nRadiographic Response \\nRadiographic changes were assessed in the PsA studies.', 'Radiographs of hands, wrists, and feet \\nwere obtained at baseline and Week 24 during the double-blind period when patients were on \\nHUMIRA or placebo and at Week 48 when all patients were on open-label HUMIRA.', 'A \\nmodified Total Sharp Score (mTSS), which included distal interphalangeal joints (i.e., not \\nidentical to the TSS used for rheumatoid arthritis), was used by readers blinded to treatment \\ngroup to assess the radiographs.', ' \\nHUMIRA-treated patients demonstrated greater inhibition of radiographic progression compared \\nto placebo-treated patients and this effect was maintained at 48 weeks (see Table 10).', ' \\nTable 10.', 'Change in Modified Total Sharp Score in Psoriatic Arthritis \\n \\nPlacebo \\nN=141 \\nHUMIRA \\nN=133 \\n \\nWeek 24 \\nWeek 24 \\nWeek 48 \\nBaseline mean \\n22.1 \\n23.4 \\n23.4 \\nMean Change ± SD \\n0.9 ± 3.1 \\n-0.1 ± 1.7 \\n-0.2 ± 4.9* \\n* <0.001 for the difference between HUMIRA, Week 48 and Placebo, Week 24 (primary \\nanalysis) \\n \\n  \\nPhysical Function Response \\nIn Study PsA-I, physical function and disability were assessed using the HAQ Disability Index \\n(HAQ-DI) and the SF-36 Health Survey.', 'Patients treated with 40 mg of HUMIRA every other \\nweek showed greater improvement from baseline in the HAQ-DI score (mean decreases of 47% \\nand 49% at Weeks 12 and 24 respectively) in comparison to placebo (mean decreases of 1% and \\n3% at Weeks 12 and 24 respectively).', 'At Weeks 12 and 24, patients treated with HUMIRA \\nshowed greater improvement from baseline in the SF-36 Physical Component Summary score \\ncompared to patients treated with placebo, and no worsening in the SF-36 Mental Component \\nSummary score.', 'Improvement in physical function based on the HAQ-DI was maintained for up \\nto 84 weeks through the open-label portion of the study.', ' \\n14.4 Ankylosing Spondylitis \\nThe safety and efficacy of HUMIRA 40 mg every other week was assessed in 315 adult patients \\nin a randomized, 24 week double-blind, placebo-controlled study in patients with active \\nankylosing spondylitis (AS) who had an inadequate response to glucocorticoids, NSAIDs, \\nanalgesics, methotrexate or sulfasalazine.', 'Active AS was defined as patients who fulfilled at \\nleast two of the following three criteria: (1) a Bath AS disease activity index (BASDAI) score ≥4 \\ncm, (2) a visual analog score (VAS) for total back pain ≥ 40 mm, and (3) morning stiffness \\n≥ 1 hour.', 'The blinded period was followed by an open-label period during which patients \\nreceived HUMIRA 40 mg every other week subcutaneously for up to an additional 28 weeks.', ' \\nImprovement in measures of disease activity was first observed at Week 2 and maintained \\nthrough 24 weeks as shown in Figure 2 and Table 11.', ' \\n'], 'page_sentence_count_spacy': 15}\n",
            "{'page_number': 41, 'text': 'Responses of patients with total spinal ankylosis (n=11) were similar to those without total \\nankylosis.  \\nFigure 2. ASAS 20 Response By Visit, Study AS-I \\n \\nAt 12 weeks, the ASAS 20/50/70 responses were achieved by 58%, 38%, and 23%, respectively, \\nof patients receiving HUMIRA, compared to 21%, 10%, and 5% respectively, of patients \\nreceiving placebo (p <0.001). Similar responses were seen at Week 24 and were sustained in \\npatients receiving open-label HUMIRA for up to 52 weeks.  \\nA greater proportion of patients treated with HUMIRA (22%) achieved a low level of disease \\nactivity at 24 weeks (defined as a value <20 [on a scale of 0 to 100 mm] in each of the four \\nASAS response parameters) compared to patients treated with placebo (6%).  \\nTable 11. Components of Ankylosing Spondylitis Disease Activity \\n  \\nPlacebo \\nN=107  \\nHUMIRA \\nN=208  \\n  \\nBaseline \\nmean \\nWeek 24 \\nmean \\nBaseline \\nmean \\nWeek 24 \\nmean \\nASAS 20 Response Criteria* \\n  \\n  \\n  \\n  \\n     Patient’s Global Assessment of Disease \\nActivitya* \\n65 \\n60 \\n63 \\n38 \\n     Total back pain* \\n67 \\n58 \\n65 \\n37 \\n     Inflammationb* \\n6.7 \\n5.6 \\n6.7 \\n3.6 \\n     BASFIc* \\n56 \\n51 \\n52 \\n34 \\nBASDAId score*  \\n6.3 \\n5.5 \\n6.3 \\n3.7 \\nBASMIe score*  \\n4.2 \\n4.1 \\n3.8 \\n3.3 \\n     Tragus to wall (cm) \\n15.9 \\n15.8 \\n15.8 \\n15.4 \\n', 'processed_text': {'sentences': [{'original_sentence': 'Responses of patients with total spinal ankylosis (n=11) were similar to those without total \\nankylosis.', 'tokens': ['Responses', 'patients', 'total', 'spinal', 'ankylosis', '(', 'n=11', ')', 'similar', 'without', 'total', 'ankylosis', '.'], 'lemmatized': ['Responses', 'patient', 'total', 'spinal', 'ankylosis', '(', 'n=11', ')', 'similar', 'without', 'total', 'ankylosis', '.'], 'stemmed': ['respons', 'patient', 'total', 'spinal', 'ankylosi', '(', 'n=11', ')', 'similar', 'without', 'total', 'ankylosi', '.'], 'dependencies': [('respons', 'compound'), ('patient', 'amod'), ('total', 'amod'), ('spinal', 'amod'), ('ankylosi', 'ROOT'), ('(', 'punct'), ('n=11', 'npadvmod'), (')', 'punct'), ('similar', 'amod'), ('without', 'prep'), ('total', 'amod'), ('ankylosi', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'Figure 2.', 'tokens': ['Figure', '2', '.'], 'lemmatized': ['Figure', '2', '.'], 'stemmed': ['figur', '2', '.'], 'dependencies': [('figur', 'ROOT'), ('2', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'ASAS 20 Response By Visit, Study AS-I \\n \\nAt 12 weeks, the ASAS 20/50/70 responses were achieved by 58%, 38%, and 23%, respectively, \\nof patients receiving HUMIRA, compared to 21%, 10%, and 5% respectively, of patients \\nreceiving placebo (p <0.001).', 'tokens': ['ASAS', '20', 'Response', 'Visit', ',', 'Study', 'AS-I', '12', 'weeks', ',', 'ASAS', '20/50/70', 'responses', 'achieved', '58', '%', ',', '38', '%', ',', '23', '%', ',', 'respectively', ',', 'patients', 'receiving', 'HUMIRA', ',', 'compared', '21', '%', ',', '10', '%', ',', '5', '%', 'respectively', ',', 'patients', 'receiving', 'placebo', '(', 'p', '<', '0.001', ')', '.'], 'lemmatized': ['ASAS', '20', 'Response', 'Visit', ',', 'Study', 'AS-I', '12', 'week', ',', 'ASAS', '20/50/70', 'response', 'achieved', '58', '%', ',', '38', '%', ',', '23', '%', ',', 'respectively', ',', 'patient', 'receiving', 'HUMIRA', ',', 'compared', '21', '%', ',', '10', '%', ',', '5', '%', 'respectively', ',', 'patient', 'receiving', 'placebo', '(', 'p', '<', '0.001', ')', '.'], 'stemmed': ['asa', '20', 'respons', 'visit', ',', 'studi', 'as-i', '12', 'week', ',', 'asa', '20/50/70', 'respons', 'achiev', '58', '%', ',', '38', '%', ',', '23', '%', ',', 'respect', ',', 'patient', 'receiv', 'humira', ',', 'compar', '21', '%', ',', '10', '%', ',', '5', '%', 'respect', ',', 'patient', 'receiv', 'placebo', '(', 'p', '<', '0.001', ')', '.'], 'dependencies': [('asa', 'compound'), ('20', 'nummod'), ('respons', 'compound'), ('visit', 'nsubj'), (',', 'punct'), ('studi', 'npadvmod'), ('as', 'prep'), ('-', 'punct'), ('i', 'pobj'), ('12', 'nummod'), ('week', 'npadvmod'), (',', 'punct'), ('asa', 'compound'), ('20/50/70', 'appos'), ('respons', 'ROOT'), ('achiev', 'advmod'), ('58', 'nummod'), ('%', 'npadvmod'), (',', 'punct'), ('38', 'nummod'), ('%', 'appos'), (',', 'punct'), ('23', 'nummod'), ('%', 'appos'), (',', 'punct'), ('respect', 'conj'), (',', 'punct'), ('patient', 'compound'), ('receiv', 'compound'), ('humira', 'conj'), (',', 'punct'), ('compar', 'conj'), ('21', 'nummod'), ('%', 'npadvmod'), (',', 'punct'), ('10', 'nummod'), ('%', 'appos'), (',', 'punct'), ('5', 'nummod'), ('%', 'compound'), ('respect', 'conj'), (',', 'punct'), ('patient', 'amod'), ('receiv', 'compound'), ('placebo', 'appos'), ('(', 'punct'), ('p', 'parataxis'), ('<', 'dep'), ('0.001', 'nummod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Similar responses were seen at Week 24 and were sustained in \\npatients receiving open-label HUMIRA for up to 52 weeks.', 'tokens': ['Similar', 'responses', 'seen', 'Week', '24', 'sustained', 'patients', 'receiving', 'open-label', 'HUMIRA', '52', 'weeks', '.'], 'lemmatized': ['Similar', 'response', 'seen', 'Week', '24', 'sustained', 'patient', 'receiving', 'open-label', 'HUMIRA', '52', 'week', '.'], 'stemmed': ['similar', 'respons', 'seen', 'week', '24', 'sustain', 'patient', 'receiv', 'open-label', 'humira', '52', 'week', '.'], 'dependencies': [('similar', 'amod'), ('respons', 'nsubj'), ('seen', 'acl'), ('week', 'npadvmod'), ('24', 'nummod'), ('sustain', 'ROOT'), ('patient', 'amod'), ('receiv', 'nmod'), ('open', 'amod'), ('-', 'punct'), ('label', 'compound'), ('humira', 'dobj'), ('52', 'nummod'), ('week', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'A greater proportion of patients treated with HUMIRA (22%) achieved a low level of disease \\nactivity at 24 weeks (defined as a value <20 [on a scale of 0 to 100 mm] in each of the four \\nASAS response parameters) compared to patients treated with placebo (6%).', 'tokens': ['greater', 'proportion', 'patients', 'treated', 'HUMIRA', '(', '22', '%', ')', 'achieved', 'low', 'level', 'disease', 'activity', '24', 'weeks', '(', 'defined', 'value', '<', '20', '[', 'scale', '0', '100', 'mm', ']', 'four', 'ASAS', 'response', 'parameters', ')', 'compared', 'patients', 'treated', 'placebo', '(', '6', '%', ')', '.'], 'lemmatized': ['greater', 'proportion', 'patient', 'treated', 'HUMIRA', '(', '22', '%', ')', 'achieved', 'low', 'level', 'disease', 'activity', '24', 'week', '(', 'defined', 'value', '<', '20', '[', 'scale', '0', '100', 'mm', ']', 'four', 'ASAS', 'response', 'parameter', ')', 'compared', 'patient', 'treated', 'placebo', '(', '6', '%', ')', '.'], 'stemmed': ['greater', 'proport', 'patient', 'treat', 'humira', '(', '22', '%', ')', 'achiev', 'low', 'level', 'diseas', 'activ', '24', 'week', '(', 'defin', 'valu', '<', '20', '[', 'scale', '0', '100', 'mm', ']', 'four', 'asa', 'respons', 'paramet', ')', 'compar', 'patient', 'treat', 'placebo', '(', '6', '%', ')', '.'], 'dependencies': [('greater', 'amod'), ('proport', 'compound'), ('patient', 'compound'), ('treat', 'compound'), ('humira', 'nsubj'), ('(', 'punct'), ('22', 'nummod'), ('%', 'appos'), (')', 'punct'), ('achiev', 'nmod'), ('low', 'amod'), ('level', 'compound'), ('diseas', 'nsubj'), ('activ', 'dobj'), ('24', 'nummod'), ('week', 'npadvmod'), ('(', 'punct'), ('defin', 'advmod'), ('valu', 'dep'), ('<', 'dep'), ('20', 'nummod'), ('[', 'punct'), ('scale', 'ROOT'), ('0', 'nummod'), ('100', 'nummod'), ('mm', 'npadvmod'), (']', 'punct'), ('four', 'nummod'), ('asa', 'compound'), ('respons', 'compound'), ('paramet', 'appos'), (')', 'punct'), ('compar', 'compound'), ('patient', 'compound'), ('treat', 'compound'), ('placebo', 'dobj'), ('(', 'punct'), ('6', 'nummod'), ('%', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Table 11.', 'tokens': ['Table', '11', '.'], 'lemmatized': ['Table', '11', '.'], 'stemmed': ['tabl', '11', '.'], 'dependencies': [('tabl', 'ROOT'), ('11', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Components of Ankylosing Spondylitis Disease Activity \\n  \\nPlacebo \\nN=107  \\nHUMIRA \\nN=208  \\n  \\nBaseline \\nmean \\nWeek 24 \\nmean \\nBaseline \\nmean \\nWeek 24 \\nmean \\nASAS 20 Response Criteria* \\n  \\n  \\n  \\n  \\n     Patient’s Global Assessment of Disease \\nActivitya* \\n65 \\n60 \\n63 \\n38 \\n     Total back pain* \\n67 \\n58 \\n65 \\n37 \\n     Inflammationb* \\n6.7 \\n5.6 \\n6.7 \\n3.6 \\n     BASFIc* \\n56 \\n51 \\n52 \\n34 \\nBASDAId score*  \\n6.3 \\n5.5 \\n6.3 \\n3.7 \\nBASMIe score*  \\n4.2 \\n4.1 \\n3.8 \\n3.3 \\n     Tragus to wall (cm) \\n15.9 \\n15.8 \\n15.8 \\n15.4', 'tokens': ['Components', 'Ankylosing', 'Spondylitis', 'Disease', 'Activity', 'Placebo', 'N=107', 'HUMIRA', 'N=208', 'Baseline', 'mean', 'Week', '24', 'mean', 'Baseline', 'mean', 'Week', '24', 'mean', 'ASAS', '20', 'Response', 'Criteria', '*', 'Patient', '’', 'Global', 'Assessment', 'Disease', 'Activitya', '*', '65', '60', '63', '38', 'Total', 'back', 'pain', '*', '67', '58', '65', '37', 'Inflammationb', '*', '6.7', '5.6', '6.7', '3.6', 'BASFIc', '*', '56', '51', '52', '34', 'BASDAId', 'score', '*', '6.3', '5.5', '6.3', '3.7', 'BASMIe', 'score', '*', '4.2', '4.1', '3.8', '3.3', 'Tragus', 'wall', '(', 'cm', ')', '15.9', '15.8', '15.8', '15.4'], 'lemmatized': ['Components', 'Ankylosing', 'Spondylitis', 'Disease', 'Activity', 'Placebo', 'N=107', 'HUMIRA', 'N=208', 'Baseline', 'mean', 'Week', '24', 'mean', 'Baseline', 'mean', 'Week', '24', 'mean', 'ASAS', '20', 'Response', 'Criteria', '*', 'Patient', '’', 'Global', 'Assessment', 'Disease', 'Activitya', '*', '65', '60', '63', '38', 'Total', 'back', 'pain', '*', '67', '58', '65', '37', 'Inflammationb', '*', '6.7', '5.6', '6.7', '3.6', 'BASFIc', '*', '56', '51', '52', '34', 'BASDAId', 'score', '*', '6.3', '5.5', '6.3', '3.7', 'BASMIe', 'score', '*', '4.2', '4.1', '3.8', '3.3', 'Tragus', 'wall', '(', 'cm', ')', '15.9', '15.8', '15.8', '15.4'], 'stemmed': ['compon', 'ankylos', 'spondyl', 'diseas', 'activ', 'placebo', 'n=107', 'humira', 'n=208', 'baselin', 'mean', 'week', '24', 'mean', 'baselin', 'mean', 'week', '24', 'mean', 'asa', '20', 'respons', 'criteria', '*', 'patient', '’', 'global', 'assess', 'diseas', 'activitya', '*', '65', '60', '63', '38', 'total', 'back', 'pain', '*', '67', '58', '65', '37', 'inflammationb', '*', '6.7', '5.6', '6.7', '3.6', 'basfic', '*', '56', '51', '52', '34', 'basdaid', 'score', '*', '6.3', '5.5', '6.3', '3.7', 'basmi', 'score', '*', '4.2', '4.1', '3.8', '3.3', 'tragu', 'wall', '(', 'cm', ')', '15.9', '15.8', '15.8', '15.4'], 'dependencies': [('compon', 'ROOT'), ('ankylos', 'compound'), ('spondyl', 'compound'), ('diseas', 'compound'), ('activ', 'compound'), ('placebo', 'compound'), ('n=107', 'compound'), ('humira', 'dobj'), ('n=208', 'npadvmod'), ('baselin', 'nmod'), ('mean', 'compound'), ('week', 'npadvmod'), ('24', 'nummod'), ('mean', 'compound'), ('baselin', 'compound'), ('mean', 'compound'), ('week', 'npadvmod'), ('24', 'nummod'), ('mean', 'parataxis'), ('asa', 'nmod'), ('20', 'nummod'), ('respons', 'compound'), ('criteria', 'nsubj'), ('*', 'punct'), ('patient', 'amod'), ('’', 'punct'), ('global', 'amod'), ('assess', 'conj'), ('diseas', 'dobj'), ('activitya', 'npadvmod'), ('*', 'punct'), ('65', 'quantmod'), ('60', 'compound'), ('63', 'compound'), ('38', 'nummod'), ('total', 'amod'), ('back', 'amod'), ('pain', 'dobj'), ('*', 'npadvmod'), ('67', 'quantmod'), ('58', 'nummod'), ('65', 'compound'), ('37', 'npadvmod'), ('inflammationb', 'quantmod'), ('*', 'punct'), ('6.7', 'quantmod'), ('5.6', 'compound'), ('6.7', 'compound'), ('3.6', 'nummod'), ('basfic', 'appos'), ('*', 'npadvmod'), ('56', 'quantmod'), ('51', 'nummod'), ('52', 'compound'), ('34', 'nummod'), ('basdaid', 'amod'), ('score', 'dobj'), ('*', 'punct'), ('6.3', 'nummod'), ('5.5', 'quantmod'), ('6.3', 'compound'), ('3.7', 'nummod'), ('basmi', 'amod'), ('score', 'dobj'), ('*', 'punct'), ('4.2', 'quantmod'), ('4.1', 'compound'), ('3.8', 'compound'), ('3.3', 'nummod'), ('tragu', 'compound'), ('wall', 'dobj'), ('(', 'punct'), ('cm', 'appos'), (')', 'punct'), ('15.9', 'nummod'), ('15.8', 'nummod'), ('15.8', 'nummod'), ('15.4', 'nummod')]}], 'text': 'Responses of patients with total spinal ankylosis (n=11) were similar to those without total \\nankylosis.  \\nFigure 2. ASAS 20 Response By Visit, Study AS-I \\n \\nAt 12 weeks, the ASAS 20/50/70 responses were achieved by 58%, 38%, and 23%, respectively, \\nof patients receiving HUMIRA, compared to 21%, 10%, and 5% respectively, of patients \\nreceiving placebo (p <0.001). Similar responses were seen at Week 24 and were sustained in \\npatients receiving open-label HUMIRA for up to 52 weeks.  \\nA greater proportion of patients treated with HUMIRA (22%) achieved a low level of disease \\nactivity at 24 weeks (defined as a value <20 [on a scale of 0 to 100 mm] in each of the four \\nASAS response parameters) compared to patients treated with placebo (6%).  \\nTable 11. Components of Ankylosing Spondylitis Disease Activity \\n  \\nPlacebo \\nN=107  \\nHUMIRA \\nN=208  \\n  \\nBaseline \\nmean \\nWeek 24 \\nmean \\nBaseline \\nmean \\nWeek 24 \\nmean \\nASAS 20 Response Criteria* \\n  \\n  \\n  \\n  \\n     Patient’s Global Assessment of Disease \\nActivitya* \\n65 \\n60 \\n63 \\n38 \\n     Total back pain* \\n67 \\n58 \\n65 \\n37 \\n     Inflammationb* \\n6.7 \\n5.6 \\n6.7 \\n3.6 \\n     BASFIc* \\n56 \\n51 \\n52 \\n34 \\nBASDAId score*  \\n6.3 \\n5.5 \\n6.3 \\n3.7 \\nBASMIe score*  \\n4.2 \\n4.1 \\n3.8 \\n3.3 \\n     Tragus to wall (cm) \\n15.9 \\n15.8 \\n15.8 \\n15.4 \\n'}, 'page_char_count': 1261, 'page_word_count': 196, 'sentences': ['Responses of patients with total spinal ankylosis (n=11) were similar to those without total \\nankylosis.', ' \\nFigure 2.', 'ASAS 20 Response By Visit, Study AS-I \\n \\nAt 12 weeks, the ASAS 20/50/70 responses were achieved by 58%, 38%, and 23%, respectively, \\nof patients receiving HUMIRA, compared to 21%, 10%, and 5% respectively, of patients \\nreceiving placebo (p <0.001).', 'Similar responses were seen at Week 24 and were sustained in \\npatients receiving open-label HUMIRA for up to 52 weeks.', ' \\nA greater proportion of patients treated with HUMIRA (22%) achieved a low level of disease \\nactivity at 24 weeks (defined as a value <20 [on a scale of 0 to 100 mm] in each of the four \\nASAS response parameters) compared to patients treated with placebo (6%).', ' \\nTable 11.', 'Components of Ankylosing Spondylitis Disease Activity \\n  \\nPlacebo \\nN=107  \\nHUMIRA \\nN=208  \\n  \\nBaseline \\nmean \\nWeek 24 \\nmean \\nBaseline \\nmean \\nWeek 24 \\nmean \\nASAS 20 Response Criteria* \\n  \\n  \\n  \\n  \\n     Patient’s Global Assessment of Disease \\nActivitya* \\n65 \\n60 \\n63 \\n38 \\n     Total back pain* \\n67 \\n58 \\n65 \\n37 \\n     Inflammationb* \\n6.7 \\n5.6 \\n6.7 \\n3.6 \\n     BASFIc* \\n56 \\n51 \\n52 \\n34 \\nBASDAId score*  \\n6.3 \\n5.5 \\n6.3 \\n3.7 \\nBASMIe score*  \\n4.2 \\n4.1 \\n3.8 \\n3.3 \\n     Tragus to wall (cm) \\n15.9 \\n15.8 \\n15.8 \\n15.4 \\n'], 'page_sentence_count_spacy': 7}\n",
            "{'page_number': 42, 'text': '     Lumbar flexion (cm) \\n4.1 \\n4.0 \\n4.2 \\n4.4 \\n     Cervical rotation (degrees) \\n42.2 \\n42.1 \\n48.4 \\n51.6 \\n     Lumbar side flexion (cm) \\n8.9 \\n9.0 \\n9.7 \\n11.7 \\n     Intermalleolar distance (cm) \\n92.9 \\n94.0 \\n93.5 \\n100.8 \\nCRPf* \\n2.2 \\n2.0 \\n1.8 \\n0.6 \\na Percent of subjects with at least a 20% and 10-unit improvement measured on a Visual \\nAnalog Scale (VAS) with 0 = “none” and 100 = “severe” \\nb mean of questions 5 and 6 of BASDAI (defined in ‘d’) \\nc Bath Ankylosing Spondylitis Functional Index \\nd Bath Ankylosing Spondylitis Disease Activity Index \\ne Bath Ankylosing Spondylitis Metrology Index \\nf C-Reactive Protein (mg/dL) \\n* statistically significant for comparisons between HUMIRA and placebo at Week 24  \\n \\n  \\nA second randomized, multicenter, double-blind, placebo-controlled study of 82 patients with \\nankylosing spondylitis showed similar results.  \\nPatients treated with HUMIRA achieved improvement from baseline in the Ankylosing \\nSpondylitis Quality of Life Questionnaire (ASQoL) score (-3.6 vs. -1.1) and in the Short Form \\nHealth Survey (SF-36) Physical Component Summary (PCS) score (7.4 vs. 1.9) compared to \\nplacebo-treated patients at Week 24.  \\n14.5 Adult Crohn’s Disease \\nThe safety and efficacy of multiple doses of HUMIRA were assessed in adult patients with \\nmoderately to severely active Crohn’s disease, CD, (Crohn’s Disease Activity Index (CDAI) ≥ \\n220 and ≤ 450) in randomized, double-blind, placebo-controlled studies. Concomitant stable \\ndoses of aminosalicylates, corticosteroids, and/or immunomodulatory agents were permitted, and \\n79% of patients continued to receive at least one of these medications.  \\nInduction of clinical remission (defined as CDAI < 150) was evaluated in two studies. In Study \\nCD-I, 299 TNF-blocker naïve patients were randomized to one of four treatment groups: the \\nplacebo group received placebo at Weeks 0 and 2, the 160/80 group received 160 mg HUMIRA \\nat Week 0 and 80 mg at Week 2, the 80/40 group received 80 mg at Week 0 and 40 mg at Week \\n2, and the 40/20 group received 40 mg at Week 0 and 20 mg at Week 2. Clinical results were \\nassessed at Week 4.  \\nIn the second induction study, Study CD-II, 325 patients who had lost response to, or were \\nintolerant to, previous infliximab therapy were randomized to receive either 160 mg HUMIRA at \\nWeek 0 and 80 mg at Week 2, or placebo at Weeks 0 and 2. Clinical results were assessed at \\nWeek 4.  \\nMaintenance of clinical remission was evaluated in Study CD-III. In this study, 854 patients with \\nactive disease received open-label HUMIRA, 80 mg at week 0 and 40 mg at Week 2. Patients \\nwere then randomized at Week 4 to 40 mg HUMIRA every other week, 40 mg HUMIRA every \\nweek, or placebo. The total study duration was 56 weeks. Patients in clinical response (decrease \\nin CDAI ≥70) at Week 4 were stratified and analyzed separately from those not in clinical \\nresponse at Week 4.  \\n', 'processed_text': {'sentences': [{'original_sentence': '     Lumbar flexion (cm) \\n4.1 \\n4.0 \\n4.2 \\n4.4 \\n     Cervical rotation (degrees) \\n42.2 \\n42.1 \\n48.4 \\n51.6 \\n     Lumbar side flexion (cm) \\n8.9 \\n9.0 \\n9.7 \\n11.7 \\n     Intermalleolar distance (cm) \\n92.9 \\n94.0 \\n93.5 \\n100.8 \\nCRPf* \\n2.2 \\n2.0 \\n1.8 \\n0.6 \\na Percent of subjects with at least a 20% and 10-unit improvement measured on a Visual \\nAnalog Scale (VAS) with 0 = “none” and 100 = “severe” \\nb mean of questions 5 and 6 of BASDAI (defined in ‘d’) \\nc Bath Ankylosing Spondylitis Functional Index \\nd Bath Ankylosing Spondylitis Disease Activity Index \\ne Bath Ankylosing Spondylitis Metrology Index \\nf C-Reactive Protein (mg/dL) \\n* statistically significant for comparisons between HUMIRA and placebo at Week 24  \\n \\n  \\nA second randomized, multicenter, double-blind, placebo-controlled study of 82 patients with \\nankylosing spondylitis showed similar results.', 'tokens': ['Lumbar', 'flexion', '(', 'cm', ')', '4.1', '4.0', '4.2', '4.4', 'Cervical', 'rotation', '(', 'degrees', ')', '42.2', '42.1', '48.4', '51.6', 'Lumbar', 'side', 'flexion', '(', 'cm', ')', '8.9', '9.0', '9.7', '11.7', 'Intermalleolar', 'distance', '(', 'cm', ')', '92.9', '94.0', '93.5', '100.8', 'CRPf', '*', '2.2', '2.0', '1.8', '0.6', 'Percent', 'subjects', 'least', '20', '%', '10-unit', 'improvement', 'measured', 'Visual', 'Analog', 'Scale', '(', 'VAS', ')', '0', '=', '“', 'none', '”', '100', '=', '“', 'severe', '”', 'b', 'mean', 'questions', '5', '6', 'BASDAI', '(', 'defined', '‘', '’', ')', 'c', 'Bath', 'Ankylosing', 'Spondylitis', 'Functional', 'Index', 'Bath', 'Ankylosing', 'Spondylitis', 'Disease', 'Activity', 'Index', 'e', 'Bath', 'Ankylosing', 'Spondylitis', 'Metrology', 'Index', 'f', 'C-Reactive', 'Protein', '(', 'mg/dL', ')', '*', 'statistically', 'significant', 'comparisons', 'HUMIRA', 'placebo', 'Week', '24', 'second', 'randomized', ',', 'multicenter', ',', 'double-blind', ',', 'placebo-controlled', 'study', '82', 'patients', 'ankylosing', 'spondylitis', 'showed', 'similar', 'results', '.'], 'lemmatized': ['Lumbar', 'flexion', '(', 'cm', ')', '4.1', '4.0', '4.2', '4.4', 'Cervical', 'rotation', '(', 'degree', ')', '42.2', '42.1', '48.4', '51.6', 'Lumbar', 'side', 'flexion', '(', 'cm', ')', '8.9', '9.0', '9.7', '11.7', 'Intermalleolar', 'distance', '(', 'cm', ')', '92.9', '94.0', '93.5', '100.8', 'CRPf', '*', '2.2', '2.0', '1.8', '0.6', 'Percent', 'subject', 'least', '20', '%', '10-unit', 'improvement', 'measured', 'Visual', 'Analog', 'Scale', '(', 'VAS', ')', '0', '=', '“', 'none', '”', '100', '=', '“', 'severe', '”', 'b', 'mean', 'question', '5', '6', 'BASDAI', '(', 'defined', '‘', '’', ')', 'c', 'Bath', 'Ankylosing', 'Spondylitis', 'Functional', 'Index', 'Bath', 'Ankylosing', 'Spondylitis', 'Disease', 'Activity', 'Index', 'e', 'Bath', 'Ankylosing', 'Spondylitis', 'Metrology', 'Index', 'f', 'C-Reactive', 'Protein', '(', 'mg/dL', ')', '*', 'statistically', 'significant', 'comparison', 'HUMIRA', 'placebo', 'Week', '24', 'second', 'randomized', ',', 'multicenter', ',', 'double-blind', ',', 'placebo-controlled', 'study', '82', 'patient', 'ankylosing', 'spondylitis', 'showed', 'similar', 'result', '.'], 'stemmed': ['lumbar', 'flexion', '(', 'cm', ')', '4.1', '4.0', '4.2', '4.4', 'cervic', 'rotat', '(', 'degre', ')', '42.2', '42.1', '48.4', '51.6', 'lumbar', 'side', 'flexion', '(', 'cm', ')', '8.9', '9.0', '9.7', '11.7', 'intermalleolar', 'distanc', '(', 'cm', ')', '92.9', '94.0', '93.5', '100.8', 'crpf', '*', '2.2', '2.0', '1.8', '0.6', 'percent', 'subject', 'least', '20', '%', '10-unit', 'improv', 'measur', 'visual', 'analog', 'scale', '(', 'va', ')', '0', '=', '“', 'none', '”', '100', '=', '“', 'sever', '”', 'b', 'mean', 'question', '5', '6', 'basdai', '(', 'defin', '‘', '’', ')', 'c', 'bath', 'ankylos', 'spondyl', 'function', 'index', 'bath', 'ankylos', 'spondyl', 'diseas', 'activ', 'index', 'e', 'bath', 'ankylos', 'spondyl', 'metrolog', 'index', 'f', 'c-reactiv', 'protein', '(', 'mg/dl', ')', '*', 'statist', 'signific', 'comparison', 'humira', 'placebo', 'week', '24', 'second', 'random', ',', 'multicent', ',', 'double-blind', ',', 'placebo-control', 'studi', '82', 'patient', 'ankylos', 'spondyl', 'show', 'similar', 'result', '.'], 'dependencies': [('lumbar', 'compound'), ('flexion', 'ROOT'), ('(', 'punct'), ('cm', 'appos'), (')', 'punct'), ('4.1', 'compound'), ('4.0', 'quantmod'), ('4.2', 'compound'), ('4.4', 'nummod'), ('cervic', 'compound'), ('rotat', 'appos'), ('(', 'punct'), ('degre', 'appos'), (')', 'punct'), ('42.2', 'quantmod'), ('42.1', 'compound'), ('48.4', 'compound'), ('51.6', 'nummod'), ('lumbar', 'compound'), ('side', 'compound'), ('flexion', 'appos'), ('(', 'punct'), ('cm', 'appos'), (')', 'punct'), ('8.9', 'quantmod'), ('9.0', 'compound'), ('9.7', 'compound'), ('11.7', 'nummod'), ('intermalleolar', 'amod'), ('distanc', 'appos'), ('(', 'punct'), ('cm', 'appos'), (')', 'punct'), ('92.9', 'npadvmod'), ('94.0', 'nummod'), ('93.5', 'nummod'), ('100.8', 'nummod'), ('crpf', 'appos'), ('*', 'punct'), ('2.2', 'nummod'), ('2.0', 'quantmod'), ('1.8', 'compound'), ('0.6', 'nummod'), ('percent', 'npadvmod'), ('subject', 'amod'), ('least', 'advmod'), ('20', 'nummod'), ('%', 'appos'), ('10', 'nummod'), ('-', 'punct'), ('unit', 'compound'), ('improv', 'nmod'), ('measur', 'nmod'), ('visual', 'amod'), ('analog', 'compound'), ('scale', 'appos'), ('(', 'punct'), ('va', 'appos'), (')', 'punct'), ('0', 'punct'), ('=', 'dep'), ('“', 'punct'), ('none', 'npadvmod'), ('”', 'punct'), ('100', 'nummod'), ('=', 'nmod'), ('“', 'punct'), ('sever', 'ROOT'), ('”', 'punct'), ('b', 'compound'), ('mean', 'compound'), ('question', 'dobj'), ('5', 'nummod'), ('6', 'nummod'), ('basdai', 'dobj'), ('(', 'punct'), ('defin', 'appos'), ('‘', 'punct'), ('’', 'punct'), (')', 'punct'), ('c', 'det'), ('bath', 'compound'), ('ankylos', 'compound'), ('spondyl', 'compound'), ('function', 'compound'), ('index', 'compound'), ('bath', 'compound'), ('ankylos', 'compound'), ('spondyl', 'nmod'), ('diseas', 'compound'), ('activ', 'compound'), ('index', 'nmod'), ('e', 'compound'), ('bath', 'appos'), ('ankylos', 'compound'), ('spondyl', 'compound'), ('metrolog', 'compound'), ('index', 'compound'), ('f', 'compound'), ('c', 'compound'), ('-', 'punct'), ('reactiv', 'compound'), ('protein', 'nsubj'), ('(', 'punct'), ('mg', 'nmod'), ('/', 'punct'), ('dl', 'appos'), (')', 'punct'), ('*', 'punct'), ('statist', 'amod'), ('signific', 'compound'), ('comparison', 'compound'), ('humira', 'compound'), ('placebo', 'compound'), ('week', 'npadvmod'), ('24', 'nummod'), ('second', 'amod'), ('random', 'amod'), (',', 'punct'), ('multicent', 'appos'), (',', 'punct'), ('double', 'amod'), ('-', 'punct'), ('blind', 'conj'), (',', 'punct'), ('placebo', 'compound'), ('-', 'punct'), ('control', 'compound'), ('studi', 'nmod'), ('82', 'nummod'), ('patient', 'appos'), ('ankylos', 'compound'), ('spondyl', 'nsubj'), ('show', 'ROOT'), ('similar', 'amod'), ('result', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Patients treated with HUMIRA achieved improvement from baseline in the Ankylosing \\nSpondylitis Quality of Life Questionnaire (ASQoL) score (-3.6 vs. -1.1) and in the Short Form \\nHealth Survey (SF-36) Physical Component Summary (PCS) score (7.4 vs. 1.9) compared to \\nplacebo-treated patients at Week 24.', 'tokens': ['Patients', 'treated', 'HUMIRA', 'achieved', 'improvement', 'baseline', 'Ankylosing', 'Spondylitis', 'Quality', 'Life', 'Questionnaire', '(', 'ASQoL', ')', 'score', '(', '-3.6', 'vs.', '-1.1', ')', 'Short', 'Form', 'Health', 'Survey', '(', 'SF-36', ')', 'Physical', 'Component', 'Summary', '(', 'PCS', ')', 'score', '(', '7.4', 'vs.', '1.9', ')', 'compared', 'placebo-treated', 'patients', 'Week', '24', '.'], 'lemmatized': ['Patients', 'treated', 'HUMIRA', 'achieved', 'improvement', 'baseline', 'Ankylosing', 'Spondylitis', 'Quality', 'Life', 'Questionnaire', '(', 'ASQoL', ')', 'score', '(', '-3.6', 'vs.', '-1.1', ')', 'Short', 'Form', 'Health', 'Survey', '(', 'SF-36', ')', 'Physical', 'Component', 'Summary', '(', 'PCS', ')', 'score', '(', '7.4', 'vs.', '1.9', ')', 'compared', 'placebo-treated', 'patient', 'Week', '24', '.'], 'stemmed': ['patient', 'treat', 'humira', 'achiev', 'improv', 'baselin', 'ankylos', 'spondyl', 'qualiti', 'life', 'questionnair', '(', 'asqol', ')', 'score', '(', '-3.6', 'vs.', '-1.1', ')', 'short', 'form', 'health', 'survey', '(', 'sf-36', ')', 'physic', 'compon', 'summari', '(', 'pc', ')', 'score', '(', '7.4', 'vs.', '1.9', ')', 'compar', 'placebo-tr', 'patient', 'week', '24', '.'], 'dependencies': [('patient', 'compound'), ('treat', 'compound'), ('humira', 'compound'), ('achiev', 'compound'), ('improv', 'compound'), ('baselin', 'compound'), ('ankylos', 'compound'), ('spondyl', 'npadvmod'), ('qualiti', 'compound'), ('life', 'compound'), ('questionnair', 'nmod'), ('(', 'punct'), ('asqol', 'nmod'), (')', 'punct'), ('score', 'nmod'), ('(', 'punct'), ('-3.6', 'appos'), ('vs.', 'prep'), ('-1.1', 'pobj'), (')', 'punct'), ('short', 'amod'), ('form', 'compound'), ('health', 'compound'), ('survey', 'ROOT'), ('(', 'punct'), ('sf-36', 'appos'), (')', 'punct'), ('physic', 'amod'), ('compon', 'appos'), ('summari', 'amod'), ('(', 'punct'), ('pc', 'nmod'), (')', 'punct'), ('score', 'dobj'), ('(', 'punct'), ('7.4', 'nummod'), ('vs.', 'prep'), ('1.9', 'pobj'), (')', 'punct'), ('compar', 'compound'), ('placebo', 'compound'), ('-', 'punct'), ('tr', 'prep'), ('patient', 'amod'), ('week', 'appos'), ('24', 'nummod'), ('.', 'punct')]}, {'original_sentence': '14.5 Adult Crohn’s Disease \\nThe safety and efficacy of multiple doses of HUMIRA were assessed in adult patients with \\nmoderately to severely active Crohn’s disease, CD, (Crohn’s Disease Activity Index (CDAI) ≥ \\n220 and ≤ 450) in randomized, double-blind, placebo-controlled studies.', 'tokens': ['14.5', 'Adult', 'Crohn', '’', 'Disease', 'safety', 'efficacy', 'multiple', 'doses', 'HUMIRA', 'assessed', 'adult', 'patients', 'moderately', 'severely', 'active', 'Crohn', '’', 'disease', ',', 'CD', ',', '(', 'Crohn', '’', 'Disease', 'Activity', 'Index', '(', 'CDAI', ')', '≥', '220', '≤', '450', ')', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'studies', '.'], 'lemmatized': ['14.5', 'Adult', 'Crohn', '’', 'Disease', 'safety', 'efficacy', 'multiple', 'dos', 'HUMIRA', 'assessed', 'adult', 'patient', 'moderately', 'severely', 'active', 'Crohn', '’', 'disease', ',', 'CD', ',', '(', 'Crohn', '’', 'Disease', 'Activity', 'Index', '(', 'CDAI', ')', '≥', '220', '≤', '450', ')', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'study', '.'], 'stemmed': ['14.5', 'adult', 'crohn', '’', 'diseas', 'safeti', 'efficaci', 'multipl', 'do', 'humira', 'assess', 'adult', 'patient', 'moder', 'sever', 'activ', 'crohn', '’', 'diseas', ',', 'cd', ',', '(', 'crohn', '’', 'diseas', 'activ', 'index', '(', 'cdai', ')', '≥', '220', '≤', '450', ')', 'random', ',', 'double-blind', ',', 'placebo-control', 'studi', '.'], 'dependencies': [('14.5', 'nummod'), ('adult', 'compound'), ('crohn', 'dep'), ('’', 'punct'), ('diseas', 'compound'), ('safeti', 'compound'), ('efficaci', 'compound'), ('multipl', 'nsubj'), ('do', 'aux'), ('humira', 'nsubj'), ('assess', 'ROOT'), ('adult', 'compound'), ('patient', 'compound'), ('moder', 'nsubj'), ('sever', 'ccomp'), ('activ', 'nmod'), ('crohn', 'nmod'), ('’', 'punct'), ('diseas', 'dobj'), (',', 'punct'), ('cd', 'appos'), (',', 'punct'), ('(', 'punct'), ('crohn', 'nmod'), ('’', 'punct'), ('diseas', 'amod'), ('activ', 'compound'), ('index', 'nmod'), ('(', 'punct'), ('cdai', 'appos'), (')', 'punct'), ('≥', 'conj'), ('220', 'nummod'), ('≤', 'npadvmod'), ('450', 'nummod'), (')', 'punct'), ('random', 'amod'), (',', 'punct'), ('double', 'amod'), ('-', 'punct'), ('blind', 'conj'), (',', 'punct'), ('placebo', 'compound'), ('-', 'punct'), ('control', 'compound'), ('studi', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Concomitant stable \\ndoses of aminosalicylates, corticosteroids, and/or immunomodulatory agents were permitted, and \\n79% of patients continued to receive at least one of these medications.', 'tokens': ['Concomitant', 'stable', 'doses', 'aminosalicylates', ',', 'corticosteroids', ',', 'and/or', 'immunomodulatory', 'agents', 'permitted', ',', '79', '%', 'patients', 'continued', 'receive', 'least', 'one', 'medications', '.'], 'lemmatized': ['Concomitant', 'stable', 'dos', 'aminosalicylates', ',', 'corticosteroid', ',', 'and/or', 'immunomodulatory', 'agent', 'permitted', ',', '79', '%', 'patient', 'continued', 'receive', 'least', 'one', 'medication', '.'], 'stemmed': ['concomit', 'stabl', 'do', 'aminosalicyl', ',', 'corticosteroid', ',', 'and/or', 'immunomodulatori', 'agent', 'permit', ',', '79', '%', 'patient', 'continu', 'receiv', 'least', 'one', 'medic', '.'], 'dependencies': [('concomit', 'nsubj'), ('stabl', 'amod'), ('do', 'amod'), ('aminosalicyl', 'dobj'), (',', 'punct'), ('corticosteroid', 'conj'), (',', 'punct'), ('and/or', 'cc'), ('immunomodulatori', 'compound'), ('agent', 'compound'), ('permit', 'dobj'), (',', 'punct'), ('79', 'nummod'), ('%', 'nmod'), ('patient', 'compound'), ('continu', 'compound'), ('receiv', 'ROOT'), ('least', 'advmod'), ('one', 'nummod'), ('medic', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Induction of clinical remission (defined as CDAI < 150) was evaluated in two studies.', 'tokens': ['Induction', 'clinical', 'remission', '(', 'defined', 'CDAI', '<', '150', ')', 'evaluated', 'two', 'studies', '.'], 'lemmatized': ['Induction', 'clinical', 'remission', '(', 'defined', 'CDAI', '<', '150', ')', 'evaluated', 'two', 'study', '.'], 'stemmed': ['induct', 'clinic', 'remiss', '(', 'defin', 'cdai', '<', '150', ')', 'evalu', 'two', 'studi', '.'], 'dependencies': [('induct', 'ROOT'), ('clinic', 'compound'), ('remiss', 'dobj'), ('(', 'punct'), ('defin', 'compound'), ('cdai', 'appos'), ('<', 'nmod'), ('150', 'appos'), (')', 'punct'), ('evalu', 'dative'), ('two', 'nummod'), ('studi', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'In Study \\nCD-I, 299 TNF-blocker naïve patients were randomized to one of four treatment groups: the \\nplacebo group received placebo at Weeks 0 and 2, the 160/80 group received 160 mg HUMIRA \\nat Week 0 and 80 mg at Week 2, the 80/40 group received 80 mg at Week 0 and 40 mg at Week \\n2, and the 40/20 group received 40 mg at Week 0 and 20 mg at Week 2.', 'tokens': ['Study', 'CD-I', ',', '299', 'TNF-blocker', 'naïve', 'patients', 'randomized', 'one', 'four', 'treatment', 'groups', ':', 'placebo', 'group', 'received', 'placebo', 'Weeks', '0', '2', ',', '160/80', 'group', 'received', '160', 'mg', 'HUMIRA', 'Week', '0', '80', 'mg', 'Week', '2', ',', '80/40', 'group', 'received', '80', 'mg', 'Week', '0', '40', 'mg', 'Week', '2', ',', '40/20', 'group', 'received', '40', 'mg', 'Week', '0', '20', 'mg', 'Week', '2', '.'], 'lemmatized': ['Study', 'CD-I', ',', '299', 'TNF-blocker', 'naïve', 'patient', 'randomized', 'one', 'four', 'treatment', 'group', ':', 'placebo', 'group', 'received', 'placebo', 'Weeks', '0', '2', ',', '160/80', 'group', 'received', '160', 'mg', 'HUMIRA', 'Week', '0', '80', 'mg', 'Week', '2', ',', '80/40', 'group', 'received', '80', 'mg', 'Week', '0', '40', 'mg', 'Week', '2', ',', '40/20', 'group', 'received', '40', 'mg', 'Week', '0', '20', 'mg', 'Week', '2', '.'], 'stemmed': ['studi', 'cd-i', ',', '299', 'tnf-blocker', 'naïv', 'patient', 'random', 'one', 'four', 'treatment', 'group', ':', 'placebo', 'group', 'receiv', 'placebo', 'week', '0', '2', ',', '160/80', 'group', 'receiv', '160', 'mg', 'humira', 'week', '0', '80', 'mg', 'week', '2', ',', '80/40', 'group', 'receiv', '80', 'mg', 'week', '0', '40', 'mg', 'week', '2', ',', '40/20', 'group', 'receiv', '40', 'mg', 'week', '0', '20', 'mg', 'week', '2', '.'], 'dependencies': [('studi', 'compound'), ('cd', 'ROOT'), ('-', 'punct'), ('i', 'appos'), (',', 'punct'), ('299', 'nummod'), ('tnf', 'compound'), ('-', 'punct'), ('blocker', 'compound'), ('naïv', 'compound'), ('patient', 'nmod'), ('random', 'amod'), ('one', 'compound'), ('four', 'nummod'), ('treatment', 'compound'), ('group', 'appos'), (':', 'punct'), ('placebo', 'compound'), ('group', 'compound'), ('receiv', 'compound'), ('placebo', 'compound'), ('week', 'appos'), ('0', 'nummod'), ('2', 'nummod'), (',', 'punct'), ('160/80', 'compound'), ('group', 'compound'), ('receiv', 'appos'), ('160', 'nummod'), ('mg', 'prep'), ('humira', 'conj'), ('week', 'npadvmod'), ('0', 'nummod'), ('80', 'nummod'), ('mg', 'prep'), ('week', 'pobj'), ('2', 'nummod'), (',', 'punct'), ('80/40', 'nummod'), ('group', 'compound'), ('receiv', 'appos'), ('80', 'nummod'), ('mg', 'prep'), ('week', 'pobj'), ('0', 'nummod'), ('40', 'nummod'), ('mg', 'prep'), ('week', 'pobj'), ('2', 'nummod'), (',', 'punct'), ('40/20', 'nummod'), ('group', 'compound'), ('receiv', 'appos'), ('40', 'nummod'), ('mg', 'prep'), ('week', 'pobj'), ('0', 'nummod'), ('20', 'nummod'), ('mg', 'prep'), ('week', 'pobj'), ('2', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Clinical results were \\nassessed at Week 4.', 'tokens': ['Clinical', 'results', 'assessed', 'Week', '4', '.'], 'lemmatized': ['Clinical', 'result', 'assessed', 'Week', '4', '.'], 'stemmed': ['clinic', 'result', 'assess', 'week', '4', '.'], 'dependencies': [('clinic', 'compound'), ('result', 'compound'), ('assess', 'ROOT'), ('week', 'npadvmod'), ('4', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'In the second induction study, Study CD-II, 325 patients who had lost response to, or were \\nintolerant to, previous infliximab therapy were randomized to receive either 160 mg HUMIRA at \\nWeek 0 and 80 mg at Week 2, or placebo at Weeks 0 and 2.', 'tokens': ['second', 'induction', 'study', ',', 'Study', 'CD-II', ',', '325', 'patients', 'lost', 'response', ',', 'intolerant', ',', 'previous', 'infliximab', 'therapy', 'randomized', 'receive', 'either', '160', 'mg', 'HUMIRA', 'Week', '0', '80', 'mg', 'Week', '2', ',', 'placebo', 'Weeks', '0', '2', '.'], 'lemmatized': ['second', 'induction', 'study', ',', 'Study', 'CD-II', ',', '325', 'patient', 'lost', 'response', ',', 'intolerant', ',', 'previous', 'infliximab', 'therapy', 'randomized', 'receive', 'either', '160', 'mg', 'HUMIRA', 'Week', '0', '80', 'mg', 'Week', '2', ',', 'placebo', 'Weeks', '0', '2', '.'], 'stemmed': ['second', 'induct', 'studi', ',', 'studi', 'cd-ii', ',', '325', 'patient', 'lost', 'respons', ',', 'intoler', ',', 'previou', 'infliximab', 'therapi', 'random', 'receiv', 'either', '160', 'mg', 'humira', 'week', '0', '80', 'mg', 'week', '2', ',', 'placebo', 'week', '0', '2', '.'], 'dependencies': [('second', 'ROOT'), ('induct', 'compound'), ('studi', 'dobj'), (',', 'punct'), ('studi', 'compound'), ('cd', 'compound'), ('-', 'punct'), ('ii', 'conj'), (',', 'punct'), ('325', 'nummod'), ('patient', 'nmod'), ('lost', 'amod'), ('respons', 'conj'), (',', 'punct'), ('intoler', 'nmod'), (',', 'punct'), ('previou', 'compound'), ('infliximab', 'nmod'), ('therapi', 'nmod'), ('random', 'amod'), ('receiv', 'conj'), ('either', 'preconj'), ('160', 'nummod'), ('mg', 'compound'), ('humira', 'compound'), ('week', 'npadvmod'), ('0', 'nummod'), ('80', 'nummod'), ('mg', 'prep'), ('week', 'pobj'), ('2', 'nummod'), (',', 'punct'), ('placebo', 'compound'), ('week', 'npadvmod'), ('0', 'nummod'), ('2', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Clinical results were assessed at \\nWeek 4.', 'tokens': ['Clinical', 'results', 'assessed', 'Week', '4', '.'], 'lemmatized': ['Clinical', 'result', 'assessed', 'Week', '4', '.'], 'stemmed': ['clinic', 'result', 'assess', 'week', '4', '.'], 'dependencies': [('clinic', 'compound'), ('result', 'compound'), ('assess', 'ROOT'), ('week', 'npadvmod'), ('4', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Maintenance of clinical remission was evaluated in Study CD-III.', 'tokens': ['Maintenance', 'clinical', 'remission', 'evaluated', 'Study', 'CD-III', '.'], 'lemmatized': ['Maintenance', 'clinical', 'remission', 'evaluated', 'Study', 'CD-III', '.'], 'stemmed': ['mainten', 'clinic', 'remiss', 'evalu', 'studi', 'cd-iii', '.'], 'dependencies': [('mainten', 'ROOT'), ('clinic', 'compound'), ('remiss', 'compound'), ('evalu', 'compound'), ('studi', 'compound'), ('cd', 'compound'), ('-', 'punct'), ('iii', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'In this study, 854 patients with \\nactive disease received open-label HUMIRA, 80 mg at week 0 and 40 mg at Week 2.', 'tokens': ['study', ',', '854', 'patients', 'active', 'disease', 'received', 'open-label', 'HUMIRA', ',', '80', 'mg', 'week', '0', '40', 'mg', 'Week', '2', '.'], 'lemmatized': ['study', ',', '854', 'patient', 'active', 'disease', 'received', 'open-label', 'HUMIRA', ',', '80', 'mg', 'week', '0', '40', 'mg', 'Week', '2', '.'], 'stemmed': ['studi', ',', '854', 'patient', 'activ', 'diseas', 'receiv', 'open-label', 'humira', ',', '80', 'mg', 'week', '0', '40', 'mg', 'week', '2', '.'], 'dependencies': [('studi', 'dep'), (',', 'punct'), ('854', 'nummod'), ('patient', 'amod'), ('activ', 'compound'), ('diseas', 'nmod'), ('receiv', 'nmod'), ('open', 'amod'), ('-', 'punct'), ('label', 'compound'), ('humira', 'ROOT'), (',', 'punct'), ('80', 'nummod'), ('mg', 'amod'), ('week', 'appos'), ('0', 'nummod'), ('40', 'nummod'), ('mg', 'prep'), ('week', 'pobj'), ('2', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Patients \\nwere then randomized at Week 4 to 40 mg HUMIRA every other week, 40 mg HUMIRA every \\nweek, or placebo.', 'tokens': ['Patients', 'randomized', 'Week', '4', '40', 'mg', 'HUMIRA', 'every', 'week', ',', '40', 'mg', 'HUMIRA', 'every', 'week', ',', 'placebo', '.'], 'lemmatized': ['Patients', 'randomized', 'Week', '4', '40', 'mg', 'HUMIRA', 'every', 'week', ',', '40', 'mg', 'HUMIRA', 'every', 'week', ',', 'placebo', '.'], 'stemmed': ['patient', 'random', 'week', '4', '40', 'mg', 'humira', 'everi', 'week', ',', '40', 'mg', 'humira', 'everi', 'week', ',', 'placebo', '.'], 'dependencies': [('patient', 'ROOT'), ('random', 'amod'), ('week', 'npadvmod'), ('4', 'compound'), ('40', 'nummod'), ('mg', 'prep'), ('humira', 'pobj'), ('everi', 'compound'), ('week', 'npadvmod'), (',', 'punct'), ('40', 'nummod'), ('mg', 'prep'), ('humira', 'pobj'), ('everi', 'compound'), ('week', 'npadvmod'), (',', 'punct'), ('placebo', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'The total study duration was 56 weeks.', 'tokens': ['total', 'study', 'duration', '56', 'weeks', '.'], 'lemmatized': ['total', 'study', 'duration', '56', 'week', '.'], 'stemmed': ['total', 'studi', 'durat', '56', 'week', '.'], 'dependencies': [('total', 'amod'), ('studi', 'compound'), ('durat', 'ROOT'), ('56', 'nummod'), ('week', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Patients in clinical response (decrease \\nin CDAI ≥70) at Week 4 were stratified and analyzed separately from those not in clinical \\nresponse at Week 4.', 'tokens': ['Patients', 'clinical', 'response', '(', 'decrease', 'CDAI', '≥70', ')', 'Week', '4', 'stratified', 'analyzed', 'separately', 'clinical', 'response', 'Week', '4', '.'], 'lemmatized': ['Patients', 'clinical', 'response', '(', 'decrease', 'CDAI', '≥70', ')', 'Week', '4', 'stratified', 'analyzed', 'separately', 'clinical', 'response', 'Week', '4', '.'], 'stemmed': ['patient', 'clinic', 'respons', '(', 'decreas', 'cdai', '≥70', ')', 'week', '4', 'stratifi', 'analyz', 'separ', 'clinic', 'respons', 'week', '4', '.'], 'dependencies': [('patient', 'amod'), ('clinic', 'compound'), ('respons', 'ROOT'), ('(', 'punct'), ('decreas', 'compound'), ('cdai', 'nmod'), ('≥70', 'punct'), (')', 'punct'), ('week', 'nmod'), ('4', 'nummod'), ('stratifi', 'compound'), ('analyz', 'compound'), ('separ', 'compound'), ('clinic', 'compound'), ('respons', 'nsubj'), ('week', 'npadvmod'), ('4', 'nummod'), ('.', 'punct')]}], 'text': '     Lumbar flexion (cm) \\n4.1 \\n4.0 \\n4.2 \\n4.4 \\n     Cervical rotation (degrees) \\n42.2 \\n42.1 \\n48.4 \\n51.6 \\n     Lumbar side flexion (cm) \\n8.9 \\n9.0 \\n9.7 \\n11.7 \\n     Intermalleolar distance (cm) \\n92.9 \\n94.0 \\n93.5 \\n100.8 \\nCRPf* \\n2.2 \\n2.0 \\n1.8 \\n0.6 \\na Percent of subjects with at least a 20% and 10-unit improvement measured on a Visual \\nAnalog Scale (VAS) with 0 = “none” and 100 = “severe” \\nb mean of questions 5 and 6 of BASDAI (defined in ‘d’) \\nc Bath Ankylosing Spondylitis Functional Index \\nd Bath Ankylosing Spondylitis Disease Activity Index \\ne Bath Ankylosing Spondylitis Metrology Index \\nf C-Reactive Protein (mg/dL) \\n* statistically significant for comparisons between HUMIRA and placebo at Week 24  \\n \\n  \\nA second randomized, multicenter, double-blind, placebo-controlled study of 82 patients with \\nankylosing spondylitis showed similar results.  \\nPatients treated with HUMIRA achieved improvement from baseline in the Ankylosing \\nSpondylitis Quality of Life Questionnaire (ASQoL) score (-3.6 vs. -1.1) and in the Short Form \\nHealth Survey (SF-36) Physical Component Summary (PCS) score (7.4 vs. 1.9) compared to \\nplacebo-treated patients at Week 24.  \\n14.5 Adult Crohn’s Disease \\nThe safety and efficacy of multiple doses of HUMIRA were assessed in adult patients with \\nmoderately to severely active Crohn’s disease, CD, (Crohn’s Disease Activity Index (CDAI) ≥ \\n220 and ≤ 450) in randomized, double-blind, placebo-controlled studies. Concomitant stable \\ndoses of aminosalicylates, corticosteroids, and/or immunomodulatory agents were permitted, and \\n79% of patients continued to receive at least one of these medications.  \\nInduction of clinical remission (defined as CDAI < 150) was evaluated in two studies. In Study \\nCD-I, 299 TNF-blocker naïve patients were randomized to one of four treatment groups: the \\nplacebo group received placebo at Weeks 0 and 2, the 160/80 group received 160 mg HUMIRA \\nat Week 0 and 80 mg at Week 2, the 80/40 group received 80 mg at Week 0 and 40 mg at Week \\n2, and the 40/20 group received 40 mg at Week 0 and 20 mg at Week 2. Clinical results were \\nassessed at Week 4.  \\nIn the second induction study, Study CD-II, 325 patients who had lost response to, or were \\nintolerant to, previous infliximab therapy were randomized to receive either 160 mg HUMIRA at \\nWeek 0 and 80 mg at Week 2, or placebo at Weeks 0 and 2. Clinical results were assessed at \\nWeek 4.  \\nMaintenance of clinical remission was evaluated in Study CD-III. In this study, 854 patients with \\nactive disease received open-label HUMIRA, 80 mg at week 0 and 40 mg at Week 2. Patients \\nwere then randomized at Week 4 to 40 mg HUMIRA every other week, 40 mg HUMIRA every \\nweek, or placebo. The total study duration was 56 weeks. Patients in clinical response (decrease \\nin CDAI ≥70) at Week 4 were stratified and analyzed separately from those not in clinical \\nresponse at Week 4.  \\n'}, 'page_char_count': 2887, 'page_word_count': 462, 'sentences': ['     Lumbar flexion (cm) \\n4.1 \\n4.0 \\n4.2 \\n4.4 \\n     Cervical rotation (degrees) \\n42.2 \\n42.1 \\n48.4 \\n51.6 \\n     Lumbar side flexion (cm) \\n8.9 \\n9.0 \\n9.7 \\n11.7 \\n     Intermalleolar distance (cm) \\n92.9 \\n94.0 \\n93.5 \\n100.8 \\nCRPf* \\n2.2 \\n2.0 \\n1.8 \\n0.6 \\na Percent of subjects with at least a 20% and 10-unit improvement measured on a Visual \\nAnalog Scale (VAS) with 0 = “none” and 100 = “severe” \\nb mean of questions 5 and 6 of BASDAI (defined in ‘d’) \\nc Bath Ankylosing Spondylitis Functional Index \\nd Bath Ankylosing Spondylitis Disease Activity Index \\ne Bath Ankylosing Spondylitis Metrology Index \\nf C-Reactive Protein (mg/dL) \\n* statistically significant for comparisons between HUMIRA and placebo at Week 24  \\n \\n  \\nA second randomized, multicenter, double-blind, placebo-controlled study of 82 patients with \\nankylosing spondylitis showed similar results.', ' \\nPatients treated with HUMIRA achieved improvement from baseline in the Ankylosing \\nSpondylitis Quality of Life Questionnaire (ASQoL) score (-3.6 vs. -1.1) and in the Short Form \\nHealth Survey (SF-36) Physical Component Summary (PCS) score (7.4 vs. 1.9) compared to \\nplacebo-treated patients at Week 24.', ' \\n14.5 Adult Crohn’s Disease \\nThe safety and efficacy of multiple doses of HUMIRA were assessed in adult patients with \\nmoderately to severely active Crohn’s disease, CD, (Crohn’s Disease Activity Index (CDAI) ≥ \\n220 and ≤ 450) in randomized, double-blind, placebo-controlled studies.', 'Concomitant stable \\ndoses of aminosalicylates, corticosteroids, and/or immunomodulatory agents were permitted, and \\n79% of patients continued to receive at least one of these medications.', ' \\nInduction of clinical remission (defined as CDAI < 150) was evaluated in two studies.', 'In Study \\nCD-I, 299 TNF-blocker naïve patients were randomized to one of four treatment groups: the \\nplacebo group received placebo at Weeks 0 and 2, the 160/80 group received 160 mg HUMIRA \\nat Week 0 and 80 mg at Week 2, the 80/40 group received 80 mg at Week 0 and 40 mg at Week \\n2, and the 40/20 group received 40 mg at Week 0 and 20 mg at Week 2.', 'Clinical results were \\nassessed at Week 4.', ' \\nIn the second induction study, Study CD-II, 325 patients who had lost response to, or were \\nintolerant to, previous infliximab therapy were randomized to receive either 160 mg HUMIRA at \\nWeek 0 and 80 mg at Week 2, or placebo at Weeks 0 and 2.', 'Clinical results were assessed at \\nWeek 4.', ' \\nMaintenance of clinical remission was evaluated in Study CD-III.', 'In this study, 854 patients with \\nactive disease received open-label HUMIRA, 80 mg at week 0 and 40 mg at Week 2.', 'Patients \\nwere then randomized at Week 4 to 40 mg HUMIRA every other week, 40 mg HUMIRA every \\nweek, or placebo.', 'The total study duration was 56 weeks.', 'Patients in clinical response (decrease \\nin CDAI ≥70) at Week 4 were stratified and analyzed separately from those not in clinical \\nresponse at Week 4.', ' \\n'], 'page_sentence_count_spacy': 15}\n",
            "{'page_number': 43, 'text': 'Induction of Clinical Remission \\nA greater percentage of the patients treated with 160/80 mg HUMIRA achieved induction of \\nclinical remission versus placebo at Week 4 regardless of whether the patients were TNF blocker \\nnaïve (CD-I), or had lost response to or were intolerant to infliximab (CD-II) (see Table 12).  \\n \\n  \\nTable 12. Induction of Clinical Remission in Studies CD-I and CD-II (Percent of Patients) \\n  \\nCD-I \\nCD-II \\n  \\nPlacebo \\nN=74 \\nHUMIRA 160/80 mg \\nN=76 \\nPlacebo \\nN=166 \\nHUMIRA 160/80 mg \\nN=159 \\nWeek 4 \\n  \\n  \\n  \\n  \\nClinical remission \\n12% \\n36%* \\n7% \\n21%* \\nClinical response \\n34% \\n58%** \\n34% \\n52%** \\nClinical remission is CDAI score < 150; clinical response is decrease in CDAI of at least 70 \\npoints. \\n* p<0.001 for HUMIRA vs. placebo pairwise comparison of proportions \\n** p<0.01 for HUMIRA vs. placebo pairwise comparison of proportions  \\nMaintenance of Clinical Remission \\nIn Study CD-III at Week 4, 58% (499/854) of patients were in clinical response and were \\nassessed in the primary analysis. At Weeks 26 and 56, greater proportions of patients who were \\nin clinical response at Week 4 achieved clinical remission in the HUMIRA 40 mg every other \\nweek maintenance group compared to patients in the placebo maintenance group (see Table 13). \\nThe group that received HUMIRA therapy every week did not demonstrate significantly higher \\nremission rates compared to the group that received HUMIRA every other week.  \\nTable 13. Maintenance of Clinical Remission in CD-III (Percent of Patients) \\n  \\nPlacebo \\n40 mg HUMIRA \\nevery other week \\n  \\nN=170 \\nN=172 \\nWeek 26 \\n  \\n  \\nClinical remission \\n17% \\n40%* \\nClinical response \\n28% \\n54%* \\nWeek 56 \\n  \\n  \\nClinical remission \\n12% \\n36%* \\nClinical response \\n18% \\n43%* \\nClinical remission is CDAI score < 150; clinical response is decrease in CDAI of at least 70 \\npoints. \\n*p<0.001 for HUMIRA vs. placebo pairwise comparisons of proportions  \\n \\n  \\nOf those in response at Week 4 who attained remission during the study, patients in the \\nHUMIRA every other week group maintained remission for a longer time than patients in the \\nplacebo maintenance group. Among patients who were not in response by Week 12, therapy \\ncontinued beyond 12 weeks did not result in significantly more responses.  \\n', 'processed_text': {'sentences': [{'original_sentence': 'Induction of Clinical Remission \\nA greater percentage of the patients treated with 160/80 mg HUMIRA achieved induction of \\nclinical remission versus placebo at Week 4 regardless of whether the patients were TNF blocker \\nnaïve (CD-I), or had lost response to or were intolerant to infliximab (CD-II) (see Table 12).', 'tokens': ['Induction', 'Clinical', 'Remission', 'greater', 'percentage', 'patients', 'treated', '160/80', 'mg', 'HUMIRA', 'achieved', 'induction', 'clinical', 'remission', 'versus', 'placebo', 'Week', '4', 'regardless', 'whether', 'patients', 'TNF', 'blocker', 'naïve', '(', 'CD-I', ')', ',', 'lost', 'response', 'intolerant', 'infliximab', '(', 'CD-II', ')', '(', 'see', 'Table', '12', ')', '.'], 'lemmatized': ['Induction', 'Clinical', 'Remission', 'greater', 'percentage', 'patient', 'treated', '160/80', 'mg', 'HUMIRA', 'achieved', 'induction', 'clinical', 'remission', 'versus', 'placebo', 'Week', '4', 'regardless', 'whether', 'patient', 'TNF', 'blocker', 'naïve', '(', 'CD-I', ')', ',', 'lost', 'response', 'intolerant', 'infliximab', '(', 'CD-II', ')', '(', 'see', 'Table', '12', ')', '.'], 'stemmed': ['induct', 'clinic', 'remiss', 'greater', 'percentag', 'patient', 'treat', '160/80', 'mg', 'humira', 'achiev', 'induct', 'clinic', 'remiss', 'versu', 'placebo', 'week', '4', 'regardless', 'whether', 'patient', 'tnf', 'blocker', 'naïv', '(', 'cd-i', ')', ',', 'lost', 'respons', 'intoler', 'infliximab', '(', 'cd-ii', ')', '(', 'see', 'tabl', '12', ')', '.'], 'dependencies': [('induct', 'advcl'), ('clinic', 'dobj'), ('remiss', 'compound'), ('greater', 'amod'), ('percentag', 'compound'), ('patient', 'nsubj'), ('treat', 'ROOT'), ('160/80', 'dobj'), ('mg', 'compound'), ('humira', 'compound'), ('achiev', 'nsubj'), ('induct', 'compound'), ('clinic', 'compound'), ('remiss', 'compound'), ('versu', 'compound'), ('placebo', 'compound'), ('week', 'npadvmod'), ('4', 'nummod'), ('regardless', 'advmod'), ('whether', 'mark'), ('patient', 'compound'), ('tnf', 'compound'), ('blocker', 'compound'), ('naïv', 'nsubj'), ('(', 'punct'), ('cd', 'compound'), ('-', 'punct'), ('i', 'appos'), (')', 'punct'), (',', 'punct'), ('lost', 'advcl'), ('respons', 'compound'), ('intoler', 'compound'), ('infliximab', 'dobj'), ('(', 'punct'), ('cd', 'compound'), ('-', 'punct'), ('ii', 'appos'), (')', 'punct'), ('(', 'punct'), ('see', 'ROOT'), ('tabl', 'dobj'), ('12', 'nummod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Table 12.', 'tokens': ['Table', '12', '.'], 'lemmatized': ['Table', '12', '.'], 'stemmed': ['tabl', '12', '.'], 'dependencies': [('tabl', 'ROOT'), ('12', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Induction of Clinical Remission in Studies CD-I and CD-II (Percent of Patients) \\n  \\nCD-I \\nCD-II \\n  \\nPlacebo \\nN=74 \\nHUMIRA 160/80 mg \\nN=76 \\nPlacebo \\nN=166 \\nHUMIRA 160/80 mg \\nN=159 \\nWeek 4 \\n  \\n  \\n  \\n  \\nClinical remission \\n12% \\n36%* \\n7% \\n21%* \\nClinical response \\n34% \\n58%** \\n34% \\n52%** \\nClinical remission is CDAI score < 150; clinical response is decrease in CDAI of at least 70 \\npoints.', 'tokens': ['Induction', 'Clinical', 'Remission', 'Studies', 'CD-I', 'CD-II', '(', 'Percent', 'Patients', ')', 'CD-I', 'CD-II', 'Placebo', 'N=74', 'HUMIRA', '160/80', 'mg', 'N=76', 'Placebo', 'N=166', 'HUMIRA', '160/80', 'mg', 'N=159', 'Week', '4', 'Clinical', 'remission', '12', '%', '36', '%', '*', '7', '%', '21', '%', '*', 'Clinical', 'response', '34', '%', '58', '%', '*', '*', '34', '%', '52', '%', '*', '*', 'Clinical', 'remission', 'CDAI', 'score', '<', '150', ';', 'clinical', 'response', 'decrease', 'CDAI', 'least', '70', 'points', '.'], 'lemmatized': ['Induction', 'Clinical', 'Remission', 'Studies', 'CD-I', 'CD-II', '(', 'Percent', 'Patients', ')', 'CD-I', 'CD-II', 'Placebo', 'N=74', 'HUMIRA', '160/80', 'mg', 'N=76', 'Placebo', 'N=166', 'HUMIRA', '160/80', 'mg', 'N=159', 'Week', '4', 'Clinical', 'remission', '12', '%', '36', '%', '*', '7', '%', '21', '%', '*', 'Clinical', 'response', '34', '%', '58', '%', '*', '*', '34', '%', '52', '%', '*', '*', 'Clinical', 'remission', 'CDAI', 'score', '<', '150', ';', 'clinical', 'response', 'decrease', 'CDAI', 'least', '70', 'point', '.'], 'stemmed': ['induct', 'clinic', 'remiss', 'studi', 'cd-i', 'cd-ii', '(', 'percent', 'patient', ')', 'cd-i', 'cd-ii', 'placebo', 'n=74', 'humira', '160/80', 'mg', 'n=76', 'placebo', 'n=166', 'humira', '160/80', 'mg', 'n=159', 'week', '4', 'clinic', 'remiss', '12', '%', '36', '%', '*', '7', '%', '21', '%', '*', 'clinic', 'respons', '34', '%', '58', '%', '*', '*', '34', '%', '52', '%', '*', '*', 'clinic', 'remiss', 'cdai', 'score', '<', '150', ';', 'clinic', 'respons', 'decreas', 'cdai', 'least', '70', 'point', '.'], 'dependencies': [('induct', 'ROOT'), ('clinic', 'compound'), ('remiss', 'compound'), ('studi', 'compound'), ('cd', 'nmod'), ('-', 'punct'), ('i', 'pobj'), ('cd', 'compound'), ('-', 'punct'), ('ii', 'nmod'), ('(', 'punct'), ('percent', 'npadvmod'), ('patient', 'nmod'), (')', 'punct'), ('cd', 'nmod'), ('-', 'punct'), ('i', 'nummod'), ('cd', 'compound'), ('-', 'punct'), ('ii', 'compound'), ('placebo', 'nmod'), ('n=74', 'compound'), ('humira', 'dobj'), ('160/80', 'nummod'), ('mg', 'prep'), ('n=76', 'compound'), ('placebo', 'compound'), ('n=166', 'nmod'), ('humira', 'compound'), ('160/80', 'pobj'), ('mg', 'prep'), ('n=159', 'nmod'), ('week', 'nmod'), ('4', 'nummod'), ('clinic', 'compound'), ('remiss', 'pobj'), ('12', 'nummod'), ('%', 'appos'), ('36', 'nummod'), ('%', 'appos'), ('*', 'punct'), ('7', 'nummod'), ('%', 'npadvmod'), ('21', 'nummod'), ('%', 'appos'), ('*', 'punct'), ('clinic', 'compound'), ('respons', 'dative'), ('34', 'nummod'), ('%', 'npadvmod'), ('58', 'nummod'), ('%', 'appos'), ('*', 'ROOT'), ('*', 'punct'), ('34', 'nummod'), ('%', 'ROOT'), ('52', 'nummod'), ('%', 'appos'), ('*', 'punct'), ('*', 'punct'), ('clinic', 'amod'), ('remiss', 'compound'), ('cdai', 'compound'), ('score', 'appos'), ('<', 'appos'), ('150', 'dep'), (';', 'punct'), ('clinic', 'amod'), ('respons', 'compound'), ('decreas', 'nsubj'), ('cdai', 'ROOT'), ('least', 'advmod'), ('70', 'nummod'), ('point', 'dobj'), ('.', 'punct')]}, {'original_sentence': '* p<0.001 for HUMIRA vs. placebo pairwise comparison of proportions \\n** p<0.01 for HUMIRA vs. placebo pairwise comparison of proportions  \\nMaintenance of Clinical Remission \\nIn Study CD-III at Week 4, 58% (499/854) of patients were in clinical response and were \\nassessed in the primary analysis.', 'tokens': ['*', 'p', '<', '0.001', 'HUMIRA', 'vs.', 'placebo', 'pairwise', 'comparison', 'proportions', '*', '*', 'p', '<', '0.01', 'HUMIRA', 'vs.', 'placebo', 'pairwise', 'comparison', 'proportions', 'Maintenance', 'Clinical', 'Remission', 'Study', 'CD-III', 'Week', '4', ',', '58', '%', '(', '499/854', ')', 'patients', 'clinical', 'response', 'assessed', 'primary', 'analysis', '.'], 'lemmatized': ['*', 'p', '<', '0.001', 'HUMIRA', 'vs.', 'placebo', 'pairwise', 'comparison', 'proportion', '*', '*', 'p', '<', '0.01', 'HUMIRA', 'vs.', 'placebo', 'pairwise', 'comparison', 'proportion', 'Maintenance', 'Clinical', 'Remission', 'Study', 'CD-III', 'Week', '4', ',', '58', '%', '(', '499/854', ')', 'patient', 'clinical', 'response', 'assessed', 'primary', 'analysis', '.'], 'stemmed': ['*', 'p', '<', '0.001', 'humira', 'vs.', 'placebo', 'pairwis', 'comparison', 'proport', '*', '*', 'p', '<', '0.01', 'humira', 'vs.', 'placebo', 'pairwis', 'comparison', 'proport', 'mainten', 'clinic', 'remiss', 'studi', 'cd-iii', 'week', '4', ',', '58', '%', '(', '499/854', ')', 'patient', 'clinic', 'respons', 'assess', 'primari', 'analysi', '.'], 'dependencies': [('*', 'punct'), ('p', 'nmod'), ('<', 'dep'), ('0.001', 'nummod'), ('humira', 'nmod'), ('vs.', 'prep'), ('placebo', 'compound'), ('pairwis', 'pobj'), ('comparison', 'compound'), ('proport', 'ROOT'), ('*', 'punct'), ('*', 'punct'), ('p', 'quantmod'), ('<', 'dep'), ('0.01', 'nummod'), ('humira', 'ROOT'), ('vs.', 'prep'), ('placebo', 'compound'), ('pairwis', 'pobj'), ('comparison', 'compound'), ('proport', 'compound'), ('mainten', 'compound'), ('clinic', 'compound'), ('remiss', 'compound'), ('studi', 'compound'), ('cd', 'compound'), ('-', 'punct'), ('iii', 'conj'), ('week', 'npadvmod'), ('4', 'nummod'), (',', 'punct'), ('58', 'nummod'), ('%', 'appos'), ('(', 'punct'), ('499/854', 'nmod'), (')', 'punct'), ('patient', 'amod'), ('clinic', 'compound'), ('respons', 'nsubj'), ('assess', 'parataxis'), ('primari', 'compound'), ('analysi', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'At Weeks 26 and 56, greater proportions of patients who were \\nin clinical response at Week 4 achieved clinical remission in the HUMIRA 40 mg every other \\nweek maintenance group compared to patients in the placebo maintenance group (see Table 13).', 'tokens': ['Weeks', '26', '56', ',', 'greater', 'proportions', 'patients', 'clinical', 'response', 'Week', '4', 'achieved', 'clinical', 'remission', 'HUMIRA', '40', 'mg', 'every', 'week', 'maintenance', 'group', 'compared', 'patients', 'placebo', 'maintenance', 'group', '(', 'see', 'Table', '13', ')', '.'], 'lemmatized': ['Weeks', '26', '56', ',', 'greater', 'proportion', 'patient', 'clinical', 'response', 'Week', '4', 'achieved', 'clinical', 'remission', 'HUMIRA', '40', 'mg', 'every', 'week', 'maintenance', 'group', 'compared', 'patient', 'placebo', 'maintenance', 'group', '(', 'see', 'Table', '13', ')', '.'], 'stemmed': ['week', '26', '56', ',', 'greater', 'proport', 'patient', 'clinic', 'respons', 'week', '4', 'achiev', 'clinic', 'remiss', 'humira', '40', 'mg', 'everi', 'week', 'mainten', 'group', 'compar', 'patient', 'placebo', 'mainten', 'group', '(', 'see', 'tabl', '13', ')', '.'], 'dependencies': [('week', 'npadvmod'), ('26', 'compound'), ('56', 'nummod'), (',', 'punct'), ('greater', 'amod'), ('proport', 'compound'), ('patient', 'compound'), ('clinic', 'compound'), ('respons', 'dep'), ('week', 'nmod'), ('4', 'nummod'), ('achiev', 'amod'), ('clinic', 'compound'), ('remiss', 'compound'), ('humira', 'ROOT'), ('40', 'nummod'), ('mg', 'nmod'), ('everi', 'amod'), ('week', 'compound'), ('mainten', 'compound'), ('group', 'compound'), ('compar', 'compound'), ('patient', 'compound'), ('placebo', 'compound'), ('mainten', 'compound'), ('group', 'appos'), ('(', 'punct'), ('see', 'parataxis'), ('tabl', 'dobj'), ('13', 'nummod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'The group that received HUMIRA therapy every week did not demonstrate significantly higher \\nremission rates compared to the group that received HUMIRA every other week.', 'tokens': ['group', 'received', 'HUMIRA', 'therapy', 'every', 'week', 'demonstrate', 'significantly', 'higher', 'remission', 'rates', 'compared', 'group', 'received', 'HUMIRA', 'every', 'week', '.'], 'lemmatized': ['group', 'received', 'HUMIRA', 'therapy', 'every', 'week', 'demonstrate', 'significantly', 'higher', 'remission', 'rate', 'compared', 'group', 'received', 'HUMIRA', 'every', 'week', '.'], 'stemmed': ['group', 'receiv', 'humira', 'therapi', 'everi', 'week', 'demonstr', 'significantli', 'higher', 'remiss', 'rate', 'compar', 'group', 'receiv', 'humira', 'everi', 'week', '.'], 'dependencies': [('group', 'compound'), ('receiv', 'compound'), ('humira', 'nsubj'), ('therapi', 'ROOT'), ('everi', 'amod'), ('week', 'npadvmod'), ('demonstr', 'nmod'), ('significantli', 'nmod'), ('higher', 'amod'), ('remiss', 'amod'), ('rate', 'compound'), ('compar', 'compound'), ('group', 'appos'), ('receiv', 'compound'), ('humira', 'npadvmod'), ('everi', 'compound'), ('week', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Table 13.', 'tokens': ['Table', '13', '.'], 'lemmatized': ['Table', '13', '.'], 'stemmed': ['tabl', '13', '.'], 'dependencies': [('tabl', 'ROOT'), ('13', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Maintenance of Clinical Remission in CD-III (Percent of Patients) \\n  \\nPlacebo \\n40 mg HUMIRA \\nevery other week \\n  \\nN=170 \\nN=172 \\nWeek 26 \\n  \\n  \\nClinical remission \\n17% \\n40%* \\nClinical response \\n28% \\n54%* \\nWeek 56 \\n  \\n  \\nClinical remission \\n12% \\n36%* \\nClinical response \\n18% \\n43%* \\nClinical remission is CDAI score < 150; clinical response is decrease in CDAI of at least 70 \\npoints.', 'tokens': ['Maintenance', 'Clinical', 'Remission', 'CD-III', '(', 'Percent', 'Patients', ')', 'Placebo', '40', 'mg', 'HUMIRA', 'every', 'week', 'N=170', 'N=172', 'Week', '26', 'Clinical', 'remission', '17', '%', '40', '%', '*', 'Clinical', 'response', '28', '%', '54', '%', '*', 'Week', '56', 'Clinical', 'remission', '12', '%', '36', '%', '*', 'Clinical', 'response', '18', '%', '43', '%', '*', 'Clinical', 'remission', 'CDAI', 'score', '<', '150', ';', 'clinical', 'response', 'decrease', 'CDAI', 'least', '70', 'points', '.'], 'lemmatized': ['Maintenance', 'Clinical', 'Remission', 'CD-III', '(', 'Percent', 'Patients', ')', 'Placebo', '40', 'mg', 'HUMIRA', 'every', 'week', 'N=170', 'N=172', 'Week', '26', 'Clinical', 'remission', '17', '%', '40', '%', '*', 'Clinical', 'response', '28', '%', '54', '%', '*', 'Week', '56', 'Clinical', 'remission', '12', '%', '36', '%', '*', 'Clinical', 'response', '18', '%', '43', '%', '*', 'Clinical', 'remission', 'CDAI', 'score', '<', '150', ';', 'clinical', 'response', 'decrease', 'CDAI', 'least', '70', 'point', '.'], 'stemmed': ['mainten', 'clinic', 'remiss', 'cd-iii', '(', 'percent', 'patient', ')', 'placebo', '40', 'mg', 'humira', 'everi', 'week', 'n=170', 'n=172', 'week', '26', 'clinic', 'remiss', '17', '%', '40', '%', '*', 'clinic', 'respons', '28', '%', '54', '%', '*', 'week', '56', 'clinic', 'remiss', '12', '%', '36', '%', '*', 'clinic', 'respons', '18', '%', '43', '%', '*', 'clinic', 'remiss', 'cdai', 'score', '<', '150', ';', 'clinic', 'respons', 'decreas', 'cdai', 'least', '70', 'point', '.'], 'dependencies': [('mainten', 'amod'), ('clinic', 'compound'), ('remiss', 'compound'), ('cd', 'compound'), ('-', 'punct'), ('iii', 'dobj'), ('(', 'punct'), ('percent', 'npadvmod'), ('patient', 'parataxis'), (')', 'punct'), ('placebo', 'nsubj'), ('40', 'nummod'), ('mg', 'prep'), ('humira', 'conj'), ('everi', 'compound'), ('week', 'compound'), ('n=170', 'npadvmod'), ('n=172', 'compound'), ('week', 'npadvmod'), ('26', 'nummod'), ('clinic', 'compound'), ('remiss', 'ROOT'), ('17', 'nummod'), ('%', 'npadvmod'), ('40', 'nummod'), ('%', 'appos'), ('*', 'punct'), ('clinic', 'compound'), ('respons', 'appos'), ('28', 'nummod'), ('%', 'npadvmod'), ('54', 'nummod'), ('%', 'appos'), ('*', 'punct'), ('week', 'npadvmod'), ('56', 'nummod'), ('clinic', 'compound'), ('remiss', 'conj'), ('12', 'nummod'), ('%', 'npadvmod'), ('36', 'nummod'), ('%', 'appos'), ('*', 'punct'), ('clinic', 'compound'), ('respons', 'appos'), ('18', 'nummod'), ('%', 'npadvmod'), ('43', 'nummod'), ('%', 'appos'), ('*', 'punct'), ('clinic', 'compound'), ('remiss', 'compound'), ('cdai', 'compound'), ('score', 'appos'), ('<', 'appos'), ('150', 'dep'), (';', 'punct'), ('clinic', 'amod'), ('respons', 'compound'), ('decreas', 'nsubj'), ('cdai', 'ROOT'), ('least', 'advmod'), ('70', 'nummod'), ('point', 'dobj'), ('.', 'punct')]}, {'original_sentence': '*p<0.001 for HUMIRA vs. placebo pairwise comparisons of proportions  \\n \\n  \\nOf those in response at Week 4 who attained remission during the study, patients in the \\nHUMIRA every other week group maintained remission for a longer time than patients in the \\nplacebo maintenance group.', 'tokens': ['*', 'p', '<', '0.001', 'HUMIRA', 'vs.', 'placebo', 'pairwise', 'comparisons', 'proportions', 'response', 'Week', '4', 'attained', 'remission', 'study', ',', 'patients', 'HUMIRA', 'every', 'week', 'group', 'maintained', 'remission', 'longer', 'time', 'patients', 'placebo', 'maintenance', 'group', '.'], 'lemmatized': ['*', 'p', '<', '0.001', 'HUMIRA', 'vs.', 'placebo', 'pairwise', 'comparison', 'proportion', 'response', 'Week', '4', 'attained', 'remission', 'study', ',', 'patient', 'HUMIRA', 'every', 'week', 'group', 'maintained', 'remission', 'longer', 'time', 'patient', 'placebo', 'maintenance', 'group', '.'], 'stemmed': ['*', 'p', '<', '0.001', 'humira', 'vs.', 'placebo', 'pairwis', 'comparison', 'proport', 'respons', 'week', '4', 'attain', 'remiss', 'studi', ',', 'patient', 'humira', 'everi', 'week', 'group', 'maintain', 'remiss', 'longer', 'time', 'patient', 'placebo', 'mainten', 'group', '.'], 'dependencies': [('*', 'punct'), ('p', 'nmod'), ('<', 'dep'), ('0.001', 'nummod'), ('humira', 'nmod'), ('vs.', 'prep'), ('placebo', 'compound'), ('pairwis', 'pobj'), ('comparison', 'compound'), ('proport', 'compound'), ('respons', 'compound'), ('week', 'nsubj'), ('4', 'nummod'), ('attain', 'advcl'), ('remiss', 'compound'), ('studi', 'dobj'), (',', 'punct'), ('patient', 'amod'), ('humira', 'compound'), ('everi', 'compound'), ('week', 'compound'), ('group', 'nsubj'), ('maintain', 'ROOT'), ('remiss', 'dobj'), ('longer', 'amod'), ('time', 'compound'), ('patient', 'compound'), ('placebo', 'compound'), ('mainten', 'compound'), ('group', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Among patients who were not in response by Week 12, therapy \\ncontinued beyond 12 weeks did not result in significantly more responses.', 'tokens': ['Among', 'patients', 'response', 'Week', '12', ',', 'therapy', 'continued', 'beyond', '12', 'weeks', 'result', 'significantly', 'responses', '.'], 'lemmatized': ['Among', 'patient', 'response', 'Week', '12', ',', 'therapy', 'continued', 'beyond', '12', 'week', 'result', 'significantly', 'response', '.'], 'stemmed': ['among', 'patient', 'respons', 'week', '12', ',', 'therapi', 'continu', 'beyond', '12', 'week', 'result', 'significantli', 'respons', '.'], 'dependencies': [('among', 'prep'), ('patient', 'amod'), ('respons', 'pobj'), ('week', 'pobj'), ('12', 'nummod'), (',', 'punct'), ('therapi', 'amod'), ('continu', 'ROOT'), ('beyond', 'prep'), ('12', 'nummod'), ('week', 'compound'), ('result', 'compound'), ('significantli', 'amod'), ('respons', 'pobj'), ('.', 'punct')]}], 'text': 'Induction of Clinical Remission \\nA greater percentage of the patients treated with 160/80 mg HUMIRA achieved induction of \\nclinical remission versus placebo at Week 4 regardless of whether the patients were TNF blocker \\nnaïve (CD-I), or had lost response to or were intolerant to infliximab (CD-II) (see Table 12).  \\n \\n  \\nTable 12. Induction of Clinical Remission in Studies CD-I and CD-II (Percent of Patients) \\n  \\nCD-I \\nCD-II \\n  \\nPlacebo \\nN=74 \\nHUMIRA 160/80 mg \\nN=76 \\nPlacebo \\nN=166 \\nHUMIRA 160/80 mg \\nN=159 \\nWeek 4 \\n  \\n  \\n  \\n  \\nClinical remission \\n12% \\n36%* \\n7% \\n21%* \\nClinical response \\n34% \\n58%** \\n34% \\n52%** \\nClinical remission is CDAI score < 150; clinical response is decrease in CDAI of at least 70 \\npoints. \\n* p<0.001 for HUMIRA vs. placebo pairwise comparison of proportions \\n** p<0.01 for HUMIRA vs. placebo pairwise comparison of proportions  \\nMaintenance of Clinical Remission \\nIn Study CD-III at Week 4, 58% (499/854) of patients were in clinical response and were \\nassessed in the primary analysis. At Weeks 26 and 56, greater proportions of patients who were \\nin clinical response at Week 4 achieved clinical remission in the HUMIRA 40 mg every other \\nweek maintenance group compared to patients in the placebo maintenance group (see Table 13). \\nThe group that received HUMIRA therapy every week did not demonstrate significantly higher \\nremission rates compared to the group that received HUMIRA every other week.  \\nTable 13. Maintenance of Clinical Remission in CD-III (Percent of Patients) \\n  \\nPlacebo \\n40 mg HUMIRA \\nevery other week \\n  \\nN=170 \\nN=172 \\nWeek 26 \\n  \\n  \\nClinical remission \\n17% \\n40%* \\nClinical response \\n28% \\n54%* \\nWeek 56 \\n  \\n  \\nClinical remission \\n12% \\n36%* \\nClinical response \\n18% \\n43%* \\nClinical remission is CDAI score < 150; clinical response is decrease in CDAI of at least 70 \\npoints. \\n*p<0.001 for HUMIRA vs. placebo pairwise comparisons of proportions  \\n \\n  \\nOf those in response at Week 4 who attained remission during the study, patients in the \\nHUMIRA every other week group maintained remission for a longer time than patients in the \\nplacebo maintenance group. Among patients who were not in response by Week 12, therapy \\ncontinued beyond 12 weeks did not result in significantly more responses.  \\n'}, 'page_char_count': 2247, 'page_word_count': 343, 'sentences': ['Induction of Clinical Remission \\nA greater percentage of the patients treated with 160/80 mg HUMIRA achieved induction of \\nclinical remission versus placebo at Week 4 regardless of whether the patients were TNF blocker \\nnaïve (CD-I), or had lost response to or were intolerant to infliximab (CD-II) (see Table 12).', ' \\n \\n  \\nTable 12.', 'Induction of Clinical Remission in Studies CD-I and CD-II (Percent of Patients) \\n  \\nCD-I \\nCD-II \\n  \\nPlacebo \\nN=74 \\nHUMIRA 160/80 mg \\nN=76 \\nPlacebo \\nN=166 \\nHUMIRA 160/80 mg \\nN=159 \\nWeek 4 \\n  \\n  \\n  \\n  \\nClinical remission \\n12% \\n36%* \\n7% \\n21%* \\nClinical response \\n34% \\n58%** \\n34% \\n52%** \\nClinical remission is CDAI score < 150; clinical response is decrease in CDAI of at least 70 \\npoints.', '\\n* p<0.001 for HUMIRA vs. placebo pairwise comparison of proportions \\n** p<0.01 for HUMIRA vs. placebo pairwise comparison of proportions  \\nMaintenance of Clinical Remission \\nIn Study CD-III at Week 4, 58% (499/854) of patients were in clinical response and were \\nassessed in the primary analysis.', 'At Weeks 26 and 56, greater proportions of patients who were \\nin clinical response at Week 4 achieved clinical remission in the HUMIRA 40 mg every other \\nweek maintenance group compared to patients in the placebo maintenance group (see Table 13).', '\\nThe group that received HUMIRA therapy every week did not demonstrate significantly higher \\nremission rates compared to the group that received HUMIRA every other week.', ' \\nTable 13.', 'Maintenance of Clinical Remission in CD-III (Percent of Patients) \\n  \\nPlacebo \\n40 mg HUMIRA \\nevery other week \\n  \\nN=170 \\nN=172 \\nWeek 26 \\n  \\n  \\nClinical remission \\n17% \\n40%* \\nClinical response \\n28% \\n54%* \\nWeek 56 \\n  \\n  \\nClinical remission \\n12% \\n36%* \\nClinical response \\n18% \\n43%* \\nClinical remission is CDAI score < 150; clinical response is decrease in CDAI of at least 70 \\npoints.', '\\n*p<0.001 for HUMIRA vs. placebo pairwise comparisons of proportions  \\n \\n  \\nOf those in response at Week 4 who attained remission during the study, patients in the \\nHUMIRA every other week group maintained remission for a longer time than patients in the \\nplacebo maintenance group.', 'Among patients who were not in response by Week 12, therapy \\ncontinued beyond 12 weeks did not result in significantly more responses.', ' \\n'], 'page_sentence_count_spacy': 11}\n",
            "{'page_number': 44, 'text': '14.6 Pediatric Crohn’s Disease  \\nA randomized, double-blind, 52-week clinical study of 2 dose concentrations of HUMIRA \\n(Study PCD-I) was conducted in 192 pediatric patients (6 to 17 years of age) with moderately to \\nseverely active Crohn’s disease (defined as Pediatric Crohn’s Disease Activity Index (PCDAI) \\nscore > 30). Enrolled patients had over the previous two year period an inadequate response to \\ncorticosteroids or an immunomodulator (i.e., azathioprine, 6-mercaptopurine, or methotrexate). \\nPatients who had previously received a TNF blocker were allowed to enroll if they had \\npreviously had loss of response or intolerance to that TNF blocker.  \\nPatients received open-label induction therapy at a dose based on their body weight (≥40 kg and \\n<40 kg). Patients weighing ≥40 kg received 160 mg (at Week 0) and 80 mg (at Week 2). Patients \\nweighing <40 kg received 80 mg (at Week 0) and 40 mg (at Week 2). At Week 4, patients within \\neach body weight category (≥40 kg and <40 kg) were randomized 1:1 to one of two maintenance \\ndose regimens (high dose and low dose). The high dose was 40 mg every other week for patients \\nweighing ≥40 kg and 20 mg every other week for patients weighing <40 kg. The low dose was \\n20 mg every other week for patients weighing ≥40 kg and 10 mg every other week for patients \\nweighing <40 kg.  \\nConcomitant stable dosages of corticosteroids (prednisone dosage ≤40 mg/day or equivalent) and \\nimmunomodulators (azathioprine, 6-mercaptopurine, or methotrexate) were permitted \\nthroughout the study.  \\nAt Week 12, patients who experienced a disease flare (increase in PCDAI of ≥ 15 from Week 4 \\nand absolute PCDAI > 30) or who were non-responders (did not achieve a decrease in the \\nPCDAI of ≥ 15 from baseline for 2 consecutive visits at least 2 weeks apart) were allowed to \\ndose-escalate (i.e., switch from blinded every other week dosing to blinded every week dosing); \\npatients who dose-escalated were considered treatment failures.  \\nAt baseline, 38% of patients were receiving corticosteroids, and 62% of patients were receiving \\nan immunomodulator. Forty-four percent (44%) of patients had previously lost response or were \\nintolerant to a TNF blocker. The median baseline PCDAI score was 40.  \\nOf the 192 patients total, 188 patients completed the 4 week induction period, 152 patients \\ncompleted 26 weeks of treatment, and 124 patients completed 52 weeks of treatment. Fifty-one \\npercent (51%) (48/95) of patients in the low maintenance dose group dose-escalated, and 38% \\n(35/93) of patients in the high maintenance dose group dose-escalated.  \\nAt Week 4, 28% (52/188) of patients were in clinical remission (defined as PCDAI ≤ 10).  \\nThe proportions of patients in clinical remission (defined as PCDAI ≤ 10) and clinical response \\n(defined as reduction in PCDAI of at least 15 points from baseline) were assessed at Weeks 26 \\nand 52.  \\nAt both Weeks 26 and 52, the proportion of patients in clinical remission and clinical response \\nwas numerically higher in the high dose group compared to the low dose group (Table 14). The \\nrecommended maintenance regimen is 20 mg every other week for patients weighing < 40 kg \\nand 40 mg every other week for patients weighing ≥ 40 kg. Every week dosing is not the \\nrecommended maintenance dosing regimen [see Dosage and Administration (2.3)].  \\n', 'processed_text': {'sentences': [{'original_sentence': '14.6 Pediatric Crohn’s Disease  \\nA randomized, double-blind, 52-week clinical study of 2 dose concentrations of HUMIRA \\n(Study PCD-I) was conducted in 192 pediatric patients (6 to 17 years of age) with moderately to \\nseverely active Crohn’s disease (defined as Pediatric Crohn’s Disease Activity Index (PCDAI) \\nscore > 30).', 'tokens': ['14.6', 'Pediatric', 'Crohn', '’', 'Disease', 'randomized', ',', 'double-blind', ',', '52-week', 'clinical', 'study', '2', 'dose', 'concentrations', 'HUMIRA', '(', 'Study', 'PCD-I', ')', 'conducted', '192', 'pediatric', 'patients', '(', '6', '17', 'years', 'age', ')', 'moderately', 'severely', 'active', 'Crohn', '’', 'disease', '(', 'defined', 'Pediatric', 'Crohn', '’', 'Disease', 'Activity', 'Index', '(', 'PCDAI', ')', 'score', '>', '30', ')', '.'], 'lemmatized': ['14.6', 'Pediatric', 'Crohn', '’', 'Disease', 'randomized', ',', 'double-blind', ',', '52-week', 'clinical', 'study', '2', 'dose', 'concentration', 'HUMIRA', '(', 'Study', 'PCD-I', ')', 'conducted', '192', 'pediatric', 'patient', '(', '6', '17', 'year', 'age', ')', 'moderately', 'severely', 'active', 'Crohn', '’', 'disease', '(', 'defined', 'Pediatric', 'Crohn', '’', 'Disease', 'Activity', 'Index', '(', 'PCDAI', ')', 'score', '>', '30', ')', '.'], 'stemmed': ['14.6', 'pediatr', 'crohn', '’', 'diseas', 'random', ',', 'double-blind', ',', '52-week', 'clinic', 'studi', '2', 'dose', 'concentr', 'humira', '(', 'studi', 'pcd-i', ')', 'conduct', '192', 'pediatr', 'patient', '(', '6', '17', 'year', 'age', ')', 'moder', 'sever', 'activ', 'crohn', '’', 'diseas', '(', 'defin', 'pediatr', 'crohn', '’', 'diseas', 'activ', 'index', '(', 'pcdai', ')', 'score', '>', '30', ')', '.'], 'dependencies': [('14.6', 'nummod'), ('pediatr', 'amod'), ('crohn', 'nmod'), ('’', 'punct'), ('diseas', 'nmod'), ('random', 'amod'), (',', 'punct'), ('double', 'amod'), ('-', 'punct'), ('blind', 'amod'), (',', 'punct'), ('52', 'nummod'), ('-', 'punct'), ('week', 'compound'), ('clinic', 'nmod'), ('studi', 'nmod'), ('2', 'nummod'), ('dose', 'compound'), ('concentr', 'compound'), ('humira', 'nsubj'), ('(', 'punct'), ('studi', 'appos'), ('pcd', 'npadvmod'), ('-', 'punct'), ('i', 'appos'), (')', 'punct'), ('conduct', 'ROOT'), ('192', 'nummod'), ('pediatr', 'amod'), ('patient', 'dobj'), ('(', 'punct'), ('6', 'nummod'), ('17', 'nummod'), ('year', 'compound'), ('age', 'appos'), (')', 'punct'), ('moder', 'nsubj'), ('sever', 'conj'), ('activ', 'compound'), ('crohn', 'nmod'), ('’', 'punct'), ('diseas', 'nmod'), ('(', 'punct'), ('defin', 'advmod'), ('pediatr', 'nsubj'), ('crohn', 'parataxis'), ('’', 'punct'), ('diseas', 'amod'), ('activ', 'compound'), ('index', 'nmod'), ('(', 'punct'), ('pcdai', 'appos'), (')', 'punct'), ('score', 'dobj'), ('>', 'nmod'), ('30', 'npadvmod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Enrolled patients had over the previous two year period an inadequate response to \\ncorticosteroids or an immunomodulator (i.e., azathioprine, 6-mercaptopurine, or methotrexate).', 'tokens': ['Enrolled', 'patients', 'previous', 'two', 'year', 'period', 'inadequate', 'response', 'corticosteroids', 'immunomodulator', '(', 'i.e.', ',', 'azathioprine', ',', '6-mercaptopurine', ',', 'methotrexate', ')', '.'], 'lemmatized': ['Enrolled', 'patient', 'previous', 'two', 'year', 'period', 'inadequate', 'response', 'corticosteroid', 'immunomodulator', '(', 'i.e.', ',', 'azathioprine', ',', '6-mercaptopurine', ',', 'methotrexate', ')', '.'], 'stemmed': ['enrol', 'patient', 'previou', 'two', 'year', 'period', 'inadequ', 'respons', 'corticosteroid', 'immunomodul', '(', 'i.e.', ',', 'azathioprin', ',', '6-mercaptopurin', ',', 'methotrex', ')', '.'], 'dependencies': [('enrol', 'ROOT'), ('patient', 'amod'), ('previou', 'dobj'), ('two', 'nummod'), ('year', 'compound'), ('period', 'compound'), ('inadequ', 'compound'), ('respons', 'dobj'), ('corticosteroid', 'amod'), ('immunomodul', 'npadvmod'), ('(', 'punct'), ('i.e.', 'advmod'), (',', 'punct'), ('azathioprin', 'meta'), (',', 'punct'), ('6', 'nummod'), ('-', 'punct'), ('mercaptopurin', 'nmod'), (',', 'punct'), ('methotrex', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Patients who had previously received a TNF blocker were allowed to enroll if they had \\npreviously had loss of response or intolerance to that TNF blocker.', 'tokens': ['Patients', 'previously', 'received', 'TNF', 'blocker', 'allowed', 'enroll', 'previously', 'loss', 'response', 'intolerance', 'TNF', 'blocker', '.'], 'lemmatized': ['Patients', 'previously', 'received', 'TNF', 'blocker', 'allowed', 'enroll', 'previously', 'loss', 'response', 'intolerance', 'TNF', 'blocker', '.'], 'stemmed': ['patient', 'previous', 'receiv', 'tnf', 'blocker', 'allow', 'enrol', 'previous', 'loss', 'respons', 'intoler', 'tnf', 'blocker', '.'], 'dependencies': [('patient', 'nsubj'), ('previous', 'amod'), ('receiv', 'compound'), ('tnf', 'compound'), ('blocker', 'compound'), ('allow', 'appos'), ('enrol', 'ROOT'), ('previous', 'amod'), ('loss', 'compound'), ('respons', 'compound'), ('intoler', 'compound'), ('tnf', 'compound'), ('blocker', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Patients received open-label induction therapy at a dose based on their body weight (≥40 kg and \\n<40 kg).', 'tokens': ['Patients', 'received', 'open-label', 'induction', 'therapy', 'dose', 'based', 'body', 'weight', '(', '≥40', 'kg', '<', '40', 'kg', ')', '.'], 'lemmatized': ['Patients', 'received', 'open-label', 'induction', 'therapy', 'dose', 'based', 'body', 'weight', '(', '≥40', 'kg', '<', '40', 'kg', ')', '.'], 'stemmed': ['patient', 'receiv', 'open-label', 'induct', 'therapi', 'dose', 'base', 'bodi', 'weight', '(', '≥40', 'kg', '<', '40', 'kg', ')', '.'], 'dependencies': [('patient', 'amod'), ('receiv', 'nmod'), ('open', 'amod'), ('-', 'punct'), ('label', 'compound'), ('induct', 'compound'), ('therapi', 'nmod'), ('dose', 'compound'), ('base', 'compound'), ('bodi', 'compound'), ('weight', 'ROOT'), ('(', 'punct'), ('≥40', 'nummod'), ('kg', 'dep'), ('<', 'dep'), ('40', 'nummod'), ('kg', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Patients weighing ≥40 kg received 160 mg (at Week 0) and 80 mg (at Week 2).', 'tokens': ['Patients', 'weighing', '≥40', 'kg', 'received', '160', 'mg', '(', 'Week', '0', ')', '80', 'mg', '(', 'Week', '2', ')', '.'], 'lemmatized': ['Patients', 'weighing', '≥40', 'kg', 'received', '160', 'mg', '(', 'Week', '0', ')', '80', 'mg', '(', 'Week', '2', ')', '.'], 'stemmed': ['patient', 'weigh', '≥40', 'kg', 'receiv', '160', 'mg', '(', 'week', '0', ')', '80', 'mg', '(', 'week', '2', ')', '.'], 'dependencies': [('patient', 'compound'), ('weigh', 'nmod'), ('≥40', 'punct'), ('kg', 'compound'), ('receiv', 'ROOT'), ('160', 'nummod'), ('mg', 'appos'), ('(', 'punct'), ('week', 'appos'), ('0', 'punct'), (')', 'punct'), ('80', 'nummod'), ('mg', 'ROOT'), ('(', 'punct'), ('week', 'appos'), ('2', 'nummod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Patients \\nweighing <40 kg received 80 mg (at Week 0) and 40 mg (at Week 2).', 'tokens': ['Patients', 'weighing', '<', '40', 'kg', 'received', '80', 'mg', '(', 'Week', '0', ')', '40', 'mg', '(', 'Week', '2', ')', '.'], 'lemmatized': ['Patients', 'weighing', '<', '40', 'kg', 'received', '80', 'mg', '(', 'Week', '0', ')', '40', 'mg', '(', 'Week', '2', ')', '.'], 'stemmed': ['patient', 'weigh', '<', '40', 'kg', 'receiv', '80', 'mg', '(', 'week', '0', ')', '40', 'mg', '(', 'week', '2', ')', '.'], 'dependencies': [('patient', 'compound'), ('weigh', 'nmod'), ('<', 'dep'), ('40', 'nummod'), ('kg', 'compound'), ('receiv', 'ROOT'), ('80', 'nummod'), ('mg', 'appos'), ('(', 'punct'), ('week', 'appos'), ('0', 'nummod'), (')', 'punct'), ('40', 'nummod'), ('mg', 'ROOT'), ('(', 'punct'), ('week', 'appos'), ('2', 'nummod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'At Week 4, patients within \\neach body weight category (≥40 kg and <40 kg) were randomized 1:1 to one of two maintenance \\ndose regimens (high dose and low dose).', 'tokens': ['Week', '4', ',', 'patients', 'within', 'body', 'weight', 'category', '(', '≥40', 'kg', '<', '40', 'kg', ')', 'randomized', '1:1', 'one', 'two', 'maintenance', 'dose', 'regimens', '(', 'high', 'dose', 'low', 'dose', ')', '.'], 'lemmatized': ['Week', '4', ',', 'patient', 'within', 'body', 'weight', 'category', '(', '≥40', 'kg', '<', '40', 'kg', ')', 'randomized', '1:1', 'one', 'two', 'maintenance', 'dose', 'regimen', '(', 'high', 'dose', 'low', 'dose', ')', '.'], 'stemmed': ['week', '4', ',', 'patient', 'within', 'bodi', 'weight', 'categori', '(', '≥40', 'kg', '<', '40', 'kg', ')', 'random', '1:1', 'one', 'two', 'mainten', 'dose', 'regimen', '(', 'high', 'dose', 'low', 'dose', ')', '.'], 'dependencies': [('week', 'npadvmod'), ('4', 'nummod'), (',', 'punct'), ('patient', 'amod'), ('within', 'prep'), ('bodi', 'compound'), ('weight', 'compound'), ('categori', 'pobj'), ('(', 'punct'), ('≥40', 'punct'), ('kg', 'intj'), ('<', 'dep'), ('40', 'nummod'), ('kg', 'appos'), (')', 'punct'), ('random', 'amod'), ('1:1', 'nummod'), ('one', 'compound'), ('two', 'nummod'), ('mainten', 'compound'), ('dose', 'compound'), ('regimen', 'ROOT'), ('(', 'punct'), ('high', 'npadvmod'), ('dose', 'appos'), ('low', 'amod'), ('dose', 'dobj'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'The high dose was 40 mg every other week for patients \\nweighing ≥40 kg and 20 mg every other week for patients weighing <40 kg.', 'tokens': ['high', 'dose', '40', 'mg', 'every', 'week', 'patients', 'weighing', '≥40', 'kg', '20', 'mg', 'every', 'week', 'patients', 'weighing', '<', '40', 'kg', '.'], 'lemmatized': ['high', 'dose', '40', 'mg', 'every', 'week', 'patient', 'weighing', '≥40', 'kg', '20', 'mg', 'every', 'week', 'patient', 'weighing', '<', '40', 'kg', '.'], 'stemmed': ['high', 'dose', '40', 'mg', 'everi', 'week', 'patient', 'weigh', '≥40', 'kg', '20', 'mg', 'everi', 'week', 'patient', 'weigh', '<', '40', 'kg', '.'], 'dependencies': [('high', 'compound'), ('dose', 'nsubj'), ('40', 'nummod'), ('mg', 'nmod'), ('everi', 'amod'), ('week', 'npadvmod'), ('patient', 'nmod'), ('weigh', 'nmod'), ('≥40', 'punct'), ('kg', 'appos'), ('20', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'npadvmod'), ('patient', 'compound'), ('weigh', 'nmod'), ('<', 'dep'), ('40', 'nummod'), ('kg', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'The low dose was \\n20 mg every other week for patients weighing ≥40 kg and 10 mg every other week for patients \\nweighing <40 kg.', 'tokens': ['low', 'dose', '20', 'mg', 'every', 'week', 'patients', 'weighing', '≥40', 'kg', '10', 'mg', 'every', 'week', 'patients', 'weighing', '<', '40', 'kg', '.'], 'lemmatized': ['low', 'dose', '20', 'mg', 'every', 'week', 'patient', 'weighing', '≥40', 'kg', '10', 'mg', 'every', 'week', 'patient', 'weighing', '<', '40', 'kg', '.'], 'stemmed': ['low', 'dose', '20', 'mg', 'everi', 'week', 'patient', 'weigh', '≥40', 'kg', '10', 'mg', 'everi', 'week', 'patient', 'weigh', '<', '40', 'kg', '.'], 'dependencies': [('low', 'compound'), ('dose', 'ROOT'), ('20', 'dobj'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'compound'), ('patient', 'conj'), ('weigh', 'nmod'), ('≥40', 'punct'), ('kg', 'appos'), ('10', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'compound'), ('patient', 'compound'), ('weigh', 'nmod'), ('<', 'dep'), ('40', 'nummod'), ('kg', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Concomitant stable dosages of corticosteroids (prednisone dosage ≤40 mg/day or equivalent) and \\nimmunomodulators (azathioprine, 6-mercaptopurine, or methotrexate) were permitted \\nthroughout the study.', 'tokens': ['Concomitant', 'stable', 'dosages', 'corticosteroids', '(', 'prednisone', 'dosage', '≤40', 'mg/day', 'equivalent', ')', 'immunomodulators', '(', 'azathioprine', ',', '6-mercaptopurine', ',', 'methotrexate', ')', 'permitted', 'throughout', 'study', '.'], 'lemmatized': ['Concomitant', 'stable', 'dosage', 'corticosteroid', '(', 'prednisone', 'dosage', '≤40', 'mg/day', 'equivalent', ')', 'immunomodulators', '(', 'azathioprine', ',', '6-mercaptopurine', ',', 'methotrexate', ')', 'permitted', 'throughout', 'study', '.'], 'stemmed': ['concomit', 'stabl', 'dosag', 'corticosteroid', '(', 'prednison', 'dosag', '≤40', 'mg/day', 'equival', ')', 'immunomodul', '(', 'azathioprin', ',', '6-mercaptopurin', ',', 'methotrex', ')', 'permit', 'throughout', 'studi', '.'], 'dependencies': [('concomit', 'npadvmod'), ('stabl', 'amod'), ('dosag', 'compound'), ('corticosteroid', 'ROOT'), ('(', 'punct'), ('prednison', 'nmod'), ('dosag', 'nmod'), ('≤40', 'nmod'), ('mg', 'nmod'), ('/', 'punct'), ('day', 'compound'), ('equival', 'appos'), (')', 'punct'), ('immunomodul', 'punct'), ('(', 'punct'), ('azathioprin', 'nmod'), (',', 'punct'), ('6', 'nummod'), ('-', 'punct'), ('mercaptopurin', 'nmod'), (',', 'punct'), ('methotrex', 'nmod'), (')', 'punct'), ('permit', 'ROOT'), ('throughout', 'prep'), ('studi', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'At Week 12, patients who experienced a disease flare (increase in PCDAI of ≥ 15 from Week 4 \\nand absolute PCDAI > 30) or who were non-responders (did not achieve a decrease in the \\nPCDAI of ≥ 15 from baseline for 2 consecutive visits at least 2 weeks apart) were allowed to \\ndose-escalate (i.e., switch from blinded every other week dosing to blinded every week dosing); \\npatients who dose-escalated were considered treatment failures.', 'tokens': ['Week', '12', ',', 'patients', 'experienced', 'disease', 'flare', '(', 'increase', 'PCDAI', '≥', '15', 'Week', '4', 'absolute', 'PCDAI', '>', '30', ')', 'non-responders', '(', 'achieve', 'decrease', 'PCDAI', '≥', '15', 'baseline', '2', 'consecutive', 'visits', 'least', '2', 'weeks', 'apart', ')', 'allowed', 'dose-escalate', '(', 'i.e.', ',', 'switch', 'blinded', 'every', 'week', 'dosing', 'blinded', 'every', 'week', 'dosing', ')', ';', 'patients', 'dose-escalated', 'considered', 'treatment', 'failures', '.'], 'lemmatized': ['Week', '12', ',', 'patient', 'experienced', 'disease', 'flare', '(', 'increase', 'PCDAI', '≥', '15', 'Week', '4', 'absolute', 'PCDAI', '>', '30', ')', 'non-responders', '(', 'achieve', 'decrease', 'PCDAI', '≥', '15', 'baseline', '2', 'consecutive', 'visit', 'least', '2', 'week', 'apart', ')', 'allowed', 'dose-escalate', '(', 'i.e.', ',', 'switch', 'blinded', 'every', 'week', 'dosing', 'blinded', 'every', 'week', 'dosing', ')', ';', 'patient', 'dose-escalated', 'considered', 'treatment', 'failure', '.'], 'stemmed': ['week', '12', ',', 'patient', 'experienc', 'diseas', 'flare', '(', 'increas', 'pcdai', '≥', '15', 'week', '4', 'absolut', 'pcdai', '>', '30', ')', 'non-respond', '(', 'achiev', 'decreas', 'pcdai', '≥', '15', 'baselin', '2', 'consecut', 'visit', 'least', '2', 'week', 'apart', ')', 'allow', 'dose-escal', '(', 'i.e.', ',', 'switch', 'blind', 'everi', 'week', 'dose', 'blind', 'everi', 'week', 'dose', ')', ';', 'patient', 'dose-escal', 'consid', 'treatment', 'failur', '.'], 'dependencies': [('week', 'npadvmod'), ('12', 'nummod'), (',', 'punct'), ('patient', 'amod'), ('experienc', 'compound'), ('diseas', 'compound'), ('flare', 'nsubj'), ('(', 'punct'), ('increas', 'compound'), ('pcdai', 'compound'), ('≥', 'parataxis'), ('15', 'nummod'), ('week', 'npadvmod'), ('4', 'nummod'), ('absolut', 'prep'), ('pcdai', 'npadvmod'), ('>', 'nmod'), ('30', 'appos'), (')', 'punct'), ('non', 'appos'), ('-', 'conj'), ('respond', 'amod'), ('(', 'punct'), ('achiev', 'compound'), ('decreas', 'compound'), ('pcdai', 'compound'), ('≥', 'appos'), ('15', 'nummod'), ('baselin', 'nsubj'), ('2', 'nummod'), ('consecut', 'compound'), ('visit', 'nsubj'), ('least', 'advmod'), ('2', 'nummod'), ('week', 'npadvmod'), ('apart', 'advmod'), (')', 'punct'), ('allow', 'ROOT'), ('dose', 'amod'), ('-', 'punct'), ('escal', 'nsubj'), ('(', 'punct'), ('i.e.', 'advmod'), (',', 'punct'), ('switch', 'ccomp'), ('blind', 'advmod'), ('everi', 'amod'), ('week', 'npadvmod'), ('dose', 'conj'), ('blind', 'amod'), ('everi', 'amod'), ('week', 'compound'), ('dose', 'dobj'), (')', 'punct'), (';', 'punct'), ('patient', 'amod'), ('dose', 'amod'), ('-', 'punct'), ('escal', 'amod'), ('consid', 'amod'), ('treatment', 'compound'), ('failur', 'appos'), ('.', 'punct')]}, {'original_sentence': 'At baseline, 38% of patients were receiving corticosteroids, and 62% of patients were receiving \\nan immunomodulator.', 'tokens': ['baseline', ',', '38', '%', 'patients', 'receiving', 'corticosteroids', ',', '62', '%', 'patients', 'receiving', 'immunomodulator', '.'], 'lemmatized': ['baseline', ',', '38', '%', 'patient', 'receiving', 'corticosteroid', ',', '62', '%', 'patient', 'receiving', 'immunomodulator', '.'], 'stemmed': ['baselin', ',', '38', '%', 'patient', 'receiv', 'corticosteroid', ',', '62', '%', 'patient', 'receiv', 'immunomodul', '.'], 'dependencies': [('baselin', 'ROOT'), (',', 'punct'), ('38', 'nummod'), ('%', 'npadvmod'), ('patient', 'amod'), ('receiv', 'compound'), ('corticosteroid', 'conj'), (',', 'punct'), ('62', 'nummod'), ('%', 'npadvmod'), ('patient', 'compound'), ('receiv', 'compound'), ('immunomodul', 'conj'), ('.', 'punct')]}, {'original_sentence': 'Forty-four percent (44%) of patients had previously lost response or were \\nintolerant to a TNF blocker.', 'tokens': ['Forty-four', 'percent', '(', '44', '%', ')', 'patients', 'previously', 'lost', 'response', 'intolerant', 'TNF', 'blocker', '.'], 'lemmatized': ['Forty-four', 'percent', '(', '44', '%', ')', 'patient', 'previously', 'lost', 'response', 'intolerant', 'TNF', 'blocker', '.'], 'stemmed': ['forty-four', 'percent', '(', '44', '%', ')', 'patient', 'previous', 'lost', 'respons', 'intoler', 'tnf', 'blocker', '.'], 'dependencies': [('forty', 'compound'), ('-', 'punct'), ('four', 'nummod'), ('percent', 'nsubj'), ('(', 'punct'), ('44', 'nummod'), ('%', 'appos'), (')', 'punct'), ('patient', 'ROOT'), ('previous', 'amod'), ('lost', 'amod'), ('respons', 'compound'), ('intoler', 'compound'), ('tnf', 'compound'), ('blocker', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The median baseline PCDAI score was 40.', 'tokens': ['median', 'baseline', 'PCDAI', 'score', '40', '.'], 'lemmatized': ['median', 'baseline', 'PCDAI', 'score', '40', '.'], 'stemmed': ['median', 'baselin', 'pcdai', 'score', '40', '.'], 'dependencies': [('median', 'amod'), ('baselin', 'compound'), ('pcdai', 'compound'), ('score', 'ROOT'), ('40', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Of the 192 patients total, 188 patients completed the 4 week induction period, 152 patients \\ncompleted 26 weeks of treatment, and 124 patients completed 52 weeks of treatment.', 'tokens': ['192', 'patients', 'total', ',', '188', 'patients', 'completed', '4', 'week', 'induction', 'period', ',', '152', 'patients', 'completed', '26', 'weeks', 'treatment', ',', '124', 'patients', 'completed', '52', 'weeks', 'treatment', '.'], 'lemmatized': ['192', 'patient', 'total', ',', '188', 'patient', 'completed', '4', 'week', 'induction', 'period', ',', '152', 'patient', 'completed', '26', 'week', 'treatment', ',', '124', 'patient', 'completed', '52', 'week', 'treatment', '.'], 'stemmed': ['192', 'patient', 'total', ',', '188', 'patient', 'complet', '4', 'week', 'induct', 'period', ',', '152', 'patient', 'complet', '26', 'week', 'treatment', ',', '124', 'patient', 'complet', '52', 'week', 'treatment', '.'], 'dependencies': [('192', 'nummod'), ('patient', 'compound'), ('total', 'dep'), (',', 'punct'), ('188', 'nummod'), ('patient', 'compound'), ('complet', 'ROOT'), ('4', 'nummod'), ('week', 'compound'), ('induct', 'compound'), ('period', 'npadvmod'), (',', 'punct'), ('152', 'nummod'), ('patient', 'amod'), ('complet', 'conj'), ('26', 'nummod'), ('week', 'compound'), ('treatment', 'appos'), (',', 'punct'), ('124', 'nummod'), ('patient', 'amod'), ('complet', 'conj'), ('52', 'nummod'), ('week', 'compound'), ('treatment', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Fifty-one \\npercent (51%) (48/95) of patients in the low maintenance dose group dose-escalated, and 38% \\n(35/93) of patients in the high maintenance dose group dose-escalated.', 'tokens': ['Fifty-one', 'percent', '(', '51', '%', ')', '(', '48/95', ')', 'patients', 'low', 'maintenance', 'dose', 'group', 'dose-escalated', ',', '38', '%', '(', '35/93', ')', 'patients', 'high', 'maintenance', 'dose', 'group', 'dose-escalated', '.'], 'lemmatized': ['Fifty-one', 'percent', '(', '51', '%', ')', '(', '48/95', ')', 'patient', 'low', 'maintenance', 'dose', 'group', 'dose-escalated', ',', '38', '%', '(', '35/93', ')', 'patient', 'high', 'maintenance', 'dose', 'group', 'dose-escalated', '.'], 'stemmed': ['fifty-on', 'percent', '(', '51', '%', ')', '(', '48/95', ')', 'patient', 'low', 'mainten', 'dose', 'group', 'dose-escal', ',', '38', '%', '(', '35/93', ')', 'patient', 'high', 'mainten', 'dose', 'group', 'dose-escal', '.'], 'dependencies': [('fifty', 'nummod'), ('-', 'punct'), ('on', 'prep'), ('percent', 'ROOT'), ('(', 'punct'), ('51', 'nummod'), ('%', 'appos'), (')', 'punct'), ('(', 'punct'), ('48/95', 'nummod'), (')', 'punct'), ('patient', 'nmod'), ('low', 'amod'), ('mainten', 'compound'), ('dose', 'compound'), ('group', 'appos'), ('dose', 'compound'), ('-', 'punct'), ('escal', 'amod'), (',', 'punct'), ('38', 'nummod'), ('%', 'appos'), ('(', 'punct'), ('35/93', 'nummod'), (')', 'punct'), ('patient', 'nmod'), ('high', 'amod'), ('mainten', 'compound'), ('dose', 'compound'), ('group', 'compound'), ('dose', 'compound'), ('-', 'punct'), ('escal', 'amod'), ('.', 'punct')]}, {'original_sentence': 'At Week 4, 28% (52/188) of patients were in clinical remission (defined as PCDAI ≤ 10).', 'tokens': ['Week', '4', ',', '28', '%', '(', '52/188', ')', 'patients', 'clinical', 'remission', '(', 'defined', 'PCDAI', '≤', '10', ')', '.'], 'lemmatized': ['Week', '4', ',', '28', '%', '(', '52/188', ')', 'patient', 'clinical', 'remission', '(', 'defined', 'PCDAI', '≤', '10', ')', '.'], 'stemmed': ['week', '4', ',', '28', '%', '(', '52/188', ')', 'patient', 'clinic', 'remiss', '(', 'defin', 'pcdai', '≤', '10', ')', '.'], 'dependencies': [('week', 'ROOT'), ('4', 'nummod'), (',', 'punct'), ('28', 'nummod'), ('%', 'appos'), ('(', 'punct'), ('52/188', 'nummod'), (')', 'punct'), ('patient', 'amod'), ('clinic', 'compound'), ('remiss', 'appos'), ('(', 'punct'), ('defin', 'compound'), ('pcdai', 'compound'), ('≤', 'appos'), ('10', 'nummod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'The proportions of patients in clinical remission (defined as PCDAI ≤ 10) and clinical response \\n(defined as reduction in PCDAI of at least 15 points from baseline) were assessed at Weeks 26 \\nand 52.', 'tokens': ['proportions', 'patients', 'clinical', 'remission', '(', 'defined', 'PCDAI', '≤', '10', ')', 'clinical', 'response', '(', 'defined', 'reduction', 'PCDAI', 'least', '15', 'points', 'baseline', ')', 'assessed', 'Weeks', '26', '52', '.'], 'lemmatized': ['proportion', 'patient', 'clinical', 'remission', '(', 'defined', 'PCDAI', '≤', '10', ')', 'clinical', 'response', '(', 'defined', 'reduction', 'PCDAI', 'least', '15', 'point', 'baseline', ')', 'assessed', 'Weeks', '26', '52', '.'], 'stemmed': ['proport', 'patient', 'clinic', 'remiss', '(', 'defin', 'pcdai', '≤', '10', ')', 'clinic', 'respons', '(', 'defin', 'reduct', 'pcdai', 'least', '15', 'point', 'baselin', ')', 'assess', 'week', '26', '52', '.'], 'dependencies': [('proport', 'compound'), ('patient', 'compound'), ('clinic', 'compound'), ('remiss', 'nsubj'), ('(', 'punct'), ('defin', 'nmod'), ('pcdai', 'compound'), ('≤', 'appos'), ('10', 'nummod'), (')', 'punct'), ('clinic', 'compound'), ('respons', 'appos'), ('(', 'punct'), ('defin', 'nmod'), ('reduct', 'compound'), ('pcdai', 'parataxis'), ('least', 'advmod'), ('15', 'nummod'), ('point', 'compound'), ('baselin', 'appos'), (')', 'punct'), ('assess', 'ROOT'), ('week', 'npadvmod'), ('26', 'nummod'), ('52', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'At both Weeks 26 and 52, the proportion of patients in clinical remission and clinical response \\nwas numerically higher in the high dose group compared to the low dose group (Table 14).', 'tokens': ['Weeks', '26', '52', ',', 'proportion', 'patients', 'clinical', 'remission', 'clinical', 'response', 'numerically', 'higher', 'high', 'dose', 'group', 'compared', 'low', 'dose', 'group', '(', 'Table', '14', ')', '.'], 'lemmatized': ['Weeks', '26', '52', ',', 'proportion', 'patient', 'clinical', 'remission', 'clinical', 'response', 'numerically', 'higher', 'high', 'dose', 'group', 'compared', 'low', 'dose', 'group', '(', 'Table', '14', ')', '.'], 'stemmed': ['week', '26', '52', ',', 'proport', 'patient', 'clinic', 'remiss', 'clinic', 'respons', 'numer', 'higher', 'high', 'dose', 'group', 'compar', 'low', 'dose', 'group', '(', 'tabl', '14', ')', '.'], 'dependencies': [('week', 'npadvmod'), ('26', 'compound'), ('52', 'nummod'), (',', 'punct'), ('proport', 'compound'), ('patient', 'nmod'), ('clinic', 'nmod'), ('remiss', 'compound'), ('clinic', 'compound'), ('respons', 'compound'), ('numer', 'nmod'), ('higher', 'amod'), ('high', 'amod'), ('dose', 'compound'), ('group', 'compound'), ('compar', 'compound'), ('low', 'compound'), ('dose', 'compound'), ('group', 'ROOT'), ('(', 'punct'), ('tabl', 'appos'), ('14', 'nummod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'The \\nrecommended maintenance regimen is 20 mg every other week for patients weighing < 40 kg \\nand 40 mg every other week for patients weighing ≥ 40 kg.', 'tokens': ['recommended', 'maintenance', 'regimen', '20', 'mg', 'every', 'week', 'patients', 'weighing', '<', '40', 'kg', '40', 'mg', 'every', 'week', 'patients', 'weighing', '≥', '40', 'kg', '.'], 'lemmatized': ['recommended', 'maintenance', 'regimen', '20', 'mg', 'every', 'week', 'patient', 'weighing', '<', '40', 'kg', '40', 'mg', 'every', 'week', 'patient', 'weighing', '≥', '40', 'kg', '.'], 'stemmed': ['recommend', 'mainten', 'regimen', '20', 'mg', 'everi', 'week', 'patient', 'weigh', '<', '40', 'kg', '40', 'mg', 'everi', 'week', 'patient', 'weigh', '≥', '40', 'kg', '.'], 'dependencies': [('recommend', 'ROOT'), ('mainten', 'compound'), ('regimen', 'dobj'), ('20', 'npadvmod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'compound'), ('patient', 'conj'), ('weigh', 'npadvmod'), ('<', 'dep'), ('40', 'nummod'), ('kg', 'appos'), ('40', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'compound'), ('patient', 'compound'), ('weigh', 'compound'), ('≥', 'npadvmod'), ('40', 'nummod'), ('kg', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Every week dosing is not the \\nrecommended maintenance dosing regimen [see Dosage and Administration (2.3)].', 'tokens': ['Every', 'week', 'dosing', 'recommended', 'maintenance', 'dosing', 'regimen', '[', 'see', 'Dosage', 'Administration', '(', '2.3', ')', ']', '.'], 'lemmatized': ['Every', 'week', 'dosing', 'recommended', 'maintenance', 'dosing', 'regimen', '[', 'see', 'Dosage', 'Administration', '(', '2.3', ')', ']', '.'], 'stemmed': ['everi', 'week', 'dose', 'recommend', 'mainten', 'dose', 'regimen', '[', 'see', 'dosag', 'administr', '(', '2.3', ')', ']', '.'], 'dependencies': [('everi', 'amod'), ('week', 'compound'), ('dose', 'compound'), ('recommend', 'nsubj'), ('mainten', 'compound'), ('dose', 'compound'), ('regimen', 'dobj'), ('[', 'punct'), ('see', 'ROOT'), ('dosag', 'compound'), ('administr', 'dobj'), ('(', 'punct'), ('2.3', 'appos'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}], 'text': '14.6 Pediatric Crohn’s Disease  \\nA randomized, double-blind, 52-week clinical study of 2 dose concentrations of HUMIRA \\n(Study PCD-I) was conducted in 192 pediatric patients (6 to 17 years of age) with moderately to \\nseverely active Crohn’s disease (defined as Pediatric Crohn’s Disease Activity Index (PCDAI) \\nscore > 30). Enrolled patients had over the previous two year period an inadequate response to \\ncorticosteroids or an immunomodulator (i.e., azathioprine, 6-mercaptopurine, or methotrexate). \\nPatients who had previously received a TNF blocker were allowed to enroll if they had \\npreviously had loss of response or intolerance to that TNF blocker.  \\nPatients received open-label induction therapy at a dose based on their body weight (≥40 kg and \\n<40 kg). Patients weighing ≥40 kg received 160 mg (at Week 0) and 80 mg (at Week 2). Patients \\nweighing <40 kg received 80 mg (at Week 0) and 40 mg (at Week 2). At Week 4, patients within \\neach body weight category (≥40 kg and <40 kg) were randomized 1:1 to one of two maintenance \\ndose regimens (high dose and low dose). The high dose was 40 mg every other week for patients \\nweighing ≥40 kg and 20 mg every other week for patients weighing <40 kg. The low dose was \\n20 mg every other week for patients weighing ≥40 kg and 10 mg every other week for patients \\nweighing <40 kg.  \\nConcomitant stable dosages of corticosteroids (prednisone dosage ≤40 mg/day or equivalent) and \\nimmunomodulators (azathioprine, 6-mercaptopurine, or methotrexate) were permitted \\nthroughout the study.  \\nAt Week 12, patients who experienced a disease flare (increase in PCDAI of ≥ 15 from Week 4 \\nand absolute PCDAI > 30) or who were non-responders (did not achieve a decrease in the \\nPCDAI of ≥ 15 from baseline for 2 consecutive visits at least 2 weeks apart) were allowed to \\ndose-escalate (i.e., switch from blinded every other week dosing to blinded every week dosing); \\npatients who dose-escalated were considered treatment failures.  \\nAt baseline, 38% of patients were receiving corticosteroids, and 62% of patients were receiving \\nan immunomodulator. Forty-four percent (44%) of patients had previously lost response or were \\nintolerant to a TNF blocker. The median baseline PCDAI score was 40.  \\nOf the 192 patients total, 188 patients completed the 4 week induction period, 152 patients \\ncompleted 26 weeks of treatment, and 124 patients completed 52 weeks of treatment. Fifty-one \\npercent (51%) (48/95) of patients in the low maintenance dose group dose-escalated, and 38% \\n(35/93) of patients in the high maintenance dose group dose-escalated.  \\nAt Week 4, 28% (52/188) of patients were in clinical remission (defined as PCDAI ≤ 10).  \\nThe proportions of patients in clinical remission (defined as PCDAI ≤ 10) and clinical response \\n(defined as reduction in PCDAI of at least 15 points from baseline) were assessed at Weeks 26 \\nand 52.  \\nAt both Weeks 26 and 52, the proportion of patients in clinical remission and clinical response \\nwas numerically higher in the high dose group compared to the low dose group (Table 14). The \\nrecommended maintenance regimen is 20 mg every other week for patients weighing < 40 kg \\nand 40 mg every other week for patients weighing ≥ 40 kg. Every week dosing is not the \\nrecommended maintenance dosing regimen [see Dosage and Administration (2.3)].  \\n'}, 'page_char_count': 3334, 'page_word_count': 537, 'sentences': ['14.6 Pediatric Crohn’s Disease  \\nA randomized, double-blind, 52-week clinical study of 2 dose concentrations of HUMIRA \\n(Study PCD-I) was conducted in 192 pediatric patients (6 to 17 years of age) with moderately to \\nseverely active Crohn’s disease (defined as Pediatric Crohn’s Disease Activity Index (PCDAI) \\nscore > 30).', 'Enrolled patients had over the previous two year period an inadequate response to \\ncorticosteroids or an immunomodulator (i.e., azathioprine, 6-mercaptopurine, or methotrexate).', '\\nPatients who had previously received a TNF blocker were allowed to enroll if they had \\npreviously had loss of response or intolerance to that TNF blocker.', ' \\nPatients received open-label induction therapy at a dose based on their body weight (≥40 kg and \\n<40 kg).', 'Patients weighing ≥40 kg received 160 mg (at Week 0) and 80 mg (at Week 2).', 'Patients \\nweighing <40 kg received 80 mg (at Week 0) and 40 mg (at Week 2).', 'At Week 4, patients within \\neach body weight category (≥40 kg and <40 kg) were randomized 1:1 to one of two maintenance \\ndose regimens (high dose and low dose).', 'The high dose was 40 mg every other week for patients \\nweighing ≥40 kg and 20 mg every other week for patients weighing <40 kg.', 'The low dose was \\n20 mg every other week for patients weighing ≥40 kg and 10 mg every other week for patients \\nweighing <40 kg.', ' \\nConcomitant stable dosages of corticosteroids (prednisone dosage ≤40 mg/day or equivalent) and \\nimmunomodulators (azathioprine, 6-mercaptopurine, or methotrexate) were permitted \\nthroughout the study.', ' \\nAt Week 12, patients who experienced a disease flare (increase in PCDAI of ≥ 15 from Week 4 \\nand absolute PCDAI > 30) or who were non-responders (did not achieve a decrease in the \\nPCDAI of ≥ 15 from baseline for 2 consecutive visits at least 2 weeks apart) were allowed to \\ndose-escalate (i.e., switch from blinded every other week dosing to blinded every week dosing); \\npatients who dose-escalated were considered treatment failures.', ' \\nAt baseline, 38% of patients were receiving corticosteroids, and 62% of patients were receiving \\nan immunomodulator.', 'Forty-four percent (44%) of patients had previously lost response or were \\nintolerant to a TNF blocker.', 'The median baseline PCDAI score was 40.', ' \\nOf the 192 patients total, 188 patients completed the 4 week induction period, 152 patients \\ncompleted 26 weeks of treatment, and 124 patients completed 52 weeks of treatment.', 'Fifty-one \\npercent (51%) (48/95) of patients in the low maintenance dose group dose-escalated, and 38% \\n(35/93) of patients in the high maintenance dose group dose-escalated.', ' \\nAt Week 4, 28% (52/188) of patients were in clinical remission (defined as PCDAI ≤ 10).', ' \\nThe proportions of patients in clinical remission (defined as PCDAI ≤ 10) and clinical response \\n(defined as reduction in PCDAI of at least 15 points from baseline) were assessed at Weeks 26 \\nand 52.', ' \\nAt both Weeks 26 and 52, the proportion of patients in clinical remission and clinical response \\nwas numerically higher in the high dose group compared to the low dose group (Table 14).', 'The \\nrecommended maintenance regimen is 20 mg every other week for patients weighing < 40 kg \\nand 40 mg every other week for patients weighing ≥ 40 kg.', 'Every week dosing is not the \\nrecommended maintenance dosing regimen [see Dosage and Administration (2.3)].', ' \\n'], 'page_sentence_count_spacy': 22}\n",
            "{'page_number': 45, 'text': 'Table 14. Clinical Remission and Clinical Response in Study PCD-I \\n  \\nLow Maintenance Dose† \\n(20 or 10 mg every other week) \\nN = 95 \\nHigh Maintenance Dose# \\n(40 or 20 mg every other week) \\nN = 93 \\nWeek 26  \\n  \\n  \\n  Clinical Remission‡ \\n28% \\n39% \\n  Clinical Response§  \\n48% \\n59% \\nWeek 52 \\n  \\n  \\n  Clinical Remission‡ \\n23% \\n33% \\n  Clinical Response§ \\n28% \\n42% \\n†The low maintenance dose was 20 mg every other week for patients weighing ≥ 40 kg and 10 \\nmg every other week for patients weighing < 40 kg. \\n#The high maintenance dose was 40 mg every other week for patients weighing ≥ 40 kg and 20 \\nmg every other week for patients weighing < 40 kg.  \\n‡Clinical remission defined as PCDAI ≤ 10. \\n§Clinical response defined as reduction in PCDAI of at least 15 points from baseline.  \\n \\n  \\n14.7 Adult Ulcerative Colitis \\nThe safety and efficacy of HUMIRA were assessed in adult patients with moderately to severely \\nactive ulcerative colitis (Mayo score 6 to 12 on a 12 point scale, with an endoscopy subscore of 2 \\nto 3 on a scale of 0 to 3) despite concurrent or prior treatment with immunosuppressants such as \\ncorticosteroids, azathioprine, or 6-MP in two randomized, double-blind, placebo-controlled \\nclinical studies (Studies UC-I and UC-II). Both studies enrolled TNF-blocker naïve patients, but \\nStudy UC-II also allowed entry of patients who lost response to or were intolerant to TNF-\\nblockers. Forty percent (40%) of patients enrolled in Study UC-II had previously used another \\nTNF-blocker.  \\nConcomitant stable doses of aminosalicylates and immunosuppressants were permitted. In \\nStudies UC-I and II, patients were receiving aminosalicylates (69%), corticosteroids (59%) \\nand/or azathioprine or 6-MP (37%) at baseline. In both studies, 92% of patients received at least \\none of these medications.  \\nInduction of clinical remission (defined as Mayo score ≤ 2 with no individual subscores > 1) at \\nWeek 8 was evaluated in both studies. Clinical remission at Week 52 and sustained clinical \\nremission (defined as clinical remission at both Weeks 8 and 52) were evaluated in Study UC-II.  \\nIn Study UC-I, 390 TNF-blocker naïve patients were randomized to one of three treatment \\ngroups for the primary efficacy analysis. The placebo group received placebo at Weeks 0, 2, 4 \\nand 6. The 160/80 group received 160 mg HUMIRA at Week 0 and 80 mg at Week 2, and the \\n80/40 group received 80 mg HUMIRA at Week 0 and 40 mg at Week 2. After Week 2, patients \\nin both HUMIRA treatment groups received 40 mg every other week.  \\nIn Study UC-II, 518 patients were randomized to receive either HUMIRA 160 mg at Week 0, 80 \\nmg at Week 2, and 40 mg every other week starting at Week 4 through Week 50, or placebo \\nstarting at Week 0 and every other week through Week 50. Corticosteroid taper was permitted \\nstarting at Week 8.  \\n', 'processed_text': {'sentences': [{'original_sentence': 'Table 14.', 'tokens': ['Table', '14', '.'], 'lemmatized': ['Table', '14', '.'], 'stemmed': ['tabl', '14', '.'], 'dependencies': [('tabl', 'ROOT'), ('14', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Clinical Remission and Clinical Response in Study PCD-I \\n  \\nLow Maintenance Dose† \\n(20 or 10 mg every other week) \\nN = 95 \\nHigh Maintenance Dose# \\n(40 or 20 mg every other week) \\nN = 93 \\nWeek 26  \\n  \\n  \\n  Clinical Remission‡ \\n28% \\n39% \\n  Clinical Response§  \\n48% \\n59% \\nWeek 52 \\n  \\n  \\n  Clinical Remission‡ \\n23% \\n33% \\n  Clinical Response§ \\n28% \\n42% \\n†The low maintenance dose was 20 mg every other week for patients weighing ≥ 40 kg and 10 \\nmg every other week for patients weighing < 40 kg.', 'tokens': ['Clinical', 'Remission', 'Clinical', 'Response', 'Study', 'PCD-I', 'Low', 'Maintenance', 'Dose†', '(', '20', '10', 'mg', 'every', 'week', ')', 'N', '=', '95', 'High', 'Maintenance', 'Dose', '#', '(', '40', '20', 'mg', 'every', 'week', ')', 'N', '=', '93', 'Week', '26', 'Clinical', 'Remission‡', '28', '%', '39', '%', 'Clinical', 'Response§', '48', '%', '59', '%', 'Week', '52', 'Clinical', 'Remission‡', '23', '%', '33', '%', 'Clinical', 'Response§', '28', '%', '42', '%', '†The', 'low', 'maintenance', 'dose', '20', 'mg', 'every', 'week', 'patients', 'weighing', '≥', '40', 'kg', '10', 'mg', 'every', 'week', 'patients', 'weighing', '<', '40', 'kg', '.'], 'lemmatized': ['Clinical', 'Remission', 'Clinical', 'Response', 'Study', 'PCD-I', 'Low', 'Maintenance', 'Dose†', '(', '20', '10', 'mg', 'every', 'week', ')', 'N', '=', '95', 'High', 'Maintenance', 'Dose', '#', '(', '40', '20', 'mg', 'every', 'week', ')', 'N', '=', '93', 'Week', '26', 'Clinical', 'Remission‡', '28', '%', '39', '%', 'Clinical', 'Response§', '48', '%', '59', '%', 'Week', '52', 'Clinical', 'Remission‡', '23', '%', '33', '%', 'Clinical', 'Response§', '28', '%', '42', '%', '†The', 'low', 'maintenance', 'dose', '20', 'mg', 'every', 'week', 'patient', 'weighing', '≥', '40', 'kg', '10', 'mg', 'every', 'week', 'patient', 'weighing', '<', '40', 'kg', '.'], 'stemmed': ['clinic', 'remiss', 'clinic', 'respons', 'studi', 'pcd-i', 'low', 'mainten', 'dose†', '(', '20', '10', 'mg', 'everi', 'week', ')', 'n', '=', '95', 'high', 'mainten', 'dose', '#', '(', '40', '20', 'mg', 'everi', 'week', ')', 'n', '=', '93', 'week', '26', 'clinic', 'remission‡', '28', '%', '39', '%', 'clinic', 'response§', '48', '%', '59', '%', 'week', '52', 'clinic', 'remission‡', '23', '%', '33', '%', 'clinic', 'response§', '28', '%', '42', '%', '†the', 'low', 'mainten', 'dose', '20', 'mg', 'everi', 'week', 'patient', 'weigh', '≥', '40', 'kg', '10', 'mg', 'everi', 'week', 'patient', 'weigh', '<', '40', 'kg', '.'], 'dependencies': [('clinic', 'compound'), ('remiss', 'compound'), ('clinic', 'compound'), ('respons', 'compound'), ('studi', 'compound'), ('pcd', 'compound'), ('-', 'punct'), ('i', 'nsubj'), ('low', 'advmod'), ('mainten', 'ROOT'), ('dose†', 'punct'), ('(', 'punct'), ('20', 'nummod'), ('10', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'npadvmod'), (')', 'punct'), ('n', 'nummod'), ('=', 'nmod'), ('95', 'nummod'), ('high', 'amod'), ('mainten', 'compound'), ('dose', 'compound'), ('#', 'conj'), ('(', 'punct'), ('40', 'compound'), ('20', 'appos'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'npadvmod'), (')', 'punct'), ('n', 'det'), ('=', 'nmod'), ('93', 'nummod'), ('week', 'nmod'), ('26', 'nummod'), ('clinic', 'nsubj'), ('remission‡', 'nmod'), ('28', 'nummod'), ('%', 'nmod'), ('39', 'nummod'), ('%', 'compound'), ('clinic', 'compound'), ('response§', 'appos'), ('48', 'nummod'), ('%', 'appos'), ('59', 'nummod'), ('%', 'compound'), ('week', 'appos'), ('52', 'nummod'), ('clinic', 'appos'), ('remission‡', 'appos'), ('23', 'nummod'), ('%', 'appos'), ('33', 'nummod'), ('%', 'appos'), ('clinic', 'compound'), ('response§', 'ROOT'), ('28', 'nummod'), ('%', 'appos'), ('42', 'nummod'), ('%', 'appos'), ('†the', 'det'), ('low', 'amod'), ('mainten', 'compound'), ('dose', 'ROOT'), ('20', 'nummod'), ('mg', 'nmod'), ('everi', 'amod'), ('week', 'compound'), ('patient', 'compound'), ('weigh', 'compound'), ('≥', 'appos'), ('40', 'nummod'), ('kg', 'nmod'), ('10', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'compound'), ('patient', 'compound'), ('weigh', 'nmod'), ('<', 'dep'), ('40', 'nummod'), ('kg', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '#The high maintenance dose was 40 mg every other week for patients weighing ≥ 40 kg and 20 \\nmg every other week for patients weighing < 40 kg.', 'tokens': ['#', 'high', 'maintenance', 'dose', '40', 'mg', 'every', 'week', 'patients', 'weighing', '≥', '40', 'kg', '20', 'mg', 'every', 'week', 'patients', 'weighing', '<', '40', 'kg', '.'], 'lemmatized': ['#', 'high', 'maintenance', 'dose', '40', 'mg', 'every', 'week', 'patient', 'weighing', '≥', '40', 'kg', '20', 'mg', 'every', 'week', 'patient', 'weighing', '<', '40', 'kg', '.'], 'stemmed': ['#', 'high', 'mainten', 'dose', '40', 'mg', 'everi', 'week', 'patient', 'weigh', '≥', '40', 'kg', '20', 'mg', 'everi', 'week', 'patient', 'weigh', '<', '40', 'kg', '.'], 'dependencies': [('#', 'nmod'), ('high', 'amod'), ('mainten', 'compound'), ('dose', 'ROOT'), ('40', 'nummod'), ('mg', 'advmod'), ('everi', 'amod'), ('week', 'compound'), ('patient', 'compound'), ('weigh', 'compound'), ('≥', 'appos'), ('40', 'nummod'), ('kg', 'npadvmod'), ('20', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'compound'), ('patient', 'compound'), ('weigh', 'nmod'), ('<', 'dep'), ('40', 'nummod'), ('kg', 'appos'), ('.', 'punct')]}, {'original_sentence': '‡Clinical remission defined as PCDAI ≤ 10.', 'tokens': ['‡Clinical', 'remission', 'defined', 'PCDAI', '≤', '10', '.'], 'lemmatized': ['‡Clinical', 'remission', 'defined', 'PCDAI', '≤', '10', '.'], 'stemmed': ['‡clinic', 'remiss', 'defin', 'pcdai', '≤', '10', '.'], 'dependencies': [('‡clinic', 'amod'), ('remiss', 'amod'), ('defin', 'compound'), ('pcdai', 'compound'), ('≤', 'ROOT'), ('10', 'nummod'), ('.', 'punct')]}, {'original_sentence': '§Clinical response defined as reduction in PCDAI of at least 15 points from baseline.', 'tokens': ['§Clinical', 'response', 'defined', 'reduction', 'PCDAI', 'least', '15', 'points', 'baseline', '.'], 'lemmatized': ['§Clinical', 'response', 'defined', 'reduction', 'PCDAI', 'least', '15', 'point', 'baseline', '.'], 'stemmed': ['§clinic', 'respons', 'defin', 'reduct', 'pcdai', 'least', '15', 'point', 'baselin', '.'], 'dependencies': [('§', 'amod'), ('clinic', 'compound'), ('respons', 'compound'), ('defin', 'nsubj'), ('reduct', 'compound'), ('pcdai', 'nmod'), ('least', 'advmod'), ('15', 'nummod'), ('point', 'compound'), ('baselin', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '14.7 Adult Ulcerative Colitis \\nThe safety and efficacy of HUMIRA were assessed in adult patients with moderately to severely \\nactive ulcerative colitis (Mayo score 6 to 12 on a 12 point scale, with an endoscopy subscore of 2 \\nto 3 on a scale of 0 to 3) despite concurrent or prior treatment with immunosuppressants such as \\ncorticosteroids, azathioprine, or 6-MP in two randomized, double-blind, placebo-controlled \\nclinical studies (Studies UC-I and UC-II).', 'tokens': ['14.7', 'Adult', 'Ulcerative', 'Colitis', 'safety', 'efficacy', 'HUMIRA', 'assessed', 'adult', 'patients', 'moderately', 'severely', 'active', 'ulcerative', 'colitis', '(', 'Mayo', 'score', '6', '12', '12', 'point', 'scale', ',', 'endoscopy', 'subscore', '2', '3', 'scale', '0', '3', ')', 'despite', 'concurrent', 'prior', 'treatment', 'immunosuppressants', 'corticosteroids', ',', 'azathioprine', ',', '6-MP', 'two', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'clinical', 'studies', '(', 'Studies', 'UC-I', 'UC-II', ')', '.'], 'lemmatized': ['14.7', 'Adult', 'Ulcerative', 'Colitis', 'safety', 'efficacy', 'HUMIRA', 'assessed', 'adult', 'patient', 'moderately', 'severely', 'active', 'ulcerative', 'colitis', '(', 'Mayo', 'score', '6', '12', '12', 'point', 'scale', ',', 'endoscopy', 'subscore', '2', '3', 'scale', '0', '3', ')', 'despite', 'concurrent', 'prior', 'treatment', 'immunosuppressant', 'corticosteroid', ',', 'azathioprine', ',', '6-MP', 'two', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'clinical', 'study', '(', 'Studies', 'UC-I', 'UC-II', ')', '.'], 'stemmed': ['14.7', 'adult', 'ulcer', 'coliti', 'safeti', 'efficaci', 'humira', 'assess', 'adult', 'patient', 'moder', 'sever', 'activ', 'ulcer', 'coliti', '(', 'mayo', 'score', '6', '12', '12', 'point', 'scale', ',', 'endoscopi', 'subscor', '2', '3', 'scale', '0', '3', ')', 'despit', 'concurr', 'prior', 'treatment', 'immunosuppress', 'corticosteroid', ',', 'azathioprin', ',', '6-mp', 'two', 'random', ',', 'double-blind', ',', 'placebo-control', 'clinic', 'studi', '(', 'studi', 'uc-i', 'uc-ii', ')', '.'], 'dependencies': [('14.7', 'nummod'), ('adult', 'compound'), ('ulcer', 'npadvmod'), ('coliti', 'compound'), ('safeti', 'compound'), ('efficaci', 'appos'), ('humira', 'nsubj'), ('assess', 'compound'), ('adult', 'compound'), ('patient', 'compound'), ('moder', 'nsubj'), ('sever', 'ROOT'), ('activ', 'compound'), ('ulcer', 'compound'), ('coliti', 'dobj'), ('(', 'punct'), ('mayo', 'compound'), ('score', 'appos'), ('6', 'nummod'), ('12', 'nummod'), ('12', 'nummod'), ('point', 'compound'), ('scale', 'npadvmod'), (',', 'punct'), ('endoscopi', 'compound'), ('subscor', 'appos'), ('2', 'nummod'), ('3', 'nummod'), ('scale', 'appos'), ('0', 'npadvmod'), ('3', 'nummod'), (')', 'punct'), ('despit', 'compound'), ('concurr', 'conj'), ('prior', 'amod'), ('treatment', 'compound'), ('immunosuppress', 'compound'), ('corticosteroid', 'advcl'), (',', 'punct'), ('azathioprin', 'conj'), (',', 'punct'), ('6', 'nummod'), ('-', 'punct'), ('mp', 'prep'), ('two', 'nummod'), ('random', 'amod'), (',', 'punct'), ('double', 'amod'), ('-', 'punct'), ('blind', 'conj'), (',', 'punct'), ('placebo', 'compound'), ('-', 'punct'), ('control', 'compound'), ('clinic', 'compound'), ('studi', 'appos'), ('(', 'punct'), ('studi', 'npadvmod'), ('uc', 'intj'), ('-', 'punct'), ('i', 'npadvmod'), ('uc', 'npadvmod'), ('-', 'npadvmod'), ('ii', 'npadvmod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Both studies enrolled TNF-blocker naïve patients, but \\nStudy UC-II also allowed entry of patients who lost response to or were intolerant to TNF-\\nblockers.', 'tokens': ['studies', 'enrolled', 'TNF-blocker', 'naïve', 'patients', ',', 'Study', 'UC-II', 'also', 'allowed', 'entry', 'patients', 'lost', 'response', 'intolerant', 'TNF-', 'blockers', '.'], 'lemmatized': ['study', 'enrolled', 'TNF-blocker', 'naïve', 'patient', ',', 'Study', 'UC-II', 'also', 'allowed', 'entry', 'patient', 'lost', 'response', 'intolerant', 'TNF-', 'blocker', '.'], 'stemmed': ['studi', 'enrol', 'tnf-blocker', 'naïv', 'patient', ',', 'studi', 'uc-ii', 'also', 'allow', 'entri', 'patient', 'lost', 'respons', 'intoler', 'tnf-', 'blocker', '.'], 'dependencies': [('studi', 'nsubj'), ('enrol', 'ccomp'), ('tnf', 'compound'), ('-', 'punct'), ('blocker', 'compound'), ('naïv', 'compound'), ('patient', 'dobj'), (',', 'punct'), ('studi', 'compound'), ('uc', 'nsubj'), ('-', 'nsubj'), ('ii', 'nsubj'), ('also', 'advmod'), ('allow', 'ROOT'), ('entri', 'amod'), ('patient', 'nsubj'), ('lost', 'amod'), ('respons', 'compound'), ('intoler', 'compound'), ('tnf-', 'compound'), ('blocker', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Forty percent (40%) of patients enrolled in Study UC-II had previously used another \\nTNF-blocker.', 'tokens': ['Forty', 'percent', '(', '40', '%', ')', 'patients', 'enrolled', 'Study', 'UC-II', 'previously', 'used', 'another', 'TNF-blocker', '.'], 'lemmatized': ['Forty', 'percent', '(', '40', '%', ')', 'patient', 'enrolled', 'Study', 'UC-II', 'previously', 'used', 'another', 'TNF-blocker', '.'], 'stemmed': ['forti', 'percent', '(', '40', '%', ')', 'patient', 'enrol', 'studi', 'uc-ii', 'previous', 'use', 'anoth', 'tnf-blocker', '.'], 'dependencies': [('forti', 'amod'), ('percent', 'npadvmod'), ('(', 'punct'), ('40', 'nummod'), ('%', 'appos'), (')', 'punct'), ('patient', 'nsubj'), ('enrol', 'ROOT'), ('studi', 'nmod'), ('uc', 'compound'), ('-', 'compound'), ('ii', 'nmod'), ('previous', 'amod'), ('use', 'dobj'), ('anoth', 'compound'), ('tnf', 'npadvmod'), ('-', 'appos'), ('blocker', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Concomitant stable doses of aminosalicylates and immunosuppressants were permitted.', 'tokens': ['Concomitant', 'stable', 'doses', 'aminosalicylates', 'immunosuppressants', 'permitted', '.'], 'lemmatized': ['Concomitant', 'stable', 'dos', 'aminosalicylates', 'immunosuppressant', 'permitted', '.'], 'stemmed': ['concomit', 'stabl', 'do', 'aminosalicyl', 'immunosuppress', 'permit', '.'], 'dependencies': [('concomit', 'ROOT'), ('stabl', 'amod'), ('do', 'aux'), ('aminosalicyl', 'compound'), ('immunosuppress', 'compound'), ('permit', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'In \\nStudies UC-I and II, patients were receiving aminosalicylates (69%), corticosteroids (59%) \\nand/or azathioprine or 6-MP (37%) at baseline.', 'tokens': ['Studies', 'UC-I', 'II', ',', 'patients', 'receiving', 'aminosalicylates', '(', '69', '%', ')', ',', 'corticosteroids', '(', '59', '%', ')', 'and/or', 'azathioprine', '6-MP', '(', '37', '%', ')', 'baseline', '.'], 'lemmatized': ['Studies', 'UC-I', 'II', ',', 'patient', 'receiving', 'aminosalicylates', '(', '69', '%', ')', ',', 'corticosteroid', '(', '59', '%', ')', 'and/or', 'azathioprine', '6-MP', '(', '37', '%', ')', 'baseline', '.'], 'stemmed': ['studi', 'uc-i', 'ii', ',', 'patient', 'receiv', 'aminosalicyl', '(', '69', '%', ')', ',', 'corticosteroid', '(', '59', '%', ')', 'and/or', 'azathioprin', '6-mp', '(', '37', '%', ')', 'baselin', '.'], 'dependencies': [('studi', 'npadvmod'), ('uc', 'compound'), ('-', 'compound'), ('i', 'compound'), ('ii', 'appos'), (',', 'punct'), ('patient', 'amod'), ('receiv', 'compound'), ('aminosalicyl', 'ROOT'), ('(', 'punct'), ('69', 'nummod'), ('%', 'appos'), (')', 'punct'), (',', 'punct'), ('corticosteroid', 'amod'), ('(', 'punct'), ('59', 'nummod'), ('%', 'parataxis'), (')', 'punct'), ('and/or', 'cc'), ('azathioprin', 'conj'), ('6', 'nummod'), ('-', 'punct'), ('mp', 'dep'), ('(', 'punct'), ('37', 'nummod'), ('%', 'parataxis'), (')', 'punct'), ('baselin', 'appos'), ('.', 'punct')]}, {'original_sentence': 'In both studies, 92% of patients received at least \\none of these medications.', 'tokens': ['studies', ',', '92', '%', 'patients', 'received', 'least', 'one', 'medications', '.'], 'lemmatized': ['study', ',', '92', '%', 'patient', 'received', 'least', 'one', 'medication', '.'], 'stemmed': ['studi', ',', '92', '%', 'patient', 'receiv', 'least', 'one', 'medic', '.'], 'dependencies': [('studi', 'dep'), (',', 'punct'), ('92', 'nummod'), ('%', 'npadvmod'), ('patient', 'compound'), ('receiv', 'npadvmod'), ('least', 'advmod'), ('one', 'nummod'), ('medic', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Induction of clinical remission (defined as Mayo score ≤ 2 with no individual subscores > 1) at \\nWeek 8 was evaluated in both studies.', 'tokens': ['Induction', 'clinical', 'remission', '(', 'defined', 'Mayo', 'score', '≤', '2', 'individual', 'subscores', '>', '1', ')', 'Week', '8', 'evaluated', 'studies', '.'], 'lemmatized': ['Induction', 'clinical', 'remission', '(', 'defined', 'Mayo', 'score', '≤', '2', 'individual', 'subscores', '>', '1', ')', 'Week', '8', 'evaluated', 'study', '.'], 'stemmed': ['induct', 'clinic', 'remiss', '(', 'defin', 'mayo', 'score', '≤', '2', 'individu', 'subscor', '>', '1', ')', 'week', '8', 'evalu', 'studi', '.'], 'dependencies': [('induct', 'ROOT'), ('clinic', 'compound'), ('remiss', 'dobj'), ('(', 'punct'), ('defin', 'compound'), ('mayo', 'compound'), ('score', 'compound'), ('≤', 'appos'), ('2', 'nummod'), ('individu', 'nmod'), ('subscor', 'appos'), ('>', 'nmod'), ('1', 'prep'), (')', 'punct'), ('week', 'appos'), ('8', 'nummod'), ('evalu', 'compound'), ('studi', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Clinical remission at Week 52 and sustained clinical \\nremission (defined as clinical remission at both Weeks 8 and 52) were evaluated in Study UC-II.', 'tokens': ['Clinical', 'remission', 'Week', '52', 'sustained', 'clinical', 'remission', '(', 'defined', 'clinical', 'remission', 'Weeks', '8', '52', ')', 'evaluated', 'Study', 'UC-II', '.'], 'lemmatized': ['Clinical', 'remission', 'Week', '52', 'sustained', 'clinical', 'remission', '(', 'defined', 'clinical', 'remission', 'Weeks', '8', '52', ')', 'evaluated', 'Study', 'UC-II', '.'], 'stemmed': ['clinic', 'remiss', 'week', '52', 'sustain', 'clinic', 'remiss', '(', 'defin', 'clinic', 'remiss', 'week', '8', '52', ')', 'evalu', 'studi', 'uc-ii', '.'], 'dependencies': [('clinic', 'compound'), ('remiss', 'compound'), ('week', 'npadvmod'), ('52', 'nummod'), ('sustain', 'ROOT'), ('clinic', 'compound'), ('remiss', 'dobj'), ('(', 'punct'), ('defin', 'compound'), ('clinic', 'appos'), ('remiss', 'compound'), ('week', 'npadvmod'), ('8', 'compound'), ('52', 'nummod'), (')', 'punct'), ('evalu', 'dobj'), ('studi', 'npadvmod'), ('uc', 'npadvmod'), ('-', 'dobj'), ('ii', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'In Study UC-I, 390 TNF-blocker naïve patients were randomized to one of three treatment \\ngroups for the primary efficacy analysis.', 'tokens': ['Study', 'UC-I', ',', '390', 'TNF-blocker', 'naïve', 'patients', 'randomized', 'one', 'three', 'treatment', 'groups', 'primary', 'efficacy', 'analysis', '.'], 'lemmatized': ['Study', 'UC-I', ',', '390', 'TNF-blocker', 'naïve', 'patient', 'randomized', 'one', 'three', 'treatment', 'group', 'primary', 'efficacy', 'analysis', '.'], 'stemmed': ['studi', 'uc-i', ',', '390', 'tnf-blocker', 'naïv', 'patient', 'random', 'one', 'three', 'treatment', 'group', 'primari', 'efficaci', 'analysi', '.'], 'dependencies': [('studi', 'ROOT'), ('uc', 'meta'), ('-', 'punct'), ('i', 'dobj'), (',', 'punct'), ('390', 'nummod'), ('tnf', 'compound'), ('-', 'punct'), ('blocker', 'compound'), ('naïv', 'compound'), ('patient', 'nmod'), ('random', 'amod'), ('one', 'nummod'), ('three', 'nummod'), ('treatment', 'compound'), ('group', 'compound'), ('primari', 'compound'), ('efficaci', 'compound'), ('analysi', 'appos'), ('.', 'punct')]}, {'original_sentence': 'The placebo group received placebo at Weeks 0, 2, 4 \\nand 6.', 'tokens': ['placebo', 'group', 'received', 'placebo', 'Weeks', '0', ',', '2', ',', '4', '6', '.'], 'lemmatized': ['placebo', 'group', 'received', 'placebo', 'Weeks', '0', ',', '2', ',', '4', '6', '.'], 'stemmed': ['placebo', 'group', 'receiv', 'placebo', 'week', '0', ',', '2', ',', '4', '6', '.'], 'dependencies': [('placebo', 'compound'), ('group', 'compound'), ('receiv', 'compound'), ('placebo', 'compound'), ('week', 'ROOT'), ('0', 'nummod'), (',', 'punct'), ('2', 'nummod'), (',', 'punct'), ('4', 'nummod'), ('6', 'appos'), ('.', 'punct')]}, {'original_sentence': 'The 160/80 group received 160 mg HUMIRA at Week 0 and 80 mg at Week 2, and the \\n80/40 group received 80 mg HUMIRA at Week 0 and 40 mg at Week 2.', 'tokens': ['160/80', 'group', 'received', '160', 'mg', 'HUMIRA', 'Week', '0', '80', 'mg', 'Week', '2', ',', '80/40', 'group', 'received', '80', 'mg', 'HUMIRA', 'Week', '0', '40', 'mg', 'Week', '2', '.'], 'lemmatized': ['160/80', 'group', 'received', '160', 'mg', 'HUMIRA', 'Week', '0', '80', 'mg', 'Week', '2', ',', '80/40', 'group', 'received', '80', 'mg', 'HUMIRA', 'Week', '0', '40', 'mg', 'Week', '2', '.'], 'stemmed': ['160/80', 'group', 'receiv', '160', 'mg', 'humira', 'week', '0', '80', 'mg', 'week', '2', ',', '80/40', 'group', 'receiv', '80', 'mg', 'humira', 'week', '0', '40', 'mg', 'week', '2', '.'], 'dependencies': [('160/80', 'compound'), ('group', 'compound'), ('receiv', 'ROOT'), ('160', 'nummod'), ('mg', 'prep'), ('humira', 'conj'), ('week', 'npadvmod'), ('0', 'nummod'), ('80', 'nummod'), ('mg', 'prep'), ('week', 'pobj'), ('2', 'nummod'), (',', 'punct'), ('80/40', 'nummod'), ('group', 'compound'), ('receiv', 'appos'), ('80', 'nummod'), ('mg', 'prep'), ('humira', 'conj'), ('week', 'npadvmod'), ('0', 'nummod'), ('40', 'nummod'), ('mg', 'prep'), ('week', 'pobj'), ('2', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'After Week 2, patients \\nin both HUMIRA treatment groups received 40 mg every other week.', 'tokens': ['Week', '2', ',', 'patients', 'HUMIRA', 'treatment', 'groups', 'received', '40', 'mg', 'every', 'week', '.'], 'lemmatized': ['Week', '2', ',', 'patient', 'HUMIRA', 'treatment', 'group', 'received', '40', 'mg', 'every', 'week', '.'], 'stemmed': ['week', '2', ',', 'patient', 'humira', 'treatment', 'group', 'receiv', '40', 'mg', 'everi', 'week', '.'], 'dependencies': [('week', 'npadvmod'), ('2', 'nummod'), (',', 'punct'), ('patient', 'amod'), ('humira', 'compound'), ('treatment', 'compound'), ('group', 'compound'), ('receiv', 'ROOT'), ('40', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'In Study UC-II, 518 patients were randomized to receive either HUMIRA 160 mg at Week 0, 80 \\nmg at Week 2, and 40 mg every other week starting at Week 4 through Week 50, or placebo \\nstarting at Week 0 and every other week through Week 50.', 'tokens': ['Study', 'UC-II', ',', '518', 'patients', 'randomized', 'receive', 'either', 'HUMIRA', '160', 'mg', 'Week', '0', ',', '80', 'mg', 'Week', '2', ',', '40', 'mg', 'every', 'week', 'starting', 'Week', '4', 'Week', '50', ',', 'placebo', 'starting', 'Week', '0', 'every', 'week', 'Week', '50', '.'], 'lemmatized': ['Study', 'UC-II', ',', '518', 'patient', 'randomized', 'receive', 'either', 'HUMIRA', '160', 'mg', 'Week', '0', ',', '80', 'mg', 'Week', '2', ',', '40', 'mg', 'every', 'week', 'starting', 'Week', '4', 'Week', '50', ',', 'placebo', 'starting', 'Week', '0', 'every', 'week', 'Week', '50', '.'], 'stemmed': ['studi', 'uc-ii', ',', '518', 'patient', 'random', 'receiv', 'either', 'humira', '160', 'mg', 'week', '0', ',', '80', 'mg', 'week', '2', ',', '40', 'mg', 'everi', 'week', 'start', 'week', '4', 'week', '50', ',', 'placebo', 'start', 'week', '0', 'everi', 'week', 'week', '50', '.'], 'dependencies': [('studi', 'nmod'), ('uc', 'compound'), ('-', 'compound'), ('ii', 'appos'), (',', 'punct'), ('518', 'nummod'), ('patient', 'amod'), ('random', 'amod'), ('receiv', 'nsubj'), ('either', 'preconj'), ('humira', 'ROOT'), ('160', 'nummod'), ('mg', 'prep'), ('week', 'pobj'), ('0', 'nummod'), (',', 'punct'), ('80', 'nummod'), ('mg', 'amod'), ('week', 'npadvmod'), ('2', 'nummod'), (',', 'punct'), ('40', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'npadvmod'), ('start', 'ROOT'), ('week', 'npadvmod'), ('4', 'nummod'), ('week', 'npadvmod'), ('50', 'nummod'), (',', 'punct'), ('placebo', 'compound'), ('start', 'compound'), ('week', 'npadvmod'), ('0', 'nummod'), ('everi', 'amod'), ('week', 'compound'), ('week', 'ROOT'), ('50', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Corticosteroid taper was permitted \\nstarting at Week 8.', 'tokens': ['Corticosteroid', 'taper', 'permitted', 'starting', 'Week', '8', '.'], 'lemmatized': ['Corticosteroid', 'taper', 'permitted', 'starting', 'Week', '8', '.'], 'stemmed': ['corticosteroid', 'taper', 'permit', 'start', 'week', '8', '.'], 'dependencies': [('corticosteroid', 'amod'), ('taper', 'compound'), ('permit', 'nsubj'), ('start', 'ROOT'), ('week', 'npadvmod'), ('8', 'nummod'), ('.', 'punct')]}], 'text': 'Table 14. Clinical Remission and Clinical Response in Study PCD-I \\n  \\nLow Maintenance Dose† \\n(20 or 10 mg every other week) \\nN = 95 \\nHigh Maintenance Dose# \\n(40 or 20 mg every other week) \\nN = 93 \\nWeek 26  \\n  \\n  \\n  Clinical Remission‡ \\n28% \\n39% \\n  Clinical Response§  \\n48% \\n59% \\nWeek 52 \\n  \\n  \\n  Clinical Remission‡ \\n23% \\n33% \\n  Clinical Response§ \\n28% \\n42% \\n†The low maintenance dose was 20 mg every other week for patients weighing ≥ 40 kg and 10 \\nmg every other week for patients weighing < 40 kg. \\n#The high maintenance dose was 40 mg every other week for patients weighing ≥ 40 kg and 20 \\nmg every other week for patients weighing < 40 kg.  \\n‡Clinical remission defined as PCDAI ≤ 10. \\n§Clinical response defined as reduction in PCDAI of at least 15 points from baseline.  \\n \\n  \\n14.7 Adult Ulcerative Colitis \\nThe safety and efficacy of HUMIRA were assessed in adult patients with moderately to severely \\nactive ulcerative colitis (Mayo score 6 to 12 on a 12 point scale, with an endoscopy subscore of 2 \\nto 3 on a scale of 0 to 3) despite concurrent or prior treatment with immunosuppressants such as \\ncorticosteroids, azathioprine, or 6-MP in two randomized, double-blind, placebo-controlled \\nclinical studies (Studies UC-I and UC-II). Both studies enrolled TNF-blocker naïve patients, but \\nStudy UC-II also allowed entry of patients who lost response to or were intolerant to TNF-\\nblockers. Forty percent (40%) of patients enrolled in Study UC-II had previously used another \\nTNF-blocker.  \\nConcomitant stable doses of aminosalicylates and immunosuppressants were permitted. In \\nStudies UC-I and II, patients were receiving aminosalicylates (69%), corticosteroids (59%) \\nand/or azathioprine or 6-MP (37%) at baseline. In both studies, 92% of patients received at least \\none of these medications.  \\nInduction of clinical remission (defined as Mayo score ≤ 2 with no individual subscores > 1) at \\nWeek 8 was evaluated in both studies. Clinical remission at Week 52 and sustained clinical \\nremission (defined as clinical remission at both Weeks 8 and 52) were evaluated in Study UC-II.  \\nIn Study UC-I, 390 TNF-blocker naïve patients were randomized to one of three treatment \\ngroups for the primary efficacy analysis. The placebo group received placebo at Weeks 0, 2, 4 \\nand 6. The 160/80 group received 160 mg HUMIRA at Week 0 and 80 mg at Week 2, and the \\n80/40 group received 80 mg HUMIRA at Week 0 and 40 mg at Week 2. After Week 2, patients \\nin both HUMIRA treatment groups received 40 mg every other week.  \\nIn Study UC-II, 518 patients were randomized to receive either HUMIRA 160 mg at Week 0, 80 \\nmg at Week 2, and 40 mg every other week starting at Week 4 through Week 50, or placebo \\nstarting at Week 0 and every other week through Week 50. Corticosteroid taper was permitted \\nstarting at Week 8.  \\n'}, 'page_char_count': 2816, 'page_word_count': 466, 'sentences': ['Table 14.', 'Clinical Remission and Clinical Response in Study PCD-I \\n  \\nLow Maintenance Dose† \\n(20 or 10 mg every other week) \\nN = 95 \\nHigh Maintenance Dose# \\n(40 or 20 mg every other week) \\nN = 93 \\nWeek 26  \\n  \\n  \\n  Clinical Remission‡ \\n28% \\n39% \\n  Clinical Response§  \\n48% \\n59% \\nWeek 52 \\n  \\n  \\n  Clinical Remission‡ \\n23% \\n33% \\n  Clinical Response§ \\n28% \\n42% \\n†The low maintenance dose was 20 mg every other week for patients weighing ≥ 40 kg and 10 \\nmg every other week for patients weighing < 40 kg.', '\\n#The high maintenance dose was 40 mg every other week for patients weighing ≥ 40 kg and 20 \\nmg every other week for patients weighing < 40 kg.', ' \\n‡Clinical remission defined as PCDAI ≤ 10.', '\\n§Clinical response defined as reduction in PCDAI of at least 15 points from baseline.', ' \\n \\n  \\n14.7 Adult Ulcerative Colitis \\nThe safety and efficacy of HUMIRA were assessed in adult patients with moderately to severely \\nactive ulcerative colitis (Mayo score 6 to 12 on a 12 point scale, with an endoscopy subscore of 2 \\nto 3 on a scale of 0 to 3) despite concurrent or prior treatment with immunosuppressants such as \\ncorticosteroids, azathioprine, or 6-MP in two randomized, double-blind, placebo-controlled \\nclinical studies (Studies UC-I and UC-II).', 'Both studies enrolled TNF-blocker naïve patients, but \\nStudy UC-II also allowed entry of patients who lost response to or were intolerant to TNF-\\nblockers.', 'Forty percent (40%) of patients enrolled in Study UC-II had previously used another \\nTNF-blocker.', ' \\nConcomitant stable doses of aminosalicylates and immunosuppressants were permitted.', 'In \\nStudies UC-I and II, patients were receiving aminosalicylates (69%), corticosteroids (59%) \\nand/or azathioprine or 6-MP (37%) at baseline.', 'In both studies, 92% of patients received at least \\none of these medications.', ' \\nInduction of clinical remission (defined as Mayo score ≤ 2 with no individual subscores > 1) at \\nWeek 8 was evaluated in both studies.', 'Clinical remission at Week 52 and sustained clinical \\nremission (defined as clinical remission at both Weeks 8 and 52) were evaluated in Study UC-II.', ' \\nIn Study UC-I, 390 TNF-blocker naïve patients were randomized to one of three treatment \\ngroups for the primary efficacy analysis.', 'The placebo group received placebo at Weeks 0, 2, 4 \\nand 6.', 'The 160/80 group received 160 mg HUMIRA at Week 0 and 80 mg at Week 2, and the \\n80/40 group received 80 mg HUMIRA at Week 0 and 40 mg at Week 2.', 'After Week 2, patients \\nin both HUMIRA treatment groups received 40 mg every other week.', ' \\nIn Study UC-II, 518 patients were randomized to receive either HUMIRA 160 mg at Week 0, 80 \\nmg at Week 2, and 40 mg every other week starting at Week 4 through Week 50, or placebo \\nstarting at Week 0 and every other week through Week 50.', 'Corticosteroid taper was permitted \\nstarting at Week 8.', ' \\n'], 'page_sentence_count_spacy': 20}\n",
            "{'page_number': 46, 'text': 'In both Studies UC-I and UC-II, a greater percentage of the patients treated with 160/80 mg of \\nHUMIRA compared to patients treated with placebo achieved induction of clinical remission. In \\nStudy UC-II, a greater percentage of the patients treated with 160/80 mg of HUMIRA compared \\nto patients treated with placebo achieved sustained clinical remission (clinical remission at both \\nWeeks 8 and 52) (Table 15).  \\n \\n  \\nTable 15. Induction of Clinical Remission in Studies UC-I and UC-II and Sustained \\nClinical Remission in Study UC-II (Percent of Patients)  \\n  \\nStudy UC-I \\nStudy UC-II \\n  \\nPlacebo \\nN=130 \\nHUMIRA \\n160/80 \\nmg \\nN=130 \\nTreatment \\nDifference \\n(95% CI) \\nPlacebo \\nN=246 \\nHUMIRA \\n160/80 \\nmg \\nN=248 \\nTreatment \\nDifference  \\n(95% CI) \\nInduction of Clinical \\nRemission (Clinical \\nRemission at Week 8) \\n9.2% \\n18.5% \\n9.3%* \\n(0.9%, \\n17.6%)  \\n9.3% \\n16.5% \\n7.2%* \\n(1.2%, \\n12.9%)  \\nSustained Clinical \\nRemission (Clinical \\nRemission at both Weeks 8 \\nand 52) \\nN/A \\nN/A \\nN/A \\n4.1% \\n8.5% \\n4.4%* \\n(0.1%, 8.6%)  \\nClinical remission is defined as Mayo score ≤ 2 with no individual subscores > 1. \\nCI=Confidence interval \\n* p<0.05 for HUMIRA vs. placebo pairwise comparison of proportions  \\n \\n  \\nIn Study UC-I, there was no statistically significant difference in clinical remission observed \\nbetween the HUMIRA 80/40 mg group and the placebo group at Week 8.  \\nIn Study UC-II, 17.3% (43/248) in the HUMIRA group were in clinical remission at Week 52 \\ncompared to 8.5% (21/246) in the placebo group (treatment difference: 8.8%; 95% confidence \\ninterval (CI): [2.8%, 14.5%]; p<0.05).  \\nIn the subgroup of patients in Study UC-II with prior TNF-blocker use, the treatment difference \\nfor induction of clinical remission appeared to be lower than that seen in the whole study \\npopulation, and the treatment differences for sustained clinical remission and clinical remission \\nat Week 52 appeared to be similar to those seen in the whole study population. The subgroup of \\npatients with prior TNF-blocker use achieved induction of clinical remission at 9% (9/98) in the \\nHUMIRA group versus 7% (7/101) in the placebo group, and sustained clinical remission at 5% \\n(5/98) in the HUMIRA group versus 1% (1/101) in the placebo group. In the subgroup of \\npatients with prior TNF-blocker use, 10% (10/98) were in clinical remission at Week 52 in the \\nHUMIRA group versus 3% (3/101) in the placebo group. \\n14.8 Pediatric Ulcerative Colitis \\nThe safety and efficacy of HUMIRA were assessed in a multicenter, randomized, double-blind \\ntrial (Study PUC-I, NCT02065557) in 93 pediatric patients 5 years to 17 years of age with \\nmoderately to severely active ulcerative colitis (Mayo score 6 to 12 with endoscopy subscore of \\n', 'processed_text': {'sentences': [{'original_sentence': 'In both Studies UC-I and UC-II, a greater percentage of the patients treated with 160/80 mg of \\nHUMIRA compared to patients treated with placebo achieved induction of clinical remission.', 'tokens': ['Studies', 'UC-I', 'UC-II', ',', 'greater', 'percentage', 'patients', 'treated', '160/80', 'mg', 'HUMIRA', 'compared', 'patients', 'treated', 'placebo', 'achieved', 'induction', 'clinical', 'remission', '.'], 'lemmatized': ['Studies', 'UC-I', 'UC-II', ',', 'greater', 'percentage', 'patient', 'treated', '160/80', 'mg', 'HUMIRA', 'compared', 'patient', 'treated', 'placebo', 'achieved', 'induction', 'clinical', 'remission', '.'], 'stemmed': ['studi', 'uc-i', 'uc-ii', ',', 'greater', 'percentag', 'patient', 'treat', '160/80', 'mg', 'humira', 'compar', 'patient', 'treat', 'placebo', 'achiev', 'induct', 'clinic', 'remiss', '.'], 'dependencies': [('studi', 'npadvmod'), ('uc', 'npadvmod'), ('-', 'punct'), ('i', 'npadvmod'), ('uc', 'npadvmod'), ('-', 'npadvmod'), ('ii', 'appos'), (',', 'punct'), ('greater', 'amod'), ('percentag', 'compound'), ('patient', 'nsubj'), ('treat', 'ROOT'), ('160/80', 'nmod'), ('mg', 'nmod'), ('humira', 'compound'), ('compar', 'compound'), ('patient', 'compound'), ('treat', 'compound'), ('placebo', 'compound'), ('achiev', 'compound'), ('induct', 'compound'), ('clinic', 'compound'), ('remiss', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'In \\nStudy UC-II, a greater percentage of the patients treated with 160/80 mg of HUMIRA compared \\nto patients treated with placebo achieved sustained clinical remission (clinical remission at both \\nWeeks 8 and 52) (Table 15).', 'tokens': ['Study', 'UC-II', ',', 'greater', 'percentage', 'patients', 'treated', '160/80', 'mg', 'HUMIRA', 'compared', 'patients', 'treated', 'placebo', 'achieved', 'sustained', 'clinical', 'remission', '(', 'clinical', 'remission', 'Weeks', '8', '52', ')', '(', 'Table', '15', ')', '.'], 'lemmatized': ['Study', 'UC-II', ',', 'greater', 'percentage', 'patient', 'treated', '160/80', 'mg', 'HUMIRA', 'compared', 'patient', 'treated', 'placebo', 'achieved', 'sustained', 'clinical', 'remission', '(', 'clinical', 'remission', 'Weeks', '8', '52', ')', '(', 'Table', '15', ')', '.'], 'stemmed': ['studi', 'uc-ii', ',', 'greater', 'percentag', 'patient', 'treat', '160/80', 'mg', 'humira', 'compar', 'patient', 'treat', 'placebo', 'achiev', 'sustain', 'clinic', 'remiss', '(', 'clinic', 'remiss', 'week', '8', '52', ')', '(', 'tabl', '15', ')', '.'], 'dependencies': [('studi', 'npadvmod'), ('uc', 'compound'), ('-', 'compound'), ('ii', 'appos'), (',', 'punct'), ('greater', 'amod'), ('percentag', 'compound'), ('patient', 'nsubj'), ('treat', 'ROOT'), ('160/80', 'nmod'), ('mg', 'nmod'), ('humira', 'compound'), ('compar', 'compound'), ('patient', 'compound'), ('treat', 'compound'), ('placebo', 'compound'), ('achiev', 'dobj'), ('sustain', 'conj'), ('clinic', 'compound'), ('remiss', 'dobj'), ('(', 'punct'), ('clinic', 'compound'), ('remiss', 'compound'), ('week', 'npadvmod'), ('8', 'compound'), ('52', 'nummod'), (')', 'punct'), ('(', 'punct'), ('tabl', 'advcl'), ('15', 'nummod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Table 15.', 'tokens': ['Table', '15', '.'], 'lemmatized': ['Table', '15', '.'], 'stemmed': ['tabl', '15', '.'], 'dependencies': [('tabl', 'ROOT'), ('15', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Induction of Clinical Remission in Studies UC-I and UC-II and Sustained \\nClinical Remission in Study UC-II (Percent of Patients)  \\n  \\nStudy UC-I \\nStudy UC-II \\n  \\nPlacebo \\nN=130 \\nHUMIRA \\n160/80 \\nmg \\nN=130 \\nTreatment \\nDifference \\n(95% CI) \\nPlacebo \\nN=246 \\nHUMIRA \\n160/80 \\nmg \\nN=248 \\nTreatment \\nDifference  \\n(95% CI) \\nInduction of Clinical \\nRemission (Clinical \\nRemission at Week 8) \\n9.2% \\n18.5% \\n9.3%* \\n(0.9%, \\n17.6%)  \\n9.3% \\n16.5% \\n7.2%* \\n(1.2%, \\n12.9%)  \\nSustained Clinical \\nRemission (Clinical \\nRemission at both Weeks 8 \\nand 52) \\nN/A \\nN/A \\nN/A \\n4.1% \\n8.5% \\n4.4%* \\n(0.1%, 8.6%)  \\nClinical remission is defined as Mayo score ≤ 2 with no individual subscores > 1.', 'tokens': ['Induction', 'Clinical', 'Remission', 'Studies', 'UC-I', 'UC-II', 'Sustained', 'Clinical', 'Remission', 'Study', 'UC-II', '(', 'Percent', 'Patients', ')', 'Study', 'UC-I', 'Study', 'UC-II', 'Placebo', 'N=130', 'HUMIRA', '160/80', 'mg', 'N=130', 'Treatment', 'Difference', '(', '95', '%', 'CI', ')', 'Placebo', 'N=246', 'HUMIRA', '160/80', 'mg', 'N=248', 'Treatment', 'Difference', '(', '95', '%', 'CI', ')', 'Induction', 'Clinical', 'Remission', '(', 'Clinical', 'Remission', 'Week', '8', ')', '9.2', '%', '18.5', '%', '9.3', '%', '*', '(', '0.9', '%', ',', '17.6', '%', ')', '9.3', '%', '16.5', '%', '7.2', '%', '*', '(', '1.2', '%', ',', '12.9', '%', ')', 'Sustained', 'Clinical', 'Remission', '(', 'Clinical', 'Remission', 'Weeks', '8', '52', ')', 'N/A', 'N/A', 'N/A', '4.1', '%', '8.5', '%', '4.4', '%', '*', '(', '0.1', '%', ',', '8.6', '%', ')', 'Clinical', 'remission', 'defined', 'Mayo', 'score', '≤', '2', 'individual', 'subscores', '>', '1', '.'], 'lemmatized': ['Induction', 'Clinical', 'Remission', 'Studies', 'UC-I', 'UC-II', 'Sustained', 'Clinical', 'Remission', 'Study', 'UC-II', '(', 'Percent', 'Patients', ')', 'Study', 'UC-I', 'Study', 'UC-II', 'Placebo', 'N=130', 'HUMIRA', '160/80', 'mg', 'N=130', 'Treatment', 'Difference', '(', '95', '%', 'CI', ')', 'Placebo', 'N=246', 'HUMIRA', '160/80', 'mg', 'N=248', 'Treatment', 'Difference', '(', '95', '%', 'CI', ')', 'Induction', 'Clinical', 'Remission', '(', 'Clinical', 'Remission', 'Week', '8', ')', '9.2', '%', '18.5', '%', '9.3', '%', '*', '(', '0.9', '%', ',', '17.6', '%', ')', '9.3', '%', '16.5', '%', '7.2', '%', '*', '(', '1.2', '%', ',', '12.9', '%', ')', 'Sustained', 'Clinical', 'Remission', '(', 'Clinical', 'Remission', 'Weeks', '8', '52', ')', 'N/A', 'N/A', 'N/A', '4.1', '%', '8.5', '%', '4.4', '%', '*', '(', '0.1', '%', ',', '8.6', '%', ')', 'Clinical', 'remission', 'defined', 'Mayo', 'score', '≤', '2', 'individual', 'subscores', '>', '1', '.'], 'stemmed': ['induct', 'clinic', 'remiss', 'studi', 'uc-i', 'uc-ii', 'sustain', 'clinic', 'remiss', 'studi', 'uc-ii', '(', 'percent', 'patient', ')', 'studi', 'uc-i', 'studi', 'uc-ii', 'placebo', 'n=130', 'humira', '160/80', 'mg', 'n=130', 'treatment', 'differ', '(', '95', '%', 'ci', ')', 'placebo', 'n=246', 'humira', '160/80', 'mg', 'n=248', 'treatment', 'differ', '(', '95', '%', 'ci', ')', 'induct', 'clinic', 'remiss', '(', 'clinic', 'remiss', 'week', '8', ')', '9.2', '%', '18.5', '%', '9.3', '%', '*', '(', '0.9', '%', ',', '17.6', '%', ')', '9.3', '%', '16.5', '%', '7.2', '%', '*', '(', '1.2', '%', ',', '12.9', '%', ')', 'sustain', 'clinic', 'remiss', '(', 'clinic', 'remiss', 'week', '8', '52', ')', 'n/a', 'n/a', 'n/a', '4.1', '%', '8.5', '%', '4.4', '%', '*', '(', '0.1', '%', ',', '8.6', '%', ')', 'clinic', 'remiss', 'defin', 'mayo', 'score', '≤', '2', 'individu', 'subscor', '>', '1', '.'], 'dependencies': [('induct', 'ROOT'), ('clinic', 'compound'), ('remiss', 'compound'), ('studi', 'compound'), ('uc', 'nmod'), ('-', 'poss'), ('i', 'nmod'), ('uc', 'compound'), ('-', 'compound'), ('ii', 'compound'), ('sustain', 'compound'), ('clinic', 'compound'), ('remiss', 'compound'), ('studi', 'nmod'), ('uc', 'compound'), ('-', 'compound'), ('ii', 'appos'), ('(', 'punct'), ('percent', 'npadvmod'), ('patient', 'dobj'), (')', 'punct'), ('studi', 'npadvmod'), ('uc', 'nsubj'), ('-', 'punct'), ('i', 'nmod'), ('studi', 'nmod'), ('uc', 'compound'), ('-', 'compound'), ('ii', 'compound'), ('placebo', 'compound'), ('n=130', 'compound'), ('humira', 'compound'), ('160/80', 'appos'), ('mg', 'prep'), ('n=130', 'compound'), ('treatment', 'pobj'), ('differ', 'ROOT'), ('(', 'punct'), ('95', 'nummod'), ('%', 'compound'), ('ci', 'appos'), (')', 'punct'), ('placebo', 'compound'), ('n=246', 'nsubj'), ('humira', 'dobj'), ('160/80', 'appos'), ('mg', 'prep'), ('n=248', 'compound'), ('treatment', 'nsubj'), ('differ', 'ccomp'), ('(', 'punct'), ('95', 'nummod'), ('%', 'compound'), ('ci', 'dobj'), (')', 'punct'), ('induct', 'conj'), ('clinic', 'compound'), ('remiss', 'dobj'), ('(', 'punct'), ('clinic', 'compound'), ('remiss', 'compound'), ('week', 'appos'), ('8', 'nummod'), (')', 'punct'), ('9.2', 'nummod'), ('%', 'appos'), ('18.5', 'nummod'), ('%', 'appos'), ('9.3', 'nummod'), ('%', 'appos'), ('*', 'punct'), ('(', 'punct'), ('0.9', 'nummod'), ('%', 'appos'), (',', 'punct'), ('17.6', 'nummod'), ('%', 'appos'), (')', 'punct'), ('9.3', 'nummod'), ('%', 'appos'), ('16.5', 'nummod'), ('%', 'appos'), ('7.2', 'nummod'), ('%', 'appos'), ('*', 'punct'), ('(', 'punct'), ('1.2', 'nummod'), ('%', 'nsubj'), (',', 'punct'), ('12.9', 'nummod'), ('%', 'appos'), (')', 'punct'), ('sustain', 'conj'), ('clinic', 'compound'), ('remiss', 'dobj'), ('(', 'punct'), ('clinic', 'amod'), ('remiss', 'compound'), ('week', 'npadvmod'), ('8', 'compound'), ('52', 'nummod'), (')', 'punct'), ('n', 'cc'), ('/', 'punct'), ('a', 'dobj'), ('n', 'cc'), ('/', 'punct'), ('a', 'conj'), ('n', 'dobj'), ('/', 'punct'), ('a', 'det'), ('4.1', 'nummod'), ('%', 'dobj'), ('8.5', 'nummod'), ('%', 'appos'), ('4.4', 'nummod'), ('%', 'appos'), ('*', 'punct'), ('(', 'punct'), ('0.1', 'nummod'), ('%', 'parataxis'), (',', 'punct'), ('8.6', 'nummod'), ('%', 'appos'), (')', 'punct'), ('clinic', 'nmod'), ('remiss', 'compound'), ('defin', 'compound'), ('mayo', 'compound'), ('score', 'compound'), ('≤', 'appos'), ('2', 'nummod'), ('individu', 'nmod'), ('subscor', 'appos'), ('>', 'nmod'), ('1', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'CI=Confidence interval \\n* p<0.05 for HUMIRA vs. placebo pairwise comparison of proportions  \\n \\n  \\nIn Study UC-I, there was no statistically significant difference in clinical remission observed \\nbetween the HUMIRA 80/40 mg group and the placebo group at Week 8.', 'tokens': ['CI=Confidence', 'interval', '*', 'p', '<', '0.05', 'HUMIRA', 'vs.', 'placebo', 'pairwise', 'comparison', 'proportions', 'Study', 'UC-I', ',', 'statistically', 'significant', 'difference', 'clinical', 'remission', 'observed', 'HUMIRA', '80/40', 'mg', 'group', 'placebo', 'group', 'Week', '8', '.'], 'lemmatized': ['CI=Confidence', 'interval', '*', 'p', '<', '0.05', 'HUMIRA', 'vs.', 'placebo', 'pairwise', 'comparison', 'proportion', 'Study', 'UC-I', ',', 'statistically', 'significant', 'difference', 'clinical', 'remission', 'observed', 'HUMIRA', '80/40', 'mg', 'group', 'placebo', 'group', 'Week', '8', '.'], 'stemmed': ['ci=confid', 'interv', '*', 'p', '<', '0.05', 'humira', 'vs.', 'placebo', 'pairwis', 'comparison', 'proport', 'studi', 'uc-i', ',', 'statist', 'signific', 'differ', 'clinic', 'remiss', 'observ', 'humira', '80/40', 'mg', 'group', 'placebo', 'group', 'week', '8', '.'], 'dependencies': [('ci', 'compound'), ('=', 'nsubj'), ('confid', 'amod'), ('interv', 'nmod'), ('*', 'punct'), ('p', 'quantmod'), ('<', 'dep'), ('0.05', 'nummod'), ('humira', 'nmod'), ('vs.', 'prep'), ('placebo', 'compound'), ('pairwis', 'pobj'), ('comparison', 'compound'), ('proport', 'appos'), ('studi', 'npadvmod'), ('uc', 'punct'), ('-', 'punct'), ('i', 'dobj'), (',', 'punct'), ('statist', 'amod'), ('signific', 'nsubj'), ('differ', 'ROOT'), ('clinic', 'compound'), ('remiss', 'compound'), ('observ', 'compound'), ('humira', 'compound'), ('80/40', 'compound'), ('mg', 'compound'), ('group', 'compound'), ('placebo', 'compound'), ('group', 'compound'), ('week', 'npadvmod'), ('8', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'In Study UC-II, 17.3% (43/248) in the HUMIRA group were in clinical remission at Week 52 \\ncompared to 8.5% (21/246) in the placebo group (treatment difference: 8.8%; 95% confidence \\ninterval (CI): [2.8%, 14.5%]; p<0.05).', 'tokens': ['Study', 'UC-II', ',', '17.3', '%', '(', '43/248', ')', 'HUMIRA', 'group', 'clinical', 'remission', 'Week', '52', 'compared', '8.5', '%', '(', '21/246', ')', 'placebo', 'group', '(', 'treatment', 'difference', ':', '8.8', '%', ';', '95', '%', 'confidence', 'interval', '(', 'CI', ')', ':', '[', '2.8', '%', ',', '14.5', '%', ']', ';', 'p', '<', '0.05', ')', '.'], 'lemmatized': ['Study', 'UC-II', ',', '17.3', '%', '(', '43/248', ')', 'HUMIRA', 'group', 'clinical', 'remission', 'Week', '52', 'compared', '8.5', '%', '(', '21/246', ')', 'placebo', 'group', '(', 'treatment', 'difference', ':', '8.8', '%', ';', '95', '%', 'confidence', 'interval', '(', 'CI', ')', ':', '[', '2.8', '%', ',', '14.5', '%', ']', ';', 'p', '<', '0.05', ')', '.'], 'stemmed': ['studi', 'uc-ii', ',', '17.3', '%', '(', '43/248', ')', 'humira', 'group', 'clinic', 'remiss', 'week', '52', 'compar', '8.5', '%', '(', '21/246', ')', 'placebo', 'group', '(', 'treatment', 'differ', ':', '8.8', '%', ';', '95', '%', 'confid', 'interv', '(', 'ci', ')', ':', '[', '2.8', '%', ',', '14.5', '%', ']', ';', 'p', '<', '0.05', ')', '.'], 'dependencies': [('studi', 'compound'), ('uc', 'compound'), ('-', 'compound'), ('ii', 'dep'), (',', 'punct'), ('17.3', 'nummod'), ('%', 'nmod'), ('(', 'punct'), ('43/248', 'appos'), (')', 'punct'), ('humira', 'compound'), ('group', 'compound'), ('clinic', 'nmod'), ('remiss', 'compound'), ('week', 'npadvmod'), ('52', 'nummod'), ('compar', 'npadvmod'), ('8.5', 'nummod'), ('%', 'appos'), ('(', 'punct'), ('21/246', 'nummod'), (')', 'punct'), ('placebo', 'compound'), ('group', 'appos'), ('(', 'punct'), ('treatment', 'nsubj'), ('differ', 'ROOT'), (':', 'punct'), ('8.8', 'nummod'), ('%', 'appos'), (';', 'punct'), ('95', 'nummod'), ('%', 'appos'), ('confid', 'amod'), ('interv', 'appos'), ('(', 'punct'), ('ci', 'appos'), (')', 'punct'), (':', 'punct'), ('[', 'punct'), ('2.8', 'nummod'), ('%', 'ROOT'), (',', 'punct'), ('14.5', 'nummod'), ('%', 'appos'), (']', 'punct'), (';', 'punct'), ('p', 'appos'), ('<', 'dep'), ('0.05', 'nummod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'In the subgroup of patients in Study UC-II with prior TNF-blocker use, the treatment difference \\nfor induction of clinical remission appeared to be lower than that seen in the whole study \\npopulation, and the treatment differences for sustained clinical remission and clinical remission \\nat Week 52 appeared to be similar to those seen in the whole study population.', 'tokens': ['subgroup', 'patients', 'Study', 'UC-II', 'prior', 'TNF-blocker', 'use', ',', 'treatment', 'difference', 'induction', 'clinical', 'remission', 'appeared', 'lower', 'seen', 'whole', 'study', 'population', ',', 'treatment', 'differences', 'sustained', 'clinical', 'remission', 'clinical', 'remission', 'Week', '52', 'appeared', 'similar', 'seen', 'whole', 'study', 'population', '.'], 'lemmatized': ['subgroup', 'patient', 'Study', 'UC-II', 'prior', 'TNF-blocker', 'use', ',', 'treatment', 'difference', 'induction', 'clinical', 'remission', 'appeared', 'lower', 'seen', 'whole', 'study', 'population', ',', 'treatment', 'difference', 'sustained', 'clinical', 'remission', 'clinical', 'remission', 'Week', '52', 'appeared', 'similar', 'seen', 'whole', 'study', 'population', '.'], 'stemmed': ['subgroup', 'patient', 'studi', 'uc-ii', 'prior', 'tnf-blocker', 'use', ',', 'treatment', 'differ', 'induct', 'clinic', 'remiss', 'appear', 'lower', 'seen', 'whole', 'studi', 'popul', ',', 'treatment', 'differ', 'sustain', 'clinic', 'remiss', 'clinic', 'remiss', 'week', '52', 'appear', 'similar', 'seen', 'whole', 'studi', 'popul', '.'], 'dependencies': [('subgroup', 'compound'), ('patient', 'compound'), ('studi', 'compound'), ('uc', 'compound'), ('-', 'nmod'), ('ii', 'punct'), ('prior', 'amod'), ('tnf', 'compound'), ('-', 'punct'), ('blocker', 'compound'), ('use', 'npadvmod'), (',', 'punct'), ('treatment', 'nsubj'), ('differ', 'ccomp'), ('induct', 'amod'), ('clinic', 'compound'), ('remiss', 'dobj'), ('appear', 'advcl'), ('lower', 'advmod'), ('seen', 'amod'), ('whole', 'amod'), ('studi', 'compound'), ('popul', 'oprd'), (',', 'punct'), ('treatment', 'nsubj'), ('differ', 'ROOT'), ('sustain', 'advcl'), ('clinic', 'compound'), ('remiss', 'compound'), ('clinic', 'dobj'), ('remiss', 'compound'), ('week', 'npadvmod'), ('52', 'nummod'), ('appear', 'advcl'), ('similar', 'amod'), ('seen', 'amod'), ('whole', 'amod'), ('studi', 'compound'), ('popul', 'oprd'), ('.', 'punct')]}, {'original_sentence': 'The subgroup of \\npatients with prior TNF-blocker use achieved induction of clinical remission at 9% (9/98) in the \\nHUMIRA group versus 7% (7/101) in the placebo group, and sustained clinical remission at 5% \\n(5/98) in the HUMIRA group versus 1% (1/101) in the placebo group.', 'tokens': ['subgroup', 'patients', 'prior', 'TNF-blocker', 'use', 'achieved', 'induction', 'clinical', 'remission', '9', '%', '(', '9/98', ')', 'HUMIRA', 'group', 'versus', '7', '%', '(', '7/101', ')', 'placebo', 'group', ',', 'sustained', 'clinical', 'remission', '5', '%', '(', '5/98', ')', 'HUMIRA', 'group', 'versus', '1', '%', '(', '1/101', ')', 'placebo', 'group', '.'], 'lemmatized': ['subgroup', 'patient', 'prior', 'TNF-blocker', 'use', 'achieved', 'induction', 'clinical', 'remission', '9', '%', '(', '9/98', ')', 'HUMIRA', 'group', 'versus', '7', '%', '(', '7/101', ')', 'placebo', 'group', ',', 'sustained', 'clinical', 'remission', '5', '%', '(', '5/98', ')', 'HUMIRA', 'group', 'versus', '1', '%', '(', '1/101', ')', 'placebo', 'group', '.'], 'stemmed': ['subgroup', 'patient', 'prior', 'tnf-blocker', 'use', 'achiev', 'induct', 'clinic', 'remiss', '9', '%', '(', '9/98', ')', 'humira', 'group', 'versu', '7', '%', '(', '7/101', ')', 'placebo', 'group', ',', 'sustain', 'clinic', 'remiss', '5', '%', '(', '5/98', ')', 'humira', 'group', 'versu', '1', '%', '(', '1/101', ')', 'placebo', 'group', '.'], 'dependencies': [('subgroup', 'compound'), ('patient', 'nsubj'), ('prior', 'amod'), ('tnf', 'compound'), ('-', 'punct'), ('blocker', 'compound'), ('use', 'nmod'), ('achiev', 'compound'), ('induct', 'compound'), ('clinic', 'appos'), ('remiss', 'nsubj'), ('9', 'nummod'), ('%', 'npadvmod'), ('(', 'punct'), ('9/98', 'nummod'), (')', 'punct'), ('humira', 'compound'), ('group', 'compound'), ('versu', 'appos'), ('7', 'nummod'), ('%', 'appos'), ('(', 'punct'), ('7/101', 'appos'), (')', 'punct'), ('placebo', 'compound'), ('group', 'appos'), (',', 'punct'), ('sustain', 'ROOT'), ('clinic', 'dobj'), ('remiss', 'dobj'), ('5', 'nummod'), ('%', 'npadvmod'), ('(', 'punct'), ('5/98', 'nummod'), (')', 'punct'), ('humira', 'compound'), ('group', 'appos'), ('versu', 'dobj'), ('1', 'nummod'), ('%', 'appos'), ('(', 'punct'), ('1/101', 'nummod'), (')', 'punct'), ('placebo', 'compound'), ('group', 'appos'), ('.', 'punct')]}, {'original_sentence': 'In the subgroup of \\npatients with prior TNF-blocker use, 10% (10/98) were in clinical remission at Week 52 in the \\nHUMIRA group versus 3% (3/101) in the placebo group.', 'tokens': ['subgroup', 'patients', 'prior', 'TNF-blocker', 'use', ',', '10', '%', '(', '10/98', ')', 'clinical', 'remission', 'Week', '52', 'HUMIRA', 'group', 'versus', '3', '%', '(', '3/101', ')', 'placebo', 'group', '.'], 'lemmatized': ['subgroup', 'patient', 'prior', 'TNF-blocker', 'use', ',', '10', '%', '(', '10/98', ')', 'clinical', 'remission', 'Week', '52', 'HUMIRA', 'group', 'versus', '3', '%', '(', '3/101', ')', 'placebo', 'group', '.'], 'stemmed': ['subgroup', 'patient', 'prior', 'tnf-blocker', 'use', ',', '10', '%', '(', '10/98', ')', 'clinic', 'remiss', 'week', '52', 'humira', 'group', 'versu', '3', '%', '(', '3/101', ')', 'placebo', 'group', '.'], 'dependencies': [('subgroup', 'compound'), ('patient', 'ROOT'), ('prior', 'amod'), ('tnf', 'compound'), ('-', 'punct'), ('blocker', 'compound'), ('use', 'appos'), (',', 'punct'), ('10', 'nummod'), ('%', 'npadvmod'), ('(', 'punct'), ('10/98', 'nummod'), (')', 'punct'), ('clinic', 'nmod'), ('remiss', 'nmod'), ('week', 'appos'), ('52', 'nummod'), ('humira', 'compound'), ('group', 'nsubj'), ('versu', 'appos'), ('3', 'nummod'), ('%', 'appos'), ('(', 'punct'), ('3/101', 'nummod'), (')', 'punct'), ('placebo', 'compound'), ('group', 'appos'), ('.', 'punct')]}, {'original_sentence': '14.8 Pediatric Ulcerative Colitis \\nThe safety and efficacy of HUMIRA were assessed in a multicenter, randomized, double-blind \\ntrial (Study PUC-I, NCT02065557) in 93 pediatric patients 5 years to 17 years of age with \\nmoderately to severely active ulcerative colitis (Mayo score 6 to 12 with endoscopy subscore of', 'tokens': ['14.8', 'Pediatric', 'Ulcerative', 'Colitis', 'safety', 'efficacy', 'HUMIRA', 'assessed', 'multicenter', ',', 'randomized', ',', 'double-blind', 'trial', '(', 'Study', 'PUC-I', ',', 'NCT02065557', ')', '93', 'pediatric', 'patients', '5', 'years', '17', 'years', 'age', 'moderately', 'severely', 'active', 'ulcerative', 'colitis', '(', 'Mayo', 'score', '6', '12', 'endoscopy', 'subscore'], 'lemmatized': ['14.8', 'Pediatric', 'Ulcerative', 'Colitis', 'safety', 'efficacy', 'HUMIRA', 'assessed', 'multicenter', ',', 'randomized', ',', 'double-blind', 'trial', '(', 'Study', 'PUC-I', ',', 'NCT02065557', ')', '93', 'pediatric', 'patient', '5', 'year', '17', 'year', 'age', 'moderately', 'severely', 'active', 'ulcerative', 'colitis', '(', 'Mayo', 'score', '6', '12', 'endoscopy', 'subscore'], 'stemmed': ['14.8', 'pediatr', 'ulcer', 'coliti', 'safeti', 'efficaci', 'humira', 'assess', 'multicent', ',', 'random', ',', 'double-blind', 'trial', '(', 'studi', 'puc-i', ',', 'nct02065557', ')', '93', 'pediatr', 'patient', '5', 'year', '17', 'year', 'age', 'moder', 'sever', 'activ', 'ulcer', 'coliti', '(', 'mayo', 'score', '6', '12', 'endoscopi', 'subscor'], 'dependencies': [('14.8', 'nummod'), ('pediatr', 'amod'), ('ulcer', 'compound'), ('coliti', 'compound'), ('safeti', 'compound'), ('efficaci', 'compound'), ('humira', 'compound'), ('assess', 'compound'), ('multicent', 'nsubj'), (',', 'punct'), ('random', 'amod'), (',', 'punct'), ('double', 'amod'), ('-', 'punct'), ('blind', 'amod'), ('trial', 'appos'), ('(', 'punct'), ('studi', 'compound'), ('puc', 'compound'), ('-', 'punct'), ('i', 'appos'), (',', 'punct'), ('nct02065557', 'appos'), (')', 'punct'), ('93', 'nummod'), ('pediatr', 'amod'), ('patient', 'appos'), ('5', 'nummod'), ('year', 'npadvmod'), ('17', 'nummod'), ('year', 'compound'), ('age', 'compound'), ('moder', 'appos'), ('sever', 'ROOT'), ('activ', 'compound'), ('ulcer', 'compound'), ('coliti', 'dobj'), ('(', 'punct'), ('mayo', 'compound'), ('score', 'appos'), ('6', 'nummod'), ('12', 'nummod'), ('endoscopi', 'compound'), ('subscor', 'npadvmod')]}], 'text': 'In both Studies UC-I and UC-II, a greater percentage of the patients treated with 160/80 mg of \\nHUMIRA compared to patients treated with placebo achieved induction of clinical remission. In \\nStudy UC-II, a greater percentage of the patients treated with 160/80 mg of HUMIRA compared \\nto patients treated with placebo achieved sustained clinical remission (clinical remission at both \\nWeeks 8 and 52) (Table 15).  \\n \\n  \\nTable 15. Induction of Clinical Remission in Studies UC-I and UC-II and Sustained \\nClinical Remission in Study UC-II (Percent of Patients)  \\n  \\nStudy UC-I \\nStudy UC-II \\n  \\nPlacebo \\nN=130 \\nHUMIRA \\n160/80 \\nmg \\nN=130 \\nTreatment \\nDifference \\n(95% CI) \\nPlacebo \\nN=246 \\nHUMIRA \\n160/80 \\nmg \\nN=248 \\nTreatment \\nDifference  \\n(95% CI) \\nInduction of Clinical \\nRemission (Clinical \\nRemission at Week 8) \\n9.2% \\n18.5% \\n9.3%* \\n(0.9%, \\n17.6%)  \\n9.3% \\n16.5% \\n7.2%* \\n(1.2%, \\n12.9%)  \\nSustained Clinical \\nRemission (Clinical \\nRemission at both Weeks 8 \\nand 52) \\nN/A \\nN/A \\nN/A \\n4.1% \\n8.5% \\n4.4%* \\n(0.1%, 8.6%)  \\nClinical remission is defined as Mayo score ≤ 2 with no individual subscores > 1. \\nCI=Confidence interval \\n* p<0.05 for HUMIRA vs. placebo pairwise comparison of proportions  \\n \\n  \\nIn Study UC-I, there was no statistically significant difference in clinical remission observed \\nbetween the HUMIRA 80/40 mg group and the placebo group at Week 8.  \\nIn Study UC-II, 17.3% (43/248) in the HUMIRA group were in clinical remission at Week 52 \\ncompared to 8.5% (21/246) in the placebo group (treatment difference: 8.8%; 95% confidence \\ninterval (CI): [2.8%, 14.5%]; p<0.05).  \\nIn the subgroup of patients in Study UC-II with prior TNF-blocker use, the treatment difference \\nfor induction of clinical remission appeared to be lower than that seen in the whole study \\npopulation, and the treatment differences for sustained clinical remission and clinical remission \\nat Week 52 appeared to be similar to those seen in the whole study population. The subgroup of \\npatients with prior TNF-blocker use achieved induction of clinical remission at 9% (9/98) in the \\nHUMIRA group versus 7% (7/101) in the placebo group, and sustained clinical remission at 5% \\n(5/98) in the HUMIRA group versus 1% (1/101) in the placebo group. In the subgroup of \\npatients with prior TNF-blocker use, 10% (10/98) were in clinical remission at Week 52 in the \\nHUMIRA group versus 3% (3/101) in the placebo group. \\n14.8 Pediatric Ulcerative Colitis \\nThe safety and efficacy of HUMIRA were assessed in a multicenter, randomized, double-blind \\ntrial (Study PUC-I, NCT02065557) in 93 pediatric patients 5 years to 17 years of age with \\nmoderately to severely active ulcerative colitis (Mayo score 6 to 12 with endoscopy subscore of \\n'}, 'page_char_count': 2706, 'page_word_count': 414, 'sentences': ['In both Studies UC-I and UC-II, a greater percentage of the patients treated with 160/80 mg of \\nHUMIRA compared to patients treated with placebo achieved induction of clinical remission.', 'In \\nStudy UC-II, a greater percentage of the patients treated with 160/80 mg of HUMIRA compared \\nto patients treated with placebo achieved sustained clinical remission (clinical remission at both \\nWeeks 8 and 52) (Table 15).', ' \\n \\n  \\nTable 15.', 'Induction of Clinical Remission in Studies UC-I and UC-II and Sustained \\nClinical Remission in Study UC-II (Percent of Patients)  \\n  \\nStudy UC-I \\nStudy UC-II \\n  \\nPlacebo \\nN=130 \\nHUMIRA \\n160/80 \\nmg \\nN=130 \\nTreatment \\nDifference \\n(95% CI) \\nPlacebo \\nN=246 \\nHUMIRA \\n160/80 \\nmg \\nN=248 \\nTreatment \\nDifference  \\n(95% CI) \\nInduction of Clinical \\nRemission (Clinical \\nRemission at Week 8) \\n9.2% \\n18.5% \\n9.3%* \\n(0.9%, \\n17.6%)  \\n9.3% \\n16.5% \\n7.2%* \\n(1.2%, \\n12.9%)  \\nSustained Clinical \\nRemission (Clinical \\nRemission at both Weeks 8 \\nand 52) \\nN/A \\nN/A \\nN/A \\n4.1% \\n8.5% \\n4.4%* \\n(0.1%, 8.6%)  \\nClinical remission is defined as Mayo score ≤ 2 with no individual subscores > 1.', '\\nCI=Confidence interval \\n* p<0.05 for HUMIRA vs. placebo pairwise comparison of proportions  \\n \\n  \\nIn Study UC-I, there was no statistically significant difference in clinical remission observed \\nbetween the HUMIRA 80/40 mg group and the placebo group at Week 8.', ' \\nIn Study UC-II, 17.3% (43/248) in the HUMIRA group were in clinical remission at Week 52 \\ncompared to 8.5% (21/246) in the placebo group (treatment difference: 8.8%; 95% confidence \\ninterval (CI): [2.8%, 14.5%]; p<0.05).', ' \\nIn the subgroup of patients in Study UC-II with prior TNF-blocker use, the treatment difference \\nfor induction of clinical remission appeared to be lower than that seen in the whole study \\npopulation, and the treatment differences for sustained clinical remission and clinical remission \\nat Week 52 appeared to be similar to those seen in the whole study population.', 'The subgroup of \\npatients with prior TNF-blocker use achieved induction of clinical remission at 9% (9/98) in the \\nHUMIRA group versus 7% (7/101) in the placebo group, and sustained clinical remission at 5% \\n(5/98) in the HUMIRA group versus 1% (1/101) in the placebo group.', 'In the subgroup of \\npatients with prior TNF-blocker use, 10% (10/98) were in clinical remission at Week 52 in the \\nHUMIRA group versus 3% (3/101) in the placebo group.', '\\n14.8 Pediatric Ulcerative Colitis \\nThe safety and efficacy of HUMIRA were assessed in a multicenter, randomized, double-blind \\ntrial (Study PUC-I, NCT02065557) in 93 pediatric patients 5 years to 17 years of age with \\nmoderately to severely active ulcerative colitis (Mayo score 6 to 12 with endoscopy subscore of \\n'], 'page_sentence_count_spacy': 10}\n",
            "{'page_number': 47, 'text': '2 to 3 points, confirmed by centrally read endoscopy) who had an inadequate response or \\nintolerance to therapy with corticosteroids and/or an immunomodulator (i.e., azathioprine, 6-\\nmercaptopurine, or methotrexate). Fifteen out of 93 patients (16%) in the study had prior \\nexperience with a TNF blocker. Patients who received corticosteroids at enrollment were \\nallowed to taper their corticosteroid therapy after Week 4. \\nSeventy-seven patients were initially randomized 3:2 to receive double-blind treatment with one \\nof two dosages of HUMIRA. Patients in both dosage groups received 2.4 mg/kg (maximum of \\n160 mg) at Week 0, 1.2 mg/kg (maximum of 80 mg) at Week 2, and 0.6 mg/kg (maximum of 40 \\nmg) at Weeks 4 and 6.  The higher dosage group also received an additional dosage of 2.4 mg/kg \\n(maximum of 160 mg) at Week 1. Following an amendment to the study design, 16 additional \\npatients were enrolled and received open-label treatment with HUMIRA at the higher dosage.   \\nAt Week 8, 62 patients who demonstrated clinical response per Partial Mayo Score (PMS; a \\nsubset of the Mayo score with no endoscopic component and defined as a decrease in PMS ≥ 2 \\npoints and ≥ 30% from baseline) were randomized equally to receive double-blind treatment \\nwith HUMIRA 0.6 mg/kg (maximum of 40 mg) every other week (lower dosage group), or 0.6 \\nmg/kg (maximum of 40 mg) every week (higher dosage group). Prior to an amendment to the \\nstudy design, 12 additional patients who demonstrated clinical response per PMS were \\nrandomized to receive placebo. \\nThere are no anticipated clinically relevant differences in efficacy between the studied higher \\ndosage administered during the 52-week PUC-I trial and the recommended dosage of HUMIRA \\n[see Dosage and Administration (2.4), Clinical Pharmacology (12.2)]. \\nPatients who met criteria for disease flare at or after Week 12 were randomized to receive a re-\\ninduction dose of 2.4 mg/kg (maximum of 160 mg) or a dose of 0.6 mg/kg (maximum of 40 mg) \\nand then continued the dose to which they were randomized at Week 8. \\nThe co-primary endpoints of the study were clinical remission per PMS (defined as PMS ≤ 2 and \\nno individual subscore > 1) at Week 8, and clinical remission per the Mayo Score (defined as \\nMayo Score ≤ 2 and no individual subscore > 1) at Week 52 in patients who achieved clinical \\nresponse per PMS at Week 8.  Secondary endpoints included Mayo Score response (defined as a \\ndecrease in Mayo Score of ≥ 3 points and ≥ 30% from baseline) at Week 52 in Week 8 PMS \\nresponders, endoscopic improvement (defined as a Mayo endoscopy subscore ≤ 1) at Week 52 in \\nWeek 8 PMS responders, and Mayo Score remission at Week 52 in Week 8 PMS remitters.  \\nWeek 8 Results \\nAt Week 8, PMS remission was achieved by 60% [28/47; 95% confidence interval (CI): (44%, \\n74%)] of patients in the higher dosage group (not including the 16 patients receiving open-label \\nhigher dosage) and 43% [13/30; 95% CI: (25%, 63%)] of patients in the lower dosage group. \\nResults from the higher dosage group are representative of the results expected with the \\nrecommended dosage [see Dosage and Administration (2.4), Clinical Pharmacology (12.2)].   \\nWeek 52 Results  \\nAt Week 52, endpoints were assessed in the population of patients who received double-blind \\nplacebo, HUMIRA 0.6 mg/kg (maximum of 40 mg) every other week, or HUMIRA 0.6 mg/kg \\n(maximum of 40 mg) every week between Week 8 and Week 52 (Table 16). \\n \\n \\n', 'processed_text': {'sentences': [{'original_sentence': '2 to 3 points, confirmed by centrally read endoscopy) who had an inadequate response or \\nintolerance to therapy with corticosteroids and/or an immunomodulator (i.e., azathioprine, 6-\\nmercaptopurine, or methotrexate).', 'tokens': ['2', '3', 'points', ',', 'confirmed', 'centrally', 'read', 'endoscopy', ')', 'inadequate', 'response', 'intolerance', 'therapy', 'corticosteroids', 'and/or', 'immunomodulator', '(', 'i.e.', ',', 'azathioprine', ',', '6-', 'mercaptopurine', ',', 'methotrexate', ')', '.'], 'lemmatized': ['2', '3', 'point', ',', 'confirmed', 'centrally', 'read', 'endoscopy', ')', 'inadequate', 'response', 'intolerance', 'therapy', 'corticosteroid', 'and/or', 'immunomodulator', '(', 'i.e.', ',', 'azathioprine', ',', '6-', 'mercaptopurine', ',', 'methotrexate', ')', '.'], 'stemmed': ['2', '3', 'point', ',', 'confirm', 'central', 'read', 'endoscopi', ')', 'inadequ', 'respons', 'intoler', 'therapi', 'corticosteroid', 'and/or', 'immunomodul', '(', 'i.e.', ',', 'azathioprin', ',', '6-', 'mercaptopurin', ',', 'methotrex', ')', '.'], 'dependencies': [('2', 'nummod'), ('3', 'nummod'), ('point', 'npadvmod'), (',', 'punct'), ('confirm', 'ccomp'), ('central', 'amod'), ('read', 'compound'), ('endoscopi', 'dobj'), (')', 'punct'), ('inadequ', 'compound'), ('respons', 'compound'), ('intoler', 'nsubj'), ('therapi', 'ROOT'), ('corticosteroid', 'dobj'), ('and/or', 'cc'), ('immunomodul', 'conj'), ('(', 'punct'), ('i.e.', 'advmod'), (',', 'punct'), ('azathioprin', 'nmod'), (',', 'punct'), ('6-', 'nummod'), ('mercaptopurin', 'conj'), (',', 'punct'), ('methotrex', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Fifteen out of 93 patients (16%) in the study had prior \\nexperience with a TNF blocker.', 'tokens': ['Fifteen', '93', 'patients', '(', '16', '%', ')', 'study', 'prior', 'experience', 'TNF', 'blocker', '.'], 'lemmatized': ['Fifteen', '93', 'patient', '(', '16', '%', ')', 'study', 'prior', 'experience', 'TNF', 'blocker', '.'], 'stemmed': ['fifteen', '93', 'patient', '(', '16', '%', ')', 'studi', 'prior', 'experi', 'tnf', 'blocker', '.'], 'dependencies': [('fifteen', 'compound'), ('93', 'nummod'), ('patient', 'ROOT'), ('(', 'punct'), ('16', 'nummod'), ('%', 'appos'), (')', 'punct'), ('studi', 'nmod'), ('prior', 'amod'), ('experi', 'compound'), ('tnf', 'compound'), ('blocker', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Patients who received corticosteroids at enrollment were \\nallowed to taper their corticosteroid therapy after Week 4.', 'tokens': ['Patients', 'received', 'corticosteroids', 'enrollment', 'allowed', 'taper', 'corticosteroid', 'therapy', 'Week', '4', '.'], 'lemmatized': ['Patients', 'received', 'corticosteroid', 'enrollment', 'allowed', 'taper', 'corticosteroid', 'therapy', 'Week', '4', '.'], 'stemmed': ['patient', 'receiv', 'corticosteroid', 'enrol', 'allow', 'taper', 'corticosteroid', 'therapi', 'week', '4', '.'], 'dependencies': [('patient', 'amod'), ('receiv', 'compound'), ('corticosteroid', 'compound'), ('enrol', 'nsubj'), ('allow', 'ROOT'), ('taper', 'dobj'), ('corticosteroid', 'amod'), ('therapi', 'amod'), ('week', 'npadvmod'), ('4', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Seventy-seven patients were initially randomized 3:2 to receive double-blind treatment with one \\nof two dosages of HUMIRA.', 'tokens': ['Seventy-seven', 'patients', 'initially', 'randomized', '3:2', 'receive', 'double-blind', 'treatment', 'one', 'two', 'dosages', 'HUMIRA', '.'], 'lemmatized': ['Seventy-seven', 'patient', 'initially', 'randomized', '3:2', 'receive', 'double-blind', 'treatment', 'one', 'two', 'dosage', 'HUMIRA', '.'], 'stemmed': ['seventy-seven', 'patient', 'initi', 'random', '3:2', 'receiv', 'double-blind', 'treatment', 'one', 'two', 'dosag', 'humira', '.'], 'dependencies': [('seventy', 'compound'), ('-', 'punct'), ('seven', 'nummod'), ('patient', 'amod'), ('initi', 'ROOT'), ('random', 'amod'), ('3:2', 'nummod'), ('receiv', 'nmod'), ('double', 'amod'), ('-', 'punct'), ('blind', 'amod'), ('treatment', 'appos'), ('one', 'nummod'), ('two', 'nummod'), ('dosag', 'compound'), ('humira', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Patients in both dosage groups received 2.4 mg/kg (maximum of \\n160 mg) at Week 0, 1.2 mg/kg (maximum of 80 mg) at Week 2, and 0.6 mg/kg (maximum of 40 \\nmg) at Weeks 4 and 6.', 'tokens': ['Patients', 'dosage', 'groups', 'received', '2.4', 'mg/kg', '(', 'maximum', '160', 'mg', ')', 'Week', '0', ',', '1.2', 'mg/kg', '(', 'maximum', '80', 'mg', ')', 'Week', '2', ',', '0.6', 'mg/kg', '(', 'maximum', '40', 'mg', ')', 'Weeks', '4', '6', '.'], 'lemmatized': ['Patients', 'dosage', 'group', 'received', '2.4', 'mg/kg', '(', 'maximum', '160', 'mg', ')', 'Week', '0', ',', '1.2', 'mg/kg', '(', 'maximum', '80', 'mg', ')', 'Week', '2', ',', '0.6', 'mg/kg', '(', 'maximum', '40', 'mg', ')', 'Weeks', '4', '6', '.'], 'stemmed': ['patient', 'dosag', 'group', 'receiv', '2.4', 'mg/kg', '(', 'maximum', '160', 'mg', ')', 'week', '0', ',', '1.2', 'mg/kg', '(', 'maximum', '80', 'mg', ')', 'week', '2', ',', '0.6', 'mg/kg', '(', 'maximum', '40', 'mg', ')', 'week', '4', '6', '.'], 'dependencies': [('patient', 'compound'), ('dosag', 'compound'), ('group', 'compound'), ('receiv', 'ROOT'), ('2.4', 'nummod'), ('mg', 'nmod'), ('/', 'punct'), ('kg', 'appos'), ('(', 'punct'), ('maximum', 'amod'), ('160', 'nummod'), ('mg', 'appos'), (')', 'punct'), ('week', 'appos'), ('0', 'nummod'), (',', 'punct'), ('1.2', 'nummod'), ('mg', 'nmod'), ('/', 'punct'), ('kg', 'appos'), ('(', 'punct'), ('maximum', 'appos'), ('80', 'nummod'), ('mg', 'appos'), (')', 'punct'), ('week', 'npadvmod'), ('2', 'nummod'), (',', 'punct'), ('0.6', 'nummod'), ('mg', 'nmod'), ('/', 'punct'), ('kg', 'appos'), ('(', 'punct'), ('maximum', 'amod'), ('40', 'nummod'), ('mg', 'appos'), (')', 'punct'), ('week', 'appos'), ('4', 'nummod'), ('6', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'The higher dosage group also received an additional dosage of 2.4 mg/kg \\n(maximum of 160 mg) at Week 1.', 'tokens': ['higher', 'dosage', 'group', 'also', 'received', 'additional', 'dosage', '2.4', 'mg/kg', '(', 'maximum', '160', 'mg', ')', 'Week', '1', '.'], 'lemmatized': ['higher', 'dosage', 'group', 'also', 'received', 'additional', 'dosage', '2.4', 'mg/kg', '(', 'maximum', '160', 'mg', ')', 'Week', '1', '.'], 'stemmed': ['higher', 'dosag', 'group', 'also', 'receiv', 'addit', 'dosag', '2.4', 'mg/kg', '(', 'maximum', '160', 'mg', ')', 'week', '1', '.'], 'dependencies': [('higher', 'amod'), ('dosag', 'compound'), ('group', 'nsubj'), ('also', 'advmod'), ('receiv', 'ROOT'), ('addit', 'compound'), ('dosag', 'dobj'), ('2.4', 'nummod'), ('mg', 'nmod'), ('/', 'punct'), ('kg', 'appos'), ('(', 'punct'), ('maximum', 'appos'), ('160', 'nummod'), ('mg', 'appos'), (')', 'punct'), ('week', 'npadvmod'), ('1', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Following an amendment to the study design, 16 additional \\npatients were enrolled and received open-label treatment with HUMIRA at the higher dosage.', 'tokens': ['Following', 'amendment', 'study', 'design', ',', '16', 'additional', 'patients', 'enrolled', 'received', 'open-label', 'treatment', 'HUMIRA', 'higher', 'dosage', '.'], 'lemmatized': ['Following', 'amendment', 'study', 'design', ',', '16', 'additional', 'patient', 'enrolled', 'received', 'open-label', 'treatment', 'HUMIRA', 'higher', 'dosage', '.'], 'stemmed': ['follow', 'amend', 'studi', 'design', ',', '16', 'addit', 'patient', 'enrol', 'receiv', 'open-label', 'treatment', 'humira', 'higher', 'dosag', '.'], 'dependencies': [('follow', 'advcl'), ('amend', 'compound'), ('studi', 'compound'), ('design', 'dobj'), (',', 'punct'), ('16', 'nummod'), ('addit', 'compound'), ('patient', 'nsubj'), ('enrol', 'ROOT'), ('receiv', 'nmod'), ('open', 'amod'), ('-', 'punct'), ('label', 'compound'), ('treatment', 'compound'), ('humira', 'nmod'), ('higher', 'amod'), ('dosag', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'At Week 8, 62 patients who demonstrated clinical response per Partial Mayo Score (PMS; a \\nsubset of the Mayo score with no endoscopic component and defined as a decrease in PMS ≥ 2 \\npoints and ≥ 30% from baseline) were randomized equally to receive double-blind treatment \\nwith HUMIRA 0.6 mg/kg (maximum of 40 mg) every other week (lower dosage group), or 0.6 \\nmg/kg (maximum of 40 mg) every week (higher dosage group).', 'tokens': ['Week', '8', ',', '62', 'patients', 'demonstrated', 'clinical', 'response', 'per', 'Partial', 'Mayo', 'Score', '(', 'PMS', ';', 'subset', 'Mayo', 'score', 'endoscopic', 'component', 'defined', 'decrease', 'PMS', '≥', '2', 'points', '≥', '30', '%', 'baseline', ')', 'randomized', 'equally', 'receive', 'double-blind', 'treatment', 'HUMIRA', '0.6', 'mg/kg', '(', 'maximum', '40', 'mg', ')', 'every', 'week', '(', 'lower', 'dosage', 'group', ')', ',', '0.6', 'mg/kg', '(', 'maximum', '40', 'mg', ')', 'every', 'week', '(', 'higher', 'dosage', 'group', ')', '.'], 'lemmatized': ['Week', '8', ',', '62', 'patient', 'demonstrated', 'clinical', 'response', 'per', 'Partial', 'Mayo', 'Score', '(', 'PMS', ';', 'subset', 'Mayo', 'score', 'endoscopic', 'component', 'defined', 'decrease', 'PMS', '≥', '2', 'point', '≥', '30', '%', 'baseline', ')', 'randomized', 'equally', 'receive', 'double-blind', 'treatment', 'HUMIRA', '0.6', 'mg/kg', '(', 'maximum', '40', 'mg', ')', 'every', 'week', '(', 'lower', 'dosage', 'group', ')', ',', '0.6', 'mg/kg', '(', 'maximum', '40', 'mg', ')', 'every', 'week', '(', 'higher', 'dosage', 'group', ')', '.'], 'stemmed': ['week', '8', ',', '62', 'patient', 'demonstr', 'clinic', 'respons', 'per', 'partial', 'mayo', 'score', '(', 'pm', ';', 'subset', 'mayo', 'score', 'endoscop', 'compon', 'defin', 'decreas', 'pm', '≥', '2', 'point', '≥', '30', '%', 'baselin', ')', 'random', 'equal', 'receiv', 'double-blind', 'treatment', 'humira', '0.6', 'mg/kg', '(', 'maximum', '40', 'mg', ')', 'everi', 'week', '(', 'lower', 'dosag', 'group', ')', ',', '0.6', 'mg/kg', '(', 'maximum', '40', 'mg', ')', 'everi', 'week', '(', 'higher', 'dosag', 'group', ')', '.'], 'dependencies': [('week', 'npadvmod'), ('8', 'nummod'), (',', 'punct'), ('62', 'nummod'), ('patient', 'amod'), ('demonstr', 'compound'), ('clinic', 'compound'), ('respons', 'conj'), ('per', 'prep'), ('partial', 'amod'), ('mayo', 'compound'), ('score', 'pobj'), ('(', 'punct'), ('pm', 'parataxis'), (';', 'punct'), ('subset', 'compound'), ('mayo', 'compound'), ('score', 'compound'), ('endoscop', 'compound'), ('compon', 'compound'), ('defin', 'compound'), ('decreas', 'nsubj'), ('pm', 'dep'), ('≥', 'npadvmod'), ('2', 'nummod'), ('point', 'compound'), ('≥', 'ROOT'), ('30', 'nummod'), ('%', 'compound'), ('baselin', 'appos'), (')', 'punct'), ('random', 'amod'), ('equal', 'amod'), ('receiv', 'nmod'), ('double', 'amod'), ('-', 'punct'), ('blind', 'amod'), ('treatment', 'compound'), ('humira', 'appos'), ('0.6', 'nummod'), ('mg', 'nmod'), ('/', 'punct'), ('kg', 'ROOT'), ('(', 'punct'), ('maximum', 'appos'), ('40', 'nummod'), ('mg', 'prep'), (')', 'punct'), ('everi', 'amod'), ('week', 'appos'), ('(', 'punct'), ('lower', 'amod'), ('dosag', 'compound'), ('group', 'appos'), (')', 'punct'), (',', 'punct'), ('0.6', 'nummod'), ('mg', 'nmod'), ('/', 'punct'), ('kg', 'appos'), ('(', 'punct'), ('maximum', 'parataxis'), ('40', 'nummod'), ('mg', 'prep'), (')', 'punct'), ('everi', 'amod'), ('week', 'ROOT'), ('(', 'punct'), ('higher', 'amod'), ('dosag', 'compound'), ('group', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Prior to an amendment to the \\nstudy design, 12 additional patients who demonstrated clinical response per PMS were \\nrandomized to receive placebo.', 'tokens': ['Prior', 'amendment', 'study', 'design', ',', '12', 'additional', 'patients', 'demonstrated', 'clinical', 'response', 'per', 'PMS', 'randomized', 'receive', 'placebo', '.'], 'lemmatized': ['Prior', 'amendment', 'study', 'design', ',', '12', 'additional', 'patient', 'demonstrated', 'clinical', 'response', 'per', 'PMS', 'randomized', 'receive', 'placebo', '.'], 'stemmed': ['prior', 'amend', 'studi', 'design', ',', '12', 'addit', 'patient', 'demonstr', 'clinic', 'respons', 'per', 'pm', 'random', 'receiv', 'placebo', '.'], 'dependencies': [('prior', 'amod'), ('amend', 'compound'), ('studi', 'compound'), ('design', 'ROOT'), (',', 'punct'), ('12', 'nummod'), ('addit', 'compound'), ('patient', 'nmod'), ('demonstr', 'compound'), ('clinic', 'compound'), ('respons', 'appos'), ('per', 'prep'), ('pm', 'nmod'), ('random', 'amod'), ('receiv', 'compound'), ('placebo', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'There are no anticipated clinically relevant differences in efficacy between the studied higher \\ndosage administered during the 52-week PUC-I trial and the recommended dosage of HUMIRA \\n[see Dosage and Administration (2.4), Clinical Pharmacology (12.2)].', 'tokens': ['anticipated', 'clinically', 'relevant', 'differences', 'efficacy', 'studied', 'higher', 'dosage', 'administered', '52-week', 'PUC-I', 'trial', 'recommended', 'dosage', 'HUMIRA', '[', 'see', 'Dosage', 'Administration', '(', '2.4', ')', ',', 'Clinical', 'Pharmacology', '(', '12.2', ')', ']', '.'], 'lemmatized': ['anticipated', 'clinically', 'relevant', 'difference', 'efficacy', 'studied', 'higher', 'dosage', 'administered', '52-week', 'PUC-I', 'trial', 'recommended', 'dosage', 'HUMIRA', '[', 'see', 'Dosage', 'Administration', '(', '2.4', ')', ',', 'Clinical', 'Pharmacology', '(', '12.2', ')', ']', '.'], 'stemmed': ['anticip', 'clinic', 'relev', 'differ', 'efficaci', 'studi', 'higher', 'dosag', 'administ', '52-week', 'puc-i', 'trial', 'recommend', 'dosag', 'humira', '[', 'see', 'dosag', 'administr', '(', '2.4', ')', ',', 'clinic', 'pharmacolog', '(', '12.2', ')', ']', '.'], 'dependencies': [('anticip', 'compound'), ('clinic', 'compound'), ('relev', 'nsubj'), ('differ', 'ccomp'), ('efficaci', 'nmod'), ('studi', 'nmod'), ('higher', 'amod'), ('dosag', 'nmod'), ('administ', 'nmod'), ('52', 'nummod'), ('-', 'punct'), ('week', 'compound'), ('puc', 'compound'), ('-', 'punct'), ('i', 'compound'), ('trial', 'nsubj'), ('recommend', 'ccomp'), ('dosag', 'compound'), ('humira', 'dobj'), ('[', 'punct'), ('see', 'ROOT'), ('dosag', 'compound'), ('administr', 'dobj'), ('(', 'punct'), ('2.4', 'appos'), (')', 'punct'), (',', 'punct'), ('clinic', 'compound'), ('pharmacolog', 'conj'), ('(', 'punct'), ('12.2', 'appos'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Patients who met criteria for disease flare at or after Week 12 were randomized to receive a re-\\ninduction dose of 2.4 mg/kg (maximum of 160 mg) or a dose of 0.6 mg/kg (maximum of 40 mg) \\nand then continued the dose to which they were randomized at Week 8.', 'tokens': ['Patients', 'met', 'criteria', 'disease', 'flare', 'Week', '12', 'randomized', 'receive', 're-', 'induction', 'dose', '2.4', 'mg/kg', '(', 'maximum', '160', 'mg', ')', 'dose', '0.6', 'mg/kg', '(', 'maximum', '40', 'mg', ')', 'continued', 'dose', 'randomized', 'Week', '8', '.'], 'lemmatized': ['Patients', 'met', 'criterion', 'disease', 'flare', 'Week', '12', 'randomized', 'receive', 're-', 'induction', 'dose', '2.4', 'mg/kg', '(', 'maximum', '160', 'mg', ')', 'dose', '0.6', 'mg/kg', '(', 'maximum', '40', 'mg', ')', 'continued', 'dose', 'randomized', 'Week', '8', '.'], 'stemmed': ['patient', 'met', 'criterion', 'diseas', 'flare', 'week', '12', 'random', 'receiv', 're-', 'induct', 'dose', '2.4', 'mg/kg', '(', 'maximum', '160', 'mg', ')', 'dose', '0.6', 'mg/kg', '(', 'maximum', '40', 'mg', ')', 'continu', 'dose', 'random', 'week', '8', '.'], 'dependencies': [('patient', 'nsubj'), ('met', 'ccomp'), ('criterion', 'compound'), ('diseas', 'dobj'), ('flare', 'amod'), ('week', 'npadvmod'), ('12', 'nummod'), ('random', 'amod'), ('receiv', 'nsubj'), ('re-', 'prep'), ('induct', 'compound'), ('dose', 'dep'), ('2.4', 'nummod'), ('mg', 'nmod'), ('/', 'punct'), ('kg', 'dobj'), ('(', 'punct'), ('maximum', 'appos'), ('160', 'nummod'), ('mg', 'appos'), (')', 'punct'), ('dose', 'conj'), ('0.6', 'nummod'), ('mg', 'nmod'), ('/', 'punct'), ('kg', 'dobj'), ('(', 'punct'), ('maximum', 'dep'), ('40', 'nummod'), ('mg', 'dobj'), (')', 'punct'), ('continu', 'nsubj'), ('dose', 'ROOT'), ('random', 'amod'), ('week', 'dobj'), ('8', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'The co-primary endpoints of the study were clinical remission per PMS (defined as PMS ≤ 2 and \\nno individual subscore > 1) at Week 8, and clinical remission per the Mayo Score (defined as \\nMayo Score ≤ 2 and no individual subscore > 1) at Week 52 in patients who achieved clinical \\nresponse per PMS at Week 8.', 'tokens': ['co-primary', 'endpoints', 'study', 'clinical', 'remission', 'per', 'PMS', '(', 'defined', 'PMS', '≤', '2', 'individual', 'subscore', '>', '1', ')', 'Week', '8', ',', 'clinical', 'remission', 'per', 'Mayo', 'Score', '(', 'defined', 'Mayo', 'Score', '≤', '2', 'individual', 'subscore', '>', '1', ')', 'Week', '52', 'patients', 'achieved', 'clinical', 'response', 'per', 'PMS', 'Week', '8', '.'], 'lemmatized': ['co-primary', 'endpoint', 'study', 'clinical', 'remission', 'per', 'PMS', '(', 'defined', 'PMS', '≤', '2', 'individual', 'subscore', '>', '1', ')', 'Week', '8', ',', 'clinical', 'remission', 'per', 'Mayo', 'Score', '(', 'defined', 'Mayo', 'Score', '≤', '2', 'individual', 'subscore', '>', '1', ')', 'Week', '52', 'patient', 'achieved', 'clinical', 'response', 'per', 'PMS', 'Week', '8', '.'], 'stemmed': ['co-primari', 'endpoint', 'studi', 'clinic', 'remiss', 'per', 'pm', '(', 'defin', 'pm', '≤', '2', 'individu', 'subscor', '>', '1', ')', 'week', '8', ',', 'clinic', 'remiss', 'per', 'mayo', 'score', '(', 'defin', 'mayo', 'score', '≤', '2', 'individu', 'subscor', '>', '1', ')', 'week', '52', 'patient', 'achiev', 'clinic', 'respons', 'per', 'pm', 'week', '8', '.'], 'dependencies': [('co', 'compound'), ('-', 'amod'), ('primari', 'amod'), ('endpoint', 'compound'), ('studi', 'compound'), ('clinic', 'compound'), ('remiss', 'nmod'), ('per', 'prep'), ('pm', 'pobj'), ('(', 'punct'), ('defin', 'advmod'), ('pm', 'compound'), ('≤', 'nmod'), ('2', 'nummod'), ('individu', 'nmod'), ('subscor', 'nmod'), ('>', 'nmod'), ('1', 'prep'), (')', 'punct'), ('week', 'npadvmod'), ('8', 'nummod'), (',', 'punct'), ('clinic', 'amod'), ('remiss', 'conj'), ('per', 'prep'), ('mayo', 'compound'), ('score', 'pobj'), ('(', 'punct'), ('defin', 'advmod'), ('mayo', 'compound'), ('score', 'compound'), ('≤', 'appos'), ('2', 'nummod'), ('individu', 'nmod'), ('subscor', 'appos'), ('>', 'nmod'), ('1', 'prep'), (')', 'punct'), ('week', 'nmod'), ('52', 'nummod'), ('patient', 'compound'), ('achiev', 'compound'), ('clinic', 'compound'), ('respons', 'ROOT'), ('per', 'prep'), ('pm', 'compound'), ('week', 'pobj'), ('8', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Secondary endpoints included Mayo Score response (defined as a \\ndecrease in Mayo Score of ≥ 3 points and ≥ 30% from baseline) at Week 52 in Week 8 PMS \\nresponders, endoscopic improvement (defined as a Mayo endoscopy subscore ≤ 1) at Week 52 in \\nWeek 8 PMS responders, and Mayo Score remission at Week 52 in Week 8 PMS remitters.', 'tokens': ['Secondary', 'endpoints', 'included', 'Mayo', 'Score', 'response', '(', 'defined', 'decrease', 'Mayo', 'Score', '≥', '3', 'points', '≥', '30', '%', 'baseline', ')', 'Week', '52', 'Week', '8', 'PMS', 'responders', ',', 'endoscopic', 'improvement', '(', 'defined', 'Mayo', 'endoscopy', 'subscore', '≤', '1', ')', 'Week', '52', 'Week', '8', 'PMS', 'responders', ',', 'Mayo', 'Score', 'remission', 'Week', '52', 'Week', '8', 'PMS', 'remitters', '.'], 'lemmatized': ['Secondary', 'endpoint', 'included', 'Mayo', 'Score', 'response', '(', 'defined', 'decrease', 'Mayo', 'Score', '≥', '3', 'point', '≥', '30', '%', 'baseline', ')', 'Week', '52', 'Week', '8', 'PMS', 'responder', ',', 'endoscopic', 'improvement', '(', 'defined', 'Mayo', 'endoscopy', 'subscore', '≤', '1', ')', 'Week', '52', 'Week', '8', 'PMS', 'responder', ',', 'Mayo', 'Score', 'remission', 'Week', '52', 'Week', '8', 'PMS', 'remitters', '.'], 'stemmed': ['secondari', 'endpoint', 'includ', 'mayo', 'score', 'respons', '(', 'defin', 'decreas', 'mayo', 'score', '≥', '3', 'point', '≥', '30', '%', 'baselin', ')', 'week', '52', 'week', '8', 'pm', 'respond', ',', 'endoscop', 'improv', '(', 'defin', 'mayo', 'endoscopi', 'subscor', '≤', '1', ')', 'week', '52', 'week', '8', 'pm', 'respond', ',', 'mayo', 'score', 'remiss', 'week', '52', 'week', '8', 'pm', 'remitt', '.'], 'dependencies': [('secondari', 'nsubj'), ('endpoint', 'ROOT'), ('includ', 'compound'), ('mayo', 'compound'), ('score', 'compound'), ('respons', 'dobj'), ('(', 'punct'), ('defin', 'nmod'), ('decreas', 'compound'), ('mayo', 'compound'), ('score', 'compound'), ('≥', 'appos'), ('3', 'nummod'), ('point', 'compound'), ('≥', 'appos'), ('30', 'nummod'), ('%', 'compound'), ('baselin', 'appos'), (')', 'punct'), ('week', 'npadvmod'), ('52', 'nummod'), ('week', 'npadvmod'), ('8', 'nummod'), ('pm', 'nsubj'), ('respond', 'dep'), (',', 'punct'), ('endoscop', 'compound'), ('improv', 'nsubj'), ('(', 'punct'), ('defin', 'compound'), ('mayo', 'compound'), ('endoscopi', 'compound'), ('subscor', 'parataxis'), ('≤', 'nmod'), ('1', 'nummod'), (')', 'punct'), ('week', 'npadvmod'), ('52', 'nummod'), ('week', 'npadvmod'), ('8', 'nummod'), ('pm', 'compound'), ('respond', 'dep'), (',', 'punct'), ('mayo', 'compound'), ('score', 'npadvmod'), ('remiss', 'compound'), ('week', 'npadvmod'), ('52', 'nummod'), ('week', 'npadvmod'), ('8', 'nummod'), ('pm', 'appos'), ('remitt', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Week 8 Results \\nAt Week 8, PMS remission was achieved by 60% [28/47; 95% confidence interval (CI): (44%, \\n74%)] of patients in the higher dosage group (not including the 16 patients receiving open-label \\nhigher dosage) and 43% [13/30; 95% CI: (25%, 63%)] of patients in the lower dosage group.', 'tokens': ['Week', '8', 'Results', 'Week', '8', ',', 'PMS', 'remission', 'achieved', '60', '%', '[', '28/47', ';', '95', '%', 'confidence', 'interval', '(', 'CI', ')', ':', '(', '44', '%', ',', '74', '%', ')', ']', 'patients', 'higher', 'dosage', 'group', '(', 'including', '16', 'patients', 'receiving', 'open-label', 'higher', 'dosage', ')', '43', '%', '[', '13/30', ';', '95', '%', 'CI', ':', '(', '25', '%', ',', '63', '%', ')', ']', 'patients', 'lower', 'dosage', 'group', '.'], 'lemmatized': ['Week', '8', 'Results', 'Week', '8', ',', 'PMS', 'remission', 'achieved', '60', '%', '[', '28/47', ';', '95', '%', 'confidence', 'interval', '(', 'CI', ')', ':', '(', '44', '%', ',', '74', '%', ')', ']', 'patient', 'higher', 'dosage', 'group', '(', 'including', '16', 'patient', 'receiving', 'open-label', 'higher', 'dosage', ')', '43', '%', '[', '13/30', ';', '95', '%', 'CI', ':', '(', '25', '%', ',', '63', '%', ')', ']', 'patient', 'lower', 'dosage', 'group', '.'], 'stemmed': ['week', '8', 'result', 'week', '8', ',', 'pm', 'remiss', 'achiev', '60', '%', '[', '28/47', ';', '95', '%', 'confid', 'interv', '(', 'ci', ')', ':', '(', '44', '%', ',', '74', '%', ')', ']', 'patient', 'higher', 'dosag', 'group', '(', 'includ', '16', 'patient', 'receiv', 'open-label', 'higher', 'dosag', ')', '43', '%', '[', '13/30', ';', '95', '%', 'ci', ':', '(', '25', '%', ',', '63', '%', ')', ']', 'patient', 'lower', 'dosag', 'group', '.'], 'dependencies': [('week', 'ROOT'), ('8', 'nummod'), ('result', 'compound'), ('week', 'npadvmod'), ('8', 'nummod'), (',', 'punct'), ('pm', 'compound'), ('remiss', 'compound'), ('achiev', 'conj'), ('60', 'nummod'), ('%', 'appos'), ('[', 'punct'), ('28/47', 'appos'), (';', 'punct'), ('95', 'nummod'), ('%', 'appos'), ('confid', 'amod'), ('interv', 'appos'), ('(', 'punct'), ('ci', 'appos'), (')', 'punct'), (':', 'punct'), ('(', 'punct'), ('44', 'nummod'), ('%', 'appos'), (',', 'punct'), ('74', 'nummod'), ('%', 'appos'), (')', 'punct'), (']', 'punct'), ('patient', 'ROOT'), ('higher', 'amod'), ('dosag', 'compound'), ('group', 'dobj'), ('(', 'punct'), ('includ', 'amod'), ('16', 'nummod'), ('patient', 'nmod'), ('receiv', 'nmod'), ('open', 'amod'), ('-', 'punct'), ('label', 'nmod'), ('higher', 'amod'), ('dosag', 'appos'), (')', 'punct'), ('43', 'nummod'), ('%', 'npadvmod'), ('[', 'punct'), ('13/30', 'dep'), (';', 'punct'), ('95', 'nummod'), ('%', 'compound'), ('ci', 'ROOT'), (':', 'punct'), ('(', 'punct'), ('25', 'nummod'), ('%', 'parataxis'), (',', 'punct'), ('63', 'nummod'), ('%', 'appos'), (')', 'punct'), (']', 'punct'), ('patient', 'ROOT'), ('lower', 'amod'), ('dosag', 'compound'), ('group', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Results from the higher dosage group are representative of the results expected with the \\nrecommended dosage [see Dosage and Administration (2.4), Clinical Pharmacology (12.2)].', 'tokens': ['Results', 'higher', 'dosage', 'group', 'representative', 'results', 'expected', 'recommended', 'dosage', '[', 'see', 'Dosage', 'Administration', '(', '2.4', ')', ',', 'Clinical', 'Pharmacology', '(', '12.2', ')', ']', '.'], 'lemmatized': ['Results', 'higher', 'dosage', 'group', 'representative', 'result', 'expected', 'recommended', 'dosage', '[', 'see', 'Dosage', 'Administration', '(', '2.4', ')', ',', 'Clinical', 'Pharmacology', '(', '12.2', ')', ']', '.'], 'stemmed': ['result', 'higher', 'dosag', 'group', 'repres', 'result', 'expect', 'recommend', 'dosag', '[', 'see', 'dosag', 'administr', '(', '2.4', ')', ',', 'clinic', 'pharmacolog', '(', '12.2', ')', ']', '.'], 'dependencies': [('result', 'ROOT'), ('higher', 'amod'), ('dosag', 'compound'), ('group', 'compound'), ('repres', 'compound'), ('result', 'nsubj'), ('expect', 'ccomp'), ('recommend', 'xcomp'), ('dosag', 'dobj'), ('[', 'punct'), ('see', 'ccomp'), ('dosag', 'compound'), ('administr', 'dobj'), ('(', 'punct'), ('2.4', 'appos'), (')', 'punct'), (',', 'punct'), ('clinic', 'compound'), ('pharmacolog', 'conj'), ('(', 'punct'), ('12.2', 'appos'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Week 52 Results  \\nAt Week 52, endpoints were assessed in the population of patients who received double-blind \\nplacebo, HUMIRA 0.6 mg/kg (maximum of 40 mg) every other week, or HUMIRA 0.6 mg/kg \\n(maximum of 40 mg) every week between Week 8 and Week 52 (Table 16).', 'tokens': ['Week', '52', 'Results', 'Week', '52', ',', 'endpoints', 'assessed', 'population', 'patients', 'received', 'double-blind', 'placebo', ',', 'HUMIRA', '0.6', 'mg/kg', '(', 'maximum', '40', 'mg', ')', 'every', 'week', ',', 'HUMIRA', '0.6', 'mg/kg', '(', 'maximum', '40', 'mg', ')', 'every', 'week', 'Week', '8', 'Week', '52', '(', 'Table', '16', ')', '.'], 'lemmatized': ['Week', '52', 'Results', 'Week', '52', ',', 'endpoint', 'assessed', 'population', 'patient', 'received', 'double-blind', 'placebo', ',', 'HUMIRA', '0.6', 'mg/kg', '(', 'maximum', '40', 'mg', ')', 'every', 'week', ',', 'HUMIRA', '0.6', 'mg/kg', '(', 'maximum', '40', 'mg', ')', 'every', 'week', 'Week', '8', 'Week', '52', '(', 'Table', '16', ')', '.'], 'stemmed': ['week', '52', 'result', 'week', '52', ',', 'endpoint', 'assess', 'popul', 'patient', 'receiv', 'double-blind', 'placebo', ',', 'humira', '0.6', 'mg/kg', '(', 'maximum', '40', 'mg', ')', 'everi', 'week', ',', 'humira', '0.6', 'mg/kg', '(', 'maximum', '40', 'mg', ')', 'everi', 'week', 'week', '8', 'week', '52', '(', 'tabl', '16', ')', '.'], 'dependencies': [('week', 'npadvmod'), ('52', 'nummod'), ('result', 'nmod'), ('week', 'npadvmod'), ('52', 'nummod'), (',', 'punct'), ('endpoint', 'compound'), ('assess', 'compound'), ('popul', 'nmod'), ('patient', 'compound'), ('receiv', 'ROOT'), ('double', 'amod'), ('-', 'punct'), ('blind', 'amod'), ('placebo', 'appos'), (',', 'punct'), ('humira', 'appos'), ('0.6', 'nummod'), ('mg', 'nmod'), ('/', 'punct'), ('kg', 'ROOT'), ('(', 'punct'), ('maximum', 'appos'), ('40', 'nummod'), ('mg', 'prep'), (')', 'punct'), ('everi', 'amod'), ('week', 'appos'), (',', 'punct'), ('humira', 'appos'), ('0.6', 'nummod'), ('mg', 'nmod'), ('/', 'punct'), ('kg', 'appos'), ('(', 'punct'), ('maximum', 'appos'), ('40', 'nummod'), ('mg', 'prep'), (')', 'punct'), ('everi', 'amod'), ('week', 'compound'), ('week', 'appos'), ('8', 'nummod'), ('week', 'npadvmod'), ('52', 'nummod'), ('(', 'punct'), ('tabl', 'appos'), ('16', 'nummod'), (')', 'punct'), ('.', 'punct')]}], 'text': '2 to 3 points, confirmed by centrally read endoscopy) who had an inadequate response or \\nintolerance to therapy with corticosteroids and/or an immunomodulator (i.e., azathioprine, 6-\\nmercaptopurine, or methotrexate). Fifteen out of 93 patients (16%) in the study had prior \\nexperience with a TNF blocker. Patients who received corticosteroids at enrollment were \\nallowed to taper their corticosteroid therapy after Week 4. \\nSeventy-seven patients were initially randomized 3:2 to receive double-blind treatment with one \\nof two dosages of HUMIRA. Patients in both dosage groups received 2.4 mg/kg (maximum of \\n160 mg) at Week 0, 1.2 mg/kg (maximum of 80 mg) at Week 2, and 0.6 mg/kg (maximum of 40 \\nmg) at Weeks 4 and 6.  The higher dosage group also received an additional dosage of 2.4 mg/kg \\n(maximum of 160 mg) at Week 1. Following an amendment to the study design, 16 additional \\npatients were enrolled and received open-label treatment with HUMIRA at the higher dosage.   \\nAt Week 8, 62 patients who demonstrated clinical response per Partial Mayo Score (PMS; a \\nsubset of the Mayo score with no endoscopic component and defined as a decrease in PMS ≥ 2 \\npoints and ≥ 30% from baseline) were randomized equally to receive double-blind treatment \\nwith HUMIRA 0.6 mg/kg (maximum of 40 mg) every other week (lower dosage group), or 0.6 \\nmg/kg (maximum of 40 mg) every week (higher dosage group). Prior to an amendment to the \\nstudy design, 12 additional patients who demonstrated clinical response per PMS were \\nrandomized to receive placebo. \\nThere are no anticipated clinically relevant differences in efficacy between the studied higher \\ndosage administered during the 52-week PUC-I trial and the recommended dosage of HUMIRA \\n[see Dosage and Administration (2.4), Clinical Pharmacology (12.2)]. \\nPatients who met criteria for disease flare at or after Week 12 were randomized to receive a re-\\ninduction dose of 2.4 mg/kg (maximum of 160 mg) or a dose of 0.6 mg/kg (maximum of 40 mg) \\nand then continued the dose to which they were randomized at Week 8. \\nThe co-primary endpoints of the study were clinical remission per PMS (defined as PMS ≤ 2 and \\nno individual subscore > 1) at Week 8, and clinical remission per the Mayo Score (defined as \\nMayo Score ≤ 2 and no individual subscore > 1) at Week 52 in patients who achieved clinical \\nresponse per PMS at Week 8.  Secondary endpoints included Mayo Score response (defined as a \\ndecrease in Mayo Score of ≥ 3 points and ≥ 30% from baseline) at Week 52 in Week 8 PMS \\nresponders, endoscopic improvement (defined as a Mayo endoscopy subscore ≤ 1) at Week 52 in \\nWeek 8 PMS responders, and Mayo Score remission at Week 52 in Week 8 PMS remitters.  \\nWeek 8 Results \\nAt Week 8, PMS remission was achieved by 60% [28/47; 95% confidence interval (CI): (44%, \\n74%)] of patients in the higher dosage group (not including the 16 patients receiving open-label \\nhigher dosage) and 43% [13/30; 95% CI: (25%, 63%)] of patients in the lower dosage group. \\nResults from the higher dosage group are representative of the results expected with the \\nrecommended dosage [see Dosage and Administration (2.4), Clinical Pharmacology (12.2)].   \\nWeek 52 Results  \\nAt Week 52, endpoints were assessed in the population of patients who received double-blind \\nplacebo, HUMIRA 0.6 mg/kg (maximum of 40 mg) every other week, or HUMIRA 0.6 mg/kg \\n(maximum of 40 mg) every week between Week 8 and Week 52 (Table 16). \\n \\n \\n'}, 'page_char_count': 3448, 'page_word_count': 570, 'sentences': ['2 to 3 points, confirmed by centrally read endoscopy) who had an inadequate response or \\nintolerance to therapy with corticosteroids and/or an immunomodulator (i.e., azathioprine, 6-\\nmercaptopurine, or methotrexate).', 'Fifteen out of 93 patients (16%) in the study had prior \\nexperience with a TNF blocker.', 'Patients who received corticosteroids at enrollment were \\nallowed to taper their corticosteroid therapy after Week 4.', '\\nSeventy-seven patients were initially randomized 3:2 to receive double-blind treatment with one \\nof two dosages of HUMIRA.', 'Patients in both dosage groups received 2.4 mg/kg (maximum of \\n160 mg) at Week 0, 1.2 mg/kg (maximum of 80 mg) at Week 2, and 0.6 mg/kg (maximum of 40 \\nmg) at Weeks 4 and 6.', ' The higher dosage group also received an additional dosage of 2.4 mg/kg \\n(maximum of 160 mg) at Week 1.', 'Following an amendment to the study design, 16 additional \\npatients were enrolled and received open-label treatment with HUMIRA at the higher dosage.', '  \\nAt Week 8, 62 patients who demonstrated clinical response per Partial Mayo Score (PMS; a \\nsubset of the Mayo score with no endoscopic component and defined as a decrease in PMS ≥ 2 \\npoints and ≥ 30% from baseline) were randomized equally to receive double-blind treatment \\nwith HUMIRA 0.6 mg/kg (maximum of 40 mg) every other week (lower dosage group), or 0.6 \\nmg/kg (maximum of 40 mg) every week (higher dosage group).', 'Prior to an amendment to the \\nstudy design, 12 additional patients who demonstrated clinical response per PMS were \\nrandomized to receive placebo.', '\\nThere are no anticipated clinically relevant differences in efficacy between the studied higher \\ndosage administered during the 52-week PUC-I trial and the recommended dosage of HUMIRA \\n[see Dosage and Administration (2.4), Clinical Pharmacology (12.2)].', '\\nPatients who met criteria for disease flare at or after Week 12 were randomized to receive a re-\\ninduction dose of 2.4 mg/kg (maximum of 160 mg) or a dose of 0.6 mg/kg (maximum of 40 mg) \\nand then continued the dose to which they were randomized at Week 8.', '\\nThe co-primary endpoints of the study were clinical remission per PMS (defined as PMS ≤ 2 and \\nno individual subscore > 1) at Week 8, and clinical remission per the Mayo Score (defined as \\nMayo Score ≤ 2 and no individual subscore > 1) at Week 52 in patients who achieved clinical \\nresponse per PMS at Week 8.', ' Secondary endpoints included Mayo Score response (defined as a \\ndecrease in Mayo Score of ≥ 3 points and ≥ 30% from baseline) at Week 52 in Week 8 PMS \\nresponders, endoscopic improvement (defined as a Mayo endoscopy subscore ≤ 1) at Week 52 in \\nWeek 8 PMS responders, and Mayo Score remission at Week 52 in Week 8 PMS remitters.', ' \\nWeek 8 Results \\nAt Week 8, PMS remission was achieved by 60% [28/47; 95% confidence interval (CI): (44%, \\n74%)] of patients in the higher dosage group (not including the 16 patients receiving open-label \\nhigher dosage) and 43% [13/30; 95% CI: (25%, 63%)] of patients in the lower dosage group.', '\\nResults from the higher dosage group are representative of the results expected with the \\nrecommended dosage [see Dosage and Administration (2.4), Clinical Pharmacology (12.2)].', '  \\nWeek 52 Results  \\nAt Week 52, endpoints were assessed in the population of patients who received double-blind \\nplacebo, HUMIRA 0.6 mg/kg (maximum of 40 mg) every other week, or HUMIRA 0.6 mg/kg \\n(maximum of 40 mg) every week between Week 8 and Week 52 (Table 16).', '\\n \\n \\n'], 'page_sentence_count_spacy': 17}\n",
            "{'page_number': 48, 'text': 'Table 16. Clinical Remission, Clinical Response and Endoscopic Improvement at Week 52 \\nin Pediatric Patients with Ulcerative Colitis (Study PUC-1)  \\n \\n  \\nPlaceboa \\n \\n \\n \\n \\nn/N (%), 95% CI \\nHUMIRA \\nMaximum of 40 mg \\n(0.6 mg/kg) every \\nother weekb \\n \\nn/N (%), 95% CI \\nHUMIRA \\nMaximum of 40 mg \\n(0.6 mg/kg) every \\nweekc \\n \\nn/N (%), 95% CI \\nClinical remission in \\nWeek 8 PMS responders \\n4/12 (33%) \\n(10%, 65%) \\n9/31 (29%) \\n(14%, 48%) \\n14/31 (45%) \\n(27%, 64%) \\nClinical response in \\nWeek 8 PMS responders \\n4/12 (33%) \\n(10%, 65%) \\n19/31 (61%) \\n(42%, 78%) \\n21/31 (68%) \\n(49%, 83%) \\nEndoscopic \\nimprovement in Week 8 \\nPMS responders \\n4/12 (33%) \\n(10%, 65%) \\n12/31 (39%) \\n(22%, 58%) \\n16/31 (52%) \\n(33%, 70%) \\nClinical remission in \\nWeek 8 PMS remitters \\n3/8 (38%) \\n(9%, 76%) \\n9/21 (43%) \\n(22%, 66%) \\n10/22 (45%) \\n(24%, 68%) \\nCI=Confidence interval \\na Twelve patients who demonstrated clinical response per PMS at Week 8 were randomized to \\nreceive placebo. There are limitations to the interpretability of the placebo data due to the \\nsmall sample size.  \\nb The every other week dosage studied during the 52-week PUC-I trial is a lower dosage than \\nthe recommended dosage of HUMIRA [see Dosage and Administration (2.4)]. \\nc There are no anticipated clinically relevant differences in efficacy between the studied higher \\ndosage administered during the 52-week PUC-I trial and the recommended dosage of \\nHUMIRA. \\nNote: Patients with missing values at Week 52 or who were randomized to receive re-\\ninduction or maintenance treatment due to disease flare were considered non-responders for \\nWeek 52 endpoints. \\n14.9 Plaque Psoriasis \\nThe safety and efficacy of HUMIRA were assessed in randomized, double-blind, placebo-\\ncontrolled studies in 1696 adult subjects with moderate to severe chronic plaque psoriasis (Ps) \\nwho were candidates for systemic therapy or phototherapy.  \\nStudy Ps-I evaluated 1212 subjects with chronic Ps with ≥10% body surface area (BSA) \\ninvolvement, Physician’s Global Assessment (PGA) of at least moderate disease severity, and \\nPsoriasis Area and Severity Index (PASI) ≥12 within three treatment periods. In period A, \\nsubjects received placebo or HUMIRA at an initial dose of 80 mg at Week 0 followed by a dose \\nof 40 mg every other week starting at Week 1. After 16 weeks of therapy, subjects who achieved \\nat least a PASI 75 response at Week 16, defined as a PASI score improvement of at least 75% \\nrelative to baseline, entered period B and received open-label 40 mg HUMIRA every other week. \\n', 'processed_text': {'sentences': [{'original_sentence': 'Table 16.', 'tokens': ['Table', '16', '.'], 'lemmatized': ['Table', '16', '.'], 'stemmed': ['tabl', '16', '.'], 'dependencies': [('tabl', 'ROOT'), ('16', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Clinical Remission, Clinical Response and Endoscopic Improvement at Week 52 \\nin Pediatric Patients with Ulcerative Colitis (Study PUC-1)  \\n \\n  \\nPlaceboa \\n \\n \\n \\n \\nn/N (%), 95% CI \\nHUMIRA \\nMaximum of 40 mg \\n(0.6 mg/kg) every \\nother weekb \\n \\nn/N (%), 95% CI \\nHUMIRA \\nMaximum of 40 mg \\n(0.6 mg/kg) every \\nweekc \\n \\nn/N (%), 95% CI \\nClinical remission in \\nWeek 8 PMS responders \\n4/12 (33%) \\n(10%, 65%) \\n9/31 (29%) \\n(14%, 48%) \\n14/31 (45%) \\n(27%, 64%) \\nClinical response in \\nWeek 8 PMS responders \\n4/12 (33%) \\n(10%, 65%) \\n19/31 (61%) \\n(42%, 78%) \\n21/31 (68%) \\n(49%, 83%) \\nEndoscopic \\nimprovement in Week 8 \\nPMS responders \\n4/12 (33%) \\n(10%, 65%) \\n12/31 (39%) \\n(22%, 58%) \\n16/31 (52%) \\n(33%, 70%) \\nClinical remission in \\nWeek 8 PMS remitters \\n3/8 (38%) \\n(9%, 76%) \\n9/21 (43%) \\n(22%, 66%) \\n10/22 (45%) \\n(24%, 68%) \\nCI=Confidence interval \\na Twelve patients who demonstrated clinical response per PMS at Week 8 were randomized to \\nreceive placebo.', 'tokens': ['Clinical', 'Remission', ',', 'Clinical', 'Response', 'Endoscopic', 'Improvement', 'Week', '52', 'Pediatric', 'Patients', 'Ulcerative', 'Colitis', '(', 'Study', 'PUC-1', ')', 'Placeboa', 'n/N', '(', '%', ')', ',', '95', '%', 'CI', 'HUMIRA', 'Maximum', '40', 'mg', '(', '0.6', 'mg/kg', ')', 'every', 'weekb', 'n/N', '(', '%', ')', ',', '95', '%', 'CI', 'HUMIRA', 'Maximum', '40', 'mg', '(', '0.6', 'mg/kg', ')', 'every', 'weekc', 'n/N', '(', '%', ')', ',', '95', '%', 'CI', 'Clinical', 'remission', 'Week', '8', 'PMS', 'responders', '4/12', '(', '33', '%', ')', '(', '10', '%', ',', '65', '%', ')', '9/31', '(', '29', '%', ')', '(', '14', '%', ',', '48', '%', ')', '14/31', '(', '45', '%', ')', '(', '27', '%', ',', '64', '%', ')', 'Clinical', 'response', 'Week', '8', 'PMS', 'responders', '4/12', '(', '33', '%', ')', '(', '10', '%', ',', '65', '%', ')', '19/31', '(', '61', '%', ')', '(', '42', '%', ',', '78', '%', ')', '21/31', '(', '68', '%', ')', '(', '49', '%', ',', '83', '%', ')', 'Endoscopic', 'improvement', 'Week', '8', 'PMS', 'responders', '4/12', '(', '33', '%', ')', '(', '10', '%', ',', '65', '%', ')', '12/31', '(', '39', '%', ')', '(', '22', '%', ',', '58', '%', ')', '16/31', '(', '52', '%', ')', '(', '33', '%', ',', '70', '%', ')', 'Clinical', 'remission', 'Week', '8', 'PMS', 'remitters', '3/8', '(', '38', '%', ')', '(', '9', '%', ',', '76', '%', ')', '9/21', '(', '43', '%', ')', '(', '22', '%', ',', '66', '%', ')', '10/22', '(', '45', '%', ')', '(', '24', '%', ',', '68', '%', ')', 'CI=Confidence', 'interval', 'Twelve', 'patients', 'demonstrated', 'clinical', 'response', 'per', 'PMS', 'Week', '8', 'randomized', 'receive', 'placebo', '.'], 'lemmatized': ['Clinical', 'Remission', ',', 'Clinical', 'Response', 'Endoscopic', 'Improvement', 'Week', '52', 'Pediatric', 'Patients', 'Ulcerative', 'Colitis', '(', 'Study', 'PUC-1', ')', 'Placeboa', 'n/N', '(', '%', ')', ',', '95', '%', 'CI', 'HUMIRA', 'Maximum', '40', 'mg', '(', '0.6', 'mg/kg', ')', 'every', 'weekb', 'n/N', '(', '%', ')', ',', '95', '%', 'CI', 'HUMIRA', 'Maximum', '40', 'mg', '(', '0.6', 'mg/kg', ')', 'every', 'weekc', 'n/N', '(', '%', ')', ',', '95', '%', 'CI', 'Clinical', 'remission', 'Week', '8', 'PMS', 'responder', '4/12', '(', '33', '%', ')', '(', '10', '%', ',', '65', '%', ')', '9/31', '(', '29', '%', ')', '(', '14', '%', ',', '48', '%', ')', '14/31', '(', '45', '%', ')', '(', '27', '%', ',', '64', '%', ')', 'Clinical', 'response', 'Week', '8', 'PMS', 'responder', '4/12', '(', '33', '%', ')', '(', '10', '%', ',', '65', '%', ')', '19/31', '(', '61', '%', ')', '(', '42', '%', ',', '78', '%', ')', '21/31', '(', '68', '%', ')', '(', '49', '%', ',', '83', '%', ')', 'Endoscopic', 'improvement', 'Week', '8', 'PMS', 'responder', '4/12', '(', '33', '%', ')', '(', '10', '%', ',', '65', '%', ')', '12/31', '(', '39', '%', ')', '(', '22', '%', ',', '58', '%', ')', '16/31', '(', '52', '%', ')', '(', '33', '%', ',', '70', '%', ')', 'Clinical', 'remission', 'Week', '8', 'PMS', 'remitters', '3/8', '(', '38', '%', ')', '(', '9', '%', ',', '76', '%', ')', '9/21', '(', '43', '%', ')', '(', '22', '%', ',', '66', '%', ')', '10/22', '(', '45', '%', ')', '(', '24', '%', ',', '68', '%', ')', 'CI=Confidence', 'interval', 'Twelve', 'patient', 'demonstrated', 'clinical', 'response', 'per', 'PMS', 'Week', '8', 'randomized', 'receive', 'placebo', '.'], 'stemmed': ['clinic', 'remiss', ',', 'clinic', 'respons', 'endoscop', 'improv', 'week', '52', 'pediatr', 'patient', 'ulcer', 'coliti', '(', 'studi', 'puc-1', ')', 'placeboa', 'n/n', '(', '%', ')', ',', '95', '%', 'ci', 'humira', 'maximum', '40', 'mg', '(', '0.6', 'mg/kg', ')', 'everi', 'weekb', 'n/n', '(', '%', ')', ',', '95', '%', 'ci', 'humira', 'maximum', '40', 'mg', '(', '0.6', 'mg/kg', ')', 'everi', 'weekc', 'n/n', '(', '%', ')', ',', '95', '%', 'ci', 'clinic', 'remiss', 'week', '8', 'pm', 'respond', '4/12', '(', '33', '%', ')', '(', '10', '%', ',', '65', '%', ')', '9/31', '(', '29', '%', ')', '(', '14', '%', ',', '48', '%', ')', '14/31', '(', '45', '%', ')', '(', '27', '%', ',', '64', '%', ')', 'clinic', 'respons', 'week', '8', 'pm', 'respond', '4/12', '(', '33', '%', ')', '(', '10', '%', ',', '65', '%', ')', '19/31', '(', '61', '%', ')', '(', '42', '%', ',', '78', '%', ')', '21/31', '(', '68', '%', ')', '(', '49', '%', ',', '83', '%', ')', 'endoscop', 'improv', 'week', '8', 'pm', 'respond', '4/12', '(', '33', '%', ')', '(', '10', '%', ',', '65', '%', ')', '12/31', '(', '39', '%', ')', '(', '22', '%', ',', '58', '%', ')', '16/31', '(', '52', '%', ')', '(', '33', '%', ',', '70', '%', ')', 'clinic', 'remiss', 'week', '8', 'pm', 'remitt', '3/8', '(', '38', '%', ')', '(', '9', '%', ',', '76', '%', ')', '9/21', '(', '43', '%', ')', '(', '22', '%', ',', '66', '%', ')', '10/22', '(', '45', '%', ')', '(', '24', '%', ',', '68', '%', ')', 'ci=confid', 'interv', 'twelv', 'patient', 'demonstr', 'clinic', 'respons', 'per', 'pm', 'week', '8', 'random', 'receiv', 'placebo', '.'], 'dependencies': [('clinic', 'compound'), ('remiss', 'nsubj'), (',', 'punct'), ('clinic', 'compound'), ('respons', 'compound'), ('endoscop', 'appos'), ('improv', 'compound'), ('week', 'appos'), ('52', 'nummod'), ('pediatr', 'amod'), ('patient', 'compound'), ('ulcer', 'compound'), ('coliti', 'appos'), ('(', 'punct'), ('studi', 'appos'), ('puc-1', 'dep'), (')', 'punct'), ('placeboa', 'conj'), ('n', 'cc'), ('/', 'punct'), ('n', 'conj'), ('(', 'punct'), ('%', 'appos'), (')', 'punct'), (',', 'punct'), ('95', 'nummod'), ('%', 'npadvmod'), ('ci', 'compound'), ('humira', 'appos'), ('maximum', 'ROOT'), ('40', 'nummod'), ('mg', 'npadvmod'), ('(', 'punct'), ('0.6', 'nummod'), ('mg', 'nmod'), ('/', 'punct'), ('kg', 'appos'), (')', 'punct'), ('everi', 'compound'), ('weekb', 'nsubj'), ('n', 'cc'), ('/', 'punct'), ('n', 'conj'), ('(', 'punct'), ('%', 'parataxis'), (')', 'punct'), (',', 'punct'), ('95', 'nummod'), ('%', 'appos'), ('ci', 'compound'), ('humira', 'appos'), ('maximum', 'ROOT'), ('40', 'nummod'), ('mg', 'appos'), ('(', 'punct'), ('0.6', 'nummod'), ('mg', 'nmod'), ('/', 'punct'), ('kg', 'appos'), (')', 'punct'), ('everi', 'compound'), ('weekc', 'nsubj'), ('n', 'cc'), ('/', 'punct'), ('n', 'conj'), ('(', 'punct'), ('%', 'parataxis'), (')', 'punct'), (',', 'punct'), ('95', 'nummod'), ('%', 'npadvmod'), ('ci', 'compound'), ('clinic', 'appos'), ('remiss', 'compound'), ('week', 'npadvmod'), ('8', 'nummod'), ('pm', 'appos'), ('respond', 'ROOT'), ('4/12', 'nummod'), ('(', 'punct'), ('33', 'nummod'), ('%', 'npadvmod'), (')', 'punct'), ('(', 'punct'), ('10', 'nummod'), ('%', 'dep'), (',', 'punct'), ('65', 'nummod'), ('%', 'appos'), (')', 'punct'), ('9/31', 'appos'), ('(', 'punct'), ('29', 'nummod'), ('%', 'parataxis'), (')', 'punct'), ('(', 'punct'), ('14', 'nummod'), ('%', 'appos'), (',', 'punct'), ('48', 'nummod'), ('%', 'appos'), (')', 'punct'), ('14/31', 'nummod'), ('(', 'punct'), ('45', 'nummod'), ('%', 'appos'), (')', 'punct'), ('(', 'punct'), ('27', 'nummod'), ('%', 'nmod'), (',', 'punct'), ('64', 'nummod'), ('%', 'appos'), (')', 'punct'), ('clinic', 'compound'), ('respons', 'compound'), ('week', 'npadvmod'), ('8', 'nummod'), ('pm', 'nsubj'), ('respond', 'ROOT'), ('4/12', 'nummod'), ('(', 'punct'), ('33', 'nummod'), ('%', 'npadvmod'), (')', 'punct'), ('(', 'punct'), ('10', 'nummod'), ('%', 'dep'), (',', 'punct'), ('65', 'nummod'), ('%', 'appos'), (')', 'punct'), ('19/31', 'nummod'), ('(', 'punct'), ('61', 'nummod'), ('%', 'appos'), (')', 'punct'), ('(', 'punct'), ('42', 'nummod'), ('%', 'appos'), (',', 'punct'), ('78', 'nummod'), ('%', 'appos'), (')', 'punct'), ('21/31', 'appos'), ('(', 'punct'), ('68', 'nummod'), ('%', 'parataxis'), (')', 'punct'), ('(', 'punct'), ('49', 'nummod'), ('%', 'nsubj'), (',', 'punct'), ('83', 'nummod'), ('%', 'appos'), (')', 'punct'), ('endoscop', 'appos'), ('improv', 'compound'), ('week', 'appos'), ('8', 'nummod'), ('pm', 'appos'), ('respond', 'ROOT'), ('4/12', 'nummod'), ('(', 'punct'), ('33', 'nummod'), ('%', 'npadvmod'), (')', 'punct'), ('(', 'punct'), ('10', 'nummod'), ('%', 'ROOT'), (',', 'punct'), ('65', 'nummod'), ('%', 'appos'), (')', 'punct'), ('12/31', 'nummod'), ('(', 'punct'), ('39', 'nummod'), ('%', 'appos'), (')', 'punct'), ('(', 'punct'), ('22', 'nummod'), ('%', 'parataxis'), (',', 'punct'), ('58', 'nummod'), ('%', 'appos'), (')', 'punct'), ('16/31', 'nummod'), ('(', 'punct'), ('52', 'nummod'), ('%', 'ROOT'), (')', 'punct'), ('(', 'punct'), ('33', 'nummod'), ('%', 'appos'), (',', 'punct'), ('70', 'nummod'), ('%', 'appos'), (')', 'punct'), ('clinic', 'appos'), ('remiss', 'compound'), ('week', 'appos'), ('8', 'nummod'), ('pm', 'appos'), ('remitt', 'appos'), ('3/8', 'nummod'), ('(', 'punct'), ('38', 'nummod'), ('%', 'parataxis'), (')', 'punct'), ('(', 'punct'), ('9', 'nummod'), ('%', 'ROOT'), (',', 'punct'), ('76', 'nummod'), ('%', 'appos'), (')', 'punct'), ('9/21', 'appos'), ('(', 'punct'), ('43', 'nummod'), ('%', 'parataxis'), (')', 'punct'), ('(', 'punct'), ('22', 'nummod'), ('%', 'appos'), (',', 'punct'), ('66', 'nummod'), ('%', 'appos'), (')', 'punct'), ('10/22', 'appos'), ('(', 'punct'), ('45', 'nummod'), ('%', 'parataxis'), (')', 'punct'), ('(', 'punct'), ('24', 'nummod'), ('%', 'appos'), (',', 'punct'), ('68', 'nummod'), ('%', 'appos'), (')', 'punct'), ('ci', 'nmod'), ('=', 'compound'), ('confid', 'compound'), ('interv', 'compound'), ('twelv', 'compound'), ('patient', 'compound'), ('demonstr', 'compound'), ('clinic', 'compound'), ('respons', 'appos'), ('per', 'prep'), ('pm', 'compound'), ('week', 'pobj'), ('8', 'nummod'), ('random', 'amod'), ('receiv', 'compound'), ('placebo', 'appos'), ('.', 'punct')]}, {'original_sentence': 'There are limitations to the interpretability of the placebo data due to the \\nsmall sample size.', 'tokens': ['limitations', 'interpretability', 'placebo', 'data', 'due', 'small', 'sample', 'size', '.'], 'lemmatized': ['limitation', 'interpretability', 'placebo', 'data', 'due', 'small', 'sample', 'size', '.'], 'stemmed': ['limit', 'interpret', 'placebo', 'data', 'due', 'small', 'sampl', 'size', '.'], 'dependencies': [('limit', 'nsubj'), ('interpret', 'ROOT'), ('placebo', 'compound'), ('data', 'dobj'), ('due', 'prep'), ('small', 'amod'), ('sampl', 'compound'), ('size', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'b The every other week dosage studied during the 52-week PUC-I trial is a lower dosage than \\nthe recommended dosage of HUMIRA [see Dosage and Administration (2.4)].', 'tokens': ['b', 'every', 'week', 'dosage', 'studied', '52-week', 'PUC-I', 'trial', 'lower', 'dosage', 'recommended', 'dosage', 'HUMIRA', '[', 'see', 'Dosage', 'Administration', '(', '2.4', ')', ']', '.'], 'lemmatized': ['b', 'every', 'week', 'dosage', 'studied', '52-week', 'PUC-I', 'trial', 'lower', 'dosage', 'recommended', 'dosage', 'HUMIRA', '[', 'see', 'Dosage', 'Administration', '(', '2.4', ')', ']', '.'], 'stemmed': ['b', 'everi', 'week', 'dosag', 'studi', '52-week', 'puc-i', 'trial', 'lower', 'dosag', 'recommend', 'dosag', 'humira', '[', 'see', 'dosag', 'administr', '(', '2.4', ')', ']', '.'], 'dependencies': [('b', 'nmod'), ('everi', 'amod'), ('week', 'compound'), ('dosag', 'nmod'), ('studi', 'npadvmod'), ('52', 'nummod'), ('-', 'punct'), ('week', 'compound'), ('puc', 'compound'), ('-', 'punct'), ('i', 'compound'), ('trial', 'nsubj'), ('lower', 'amod'), ('dosag', 'compound'), ('recommend', 'compound'), ('dosag', 'compound'), ('humira', 'nsubj'), ('[', 'punct'), ('see', 'ROOT'), ('dosag', 'compound'), ('administr', 'dobj'), ('(', 'punct'), ('2.4', 'appos'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': 'c There are no anticipated clinically relevant differences in efficacy between the studied higher \\ndosage administered during the 52-week PUC-I trial and the recommended dosage of \\nHUMIRA.', 'tokens': ['c', 'anticipated', 'clinically', 'relevant', 'differences', 'efficacy', 'studied', 'higher', 'dosage', 'administered', '52-week', 'PUC-I', 'trial', 'recommended', 'dosage', 'HUMIRA', '.'], 'lemmatized': ['c', 'anticipated', 'clinically', 'relevant', 'difference', 'efficacy', 'studied', 'higher', 'dosage', 'administered', '52-week', 'PUC-I', 'trial', 'recommended', 'dosage', 'HUMIRA', '.'], 'stemmed': ['c', 'anticip', 'clinic', 'relev', 'differ', 'efficaci', 'studi', 'higher', 'dosag', 'administ', '52-week', 'puc-i', 'trial', 'recommend', 'dosag', 'humira', '.'], 'dependencies': [('c', 'compound'), ('anticip', 'compound'), ('clinic', 'compound'), ('relev', 'nsubj'), ('differ', 'ROOT'), ('efficaci', 'nmod'), ('studi', 'nmod'), ('higher', 'amod'), ('dosag', 'nmod'), ('administ', 'nmod'), ('52', 'nummod'), ('-', 'punct'), ('week', 'compound'), ('puc', 'compound'), ('-', 'punct'), ('i', 'compound'), ('trial', 'nsubj'), ('recommend', 'ccomp'), ('dosag', 'compound'), ('humira', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Note: Patients with missing values at Week 52 or who were randomized to receive re-\\ninduction or maintenance treatment due to disease flare were considered non-responders for \\nWeek 52 endpoints.', 'tokens': ['Note', ':', 'Patients', 'missing', 'values', 'Week', '52', 'randomized', 'receive', 're-', 'induction', 'maintenance', 'treatment', 'due', 'disease', 'flare', 'considered', 'non-responders', 'Week', '52', 'endpoints', '.'], 'lemmatized': ['Note', ':', 'Patients', 'missing', 'value', 'Week', '52', 'randomized', 'receive', 're-', 'induction', 'maintenance', 'treatment', 'due', 'disease', 'flare', 'considered', 'non-responders', 'Week', '52', 'endpoint', '.'], 'stemmed': ['note', ':', 'patient', 'miss', 'valu', 'week', '52', 'random', 'receiv', 're-', 'induct', 'mainten', 'treatment', 'due', 'diseas', 'flare', 'consid', 'non-respond', 'week', '52', 'endpoint', '.'], 'dependencies': [('note', 'ROOT'), (':', 'punct'), ('patient', 'compound'), ('miss', 'compound'), ('valu', 'compound'), ('week', 'npadvmod'), ('52', 'nummod'), ('random', 'amod'), ('receiv', 'nmod'), ('re-', 'prep'), ('induct', 'amod'), ('mainten', 'compound'), ('treatment', 'nsubj'), ('due', 'amod'), ('diseas', 'dobj'), ('flare', 'ccomp'), ('consid', 'advmod'), ('non', 'amod'), ('-', 'amod'), ('respond', 'amod'), ('week', 'nmod'), ('52', 'nummod'), ('endpoint', 'dobj'), ('.', 'punct')]}, {'original_sentence': '14.9 Plaque Psoriasis \\nThe safety and efficacy of HUMIRA were assessed in randomized, double-blind, placebo-\\ncontrolled studies in 1696 adult subjects with moderate to severe chronic plaque psoriasis (Ps) \\nwho were candidates for systemic therapy or phototherapy.', 'tokens': ['14.9', 'Plaque', 'Psoriasis', 'safety', 'efficacy', 'HUMIRA', 'assessed', 'randomized', ',', 'double-blind', ',', 'placebo-', 'controlled', 'studies', '1696', 'adult', 'subjects', 'moderate', 'severe', 'chronic', 'plaque', 'psoriasis', '(', 'Ps', ')', 'candidates', 'systemic', 'therapy', 'phototherapy', '.'], 'lemmatized': ['14.9', 'Plaque', 'Psoriasis', 'safety', 'efficacy', 'HUMIRA', 'assessed', 'randomized', ',', 'double-blind', ',', 'placebo-', 'controlled', 'study', '1696', 'adult', 'subject', 'moderate', 'severe', 'chronic', 'plaque', 'psoriasis', '(', 'Ps', ')', 'candidate', 'systemic', 'therapy', 'phototherapy', '.'], 'stemmed': ['14.9', 'plaqu', 'psoriasi', 'safeti', 'efficaci', 'humira', 'assess', 'random', ',', 'double-blind', ',', 'placebo-', 'control', 'studi', '1696', 'adult', 'subject', 'moder', 'sever', 'chronic', 'plaqu', 'psoriasi', '(', 'ps', ')', 'candid', 'system', 'therapi', 'phototherapi', '.'], 'dependencies': [('14.9', 'nummod'), ('plaqu', 'compound'), ('psoriasi', 'compound'), ('safeti', 'compound'), ('efficaci', 'compound'), ('humira', 'nsubj'), ('assess', 'ROOT'), ('random', 'dobj'), (',', 'punct'), ('double', 'amod'), ('-', 'punct'), ('blind', 'conj'), (',', 'punct'), ('placebo-', 'npadvmod'), ('control', 'compound'), ('studi', 'npadvmod'), ('1696', 'nummod'), ('adult', 'compound'), ('subject', 'compound'), ('moder', 'appos'), ('sever', 'compound'), ('chronic', 'amod'), ('plaqu', 'compound'), ('psoriasi', 'nsubj'), ('(', 'punct'), ('ps', 'nmod'), (')', 'punct'), ('candid', 'amod'), ('system', 'appos'), ('therapi', 'ccomp'), ('phototherapi', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Study Ps-I evaluated 1212 subjects with chronic Ps with ≥10% body surface area (BSA) \\ninvolvement, Physician’s Global Assessment (PGA) of at least moderate disease severity, and \\nPsoriasis Area and Severity Index (PASI) ≥12 within three treatment periods.', 'tokens': ['Study', 'Ps-I', 'evaluated', '1212', 'subjects', 'chronic', 'Ps', '≥10', '%', 'body', 'surface', 'area', '(', 'BSA', ')', 'involvement', ',', 'Physician', '’', 'Global', 'Assessment', '(', 'PGA', ')', 'least', 'moderate', 'disease', 'severity', ',', 'Psoriasis', 'Area', 'Severity', 'Index', '(', 'PASI', ')', '≥12', 'within', 'three', 'treatment', 'periods', '.'], 'lemmatized': ['Study', 'Ps-I', 'evaluated', '1212', 'subject', 'chronic', 'Ps', '≥10', '%', 'body', 'surface', 'area', '(', 'BSA', ')', 'involvement', ',', 'Physician', '’', 'Global', 'Assessment', '(', 'PGA', ')', 'least', 'moderate', 'disease', 'severity', ',', 'Psoriasis', 'Area', 'Severity', 'Index', '(', 'PASI', ')', '≥12', 'within', 'three', 'treatment', 'period', '.'], 'stemmed': ['studi', 'ps-i', 'evalu', '1212', 'subject', 'chronic', 'ps', '≥10', '%', 'bodi', 'surfac', 'area', '(', 'bsa', ')', 'involv', ',', 'physician', '’', 'global', 'assess', '(', 'pga', ')', 'least', 'moder', 'diseas', 'sever', ',', 'psoriasi', 'area', 'sever', 'index', '(', 'pasi', ')', '≥12', 'within', 'three', 'treatment', 'period', '.'], 'dependencies': [('studi', 'compound'), ('ps', 'compound'), ('-', 'punct'), ('i', 'nsubj'), ('evalu', 'nmod'), ('1212', 'nummod'), ('subject', 'compound'), ('chronic', 'compound'), ('ps', 'ROOT'), ('≥10', 'nummod'), ('%', 'compound'), ('bodi', 'compound'), ('surfac', 'compound'), ('area', 'nsubj'), ('(', 'punct'), ('bsa', 'appos'), (')', 'punct'), ('involv', 'ROOT'), (',', 'punct'), ('physician', 'nmod'), ('’', 'punct'), ('global', 'amod'), ('assess', 'conj'), ('(', 'punct'), ('pga', 'appos'), (')', 'punct'), ('least', 'advmod'), ('moder', 'conj'), ('diseas', 'nsubj'), ('sever', 'ccomp'), (',', 'punct'), ('psoriasi', 'compound'), ('area', 'compound'), ('sever', 'compound'), ('index', 'conj'), ('(', 'punct'), ('pasi', 'appos'), (')', 'punct'), ('≥12', 'ROOT'), ('within', 'prep'), ('three', 'nummod'), ('treatment', 'compound'), ('period', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'In period A, \\nsubjects received placebo or HUMIRA at an initial dose of 80 mg at Week 0 followed by a dose \\nof 40 mg every other week starting at Week 1.', 'tokens': ['period', ',', 'subjects', 'received', 'placebo', 'HUMIRA', 'initial', 'dose', '80', 'mg', 'Week', '0', 'followed', 'dose', '40', 'mg', 'every', 'week', 'starting', 'Week', '1', '.'], 'lemmatized': ['period', ',', 'subject', 'received', 'placebo', 'HUMIRA', 'initial', 'dose', '80', 'mg', 'Week', '0', 'followed', 'dose', '40', 'mg', 'every', 'week', 'starting', 'Week', '1', '.'], 'stemmed': ['period', ',', 'subject', 'receiv', 'placebo', 'humira', 'initi', 'dose', '80', 'mg', 'week', '0', 'follow', 'dose', '40', 'mg', 'everi', 'week', 'start', 'week', '1', '.'], 'dependencies': [('period', 'npadvmod'), (',', 'punct'), ('subject', 'amod'), ('receiv', 'compound'), ('placebo', 'compound'), ('humira', 'compound'), ('initi', 'nsubj'), ('dose', 'ROOT'), ('80', 'dobj'), ('mg', 'amod'), ('week', 'nmod'), ('0', 'nummod'), ('follow', 'compound'), ('dose', 'dobj'), ('40', 'nummod'), ('mg', 'nmod'), ('everi', 'amod'), ('week', 'npadvmod'), ('start', 'conj'), ('week', 'npadvmod'), ('1', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'After 16 weeks of therapy, subjects who achieved \\nat least a PASI 75 response at Week 16, defined as a PASI score improvement of at least 75% \\nrelative to baseline, entered period B and received open-label 40 mg HUMIRA every other week.', 'tokens': ['16', 'weeks', 'therapy', ',', 'subjects', 'achieved', 'least', 'PASI', '75', 'response', 'Week', '16', ',', 'defined', 'PASI', 'score', 'improvement', 'least', '75', '%', 'relative', 'baseline', ',', 'entered', 'period', 'B', 'received', 'open-label', '40', 'mg', 'HUMIRA', 'every', 'week', '.'], 'lemmatized': ['16', 'week', 'therapy', ',', 'subject', 'achieved', 'least', 'PASI', '75', 'response', 'Week', '16', ',', 'defined', 'PASI', 'score', 'improvement', 'least', '75', '%', 'relative', 'baseline', ',', 'entered', 'period', 'B', 'received', 'open-label', '40', 'mg', 'HUMIRA', 'every', 'week', '.'], 'stemmed': ['16', 'week', 'therapi', ',', 'subject', 'achiev', 'least', 'pasi', '75', 'respons', 'week', '16', ',', 'defin', 'pasi', 'score', 'improv', 'least', '75', '%', 'rel', 'baselin', ',', 'enter', 'period', 'b', 'receiv', 'open-label', '40', 'mg', 'humira', 'everi', 'week', '.'], 'dependencies': [('16', 'nummod'), ('week', 'npadvmod'), ('therapi', 'nsubj'), (',', 'punct'), ('subject', 'meta'), ('achiev', 'advmod'), ('least', 'nsubj'), ('pasi', 'ccomp'), ('75', 'nummod'), ('respons', 'compound'), ('week', 'npadvmod'), ('16', 'nummod'), (',', 'punct'), ('defin', 'dep'), ('pasi', 'compound'), ('score', 'ROOT'), ('improv', 'advmod'), ('least', 'advmod'), ('75', 'nummod'), ('%', 'compound'), ('rel', 'compound'), ('baselin', 'dobj'), (',', 'punct'), ('enter', 'conj'), ('period', 'dobj'), ('b', 'compound'), ('receiv', 'nmod'), ('open', 'amod'), ('-', 'punct'), ('label', 'dobj'), ('40', 'nummod'), ('mg', 'prep'), ('humira', 'pobj'), ('everi', 'compound'), ('week', 'npadvmod'), ('.', 'punct')]}], 'text': 'Table 16. Clinical Remission, Clinical Response and Endoscopic Improvement at Week 52 \\nin Pediatric Patients with Ulcerative Colitis (Study PUC-1)  \\n \\n  \\nPlaceboa \\n \\n \\n \\n \\nn/N (%), 95% CI \\nHUMIRA \\nMaximum of 40 mg \\n(0.6 mg/kg) every \\nother weekb \\n \\nn/N (%), 95% CI \\nHUMIRA \\nMaximum of 40 mg \\n(0.6 mg/kg) every \\nweekc \\n \\nn/N (%), 95% CI \\nClinical remission in \\nWeek 8 PMS responders \\n4/12 (33%) \\n(10%, 65%) \\n9/31 (29%) \\n(14%, 48%) \\n14/31 (45%) \\n(27%, 64%) \\nClinical response in \\nWeek 8 PMS responders \\n4/12 (33%) \\n(10%, 65%) \\n19/31 (61%) \\n(42%, 78%) \\n21/31 (68%) \\n(49%, 83%) \\nEndoscopic \\nimprovement in Week 8 \\nPMS responders \\n4/12 (33%) \\n(10%, 65%) \\n12/31 (39%) \\n(22%, 58%) \\n16/31 (52%) \\n(33%, 70%) \\nClinical remission in \\nWeek 8 PMS remitters \\n3/8 (38%) \\n(9%, 76%) \\n9/21 (43%) \\n(22%, 66%) \\n10/22 (45%) \\n(24%, 68%) \\nCI=Confidence interval \\na Twelve patients who demonstrated clinical response per PMS at Week 8 were randomized to \\nreceive placebo. There are limitations to the interpretability of the placebo data due to the \\nsmall sample size.  \\nb The every other week dosage studied during the 52-week PUC-I trial is a lower dosage than \\nthe recommended dosage of HUMIRA [see Dosage and Administration (2.4)]. \\nc There are no anticipated clinically relevant differences in efficacy between the studied higher \\ndosage administered during the 52-week PUC-I trial and the recommended dosage of \\nHUMIRA. \\nNote: Patients with missing values at Week 52 or who were randomized to receive re-\\ninduction or maintenance treatment due to disease flare were considered non-responders for \\nWeek 52 endpoints. \\n14.9 Plaque Psoriasis \\nThe safety and efficacy of HUMIRA were assessed in randomized, double-blind, placebo-\\ncontrolled studies in 1696 adult subjects with moderate to severe chronic plaque psoriasis (Ps) \\nwho were candidates for systemic therapy or phototherapy.  \\nStudy Ps-I evaluated 1212 subjects with chronic Ps with ≥10% body surface area (BSA) \\ninvolvement, Physician’s Global Assessment (PGA) of at least moderate disease severity, and \\nPsoriasis Area and Severity Index (PASI) ≥12 within three treatment periods. In period A, \\nsubjects received placebo or HUMIRA at an initial dose of 80 mg at Week 0 followed by a dose \\nof 40 mg every other week starting at Week 1. After 16 weeks of therapy, subjects who achieved \\nat least a PASI 75 response at Week 16, defined as a PASI score improvement of at least 75% \\nrelative to baseline, entered period B and received open-label 40 mg HUMIRA every other week. \\n'}, 'page_char_count': 2513, 'page_word_count': 395, 'sentences': ['Table 16.', 'Clinical Remission, Clinical Response and Endoscopic Improvement at Week 52 \\nin Pediatric Patients with Ulcerative Colitis (Study PUC-1)  \\n \\n  \\nPlaceboa \\n \\n \\n \\n \\nn/N (%), 95% CI \\nHUMIRA \\nMaximum of 40 mg \\n(0.6 mg/kg) every \\nother weekb \\n \\nn/N (%), 95% CI \\nHUMIRA \\nMaximum of 40 mg \\n(0.6 mg/kg) every \\nweekc \\n \\nn/N (%), 95% CI \\nClinical remission in \\nWeek 8 PMS responders \\n4/12 (33%) \\n(10%, 65%) \\n9/31 (29%) \\n(14%, 48%) \\n14/31 (45%) \\n(27%, 64%) \\nClinical response in \\nWeek 8 PMS responders \\n4/12 (33%) \\n(10%, 65%) \\n19/31 (61%) \\n(42%, 78%) \\n21/31 (68%) \\n(49%, 83%) \\nEndoscopic \\nimprovement in Week 8 \\nPMS responders \\n4/12 (33%) \\n(10%, 65%) \\n12/31 (39%) \\n(22%, 58%) \\n16/31 (52%) \\n(33%, 70%) \\nClinical remission in \\nWeek 8 PMS remitters \\n3/8 (38%) \\n(9%, 76%) \\n9/21 (43%) \\n(22%, 66%) \\n10/22 (45%) \\n(24%, 68%) \\nCI=Confidence interval \\na Twelve patients who demonstrated clinical response per PMS at Week 8 were randomized to \\nreceive placebo.', 'There are limitations to the interpretability of the placebo data due to the \\nsmall sample size.', ' \\nb The every other week dosage studied during the 52-week PUC-I trial is a lower dosage than \\nthe recommended dosage of HUMIRA [see Dosage and Administration (2.4)].', '\\nc There are no anticipated clinically relevant differences in efficacy between the studied higher \\ndosage administered during the 52-week PUC-I trial and the recommended dosage of \\nHUMIRA.', '\\nNote: Patients with missing values at Week 52 or who were randomized to receive re-\\ninduction or maintenance treatment due to disease flare were considered non-responders for \\nWeek 52 endpoints.', '\\n14.9 Plaque Psoriasis \\nThe safety and efficacy of HUMIRA were assessed in randomized, double-blind, placebo-\\ncontrolled studies in 1696 adult subjects with moderate to severe chronic plaque psoriasis (Ps) \\nwho were candidates for systemic therapy or phototherapy.', ' \\nStudy Ps-I evaluated 1212 subjects with chronic Ps with ≥10% body surface area (BSA) \\ninvolvement, Physician’s Global Assessment (PGA) of at least moderate disease severity, and \\nPsoriasis Area and Severity Index (PASI) ≥12 within three treatment periods.', 'In period A, \\nsubjects received placebo or HUMIRA at an initial dose of 80 mg at Week 0 followed by a dose \\nof 40 mg every other week starting at Week 1.', 'After 16 weeks of therapy, subjects who achieved \\nat least a PASI 75 response at Week 16, defined as a PASI score improvement of at least 75% \\nrelative to baseline, entered period B and received open-label 40 mg HUMIRA every other week.', '\\n'], 'page_sentence_count_spacy': 11}\n",
            "{'page_number': 49, 'text': 'After 17 weeks of open label therapy, subjects who maintained at least a PASI 75 response at \\nWeek 33 and were originally randomized to active therapy in period A were re-randomized in \\nperiod C to receive 40 mg HUMIRA every other week or placebo for an additional 19 weeks. \\nAcross all treatment groups the mean baseline PASI score was 19 and the baseline Physician’s \\nGlobal Assessment score ranged from “moderate” (53%) to “severe” (41%) to “very severe” \\n(6%).  \\nStudy Ps-II evaluated 99 subjects randomized to HUMIRA and 48 subjects randomized to \\nplacebo with chronic plaque psoriasis with ≥10% BSA involvement and PASI ≥12. Subjects \\nreceived placebo, or an initial dose of 80 mg HUMIRA at Week 0 followed by 40 mg every \\nother week starting at Week 1 for 16 weeks. Across all treatment groups the mean baseline PASI \\nscore was 21 and the baseline PGA score ranged from “moderate” (41%) to “severe” (51%) to \\n“very severe” (8%).  \\nStudies Ps-I and II evaluated the proportion of subjects who achieved “clear” or “minimal” \\ndisease on the 6-point PGA scale and the proportion of subjects who achieved a reduction in \\nPASI score of at least 75% (PASI 75) from baseline at Week 16 (see Table 17 and 18).  \\nAdditionally, Study Ps-I evaluated the proportion of subjects who maintained a PGA of “clear” \\nor “minimal” disease or a PASI 75 response after Week 33 and on or before Week 52.  \\nTable 17. Efficacy Results at 16 Weeks in Study Ps-I Number of Subjects (%) \\n  \\nHUMIRA 40 mg every other week \\nPlacebo \\n  \\nN = 814 \\nN = 398 \\nPGA: Clear or minimal*  \\n506 (62%) \\n17 (4%) \\nPASI 75 \\n578 (71%) \\n26 (7%) \\n* Clear = no plaque elevation, no scale, plus or minus hyperpigmentation or diffuse pink or red \\ncoloration \\nMinimal = possible but difficult to ascertain whether there is slight elevation of plaque above \\nnormal skin, plus or minus surface dryness with some white coloration, plus or minus up to red \\ncoloration  \\n \\n  \\nTable 18. Efficacy Results at 16 Weeks in Study Ps-II Number of Subjects (%) \\n  \\nHUMIRA 40 mg every other week \\nPlacebo \\n  \\nN = 99 \\nN = 48 \\nPGA: Clear or minimal*  \\n70 (71%) \\n5 (10%) \\nPASI 75 \\n77 (78%) \\n9 (19%) \\n* Clear = no plaque elevation, no scale, plus or minus hyperpigmentation or diffuse pink or red \\ncoloration \\nMinimal = possible but difficult to ascertain whether there is slight elevation of plaque above \\nnormal skin, plus or minus surface dryness with some white coloration, plus or minus up to red \\ncoloration  \\nAdditionally, in Study Ps-I, subjects on HUMIRA who maintained a PASI 75 were re-\\nrandomized to HUMIRA (N = 250) or placebo (N = 240) at Week 33. After 52 weeks of \\ntreatment with HUMIRA, more subjects on HUMIRA maintained efficacy when compared to \\n', 'processed_text': {'sentences': [{'original_sentence': 'After 17 weeks of open label therapy, subjects who maintained at least a PASI 75 response at \\nWeek 33 and were originally randomized to active therapy in period A were re-randomized in \\nperiod C to receive 40 mg HUMIRA every other week or placebo for an additional 19 weeks.', 'tokens': ['17', 'weeks', 'open', 'label', 'therapy', ',', 'subjects', 'maintained', 'least', 'PASI', '75', 'response', 'Week', '33', 'originally', 'randomized', 'active', 'therapy', 'period', 're-randomized', 'period', 'C', 'receive', '40', 'mg', 'HUMIRA', 'every', 'week', 'placebo', 'additional', '19', 'weeks', '.'], 'lemmatized': ['17', 'week', 'open', 'label', 'therapy', ',', 'subject', 'maintained', 'least', 'PASI', '75', 'response', 'Week', '33', 'originally', 'randomized', 'active', 'therapy', 'period', 're-randomized', 'period', 'C', 'receive', '40', 'mg', 'HUMIRA', 'every', 'week', 'placebo', 'additional', '19', 'week', '.'], 'stemmed': ['17', 'week', 'open', 'label', 'therapi', ',', 'subject', 'maintain', 'least', 'pasi', '75', 'respons', 'week', '33', 'origin', 'random', 'activ', 'therapi', 'period', 're-random', 'period', 'c', 'receiv', '40', 'mg', 'humira', 'everi', 'week', 'placebo', 'addit', '19', 'week', '.'], 'dependencies': [('17', 'nummod'), ('week', 'npadvmod'), ('open', 'amod'), ('label', 'compound'), ('therapi', 'nsubj'), (',', 'punct'), ('subject', 'conj'), ('maintain', 'ROOT'), ('least', 'advmod'), ('pasi', 'ccomp'), ('75', 'nummod'), ('respons', 'compound'), ('week', 'npadvmod'), ('33', 'nummod'), ('origin', 'appos'), ('random', 'amod'), ('activ', 'nmod'), ('therapi', 'amod'), ('period', 'appos'), ('re', 'amod'), ('-', 'amod'), ('random', 'amod'), ('period', 'compound'), ('c', 'compound'), ('receiv', 'dobj'), ('40', 'nummod'), ('mg', 'prep'), ('humira', 'compound'), ('everi', 'compound'), ('week', 'compound'), ('placebo', 'compound'), ('addit', 'conj'), ('19', 'nummod'), ('week', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Across all treatment groups the mean baseline PASI score was 19 and the baseline Physician’s \\nGlobal Assessment score ranged from “moderate” (53%) to “severe” (41%) to “very severe” \\n(6%).', 'tokens': ['Across', 'treatment', 'groups', 'mean', 'baseline', 'PASI', 'score', '19', 'baseline', 'Physician', '’', 'Global', 'Assessment', 'score', 'ranged', '“', 'moderate', '”', '(', '53', '%', ')', '“', 'severe', '”', '(', '41', '%', ')', '“', 'severe', '”', '(', '6', '%', ')', '.'], 'lemmatized': ['Across', 'treatment', 'group', 'mean', 'baseline', 'PASI', 'score', '19', 'baseline', 'Physician', '’', 'Global', 'Assessment', 'score', 'ranged', '“', 'moderate', '”', '(', '53', '%', ')', '“', 'severe', '”', '(', '41', '%', ')', '“', 'severe', '”', '(', '6', '%', ')', '.'], 'stemmed': ['across', 'treatment', 'group', 'mean', 'baselin', 'pasi', 'score', '19', 'baselin', 'physician', '’', 'global', 'assess', 'score', 'rang', '“', 'moder', '”', '(', '53', '%', ')', '“', 'sever', '”', '(', '41', '%', ')', '“', 'sever', '”', '(', '6', '%', ')', '.'], 'dependencies': [('across', 'prep'), ('treatment', 'compound'), ('group', 'pobj'), ('mean', 'nmod'), ('baselin', 'compound'), ('pasi', 'nsubj'), ('score', 'ccomp'), ('19', 'nummod'), ('baselin', 'compound'), ('physician', 'dobj'), ('’', 'punct'), ('global', 'amod'), ('assess', 'compound'), ('score', 'nsubj'), ('rang', 'nmod'), ('“', 'punct'), ('moder', 'appos'), ('”', 'punct'), ('(', 'punct'), ('53', 'nummod'), ('%', 'appos'), (')', 'punct'), ('“', 'punct'), ('sever', 'ROOT'), ('”', 'punct'), ('(', 'punct'), ('41', 'nummod'), ('%', 'dep'), (')', 'punct'), ('“', 'punct'), ('sever', 'dobj'), ('”', 'punct'), ('(', 'punct'), ('6', 'nummod'), ('%', 'dep'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Study Ps-II evaluated 99 subjects randomized to HUMIRA and 48 subjects randomized to \\nplacebo with chronic plaque psoriasis with ≥10% BSA involvement and PASI ≥12.', 'tokens': ['Study', 'Ps-II', 'evaluated', '99', 'subjects', 'randomized', 'HUMIRA', '48', 'subjects', 'randomized', 'placebo', 'chronic', 'plaque', 'psoriasis', '≥10', '%', 'BSA', 'involvement', 'PASI', '≥12', '.'], 'lemmatized': ['Study', 'Ps-II', 'evaluated', '99', 'subject', 'randomized', 'HUMIRA', '48', 'subject', 'randomized', 'placebo', 'chronic', 'plaque', 'psoriasis', '≥10', '%', 'BSA', 'involvement', 'PASI', '≥12', '.'], 'stemmed': ['studi', 'ps-ii', 'evalu', '99', 'subject', 'random', 'humira', '48', 'subject', 'random', 'placebo', 'chronic', 'plaqu', 'psoriasi', '≥10', '%', 'bsa', 'involv', 'pasi', '≥12', '.'], 'dependencies': [('studi', 'nmod'), ('ps', 'compound'), ('-', 'punct'), ('ii', 'nmod'), ('evalu', 'nmod'), ('99', 'nummod'), ('subject', 'nmod'), ('random', 'amod'), ('humira', 'nmod'), ('48', 'nummod'), ('subject', 'nmod'), ('random', 'amod'), ('placebo', 'compound'), ('chronic', 'amod'), ('plaqu', 'compound'), ('psoriasi', 'dep'), ('≥10', 'nummod'), ('%', 'compound'), ('bsa', 'nsubj'), ('involv', 'ROOT'), ('pasi', 'dobj'), ('≥12', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Subjects \\nreceived placebo, or an initial dose of 80 mg HUMIRA at Week 0 followed by 40 mg every \\nother week starting at Week 1 for 16 weeks.', 'tokens': ['Subjects', 'received', 'placebo', ',', 'initial', 'dose', '80', 'mg', 'HUMIRA', 'Week', '0', 'followed', '40', 'mg', 'every', 'week', 'starting', 'Week', '1', '16', 'weeks', '.'], 'lemmatized': ['Subjects', 'received', 'placebo', ',', 'initial', 'dose', '80', 'mg', 'HUMIRA', 'Week', '0', 'followed', '40', 'mg', 'every', 'week', 'starting', 'Week', '1', '16', 'week', '.'], 'stemmed': ['subject', 'receiv', 'placebo', ',', 'initi', 'dose', '80', 'mg', 'humira', 'week', '0', 'follow', '40', 'mg', 'everi', 'week', 'start', 'week', '1', '16', 'week', '.'], 'dependencies': [('subject', 'compound'), ('receiv', 'compound'), ('placebo', 'npadvmod'), (',', 'punct'), ('initi', 'npadvmod'), ('dose', 'ROOT'), ('80', 'nummod'), ('mg', 'compound'), ('humira', 'compound'), ('week', 'npadvmod'), ('0', 'nummod'), ('follow', 'dobj'), ('40', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'npadvmod'), ('start', 'conj'), ('week', 'npadvmod'), ('1', 'nummod'), ('16', 'nummod'), ('week', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Across all treatment groups the mean baseline PASI \\nscore was 21 and the baseline PGA score ranged from “moderate” (41%) to “severe” (51%) to \\n“very severe” (8%).', 'tokens': ['Across', 'treatment', 'groups', 'mean', 'baseline', 'PASI', 'score', '21', 'baseline', 'PGA', 'score', 'ranged', '“', 'moderate', '”', '(', '41', '%', ')', '“', 'severe', '”', '(', '51', '%', ')', '“', 'severe', '”', '(', '8', '%', ')', '.'], 'lemmatized': ['Across', 'treatment', 'group', 'mean', 'baseline', 'PASI', 'score', '21', 'baseline', 'PGA', 'score', 'ranged', '“', 'moderate', '”', '(', '41', '%', ')', '“', 'severe', '”', '(', '51', '%', ')', '“', 'severe', '”', '(', '8', '%', ')', '.'], 'stemmed': ['across', 'treatment', 'group', 'mean', 'baselin', 'pasi', 'score', '21', 'baselin', 'pga', 'score', 'rang', '“', 'moder', '”', '(', '41', '%', ')', '“', 'sever', '”', '(', '51', '%', ')', '“', 'sever', '”', '(', '8', '%', ')', '.'], 'dependencies': [('across', 'prep'), ('treatment', 'compound'), ('group', 'pobj'), ('mean', 'nmod'), ('baselin', 'compound'), ('pasi', 'nsubj'), ('score', 'nmod'), ('21', 'nummod'), ('baselin', 'compound'), ('pga', 'compound'), ('score', 'nsubj'), ('rang', 'nmod'), ('“', 'punct'), ('moder', 'dobj'), ('”', 'punct'), ('(', 'punct'), ('41', 'nummod'), ('%', 'appos'), (')', 'punct'), ('“', 'punct'), ('sever', 'ROOT'), ('”', 'punct'), ('(', 'punct'), ('51', 'nummod'), ('%', 'appos'), (')', 'punct'), ('“', 'punct'), ('sever', 'ccomp'), ('”', 'punct'), ('(', 'punct'), ('8', 'nummod'), ('%', 'npadvmod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Studies Ps-I and II evaluated the proportion of subjects who achieved “clear” or “minimal” \\ndisease on the 6-point PGA scale and the proportion of subjects who achieved a reduction in \\nPASI score of at least 75% (PASI 75) from baseline at Week 16 (see Table 17 and 18).', 'tokens': ['Studies', 'Ps-I', 'II', 'evaluated', 'proportion', 'subjects', 'achieved', '“', 'clear', '”', '“', 'minimal', '”', 'disease', '6-point', 'PGA', 'scale', 'proportion', 'subjects', 'achieved', 'reduction', 'PASI', 'score', 'least', '75', '%', '(', 'PASI', '75', ')', 'baseline', 'Week', '16', '(', 'see', 'Table', '17', '18', ')', '.'], 'lemmatized': ['Studies', 'Ps-I', 'II', 'evaluated', 'proportion', 'subject', 'achieved', '“', 'clear', '”', '“', 'minimal', '”', 'disease', '6-point', 'PGA', 'scale', 'proportion', 'subject', 'achieved', 'reduction', 'PASI', 'score', 'least', '75', '%', '(', 'PASI', '75', ')', 'baseline', 'Week', '16', '(', 'see', 'Table', '17', '18', ')', '.'], 'stemmed': ['studi', 'ps-i', 'ii', 'evalu', 'proport', 'subject', 'achiev', '“', 'clear', '”', '“', 'minim', '”', 'diseas', '6-point', 'pga', 'scale', 'proport', 'subject', 'achiev', 'reduct', 'pasi', 'score', 'least', '75', '%', '(', 'pasi', '75', ')', 'baselin', 'week', '16', '(', 'see', 'tabl', '17', '18', ')', '.'], 'dependencies': [('studi', 'nmod'), ('ps', 'nmod'), ('-', 'punct'), ('i', 'compound'), ('ii', 'compound'), ('evalu', 'compound'), ('proport', 'nmod'), ('subject', 'nmod'), ('achiev', 'amod'), ('“', 'punct'), ('clear', 'amod'), ('”', 'punct'), ('“', 'punct'), ('minim', 'nmod'), ('”', 'punct'), ('diseas', 'nmod'), ('6', 'nummod'), ('-', 'punct'), ('point', 'nmod'), ('pga', 'compound'), ('scale', 'compound'), ('proport', 'nmod'), ('subject', 'amod'), ('achiev', 'compound'), ('reduct', 'compound'), ('pasi', 'compound'), ('score', 'ROOT'), ('least', 'advmod'), ('75', 'nummod'), ('%', 'appos'), ('(', 'punct'), ('pasi', 'appos'), ('75', 'nummod'), (')', 'punct'), ('baselin', 'compound'), ('week', 'npadvmod'), ('16', 'nummod'), ('(', 'punct'), ('see', 'parataxis'), ('tabl', 'npadvmod'), ('17', 'nummod'), ('18', 'nummod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Additionally, Study Ps-I evaluated the proportion of subjects who maintained a PGA of “clear” \\nor “minimal” disease or a PASI 75 response after Week 33 and on or before Week 52.', 'tokens': ['Additionally', ',', 'Study', 'Ps-I', 'evaluated', 'proportion', 'subjects', 'maintained', 'PGA', '“', 'clear', '”', '“', 'minimal', '”', 'disease', 'PASI', '75', 'response', 'Week', '33', 'Week', '52', '.'], 'lemmatized': ['Additionally', ',', 'Study', 'Ps-I', 'evaluated', 'proportion', 'subject', 'maintained', 'PGA', '“', 'clear', '”', '“', 'minimal', '”', 'disease', 'PASI', '75', 'response', 'Week', '33', 'Week', '52', '.'], 'stemmed': ['addit', ',', 'studi', 'ps-i', 'evalu', 'proport', 'subject', 'maintain', 'pga', '“', 'clear', '”', '“', 'minim', '”', 'diseas', 'pasi', '75', 'respons', 'week', '33', 'week', '52', '.'], 'dependencies': [('addit', 'dep'), (',', 'punct'), ('studi', 'npadvmod'), ('ps', 'compound'), ('-', 'punct'), ('i', 'nsubj'), ('evalu', 'nsubj'), ('proport', 'compound'), ('subject', 'dobj'), ('maintain', 'ROOT'), ('pga', 'nmod'), ('“', 'punct'), ('clear', 'amod'), ('”', 'punct'), ('“', 'punct'), ('minim', 'nmod'), ('”', 'punct'), ('diseas', 'nsubj'), ('pasi', 'ccomp'), ('75', 'nummod'), ('respons', 'compound'), ('week', 'npadvmod'), ('33', 'nummod'), ('week', 'npadvmod'), ('52', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Table 17.', 'tokens': ['Table', '17', '.'], 'lemmatized': ['Table', '17', '.'], 'stemmed': ['tabl', '17', '.'], 'dependencies': [('tabl', 'ROOT'), ('17', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Efficacy Results at 16 Weeks in Study Ps-I Number of Subjects (%) \\n  \\nHUMIRA 40 mg every other week \\nPlacebo \\n  \\nN = 814 \\nN = 398 \\nPGA: Clear or minimal*  \\n506 (62%) \\n17 (4%) \\nPASI 75 \\n578 (71%) \\n26 (7%) \\n* Clear = no plaque elevation, no scale, plus or minus hyperpigmentation or diffuse pink or red \\ncoloration \\nMinimal = possible but difficult to ascertain whether there is slight elevation of plaque above \\nnormal skin, plus or minus surface dryness with some white coloration, plus or minus up to red \\ncoloration  \\n \\n  \\nTable 18.', 'tokens': ['Efficacy', 'Results', '16', 'Weeks', 'Study', 'Ps-I', 'Number', 'Subjects', '(', '%', ')', 'HUMIRA', '40', 'mg', 'every', 'week', 'Placebo', 'N', '=', '814', 'N', '=', '398', 'PGA', ':', 'Clear', 'minimal', '*', '506', '(', '62', '%', ')', '17', '(', '4', '%', ')', 'PASI', '75', '578', '(', '71', '%', ')', '26', '(', '7', '%', ')', '*', 'Clear', '=', 'plaque', 'elevation', ',', 'scale', ',', 'plus', 'minus', 'hyperpigmentation', 'diffuse', 'pink', 'red', 'coloration', 'Minimal', '=', 'possible', 'difficult', 'ascertain', 'whether', 'slight', 'elevation', 'plaque', 'normal', 'skin', ',', 'plus', 'minus', 'surface', 'dryness', 'white', 'coloration', ',', 'plus', 'minus', 'red', 'coloration', 'Table', '18', '.'], 'lemmatized': ['Efficacy', 'Results', '16', 'Weeks', 'Study', 'Ps-I', 'Number', 'Subjects', '(', '%', ')', 'HUMIRA', '40', 'mg', 'every', 'week', 'Placebo', 'N', '=', '814', 'N', '=', '398', 'PGA', ':', 'Clear', 'minimal', '*', '506', '(', '62', '%', ')', '17', '(', '4', '%', ')', 'PASI', '75', '578', '(', '71', '%', ')', '26', '(', '7', '%', ')', '*', 'Clear', '=', 'plaque', 'elevation', ',', 'scale', ',', 'plus', 'minus', 'hyperpigmentation', 'diffuse', 'pink', 'red', 'coloration', 'Minimal', '=', 'possible', 'difficult', 'ascertain', 'whether', 'slight', 'elevation', 'plaque', 'normal', 'skin', ',', 'plus', 'minus', 'surface', 'dryness', 'white', 'coloration', ',', 'plus', 'minus', 'red', 'coloration', 'Table', '18', '.'], 'stemmed': ['efficaci', 'result', '16', 'week', 'studi', 'ps-i', 'number', 'subject', '(', '%', ')', 'humira', '40', 'mg', 'everi', 'week', 'placebo', 'n', '=', '814', 'n', '=', '398', 'pga', ':', 'clear', 'minim', '*', '506', '(', '62', '%', ')', '17', '(', '4', '%', ')', 'pasi', '75', '578', '(', '71', '%', ')', '26', '(', '7', '%', ')', '*', 'clear', '=', 'plaqu', 'elev', ',', 'scale', ',', 'plu', 'minu', 'hyperpigment', 'diffus', 'pink', 'red', 'color', 'minim', '=', 'possibl', 'difficult', 'ascertain', 'whether', 'slight', 'elev', 'plaqu', 'normal', 'skin', ',', 'plu', 'minu', 'surfac', 'dryness', 'white', 'color', ',', 'plu', 'minu', 'red', 'color', 'tabl', '18', '.'], 'dependencies': [('efficaci', 'nsubj'), ('result', 'ROOT'), ('16', 'nummod'), ('week', 'npadvmod'), ('studi', 'compound'), ('ps', 'compound'), ('-', 'punct'), ('i', 'compound'), ('number', 'appos'), ('subject', 'appos'), ('(', 'punct'), ('%', 'parataxis'), (')', 'punct'), ('humira', 'appos'), ('40', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'compound'), ('placebo', 'npadvmod'), ('n', 'punct'), ('=', 'conj'), ('814', 'npadvmod'), ('n', 'cc'), ('=', 'nmod'), ('398', 'nummod'), ('pga', 'conj'), (':', 'punct'), ('clear', 'amod'), ('minim', 'appos'), ('*', 'punct'), ('506', 'nummod'), ('(', 'punct'), ('62', 'nummod'), ('%', 'nsubj'), (')', 'punct'), ('17', 'nummod'), ('(', 'punct'), ('4', 'nummod'), ('%', 'appos'), (')', 'punct'), ('pasi', 'ROOT'), ('75', 'compound'), ('578', 'nummod'), ('(', 'punct'), ('71', 'nummod'), ('%', 'npadvmod'), (')', 'punct'), ('26', 'appos'), ('(', 'punct'), ('7', 'nummod'), ('%', 'npadvmod'), (')', 'punct'), ('*', 'punct'), ('clear', 'amod'), ('=', 'nsubj'), ('plaqu', 'ccomp'), ('elev', 'dobj'), (',', 'punct'), ('scale', 'appos'), (',', 'punct'), ('plu', 'compound'), ('minu', 'compound'), ('hyperpigment', 'compound'), ('diffus', 'conj'), ('pink', 'amod'), ('red', 'amod'), ('color', 'compound'), ('minim', 'appos'), ('=', 'nsubj'), ('possibl', 'conj'), ('difficult', 'amod'), ('ascertain', 'dobj'), ('whether', 'mark'), ('slight', 'amod'), ('elev', 'nsubj'), ('plaqu', 'conj'), ('normal', 'amod'), ('skin', 'dobj'), (',', 'punct'), ('plu', 'compound'), ('minu', 'nsubj'), ('surfac', 'conj'), ('dryness', 'nmod'), ('white', 'amod'), ('color', 'dobj'), (',', 'punct'), ('plu', 'compound'), ('minu', 'ROOT'), ('red', 'amod'), ('color', 'dobj'), ('tabl', 'npadvmod'), ('18', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Efficacy Results at 16 Weeks in Study Ps-II Number of Subjects (%) \\n  \\nHUMIRA 40 mg every other week \\nPlacebo \\n  \\nN = 99 \\nN = 48 \\nPGA: Clear or minimal*  \\n70 (71%) \\n5 (10%) \\nPASI 75 \\n77 (78%) \\n9 (19%) \\n* Clear = no plaque elevation, no scale, plus or minus hyperpigmentation or diffuse pink or red \\ncoloration \\nMinimal = possible but difficult to ascertain whether there is slight elevation of plaque above \\nnormal skin, plus or minus surface dryness with some white coloration, plus or minus up to red \\ncoloration  \\nAdditionally, in Study Ps-I, subjects on HUMIRA who maintained a PASI 75 were re-\\nrandomized to HUMIRA (N = 250) or placebo (N = 240) at Week 33.', 'tokens': ['Efficacy', 'Results', '16', 'Weeks', 'Study', 'Ps-II', 'Number', 'Subjects', '(', '%', ')', 'HUMIRA', '40', 'mg', 'every', 'week', 'Placebo', 'N', '=', '99', 'N', '=', '48', 'PGA', ':', 'Clear', 'minimal', '*', '70', '(', '71', '%', ')', '5', '(', '10', '%', ')', 'PASI', '75', '77', '(', '78', '%', ')', '9', '(', '19', '%', ')', '*', 'Clear', '=', 'plaque', 'elevation', ',', 'scale', ',', 'plus', 'minus', 'hyperpigmentation', 'diffuse', 'pink', 'red', 'coloration', 'Minimal', '=', 'possible', 'difficult', 'ascertain', 'whether', 'slight', 'elevation', 'plaque', 'normal', 'skin', ',', 'plus', 'minus', 'surface', 'dryness', 'white', 'coloration', ',', 'plus', 'minus', 'red', 'coloration', 'Additionally', ',', 'Study', 'Ps-I', ',', 'subjects', 'HUMIRA', 'maintained', 'PASI', '75', 're-', 'randomized', 'HUMIRA', '(', 'N', '=', '250', ')', 'placebo', '(', 'N', '=', '240', ')', 'Week', '33', '.'], 'lemmatized': ['Efficacy', 'Results', '16', 'Weeks', 'Study', 'Ps-II', 'Number', 'Subjects', '(', '%', ')', 'HUMIRA', '40', 'mg', 'every', 'week', 'Placebo', 'N', '=', '99', 'N', '=', '48', 'PGA', ':', 'Clear', 'minimal', '*', '70', '(', '71', '%', ')', '5', '(', '10', '%', ')', 'PASI', '75', '77', '(', '78', '%', ')', '9', '(', '19', '%', ')', '*', 'Clear', '=', 'plaque', 'elevation', ',', 'scale', ',', 'plus', 'minus', 'hyperpigmentation', 'diffuse', 'pink', 'red', 'coloration', 'Minimal', '=', 'possible', 'difficult', 'ascertain', 'whether', 'slight', 'elevation', 'plaque', 'normal', 'skin', ',', 'plus', 'minus', 'surface', 'dryness', 'white', 'coloration', ',', 'plus', 'minus', 'red', 'coloration', 'Additionally', ',', 'Study', 'Ps-I', ',', 'subject', 'HUMIRA', 'maintained', 'PASI', '75', 're-', 'randomized', 'HUMIRA', '(', 'N', '=', '250', ')', 'placebo', '(', 'N', '=', '240', ')', 'Week', '33', '.'], 'stemmed': ['efficaci', 'result', '16', 'week', 'studi', 'ps-ii', 'number', 'subject', '(', '%', ')', 'humira', '40', 'mg', 'everi', 'week', 'placebo', 'n', '=', '99', 'n', '=', '48', 'pga', ':', 'clear', 'minim', '*', '70', '(', '71', '%', ')', '5', '(', '10', '%', ')', 'pasi', '75', '77', '(', '78', '%', ')', '9', '(', '19', '%', ')', '*', 'clear', '=', 'plaqu', 'elev', ',', 'scale', ',', 'plu', 'minu', 'hyperpigment', 'diffus', 'pink', 'red', 'color', 'minim', '=', 'possibl', 'difficult', 'ascertain', 'whether', 'slight', 'elev', 'plaqu', 'normal', 'skin', ',', 'plu', 'minu', 'surfac', 'dryness', 'white', 'color', ',', 'plu', 'minu', 'red', 'color', 'addit', ',', 'studi', 'ps-i', ',', 'subject', 'humira', 'maintain', 'pasi', '75', 're-', 'random', 'humira', '(', 'n', '=', '250', ')', 'placebo', '(', 'n', '=', '240', ')', 'week', '33', '.'], 'dependencies': [('efficaci', 'nsubj'), ('result', 'nsubj'), ('16', 'nummod'), ('week', 'npadvmod'), ('studi', 'compound'), ('ps', 'compound'), ('-', 'punct'), ('ii', 'compound'), ('number', 'compound'), ('subject', 'acomp'), ('(', 'punct'), ('%', 'appos'), (')', 'punct'), ('humira', 'appos'), ('40', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'compound'), ('placebo', 'npadvmod'), ('n', 'cc'), ('=', 'conj'), ('99', 'appos'), ('n', 'cc'), ('=', 'conj'), ('48', 'nummod'), ('pga', 'appos'), (':', 'punct'), ('clear', 'amod'), ('minim', 'appos'), ('*', 'punct'), ('70', 'appos'), ('(', 'punct'), ('71', 'nummod'), ('%', 'parataxis'), (')', 'punct'), ('5', 'nummod'), ('(', 'punct'), ('10', 'nummod'), ('%', 'appos'), (')', 'punct'), ('pasi', 'ROOT'), ('75', 'compound'), ('77', 'nummod'), ('(', 'punct'), ('78', 'nummod'), ('%', 'npadvmod'), (')', 'punct'), ('9', 'appos'), ('(', 'punct'), ('19', 'nummod'), ('%', 'parataxis'), (')', 'punct'), ('*', 'punct'), ('clear', 'amod'), ('=', 'nsubj'), ('plaqu', 'npadvmod'), ('elev', 'dobj'), (',', 'punct'), ('scale', 'appos'), (',', 'punct'), ('plu', 'compound'), ('minu', 'compound'), ('hyperpigment', 'compound'), ('diffus', 'conj'), ('pink', 'amod'), ('red', 'amod'), ('color', 'compound'), ('minim', 'appos'), ('=', 'nsubj'), ('possibl', 'conj'), ('difficult', 'amod'), ('ascertain', 'dobj'), ('whether', 'mark'), ('slight', 'amod'), ('elev', 'nsubj'), ('plaqu', 'advcl'), ('normal', 'amod'), ('skin', 'dobj'), (',', 'punct'), ('plu', 'compound'), ('minu', 'nsubj'), ('surfac', 'conj'), ('dryness', 'nmod'), ('white', 'amod'), ('color', 'dobj'), (',', 'punct'), ('plu', 'compound'), ('minu', 'compound'), ('red', 'amod'), ('color', 'compound'), ('addit', 'nsubj'), (',', 'punct'), ('studi', 'compound'), ('ps', 'compound'), ('-', 'punct'), ('i', 'conj'), (',', 'punct'), ('subject', 'amod'), ('humira', 'appos'), ('maintain', 'ROOT'), ('pasi', 'dative'), ('75', 'nummod'), ('re-', 'dep'), ('random', 'amod'), ('humira', 'nmod'), ('(', 'punct'), ('n', 'dep'), ('=', 'nmod'), ('250', 'nummod'), (')', 'punct'), ('placebo', 'nmod'), ('(', 'punct'), ('n', 'cc'), ('=', 'nmod'), ('240', 'nummod'), (')', 'punct'), ('week', 'npadvmod'), ('33', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'After 52 weeks of \\ntreatment with HUMIRA, more subjects on HUMIRA maintained efficacy when compared to', 'tokens': ['52', 'weeks', 'treatment', 'HUMIRA', ',', 'subjects', 'HUMIRA', 'maintained', 'efficacy', 'compared'], 'lemmatized': ['52', 'week', 'treatment', 'HUMIRA', ',', 'subject', 'HUMIRA', 'maintained', 'efficacy', 'compared'], 'stemmed': ['52', 'week', 'treatment', 'humira', ',', 'subject', 'humira', 'maintain', 'efficaci', 'compar'], 'dependencies': [('52', 'nummod'), ('week', 'compound'), ('treatment', 'compound'), ('humira', 'nsubj'), (',', 'punct'), ('subject', 'amod'), ('humira', 'nsubj'), ('maintain', 'ROOT'), ('efficaci', 'compound'), ('compar', 'dobj')]}], 'text': 'After 17 weeks of open label therapy, subjects who maintained at least a PASI 75 response at \\nWeek 33 and were originally randomized to active therapy in period A were re-randomized in \\nperiod C to receive 40 mg HUMIRA every other week or placebo for an additional 19 weeks. \\nAcross all treatment groups the mean baseline PASI score was 19 and the baseline Physician’s \\nGlobal Assessment score ranged from “moderate” (53%) to “severe” (41%) to “very severe” \\n(6%).  \\nStudy Ps-II evaluated 99 subjects randomized to HUMIRA and 48 subjects randomized to \\nplacebo with chronic plaque psoriasis with ≥10% BSA involvement and PASI ≥12. Subjects \\nreceived placebo, or an initial dose of 80 mg HUMIRA at Week 0 followed by 40 mg every \\nother week starting at Week 1 for 16 weeks. Across all treatment groups the mean baseline PASI \\nscore was 21 and the baseline PGA score ranged from “moderate” (41%) to “severe” (51%) to \\n“very severe” (8%).  \\nStudies Ps-I and II evaluated the proportion of subjects who achieved “clear” or “minimal” \\ndisease on the 6-point PGA scale and the proportion of subjects who achieved a reduction in \\nPASI score of at least 75% (PASI 75) from baseline at Week 16 (see Table 17 and 18).  \\nAdditionally, Study Ps-I evaluated the proportion of subjects who maintained a PGA of “clear” \\nor “minimal” disease or a PASI 75 response after Week 33 and on or before Week 52.  \\nTable 17. Efficacy Results at 16 Weeks in Study Ps-I Number of Subjects (%) \\n  \\nHUMIRA 40 mg every other week \\nPlacebo \\n  \\nN = 814 \\nN = 398 \\nPGA: Clear or minimal*  \\n506 (62%) \\n17 (4%) \\nPASI 75 \\n578 (71%) \\n26 (7%) \\n* Clear = no plaque elevation, no scale, plus or minus hyperpigmentation or diffuse pink or red \\ncoloration \\nMinimal = possible but difficult to ascertain whether there is slight elevation of plaque above \\nnormal skin, plus or minus surface dryness with some white coloration, plus or minus up to red \\ncoloration  \\n \\n  \\nTable 18. Efficacy Results at 16 Weeks in Study Ps-II Number of Subjects (%) \\n  \\nHUMIRA 40 mg every other week \\nPlacebo \\n  \\nN = 99 \\nN = 48 \\nPGA: Clear or minimal*  \\n70 (71%) \\n5 (10%) \\nPASI 75 \\n77 (78%) \\n9 (19%) \\n* Clear = no plaque elevation, no scale, plus or minus hyperpigmentation or diffuse pink or red \\ncoloration \\nMinimal = possible but difficult to ascertain whether there is slight elevation of plaque above \\nnormal skin, plus or minus surface dryness with some white coloration, plus or minus up to red \\ncoloration  \\nAdditionally, in Study Ps-I, subjects on HUMIRA who maintained a PASI 75 were re-\\nrandomized to HUMIRA (N = 250) or placebo (N = 240) at Week 33. After 52 weeks of \\ntreatment with HUMIRA, more subjects on HUMIRA maintained efficacy when compared to \\n'}, 'page_char_count': 2702, 'page_word_count': 465, 'sentences': ['After 17 weeks of open label therapy, subjects who maintained at least a PASI 75 response at \\nWeek 33 and were originally randomized to active therapy in period A were re-randomized in \\nperiod C to receive 40 mg HUMIRA every other week or placebo for an additional 19 weeks.', '\\nAcross all treatment groups the mean baseline PASI score was 19 and the baseline Physician’s \\nGlobal Assessment score ranged from “moderate” (53%) to “severe” (41%) to “very severe” \\n(6%).', ' \\nStudy Ps-II evaluated 99 subjects randomized to HUMIRA and 48 subjects randomized to \\nplacebo with chronic plaque psoriasis with ≥10% BSA involvement and PASI ≥12.', 'Subjects \\nreceived placebo, or an initial dose of 80 mg HUMIRA at Week 0 followed by 40 mg every \\nother week starting at Week 1 for 16 weeks.', 'Across all treatment groups the mean baseline PASI \\nscore was 21 and the baseline PGA score ranged from “moderate” (41%) to “severe” (51%) to \\n“very severe” (8%).', ' \\nStudies Ps-I and II evaluated the proportion of subjects who achieved “clear” or “minimal” \\ndisease on the 6-point PGA scale and the proportion of subjects who achieved a reduction in \\nPASI score of at least 75% (PASI 75) from baseline at Week 16 (see Table 17 and 18).', ' \\nAdditionally, Study Ps-I evaluated the proportion of subjects who maintained a PGA of “clear” \\nor “minimal” disease or a PASI 75 response after Week 33 and on or before Week 52.', ' \\nTable 17.', 'Efficacy Results at 16 Weeks in Study Ps-I Number of Subjects (%) \\n  \\nHUMIRA 40 mg every other week \\nPlacebo \\n  \\nN = 814 \\nN = 398 \\nPGA: Clear or minimal*  \\n506 (62%) \\n17 (4%) \\nPASI 75 \\n578 (71%) \\n26 (7%) \\n* Clear = no plaque elevation, no scale, plus or minus hyperpigmentation or diffuse pink or red \\ncoloration \\nMinimal = possible but difficult to ascertain whether there is slight elevation of plaque above \\nnormal skin, plus or minus surface dryness with some white coloration, plus or minus up to red \\ncoloration  \\n \\n  \\nTable 18.', 'Efficacy Results at 16 Weeks in Study Ps-II Number of Subjects (%) \\n  \\nHUMIRA 40 mg every other week \\nPlacebo \\n  \\nN = 99 \\nN = 48 \\nPGA: Clear or minimal*  \\n70 (71%) \\n5 (10%) \\nPASI 75 \\n77 (78%) \\n9 (19%) \\n* Clear = no plaque elevation, no scale, plus or minus hyperpigmentation or diffuse pink or red \\ncoloration \\nMinimal = possible but difficult to ascertain whether there is slight elevation of plaque above \\nnormal skin, plus or minus surface dryness with some white coloration, plus or minus up to red \\ncoloration  \\nAdditionally, in Study Ps-I, subjects on HUMIRA who maintained a PASI 75 were re-\\nrandomized to HUMIRA (N = 250) or placebo (N = 240) at Week 33.', 'After 52 weeks of \\ntreatment with HUMIRA, more subjects on HUMIRA maintained efficacy when compared to \\n'], 'page_sentence_count_spacy': 11}\n",
            "{'page_number': 50, 'text': 'subjects who were re-randomized to placebo based on maintenance of PGA of “clear” or \\n“minimal” disease (68% vs. 28%) or a PASI 75 (79% vs. 43%).  \\nA total of 347 stable responders participated in a withdrawal and retreatment evaluation in an \\nopen-label extension study. Median time to relapse (decline to PGA “moderate” or worse) was \\napproximately 5 months. During the withdrawal period, no subject experienced transformation to \\neither pustular or erythrodermic psoriasis. A total of 178 subjects who relapsed re-initiated \\ntreatment with 80 mg of HUMIRA, then 40 mg every other week beginning at week 1. At week \\n16, 69% (123/178) of subjects had a response of PGA “clear” or “minimal”.  \\nA randomized, double-blind study (Study Ps-III) compared the efficacy and safety of HUMIRA \\nversus placebo in 217 adult subjects. Subjects in the study had to have chronic plaque psoriasis \\nof at least moderate severity on the PGA scale, fingernail involvement of at least moderate \\nseverity on a 5-point Physician’s Global Assessment of Fingernail Psoriasis (PGA-F) scale, a \\nModified Nail Psoriasis Severity Index (mNAPSI) score for the target-fingernail of ≥ 8, and \\neither a BSA involvement of at least 10% or a BSA involvement of at least 5% with a total \\nmNAPSI score for all fingernails of ≥ 20. Subjects received an initial dose of 80 mg HUMIRA \\nfollowed by 40 mg every other week (starting one week after the initial dose) or placebo for 26 \\nweeks followed by open-label HUMIRA treatment for an additional 26 weeks. This study \\nevaluated the proportion of subjects who achieved “clear” or “minimal” assessment with at least \\na 2-grade improvement on the PGA-F scale and the proportion of subjects who achieved at least \\na 75% improvement from baseline in the mNAPSI score (mNAPSI 75) at Week 26.  \\nAt Week 26, a higher proportion of subjects in the HUMIRA group than in the placebo group \\nachieved the PGA-F endpoint. Furthermore, a higher proportion of subjects in the HUMIRA \\ngroup than in the placebo group achieved mNAPSI 75 at Week 26 (see Table 19).  \\nTable 19. Efficacy Results at 26 Weeks \\n Endpoint \\nHUMIRA 40 mg \\nevery other week* \\nN=109  \\nPlacebo \\nN=108  \\nPGA-F: ≥2-grade improvement and \\nclear or minimal \\n49% \\n7% \\nmNAPSI 75 \\n47% \\n3% \\n*Subjects received 80 mg of HUMIRA at Week 0, followed by 40 mg every other week starting \\nat Week 1.  \\n \\n  \\nNail pain was also evaluated and improvement in nail pain was observed in Study Ps-III.  \\n14.10 Hidradenitis Suppurativa \\nTwo randomized, double-blind, placebo-controlled studies (Studies HS-I and II) evaluated the \\nsafety and efficacy of HUMIRA in a total of 633 adult subjects with moderate to severe \\nhidradenitis suppurativa (HS) with Hurley Stage II or III disease and with at least 3 abscesses or \\ninflammatory nodules. In both studies, subjects received placebo or HUMIRA at an initial dose \\nof 160 mg at Week 0, 80 mg at Week 2, and 40 mg every week starting at Week 4 and continued \\nthrough Week 11. Subjects used topical antiseptic wash daily. Concomitant oral antibiotic use \\nwas allowed in Study HS-II.  \\n', 'processed_text': {'sentences': [{'original_sentence': 'subjects who were re-randomized to placebo based on maintenance of PGA of “clear” or \\n“minimal” disease (68% vs. 28%) or a PASI 75 (79% vs. 43%).', 'tokens': ['subjects', 're-randomized', 'placebo', 'based', 'maintenance', 'PGA', '“', 'clear', '”', '“', 'minimal', '”', 'disease', '(', '68', '%', 'vs.', '28', '%', ')', 'PASI', '75', '(', '79', '%', 'vs.', '43', '%', ')', '.'], 'lemmatized': ['subject', 're-randomized', 'placebo', 'based', 'maintenance', 'PGA', '“', 'clear', '”', '“', 'minimal', '”', 'disease', '(', '68', '%', 'vs.', '28', '%', ')', 'PASI', '75', '(', '79', '%', 'vs.', '43', '%', ')', '.'], 'stemmed': ['subject', 're-random', 'placebo', 'base', 'mainten', 'pga', '“', 'clear', '”', '“', 'minim', '”', 'diseas', '(', '68', '%', 'vs.', '28', '%', ')', 'pasi', '75', '(', '79', '%', 'vs.', '43', '%', ')', '.'], 'dependencies': [('subject', 'amod'), ('re', 'amod'), ('-', 'amod'), ('random', 'amod'), ('placebo', 'compound'), ('base', 'nmod'), ('mainten', 'nmod'), ('pga', 'nmod'), ('“', 'punct'), ('clear', 'amod'), ('”', 'punct'), ('“', 'punct'), ('minim', 'nmod'), ('”', 'punct'), ('diseas', 'ROOT'), ('(', 'punct'), ('68', 'nummod'), ('%', 'nmod'), ('vs.', 'prep'), ('28', 'nummod'), ('%', 'pobj'), (')', 'punct'), ('pasi', 'appos'), ('75', 'nummod'), ('(', 'punct'), ('79', 'nummod'), ('%', 'appos'), ('vs.', 'prep'), ('43', 'nummod'), ('%', 'pobj'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'A total of 347 stable responders participated in a withdrawal and retreatment evaluation in an \\nopen-label extension study.', 'tokens': ['total', '347', 'stable', 'responders', 'participated', 'withdrawal', 'retreatment', 'evaluation', 'open-label', 'extension', 'study', '.'], 'lemmatized': ['total', '347', 'stable', 'responder', 'participated', 'withdrawal', 'retreatment', 'evaluation', 'open-label', 'extension', 'study', '.'], 'stemmed': ['total', '347', 'stabl', 'respond', 'particip', 'withdraw', 'retreat', 'evalu', 'open-label', 'extens', 'studi', '.'], 'dependencies': [('total', 'ROOT'), ('347', 'nummod'), ('stabl', 'amod'), ('respond', 'compound'), ('particip', 'nsubj'), ('withdraw', 'xcomp'), ('retreat', 'nmod'), ('evalu', 'compound'), ('open', 'amod'), ('-', 'punct'), ('label', 'compound'), ('extens', 'compound'), ('studi', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Median time to relapse (decline to PGA “moderate” or worse) was \\napproximately 5 months.', 'tokens': ['Median', 'time', 'relapse', '(', 'decline', 'PGA', '“', 'moderate', '”', 'worse', ')', 'approximately', '5', 'months', '.'], 'lemmatized': ['Median', 'time', 'relapse', '(', 'decline', 'PGA', '“', 'moderate', '”', 'worse', ')', 'approximately', '5', 'month', '.'], 'stemmed': ['median', 'time', 'relaps', '(', 'declin', 'pga', '“', 'moder', '”', 'wors', ')', 'approxim', '5', 'month', '.'], 'dependencies': [('median', 'amod'), ('time', 'compound'), ('relaps', 'nsubj'), ('(', 'punct'), ('declin', 'nmod'), ('pga', 'nmod'), ('“', 'punct'), ('moder', 'nmod'), ('”', 'punct'), ('wors', 'appos'), (')', 'punct'), ('approxim', 'ROOT'), ('5', 'nummod'), ('month', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'During the withdrawal period, no subject experienced transformation to \\neither pustular or erythrodermic psoriasis.', 'tokens': ['withdrawal', 'period', ',', 'subject', 'experienced', 'transformation', 'either', 'pustular', 'erythrodermic', 'psoriasis', '.'], 'lemmatized': ['withdrawal', 'period', ',', 'subject', 'experienced', 'transformation', 'either', 'pustular', 'erythrodermic', 'psoriasis', '.'], 'stemmed': ['withdraw', 'period', ',', 'subject', 'experienc', 'transform', 'either', 'pustular', 'erythroderm', 'psoriasi', '.'], 'dependencies': [('withdraw', 'advcl'), ('period', 'dobj'), (',', 'punct'), ('subject', 'amod'), ('experienc', 'compound'), ('transform', 'ROOT'), ('either', 'det'), ('pustular', 'amod'), ('erythroderm', 'compound'), ('psoriasi', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'A total of 178 subjects who relapsed re-initiated \\ntreatment with 80 mg of HUMIRA, then 40 mg every other week beginning at week 1.', 'tokens': ['total', '178', 'subjects', 'relapsed', 're-initiated', 'treatment', '80', 'mg', 'HUMIRA', ',', '40', 'mg', 'every', 'week', 'beginning', 'week', '1', '.'], 'lemmatized': ['total', '178', 'subject', 'relapsed', 're-initiated', 'treatment', '80', 'mg', 'HUMIRA', ',', '40', 'mg', 'every', 'week', 'beginning', 'week', '1', '.'], 'stemmed': ['total', '178', 'subject', 'relaps', 're-initi', 'treatment', '80', 'mg', 'humira', ',', '40', 'mg', 'everi', 'week', 'begin', 'week', '1', '.'], 'dependencies': [('total', 'advcl'), ('178', 'nummod'), ('subject', 'amod'), ('relaps', 'dobj'), ('re', 'dobj'), ('-', 'compound'), ('initi', 'compound'), ('treatment', 'dobj'), ('80', 'nummod'), ('mg', 'prep'), ('humira', 'pobj'), (',', 'punct'), ('40', 'nummod'), ('mg', 'nmod'), ('everi', 'amod'), ('week', 'npadvmod'), ('begin', 'ROOT'), ('week', 'npadvmod'), ('1', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'At week \\n16, 69% (123/178) of subjects had a response of PGA “clear” or “minimal”.', 'tokens': ['week', '16', ',', '69', '%', '(', '123/178', ')', 'subjects', 'response', 'PGA', '“', 'clear', '”', '“', 'minimal', '”', '.'], 'lemmatized': ['week', '16', ',', '69', '%', '(', '123/178', ')', 'subject', 'response', 'PGA', '“', 'clear', '”', '“', 'minimal', '”', '.'], 'stemmed': ['week', '16', ',', '69', '%', '(', '123/178', ')', 'subject', 'respons', 'pga', '“', 'clear', '”', '“', 'minim', '”', '.'], 'dependencies': [('week', 'npadvmod'), ('16', 'nummod'), (',', 'punct'), ('69', 'nummod'), ('%', 'nmod'), ('(', 'punct'), ('123/178', 'nmod'), (')', 'punct'), ('subject', 'amod'), ('respons', 'compound'), ('pga', 'nmod'), ('“', 'punct'), ('clear', 'amod'), ('”', 'punct'), ('“', 'punct'), ('minim', 'ROOT'), ('”', 'punct'), ('.', 'punct')]}, {'original_sentence': 'A randomized, double-blind study (Study Ps-III) compared the efficacy and safety of HUMIRA \\nversus placebo in 217 adult subjects.', 'tokens': ['randomized', ',', 'double-blind', 'study', '(', 'Study', 'Ps-III', ')', 'compared', 'efficacy', 'safety', 'HUMIRA', 'versus', 'placebo', '217', 'adult', 'subjects', '.'], 'lemmatized': ['randomized', ',', 'double-blind', 'study', '(', 'Study', 'Ps-III', ')', 'compared', 'efficacy', 'safety', 'HUMIRA', 'versus', 'placebo', '217', 'adult', 'subject', '.'], 'stemmed': ['random', ',', 'double-blind', 'studi', '(', 'studi', 'ps-iii', ')', 'compar', 'efficaci', 'safeti', 'humira', 'versu', 'placebo', '217', 'adult', 'subject', '.'], 'dependencies': [('random', 'amod'), (',', 'punct'), ('double', 'amod'), ('-', 'punct'), ('blind', 'amod'), ('studi', 'nsubj'), ('(', 'punct'), ('studi', 'compound'), ('ps', 'compound'), ('-', 'punct'), ('iii', 'appos'), (')', 'punct'), ('compar', 'compound'), ('efficaci', 'compound'), ('safeti', 'compound'), ('humira', 'compound'), ('versu', 'nmod'), ('placebo', 'nmod'), ('217', 'nummod'), ('adult', 'compound'), ('subject', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Subjects in the study had to have chronic plaque psoriasis \\nof at least moderate severity on the PGA scale, fingernail involvement of at least moderate \\nseverity on a 5-point Physician’s Global Assessment of Fingernail Psoriasis (PGA-F) scale, a \\nModified Nail Psoriasis Severity Index (mNAPSI) score for the target-fingernail of ≥ 8, and \\neither a BSA involvement of at least 10% or a BSA involvement of at least 5% with a total \\nmNAPSI score for all fingernails of ≥ 20.', 'tokens': ['Subjects', 'study', 'chronic', 'plaque', 'psoriasis', 'least', 'moderate', 'severity', 'PGA', 'scale', ',', 'fingernail', 'involvement', 'least', 'moderate', 'severity', '5-point', 'Physician', '’', 'Global', 'Assessment', 'Fingernail', 'Psoriasis', '(', 'PGA-F', ')', 'scale', ',', 'Modified', 'Nail', 'Psoriasis', 'Severity', 'Index', '(', 'mNAPSI', ')', 'score', 'target-fingernail', '≥', '8', ',', 'either', 'BSA', 'involvement', 'least', '10', '%', 'BSA', 'involvement', 'least', '5', '%', 'total', 'mNAPSI', 'score', 'fingernails', '≥', '20', '.'], 'lemmatized': ['Subjects', 'study', 'chronic', 'plaque', 'psoriasis', 'least', 'moderate', 'severity', 'PGA', 'scale', ',', 'fingernail', 'involvement', 'least', 'moderate', 'severity', '5-point', 'Physician', '’', 'Global', 'Assessment', 'Fingernail', 'Psoriasis', '(', 'PGA-F', ')', 'scale', ',', 'Modified', 'Nail', 'Psoriasis', 'Severity', 'Index', '(', 'mNAPSI', ')', 'score', 'target-fingernail', '≥', '8', ',', 'either', 'BSA', 'involvement', 'least', '10', '%', 'BSA', 'involvement', 'least', '5', '%', 'total', 'mNAPSI', 'score', 'fingernail', '≥', '20', '.'], 'stemmed': ['subject', 'studi', 'chronic', 'plaqu', 'psoriasi', 'least', 'moder', 'sever', 'pga', 'scale', ',', 'fingernail', 'involv', 'least', 'moder', 'sever', '5-point', 'physician', '’', 'global', 'assess', 'fingernail', 'psoriasi', '(', 'pga-f', ')', 'scale', ',', 'modifi', 'nail', 'psoriasi', 'sever', 'index', '(', 'mnapsi', ')', 'score', 'target-fingernail', '≥', '8', ',', 'either', 'bsa', 'involv', 'least', '10', '%', 'bsa', 'involv', 'least', '5', '%', 'total', 'mnapsi', 'score', 'fingernail', '≥', '20', '.'], 'dependencies': [('subject', 'compound'), ('studi', 'nmod'), ('chronic', 'amod'), ('plaqu', 'compound'), ('psoriasi', 'npadvmod'), ('least', 'advmod'), ('moder', 'nsubj'), ('sever', 'advcl'), ('pga', 'compound'), ('scale', 'dobj'), (',', 'punct'), ('fingernail', 'nsubj'), ('involv', 'nmod'), ('least', 'amod'), ('moder', 'nsubj'), ('sever', 'ccomp'), ('5', 'nummod'), ('-', 'punct'), ('point', 'compound'), ('physician', 'nmod'), ('’', 'punct'), ('global', 'amod'), ('assess', 'compound'), ('fingernail', 'compound'), ('psoriasi', 'nmod'), ('(', 'punct'), ('pga', 'nmod'), ('-', 'punct'), ('f', 'dep'), (')', 'punct'), ('scale', 'dobj'), (',', 'punct'), ('modifi', 'nmod'), ('nail', 'compound'), ('psoriasi', 'compound'), ('sever', 'compound'), ('index', 'appos'), ('(', 'punct'), ('mnapsi', 'nmod'), (')', 'punct'), ('score', 'nmod'), ('target', 'compound'), ('-', 'punct'), ('fingernail', 'compound'), ('≥', 'appos'), ('8', 'nummod'), (',', 'punct'), ('either', 'det'), ('bsa', 'nsubj'), ('involv', 'ROOT'), ('least', 'advmod'), ('10', 'nummod'), ('%', 'compound'), ('bsa', 'nsubj'), ('involv', 'conj'), ('least', 'advmod'), ('5', 'nummod'), ('%', 'npadvmod'), ('total', 'amod'), ('mnapsi', 'compound'), ('score', 'compound'), ('fingernail', 'npadvmod'), ('≥', 'nummod'), ('20', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Subjects received an initial dose of 80 mg HUMIRA \\nfollowed by 40 mg every other week (starting one week after the initial dose) or placebo for 26 \\nweeks followed by open-label HUMIRA treatment for an additional 26 weeks.', 'tokens': ['Subjects', 'received', 'initial', 'dose', '80', 'mg', 'HUMIRA', 'followed', '40', 'mg', 'every', 'week', '(', 'starting', 'one', 'week', 'initial', 'dose', ')', 'placebo', '26', 'weeks', 'followed', 'open-label', 'HUMIRA', 'treatment', 'additional', '26', 'weeks', '.'], 'lemmatized': ['Subjects', 'received', 'initial', 'dose', '80', 'mg', 'HUMIRA', 'followed', '40', 'mg', 'every', 'week', '(', 'starting', 'one', 'week', 'initial', 'dose', ')', 'placebo', '26', 'week', 'followed', 'open-label', 'HUMIRA', 'treatment', 'additional', '26', 'week', '.'], 'stemmed': ['subject', 'receiv', 'initi', 'dose', '80', 'mg', 'humira', 'follow', '40', 'mg', 'everi', 'week', '(', 'start', 'one', 'week', 'initi', 'dose', ')', 'placebo', '26', 'week', 'follow', 'open-label', 'humira', 'treatment', 'addit', '26', 'week', '.'], 'dependencies': [('subject', 'compound'), ('receiv', 'compound'), ('initi', 'nsubj'), ('dose', 'ROOT'), ('80', 'nummod'), ('mg', 'nmod'), ('humira', 'dobj'), ('follow', 'dep'), ('40', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'npadvmod'), ('(', 'punct'), ('start', 'parataxis'), ('one', 'nummod'), ('week', 'compound'), ('initi', 'compound'), ('dose', 'npadvmod'), (')', 'punct'), ('placebo', 'dobj'), ('26', 'nummod'), ('week', 'npadvmod'), ('follow', 'conj'), ('open', 'amod'), ('-', 'punct'), ('label', 'compound'), ('humira', 'compound'), ('treatment', 'compound'), ('addit', 'dobj'), ('26', 'nummod'), ('week', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'This study \\nevaluated the proportion of subjects who achieved “clear” or “minimal” assessment with at least \\na 2-grade improvement on the PGA-F scale and the proportion of subjects who achieved at least \\na 75% improvement from baseline in the mNAPSI score (mNAPSI 75) at Week 26.', 'tokens': ['study', 'evaluated', 'proportion', 'subjects', 'achieved', '“', 'clear', '”', '“', 'minimal', '”', 'assessment', 'least', '2-grade', 'improvement', 'PGA-F', 'scale', 'proportion', 'subjects', 'achieved', 'least', '75', '%', 'improvement', 'baseline', 'mNAPSI', 'score', '(', 'mNAPSI', '75', ')', 'Week', '26', '.'], 'lemmatized': ['study', 'evaluated', 'proportion', 'subject', 'achieved', '“', 'clear', '”', '“', 'minimal', '”', 'assessment', 'least', '2-grade', 'improvement', 'PGA-F', 'scale', 'proportion', 'subject', 'achieved', 'least', '75', '%', 'improvement', 'baseline', 'mNAPSI', 'score', '(', 'mNAPSI', '75', ')', 'Week', '26', '.'], 'stemmed': ['studi', 'evalu', 'proport', 'subject', 'achiev', '“', 'clear', '”', '“', 'minim', '”', 'assess', 'least', '2-grade', 'improv', 'pga-f', 'scale', 'proport', 'subject', 'achiev', 'least', '75', '%', 'improv', 'baselin', 'mnapsi', 'score', '(', 'mnapsi', '75', ')', 'week', '26', '.'], 'dependencies': [('studi', 'compound'), ('evalu', 'compound'), ('proport', 'nmod'), ('subject', 'npadvmod'), ('achiev', 'amod'), ('“', 'punct'), ('clear', 'amod'), ('”', 'punct'), ('“', 'punct'), ('minim', 'nmod'), ('”', 'punct'), ('assess', 'appos'), ('least', 'advmod'), ('2', 'nummod'), ('-', 'punct'), ('grade', 'npadvmod'), ('improv', 'nmod'), ('pga', 'compound'), ('-', 'punct'), ('f', 'advmod'), ('scale', 'compound'), ('proport', 'compound'), ('subject', 'amod'), ('achiev', 'ROOT'), ('least', 'advmod'), ('75', 'nummod'), ('%', 'npadvmod'), ('improv', 'compound'), ('baselin', 'compound'), ('mnapsi', 'compound'), ('score', 'conj'), ('(', 'punct'), ('mnapsi', 'npadvmod'), ('75', 'nummod'), (')', 'punct'), ('week', 'appos'), ('26', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'At Week 26, a higher proportion of subjects in the HUMIRA group than in the placebo group \\nachieved the PGA-F endpoint.', 'tokens': ['Week', '26', ',', 'higher', 'proportion', 'subjects', 'HUMIRA', 'group', 'placebo', 'group', 'achieved', 'PGA-F', 'endpoint', '.'], 'lemmatized': ['Week', '26', ',', 'higher', 'proportion', 'subject', 'HUMIRA', 'group', 'placebo', 'group', 'achieved', 'PGA-F', 'endpoint', '.'], 'stemmed': ['week', '26', ',', 'higher', 'proport', 'subject', 'humira', 'group', 'placebo', 'group', 'achiev', 'pga-f', 'endpoint', '.'], 'dependencies': [('week', 'npadvmod'), ('26', 'nummod'), (',', 'punct'), ('higher', 'amod'), ('proport', 'nmod'), ('subject', 'nmod'), ('humira', 'compound'), ('group', 'compound'), ('placebo', 'compound'), ('group', 'nsubj'), ('achiev', 'compound'), ('pga', 'compound'), ('-', 'punct'), ('f', 'compound'), ('endpoint', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Furthermore, a higher proportion of subjects in the HUMIRA \\ngroup than in the placebo group achieved mNAPSI 75 at Week 26 (see Table 19).', 'tokens': ['Furthermore', ',', 'higher', 'proportion', 'subjects', 'HUMIRA', 'group', 'placebo', 'group', 'achieved', 'mNAPSI', '75', 'Week', '26', '(', 'see', 'Table', '19', ')', '.'], 'lemmatized': ['Furthermore', ',', 'higher', 'proportion', 'subject', 'HUMIRA', 'group', 'placebo', 'group', 'achieved', 'mNAPSI', '75', 'Week', '26', '(', 'see', 'Table', '19', ')', '.'], 'stemmed': ['furthermor', ',', 'higher', 'proport', 'subject', 'humira', 'group', 'placebo', 'group', 'achiev', 'mnapsi', '75', 'week', '26', '(', 'see', 'tabl', '19', ')', '.'], 'dependencies': [('furthermor', 'ROOT'), (',', 'punct'), ('higher', 'amod'), ('proport', 'nmod'), ('subject', 'nmod'), ('humira', 'compound'), ('group', 'compound'), ('placebo', 'compound'), ('group', 'appos'), ('achiev', 'appos'), ('mnapsi', 'appos'), ('75', 'nummod'), ('week', 'npadvmod'), ('26', 'nummod'), ('(', 'punct'), ('see', 'parataxis'), ('tabl', 'dobj'), ('19', 'nummod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Table 19.', 'tokens': ['Table', '19', '.'], 'lemmatized': ['Table', '19', '.'], 'stemmed': ['tabl', '19', '.'], 'dependencies': [('tabl', 'ROOT'), ('19', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Efficacy Results at 26 Weeks \\n Endpoint \\nHUMIRA 40 mg \\nevery other week* \\nN=109  \\nPlacebo \\nN=108  \\nPGA-F: ≥2-grade improvement and \\nclear or minimal \\n49% \\n7% \\nmNAPSI 75 \\n47% \\n3% \\n*Subjects received 80 mg of HUMIRA at Week 0, followed by 40 mg every other week starting \\nat Week 1.', 'tokens': ['Efficacy', 'Results', '26', 'Weeks', 'Endpoint', 'HUMIRA', '40', 'mg', 'every', 'week', '*', 'N=109', 'Placebo', 'N=108', 'PGA-F', ':', '≥2-grade', 'improvement', 'clear', 'minimal', '49', '%', '7', '%', 'mNAPSI', '75', '47', '%', '3', '%', '*', 'Subjects', 'received', '80', 'mg', 'HUMIRA', 'Week', '0', ',', 'followed', '40', 'mg', 'every', 'week', 'starting', 'Week', '1', '.'], 'lemmatized': ['Efficacy', 'Results', '26', 'Weeks', 'Endpoint', 'HUMIRA', '40', 'mg', 'every', 'week', '*', 'N=109', 'Placebo', 'N=108', 'PGA-F', ':', '≥2-grade', 'improvement', 'clear', 'minimal', '49', '%', '7', '%', 'mNAPSI', '75', '47', '%', '3', '%', '*', 'Subjects', 'received', '80', 'mg', 'HUMIRA', 'Week', '0', ',', 'followed', '40', 'mg', 'every', 'week', 'starting', 'Week', '1', '.'], 'stemmed': ['efficaci', 'result', '26', 'week', 'endpoint', 'humira', '40', 'mg', 'everi', 'week', '*', 'n=109', 'placebo', 'n=108', 'pga-f', ':', '≥2-grade', 'improv', 'clear', 'minim', '49', '%', '7', '%', 'mnapsi', '75', '47', '%', '3', '%', '*', 'subject', 'receiv', '80', 'mg', 'humira', 'week', '0', ',', 'follow', '40', 'mg', 'everi', 'week', 'start', 'week', '1', '.'], 'dependencies': [('efficaci', 'compound'), ('result', 'ROOT'), ('26', 'nummod'), ('week', 'compound'), ('endpoint', 'compound'), ('humira', 'npadvmod'), ('40', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'npadvmod'), ('*', 'punct'), ('n=109', 'amod'), ('placebo', 'compound'), ('n=108', 'appos'), ('pga', 'appos'), ('-', 'punct'), ('f', 'dep'), (':', 'punct'), ('≥2', 'appos'), ('-', 'punct'), ('grade', 'npadvmod'), ('improv', 'amod'), ('clear', 'amod'), ('minim', 'appos'), ('49', 'nummod'), ('%', 'ROOT'), ('7', 'nummod'), ('%', 'appos'), ('mnapsi', 'appos'), ('75', 'nummod'), ('47', 'nummod'), ('%', 'npadvmod'), ('3', 'nummod'), ('%', 'appos'), ('*', 'punct'), ('subject', 'nmod'), ('receiv', 'appos'), ('80', 'nummod'), ('mg', 'compound'), ('humira', 'compound'), ('week', 'appos'), ('0', 'nummod'), (',', 'punct'), ('follow', 'ROOT'), ('40', 'nummod'), ('mg', 'nmod'), ('everi', 'amod'), ('week', 'npadvmod'), ('start', 'ccomp'), ('week', 'npadvmod'), ('1', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Nail pain was also evaluated and improvement in nail pain was observed in Study Ps-III.', 'tokens': ['Nail', 'pain', 'also', 'evaluated', 'improvement', 'nail', 'pain', 'observed', 'Study', 'Ps-III', '.'], 'lemmatized': ['Nail', 'pain', 'also', 'evaluated', 'improvement', 'nail', 'pain', 'observed', 'Study', 'Ps-III', '.'], 'stemmed': ['nail', 'pain', 'also', 'evalu', 'improv', 'nail', 'pain', 'observ', 'studi', 'ps-iii', '.'], 'dependencies': [('nail', 'compound'), ('pain', 'nsubj'), ('also', 'advmod'), ('evalu', 'ROOT'), ('improv', 'compound'), ('nail', 'compound'), ('pain', 'compound'), ('observ', 'compound'), ('studi', 'compound'), ('ps', 'compound'), ('-', 'punct'), ('iii', 'dobj'), ('.', 'punct')]}, {'original_sentence': '14.10 Hidradenitis Suppurativa \\nTwo randomized, double-blind, placebo-controlled studies (Studies HS-I and II) evaluated the \\nsafety and efficacy of HUMIRA in a total of 633 adult subjects with moderate to severe \\nhidradenitis suppurativa (HS) with Hurley Stage II or III disease and with at least 3 abscesses or \\ninflammatory nodules.', 'tokens': ['14.10', 'Hidradenitis', 'Suppurativa', 'Two', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'studies', '(', 'Studies', 'HS-I', 'II', ')', 'evaluated', 'safety', 'efficacy', 'HUMIRA', 'total', '633', 'adult', 'subjects', 'moderate', 'severe', 'hidradenitis', 'suppurativa', '(', 'HS', ')', 'Hurley', 'Stage', 'II', 'III', 'disease', 'least', '3', 'abscesses', 'inflammatory', 'nodules', '.'], 'lemmatized': ['14.10', 'Hidradenitis', 'Suppurativa', 'Two', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'study', '(', 'Studies', 'HS-I', 'II', ')', 'evaluated', 'safety', 'efficacy', 'HUMIRA', 'total', '633', 'adult', 'subject', 'moderate', 'severe', 'hidradenitis', 'suppurativa', '(', 'HS', ')', 'Hurley', 'Stage', 'II', 'III', 'disease', 'least', '3', 'abscess', 'inflammatory', 'nodule', '.'], 'stemmed': ['14.10', 'hidraden', 'suppurativa', 'two', 'random', ',', 'double-blind', ',', 'placebo-control', 'studi', '(', 'studi', 'hs-i', 'ii', ')', 'evalu', 'safeti', 'efficaci', 'humira', 'total', '633', 'adult', 'subject', 'moder', 'sever', 'hidraden', 'suppurativa', '(', 'hs', ')', 'hurley', 'stage', 'ii', 'iii', 'diseas', 'least', '3', 'abscess', 'inflammatori', 'nodul', '.'], 'dependencies': [('14.10', 'nummod'), ('hidraden', 'compound'), ('suppurativa', 'nmod'), ('two', 'nummod'), ('random', 'amod'), (',', 'punct'), ('double', 'amod'), ('-', 'punct'), ('blind', 'conj'), (',', 'punct'), ('placebo', 'compound'), ('-', 'punct'), ('control', 'compound'), ('studi', 'appos'), ('(', 'punct'), ('studi', 'nmod'), ('hs', 'nmod'), ('-', 'nmod'), ('i', 'compound'), ('ii', 'appos'), (')', 'punct'), ('evalu', 'compound'), ('safeti', 'compound'), ('efficaci', 'compound'), ('humira', 'nsubj'), ('total', 'ROOT'), ('633', 'nummod'), ('adult', 'nmod'), ('subject', 'compound'), ('moder', 'compound'), ('sever', 'compound'), ('hidraden', 'compound'), ('suppurativa', 'dobj'), ('(', 'punct'), ('hs', 'nmod'), (')', 'punct'), ('hurley', 'appos'), ('stage', 'compound'), ('ii', 'compound'), ('iii', 'nummod'), ('diseas', 'advmod'), ('least', 'advmod'), ('3', 'nummod'), ('abscess', 'compound'), ('inflammatori', 'compound'), ('nodul', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'In both studies, subjects received placebo or HUMIRA at an initial dose \\nof 160 mg at Week 0, 80 mg at Week 2, and 40 mg every week starting at Week 4 and continued \\nthrough Week 11.', 'tokens': ['studies', ',', 'subjects', 'received', 'placebo', 'HUMIRA', 'initial', 'dose', '160', 'mg', 'Week', '0', ',', '80', 'mg', 'Week', '2', ',', '40', 'mg', 'every', 'week', 'starting', 'Week', '4', 'continued', 'Week', '11', '.'], 'lemmatized': ['study', ',', 'subject', 'received', 'placebo', 'HUMIRA', 'initial', 'dose', '160', 'mg', 'Week', '0', ',', '80', 'mg', 'Week', '2', ',', '40', 'mg', 'every', 'week', 'starting', 'Week', '4', 'continued', 'Week', '11', '.'], 'stemmed': ['studi', ',', 'subject', 'receiv', 'placebo', 'humira', 'initi', 'dose', '160', 'mg', 'week', '0', ',', '80', 'mg', 'week', '2', ',', '40', 'mg', 'everi', 'week', 'start', 'week', '4', 'continu', 'week', '11', '.'], 'dependencies': [('studi', 'npadvmod'), (',', 'punct'), ('subject', 'amod'), ('receiv', 'compound'), ('placebo', 'compound'), ('humira', 'compound'), ('initi', 'nsubj'), ('dose', 'ROOT'), ('160', 'dobj'), ('mg', 'amod'), ('week', 'npadvmod'), ('0', 'nummod'), (',', 'punct'), ('80', 'nummod'), ('mg', 'amod'), ('week', 'npadvmod'), ('2', 'nummod'), (',', 'punct'), ('40', 'nummod'), ('mg', 'advmod'), ('everi', 'amod'), ('week', 'npadvmod'), ('start', 'dep'), ('week', 'npadvmod'), ('4', 'nummod'), ('continu', 'compound'), ('week', 'npadvmod'), ('11', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Subjects used topical antiseptic wash daily.', 'tokens': ['Subjects', 'used', 'topical', 'antiseptic', 'wash', 'daily', '.'], 'lemmatized': ['Subjects', 'used', 'topical', 'antiseptic', 'wash', 'daily', '.'], 'stemmed': ['subject', 'use', 'topic', 'antisept', 'wash', 'daili', '.'], 'dependencies': [('subject', 'compound'), ('use', 'compound'), ('topic', 'compound'), ('antisept', 'compound'), ('wash', 'compound'), ('daili', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Concomitant oral antibiotic use \\nwas allowed in Study HS-II.', 'tokens': ['Concomitant', 'oral', 'antibiotic', 'use', 'allowed', 'Study', 'HS-II', '.'], 'lemmatized': ['Concomitant', 'oral', 'antibiotic', 'use', 'allowed', 'Study', 'HS-II', '.'], 'stemmed': ['concomit', 'oral', 'antibiot', 'use', 'allow', 'studi', 'hs-ii', '.'], 'dependencies': [('concomit', 'nmod'), ('oral', 'amod'), ('antibiot', 'compound'), ('use', 'nsubj'), ('allow', 'ROOT'), ('studi', 'compound'), ('hs', 'compound'), ('-', 'compound'), ('ii', 'dobj'), ('.', 'punct')]}], 'text': 'subjects who were re-randomized to placebo based on maintenance of PGA of “clear” or \\n“minimal” disease (68% vs. 28%) or a PASI 75 (79% vs. 43%).  \\nA total of 347 stable responders participated in a withdrawal and retreatment evaluation in an \\nopen-label extension study. Median time to relapse (decline to PGA “moderate” or worse) was \\napproximately 5 months. During the withdrawal period, no subject experienced transformation to \\neither pustular or erythrodermic psoriasis. A total of 178 subjects who relapsed re-initiated \\ntreatment with 80 mg of HUMIRA, then 40 mg every other week beginning at week 1. At week \\n16, 69% (123/178) of subjects had a response of PGA “clear” or “minimal”.  \\nA randomized, double-blind study (Study Ps-III) compared the efficacy and safety of HUMIRA \\nversus placebo in 217 adult subjects. Subjects in the study had to have chronic plaque psoriasis \\nof at least moderate severity on the PGA scale, fingernail involvement of at least moderate \\nseverity on a 5-point Physician’s Global Assessment of Fingernail Psoriasis (PGA-F) scale, a \\nModified Nail Psoriasis Severity Index (mNAPSI) score for the target-fingernail of ≥ 8, and \\neither a BSA involvement of at least 10% or a BSA involvement of at least 5% with a total \\nmNAPSI score for all fingernails of ≥ 20. Subjects received an initial dose of 80 mg HUMIRA \\nfollowed by 40 mg every other week (starting one week after the initial dose) or placebo for 26 \\nweeks followed by open-label HUMIRA treatment for an additional 26 weeks. This study \\nevaluated the proportion of subjects who achieved “clear” or “minimal” assessment with at least \\na 2-grade improvement on the PGA-F scale and the proportion of subjects who achieved at least \\na 75% improvement from baseline in the mNAPSI score (mNAPSI 75) at Week 26.  \\nAt Week 26, a higher proportion of subjects in the HUMIRA group than in the placebo group \\nachieved the PGA-F endpoint. Furthermore, a higher proportion of subjects in the HUMIRA \\ngroup than in the placebo group achieved mNAPSI 75 at Week 26 (see Table 19).  \\nTable 19. Efficacy Results at 26 Weeks \\n Endpoint \\nHUMIRA 40 mg \\nevery other week* \\nN=109  \\nPlacebo \\nN=108  \\nPGA-F: ≥2-grade improvement and \\nclear or minimal \\n49% \\n7% \\nmNAPSI 75 \\n47% \\n3% \\n*Subjects received 80 mg of HUMIRA at Week 0, followed by 40 mg every other week starting \\nat Week 1.  \\n \\n  \\nNail pain was also evaluated and improvement in nail pain was observed in Study Ps-III.  \\n14.10 Hidradenitis Suppurativa \\nTwo randomized, double-blind, placebo-controlled studies (Studies HS-I and II) evaluated the \\nsafety and efficacy of HUMIRA in a total of 633 adult subjects with moderate to severe \\nhidradenitis suppurativa (HS) with Hurley Stage II or III disease and with at least 3 abscesses or \\ninflammatory nodules. In both studies, subjects received placebo or HUMIRA at an initial dose \\nof 160 mg at Week 0, 80 mg at Week 2, and 40 mg every week starting at Week 4 and continued \\nthrough Week 11. Subjects used topical antiseptic wash daily. Concomitant oral antibiotic use \\nwas allowed in Study HS-II.  \\n'}, 'page_char_count': 3076, 'page_word_count': 504, 'sentences': ['subjects who were re-randomized to placebo based on maintenance of PGA of “clear” or \\n“minimal” disease (68% vs. 28%) or a PASI 75 (79% vs. 43%).', ' \\nA total of 347 stable responders participated in a withdrawal and retreatment evaluation in an \\nopen-label extension study.', 'Median time to relapse (decline to PGA “moderate” or worse) was \\napproximately 5 months.', 'During the withdrawal period, no subject experienced transformation to \\neither pustular or erythrodermic psoriasis.', 'A total of 178 subjects who relapsed re-initiated \\ntreatment with 80 mg of HUMIRA, then 40 mg every other week beginning at week 1.', 'At week \\n16, 69% (123/178) of subjects had a response of PGA “clear” or “minimal”.', ' \\nA randomized, double-blind study (Study Ps-III) compared the efficacy and safety of HUMIRA \\nversus placebo in 217 adult subjects.', 'Subjects in the study had to have chronic plaque psoriasis \\nof at least moderate severity on the PGA scale, fingernail involvement of at least moderate \\nseverity on a 5-point Physician’s Global Assessment of Fingernail Psoriasis (PGA-F) scale, a \\nModified Nail Psoriasis Severity Index (mNAPSI) score for the target-fingernail of ≥ 8, and \\neither a BSA involvement of at least 10% or a BSA involvement of at least 5% with a total \\nmNAPSI score for all fingernails of ≥ 20.', 'Subjects received an initial dose of 80 mg HUMIRA \\nfollowed by 40 mg every other week (starting one week after the initial dose) or placebo for 26 \\nweeks followed by open-label HUMIRA treatment for an additional 26 weeks.', 'This study \\nevaluated the proportion of subjects who achieved “clear” or “minimal” assessment with at least \\na 2-grade improvement on the PGA-F scale and the proportion of subjects who achieved at least \\na 75% improvement from baseline in the mNAPSI score (mNAPSI 75) at Week 26.', ' \\nAt Week 26, a higher proportion of subjects in the HUMIRA group than in the placebo group \\nachieved the PGA-F endpoint.', 'Furthermore, a higher proportion of subjects in the HUMIRA \\ngroup than in the placebo group achieved mNAPSI 75 at Week 26 (see Table 19).', ' \\nTable 19.', 'Efficacy Results at 26 Weeks \\n Endpoint \\nHUMIRA 40 mg \\nevery other week* \\nN=109  \\nPlacebo \\nN=108  \\nPGA-F: ≥2-grade improvement and \\nclear or minimal \\n49% \\n7% \\nmNAPSI 75 \\n47% \\n3% \\n*Subjects received 80 mg of HUMIRA at Week 0, followed by 40 mg every other week starting \\nat Week 1.', ' \\n \\n  \\nNail pain was also evaluated and improvement in nail pain was observed in Study Ps-III.', ' \\n14.10 Hidradenitis Suppurativa \\nTwo randomized, double-blind, placebo-controlled studies (Studies HS-I and II) evaluated the \\nsafety and efficacy of HUMIRA in a total of 633 adult subjects with moderate to severe \\nhidradenitis suppurativa (HS) with Hurley Stage II or III disease and with at least 3 abscesses or \\ninflammatory nodules.', 'In both studies, subjects received placebo or HUMIRA at an initial dose \\nof 160 mg at Week 0, 80 mg at Week 2, and 40 mg every week starting at Week 4 and continued \\nthrough Week 11.', 'Subjects used topical antiseptic wash daily.', 'Concomitant oral antibiotic use \\nwas allowed in Study HS-II.', ' \\n'], 'page_sentence_count_spacy': 20}\n",
            "{'page_number': 51, 'text': 'Both studies evaluated Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12. HiSCR \\nwas defined as at least a 50% reduction in total abscess and inflammatory nodule count with no \\nincrease in abscess count and no increase in draining fistula count relative to baseline (see Table \\n18). Reduction in HS-related skin pain was assessed using a Numeric Rating Scale in patients \\nwho entered the study with an initial baseline score of 3 or greater on a 11 point scale.  \\nIn both studies, a higher proportion of HUMIRA- than placebo-treated subjects achieved HiSCR \\n(see Table 20).  \\nTable 20. Efficacy Results at 12 Weeks in Subjects with Moderate to Severe Hidradenitis \\nSuppurativa \\n  \\nHS Study I \\nHS Study II* \\n  \\nPlacebo \\nHumira 40 mg \\nWeekly \\nPlacebo \\nHumira 40 mg \\nWeekly \\nHidradenitis \\nSuppurativa Clinical \\nResponse (HiSCR) \\nN = 154 \\n40 (26%)  \\nN = 153 \\n64 (42%)  \\nN=163 \\n45 (28%)  \\nN=163 \\n96 (59%)  \\n*19.3% of subjects in Study HS-II continued baseline oral antibiotic therapy during the study.  \\n \\n  \\nIn both studies, from Week 12 to Week 35 (Period B), subjects who had received HUMIRA were \\nre-randomized to 1 of 3 treatment groups (HUMIRA 40 mg every week, HUMIRA 40 mg every \\nother week, or placebo). Subjects who had been randomized to placebo were assigned to receive \\nHUMIRA 40 mg every week (Study HS-I) or placebo (Study HS-II).  \\nDuring Period B, flare of HS, defined as ≥25% increase from baseline in abscesses and \\ninflammatory nodule counts and with a minimum of 2 additional lesions, was documented in 22 \\n(22%) of the 100 subjects who were withdrawn from HUMIRA treatment following the primary \\nefficacy timepoint in two studies.  \\n14.11 Adult Uveitis \\nThe safety and efficacy of HUMIRA were assessed in adult patients with non-infectious \\nintermediate, posterior and panuveitis excluding patients with isolated anterior uveitis, in two \\nrandomized, double-masked, placebo-controlled studies (UV I and II). Patients received placebo \\nor HUMIRA at an initial dose of 80 mg followed by 40 mg every other week starting one week \\nafter the initial dose. The primary efficacy endpoint in both studies was ´time to treatment \\nfailure´.  \\nTreatment failure was a multi-component outcome defined as the development of new \\ninflammatory chorioretinal and/or inflammatory retinal vascular lesions, an increase in anterior \\nchamber (AC) cell grade or vitreous haze (VH) grade or a decrease in best corrected visual \\nacuity (BCVA).  \\nStudy UV I evaluated 217 patients with active uveitis while being treated with corticosteroids \\n(oral prednisone at a dose of 10 to 60 mg/day). All patients received a standardized dose of \\nprednisone 60 mg/day at study entry followed by a mandatory taper schedule, with complete \\ncorticosteroid discontinuation by Week 15.  \\n', 'processed_text': {'sentences': [{'original_sentence': 'Both studies evaluated Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12.', 'tokens': ['studies', 'evaluated', 'Hidradenitis', 'Suppurativa', 'Clinical', 'Response', '(', 'HiSCR', ')', 'Week', '12', '.'], 'lemmatized': ['study', 'evaluated', 'Hidradenitis', 'Suppurativa', 'Clinical', 'Response', '(', 'HiSCR', ')', 'Week', '12', '.'], 'stemmed': ['studi', 'evalu', 'hidraden', 'suppurativa', 'clinic', 'respons', '(', 'hiscr', ')', 'week', '12', '.'], 'dependencies': [('studi', 'compound'), ('evalu', 'compound'), ('hidraden', 'compound'), ('suppurativa', 'compound'), ('clinic', 'compound'), ('respons', 'ROOT'), ('(', 'punct'), ('hiscr', 'appos'), (')', 'punct'), ('week', 'npadvmod'), ('12', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'HiSCR \\nwas defined as at least a 50% reduction in total abscess and inflammatory nodule count with no \\nincrease in abscess count and no increase in draining fistula count relative to baseline (see Table \\n18).', 'tokens': ['HiSCR', 'defined', 'least', '50', '%', 'reduction', 'total', 'abscess', 'inflammatory', 'nodule', 'count', 'increase', 'abscess', 'count', 'increase', 'draining', 'fistula', 'count', 'relative', 'baseline', '(', 'see', 'Table', '18', ')', '.'], 'lemmatized': ['HiSCR', 'defined', 'least', '50', '%', 'reduction', 'total', 'abscess', 'inflammatory', 'nodule', 'count', 'increase', 'abscess', 'count', 'increase', 'draining', 'fistula', 'count', 'relative', 'baseline', '(', 'see', 'Table', '18', ')', '.'], 'stemmed': ['hiscr', 'defin', 'least', '50', '%', 'reduct', 'total', 'abscess', 'inflammatori', 'nodul', 'count', 'increas', 'abscess', 'count', 'increas', 'drain', 'fistula', 'count', 'rel', 'baselin', '(', 'see', 'tabl', '18', ')', '.'], 'dependencies': [('hiscr', 'dobj'), ('defin', 'advmod'), ('least', 'amod'), ('50', 'nummod'), ('%', 'compound'), ('reduct', 'compound'), ('total', 'compound'), ('abscess', 'compound'), ('inflammatori', 'dobj'), ('nodul', 'compound'), ('count', 'compound'), ('increas', 'compound'), ('abscess', 'compound'), ('count', 'compound'), ('increas', 'compound'), ('drain', 'compound'), ('fistula', 'nsubj'), ('count', 'ROOT'), ('rel', 'compound'), ('baselin', 'dobj'), ('(', 'punct'), ('see', 'parataxis'), ('tabl', 'dobj'), ('18', 'nummod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Reduction in HS-related skin pain was assessed using a Numeric Rating Scale in patients \\nwho entered the study with an initial baseline score of 3 or greater on a 11 point scale.', 'tokens': ['Reduction', 'HS-related', 'skin', 'pain', 'assessed', 'using', 'Numeric', 'Rating', 'Scale', 'patients', 'entered', 'study', 'initial', 'baseline', 'score', '3', 'greater', '11', 'point', 'scale', '.'], 'lemmatized': ['Reduction', 'HS-related', 'skin', 'pain', 'assessed', 'using', 'Numeric', 'Rating', 'Scale', 'patient', 'entered', 'study', 'initial', 'baseline', 'score', '3', 'greater', '11', 'point', 'scale', '.'], 'stemmed': ['reduct', 'hs-relat', 'skin', 'pain', 'assess', 'use', 'numer', 'rate', 'scale', 'patient', 'enter', 'studi', 'initi', 'baselin', 'score', '3', 'greater', '11', 'point', 'scale', '.'], 'dependencies': [('reduct', 'ROOT'), ('hs', 'compound'), ('-', 'amod'), ('relat', 'compound'), ('skin', 'compound'), ('pain', 'compound'), ('assess', 'compound'), ('use', 'compound'), ('numer', 'compound'), ('rate', 'compound'), ('scale', 'compound'), ('patient', 'dobj'), ('enter', 'dep'), ('studi', 'compound'), ('initi', 'compound'), ('baselin', 'compound'), ('score', 'dative'), ('3', 'nummod'), ('greater', 'amod'), ('11', 'nummod'), ('point', 'compound'), ('scale', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'In both studies, a higher proportion of HUMIRA- than placebo-treated subjects achieved HiSCR \\n(see Table 20).', 'tokens': ['studies', ',', 'higher', 'proportion', 'HUMIRA-', 'placebo-treated', 'subjects', 'achieved', 'HiSCR', '(', 'see', 'Table', '20', ')', '.'], 'lemmatized': ['study', ',', 'higher', 'proportion', 'HUMIRA-', 'placebo-treated', 'subject', 'achieved', 'HiSCR', '(', 'see', 'Table', '20', ')', '.'], 'stemmed': ['studi', ',', 'higher', 'proport', 'humira-', 'placebo-tr', 'subject', 'achiev', 'hiscr', '(', 'see', 'tabl', '20', ')', '.'], 'dependencies': [('studi', 'dep'), (',', 'punct'), ('higher', 'amod'), ('proport', 'npadvmod'), ('humira-', 'dep'), ('placebo', 'compound'), ('-', 'punct'), ('tr', 'meta'), ('subject', 'amod'), ('achiev', 'amod'), ('hiscr', 'ROOT'), ('(', 'punct'), ('see', 'parataxis'), ('tabl', 'dobj'), ('20', 'nummod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Table 20.', 'tokens': ['Table', '20', '.'], 'lemmatized': ['Table', '20', '.'], 'stemmed': ['tabl', '20', '.'], 'dependencies': [('tabl', 'ROOT'), ('20', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Efficacy Results at 12 Weeks in Subjects with Moderate to Severe Hidradenitis \\nSuppurativa \\n  \\nHS Study I \\nHS Study II* \\n  \\nPlacebo \\nHumira 40 mg \\nWeekly \\nPlacebo \\nHumira 40 mg \\nWeekly \\nHidradenitis \\nSuppurativa Clinical \\nResponse (HiSCR) \\nN = 154 \\n40 (26%)  \\nN = 153 \\n64 (42%)  \\nN=163 \\n45 (28%)  \\nN=163 \\n96 (59%)  \\n*19.3% of subjects in Study HS-II continued baseline oral antibiotic therapy during the study.', 'tokens': ['Efficacy', 'Results', '12', 'Weeks', 'Subjects', 'Moderate', 'Severe', 'Hidradenitis', 'Suppurativa', 'HS', 'Study', 'HS', 'Study', 'II', '*', 'Placebo', 'Humira', '40', 'mg', 'Weekly', 'Placebo', 'Humira', '40', 'mg', 'Weekly', 'Hidradenitis', 'Suppurativa', 'Clinical', 'Response', '(', 'HiSCR', ')', 'N', '=', '154', '40', '(', '26', '%', ')', 'N', '=', '153', '64', '(', '42', '%', ')', 'N=163', '45', '(', '28', '%', ')', 'N=163', '96', '(', '59', '%', ')', '*', '19.3', '%', 'subjects', 'Study', 'HS-II', 'continued', 'baseline', 'oral', 'antibiotic', 'therapy', 'study', '.'], 'lemmatized': ['Efficacy', 'Results', '12', 'Weeks', 'Subjects', 'Moderate', 'Severe', 'Hidradenitis', 'Suppurativa', 'HS', 'Study', 'HS', 'Study', 'II', '*', 'Placebo', 'Humira', '40', 'mg', 'Weekly', 'Placebo', 'Humira', '40', 'mg', 'Weekly', 'Hidradenitis', 'Suppurativa', 'Clinical', 'Response', '(', 'HiSCR', ')', 'N', '=', '154', '40', '(', '26', '%', ')', 'N', '=', '153', '64', '(', '42', '%', ')', 'N=163', '45', '(', '28', '%', ')', 'N=163', '96', '(', '59', '%', ')', '*', '19.3', '%', 'subject', 'Study', 'HS-II', 'continued', 'baseline', 'oral', 'antibiotic', 'therapy', 'study', '.'], 'stemmed': ['efficaci', 'result', '12', 'week', 'subject', 'moder', 'sever', 'hidraden', 'suppurativa', 'hs', 'studi', 'hs', 'studi', 'ii', '*', 'placebo', 'humira', '40', 'mg', 'weekli', 'placebo', 'humira', '40', 'mg', 'weekli', 'hidraden', 'suppurativa', 'clinic', 'respons', '(', 'hiscr', ')', 'n', '=', '154', '40', '(', '26', '%', ')', 'n', '=', '153', '64', '(', '42', '%', ')', 'n=163', '45', '(', '28', '%', ')', 'n=163', '96', '(', '59', '%', ')', '*', '19.3', '%', 'subject', 'studi', 'hs-ii', 'continu', 'baselin', 'oral', 'antibiot', 'therapi', 'studi', '.'], 'dependencies': [('efficaci', 'nsubj'), ('result', 'ROOT'), ('12', 'nummod'), ('week', 'compound'), ('subject', 'compound'), ('moder', 'compound'), ('sever', 'compound'), ('hidraden', 'compound'), ('suppurativa', 'appos'), ('hs', 'compound'), ('studi', 'appos'), ('hs', 'compound'), ('studi', 'compound'), ('ii', 'compound'), ('*', 'compound'), ('placebo', 'compound'), ('humira', 'appos'), ('40', 'nummod'), ('mg', 'nmod'), ('weekli', 'compound'), ('placebo', 'compound'), ('humira', 'appos'), ('40', 'nummod'), ('mg', 'compound'), ('weekli', 'compound'), ('hidraden', 'compound'), ('suppurativa', 'compound'), ('clinic', 'compound'), ('respons', 'conj'), ('(', 'punct'), ('hiscr', 'appos'), (')', 'punct'), ('n', 'nummod'), ('=', 'nmod'), ('154', 'compound'), ('40', 'nummod'), ('(', 'punct'), ('26', 'nummod'), ('%', 'parataxis'), (')', 'punct'), ('n', 'cc'), ('=', 'quantmod'), ('153', 'compound'), ('64', 'dep'), ('(', 'punct'), ('42', 'nummod'), ('%', 'parataxis'), (')', 'punct'), ('n=163', 'ROOT'), ('45', 'nummod'), ('(', 'punct'), ('28', 'nummod'), ('%', 'npadvmod'), (')', 'punct'), ('n=163', 'punct'), ('96', 'ROOT'), ('(', 'punct'), ('59', 'nummod'), ('%', 'ROOT'), (')', 'punct'), ('*', 'punct'), ('19.3', 'nummod'), ('%', 'compound'), ('subject', 'ROOT'), ('studi', 'nmod'), ('hs', 'compound'), ('-', 'nmod'), ('ii', 'compound'), ('continu', 'compound'), ('baselin', 'nmod'), ('oral', 'compound'), ('antibiot', 'appos'), ('therapi', 'compound'), ('studi', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'In both studies, from Week 12 to Week 35 (Period B), subjects who had received HUMIRA were \\nre-randomized to 1 of 3 treatment groups (HUMIRA 40 mg every week, HUMIRA 40 mg every \\nother week, or placebo).', 'tokens': ['studies', ',', 'Week', '12', 'Week', '35', '(', 'Period', 'B', ')', ',', 'subjects', 'received', 'HUMIRA', 're-randomized', '1', '3', 'treatment', 'groups', '(', 'HUMIRA', '40', 'mg', 'every', 'week', ',', 'HUMIRA', '40', 'mg', 'every', 'week', ',', 'placebo', ')', '.'], 'lemmatized': ['study', ',', 'Week', '12', 'Week', '35', '(', 'Period', 'B', ')', ',', 'subject', 'received', 'HUMIRA', 're-randomized', '1', '3', 'treatment', 'group', '(', 'HUMIRA', '40', 'mg', 'every', 'week', ',', 'HUMIRA', '40', 'mg', 'every', 'week', ',', 'placebo', ')', '.'], 'stemmed': ['studi', ',', 'week', '12', 'week', '35', '(', 'period', 'b', ')', ',', 'subject', 'receiv', 'humira', 're-random', '1', '3', 'treatment', 'group', '(', 'humira', '40', 'mg', 'everi', 'week', ',', 'humira', '40', 'mg', 'everi', 'week', ',', 'placebo', ')', '.'], 'dependencies': [('studi', 'nsubj'), (',', 'punct'), ('week', 'meta'), ('12', 'nummod'), ('week', 'npadvmod'), ('35', 'nummod'), ('(', 'punct'), ('period', 'appos'), ('b', 'nummod'), (')', 'punct'), (',', 'punct'), ('subject', 'conj'), ('receiv', 'compound'), ('humira', 'npadvmod'), ('re', 'compound'), ('-', 'amod'), ('random', 'amod'), ('1', 'compound'), ('3', 'nummod'), ('treatment', 'compound'), ('group', 'ROOT'), ('(', 'punct'), ('humira', 'appos'), ('40', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'npadvmod'), (',', 'punct'), ('humira', 'appos'), ('40', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'npadvmod'), (',', 'punct'), ('placebo', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Subjects who had been randomized to placebo were assigned to receive \\nHUMIRA 40 mg every week (Study HS-I) or placebo (Study HS-II).', 'tokens': ['Subjects', 'randomized', 'placebo', 'assigned', 'receive', 'HUMIRA', '40', 'mg', 'every', 'week', '(', 'Study', 'HS-I', ')', 'placebo', '(', 'Study', 'HS-II', ')', '.'], 'lemmatized': ['Subjects', 'randomized', 'placebo', 'assigned', 'receive', 'HUMIRA', '40', 'mg', 'every', 'week', '(', 'Study', 'HS-I', ')', 'placebo', '(', 'Study', 'HS-II', ')', '.'], 'stemmed': ['subject', 'random', 'placebo', 'assign', 'receiv', 'humira', '40', 'mg', 'everi', 'week', '(', 'studi', 'hs-i', ')', 'placebo', '(', 'studi', 'hs-ii', ')', '.'], 'dependencies': [('subject', 'ROOT'), ('random', 'amod'), ('placebo', 'compound'), ('assign', 'compound'), ('receiv', 'compound'), ('humira', 'dobj'), ('40', 'nummod'), ('mg', 'prep'), ('everi', 'amod'), ('week', 'npadvmod'), ('(', 'punct'), ('studi', 'nmod'), ('hs', 'npadvmod'), ('-', 'punct'), ('i', 'nmod'), (')', 'punct'), ('placebo', 'appos'), ('(', 'punct'), ('studi', 'compound'), ('hs', 'npadvmod'), ('-', 'npadvmod'), ('ii', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'During Period B, flare of HS, defined as ≥25% increase from baseline in abscesses and \\ninflammatory nodule counts and with a minimum of 2 additional lesions, was documented in 22 \\n(22%) of the 100 subjects who were withdrawn from HUMIRA treatment following the primary \\nefficacy timepoint in two studies.', 'tokens': ['Period', 'B', ',', 'flare', 'HS', ',', 'defined', '≥25', '%', 'increase', 'baseline', 'abscesses', 'inflammatory', 'nodule', 'counts', 'minimum', '2', 'additional', 'lesions', ',', 'documented', '22', '(', '22', '%', ')', '100', 'subjects', 'withdrawn', 'HUMIRA', 'treatment', 'following', 'primary', 'efficacy', 'timepoint', 'two', 'studies', '.'], 'lemmatized': ['Period', 'B', ',', 'flare', 'HS', ',', 'defined', '≥25', '%', 'increase', 'baseline', 'abscess', 'inflammatory', 'nodule', 'count', 'minimum', '2', 'additional', 'lesion', ',', 'documented', '22', '(', '22', '%', ')', '100', 'subject', 'withdrawn', 'HUMIRA', 'treatment', 'following', 'primary', 'efficacy', 'timepoint', 'two', 'study', '.'], 'stemmed': ['period', 'b', ',', 'flare', 'hs', ',', 'defin', '≥25', '%', 'increas', 'baselin', 'abscess', 'inflammatori', 'nodul', 'count', 'minimum', '2', 'addit', 'lesion', ',', 'document', '22', '(', '22', '%', ')', '100', 'subject', 'withdrawn', 'humira', 'treatment', 'follow', 'primari', 'efficaci', 'timepoint', 'two', 'studi', '.'], 'dependencies': [('period', 'npadvmod'), ('b', 'nummod'), (',', 'punct'), ('flare', 'amod'), ('hs', 'dobj'), (',', 'punct'), ('defin', 'advmod'), ('≥25', 'amod'), ('%', 'compound'), ('increas', 'compound'), ('baselin', 'compound'), ('abscess', 'compound'), ('inflammatori', 'nsubj'), ('nodul', 'nsubj'), ('count', 'ROOT'), ('minimum', 'amod'), ('2', 'nummod'), ('addit', 'compound'), ('lesion', 'dobj'), (',', 'punct'), ('document', 'appos'), ('22', 'nummod'), ('(', 'punct'), ('22', 'nummod'), ('%', 'dep'), (')', 'punct'), ('100', 'nummod'), ('subject', 'npadvmod'), ('withdrawn', 'amod'), ('humira', 'compound'), ('treatment', 'compound'), ('follow', 'compound'), ('primari', 'compound'), ('efficaci', 'nsubj'), ('timepoint', 'conj'), ('two', 'nummod'), ('studi', 'dobj'), ('.', 'punct')]}, {'original_sentence': '14.11 Adult Uveitis \\nThe safety and efficacy of HUMIRA were assessed in adult patients with non-infectious \\nintermediate, posterior and panuveitis excluding patients with isolated anterior uveitis, in two \\nrandomized, double-masked, placebo-controlled studies (UV I and II).', 'tokens': ['14.11', 'Adult', 'Uveitis', 'safety', 'efficacy', 'HUMIRA', 'assessed', 'adult', 'patients', 'non-infectious', 'intermediate', ',', 'posterior', 'panuveitis', 'excluding', 'patients', 'isolated', 'anterior', 'uveitis', ',', 'two', 'randomized', ',', 'double-masked', ',', 'placebo-controlled', 'studies', '(', 'UV', 'II', ')', '.'], 'lemmatized': ['14.11', 'Adult', 'Uveitis', 'safety', 'efficacy', 'HUMIRA', 'assessed', 'adult', 'patient', 'non-infectious', 'intermediate', ',', 'posterior', 'panuveitis', 'excluding', 'patient', 'isolated', 'anterior', 'uveitis', ',', 'two', 'randomized', ',', 'double-masked', ',', 'placebo-controlled', 'study', '(', 'UV', 'II', ')', '.'], 'stemmed': ['14.11', 'adult', 'uveiti', 'safeti', 'efficaci', 'humira', 'assess', 'adult', 'patient', 'non-infecti', 'intermedi', ',', 'posterior', 'panuv', 'exclud', 'patient', 'isol', 'anterior', 'uveiti', ',', 'two', 'random', ',', 'double-mask', ',', 'placebo-control', 'studi', '(', 'uv', 'ii', ')', '.'], 'dependencies': [('14.11', 'nummod'), ('adult', 'compound'), ('uveiti', 'compound'), ('safeti', 'compound'), ('efficaci', 'compound'), ('humira', 'nsubj'), ('assess', 'ROOT'), ('adult', 'compound'), ('patient', 'amod'), ('non', 'amod'), ('-', 'amod'), ('infecti', 'amod'), ('intermedi', 'amod'), (',', 'punct'), ('posterior', 'amod'), ('panuv', 'compound'), ('exclud', 'compound'), ('patient', 'nsubj'), ('isol', 'amod'), ('anterior', 'amod'), ('uveiti', 'dobj'), (',', 'punct'), ('two', 'nummod'), ('random', 'amod'), (',', 'punct'), ('double', 'amod'), ('-', 'punct'), ('mask', 'appos'), (',', 'punct'), ('placebo', 'compound'), ('-', 'punct'), ('control', 'compound'), ('studi', 'appos'), ('(', 'punct'), ('uv', 'compound'), ('ii', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Patients received placebo \\nor HUMIRA at an initial dose of 80 mg followed by 40 mg every other week starting one week \\nafter the initial dose.', 'tokens': ['Patients', 'received', 'placebo', 'HUMIRA', 'initial', 'dose', '80', 'mg', 'followed', '40', 'mg', 'every', 'week', 'starting', 'one', 'week', 'initial', 'dose', '.'], 'lemmatized': ['Patients', 'received', 'placebo', 'HUMIRA', 'initial', 'dose', '80', 'mg', 'followed', '40', 'mg', 'every', 'week', 'starting', 'one', 'week', 'initial', 'dose', '.'], 'stemmed': ['patient', 'receiv', 'placebo', 'humira', 'initi', 'dose', '80', 'mg', 'follow', '40', 'mg', 'everi', 'week', 'start', 'one', 'week', 'initi', 'dose', '.'], 'dependencies': [('patient', 'compound'), ('receiv', 'compound'), ('placebo', 'compound'), ('humira', 'compound'), ('initi', 'nsubj'), ('dose', 'ROOT'), ('80', 'dobj'), ('mg', 'nsubj'), ('follow', 'advcl'), ('40', 'nummod'), ('mg', 'npadvmod'), ('everi', 'amod'), ('week', 'npadvmod'), ('start', 'dep'), ('one', 'nummod'), ('week', 'compound'), ('initi', 'compound'), ('dose', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The primary efficacy endpoint in both studies was ´time to treatment \\nfailure´.', 'tokens': ['primary', 'efficacy', 'endpoint', 'studies', '´time', 'treatment', 'failure´', '.'], 'lemmatized': ['primary', 'efficacy', 'endpoint', 'study', '´time', 'treatment', 'failure´', '.'], 'stemmed': ['primari', 'efficaci', 'endpoint', 'studi', '´time', 'treatment', 'failure´', '.'], 'dependencies': [('primari', 'compound'), ('efficaci', 'compound'), ('endpoint', 'compound'), ('studi', 'compound'), ('´', 'compound'), ('time', 'compound'), ('treatment', 'compound'), ('failure', 'nsubj'), ('´', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Treatment failure was a multi-component outcome defined as the development of new \\ninflammatory chorioretinal and/or inflammatory retinal vascular lesions, an increase in anterior \\nchamber (AC) cell grade or vitreous haze (VH) grade or a decrease in best corrected visual \\nacuity (BCVA).', 'tokens': ['Treatment', 'failure', 'multi-component', 'outcome', 'defined', 'development', 'new', 'inflammatory', 'chorioretinal', 'and/or', 'inflammatory', 'retinal', 'vascular', 'lesions', ',', 'increase', 'anterior', 'chamber', '(', 'AC', ')', 'cell', 'grade', 'vitreous', 'haze', '(', 'VH', ')', 'grade', 'decrease', 'best', 'corrected', 'visual', 'acuity', '(', 'BCVA', ')', '.'], 'lemmatized': ['Treatment', 'failure', 'multi-component', 'outcome', 'defined', 'development', 'new', 'inflammatory', 'chorioretinal', 'and/or', 'inflammatory', 'retinal', 'vascular', 'lesion', ',', 'increase', 'anterior', 'chamber', '(', 'AC', ')', 'cell', 'grade', 'vitreous', 'haze', '(', 'VH', ')', 'grade', 'decrease', 'best', 'corrected', 'visual', 'acuity', '(', 'BCVA', ')', '.'], 'stemmed': ['treatment', 'failur', 'multi-compon', 'outcom', 'defin', 'develop', 'new', 'inflammatori', 'chorioretin', 'and/or', 'inflammatori', 'retin', 'vascular', 'lesion', ',', 'increas', 'anterior', 'chamber', '(', 'ac', ')', 'cell', 'grade', 'vitreou', 'haze', '(', 'vh', ')', 'grade', 'decreas', 'best', 'correct', 'visual', 'acuiti', '(', 'bcva', ')', '.'], 'dependencies': [('treatment', 'compound'), ('failur', 'compound'), ('multi', 'amod'), ('-', 'amod'), ('compon', 'amod'), ('outcom', 'compound'), ('defin', 'nsubj'), ('develop', 'ROOT'), ('new', 'amod'), ('inflammatori', 'compound'), ('chorioretin', 'dobj'), ('and/or', 'cc'), ('inflammatori', 'conj'), ('retin', 'nmod'), ('vascular', 'amod'), ('lesion', 'dobj'), (',', 'punct'), ('increas', 'nmod'), ('anterior', 'compound'), ('chamber', 'appos'), ('(', 'punct'), ('ac', 'appos'), (')', 'punct'), ('cell', 'compound'), ('grade', 'nmod'), ('vitreou', 'compound'), ('haze', 'nmod'), ('(', 'punct'), ('vh', 'nmod'), (')', 'punct'), ('grade', 'nmod'), ('decreas', 'conj'), ('best', 'advmod'), ('correct', 'amod'), ('visual', 'amod'), ('acuiti', 'conj'), ('(', 'punct'), ('bcva', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Study UV I evaluated 217 patients with active uveitis while being treated with corticosteroids \\n(oral prednisone at a dose of 10 to 60 mg/day).', 'tokens': ['Study', 'UV', 'evaluated', '217', 'patients', 'active', 'uveitis', 'treated', 'corticosteroids', '(', 'oral', 'prednisone', 'dose', '10', '60', 'mg/day', ')', '.'], 'lemmatized': ['Study', 'UV', 'evaluated', '217', 'patient', 'active', 'uveitis', 'treated', 'corticosteroid', '(', 'oral', 'prednisone', 'dose', '10', '60', 'mg/day', ')', '.'], 'stemmed': ['studi', 'uv', 'evalu', '217', 'patient', 'activ', 'uveiti', 'treat', 'corticosteroid', '(', 'oral', 'prednison', 'dose', '10', '60', 'mg/day', ')', '.'], 'dependencies': [('studi', 'npadvmod'), ('uv', 'nmod'), ('evalu', 'nmod'), ('217', 'nummod'), ('patient', 'amod'), ('activ', 'compound'), ('uveiti', 'nsubj'), ('treat', 'ROOT'), ('corticosteroid', 'amod'), ('(', 'punct'), ('oral', 'amod'), ('prednison', 'nsubj'), ('dose', 'parataxis'), ('10', 'compound'), ('60', 'nummod'), ('mg', 'nmod'), ('/', 'punct'), ('day', 'npadvmod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'All patients received a standardized dose of \\nprednisone 60 mg/day at study entry followed by a mandatory taper schedule, with complete \\ncorticosteroid discontinuation by Week 15.', 'tokens': ['patients', 'received', 'standardized', 'dose', 'prednisone', '60', 'mg/day', 'study', 'entry', 'followed', 'mandatory', 'taper', 'schedule', ',', 'complete', 'corticosteroid', 'discontinuation', 'Week', '15', '.'], 'lemmatized': ['patient', 'received', 'standardized', 'dose', 'prednisone', '60', 'mg/day', 'study', 'entry', 'followed', 'mandatory', 'taper', 'schedule', ',', 'complete', 'corticosteroid', 'discontinuation', 'Week', '15', '.'], 'stemmed': ['patient', 'receiv', 'standard', 'dose', 'prednison', '60', 'mg/day', 'studi', 'entri', 'follow', 'mandatori', 'taper', 'schedul', ',', 'complet', 'corticosteroid', 'discontinu', 'week', '15', '.'], 'dependencies': [('patient', 'compound'), ('receiv', 'compound'), ('standard', 'compound'), ('dose', 'compound'), ('prednison', 'nsubj'), ('60', 'nummod'), ('mg', 'nmod'), ('/', 'punct'), ('day', 'appos'), ('studi', 'compound'), ('entri', 'compound'), ('follow', 'compound'), ('mandatori', 'compound'), ('taper', 'compound'), ('schedul', 'appos'), (',', 'punct'), ('complet', 'ROOT'), ('corticosteroid', 'amod'), ('discontinu', 'compound'), ('week', 'npadvmod'), ('15', 'nummod'), ('.', 'punct')]}], 'text': 'Both studies evaluated Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12. HiSCR \\nwas defined as at least a 50% reduction in total abscess and inflammatory nodule count with no \\nincrease in abscess count and no increase in draining fistula count relative to baseline (see Table \\n18). Reduction in HS-related skin pain was assessed using a Numeric Rating Scale in patients \\nwho entered the study with an initial baseline score of 3 or greater on a 11 point scale.  \\nIn both studies, a higher proportion of HUMIRA- than placebo-treated subjects achieved HiSCR \\n(see Table 20).  \\nTable 20. Efficacy Results at 12 Weeks in Subjects with Moderate to Severe Hidradenitis \\nSuppurativa \\n  \\nHS Study I \\nHS Study II* \\n  \\nPlacebo \\nHumira 40 mg \\nWeekly \\nPlacebo \\nHumira 40 mg \\nWeekly \\nHidradenitis \\nSuppurativa Clinical \\nResponse (HiSCR) \\nN = 154 \\n40 (26%)  \\nN = 153 \\n64 (42%)  \\nN=163 \\n45 (28%)  \\nN=163 \\n96 (59%)  \\n*19.3% of subjects in Study HS-II continued baseline oral antibiotic therapy during the study.  \\n \\n  \\nIn both studies, from Week 12 to Week 35 (Period B), subjects who had received HUMIRA were \\nre-randomized to 1 of 3 treatment groups (HUMIRA 40 mg every week, HUMIRA 40 mg every \\nother week, or placebo). Subjects who had been randomized to placebo were assigned to receive \\nHUMIRA 40 mg every week (Study HS-I) or placebo (Study HS-II).  \\nDuring Period B, flare of HS, defined as ≥25% increase from baseline in abscesses and \\ninflammatory nodule counts and with a minimum of 2 additional lesions, was documented in 22 \\n(22%) of the 100 subjects who were withdrawn from HUMIRA treatment following the primary \\nefficacy timepoint in two studies.  \\n14.11 Adult Uveitis \\nThe safety and efficacy of HUMIRA were assessed in adult patients with non-infectious \\nintermediate, posterior and panuveitis excluding patients with isolated anterior uveitis, in two \\nrandomized, double-masked, placebo-controlled studies (UV I and II). Patients received placebo \\nor HUMIRA at an initial dose of 80 mg followed by 40 mg every other week starting one week \\nafter the initial dose. The primary efficacy endpoint in both studies was ´time to treatment \\nfailure´.  \\nTreatment failure was a multi-component outcome defined as the development of new \\ninflammatory chorioretinal and/or inflammatory retinal vascular lesions, an increase in anterior \\nchamber (AC) cell grade or vitreous haze (VH) grade or a decrease in best corrected visual \\nacuity (BCVA).  \\nStudy UV I evaluated 217 patients with active uveitis while being treated with corticosteroids \\n(oral prednisone at a dose of 10 to 60 mg/day). All patients received a standardized dose of \\nprednisone 60 mg/day at study entry followed by a mandatory taper schedule, with complete \\ncorticosteroid discontinuation by Week 15.  \\n'}, 'page_char_count': 2778, 'page_word_count': 433, 'sentences': ['Both studies evaluated Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12.', 'HiSCR \\nwas defined as at least a 50% reduction in total abscess and inflammatory nodule count with no \\nincrease in abscess count and no increase in draining fistula count relative to baseline (see Table \\n18).', 'Reduction in HS-related skin pain was assessed using a Numeric Rating Scale in patients \\nwho entered the study with an initial baseline score of 3 or greater on a 11 point scale.', ' \\nIn both studies, a higher proportion of HUMIRA- than placebo-treated subjects achieved HiSCR \\n(see Table 20).', ' \\nTable 20.', 'Efficacy Results at 12 Weeks in Subjects with Moderate to Severe Hidradenitis \\nSuppurativa \\n  \\nHS Study I \\nHS Study II* \\n  \\nPlacebo \\nHumira 40 mg \\nWeekly \\nPlacebo \\nHumira 40 mg \\nWeekly \\nHidradenitis \\nSuppurativa Clinical \\nResponse (HiSCR) \\nN = 154 \\n40 (26%)  \\nN = 153 \\n64 (42%)  \\nN=163 \\n45 (28%)  \\nN=163 \\n96 (59%)  \\n*19.3% of subjects in Study HS-II continued baseline oral antibiotic therapy during the study.', ' \\n \\n  \\nIn both studies, from Week 12 to Week 35 (Period B), subjects who had received HUMIRA were \\nre-randomized to 1 of 3 treatment groups (HUMIRA 40 mg every week, HUMIRA 40 mg every \\nother week, or placebo).', 'Subjects who had been randomized to placebo were assigned to receive \\nHUMIRA 40 mg every week (Study HS-I) or placebo (Study HS-II).', ' \\nDuring Period B, flare of HS, defined as ≥25% increase from baseline in abscesses and \\ninflammatory nodule counts and with a minimum of 2 additional lesions, was documented in 22 \\n(22%) of the 100 subjects who were withdrawn from HUMIRA treatment following the primary \\nefficacy timepoint in two studies.', ' \\n14.11 Adult Uveitis \\nThe safety and efficacy of HUMIRA were assessed in adult patients with non-infectious \\nintermediate, posterior and panuveitis excluding patients with isolated anterior uveitis, in two \\nrandomized, double-masked, placebo-controlled studies (UV I and II).', 'Patients received placebo \\nor HUMIRA at an initial dose of 80 mg followed by 40 mg every other week starting one week \\nafter the initial dose.', 'The primary efficacy endpoint in both studies was ´time to treatment \\nfailure´.', ' \\nTreatment failure was a multi-component outcome defined as the development of new \\ninflammatory chorioretinal and/or inflammatory retinal vascular lesions, an increase in anterior \\nchamber (AC) cell grade or vitreous haze (VH) grade or a decrease in best corrected visual \\nacuity (BCVA).', ' \\nStudy UV I evaluated 217 patients with active uveitis while being treated with corticosteroids \\n(oral prednisone at a dose of 10 to 60 mg/day).', 'All patients received a standardized dose of \\nprednisone 60 mg/day at study entry followed by a mandatory taper schedule, with complete \\ncorticosteroid discontinuation by Week 15.', ' \\n'], 'page_sentence_count_spacy': 16}\n",
            "{'page_number': 52, 'text': 'Study UV II evaluated 226 patients with inactive uveitis while being treated with corticosteroids \\n(oral prednisone 10 to 35 mg/day) at baseline to control their disease. Patients subsequently \\nunderwent a mandatory taper schedule, with complete corticosteroid discontinuation by Week \\n19.  \\nClinical Response \\nResults from both studies demonstrated statistically significant reduction of the risk of treatment \\nfailure in patients treated with HUMIRA versus patients receiving placebo. In both studies, all \\ncomponents of the primary endpoint contributed cumulatively to the overall difference between \\nHUMIRA and placebo groups (Table 21).  \\nTable 21. Time to Treatment Failure in Studies UV I and UV II \\n  \\nUV I \\nUV II \\n  \\nPlacebo  \\n(N = 107)  \\nHUMIRA  \\n(N = 110)  \\nHR  \\n[95% CI]a \\nPlacebo \\n(N = 111)  \\nHUMIRA \\n(N = 115)  \\nHR  \\n[95% CI]a \\nFailureb n (%)  \\n84 (78.5) \\n60 (54.5) \\n0.50 \\n[0.36, 0.70]  61 (55.0) \\n45 (39.1) \\n0.57 \\n[0.39, 0.84]  \\nMedian Time \\nto Failure \\n(Months)  \\n[95% CI]  \\n3.0 \\n[2.7, 3.7]  \\n5.6 \\n[3.9, 9.2]  \\nN/A \\n8.3 \\n[4.8, 12.0]  \\nNEc \\nN/A \\nª HR of HUMIRA versus placebo from proportional hazards regression with treatment as factor.  \\nb Treatment failure at or after Week 6 in Study UV I, or at or after Week 2 in Study UV II, was \\ncounted as event. Subjects who discontinued the study were censored at the time of dropping \\nout.  \\nc NE = not estimable. Fewer than half of at-risk subjects had an event.  \\n \\n  \\nFigure 3: Kaplan-Meier Curves Summarizing Time to Treatment Failure on or after Week \\n6 (Study UV I) or Week 2 (Study UV II) \\n \\nStudy UV I  \\n \\n', 'processed_text': {'sentences': [{'original_sentence': 'Study UV II evaluated 226 patients with inactive uveitis while being treated with corticosteroids \\n(oral prednisone 10 to 35 mg/day) at baseline to control their disease.', 'tokens': ['Study', 'UV', 'II', 'evaluated', '226', 'patients', 'inactive', 'uveitis', 'treated', 'corticosteroids', '(', 'oral', 'prednisone', '10', '35', 'mg/day', ')', 'baseline', 'control', 'disease', '.'], 'lemmatized': ['Study', 'UV', 'II', 'evaluated', '226', 'patient', 'inactive', 'uveitis', 'treated', 'corticosteroid', '(', 'oral', 'prednisone', '10', '35', 'mg/day', ')', 'baseline', 'control', 'disease', '.'], 'stemmed': ['studi', 'uv', 'ii', 'evalu', '226', 'patient', 'inact', 'uveiti', 'treat', 'corticosteroid', '(', 'oral', 'prednison', '10', '35', 'mg/day', ')', 'baselin', 'control', 'diseas', '.'], 'dependencies': [('studi', 'compound'), ('uv', 'compound'), ('ii', 'compound'), ('evalu', 'nmod'), ('226', 'nummod'), ('patient', 'compound'), ('inact', 'compound'), ('uveiti', 'nsubj'), ('treat', 'ROOT'), ('corticosteroid', 'amod'), ('(', 'punct'), ('oral', 'amod'), ('prednison', 'dobj'), ('10', 'nummod'), ('35', 'nummod'), ('mg', 'nmod'), ('/', 'punct'), ('day', 'npadvmod'), (')', 'punct'), ('baselin', 'compound'), ('control', 'compound'), ('diseas', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Patients subsequently \\nunderwent a mandatory taper schedule, with complete corticosteroid discontinuation by Week \\n19.', 'tokens': ['Patients', 'subsequently', 'underwent', 'mandatory', 'taper', 'schedule', ',', 'complete', 'corticosteroid', 'discontinuation', 'Week', '19', '.'], 'lemmatized': ['Patients', 'subsequently', 'underwent', 'mandatory', 'taper', 'schedule', ',', 'complete', 'corticosteroid', 'discontinuation', 'Week', '19', '.'], 'stemmed': ['patient', 'subsequ', 'underw', 'mandatori', 'taper', 'schedul', ',', 'complet', 'corticosteroid', 'discontinu', 'week', '19', '.'], 'dependencies': [('patient', 'compound'), ('subsequ', 'compound'), ('underw', 'compound'), ('mandatori', 'compound'), ('taper', 'compound'), ('schedul', 'nsubj'), (',', 'punct'), ('complet', 'ROOT'), ('corticosteroid', 'amod'), ('discontinu', 'compound'), ('week', 'npadvmod'), ('19', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Clinical Response \\nResults from both studies demonstrated statistically significant reduction of the risk of treatment \\nfailure in patients treated with HUMIRA versus patients receiving placebo.', 'tokens': ['Clinical', 'Response', 'Results', 'studies', 'demonstrated', 'statistically', 'significant', 'reduction', 'risk', 'treatment', 'failure', 'patients', 'treated', 'HUMIRA', 'versus', 'patients', 'receiving', 'placebo', '.'], 'lemmatized': ['Clinical', 'Response', 'Results', 'study', 'demonstrated', 'statistically', 'significant', 'reduction', 'risk', 'treatment', 'failure', 'patient', 'treated', 'HUMIRA', 'versus', 'patient', 'receiving', 'placebo', '.'], 'stemmed': ['clinic', 'respons', 'result', 'studi', 'demonstr', 'statist', 'signific', 'reduct', 'risk', 'treatment', 'failur', 'patient', 'treat', 'humira', 'versu', 'patient', 'receiv', 'placebo', '.'], 'dependencies': [('clinic', 'compound'), ('respons', 'nsubj'), ('result', 'ROOT'), ('studi', 'compound'), ('demonstr', 'nmod'), ('statist', 'amod'), ('signific', 'compound'), ('reduct', 'compound'), ('risk', 'compound'), ('treatment', 'compound'), ('failur', 'compound'), ('patient', 'compound'), ('treat', 'compound'), ('humira', 'compound'), ('versu', 'compound'), ('patient', 'compound'), ('receiv', 'compound'), ('placebo', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'In both studies, all \\ncomponents of the primary endpoint contributed cumulatively to the overall difference between \\nHUMIRA and placebo groups (Table 21).', 'tokens': ['studies', ',', 'components', 'primary', 'endpoint', 'contributed', 'cumulatively', 'overall', 'difference', 'HUMIRA', 'placebo', 'groups', '(', 'Table', '21', ')', '.'], 'lemmatized': ['study', ',', 'component', 'primary', 'endpoint', 'contributed', 'cumulatively', 'overall', 'difference', 'HUMIRA', 'placebo', 'group', '(', 'Table', '21', ')', '.'], 'stemmed': ['studi', ',', 'compon', 'primari', 'endpoint', 'contribut', 'cumul', 'overal', 'differ', 'humira', 'placebo', 'group', '(', 'tabl', '21', ')', '.'], 'dependencies': [('studi', 'npadvmod'), (',', 'punct'), ('compon', 'nsubj'), ('primari', 'nmod'), ('endpoint', 'nmod'), ('contribut', 'nmod'), ('cumul', 'amod'), ('overal', 'dobj'), ('differ', 'ROOT'), ('humira', 'compound'), ('placebo', 'compound'), ('group', 'dobj'), ('(', 'punct'), ('tabl', 'appos'), ('21', 'nummod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Table 21.', 'tokens': ['Table', '21', '.'], 'lemmatized': ['Table', '21', '.'], 'stemmed': ['tabl', '21', '.'], 'dependencies': [('tabl', 'ROOT'), ('21', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Time to Treatment Failure in Studies UV I and UV II \\n  \\nUV I \\nUV II \\n  \\nPlacebo  \\n(N = 107)  \\nHUMIRA  \\n(N = 110)  \\nHR  \\n[95% CI]a \\nPlacebo \\n(N = 111)  \\nHUMIRA \\n(N = 115)  \\nHR  \\n[95% CI]a \\nFailureb n (%)  \\n84 (78.5) \\n60 (54.5) \\n0.50 \\n[0.36, 0.70]  61 (55.0) \\n45 (39.1) \\n0.57 \\n[0.39, 0.84]  \\nMedian Time \\nto Failure \\n(Months)  \\n[95% CI]  \\n3.0 \\n[2.7, 3.7]  \\n5.6 \\n[3.9, 9.2]  \\nN/A \\n8.3 \\n[4.8, 12.0]  \\nNEc \\nN/A \\nª HR of HUMIRA versus placebo from proportional hazards regression with treatment as factor.', 'tokens': ['Time', 'Treatment', 'Failure', 'Studies', 'UV', 'UV', 'II', 'UV', 'UV', 'II', 'Placebo', '(', 'N', '=', '107', ')', 'HUMIRA', '(', 'N', '=', '110', ')', 'HR', '[', '95', '%', 'CI', ']', 'Placebo', '(', 'N', '=', '111', ')', 'HUMIRA', '(', 'N', '=', '115', ')', 'HR', '[', '95', '%', 'CI', ']', 'Failureb', 'n', '(', '%', ')', '84', '(', '78.5', ')', '60', '(', '54.5', ')', '0.50', '[', '0.36', ',', '0.70', ']', '61', '(', '55.0', ')', '45', '(', '39.1', ')', '0.57', '[', '0.39', ',', '0.84', ']', 'Median', 'Time', 'Failure', '(', 'Months', ')', '[', '95', '%', 'CI', ']', '3.0', '[', '2.7', ',', '3.7', ']', '5.6', '[', '3.9', ',', '9.2', ']', 'N/A', '8.3', '[', '4.8', ',', '12.0', ']', 'NEc', 'N/A', 'ª', 'HR', 'HUMIRA', 'versus', 'placebo', 'proportional', 'hazards', 'regression', 'treatment', 'factor', '.'], 'lemmatized': ['Time', 'Treatment', 'Failure', 'Studies', 'UV', 'UV', 'II', 'UV', 'UV', 'II', 'Placebo', '(', 'N', '=', '107', ')', 'HUMIRA', '(', 'N', '=', '110', ')', 'HR', '[', '95', '%', 'CI', ']', 'Placebo', '(', 'N', '=', '111', ')', 'HUMIRA', '(', 'N', '=', '115', ')', 'HR', '[', '95', '%', 'CI', ']', 'Failureb', 'n', '(', '%', ')', '84', '(', '78.5', ')', '60', '(', '54.5', ')', '0.50', '[', '0.36', ',', '0.70', ']', '61', '(', '55.0', ')', '45', '(', '39.1', ')', '0.57', '[', '0.39', ',', '0.84', ']', 'Median', 'Time', 'Failure', '(', 'Months', ')', '[', '95', '%', 'CI', ']', '3.0', '[', '2.7', ',', '3.7', ']', '5.6', '[', '3.9', ',', '9.2', ']', 'N/A', '8.3', '[', '4.8', ',', '12.0', ']', 'NEc', 'N/A', 'ª', 'HR', 'HUMIRA', 'versus', 'placebo', 'proportional', 'hazard', 'regression', 'treatment', 'factor', '.'], 'stemmed': ['time', 'treatment', 'failur', 'studi', 'uv', 'uv', 'ii', 'uv', 'uv', 'ii', 'placebo', '(', 'n', '=', '107', ')', 'humira', '(', 'n', '=', '110', ')', 'hr', '[', '95', '%', 'ci', ']', 'placebo', '(', 'n', '=', '111', ')', 'humira', '(', 'n', '=', '115', ')', 'hr', '[', '95', '%', 'ci', ']', 'failureb', 'n', '(', '%', ')', '84', '(', '78.5', ')', '60', '(', '54.5', ')', '0.50', '[', '0.36', ',', '0.70', ']', '61', '(', '55.0', ')', '45', '(', '39.1', ')', '0.57', '[', '0.39', ',', '0.84', ']', 'median', 'time', 'failur', '(', 'month', ')', '[', '95', '%', 'ci', ']', '3.0', '[', '2.7', ',', '3.7', ']', '5.6', '[', '3.9', ',', '9.2', ']', 'n/a', '8.3', '[', '4.8', ',', '12.0', ']', 'nec', 'n/a', 'ª', 'hr', 'humira', 'versu', 'placebo', 'proport', 'hazard', 'regress', 'treatment', 'factor', '.'], 'dependencies': [('time', 'compound'), ('treatment', 'ROOT'), ('failur', 'compound'), ('studi', 'npadvmod'), ('uv', 'nmod'), ('uv', 'compound'), ('ii', 'compound'), ('uv', 'nmod'), ('uv', 'compound'), ('ii', 'compound'), ('placebo', 'nmod'), ('(', 'punct'), ('n', 'meta'), ('=', 'nmod'), ('107', 'dep'), (')', 'punct'), ('humira', 'nmod'), ('(', 'punct'), ('n', 'dep'), ('=', 'nmod'), ('110', 'nummod'), (')', 'punct'), ('hr', 'nmod'), ('[', 'punct'), ('95', 'nummod'), ('%', 'nmod'), ('ci', 'nmod'), (']', 'punct'), ('placebo', 'nmod'), ('(', 'punct'), ('n', 'appos'), ('=', 'nmod'), ('111', 'nummod'), (')', 'punct'), ('humira', 'nmod'), ('(', 'punct'), ('n', 'cc'), ('=', 'nmod'), ('115', 'dep'), (')', 'punct'), ('hr', 'nmod'), ('[', 'punct'), ('95', 'nummod'), ('%', 'compound'), ('ci', 'dep'), (']', 'punct'), ('failureb', 'appos'), ('n', 'cc'), ('(', 'punct'), ('%', 'parataxis'), (')', 'punct'), ('84', 'nummod'), ('(', 'punct'), ('78.5', 'nummod'), (')', 'punct'), ('60', 'ROOT'), ('(', 'punct'), ('54.5', 'npadvmod'), (')', 'punct'), ('0.50', 'punct'), ('[', 'punct'), ('0.36', 'ROOT'), (',', 'punct'), ('0.70', 'npadvmod'), (']', 'punct'), ('61', 'nummod'), ('(', 'punct'), ('55.0', 'npadvmod'), (')', 'punct'), ('45', 'punct'), ('(', 'punct'), ('39.1', 'ROOT'), (')', 'punct'), ('0.57', 'punct'), ('[', 'punct'), ('0.39', 'ROOT'), (',', 'punct'), ('0.84', 'npadvmod'), (']', 'punct'), ('median', 'amod'), ('time', 'compound'), ('failur', 'ROOT'), ('(', 'punct'), ('month', 'appos'), (')', 'punct'), ('[', 'punct'), ('95', 'nummod'), ('%', 'ROOT'), ('ci', 'appos'), (']', 'dep'), ('3.0', 'appos'), ('[', 'punct'), ('2.7', 'appos'), (',', 'punct'), ('3.7', 'appos'), (']', 'compound'), ('5.6', 'prep'), ('[', 'punct'), ('3.9', 'appos'), (',', 'punct'), ('9.2', 'appos'), (']', 'punct'), ('n', 'cc'), ('/', 'punct'), ('a', 'quantmod'), ('8.3', 'nummod'), ('[', 'punct'), ('4.8', 'appos'), (',', 'punct'), ('12.0', 'appos'), (']', 'punct'), ('nec', 'ROOT'), ('n', 'appos'), ('/', 'punct'), ('a', 'det'), ('ª', 'nmod'), ('hr', 'nmod'), ('humira', 'nmod'), ('versu', 'nmod'), ('placebo', 'compound'), ('proport', 'compound'), ('hazard', 'compound'), ('regress', 'compound'), ('treatment', 'compound'), ('factor', 'appos'), ('.', 'punct')]}, {'original_sentence': 'b Treatment failure at or after Week 6 in Study UV I, or at or after Week 2 in Study UV II, was \\ncounted as event.', 'tokens': ['b', 'Treatment', 'failure', 'Week', '6', 'Study', 'UV', ',', 'Week', '2', 'Study', 'UV', 'II', ',', 'counted', 'event', '.'], 'lemmatized': ['b', 'Treatment', 'failure', 'Week', '6', 'Study', 'UV', ',', 'Week', '2', 'Study', 'UV', 'II', ',', 'counted', 'event', '.'], 'stemmed': ['b', 'treatment', 'failur', 'week', '6', 'studi', 'uv', ',', 'week', '2', 'studi', 'uv', 'ii', ',', 'count', 'event', '.'], 'dependencies': [('b', 'compound'), ('treatment', 'ROOT'), ('failur', 'compound'), ('week', 'npadvmod'), ('6', 'nummod'), ('studi', 'compound'), ('uv', 'npadvmod'), (',', 'punct'), ('week', 'npadvmod'), ('2', 'nummod'), ('studi', 'compound'), ('uv', 'compound'), ('ii', 'appos'), (',', 'punct'), ('count', 'compound'), ('event', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Subjects who discontinued the study were censored at the time of dropping \\nout.', 'tokens': ['Subjects', 'discontinued', 'study', 'censored', 'time', 'dropping', '.'], 'lemmatized': ['Subjects', 'discontinued', 'study', 'censored', 'time', 'dropping', '.'], 'stemmed': ['subject', 'discontinu', 'studi', 'censor', 'time', 'drop', '.'], 'dependencies': [('subject', 'amod'), ('discontinu', 'compound'), ('studi', 'compound'), ('censor', 'compound'), ('time', 'compound'), ('drop', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'c NE = not estimable.', 'tokens': ['c', 'NE', '=', 'estimable', '.'], 'lemmatized': ['c', 'NE', '=', 'estimable', '.'], 'stemmed': ['c', 'ne', '=', 'estim', '.'], 'dependencies': [('c', 'compound'), ('ne', 'compound'), ('=', 'compound'), ('estim', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Fewer than half of at-risk subjects had an event.', 'tokens': ['Fewer', 'half', 'at-risk', 'subjects', 'event', '.'], 'lemmatized': ['Fewer', 'half', 'at-risk', 'subject', 'event', '.'], 'stemmed': ['fewer', 'half', 'at-risk', 'subject', 'event', '.'], 'dependencies': [('fewer', 'amod'), ('half', 'amod'), ('at', 'nmod'), ('-', 'punct'), ('risk', 'pobj'), ('subject', 'compound'), ('event', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Figure 3: Kaplan-Meier Curves Summarizing Time to Treatment Failure on or after Week \\n6 (Study UV I) or Week 2 (Study UV II) \\n \\nStudy UV I', 'tokens': ['Figure', '3', ':', 'Kaplan-Meier', 'Curves', 'Summarizing', 'Time', 'Treatment', 'Failure', 'Week', '6', '(', 'Study', 'UV', ')', 'Week', '2', '(', 'Study', 'UV', 'II', ')', 'Study', 'UV'], 'lemmatized': ['Figure', '3', ':', 'Kaplan-Meier', 'Curves', 'Summarizing', 'Time', 'Treatment', 'Failure', 'Week', '6', '(', 'Study', 'UV', ')', 'Week', '2', '(', 'Study', 'UV', 'II', ')', 'Study', 'UV'], 'stemmed': ['figur', '3', ':', 'kaplan-mei', 'curv', 'summar', 'time', 'treatment', 'failur', 'week', '6', '(', 'studi', 'uv', ')', 'week', '2', '(', 'studi', 'uv', 'ii', ')', 'studi', 'uv'], 'dependencies': [('figur', 'ROOT'), ('3', 'nummod'), (':', 'punct'), ('kaplan', 'compound'), ('-', 'punct'), ('mei', 'compound'), ('curv', 'compound'), ('summar', 'compound'), ('time', 'compound'), ('treatment', 'appos'), ('failur', 'compound'), ('week', 'npadvmod'), ('6', 'nummod'), ('(', 'punct'), ('studi', 'compound'), ('uv', 'appos'), (')', 'punct'), ('week', 'npadvmod'), ('2', 'nummod'), ('(', 'punct'), ('studi', 'nmod'), ('uv', 'compound'), ('ii', 'appos'), (')', 'punct'), ('studi', 'compound'), ('uv', 'ROOT')]}], 'text': 'Study UV II evaluated 226 patients with inactive uveitis while being treated with corticosteroids \\n(oral prednisone 10 to 35 mg/day) at baseline to control their disease. Patients subsequently \\nunderwent a mandatory taper schedule, with complete corticosteroid discontinuation by Week \\n19.  \\nClinical Response \\nResults from both studies demonstrated statistically significant reduction of the risk of treatment \\nfailure in patients treated with HUMIRA versus patients receiving placebo. In both studies, all \\ncomponents of the primary endpoint contributed cumulatively to the overall difference between \\nHUMIRA and placebo groups (Table 21).  \\nTable 21. Time to Treatment Failure in Studies UV I and UV II \\n  \\nUV I \\nUV II \\n  \\nPlacebo  \\n(N = 107)  \\nHUMIRA  \\n(N = 110)  \\nHR  \\n[95% CI]a \\nPlacebo \\n(N = 111)  \\nHUMIRA \\n(N = 115)  \\nHR  \\n[95% CI]a \\nFailureb n (%)  \\n84 (78.5) \\n60 (54.5) \\n0.50 \\n[0.36, 0.70]  61 (55.0) \\n45 (39.1) \\n0.57 \\n[0.39, 0.84]  \\nMedian Time \\nto Failure \\n(Months)  \\n[95% CI]  \\n3.0 \\n[2.7, 3.7]  \\n5.6 \\n[3.9, 9.2]  \\nN/A \\n8.3 \\n[4.8, 12.0]  \\nNEc \\nN/A \\nª HR of HUMIRA versus placebo from proportional hazards regression with treatment as factor.  \\nb Treatment failure at or after Week 6 in Study UV I, or at or after Week 2 in Study UV II, was \\ncounted as event. Subjects who discontinued the study were censored at the time of dropping \\nout.  \\nc NE = not estimable. Fewer than half of at-risk subjects had an event.  \\n \\n  \\nFigure 3: Kaplan-Meier Curves Summarizing Time to Treatment Failure on or after Week \\n6 (Study UV I) or Week 2 (Study UV II) \\n \\nStudy UV I  \\n \\n'}, 'page_char_count': 1575, 'page_word_count': 255, 'sentences': ['Study UV II evaluated 226 patients with inactive uveitis while being treated with corticosteroids \\n(oral prednisone 10 to 35 mg/day) at baseline to control their disease.', 'Patients subsequently \\nunderwent a mandatory taper schedule, with complete corticosteroid discontinuation by Week \\n19.', ' \\nClinical Response \\nResults from both studies demonstrated statistically significant reduction of the risk of treatment \\nfailure in patients treated with HUMIRA versus patients receiving placebo.', 'In both studies, all \\ncomponents of the primary endpoint contributed cumulatively to the overall difference between \\nHUMIRA and placebo groups (Table 21).', ' \\nTable 21.', 'Time to Treatment Failure in Studies UV I and UV II \\n  \\nUV I \\nUV II \\n  \\nPlacebo  \\n(N = 107)  \\nHUMIRA  \\n(N = 110)  \\nHR  \\n[95% CI]a \\nPlacebo \\n(N = 111)  \\nHUMIRA \\n(N = 115)  \\nHR  \\n[95% CI]a \\nFailureb n (%)  \\n84 (78.5) \\n60 (54.5) \\n0.50 \\n[0.36, 0.70]  61 (55.0) \\n45 (39.1) \\n0.57 \\n[0.39, 0.84]  \\nMedian Time \\nto Failure \\n(Months)  \\n[95% CI]  \\n3.0 \\n[2.7, 3.7]  \\n5.6 \\n[3.9, 9.2]  \\nN/A \\n8.3 \\n[4.8, 12.0]  \\nNEc \\nN/A \\nª HR of HUMIRA versus placebo from proportional hazards regression with treatment as factor.', ' \\nb Treatment failure at or after Week 6 in Study UV I, or at or after Week 2 in Study UV II, was \\ncounted as event.', 'Subjects who discontinued the study were censored at the time of dropping \\nout.', ' \\nc NE = not estimable.', 'Fewer than half of at-risk subjects had an event.', ' \\n \\n  \\nFigure 3: Kaplan-Meier Curves Summarizing Time to Treatment Failure on or after Week \\n6 (Study UV I) or Week 2 (Study UV II) \\n \\nStudy UV I  \\n \\n'], 'page_sentence_count_spacy': 11}\n",
            "{'page_number': 53, 'text': ' \\nStudy UV II  \\nNote: P# = Placebo (Number of Events/Number at Risk); A# = HUMIRA (Number of \\nEvents/Number at Risk).  \\n14.12 Pediatric Uveitis \\nThe safety and efficacy of HUMIRA were assessed in a randomized, double-masked, placebo-\\ncontrolled study of 90 pediatric patients from 2 to < 18 years of age with active JIA-associated \\nnon-infectious uveitis (PUV-I). Patients received either placebo or 20 mg adalimumab (if < 30 \\nkg) or 40 mg adalimumab (if ≥ 30 kg) every other week in combination with a dose of \\nmethotrexate. Concomitant dosages of corticosteroids were permitted at study entry followed by \\na mandatory reduction in topical corticosteroids within 3 months.  \\nThe primary endpoint was ‘time to treatment failure’. The criteria determining treatment failure \\nwere worsening or sustained non-improvement in ocular inflammation, or worsening of ocular \\nco-morbidities.  \\nClinical Response \\nHUMIRA significantly decreased the risk of treatment failure by 75% relative to placebo (HR = \\n0.25 [95% CI: 0.12, 0.49]) (Table 22).  \\n \\n  \\nTable 22. Analysis Results of Time to Treatment Failure (Study PUV-I) \\n  \\nPlacebo \\n(N=30) \\nHUMIRA \\n(N=60) \\nHR (95% CI)ª \\nFailure (n[%]) \\n18 (60%) \\n16 (26.7%) \\n0.25 \\n(0.12, 0.49)  \\nMedian Time to \\nFailure (Weeks) \\n(95% CI)ᵇ \\n24.1 \\n(12.4, 81.0)  \\nNEᶜ \\n  \\na HR of adalimumab versus placebo from proportional hazards regression with treatment as \\nfactor. \\nb Estimated based on Kaplan-Meier curve. \\nc NE = not estimable. Fewer than half of at-risk subjects had an event.  \\n \\n  \\n', 'processed_text': {'sentences': [{'original_sentence': ' \\nStudy UV II  \\nNote: P# = Placebo (Number of Events/Number at Risk); A# = HUMIRA (Number of \\nEvents/Number at Risk).', 'tokens': ['Study', 'UV', 'II', 'Note', ':', 'P', '#', '=', 'Placebo', '(', 'Number', 'Events/Number', 'Risk', ')', ';', '#', '=', 'HUMIRA', '(', 'Number', 'Events/Number', 'Risk', ')', '.'], 'lemmatized': ['Study', 'UV', 'II', 'Note', ':', 'P', '#', '=', 'Placebo', '(', 'Number', 'Events/Number', 'Risk', ')', ';', '#', '=', 'HUMIRA', '(', 'Number', 'Events/Number', 'Risk', ')', '.'], 'stemmed': ['studi', 'uv', 'ii', 'note', ':', 'p', '#', '=', 'placebo', '(', 'number', 'events/numb', 'risk', ')', ';', '#', '=', 'humira', '(', 'number', 'events/numb', 'risk', ')', '.'], 'dependencies': [('studi', 'compound'), ('uv', 'compound'), ('ii', 'compound'), ('note', 'ROOT'), (':', 'punct'), ('p', 'compound'), ('#', 'npadvmod'), ('=', 'prep'), ('placebo', 'appos'), ('(', 'punct'), ('number', 'nmod'), ('events', 'nmod'), ('/', 'punct'), ('numb', 'amod'), ('risk', 'appos'), (')', 'punct'), (';', 'punct'), ('#', 'nmod'), ('=', 'punct'), ('humira', 'conj'), ('(', 'punct'), ('number', 'compound'), ('events', 'nmod'), ('/', 'punct'), ('numb', 'amod'), ('risk', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': '14.12 Pediatric Uveitis \\nThe safety and efficacy of HUMIRA were assessed in a randomized, double-masked, placebo-\\ncontrolled study of 90 pediatric patients from 2 to < 18 years of age with active JIA-associated \\nnon-infectious uveitis (PUV-I).', 'tokens': ['14.12', 'Pediatric', 'Uveitis', 'safety', 'efficacy', 'HUMIRA', 'assessed', 'randomized', ',', 'double-masked', ',', 'placebo-', 'controlled', 'study', '90', 'pediatric', 'patients', '2', '<', '18', 'years', 'age', 'active', 'JIA-associated', 'non-infectious', 'uveitis', '(', 'PUV-I', ')', '.'], 'lemmatized': ['14.12', 'Pediatric', 'Uveitis', 'safety', 'efficacy', 'HUMIRA', 'assessed', 'randomized', ',', 'double-masked', ',', 'placebo-', 'controlled', 'study', '90', 'pediatric', 'patient', '2', '<', '18', 'year', 'age', 'active', 'JIA-associated', 'non-infectious', 'uveitis', '(', 'PUV-I', ')', '.'], 'stemmed': ['14.12', 'pediatr', 'uveiti', 'safeti', 'efficaci', 'humira', 'assess', 'random', ',', 'double-mask', ',', 'placebo-', 'control', 'studi', '90', 'pediatr', 'patient', '2', '<', '18', 'year', 'age', 'activ', 'jia-associ', 'non-infecti', 'uveiti', '(', 'puv-i', ')', '.'], 'dependencies': [('14.12', 'nummod'), ('pediatr', 'amod'), ('uveiti', 'compound'), ('safeti', 'compound'), ('efficaci', 'compound'), ('humira', 'nsubj'), ('assess', 'ROOT'), ('random', 'dobj'), (',', 'punct'), ('double', 'amod'), ('-', 'punct'), ('mask', 'conj'), (',', 'punct'), ('placebo-', 'compound'), ('control', 'compound'), ('studi', 'npadvmod'), ('90', 'nummod'), ('pediatr', 'amod'), ('patient', 'npadvmod'), ('2', 'nummod'), ('<', 'appos'), ('18', 'nummod'), ('year', 'compound'), ('age', 'compound'), ('activ', 'nmod'), ('jia', 'nmod'), ('-', 'punct'), ('associ', 'nmod'), ('non', 'amod'), ('-', 'amod'), ('infecti', 'amod'), ('uveiti', 'appos'), ('(', 'punct'), ('puv', 'compound'), ('-', 'punct'), ('i', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Patients received either placebo or 20 mg adalimumab (if < 30 \\nkg) or 40 mg adalimumab (if ≥ 30 kg) every other week in combination with a dose of \\nmethotrexate.', 'tokens': ['Patients', 'received', 'either', 'placebo', '20', 'mg', 'adalimumab', '(', '<', '30', 'kg', ')', '40', 'mg', 'adalimumab', '(', '≥', '30', 'kg', ')', 'every', 'week', 'combination', 'dose', 'methotrexate', '.'], 'lemmatized': ['Patients', 'received', 'either', 'placebo', '20', 'mg', 'adalimumab', '(', '<', '30', 'kg', ')', '40', 'mg', 'adalimumab', '(', '≥', '30', 'kg', ')', 'every', 'week', 'combination', 'dose', 'methotrexate', '.'], 'stemmed': ['patient', 'receiv', 'either', 'placebo', '20', 'mg', 'adalimumab', '(', '<', '30', 'kg', ')', '40', 'mg', 'adalimumab', '(', '≥', '30', 'kg', ')', 'everi', 'week', 'combin', 'dose', 'methotrex', '.'], 'dependencies': [('patient', 'compound'), ('receiv', 'ROOT'), ('either', 'preconj'), ('placebo', 'appos'), ('20', 'nummod'), ('mg', 'prep'), ('adalimumab', 'appos'), ('(', 'punct'), ('<', 'dep'), ('30', 'nummod'), ('kg', 'ROOT'), (')', 'punct'), ('40', 'nummod'), ('mg', 'npadvmod'), ('adalimumab', 'ROOT'), ('(', 'punct'), ('≥', 'appos'), ('30', 'nummod'), ('kg', 'appos'), (')', 'punct'), ('everi', 'amod'), ('week', 'compound'), ('combin', 'compound'), ('dose', 'compound'), ('methotrex', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Concomitant dosages of corticosteroids were permitted at study entry followed by \\na mandatory reduction in topical corticosteroids within 3 months.', 'tokens': ['Concomitant', 'dosages', 'corticosteroids', 'permitted', 'study', 'entry', 'followed', 'mandatory', 'reduction', 'topical', 'corticosteroids', 'within', '3', 'months', '.'], 'lemmatized': ['Concomitant', 'dosage', 'corticosteroid', 'permitted', 'study', 'entry', 'followed', 'mandatory', 'reduction', 'topical', 'corticosteroid', 'within', '3', 'month', '.'], 'stemmed': ['concomit', 'dosag', 'corticosteroid', 'permit', 'studi', 'entri', 'follow', 'mandatori', 'reduct', 'topic', 'corticosteroid', 'within', '3', 'month', '.'], 'dependencies': [('concomit', 'compound'), ('dosag', 'nmod'), ('corticosteroid', 'compound'), ('permit', 'compound'), ('studi', 'compound'), ('entri', 'amod'), ('follow', 'compound'), ('mandatori', 'compound'), ('reduct', 'compound'), ('topic', 'ROOT'), ('corticosteroid', 'amod'), ('within', 'prep'), ('3', 'nummod'), ('month', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'The primary endpoint was ‘time to treatment failure’.', 'tokens': ['primary', 'endpoint', '‘', 'time', 'treatment', 'failure', '’', '.'], 'lemmatized': ['primary', 'endpoint', '‘', 'time', 'treatment', 'failure', '’', '.'], 'stemmed': ['primari', 'endpoint', '‘', 'time', 'treatment', 'failur', '’', '.'], 'dependencies': [('primari', 'compound'), ('endpoint', 'nmod'), ('‘', 'punct'), ('time', 'compound'), ('treatment', 'compound'), ('failur', 'ROOT'), ('’', 'punct'), ('.', 'punct')]}, {'original_sentence': 'The criteria determining treatment failure \\nwere worsening or sustained non-improvement in ocular inflammation, or worsening of ocular \\nco-morbidities.', 'tokens': ['criteria', 'determining', 'treatment', 'failure', 'worsening', 'sustained', 'non-improvement', 'ocular', 'inflammation', ',', 'worsening', 'ocular', 'co-morbidities', '.'], 'lemmatized': ['criterion', 'determining', 'treatment', 'failure', 'worsening', 'sustained', 'non-improvement', 'ocular', 'inflammation', ',', 'worsening', 'ocular', 'co-morbidities', '.'], 'stemmed': ['criterion', 'determin', 'treatment', 'failur', 'worsen', 'sustain', 'non-improv', 'ocular', 'inflamm', ',', 'worsen', 'ocular', 'co-morbid', '.'], 'dependencies': [('criterion', 'compound'), ('determin', 'compound'), ('treatment', 'compound'), ('failur', 'compound'), ('worsen', 'nsubj'), ('sustain', 'ROOT'), ('non', 'amod'), ('-', 'amod'), ('improv', 'amod'), ('ocular', 'amod'), ('inflamm', 'dobj'), (',', 'punct'), ('worsen', 'conj'), ('ocular', 'amod'), ('co', 'dobj'), ('-', 'dobj'), ('morbid', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Clinical Response \\nHUMIRA significantly decreased the risk of treatment failure by 75% relative to placebo (HR = \\n0.25 [95% CI: 0.12, 0.49]) (Table 22).', 'tokens': ['Clinical', 'Response', 'HUMIRA', 'significantly', 'decreased', 'risk', 'treatment', 'failure', '75', '%', 'relative', 'placebo', '(', 'HR', '=', '0.25', '[', '95', '%', 'CI', ':', '0.12', ',', '0.49', ']', ')', '(', 'Table', '22', ')', '.'], 'lemmatized': ['Clinical', 'Response', 'HUMIRA', 'significantly', 'decreased', 'risk', 'treatment', 'failure', '75', '%', 'relative', 'placebo', '(', 'HR', '=', '0.25', '[', '95', '%', 'CI', ':', '0.12', ',', '0.49', ']', ')', '(', 'Table', '22', ')', '.'], 'stemmed': ['clinic', 'respons', 'humira', 'significantli', 'decreas', 'risk', 'treatment', 'failur', '75', '%', 'rel', 'placebo', '(', 'hr', '=', '0.25', '[', '95', '%', 'ci', ':', '0.12', ',', '0.49', ']', ')', '(', 'tabl', '22', ')', '.'], 'dependencies': [('clinic', 'compound'), ('respons', 'compound'), ('humira', 'compound'), ('significantli', 'nsubj'), ('decreas', 'ROOT'), ('risk', 'compound'), ('treatment', 'compound'), ('failur', 'dobj'), ('75', 'nummod'), ('%', 'compound'), ('rel', 'compound'), ('placebo', 'appos'), ('(', 'punct'), ('hr', 'nmod'), ('=', 'nmod'), ('0.25', 'nummod'), ('[', 'punct'), ('95', 'nummod'), ('%', 'compound'), ('ci', 'ROOT'), (':', 'punct'), ('0.12', 'appos'), (',', 'punct'), ('0.49', 'appos'), (']', 'punct'), (')', 'punct'), ('(', 'punct'), ('tabl', 'ROOT'), ('22', 'npadvmod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Table 22.', 'tokens': ['Table', '22', '.'], 'lemmatized': ['Table', '22', '.'], 'stemmed': ['tabl', '22', '.'], 'dependencies': [('tabl', 'ROOT'), ('22', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Analysis Results of Time to Treatment Failure (Study PUV-I) \\n  \\nPlacebo \\n(N=30) \\nHUMIRA \\n(N=60) \\nHR (95% CI)ª \\nFailure (n[%]) \\n18 (60%) \\n16 (26.7%) \\n0.25 \\n(0.12, 0.49)  \\nMedian Time to \\nFailure (Weeks) \\n(95% CI)ᵇ \\n24.1 \\n(12.4, 81.0)  \\nNEᶜ \\n  \\na HR of adalimumab versus placebo from proportional hazards regression with treatment as \\nfactor.', 'tokens': ['Analysis', 'Results', 'Time', 'Treatment', 'Failure', '(', 'Study', 'PUV-I', ')', 'Placebo', '(', 'N=30', ')', 'HUMIRA', '(', 'N=60', ')', 'HR', '(', '95', '%', 'CI', ')', 'ª', 'Failure', '(', 'n', '[', '%', ']', ')', '18', '(', '60', '%', ')', '16', '(', '26.7', '%', ')', '0.25', '(', '0.12', ',', '0.49', ')', 'Median', 'Time', 'Failure', '(', 'Weeks', ')', '(', '95', '%', 'CI', ')', 'ᵇ', '24.1', '(', '12.4', ',', '81.0', ')', 'NEᶜ', 'HR', 'adalimumab', 'versus', 'placebo', 'proportional', 'hazards', 'regression', 'treatment', 'factor', '.'], 'lemmatized': ['Analysis', 'Results', 'Time', 'Treatment', 'Failure', '(', 'Study', 'PUV-I', ')', 'Placebo', '(', 'N=30', ')', 'HUMIRA', '(', 'N=60', ')', 'HR', '(', '95', '%', 'CI', ')', 'ª', 'Failure', '(', 'n', '[', '%', ']', ')', '18', '(', '60', '%', ')', '16', '(', '26.7', '%', ')', '0.25', '(', '0.12', ',', '0.49', ')', 'Median', 'Time', 'Failure', '(', 'Weeks', ')', '(', '95', '%', 'CI', ')', 'ᵇ', '24.1', '(', '12.4', ',', '81.0', ')', 'NEᶜ', 'HR', 'adalimumab', 'versus', 'placebo', 'proportional', 'hazard', 'regression', 'treatment', 'factor', '.'], 'stemmed': ['analysi', 'result', 'time', 'treatment', 'failur', '(', 'studi', 'puv-i', ')', 'placebo', '(', 'n=30', ')', 'humira', '(', 'n=60', ')', 'hr', '(', '95', '%', 'ci', ')', 'ª', 'failur', '(', 'n', '[', '%', ']', ')', '18', '(', '60', '%', ')', '16', '(', '26.7', '%', ')', '0.25', '(', '0.12', ',', '0.49', ')', 'median', 'time', 'failur', '(', 'week', ')', '(', '95', '%', 'ci', ')', 'ᵇ', '24.1', '(', '12.4', ',', '81.0', ')', 'neᶜ', 'hr', 'adalimumab', 'versu', 'placebo', 'proport', 'hazard', 'regress', 'treatment', 'factor', '.'], 'dependencies': [('analysi', 'compound'), ('result', 'compound'), ('time', 'compound'), ('treatment', 'compound'), ('failur', 'ROOT'), ('(', 'punct'), ('studi', 'compound'), ('puv', 'nmod'), ('-', 'punct'), ('i', 'appos'), (')', 'punct'), ('placebo', 'appos'), ('(', 'punct'), ('n=30', 'nmod'), (')', 'punct'), ('humira', 'appos'), ('(', 'punct'), ('n=60', 'nmod'), (')', 'punct'), ('hr', 'dep'), ('(', 'punct'), ('95', 'nummod'), ('%', 'compound'), ('ci', 'appos'), (')', 'punct'), ('ª', 'compound'), ('failur', 'appos'), ('(', 'punct'), ('n', 'cc'), ('[', 'compound'), ('%', 'intj'), (']', 'punct'), (')', 'punct'), ('18', 'nummod'), ('(', 'punct'), ('60', 'nummod'), ('%', 'ROOT'), (')', 'punct'), ('16', 'nummod'), ('(', 'punct'), ('26.7', 'nummod'), ('%', 'appos'), (')', 'punct'), ('0.25', 'appos'), ('(', 'punct'), ('0.12', 'appos'), (',', 'punct'), ('0.49', 'dep'), (')', 'punct'), ('median', 'amod'), ('time', 'compound'), ('failur', 'conj'), ('(', 'punct'), ('week', 'ROOT'), (')', 'punct'), ('(', 'punct'), ('95', 'nummod'), ('%', 'compound'), ('ci', 'parataxis'), (')', 'punct'), ('ᵇ', 'ROOT'), ('24.1', 'nummod'), ('(', 'punct'), ('12.4', 'prep'), (',', 'punct'), ('81.0', 'punct'), (')', 'punct'), ('neᶜ', 'compound'), ('hr', 'compound'), ('adalimumab', 'nmod'), ('versu', 'nmod'), ('placebo', 'compound'), ('proport', 'nmod'), ('hazard', 'compound'), ('regress', 'compound'), ('treatment', 'compound'), ('factor', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'b Estimated based on Kaplan-Meier curve.', 'tokens': ['b', 'Estimated', 'based', 'Kaplan-Meier', 'curve', '.'], 'lemmatized': ['b', 'Estimated', 'based', 'Kaplan-Meier', 'curve', '.'], 'stemmed': ['b', 'estim', 'base', 'kaplan-mei', 'curv', '.'], 'dependencies': [('b', 'compound'), ('estim', 'compound'), ('base', 'compound'), ('kaplan', 'compound'), ('-', 'punct'), ('mei', 'compound'), ('curv', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'c NE = not estimable.', 'tokens': ['c', 'NE', '=', 'estimable', '.'], 'lemmatized': ['c', 'NE', '=', 'estimable', '.'], 'stemmed': ['c', 'ne', '=', 'estim', '.'], 'dependencies': [('c', 'compound'), ('ne', 'compound'), ('=', 'compound'), ('estim', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Fewer than half of at-risk subjects had an event.', 'tokens': ['Fewer', 'half', 'at-risk', 'subjects', 'event', '.'], 'lemmatized': ['Fewer', 'half', 'at-risk', 'subject', 'event', '.'], 'stemmed': ['fewer', 'half', 'at-risk', 'subject', 'event', '.'], 'dependencies': [('fewer', 'amod'), ('half', 'amod'), ('at', 'nmod'), ('-', 'punct'), ('risk', 'pobj'), ('subject', 'compound'), ('event', 'ROOT'), ('.', 'punct')]}], 'text': ' \\nStudy UV II  \\nNote: P# = Placebo (Number of Events/Number at Risk); A# = HUMIRA (Number of \\nEvents/Number at Risk).  \\n14.12 Pediatric Uveitis \\nThe safety and efficacy of HUMIRA were assessed in a randomized, double-masked, placebo-\\ncontrolled study of 90 pediatric patients from 2 to < 18 years of age with active JIA-associated \\nnon-infectious uveitis (PUV-I). Patients received either placebo or 20 mg adalimumab (if < 30 \\nkg) or 40 mg adalimumab (if ≥ 30 kg) every other week in combination with a dose of \\nmethotrexate. Concomitant dosages of corticosteroids were permitted at study entry followed by \\na mandatory reduction in topical corticosteroids within 3 months.  \\nThe primary endpoint was ‘time to treatment failure’. The criteria determining treatment failure \\nwere worsening or sustained non-improvement in ocular inflammation, or worsening of ocular \\nco-morbidities.  \\nClinical Response \\nHUMIRA significantly decreased the risk of treatment failure by 75% relative to placebo (HR = \\n0.25 [95% CI: 0.12, 0.49]) (Table 22).  \\n \\n  \\nTable 22. Analysis Results of Time to Treatment Failure (Study PUV-I) \\n  \\nPlacebo \\n(N=30) \\nHUMIRA \\n(N=60) \\nHR (95% CI)ª \\nFailure (n[%]) \\n18 (60%) \\n16 (26.7%) \\n0.25 \\n(0.12, 0.49)  \\nMedian Time to \\nFailure (Weeks) \\n(95% CI)ᵇ \\n24.1 \\n(12.4, 81.0)  \\nNEᶜ \\n  \\na HR of adalimumab versus placebo from proportional hazards regression with treatment as \\nfactor. \\nb Estimated based on Kaplan-Meier curve. \\nc NE = not estimable. Fewer than half of at-risk subjects had an event.  \\n \\n  \\n'}, 'page_char_count': 1517, 'page_word_count': 228, 'sentences': [' \\nStudy UV II  \\nNote: P# = Placebo (Number of Events/Number at Risk); A# = HUMIRA (Number of \\nEvents/Number at Risk).', ' \\n14.12 Pediatric Uveitis \\nThe safety and efficacy of HUMIRA were assessed in a randomized, double-masked, placebo-\\ncontrolled study of 90 pediatric patients from 2 to < 18 years of age with active JIA-associated \\nnon-infectious uveitis (PUV-I).', 'Patients received either placebo or 20 mg adalimumab (if < 30 \\nkg) or 40 mg adalimumab (if ≥ 30 kg) every other week in combination with a dose of \\nmethotrexate.', 'Concomitant dosages of corticosteroids were permitted at study entry followed by \\na mandatory reduction in topical corticosteroids within 3 months.', ' \\nThe primary endpoint was ‘time to treatment failure’.', 'The criteria determining treatment failure \\nwere worsening or sustained non-improvement in ocular inflammation, or worsening of ocular \\nco-morbidities.', ' \\nClinical Response \\nHUMIRA significantly decreased the risk of treatment failure by 75% relative to placebo (HR = \\n0.25 [95% CI: 0.12, 0.49]) (Table 22).', ' \\n \\n  \\nTable 22.', 'Analysis Results of Time to Treatment Failure (Study PUV-I) \\n  \\nPlacebo \\n(N=30) \\nHUMIRA \\n(N=60) \\nHR (95% CI)ª \\nFailure (n[%]) \\n18 (60%) \\n16 (26.7%) \\n0.25 \\n(0.12, 0.49)  \\nMedian Time to \\nFailure (Weeks) \\n(95% CI)ᵇ \\n24.1 \\n(12.4, 81.0)  \\nNEᶜ \\n  \\na HR of adalimumab versus placebo from proportional hazards regression with treatment as \\nfactor.', '\\nb Estimated based on Kaplan-Meier curve.', '\\nc NE = not estimable.', 'Fewer than half of at-risk subjects had an event.', ' \\n \\n  \\n'], 'page_sentence_count_spacy': 13}\n",
            "{'page_number': 54, 'text': 'Figure 4: Kaplan-Meier Curves Summarizing Time to Treatment Failure (Study PUV-I) \\n \\nStudy PUV-I \\nNote: P = Placebo (Number at Risk); H = HUMIRA (Number at Risk).  \\n15 REFERENCES \\n1. National Cancer Institute. Surveillance, Epidemiology, and End Results Database (SEER) \\nProgram. SEER Incidence Crude Rates, 17 Registries, 2000-2007.  \\n  \\n16 HOW SUPPLIED/STORAGE AND HANDLING \\nHUMIRA® (adalimumab) is supplied as a preservative-free, sterile, clear and colorless solution \\nfor subcutaneous administration. The following packaging configurations are available.  \\n• HUMIRA Pen Carton - 40 mg/0.8 mL \\nHUMIRA is supplied in a carton containing two alcohol preps and two dose trays. Each dose \\ntray consists of a single-dose pen, containing a 1 mL prefilled glass syringe with a fixed ½ \\ninch needle, providing 40 mg/0.8 mL of HUMIRA. The needle cover may contain natural \\nrubber latex. The NDC number is 0074-4339-02.  \\n  \\n• HUMIRA Pen Carton - 40 mg/0.4 mL \\nHUMIRA is supplied in a carton containing two alcohol preps and two dose trays. Each dose \\n', 'processed_text': {'sentences': [{'original_sentence': 'Figure 4: Kaplan-Meier Curves Summarizing Time to Treatment Failure (Study PUV-I) \\n \\nStudy PUV-I \\nNote: P = Placebo (Number at Risk); H = HUMIRA (Number at Risk).', 'tokens': ['Figure', '4', ':', 'Kaplan-Meier', 'Curves', 'Summarizing', 'Time', 'Treatment', 'Failure', '(', 'Study', 'PUV-I', ')', 'Study', 'PUV-I', 'Note', ':', 'P', '=', 'Placebo', '(', 'Number', 'Risk', ')', ';', 'H', '=', 'HUMIRA', '(', 'Number', 'Risk', ')', '.'], 'lemmatized': ['Figure', '4', ':', 'Kaplan-Meier', 'Curves', 'Summarizing', 'Time', 'Treatment', 'Failure', '(', 'Study', 'PUV-I', ')', 'Study', 'PUV-I', 'Note', ':', 'P', '=', 'Placebo', '(', 'Number', 'Risk', ')', ';', 'H', '=', 'HUMIRA', '(', 'Number', 'Risk', ')', '.'], 'stemmed': ['figur', '4', ':', 'kaplan-mei', 'curv', 'summar', 'time', 'treatment', 'failur', '(', 'studi', 'puv-i', ')', 'studi', 'puv-i', 'note', ':', 'p', '=', 'placebo', '(', 'number', 'risk', ')', ';', 'h', '=', 'humira', '(', 'number', 'risk', ')', '.'], 'dependencies': [('figur', 'ROOT'), ('4', 'nummod'), (':', 'punct'), ('kaplan', 'compound'), ('-', 'punct'), ('mei', 'compound'), ('curv', 'compound'), ('summar', 'compound'), ('time', 'compound'), ('treatment', 'compound'), ('failur', 'appos'), ('(', 'punct'), ('studi', 'compound'), ('puv', 'compound'), ('-', 'punct'), ('i', 'appos'), (')', 'punct'), ('studi', 'compound'), ('puv', 'compound'), ('-', 'punct'), ('i', 'nsubj'), ('note', 'parataxis'), (':', 'punct'), ('p', 'nmod'), ('=', 'compound'), ('placebo', 'appos'), ('(', 'punct'), ('number', 'compound'), ('risk', 'parataxis'), (')', 'punct'), (';', 'punct'), ('h', 'nmod'), ('=', 'punct'), ('humira', 'conj'), ('(', 'punct'), ('number', 'compound'), ('risk', 'parataxis'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': '15 REFERENCES \\n1.', 'tokens': ['15', 'REFERENCES', '1', '.'], 'lemmatized': ['15', 'REFERENCES', '1', '.'], 'stemmed': ['15', 'refer', '1', '.'], 'dependencies': [('15', 'nsubj'), ('refer', 'ROOT'), ('1', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'National Cancer Institute.', 'tokens': ['National', 'Cancer', 'Institute', '.'], 'lemmatized': ['National', 'Cancer', 'Institute', '.'], 'stemmed': ['nation', 'cancer', 'institut', '.'], 'dependencies': [('nation', 'compound'), ('cancer', 'compound'), ('institut', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Surveillance, Epidemiology, and End Results Database (SEER) \\nProgram.', 'tokens': ['Surveillance', ',', 'Epidemiology', ',', 'End', 'Results', 'Database', '(', 'SEER', ')', 'Program', '.'], 'lemmatized': ['Surveillance', ',', 'Epidemiology', ',', 'End', 'Results', 'Database', '(', 'SEER', ')', 'Program', '.'], 'stemmed': ['surveil', ',', 'epidemiolog', ',', 'end', 'result', 'databas', '(', 'seer', ')', 'program', '.'], 'dependencies': [('surveil', 'nmod'), (',', 'punct'), ('epidemiolog', 'conj'), (',', 'punct'), ('end', 'compound'), ('result', 'conj'), ('databas', 'conj'), ('(', 'punct'), ('seer', 'nmod'), (')', 'punct'), ('program', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'SEER Incidence Crude Rates, 17 Registries, 2000-2007.', 'tokens': ['SEER', 'Incidence', 'Crude', 'Rates', ',', '17', 'Registries', ',', '2000-2007', '.'], 'lemmatized': ['SEER', 'Incidence', 'Crude', 'Rates', ',', '17', 'Registries', ',', '2000-2007', '.'], 'stemmed': ['seer', 'incid', 'crude', 'rate', ',', '17', 'registri', ',', '2000-2007', '.'], 'dependencies': [('seer', 'nmod'), ('incid', 'amod'), ('crude', 'amod'), ('rate', 'npadvmod'), (',', 'punct'), ('17', 'nsubj'), ('registri', 'ROOT'), (',', 'punct'), ('2000', 'npadvmod'), ('-', 'punct'), ('2007', 'prep'), ('.', 'punct')]}, {'original_sentence': '16 HOW SUPPLIED/STORAGE AND HANDLING \\nHUMIRA® (adalimumab) is supplied as a preservative-free, sterile, clear and colorless solution \\nfor subcutaneous administration.', 'tokens': ['16', 'SUPPLIED/STORAGE', 'HANDLING', 'HUMIRA®', '(', 'adalimumab', ')', 'supplied', 'preservative-free', ',', 'sterile', ',', 'clear', 'colorless', 'solution', 'subcutaneous', 'administration', '.'], 'lemmatized': ['16', 'SUPPLIED/STORAGE', 'HANDLING', 'HUMIRA®', '(', 'adalimumab', ')', 'supplied', 'preservative-free', ',', 'sterile', ',', 'clear', 'colorless', 'solution', 'subcutaneous', 'administration', '.'], 'stemmed': ['16', 'supplied/storag', 'handl', 'humira®', '(', 'adalimumab', ')', 'suppli', 'preservative-fre', ',', 'steril', ',', 'clear', 'colorless', 'solut', 'subcutan', 'administr', '.'], 'dependencies': [('16', 'nummod'), ('supplied', 'nmod'), ('/', 'punct'), ('storag', 'compound'), ('handl', 'compound'), ('humira', 'nmod'), ('®', 'nmod'), ('(', 'punct'), ('adalimumab', 'nmod'), (')', 'punct'), ('suppli', 'nmod'), ('preservative', 'amod'), ('-', 'punct'), ('fre', 'amod'), (',', 'punct'), ('steril', 'ROOT'), (',', 'punct'), ('clear', 'amod'), ('colorless', 'compound'), ('solut', 'compound'), ('subcutan', 'compound'), ('administr', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'The following packaging configurations are available.', 'tokens': ['following', 'packaging', 'configurations', 'available', '.'], 'lemmatized': ['following', 'packaging', 'configuration', 'available', '.'], 'stemmed': ['follow', 'packag', 'configur', 'avail', '.'], 'dependencies': [('follow', 'ROOT'), ('packag', 'compound'), ('configur', 'compound'), ('avail', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• HUMIRA Pen Carton - 40 mg/0.8 mL \\nHUMIRA is supplied in a carton containing two alcohol preps and two dose trays.', 'tokens': ['•', 'HUMIRA', 'Pen', 'Carton', '-', '40', 'mg/0.8', 'mL', 'HUMIRA', 'supplied', 'carton', 'containing', 'two', 'alcohol', 'preps', 'two', 'dose', 'trays', '.'], 'lemmatized': ['•', 'HUMIRA', 'Pen', 'Carton', '-', '40', 'mg/0.8', 'mL', 'HUMIRA', 'supplied', 'carton', 'containing', 'two', 'alcohol', 'prep', 'two', 'dose', 'tray', '.'], 'stemmed': ['•', 'humira', 'pen', 'carton', '-', '40', 'mg/0.8', 'ml', 'humira', 'suppli', 'carton', 'contain', 'two', 'alcohol', 'prep', 'two', 'dose', 'tray', '.'], 'dependencies': [('•', 'nummod'), ('humira', 'compound'), ('pen', 'compound'), ('carton', 'nmod'), ('-', 'punct'), ('40', 'nummod'), ('mg/0.8', 'quantmod'), ('ml', 'dep'), ('humira', 'compound'), ('suppli', 'compound'), ('carton', 'nsubj'), ('contain', 'ROOT'), ('two', 'nummod'), ('alcohol', 'compound'), ('prep', 'compound'), ('two', 'nummod'), ('dose', 'compound'), ('tray', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Each dose \\ntray consists of a single-dose pen, containing a 1 mL prefilled glass syringe with a fixed ½ \\ninch needle, providing 40 mg/0.8 mL of HUMIRA.', 'tokens': ['dose', 'tray', 'consists', 'single-dose', 'pen', ',', 'containing', '1', 'mL', 'prefilled', 'glass', 'syringe', 'fixed', '½', 'inch', 'needle', ',', 'providing', '40', 'mg/0.8', 'mL', 'HUMIRA', '.'], 'lemmatized': ['dose', 'tray', 'consists', 'single-dose', 'pen', ',', 'containing', '1', 'mL', 'prefilled', 'glass', 'syringe', 'fixed', '½', 'inch', 'needle', ',', 'providing', '40', 'mg/0.8', 'mL', 'HUMIRA', '.'], 'stemmed': ['dose', 'tray', 'consist', 'single-dos', 'pen', ',', 'contain', '1', 'ml', 'prefil', 'glass', 'syring', 'fix', '½', 'inch', 'needl', ',', 'provid', '40', 'mg/0.8', 'ml', 'humira', '.'], 'dependencies': [('dose', 'compound'), ('tray', 'compound'), ('consist', 'amod'), ('single', 'amod'), ('-', 'punct'), ('dos', 'compound'), ('pen', 'nsubj'), (',', 'punct'), ('contain', 'ROOT'), ('1', 'nummod'), ('ml', 'compound'), ('prefil', 'compound'), ('glass', 'compound'), ('syring', 'amod'), ('fix', 'compound'), ('½', 'compound'), ('inch', 'compound'), ('needl', 'dobj'), (',', 'punct'), ('provid', 'npadvmod'), ('40', 'nummod'), ('mg/0.8', 'appos'), ('ml', 'compound'), ('humira', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'The needle cover may contain natural \\nrubber latex.', 'tokens': ['needle', 'cover', 'may', 'contain', 'natural', 'rubber', 'latex', '.'], 'lemmatized': ['needle', 'cover', 'may', 'contain', 'natural', 'rubber', 'latex', '.'], 'stemmed': ['needl', 'cover', 'may', 'contain', 'natur', 'rubber', 'latex', '.'], 'dependencies': [('needl', 'compound'), ('cover', 'nsubj'), ('may', 'aux'), ('contain', 'ROOT'), ('natur', 'compound'), ('rubber', 'compound'), ('latex', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The NDC number is 0074-4339-02.', 'tokens': ['NDC', 'number', '0074-4339-02', '.'], 'lemmatized': ['NDC', 'number', '0074-4339-02', '.'], 'stemmed': ['ndc', 'number', '0074-4339-02', '.'], 'dependencies': [('ndc', 'compound'), ('number', 'ROOT'), ('0074', 'nummod'), ('-', 'punct'), ('4339', 'nummod'), ('-', 'punct'), ('02', 'prep'), ('.', 'punct')]}, {'original_sentence': '• HUMIRA Pen Carton - 40 mg/0.4 mL \\nHUMIRA is supplied in a carton containing two alcohol preps and two dose trays.', 'tokens': ['•', 'HUMIRA', 'Pen', 'Carton', '-', '40', 'mg/0.4', 'mL', 'HUMIRA', 'supplied', 'carton', 'containing', 'two', 'alcohol', 'preps', 'two', 'dose', 'trays', '.'], 'lemmatized': ['•', 'HUMIRA', 'Pen', 'Carton', '-', '40', 'mg/0.4', 'mL', 'HUMIRA', 'supplied', 'carton', 'containing', 'two', 'alcohol', 'prep', 'two', 'dose', 'tray', '.'], 'stemmed': ['•', 'humira', 'pen', 'carton', '-', '40', 'mg/0.4', 'ml', 'humira', 'suppli', 'carton', 'contain', 'two', 'alcohol', 'prep', 'two', 'dose', 'tray', '.'], 'dependencies': [('•', 'nummod'), ('humira', 'compound'), ('pen', 'compound'), ('carton', 'ROOT'), ('-', 'punct'), ('40', 'nummod'), ('mg/0.4', 'punct'), ('ml', 'dep'), ('humira', 'compound'), ('suppli', 'compound'), ('carton', 'nsubj'), ('contain', 'ROOT'), ('two', 'nummod'), ('alcohol', 'compound'), ('prep', 'compound'), ('two', 'nummod'), ('dose', 'compound'), ('tray', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Each dose', 'tokens': ['dose'], 'lemmatized': ['dose'], 'stemmed': ['dose'], 'dependencies': [('dose', 'ROOT')]}], 'text': 'Figure 4: Kaplan-Meier Curves Summarizing Time to Treatment Failure (Study PUV-I) \\n \\nStudy PUV-I \\nNote: P = Placebo (Number at Risk); H = HUMIRA (Number at Risk).  \\n15 REFERENCES \\n1. National Cancer Institute. Surveillance, Epidemiology, and End Results Database (SEER) \\nProgram. SEER Incidence Crude Rates, 17 Registries, 2000-2007.  \\n  \\n16 HOW SUPPLIED/STORAGE AND HANDLING \\nHUMIRA® (adalimumab) is supplied as a preservative-free, sterile, clear and colorless solution \\nfor subcutaneous administration. The following packaging configurations are available.  \\n• HUMIRA Pen Carton - 40 mg/0.8 mL \\nHUMIRA is supplied in a carton containing two alcohol preps and two dose trays. Each dose \\ntray consists of a single-dose pen, containing a 1 mL prefilled glass syringe with a fixed ½ \\ninch needle, providing 40 mg/0.8 mL of HUMIRA. The needle cover may contain natural \\nrubber latex. The NDC number is 0074-4339-02.  \\n  \\n• HUMIRA Pen Carton - 40 mg/0.4 mL \\nHUMIRA is supplied in a carton containing two alcohol preps and two dose trays. Each dose \\n'}, 'page_char_count': 1046, 'page_word_count': 159, 'sentences': ['Figure 4: Kaplan-Meier Curves Summarizing Time to Treatment Failure (Study PUV-I) \\n \\nStudy PUV-I \\nNote: P = Placebo (Number at Risk); H = HUMIRA (Number at Risk).', ' \\n15 REFERENCES \\n1.', 'National Cancer Institute.', 'Surveillance, Epidemiology, and End Results Database (SEER) \\nProgram.', 'SEER Incidence Crude Rates, 17 Registries, 2000-2007.', ' \\n  \\n16 HOW SUPPLIED/STORAGE AND HANDLING \\nHUMIRA® (adalimumab) is supplied as a preservative-free, sterile, clear and colorless solution \\nfor subcutaneous administration.', 'The following packaging configurations are available.', ' \\n• HUMIRA Pen Carton - 40 mg/0.8 mL \\nHUMIRA is supplied in a carton containing two alcohol preps and two dose trays.', 'Each dose \\ntray consists of a single-dose pen, containing a 1 mL prefilled glass syringe with a fixed ½ \\ninch needle, providing 40 mg/0.8 mL of HUMIRA.', 'The needle cover may contain natural \\nrubber latex.', 'The NDC number is 0074-4339-02.', ' \\n  \\n• HUMIRA Pen Carton - 40 mg/0.4 mL \\nHUMIRA is supplied in a carton containing two alcohol preps and two dose trays.', 'Each dose \\n'], 'page_sentence_count_spacy': 13}\n",
            "{'page_number': 55, 'text': \"tray consists of a single-dose pen, containing a 1 mL prefilled glass syringe with a fixed thin \\nwall, ½ inch needle, providing 40 mg/0.4 mL of HUMIRA. The black needle cover is not \\nmade with natural rubber latex. The NDC number is 0074-0554-02.  \\n  \\n• HUMIRA Pen Carton – 80 mg/0.8 mL \\nHUMIRA is supplied in a carton containing two alcohol preps and two dose trays.  Each dose \\ntray consists of a single-dose pen, containing a 1 mL prefilled glass syringe with a fixed thin \\nwall, ½ inch needle, providing 80 mg/0.8 mL of HUMIRA.  The black needle cover is not \\nmade with natural rubber latex.  The NDC number is 0074-0124-02. \\n• HUMIRA Pen 40 mg/0.8 mL - Starter Package for Crohn's Disease, Ulcerative Colitis \\nor Hidradenitis Suppurativa \\nHUMIRA is supplied in a carton containing 6 alcohol preps and 6 dose trays (Starter Package \\nfor Crohn’s Disease, Ulcerative Colitis or Hidradenitis Suppurativa). Each dose tray consists \\nof a single-dose pen, containing a 1 mL prefilled glass syringe with a fixed ½ inch needle, \\nproviding 40 mg/0.8 mL of HUMIRA. The needle cover may contain natural rubber latex. \\nThe NDC number is 0074-4339-06.  \\n  \\n  \\n• HUMIRA Pen 80 mg/0.8 mL - Starter Package for Crohn's Disease, Ulcerative Colitis \\nor Hidradenitis Suppurativa \\nHUMIRA is supplied in a carton containing 4 alcohol preps and 3 dose trays (Starter Package \\nfor Crohn’s Disease, Ulcerative Colitis or Hidradenitis Suppurativa). Each dose tray consists \\nof a single-dose pen, containing a 1 mL prefilled glass syringe with a fixed thin wall, ½ inch \\nneedle, providing 80 mg/0.8 mL of HUMIRA. The black needle cover is not made with \\nnatural rubber latex. The NDC number is 0074-0124-03.  \\n  \\n  \\n  \\n• HUMIRA Pen 80 mg/0.8 mL and 40 mg/0.4 mL - Psoriasis, Uveitis or Adolescent \\nHidradenitis Suppurativa Starter Package \\nHUMIRA is supplied in a carton containing 4 alcohol preps and 3 dose trays (Psoriasis, \\nUveitis or Adolescent Hidradenitis Suppurativa Starter Package). One dose tray consists of a \\nsingle-dose pen, containing a 1 mL prefilled glass syringe with a fixed thin wall, ½ inch \\nneedle, providing 80 mg/0.8 mL of HUMIRA. The other two dose trays each consist of a \\nsingle-dose pen, containing a 1 mL prefilled glass syringe with a fixed thin wall, ½ inch \\nneedle, providing 40 mg/0.4 mL of HUMIRA. The black needle cover is not made with \\nnatural rubber latex. The NDC number is 0074-1539-03.  \\n• HUMIRA Pen 80 mg/0.8 mL – Starter Package for Pediatric Ulcerative Colitis (4 count) \\nHUMIRA is supplied in a carton containing 4 alcohol preps and 4 dose trays (Starter Package \\nfor Pediatric Ulcerative Colitis). Each dose tray consists of a single-dose pen, containing a 1 \\nmL prefilled glass syringe with a fixed thin wall, ½ inch needle, providing 80 mg/0.8 mL of \\nHUMIRA. The black needle cover is not made with natural rubber latex. The NDC number is \\n0074-0124-04.   \\n  \\n• Prefilled Syringe Carton - 40 mg/0.8 mL \\nHUMIRA is supplied in a carton containing two alcohol preps and two dose trays. Each dose \\ntray consists of a single-dose, 1 mL prefilled glass syringe with a fixed ½ inch needle, \\nproviding 40 mg/0.8 mL of HUMIRA. The needle cover may contain natural rubber latex. \\nThe NDC number is 0074-3799-02.  \\n  \\n\", 'processed_text': {'sentences': [{'original_sentence': 'tray consists of a single-dose pen, containing a 1 mL prefilled glass syringe with a fixed thin \\nwall, ½ inch needle, providing 40 mg/0.4 mL of HUMIRA.', 'tokens': ['tray', 'consists', 'single-dose', 'pen', ',', 'containing', '1', 'mL', 'prefilled', 'glass', 'syringe', 'fixed', 'thin', 'wall', ',', '½', 'inch', 'needle', ',', 'providing', '40', 'mg/0.4', 'mL', 'HUMIRA', '.'], 'lemmatized': ['tray', 'consists', 'single-dose', 'pen', ',', 'containing', '1', 'mL', 'prefilled', 'glass', 'syringe', 'fixed', 'thin', 'wall', ',', '½', 'inch', 'needle', ',', 'providing', '40', 'mg/0.4', 'mL', 'HUMIRA', '.'], 'stemmed': ['tray', 'consist', 'single-dos', 'pen', ',', 'contain', '1', 'ml', 'prefil', 'glass', 'syring', 'fix', 'thin', 'wall', ',', '½', 'inch', 'needl', ',', 'provid', '40', 'mg/0.4', 'ml', 'humira', '.'], 'dependencies': [('tray', 'nmod'), ('consist', 'amod'), ('single', 'amod'), ('-', 'punct'), ('dos', 'compound'), ('pen', 'nsubj'), (',', 'punct'), ('contain', 'ROOT'), ('1', 'nummod'), ('ml', 'dobj'), ('prefil', 'compound'), ('glass', 'compound'), ('syring', 'compound'), ('fix', 'nmod'), ('thin', 'amod'), ('wall', 'dobj'), (',', 'punct'), ('½', 'compound'), ('inch', 'nsubj'), ('needl', 'conj'), (',', 'punct'), ('provid', 'npadvmod'), ('40', 'nummod'), ('mg/0.4', 'appos'), ('ml', 'compound'), ('humira', 'dep'), ('.', 'punct')]}, {'original_sentence': 'The black needle cover is not \\nmade with natural rubber latex.', 'tokens': ['black', 'needle', 'cover', 'made', 'natural', 'rubber', 'latex', '.'], 'lemmatized': ['black', 'needle', 'cover', 'made', 'natural', 'rubber', 'latex', '.'], 'stemmed': ['black', 'needl', 'cover', 'made', 'natur', 'rubber', 'latex', '.'], 'dependencies': [('black', 'amod'), ('needl', 'compound'), ('cover', 'nsubj'), ('made', 'ROOT'), ('natur', 'compound'), ('rubber', 'compound'), ('latex', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The NDC number is 0074-0554-02.', 'tokens': ['NDC', 'number', '0074-0554-02', '.'], 'lemmatized': ['NDC', 'number', '0074-0554-02', '.'], 'stemmed': ['ndc', 'number', '0074-0554-02', '.'], 'dependencies': [('ndc', 'compound'), ('number', 'ROOT'), ('0074', 'npadvmod'), ('-', 'punct'), ('0554', 'nummod'), ('-', 'punct'), ('02', 'prep'), ('.', 'punct')]}, {'original_sentence': '• HUMIRA Pen Carton – 80 mg/0.8 mL \\nHUMIRA is supplied in a carton containing two alcohol preps and two dose trays.', 'tokens': ['•', 'HUMIRA', 'Pen', 'Carton', '–', '80', 'mg/0.8', 'mL', 'HUMIRA', 'supplied', 'carton', 'containing', 'two', 'alcohol', 'preps', 'two', 'dose', 'trays', '.'], 'lemmatized': ['•', 'HUMIRA', 'Pen', 'Carton', '–', '80', 'mg/0.8', 'mL', 'HUMIRA', 'supplied', 'carton', 'containing', 'two', 'alcohol', 'prep', 'two', 'dose', 'tray', '.'], 'stemmed': ['•', 'humira', 'pen', 'carton', '–', '80', 'mg/0.8', 'ml', 'humira', 'suppli', 'carton', 'contain', 'two', 'alcohol', 'prep', 'two', 'dose', 'tray', '.'], 'dependencies': [('•', 'nummod'), ('humira', 'compound'), ('pen', 'compound'), ('carton', 'nsubj'), ('–', 'punct'), ('80', 'nummod'), ('mg/0.8', 'dep'), ('ml', 'nmod'), ('humira', 'compound'), ('suppli', 'compound'), ('carton', 'nsubj'), ('contain', 'ROOT'), ('two', 'nummod'), ('alcohol', 'compound'), ('prep', 'compound'), ('two', 'nummod'), ('dose', 'compound'), ('tray', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Each dose \\ntray consists of a single-dose pen, containing a 1 mL prefilled glass syringe with a fixed thin \\nwall, ½ inch needle, providing 80 mg/0.8 mL of HUMIRA.', 'tokens': ['dose', 'tray', 'consists', 'single-dose', 'pen', ',', 'containing', '1', 'mL', 'prefilled', 'glass', 'syringe', 'fixed', 'thin', 'wall', ',', '½', 'inch', 'needle', ',', 'providing', '80', 'mg/0.8', 'mL', 'HUMIRA', '.'], 'lemmatized': ['dose', 'tray', 'consists', 'single-dose', 'pen', ',', 'containing', '1', 'mL', 'prefilled', 'glass', 'syringe', 'fixed', 'thin', 'wall', ',', '½', 'inch', 'needle', ',', 'providing', '80', 'mg/0.8', 'mL', 'HUMIRA', '.'], 'stemmed': ['dose', 'tray', 'consist', 'single-dos', 'pen', ',', 'contain', '1', 'ml', 'prefil', 'glass', 'syring', 'fix', 'thin', 'wall', ',', '½', 'inch', 'needl', ',', 'provid', '80', 'mg/0.8', 'ml', 'humira', '.'], 'dependencies': [('dose', 'compound'), ('tray', 'compound'), ('consist', 'amod'), ('single', 'amod'), ('-', 'punct'), ('dos', 'compound'), ('pen', 'nsubj'), (',', 'punct'), ('contain', 'ROOT'), ('1', 'nummod'), ('ml', 'dobj'), ('prefil', 'compound'), ('glass', 'compound'), ('syring', 'compound'), ('fix', 'nmod'), ('thin', 'amod'), ('wall', 'dobj'), (',', 'punct'), ('½', 'compound'), ('inch', 'nsubj'), ('needl', 'conj'), (',', 'punct'), ('provid', 'npadvmod'), ('80', 'nummod'), ('mg/0.8', 'appos'), ('ml', 'compound'), ('humira', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'The black needle cover is not \\nmade with natural rubber latex.', 'tokens': ['black', 'needle', 'cover', 'made', 'natural', 'rubber', 'latex', '.'], 'lemmatized': ['black', 'needle', 'cover', 'made', 'natural', 'rubber', 'latex', '.'], 'stemmed': ['black', 'needl', 'cover', 'made', 'natur', 'rubber', 'latex', '.'], 'dependencies': [('black', 'amod'), ('needl', 'compound'), ('cover', 'nsubj'), ('made', 'ROOT'), ('natur', 'compound'), ('rubber', 'compound'), ('latex', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The NDC number is 0074-0124-02.', 'tokens': ['NDC', 'number', '0074-0124-02', '.'], 'lemmatized': ['NDC', 'number', '0074-0124-02', '.'], 'stemmed': ['ndc', 'number', '0074-0124-02', '.'], 'dependencies': [('ndc', 'compound'), ('number', 'ROOT'), ('0074', 'nummod'), ('-', 'punct'), ('0124', 'npadvmod'), ('-', 'punct'), ('02', 'prep'), ('.', 'punct')]}, {'original_sentence': \"• HUMIRA Pen 40 mg/0.8 mL - Starter Package for Crohn's Disease, Ulcerative Colitis \\nor Hidradenitis Suppurativa \\nHUMIRA is supplied in a carton containing 6 alcohol preps and 6 dose trays (Starter Package \\nfor Crohn’s Disease, Ulcerative Colitis or Hidradenitis Suppurativa).\", 'tokens': ['•', 'HUMIRA', 'Pen', '40', 'mg/0.8', 'mL', '-', 'Starter', 'Package', 'Crohn', \"'s\", 'Disease', ',', 'Ulcerative', 'Colitis', 'Hidradenitis', 'Suppurativa', 'HUMIRA', 'supplied', 'carton', 'containing', '6', 'alcohol', 'preps', '6', 'dose', 'trays', '(', 'Starter', 'Package', 'Crohn', '’', 'Disease', ',', 'Ulcerative', 'Colitis', 'Hidradenitis', 'Suppurativa', ')', '.'], 'lemmatized': ['•', 'HUMIRA', 'Pen', '40', 'mg/0.8', 'mL', '-', 'Starter', 'Package', 'Crohn', \"'s\", 'Disease', ',', 'Ulcerative', 'Colitis', 'Hidradenitis', 'Suppurativa', 'HUMIRA', 'supplied', 'carton', 'containing', '6', 'alcohol', 'prep', '6', 'dose', 'tray', '(', 'Starter', 'Package', 'Crohn', '’', 'Disease', ',', 'Ulcerative', 'Colitis', 'Hidradenitis', 'Suppurativa', ')', '.'], 'stemmed': ['•', 'humira', 'pen', '40', 'mg/0.8', 'ml', '-', 'starter', 'packag', 'crohn', \"'s\", 'diseas', ',', 'ulcer', 'coliti', 'hidraden', 'suppurativa', 'humira', 'suppli', 'carton', 'contain', '6', 'alcohol', 'prep', '6', 'dose', 'tray', '(', 'starter', 'packag', 'crohn', '’', 'diseas', ',', 'ulcer', 'coliti', 'hidraden', 'suppurativa', ')', '.'], 'dependencies': [('•', 'nummod'), ('humira', 'compound'), ('pen', 'dep'), ('40', 'nummod'), ('mg/0.8', 'appos'), ('ml', 'compound'), ('-', 'punct'), ('starter', 'compound'), ('packag', 'compound'), ('crohn', 'poss'), (\"'s\", 'case'), ('diseas', 'appos'), (',', 'punct'), ('ulcer', 'compound'), ('coliti', 'compound'), ('hidraden', 'compound'), ('suppurativa', 'compound'), ('humira', 'compound'), ('suppli', 'compound'), ('carton', 'nsubj'), ('contain', 'ROOT'), ('6', 'nummod'), ('alcohol', 'compound'), ('prep', 'dobj'), ('6', 'nummod'), ('dose', 'compound'), ('tray', 'dobj'), ('(', 'punct'), ('starter', 'amod'), ('packag', 'nsubj'), ('crohn', 'parataxis'), ('’', 'punct'), ('diseas', 'appos'), (',', 'punct'), ('ulcer', 'compound'), ('coliti', 'compound'), ('hidraden', 'compound'), ('suppurativa', 'npadvmod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Each dose tray consists \\nof a single-dose pen, containing a 1 mL prefilled glass syringe with a fixed ½ inch needle, \\nproviding 40 mg/0.8 mL of HUMIRA.', 'tokens': ['dose', 'tray', 'consists', 'single-dose', 'pen', ',', 'containing', '1', 'mL', 'prefilled', 'glass', 'syringe', 'fixed', '½', 'inch', 'needle', ',', 'providing', '40', 'mg/0.8', 'mL', 'HUMIRA', '.'], 'lemmatized': ['dose', 'tray', 'consists', 'single-dose', 'pen', ',', 'containing', '1', 'mL', 'prefilled', 'glass', 'syringe', 'fixed', '½', 'inch', 'needle', ',', 'providing', '40', 'mg/0.8', 'mL', 'HUMIRA', '.'], 'stemmed': ['dose', 'tray', 'consist', 'single-dos', 'pen', ',', 'contain', '1', 'ml', 'prefil', 'glass', 'syring', 'fix', '½', 'inch', 'needl', ',', 'provid', '40', 'mg/0.8', 'ml', 'humira', '.'], 'dependencies': [('dose', 'compound'), ('tray', 'compound'), ('consist', 'amod'), ('single', 'amod'), ('-', 'punct'), ('dos', 'compound'), ('pen', 'nsubj'), (',', 'punct'), ('contain', 'ROOT'), ('1', 'nummod'), ('ml', 'compound'), ('prefil', 'compound'), ('glass', 'compound'), ('syring', 'amod'), ('fix', 'compound'), ('½', 'compound'), ('inch', 'compound'), ('needl', 'dobj'), (',', 'punct'), ('provid', 'npadvmod'), ('40', 'nummod'), ('mg/0.8', 'appos'), ('ml', 'compound'), ('humira', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'The needle cover may contain natural rubber latex.', 'tokens': ['needle', 'cover', 'may', 'contain', 'natural', 'rubber', 'latex', '.'], 'lemmatized': ['needle', 'cover', 'may', 'contain', 'natural', 'rubber', 'latex', '.'], 'stemmed': ['needl', 'cover', 'may', 'contain', 'natur', 'rubber', 'latex', '.'], 'dependencies': [('needl', 'compound'), ('cover', 'nsubj'), ('may', 'aux'), ('contain', 'ROOT'), ('natur', 'compound'), ('rubber', 'compound'), ('latex', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The NDC number is 0074-4339-06.', 'tokens': ['NDC', 'number', '0074-4339-06', '.'], 'lemmatized': ['NDC', 'number', '0074-4339-06', '.'], 'stemmed': ['ndc', 'number', '0074-4339-06', '.'], 'dependencies': [('ndc', 'compound'), ('number', 'ROOT'), ('0074', 'nummod'), ('-', 'punct'), ('4339', 'npadvmod'), ('-', 'punct'), ('06', 'prep'), ('.', 'punct')]}, {'original_sentence': \"• HUMIRA Pen 80 mg/0.8 mL - Starter Package for Crohn's Disease, Ulcerative Colitis \\nor Hidradenitis Suppurativa \\nHUMIRA is supplied in a carton containing 4 alcohol preps and 3 dose trays (Starter Package \\nfor Crohn’s Disease, Ulcerative Colitis or Hidradenitis Suppurativa).\", 'tokens': ['•', 'HUMIRA', 'Pen', '80', 'mg/0.8', 'mL', '-', 'Starter', 'Package', 'Crohn', \"'s\", 'Disease', ',', 'Ulcerative', 'Colitis', 'Hidradenitis', 'Suppurativa', 'HUMIRA', 'supplied', 'carton', 'containing', '4', 'alcohol', 'preps', '3', 'dose', 'trays', '(', 'Starter', 'Package', 'Crohn', '’', 'Disease', ',', 'Ulcerative', 'Colitis', 'Hidradenitis', 'Suppurativa', ')', '.'], 'lemmatized': ['•', 'HUMIRA', 'Pen', '80', 'mg/0.8', 'mL', '-', 'Starter', 'Package', 'Crohn', \"'s\", 'Disease', ',', 'Ulcerative', 'Colitis', 'Hidradenitis', 'Suppurativa', 'HUMIRA', 'supplied', 'carton', 'containing', '4', 'alcohol', 'prep', '3', 'dose', 'tray', '(', 'Starter', 'Package', 'Crohn', '’', 'Disease', ',', 'Ulcerative', 'Colitis', 'Hidradenitis', 'Suppurativa', ')', '.'], 'stemmed': ['•', 'humira', 'pen', '80', 'mg/0.8', 'ml', '-', 'starter', 'packag', 'crohn', \"'s\", 'diseas', ',', 'ulcer', 'coliti', 'hidraden', 'suppurativa', 'humira', 'suppli', 'carton', 'contain', '4', 'alcohol', 'prep', '3', 'dose', 'tray', '(', 'starter', 'packag', 'crohn', '’', 'diseas', ',', 'ulcer', 'coliti', 'hidraden', 'suppurativa', ')', '.'], 'dependencies': [('•', 'nummod'), ('humira', 'compound'), ('pen', 'nmod'), ('80', 'nummod'), ('mg/0.8', 'appos'), ('ml', 'compound'), ('-', 'punct'), ('starter', 'compound'), ('packag', 'compound'), ('crohn', 'poss'), (\"'s\", 'case'), ('diseas', 'dep'), (',', 'punct'), ('ulcer', 'compound'), ('coliti', 'compound'), ('hidraden', 'compound'), ('suppurativa', 'compound'), ('humira', 'compound'), ('suppli', 'compound'), ('carton', 'nsubj'), ('contain', 'ROOT'), ('4', 'nummod'), ('alcohol', 'dobj'), ('prep', 'compound'), ('3', 'nummod'), ('dose', 'compound'), ('tray', 'dobj'), ('(', 'punct'), ('starter', 'amod'), ('packag', 'nsubj'), ('crohn', 'parataxis'), ('’', 'punct'), ('diseas', 'appos'), (',', 'punct'), ('ulcer', 'compound'), ('coliti', 'compound'), ('hidraden', 'compound'), ('suppurativa', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Each dose tray consists \\nof a single-dose pen, containing a 1 mL prefilled glass syringe with a fixed thin wall, ½ inch \\nneedle, providing 80 mg/0.8 mL of HUMIRA.', 'tokens': ['dose', 'tray', 'consists', 'single-dose', 'pen', ',', 'containing', '1', 'mL', 'prefilled', 'glass', 'syringe', 'fixed', 'thin', 'wall', ',', '½', 'inch', 'needle', ',', 'providing', '80', 'mg/0.8', 'mL', 'HUMIRA', '.'], 'lemmatized': ['dose', 'tray', 'consists', 'single-dose', 'pen', ',', 'containing', '1', 'mL', 'prefilled', 'glass', 'syringe', 'fixed', 'thin', 'wall', ',', '½', 'inch', 'needle', ',', 'providing', '80', 'mg/0.8', 'mL', 'HUMIRA', '.'], 'stemmed': ['dose', 'tray', 'consist', 'single-dos', 'pen', ',', 'contain', '1', 'ml', 'prefil', 'glass', 'syring', 'fix', 'thin', 'wall', ',', '½', 'inch', 'needl', ',', 'provid', '80', 'mg/0.8', 'ml', 'humira', '.'], 'dependencies': [('dose', 'compound'), ('tray', 'compound'), ('consist', 'amod'), ('single', 'amod'), ('-', 'punct'), ('dos', 'compound'), ('pen', 'nsubj'), (',', 'punct'), ('contain', 'ROOT'), ('1', 'nummod'), ('ml', 'dobj'), ('prefil', 'compound'), ('glass', 'compound'), ('syring', 'compound'), ('fix', 'nmod'), ('thin', 'amod'), ('wall', 'dobj'), (',', 'punct'), ('½', 'compound'), ('inch', 'nsubj'), ('needl', 'conj'), (',', 'punct'), ('provid', 'npadvmod'), ('80', 'nummod'), ('mg/0.8', 'appos'), ('ml', 'compound'), ('humira', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'The black needle cover is not made with \\nnatural rubber latex.', 'tokens': ['black', 'needle', 'cover', 'made', 'natural', 'rubber', 'latex', '.'], 'lemmatized': ['black', 'needle', 'cover', 'made', 'natural', 'rubber', 'latex', '.'], 'stemmed': ['black', 'needl', 'cover', 'made', 'natur', 'rubber', 'latex', '.'], 'dependencies': [('black', 'amod'), ('needl', 'compound'), ('cover', 'nsubj'), ('made', 'ROOT'), ('natur', 'compound'), ('rubber', 'compound'), ('latex', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The NDC number is 0074-0124-03.', 'tokens': ['NDC', 'number', '0074-0124-03', '.'], 'lemmatized': ['NDC', 'number', '0074-0124-03', '.'], 'stemmed': ['ndc', 'number', '0074-0124-03', '.'], 'dependencies': [('ndc', 'compound'), ('number', 'ROOT'), ('0074', 'nummod'), ('-', 'punct'), ('0124', 'nummod'), ('-', 'punct'), ('03', 'nummod'), ('.', 'punct')]}, {'original_sentence': '• HUMIRA Pen 80 mg/0.8 mL and 40 mg/0.4 mL - Psoriasis, Uveitis or Adolescent \\nHidradenitis Suppurativa Starter Package \\nHUMIRA is supplied in a carton containing 4 alcohol preps and 3 dose trays (Psoriasis, \\nUveitis or Adolescent Hidradenitis Suppurativa Starter Package).', 'tokens': ['•', 'HUMIRA', 'Pen', '80', 'mg/0.8', 'mL', '40', 'mg/0.4', 'mL', '-', 'Psoriasis', ',', 'Uveitis', 'Adolescent', 'Hidradenitis', 'Suppurativa', 'Starter', 'Package', 'HUMIRA', 'supplied', 'carton', 'containing', '4', 'alcohol', 'preps', '3', 'dose', 'trays', '(', 'Psoriasis', ',', 'Uveitis', 'Adolescent', 'Hidradenitis', 'Suppurativa', 'Starter', 'Package', ')', '.'], 'lemmatized': ['•', 'HUMIRA', 'Pen', '80', 'mg/0.8', 'mL', '40', 'mg/0.4', 'mL', '-', 'Psoriasis', ',', 'Uveitis', 'Adolescent', 'Hidradenitis', 'Suppurativa', 'Starter', 'Package', 'HUMIRA', 'supplied', 'carton', 'containing', '4', 'alcohol', 'prep', '3', 'dose', 'tray', '(', 'Psoriasis', ',', 'Uveitis', 'Adolescent', 'Hidradenitis', 'Suppurativa', 'Starter', 'Package', ')', '.'], 'stemmed': ['•', 'humira', 'pen', '80', 'mg/0.8', 'ml', '40', 'mg/0.4', 'ml', '-', 'psoriasi', ',', 'uveiti', 'adolesc', 'hidraden', 'suppurativa', 'starter', 'packag', 'humira', 'suppli', 'carton', 'contain', '4', 'alcohol', 'prep', '3', 'dose', 'tray', '(', 'psoriasi', ',', 'uveiti', 'adolesc', 'hidraden', 'suppurativa', 'starter', 'packag', ')', '.'], 'dependencies': [('•', 'nummod'), ('humira', 'compound'), ('pen', 'nsubj'), ('80', 'nummod'), ('mg/0.8', 'npadvmod'), ('ml', 'ccomp'), ('40', 'nummod'), ('mg/0.4', 'npadvmod'), ('ml', 'compound'), ('-', 'punct'), ('psoriasi', 'dobj'), (',', 'punct'), ('uveiti', 'compound'), ('adolesc', 'compound'), ('hidraden', 'compound'), ('suppurativa', 'compound'), ('starter', 'compound'), ('packag', 'compound'), ('humira', 'compound'), ('suppli', 'compound'), ('carton', 'nsubj'), ('contain', 'ROOT'), ('4', 'nummod'), ('alcohol', 'dobj'), ('prep', 'compound'), ('3', 'nummod'), ('dose', 'compound'), ('tray', 'dobj'), ('(', 'punct'), ('psoriasi', 'appos'), (',', 'punct'), ('uveiti', 'compound'), ('adolesc', 'compound'), ('hidraden', 'compound'), ('suppurativa', 'compound'), ('starter', 'compound'), ('packag', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'One dose tray consists of a \\nsingle-dose pen, containing a 1 mL prefilled glass syringe with a fixed thin wall, ½ inch \\nneedle, providing 80 mg/0.8 mL of HUMIRA.', 'tokens': ['One', 'dose', 'tray', 'consists', 'single-dose', 'pen', ',', 'containing', '1', 'mL', 'prefilled', 'glass', 'syringe', 'fixed', 'thin', 'wall', ',', '½', 'inch', 'needle', ',', 'providing', '80', 'mg/0.8', 'mL', 'HUMIRA', '.'], 'lemmatized': ['One', 'dose', 'tray', 'consists', 'single-dose', 'pen', ',', 'containing', '1', 'mL', 'prefilled', 'glass', 'syringe', 'fixed', 'thin', 'wall', ',', '½', 'inch', 'needle', ',', 'providing', '80', 'mg/0.8', 'mL', 'HUMIRA', '.'], 'stemmed': ['one', 'dose', 'tray', 'consist', 'single-dos', 'pen', ',', 'contain', '1', 'ml', 'prefil', 'glass', 'syring', 'fix', 'thin', 'wall', ',', '½', 'inch', 'needl', ',', 'provid', '80', 'mg/0.8', 'ml', 'humira', '.'], 'dependencies': [('one', 'nummod'), ('dose', 'compound'), ('tray', 'nsubj'), ('consist', 'amod'), ('single', 'amod'), ('-', 'punct'), ('dos', 'compound'), ('pen', 'appos'), (',', 'punct'), ('contain', 'ROOT'), ('1', 'nummod'), ('ml', 'dobj'), ('prefil', 'compound'), ('glass', 'compound'), ('syring', 'compound'), ('fix', 'nmod'), ('thin', 'amod'), ('wall', 'dobj'), (',', 'punct'), ('½', 'compound'), ('inch', 'nsubj'), ('needl', 'conj'), (',', 'punct'), ('provid', 'npadvmod'), ('80', 'nummod'), ('mg/0.8', 'appos'), ('ml', 'compound'), ('humira', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'The other two dose trays each consist of a \\nsingle-dose pen, containing a 1 mL prefilled glass syringe with a fixed thin wall, ½ inch \\nneedle, providing 40 mg/0.4 mL of HUMIRA.', 'tokens': ['two', 'dose', 'trays', 'consist', 'single-dose', 'pen', ',', 'containing', '1', 'mL', 'prefilled', 'glass', 'syringe', 'fixed', 'thin', 'wall', ',', '½', 'inch', 'needle', ',', 'providing', '40', 'mg/0.4', 'mL', 'HUMIRA', '.'], 'lemmatized': ['two', 'dose', 'tray', 'consist', 'single-dose', 'pen', ',', 'containing', '1', 'mL', 'prefilled', 'glass', 'syringe', 'fixed', 'thin', 'wall', ',', '½', 'inch', 'needle', ',', 'providing', '40', 'mg/0.4', 'mL', 'HUMIRA', '.'], 'stemmed': ['two', 'dose', 'tray', 'consist', 'single-dos', 'pen', ',', 'contain', '1', 'ml', 'prefil', 'glass', 'syring', 'fix', 'thin', 'wall', ',', '½', 'inch', 'needl', ',', 'provid', '40', 'mg/0.4', 'ml', 'humira', '.'], 'dependencies': [('two', 'nummod'), ('dose', 'amod'), ('tray', 'nsubj'), ('consist', 'amod'), ('single', 'amod'), ('-', 'punct'), ('dos', 'compound'), ('pen', 'appos'), (',', 'punct'), ('contain', 'ROOT'), ('1', 'nummod'), ('ml', 'dobj'), ('prefil', 'compound'), ('glass', 'compound'), ('syring', 'compound'), ('fix', 'nmod'), ('thin', 'amod'), ('wall', 'dobj'), (',', 'punct'), ('½', 'compound'), ('inch', 'nsubj'), ('needl', 'conj'), (',', 'punct'), ('provid', 'npadvmod'), ('40', 'nummod'), ('mg/0.4', 'appos'), ('ml', 'compound'), ('humira', 'dep'), ('.', 'punct')]}, {'original_sentence': 'The black needle cover is not made with \\nnatural rubber latex.', 'tokens': ['black', 'needle', 'cover', 'made', 'natural', 'rubber', 'latex', '.'], 'lemmatized': ['black', 'needle', 'cover', 'made', 'natural', 'rubber', 'latex', '.'], 'stemmed': ['black', 'needl', 'cover', 'made', 'natur', 'rubber', 'latex', '.'], 'dependencies': [('black', 'amod'), ('needl', 'compound'), ('cover', 'nsubj'), ('made', 'ROOT'), ('natur', 'compound'), ('rubber', 'compound'), ('latex', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The NDC number is 0074-1539-03.', 'tokens': ['NDC', 'number', '0074-1539-03', '.'], 'lemmatized': ['NDC', 'number', '0074-1539-03', '.'], 'stemmed': ['ndc', 'number', '0074-1539-03', '.'], 'dependencies': [('ndc', 'compound'), ('number', 'ROOT'), ('0074', 'nummod'), ('-', 'punct'), ('1539', 'nummod'), ('-', 'punct'), ('03', 'prep'), ('.', 'punct')]}, {'original_sentence': '• HUMIRA Pen 80 mg/0.8 mL – Starter Package for Pediatric Ulcerative Colitis (4 count) \\nHUMIRA is supplied in a carton containing 4 alcohol preps and 4 dose trays (Starter Package \\nfor Pediatric Ulcerative Colitis).', 'tokens': ['•', 'HUMIRA', 'Pen', '80', 'mg/0.8', 'mL', '–', 'Starter', 'Package', 'Pediatric', 'Ulcerative', 'Colitis', '(', '4', 'count', ')', 'HUMIRA', 'supplied', 'carton', 'containing', '4', 'alcohol', 'preps', '4', 'dose', 'trays', '(', 'Starter', 'Package', 'Pediatric', 'Ulcerative', 'Colitis', ')', '.'], 'lemmatized': ['•', 'HUMIRA', 'Pen', '80', 'mg/0.8', 'mL', '–', 'Starter', 'Package', 'Pediatric', 'Ulcerative', 'Colitis', '(', '4', 'count', ')', 'HUMIRA', 'supplied', 'carton', 'containing', '4', 'alcohol', 'prep', '4', 'dose', 'tray', '(', 'Starter', 'Package', 'Pediatric', 'Ulcerative', 'Colitis', ')', '.'], 'stemmed': ['•', 'humira', 'pen', '80', 'mg/0.8', 'ml', '–', 'starter', 'packag', 'pediatr', 'ulcer', 'coliti', '(', '4', 'count', ')', 'humira', 'suppli', 'carton', 'contain', '4', 'alcohol', 'prep', '4', 'dose', 'tray', '(', 'starter', 'packag', 'pediatr', 'ulcer', 'coliti', ')', '.'], 'dependencies': [('•', 'nummod'), ('humira', 'compound'), ('pen', 'nsubj'), ('80', 'nummod'), ('mg/0.8', 'dep'), ('ml', 'dep'), ('–', 'punct'), ('starter', 'amod'), ('packag', 'compound'), ('pediatr', 'amod'), ('ulcer', 'compound'), ('coliti', 'appos'), ('(', 'punct'), ('4', 'nummod'), ('count', 'appos'), (')', 'punct'), ('humira', 'compound'), ('suppli', 'compound'), ('carton', 'nsubj'), ('contain', 'ROOT'), ('4', 'nummod'), ('alcohol', 'dobj'), ('prep', 'compound'), ('4', 'nummod'), ('dose', 'compound'), ('tray', 'dobj'), ('(', 'punct'), ('starter', 'amod'), ('packag', 'compound'), ('pediatr', 'amod'), ('ulcer', 'compound'), ('coliti', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Each dose tray consists of a single-dose pen, containing a 1 \\nmL prefilled glass syringe with a fixed thin wall, ½ inch needle, providing 80 mg/0.8 mL of \\nHUMIRA.', 'tokens': ['dose', 'tray', 'consists', 'single-dose', 'pen', ',', 'containing', '1', 'mL', 'prefilled', 'glass', 'syringe', 'fixed', 'thin', 'wall', ',', '½', 'inch', 'needle', ',', 'providing', '80', 'mg/0.8', 'mL', 'HUMIRA', '.'], 'lemmatized': ['dose', 'tray', 'consists', 'single-dose', 'pen', ',', 'containing', '1', 'mL', 'prefilled', 'glass', 'syringe', 'fixed', 'thin', 'wall', ',', '½', 'inch', 'needle', ',', 'providing', '80', 'mg/0.8', 'mL', 'HUMIRA', '.'], 'stemmed': ['dose', 'tray', 'consist', 'single-dos', 'pen', ',', 'contain', '1', 'ml', 'prefil', 'glass', 'syring', 'fix', 'thin', 'wall', ',', '½', 'inch', 'needl', ',', 'provid', '80', 'mg/0.8', 'ml', 'humira', '.'], 'dependencies': [('dose', 'compound'), ('tray', 'compound'), ('consist', 'amod'), ('single', 'amod'), ('-', 'punct'), ('dos', 'compound'), ('pen', 'nsubj'), (',', 'punct'), ('contain', 'ROOT'), ('1', 'nummod'), ('ml', 'dobj'), ('prefil', 'compound'), ('glass', 'compound'), ('syring', 'compound'), ('fix', 'nmod'), ('thin', 'amod'), ('wall', 'dobj'), (',', 'punct'), ('½', 'compound'), ('inch', 'nsubj'), ('needl', 'conj'), (',', 'punct'), ('provid', 'npadvmod'), ('80', 'nummod'), ('mg/0.8', 'appos'), ('ml', 'compound'), ('humira', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'The black needle cover is not made with natural rubber latex.', 'tokens': ['black', 'needle', 'cover', 'made', 'natural', 'rubber', 'latex', '.'], 'lemmatized': ['black', 'needle', 'cover', 'made', 'natural', 'rubber', 'latex', '.'], 'stemmed': ['black', 'needl', 'cover', 'made', 'natur', 'rubber', 'latex', '.'], 'dependencies': [('black', 'amod'), ('needl', 'compound'), ('cover', 'nsubj'), ('made', 'ROOT'), ('natur', 'compound'), ('rubber', 'compound'), ('latex', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The NDC number is \\n0074-0124-04.', 'tokens': ['NDC', 'number', '0074-0124-04', '.'], 'lemmatized': ['NDC', 'number', '0074-0124-04', '.'], 'stemmed': ['ndc', 'number', '0074-0124-04', '.'], 'dependencies': [('ndc', 'compound'), ('number', 'ROOT'), ('0074', 'nummod'), ('-', 'punct'), ('0124', 'nummod'), ('-', 'punct'), ('04', 'appos'), ('.', 'punct')]}, {'original_sentence': '• Prefilled Syringe Carton - 40 mg/0.8 mL \\nHUMIRA is supplied in a carton containing two alcohol preps and two dose trays.', 'tokens': ['•', 'Prefilled', 'Syringe', 'Carton', '-', '40', 'mg/0.8', 'mL', 'HUMIRA', 'supplied', 'carton', 'containing', 'two', 'alcohol', 'preps', 'two', 'dose', 'trays', '.'], 'lemmatized': ['•', 'Prefilled', 'Syringe', 'Carton', '-', '40', 'mg/0.8', 'mL', 'HUMIRA', 'supplied', 'carton', 'containing', 'two', 'alcohol', 'prep', 'two', 'dose', 'tray', '.'], 'stemmed': ['•', 'prefil', 'syring', 'carton', '-', '40', 'mg/0.8', 'ml', 'humira', 'suppli', 'carton', 'contain', 'two', 'alcohol', 'prep', 'two', 'dose', 'tray', '.'], 'dependencies': [('•', 'nummod'), ('prefil', 'nmod'), ('syring', 'compound'), ('carton', 'nsubj'), ('-', 'punct'), ('40', 'prep'), ('mg/0.8', 'quantmod'), ('ml', 'nmod'), ('humira', 'compound'), ('suppli', 'compound'), ('carton', 'nsubj'), ('contain', 'ROOT'), ('two', 'nummod'), ('alcohol', 'compound'), ('prep', 'compound'), ('two', 'nummod'), ('dose', 'compound'), ('tray', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Each dose \\ntray consists of a single-dose, 1 mL prefilled glass syringe with a fixed ½ inch needle, \\nproviding 40 mg/0.8 mL of HUMIRA.', 'tokens': ['dose', 'tray', 'consists', 'single-dose', ',', '1', 'mL', 'prefilled', 'glass', 'syringe', 'fixed', '½', 'inch', 'needle', ',', 'providing', '40', 'mg/0.8', 'mL', 'HUMIRA', '.'], 'lemmatized': ['dose', 'tray', 'consists', 'single-dose', ',', '1', 'mL', 'prefilled', 'glass', 'syringe', 'fixed', '½', 'inch', 'needle', ',', 'providing', '40', 'mg/0.8', 'mL', 'HUMIRA', '.'], 'stemmed': ['dose', 'tray', 'consist', 'single-dos', ',', '1', 'ml', 'prefil', 'glass', 'syring', 'fix', '½', 'inch', 'needl', ',', 'provid', '40', 'mg/0.8', 'ml', 'humira', '.'], 'dependencies': [('dose', 'compound'), ('tray', 'dep'), ('consist', 'appos'), ('single', 'amod'), ('-', 'punct'), ('dos', 'appos'), (',', 'punct'), ('1', 'nummod'), ('ml', 'dep'), ('prefil', 'compound'), ('glass', 'compound'), ('syring', 'amod'), ('fix', 'compound'), ('½', 'compound'), ('inch', 'compound'), ('needl', 'ROOT'), (',', 'punct'), ('provid', 'npadvmod'), ('40', 'nummod'), ('mg/0.8', 'appos'), ('ml', 'compound'), ('humira', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'The needle cover may contain natural rubber latex.', 'tokens': ['needle', 'cover', 'may', 'contain', 'natural', 'rubber', 'latex', '.'], 'lemmatized': ['needle', 'cover', 'may', 'contain', 'natural', 'rubber', 'latex', '.'], 'stemmed': ['needl', 'cover', 'may', 'contain', 'natur', 'rubber', 'latex', '.'], 'dependencies': [('needl', 'compound'), ('cover', 'nsubj'), ('may', 'aux'), ('contain', 'ROOT'), ('natur', 'compound'), ('rubber', 'compound'), ('latex', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The NDC number is 0074-3799-02.', 'tokens': ['NDC', 'number', '0074-3799-02', '.'], 'lemmatized': ['NDC', 'number', '0074-3799-02', '.'], 'stemmed': ['ndc', 'number', '0074-3799-02', '.'], 'dependencies': [('ndc', 'compound'), ('number', 'ROOT'), ('0074', 'nummod'), ('-', 'punct'), ('3799', 'npadvmod'), ('-', 'punct'), ('02', 'prep'), ('.', 'punct')]}], 'text': \"tray consists of a single-dose pen, containing a 1 mL prefilled glass syringe with a fixed thin \\nwall, ½ inch needle, providing 40 mg/0.4 mL of HUMIRA. The black needle cover is not \\nmade with natural rubber latex. The NDC number is 0074-0554-02.  \\n  \\n• HUMIRA Pen Carton – 80 mg/0.8 mL \\nHUMIRA is supplied in a carton containing two alcohol preps and two dose trays.  Each dose \\ntray consists of a single-dose pen, containing a 1 mL prefilled glass syringe with a fixed thin \\nwall, ½ inch needle, providing 80 mg/0.8 mL of HUMIRA.  The black needle cover is not \\nmade with natural rubber latex.  The NDC number is 0074-0124-02. \\n• HUMIRA Pen 40 mg/0.8 mL - Starter Package for Crohn's Disease, Ulcerative Colitis \\nor Hidradenitis Suppurativa \\nHUMIRA is supplied in a carton containing 6 alcohol preps and 6 dose trays (Starter Package \\nfor Crohn’s Disease, Ulcerative Colitis or Hidradenitis Suppurativa). Each dose tray consists \\nof a single-dose pen, containing a 1 mL prefilled glass syringe with a fixed ½ inch needle, \\nproviding 40 mg/0.8 mL of HUMIRA. The needle cover may contain natural rubber latex. \\nThe NDC number is 0074-4339-06.  \\n  \\n  \\n• HUMIRA Pen 80 mg/0.8 mL - Starter Package for Crohn's Disease, Ulcerative Colitis \\nor Hidradenitis Suppurativa \\nHUMIRA is supplied in a carton containing 4 alcohol preps and 3 dose trays (Starter Package \\nfor Crohn’s Disease, Ulcerative Colitis or Hidradenitis Suppurativa). Each dose tray consists \\nof a single-dose pen, containing a 1 mL prefilled glass syringe with a fixed thin wall, ½ inch \\nneedle, providing 80 mg/0.8 mL of HUMIRA. The black needle cover is not made with \\nnatural rubber latex. The NDC number is 0074-0124-03.  \\n  \\n  \\n  \\n• HUMIRA Pen 80 mg/0.8 mL and 40 mg/0.4 mL - Psoriasis, Uveitis or Adolescent \\nHidradenitis Suppurativa Starter Package \\nHUMIRA is supplied in a carton containing 4 alcohol preps and 3 dose trays (Psoriasis, \\nUveitis or Adolescent Hidradenitis Suppurativa Starter Package). One dose tray consists of a \\nsingle-dose pen, containing a 1 mL prefilled glass syringe with a fixed thin wall, ½ inch \\nneedle, providing 80 mg/0.8 mL of HUMIRA. The other two dose trays each consist of a \\nsingle-dose pen, containing a 1 mL prefilled glass syringe with a fixed thin wall, ½ inch \\nneedle, providing 40 mg/0.4 mL of HUMIRA. The black needle cover is not made with \\nnatural rubber latex. The NDC number is 0074-1539-03.  \\n• HUMIRA Pen 80 mg/0.8 mL – Starter Package for Pediatric Ulcerative Colitis (4 count) \\nHUMIRA is supplied in a carton containing 4 alcohol preps and 4 dose trays (Starter Package \\nfor Pediatric Ulcerative Colitis). Each dose tray consists of a single-dose pen, containing a 1 \\nmL prefilled glass syringe with a fixed thin wall, ½ inch needle, providing 80 mg/0.8 mL of \\nHUMIRA. The black needle cover is not made with natural rubber latex. The NDC number is \\n0074-0124-04.   \\n  \\n• Prefilled Syringe Carton - 40 mg/0.8 mL \\nHUMIRA is supplied in a carton containing two alcohol preps and two dose trays. Each dose \\ntray consists of a single-dose, 1 mL prefilled glass syringe with a fixed ½ inch needle, \\nproviding 40 mg/0.8 mL of HUMIRA. The needle cover may contain natural rubber latex. \\nThe NDC number is 0074-3799-02.  \\n  \\n\"}, 'page_char_count': 3234, 'page_word_count': 534, 'sentences': ['tray consists of a single-dose pen, containing a 1 mL prefilled glass syringe with a fixed thin \\nwall, ½ inch needle, providing 40 mg/0.4 mL of HUMIRA.', 'The black needle cover is not \\nmade with natural rubber latex.', 'The NDC number is 0074-0554-02.', ' \\n  \\n• HUMIRA Pen Carton – 80 mg/0.8 mL \\nHUMIRA is supplied in a carton containing two alcohol preps and two dose trays.', ' Each dose \\ntray consists of a single-dose pen, containing a 1 mL prefilled glass syringe with a fixed thin \\nwall, ½ inch needle, providing 80 mg/0.8 mL of HUMIRA.', ' The black needle cover is not \\nmade with natural rubber latex.', ' The NDC number is 0074-0124-02.', \"\\n• HUMIRA Pen 40 mg/0.8 mL - Starter Package for Crohn's Disease, Ulcerative Colitis \\nor Hidradenitis Suppurativa \\nHUMIRA is supplied in a carton containing 6 alcohol preps and 6 dose trays (Starter Package \\nfor Crohn’s Disease, Ulcerative Colitis or Hidradenitis Suppurativa).\", 'Each dose tray consists \\nof a single-dose pen, containing a 1 mL prefilled glass syringe with a fixed ½ inch needle, \\nproviding 40 mg/0.8 mL of HUMIRA.', 'The needle cover may contain natural rubber latex.', '\\nThe NDC number is 0074-4339-06.', \" \\n  \\n  \\n• HUMIRA Pen 80 mg/0.8 mL - Starter Package for Crohn's Disease, Ulcerative Colitis \\nor Hidradenitis Suppurativa \\nHUMIRA is supplied in a carton containing 4 alcohol preps and 3 dose trays (Starter Package \\nfor Crohn’s Disease, Ulcerative Colitis or Hidradenitis Suppurativa).\", 'Each dose tray consists \\nof a single-dose pen, containing a 1 mL prefilled glass syringe with a fixed thin wall, ½ inch \\nneedle, providing 80 mg/0.8 mL of HUMIRA.', 'The black needle cover is not made with \\nnatural rubber latex.', 'The NDC number is 0074-0124-03.', ' \\n  \\n  \\n  \\n• HUMIRA Pen 80 mg/0.8 mL and 40 mg/0.4 mL - Psoriasis, Uveitis or Adolescent \\nHidradenitis Suppurativa Starter Package \\nHUMIRA is supplied in a carton containing 4 alcohol preps and 3 dose trays (Psoriasis, \\nUveitis or Adolescent Hidradenitis Suppurativa Starter Package).', 'One dose tray consists of a \\nsingle-dose pen, containing a 1 mL prefilled glass syringe with a fixed thin wall, ½ inch \\nneedle, providing 80 mg/0.8 mL of HUMIRA.', 'The other two dose trays each consist of a \\nsingle-dose pen, containing a 1 mL prefilled glass syringe with a fixed thin wall, ½ inch \\nneedle, providing 40 mg/0.4 mL of HUMIRA.', 'The black needle cover is not made with \\nnatural rubber latex.', 'The NDC number is 0074-1539-03.', ' \\n• HUMIRA Pen 80 mg/0.8 mL – Starter Package for Pediatric Ulcerative Colitis (4 count) \\nHUMIRA is supplied in a carton containing 4 alcohol preps and 4 dose trays (Starter Package \\nfor Pediatric Ulcerative Colitis).', 'Each dose tray consists of a single-dose pen, containing a 1 \\nmL prefilled glass syringe with a fixed thin wall, ½ inch needle, providing 80 mg/0.8 mL of \\nHUMIRA.', 'The black needle cover is not made with natural rubber latex.', 'The NDC number is \\n0074-0124-04.', '  \\n  \\n• Prefilled Syringe Carton - 40 mg/0.8 mL \\nHUMIRA is supplied in a carton containing two alcohol preps and two dose trays.', 'Each dose \\ntray consists of a single-dose, 1 mL prefilled glass syringe with a fixed ½ inch needle, \\nproviding 40 mg/0.8 mL of HUMIRA.', 'The needle cover may contain natural rubber latex.', '\\nThe NDC number is 0074-3799-02.', ' \\n  \\n'], 'page_sentence_count_spacy': 29}\n",
            "{'page_number': 56, 'text': '• Prefilled Syringe Carton - 40 mg/0.4 mL \\nHUMIRA is supplied in a carton containing two alcohol preps and two dose trays. Each dose \\ntray consists of a single-dose, 1 mL prefilled glass syringe with a fixed thin wall, ½ inch \\nneedle, providing 40 mg/0.4 mL of HUMIRA. The black needle cover is not made with \\nnatural rubber latex. The NDC number is 0074-0243-02.  \\n  \\n• Prefilled Syringe Carton - 20 mg/0.4 mL \\nHUMIRA is supplied in a carton containing two alcohol preps and two dose trays. Each dose \\ntray consists of a single-dose, 1 mL prefilled glass syringe with a fixed ½ inch needle, \\nproviding 20 mg/0.4 mL of HUMIRA. The needle cover may contain natural rubber latex. \\nThe NDC number is 0074-9374-02.  \\n  \\n• Prefilled Syringe Carton - 20 mg/0.2 mL \\nHUMIRA is supplied in a carton containing two alcohol preps and two dose trays. Each dose \\ntray consists of a single-dose, 1 mL prefilled glass syringe with a fixed thin wall, ½ inch \\nneedle, providing 20 mg/0.2 mL of HUMIRA. The black needle cover is not made with \\nnatural rubber latex. The NDC number is 0074-0616-02.  \\n  \\n• Prefilled Syringe Carton - 10 mg/0.2 mL \\nHUMIRA is supplied in a carton containing two alcohol preps and two dose trays. Each dose \\ntray consists of a single-dose, 1 mL prefilled glass syringe with a fixed ½ inch needle, \\nproviding 10 mg/0.2 mL of HUMIRA. The needle cover may contain natural rubber latex. \\nThe NDC number is 0074-6347-02.  \\n  \\n• Prefilled Syringe Carton - 10 mg/0.1 mL \\nHUMIRA is supplied in a carton containing two alcohol preps and two dose trays. Each dose \\ntray consists of a single-dose, 1 mL prefilled glass syringe with a fixed thin wall, ½ inch \\nneedle, providing 10 mg/0.1 mL of HUMIRA. The black needle cover is not made with \\nnatural rubber latex. The NDC number is 0074-0817-02.  \\n  \\n  \\n• HUMIRA Prefilled Syringe 80 mg/0.8 mL - Pediatric Crohn’s Disease Starter Package \\n(3 count)  \\nHUMIRA is supplied in a carton containing 4 alcohol preps and 3 dose trays (Pediatric \\nStarter Package). Each dose tray consists of a single-dose, 1 mL prefilled glass syringe with a \\nfixed thin wall, ½ inch needle, providing 80 mg/0.8 mL of HUMIRA. The black needle cover \\nis not made with natural rubber latex. The NDC number is 0074-2540-03.  \\n  \\n  \\n• HUMIRA Prefilled Syringe 80 mg/0.8 mL and 40 mg/0.4 mL - Pediatric Crohn’s \\nDisease Starter Package (2 count)  \\nHUMIRA is supplied in a carton containing 2 alcohol preps and 2 dose trays (Pediatric \\nStarter Package). One dose tray consists of a single-dose, 1 mL prefilled glass syringe with a \\nfixed thin wall, ½ inch needle, providing 80 mg/0.8 mL of HUMIRA. The other dose tray \\nconsists of a single-dose, 1 mL prefilled glass syringe with a fixed thin wall, ½ inch needle, \\nproviding 40 mg/0.4 mL of HUMIRA. The black needle cover is not made with natural \\nrubber latex. The NDC number is 0074-0067-02.  \\n  \\n• Single-Dose Institutional Use Vial Carton - 40 mg/0.8 mL \\nHUMIRA is supplied for institutional use only in a carton containing a single-dose, glass \\nvial, providing 40 mg/0.8 mL of HUMIRA. The vial stopper is not made with natural rubber \\nlatex. The NDC number is 0074-3797-01.  \\n  \\n', 'processed_text': {'sentences': [{'original_sentence': '• Prefilled Syringe Carton - 40 mg/0.4 mL \\nHUMIRA is supplied in a carton containing two alcohol preps and two dose trays.', 'tokens': ['•', 'Prefilled', 'Syringe', 'Carton', '-', '40', 'mg/0.4', 'mL', 'HUMIRA', 'supplied', 'carton', 'containing', 'two', 'alcohol', 'preps', 'two', 'dose', 'trays', '.'], 'lemmatized': ['•', 'Prefilled', 'Syringe', 'Carton', '-', '40', 'mg/0.4', 'mL', 'HUMIRA', 'supplied', 'carton', 'containing', 'two', 'alcohol', 'prep', 'two', 'dose', 'tray', '.'], 'stemmed': ['•', 'prefil', 'syring', 'carton', '-', '40', 'mg/0.4', 'ml', 'humira', 'suppli', 'carton', 'contain', 'two', 'alcohol', 'prep', 'two', 'dose', 'tray', '.'], 'dependencies': [('•', 'nummod'), ('prefil', 'nmod'), ('syring', 'compound'), ('carton', 'ROOT'), ('-', 'punct'), ('40', 'npadvmod'), ('mg/0.4', 'punct'), ('ml', 'dep'), ('humira', 'compound'), ('suppli', 'compound'), ('carton', 'nsubj'), ('contain', 'ROOT'), ('two', 'nummod'), ('alcohol', 'compound'), ('prep', 'compound'), ('two', 'nummod'), ('dose', 'compound'), ('tray', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Each dose \\ntray consists of a single-dose, 1 mL prefilled glass syringe with a fixed thin wall, ½ inch \\nneedle, providing 40 mg/0.4 mL of HUMIRA.', 'tokens': ['dose', 'tray', 'consists', 'single-dose', ',', '1', 'mL', 'prefilled', 'glass', 'syringe', 'fixed', 'thin', 'wall', ',', '½', 'inch', 'needle', ',', 'providing', '40', 'mg/0.4', 'mL', 'HUMIRA', '.'], 'lemmatized': ['dose', 'tray', 'consists', 'single-dose', ',', '1', 'mL', 'prefilled', 'glass', 'syringe', 'fixed', 'thin', 'wall', ',', '½', 'inch', 'needle', ',', 'providing', '40', 'mg/0.4', 'mL', 'HUMIRA', '.'], 'stemmed': ['dose', 'tray', 'consist', 'single-dos', ',', '1', 'ml', 'prefil', 'glass', 'syring', 'fix', 'thin', 'wall', ',', '½', 'inch', 'needl', ',', 'provid', '40', 'mg/0.4', 'ml', 'humira', '.'], 'dependencies': [('dose', 'compound'), ('tray', 'nmod'), ('consist', 'appos'), ('single', 'amod'), ('-', 'punct'), ('dos', 'appos'), (',', 'punct'), ('1', 'nummod'), ('ml', 'appos'), ('prefil', 'compound'), ('glass', 'compound'), ('syring', 'compound'), ('fix', 'compound'), ('thin', 'amod'), ('wall', 'ROOT'), (',', 'punct'), ('½', 'compound'), ('inch', 'nsubj'), ('needl', 'appos'), (',', 'punct'), ('provid', 'appos'), ('40', 'nummod'), ('mg/0.4', 'appos'), ('ml', 'compound'), ('humira', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'The black needle cover is not made with \\nnatural rubber latex.', 'tokens': ['black', 'needle', 'cover', 'made', 'natural', 'rubber', 'latex', '.'], 'lemmatized': ['black', 'needle', 'cover', 'made', 'natural', 'rubber', 'latex', '.'], 'stemmed': ['black', 'needl', 'cover', 'made', 'natur', 'rubber', 'latex', '.'], 'dependencies': [('black', 'amod'), ('needl', 'compound'), ('cover', 'nsubj'), ('made', 'ROOT'), ('natur', 'compound'), ('rubber', 'compound'), ('latex', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The NDC number is 0074-0243-02.', 'tokens': ['NDC', 'number', '0074-0243-02', '.'], 'lemmatized': ['NDC', 'number', '0074-0243-02', '.'], 'stemmed': ['ndc', 'number', '0074-0243-02', '.'], 'dependencies': [('ndc', 'compound'), ('number', 'ROOT'), ('0074', 'npadvmod'), ('-', 'punct'), ('0243', 'nummod'), ('-', 'punct'), ('02', 'prep'), ('.', 'punct')]}, {'original_sentence': '• Prefilled Syringe Carton - 20 mg/0.4 mL \\nHUMIRA is supplied in a carton containing two alcohol preps and two dose trays.', 'tokens': ['•', 'Prefilled', 'Syringe', 'Carton', '-', '20', 'mg/0.4', 'mL', 'HUMIRA', 'supplied', 'carton', 'containing', 'two', 'alcohol', 'preps', 'two', 'dose', 'trays', '.'], 'lemmatized': ['•', 'Prefilled', 'Syringe', 'Carton', '-', '20', 'mg/0.4', 'mL', 'HUMIRA', 'supplied', 'carton', 'containing', 'two', 'alcohol', 'prep', 'two', 'dose', 'tray', '.'], 'stemmed': ['•', 'prefil', 'syring', 'carton', '-', '20', 'mg/0.4', 'ml', 'humira', 'suppli', 'carton', 'contain', 'two', 'alcohol', 'prep', 'two', 'dose', 'tray', '.'], 'dependencies': [('•', 'nummod'), ('prefil', 'nmod'), ('syring', 'compound'), ('carton', 'ROOT'), ('-', 'punct'), ('20', 'prep'), ('mg/0.4', 'punct'), ('ml', 'dep'), ('humira', 'compound'), ('suppli', 'compound'), ('carton', 'nsubj'), ('contain', 'ROOT'), ('two', 'nummod'), ('alcohol', 'compound'), ('prep', 'compound'), ('two', 'nummod'), ('dose', 'compound'), ('tray', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Each dose \\ntray consists of a single-dose, 1 mL prefilled glass syringe with a fixed ½ inch needle, \\nproviding 20 mg/0.4 mL of HUMIRA.', 'tokens': ['dose', 'tray', 'consists', 'single-dose', ',', '1', 'mL', 'prefilled', 'glass', 'syringe', 'fixed', '½', 'inch', 'needle', ',', 'providing', '20', 'mg/0.4', 'mL', 'HUMIRA', '.'], 'lemmatized': ['dose', 'tray', 'consists', 'single-dose', ',', '1', 'mL', 'prefilled', 'glass', 'syringe', 'fixed', '½', 'inch', 'needle', ',', 'providing', '20', 'mg/0.4', 'mL', 'HUMIRA', '.'], 'stemmed': ['dose', 'tray', 'consist', 'single-dos', ',', '1', 'ml', 'prefil', 'glass', 'syring', 'fix', '½', 'inch', 'needl', ',', 'provid', '20', 'mg/0.4', 'ml', 'humira', '.'], 'dependencies': [('dose', 'compound'), ('tray', 'dep'), ('consist', 'appos'), ('single', 'amod'), ('-', 'punct'), ('dos', 'appos'), (',', 'punct'), ('1', 'nummod'), ('ml', 'dep'), ('prefil', 'compound'), ('glass', 'compound'), ('syring', 'amod'), ('fix', 'compound'), ('½', 'compound'), ('inch', 'compound'), ('needl', 'ROOT'), (',', 'punct'), ('provid', 'npadvmod'), ('20', 'nummod'), ('mg/0.4', 'appos'), ('ml', 'compound'), ('humira', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'The needle cover may contain natural rubber latex.', 'tokens': ['needle', 'cover', 'may', 'contain', 'natural', 'rubber', 'latex', '.'], 'lemmatized': ['needle', 'cover', 'may', 'contain', 'natural', 'rubber', 'latex', '.'], 'stemmed': ['needl', 'cover', 'may', 'contain', 'natur', 'rubber', 'latex', '.'], 'dependencies': [('needl', 'compound'), ('cover', 'nsubj'), ('may', 'aux'), ('contain', 'ROOT'), ('natur', 'compound'), ('rubber', 'compound'), ('latex', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The NDC number is 0074-9374-02.', 'tokens': ['NDC', 'number', '0074-9374-02', '.'], 'lemmatized': ['NDC', 'number', '0074-9374-02', '.'], 'stemmed': ['ndc', 'number', '0074-9374-02', '.'], 'dependencies': [('ndc', 'compound'), ('number', 'ROOT'), ('0074', 'nummod'), ('-', 'punct'), ('9374', 'prep'), ('-', 'punct'), ('02', 'prep'), ('.', 'punct')]}, {'original_sentence': '• Prefilled Syringe Carton - 20 mg/0.2 mL \\nHUMIRA is supplied in a carton containing two alcohol preps and two dose trays.', 'tokens': ['•', 'Prefilled', 'Syringe', 'Carton', '-', '20', 'mg/0.2', 'mL', 'HUMIRA', 'supplied', 'carton', 'containing', 'two', 'alcohol', 'preps', 'two', 'dose', 'trays', '.'], 'lemmatized': ['•', 'Prefilled', 'Syringe', 'Carton', '-', '20', 'mg/0.2', 'mL', 'HUMIRA', 'supplied', 'carton', 'containing', 'two', 'alcohol', 'prep', 'two', 'dose', 'tray', '.'], 'stemmed': ['•', 'prefil', 'syring', 'carton', '-', '20', 'mg/0.2', 'ml', 'humira', 'suppli', 'carton', 'contain', 'two', 'alcohol', 'prep', 'two', 'dose', 'tray', '.'], 'dependencies': [('•', 'dep'), ('prefil', 'nmod'), ('syring', 'compound'), ('carton', 'dep'), ('-', 'punct'), ('20', 'compound'), ('mg/0.2', 'npadvmod'), ('ml', 'nmod'), ('humira', 'compound'), ('suppli', 'compound'), ('carton', 'nsubj'), ('contain', 'ROOT'), ('two', 'nummod'), ('alcohol', 'compound'), ('prep', 'compound'), ('two', 'nummod'), ('dose', 'compound'), ('tray', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Each dose \\ntray consists of a single-dose, 1 mL prefilled glass syringe with a fixed thin wall, ½ inch \\nneedle, providing 20 mg/0.2 mL of HUMIRA.', 'tokens': ['dose', 'tray', 'consists', 'single-dose', ',', '1', 'mL', 'prefilled', 'glass', 'syringe', 'fixed', 'thin', 'wall', ',', '½', 'inch', 'needle', ',', 'providing', '20', 'mg/0.2', 'mL', 'HUMIRA', '.'], 'lemmatized': ['dose', 'tray', 'consists', 'single-dose', ',', '1', 'mL', 'prefilled', 'glass', 'syringe', 'fixed', 'thin', 'wall', ',', '½', 'inch', 'needle', ',', 'providing', '20', 'mg/0.2', 'mL', 'HUMIRA', '.'], 'stemmed': ['dose', 'tray', 'consist', 'single-dos', ',', '1', 'ml', 'prefil', 'glass', 'syring', 'fix', 'thin', 'wall', ',', '½', 'inch', 'needl', ',', 'provid', '20', 'mg/0.2', 'ml', 'humira', '.'], 'dependencies': [('dose', 'compound'), ('tray', 'nmod'), ('consist', 'appos'), ('single', 'amod'), ('-', 'punct'), ('dos', 'appos'), (',', 'punct'), ('1', 'nummod'), ('ml', 'appos'), ('prefil', 'compound'), ('glass', 'compound'), ('syring', 'compound'), ('fix', 'compound'), ('thin', 'amod'), ('wall', 'ROOT'), (',', 'punct'), ('½', 'compound'), ('inch', 'nsubj'), ('needl', 'appos'), (',', 'punct'), ('provid', 'appos'), ('20', 'nummod'), ('mg/0.2', 'appos'), ('ml', 'compound'), ('humira', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'The black needle cover is not made with \\nnatural rubber latex.', 'tokens': ['black', 'needle', 'cover', 'made', 'natural', 'rubber', 'latex', '.'], 'lemmatized': ['black', 'needle', 'cover', 'made', 'natural', 'rubber', 'latex', '.'], 'stemmed': ['black', 'needl', 'cover', 'made', 'natur', 'rubber', 'latex', '.'], 'dependencies': [('black', 'amod'), ('needl', 'compound'), ('cover', 'nsubj'), ('made', 'ROOT'), ('natur', 'compound'), ('rubber', 'compound'), ('latex', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The NDC number is 0074-0616-02.', 'tokens': ['NDC', 'number', '0074-0616-02', '.'], 'lemmatized': ['NDC', 'number', '0074-0616-02', '.'], 'stemmed': ['ndc', 'number', '0074-0616-02', '.'], 'dependencies': [('ndc', 'compound'), ('number', 'ROOT'), ('0074', 'nummod'), ('-', 'punct'), ('0616', 'appos'), ('-', 'punct'), ('02', 'prep'), ('.', 'punct')]}, {'original_sentence': '• Prefilled Syringe Carton - 10 mg/0.2 mL \\nHUMIRA is supplied in a carton containing two alcohol preps and two dose trays.', 'tokens': ['•', 'Prefilled', 'Syringe', 'Carton', '-', '10', 'mg/0.2', 'mL', 'HUMIRA', 'supplied', 'carton', 'containing', 'two', 'alcohol', 'preps', 'two', 'dose', 'trays', '.'], 'lemmatized': ['•', 'Prefilled', 'Syringe', 'Carton', '-', '10', 'mg/0.2', 'mL', 'HUMIRA', 'supplied', 'carton', 'containing', 'two', 'alcohol', 'prep', 'two', 'dose', 'tray', '.'], 'stemmed': ['•', 'prefil', 'syring', 'carton', '-', '10', 'mg/0.2', 'ml', 'humira', 'suppli', 'carton', 'contain', 'two', 'alcohol', 'prep', 'two', 'dose', 'tray', '.'], 'dependencies': [('•', 'nummod'), ('prefil', 'nmod'), ('syring', 'compound'), ('carton', 'nsubj'), ('-', 'punct'), ('10', 'compound'), ('mg/0.2', 'appos'), ('ml', 'nmod'), ('humira', 'compound'), ('suppli', 'compound'), ('carton', 'nsubj'), ('contain', 'ROOT'), ('two', 'nummod'), ('alcohol', 'compound'), ('prep', 'compound'), ('two', 'nummod'), ('dose', 'compound'), ('tray', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Each dose \\ntray consists of a single-dose, 1 mL prefilled glass syringe with a fixed ½ inch needle, \\nproviding 10 mg/0.2 mL of HUMIRA.', 'tokens': ['dose', 'tray', 'consists', 'single-dose', ',', '1', 'mL', 'prefilled', 'glass', 'syringe', 'fixed', '½', 'inch', 'needle', ',', 'providing', '10', 'mg/0.2', 'mL', 'HUMIRA', '.'], 'lemmatized': ['dose', 'tray', 'consists', 'single-dose', ',', '1', 'mL', 'prefilled', 'glass', 'syringe', 'fixed', '½', 'inch', 'needle', ',', 'providing', '10', 'mg/0.2', 'mL', 'HUMIRA', '.'], 'stemmed': ['dose', 'tray', 'consist', 'single-dos', ',', '1', 'ml', 'prefil', 'glass', 'syring', 'fix', '½', 'inch', 'needl', ',', 'provid', '10', 'mg/0.2', 'ml', 'humira', '.'], 'dependencies': [('dose', 'compound'), ('tray', 'dep'), ('consist', 'appos'), ('single', 'amod'), ('-', 'punct'), ('dos', 'appos'), (',', 'punct'), ('1', 'nummod'), ('ml', 'nsubj'), ('prefil', 'compound'), ('glass', 'compound'), ('syring', 'amod'), ('fix', 'compound'), ('½', 'compound'), ('inch', 'compound'), ('needl', 'ROOT'), (',', 'punct'), ('provid', 'npadvmod'), ('10', 'nummod'), ('mg/0.2', 'punct'), ('ml', 'compound'), ('humira', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'The needle cover may contain natural rubber latex.', 'tokens': ['needle', 'cover', 'may', 'contain', 'natural', 'rubber', 'latex', '.'], 'lemmatized': ['needle', 'cover', 'may', 'contain', 'natural', 'rubber', 'latex', '.'], 'stemmed': ['needl', 'cover', 'may', 'contain', 'natur', 'rubber', 'latex', '.'], 'dependencies': [('needl', 'compound'), ('cover', 'nsubj'), ('may', 'aux'), ('contain', 'ROOT'), ('natur', 'compound'), ('rubber', 'compound'), ('latex', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The NDC number is 0074-6347-02.', 'tokens': ['NDC', 'number', '0074-6347-02', '.'], 'lemmatized': ['NDC', 'number', '0074-6347-02', '.'], 'stemmed': ['ndc', 'number', '0074-6347-02', '.'], 'dependencies': [('ndc', 'compound'), ('number', 'ROOT'), ('0074', 'nummod'), ('-', 'punct'), ('6347', 'nummod'), ('-', 'punct'), ('02', 'nummod'), ('.', 'punct')]}, {'original_sentence': '• Prefilled Syringe Carton - 10 mg/0.1 mL \\nHUMIRA is supplied in a carton containing two alcohol preps and two dose trays.', 'tokens': ['•', 'Prefilled', 'Syringe', 'Carton', '-', '10', 'mg/0.1', 'mL', 'HUMIRA', 'supplied', 'carton', 'containing', 'two', 'alcohol', 'preps', 'two', 'dose', 'trays', '.'], 'lemmatized': ['•', 'Prefilled', 'Syringe', 'Carton', '-', '10', 'mg/0.1', 'mL', 'HUMIRA', 'supplied', 'carton', 'containing', 'two', 'alcohol', 'prep', 'two', 'dose', 'tray', '.'], 'stemmed': ['•', 'prefil', 'syring', 'carton', '-', '10', 'mg/0.1', 'ml', 'humira', 'suppli', 'carton', 'contain', 'two', 'alcohol', 'prep', 'two', 'dose', 'tray', '.'], 'dependencies': [('•', 'dep'), ('prefil', 'nmod'), ('syring', 'compound'), ('carton', 'nsubj'), ('-', 'punct'), ('10', 'nummod'), ('mg/0.1', 'dep'), ('ml', 'compound'), ('humira', 'compound'), ('suppli', 'compound'), ('carton', 'nsubj'), ('contain', 'ROOT'), ('two', 'nummod'), ('alcohol', 'compound'), ('prep', 'compound'), ('two', 'nummod'), ('dose', 'compound'), ('tray', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Each dose \\ntray consists of a single-dose, 1 mL prefilled glass syringe with a fixed thin wall, ½ inch \\nneedle, providing 10 mg/0.1 mL of HUMIRA.', 'tokens': ['dose', 'tray', 'consists', 'single-dose', ',', '1', 'mL', 'prefilled', 'glass', 'syringe', 'fixed', 'thin', 'wall', ',', '½', 'inch', 'needle', ',', 'providing', '10', 'mg/0.1', 'mL', 'HUMIRA', '.'], 'lemmatized': ['dose', 'tray', 'consists', 'single-dose', ',', '1', 'mL', 'prefilled', 'glass', 'syringe', 'fixed', 'thin', 'wall', ',', '½', 'inch', 'needle', ',', 'providing', '10', 'mg/0.1', 'mL', 'HUMIRA', '.'], 'stemmed': ['dose', 'tray', 'consist', 'single-dos', ',', '1', 'ml', 'prefil', 'glass', 'syring', 'fix', 'thin', 'wall', ',', '½', 'inch', 'needl', ',', 'provid', '10', 'mg/0.1', 'ml', 'humira', '.'], 'dependencies': [('dose', 'compound'), ('tray', 'nmod'), ('consist', 'appos'), ('single', 'amod'), ('-', 'punct'), ('dos', 'appos'), (',', 'punct'), ('1', 'nummod'), ('ml', 'appos'), ('prefil', 'compound'), ('glass', 'compound'), ('syring', 'compound'), ('fix', 'compound'), ('thin', 'amod'), ('wall', 'ROOT'), (',', 'punct'), ('½', 'compound'), ('inch', 'nsubj'), ('needl', 'appos'), (',', 'punct'), ('provid', 'appos'), ('10', 'nummod'), ('mg/0.1', 'punct'), ('ml', 'compound'), ('humira', 'appos'), ('.', 'punct')]}, {'original_sentence': 'The black needle cover is not made with \\nnatural rubber latex.', 'tokens': ['black', 'needle', 'cover', 'made', 'natural', 'rubber', 'latex', '.'], 'lemmatized': ['black', 'needle', 'cover', 'made', 'natural', 'rubber', 'latex', '.'], 'stemmed': ['black', 'needl', 'cover', 'made', 'natur', 'rubber', 'latex', '.'], 'dependencies': [('black', 'amod'), ('needl', 'compound'), ('cover', 'nsubj'), ('made', 'ROOT'), ('natur', 'compound'), ('rubber', 'compound'), ('latex', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The NDC number is 0074-0817-02.', 'tokens': ['NDC', 'number', '0074-0817-02', '.'], 'lemmatized': ['NDC', 'number', '0074-0817-02', '.'], 'stemmed': ['ndc', 'number', '0074-0817-02', '.'], 'dependencies': [('ndc', 'compound'), ('number', 'ROOT'), ('0074', 'nummod'), ('-', 'punct'), ('0817', 'prep'), ('-', 'punct'), ('02', 'prep'), ('.', 'punct')]}, {'original_sentence': '• HUMIRA Prefilled Syringe 80 mg/0.8 mL - Pediatric Crohn’s Disease Starter Package \\n(3 count)  \\nHUMIRA is supplied in a carton containing 4 alcohol preps and 3 dose trays (Pediatric \\nStarter Package).', 'tokens': ['•', 'HUMIRA', 'Prefilled', 'Syringe', '80', 'mg/0.8', 'mL', '-', 'Pediatric', 'Crohn', '’', 'Disease', 'Starter', 'Package', '(', '3', 'count', ')', 'HUMIRA', 'supplied', 'carton', 'containing', '4', 'alcohol', 'preps', '3', 'dose', 'trays', '(', 'Pediatric', 'Starter', 'Package', ')', '.'], 'lemmatized': ['•', 'HUMIRA', 'Prefilled', 'Syringe', '80', 'mg/0.8', 'mL', '-', 'Pediatric', 'Crohn', '’', 'Disease', 'Starter', 'Package', '(', '3', 'count', ')', 'HUMIRA', 'supplied', 'carton', 'containing', '4', 'alcohol', 'prep', '3', 'dose', 'tray', '(', 'Pediatric', 'Starter', 'Package', ')', '.'], 'stemmed': ['•', 'humira', 'prefil', 'syring', '80', 'mg/0.8', 'ml', '-', 'pediatr', 'crohn', '’', 'diseas', 'starter', 'packag', '(', '3', 'count', ')', 'humira', 'suppli', 'carton', 'contain', '4', 'alcohol', 'prep', '3', 'dose', 'tray', '(', 'pediatr', 'starter', 'packag', ')', '.'], 'dependencies': [('•', 'nummod'), ('humira', 'compound'), ('prefil', 'nsubj'), ('syring', 'acl'), ('80', 'nummod'), ('mg/0.8', 'punct'), ('ml', 'compound'), ('-', 'punct'), ('pediatr', 'amod'), ('crohn', 'dep'), ('’', 'punct'), ('diseas', 'compound'), ('starter', 'compound'), ('packag', 'nmod'), ('(', 'punct'), ('3', 'nummod'), ('count', 'appos'), (')', 'punct'), ('humira', 'compound'), ('suppli', 'compound'), ('carton', 'nsubj'), ('contain', 'ROOT'), ('4', 'nummod'), ('alcohol', 'dobj'), ('prep', 'compound'), ('3', 'nummod'), ('dose', 'compound'), ('tray', 'dobj'), ('(', 'punct'), ('pediatr', 'amod'), ('starter', 'amod'), ('packag', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Each dose tray consists of a single-dose, 1 mL prefilled glass syringe with a \\nfixed thin wall, ½ inch needle, providing 80 mg/0.8 mL of HUMIRA.', 'tokens': ['dose', 'tray', 'consists', 'single-dose', ',', '1', 'mL', 'prefilled', 'glass', 'syringe', 'fixed', 'thin', 'wall', ',', '½', 'inch', 'needle', ',', 'providing', '80', 'mg/0.8', 'mL', 'HUMIRA', '.'], 'lemmatized': ['dose', 'tray', 'consists', 'single-dose', ',', '1', 'mL', 'prefilled', 'glass', 'syringe', 'fixed', 'thin', 'wall', ',', '½', 'inch', 'needle', ',', 'providing', '80', 'mg/0.8', 'mL', 'HUMIRA', '.'], 'stemmed': ['dose', 'tray', 'consist', 'single-dos', ',', '1', 'ml', 'prefil', 'glass', 'syring', 'fix', 'thin', 'wall', ',', '½', 'inch', 'needl', ',', 'provid', '80', 'mg/0.8', 'ml', 'humira', '.'], 'dependencies': [('dose', 'compound'), ('tray', 'nmod'), ('consist', 'appos'), ('single', 'amod'), ('-', 'punct'), ('dos', 'appos'), (',', 'punct'), ('1', 'nummod'), ('ml', 'appos'), ('prefil', 'compound'), ('glass', 'compound'), ('syring', 'compound'), ('fix', 'compound'), ('thin', 'amod'), ('wall', 'ROOT'), (',', 'punct'), ('½', 'compound'), ('inch', 'nsubj'), ('needl', 'conj'), (',', 'punct'), ('provid', 'appos'), ('80', 'nummod'), ('mg/0.8', 'appos'), ('ml', 'dep'), ('humira', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'The black needle cover \\nis not made with natural rubber latex.', 'tokens': ['black', 'needle', 'cover', 'made', 'natural', 'rubber', 'latex', '.'], 'lemmatized': ['black', 'needle', 'cover', 'made', 'natural', 'rubber', 'latex', '.'], 'stemmed': ['black', 'needl', 'cover', 'made', 'natur', 'rubber', 'latex', '.'], 'dependencies': [('black', 'amod'), ('needl', 'compound'), ('cover', 'nsubj'), ('made', 'ROOT'), ('natur', 'compound'), ('rubber', 'compound'), ('latex', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The NDC number is 0074-2540-03.', 'tokens': ['NDC', 'number', '0074-2540-03', '.'], 'lemmatized': ['NDC', 'number', '0074-2540-03', '.'], 'stemmed': ['ndc', 'number', '0074-2540-03', '.'], 'dependencies': [('ndc', 'compound'), ('number', 'ROOT'), ('0074', 'nummod'), ('-', 'punct'), ('2540', 'nummod'), ('-', 'punct'), ('03', 'appos'), ('.', 'punct')]}, {'original_sentence': '• HUMIRA Prefilled Syringe 80 mg/0.8 mL and 40 mg/0.4 mL - Pediatric Crohn’s \\nDisease Starter Package (2 count)  \\nHUMIRA is supplied in a carton containing 2 alcohol preps and 2 dose trays (Pediatric \\nStarter Package).', 'tokens': ['•', 'HUMIRA', 'Prefilled', 'Syringe', '80', 'mg/0.8', 'mL', '40', 'mg/0.4', 'mL', '-', 'Pediatric', 'Crohn', '’', 'Disease', 'Starter', 'Package', '(', '2', 'count', ')', 'HUMIRA', 'supplied', 'carton', 'containing', '2', 'alcohol', 'preps', '2', 'dose', 'trays', '(', 'Pediatric', 'Starter', 'Package', ')', '.'], 'lemmatized': ['•', 'HUMIRA', 'Prefilled', 'Syringe', '80', 'mg/0.8', 'mL', '40', 'mg/0.4', 'mL', '-', 'Pediatric', 'Crohn', '’', 'Disease', 'Starter', 'Package', '(', '2', 'count', ')', 'HUMIRA', 'supplied', 'carton', 'containing', '2', 'alcohol', 'prep', '2', 'dose', 'tray', '(', 'Pediatric', 'Starter', 'Package', ')', '.'], 'stemmed': ['•', 'humira', 'prefil', 'syring', '80', 'mg/0.8', 'ml', '40', 'mg/0.4', 'ml', '-', 'pediatr', 'crohn', '’', 'diseas', 'starter', 'packag', '(', '2', 'count', ')', 'humira', 'suppli', 'carton', 'contain', '2', 'alcohol', 'prep', '2', 'dose', 'tray', '(', 'pediatr', 'starter', 'packag', ')', '.'], 'dependencies': [('•', 'nummod'), ('humira', 'compound'), ('prefil', 'nsubj'), ('syring', 'acl'), ('80', 'nummod'), ('mg/0.8', 'npadvmod'), ('ml', 'ROOT'), ('40', 'nummod'), ('mg/0.4', 'npadvmod'), ('ml', 'compound'), ('-', 'punct'), ('pediatr', 'nsubj'), ('crohn', 'parataxis'), ('’', 'punct'), ('diseas', 'compound'), ('starter', 'amod'), ('packag', 'npadvmod'), ('(', 'punct'), ('2', 'nummod'), ('count', 'appos'), (')', 'punct'), ('humira', 'compound'), ('suppli', 'compound'), ('carton', 'nsubj'), ('contain', 'relcl'), ('2', 'nummod'), ('alcohol', 'compound'), ('prep', 'compound'), ('2', 'nummod'), ('dose', 'compound'), ('tray', 'dobj'), ('(', 'punct'), ('pediatr', 'amod'), ('starter', 'amod'), ('packag', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'One dose tray consists of a single-dose, 1 mL prefilled glass syringe with a \\nfixed thin wall, ½ inch needle, providing 80 mg/0.8 mL of HUMIRA.', 'tokens': ['One', 'dose', 'tray', 'consists', 'single-dose', ',', '1', 'mL', 'prefilled', 'glass', 'syringe', 'fixed', 'thin', 'wall', ',', '½', 'inch', 'needle', ',', 'providing', '80', 'mg/0.8', 'mL', 'HUMIRA', '.'], 'lemmatized': ['One', 'dose', 'tray', 'consists', 'single-dose', ',', '1', 'mL', 'prefilled', 'glass', 'syringe', 'fixed', 'thin', 'wall', ',', '½', 'inch', 'needle', ',', 'providing', '80', 'mg/0.8', 'mL', 'HUMIRA', '.'], 'stemmed': ['one', 'dose', 'tray', 'consist', 'single-dos', ',', '1', 'ml', 'prefil', 'glass', 'syring', 'fix', 'thin', 'wall', ',', '½', 'inch', 'needl', ',', 'provid', '80', 'mg/0.8', 'ml', 'humira', '.'], 'dependencies': [('one', 'nummod'), ('dose', 'compound'), ('tray', 'ROOT'), ('consist', 'amod'), ('single', 'amod'), ('-', 'punct'), ('dos', 'appos'), (',', 'punct'), ('1', 'nummod'), ('ml', 'appos'), ('prefil', 'compound'), ('glass', 'compound'), ('syring', 'compound'), ('fix', 'compound'), ('thin', 'amod'), ('wall', 'appos'), (',', 'punct'), ('½', 'compound'), ('inch', 'nsubj'), ('needl', 'appos'), (',', 'punct'), ('provid', 'nmod'), ('80', 'nummod'), ('mg/0.8', 'appos'), ('ml', 'compound'), ('humira', 'appos'), ('.', 'punct')]}, {'original_sentence': 'The other dose tray \\nconsists of a single-dose, 1 mL prefilled glass syringe with a fixed thin wall, ½ inch needle, \\nproviding 40 mg/0.4 mL of HUMIRA.', 'tokens': ['dose', 'tray', 'consists', 'single-dose', ',', '1', 'mL', 'prefilled', 'glass', 'syringe', 'fixed', 'thin', 'wall', ',', '½', 'inch', 'needle', ',', 'providing', '40', 'mg/0.4', 'mL', 'HUMIRA', '.'], 'lemmatized': ['dose', 'tray', 'consists', 'single-dose', ',', '1', 'mL', 'prefilled', 'glass', 'syringe', 'fixed', 'thin', 'wall', ',', '½', 'inch', 'needle', ',', 'providing', '40', 'mg/0.4', 'mL', 'HUMIRA', '.'], 'stemmed': ['dose', 'tray', 'consist', 'single-dos', ',', '1', 'ml', 'prefil', 'glass', 'syring', 'fix', 'thin', 'wall', ',', '½', 'inch', 'needl', ',', 'provid', '40', 'mg/0.4', 'ml', 'humira', '.'], 'dependencies': [('dose', 'compound'), ('tray', 'nmod'), ('consist', 'appos'), ('single', 'amod'), ('-', 'punct'), ('dos', 'appos'), (',', 'punct'), ('1', 'nummod'), ('ml', 'appos'), ('prefil', 'compound'), ('glass', 'compound'), ('syring', 'compound'), ('fix', 'compound'), ('thin', 'amod'), ('wall', 'ROOT'), (',', 'punct'), ('½', 'compound'), ('inch', 'nsubj'), ('needl', 'appos'), (',', 'punct'), ('provid', 'appos'), ('40', 'nummod'), ('mg/0.4', 'appos'), ('ml', 'compound'), ('humira', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'The black needle cover is not made with natural \\nrubber latex.', 'tokens': ['black', 'needle', 'cover', 'made', 'natural', 'rubber', 'latex', '.'], 'lemmatized': ['black', 'needle', 'cover', 'made', 'natural', 'rubber', 'latex', '.'], 'stemmed': ['black', 'needl', 'cover', 'made', 'natur', 'rubber', 'latex', '.'], 'dependencies': [('black', 'amod'), ('needl', 'compound'), ('cover', 'nsubj'), ('made', 'ROOT'), ('natur', 'compound'), ('rubber', 'compound'), ('latex', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The NDC number is 0074-0067-02.', 'tokens': ['NDC', 'number', '0074-0067-02', '.'], 'lemmatized': ['NDC', 'number', '0074-0067-02', '.'], 'stemmed': ['ndc', 'number', '0074-0067-02', '.'], 'dependencies': [('ndc', 'compound'), ('number', 'ROOT'), ('0074', 'nummod'), ('-', 'punct'), ('0067', 'appos'), ('-', 'punct'), ('02', 'prep'), ('.', 'punct')]}, {'original_sentence': '• Single-Dose Institutional Use Vial Carton - 40 mg/0.8 mL \\nHUMIRA is supplied for institutional use only in a carton containing a single-dose, glass \\nvial, providing 40 mg/0.8 mL of HUMIRA.', 'tokens': ['•', 'Single-Dose', 'Institutional', 'Use', 'Vial', 'Carton', '-', '40', 'mg/0.8', 'mL', 'HUMIRA', 'supplied', 'institutional', 'use', 'carton', 'containing', 'single-dose', ',', 'glass', 'vial', ',', 'providing', '40', 'mg/0.8', 'mL', 'HUMIRA', '.'], 'lemmatized': ['•', 'Single-Dose', 'Institutional', 'Use', 'Vial', 'Carton', '-', '40', 'mg/0.8', 'mL', 'HUMIRA', 'supplied', 'institutional', 'use', 'carton', 'containing', 'single-dose', ',', 'glass', 'vial', ',', 'providing', '40', 'mg/0.8', 'mL', 'HUMIRA', '.'], 'stemmed': ['•', 'single-dos', 'institut', 'use', 'vial', 'carton', '-', '40', 'mg/0.8', 'ml', 'humira', 'suppli', 'institut', 'use', 'carton', 'contain', 'single-dos', ',', 'glass', 'vial', ',', 'provid', '40', 'mg/0.8', 'ml', 'humira', '.'], 'dependencies': [('•', 'meta'), ('single', 'amod'), ('-', 'punct'), ('dos', 'compound'), ('institut', 'nsubj'), ('use', 'ROOT'), ('vial', 'amod'), ('carton', 'dobj'), ('-', 'punct'), ('40', 'nummod'), ('mg/0.8', 'quantmod'), ('ml', 'dep'), ('humira', 'compound'), ('suppli', 'compound'), ('institut', 'nsubj'), ('use', 'conj'), ('carton', 'compound'), ('contain', 'dobj'), ('single', 'amod'), ('-', 'punct'), ('dos', 'dobj'), (',', 'punct'), ('glass', 'compound'), ('vial', 'conj'), (',', 'punct'), ('provid', 'conj'), ('40', 'nummod'), ('mg/0.8', 'advmod'), ('ml', 'compound'), ('humira', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The vial stopper is not made with natural rubber \\nlatex.', 'tokens': ['vial', 'stopper', 'made', 'natural', 'rubber', 'latex', '.'], 'lemmatized': ['vial', 'stopper', 'made', 'natural', 'rubber', 'latex', '.'], 'stemmed': ['vial', 'stopper', 'made', 'natur', 'rubber', 'latex', '.'], 'dependencies': [('vial', 'amod'), ('stopper', 'nsubj'), ('made', 'ROOT'), ('natur', 'compound'), ('rubber', 'compound'), ('latex', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The NDC number is 0074-3797-01.', 'tokens': ['NDC', 'number', '0074-3797-01', '.'], 'lemmatized': ['NDC', 'number', '0074-3797-01', '.'], 'stemmed': ['ndc', 'number', '0074-3797-01', '.'], 'dependencies': [('ndc', 'compound'), ('number', 'ROOT'), ('0074', 'nummod'), ('-', 'punct'), ('3797', 'nummod'), ('-', 'punct'), ('01', 'prep'), ('.', 'punct')]}], 'text': '• Prefilled Syringe Carton - 40 mg/0.4 mL \\nHUMIRA is supplied in a carton containing two alcohol preps and two dose trays. Each dose \\ntray consists of a single-dose, 1 mL prefilled glass syringe with a fixed thin wall, ½ inch \\nneedle, providing 40 mg/0.4 mL of HUMIRA. The black needle cover is not made with \\nnatural rubber latex. The NDC number is 0074-0243-02.  \\n  \\n• Prefilled Syringe Carton - 20 mg/0.4 mL \\nHUMIRA is supplied in a carton containing two alcohol preps and two dose trays. Each dose \\ntray consists of a single-dose, 1 mL prefilled glass syringe with a fixed ½ inch needle, \\nproviding 20 mg/0.4 mL of HUMIRA. The needle cover may contain natural rubber latex. \\nThe NDC number is 0074-9374-02.  \\n  \\n• Prefilled Syringe Carton - 20 mg/0.2 mL \\nHUMIRA is supplied in a carton containing two alcohol preps and two dose trays. Each dose \\ntray consists of a single-dose, 1 mL prefilled glass syringe with a fixed thin wall, ½ inch \\nneedle, providing 20 mg/0.2 mL of HUMIRA. The black needle cover is not made with \\nnatural rubber latex. The NDC number is 0074-0616-02.  \\n  \\n• Prefilled Syringe Carton - 10 mg/0.2 mL \\nHUMIRA is supplied in a carton containing two alcohol preps and two dose trays. Each dose \\ntray consists of a single-dose, 1 mL prefilled glass syringe with a fixed ½ inch needle, \\nproviding 10 mg/0.2 mL of HUMIRA. The needle cover may contain natural rubber latex. \\nThe NDC number is 0074-6347-02.  \\n  \\n• Prefilled Syringe Carton - 10 mg/0.1 mL \\nHUMIRA is supplied in a carton containing two alcohol preps and two dose trays. Each dose \\ntray consists of a single-dose, 1 mL prefilled glass syringe with a fixed thin wall, ½ inch \\nneedle, providing 10 mg/0.1 mL of HUMIRA. The black needle cover is not made with \\nnatural rubber latex. The NDC number is 0074-0817-02.  \\n  \\n  \\n• HUMIRA Prefilled Syringe 80 mg/0.8 mL - Pediatric Crohn’s Disease Starter Package \\n(3 count)  \\nHUMIRA is supplied in a carton containing 4 alcohol preps and 3 dose trays (Pediatric \\nStarter Package). Each dose tray consists of a single-dose, 1 mL prefilled glass syringe with a \\nfixed thin wall, ½ inch needle, providing 80 mg/0.8 mL of HUMIRA. The black needle cover \\nis not made with natural rubber latex. The NDC number is 0074-2540-03.  \\n  \\n  \\n• HUMIRA Prefilled Syringe 80 mg/0.8 mL and 40 mg/0.4 mL - Pediatric Crohn’s \\nDisease Starter Package (2 count)  \\nHUMIRA is supplied in a carton containing 2 alcohol preps and 2 dose trays (Pediatric \\nStarter Package). One dose tray consists of a single-dose, 1 mL prefilled glass syringe with a \\nfixed thin wall, ½ inch needle, providing 80 mg/0.8 mL of HUMIRA. The other dose tray \\nconsists of a single-dose, 1 mL prefilled glass syringe with a fixed thin wall, ½ inch needle, \\nproviding 40 mg/0.4 mL of HUMIRA. The black needle cover is not made with natural \\nrubber latex. The NDC number is 0074-0067-02.  \\n  \\n• Single-Dose Institutional Use Vial Carton - 40 mg/0.8 mL \\nHUMIRA is supplied for institutional use only in a carton containing a single-dose, glass \\nvial, providing 40 mg/0.8 mL of HUMIRA. The vial stopper is not made with natural rubber \\nlatex. The NDC number is 0074-3797-01.  \\n  \\n'}, 'page_char_count': 3153, 'page_word_count': 535, 'sentences': ['• Prefilled Syringe Carton - 40 mg/0.4 mL \\nHUMIRA is supplied in a carton containing two alcohol preps and two dose trays.', 'Each dose \\ntray consists of a single-dose, 1 mL prefilled glass syringe with a fixed thin wall, ½ inch \\nneedle, providing 40 mg/0.4 mL of HUMIRA.', 'The black needle cover is not made with \\nnatural rubber latex.', 'The NDC number is 0074-0243-02.', ' \\n  \\n• Prefilled Syringe Carton - 20 mg/0.4 mL \\nHUMIRA is supplied in a carton containing two alcohol preps and two dose trays.', 'Each dose \\ntray consists of a single-dose, 1 mL prefilled glass syringe with a fixed ½ inch needle, \\nproviding 20 mg/0.4 mL of HUMIRA.', 'The needle cover may contain natural rubber latex.', '\\nThe NDC number is 0074-9374-02.', ' \\n  \\n• Prefilled Syringe Carton - 20 mg/0.2 mL \\nHUMIRA is supplied in a carton containing two alcohol preps and two dose trays.', 'Each dose \\ntray consists of a single-dose, 1 mL prefilled glass syringe with a fixed thin wall, ½ inch \\nneedle, providing 20 mg/0.2 mL of HUMIRA.', 'The black needle cover is not made with \\nnatural rubber latex.', 'The NDC number is 0074-0616-02.', ' \\n  \\n• Prefilled Syringe Carton - 10 mg/0.2 mL \\nHUMIRA is supplied in a carton containing two alcohol preps and two dose trays.', 'Each dose \\ntray consists of a single-dose, 1 mL prefilled glass syringe with a fixed ½ inch needle, \\nproviding 10 mg/0.2 mL of HUMIRA.', 'The needle cover may contain natural rubber latex.', '\\nThe NDC number is 0074-6347-02.', ' \\n  \\n• Prefilled Syringe Carton - 10 mg/0.1 mL \\nHUMIRA is supplied in a carton containing two alcohol preps and two dose trays.', 'Each dose \\ntray consists of a single-dose, 1 mL prefilled glass syringe with a fixed thin wall, ½ inch \\nneedle, providing 10 mg/0.1 mL of HUMIRA.', 'The black needle cover is not made with \\nnatural rubber latex.', 'The NDC number is 0074-0817-02.', ' \\n  \\n  \\n• HUMIRA Prefilled Syringe 80 mg/0.8 mL - Pediatric Crohn’s Disease Starter Package \\n(3 count)  \\nHUMIRA is supplied in a carton containing 4 alcohol preps and 3 dose trays (Pediatric \\nStarter Package).', 'Each dose tray consists of a single-dose, 1 mL prefilled glass syringe with a \\nfixed thin wall, ½ inch needle, providing 80 mg/0.8 mL of HUMIRA.', 'The black needle cover \\nis not made with natural rubber latex.', 'The NDC number is 0074-2540-03.', ' \\n  \\n  \\n• HUMIRA Prefilled Syringe 80 mg/0.8 mL and 40 mg/0.4 mL - Pediatric Crohn’s \\nDisease Starter Package (2 count)  \\nHUMIRA is supplied in a carton containing 2 alcohol preps and 2 dose trays (Pediatric \\nStarter Package).', 'One dose tray consists of a single-dose, 1 mL prefilled glass syringe with a \\nfixed thin wall, ½ inch needle, providing 80 mg/0.8 mL of HUMIRA.', 'The other dose tray \\nconsists of a single-dose, 1 mL prefilled glass syringe with a fixed thin wall, ½ inch needle, \\nproviding 40 mg/0.4 mL of HUMIRA.', 'The black needle cover is not made with natural \\nrubber latex.', 'The NDC number is 0074-0067-02.', ' \\n  \\n• Single-Dose Institutional Use Vial Carton - 40 mg/0.8 mL \\nHUMIRA is supplied for institutional use only in a carton containing a single-dose, glass \\nvial, providing 40 mg/0.8 mL of HUMIRA.', 'The vial stopper is not made with natural rubber \\nlatex.', 'The NDC number is 0074-3797-01.', ' \\n  \\n'], 'page_sentence_count_spacy': 33}\n",
            "{'page_number': 57, 'text': 'Storage and Stability \\nDo not use beyond the expiration date on the container. HUMIRA must be refrigerated at 36°F to \\n46°F (2°C to 8°C). DO NOT FREEZE. Do not use if frozen even if it has been thawed.  \\nStore in original carton until time of administration to protect from light.  \\nIf needed, for example when traveling, HUMIRA may be stored at room temperature up to a \\nmaximum of 77°F (25°C) for a period of up to 14 days, with protection from light. HUMIRA \\nshould be discarded if not used within the 14-day period. Record the date when HUMIRA is first \\nremoved from the refrigerator in the spaces provided on the carton and dose tray.  \\nDo not store HUMIRA in extreme heat or cold.  \\n17 PATIENT COUNSELING INFORMATION \\nAdvise the patient or caregiver to read the FDA-approved patient labeling (Medication Guide \\nand Instructions for Use).  \\nInfections \\nInform patients that HUMIRA may lower the ability of their immune system to fight infections. \\nInstruct patients of the importance of contacting their doctor if they develop any symptoms of \\ninfection, including tuberculosis, invasive fungal infections, and reactivation of hepatitis B virus \\ninfections [see Warnings and Precautions (5.1, 5.2, 5.4)].  \\n  \\nMalignancies \\nCounsel patients about the risk of malignancies while receiving HUMIRA [see Warnings and \\nPrecautions (5.2)]  \\n  \\nHypersensitivity Reactions \\nAdvise patients to seek immediate medical attention if they experience any symptoms of severe \\nhypersensitivity reactions. Advise latex-sensitive patients that the needle cap of the HUMIRA 40 \\nmg/0.8 mL Pen and 40 mg/0.8 mL, 20 mg/0.4 mL and 10 mg/0.2 mL prefilled syringe may \\ncontain natural rubber latex [see Warnings and Precautions (5.3), How Supplied/Storage and \\nHandling (16)].  \\n  \\nOther Medical Conditions \\nAdvise patients to report any signs of new or worsening medical conditions such as congestive \\nheart failure, neurological disease, autoimmune disorders, or cytopenias. Advise patients to \\nreport any symptoms suggestive of a cytopenia such as bruising, bleeding, or persistent fever \\n[see Warnings and Precautions (5.5, 5.6, 5.8, 5.9)].  \\n  \\nInstructions on Injection Technique \\nInform patients that the first injection is to be performed under the supervision of a qualified \\nhealth care professional. If a patient or caregiver is to administer HUMIRA, instruct them in \\ninjection techniques and assess their ability to inject subcutaneously to ensure the proper \\nadministration of HUMIRA [see Instructions for Use]. \\nFor patients who will use the HUMIRA Pen, tell them that they:  \\n• Will hear a loud ‘click’ when the plum-colored activator button is pressed. The loud click \\nmeans the start of the injection.  \\n', 'processed_text': {'sentences': [{'original_sentence': 'Storage and Stability \\nDo not use beyond the expiration date on the container.', 'tokens': ['Storage', 'Stability', 'use', 'beyond', 'expiration', 'date', 'container', '.'], 'lemmatized': ['Storage', 'Stability', 'use', 'beyond', 'expiration', 'date', 'container', '.'], 'stemmed': ['storag', 'stabil', 'use', 'beyond', 'expir', 'date', 'contain', '.'], 'dependencies': [('storag', 'compound'), ('stabil', 'compound'), ('use', 'nsubj'), ('beyond', 'prep'), ('expir', 'compound'), ('date', 'pobj'), ('contain', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'HUMIRA must be refrigerated at 36°F to \\n46°F (2°C to 8°C).', 'tokens': ['HUMIRA', 'must', 'refrigerated', '36°F', '46°F', '(', '2°C', '8°C', ')', '.'], 'lemmatized': ['HUMIRA', 'must', 'refrigerated', '36°F', '46°F', '(', '2°C', '8°C', ')', '.'], 'stemmed': ['humira', 'must', 'refriger', '36°f', '46°f', '(', '2°c', '8°c', ')', '.'], 'dependencies': [('humira', 'nsubj'), ('must', 'aux'), ('refriger', 'ROOT'), ('36', 'npadvmod'), ('°', 'npadvmod'), ('f', 'npadvmod'), ('46', 'nummod'), ('°', 'npadvmod'), ('f', 'npadvmod'), ('(', 'punct'), ('2', 'appos'), ('°', 'npadvmod'), ('c', 'npadvmod'), ('8', 'npadvmod'), ('°', 'dobj'), ('c', 'dobj'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'DO NOT FREEZE.', 'tokens': ['FREEZE', '.'], 'lemmatized': ['FREEZE', '.'], 'stemmed': ['freez', '.'], 'dependencies': [('freez', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Do not use if frozen even if it has been thawed.', 'tokens': ['use', 'frozen', 'even', 'thawed', '.'], 'lemmatized': ['use', 'frozen', 'even', 'thawed', '.'], 'stemmed': ['use', 'frozen', 'even', 'thaw', '.'], 'dependencies': [('use', 'ROOT'), ('frozen', 'xcomp'), ('even', 'advmod'), ('thaw', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Store in original carton until time of administration to protect from light.', 'tokens': ['Store', 'original', 'carton', 'time', 'administration', 'protect', 'light', '.'], 'lemmatized': ['Store', 'original', 'carton', 'time', 'administration', 'protect', 'light', '.'], 'stemmed': ['store', 'origin', 'carton', 'time', 'administr', 'protect', 'light', '.'], 'dependencies': [('store', 'compound'), ('origin', 'compound'), ('carton', 'compound'), ('time', 'npadvmod'), ('administr', 'nsubj'), ('protect', 'ROOT'), ('light', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'If needed, for example when traveling, HUMIRA may be stored at room temperature up to a \\nmaximum of 77°F (25°C) for a period of up to 14 days, with protection from light.', 'tokens': ['needed', ',', 'example', 'traveling', ',', 'HUMIRA', 'may', 'stored', 'room', 'temperature', 'maximum', '77°F', '(', '25°C', ')', 'period', '14', 'days', ',', 'protection', 'light', '.'], 'lemmatized': ['needed', ',', 'example', 'traveling', ',', 'HUMIRA', 'may', 'stored', 'room', 'temperature', 'maximum', '77°F', '(', '25°C', ')', 'period', '14', 'day', ',', 'protection', 'light', '.'], 'stemmed': ['need', ',', 'exampl', 'travel', ',', 'humira', 'may', 'store', 'room', 'temperatur', 'maximum', '77°f', '(', '25°c', ')', 'period', '14', 'day', ',', 'protect', 'light', '.'], 'dependencies': [('need', 'advcl'), (',', 'punct'), ('exampl', 'nsubj'), ('travel', 'meta'), (',', 'punct'), ('humira', 'nsubj'), ('may', 'aux'), ('store', 'ROOT'), ('room', 'dobj'), ('temperatur', 'compound'), ('maximum', 'dobj'), ('77', 'nummod'), ('°', 'npadvmod'), ('f', 'dobj'), ('(', 'punct'), ('25', 'nummod'), ('°', 'nmod'), ('c', 'appos'), (')', 'punct'), ('period', 'dobj'), ('14', 'nummod'), ('day', 'npadvmod'), (',', 'punct'), ('protect', 'conj'), ('light', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'HUMIRA \\nshould be discarded if not used within the 14-day period.', 'tokens': ['HUMIRA', 'discarded', 'used', 'within', '14-day', 'period', '.'], 'lemmatized': ['HUMIRA', 'discarded', 'used', 'within', '14-day', 'period', '.'], 'stemmed': ['humira', 'discard', 'use', 'within', '14-day', 'period', '.'], 'dependencies': [('humira', 'compound'), ('discard', 'nsubj'), ('use', 'ROOT'), ('within', 'prep'), ('14', 'nummod'), ('-', 'punct'), ('day', 'compound'), ('period', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'Record the date when HUMIRA is first \\nremoved from the refrigerator in the spaces provided on the carton and dose tray.', 'tokens': ['Record', 'date', 'HUMIRA', 'first', 'removed', 'refrigerator', 'spaces', 'provided', 'carton', 'dose', 'tray', '.'], 'lemmatized': ['Record', 'date', 'HUMIRA', 'first', 'removed', 'refrigerator', 'space', 'provided', 'carton', 'dose', 'tray', '.'], 'stemmed': ['record', 'date', 'humira', 'first', 'remov', 'refriger', 'space', 'provid', 'carton', 'dose', 'tray', '.'], 'dependencies': [('record', 'compound'), ('date', 'compound'), ('humira', 'compound'), ('first', 'advmod'), ('remov', 'compound'), ('refriger', 'compound'), ('space', 'compound'), ('provid', 'compound'), ('carton', 'compound'), ('dose', 'compound'), ('tray', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Do not store HUMIRA in extreme heat or cold.', 'tokens': ['store', 'HUMIRA', 'extreme', 'heat', 'cold', '.'], 'lemmatized': ['store', 'HUMIRA', 'extreme', 'heat', 'cold', '.'], 'stemmed': ['store', 'humira', 'extrem', 'heat', 'cold', '.'], 'dependencies': [('store', 'compound'), ('humira', 'compound'), ('extrem', 'compound'), ('heat', 'compound'), ('cold', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '17 PATIENT COUNSELING INFORMATION \\nAdvise the patient or caregiver to read the FDA-approved patient labeling (Medication Guide \\nand Instructions for Use).', 'tokens': ['17', 'PATIENT', 'COUNSELING', 'INFORMATION', 'Advise', 'patient', 'caregiver', 'read', 'FDA-approved', 'patient', 'labeling', '(', 'Medication', 'Guide', 'Instructions', 'Use', ')', '.'], 'lemmatized': ['17', 'PATIENT', 'COUNSELING', 'INFORMATION', 'Advise', 'patient', 'caregiver', 'read', 'FDA-approved', 'patient', 'labeling', '(', 'Medication', 'Guide', 'Instructions', 'Use', ')', '.'], 'stemmed': ['17', 'patient', 'counsel', 'inform', 'advis', 'patient', 'caregiv', 'read', 'fda-approv', 'patient', 'label', '(', 'medic', 'guid', 'instruct', 'use', ')', '.'], 'dependencies': [('17', 'nummod'), ('patient', 'amod'), ('counsel', 'compound'), ('inform', 'compound'), ('advis', 'nmod'), ('patient', 'compound'), ('caregiv', 'nsubj'), ('read', 'ROOT'), ('fda', 'compound'), ('-', 'punct'), ('approv', 'amod'), ('patient', 'amod'), ('label', 'dobj'), ('(', 'punct'), ('medic', 'compound'), ('guid', 'amod'), ('instruct', 'compound'), ('use', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Infections \\nInform patients that HUMIRA may lower the ability of their immune system to fight infections.', 'tokens': ['Infections', 'Inform', 'patients', 'HUMIRA', 'may', 'lower', 'ability', 'immune', 'system', 'fight', 'infections', '.'], 'lemmatized': ['Infections', 'Inform', 'patient', 'HUMIRA', 'may', 'lower', 'ability', 'immune', 'system', 'fight', 'infection', '.'], 'stemmed': ['infect', 'inform', 'patient', 'humira', 'may', 'lower', 'abil', 'immun', 'system', 'fight', 'infect', '.'], 'dependencies': [('infect', 'amod'), ('inform', 'dobj'), ('patient', 'compound'), ('humira', 'nsubj'), ('may', 'aux'), ('lower', 'ROOT'), ('abil', 'compound'), ('immun', 'compound'), ('system', 'compound'), ('fight', 'nsubj'), ('infect', 'ccomp'), ('.', 'punct')]}, {'original_sentence': 'Instruct patients of the importance of contacting their doctor if they develop any symptoms of \\ninfection, including tuberculosis, invasive fungal infections, and reactivation of hepatitis B virus \\ninfections [see Warnings and Precautions (5.1, 5.2, 5.4)].', 'tokens': ['Instruct', 'patients', 'importance', 'contacting', 'doctor', 'develop', 'symptoms', 'infection', ',', 'including', 'tuberculosis', ',', 'invasive', 'fungal', 'infections', ',', 'reactivation', 'hepatitis', 'B', 'virus', 'infections', '[', 'see', 'Warnings', 'Precautions', '(', '5.1', ',', '5.2', ',', '5.4', ')', ']', '.'], 'lemmatized': ['Instruct', 'patient', 'importance', 'contacting', 'doctor', 'develop', 'symptom', 'infection', ',', 'including', 'tuberculosis', ',', 'invasive', 'fungal', 'infection', ',', 'reactivation', 'hepatitis', 'B', 'virus', 'infection', '[', 'see', 'Warnings', 'Precautions', '(', '5.1', ',', '5.2', ',', '5.4', ')', ']', '.'], 'stemmed': ['instruct', 'patient', 'import', 'contact', 'doctor', 'develop', 'symptom', 'infect', ',', 'includ', 'tuberculosi', ',', 'invas', 'fungal', 'infect', ',', 'reactiv', 'hepat', 'b', 'viru', 'infect', '[', 'see', 'warn', 'precaut', '(', '5.1', ',', '5.2', ',', '5.4', ')', ']', '.'], 'dependencies': [('instruct', 'ROOT'), ('patient', 'amod'), ('import', 'compound'), ('contact', 'compound'), ('doctor', 'nsubj'), ('develop', 'ccomp'), ('symptom', 'compound'), ('infect', 'dobj'), (',', 'punct'), ('includ', 'compound'), ('tuberculosi', 'conj'), (',', 'punct'), ('invas', 'compound'), ('fungal', 'compound'), ('infect', 'conj'), (',', 'punct'), ('reactiv', 'compound'), ('hepat', 'compound'), ('b', 'compound'), ('viru', 'compound'), ('infect', 'conj'), ('[', 'punct'), ('see', 'parataxis'), ('warn', 'compound'), ('precaut', 'dobj'), ('(', 'punct'), ('5.1', 'appos'), (',', 'punct'), ('5.2', 'conj'), (',', 'punct'), ('5.4', 'npadvmod'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Malignancies \\nCounsel patients about the risk of malignancies while receiving HUMIRA [see Warnings and \\nPrecautions (5.2)]  \\n  \\nHypersensitivity Reactions \\nAdvise patients to seek immediate medical attention if they experience any symptoms of severe \\nhypersensitivity reactions.', 'tokens': ['Malignancies', 'Counsel', 'patients', 'risk', 'malignancies', 'receiving', 'HUMIRA', '[', 'see', 'Warnings', 'Precautions', '(', '5.2', ')', ']', 'Hypersensitivity', 'Reactions', 'Advise', 'patients', 'seek', 'immediate', 'medical', 'attention', 'experience', 'symptoms', 'severe', 'hypersensitivity', 'reactions', '.'], 'lemmatized': ['Malignancies', 'Counsel', 'patient', 'risk', 'malignancy', 'receiving', 'HUMIRA', '[', 'see', 'Warnings', 'Precautions', '(', '5.2', ')', ']', 'Hypersensitivity', 'Reactions', 'Advise', 'patient', 'seek', 'immediate', 'medical', 'attention', 'experience', 'symptom', 'severe', 'hypersensitivity', 'reaction', '.'], 'stemmed': ['malign', 'counsel', 'patient', 'risk', 'malign', 'receiv', 'humira', '[', 'see', 'warn', 'precaut', '(', '5.2', ')', ']', 'hypersensit', 'reaction', 'advis', 'patient', 'seek', 'immedi', 'medic', 'attent', 'experi', 'symptom', 'sever', 'hypersensit', 'reaction', '.'], 'dependencies': [('malign', 'compound'), ('counsel', 'compound'), ('patient', 'compound'), ('risk', 'compound'), ('malign', 'compound'), ('receiv', 'compound'), ('humira', 'nsubj'), ('[', 'punct'), ('see', 'ROOT'), ('warn', 'xcomp'), ('precaut', 'dobj'), ('(', 'punct'), ('5.2', 'nsubj'), (')', 'punct'), (']', 'punct'), ('hypersensit', 'compound'), ('reaction', 'nmod'), ('advis', 'nmod'), ('patient', 'appos'), ('seek', 'ccomp'), ('immedi', 'compound'), ('medic', 'compound'), ('attent', 'compound'), ('experi', 'compound'), ('symptom', 'compound'), ('sever', 'compound'), ('hypersensit', 'compound'), ('reaction', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Advise latex-sensitive patients that the needle cap of the HUMIRA 40 \\nmg/0.8 mL Pen and 40 mg/0.8 mL, 20 mg/0.4 mL and 10 mg/0.2 mL prefilled syringe may \\ncontain natural rubber latex [see Warnings and Precautions (5.3), How Supplied/Storage and \\nHandling (16)].', 'tokens': ['Advise', 'latex-sensitive', 'patients', 'needle', 'cap', 'HUMIRA', '40', 'mg/0.8', 'mL', 'Pen', '40', 'mg/0.8', 'mL', ',', '20', 'mg/0.4', 'mL', '10', 'mg/0.2', 'mL', 'prefilled', 'syringe', 'may', 'contain', 'natural', 'rubber', 'latex', '[', 'see', 'Warnings', 'Precautions', '(', '5.3', ')', ',', 'Supplied/Storage', 'Handling', '(', '16', ')', ']', '.'], 'lemmatized': ['Advise', 'latex-sensitive', 'patient', 'needle', 'cap', 'HUMIRA', '40', 'mg/0.8', 'mL', 'Pen', '40', 'mg/0.8', 'mL', ',', '20', 'mg/0.4', 'mL', '10', 'mg/0.2', 'mL', 'prefilled', 'syringe', 'may', 'contain', 'natural', 'rubber', 'latex', '[', 'see', 'Warnings', 'Precautions', '(', '5.3', ')', ',', 'Supplied/Storage', 'Handling', '(', '16', ')', ']', '.'], 'stemmed': ['advis', 'latex-sensit', 'patient', 'needl', 'cap', 'humira', '40', 'mg/0.8', 'ml', 'pen', '40', 'mg/0.8', 'ml', ',', '20', 'mg/0.4', 'ml', '10', 'mg/0.2', 'ml', 'prefil', 'syring', 'may', 'contain', 'natur', 'rubber', 'latex', '[', 'see', 'warn', 'precaut', '(', '5.3', ')', ',', 'supplied/storag', 'handl', '(', '16', ')', ']', '.'], 'dependencies': [('advis', 'compound'), ('latex', 'compound'), ('-', 'punct'), ('sensit', 'compound'), ('patient', 'nsubj'), ('needl', 'nsubj'), ('cap', 'compound'), ('humira', 'dobj'), ('40', 'nummod'), ('mg/0.8', 'dep'), ('ml', 'aux'), ('pen', 'ccomp'), ('40', 'nummod'), ('mg/0.8', 'quantmod'), ('ml', 'dobj'), (',', 'punct'), ('20', 'nummod'), ('mg/0.4', 'punct'), ('ml', 'ROOT'), ('10', 'nummod'), ('mg/0.2', 'npadvmod'), ('ml', 'nmod'), ('prefil', 'compound'), ('syring', 'nsubj'), ('may', 'aux'), ('contain', 'ROOT'), ('natur', 'compound'), ('rubber', 'compound'), ('latex', 'dobj'), ('[', 'punct'), ('see', 'ROOT'), ('warn', 'dep'), ('precaut', 'dobj'), ('(', 'punct'), ('5.3', 'dobj'), (')', 'punct'), (',', 'punct'), ('supplied', 'amod'), ('/', 'punct'), ('storag', 'compound'), ('handl', 'conj'), ('(', 'punct'), ('16', 'appos'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Other Medical Conditions \\nAdvise patients to report any signs of new or worsening medical conditions such as congestive \\nheart failure, neurological disease, autoimmune disorders, or cytopenias.', 'tokens': ['Medical', 'Conditions', 'Advise', 'patients', 'report', 'signs', 'new', 'worsening', 'medical', 'conditions', 'congestive', 'heart', 'failure', ',', 'neurological', 'disease', ',', 'autoimmune', 'disorders', ',', 'cytopenias', '.'], 'lemmatized': ['Medical', 'Conditions', 'Advise', 'patient', 'report', 'sign', 'new', 'worsening', 'medical', 'condition', 'congestive', 'heart', 'failure', ',', 'neurological', 'disease', ',', 'autoimmune', 'disorder', ',', 'cytopenia', '.'], 'stemmed': ['medic', 'condit', 'advis', 'patient', 'report', 'sign', 'new', 'worsen', 'medic', 'condit', 'congest', 'heart', 'failur', ',', 'neurolog', 'diseas', ',', 'autoimmun', 'disord', ',', 'cytopenia', '.'], 'dependencies': [('medic', 'npadvmod'), ('condit', 'nmod'), ('advis', 'nmod'), ('patient', 'compound'), ('report', 'compound'), ('sign', 'ROOT'), ('new', 'compound'), ('worsen', 'compound'), ('medic', 'compound'), ('condit', 'compound'), ('congest', 'compound'), ('heart', 'compound'), ('failur', 'dobj'), (',', 'punct'), ('neurolog', 'compound'), ('diseas', 'conj'), (',', 'punct'), ('autoimmun', 'amod'), ('disord', 'conj'), (',', 'punct'), ('cytopenia', 'conj'), ('.', 'punct')]}, {'original_sentence': 'Advise patients to \\nreport any symptoms suggestive of a cytopenia such as bruising, bleeding, or persistent fever \\n[see Warnings and Precautions (5.5, 5.6, 5.8, 5.9)].', 'tokens': ['Advise', 'patients', 'report', 'symptoms', 'suggestive', 'cytopenia', 'bruising', ',', 'bleeding', ',', 'persistent', 'fever', '[', 'see', 'Warnings', 'Precautions', '(', '5.5', ',', '5.6', ',', '5.8', ',', '5.9', ')', ']', '.'], 'lemmatized': ['Advise', 'patient', 'report', 'symptom', 'suggestive', 'cytopenia', 'bruising', ',', 'bleeding', ',', 'persistent', 'fever', '[', 'see', 'Warnings', 'Precautions', '(', '5.5', ',', '5.6', ',', '5.8', ',', '5.9', ')', ']', '.'], 'stemmed': ['advis', 'patient', 'report', 'symptom', 'suggest', 'cytopenia', 'bruis', ',', 'bleed', ',', 'persist', 'fever', '[', 'see', 'warn', 'precaut', '(', '5.5', ',', '5.6', ',', '5.8', ',', '5.9', ')', ']', '.'], 'dependencies': [('advis', 'nmod'), ('patient', 'compound'), ('report', 'compound'), ('symptom', 'nsubj'), ('suggest', 'ROOT'), ('cytopenia', 'compound'), ('bruis', 'dobj'), (',', 'punct'), ('bleed', 'conj'), (',', 'punct'), ('persist', 'amod'), ('fever', 'conj'), ('[', 'punct'), ('see', 'parataxis'), ('warn', 'dep'), ('precaut', 'dobj'), ('(', 'punct'), ('5.5', 'npadvmod'), (',', 'punct'), ('5.6', 'npadvmod'), (',', 'punct'), ('5.8', 'conj'), (',', 'punct'), ('5.9', 'npadvmod'), (')', 'punct'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Instructions on Injection Technique \\nInform patients that the first injection is to be performed under the supervision of a qualified \\nhealth care professional.', 'tokens': ['Instructions', 'Injection', 'Technique', 'Inform', 'patients', 'first', 'injection', 'performed', 'supervision', 'qualified', 'health', 'care', 'professional', '.'], 'lemmatized': ['Instructions', 'Injection', 'Technique', 'Inform', 'patient', 'first', 'injection', 'performed', 'supervision', 'qualified', 'health', 'care', 'professional', '.'], 'stemmed': ['instruct', 'inject', 'techniqu', 'inform', 'patient', 'first', 'inject', 'perform', 'supervis', 'qualifi', 'health', 'care', 'profession', '.'], 'dependencies': [('instruct', 'ROOT'), ('inject', 'compound'), ('techniqu', 'compound'), ('inform', 'dobj'), ('patient', 'amod'), ('first', 'advmod'), ('inject', 'compound'), ('perform', 'compound'), ('supervis', 'appos'), ('qualifi', 'compound'), ('health', 'compound'), ('care', 'compound'), ('profession', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'If a patient or caregiver is to administer HUMIRA, instruct them in \\ninjection techniques and assess their ability to inject subcutaneously to ensure the proper \\nadministration of HUMIRA [see Instructions for Use].', 'tokens': ['patient', 'caregiver', 'administer', 'HUMIRA', ',', 'instruct', 'injection', 'techniques', 'assess', 'ability', 'inject', 'subcutaneously', 'ensure', 'proper', 'administration', 'HUMIRA', '[', 'see', 'Instructions', 'Use', ']', '.'], 'lemmatized': ['patient', 'caregiver', 'administer', 'HUMIRA', ',', 'instruct', 'injection', 'technique', 'assess', 'ability', 'inject', 'subcutaneously', 'ensure', 'proper', 'administration', 'HUMIRA', '[', 'see', 'Instructions', 'Use', ']', '.'], 'stemmed': ['patient', 'caregiv', 'administ', 'humira', ',', 'instruct', 'inject', 'techniqu', 'assess', 'abil', 'inject', 'subcutan', 'ensur', 'proper', 'administr', 'humira', '[', 'see', 'instruct', 'use', ']', '.'], 'dependencies': [('patient', 'compound'), ('caregiv', 'compound'), ('administ', 'compound'), ('humira', 'nsubj'), (',', 'punct'), ('instruct', 'ROOT'), ('inject', 'compound'), ('techniqu', 'compound'), ('assess', 'compound'), ('abil', 'compound'), ('inject', 'dobj'), ('subcutan', 'compound'), ('ensur', 'appos'), ('proper', 'amod'), ('administr', 'compound'), ('humira', 'dobj'), ('[', 'punct'), ('see', 'parataxis'), ('instruct', 'compound'), ('use', 'dobj'), (']', 'punct'), ('.', 'punct')]}, {'original_sentence': 'For patients who will use the HUMIRA Pen, tell them that they:  \\n• Will hear a loud ‘click’ when the plum-colored activator button is pressed.', 'tokens': ['patients', 'use', 'HUMIRA', 'Pen', ',', 'tell', ':', '•', 'hear', 'loud', '‘', 'click', '’', 'plum-colored', 'activator', 'button', 'pressed', '.'], 'lemmatized': ['patient', 'use', 'HUMIRA', 'Pen', ',', 'tell', ':', '•', 'hear', 'loud', '‘', 'click', '’', 'plum-colored', 'activator', 'button', 'pressed', '.'], 'stemmed': ['patient', 'use', 'humira', 'pen', ',', 'tell', ':', '•', 'hear', 'loud', '‘', 'click', '’', 'plum-color', 'activ', 'button', 'press', '.'], 'dependencies': [('patient', 'compound'), ('use', 'compound'), ('humira', 'compound'), ('pen', 'nsubj'), (',', 'punct'), ('tell', 'ROOT'), (':', 'punct'), ('•', 'nsubj'), ('hear', 'ccomp'), ('loud', 'advmod'), ('‘', 'punct'), ('click', 'xcomp'), ('’', 'punct'), ('plum', 'compound'), ('-', 'punct'), ('color', 'compound'), ('activ', 'compound'), ('button', 'compound'), ('press', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The loud click \\nmeans the start of the injection.', 'tokens': ['loud', 'click', 'means', 'start', 'injection', '.'], 'lemmatized': ['loud', 'click', 'mean', 'start', 'injection', '.'], 'stemmed': ['loud', 'click', 'mean', 'start', 'inject', '.'], 'dependencies': [('loud', 'advmod'), ('click', 'ROOT'), ('mean', 'advmod'), ('start', 'dep'), ('inject', 'dobj'), ('.', 'punct')]}], 'text': 'Storage and Stability \\nDo not use beyond the expiration date on the container. HUMIRA must be refrigerated at 36°F to \\n46°F (2°C to 8°C). DO NOT FREEZE. Do not use if frozen even if it has been thawed.  \\nStore in original carton until time of administration to protect from light.  \\nIf needed, for example when traveling, HUMIRA may be stored at room temperature up to a \\nmaximum of 77°F (25°C) for a period of up to 14 days, with protection from light. HUMIRA \\nshould be discarded if not used within the 14-day period. Record the date when HUMIRA is first \\nremoved from the refrigerator in the spaces provided on the carton and dose tray.  \\nDo not store HUMIRA in extreme heat or cold.  \\n17 PATIENT COUNSELING INFORMATION \\nAdvise the patient or caregiver to read the FDA-approved patient labeling (Medication Guide \\nand Instructions for Use).  \\nInfections \\nInform patients that HUMIRA may lower the ability of their immune system to fight infections. \\nInstruct patients of the importance of contacting their doctor if they develop any symptoms of \\ninfection, including tuberculosis, invasive fungal infections, and reactivation of hepatitis B virus \\ninfections [see Warnings and Precautions (5.1, 5.2, 5.4)].  \\n  \\nMalignancies \\nCounsel patients about the risk of malignancies while receiving HUMIRA [see Warnings and \\nPrecautions (5.2)]  \\n  \\nHypersensitivity Reactions \\nAdvise patients to seek immediate medical attention if they experience any symptoms of severe \\nhypersensitivity reactions. Advise latex-sensitive patients that the needle cap of the HUMIRA 40 \\nmg/0.8 mL Pen and 40 mg/0.8 mL, 20 mg/0.4 mL and 10 mg/0.2 mL prefilled syringe may \\ncontain natural rubber latex [see Warnings and Precautions (5.3), How Supplied/Storage and \\nHandling (16)].  \\n  \\nOther Medical Conditions \\nAdvise patients to report any signs of new or worsening medical conditions such as congestive \\nheart failure, neurological disease, autoimmune disorders, or cytopenias. Advise patients to \\nreport any symptoms suggestive of a cytopenia such as bruising, bleeding, or persistent fever \\n[see Warnings and Precautions (5.5, 5.6, 5.8, 5.9)].  \\n  \\nInstructions on Injection Technique \\nInform patients that the first injection is to be performed under the supervision of a qualified \\nhealth care professional. If a patient or caregiver is to administer HUMIRA, instruct them in \\ninjection techniques and assess their ability to inject subcutaneously to ensure the proper \\nadministration of HUMIRA [see Instructions for Use]. \\nFor patients who will use the HUMIRA Pen, tell them that they:  \\n• Will hear a loud ‘click’ when the plum-colored activator button is pressed. The loud click \\nmeans the start of the injection.  \\n'}, 'page_char_count': 2702, 'page_word_count': 411, 'sentences': ['Storage and Stability \\nDo not use beyond the expiration date on the container.', 'HUMIRA must be refrigerated at 36°F to \\n46°F (2°C to 8°C).', 'DO NOT FREEZE.', 'Do not use if frozen even if it has been thawed.', ' \\nStore in original carton until time of administration to protect from light.', ' \\nIf needed, for example when traveling, HUMIRA may be stored at room temperature up to a \\nmaximum of 77°F (25°C) for a period of up to 14 days, with protection from light.', 'HUMIRA \\nshould be discarded if not used within the 14-day period.', 'Record the date when HUMIRA is first \\nremoved from the refrigerator in the spaces provided on the carton and dose tray.', ' \\nDo not store HUMIRA in extreme heat or cold.', ' \\n17 PATIENT COUNSELING INFORMATION \\nAdvise the patient or caregiver to read the FDA-approved patient labeling (Medication Guide \\nand Instructions for Use).', ' \\nInfections \\nInform patients that HUMIRA may lower the ability of their immune system to fight infections.', '\\nInstruct patients of the importance of contacting their doctor if they develop any symptoms of \\ninfection, including tuberculosis, invasive fungal infections, and reactivation of hepatitis B virus \\ninfections [see Warnings and Precautions (5.1, 5.2, 5.4)].', ' \\n  \\nMalignancies \\nCounsel patients about the risk of malignancies while receiving HUMIRA [see Warnings and \\nPrecautions (5.2)]  \\n  \\nHypersensitivity Reactions \\nAdvise patients to seek immediate medical attention if they experience any symptoms of severe \\nhypersensitivity reactions.', 'Advise latex-sensitive patients that the needle cap of the HUMIRA 40 \\nmg/0.8 mL Pen and 40 mg/0.8 mL, 20 mg/0.4 mL and 10 mg/0.2 mL prefilled syringe may \\ncontain natural rubber latex [see Warnings and Precautions (5.3), How Supplied/Storage and \\nHandling (16)].', ' \\n  \\nOther Medical Conditions \\nAdvise patients to report any signs of new or worsening medical conditions such as congestive \\nheart failure, neurological disease, autoimmune disorders, or cytopenias.', 'Advise patients to \\nreport any symptoms suggestive of a cytopenia such as bruising, bleeding, or persistent fever \\n[see Warnings and Precautions (5.5, 5.6, 5.8, 5.9)].', ' \\n  \\nInstructions on Injection Technique \\nInform patients that the first injection is to be performed under the supervision of a qualified \\nhealth care professional.', 'If a patient or caregiver is to administer HUMIRA, instruct them in \\ninjection techniques and assess their ability to inject subcutaneously to ensure the proper \\nadministration of HUMIRA [see Instructions for Use].', '\\nFor patients who will use the HUMIRA Pen, tell them that they:  \\n• Will hear a loud ‘click’ when the plum-colored activator button is pressed.', 'The loud click \\nmeans the start of the injection.', ' \\n'], 'page_sentence_count_spacy': 21}\n",
            "{'page_number': 58, 'text': '• Must keep holding the HUMIRA Pen against their squeezed, raised skin until all of the \\nmedicine is injected. This can take up to 15 seconds.  \\n• Will know that the injection has finished when the yellow marker fully appears in the \\nwindow view and stops moving.  \\n  \\nInstruct patients to dispose of their used needles and syringes or used Pen in a FDA-cleared \\nsharps disposal container immediately after use. Instruct patients not to dispose of loose \\nneedles and syringes or Pen in their household trash. Instruct patients that if they do not have \\na FDA-cleared sharps disposal container, they may use a household container that is made of a \\nheavy-duty plastic, can be closed with a tight-fitting and puncture-resistant lid without sharps \\nbeing able to come out, upright and stable during use, leak-resistant, and properly labeled to \\nwarn of hazardous waste inside the container.  \\nInstruct patients that when their sharps disposal container is almost full, they will need to follow \\ntheir community guidelines for the correct way to dispose of their sharps disposal container. \\nInstruct patients that there may be state or local laws regarding disposal of used needles and \\nsyringes. Refer patients to the FDA’s website at http://www.fda.gov/safesharpsdisposal for more \\ninformation about safe sharps disposal, and for specific information about sharps disposal in the \\nstate that they live in.  \\nInstruct patients not to dispose of their used sharps disposal container in their household \\ntrash unless their community guidelines permit this. Instruct patients not to recycle their \\nused sharps disposal container. \\nAbbVie Inc.  \\nNorth Chicago, IL 60064, U.S.A.  \\nUS License Number 1889  \\n20083870 2/2024\\n', 'processed_text': {'sentences': [{'original_sentence': '• Must keep holding the HUMIRA Pen against their squeezed, raised skin until all of the \\nmedicine is injected.', 'tokens': ['•', 'Must', 'keep', 'holding', 'HUMIRA', 'Pen', 'squeezed', ',', 'raised', 'skin', 'medicine', 'injected', '.'], 'lemmatized': ['•', 'Must', 'keep', 'holding', 'HUMIRA', 'Pen', 'squeezed', ',', 'raised', 'skin', 'medicine', 'injected', '.'], 'stemmed': ['•', 'must', 'keep', 'hold', 'humira', 'pen', 'squeez', ',', 'rais', 'skin', 'medicin', 'inject', '.'], 'dependencies': [('•', 'nsubj'), ('must', 'aux'), ('keep', 'ccomp'), ('hold', 'xcomp'), ('humira', 'compound'), ('pen', 'compound'), ('squeez', 'dobj'), (',', 'punct'), ('rais', 'compound'), ('skin', 'compound'), ('medicin', 'compound'), ('inject', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'This can take up to 15 seconds.', 'tokens': ['take', '15', 'seconds', '.'], 'lemmatized': ['take', '15', 'second', '.'], 'stemmed': ['take', '15', 'second', '.'], 'dependencies': [('take', 'ROOT'), ('15', 'nummod'), ('second', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• Will know that the injection has finished when the yellow marker fully appears in the \\nwindow view and stops moving.', 'tokens': ['•', 'know', 'injection', 'finished', 'yellow', 'marker', 'fully', 'appears', 'window', 'view', 'stops', 'moving', '.'], 'lemmatized': ['•', 'know', 'injection', 'finished', 'yellow', 'marker', 'fully', 'appears', 'window', 'view', 'stop', 'moving', '.'], 'stemmed': ['•', 'know', 'inject', 'finish', 'yellow', 'marker', 'fulli', 'appear', 'window', 'view', 'stop', 'move', '.'], 'dependencies': [('•', 'meta'), ('know', 'parataxis'), ('inject', 'nsubj'), ('finish', 'compound'), ('yellow', 'amod'), ('marker', 'compound'), ('fulli', 'nsubj'), ('appear', 'ccomp'), ('window', 'compound'), ('view', 'nsubj'), ('stop', 'ROOT'), ('move', 'xcomp'), ('.', 'punct')]}, {'original_sentence': 'Instruct patients to dispose of their used needles and syringes or used Pen in a FDA-cleared \\nsharps disposal container immediately after use.', 'tokens': ['Instruct', 'patients', 'dispose', 'used', 'needles', 'syringes', 'used', 'Pen', 'FDA-cleared', 'sharps', 'disposal', 'container', 'immediately', 'use', '.'], 'lemmatized': ['Instruct', 'patient', 'dispose', 'used', 'needle', 'syrinx', 'used', 'Pen', 'FDA-cleared', 'sharp', 'disposal', 'container', 'immediately', 'use', '.'], 'stemmed': ['instruct', 'patient', 'dispos', 'use', 'needl', 'syrinx', 'use', 'pen', 'fda-clear', 'sharp', 'dispos', 'contain', 'immedi', 'use', '.'], 'dependencies': [('instruct', 'ROOT'), ('patient', 'amod'), ('dispos', 'compound'), ('use', 'dobj'), ('needl', 'dobj'), ('syrinx', 'compound'), ('use', 'compound'), ('pen', 'compound'), ('fda', 'compound'), ('-', 'punct'), ('clear', 'amod'), ('sharp', 'amod'), ('dispos', 'nsubj'), ('contain', 'ccomp'), ('immedi', 'amod'), ('use', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Instruct patients not to dispose of loose \\nneedles and syringes or Pen in their household trash.', 'tokens': ['Instruct', 'patients', 'dispose', 'loose', 'needles', 'syringes', 'Pen', 'household', 'trash', '.'], 'lemmatized': ['Instruct', 'patient', 'dispose', 'loose', 'needle', 'syrinx', 'Pen', 'household', 'trash', '.'], 'stemmed': ['instruct', 'patient', 'dispos', 'loos', 'needl', 'syrinx', 'pen', 'household', 'trash', '.'], 'dependencies': [('instruct', 'ROOT'), ('patient', 'amod'), ('dispos', 'compound'), ('loos', 'dobj'), ('needl', 'ccomp'), ('syrinx', 'compound'), ('pen', 'compound'), ('household', 'compound'), ('trash', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Instruct patients that if they do not have \\na FDA-cleared sharps disposal container, they may use a household container that is made of a \\nheavy-duty plastic, can be closed with a tight-fitting and puncture-resistant lid without sharps \\nbeing able to come out, upright and stable during use, leak-resistant, and properly labeled to \\nwarn of hazardous waste inside the container.', 'tokens': ['Instruct', 'patients', 'FDA-cleared', 'sharps', 'disposal', 'container', ',', 'may', 'use', 'household', 'container', 'made', 'heavy-duty', 'plastic', ',', 'closed', 'tight-fitting', 'puncture-resistant', 'lid', 'without', 'sharps', 'able', 'come', ',', 'upright', 'stable', 'use', ',', 'leak-resistant', ',', 'properly', 'labeled', 'warn', 'hazardous', 'waste', 'inside', 'container', '.'], 'lemmatized': ['Instruct', 'patient', 'FDA-cleared', 'sharp', 'disposal', 'container', ',', 'may', 'use', 'household', 'container', 'made', 'heavy-duty', 'plastic', ',', 'closed', 'tight-fitting', 'puncture-resistant', 'lid', 'without', 'sharp', 'able', 'come', ',', 'upright', 'stable', 'use', ',', 'leak-resistant', ',', 'properly', 'labeled', 'warn', 'hazardous', 'waste', 'inside', 'container', '.'], 'stemmed': ['instruct', 'patient', 'fda-clear', 'sharp', 'dispos', 'contain', ',', 'may', 'use', 'household', 'contain', 'made', 'heavy-duti', 'plastic', ',', 'close', 'tight-fit', 'puncture-resist', 'lid', 'without', 'sharp', 'abl', 'come', ',', 'upright', 'stabl', 'use', ',', 'leak-resist', ',', 'properli', 'label', 'warn', 'hazard', 'wast', 'insid', 'contain', '.'], 'dependencies': [('instruct', 'advcl'), ('patient', 'amod'), ('fda', 'nmod'), ('-', 'punct'), ('clear', 'amod'), ('sharp', 'amod'), ('dispos', 'nsubj'), ('contain', 'ccomp'), (',', 'punct'), ('may', 'aux'), ('use', 'ROOT'), ('household', 'compound'), ('contain', 'dobj'), ('made', 'xcomp'), ('heavy', 'amod'), ('-', 'punct'), ('duti', 'compound'), ('plastic', 'dobj'), (',', 'punct'), ('close', 'amod'), ('tight', 'amod'), ('-', 'punct'), ('fit', 'compound'), ('puncture', 'compound'), ('-', 'punct'), ('resist', 'compound'), ('lid', 'dobj'), ('without', 'prep'), ('sharp', 'amod'), ('abl', 'pobj'), ('come', 'nsubj'), (',', 'punct'), ('upright', 'amod'), ('stabl', 'amod'), ('use', 'meta'), (',', 'punct'), ('leak', 'compound'), ('-', 'punct'), ('resist', 'conj'), (',', 'punct'), ('properli', 'compound'), ('label', 'conj'), ('warn', 'conj'), ('hazard', 'compound'), ('wast', 'compound'), ('insid', 'amod'), ('contain', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Instruct patients that when their sharps disposal container is almost full, they will need to follow \\ntheir community guidelines for the correct way to dispose of their sharps disposal container.', 'tokens': ['Instruct', 'patients', 'sharps', 'disposal', 'container', 'almost', 'full', ',', 'need', 'follow', 'community', 'guidelines', 'correct', 'way', 'dispose', 'sharps', 'disposal', 'container', '.'], 'lemmatized': ['Instruct', 'patient', 'sharp', 'disposal', 'container', 'almost', 'full', ',', 'need', 'follow', 'community', 'guideline', 'correct', 'way', 'dispose', 'sharp', 'disposal', 'container', '.'], 'stemmed': ['instruct', 'patient', 'sharp', 'dispos', 'contain', 'almost', 'full', ',', 'need', 'follow', 'commun', 'guidelin', 'correct', 'way', 'dispos', 'sharp', 'dispos', 'contain', '.'], 'dependencies': [('instruct', 'ROOT'), ('patient', 'amod'), ('sharp', 'amod'), ('dispos', 'nsubj'), ('contain', 'ccomp'), ('almost', 'advmod'), ('full', 'acomp'), (',', 'punct'), ('need', 'conj'), ('follow', 'dobj'), ('commun', 'dobj'), ('guidelin', 'compound'), ('correct', 'amod'), ('way', 'compound'), ('dispos', 'compound'), ('sharp', 'amod'), ('dispos', 'nsubj'), ('contain', 'ccomp'), ('.', 'punct')]}, {'original_sentence': 'Instruct patients that there may be state or local laws regarding disposal of used needles and \\nsyringes.', 'tokens': ['Instruct', 'patients', 'may', 'state', 'local', 'laws', 'regarding', 'disposal', 'used', 'needles', 'syringes', '.'], 'lemmatized': ['Instruct', 'patient', 'may', 'state', 'local', 'law', 'regarding', 'disposal', 'used', 'needle', 'syrinx', '.'], 'stemmed': ['instruct', 'patient', 'may', 'state', 'local', 'law', 'regard', 'dispos', 'use', 'needl', 'syrinx', '.'], 'dependencies': [('instruct', 'csubj'), ('patient', 'dobj'), ('may', 'aux'), ('state', 'ROOT'), ('local', 'amod'), ('law', 'compound'), ('regard', 'compound'), ('dispos', 'compound'), ('use', 'dobj'), ('needl', 'dobj'), ('syrinx', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Refer patients to the FDA’s website at http://www.fda.gov/safesharpsdisposal for more \\ninformation about safe sharps disposal, and for specific information about sharps disposal in the \\nstate that they live in.', 'tokens': ['Refer', 'patients', 'FDA', '’', 'website', 'http', ':', '//www.fda.gov/safesharpsdisposal', 'information', 'safe', 'sharps', 'disposal', ',', 'specific', 'information', 'sharps', 'disposal', 'state', 'live', '.'], 'lemmatized': ['Refer', 'patient', 'FDA', '’', 'website', 'http', ':', '//www.fda.gov/safesharpsdisposal', 'information', 'safe', 'sharp', 'disposal', ',', 'specific', 'information', 'sharp', 'disposal', 'state', 'live', '.'], 'stemmed': ['refer', 'patient', 'fda', '’', 'websit', 'http', ':', '//www.fda.gov/safesharpsdispos', 'inform', 'safe', 'sharp', 'dispos', ',', 'specif', 'inform', 'sharp', 'dispos', 'state', 'live', '.'], 'dependencies': [('refer', 'ROOT'), ('patient', 'amod'), ('fda', 'poss'), ('’', 'punct'), ('websit', 'compound'), ('http', 'dobj'), (':', 'punct'), ('//www.fda.gov', 'nmod'), ('/', 'punct'), ('safesharpsdispos', 'nsubj'), ('inform', 'ccomp'), ('safe', 'amod'), ('sharp', 'amod'), ('dispos', 'dobj'), (',', 'punct'), ('specif', 'nsubj'), ('inform', 'conj'), ('sharp', 'amod'), ('dispos', 'compound'), ('state', 'dobj'), ('live', 'advmod'), ('.', 'punct')]}, {'original_sentence': 'Instruct patients not to dispose of their used sharps disposal container in their household \\ntrash unless their community guidelines permit this.', 'tokens': ['Instruct', 'patients', 'dispose', 'used', 'sharps', 'disposal', 'container', 'household', 'trash', 'unless', 'community', 'guidelines', 'permit', '.'], 'lemmatized': ['Instruct', 'patient', 'dispose', 'used', 'sharp', 'disposal', 'container', 'household', 'trash', 'unless', 'community', 'guideline', 'permit', '.'], 'stemmed': ['instruct', 'patient', 'dispos', 'use', 'sharp', 'dispos', 'contain', 'household', 'trash', 'unless', 'commun', 'guidelin', 'permit', '.'], 'dependencies': [('instruct', 'ROOT'), ('patient', 'amod'), ('dispos', 'nsubj'), ('use', 'ccomp'), ('sharp', 'amod'), ('dispos', 'dobj'), ('contain', 'xcomp'), ('household', 'compound'), ('trash', 'dobj'), ('unless', 'mark'), ('commun', 'amod'), ('guidelin', 'compound'), ('permit', 'advcl'), ('.', 'punct')]}, {'original_sentence': 'Instruct patients not to recycle their \\nused sharps disposal container.', 'tokens': ['Instruct', 'patients', 'recycle', 'used', 'sharps', 'disposal', 'container', '.'], 'lemmatized': ['Instruct', 'patient', 'recycle', 'used', 'sharp', 'disposal', 'container', '.'], 'stemmed': ['instruct', 'patient', 'recycl', 'use', 'sharp', 'dispos', 'contain', '.'], 'dependencies': [('instruct', 'ROOT'), ('patient', 'compound'), ('recycl', 'nsubj'), ('use', 'dobj'), ('sharp', 'amod'), ('dispos', 'nsubj'), ('contain', 'ccomp'), ('.', 'punct')]}, {'original_sentence': 'AbbVie Inc.  \\nNorth Chicago, IL 60064, U.S.A.', 'tokens': ['AbbVie', 'Inc.', 'North', 'Chicago', ',', 'IL', '60064', ',', 'U.S.A', '.'], 'lemmatized': ['AbbVie', 'Inc.', 'North', 'Chicago', ',', 'IL', '60064', ',', 'U.S.A', '.'], 'stemmed': ['abbvi', 'inc.', 'north', 'chicago', ',', 'il', '60064', ',', 'u.s.a', '.'], 'dependencies': [('abbvi', 'ROOT'), ('inc', 'compound'), ('.', 'compound'), ('north', 'compound'), ('chicago', 'dobj'), (',', 'punct'), ('il', 'npadvmod'), ('60064', 'nummod'), (',', 'punct'), ('u.s.a', 'intj'), ('.', 'punct')]}, {'original_sentence': 'US License Number 1889  \\n20083870 2/2024', 'tokens': ['US', 'License', 'Number', '1889', '20083870', '2/2024'], 'lemmatized': ['US', 'License', 'Number', '1889', '20083870', '2/2024'], 'stemmed': ['us', 'licens', 'number', '1889', '20083870', '2/2024'], 'dependencies': [('us', 'compound'), ('licens', 'compound'), ('number', 'ROOT'), ('1889', 'nummod'), ('20083870', 'nummod'), ('2/2024', 'nummod')]}], 'text': '• Must keep holding the HUMIRA Pen against their squeezed, raised skin until all of the \\nmedicine is injected. This can take up to 15 seconds.  \\n• Will know that the injection has finished when the yellow marker fully appears in the \\nwindow view and stops moving.  \\n  \\nInstruct patients to dispose of their used needles and syringes or used Pen in a FDA-cleared \\nsharps disposal container immediately after use. Instruct patients not to dispose of loose \\nneedles and syringes or Pen in their household trash. Instruct patients that if they do not have \\na FDA-cleared sharps disposal container, they may use a household container that is made of a \\nheavy-duty plastic, can be closed with a tight-fitting and puncture-resistant lid without sharps \\nbeing able to come out, upright and stable during use, leak-resistant, and properly labeled to \\nwarn of hazardous waste inside the container.  \\nInstruct patients that when their sharps disposal container is almost full, they will need to follow \\ntheir community guidelines for the correct way to dispose of their sharps disposal container. \\nInstruct patients that there may be state or local laws regarding disposal of used needles and \\nsyringes. Refer patients to the FDA’s website at http://www.fda.gov/safesharpsdisposal for more \\ninformation about safe sharps disposal, and for specific information about sharps disposal in the \\nstate that they live in.  \\nInstruct patients not to dispose of their used sharps disposal container in their household \\ntrash unless their community guidelines permit this. Instruct patients not to recycle their \\nused sharps disposal container. \\nAbbVie Inc.  \\nNorth Chicago, IL 60064, U.S.A.  \\nUS License Number 1889  \\n20083870 2/2024\\n'}, 'page_char_count': 1714, 'page_word_count': 264, 'sentences': ['• Must keep holding the HUMIRA Pen against their squeezed, raised skin until all of the \\nmedicine is injected.', 'This can take up to 15 seconds.', ' \\n• Will know that the injection has finished when the yellow marker fully appears in the \\nwindow view and stops moving.', ' \\n  \\nInstruct patients to dispose of their used needles and syringes or used Pen in a FDA-cleared \\nsharps disposal container immediately after use.', 'Instruct patients not to dispose of loose \\nneedles and syringes or Pen in their household trash.', 'Instruct patients that if they do not have \\na FDA-cleared sharps disposal container, they may use a household container that is made of a \\nheavy-duty plastic, can be closed with a tight-fitting and puncture-resistant lid without sharps \\nbeing able to come out, upright and stable during use, leak-resistant, and properly labeled to \\nwarn of hazardous waste inside the container.', ' \\nInstruct patients that when their sharps disposal container is almost full, they will need to follow \\ntheir community guidelines for the correct way to dispose of their sharps disposal container.', '\\nInstruct patients that there may be state or local laws regarding disposal of used needles and \\nsyringes.', 'Refer patients to the FDA’s website at http://www.fda.gov/safesharpsdisposal for more \\ninformation about safe sharps disposal, and for specific information about sharps disposal in the \\nstate that they live in.', ' \\nInstruct patients not to dispose of their used sharps disposal container in their household \\ntrash unless their community guidelines permit this.', 'Instruct patients not to recycle their \\nused sharps disposal container.', '\\nAbbVie Inc.  \\nNorth Chicago, IL 60064, U.S.A.  \\nUS License Number 1889  \\n20083870 2/2024\\n'], 'page_sentence_count_spacy': 12}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            " 60%|██████    | 67/111 [00:01<00:00, 70.20it/s]"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "{'page_number': 59, 'text': 'MEDICATION GUIDE \\nHUMIRA® (Hu-MARE-ah) \\n(adalimumab) \\ninjection, for subcutaneous use \\nRead the Medication Guide that comes with HUMIRA before you start taking it and each time \\nyou get a refill. There may be new information. This Medication Guide does not take the place \\nof talking with your doctor about your medical condition or treatment.  \\nWhat is the most important information I should know about HUMIRA? \\nHUMIRA is a medicine that affects your immune system. HUMIRA can lower the ability of your \\nimmune system to fight infections. Serious infections have happened in people taking \\nHUMIRA. These serious infections include tuberculosis (TB) and infections caused by \\nviruses, fungi or bacteria that have spread throughout the body. Some people have died \\nfrom these infections. \\n• Your doctor should test you for TB before starting HUMIRA. \\n• Your doctor should check you closely for signs and symptoms of TB during treatment with \\nHUMIRA. \\nYou should not start taking HUMIRA if you have any kind of infection unless your doctor says it \\nis okay.  \\nBefore starting HUMIRA, tell your doctor if you: \\n• think you have an infection or have symptoms of an infection such as: \\n  \\n◦ fever, sweats, or chills \\n◦ muscle aches \\n◦ cough \\n◦ shortness of breath \\n◦ blood in phlegm \\n◦ warm, red, or painful skin or sores on \\nyour body \\n◦ diarrhea or stomach pain \\n◦ burning when you urinate or urinate \\nmore often than normal \\n◦ feel very tired \\n◦ weight loss \\n• are being treated for an infection. \\n• get a lot of infections or have infections that keep coming back. \\n• have diabetes. \\n• have TB, or have been in close contact with someone with TB. \\n• were born in, lived in, or traveled to countries where there is more risk for getting TB. Ask \\nyour doctor if you are not sure. \\n• live or have lived in certain parts of the country (such as the Ohio and Mississippi River \\nvalleys) where there is an increased risk for getting certain kinds of fungal infections \\n(histoplasmosis, coccidioidomycosis, or blastomycosis). These infections may happen or \\nbecome more severe if you use HUMIRA. Ask your doctor if you do not know if you have \\nlived in an area where these infections are common.  \\n• have or have had hepatitis B. \\n• use the medicine ORENCIA (abatacept), KINERET (anakinra), RITUXAN (rituximab), \\nIMURAN (azathioprine), or PURINETHOL (6–mercaptopurine, 6-MP).  \\n• are scheduled to have major surgery. \\nAfter starting HUMIRA, call your doctor right away if you have an infection, or any sign of \\nan infection.  \\nHUMIRA can make you more likely to get infections or make any infection that you may have \\nworse.  \\nCancer \\n• For children and adults taking Tumor Necrosis Factor (TNF)-blockers, including HUMIRA, \\nthe chances of getting cancer may increase. \\n', 'processed_text': {'sentences': [{'original_sentence': 'MEDICATION GUIDE \\nHUMIRA® (Hu-MARE-ah) \\n(adalimumab) \\ninjection, for subcutaneous use \\nRead the Medication Guide that comes with HUMIRA before you start taking it and each time \\nyou get a refill.', 'tokens': ['MEDICATION', 'GUIDE', 'HUMIRA®', '(', 'Hu-MARE-ah', ')', '(', 'adalimumab', ')', 'injection', ',', 'subcutaneous', 'use', 'Read', 'Medication', 'Guide', 'comes', 'HUMIRA', 'start', 'taking', 'time', 'get', 'refill', '.'], 'lemmatized': ['MEDICATION', 'GUIDE', 'HUMIRA®', '(', 'Hu-MARE-ah', ')', '(', 'adalimumab', ')', 'injection', ',', 'subcutaneous', 'use', 'Read', 'Medication', 'Guide', 'come', 'HUMIRA', 'start', 'taking', 'time', 'get', 'refill', '.'], 'stemmed': ['medic', 'guid', 'humira®', '(', 'hu-mare-ah', ')', '(', 'adalimumab', ')', 'inject', ',', 'subcutan', 'use', 'read', 'medic', 'guid', 'come', 'humira', 'start', 'take', 'time', 'get', 'refil', '.'], 'dependencies': [('medic', 'compound'), ('guid', 'compound'), ('humira', 'compound'), ('®', 'nsubj'), ('(', 'punct'), ('hu', 'appos'), ('-', 'punct'), ('mare', 'dobj'), ('-', 'punct'), ('ah', 'intj'), (')', 'punct'), ('(', 'punct'), ('adalimumab', 'nmod'), (')', 'punct'), ('inject', 'appos'), (',', 'punct'), ('subcutan', 'amod'), ('use', 'conj'), ('read', 'acl'), ('medic', 'compound'), ('guid', 'compound'), ('come', 'compound'), ('humira', 'appos'), ('start', 'nsubj'), ('take', 'ROOT'), ('time', 'dobj'), ('get', 'dep'), ('refil', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'There may be new information.', 'tokens': ['may', 'new', 'information', '.'], 'lemmatized': ['may', 'new', 'information', '.'], 'stemmed': ['may', 'new', 'inform', '.'], 'dependencies': [('may', 'aux'), ('new', 'amod'), ('inform', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'This Medication Guide does not take the place \\nof talking with your doctor about your medical condition or treatment.', 'tokens': ['Medication', 'Guide', 'take', 'place', 'talking', 'doctor', 'medical', 'condition', 'treatment', '.'], 'lemmatized': ['Medication', 'Guide', 'take', 'place', 'talking', 'doctor', 'medical', 'condition', 'treatment', '.'], 'stemmed': ['medic', 'guid', 'take', 'place', 'talk', 'doctor', 'medic', 'condit', 'treatment', '.'], 'dependencies': [('medic', 'compound'), ('guid', 'compound'), ('take', 'compound'), ('place', 'compound'), ('talk', 'compound'), ('doctor', 'compound'), ('medic', 'compound'), ('condit', 'compound'), ('treatment', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'What is the most important information I should know about HUMIRA?', 'tokens': ['important', 'information', 'know', 'HUMIRA', '?'], 'lemmatized': ['important', 'information', 'know', 'HUMIRA', '?'], 'stemmed': ['import', 'inform', 'know', 'humira', '?'], 'dependencies': [('import', 'compound'), ('inform', 'nsubj'), ('know', 'ROOT'), ('humira', 'dobj'), ('?', 'punct')]}, {'original_sentence': 'HUMIRA is a medicine that affects your immune system.', 'tokens': ['HUMIRA', 'medicine', 'affects', 'immune', 'system', '.'], 'lemmatized': ['HUMIRA', 'medicine', 'affect', 'immune', 'system', '.'], 'stemmed': ['humira', 'medicin', 'affect', 'immun', 'system', '.'], 'dependencies': [('humira', 'compound'), ('medicin', 'nsubj'), ('affect', 'ROOT'), ('immun', 'compound'), ('system', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'HUMIRA can lower the ability of your \\nimmune system to fight infections.', 'tokens': ['HUMIRA', 'lower', 'ability', 'immune', 'system', 'fight', 'infections', '.'], 'lemmatized': ['HUMIRA', 'lower', 'ability', 'immune', 'system', 'fight', 'infection', '.'], 'stemmed': ['humira', 'lower', 'abil', 'immun', 'system', 'fight', 'infect', '.'], 'dependencies': [('humira', 'compound'), ('lower', 'amod'), ('abil', 'compound'), ('immun', 'compound'), ('system', 'compound'), ('fight', 'nsubj'), ('infect', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Serious infections have happened in people taking \\nHUMIRA.', 'tokens': ['Serious', 'infections', 'happened', 'people', 'taking', 'HUMIRA', '.'], 'lemmatized': ['Serious', 'infection', 'happened', 'people', 'taking', 'HUMIRA', '.'], 'stemmed': ['seriou', 'infect', 'happen', 'peopl', 'take', 'humira', '.'], 'dependencies': [('seriou', 'compound'), ('infect', 'ROOT'), ('happen', 'compound'), ('peopl', 'compound'), ('take', 'compound'), ('humira', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'These serious infections include tuberculosis (TB) and infections caused by \\nviruses, fungi or bacteria that have spread throughout the body.', 'tokens': ['serious', 'infections', 'include', 'tuberculosis', '(', 'TB', ')', 'infections', 'caused', 'viruses', ',', 'fungi', 'bacteria', 'spread', 'throughout', 'body', '.'], 'lemmatized': ['serious', 'infection', 'include', 'tuberculosis', '(', 'TB', ')', 'infection', 'caused', 'virus', ',', 'fungi', 'bacteria', 'spread', 'throughout', 'body', '.'], 'stemmed': ['seriou', 'infect', 'includ', 'tuberculosi', '(', 'tb', ')', 'infect', 'caus', 'viru', ',', 'fungi', 'bacteria', 'spread', 'throughout', 'bodi', '.'], 'dependencies': [('seriou', 'nsubj'), ('infect', 'ccomp'), ('includ', 'compound'), ('tuberculosi', 'nsubj'), ('(', 'punct'), ('tb', 'appos'), (')', 'punct'), ('infect', 'ccomp'), ('caus', 'compound'), ('viru', 'dobj'), (',', 'punct'), ('fungi', 'compound'), ('bacteria', 'nsubj'), ('spread', 'ROOT'), ('throughout', 'prep'), ('bodi', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'Some people have died \\nfrom these infections.', 'tokens': ['people', 'died', 'infections', '.'], 'lemmatized': ['people', 'died', 'infection', '.'], 'stemmed': ['peopl', 'die', 'infect', '.'], 'dependencies': [('peopl', 'compound'), ('die', 'compound'), ('infect', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• Your doctor should test you for TB before starting HUMIRA.', 'tokens': ['•', 'doctor', 'test', 'TB', 'starting', 'HUMIRA', '.'], 'lemmatized': ['•', 'doctor', 'test', 'TB', 'starting', 'HUMIRA', '.'], 'stemmed': ['•', 'doctor', 'test', 'tb', 'start', 'humira', '.'], 'dependencies': [('•', 'nummod'), ('doctor', 'compound'), ('test', 'ROOT'), ('tb', 'compound'), ('start', 'compound'), ('humira', 'appos'), ('.', 'punct')]}, {'original_sentence': '• Your doctor should check you closely for signs and symptoms of TB during treatment with \\nHUMIRA.', 'tokens': ['•', 'doctor', 'check', 'closely', 'signs', 'symptoms', 'TB', 'treatment', 'HUMIRA', '.'], 'lemmatized': ['•', 'doctor', 'check', 'closely', 'sign', 'symptom', 'TB', 'treatment', 'HUMIRA', '.'], 'stemmed': ['•', 'doctor', 'check', 'close', 'sign', 'symptom', 'tb', 'treatment', 'humira', '.'], 'dependencies': [('•', 'nummod'), ('doctor', 'nsubj'), ('check', 'ROOT'), ('close', 'amod'), ('sign', 'compound'), ('symptom', 'compound'), ('tb', 'compound'), ('treatment', 'compound'), ('humira', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'You should not start taking HUMIRA if you have any kind of infection unless your doctor says it \\nis okay.', 'tokens': ['start', 'taking', 'HUMIRA', 'kind', 'infection', 'unless', 'doctor', 'says', 'okay', '.'], 'lemmatized': ['start', 'taking', 'HUMIRA', 'kind', 'infection', 'unless', 'doctor', 'say', 'okay', '.'], 'stemmed': ['start', 'take', 'humira', 'kind', 'infect', 'unless', 'doctor', 'say', 'okay', '.'], 'dependencies': [('start', 'ROOT'), ('take', 'xcomp'), ('humira', 'dobj'), ('kind', 'advmod'), ('infect', 'dobj'), ('unless', 'mark'), ('doctor', 'nsubj'), ('say', 'advcl'), ('okay', 'intj'), ('.', 'punct')]}, {'original_sentence': 'Before starting HUMIRA, tell your doctor if you: \\n• think you have an infection or have symptoms of an infection such as: \\n  \\n◦ fever, sweats, or chills \\n◦ muscle aches \\n◦ cough \\n◦ shortness of breath \\n◦ blood in phlegm \\n◦ warm, red, or painful skin or sores on \\nyour body \\n◦ diarrhea or stomach pain \\n◦ burning when you urinate or urinate \\nmore often than normal \\n◦ feel very tired \\n◦ weight loss \\n• are being treated for an infection.', 'tokens': ['starting', 'HUMIRA', ',', 'tell', 'doctor', ':', '•', 'think', 'infection', 'symptoms', 'infection', ':', '◦', 'fever', ',', 'sweats', ',', 'chills', '◦', 'muscle', 'aches', '◦', 'cough', '◦', 'shortness', 'breath', '◦', 'blood', 'phlegm', '◦', 'warm', ',', 'red', ',', 'painful', 'skin', 'sores', 'body', '◦', 'diarrhea', 'stomach', 'pain', '◦', 'burning', 'urinate', 'urinate', 'often', 'normal', '◦', 'feel', 'tired', '◦', 'weight', 'loss', '•', 'treated', 'infection', '.'], 'lemmatized': ['starting', 'HUMIRA', ',', 'tell', 'doctor', ':', '•', 'think', 'infection', 'symptom', 'infection', ':', '◦', 'fever', ',', 'sweat', ',', 'chill', '◦', 'muscle', 'ache', '◦', 'cough', '◦', 'shortness', 'breath', '◦', 'blood', 'phlegm', '◦', 'warm', ',', 'red', ',', 'painful', 'skin', 'sore', 'body', '◦', 'diarrhea', 'stomach', 'pain', '◦', 'burning', 'urinate', 'urinate', 'often', 'normal', '◦', 'feel', 'tired', '◦', 'weight', 'loss', '•', 'treated', 'infection', '.'], 'stemmed': ['start', 'humira', ',', 'tell', 'doctor', ':', '•', 'think', 'infect', 'symptom', 'infect', ':', '◦', 'fever', ',', 'sweat', ',', 'chill', '◦', 'muscl', 'ach', '◦', 'cough', '◦', 'short', 'breath', '◦', 'blood', 'phlegm', '◦', 'warm', ',', 'red', ',', 'pain', 'skin', 'sore', 'bodi', '◦', 'diarrhea', 'stomach', 'pain', '◦', 'burn', 'urin', 'urin', 'often', 'normal', '◦', 'feel', 'tire', '◦', 'weight', 'loss', '•', 'treat', 'infect', '.'], 'dependencies': [('start', 'advcl'), ('humira', 'dobj'), (',', 'punct'), ('tell', 'ROOT'), ('doctor', 'dobj'), (':', 'punct'), ('•', 'nsubj'), ('think', 'ccomp'), ('infect', 'compound'), ('symptom', 'compound'), ('infect', 'dobj'), (':', 'punct'), ('◦', 'compound'), ('fever', 'appos'), (',', 'punct'), ('sweat', 'conj'), (',', 'punct'), ('chill', 'compound'), ('◦', 'conj'), ('muscl', 'compound'), ('ach', 'compound'), ('◦', 'compound'), ('cough', 'compound'), ('◦', 'dep'), ('short', 'amod'), ('breath', 'compound'), ('◦', 'compound'), ('blood', 'compound'), ('phlegm', 'nsubj'), ('◦', 'dep'), ('warm', 'amod'), (',', 'punct'), ('red', 'conj'), (',', 'punct'), ('pain', 'compound'), ('skin', 'conj'), ('sore', 'amod'), ('bodi', 'nsubj'), ('◦', 'ROOT'), ('diarrhea', 'compound'), ('stomach', 'compound'), ('pain', 'compound'), ('◦', 'compound'), ('burn', 'compound'), ('urin', 'compound'), ('urin', 'nsubj'), ('often', 'advmod'), ('normal', 'amod'), ('◦', 'nsubj'), ('feel', 'ccomp'), ('tire', 'compound'), ('◦', 'compound'), ('weight', 'compound'), ('loss', 'compound'), ('•', 'appos'), ('treat', 'compound'), ('infect', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• get a lot of infections or have infections that keep coming back.', 'tokens': ['•', 'get', 'lot', 'infections', 'infections', 'keep', 'coming', 'back', '.'], 'lemmatized': ['•', 'get', 'lot', 'infection', 'infection', 'keep', 'coming', 'back', '.'], 'stemmed': ['•', 'get', 'lot', 'infect', 'infect', 'keep', 'come', 'back', '.'], 'dependencies': [('•', 'meta'), ('get', 'ROOT'), ('lot', 'npadvmod'), ('infect', 'amod'), ('infect', 'compound'), ('keep', 'nsubj'), ('come', 'ccomp'), ('back', 'advmod'), ('.', 'punct')]}, {'original_sentence': '• have diabetes.', 'tokens': ['•', 'diabetes', '.'], 'lemmatized': ['•', 'diabetes', '.'], 'stemmed': ['•', 'diabet', '.'], 'dependencies': [('•', 'nummod'), ('diabet', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• have TB, or have been in close contact with someone with TB.', 'tokens': ['•', 'TB', ',', 'close', 'contact', 'someone', 'TB', '.'], 'lemmatized': ['•', 'TB', ',', 'close', 'contact', 'someone', 'TB', '.'], 'stemmed': ['•', 'tb', ',', 'close', 'contact', 'someon', 'tb', '.'], 'dependencies': [('•', 'npadvmod'), ('tb', 'ROOT'), (',', 'punct'), ('close', 'amod'), ('contact', 'compound'), ('someon', 'compound'), ('tb', 'conj'), ('.', 'punct')]}, {'original_sentence': '• were born in, lived in, or traveled to countries where there is more risk for getting TB.', 'tokens': ['•', 'born', ',', 'lived', ',', 'traveled', 'countries', 'risk', 'getting', 'TB', '.'], 'lemmatized': ['•', 'born', ',', 'lived', ',', 'traveled', 'country', 'risk', 'getting', 'TB', '.'], 'stemmed': ['•', 'born', ',', 'live', ',', 'travel', 'countri', 'risk', 'get', 'tb', '.'], 'dependencies': [('•', 'dep'), ('born', 'amod'), (',', 'punct'), ('live', 'advcl'), (',', 'punct'), ('travel', 'ROOT'), ('countri', 'amod'), ('risk', 'dobj'), ('get', 'acl'), ('tb', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Ask \\nyour doctor if you are not sure.', 'tokens': ['Ask', 'doctor', 'sure', '.'], 'lemmatized': ['Ask', 'doctor', 'sure', '.'], 'stemmed': ['ask', 'doctor', 'sure', '.'], 'dependencies': [('ask', 'ROOT'), ('doctor', 'dobj'), ('sure', 'oprd'), ('.', 'punct')]}, {'original_sentence': '• live or have lived in certain parts of the country (such as the Ohio and Mississippi River \\nvalleys) where there is an increased risk for getting certain kinds of fungal infections \\n(histoplasmosis, coccidioidomycosis, or blastomycosis).', 'tokens': ['•', 'live', 'lived', 'certain', 'parts', 'country', '(', 'Ohio', 'Mississippi', 'River', 'valleys', ')', 'increased', 'risk', 'getting', 'certain', 'kinds', 'fungal', 'infections', '(', 'histoplasmosis', ',', 'coccidioidomycosis', ',', 'blastomycosis', ')', '.'], 'lemmatized': ['•', 'live', 'lived', 'certain', 'part', 'country', '(', 'Ohio', 'Mississippi', 'River', 'valley', ')', 'increased', 'risk', 'getting', 'certain', 'kind', 'fungal', 'infection', '(', 'histoplasmosis', ',', 'coccidioidomycosis', ',', 'blastomycosis', ')', '.'], 'stemmed': ['•', 'live', 'live', 'certain', 'part', 'countri', '(', 'ohio', 'mississippi', 'river', 'valley', ')', 'increas', 'risk', 'get', 'certain', 'kind', 'fungal', 'infect', '(', 'histoplasmosi', ',', 'coccidioidomycosi', ',', 'blastomycosi', ')', '.'], 'dependencies': [('•', 'neg'), ('live', 'advcl'), ('live', 'advmod'), ('certain', 'amod'), ('part', 'npadvmod'), ('countri', 'amod'), ('(', 'punct'), ('ohio', 'compound'), ('mississippi', 'compound'), ('river', 'compound'), ('valley', 'appos'), (')', 'punct'), ('increas', 'compound'), ('risk', 'nsubj'), ('get', 'ROOT'), ('certain', 'amod'), ('kind', 'nmod'), ('fungal', 'amod'), ('infect', 'dobj'), ('(', 'punct'), ('histoplasmosi', 'appos'), (',', 'punct'), ('coccidioidomycosi', 'conj'), (',', 'punct'), ('blastomycosi', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'These infections may happen or \\nbecome more severe if you use HUMIRA.', 'tokens': ['infections', 'may', 'happen', 'become', 'severe', 'use', 'HUMIRA', '.'], 'lemmatized': ['infection', 'may', 'happen', 'become', 'severe', 'use', 'HUMIRA', '.'], 'stemmed': ['infect', 'may', 'happen', 'becom', 'sever', 'use', 'humira', '.'], 'dependencies': [('infect', 'nsubj'), ('may', 'aux'), ('happen', 'ROOT'), ('becom', 'compound'), ('sever', 'compound'), ('use', 'dobj'), ('humira', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Ask your doctor if you do not know if you have \\nlived in an area where these infections are common.', 'tokens': ['Ask', 'doctor', 'know', 'lived', 'area', 'infections', 'common', '.'], 'lemmatized': ['Ask', 'doctor', 'know', 'lived', 'area', 'infection', 'common', '.'], 'stemmed': ['ask', 'doctor', 'know', 'live', 'area', 'infect', 'common', '.'], 'dependencies': [('ask', 'ROOT'), ('doctor', 'nsubj'), ('know', 'dep'), ('live', 'amod'), ('area', 'nsubj'), ('infect', 'ccomp'), ('common', 'acomp'), ('.', 'punct')]}, {'original_sentence': '• have or have had hepatitis B.', 'tokens': ['•', 'hepatitis', 'B', '.'], 'lemmatized': ['•', 'hepatitis', 'B', '.'], 'stemmed': ['•', 'hepat', 'b', '.'], 'dependencies': [('•', 'nummod'), ('hepat', 'compound'), ('b', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• use the medicine ORENCIA (abatacept), KINERET (anakinra), RITUXAN (rituximab), \\nIMURAN (azathioprine), or PURINETHOL (6–mercaptopurine, 6-MP).', 'tokens': ['•', 'use', 'medicine', 'ORENCIA', '(', 'abatacept', ')', ',', 'KINERET', '(', 'anakinra', ')', ',', 'RITUXAN', '(', 'rituximab', ')', ',', 'IMURAN', '(', 'azathioprine', ')', ',', 'PURINETHOL', '(', '6–mercaptopurine', ',', '6-MP', ')', '.'], 'lemmatized': ['•', 'use', 'medicine', 'ORENCIA', '(', 'abatacept', ')', ',', 'KINERET', '(', 'anakinra', ')', ',', 'RITUXAN', '(', 'rituximab', ')', ',', 'IMURAN', '(', 'azathioprine', ')', ',', 'PURINETHOL', '(', '6–mercaptopurine', ',', '6-MP', ')', '.'], 'stemmed': ['•', 'use', 'medicin', 'orencia', '(', 'abatacept', ')', ',', 'kineret', '(', 'anakinra', ')', ',', 'rituxan', '(', 'rituximab', ')', ',', 'imuran', '(', 'azathioprin', ')', ',', 'purinethol', '(', '6–mercaptopurin', ',', '6-mp', ')', '.'], 'dependencies': [('•', 'meta'), ('use', 'ROOT'), ('medicin', 'compound'), ('orencia', 'dobj'), ('(', 'punct'), ('abatacept', 'parataxis'), (')', 'punct'), (',', 'punct'), ('kineret', 'conj'), ('(', 'punct'), ('anakinra', 'appos'), (')', 'punct'), (',', 'punct'), ('rituxan', 'conj'), ('(', 'punct'), ('rituximab', 'appos'), (')', 'punct'), (',', 'punct'), ('imuran', 'conj'), ('(', 'punct'), ('azathioprin', 'appos'), (')', 'punct'), (',', 'punct'), ('purinethol', 'conj'), ('(', 'punct'), ('6', 'appos'), ('–', 'punct'), ('mercaptopurin', 'appos'), (',', 'punct'), ('6', 'nummod'), ('-', 'punct'), ('mp', 'conj'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': '• are scheduled to have major surgery.', 'tokens': ['•', 'scheduled', 'major', 'surgery', '.'], 'lemmatized': ['•', 'scheduled', 'major', 'surgery', '.'], 'stemmed': ['•', 'schedul', 'major', 'surgeri', '.'], 'dependencies': [('•', 'nmod'), ('schedul', 'npadvmod'), ('major', 'amod'), ('surgeri', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'After starting HUMIRA, call your doctor right away if you have an infection, or any sign of \\nan infection.', 'tokens': ['starting', 'HUMIRA', ',', 'call', 'doctor', 'right', 'away', 'infection', ',', 'sign', 'infection', '.'], 'lemmatized': ['starting', 'HUMIRA', ',', 'call', 'doctor', 'right', 'away', 'infection', ',', 'sign', 'infection', '.'], 'stemmed': ['start', 'humira', ',', 'call', 'doctor', 'right', 'away', 'infect', ',', 'sign', 'infect', '.'], 'dependencies': [('start', 'advcl'), ('humira', 'dobj'), (',', 'punct'), ('call', 'dep'), ('doctor', 'dobj'), ('right', 'advmod'), ('away', 'advmod'), ('infect', 'oprd'), (',', 'punct'), ('sign', 'compound'), ('infect', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'HUMIRA can make you more likely to get infections or make any infection that you may have \\nworse.', 'tokens': ['HUMIRA', 'make', 'likely', 'get', 'infections', 'make', 'infection', 'may', 'worse', '.'], 'lemmatized': ['HUMIRA', 'make', 'likely', 'get', 'infection', 'make', 'infection', 'may', 'worse', '.'], 'stemmed': ['humira', 'make', 'like', 'get', 'infect', 'make', 'infect', 'may', 'wors', '.'], 'dependencies': [('humira', 'nsubj'), ('make', 'ROOT'), ('like', 'intj'), ('get', 'csubj'), ('infect', 'acomp'), ('make', 'advcl'), ('infect', 'dobj'), ('may', 'aux'), ('wors', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Cancer \\n• For children and adults taking Tumor Necrosis Factor (TNF)-blockers, including HUMIRA, \\nthe chances of getting cancer may increase.', 'tokens': ['Cancer', '•', 'children', 'adults', 'taking', 'Tumor', 'Necrosis', 'Factor', '(', 'TNF', ')', '-blockers', ',', 'including', 'HUMIRA', ',', 'chances', 'getting', 'cancer', 'may', 'increase', '.'], 'lemmatized': ['Cancer', '•', 'child', 'adult', 'taking', 'Tumor', 'Necrosis', 'Factor', '(', 'TNF', ')', '-blockers', ',', 'including', 'HUMIRA', ',', 'chance', 'getting', 'cancer', 'may', 'increase', '.'], 'stemmed': ['cancer', '•', 'child', 'adult', 'take', 'tumor', 'necrosi', 'factor', '(', 'tnf', ')', '-blocker', ',', 'includ', 'humira', ',', 'chanc', 'get', 'cancer', 'may', 'increas', '.'], 'dependencies': [('cancer', 'nmod'), ('•', 'nummod'), ('child', 'compound'), ('adult', 'nsubj'), ('take', 'advcl'), ('tumor', 'dobj'), ('necrosi', 'compound'), ('factor', 'dobj'), ('(', 'punct'), ('tnf', 'nmod'), (')', 'punct'), ('-blocker', 'appos'), (',', 'punct'), ('includ', 'compound'), ('humira', 'appos'), (',', 'punct'), ('chanc', 'nsubj'), ('get', 'ROOT'), ('cancer', 'nsubj'), ('may', 'aux'), ('increas', 'ccomp'), ('.', 'punct')]}], 'text': 'MEDICATION GUIDE \\nHUMIRA® (Hu-MARE-ah) \\n(adalimumab) \\ninjection, for subcutaneous use \\nRead the Medication Guide that comes with HUMIRA before you start taking it and each time \\nyou get a refill. There may be new information. This Medication Guide does not take the place \\nof talking with your doctor about your medical condition or treatment.  \\nWhat is the most important information I should know about HUMIRA? \\nHUMIRA is a medicine that affects your immune system. HUMIRA can lower the ability of your \\nimmune system to fight infections. Serious infections have happened in people taking \\nHUMIRA. These serious infections include tuberculosis (TB) and infections caused by \\nviruses, fungi or bacteria that have spread throughout the body. Some people have died \\nfrom these infections. \\n• Your doctor should test you for TB before starting HUMIRA. \\n• Your doctor should check you closely for signs and symptoms of TB during treatment with \\nHUMIRA. \\nYou should not start taking HUMIRA if you have any kind of infection unless your doctor says it \\nis okay.  \\nBefore starting HUMIRA, tell your doctor if you: \\n• think you have an infection or have symptoms of an infection such as: \\n  \\n◦ fever, sweats, or chills \\n◦ muscle aches \\n◦ cough \\n◦ shortness of breath \\n◦ blood in phlegm \\n◦ warm, red, or painful skin or sores on \\nyour body \\n◦ diarrhea or stomach pain \\n◦ burning when you urinate or urinate \\nmore often than normal \\n◦ feel very tired \\n◦ weight loss \\n• are being treated for an infection. \\n• get a lot of infections or have infections that keep coming back. \\n• have diabetes. \\n• have TB, or have been in close contact with someone with TB. \\n• were born in, lived in, or traveled to countries where there is more risk for getting TB. Ask \\nyour doctor if you are not sure. \\n• live or have lived in certain parts of the country (such as the Ohio and Mississippi River \\nvalleys) where there is an increased risk for getting certain kinds of fungal infections \\n(histoplasmosis, coccidioidomycosis, or blastomycosis). These infections may happen or \\nbecome more severe if you use HUMIRA. Ask your doctor if you do not know if you have \\nlived in an area where these infections are common.  \\n• have or have had hepatitis B. \\n• use the medicine ORENCIA (abatacept), KINERET (anakinra), RITUXAN (rituximab), \\nIMURAN (azathioprine), or PURINETHOL (6–mercaptopurine, 6-MP).  \\n• are scheduled to have major surgery. \\nAfter starting HUMIRA, call your doctor right away if you have an infection, or any sign of \\nan infection.  \\nHUMIRA can make you more likely to get infections or make any infection that you may have \\nworse.  \\nCancer \\n• For children and adults taking Tumor Necrosis Factor (TNF)-blockers, including HUMIRA, \\nthe chances of getting cancer may increase. \\n'}, 'page_char_count': 2763, 'page_word_count': 459, 'sentences': ['MEDICATION GUIDE \\nHUMIRA® (Hu-MARE-ah) \\n(adalimumab) \\ninjection, for subcutaneous use \\nRead the Medication Guide that comes with HUMIRA before you start taking it and each time \\nyou get a refill.', 'There may be new information.', 'This Medication Guide does not take the place \\nof talking with your doctor about your medical condition or treatment.', ' \\nWhat is the most important information I should know about HUMIRA?', '\\nHUMIRA is a medicine that affects your immune system.', 'HUMIRA can lower the ability of your \\nimmune system to fight infections.', 'Serious infections have happened in people taking \\nHUMIRA.', 'These serious infections include tuberculosis (TB) and infections caused by \\nviruses, fungi or bacteria that have spread throughout the body.', 'Some people have died \\nfrom these infections.', '\\n• Your doctor should test you for TB before starting HUMIRA.', '\\n• Your doctor should check you closely for signs and symptoms of TB during treatment with \\nHUMIRA.', '\\nYou should not start taking HUMIRA if you have any kind of infection unless your doctor says it \\nis okay.', ' \\nBefore starting HUMIRA, tell your doctor if you: \\n• think you have an infection or have symptoms of an infection such as: \\n  \\n◦ fever, sweats, or chills \\n◦ muscle aches \\n◦ cough \\n◦ shortness of breath \\n◦ blood in phlegm \\n◦ warm, red, or painful skin or sores on \\nyour body \\n◦ diarrhea or stomach pain \\n◦ burning when you urinate or urinate \\nmore often than normal \\n◦ feel very tired \\n◦ weight loss \\n• are being treated for an infection.', '\\n• get a lot of infections or have infections that keep coming back.', '\\n• have diabetes.', '\\n• have TB, or have been in close contact with someone with TB.', '\\n• were born in, lived in, or traveled to countries where there is more risk for getting TB.', 'Ask \\nyour doctor if you are not sure.', '\\n• live or have lived in certain parts of the country (such as the Ohio and Mississippi River \\nvalleys) where there is an increased risk for getting certain kinds of fungal infections \\n(histoplasmosis, coccidioidomycosis, or blastomycosis).', 'These infections may happen or \\nbecome more severe if you use HUMIRA.', 'Ask your doctor if you do not know if you have \\nlived in an area where these infections are common.', ' \\n• have or have had hepatitis B. \\n• use the medicine ORENCIA (abatacept), KINERET (anakinra), RITUXAN (rituximab), \\nIMURAN (azathioprine), or PURINETHOL (6–mercaptopurine, 6-MP).', ' \\n• are scheduled to have major surgery.', '\\nAfter starting HUMIRA, call your doctor right away if you have an infection, or any sign of \\nan infection.', ' \\nHUMIRA can make you more likely to get infections or make any infection that you may have \\nworse.', ' \\nCancer \\n• For children and adults taking Tumor Necrosis Factor (TNF)-blockers, including HUMIRA, \\nthe chances of getting cancer may increase.', '\\n'], 'page_sentence_count_spacy': 27}\n",
            "{'page_number': 60, 'text': '• There have been cases of unusual cancers in children, teenagers, and young adults using \\nTNF-blockers. \\n• People with rheumatoid arthritis (RA), especially more serious RA, may have a higher \\nchance for getting a kind of cancer called lymphoma. \\n• If you use TNF blockers including HUMIRA your chance of getting two types of skin cancer \\nmay increase (basal cell cancer and squamous cell cancer of the skin). These types of \\ncancer are generally not life-threatening if treated. Tell your doctor if you have a bump or \\nopen sore that does not heal.  \\n• Some people receiving TNF blockers including HUMIRA developed a rare type of cancer \\ncalled hepatosplenic T-cell lymphoma. This type of cancer often results in death. Most of \\nthese people were male teenagers or young men. Also, most people were being treated for \\nCrohn’s disease or ulcerative colitis with another medicine called IMURAN (azathioprine) \\nor PURINETHOL (6-mercaptopurine, 6–MP).  \\nWhat is HUMIRA? \\nHUMIRA is a medicine called a Tumor Necrosis Factor (TNF) blocker. HUMIRA is used:  \\n• To reduce the signs and symptoms of:  \\n◦ moderate to severe RA in adults. HUMIRA can be used alone, with methotrexate, or \\nwith certain other medicines.  \\n◦ moderate to severe polyarticular juvenile idiopathic arthritis (JIA) in children 2 \\nyears and older. HUMIRA can be used alone or with methotrexate.  \\n◦ psoriatic arthritis (PsA) in adults. HUMIRA can be used alone or with certain other \\nmedicines.  \\n◦ ankylosing spondylitis (AS) in adults. \\n◦ moderate to severe hidradenitis suppurativa (HS) in people 12 years and older. \\n• To treat moderate to severe Crohn’s disease (CD) in adults and children 6 years of \\nage and older.  \\n• To treat moderate to severe ulcerative colitis (UC) in adults and children 5 years of \\nage and older. It is not known if HUMIRA is effective in people who stopped responding to \\nor could not tolerate TNF-blocker medicines. \\n• To treat moderate to severe chronic (lasting a long time) plaque psoriasis (Ps) in \\nadults who have the condition in many areas of their body and who may benefit from \\ntaking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light \\nalone or with pills).  \\n• To treat non-infectious intermediate, posterior, and panuveitis in adults and children \\n2 years of age and older.  \\nWhat should I tell my doctor before taking HUMIRA? \\nHUMIRA may not be right for you. Before starting HUMIRA, tell your doctor about all of your \\nmedical conditions, including if you:  \\n• have an infection. See “What is the most important information I should know about \\nHUMIRA?” \\n• have or have had cancer. \\n• have any numbness or tingling or have a disease that affects your nervous system such as \\nmultiple sclerosis or Guillain-Barré syndrome.  \\n• have or had heart failure. \\n• have recently received or are scheduled to receive a vaccine. You may receive vaccines, \\nexcept for live vaccines while using HUMIRA. Children should be brought up to date with \\nall vaccines before starting HUMIRA.  \\n• are allergic to rubber or latex. Tell your doctor if you have any allergies to rubber or latex.  \\n', 'processed_text': {'sentences': [{'original_sentence': '• There have been cases of unusual cancers in children, teenagers, and young adults using \\nTNF-blockers.', 'tokens': ['•', 'cases', 'unusual', 'cancers', 'children', ',', 'teenagers', ',', 'young', 'adults', 'using', 'TNF-blockers', '.'], 'lemmatized': ['•', 'case', 'unusual', 'cancer', 'child', ',', 'teenager', ',', 'young', 'adult', 'using', 'TNF-blockers', '.'], 'stemmed': ['•', 'case', 'unusu', 'cancer', 'child', ',', 'teenag', ',', 'young', 'adult', 'use', 'tnf-blocker', '.'], 'dependencies': [('•', 'nummod'), ('case', 'compound'), ('unusu', 'compound'), ('cancer', 'compound'), ('child', 'ROOT'), (',', 'punct'), ('teenag', 'appos'), (',', 'punct'), ('young', 'amod'), ('adult', 'compound'), ('use', 'appos'), ('tnf', 'appos'), ('-', 'conj'), ('blocker', 'appos'), ('.', 'punct')]}, {'original_sentence': '• People with rheumatoid arthritis (RA), especially more serious RA, may have a higher \\nchance for getting a kind of cancer called lymphoma.', 'tokens': ['•', 'People', 'rheumatoid', 'arthritis', '(', 'RA', ')', ',', 'especially', 'serious', 'RA', ',', 'may', 'higher', 'chance', 'getting', 'kind', 'cancer', 'called', 'lymphoma', '.'], 'lemmatized': ['•', 'People', 'rheumatoid', 'arthritis', '(', 'RA', ')', ',', 'especially', 'serious', 'RA', ',', 'may', 'higher', 'chance', 'getting', 'kind', 'cancer', 'called', 'lymphoma', '.'], 'stemmed': ['•', 'peopl', 'rheumatoid', 'arthriti', '(', 'ra', ')', ',', 'especi', 'seriou', 'ra', ',', 'may', 'higher', 'chanc', 'get', 'kind', 'cancer', 'call', 'lymphoma', '.'], 'dependencies': [('•', 'nummod'), ('peopl', 'nmod'), ('rheumatoid', 'amod'), ('arthriti', 'nsubj'), ('(', 'punct'), ('ra', 'appos'), (')', 'punct'), (',', 'punct'), ('especi', 'ROOT'), ('seriou', 'compound'), ('ra', 'dobj'), (',', 'punct'), ('may', 'aux'), ('higher', 'amod'), ('chanc', 'nsubj'), ('get', 'conj'), ('kind', 'amod'), ('cancer', 'compound'), ('call', 'compound'), ('lymphoma', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• If you use TNF blockers including HUMIRA your chance of getting two types of skin cancer \\nmay increase (basal cell cancer and squamous cell cancer of the skin).', 'tokens': ['•', 'use', 'TNF', 'blockers', 'including', 'HUMIRA', 'chance', 'getting', 'two', 'types', 'skin', 'cancer', 'may', 'increase', '(', 'basal', 'cell', 'cancer', 'squamous', 'cell', 'cancer', 'skin', ')', '.'], 'lemmatized': ['•', 'use', 'TNF', 'blocker', 'including', 'HUMIRA', 'chance', 'getting', 'two', 'type', 'skin', 'cancer', 'may', 'increase', '(', 'basal', 'cell', 'cancer', 'squamous', 'cell', 'cancer', 'skin', ')', '.'], 'stemmed': ['•', 'use', 'tnf', 'blocker', 'includ', 'humira', 'chanc', 'get', 'two', 'type', 'skin', 'cancer', 'may', 'increas', '(', 'basal', 'cell', 'cancer', 'squamou', 'cell', 'cancer', 'skin', ')', '.'], 'dependencies': [('•', 'meta'), ('use', 'nsubj'), ('tnf', 'compound'), ('blocker', 'compound'), ('includ', 'compound'), ('humira', 'compound'), ('chanc', 'dobj'), ('get', 'ROOT'), ('two', 'nummod'), ('type', 'compound'), ('skin', 'compound'), ('cancer', 'nsubj'), ('may', 'aux'), ('increas', 'ccomp'), ('(', 'punct'), ('basal', 'compound'), ('cell', 'compound'), ('cancer', 'compound'), ('squamou', 'compound'), ('cell', 'compound'), ('cancer', 'compound'), ('skin', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'These types of \\ncancer are generally not life-threatening if treated.', 'tokens': ['types', 'cancer', 'generally', 'life-threatening', 'treated', '.'], 'lemmatized': ['type', 'cancer', 'generally', 'life-threatening', 'treated', '.'], 'stemmed': ['type', 'cancer', 'gener', 'life-threaten', 'treat', '.'], 'dependencies': [('type', 'compound'), ('cancer', 'compound'), ('gener', 'compound'), ('life', 'npadvmod'), ('-', 'punct'), ('threaten', 'amod'), ('treat', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Tell your doctor if you have a bump or \\nopen sore that does not heal.', 'tokens': ['Tell', 'doctor', 'bump', 'open', 'sore', 'heal', '.'], 'lemmatized': ['Tell', 'doctor', 'bump', 'open', 'sore', 'heal', '.'], 'stemmed': ['tell', 'doctor', 'bump', 'open', 'sore', 'heal', '.'], 'dependencies': [('tell', 'ROOT'), ('doctor', 'dobj'), ('bump', 'ccomp'), ('open', 'amod'), ('sore', 'amod'), ('heal', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• Some people receiving TNF blockers including HUMIRA developed a rare type of cancer \\ncalled hepatosplenic T-cell lymphoma.', 'tokens': ['•', 'people', 'receiving', 'TNF', 'blockers', 'including', 'HUMIRA', 'developed', 'rare', 'type', 'cancer', 'called', 'hepatosplenic', 'T-cell', 'lymphoma', '.'], 'lemmatized': ['•', 'people', 'receiving', 'TNF', 'blocker', 'including', 'HUMIRA', 'developed', 'rare', 'type', 'cancer', 'called', 'hepatosplenic', 'T-cell', 'lymphoma', '.'], 'stemmed': ['•', 'peopl', 'receiv', 'tnf', 'blocker', 'includ', 'humira', 'develop', 'rare', 'type', 'cancer', 'call', 'hepatosplen', 't-cell', 'lymphoma', '.'], 'dependencies': [('•', 'nummod'), ('peopl', 'compound'), ('receiv', 'compound'), ('tnf', 'compound'), ('blocker', 'compound'), ('includ', 'compound'), ('humira', 'nsubj'), ('develop', 'ROOT'), ('rare', 'amod'), ('type', 'compound'), ('cancer', 'compound'), ('call', 'nmod'), ('hepatosplen', 'amod'), ('t', 'compound'), ('-', 'punct'), ('cell', 'compound'), ('lymphoma', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'This type of cancer often results in death.', 'tokens': ['type', 'cancer', 'often', 'results', 'death', '.'], 'lemmatized': ['type', 'cancer', 'often', 'result', 'death', '.'], 'stemmed': ['type', 'cancer', 'often', 'result', 'death', '.'], 'dependencies': [('type', 'compound'), ('cancer', 'nsubj'), ('often', 'advmod'), ('result', 'ROOT'), ('death', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Most of \\nthese people were male teenagers or young men.', 'tokens': ['people', 'male', 'teenagers', 'young', 'men', '.'], 'lemmatized': ['people', 'male', 'teenager', 'young', 'men', '.'], 'stemmed': ['peopl', 'male', 'teenag', 'young', 'men', '.'], 'dependencies': [('peopl', 'compound'), ('male', 'compound'), ('teenag', 'nmod'), ('young', 'amod'), ('men', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Also, most people were being treated for \\nCrohn’s disease or ulcerative colitis with another medicine called IMURAN (azathioprine) \\nor PURINETHOL (6-mercaptopurine, 6–MP).', 'tokens': ['Also', ',', 'people', 'treated', 'Crohn', '’', 'disease', 'ulcerative', 'colitis', 'another', 'medicine', 'called', 'IMURAN', '(', 'azathioprine', ')', 'PURINETHOL', '(', '6-mercaptopurine', ',', '6–MP', ')', '.'], 'lemmatized': ['Also', ',', 'people', 'treated', 'Crohn', '’', 'disease', 'ulcerative', 'colitis', 'another', 'medicine', 'called', 'IMURAN', '(', 'azathioprine', ')', 'PURINETHOL', '(', '6-mercaptopurine', ',', '6–MP', ')', '.'], 'stemmed': ['also', ',', 'peopl', 'treat', 'crohn', '’', 'diseas', 'ulcer', 'coliti', 'anoth', 'medicin', 'call', 'imuran', '(', 'azathioprin', ')', 'purinethol', '(', '6-mercaptopurin', ',', '6–mp', ')', '.'], 'dependencies': [('also', 'advmod'), (',', 'punct'), ('peopl', 'compound'), ('treat', 'nsubj'), ('crohn', 'nmod'), ('’', 'punct'), ('diseas', 'compound'), ('ulcer', 'nmod'), ('coliti', 'nsubj'), ('anoth', 'compound'), ('medicin', 'appos'), ('call', 'appos'), ('imuran', 'dobj'), ('(', 'punct'), ('azathioprin', 'appos'), (')', 'punct'), ('purinethol', 'ROOT'), ('(', 'punct'), ('6', 'nummod'), ('-', 'punct'), ('mercaptopurin', 'appos'), (',', 'punct'), ('6', 'appos'), ('–', 'punct'), ('mp', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'What is HUMIRA?', 'tokens': ['HUMIRA', '?'], 'lemmatized': ['HUMIRA', '?'], 'stemmed': ['humira', '?'], 'dependencies': [('humira', 'ROOT'), ('?', 'punct')]}, {'original_sentence': 'HUMIRA is a medicine called a Tumor Necrosis Factor (TNF) blocker.', 'tokens': ['HUMIRA', 'medicine', 'called', 'Tumor', 'Necrosis', 'Factor', '(', 'TNF', ')', 'blocker', '.'], 'lemmatized': ['HUMIRA', 'medicine', 'called', 'Tumor', 'Necrosis', 'Factor', '(', 'TNF', ')', 'blocker', '.'], 'stemmed': ['humira', 'medicin', 'call', 'tumor', 'necrosi', 'factor', '(', 'tnf', ')', 'blocker', '.'], 'dependencies': [('humira', 'compound'), ('medicin', 'nsubj'), ('call', 'ROOT'), ('tumor', 'nmod'), ('necrosi', 'compound'), ('factor', 'oprd'), ('(', 'punct'), ('tnf', 'advmod'), (')', 'punct'), ('blocker', 'appos'), ('.', 'punct')]}, {'original_sentence': 'HUMIRA is used:  \\n• To reduce the signs and symptoms of:  \\n◦ moderate to severe RA in adults.', 'tokens': ['HUMIRA', 'used', ':', '•', 'reduce', 'signs', 'symptoms', ':', '◦', 'moderate', 'severe', 'RA', 'adults', '.'], 'lemmatized': ['HUMIRA', 'used', ':', '•', 'reduce', 'sign', 'symptom', ':', '◦', 'moderate', 'severe', 'RA', 'adult', '.'], 'stemmed': ['humira', 'use', ':', '•', 'reduc', 'sign', 'symptom', ':', '◦', 'moder', 'sever', 'ra', 'adult', '.'], 'dependencies': [('humira', 'compound'), ('use', 'ROOT'), (':', 'punct'), ('•', 'appos'), ('reduc', 'compound'), ('sign', 'compound'), ('symptom', 'appos'), (':', 'punct'), ('◦', 'dep'), ('moder', 'nsubj'), ('sever', 'ccomp'), ('ra', 'compound'), ('adult', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'HUMIRA can be used alone, with methotrexate, or \\nwith certain other medicines.', 'tokens': ['HUMIRA', 'used', 'alone', ',', 'methotrexate', ',', 'certain', 'medicines', '.'], 'lemmatized': ['HUMIRA', 'used', 'alone', ',', 'methotrexate', ',', 'certain', 'medicine', '.'], 'stemmed': ['humira', 'use', 'alon', ',', 'methotrex', ',', 'certain', 'medicin', '.'], 'dependencies': [('humira', 'nsubj'), ('use', 'ROOT'), ('alon', 'dobj'), (',', 'punct'), ('methotrex', 'amod'), (',', 'punct'), ('certain', 'amod'), ('medicin', 'appos'), ('.', 'punct')]}, {'original_sentence': '◦ moderate to severe polyarticular juvenile idiopathic arthritis (JIA) in children 2 \\nyears and older.', 'tokens': ['◦', 'moderate', 'severe', 'polyarticular', 'juvenile', 'idiopathic', 'arthritis', '(', 'JIA', ')', 'children', '2', 'years', 'older', '.'], 'lemmatized': ['◦', 'moderate', 'severe', 'polyarticular', 'juvenile', 'idiopathic', 'arthritis', '(', 'JIA', ')', 'child', '2', 'year', 'older', '.'], 'stemmed': ['◦', 'moder', 'sever', 'polyarticular', 'juvenil', 'idiopath', 'arthriti', '(', 'jia', ')', 'child', '2', 'year', 'older', '.'], 'dependencies': [('◦', 'ROOT'), ('moder', 'nsubj'), ('sever', 'ccomp'), ('polyarticular', 'amod'), ('juvenil', 'amod'), ('idiopath', 'compound'), ('arthriti', 'dobj'), ('(', 'punct'), ('jia', 'nmod'), (')', 'punct'), ('child', 'ROOT'), ('2', 'nummod'), ('year', 'npadvmod'), ('older', 'amod'), ('.', 'punct')]}, {'original_sentence': 'HUMIRA can be used alone or with methotrexate.', 'tokens': ['HUMIRA', 'used', 'alone', 'methotrexate', '.'], 'lemmatized': ['HUMIRA', 'used', 'alone', 'methotrexate', '.'], 'stemmed': ['humira', 'use', 'alon', 'methotrex', '.'], 'dependencies': [('humira', 'nsubj'), ('use', 'ROOT'), ('alon', 'compound'), ('methotrex', 'dobj'), ('.', 'punct')]}, {'original_sentence': '◦ psoriatic arthritis (PsA) in adults.', 'tokens': ['◦', 'psoriatic', 'arthritis', '(', 'PsA', ')', 'adults', '.'], 'lemmatized': ['◦', 'psoriatic', 'arthritis', '(', 'PsA', ')', 'adult', '.'], 'stemmed': ['◦', 'psoriat', 'arthriti', '(', 'psa', ')', 'adult', '.'], 'dependencies': [('◦', 'ROOT'), ('psoriat', 'compound'), ('arthriti', 'dobj'), ('(', 'punct'), ('psa', 'nmod'), (')', 'punct'), ('adult', 'appos'), ('.', 'punct')]}, {'original_sentence': 'HUMIRA can be used alone or with certain other \\nmedicines.', 'tokens': ['HUMIRA', 'used', 'alone', 'certain', 'medicines', '.'], 'lemmatized': ['HUMIRA', 'used', 'alone', 'certain', 'medicine', '.'], 'stemmed': ['humira', 'use', 'alon', 'certain', 'medicin', '.'], 'dependencies': [('humira', 'nsubj'), ('use', 'ROOT'), ('alon', 'dobj'), ('certain', 'amod'), ('medicin', 'appos'), ('.', 'punct')]}, {'original_sentence': '◦ ankylosing spondylitis (AS) in adults.', 'tokens': ['◦', 'ankylosing', 'spondylitis', '(', ')', 'adults', '.'], 'lemmatized': ['◦', 'ankylosing', 'spondylitis', '(', ')', 'adult', '.'], 'stemmed': ['◦', 'ankylos', 'spondyl', '(', ')', 'adult', '.'], 'dependencies': [('◦', 'ROOT'), ('ankylos', 'compound'), ('spondyl', 'appos'), ('(', 'punct'), (')', 'punct'), ('adult', 'appos'), ('.', 'punct')]}, {'original_sentence': '◦ moderate to severe hidradenitis suppurativa (HS) in people 12 years and older.', 'tokens': ['◦', 'moderate', 'severe', 'hidradenitis', 'suppurativa', '(', 'HS', ')', 'people', '12', 'years', 'older', '.'], 'lemmatized': ['◦', 'moderate', 'severe', 'hidradenitis', 'suppurativa', '(', 'HS', ')', 'people', '12', 'year', 'older', '.'], 'stemmed': ['◦', 'moder', 'sever', 'hidraden', 'suppurativa', '(', 'hs', ')', 'peopl', '12', 'year', 'older', '.'], 'dependencies': [('◦', 'ROOT'), ('moder', 'nsubj'), ('sever', 'ccomp'), ('hidraden', 'compound'), ('suppurativa', 'nmod'), ('(', 'punct'), ('hs', 'nmod'), (')', 'punct'), ('peopl', 'dobj'), ('12', 'nummod'), ('year', 'npadvmod'), ('older', 'advmod'), ('.', 'punct')]}, {'original_sentence': '• To treat moderate to severe Crohn’s disease (CD) in adults and children 6 years of \\nage and older.', 'tokens': ['•', 'treat', 'moderate', 'severe', 'Crohn', '’', 'disease', '(', 'CD', ')', 'adults', 'children', '6', 'years', 'age', 'older', '.'], 'lemmatized': ['•', 'treat', 'moderate', 'severe', 'Crohn', '’', 'disease', '(', 'CD', ')', 'adult', 'child', '6', 'year', 'age', 'older', '.'], 'stemmed': ['•', 'treat', 'moder', 'sever', 'crohn', '’', 'diseas', '(', 'cd', ')', 'adult', 'child', '6', 'year', 'age', 'older', '.'], 'dependencies': [('•', 'npadvmod'), ('treat', 'compound'), ('moder', 'compound'), ('sever', 'compound'), ('crohn', 'nmod'), ('’', 'punct'), ('diseas', 'ROOT'), ('(', 'punct'), ('cd', 'nmod'), (')', 'punct'), ('adult', 'compound'), ('child', 'appos'), ('6', 'nummod'), ('year', 'compound'), ('age', 'appos'), ('older', 'amod'), ('.', 'punct')]}, {'original_sentence': '• To treat moderate to severe ulcerative colitis (UC) in adults and children 5 years of \\nage and older.', 'tokens': ['•', 'treat', 'moderate', 'severe', 'ulcerative', 'colitis', '(', 'UC', ')', 'adults', 'children', '5', 'years', 'age', 'older', '.'], 'lemmatized': ['•', 'treat', 'moderate', 'severe', 'ulcerative', 'colitis', '(', 'UC', ')', 'adult', 'child', '5', 'year', 'age', 'older', '.'], 'stemmed': ['•', 'treat', 'moder', 'sever', 'ulcer', 'coliti', '(', 'uc', ')', 'adult', 'child', '5', 'year', 'age', 'older', '.'], 'dependencies': [('•', 'nummod'), ('treat', 'compound'), ('moder', 'compound'), ('sever', 'compound'), ('ulcer', 'compound'), ('coliti', 'ROOT'), ('(', 'punct'), ('uc', 'nmod'), (')', 'punct'), ('adult', 'nmod'), ('child', 'appos'), ('5', 'nummod'), ('year', 'compound'), ('age', 'appos'), ('older', 'amod'), ('.', 'punct')]}, {'original_sentence': 'It is not known if HUMIRA is effective in people who stopped responding to \\nor could not tolerate TNF-blocker medicines.', 'tokens': ['known', 'HUMIRA', 'effective', 'people', 'stopped', 'responding', 'could', 'tolerate', 'TNF-blocker', 'medicines', '.'], 'lemmatized': ['known', 'HUMIRA', 'effective', 'people', 'stopped', 'responding', 'could', 'tolerate', 'TNF-blocker', 'medicine', '.'], 'stemmed': ['known', 'humira', 'effect', 'peopl', 'stop', 'respond', 'could', 'toler', 'tnf-blocker', 'medicin', '.'], 'dependencies': [('known', 'amod'), ('humira', 'compound'), ('effect', 'compound'), ('peopl', 'compound'), ('stop', 'nsubj'), ('respond', 'ROOT'), ('could', 'prep'), ('toler', 'compound'), ('tnf', 'compound'), ('-', 'compound'), ('blocker', 'compound'), ('medicin', 'pobj'), ('.', 'punct')]}, {'original_sentence': '• To treat moderate to severe chronic (lasting a long time) plaque psoriasis (Ps) in \\nadults who have the condition in many areas of their body and who may benefit from \\ntaking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light \\nalone or with pills).', 'tokens': ['•', 'treat', 'moderate', 'severe', 'chronic', '(', 'lasting', 'long', 'time', ')', 'plaque', 'psoriasis', '(', 'Ps', ')', 'adults', 'condition', 'many', 'areas', 'body', 'may', 'benefit', 'taking', 'injections', 'pills', '(', 'systemic', 'therapy', ')', 'phototherapy', '(', 'treatment', 'using', 'ultraviolet', 'light', 'alone', 'pills', ')', '.'], 'lemmatized': ['•', 'treat', 'moderate', 'severe', 'chronic', '(', 'lasting', 'long', 'time', ')', 'plaque', 'psoriasis', '(', 'Ps', ')', 'adult', 'condition', 'many', 'area', 'body', 'may', 'benefit', 'taking', 'injection', 'pill', '(', 'systemic', 'therapy', ')', 'phototherapy', '(', 'treatment', 'using', 'ultraviolet', 'light', 'alone', 'pill', ')', '.'], 'stemmed': ['•', 'treat', 'moder', 'sever', 'chronic', '(', 'last', 'long', 'time', ')', 'plaqu', 'psoriasi', '(', 'ps', ')', 'adult', 'condit', 'mani', 'area', 'bodi', 'may', 'benefit', 'take', 'inject', 'pill', '(', 'system', 'therapi', ')', 'phototherapi', '(', 'treatment', 'use', 'ultraviolet', 'light', 'alon', 'pill', ')', '.'], 'dependencies': [('•', 'meta'), ('treat', 'nsubj'), ('moder', 'compound'), ('sever', 'compound'), ('chronic', 'dobj'), ('(', 'punct'), ('last', 'amod'), ('long', 'amod'), ('time', 'appos'), (')', 'punct'), ('plaqu', 'ROOT'), ('psoriasi', 'dobj'), ('(', 'punct'), ('ps', 'nmod'), (')', 'punct'), ('adult', 'compound'), ('condit', 'compound'), ('mani', 'compound'), ('area', 'compound'), ('bodi', 'nsubj'), ('may', 'aux'), ('benefit', 'conj'), ('take', 'xcomp'), ('inject', 'compound'), ('pill', 'dobj'), ('(', 'punct'), ('system', 'nsubj'), ('therapi', 'parataxis'), (')', 'punct'), ('phototherapi', 'nsubj'), ('(', 'punct'), ('treatment', 'compound'), ('use', 'parataxis'), ('ultraviolet', 'amod'), ('light', 'amod'), ('alon', 'compound'), ('pill', 'dobj'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': '• To treat non-infectious intermediate, posterior, and panuveitis in adults and children \\n2 years of age and older.', 'tokens': ['•', 'treat', 'non-infectious', 'intermediate', ',', 'posterior', ',', 'panuveitis', 'adults', 'children', '2', 'years', 'age', 'older', '.'], 'lemmatized': ['•', 'treat', 'non-infectious', 'intermediate', ',', 'posterior', ',', 'panuveitis', 'adult', 'child', '2', 'year', 'age', 'older', '.'], 'stemmed': ['•', 'treat', 'non-infecti', 'intermedi', ',', 'posterior', ',', 'panuv', 'adult', 'child', '2', 'year', 'age', 'older', '.'], 'dependencies': [('•', 'npadvmod'), ('treat', 'ROOT'), ('non', 'amod'), ('-', 'amod'), ('infecti', 'amod'), ('intermedi', 'dobj'), (',', 'punct'), ('posterior', 'amod'), (',', 'punct'), ('panuv', 'nmod'), ('adult', 'compound'), ('child', 'nmod'), ('2', 'nummod'), ('year', 'compound'), ('age', 'npadvmod'), ('older', 'advmod'), ('.', 'punct')]}, {'original_sentence': 'What should I tell my doctor before taking HUMIRA?', 'tokens': ['tell', 'doctor', 'taking', 'HUMIRA', '?'], 'lemmatized': ['tell', 'doctor', 'taking', 'HUMIRA', '?'], 'stemmed': ['tell', 'doctor', 'take', 'humira', '?'], 'dependencies': [('tell', 'ROOT'), ('doctor', 'dobj'), ('take', 'xcomp'), ('humira', 'dobj'), ('?', 'punct')]}, {'original_sentence': 'HUMIRA may not be right for you.', 'tokens': ['HUMIRA', 'may', 'right', '.'], 'lemmatized': ['HUMIRA', 'may', 'right', '.'], 'stemmed': ['humira', 'may', 'right', '.'], 'dependencies': [('humira', 'nsubj'), ('may', 'aux'), ('right', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Before starting HUMIRA, tell your doctor about all of your \\nmedical conditions, including if you:  \\n• have an infection.', 'tokens': ['starting', 'HUMIRA', ',', 'tell', 'doctor', 'medical', 'conditions', ',', 'including', ':', '•', 'infection', '.'], 'lemmatized': ['starting', 'HUMIRA', ',', 'tell', 'doctor', 'medical', 'condition', ',', 'including', ':', '•', 'infection', '.'], 'stemmed': ['start', 'humira', ',', 'tell', 'doctor', 'medic', 'condit', ',', 'includ', ':', '•', 'infect', '.'], 'dependencies': [('start', 'advcl'), ('humira', 'dobj'), (',', 'punct'), ('tell', 'ROOT'), ('doctor', 'compound'), ('medic', 'compound'), ('condit', 'dobj'), (',', 'punct'), ('includ', 'conj'), (':', 'punct'), ('•', 'nummod'), ('infect', 'acl'), ('.', 'punct')]}, {'original_sentence': 'See “What is the most important information I should know about \\nHUMIRA?” \\n• have or have had cancer.', 'tokens': ['See', '“', 'important', 'information', 'know', 'HUMIRA', '?', '”', '•', 'cancer', '.'], 'lemmatized': ['See', '“', 'important', 'information', 'know', 'HUMIRA', '?', '”', '•', 'cancer', '.'], 'stemmed': ['see', '“', 'import', 'inform', 'know', 'humira', '?', '”', '•', 'cancer', '.'], 'dependencies': [('see', 'ROOT'), ('“', 'punct'), ('import', 'compound'), ('inform', 'nsubj'), ('know', 'ccomp'), ('humira', 'dobj'), ('?', 'punct'), ('”', 'punct'), ('•', 'nummod'), ('cancer', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• have any numbness or tingling or have a disease that affects your nervous system such as \\nmultiple sclerosis or Guillain-Barré syndrome.', 'tokens': ['•', 'numbness', 'tingling', 'disease', 'affects', 'nervous', 'system', 'multiple', 'sclerosis', 'Guillain-Barré', 'syndrome', '.'], 'lemmatized': ['•', 'numbness', 'tingling', 'disease', 'affect', 'nervous', 'system', 'multiple', 'sclerosis', 'Guillain-Barré', 'syndrome', '.'], 'stemmed': ['•', 'numb', 'tingl', 'diseas', 'affect', 'nervou', 'system', 'multipl', 'sclerosi', 'guillain-barré', 'syndrom', '.'], 'dependencies': [('•', 'nummod'), ('numb', 'amod'), ('tingl', 'compound'), ('diseas', 'nsubj'), ('affect', 'ROOT'), ('nervou', 'amod'), ('system', 'compound'), ('multipl', 'dobj'), ('sclerosi', 'dobj'), ('guillain', 'compound'), ('-', 'punct'), ('barré', 'amod'), ('syndrom', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• have or had heart failure.', 'tokens': ['•', 'heart', 'failure', '.'], 'lemmatized': ['•', 'heart', 'failure', '.'], 'stemmed': ['•', 'heart', 'failur', '.'], 'dependencies': [('•', 'nummod'), ('heart', 'compound'), ('failur', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• have recently received or are scheduled to receive a vaccine.', 'tokens': ['•', 'recently', 'received', 'scheduled', 'receive', 'vaccine', '.'], 'lemmatized': ['•', 'recently', 'received', 'scheduled', 'receive', 'vaccine', '.'], 'stemmed': ['•', 'recent', 'receiv', 'schedul', 'receiv', 'vaccin', '.'], 'dependencies': [('•', 'dep'), ('recent', 'amod'), ('receiv', 'compound'), ('schedul', 'compound'), ('receiv', 'nsubj'), ('vaccin', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'You may receive vaccines, \\nexcept for live vaccines while using HUMIRA.', 'tokens': ['may', 'receive', 'vaccines', ',', 'except', 'live', 'vaccines', 'using', 'HUMIRA', '.'], 'lemmatized': ['may', 'receive', 'vaccine', ',', 'except', 'live', 'vaccine', 'using', 'HUMIRA', '.'], 'stemmed': ['may', 'receiv', 'vaccin', ',', 'except', 'live', 'vaccin', 'use', 'humira', '.'], 'dependencies': [('may', 'aux'), ('receiv', 'ROOT'), ('vaccin', 'dobj'), (',', 'punct'), ('except', 'prep'), ('live', 'amod'), ('vaccin', 'compound'), ('use', 'compound'), ('humira', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'Children should be brought up to date with \\nall vaccines before starting HUMIRA.', 'tokens': ['Children', 'brought', 'date', 'vaccines', 'starting', 'HUMIRA', '.'], 'lemmatized': ['Children', 'brought', 'date', 'vaccine', 'starting', 'HUMIRA', '.'], 'stemmed': ['children', 'brought', 'date', 'vaccin', 'start', 'humira', '.'], 'dependencies': [('children', 'nsubj'), ('brought', 'ROOT'), ('date', 'dobj'), ('vaccin', 'advcl'), ('start', 'compound'), ('humira', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• are allergic to rubber or latex.', 'tokens': ['•', 'allergic', 'rubber', 'latex', '.'], 'lemmatized': ['•', 'allergic', 'rubber', 'latex', '.'], 'stemmed': ['•', 'allerg', 'rubber', 'latex', '.'], 'dependencies': [('•', 'nummod'), ('allerg', 'compound'), ('rubber', 'compound'), ('latex', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Tell your doctor if you have any allergies to rubber or latex.', 'tokens': ['Tell', 'doctor', 'allergies', 'rubber', 'latex', '.'], 'lemmatized': ['Tell', 'doctor', 'allergy', 'rubber', 'latex', '.'], 'stemmed': ['tell', 'doctor', 'allergi', 'rubber', 'latex', '.'], 'dependencies': [('tell', 'ROOT'), ('doctor', 'compound'), ('allergi', 'compound'), ('rubber', 'compound'), ('latex', 'dobj'), ('.', 'punct')]}], 'text': '• There have been cases of unusual cancers in children, teenagers, and young adults using \\nTNF-blockers. \\n• People with rheumatoid arthritis (RA), especially more serious RA, may have a higher \\nchance for getting a kind of cancer called lymphoma. \\n• If you use TNF blockers including HUMIRA your chance of getting two types of skin cancer \\nmay increase (basal cell cancer and squamous cell cancer of the skin). These types of \\ncancer are generally not life-threatening if treated. Tell your doctor if you have a bump or \\nopen sore that does not heal.  \\n• Some people receiving TNF blockers including HUMIRA developed a rare type of cancer \\ncalled hepatosplenic T-cell lymphoma. This type of cancer often results in death. Most of \\nthese people were male teenagers or young men. Also, most people were being treated for \\nCrohn’s disease or ulcerative colitis with another medicine called IMURAN (azathioprine) \\nor PURINETHOL (6-mercaptopurine, 6–MP).  \\nWhat is HUMIRA? \\nHUMIRA is a medicine called a Tumor Necrosis Factor (TNF) blocker. HUMIRA is used:  \\n• To reduce the signs and symptoms of:  \\n◦ moderate to severe RA in adults. HUMIRA can be used alone, with methotrexate, or \\nwith certain other medicines.  \\n◦ moderate to severe polyarticular juvenile idiopathic arthritis (JIA) in children 2 \\nyears and older. HUMIRA can be used alone or with methotrexate.  \\n◦ psoriatic arthritis (PsA) in adults. HUMIRA can be used alone or with certain other \\nmedicines.  \\n◦ ankylosing spondylitis (AS) in adults. \\n◦ moderate to severe hidradenitis suppurativa (HS) in people 12 years and older. \\n• To treat moderate to severe Crohn’s disease (CD) in adults and children 6 years of \\nage and older.  \\n• To treat moderate to severe ulcerative colitis (UC) in adults and children 5 years of \\nage and older. It is not known if HUMIRA is effective in people who stopped responding to \\nor could not tolerate TNF-blocker medicines. \\n• To treat moderate to severe chronic (lasting a long time) plaque psoriasis (Ps) in \\nadults who have the condition in many areas of their body and who may benefit from \\ntaking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light \\nalone or with pills).  \\n• To treat non-infectious intermediate, posterior, and panuveitis in adults and children \\n2 years of age and older.  \\nWhat should I tell my doctor before taking HUMIRA? \\nHUMIRA may not be right for you. Before starting HUMIRA, tell your doctor about all of your \\nmedical conditions, including if you:  \\n• have an infection. See “What is the most important information I should know about \\nHUMIRA?” \\n• have or have had cancer. \\n• have any numbness or tingling or have a disease that affects your nervous system such as \\nmultiple sclerosis or Guillain-Barré syndrome.  \\n• have or had heart failure. \\n• have recently received or are scheduled to receive a vaccine. You may receive vaccines, \\nexcept for live vaccines while using HUMIRA. Children should be brought up to date with \\nall vaccines before starting HUMIRA.  \\n• are allergic to rubber or latex. Tell your doctor if you have any allergies to rubber or latex.  \\n'}, 'page_char_count': 3125, 'page_word_count': 511, 'sentences': ['• There have been cases of unusual cancers in children, teenagers, and young adults using \\nTNF-blockers.', '\\n• People with rheumatoid arthritis (RA), especially more serious RA, may have a higher \\nchance for getting a kind of cancer called lymphoma.', '\\n• If you use TNF blockers including HUMIRA your chance of getting two types of skin cancer \\nmay increase (basal cell cancer and squamous cell cancer of the skin).', 'These types of \\ncancer are generally not life-threatening if treated.', 'Tell your doctor if you have a bump or \\nopen sore that does not heal.', ' \\n• Some people receiving TNF blockers including HUMIRA developed a rare type of cancer \\ncalled hepatosplenic T-cell lymphoma.', 'This type of cancer often results in death.', 'Most of \\nthese people were male teenagers or young men.', 'Also, most people were being treated for \\nCrohn’s disease or ulcerative colitis with another medicine called IMURAN (azathioprine) \\nor PURINETHOL (6-mercaptopurine, 6–MP).', ' \\nWhat is HUMIRA?', '\\nHUMIRA is a medicine called a Tumor Necrosis Factor (TNF) blocker.', 'HUMIRA is used:  \\n• To reduce the signs and symptoms of:  \\n◦ moderate to severe RA in adults.', 'HUMIRA can be used alone, with methotrexate, or \\nwith certain other medicines.', ' \\n◦ moderate to severe polyarticular juvenile idiopathic arthritis (JIA) in children 2 \\nyears and older.', 'HUMIRA can be used alone or with methotrexate.', ' \\n◦ psoriatic arthritis (PsA) in adults.', 'HUMIRA can be used alone or with certain other \\nmedicines.', ' \\n◦ ankylosing spondylitis (AS) in adults.', '\\n◦ moderate to severe hidradenitis suppurativa (HS) in people 12 years and older.', '\\n• To treat moderate to severe Crohn’s disease (CD) in adults and children 6 years of \\nage and older.', ' \\n• To treat moderate to severe ulcerative colitis (UC) in adults and children 5 years of \\nage and older.', 'It is not known if HUMIRA is effective in people who stopped responding to \\nor could not tolerate TNF-blocker medicines.', '\\n• To treat moderate to severe chronic (lasting a long time) plaque psoriasis (Ps) in \\nadults who have the condition in many areas of their body and who may benefit from \\ntaking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light \\nalone or with pills).', ' \\n• To treat non-infectious intermediate, posterior, and panuveitis in adults and children \\n2 years of age and older.', ' \\nWhat should I tell my doctor before taking HUMIRA?', '\\nHUMIRA may not be right for you.', 'Before starting HUMIRA, tell your doctor about all of your \\nmedical conditions, including if you:  \\n• have an infection.', 'See “What is the most important information I should know about \\nHUMIRA?”', '\\n• have or have had cancer.', '\\n• have any numbness or tingling or have a disease that affects your nervous system such as \\nmultiple sclerosis or Guillain-Barré syndrome.', ' \\n• have or had heart failure.', '\\n• have recently received or are scheduled to receive a vaccine.', 'You may receive vaccines, \\nexcept for live vaccines while using HUMIRA.', 'Children should be brought up to date with \\nall vaccines before starting HUMIRA.', ' \\n• are allergic to rubber or latex.', 'Tell your doctor if you have any allergies to rubber or latex.', ' \\n'], 'page_sentence_count_spacy': 37}\n",
            "{'page_number': 61, 'text': '◦ The needle cover for the HUMIRA Pen 40 mg/0.8 mL, HUMIRA 40 mg/0.8 mL prefilled \\nsyringe, HUMIRA 20 mg/0.4 mL prefilled syringe, and HUMIRA 10 mg/0.2 mL prefilled \\nsyringe may contain natural rubber or latex.  \\n◦ The black needle cover for the HUMIRA Pen 80 mg/0.8 mL, HUMIRA 80 mg/0.8 mL \\nprefilled syringe, HUMIRA Pen 40 mg/0.4 mL, HUMIRA 40 mg/0.4 mL prefilled syringe, \\nHUMIRA 20 mg/0.2 mL prefilled syringe, HUMIRA 10 mg/0.1 mL prefilled syringe and \\nthe vial stopper on the HUMIRA institutional use vial are not made with natural rubber \\nor latex.  \\n• are allergic to HUMIRA or to any of its ingredients. See the end of this Medication Guide \\nfor a list of ingredients in HUMIRA. \\n• are pregnant or plan to become pregnant, breastfeeding or plan to breastfeed. You and \\nyour doctor should decide if you should take HUMIRA while you are pregnant or \\nbreastfeeding.  \\n• have a baby and you were using HUMIRA during your pregnancy. Tell your baby’s doctor \\nbefore your baby receives any vaccines. \\nTell your doctor about all the medicines you take, including prescription and over-the-\\ncounter medicines, vitamins, and herbal supplements.  \\nEspecially tell your doctor if you use: \\n• ORENCIA (abatacept), KINERET (anakinra), REMICADE (infliximab), ENBREL \\n(etanercept), CIMZIA (certolizumab pegol) or SIMPONI (golimumab), because you should \\nnot use HUMIRA while you are also using one of these medicines.  \\n• RITUXAN (rituximab). Your doctor may not want to give you HUMIRA if you have received \\nRITUXAN (rituximab) recently.  \\n• IMURAN (azathioprine) or PURINETHOL (6–mercaptopurine, 6-MP).  \\nKeep a list of your medicines with you to show your doctor and pharmacist each time \\nyou get a new medicine. \\nHow should I take HUMIRA? \\n• HUMIRA is given by an injection under the skin. Your doctor will tell you how often to take \\nan injection of HUMIRA. This is based on your condition to be treated. Do not inject \\nHUMIRA more often than you were prescribed. \\n• See the Instructions for Use inside the carton for complete instructions for the right way \\nto prepare and inject HUMIRA.  \\n• Make sure you have been shown how to inject HUMIRA before you do it yourself. You can \\ncall your doctor or 1-800-4HUMIRA (1-800-448-6472) if you have any questions about \\ngiving yourself an injection. Someone you know can also help you with your injection after \\nthey have been shown how to prepare and inject HUMIRA.  \\n• Do not try to inject HUMIRA yourself until you have been shown the right way to give the \\ninjections. If your doctor decides that you or a caregiver may be able to give your injections \\nof HUMIRA at home, you should receive training on the right way to prepare and inject \\nHUMIRA.  \\n• Do not miss any doses of HUMIRA unless your doctor says it is okay. If you forget to take \\nHUMIRA, inject a dose as soon as you remember. Then, take your next dose at your \\nregular scheduled time. This will put you back on schedule. In case you are not sure when \\nto inject HUMIRA, call your doctor or pharmacist. \\n• If you take more HUMIRA than you were told to take, call your doctor. \\nWhat are the possible side effects of HUMIRA? \\nHUMIRA can cause serious side effects, including:  \\nSee “What is the most important information I should know about HUMIRA?” \\n• Serious Infections. \\nYour doctor will examine you for TB and perform a test to see if you have TB. If your doctor \\n', 'processed_text': {'sentences': [{'original_sentence': '◦ The needle cover for the HUMIRA Pen 40 mg/0.8 mL, HUMIRA 40 mg/0.8 mL prefilled \\nsyringe, HUMIRA 20 mg/0.4 mL prefilled syringe, and HUMIRA 10 mg/0.2 mL prefilled \\nsyringe may contain natural rubber or latex.', 'tokens': ['◦', 'needle', 'cover', 'HUMIRA', 'Pen', '40', 'mg/0.8', 'mL', ',', 'HUMIRA', '40', 'mg/0.8', 'mL', 'prefilled', 'syringe', ',', 'HUMIRA', '20', 'mg/0.4', 'mL', 'prefilled', 'syringe', ',', 'HUMIRA', '10', 'mg/0.2', 'mL', 'prefilled', 'syringe', 'may', 'contain', 'natural', 'rubber', 'latex', '.'], 'lemmatized': ['◦', 'needle', 'cover', 'HUMIRA', 'Pen', '40', 'mg/0.8', 'mL', ',', 'HUMIRA', '40', 'mg/0.8', 'mL', 'prefilled', 'syringe', ',', 'HUMIRA', '20', 'mg/0.4', 'mL', 'prefilled', 'syringe', ',', 'HUMIRA', '10', 'mg/0.2', 'mL', 'prefilled', 'syringe', 'may', 'contain', 'natural', 'rubber', 'latex', '.'], 'stemmed': ['◦', 'needl', 'cover', 'humira', 'pen', '40', 'mg/0.8', 'ml', ',', 'humira', '40', 'mg/0.8', 'ml', 'prefil', 'syring', ',', 'humira', '20', 'mg/0.4', 'ml', 'prefil', 'syring', ',', 'humira', '10', 'mg/0.2', 'ml', 'prefil', 'syring', 'may', 'contain', 'natur', 'rubber', 'latex', '.'], 'dependencies': [('◦', 'compound'), ('needl', 'nsubj'), ('cover', 'ROOT'), ('humira', 'compound'), ('pen', 'dobj'), ('40', 'nummod'), ('mg/0.8', 'dep'), ('ml', 'nmod'), (',', 'punct'), ('humira', 'appos'), ('40', 'nummod'), ('mg/0.8', 'appos'), ('ml', 'aux'), ('prefil', 'conj'), ('syring', 'dobj'), (',', 'punct'), ('humira', 'conj'), ('20', 'nummod'), ('mg/0.4', 'npadvmod'), ('ml', 'aux'), ('prefil', 'nsubj'), ('syring', 'dobj'), (',', 'punct'), ('humira', 'appos'), ('10', 'nummod'), ('mg/0.2', 'npadvmod'), ('ml', 'nmod'), ('prefil', 'compound'), ('syring', 'appos'), ('may', 'aux'), ('contain', 'ROOT'), ('natur', 'compound'), ('rubber', 'compound'), ('latex', 'dobj'), ('.', 'punct')]}, {'original_sentence': '◦ The black needle cover for the HUMIRA Pen 80 mg/0.8 mL, HUMIRA 80 mg/0.8 mL \\nprefilled syringe, HUMIRA Pen 40 mg/0.4 mL, HUMIRA 40 mg/0.4 mL prefilled syringe, \\nHUMIRA 20 mg/0.2 mL prefilled syringe, HUMIRA 10 mg/0.1 mL prefilled syringe and \\nthe vial stopper on the HUMIRA institutional use vial are not made with natural rubber \\nor latex.', 'tokens': ['◦', 'black', 'needle', 'cover', 'HUMIRA', 'Pen', '80', 'mg/0.8', 'mL', ',', 'HUMIRA', '80', 'mg/0.8', 'mL', 'prefilled', 'syringe', ',', 'HUMIRA', 'Pen', '40', 'mg/0.4', 'mL', ',', 'HUMIRA', '40', 'mg/0.4', 'mL', 'prefilled', 'syringe', ',', 'HUMIRA', '20', 'mg/0.2', 'mL', 'prefilled', 'syringe', ',', 'HUMIRA', '10', 'mg/0.1', 'mL', 'prefilled', 'syringe', 'vial', 'stopper', 'HUMIRA', 'institutional', 'use', 'vial', 'made', 'natural', 'rubber', 'latex', '.'], 'lemmatized': ['◦', 'black', 'needle', 'cover', 'HUMIRA', 'Pen', '80', 'mg/0.8', 'mL', ',', 'HUMIRA', '80', 'mg/0.8', 'mL', 'prefilled', 'syringe', ',', 'HUMIRA', 'Pen', '40', 'mg/0.4', 'mL', ',', 'HUMIRA', '40', 'mg/0.4', 'mL', 'prefilled', 'syringe', ',', 'HUMIRA', '20', 'mg/0.2', 'mL', 'prefilled', 'syringe', ',', 'HUMIRA', '10', 'mg/0.1', 'mL', 'prefilled', 'syringe', 'vial', 'stopper', 'HUMIRA', 'institutional', 'use', 'vial', 'made', 'natural', 'rubber', 'latex', '.'], 'stemmed': ['◦', 'black', 'needl', 'cover', 'humira', 'pen', '80', 'mg/0.8', 'ml', ',', 'humira', '80', 'mg/0.8', 'ml', 'prefil', 'syring', ',', 'humira', 'pen', '40', 'mg/0.4', 'ml', ',', 'humira', '40', 'mg/0.4', 'ml', 'prefil', 'syring', ',', 'humira', '20', 'mg/0.2', 'ml', 'prefil', 'syring', ',', 'humira', '10', 'mg/0.1', 'ml', 'prefil', 'syring', 'vial', 'stopper', 'humira', 'institut', 'use', 'vial', 'made', 'natur', 'rubber', 'latex', '.'], 'dependencies': [('◦', 'dep'), ('black', 'amod'), ('needl', 'nsubj'), ('cover', 'dep'), ('humira', 'compound'), ('pen', 'dobj'), ('80', 'nummod'), ('mg/0.8', 'dep'), ('ml', 'dobj'), (',', 'punct'), ('humira', 'appos'), ('80', 'nummod'), ('mg/0.8', 'npadvmod'), ('ml', 'aux'), ('prefil', 'conj'), ('syring', 'dobj'), (',', 'punct'), ('humira', 'compound'), ('pen', 'conj'), ('40', 'nummod'), ('mg/0.4', 'dep'), ('ml', 'ROOT'), (',', 'punct'), ('humira', 'appos'), ('40', 'nummod'), ('mg/0.4', 'punct'), ('ml', 'aux'), ('prefil', 'nsubj'), ('syring', 'dobj'), (',', 'punct'), ('humira', 'appos'), ('20', 'nummod'), ('mg/0.2', 'npadvmod'), ('ml', 'aux'), ('prefil', 'compound'), ('syring', 'dobj'), (',', 'punct'), ('humira', 'appos'), ('10', 'nummod'), ('mg/0.1', 'npadvmod'), ('ml', 'compound'), ('prefil', 'nmod'), ('syring', 'dobj'), ('vial', 'amod'), ('stopper', 'compound'), ('humira', 'nsubj'), ('institut', 'nsubj'), ('use', 'ROOT'), ('vial', 'advmod'), ('made', 'dep'), ('natur', 'compound'), ('rubber', 'compound'), ('latex', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• are allergic to HUMIRA or to any of its ingredients.', 'tokens': ['•', 'allergic', 'HUMIRA', 'ingredients', '.'], 'lemmatized': ['•', 'allergic', 'HUMIRA', 'ingredient', '.'], 'stemmed': ['•', 'allerg', 'humira', 'ingredi', '.'], 'dependencies': [('•', 'nummod'), ('allerg', 'compound'), ('humira', 'compound'), ('ingredi', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'See the end of this Medication Guide \\nfor a list of ingredients in HUMIRA.', 'tokens': ['See', 'end', 'Medication', 'Guide', 'list', 'ingredients', 'HUMIRA', '.'], 'lemmatized': ['See', 'end', 'Medication', 'Guide', 'list', 'ingredient', 'HUMIRA', '.'], 'stemmed': ['see', 'end', 'medic', 'guid', 'list', 'ingredi', 'humira', '.'], 'dependencies': [('see', 'ROOT'), ('end', 'compound'), ('medic', 'compound'), ('guid', 'compound'), ('list', 'compound'), ('ingredi', 'compound'), ('humira', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• are pregnant or plan to become pregnant, breastfeeding or plan to breastfeed.', 'tokens': ['•', 'pregnant', 'plan', 'become', 'pregnant', ',', 'breastfeeding', 'plan', 'breastfeed', '.'], 'lemmatized': ['•', 'pregnant', 'plan', 'become', 'pregnant', ',', 'breastfeeding', 'plan', 'breastfeed', '.'], 'stemmed': ['•', 'pregnant', 'plan', 'becom', 'pregnant', ',', 'breastfeed', 'plan', 'breastfe', '.'], 'dependencies': [('•', 'nummod'), ('pregnant', 'amod'), ('plan', 'compound'), ('becom', 'compound'), ('pregnant', 'advcl'), (',', 'punct'), ('breastfeed', 'ROOT'), ('plan', 'compound'), ('breastfe', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'You and \\nyour doctor should decide if you should take HUMIRA while you are pregnant or \\nbreastfeeding.', 'tokens': ['doctor', 'decide', 'take', 'HUMIRA', 'pregnant', 'breastfeeding', '.'], 'lemmatized': ['doctor', 'decide', 'take', 'HUMIRA', 'pregnant', 'breastfeeding', '.'], 'stemmed': ['doctor', 'decid', 'take', 'humira', 'pregnant', 'breastfeed', '.'], 'dependencies': [('doctor', 'compound'), ('decid', 'nsubj'), ('take', 'ROOT'), ('humira', 'nmod'), ('pregnant', 'amod'), ('breastfeed', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• have a baby and you were using HUMIRA during your pregnancy.', 'tokens': ['•', 'baby', 'using', 'HUMIRA', 'pregnancy', '.'], 'lemmatized': ['•', 'baby', 'using', 'HUMIRA', 'pregnancy', '.'], 'stemmed': ['•', 'babi', 'use', 'humira', 'pregnanc', '.'], 'dependencies': [('•', 'compound'), ('babi', 'nsubj'), ('use', 'ROOT'), ('humira', 'compound'), ('pregnanc', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Tell your baby’s doctor \\nbefore your baby receives any vaccines.', 'tokens': ['Tell', 'baby', '’', 'doctor', 'baby', 'receives', 'vaccines', '.'], 'lemmatized': ['Tell', 'baby', '’', 'doctor', 'baby', 'receives', 'vaccine', '.'], 'stemmed': ['tell', 'babi', '’', 'doctor', 'babi', 'receiv', 'vaccin', '.'], 'dependencies': [('tell', 'ROOT'), ('babi', 'poss'), ('’', 'punct'), ('doctor', 'compound'), ('babi', 'compound'), ('receiv', 'compound'), ('vaccin', 'ccomp'), ('.', 'punct')]}, {'original_sentence': 'Tell your doctor about all the medicines you take, including prescription and over-the-\\ncounter medicines, vitamins, and herbal supplements.', 'tokens': ['Tell', 'doctor', 'medicines', 'take', ',', 'including', 'prescription', 'over-the-', 'counter', 'medicines', ',', 'vitamins', ',', 'herbal', 'supplements', '.'], 'lemmatized': ['Tell', 'doctor', 'medicine', 'take', ',', 'including', 'prescription', 'over-the-', 'counter', 'medicine', ',', 'vitamin', ',', 'herbal', 'supplement', '.'], 'stemmed': ['tell', 'doctor', 'medicin', 'take', ',', 'includ', 'prescript', 'over-the-', 'counter', 'medicin', ',', 'vitamin', ',', 'herbal', 'supplement', '.'], 'dependencies': [('tell', 'ROOT'), ('doctor', 'compound'), ('medicin', 'dobj'), ('take', 'dobj'), (',', 'punct'), ('includ', 'amod'), ('prescript', 'nmod'), ('over', 'amod'), ('-', 'punct'), ('the-', 'dep'), ('counter', 'compound'), ('medicin', 'conj'), (',', 'punct'), ('vitamin', 'conj'), (',', 'punct'), ('herbal', 'amod'), ('supplement', 'conj'), ('.', 'punct')]}, {'original_sentence': 'Especially tell your doctor if you use: \\n• ORENCIA (abatacept), KINERET (anakinra), REMICADE (infliximab), ENBREL \\n(etanercept), CIMZIA (certolizumab pegol) or SIMPONI (golimumab), because you should \\nnot use HUMIRA while you are also using one of these medicines.', 'tokens': ['Especially', 'tell', 'doctor', 'use', ':', '•', 'ORENCIA', '(', 'abatacept', ')', ',', 'KINERET', '(', 'anakinra', ')', ',', 'REMICADE', '(', 'infliximab', ')', ',', 'ENBREL', '(', 'etanercept', ')', ',', 'CIMZIA', '(', 'certolizumab', 'pegol', ')', 'SIMPONI', '(', 'golimumab', ')', ',', 'use', 'HUMIRA', 'also', 'using', 'one', 'medicines', '.'], 'lemmatized': ['Especially', 'tell', 'doctor', 'use', ':', '•', 'ORENCIA', '(', 'abatacept', ')', ',', 'KINERET', '(', 'anakinra', ')', ',', 'REMICADE', '(', 'infliximab', ')', ',', 'ENBREL', '(', 'etanercept', ')', ',', 'CIMZIA', '(', 'certolizumab', 'pegol', ')', 'SIMPONI', '(', 'golimumab', ')', ',', 'use', 'HUMIRA', 'also', 'using', 'one', 'medicine', '.'], 'stemmed': ['especi', 'tell', 'doctor', 'use', ':', '•', 'orencia', '(', 'abatacept', ')', ',', 'kineret', '(', 'anakinra', ')', ',', 'remicad', '(', 'infliximab', ')', ',', 'enbrel', '(', 'etanercept', ')', ',', 'cimzia', '(', 'certolizumab', 'pegol', ')', 'simponi', '(', 'golimumab', ')', ',', 'use', 'humira', 'also', 'use', 'one', 'medicin', '.'], 'dependencies': [('especi', 'nsubj'), ('tell', 'ROOT'), ('doctor', 'compound'), ('use', 'dobj'), (':', 'punct'), ('•', 'compound'), ('orencia', 'nmod'), ('(', 'punct'), ('abatacept', 'parataxis'), (')', 'punct'), (',', 'punct'), ('kineret', 'conj'), ('(', 'punct'), ('anakinra', 'appos'), (')', 'punct'), (',', 'punct'), ('remicad', 'conj'), ('(', 'punct'), ('infliximab', 'appos'), (')', 'punct'), (',', 'punct'), ('enbrel', 'conj'), ('(', 'punct'), ('etanercept', 'parataxis'), (')', 'punct'), (',', 'punct'), ('cimzia', 'conj'), ('(', 'punct'), ('certolizumab', 'compound'), ('pegol', 'parataxis'), (')', 'punct'), ('simponi', 'appos'), ('(', 'punct'), ('golimumab', 'appos'), (')', 'punct'), (',', 'punct'), ('use', 'conj'), ('humira', 'dobj'), ('also', 'advmod'), ('use', 'ccomp'), ('one', 'nummod'), ('medicin', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• RITUXAN (rituximab).', 'tokens': ['•', 'RITUXAN', '(', 'rituximab', ')', '.'], 'lemmatized': ['•', 'RITUXAN', '(', 'rituximab', ')', '.'], 'stemmed': ['•', 'rituxan', '(', 'rituximab', ')', '.'], 'dependencies': [('•', 'nummod'), ('rituxan', 'ROOT'), ('(', 'punct'), ('rituximab', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Your doctor may not want to give you HUMIRA if you have received \\nRITUXAN (rituximab) recently.', 'tokens': ['doctor', 'may', 'want', 'give', 'HUMIRA', 'received', 'RITUXAN', '(', 'rituximab', ')', 'recently', '.'], 'lemmatized': ['doctor', 'may', 'want', 'give', 'HUMIRA', 'received', 'RITUXAN', '(', 'rituximab', ')', 'recently', '.'], 'stemmed': ['doctor', 'may', 'want', 'give', 'humira', 'receiv', 'rituxan', '(', 'rituximab', ')', 'recent', '.'], 'dependencies': [('doctor', 'nsubj'), ('may', 'aux'), ('want', 'ROOT'), ('give', 'xcomp'), ('humira', 'compound'), ('receiv', 'compound'), ('rituxan', 'dobj'), ('(', 'punct'), ('rituximab', 'appos'), (')', 'punct'), ('recent', 'conj'), ('.', 'punct')]}, {'original_sentence': '• IMURAN (azathioprine) or PURINETHOL (6–mercaptopurine, 6-MP).', 'tokens': ['•', 'IMURAN', '(', 'azathioprine', ')', 'PURINETHOL', '(', '6–mercaptopurine', ',', '6-MP', ')', '.'], 'lemmatized': ['•', 'IMURAN', '(', 'azathioprine', ')', 'PURINETHOL', '(', '6–mercaptopurine', ',', '6-MP', ')', '.'], 'stemmed': ['•', 'imuran', '(', 'azathioprin', ')', 'purinethol', '(', '6–mercaptopurin', ',', '6-mp', ')', '.'], 'dependencies': [('•', 'nummod'), ('imuran', 'ROOT'), ('(', 'punct'), ('azathioprin', 'appos'), (')', 'punct'), ('purinethol', 'appos'), ('(', 'punct'), ('6', 'appos'), ('–', 'punct'), ('mercaptopurin', 'appos'), (',', 'punct'), ('6', 'nummod'), ('-', 'punct'), ('mp', 'conj'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Keep a list of your medicines with you to show your doctor and pharmacist each time \\nyou get a new medicine.', 'tokens': ['Keep', 'list', 'medicines', 'show', 'doctor', 'pharmacist', 'time', 'get', 'new', 'medicine', '.'], 'lemmatized': ['Keep', 'list', 'medicine', 'show', 'doctor', 'pharmacist', 'time', 'get', 'new', 'medicine', '.'], 'stemmed': ['keep', 'list', 'medicin', 'show', 'doctor', 'pharmacist', 'time', 'get', 'new', 'medicin', '.'], 'dependencies': [('keep', 'ROOT'), ('list', 'compound'), ('medicin', 'dobj'), ('show', 'compound'), ('doctor', 'compound'), ('pharmacist', 'compound'), ('time', 'npadvmod'), ('get', 'dep'), ('new', 'amod'), ('medicin', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'How should I take HUMIRA?', 'tokens': ['take', 'HUMIRA', '?'], 'lemmatized': ['take', 'HUMIRA', '?'], 'stemmed': ['take', 'humira', '?'], 'dependencies': [('take', 'ROOT'), ('humira', 'dobj'), ('?', 'punct')]}, {'original_sentence': '• HUMIRA is given by an injection under the skin.', 'tokens': ['•', 'HUMIRA', 'given', 'injection', 'skin', '.'], 'lemmatized': ['•', 'HUMIRA', 'given', 'injection', 'skin', '.'], 'stemmed': ['•', 'humira', 'given', 'inject', 'skin', '.'], 'dependencies': [('•', 'nummod'), ('humira', 'nsubj'), ('given', 'ROOT'), ('inject', 'compound'), ('skin', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Your doctor will tell you how often to take \\nan injection of HUMIRA.', 'tokens': ['doctor', 'tell', 'often', 'take', 'injection', 'HUMIRA', '.'], 'lemmatized': ['doctor', 'tell', 'often', 'take', 'injection', 'HUMIRA', '.'], 'stemmed': ['doctor', 'tell', 'often', 'take', 'inject', 'humira', '.'], 'dependencies': [('doctor', 'compound'), ('tell', 'nsubj'), ('often', 'advmod'), ('take', 'ROOT'), ('inject', 'compound'), ('humira', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'This is based on your condition to be treated.', 'tokens': ['based', 'condition', 'treated', '.'], 'lemmatized': ['based', 'condition', 'treated', '.'], 'stemmed': ['base', 'condit', 'treat', '.'], 'dependencies': [('base', 'compound'), ('condit', 'compound'), ('treat', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Do not inject \\nHUMIRA more often than you were prescribed.', 'tokens': ['inject', 'HUMIRA', 'often', 'prescribed', '.'], 'lemmatized': ['inject', 'HUMIRA', 'often', 'prescribed', '.'], 'stemmed': ['inject', 'humira', 'often', 'prescrib', '.'], 'dependencies': [('inject', 'compound'), ('humira', 'nsubj'), ('often', 'advmod'), ('prescrib', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• See the Instructions for Use inside the carton for complete instructions for the right way \\nto prepare and inject HUMIRA.', 'tokens': ['•', 'See', 'Instructions', 'Use', 'inside', 'carton', 'complete', 'instructions', 'right', 'way', 'prepare', 'inject', 'HUMIRA', '.'], 'lemmatized': ['•', 'See', 'Instructions', 'Use', 'inside', 'carton', 'complete', 'instruction', 'right', 'way', 'prepare', 'inject', 'HUMIRA', '.'], 'stemmed': ['•', 'see', 'instruct', 'use', 'insid', 'carton', 'complet', 'instruct', 'right', 'way', 'prepar', 'inject', 'humira', '.'], 'dependencies': [('•', 'dep'), ('see', 'ROOT'), ('instruct', 'compound'), ('use', 'compound'), ('insid', 'compound'), ('carton', 'compound'), ('complet', 'nsubj'), ('instruct', 'ccomp'), ('right', 'amod'), ('way', 'npadvmod'), ('prepar', 'compound'), ('inject', 'compound'), ('humira', 'appos'), ('.', 'punct')]}, {'original_sentence': '• Make sure you have been shown how to inject HUMIRA before you do it yourself.', 'tokens': ['•', 'Make', 'sure', 'shown', 'inject', 'HUMIRA', '.'], 'lemmatized': ['•', 'Make', 'sure', 'shown', 'inject', 'HUMIRA', '.'], 'stemmed': ['•', 'make', 'sure', 'shown', 'inject', 'humira', '.'], 'dependencies': [('•', 'dep'), ('make', 'ROOT'), ('sure', 'advmod'), ('shown', 'ccomp'), ('inject', 'compound'), ('humira', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'You can \\ncall your doctor or 1-800-4HUMIRA (1-800-448-6472) if you have any questions about \\ngiving yourself an injection.', 'tokens': ['call', 'doctor', '1-800-4HUMIRA', '(', '1-800-448-6472', ')', 'questions', 'giving', 'injection', '.'], 'lemmatized': ['call', 'doctor', '1-800-4HUMIRA', '(', '1-800-448-6472', ')', 'question', 'giving', 'injection', '.'], 'stemmed': ['call', 'doctor', '1-800-4humira', '(', '1-800-448-6472', ')', 'question', 'give', 'inject', '.'], 'dependencies': [('call', 'ROOT'), ('doctor', 'dobj'), ('1', 'npadvmod'), ('-', 'punct'), ('800', 'dobj'), ('-', 'punct'), ('4humira', 'dobj'), ('(', 'punct'), ('1', 'appos'), ('-', 'punct'), ('800', 'prep'), ('-', 'punct'), ('448', 'pobj'), ('-', 'punct'), ('6472', 'prep'), (')', 'punct'), ('question', 'dobj'), ('give', 'dep'), ('inject', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Someone you know can also help you with your injection after \\nthey have been shown how to prepare and inject HUMIRA.', 'tokens': ['Someone', 'know', 'also', 'help', 'injection', 'shown', 'prepare', 'inject', 'HUMIRA', '.'], 'lemmatized': ['Someone', 'know', 'also', 'help', 'injection', 'shown', 'prepare', 'inject', 'HUMIRA', '.'], 'stemmed': ['someon', 'know', 'also', 'help', 'inject', 'shown', 'prepar', 'inject', 'humira', '.'], 'dependencies': [('someon', 'nsubj'), ('know', 'aux'), ('also', 'advmod'), ('help', 'ROOT'), ('inject', 'xcomp'), ('shown', 'xcomp'), ('prepar', 'compound'), ('inject', 'compound'), ('humira', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• Do not try to inject HUMIRA yourself until you have been shown the right way to give the \\ninjections.', 'tokens': ['•', 'try', 'inject', 'HUMIRA', 'shown', 'right', 'way', 'give', 'injections', '.'], 'lemmatized': ['•', 'try', 'inject', 'HUMIRA', 'shown', 'right', 'way', 'give', 'injection', '.'], 'stemmed': ['•', 'tri', 'inject', 'humira', 'shown', 'right', 'way', 'give', 'inject', '.'], 'dependencies': [('•', 'dep'), ('tri', 'compound'), ('inject', 'compound'), ('humira', 'nsubj'), ('shown', 'ROOT'), ('right', 'amod'), ('way', 'dobj'), ('give', 'xcomp'), ('inject', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'If your doctor decides that you or a caregiver may be able to give your injections \\nof HUMIRA at home, you should receive training on the right way to prepare and inject \\nHUMIRA.', 'tokens': ['doctor', 'decides', 'caregiver', 'may', 'able', 'give', 'injections', 'HUMIRA', 'home', ',', 'receive', 'training', 'right', 'way', 'prepare', 'inject', 'HUMIRA', '.'], 'lemmatized': ['doctor', 'decides', 'caregiver', 'may', 'able', 'give', 'injection', 'HUMIRA', 'home', ',', 'receive', 'training', 'right', 'way', 'prepare', 'inject', 'HUMIRA', '.'], 'stemmed': ['doctor', 'decid', 'caregiv', 'may', 'abl', 'give', 'inject', 'humira', 'home', ',', 'receiv', 'train', 'right', 'way', 'prepar', 'inject', 'humira', '.'], 'dependencies': [('doctor', 'compound'), ('decid', 'compound'), ('caregiv', 'nsubj'), ('may', 'aux'), ('abl', 'advmod'), ('give', 'ccomp'), ('inject', 'compound'), ('humira', 'compound'), ('home', 'dobj'), (',', 'punct'), ('receiv', 'compound'), ('train', 'ROOT'), ('right', 'amod'), ('way', 'npadvmod'), ('prepar', 'compound'), ('inject', 'compound'), ('humira', 'appos'), ('.', 'punct')]}, {'original_sentence': '• Do not miss any doses of HUMIRA unless your doctor says it is okay.', 'tokens': ['•', 'miss', 'doses', 'HUMIRA', 'unless', 'doctor', 'says', 'okay', '.'], 'lemmatized': ['•', 'miss', 'dos', 'HUMIRA', 'unless', 'doctor', 'say', 'okay', '.'], 'stemmed': ['•', 'miss', 'do', 'humira', 'unless', 'doctor', 'say', 'okay', '.'], 'dependencies': [('•', 'nummod'), ('miss', 'nmod'), ('do', 'aux'), ('humira', 'ROOT'), ('unless', 'mark'), ('doctor', 'nsubj'), ('say', 'advcl'), ('okay', 'intj'), ('.', 'punct')]}, {'original_sentence': 'If you forget to take \\nHUMIRA, inject a dose as soon as you remember.', 'tokens': ['forget', 'take', 'HUMIRA', ',', 'inject', 'dose', 'soon', 'remember', '.'], 'lemmatized': ['forget', 'take', 'HUMIRA', ',', 'inject', 'dose', 'soon', 'remember', '.'], 'stemmed': ['forget', 'take', 'humira', ',', 'inject', 'dose', 'soon', 'rememb', '.'], 'dependencies': [('forget', 'advcl'), ('take', 'xcomp'), ('humira', 'dobj'), (',', 'punct'), ('inject', 'compound'), ('dose', 'ROOT'), ('soon', 'advmod'), ('rememb', 'advmod'), ('.', 'punct')]}, {'original_sentence': 'Then, take your next dose at your \\nregular scheduled time.', 'tokens': [',', 'take', 'next', 'dose', 'regular', 'scheduled', 'time', '.'], 'lemmatized': [',', 'take', 'next', 'dose', 'regular', 'scheduled', 'time', '.'], 'stemmed': [',', 'take', 'next', 'dose', 'regular', 'schedul', 'time', '.'], 'dependencies': [(',', 'punct'), ('take', 'ROOT'), ('next', 'amod'), ('dose', 'dobj'), ('regular', 'amod'), ('schedul', 'compound'), ('time', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'This will put you back on schedule.', 'tokens': ['put', 'back', 'schedule', '.'], 'lemmatized': ['put', 'back', 'schedule', '.'], 'stemmed': ['put', 'back', 'schedul', '.'], 'dependencies': [('put', 'ROOT'), ('back', 'prt'), ('schedul', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'In case you are not sure when \\nto inject HUMIRA, call your doctor or pharmacist.', 'tokens': ['case', 'sure', 'inject', 'HUMIRA', ',', 'call', 'doctor', 'pharmacist', '.'], 'lemmatized': ['case', 'sure', 'inject', 'HUMIRA', ',', 'call', 'doctor', 'pharmacist', '.'], 'stemmed': ['case', 'sure', 'inject', 'humira', ',', 'call', 'doctor', 'pharmacist', '.'], 'dependencies': [('case', 'dep'), ('sure', 'advmod'), ('inject', 'compound'), ('humira', 'dobj'), (',', 'punct'), ('call', 'ROOT'), ('doctor', 'compound'), ('pharmacist', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• If you take more HUMIRA than you were told to take, call your doctor.', 'tokens': ['•', 'take', 'HUMIRA', 'told', 'take', ',', 'call', 'doctor', '.'], 'lemmatized': ['•', 'take', 'HUMIRA', 'told', 'take', ',', 'call', 'doctor', '.'], 'stemmed': ['•', 'take', 'humira', 'told', 'take', ',', 'call', 'doctor', '.'], 'dependencies': [('•', 'dep'), ('take', 'compound'), ('humira', 'nsubj'), ('told', 'ROOT'), ('take', 'xcomp'), (',', 'punct'), ('call', 'compound'), ('doctor', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'What are the possible side effects of HUMIRA?', 'tokens': ['possible', 'side', 'effects', 'HUMIRA', '?'], 'lemmatized': ['possible', 'side', 'effect', 'HUMIRA', '?'], 'stemmed': ['possibl', 'side', 'effect', 'humira', '?'], 'dependencies': [('possibl', 'compound'), ('side', 'compound'), ('effect', 'compound'), ('humira', 'ROOT'), ('?', 'punct')]}, {'original_sentence': 'HUMIRA can cause serious side effects, including:  \\nSee “What is the most important information I should know about HUMIRA?” \\n• Serious Infections.', 'tokens': ['HUMIRA', 'cause', 'serious', 'side', 'effects', ',', 'including', ':', 'See', '“', 'important', 'information', 'know', 'HUMIRA', '?', '”', '•', 'Serious', 'Infections', '.'], 'lemmatized': ['HUMIRA', 'cause', 'serious', 'side', 'effect', ',', 'including', ':', 'See', '“', 'important', 'information', 'know', 'HUMIRA', '?', '”', '•', 'Serious', 'Infections', '.'], 'stemmed': ['humira', 'caus', 'seriou', 'side', 'effect', ',', 'includ', ':', 'see', '“', 'import', 'inform', 'know', 'humira', '?', '”', '•', 'seriou', 'infect', '.'], 'dependencies': [('humira', 'compound'), ('caus', 'compound'), ('seriou', 'compound'), ('side', 'compound'), ('effect', 'nsubj'), (',', 'punct'), ('includ', 'ROOT'), (':', 'punct'), ('see', 'xcomp'), ('“', 'punct'), ('import', 'compound'), ('inform', 'nsubj'), ('know', 'ccomp'), ('humira', 'dobj'), ('?', 'punct'), ('”', 'punct'), ('•', 'nummod'), ('seriou', 'compound'), ('infect', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Your doctor will examine you for TB and perform a test to see if you have TB.', 'tokens': ['doctor', 'examine', 'TB', 'perform', 'test', 'see', 'TB', '.'], 'lemmatized': ['doctor', 'examine', 'TB', 'perform', 'test', 'see', 'TB', '.'], 'stemmed': ['doctor', 'examin', 'tb', 'perform', 'test', 'see', 'tb', '.'], 'dependencies': [('doctor', 'compound'), ('examin', 'nsubj'), ('tb', 'prep'), ('perform', 'compound'), ('test', 'pobj'), ('see', 'ROOT'), ('tb', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'If your doctor', 'tokens': ['doctor'], 'lemmatized': ['doctor'], 'stemmed': ['doctor'], 'dependencies': [('doctor', 'ROOT')]}], 'text': '◦ The needle cover for the HUMIRA Pen 40 mg/0.8 mL, HUMIRA 40 mg/0.8 mL prefilled \\nsyringe, HUMIRA 20 mg/0.4 mL prefilled syringe, and HUMIRA 10 mg/0.2 mL prefilled \\nsyringe may contain natural rubber or latex.  \\n◦ The black needle cover for the HUMIRA Pen 80 mg/0.8 mL, HUMIRA 80 mg/0.8 mL \\nprefilled syringe, HUMIRA Pen 40 mg/0.4 mL, HUMIRA 40 mg/0.4 mL prefilled syringe, \\nHUMIRA 20 mg/0.2 mL prefilled syringe, HUMIRA 10 mg/0.1 mL prefilled syringe and \\nthe vial stopper on the HUMIRA institutional use vial are not made with natural rubber \\nor latex.  \\n• are allergic to HUMIRA or to any of its ingredients. See the end of this Medication Guide \\nfor a list of ingredients in HUMIRA. \\n• are pregnant or plan to become pregnant, breastfeeding or plan to breastfeed. You and \\nyour doctor should decide if you should take HUMIRA while you are pregnant or \\nbreastfeeding.  \\n• have a baby and you were using HUMIRA during your pregnancy. Tell your baby’s doctor \\nbefore your baby receives any vaccines. \\nTell your doctor about all the medicines you take, including prescription and over-the-\\ncounter medicines, vitamins, and herbal supplements.  \\nEspecially tell your doctor if you use: \\n• ORENCIA (abatacept), KINERET (anakinra), REMICADE (infliximab), ENBREL \\n(etanercept), CIMZIA (certolizumab pegol) or SIMPONI (golimumab), because you should \\nnot use HUMIRA while you are also using one of these medicines.  \\n• RITUXAN (rituximab). Your doctor may not want to give you HUMIRA if you have received \\nRITUXAN (rituximab) recently.  \\n• IMURAN (azathioprine) or PURINETHOL (6–mercaptopurine, 6-MP).  \\nKeep a list of your medicines with you to show your doctor and pharmacist each time \\nyou get a new medicine. \\nHow should I take HUMIRA? \\n• HUMIRA is given by an injection under the skin. Your doctor will tell you how often to take \\nan injection of HUMIRA. This is based on your condition to be treated. Do not inject \\nHUMIRA more often than you were prescribed. \\n• See the Instructions for Use inside the carton for complete instructions for the right way \\nto prepare and inject HUMIRA.  \\n• Make sure you have been shown how to inject HUMIRA before you do it yourself. You can \\ncall your doctor or 1-800-4HUMIRA (1-800-448-6472) if you have any questions about \\ngiving yourself an injection. Someone you know can also help you with your injection after \\nthey have been shown how to prepare and inject HUMIRA.  \\n• Do not try to inject HUMIRA yourself until you have been shown the right way to give the \\ninjections. If your doctor decides that you or a caregiver may be able to give your injections \\nof HUMIRA at home, you should receive training on the right way to prepare and inject \\nHUMIRA.  \\n• Do not miss any doses of HUMIRA unless your doctor says it is okay. If you forget to take \\nHUMIRA, inject a dose as soon as you remember. Then, take your next dose at your \\nregular scheduled time. This will put you back on schedule. In case you are not sure when \\nto inject HUMIRA, call your doctor or pharmacist. \\n• If you take more HUMIRA than you were told to take, call your doctor. \\nWhat are the possible side effects of HUMIRA? \\nHUMIRA can cause serious side effects, including:  \\nSee “What is the most important information I should know about HUMIRA?” \\n• Serious Infections. \\nYour doctor will examine you for TB and perform a test to see if you have TB. If your doctor \\n'}, 'page_char_count': 3376, 'page_word_count': 577, 'sentences': ['◦ The needle cover for the HUMIRA Pen 40 mg/0.8 mL, HUMIRA 40 mg/0.8 mL prefilled \\nsyringe, HUMIRA 20 mg/0.4 mL prefilled syringe, and HUMIRA 10 mg/0.2 mL prefilled \\nsyringe may contain natural rubber or latex.', ' \\n◦ The black needle cover for the HUMIRA Pen 80 mg/0.8 mL, HUMIRA 80 mg/0.8 mL \\nprefilled syringe, HUMIRA Pen 40 mg/0.4 mL, HUMIRA 40 mg/0.4 mL prefilled syringe, \\nHUMIRA 20 mg/0.2 mL prefilled syringe, HUMIRA 10 mg/0.1 mL prefilled syringe and \\nthe vial stopper on the HUMIRA institutional use vial are not made with natural rubber \\nor latex.', ' \\n• are allergic to HUMIRA or to any of its ingredients.', 'See the end of this Medication Guide \\nfor a list of ingredients in HUMIRA.', '\\n• are pregnant or plan to become pregnant, breastfeeding or plan to breastfeed.', 'You and \\nyour doctor should decide if you should take HUMIRA while you are pregnant or \\nbreastfeeding.', ' \\n• have a baby and you were using HUMIRA during your pregnancy.', 'Tell your baby’s doctor \\nbefore your baby receives any vaccines.', '\\nTell your doctor about all the medicines you take, including prescription and over-the-\\ncounter medicines, vitamins, and herbal supplements.', ' \\nEspecially tell your doctor if you use: \\n• ORENCIA (abatacept), KINERET (anakinra), REMICADE (infliximab), ENBREL \\n(etanercept), CIMZIA (certolizumab pegol) or SIMPONI (golimumab), because you should \\nnot use HUMIRA while you are also using one of these medicines.', ' \\n• RITUXAN (rituximab).', 'Your doctor may not want to give you HUMIRA if you have received \\nRITUXAN (rituximab) recently.', ' \\n• IMURAN (azathioprine) or PURINETHOL (6–mercaptopurine, 6-MP).', ' \\nKeep a list of your medicines with you to show your doctor and pharmacist each time \\nyou get a new medicine.', '\\nHow should I take HUMIRA?', '\\n• HUMIRA is given by an injection under the skin.', 'Your doctor will tell you how often to take \\nan injection of HUMIRA.', 'This is based on your condition to be treated.', 'Do not inject \\nHUMIRA more often than you were prescribed.', '\\n• See the Instructions for Use inside the carton for complete instructions for the right way \\nto prepare and inject HUMIRA.', ' \\n• Make sure you have been shown how to inject HUMIRA before you do it yourself.', 'You can \\ncall your doctor or 1-800-4HUMIRA (1-800-448-6472) if you have any questions about \\ngiving yourself an injection.', 'Someone you know can also help you with your injection after \\nthey have been shown how to prepare and inject HUMIRA.', ' \\n• Do not try to inject HUMIRA yourself until you have been shown the right way to give the \\ninjections.', 'If your doctor decides that you or a caregiver may be able to give your injections \\nof HUMIRA at home, you should receive training on the right way to prepare and inject \\nHUMIRA.', ' \\n• Do not miss any doses of HUMIRA unless your doctor says it is okay.', 'If you forget to take \\nHUMIRA, inject a dose as soon as you remember.', 'Then, take your next dose at your \\nregular scheduled time.', 'This will put you back on schedule.', 'In case you are not sure when \\nto inject HUMIRA, call your doctor or pharmacist.', '\\n• If you take more HUMIRA than you were told to take, call your doctor.', '\\nWhat are the possible side effects of HUMIRA?', '\\nHUMIRA can cause serious side effects, including:  \\nSee “What is the most important information I should know about HUMIRA?”', '\\n• Serious Infections.', '\\nYour doctor will examine you for TB and perform a test to see if you have TB.', 'If your doctor \\n'], 'page_sentence_count_spacy': 36}\n",
            "{'page_number': 62, 'text': 'feels that you are at risk for TB, you may be treated with medicine for TB before you begin \\ntreatment with HUMIRA and during treatment with HUMIRA. Even if your TB test is \\nnegative your doctor should carefully monitor you for TB infections while you are taking \\nHUMIRA. People who had a negative TB skin test before receiving HUMIRA have \\ndeveloped active TB. Tell your doctor if you have any of the following symptoms while \\ntaking or after taking HUMIRA:  \\n  \\n◦ cough that does not go away \\n◦ low grade fever \\n◦ weight loss \\n◦ loss of body fat and muscle (wasting) \\n• Hepatitis B infection in people who carry the virus in their blood. \\nIf you are a carrier of the hepatitis B virus (a virus that affects the liver), the virus can \\nbecome active while you use HUMIRA. Your doctor should do blood tests before you start \\ntreatment, while you are using HUMIRA, and for several months after you stop treatment \\nwith HUMIRA. Tell your doctor if you have any of the following symptoms of a possible \\nhepatitis B infection:  \\n  \\n◦ muscle aches \\n◦ feel very tired \\n◦ dark urine \\n◦ skin or eyes look yellow \\n◦ little or no appetite \\n◦ vomiting \\n◦ clay-colored bowel movements \\n◦ fever \\n◦ chills \\n◦ stomach discomfort  \\n◦ skin rash \\n• \\nAllergic reactions. Allergic reactions can happen in people who use HUMIRA. Call your \\ndoctor or get medical help right away if you have any of these symptoms of a serious \\nallergic reaction: \\no hives \\no trouble breathing \\n◦ swelling of your face, eyes, lips or mouth \\n• Nervous system problems. Signs and symptoms of a nervous system problem include: \\nnumbness or tingling, problems with your vision, weakness in your arms or legs, and \\ndizziness.  \\n• Blood problems. Your body may not make enough of the blood cells that help fight \\ninfections or help to stop bleeding. Symptoms include a fever that does not go away, \\nbruising or bleeding very easily, or looking very pale.  \\n• New heart failure or worsening of heart failure you already have. Call your doctor \\nright away if you get new worsening symptoms of heart failure while taking HUMIRA, \\nincluding:  \\n  \\n◦ shortness of breath \\n◦ sudden weight gain \\n◦ swelling of your ankles or feet \\n• Immune reactions including a lupus-like syndrome. Symptoms include chest \\ndiscomfort or pain that does not go away, shortness of breath, joint pain, or a rash on your \\ncheeks or arms that gets worse in the sun. Symptoms may improve when you stop \\nHUMIRA.  \\n• Liver problems. Liver problems can happen in people who use TNF-blocker medicines. \\nThese problems can lead to liver failure and death. Call your doctor right away if you have \\nany of these symptoms:  \\no \\nfeel very tired \\no \\nskin or eyes look yellow \\no \\npoor appetite or vomiting \\no \\npain on the right side of your \\nstomach (abdomen) \\n• Psoriasis. Some people using HUMIRA had new psoriasis or worsening of psoriasis they \\nalready had. Tell your doctor if you develop red scaly patches or raised bumps that are \\nfilled with pus. Your doctor may decide to stop your treatment with HUMIRA. \\n', 'processed_text': {'sentences': [{'original_sentence': 'feels that you are at risk for TB, you may be treated with medicine for TB before you begin \\ntreatment with HUMIRA and during treatment with HUMIRA.', 'tokens': ['feels', 'risk', 'TB', ',', 'may', 'treated', 'medicine', 'TB', 'begin', 'treatment', 'HUMIRA', 'treatment', 'HUMIRA', '.'], 'lemmatized': ['feel', 'risk', 'TB', ',', 'may', 'treated', 'medicine', 'TB', 'begin', 'treatment', 'HUMIRA', 'treatment', 'HUMIRA', '.'], 'stemmed': ['feel', 'risk', 'tb', ',', 'may', 'treat', 'medicin', 'tb', 'begin', 'treatment', 'humira', 'treatment', 'humira', '.'], 'dependencies': [('feel', 'ROOT'), ('risk', 'compound'), ('tb', 'dobj'), (',', 'punct'), ('may', 'aux'), ('treat', 'conj'), ('medicin', 'dobj'), ('tb', 'prep'), ('begin', 'advcl'), ('treatment', 'compound'), ('humira', 'compound'), ('treatment', 'compound'), ('humira', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Even if your TB test is \\nnegative your doctor should carefully monitor you for TB infections while you are taking \\nHUMIRA.', 'tokens': ['Even', 'TB', 'test', 'negative', 'doctor', 'carefully', 'monitor', 'TB', 'infections', 'taking', 'HUMIRA', '.'], 'lemmatized': ['Even', 'TB', 'test', 'negative', 'doctor', 'carefully', 'monitor', 'TB', 'infection', 'taking', 'HUMIRA', '.'], 'stemmed': ['even', 'tb', 'test', 'neg', 'doctor', 'care', 'monitor', 'tb', 'infect', 'take', 'humira', '.'], 'dependencies': [('even', 'advmod'), ('tb', 'ROOT'), ('test', 'compound'), ('neg', 'compound'), ('doctor', 'compound'), ('care', 'compound'), ('monitor', 'pobj'), ('tb', 'compound'), ('infect', 'compound'), ('take', 'compound'), ('humira', 'appos'), ('.', 'punct')]}, {'original_sentence': 'People who had a negative TB skin test before receiving HUMIRA have \\ndeveloped active TB.', 'tokens': ['People', 'negative', 'TB', 'skin', 'test', 'receiving', 'HUMIRA', 'developed', 'active', 'TB', '.'], 'lemmatized': ['People', 'negative', 'TB', 'skin', 'test', 'receiving', 'HUMIRA', 'developed', 'active', 'TB', '.'], 'stemmed': ['peopl', 'neg', 'tb', 'skin', 'test', 'receiv', 'humira', 'develop', 'activ', 'tb', '.'], 'dependencies': [('peopl', 'compound'), ('neg', 'compound'), ('tb', 'compound'), ('skin', 'compound'), ('test', 'compound'), ('receiv', 'compound'), ('humira', 'nsubj'), ('develop', 'ROOT'), ('activ', 'compound'), ('tb', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Tell your doctor if you have any of the following symptoms while \\ntaking or after taking HUMIRA:  \\n  \\n◦ cough that does not go away \\n◦ low grade fever \\n◦ weight loss \\n◦ loss of body fat and muscle (wasting) \\n• Hepatitis B infection in people who carry the virus in their blood.', 'tokens': ['Tell', 'doctor', 'following', 'symptoms', 'taking', 'taking', 'HUMIRA', ':', '◦', 'cough', 'go', 'away', '◦', 'low', 'grade', 'fever', '◦', 'weight', 'loss', '◦', 'loss', 'body', 'fat', 'muscle', '(', 'wasting', ')', '•', 'Hepatitis', 'B', 'infection', 'people', 'carry', 'virus', 'blood', '.'], 'lemmatized': ['Tell', 'doctor', 'following', 'symptom', 'taking', 'taking', 'HUMIRA', ':', '◦', 'cough', 'go', 'away', '◦', 'low', 'grade', 'fever', '◦', 'weight', 'loss', '◦', 'loss', 'body', 'fat', 'muscle', '(', 'wasting', ')', '•', 'Hepatitis', 'B', 'infection', 'people', 'carry', 'virus', 'blood', '.'], 'stemmed': ['tell', 'doctor', 'follow', 'symptom', 'take', 'take', 'humira', ':', '◦', 'cough', 'go', 'away', '◦', 'low', 'grade', 'fever', '◦', 'weight', 'loss', '◦', 'loss', 'bodi', 'fat', 'muscl', '(', 'wast', ')', '•', 'hepat', 'b', 'infect', 'peopl', 'carri', 'viru', 'blood', '.'], 'dependencies': [('tell', 'ccomp'), ('doctor', 'compound'), ('follow', 'compound'), ('symptom', 'nsubj'), ('take', 'compound'), ('take', 'dobj'), ('humira', 'dobj'), (':', 'punct'), ('◦', 'compound'), ('cough', 'nsubj'), ('go', 'ROOT'), ('away', 'advmod'), ('◦', 'advcl'), ('low', 'amod'), ('grade', 'compound'), ('fever', 'compound'), ('◦', 'compound'), ('weight', 'compound'), ('loss', 'compound'), ('◦', 'compound'), ('loss', 'compound'), ('bodi', 'dobj'), ('fat', 'compound'), ('muscl', 'appos'), ('(', 'punct'), ('wast', 'appos'), (')', 'punct'), ('•', 'nummod'), ('hepat', 'compound'), ('b', 'compound'), ('infect', 'amod'), ('peopl', 'compound'), ('carri', 'compound'), ('viru', 'compound'), ('blood', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'If you are a carrier of the hepatitis B virus (a virus that affects the liver), the virus can \\nbecome active while you use HUMIRA.', 'tokens': ['carrier', 'hepatitis', 'B', 'virus', '(', 'virus', 'affects', 'liver', ')', ',', 'virus', 'become', 'active', 'use', 'HUMIRA', '.'], 'lemmatized': ['carrier', 'hepatitis', 'B', 'virus', '(', 'virus', 'affect', 'liver', ')', ',', 'virus', 'become', 'active', 'use', 'HUMIRA', '.'], 'stemmed': ['carrier', 'hepat', 'b', 'viru', '(', 'viru', 'affect', 'liver', ')', ',', 'viru', 'becom', 'activ', 'use', 'humira', '.'], 'dependencies': [('carrier', 'compound'), ('hepat', 'compound'), ('b', 'compound'), ('viru', 'ROOT'), ('(', 'punct'), ('viru', 'nsubj'), ('affect', 'parataxis'), ('liver', 'dobj'), (')', 'punct'), (',', 'punct'), ('viru', 'compound'), ('becom', 'compound'), ('activ', 'compound'), ('use', 'appos'), ('humira', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Your doctor should do blood tests before you start \\ntreatment, while you are using HUMIRA, and for several months after you stop treatment \\nwith HUMIRA.', 'tokens': ['doctor', 'blood', 'tests', 'start', 'treatment', ',', 'using', 'HUMIRA', ',', 'several', 'months', 'stop', 'treatment', 'HUMIRA', '.'], 'lemmatized': ['doctor', 'blood', 'test', 'start', 'treatment', ',', 'using', 'HUMIRA', ',', 'several', 'month', 'stop', 'treatment', 'HUMIRA', '.'], 'stemmed': ['doctor', 'blood', 'test', 'start', 'treatment', ',', 'use', 'humira', ',', 'sever', 'month', 'stop', 'treatment', 'humira', '.'], 'dependencies': [('doctor', 'compound'), ('blood', 'compound'), ('test', 'nsubj'), ('start', 'advcl'), ('treatment', 'dobj'), (',', 'punct'), ('use', 'conj'), ('humira', 'dobj'), (',', 'punct'), ('sever', 'amod'), ('month', 'npadvmod'), ('stop', 'ROOT'), ('treatment', 'compound'), ('humira', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Tell your doctor if you have any of the following symptoms of a possible \\nhepatitis B infection:  \\n  \\n◦ muscle aches \\n◦ feel very tired \\n◦ dark urine \\n◦ skin or eyes look yellow \\n◦ little or no appetite \\n◦ vomiting \\n◦ clay-colored bowel movements \\n◦ fever \\n◦ chills \\n◦ stomach discomfort  \\n◦ skin rash \\n• \\nAllergic reactions.', 'tokens': ['Tell', 'doctor', 'following', 'symptoms', 'possible', 'hepatitis', 'B', 'infection', ':', '◦', 'muscle', 'aches', '◦', 'feel', 'tired', '◦', 'dark', 'urine', '◦', 'skin', 'eyes', 'look', 'yellow', '◦', 'little', 'appetite', '◦', 'vomiting', '◦', 'clay-colored', 'bowel', 'movements', '◦', 'fever', '◦', 'chills', '◦', 'stomach', 'discomfort', '◦', 'skin', 'rash', '•', 'Allergic', 'reactions', '.'], 'lemmatized': ['Tell', 'doctor', 'following', 'symptom', 'possible', 'hepatitis', 'B', 'infection', ':', '◦', 'muscle', 'ache', '◦', 'feel', 'tired', '◦', 'dark', 'urine', '◦', 'skin', 'eye', 'look', 'yellow', '◦', 'little', 'appetite', '◦', 'vomiting', '◦', 'clay-colored', 'bowel', 'movement', '◦', 'fever', '◦', 'chill', '◦', 'stomach', 'discomfort', '◦', 'skin', 'rash', '•', 'Allergic', 'reaction', '.'], 'stemmed': ['tell', 'doctor', 'follow', 'symptom', 'possibl', 'hepat', 'b', 'infect', ':', '◦', 'muscl', 'ach', '◦', 'feel', 'tire', '◦', 'dark', 'urin', '◦', 'skin', 'eye', 'look', 'yellow', '◦', 'littl', 'appetit', '◦', 'vomit', '◦', 'clay-color', 'bowel', 'movement', '◦', 'fever', '◦', 'chill', '◦', 'stomach', 'discomfort', '◦', 'skin', 'rash', '•', 'allerg', 'reaction', '.'], 'dependencies': [('tell', 'ROOT'), ('doctor', 'compound'), ('follow', 'compound'), ('symptom', 'compound'), ('possibl', 'compound'), ('hepat', 'compound'), ('b', 'compound'), ('infect', 'dobj'), (':', 'punct'), ('◦', 'advcl'), ('muscl', 'compound'), ('ach', 'compound'), ('◦', 'nsubj'), ('feel', 'ccomp'), ('tire', 'compound'), ('◦', 'dep'), ('dark', 'amod'), ('urin', 'compound'), ('◦', 'npadvmod'), ('skin', 'compound'), ('eye', 'nsubj'), ('look', 'ccomp'), ('yellow', 'amod'), ('◦', 'compound'), ('littl', 'compound'), ('appetit', 'compound'), ('◦', 'compound'), ('vomit', 'advcl'), ('◦', 'compound'), ('clay', 'compound'), ('-', 'punct'), ('color', 'compound'), ('bowel', 'compound'), ('movement', 'compound'), ('◦', 'compound'), ('fever', 'compound'), ('◦', 'compound'), ('chill', 'compound'), ('◦', 'compound'), ('stomach', 'compound'), ('discomfort', 'compound'), ('◦', 'compound'), ('skin', 'nsubj'), ('rash', 'nmod'), ('•', 'cc'), ('allerg', 'compound'), ('reaction', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Allergic reactions can happen in people who use HUMIRA.', 'tokens': ['Allergic', 'reactions', 'happen', 'people', 'use', 'HUMIRA', '.'], 'lemmatized': ['Allergic', 'reaction', 'happen', 'people', 'use', 'HUMIRA', '.'], 'stemmed': ['allerg', 'reaction', 'happen', 'peopl', 'use', 'humira', '.'], 'dependencies': [('allerg', 'compound'), ('reaction', 'nsubj'), ('happen', 'ROOT'), ('peopl', 'compound'), ('use', 'compound'), ('humira', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Call your \\ndoctor or get medical help right away if you have any of these symptoms of a serious \\nallergic reaction: \\no hives \\no trouble breathing \\n◦ swelling of your face, eyes, lips or mouth \\n• Nervous system problems.', 'tokens': ['Call', 'doctor', 'get', 'medical', 'help', 'right', 'away', 'symptoms', 'serious', 'allergic', 'reaction', ':', 'hives', 'trouble', 'breathing', '◦', 'swelling', 'face', ',', 'eyes', ',', 'lips', 'mouth', '•', 'Nervous', 'system', 'problems', '.'], 'lemmatized': ['Call', 'doctor', 'get', 'medical', 'help', 'right', 'away', 'symptom', 'serious', 'allergic', 'reaction', ':', 'hive', 'trouble', 'breathing', '◦', 'swelling', 'face', ',', 'eye', ',', 'lip', 'mouth', '•', 'Nervous', 'system', 'problem', '.'], 'stemmed': ['call', 'doctor', 'get', 'medic', 'help', 'right', 'away', 'symptom', 'seriou', 'allerg', 'reaction', ':', 'hive', 'troubl', 'breath', '◦', 'swell', 'face', ',', 'eye', ',', 'lip', 'mouth', '•', 'nervou', 'system', 'problem', '.'], 'dependencies': [('call', 'advcl'), ('doctor', 'dobj'), ('get', 'dep'), ('medic', 'compound'), ('help', 'dobj'), ('right', 'advmod'), ('away', 'advmod'), ('symptom', 'compound'), ('seriou', 'compound'), ('allerg', 'compound'), ('reaction', 'dobj'), (':', 'punct'), ('hive', 'compound'), ('troubl', 'compound'), ('breath', 'compound'), ('◦', 'nmod'), ('swell', 'amod'), ('face', 'appos'), (',', 'punct'), ('eye', 'conj'), (',', 'punct'), ('lip', 'compound'), ('mouth', 'ROOT'), ('•', 'case'), ('nervou', 'compound'), ('system', 'compound'), ('problem', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Signs and symptoms of a nervous system problem include: \\nnumbness or tingling, problems with your vision, weakness in your arms or legs, and \\ndizziness.', 'tokens': ['Signs', 'symptoms', 'nervous', 'system', 'problem', 'include', ':', 'numbness', 'tingling', ',', 'problems', 'vision', ',', 'weakness', 'arms', 'legs', ',', 'dizziness', '.'], 'lemmatized': ['Signs', 'symptom', 'nervous', 'system', 'problem', 'include', ':', 'numbness', 'tingling', ',', 'problem', 'vision', ',', 'weakness', 'arm', 'leg', ',', 'dizziness', '.'], 'stemmed': ['sign', 'symptom', 'nervou', 'system', 'problem', 'includ', ':', 'numb', 'tingl', ',', 'problem', 'vision', ',', 'weak', 'arm', 'leg', ',', 'dizzi', '.'], 'dependencies': [('sign', 'compound'), ('symptom', 'compound'), ('nervou', 'compound'), ('system', 'compound'), ('problem', 'nsubj'), ('includ', 'ROOT'), (':', 'punct'), ('numb', 'amod'), ('tingl', 'appos'), (',', 'punct'), ('problem', 'compound'), ('vision', 'conj'), (',', 'punct'), ('weak', 'amod'), ('arm', 'compound'), ('leg', 'conj'), (',', 'punct'), ('dizzi', 'conj'), ('.', 'punct')]}, {'original_sentence': '• Blood problems.', 'tokens': ['•', 'Blood', 'problems', '.'], 'lemmatized': ['•', 'Blood', 'problem', '.'], 'stemmed': ['•', 'blood', 'problem', '.'], 'dependencies': [('•', 'nummod'), ('blood', 'compound'), ('problem', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Your body may not make enough of the blood cells that help fight \\ninfections or help to stop bleeding.', 'tokens': ['body', 'may', 'make', 'enough', 'blood', 'cells', 'help', 'fight', 'infections', 'help', 'stop', 'bleeding', '.'], 'lemmatized': ['body', 'may', 'make', 'enough', 'blood', 'cell', 'help', 'fight', 'infection', 'help', 'stop', 'bleeding', '.'], 'stemmed': ['bodi', 'may', 'make', 'enough', 'blood', 'cell', 'help', 'fight', 'infect', 'help', 'stop', 'bleed', '.'], 'dependencies': [('bodi', 'nsubj'), ('may', 'aux'), ('make', 'ROOT'), ('enough', 'amod'), ('blood', 'compound'), ('cell', 'compound'), ('help', 'nsubj'), ('fight', 'xcomp'), ('infect', 'amod'), ('help', 'dobj'), ('stop', 'ccomp'), ('bleed', 'xcomp'), ('.', 'punct')]}, {'original_sentence': 'Symptoms include a fever that does not go away, \\nbruising or bleeding very easily, or looking very pale.', 'tokens': ['Symptoms', 'include', 'fever', 'go', 'away', ',', 'bruising', 'bleeding', 'easily', ',', 'looking', 'pale', '.'], 'lemmatized': ['Symptoms', 'include', 'fever', 'go', 'away', ',', 'bruising', 'bleeding', 'easily', ',', 'looking', 'pale', '.'], 'stemmed': ['symptom', 'includ', 'fever', 'go', 'away', ',', 'bruis', 'bleed', 'easili', ',', 'look', 'pale', '.'], 'dependencies': [('symptom', 'compound'), ('includ', 'compound'), ('fever', 'nsubj'), ('go', 'ccomp'), ('away', 'advmod'), (',', 'punct'), ('bruis', 'compound'), ('bleed', 'compound'), ('easili', 'nsubj'), (',', 'punct'), ('look', 'ROOT'), ('pale', 'acomp'), ('.', 'punct')]}, {'original_sentence': '• New heart failure or worsening of heart failure you already have.', 'tokens': ['•', 'New', 'heart', 'failure', 'worsening', 'heart', 'failure', 'already', '.'], 'lemmatized': ['•', 'New', 'heart', 'failure', 'worsening', 'heart', 'failure', 'already', '.'], 'stemmed': ['•', 'new', 'heart', 'failur', 'worsen', 'heart', 'failur', 'alreadi', '.'], 'dependencies': [('•', 'nummod'), ('new', 'amod'), ('heart', 'compound'), ('failur', 'compound'), ('worsen', 'compound'), ('heart', 'compound'), ('failur', 'compound'), ('alreadi', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Call your doctor \\nright away if you get new worsening symptoms of heart failure while taking HUMIRA, \\nincluding:  \\n  \\n◦ shortness of breath \\n◦ sudden weight gain \\n◦ swelling of your ankles or feet \\n• Immune reactions including a lupus-like syndrome.', 'tokens': ['Call', 'doctor', 'right', 'away', 'get', 'new', 'worsening', 'symptoms', 'heart', 'failure', 'taking', 'HUMIRA', ',', 'including', ':', '◦', 'shortness', 'breath', '◦', 'sudden', 'weight', 'gain', '◦', 'swelling', 'ankles', 'feet', '•', 'Immune', 'reactions', 'including', 'lupus-like', 'syndrome', '.'], 'lemmatized': ['Call', 'doctor', 'right', 'away', 'get', 'new', 'worsening', 'symptom', 'heart', 'failure', 'taking', 'HUMIRA', ',', 'including', ':', '◦', 'shortness', 'breath', '◦', 'sudden', 'weight', 'gain', '◦', 'swelling', 'ankle', 'foot', '•', 'Immune', 'reaction', 'including', 'lupus-like', 'syndrome', '.'], 'stemmed': ['call', 'doctor', 'right', 'away', 'get', 'new', 'worsen', 'symptom', 'heart', 'failur', 'take', 'humira', ',', 'includ', ':', '◦', 'short', 'breath', '◦', 'sudden', 'weight', 'gain', '◦', 'swell', 'ankl', 'foot', '•', 'immun', 'reaction', 'includ', 'lupus-lik', 'syndrom', '.'], 'dependencies': [('call', 'advcl'), ('doctor', 'dobj'), ('right', 'advmod'), ('away', 'advmod'), ('get', 'dep'), ('new', 'amod'), ('worsen', 'compound'), ('symptom', 'compound'), ('heart', 'compound'), ('failur', 'compound'), ('take', 'compound'), ('humira', 'dobj'), (',', 'punct'), ('includ', 'ROOT'), (':', 'punct'), ('◦', 'xcomp'), ('short', 'amod'), ('breath', 'dobj'), ('◦', 'nmod'), ('sudden', 'amod'), ('weight', 'compound'), ('gain', 'dobj'), ('◦', 'nmod'), ('swell', 'compound'), ('ankl', 'compound'), ('foot', 'nmod'), ('•', 'nummod'), ('immun', 'compound'), ('reaction', 'compound'), ('includ', 'compound'), ('lupus', 'compound'), ('-', 'punct'), ('lik', 'compound'), ('syndrom', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Symptoms include chest \\ndiscomfort or pain that does not go away, shortness of breath, joint pain, or a rash on your \\ncheeks or arms that gets worse in the sun.', 'tokens': ['Symptoms', 'include', 'chest', 'discomfort', 'pain', 'go', 'away', ',', 'shortness', 'breath', ',', 'joint', 'pain', ',', 'rash', 'cheeks', 'arms', 'gets', 'worse', 'sun', '.'], 'lemmatized': ['Symptoms', 'include', 'chest', 'discomfort', 'pain', 'go', 'away', ',', 'shortness', 'breath', ',', 'joint', 'pain', ',', 'rash', 'cheek', 'arm', 'get', 'worse', 'sun', '.'], 'stemmed': ['symptom', 'includ', 'chest', 'discomfort', 'pain', 'go', 'away', ',', 'short', 'breath', ',', 'joint', 'pain', ',', 'rash', 'cheek', 'arm', 'get', 'wors', 'sun', '.'], 'dependencies': [('symptom', 'compound'), ('includ', 'compound'), ('chest', 'compound'), ('discomfort', 'compound'), ('pain', 'nsubj'), ('go', 'ccomp'), ('away', 'advmod'), (',', 'punct'), ('short', 'amod'), ('breath', 'nsubj'), (',', 'punct'), ('joint', 'amod'), ('pain', 'conj'), (',', 'punct'), ('rash', 'amod'), ('cheek', 'compound'), ('arm', 'conj'), ('get', 'ROOT'), ('wors', 'nsubj'), ('sun', 'ccomp'), ('.', 'punct')]}, {'original_sentence': 'Symptoms may improve when you stop \\nHUMIRA.', 'tokens': ['Symptoms', 'may', 'improve', 'stop', 'HUMIRA', '.'], 'lemmatized': ['Symptoms', 'may', 'improve', 'stop', 'HUMIRA', '.'], 'stemmed': ['symptom', 'may', 'improv', 'stop', 'humira', '.'], 'dependencies': [('symptom', 'nsubj'), ('may', 'aux'), ('improv', 'advmod'), ('stop', 'ROOT'), ('humira', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• Liver problems.', 'tokens': ['•', 'Liver', 'problems', '.'], 'lemmatized': ['•', 'Liver', 'problem', '.'], 'stemmed': ['•', 'liver', 'problem', '.'], 'dependencies': [('•', 'nummod'), ('liver', 'compound'), ('problem', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Liver problems can happen in people who use TNF-blocker medicines.', 'tokens': ['Liver', 'problems', 'happen', 'people', 'use', 'TNF-blocker', 'medicines', '.'], 'lemmatized': ['Liver', 'problem', 'happen', 'people', 'use', 'TNF-blocker', 'medicine', '.'], 'stemmed': ['liver', 'problem', 'happen', 'peopl', 'use', 'tnf-blocker', 'medicin', '.'], 'dependencies': [('liver', 'compound'), ('problem', 'nsubj'), ('happen', 'ROOT'), ('peopl', 'compound'), ('use', 'compound'), ('tnf', 'compound'), ('-', 'compound'), ('blocker', 'compound'), ('medicin', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'These problems can lead to liver failure and death.', 'tokens': ['problems', 'lead', 'liver', 'failure', 'death', '.'], 'lemmatized': ['problem', 'lead', 'liver', 'failure', 'death', '.'], 'stemmed': ['problem', 'lead', 'liver', 'failur', 'death', '.'], 'dependencies': [('problem', 'nsubj'), ('lead', 'ROOT'), ('liver', 'compound'), ('failur', 'compound'), ('death', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Call your doctor right away if you have \\nany of these symptoms:  \\no \\nfeel very tired \\no \\nskin or eyes look yellow \\no \\npoor appetite or vomiting \\no \\npain on the right side of your \\nstomach (abdomen) \\n• Psoriasis.', 'tokens': ['Call', 'doctor', 'right', 'away', 'symptoms', ':', 'feel', 'tired', 'skin', 'eyes', 'look', 'yellow', 'poor', 'appetite', 'vomiting', 'pain', 'right', 'side', 'stomach', '(', 'abdomen', ')', '•', 'Psoriasis', '.'], 'lemmatized': ['Call', 'doctor', 'right', 'away', 'symptom', ':', 'feel', 'tired', 'skin', 'eye', 'look', 'yellow', 'poor', 'appetite', 'vomiting', 'pain', 'right', 'side', 'stomach', '(', 'abdomen', ')', '•', 'Psoriasis', '.'], 'stemmed': ['call', 'doctor', 'right', 'away', 'symptom', ':', 'feel', 'tire', 'skin', 'eye', 'look', 'yellow', 'poor', 'appetit', 'vomit', 'pain', 'right', 'side', 'stomach', '(', 'abdomen', ')', '•', 'psoriasi', '.'], 'dependencies': [('call', 'ccomp'), ('doctor', 'dobj'), ('right', 'advmod'), ('away', 'advmod'), ('symptom', 'dobj'), (':', 'punct'), ('feel', 'ROOT'), ('tire', 'compound'), ('skin', 'compound'), ('eye', 'nsubj'), ('look', 'ccomp'), ('yellow', 'amod'), ('poor', 'amod'), ('appetit', 'dobj'), ('vomit', 'conj'), ('pain', 'compound'), ('right', 'amod'), ('side', 'compound'), ('stomach', 'dobj'), ('(', 'punct'), ('abdomen', 'appos'), (')', 'punct'), ('•', 'nummod'), ('psoriasi', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Some people using HUMIRA had new psoriasis or worsening of psoriasis they \\nalready had.', 'tokens': ['people', 'using', 'HUMIRA', 'new', 'psoriasis', 'worsening', 'psoriasis', 'already', '.'], 'lemmatized': ['people', 'using', 'HUMIRA', 'new', 'psoriasis', 'worsening', 'psoriasis', 'already', '.'], 'stemmed': ['peopl', 'use', 'humira', 'new', 'psoriasi', 'worsen', 'psoriasi', 'alreadi', '.'], 'dependencies': [('peopl', 'compound'), ('use', 'ROOT'), ('humira', 'nmod'), ('new', 'amod'), ('psoriasi', 'compound'), ('worsen', 'compound'), ('psoriasi', 'compound'), ('alreadi', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Tell your doctor if you develop red scaly patches or raised bumps that are \\nfilled with pus.', 'tokens': ['Tell', 'doctor', 'develop', 'red', 'scaly', 'patches', 'raised', 'bumps', 'filled', 'pus', '.'], 'lemmatized': ['Tell', 'doctor', 'develop', 'red', 'scaly', 'patch', 'raised', 'bump', 'filled', 'pu', '.'], 'stemmed': ['tell', 'doctor', 'develop', 'red', 'scali', 'patch', 'rais', 'bump', 'fill', 'pu', '.'], 'dependencies': [('tell', 'ROOT'), ('doctor', 'dobj'), ('develop', 'xcomp'), ('red', 'amod'), ('scali', 'compound'), ('patch', 'compound'), ('rais', 'compound'), ('bump', 'compound'), ('fill', 'dobj'), ('pu', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Your doctor may decide to stop your treatment with HUMIRA.', 'tokens': ['doctor', 'may', 'decide', 'stop', 'treatment', 'HUMIRA', '.'], 'lemmatized': ['doctor', 'may', 'decide', 'stop', 'treatment', 'HUMIRA', '.'], 'stemmed': ['doctor', 'may', 'decid', 'stop', 'treatment', 'humira', '.'], 'dependencies': [('doctor', 'nsubj'), ('may', 'aux'), ('decid', 'ROOT'), ('stop', 'xcomp'), ('treatment', 'compound'), ('humira', 'dobj'), ('.', 'punct')]}], 'text': 'feels that you are at risk for TB, you may be treated with medicine for TB before you begin \\ntreatment with HUMIRA and during treatment with HUMIRA. Even if your TB test is \\nnegative your doctor should carefully monitor you for TB infections while you are taking \\nHUMIRA. People who had a negative TB skin test before receiving HUMIRA have \\ndeveloped active TB. Tell your doctor if you have any of the following symptoms while \\ntaking or after taking HUMIRA:  \\n  \\n◦ cough that does not go away \\n◦ low grade fever \\n◦ weight loss \\n◦ loss of body fat and muscle (wasting) \\n• Hepatitis B infection in people who carry the virus in their blood. \\nIf you are a carrier of the hepatitis B virus (a virus that affects the liver), the virus can \\nbecome active while you use HUMIRA. Your doctor should do blood tests before you start \\ntreatment, while you are using HUMIRA, and for several months after you stop treatment \\nwith HUMIRA. Tell your doctor if you have any of the following symptoms of a possible \\nhepatitis B infection:  \\n  \\n◦ muscle aches \\n◦ feel very tired \\n◦ dark urine \\n◦ skin or eyes look yellow \\n◦ little or no appetite \\n◦ vomiting \\n◦ clay-colored bowel movements \\n◦ fever \\n◦ chills \\n◦ stomach discomfort  \\n◦ skin rash \\n• \\nAllergic reactions. Allergic reactions can happen in people who use HUMIRA. Call your \\ndoctor or get medical help right away if you have any of these symptoms of a serious \\nallergic reaction: \\no hives \\no trouble breathing \\n◦ swelling of your face, eyes, lips or mouth \\n• Nervous system problems. Signs and symptoms of a nervous system problem include: \\nnumbness or tingling, problems with your vision, weakness in your arms or legs, and \\ndizziness.  \\n• Blood problems. Your body may not make enough of the blood cells that help fight \\ninfections or help to stop bleeding. Symptoms include a fever that does not go away, \\nbruising or bleeding very easily, or looking very pale.  \\n• New heart failure or worsening of heart failure you already have. Call your doctor \\nright away if you get new worsening symptoms of heart failure while taking HUMIRA, \\nincluding:  \\n  \\n◦ shortness of breath \\n◦ sudden weight gain \\n◦ swelling of your ankles or feet \\n• Immune reactions including a lupus-like syndrome. Symptoms include chest \\ndiscomfort or pain that does not go away, shortness of breath, joint pain, or a rash on your \\ncheeks or arms that gets worse in the sun. Symptoms may improve when you stop \\nHUMIRA.  \\n• Liver problems. Liver problems can happen in people who use TNF-blocker medicines. \\nThese problems can lead to liver failure and death. Call your doctor right away if you have \\nany of these symptoms:  \\no \\nfeel very tired \\no \\nskin or eyes look yellow \\no \\npoor appetite or vomiting \\no \\npain on the right side of your \\nstomach (abdomen) \\n• Psoriasis. Some people using HUMIRA had new psoriasis or worsening of psoriasis they \\nalready had. Tell your doctor if you develop red scaly patches or raised bumps that are \\nfilled with pus. Your doctor may decide to stop your treatment with HUMIRA. \\n'}, 'page_char_count': 3026, 'page_word_count': 525, 'sentences': ['feels that you are at risk for TB, you may be treated with medicine for TB before you begin \\ntreatment with HUMIRA and during treatment with HUMIRA.', 'Even if your TB test is \\nnegative your doctor should carefully monitor you for TB infections while you are taking \\nHUMIRA.', 'People who had a negative TB skin test before receiving HUMIRA have \\ndeveloped active TB.', 'Tell your doctor if you have any of the following symptoms while \\ntaking or after taking HUMIRA:  \\n  \\n◦ cough that does not go away \\n◦ low grade fever \\n◦ weight loss \\n◦ loss of body fat and muscle (wasting) \\n• Hepatitis B infection in people who carry the virus in their blood.', '\\nIf you are a carrier of the hepatitis B virus (a virus that affects the liver), the virus can \\nbecome active while you use HUMIRA.', 'Your doctor should do blood tests before you start \\ntreatment, while you are using HUMIRA, and for several months after you stop treatment \\nwith HUMIRA.', 'Tell your doctor if you have any of the following symptoms of a possible \\nhepatitis B infection:  \\n  \\n◦ muscle aches \\n◦ feel very tired \\n◦ dark urine \\n◦ skin or eyes look yellow \\n◦ little or no appetite \\n◦ vomiting \\n◦ clay-colored bowel movements \\n◦ fever \\n◦ chills \\n◦ stomach discomfort  \\n◦ skin rash \\n• \\nAllergic reactions.', 'Allergic reactions can happen in people who use HUMIRA.', 'Call your \\ndoctor or get medical help right away if you have any of these symptoms of a serious \\nallergic reaction: \\no hives \\no trouble breathing \\n◦ swelling of your face, eyes, lips or mouth \\n• Nervous system problems.', 'Signs and symptoms of a nervous system problem include: \\nnumbness or tingling, problems with your vision, weakness in your arms or legs, and \\ndizziness.', ' \\n• Blood problems.', 'Your body may not make enough of the blood cells that help fight \\ninfections or help to stop bleeding.', 'Symptoms include a fever that does not go away, \\nbruising or bleeding very easily, or looking very pale.', ' \\n• New heart failure or worsening of heart failure you already have.', 'Call your doctor \\nright away if you get new worsening symptoms of heart failure while taking HUMIRA, \\nincluding:  \\n  \\n◦ shortness of breath \\n◦ sudden weight gain \\n◦ swelling of your ankles or feet \\n• Immune reactions including a lupus-like syndrome.', 'Symptoms include chest \\ndiscomfort or pain that does not go away, shortness of breath, joint pain, or a rash on your \\ncheeks or arms that gets worse in the sun.', 'Symptoms may improve when you stop \\nHUMIRA.', ' \\n• Liver problems.', 'Liver problems can happen in people who use TNF-blocker medicines.', '\\nThese problems can lead to liver failure and death.', 'Call your doctor right away if you have \\nany of these symptoms:  \\no \\nfeel very tired \\no \\nskin or eyes look yellow \\no \\npoor appetite or vomiting \\no \\npain on the right side of your \\nstomach (abdomen) \\n• Psoriasis.', 'Some people using HUMIRA had new psoriasis or worsening of psoriasis they \\nalready had.', 'Tell your doctor if you develop red scaly patches or raised bumps that are \\nfilled with pus.', 'Your doctor may decide to stop your treatment with HUMIRA.', '\\n'], 'page_sentence_count_spacy': 25}\n",
            "{'page_number': 63, 'text': 'Call your doctor or get medical care right away if you develop any of the above \\nsymptoms. Your treatment with HUMIRA may be stopped. \\n \\nThe most common side effects of HUMIRA include: \\n• injection site reactions: redness, rash, swelling, itching, or bruising. These symptoms \\nusually will go away within a few days. Call your doctor right away if you have pain, \\nredness or swelling around the injection site that does not go away within a few days or \\ngets worse.  \\n• upper respiratory infections (including sinus infections). \\n• headaches. \\n• rash. \\nThese are not all the possible side effects with HUMIRA. Tell your doctor if you have any side \\neffect that bothers you or that does not go away. Ask your doctor or pharmacist for more \\ninformation.  \\nCall your doctor for medical advice about side effects. You may report side effects to FDA at 1-\\n800-FDA-1088.  \\nHow should I store HUMIRA? \\n• Store HUMIRA in the refrigerator at 36ºF to 46ºF (2ºC to 8ºC). Store HUMIRA in the \\noriginal carton until use to protect it from light.  \\n• Do not freeze HUMIRA. Do not use HUMIRA if frozen, even if it has been thawed.  \\n• Refrigerated HUMIRA may be used until the expiration date printed on the HUMIRA carton, \\ndose tray, Pen or prefilled syringe. Do not use HUMIRA after the expiration date.  \\n• If needed, for example when you are traveling, you may also store HUMIRA at room \\ntemperature up to 77°F (25°C) for up to 14 days. Store HUMIRA in the original carton until \\nuse to protect it from light.  \\n• Throw away HUMIRA if it has been kept at room temperature and not been used within 14 \\ndays. \\n• Record the date you first remove HUMIRA from the refrigerator in the spaces provided on \\nthe carton and dose tray. \\n• Do not store HUMIRA in extreme heat or cold. \\n• Do not use a Pen or prefilled syringe if the liquid is cloudy, discolored, or has flakes or \\nparticles in it. \\n• Do not drop or crush HUMIRA. The prefilled syringe is glass. \\nKeep HUMIRA, injection supplies, and all other medicines out of the reach of children. \\nGeneral information about the safe and effective use of HUMIRA. \\nMedicines are sometimes prescribed for purposes other than those listed in a Medication \\nGuide. Do not use HUMIRA for a condition for which it was not prescribed. Do not give \\nHUMIRA to other people, even if they have the same condition. It may harm them.  \\nThis Medication Guide summarizes the most important information about HUMIRA. If you \\nwould like more information, talk with your doctor. You can ask your pharmacist or doctor for \\ninformation about HUMIRA that is written for health professionals.  \\nWhat are the ingredients in HUMIRA? \\nActive ingredient: adalimumab  \\n \\nHUMIRA Pen 40 mg/0.8 mL, HUMIRA 40 mg/0.8 mL prefilled syringe, HUMIRA 20 mg/0.4 mL \\nprefilled syringe, HUMIRA 10 mg/0.2 mL prefilled syringe, and HUMIRA 40 mg/0.8 mL \\ninstitutional use vial:  \\n \\n', 'processed_text': {'sentences': [{'original_sentence': 'Call your doctor or get medical care right away if you develop any of the above \\nsymptoms.', 'tokens': ['Call', 'doctor', 'get', 'medical', 'care', 'right', 'away', 'develop', 'symptoms', '.'], 'lemmatized': ['Call', 'doctor', 'get', 'medical', 'care', 'right', 'away', 'develop', 'symptom', '.'], 'stemmed': ['call', 'doctor', 'get', 'medic', 'care', 'right', 'away', 'develop', 'symptom', '.'], 'dependencies': [('call', 'nsubj'), ('doctor', 'dobj'), ('get', 'ROOT'), ('medic', 'compound'), ('care', 'dobj'), ('right', 'advmod'), ('away', 'advmod'), ('develop', 'dep'), ('symptom', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Your treatment with HUMIRA may be stopped.', 'tokens': ['treatment', 'HUMIRA', 'may', 'stopped', '.'], 'lemmatized': ['treatment', 'HUMIRA', 'may', 'stopped', '.'], 'stemmed': ['treatment', 'humira', 'may', 'stop', '.'], 'dependencies': [('treatment', 'compound'), ('humira', 'nsubj'), ('may', 'aux'), ('stop', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'The most common side effects of HUMIRA include: \\n• injection site reactions: redness, rash, swelling, itching, or bruising.', 'tokens': ['common', 'side', 'effects', 'HUMIRA', 'include', ':', '•', 'injection', 'site', 'reactions', ':', 'redness', ',', 'rash', ',', 'swelling', ',', 'itching', ',', 'bruising', '.'], 'lemmatized': ['common', 'side', 'effect', 'HUMIRA', 'include', ':', '•', 'injection', 'site', 'reaction', ':', 'redness', ',', 'rash', ',', 'swelling', ',', 'itching', ',', 'bruising', '.'], 'stemmed': ['common', 'side', 'effect', 'humira', 'includ', ':', '•', 'inject', 'site', 'reaction', ':', 'red', ',', 'rash', ',', 'swell', ',', 'itch', ',', 'bruis', '.'], 'dependencies': [('common', 'amod'), ('side', 'compound'), ('effect', 'nsubj'), ('humira', 'nsubj'), ('includ', 'ROOT'), (':', 'punct'), ('•', 'nummod'), ('inject', 'compound'), ('site', 'compound'), ('reaction', 'appos'), (':', 'punct'), ('red', 'amod'), (',', 'punct'), ('rash', 'conj'), (',', 'punct'), ('swell', 'conj'), (',', 'punct'), ('itch', 'conj'), (',', 'punct'), ('bruis', 'conj'), ('.', 'punct')]}, {'original_sentence': 'These symptoms \\nusually will go away within a few days.', 'tokens': ['symptoms', 'usually', 'go', 'away', 'within', 'days', '.'], 'lemmatized': ['symptom', 'usually', 'go', 'away', 'within', 'day', '.'], 'stemmed': ['symptom', 'usual', 'go', 'away', 'within', 'day', '.'], 'dependencies': [('symptom', 'compound'), ('usual', 'nsubj'), ('go', 'ROOT'), ('away', 'advmod'), ('within', 'prep'), ('day', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'Call your doctor right away if you have pain, \\nredness or swelling around the injection site that does not go away within a few days or \\ngets worse.', 'tokens': ['Call', 'doctor', 'right', 'away', 'pain', ',', 'redness', 'swelling', 'around', 'injection', 'site', 'go', 'away', 'within', 'days', 'gets', 'worse', '.'], 'lemmatized': ['Call', 'doctor', 'right', 'away', 'pain', ',', 'redness', 'swelling', 'around', 'injection', 'site', 'go', 'away', 'within', 'day', 'get', 'worse', '.'], 'stemmed': ['call', 'doctor', 'right', 'away', 'pain', ',', 'red', 'swell', 'around', 'inject', 'site', 'go', 'away', 'within', 'day', 'get', 'wors', '.'], 'dependencies': [('call', 'advcl'), ('doctor', 'dobj'), ('right', 'advmod'), ('away', 'advmod'), ('pain', 'dobj'), (',', 'punct'), ('red', 'amod'), ('swell', 'nsubj'), ('around', 'prep'), ('inject', 'compound'), ('site', 'pobj'), ('go', 'ROOT'), ('away', 'advmod'), ('within', 'prep'), ('day', 'pobj'), ('get', 'advcl'), ('wors', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• upper respiratory infections (including sinus infections).', 'tokens': ['•', 'upper', 'respiratory', 'infections', '(', 'including', 'sinus', 'infections', ')', '.'], 'lemmatized': ['•', 'upper', 'respiratory', 'infection', '(', 'including', 'sinus', 'infection', ')', '.'], 'stemmed': ['•', 'upper', 'respiratori', 'infect', '(', 'includ', 'sinu', 'infect', ')', '.'], 'dependencies': [('•', 'nummod'), ('upper', 'amod'), ('respiratori', 'compound'), ('infect', 'ROOT'), ('(', 'punct'), ('includ', 'compound'), ('sinu', 'compound'), ('infect', 'parataxis'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': '• headaches.', 'tokens': ['•', 'headaches', '.'], 'lemmatized': ['•', 'headache', '.'], 'stemmed': ['•', 'headach', '.'], 'dependencies': [('•', 'nummod'), ('headach', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• rash.', 'tokens': ['•', 'rash', '.'], 'lemmatized': ['•', 'rash', '.'], 'stemmed': ['•', 'rash', '.'], 'dependencies': [('•', 'nummod'), ('rash', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'These are not all the possible side effects with HUMIRA.', 'tokens': ['possible', 'side', 'effects', 'HUMIRA', '.'], 'lemmatized': ['possible', 'side', 'effect', 'HUMIRA', '.'], 'stemmed': ['possibl', 'side', 'effect', 'humira', '.'], 'dependencies': [('possibl', 'compound'), ('side', 'compound'), ('effect', 'compound'), ('humira', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Tell your doctor if you have any side \\neffect that bothers you or that does not go away.', 'tokens': ['Tell', 'doctor', 'side', 'effect', 'bothers', 'go', 'away', '.'], 'lemmatized': ['Tell', 'doctor', 'side', 'effect', 'bother', 'go', 'away', '.'], 'stemmed': ['tell', 'doctor', 'side', 'effect', 'bother', 'go', 'away', '.'], 'dependencies': [('tell', 'ROOT'), ('doctor', 'compound'), ('side', 'compound'), ('effect', 'compound'), ('bother', 'ccomp'), ('go', 'xcomp'), ('away', 'advmod'), ('.', 'punct')]}, {'original_sentence': 'Ask your doctor or pharmacist for more \\ninformation.', 'tokens': ['Ask', 'doctor', 'pharmacist', 'information', '.'], 'lemmatized': ['Ask', 'doctor', 'pharmacist', 'information', '.'], 'stemmed': ['ask', 'doctor', 'pharmacist', 'inform', '.'], 'dependencies': [('ask', 'ROOT'), ('doctor', 'compound'), ('pharmacist', 'compound'), ('inform', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Call your doctor for medical advice about side effects.', 'tokens': ['Call', 'doctor', 'medical', 'advice', 'side', 'effects', '.'], 'lemmatized': ['Call', 'doctor', 'medical', 'advice', 'side', 'effect', '.'], 'stemmed': ['call', 'doctor', 'medic', 'advic', 'side', 'effect', '.'], 'dependencies': [('call', 'ROOT'), ('doctor', 'compound'), ('medic', 'npadvmod'), ('advic', 'amod'), ('side', 'compound'), ('effect', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'You may report side effects to FDA at 1-\\n800-FDA-1088.', 'tokens': ['may', 'report', 'side', 'effects', 'FDA', '1-', '800-FDA-1088', '.'], 'lemmatized': ['may', 'report', 'side', 'effect', 'FDA', '1-', '800-FDA-1088', '.'], 'stemmed': ['may', 'report', 'side', 'effect', 'fda', '1-', '800-fda-1088', '.'], 'dependencies': [('may', 'aux'), ('report', 'ROOT'), ('side', 'compound'), ('effect', 'dobj'), ('fda', 'npadvmod'), ('1-', 'compound'), ('800', 'nummod'), ('-', 'punct'), ('fda-1088', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'How should I store HUMIRA?', 'tokens': ['store', 'HUMIRA', '?'], 'lemmatized': ['store', 'HUMIRA', '?'], 'stemmed': ['store', 'humira', '?'], 'dependencies': [('store', 'compound'), ('humira', 'ROOT'), ('?', 'punct')]}, {'original_sentence': '• Store HUMIRA in the refrigerator at 36ºF to 46ºF (2ºC to 8ºC).', 'tokens': ['•', 'Store', 'HUMIRA', 'refrigerator', '36ºF', '46ºF', '(', '2ºC', '8ºC', ')', '.'], 'lemmatized': ['•', 'Store', 'HUMIRA', 'refrigerator', '36ºF', '46ºF', '(', '2ºC', '8ºC', ')', '.'], 'stemmed': ['•', 'store', 'humira', 'refriger', '36ºf', '46ºf', '(', '2ºc', '8ºc', ')', '.'], 'dependencies': [('•', 'nummod'), ('store', 'nmod'), ('humira', 'compound'), ('refriger', 'compound'), ('36ºf', 'compound'), ('46ºf', 'ROOT'), ('(', 'punct'), ('2ºc', 'amod'), ('8ºc', 'parataxis'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Store HUMIRA in the \\noriginal carton until use to protect it from light.', 'tokens': ['Store', 'HUMIRA', 'original', 'carton', 'use', 'protect', 'light', '.'], 'lemmatized': ['Store', 'HUMIRA', 'original', 'carton', 'use', 'protect', 'light', '.'], 'stemmed': ['store', 'humira', 'origin', 'carton', 'use', 'protect', 'light', '.'], 'dependencies': [('store', 'compound'), ('humira', 'compound'), ('origin', 'compound'), ('carton', 'compound'), ('use', 'compound'), ('protect', 'compound'), ('light', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• Do not freeze HUMIRA.', 'tokens': ['•', 'freeze', 'HUMIRA', '.'], 'lemmatized': ['•', 'freeze', 'HUMIRA', '.'], 'stemmed': ['•', 'freez', 'humira', '.'], 'dependencies': [('•', 'nummod'), ('freez', 'compound'), ('humira', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Do not use HUMIRA if frozen, even if it has been thawed.', 'tokens': ['use', 'HUMIRA', 'frozen', ',', 'even', 'thawed', '.'], 'lemmatized': ['use', 'HUMIRA', 'frozen', ',', 'even', 'thawed', '.'], 'stemmed': ['use', 'humira', 'frozen', ',', 'even', 'thaw', '.'], 'dependencies': [('use', 'ROOT'), ('humira', 'npadvmod'), ('frozen', 'amod'), (',', 'punct'), ('even', 'advmod'), ('thaw', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• Refrigerated HUMIRA may be used until the expiration date printed on the HUMIRA carton, \\ndose tray, Pen or prefilled syringe.', 'tokens': ['•', 'Refrigerated', 'HUMIRA', 'may', 'used', 'expiration', 'date', 'printed', 'HUMIRA', 'carton', ',', 'dose', 'tray', ',', 'Pen', 'prefilled', 'syringe', '.'], 'lemmatized': ['•', 'Refrigerated', 'HUMIRA', 'may', 'used', 'expiration', 'date', 'printed', 'HUMIRA', 'carton', ',', 'dose', 'tray', ',', 'Pen', 'prefilled', 'syringe', '.'], 'stemmed': ['•', 'refriger', 'humira', 'may', 'use', 'expir', 'date', 'print', 'humira', 'carton', ',', 'dose', 'tray', ',', 'pen', 'prefil', 'syring', '.'], 'dependencies': [('•', 'nummod'), ('refriger', 'compound'), ('humira', 'nsubj'), ('may', 'aux'), ('use', 'ROOT'), ('expir', 'compound'), ('date', 'compound'), ('print', 'compound'), ('humira', 'compound'), ('carton', 'dobj'), (',', 'punct'), ('dose', 'compound'), ('tray', 'conj'), (',', 'punct'), ('pen', 'compound'), ('prefil', 'nsubj'), ('syring', 'ccomp'), ('.', 'punct')]}, {'original_sentence': 'Do not use HUMIRA after the expiration date.', 'tokens': ['use', 'HUMIRA', 'expiration', 'date', '.'], 'lemmatized': ['use', 'HUMIRA', 'expiration', 'date', '.'], 'stemmed': ['use', 'humira', 'expir', 'date', '.'], 'dependencies': [('use', 'ROOT'), ('humira', 'compound'), ('expir', 'compound'), ('date', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• If needed, for example when you are traveling, you may also store HUMIRA at room \\ntemperature up to 77°F (25°C) for up to 14 days.', 'tokens': ['•', 'needed', ',', 'example', 'traveling', ',', 'may', 'also', 'store', 'HUMIRA', 'room', 'temperature', '77°F', '(', '25°C', ')', '14', 'days', '.'], 'lemmatized': ['•', 'needed', ',', 'example', 'traveling', ',', 'may', 'also', 'store', 'HUMIRA', 'room', 'temperature', '77°F', '(', '25°C', ')', '14', 'day', '.'], 'stemmed': ['•', 'need', ',', 'exampl', 'travel', ',', 'may', 'also', 'store', 'humira', 'room', 'temperatur', '77°f', '(', '25°c', ')', '14', 'day', '.'], 'dependencies': [('•', 'nummod'), ('need', 'advcl'), (',', 'punct'), ('exampl', 'nsubj'), ('travel', 'meta'), (',', 'punct'), ('may', 'aux'), ('also', 'advmod'), ('store', 'ROOT'), ('humira', 'compound'), ('room', 'dobj'), ('temperatur', 'nmod'), ('77', 'nummod'), ('°', 'npadvmod'), ('f', 'dobj'), ('(', 'punct'), ('25', 'nummod'), ('°', 'appos'), ('c', 'punct'), (')', 'punct'), ('14', 'nummod'), ('day', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Store HUMIRA in the original carton until \\nuse to protect it from light.', 'tokens': ['Store', 'HUMIRA', 'original', 'carton', 'use', 'protect', 'light', '.'], 'lemmatized': ['Store', 'HUMIRA', 'original', 'carton', 'use', 'protect', 'light', '.'], 'stemmed': ['store', 'humira', 'origin', 'carton', 'use', 'protect', 'light', '.'], 'dependencies': [('store', 'compound'), ('humira', 'compound'), ('origin', 'compound'), ('carton', 'compound'), ('use', 'compound'), ('protect', 'compound'), ('light', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• Throw away HUMIRA if it has been kept at room temperature and not been used within 14 \\ndays.', 'tokens': ['•', 'Throw', 'away', 'HUMIRA', 'kept', 'room', 'temperature', 'used', 'within', '14', 'days', '.'], 'lemmatized': ['•', 'Throw', 'away', 'HUMIRA', 'kept', 'room', 'temperature', 'used', 'within', '14', 'day', '.'], 'stemmed': ['•', 'throw', 'away', 'humira', 'kept', 'room', 'temperatur', 'use', 'within', '14', 'day', '.'], 'dependencies': [('•', 'npadvmod'), ('throw', 'csubj'), ('away', 'prt'), ('humira', 'dobj'), ('kept', 'ROOT'), ('room', 'compound'), ('temperatur', 'compound'), ('use', 'dobj'), ('within', 'prep'), ('14', 'nummod'), ('day', 'pobj'), ('.', 'punct')]}, {'original_sentence': '• Record the date you first remove HUMIRA from the refrigerator in the spaces provided on \\nthe carton and dose tray.', 'tokens': ['•', 'Record', 'date', 'first', 'remove', 'HUMIRA', 'refrigerator', 'spaces', 'provided', 'carton', 'dose', 'tray', '.'], 'lemmatized': ['•', 'Record', 'date', 'first', 'remove', 'HUMIRA', 'refrigerator', 'space', 'provided', 'carton', 'dose', 'tray', '.'], 'stemmed': ['•', 'record', 'date', 'first', 'remov', 'humira', 'refriger', 'space', 'provid', 'carton', 'dose', 'tray', '.'], 'dependencies': [('•', 'nummod'), ('record', 'compound'), ('date', 'compound'), ('first', 'amod'), ('remov', 'compound'), ('humira', 'compound'), ('refriger', 'compound'), ('space', 'compound'), ('provid', 'compound'), ('carton', 'compound'), ('dose', 'compound'), ('tray', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• Do not store HUMIRA in extreme heat or cold.', 'tokens': ['•', 'store', 'HUMIRA', 'extreme', 'heat', 'cold', '.'], 'lemmatized': ['•', 'store', 'HUMIRA', 'extreme', 'heat', 'cold', '.'], 'stemmed': ['•', 'store', 'humira', 'extrem', 'heat', 'cold', '.'], 'dependencies': [('•', 'nummod'), ('store', 'compound'), ('humira', 'compound'), ('extrem', 'compound'), ('heat', 'compound'), ('cold', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• Do not use a Pen or prefilled syringe if the liquid is cloudy, discolored, or has flakes or \\nparticles in it.', 'tokens': ['•', 'use', 'Pen', 'prefilled', 'syringe', 'liquid', 'cloudy', ',', 'discolored', ',', 'flakes', 'particles', '.'], 'lemmatized': ['•', 'use', 'Pen', 'prefilled', 'syringe', 'liquid', 'cloudy', ',', 'discolored', ',', 'flake', 'particle', '.'], 'stemmed': ['•', 'use', 'pen', 'prefil', 'syring', 'liquid', 'cloudi', ',', 'discolor', ',', 'flake', 'particl', '.'], 'dependencies': [('•', 'meta'), ('use', 'compound'), ('pen', 'compound'), ('prefil', 'nmod'), ('syring', 'appos'), ('liquid', 'compound'), ('cloudi', 'nmod'), (',', 'punct'), ('discolor', 'nmod'), (',', 'punct'), ('flake', 'compound'), ('particl', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• Do not drop or crush HUMIRA.', 'tokens': ['•', 'drop', 'crush', 'HUMIRA', '.'], 'lemmatized': ['•', 'drop', 'crush', 'HUMIRA', '.'], 'stemmed': ['•', 'drop', 'crush', 'humira', '.'], 'dependencies': [('•', 'nummod'), ('drop', 'compound'), ('crush', 'compound'), ('humira', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'The prefilled syringe is glass.', 'tokens': ['prefilled', 'syringe', 'glass', '.'], 'lemmatized': ['prefilled', 'syringe', 'glass', '.'], 'stemmed': ['prefil', 'syring', 'glass', '.'], 'dependencies': [('prefil', 'compound'), ('syring', 'compound'), ('glass', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Keep HUMIRA, injection supplies, and all other medicines out of the reach of children.', 'tokens': ['Keep', 'HUMIRA', ',', 'injection', 'supplies', ',', 'medicines', 'reach', 'children', '.'], 'lemmatized': ['Keep', 'HUMIRA', ',', 'injection', 'supply', ',', 'medicine', 'reach', 'child', '.'], 'stemmed': ['keep', 'humira', ',', 'inject', 'suppli', ',', 'medicin', 'reach', 'child', '.'], 'dependencies': [('keep', 'advcl'), ('humira', 'dobj'), (',', 'punct'), ('inject', 'compound'), ('suppli', 'conj'), (',', 'punct'), ('medicin', 'nsubj'), ('reach', 'ROOT'), ('child', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'General information about the safe and effective use of HUMIRA.', 'tokens': ['General', 'information', 'safe', 'effective', 'use', 'HUMIRA', '.'], 'lemmatized': ['General', 'information', 'safe', 'effective', 'use', 'HUMIRA', '.'], 'stemmed': ['gener', 'inform', 'safe', 'effect', 'use', 'humira', '.'], 'dependencies': [('gener', 'nsubj'), ('inform', 'ROOT'), ('safe', 'amod'), ('effect', 'compound'), ('use', 'dobj'), ('humira', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Medicines are sometimes prescribed for purposes other than those listed in a Medication \\nGuide.', 'tokens': ['Medicines', 'sometimes', 'prescribed', 'purposes', 'listed', 'Medication', 'Guide', '.'], 'lemmatized': ['Medicines', 'sometimes', 'prescribed', 'purpose', 'listed', 'Medication', 'Guide', '.'], 'stemmed': ['medicin', 'sometim', 'prescrib', 'purpos', 'list', 'medic', 'guid', '.'], 'dependencies': [('medicin', 'compound'), ('sometim', 'compound'), ('prescrib', 'compound'), ('purpos', 'nsubj'), ('list', 'compound'), ('medic', 'compound'), ('guid', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Do not use HUMIRA for a condition for which it was not prescribed.', 'tokens': ['use', 'HUMIRA', 'condition', 'prescribed', '.'], 'lemmatized': ['use', 'HUMIRA', 'condition', 'prescribed', '.'], 'stemmed': ['use', 'humira', 'condit', 'prescrib', '.'], 'dependencies': [('use', 'ROOT'), ('humira', 'compound'), ('condit', 'compound'), ('prescrib', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Do not give \\nHUMIRA to other people, even if they have the same condition.', 'tokens': ['give', 'HUMIRA', 'people', ',', 'even', 'condition', '.'], 'lemmatized': ['give', 'HUMIRA', 'people', ',', 'even', 'condition', '.'], 'stemmed': ['give', 'humira', 'peopl', ',', 'even', 'condit', '.'], 'dependencies': [('give', 'ROOT'), ('humira', 'compound'), ('peopl', 'dobj'), (',', 'punct'), ('even', 'advmod'), ('condit', 'dep'), ('.', 'punct')]}, {'original_sentence': 'It may harm them.', 'tokens': ['may', 'harm', '.'], 'lemmatized': ['may', 'harm', '.'], 'stemmed': ['may', 'harm', '.'], 'dependencies': [('may', 'aux'), ('harm', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'This Medication Guide summarizes the most important information about HUMIRA.', 'tokens': ['Medication', 'Guide', 'summarizes', 'important', 'information', 'HUMIRA', '.'], 'lemmatized': ['Medication', 'Guide', 'summarizes', 'important', 'information', 'HUMIRA', '.'], 'stemmed': ['medic', 'guid', 'summar', 'import', 'inform', 'humira', '.'], 'dependencies': [('medic', 'npadvmod'), ('guid', 'amod'), ('summar', 'compound'), ('import', 'compound'), ('inform', 'compound'), ('humira', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'If you \\nwould like more information, talk with your doctor.', 'tokens': ['would', 'like', 'information', ',', 'talk', 'doctor', '.'], 'lemmatized': ['would', 'like', 'information', ',', 'talk', 'doctor', '.'], 'stemmed': ['would', 'like', 'inform', ',', 'talk', 'doctor', '.'], 'dependencies': [('would', 'aux'), ('like', 'ROOT'), ('inform', 'dobj'), (',', 'punct'), ('talk', 'compound'), ('doctor', 'conj'), ('.', 'punct')]}, {'original_sentence': 'You can ask your pharmacist or doctor for \\ninformation about HUMIRA that is written for health professionals.', 'tokens': ['ask', 'pharmacist', 'doctor', 'information', 'HUMIRA', 'written', 'health', 'professionals', '.'], 'lemmatized': ['ask', 'pharmacist', 'doctor', 'information', 'HUMIRA', 'written', 'health', 'professional', '.'], 'stemmed': ['ask', 'pharmacist', 'doctor', 'inform', 'humira', 'written', 'health', 'profession', '.'], 'dependencies': [('ask', 'ROOT'), ('pharmacist', 'compound'), ('doctor', 'compound'), ('inform', 'dobj'), ('humira', 'dobj'), ('written', 'dep'), ('health', 'compound'), ('profession', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'What are the ingredients in HUMIRA?', 'tokens': ['ingredients', 'HUMIRA', '?'], 'lemmatized': ['ingredient', 'HUMIRA', '?'], 'stemmed': ['ingredi', 'humira', '?'], 'dependencies': [('ingredi', 'compound'), ('humira', 'ROOT'), ('?', 'punct')]}, {'original_sentence': 'Active ingredient: adalimumab  \\n \\nHUMIRA Pen 40 mg/0.8 mL, HUMIRA 40 mg/0.8 mL prefilled syringe, HUMIRA 20 mg/0.4 mL \\nprefilled syringe, HUMIRA 10 mg/0.2 mL prefilled syringe, and HUMIRA 40 mg/0.8 mL \\ninstitutional use vial:', 'tokens': ['Active', 'ingredient', ':', 'adalimumab', 'HUMIRA', 'Pen', '40', 'mg/0.8', 'mL', ',', 'HUMIRA', '40', 'mg/0.8', 'mL', 'prefilled', 'syringe', ',', 'HUMIRA', '20', 'mg/0.4', 'mL', 'prefilled', 'syringe', ',', 'HUMIRA', '10', 'mg/0.2', 'mL', 'prefilled', 'syringe', ',', 'HUMIRA', '40', 'mg/0.8', 'mL', 'institutional', 'use', 'vial', ':'], 'lemmatized': ['Active', 'ingredient', ':', 'adalimumab', 'HUMIRA', 'Pen', '40', 'mg/0.8', 'mL', ',', 'HUMIRA', '40', 'mg/0.8', 'mL', 'prefilled', 'syringe', ',', 'HUMIRA', '20', 'mg/0.4', 'mL', 'prefilled', 'syringe', ',', 'HUMIRA', '10', 'mg/0.2', 'mL', 'prefilled', 'syringe', ',', 'HUMIRA', '40', 'mg/0.8', 'mL', 'institutional', 'use', 'vial', ':'], 'stemmed': ['activ', 'ingredi', ':', 'adalimumab', 'humira', 'pen', '40', 'mg/0.8', 'ml', ',', 'humira', '40', 'mg/0.8', 'ml', 'prefil', 'syring', ',', 'humira', '20', 'mg/0.4', 'ml', 'prefil', 'syring', ',', 'humira', '10', 'mg/0.2', 'ml', 'prefil', 'syring', ',', 'humira', '40', 'mg/0.8', 'ml', 'institut', 'use', 'vial', ':'], 'dependencies': [('activ', 'compound'), ('ingredi', 'dep'), (':', 'punct'), ('adalimumab', 'compound'), ('humira', 'compound'), ('pen', 'ROOT'), ('40', 'nummod'), ('mg/0.8', 'dep'), ('ml', 'appos'), (',', 'punct'), ('humira', 'appos'), ('40', 'nummod'), ('mg/0.8', 'appos'), ('ml', 'aux'), ('prefil', 'appos'), ('syring', 'dobj'), (',', 'punct'), ('humira', 'appos'), ('20', 'nummod'), ('mg/0.4', 'npadvmod'), ('ml', 'aux'), ('prefil', 'nsubj'), ('syring', 'dobj'), (',', 'punct'), ('humira', 'appos'), ('10', 'nummod'), ('mg/0.2', 'npadvmod'), ('ml', 'compound'), ('prefil', 'nsubj'), ('syring', 'dobj'), (',', 'punct'), ('humira', 'conj'), ('40', 'nummod'), ('mg/0.8', 'punct'), ('ml', 'aux'), ('institut', 'nsubj'), ('use', 'ROOT'), ('vial', 'dobj'), (':', 'punct')]}], 'text': 'Call your doctor or get medical care right away if you develop any of the above \\nsymptoms. Your treatment with HUMIRA may be stopped. \\n \\nThe most common side effects of HUMIRA include: \\n• injection site reactions: redness, rash, swelling, itching, or bruising. These symptoms \\nusually will go away within a few days. Call your doctor right away if you have pain, \\nredness or swelling around the injection site that does not go away within a few days or \\ngets worse.  \\n• upper respiratory infections (including sinus infections). \\n• headaches. \\n• rash. \\nThese are not all the possible side effects with HUMIRA. Tell your doctor if you have any side \\neffect that bothers you or that does not go away. Ask your doctor or pharmacist for more \\ninformation.  \\nCall your doctor for medical advice about side effects. You may report side effects to FDA at 1-\\n800-FDA-1088.  \\nHow should I store HUMIRA? \\n• Store HUMIRA in the refrigerator at 36ºF to 46ºF (2ºC to 8ºC). Store HUMIRA in the \\noriginal carton until use to protect it from light.  \\n• Do not freeze HUMIRA. Do not use HUMIRA if frozen, even if it has been thawed.  \\n• Refrigerated HUMIRA may be used until the expiration date printed on the HUMIRA carton, \\ndose tray, Pen or prefilled syringe. Do not use HUMIRA after the expiration date.  \\n• If needed, for example when you are traveling, you may also store HUMIRA at room \\ntemperature up to 77°F (25°C) for up to 14 days. Store HUMIRA in the original carton until \\nuse to protect it from light.  \\n• Throw away HUMIRA if it has been kept at room temperature and not been used within 14 \\ndays. \\n• Record the date you first remove HUMIRA from the refrigerator in the spaces provided on \\nthe carton and dose tray. \\n• Do not store HUMIRA in extreme heat or cold. \\n• Do not use a Pen or prefilled syringe if the liquid is cloudy, discolored, or has flakes or \\nparticles in it. \\n• Do not drop or crush HUMIRA. The prefilled syringe is glass. \\nKeep HUMIRA, injection supplies, and all other medicines out of the reach of children. \\nGeneral information about the safe and effective use of HUMIRA. \\nMedicines are sometimes prescribed for purposes other than those listed in a Medication \\nGuide. Do not use HUMIRA for a condition for which it was not prescribed. Do not give \\nHUMIRA to other people, even if they have the same condition. It may harm them.  \\nThis Medication Guide summarizes the most important information about HUMIRA. If you \\nwould like more information, talk with your doctor. You can ask your pharmacist or doctor for \\ninformation about HUMIRA that is written for health professionals.  \\nWhat are the ingredients in HUMIRA? \\nActive ingredient: adalimumab  \\n \\nHUMIRA Pen 40 mg/0.8 mL, HUMIRA 40 mg/0.8 mL prefilled syringe, HUMIRA 20 mg/0.4 mL \\nprefilled syringe, HUMIRA 10 mg/0.2 mL prefilled syringe, and HUMIRA 40 mg/0.8 mL \\ninstitutional use vial:  \\n \\n'}, 'page_char_count': 2868, 'page_word_count': 492, 'sentences': ['Call your doctor or get medical care right away if you develop any of the above \\nsymptoms.', 'Your treatment with HUMIRA may be stopped.', '\\n \\nThe most common side effects of HUMIRA include: \\n• injection site reactions: redness, rash, swelling, itching, or bruising.', 'These symptoms \\nusually will go away within a few days.', 'Call your doctor right away if you have pain, \\nredness or swelling around the injection site that does not go away within a few days or \\ngets worse.', ' \\n• upper respiratory infections (including sinus infections).', '\\n• headaches.', '\\n• rash.', '\\nThese are not all the possible side effects with HUMIRA.', 'Tell your doctor if you have any side \\neffect that bothers you or that does not go away.', 'Ask your doctor or pharmacist for more \\ninformation.', ' \\nCall your doctor for medical advice about side effects.', 'You may report side effects to FDA at 1-\\n800-FDA-1088.', ' \\nHow should I store HUMIRA?', '\\n• Store HUMIRA in the refrigerator at 36ºF to 46ºF (2ºC to 8ºC).', 'Store HUMIRA in the \\noriginal carton until use to protect it from light.', ' \\n• Do not freeze HUMIRA.', 'Do not use HUMIRA if frozen, even if it has been thawed.', ' \\n• Refrigerated HUMIRA may be used until the expiration date printed on the HUMIRA carton, \\ndose tray, Pen or prefilled syringe.', 'Do not use HUMIRA after the expiration date.', ' \\n• If needed, for example when you are traveling, you may also store HUMIRA at room \\ntemperature up to 77°F (25°C) for up to 14 days.', 'Store HUMIRA in the original carton until \\nuse to protect it from light.', ' \\n• Throw away HUMIRA if it has been kept at room temperature and not been used within 14 \\ndays.', '\\n• Record the date you first remove HUMIRA from the refrigerator in the spaces provided on \\nthe carton and dose tray.', '\\n• Do not store HUMIRA in extreme heat or cold.', '\\n• Do not use a Pen or prefilled syringe if the liquid is cloudy, discolored, or has flakes or \\nparticles in it.', '\\n• Do not drop or crush HUMIRA.', 'The prefilled syringe is glass.', '\\nKeep HUMIRA, injection supplies, and all other medicines out of the reach of children.', '\\nGeneral information about the safe and effective use of HUMIRA.', '\\nMedicines are sometimes prescribed for purposes other than those listed in a Medication \\nGuide.', 'Do not use HUMIRA for a condition for which it was not prescribed.', 'Do not give \\nHUMIRA to other people, even if they have the same condition.', 'It may harm them.', ' \\nThis Medication Guide summarizes the most important information about HUMIRA.', 'If you \\nwould like more information, talk with your doctor.', 'You can ask your pharmacist or doctor for \\ninformation about HUMIRA that is written for health professionals.', ' \\nWhat are the ingredients in HUMIRA?', '\\nActive ingredient: adalimumab  \\n \\nHUMIRA Pen 40 mg/0.8 mL, HUMIRA 40 mg/0.8 mL prefilled syringe, HUMIRA 20 mg/0.4 mL \\nprefilled syringe, HUMIRA 10 mg/0.2 mL prefilled syringe, and HUMIRA 40 mg/0.8 mL \\ninstitutional use vial:  \\n \\n'], 'page_sentence_count_spacy': 39}\n",
            "{'page_number': 64, 'text': 'Inactive ingredients: citric acid monohydrate, dibasic sodium phosphate dihydrate, mannitol, \\nmonobasic sodium phosphate dihydrate, polysorbate 80, sodium chloride, sodium citrate and \\nWater for Injection. Sodium hydroxide is added as necessary to adjust pH.  \\n \\nHUMIRA Pen 80 mg/0.8 mL, HUMIRA 80 mg/0.8 mL prefilled syringe, HUMIRA Pen 40 mg/0.4 \\nmL, HUMIRA 40 mg/0.4 mL prefilled syringe, HUMIRA 20 mg/0.2 mL prefilled syringe and \\nHUMIRA 10 mg/0.1 mL prefilled syringe:  \\n \\nInactive ingredients: mannitol, polysorbate 80, and Water for Injection.  \\n \\nManufactured by: AbbVie Inc., North Chicago, IL 60064, U.S.A. \\nFor more information go to www.HUMIRA.com or you can enroll in a patient support program \\nby calling 1-800-4HUMIRA (1-800-448-6472). \\nUS License Number 1889  \\nThis Medication Guide has been approved by the U.S. Food and Drug \\nAdministration. \\n20066566  \\nRevised: 02/2021 \\n', 'processed_text': {'sentences': [{'original_sentence': 'Inactive ingredients: citric acid monohydrate, dibasic sodium phosphate dihydrate, mannitol, \\nmonobasic sodium phosphate dihydrate, polysorbate 80, sodium chloride, sodium citrate and \\nWater for Injection.', 'tokens': ['Inactive', 'ingredients', ':', 'citric', 'acid', 'monohydrate', ',', 'dibasic', 'sodium', 'phosphate', 'dihydrate', ',', 'mannitol', ',', 'monobasic', 'sodium', 'phosphate', 'dihydrate', ',', 'polysorbate', '80', ',', 'sodium', 'chloride', ',', 'sodium', 'citrate', 'Water', 'Injection', '.'], 'lemmatized': ['Inactive', 'ingredient', ':', 'citric', 'acid', 'monohydrate', ',', 'dibasic', 'sodium', 'phosphate', 'dihydrate', ',', 'mannitol', ',', 'monobasic', 'sodium', 'phosphate', 'dihydrate', ',', 'polysorbate', '80', ',', 'sodium', 'chloride', ',', 'sodium', 'citrate', 'Water', 'Injection', '.'], 'stemmed': ['inact', 'ingredi', ':', 'citric', 'acid', 'monohydr', ',', 'dibas', 'sodium', 'phosphat', 'dihydr', ',', 'mannitol', ',', 'monobas', 'sodium', 'phosphat', 'dihydr', ',', 'polysorb', '80', ',', 'sodium', 'chlorid', ',', 'sodium', 'citrat', 'water', 'inject', '.'], 'dependencies': [('inact', 'compound'), ('ingredi', 'nsubj'), (':', 'punct'), ('citric', 'compound'), ('acid', 'compound'), ('monohydr', 'appos'), (',', 'punct'), ('dibas', 'compound'), ('sodium', 'compound'), ('phosphat', 'dep'), ('dihydr', 'amod'), (',', 'punct'), ('mannitol', 'nsubj'), (',', 'punct'), ('monobas', 'compound'), ('sodium', 'compound'), ('phosphat', 'conj'), ('dihydr', 'advmod'), (',', 'punct'), ('polysorb', 'ROOT'), ('80', 'dobj'), (',', 'punct'), ('sodium', 'compound'), ('chlorid', 'advcl'), (',', 'punct'), ('sodium', 'compound'), ('citrat', 'compound'), ('water', 'compound'), ('inject', 'conj'), ('.', 'punct')]}, {'original_sentence': 'Sodium hydroxide is added as necessary to adjust pH.', 'tokens': ['Sodium', 'hydroxide', 'added', 'necessary', 'adjust', 'pH', '.'], 'lemmatized': ['Sodium', 'hydroxide', 'added', 'necessary', 'adjust', 'pH', '.'], 'stemmed': ['sodium', 'hydroxid', 'ad', 'necessari', 'adjust', 'ph', '.'], 'dependencies': [('sodium', 'compound'), ('hydroxid', 'amod'), ('ad', 'compound'), ('necessari', 'nsubj'), ('adjust', 'ROOT'), ('ph', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'HUMIRA Pen 80 mg/0.8 mL, HUMIRA 80 mg/0.8 mL prefilled syringe, HUMIRA Pen 40 mg/0.4 \\nmL, HUMIRA 40 mg/0.4 mL prefilled syringe, HUMIRA 20 mg/0.2 mL prefilled syringe and \\nHUMIRA 10 mg/0.1 mL prefilled syringe:  \\n \\nInactive ingredients: mannitol, polysorbate 80, and Water for Injection.', 'tokens': ['HUMIRA', 'Pen', '80', 'mg/0.8', 'mL', ',', 'HUMIRA', '80', 'mg/0.8', 'mL', 'prefilled', 'syringe', ',', 'HUMIRA', 'Pen', '40', 'mg/0.4', 'mL', ',', 'HUMIRA', '40', 'mg/0.4', 'mL', 'prefilled', 'syringe', ',', 'HUMIRA', '20', 'mg/0.2', 'mL', 'prefilled', 'syringe', 'HUMIRA', '10', 'mg/0.1', 'mL', 'prefilled', 'syringe', ':', 'Inactive', 'ingredients', ':', 'mannitol', ',', 'polysorbate', '80', ',', 'Water', 'Injection', '.'], 'lemmatized': ['HUMIRA', 'Pen', '80', 'mg/0.8', 'mL', ',', 'HUMIRA', '80', 'mg/0.8', 'mL', 'prefilled', 'syringe', ',', 'HUMIRA', 'Pen', '40', 'mg/0.4', 'mL', ',', 'HUMIRA', '40', 'mg/0.4', 'mL', 'prefilled', 'syringe', ',', 'HUMIRA', '20', 'mg/0.2', 'mL', 'prefilled', 'syringe', 'HUMIRA', '10', 'mg/0.1', 'mL', 'prefilled', 'syringe', ':', 'Inactive', 'ingredient', ':', 'mannitol', ',', 'polysorbate', '80', ',', 'Water', 'Injection', '.'], 'stemmed': ['humira', 'pen', '80', 'mg/0.8', 'ml', ',', 'humira', '80', 'mg/0.8', 'ml', 'prefil', 'syring', ',', 'humira', 'pen', '40', 'mg/0.4', 'ml', ',', 'humira', '40', 'mg/0.4', 'ml', 'prefil', 'syring', ',', 'humira', '20', 'mg/0.2', 'ml', 'prefil', 'syring', 'humira', '10', 'mg/0.1', 'ml', 'prefil', 'syring', ':', 'inact', 'ingredi', ':', 'mannitol', ',', 'polysorb', '80', ',', 'water', 'inject', '.'], 'dependencies': [('humira', 'compound'), ('pen', 'nsubj'), ('80', 'nummod'), ('mg/0.8', 'dep'), ('ml', 'appos'), (',', 'punct'), ('humira', 'appos'), ('80', 'nummod'), ('mg/0.8', 'appos'), ('ml', 'aux'), ('prefil', 'ROOT'), ('syring', 'dobj'), (',', 'punct'), ('humira', 'compound'), ('pen', 'conj'), ('40', 'nummod'), ('mg/0.4', 'dep'), ('ml', 'appos'), (',', 'punct'), ('humira', 'appos'), ('40', 'nummod'), ('mg/0.4', 'appos'), ('ml', 'aux'), ('prefil', 'conj'), ('syring', 'dobj'), (',', 'punct'), ('humira', 'appos'), ('20', 'nummod'), ('mg/0.2', 'npadvmod'), ('ml', 'dep'), ('prefil', 'conj'), ('syring', 'compound'), ('humira', 'dobj'), ('10', 'nummod'), ('mg/0.1', 'npadvmod'), ('ml', 'compound'), ('prefil', 'compound'), ('syring', 'appos'), (':', 'punct'), ('inact', 'compound'), ('ingredi', 'conj'), (':', 'punct'), ('mannitol', 'appos'), (',', 'punct'), ('polysorb', 'conj'), ('80', 'nummod'), (',', 'punct'), ('water', 'compound'), ('inject', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Manufactured by: AbbVie Inc., North Chicago, IL 60064, U.S.A. \\nFor more information go to www.HUMIRA.com or you can enroll in a patient support program \\nby calling 1-800-4HUMIRA (1-800-448-6472).', 'tokens': ['Manufactured', ':', 'AbbVie', 'Inc.', ',', 'North', 'Chicago', ',', 'IL', '60064', ',', 'U.S.A.', 'information', 'go', 'www.HUMIRA.com', 'enroll', 'patient', 'support', 'program', 'calling', '1-800-4HUMIRA', '(', '1-800-448-6472', ')', '.'], 'lemmatized': ['Manufactured', ':', 'AbbVie', 'Inc.', ',', 'North', 'Chicago', ',', 'IL', '60064', ',', 'U.S.A.', 'information', 'go', 'www.HUMIRA.com', 'enroll', 'patient', 'support', 'program', 'calling', '1-800-4HUMIRA', '(', '1-800-448-6472', ')', '.'], 'stemmed': ['manufactur', ':', 'abbvi', 'inc.', ',', 'north', 'chicago', ',', 'il', '60064', ',', 'u.s.a.', 'inform', 'go', 'www.humira.com', 'enrol', 'patient', 'support', 'program', 'call', '1-800-4humira', '(', '1-800-448-6472', ')', '.'], 'dependencies': [('manufactur', 'dep'), (':', 'punct'), ('abbvi', 'compound'), ('inc', 'nsubj'), ('.', 'punct'), (',', 'punct'), ('north', 'compound'), ('chicago', 'conj'), (',', 'punct'), ('il', 'npadvmod'), ('60064', 'nummod'), (',', 'punct'), ('u.s.a', 'amod'), ('.', 'compound'), ('inform', 'nsubj'), ('go', 'ROOT'), ('www.humira.com', 'npadvmod'), ('enrol', 'conj'), ('patient', 'compound'), ('support', 'compound'), ('program', 'compound'), ('call', 'dobj'), ('1', 'npadvmod'), ('-', 'punct'), ('800', 'appos'), ('-', 'punct'), ('4humira', 'appos'), ('(', 'punct'), ('1', 'appos'), ('-', 'punct'), ('800', 'prep'), ('-', 'punct'), ('448', 'npadvmod'), ('-', 'punct'), ('6472', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'US License Number 1889  \\nThis Medication Guide has been approved by the U.S. Food and Drug \\nAdministration.', 'tokens': ['US', 'License', 'Number', '1889', 'Medication', 'Guide', 'approved', 'U.S.', 'Food', 'Drug', 'Administration', '.'], 'lemmatized': ['US', 'License', 'Number', '1889', 'Medication', 'Guide', 'approved', 'U.S.', 'Food', 'Drug', 'Administration', '.'], 'stemmed': ['us', 'licens', 'number', '1889', 'medic', 'guid', 'approv', 'u.s.', 'food', 'drug', 'administr', '.'], 'dependencies': [('us', 'compound'), ('licens', 'nsubj'), ('number', 'appos'), ('1889', 'nummod'), ('medic', 'npadvmod'), ('guid', 'ROOT'), ('approv', 'compound'), ('u.s', 'compound'), ('.', 'compound'), ('food', 'compound'), ('drug', 'compound'), ('administr', 'dobj'), ('.', 'punct')]}, {'original_sentence': '20066566  \\nRevised: 02/2021', 'tokens': ['20066566', 'Revised', ':', '02/2021'], 'lemmatized': ['20066566', 'Revised', ':', '02/2021'], 'stemmed': ['20066566', 'revis', ':', '02/2021'], 'dependencies': [('20066566', 'nummod'), ('revis', 'ROOT'), (':', 'punct'), ('02/2021', 'appos')]}], 'text': 'Inactive ingredients: citric acid monohydrate, dibasic sodium phosphate dihydrate, mannitol, \\nmonobasic sodium phosphate dihydrate, polysorbate 80, sodium chloride, sodium citrate and \\nWater for Injection. Sodium hydroxide is added as necessary to adjust pH.  \\n \\nHUMIRA Pen 80 mg/0.8 mL, HUMIRA 80 mg/0.8 mL prefilled syringe, HUMIRA Pen 40 mg/0.4 \\nmL, HUMIRA 40 mg/0.4 mL prefilled syringe, HUMIRA 20 mg/0.2 mL prefilled syringe and \\nHUMIRA 10 mg/0.1 mL prefilled syringe:  \\n \\nInactive ingredients: mannitol, polysorbate 80, and Water for Injection.  \\n \\nManufactured by: AbbVie Inc., North Chicago, IL 60064, U.S.A. \\nFor more information go to www.HUMIRA.com or you can enroll in a patient support program \\nby calling 1-800-4HUMIRA (1-800-448-6472). \\nUS License Number 1889  \\nThis Medication Guide has been approved by the U.S. Food and Drug \\nAdministration. \\n20066566  \\nRevised: 02/2021 \\n'}, 'page_char_count': 890, 'page_word_count': 125, 'sentences': ['Inactive ingredients: citric acid monohydrate, dibasic sodium phosphate dihydrate, mannitol, \\nmonobasic sodium phosphate dihydrate, polysorbate 80, sodium chloride, sodium citrate and \\nWater for Injection.', 'Sodium hydroxide is added as necessary to adjust pH.  \\n \\nHUMIRA Pen 80 mg/0.8 mL, HUMIRA 80 mg/0.8 mL prefilled syringe, HUMIRA Pen 40 mg/0.4 \\nmL, HUMIRA 40 mg/0.4 mL prefilled syringe, HUMIRA 20 mg/0.2 mL prefilled syringe and \\nHUMIRA 10 mg/0.1 mL prefilled syringe:  \\n \\nInactive ingredients: mannitol, polysorbate 80, and Water for Injection.', ' \\n \\nManufactured by: AbbVie Inc., North Chicago, IL 60064, U.S.A. \\nFor more information go to www.HUMIRA.com or you can enroll in a patient support program \\nby calling 1-800-4HUMIRA (1-800-448-6472).', '\\nUS License Number 1889  \\nThis Medication Guide has been approved by the U.S. Food and Drug \\nAdministration.', '\\n20066566  \\nRevised: 02/2021 \\n'], 'page_sentence_count_spacy': 5}\n",
            "{'page_number': 65, 'text': 'INSTRUCTIONS FOR USE \\nHUMIRA® (Hu-MARE-ah) \\n(adalimumab) \\n40 MG/0.8 ML \\nSINGLE-DOSE PEN \\nDo not try to inject HUMIRA yourself until you have been shown the right way to give the \\ninjections and have read and understand this Instructions for Use. If your doctor decides that \\nyou or a caregiver may be able to give your injections of HUMIRA at home, you should receive \\ntraining on the right way to prepare and inject HUMIRA. It is important that you read, \\nunderstand, and follow these instructions so that you inject HUMIRA the right way. It is also \\nimportant to talk to your doctor to be sure you understand your HUMIRA dosing instructions. To \\nhelp you remember when to inject HUMIRA, you can mark your calendar ahead of time. Call \\nyour healthcare provider if you or your caregiver have any questions about the right way to \\ninject HUMIRA.  \\nIMPORTANT: \\n• Do not use HUMIRA if frozen, even if it has been thawed. \\n• The HUMIRA Pen contains glass. Do not drop or crush the Pen because the glass inside \\nmay break. \\n• Each HUMIRA Pen has 2 caps on it. Do not remove the gray cap (Cap #1) or the plum-\\ncolored cap (Cap #2) until right before your injection.  \\n• When the plum-colored button on the HUMIRA Pen is pressed to give your dose of \\nHUMIRA, you will hear a loud “click” sound. \\n• You must practice injecting HUMIRA with your doctor or nurse so that you are not \\nstartled by this click when you start giving yourself the injections at home.  \\n• The loud click sound means the start of the injection. \\n• You will know that the injection has finished when the yellow indicator appears fully in \\nthe window view and stops moving. \\n  \\nSee the section below called “Preparing the HUMIRA Pen”.  \\nGather the Supplies for Your Injection \\n• You will need the following supplies for each injection of HUMIRA. \\nFind a clean, flat surface to place the supplies on. \\n• 1 alcohol swab \\n• 1 cotton ball or gauze pad (not included in your HUMIRA carton) \\n• 1 HUMIRA Pen (See Figure A) \\n• Puncture-resistant sharps disposal container for HUMIRA Pen disposal (not included in \\nyour HUMIRA carton). See the “How should I throw away (dispose of) the used \\nHUMIRA Pen?” section at the end of this Instructions for Use.  \\n  \\nIf more comfortable, take your HUMIRA Pen out of the refrigerator 15 to 30 minutes before \\ninjecting to allow the liquid to reach room temperature. Do not remove the gray cap (Cap #1) or \\nthe plum-colored cap (Cap #2) while allowing it to reach room temperature. Do not warm \\nHUMIRA in any other way (for example, do not warm it in a microwave or in hot water).  \\n', 'processed_text': {'sentences': [{'original_sentence': 'INSTRUCTIONS FOR USE \\nHUMIRA® (Hu-MARE-ah) \\n(adalimumab) \\n40 MG/0.8 ML \\nSINGLE-DOSE PEN \\nDo not try to inject HUMIRA yourself until you have been shown the right way to give the \\ninjections and have read and understand this Instructions for Use.', 'tokens': ['INSTRUCTIONS', 'USE', 'HUMIRA®', '(', 'Hu-MARE-ah', ')', '(', 'adalimumab', ')', '40', 'MG/0.8', 'ML', 'SINGLE-DOSE', 'PEN', 'try', 'inject', 'HUMIRA', 'shown', 'right', 'way', 'give', 'injections', 'read', 'understand', 'Instructions', 'Use', '.'], 'lemmatized': ['INSTRUCTIONS', 'USE', 'HUMIRA®', '(', 'Hu-MARE-ah', ')', '(', 'adalimumab', ')', '40', 'MG/0.8', 'ML', 'SINGLE-DOSE', 'PEN', 'try', 'inject', 'HUMIRA', 'shown', 'right', 'way', 'give', 'injection', 'read', 'understand', 'Instructions', 'Use', '.'], 'stemmed': ['instruct', 'use', 'humira®', '(', 'hu-mare-ah', ')', '(', 'adalimumab', ')', '40', 'mg/0.8', 'ml', 'single-dos', 'pen', 'tri', 'inject', 'humira', 'shown', 'right', 'way', 'give', 'inject', 'read', 'understand', 'instruct', 'use', '.'], 'dependencies': [('instruct', 'aux'), ('use', 'ROOT'), ('humira', 'compound'), ('®', 'dobj'), ('(', 'punct'), ('hu', 'appos'), ('-', 'punct'), ('mare', 'npadvmod'), ('-', 'punct'), ('ah', 'intj'), (')', 'punct'), ('(', 'punct'), ('adalimumab', 'dep'), (')', 'punct'), ('40', 'nummod'), ('mg/0.8', 'acl'), ('ml', 'dep'), ('single', 'amod'), ('-', 'punct'), ('dos', 'compound'), ('pen', 'dobj'), ('tri', 'compound'), ('inject', 'compound'), ('humira', 'nsubj'), ('shown', 'ROOT'), ('right', 'amod'), ('way', 'dobj'), ('give', 'xcomp'), ('inject', 'dative'), ('read', 'compound'), ('understand', 'compound'), ('instruct', 'ccomp'), ('use', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'If your doctor decides that \\nyou or a caregiver may be able to give your injections of HUMIRA at home, you should receive \\ntraining on the right way to prepare and inject HUMIRA.', 'tokens': ['doctor', 'decides', 'caregiver', 'may', 'able', 'give', 'injections', 'HUMIRA', 'home', ',', 'receive', 'training', 'right', 'way', 'prepare', 'inject', 'HUMIRA', '.'], 'lemmatized': ['doctor', 'decides', 'caregiver', 'may', 'able', 'give', 'injection', 'HUMIRA', 'home', ',', 'receive', 'training', 'right', 'way', 'prepare', 'inject', 'HUMIRA', '.'], 'stemmed': ['doctor', 'decid', 'caregiv', 'may', 'abl', 'give', 'inject', 'humira', 'home', ',', 'receiv', 'train', 'right', 'way', 'prepar', 'inject', 'humira', '.'], 'dependencies': [('doctor', 'compound'), ('decid', 'compound'), ('caregiv', 'nsubj'), ('may', 'aux'), ('abl', 'advmod'), ('give', 'ccomp'), ('inject', 'compound'), ('humira', 'compound'), ('home', 'dobj'), (',', 'punct'), ('receiv', 'compound'), ('train', 'ROOT'), ('right', 'amod'), ('way', 'npadvmod'), ('prepar', 'compound'), ('inject', 'compound'), ('humira', 'appos'), ('.', 'punct')]}, {'original_sentence': 'It is important that you read, \\nunderstand, and follow these instructions so that you inject HUMIRA the right way.', 'tokens': ['important', 'read', ',', 'understand', ',', 'follow', 'instructions', 'inject', 'HUMIRA', 'right', 'way', '.'], 'lemmatized': ['important', 'read', ',', 'understand', ',', 'follow', 'instruction', 'inject', 'HUMIRA', 'right', 'way', '.'], 'stemmed': ['import', 'read', ',', 'understand', ',', 'follow', 'instruct', 'inject', 'humira', 'right', 'way', '.'], 'dependencies': [('import', 'compound'), ('read', 'nsubj'), (',', 'punct'), ('understand', 'conj'), (',', 'punct'), ('follow', 'conj'), ('instruct', 'ROOT'), ('inject', 'compound'), ('humira', 'dobj'), ('right', 'amod'), ('way', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'It is also \\nimportant to talk to your doctor to be sure you understand your HUMIRA dosing instructions.', 'tokens': ['also', 'important', 'talk', 'doctor', 'sure', 'understand', 'HUMIRA', 'dosing', 'instructions', '.'], 'lemmatized': ['also', 'important', 'talk', 'doctor', 'sure', 'understand', 'HUMIRA', 'dosing', 'instruction', '.'], 'stemmed': ['also', 'import', 'talk', 'doctor', 'sure', 'understand', 'humira', 'dose', 'instruct', '.'], 'dependencies': [('also', 'advmod'), ('import', 'ROOT'), ('talk', 'compound'), ('doctor', 'nsubj'), ('sure', 'advmod'), ('understand', 'ccomp'), ('humira', 'compound'), ('dose', 'compound'), ('instruct', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'To \\nhelp you remember when to inject HUMIRA, you can mark your calendar ahead of time.', 'tokens': ['help', 'remember', 'inject', 'HUMIRA', ',', 'mark', 'calendar', 'ahead', 'time', '.'], 'lemmatized': ['help', 'remember', 'inject', 'HUMIRA', ',', 'mark', 'calendar', 'ahead', 'time', '.'], 'stemmed': ['help', 'rememb', 'inject', 'humira', ',', 'mark', 'calendar', 'ahead', 'time', '.'], 'dependencies': [('help', 'advcl'), ('rememb', 'amod'), ('inject', 'compound'), ('humira', 'dobj'), (',', 'punct'), ('mark', 'compound'), ('calendar', 'ROOT'), ('ahead', 'amod'), ('time', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Call \\nyour healthcare provider if you or your caregiver have any questions about the right way to \\ninject HUMIRA.', 'tokens': ['Call', 'healthcare', 'provider', 'caregiver', 'questions', 'right', 'way', 'inject', 'HUMIRA', '.'], 'lemmatized': ['Call', 'healthcare', 'provider', 'caregiver', 'question', 'right', 'way', 'inject', 'HUMIRA', '.'], 'stemmed': ['call', 'healthcar', 'provid', 'caregiv', 'question', 'right', 'way', 'inject', 'humira', '.'], 'dependencies': [('call', 'ROOT'), ('healthcar', 'compound'), ('provid', 'compound'), ('caregiv', 'dobj'), ('question', 'dobj'), ('right', 'amod'), ('way', 'npadvmod'), ('inject', 'compound'), ('humira', 'oprd'), ('.', 'punct')]}, {'original_sentence': 'IMPORTANT: \\n• Do not use HUMIRA if frozen, even if it has been thawed.', 'tokens': ['IMPORTANT', ':', '•', 'use', 'HUMIRA', 'frozen', ',', 'even', 'thawed', '.'], 'lemmatized': ['IMPORTANT', ':', '•', 'use', 'HUMIRA', 'frozen', ',', 'even', 'thawed', '.'], 'stemmed': ['import', ':', '•', 'use', 'humira', 'frozen', ',', 'even', 'thaw', '.'], 'dependencies': [('import', 'ROOT'), (':', 'punct'), ('•', 'meta'), ('use', 'xcomp'), ('humira', 'npadvmod'), ('frozen', 'amod'), (',', 'punct'), ('even', 'advmod'), ('thaw', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• The HUMIRA Pen contains glass.', 'tokens': ['•', 'HUMIRA', 'Pen', 'contains', 'glass', '.'], 'lemmatized': ['•', 'HUMIRA', 'Pen', 'contains', 'glass', '.'], 'stemmed': ['•', 'humira', 'pen', 'contain', 'glass', '.'], 'dependencies': [('•', 'meta'), ('humira', 'compound'), ('pen', 'compound'), ('contain', 'ROOT'), ('glass', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Do not drop or crush the Pen because the glass inside \\nmay break.', 'tokens': ['drop', 'crush', 'Pen', 'glass', 'inside', 'may', 'break', '.'], 'lemmatized': ['drop', 'crush', 'Pen', 'glass', 'inside', 'may', 'break', '.'], 'stemmed': ['drop', 'crush', 'pen', 'glass', 'insid', 'may', 'break', '.'], 'dependencies': [('drop', 'compound'), ('crush', 'compound'), ('pen', 'compound'), ('glass', 'nsubj'), ('insid', 'amod'), ('may', 'aux'), ('break', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• Each HUMIRA Pen has 2 caps on it.', 'tokens': ['•', 'HUMIRA', 'Pen', '2', 'caps', '.'], 'lemmatized': ['•', 'HUMIRA', 'Pen', '2', 'cap', '.'], 'stemmed': ['•', 'humira', 'pen', '2', 'cap', '.'], 'dependencies': [('•', 'nummod'), ('humira', 'compound'), ('pen', 'nmod'), ('2', 'nummod'), ('cap', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Do not remove the gray cap (Cap #1) or the plum-\\ncolored cap (Cap #2) until right before your injection.', 'tokens': ['remove', 'gray', 'cap', '(', 'Cap', '#', '1', ')', 'plum-', 'colored', 'cap', '(', 'Cap', '#', '2', ')', 'right', 'injection', '.'], 'lemmatized': ['remove', 'gray', 'cap', '(', 'Cap', '#', '1', ')', 'plum-', 'colored', 'cap', '(', 'Cap', '#', '2', ')', 'right', 'injection', '.'], 'stemmed': ['remov', 'gray', 'cap', '(', 'cap', '#', '1', ')', 'plum-', 'color', 'cap', '(', 'cap', '#', '2', ')', 'right', 'inject', '.'], 'dependencies': [('remov', 'amod'), ('gray', 'amod'), ('cap', 'ROOT'), ('(', 'punct'), ('cap', 'dep'), ('#', 'nmod'), ('1', 'nummod'), (')', 'punct'), ('plum-', 'amod'), ('color', 'compound'), ('cap', 'dobj'), ('(', 'punct'), ('cap', 'appos'), ('#', 'nmod'), ('2', 'nummod'), (')', 'punct'), ('right', 'advmod'), ('inject', 'appos'), ('.', 'punct')]}, {'original_sentence': '• When the plum-colored button on the HUMIRA Pen is pressed to give your dose of \\nHUMIRA, you will hear a loud “click” sound.', 'tokens': ['•', 'plum-colored', 'button', 'HUMIRA', 'Pen', 'pressed', 'give', 'dose', 'HUMIRA', ',', 'hear', 'loud', '“', 'click', '”', 'sound', '.'], 'lemmatized': ['•', 'plum-colored', 'button', 'HUMIRA', 'Pen', 'pressed', 'give', 'dose', 'HUMIRA', ',', 'hear', 'loud', '“', 'click', '”', 'sound', '.'], 'stemmed': ['•', 'plum-color', 'button', 'humira', 'pen', 'press', 'give', 'dose', 'humira', ',', 'hear', 'loud', '“', 'click', '”', 'sound', '.'], 'dependencies': [('•', 'dep'), ('plum', 'compound'), ('-', 'punct'), ('color', 'compound'), ('button', 'compound'), ('humira', 'compound'), ('pen', 'compound'), ('press', 'nsubj'), ('give', 'ROOT'), ('dose', 'compound'), ('humira', 'dobj'), (',', 'punct'), ('hear', 'conj'), ('loud', 'advmod'), ('“', 'punct'), ('click', 'amod'), ('”', 'punct'), ('sound', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• You must practice injecting HUMIRA with your doctor or nurse so that you are not \\nstartled by this click when you start giving yourself the injections at home.', 'tokens': ['•', 'must', 'practice', 'injecting', 'HUMIRA', 'doctor', 'nurse', 'startled', 'click', 'start', 'giving', 'injections', 'home', '.'], 'lemmatized': ['•', 'must', 'practice', 'injecting', 'HUMIRA', 'doctor', 'nurse', 'startled', 'click', 'start', 'giving', 'injection', 'home', '.'], 'stemmed': ['•', 'must', 'practic', 'inject', 'humira', 'doctor', 'nurs', 'startl', 'click', 'start', 'give', 'inject', 'home', '.'], 'dependencies': [('•', 'nsubj'), ('must', 'aux'), ('practic', 'ROOT'), ('inject', 'compound'), ('humira', 'compound'), ('doctor', 'dobj'), ('nurs', 'conj'), ('startl', 'dobj'), ('click', 'dep'), ('start', 'dobj'), ('give', 'dep'), ('inject', 'compound'), ('home', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• The loud click sound means the start of the injection.', 'tokens': ['•', 'loud', 'click', 'sound', 'means', 'start', 'injection', '.'], 'lemmatized': ['•', 'loud', 'click', 'sound', 'mean', 'start', 'injection', '.'], 'stemmed': ['•', 'loud', 'click', 'sound', 'mean', 'start', 'inject', '.'], 'dependencies': [('•', 'nsubj'), ('loud', 'amod'), ('click', 'ROOT'), ('sound', 'compound'), ('mean', 'dobj'), ('start', 'dep'), ('inject', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• You will know that the injection has finished when the yellow indicator appears fully in \\nthe window view and stops moving.', 'tokens': ['•', 'know', 'injection', 'finished', 'yellow', 'indicator', 'appears', 'fully', 'window', 'view', 'stops', 'moving', '.'], 'lemmatized': ['•', 'know', 'injection', 'finished', 'yellow', 'indicator', 'appears', 'fully', 'window', 'view', 'stop', 'moving', '.'], 'stemmed': ['•', 'know', 'inject', 'finish', 'yellow', 'indic', 'appear', 'fulli', 'window', 'view', 'stop', 'move', '.'], 'dependencies': [('•', 'meta'), ('know', 'parataxis'), ('inject', 'compound'), ('finish', 'nmod'), ('yellow', 'amod'), ('indic', 'nsubj'), ('appear', 'compound'), ('fulli', 'compound'), ('window', 'compound'), ('view', 'nsubj'), ('stop', 'ROOT'), ('move', 'xcomp'), ('.', 'punct')]}, {'original_sentence': 'See the section below called “Preparing the HUMIRA Pen”.', 'tokens': ['See', 'section', 'called', '“', 'Preparing', 'HUMIRA', 'Pen', '”', '.'], 'lemmatized': ['See', 'section', 'called', '“', 'Preparing', 'HUMIRA', 'Pen', '”', '.'], 'stemmed': ['see', 'section', 'call', '“', 'prepar', 'humira', 'pen', '”', '.'], 'dependencies': [('see', 'ROOT'), ('section', 'nsubj'), ('call', 'ccomp'), ('“', 'punct'), ('prepar', 'compound'), ('humira', 'compound'), ('pen', 'dobj'), ('”', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Gather the Supplies for Your Injection \\n• You will need the following supplies for each injection of HUMIRA.', 'tokens': ['Gather', 'Supplies', 'Injection', '•', 'need', 'following', 'supplies', 'injection', 'HUMIRA', '.'], 'lemmatized': ['Gather', 'Supplies', 'Injection', '•', 'need', 'following', 'supply', 'injection', 'HUMIRA', '.'], 'stemmed': ['gather', 'suppli', 'inject', '•', 'need', 'follow', 'suppli', 'inject', 'humira', '.'], 'dependencies': [('gather', 'ROOT'), ('suppli', 'nsubj'), ('inject', 'ccomp'), ('•', 'punct'), ('need', 'dobj'), ('follow', 'compound'), ('suppli', 'compound'), ('inject', 'compound'), ('humira', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Find a clean, flat surface to place the supplies on.', 'tokens': ['Find', 'clean', ',', 'flat', 'surface', 'place', 'supplies', '.'], 'lemmatized': ['Find', 'clean', ',', 'flat', 'surface', 'place', 'supply', '.'], 'stemmed': ['find', 'clean', ',', 'flat', 'surfac', 'place', 'suppli', '.'], 'dependencies': [('find', 'ROOT'), ('clean', 'amod'), (',', 'punct'), ('flat', 'amod'), ('surfac', 'compound'), ('place', 'compound'), ('suppli', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• 1 alcohol swab \\n• 1 cotton ball or gauze pad (not included in your HUMIRA carton) \\n• 1 HUMIRA Pen (See Figure A) \\n• Puncture-resistant sharps disposal container for HUMIRA Pen disposal (not included in \\nyour HUMIRA carton).', 'tokens': ['•', '1', 'alcohol', 'swab', '•', '1', 'cotton', 'ball', 'gauze', 'pad', '(', 'included', 'HUMIRA', 'carton', ')', '•', '1', 'HUMIRA', 'Pen', '(', 'See', 'Figure', ')', '•', 'Puncture-resistant', 'sharps', 'disposal', 'container', 'HUMIRA', 'Pen', 'disposal', '(', 'included', 'HUMIRA', 'carton', ')', '.'], 'lemmatized': ['•', '1', 'alcohol', 'swab', '•', '1', 'cotton', 'ball', 'gauze', 'pad', '(', 'included', 'HUMIRA', 'carton', ')', '•', '1', 'HUMIRA', 'Pen', '(', 'See', 'Figure', ')', '•', 'Puncture-resistant', 'sharp', 'disposal', 'container', 'HUMIRA', 'Pen', 'disposal', '(', 'included', 'HUMIRA', 'carton', ')', '.'], 'stemmed': ['•', '1', 'alcohol', 'swab', '•', '1', 'cotton', 'ball', 'gauz', 'pad', '(', 'includ', 'humira', 'carton', ')', '•', '1', 'humira', 'pen', '(', 'see', 'figur', ')', '•', 'puncture-resist', 'sharp', 'dispos', 'contain', 'humira', 'pen', 'dispos', '(', 'includ', 'humira', 'carton', ')', '.'], 'dependencies': [('•', 'nmod'), ('1', 'nummod'), ('alcohol', 'compound'), ('swab', 'compound'), ('•', 'nummod'), ('1', 'nummod'), ('cotton', 'compound'), ('ball', 'compound'), ('gauz', 'compound'), ('pad', 'nsubj'), ('(', 'punct'), ('includ', 'compound'), ('humira', 'compound'), ('carton', 'appos'), (')', 'punct'), ('•', 'nummod'), ('1', 'nummod'), ('humira', 'compound'), ('pen', 'ROOT'), ('(', 'punct'), ('see', 'parataxis'), ('figur', 'dobj'), (')', 'punct'), ('•', 'meta'), ('puncture', 'npadvmod'), ('-', 'punct'), ('resist', 'amod'), ('sharp', 'amod'), ('dispos', 'nsubj'), ('contain', 'ROOT'), ('humira', 'compound'), ('pen', 'compound'), ('dispos', 'dobj'), ('(', 'punct'), ('includ', 'compound'), ('humira', 'compound'), ('carton', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'See the “How should I throw away (dispose of) the used \\nHUMIRA Pen?” section at the end of this Instructions for Use.', 'tokens': ['See', '“', 'throw', 'away', '(', 'dispose', ')', 'used', 'HUMIRA', 'Pen', '?', '”', 'section', 'end', 'Instructions', 'Use', '.'], 'lemmatized': ['See', '“', 'throw', 'away', '(', 'dispose', ')', 'used', 'HUMIRA', 'Pen', '?', '”', 'section', 'end', 'Instructions', 'Use', '.'], 'stemmed': ['see', '“', 'throw', 'away', '(', 'dispos', ')', 'use', 'humira', 'pen', '?', '”', 'section', 'end', 'instruct', 'use', '.'], 'dependencies': [('see', 'ROOT'), ('“', 'punct'), ('throw', 'xcomp'), ('away', 'advmod'), ('(', 'punct'), ('dispos', 'npadvmod'), (')', 'punct'), ('use', 'conj'), ('humira', 'compound'), ('pen', 'dobj'), ('?', 'punct'), ('”', 'punct'), ('section', 'compound'), ('end', 'nsubj'), ('instruct', 'ROOT'), ('use', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'If more comfortable, take your HUMIRA Pen out of the refrigerator 15 to 30 minutes before \\ninjecting to allow the liquid to reach room temperature.', 'tokens': ['comfortable', ',', 'take', 'HUMIRA', 'Pen', 'refrigerator', '15', '30', 'minutes', 'injecting', 'allow', 'liquid', 'reach', 'room', 'temperature', '.'], 'lemmatized': ['comfortable', ',', 'take', 'HUMIRA', 'Pen', 'refrigerator', '15', '30', 'minute', 'injecting', 'allow', 'liquid', 'reach', 'room', 'temperature', '.'], 'stemmed': ['comfort', ',', 'take', 'humira', 'pen', 'refriger', '15', '30', 'minut', 'inject', 'allow', 'liquid', 'reach', 'room', 'temperatur', '.'], 'dependencies': [('comfort', 'npadvmod'), (',', 'punct'), ('take', 'ROOT'), ('humira', 'compound'), ('pen', 'compound'), ('refriger', 'dobj'), ('15', 'npadvmod'), ('30', 'nummod'), ('minut', 'compound'), ('inject', 'nsubj'), ('allow', 'ccomp'), ('liquid', 'compound'), ('reach', 'compound'), ('room', 'compound'), ('temperatur', 'ccomp'), ('.', 'punct')]}, {'original_sentence': 'Do not remove the gray cap (Cap #1) or \\nthe plum-colored cap (Cap #2) while allowing it to reach room temperature.', 'tokens': ['remove', 'gray', 'cap', '(', 'Cap', '#', '1', ')', 'plum-colored', 'cap', '(', 'Cap', '#', '2', ')', 'allowing', 'reach', 'room', 'temperature', '.'], 'lemmatized': ['remove', 'gray', 'cap', '(', 'Cap', '#', '1', ')', 'plum-colored', 'cap', '(', 'Cap', '#', '2', ')', 'allowing', 'reach', 'room', 'temperature', '.'], 'stemmed': ['remov', 'gray', 'cap', '(', 'cap', '#', '1', ')', 'plum-color', 'cap', '(', 'cap', '#', '2', ')', 'allow', 'reach', 'room', 'temperatur', '.'], 'dependencies': [('remov', 'amod'), ('gray', 'amod'), ('cap', 'nsubj'), ('(', 'punct'), ('cap', 'parataxis'), ('#', 'npadvmod'), ('1', 'nummod'), (')', 'punct'), ('plum', 'compound'), ('-', 'punct'), ('color', 'compound'), ('cap', 'appos'), ('(', 'punct'), ('cap', 'parataxis'), ('#', 'nmod'), ('2', 'nummod'), (')', 'punct'), ('allow', 'ROOT'), ('reach', 'compound'), ('room', 'compound'), ('temperatur', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Do not warm \\nHUMIRA in any other way (for example, do not warm it in a microwave or in hot water).', 'tokens': ['warm', 'HUMIRA', 'way', '(', 'example', ',', 'warm', 'microwave', 'hot', 'water', ')', '.'], 'lemmatized': ['warm', 'HUMIRA', 'way', '(', 'example', ',', 'warm', 'microwave', 'hot', 'water', ')', '.'], 'stemmed': ['warm', 'humira', 'way', '(', 'exampl', ',', 'warm', 'microwav', 'hot', 'water', ')', '.'], 'dependencies': [('warm', 'amod'), ('humira', 'compound'), ('way', 'ROOT'), ('(', 'punct'), ('exampl', 'appos'), (',', 'punct'), ('warm', 'amod'), ('microwav', 'amod'), ('hot', 'amod'), ('water', 'conj'), (')', 'punct'), ('.', 'punct')]}], 'text': 'INSTRUCTIONS FOR USE \\nHUMIRA® (Hu-MARE-ah) \\n(adalimumab) \\n40 MG/0.8 ML \\nSINGLE-DOSE PEN \\nDo not try to inject HUMIRA yourself until you have been shown the right way to give the \\ninjections and have read and understand this Instructions for Use. If your doctor decides that \\nyou or a caregiver may be able to give your injections of HUMIRA at home, you should receive \\ntraining on the right way to prepare and inject HUMIRA. It is important that you read, \\nunderstand, and follow these instructions so that you inject HUMIRA the right way. It is also \\nimportant to talk to your doctor to be sure you understand your HUMIRA dosing instructions. To \\nhelp you remember when to inject HUMIRA, you can mark your calendar ahead of time. Call \\nyour healthcare provider if you or your caregiver have any questions about the right way to \\ninject HUMIRA.  \\nIMPORTANT: \\n• Do not use HUMIRA if frozen, even if it has been thawed. \\n• The HUMIRA Pen contains glass. Do not drop or crush the Pen because the glass inside \\nmay break. \\n• Each HUMIRA Pen has 2 caps on it. Do not remove the gray cap (Cap #1) or the plum-\\ncolored cap (Cap #2) until right before your injection.  \\n• When the plum-colored button on the HUMIRA Pen is pressed to give your dose of \\nHUMIRA, you will hear a loud “click” sound. \\n• You must practice injecting HUMIRA with your doctor or nurse so that you are not \\nstartled by this click when you start giving yourself the injections at home.  \\n• The loud click sound means the start of the injection. \\n• You will know that the injection has finished when the yellow indicator appears fully in \\nthe window view and stops moving. \\n  \\nSee the section below called “Preparing the HUMIRA Pen”.  \\nGather the Supplies for Your Injection \\n• You will need the following supplies for each injection of HUMIRA. \\nFind a clean, flat surface to place the supplies on. \\n• 1 alcohol swab \\n• 1 cotton ball or gauze pad (not included in your HUMIRA carton) \\n• 1 HUMIRA Pen (See Figure A) \\n• Puncture-resistant sharps disposal container for HUMIRA Pen disposal (not included in \\nyour HUMIRA carton). See the “How should I throw away (dispose of) the used \\nHUMIRA Pen?” section at the end of this Instructions for Use.  \\n  \\nIf more comfortable, take your HUMIRA Pen out of the refrigerator 15 to 30 minutes before \\ninjecting to allow the liquid to reach room temperature. Do not remove the gray cap (Cap #1) or \\nthe plum-colored cap (Cap #2) while allowing it to reach room temperature. Do not warm \\nHUMIRA in any other way (for example, do not warm it in a microwave or in hot water).  \\n'}, 'page_char_count': 2577, 'page_word_count': 457, 'sentences': ['INSTRUCTIONS FOR USE \\nHUMIRA® (Hu-MARE-ah) \\n(adalimumab) \\n40 MG/0.8 ML \\nSINGLE-DOSE PEN \\nDo not try to inject HUMIRA yourself until you have been shown the right way to give the \\ninjections and have read and understand this Instructions for Use.', 'If your doctor decides that \\nyou or a caregiver may be able to give your injections of HUMIRA at home, you should receive \\ntraining on the right way to prepare and inject HUMIRA.', 'It is important that you read, \\nunderstand, and follow these instructions so that you inject HUMIRA the right way.', 'It is also \\nimportant to talk to your doctor to be sure you understand your HUMIRA dosing instructions.', 'To \\nhelp you remember when to inject HUMIRA, you can mark your calendar ahead of time.', 'Call \\nyour healthcare provider if you or your caregiver have any questions about the right way to \\ninject HUMIRA.', ' \\nIMPORTANT: \\n• Do not use HUMIRA if frozen, even if it has been thawed.', '\\n• The HUMIRA Pen contains glass.', 'Do not drop or crush the Pen because the glass inside \\nmay break.', '\\n• Each HUMIRA Pen has 2 caps on it.', 'Do not remove the gray cap (Cap #1) or the plum-\\ncolored cap (Cap #2) until right before your injection.', ' \\n• When the plum-colored button on the HUMIRA Pen is pressed to give your dose of \\nHUMIRA, you will hear a loud “click” sound.', '\\n• You must practice injecting HUMIRA with your doctor or nurse so that you are not \\nstartled by this click when you start giving yourself the injections at home.', ' \\n• The loud click sound means the start of the injection.', '\\n• You will know that the injection has finished when the yellow indicator appears fully in \\nthe window view and stops moving.', '\\n  \\nSee the section below called “Preparing the HUMIRA Pen”.', ' \\nGather the Supplies for Your Injection \\n• You will need the following supplies for each injection of HUMIRA.', '\\nFind a clean, flat surface to place the supplies on.', '\\n• 1 alcohol swab \\n• 1 cotton ball or gauze pad (not included in your HUMIRA carton) \\n• 1 HUMIRA Pen (See Figure A) \\n• Puncture-resistant sharps disposal container for HUMIRA Pen disposal (not included in \\nyour HUMIRA carton).', 'See the “How should I throw away (dispose of) the used \\nHUMIRA Pen?”', 'section at the end of this Instructions for Use.', ' \\n  \\nIf more comfortable, take your HUMIRA Pen out of the refrigerator 15 to 30 minutes before \\ninjecting to allow the liquid to reach room temperature.', 'Do not remove the gray cap (Cap #1) or \\nthe plum-colored cap (Cap #2) while allowing it to reach room temperature.', 'Do not warm \\nHUMIRA in any other way (for example, do not warm it in a microwave or in hot water).', ' \\n'], 'page_sentence_count_spacy': 25}\n",
            "{'page_number': 66, 'text': 'If you do not have all the supplies you need to give yourself an injection, go to a pharmacy or \\ncall your pharmacist. The figure below shows what the HUMIRA Pen looks like. See Figure A.  \\nFigure A \\n \\nCheck the carton, dose tray, and HUMIRA Pen.  \\n1. Make sure the name HUMIRA appears on the carton, dose tray, and HUMIRA Pen label.  \\n2. Do not use and do call your doctor or pharmacist if:  \\n• you drop or crush your HUMIRA Pen. \\n• the seals on the top or bottom of the carton are broken or missing. \\n• the expiration date on the carton, dose tray, and Pen has passed. \\n• the HUMIRA Pen has been frozen or left in direct sunlight.  \\n• HUMIRA has been kept at room temperature for longer than 14 days or HUMIRA has been \\nstored above 77°F (25°C).  \\n  \\nSee the “How should I store HUMIRA?” section at the end of this Instructions for Use.  \\n3. Hold the Pen with the gray cap (Cap # 1) pointed down.  \\n4. Make sure the amount of liquid in the Pen is at the fill line or close to the fill line seen through \\nthe window. This is the full dose of HUMIRA that you will inject. See Figure B.  \\n5. If the Pen does not have the full amount of liquid, do not use that Pen. Call your pharmacist.  \\n', 'processed_text': {'sentences': [{'original_sentence': 'If you do not have all the supplies you need to give yourself an injection, go to a pharmacy or \\ncall your pharmacist.', 'tokens': ['supplies', 'need', 'give', 'injection', ',', 'go', 'pharmacy', 'call', 'pharmacist', '.'], 'lemmatized': ['supply', 'need', 'give', 'injection', ',', 'go', 'pharmacy', 'call', 'pharmacist', '.'], 'stemmed': ['suppli', 'need', 'give', 'inject', ',', 'go', 'pharmaci', 'call', 'pharmacist', '.'], 'dependencies': [('suppli', 'nsubj'), ('need', 'ccomp'), ('give', 'xcomp'), ('inject', 'dobj'), (',', 'punct'), ('go', 'ROOT'), ('pharmaci', 'compound'), ('call', 'compound'), ('pharmacist', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The figure below shows what the HUMIRA Pen looks like.', 'tokens': ['figure', 'shows', 'HUMIRA', 'Pen', 'looks', 'like', '.'], 'lemmatized': ['figure', 'show', 'HUMIRA', 'Pen', 'look', 'like', '.'], 'stemmed': ['figur', 'show', 'humira', 'pen', 'look', 'like', '.'], 'dependencies': [('figur', 'nsubj'), ('show', 'ROOT'), ('humira', 'compound'), ('pen', 'dobj'), ('look', 'ccomp'), ('like', 'prep'), ('.', 'punct')]}, {'original_sentence': 'See Figure A.', 'tokens': ['See', 'Figure', '.'], 'lemmatized': ['See', 'Figure', '.'], 'stemmed': ['see', 'figur', '.'], 'dependencies': [('see', 'ROOT'), ('figur', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Figure A \\n \\nCheck the carton, dose tray, and HUMIRA Pen.', 'tokens': ['Figure', 'Check', 'carton', ',', 'dose', 'tray', ',', 'HUMIRA', 'Pen', '.'], 'lemmatized': ['Figure', 'Check', 'carton', ',', 'dose', 'tray', ',', 'HUMIRA', 'Pen', '.'], 'stemmed': ['figur', 'check', 'carton', ',', 'dose', 'tray', ',', 'humira', 'pen', '.'], 'dependencies': [('figur', 'nsubj'), ('check', 'ROOT'), ('carton', 'dobj'), (',', 'punct'), ('dose', 'compound'), ('tray', 'conj'), (',', 'punct'), ('humira', 'compound'), ('pen', 'appos'), ('.', 'punct')]}, {'original_sentence': '1.', 'tokens': ['1', '.'], 'lemmatized': ['1', '.'], 'stemmed': ['1', '.'], 'dependencies': [('1', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Make sure the name HUMIRA appears on the carton, dose tray, and HUMIRA Pen label.', 'tokens': ['Make', 'sure', 'name', 'HUMIRA', 'appears', 'carton', ',', 'dose', 'tray', ',', 'HUMIRA', 'Pen', 'label', '.'], 'lemmatized': ['Make', 'sure', 'name', 'HUMIRA', 'appears', 'carton', ',', 'dose', 'tray', ',', 'HUMIRA', 'Pen', 'label', '.'], 'stemmed': ['make', 'sure', 'name', 'humira', 'appear', 'carton', ',', 'dose', 'tray', ',', 'humira', 'pen', 'label', '.'], 'dependencies': [('make', 'ROOT'), ('sure', 'ccomp'), ('name', 'compound'), ('humira', 'nsubj'), ('appear', 'ccomp'), ('carton', 'dobj'), (',', 'punct'), ('dose', 'compound'), ('tray', 'conj'), (',', 'punct'), ('humira', 'compound'), ('pen', 'compound'), ('label', 'conj'), ('.', 'punct')]}, {'original_sentence': '2.', 'tokens': ['2', '.'], 'lemmatized': ['2', '.'], 'stemmed': ['2', '.'], 'dependencies': [('2', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Do not use and do call your doctor or pharmacist if:  \\n• you drop or crush your HUMIRA Pen.', 'tokens': ['use', 'call', 'doctor', 'pharmacist', ':', '•', 'drop', 'crush', 'HUMIRA', 'Pen', '.'], 'lemmatized': ['use', 'call', 'doctor', 'pharmacist', ':', '•', 'drop', 'crush', 'HUMIRA', 'Pen', '.'], 'stemmed': ['use', 'call', 'doctor', 'pharmacist', ':', '•', 'drop', 'crush', 'humira', 'pen', '.'], 'dependencies': [('use', 'ROOT'), ('call', 'compound'), ('doctor', 'compound'), ('pharmacist', 'dobj'), (':', 'punct'), ('•', 'nummod'), ('drop', 'compound'), ('crush', 'compound'), ('humira', 'compound'), ('pen', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• the seals on the top or bottom of the carton are broken or missing.', 'tokens': ['•', 'seals', 'top', 'bottom', 'carton', 'broken', 'missing', '.'], 'lemmatized': ['•', 'seal', 'top', 'bottom', 'carton', 'broken', 'missing', '.'], 'stemmed': ['•', 'seal', 'top', 'bottom', 'carton', 'broken', 'miss', '.'], 'dependencies': [('•', 'nummod'), ('seal', 'compound'), ('top', 'amod'), ('bottom', 'compound'), ('carton', 'compound'), ('broken', 'compound'), ('miss', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• the expiration date on the carton, dose tray, and Pen has passed.', 'tokens': ['•', 'expiration', 'date', 'carton', ',', 'dose', 'tray', ',', 'Pen', 'passed', '.'], 'lemmatized': ['•', 'expiration', 'date', 'carton', ',', 'dose', 'tray', ',', 'Pen', 'passed', '.'], 'stemmed': ['•', 'expir', 'date', 'carton', ',', 'dose', 'tray', ',', 'pen', 'pass', '.'], 'dependencies': [('•', 'nummod'), ('expir', 'compound'), ('date', 'compound'), ('carton', 'dep'), (',', 'punct'), ('dose', 'compound'), ('tray', 'conj'), (',', 'punct'), ('pen', 'compound'), ('pass', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• the HUMIRA Pen has been frozen or left in direct sunlight.', 'tokens': ['•', 'HUMIRA', 'Pen', 'frozen', 'left', 'direct', 'sunlight', '.'], 'lemmatized': ['•', 'HUMIRA', 'Pen', 'frozen', 'left', 'direct', 'sunlight', '.'], 'stemmed': ['•', 'humira', 'pen', 'frozen', 'left', 'direct', 'sunlight', '.'], 'dependencies': [('•', 'dep'), ('humira', 'compound'), ('pen', 'compound'), ('frozen', 'nsubj'), ('left', 'ROOT'), ('direct', 'amod'), ('sunlight', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• HUMIRA has been kept at room temperature for longer than 14 days or HUMIRA has been \\nstored above 77°F (25°C).', 'tokens': ['•', 'HUMIRA', 'kept', 'room', 'temperature', 'longer', '14', 'days', 'HUMIRA', 'stored', '77°F', '(', '25°C', ')', '.'], 'lemmatized': ['•', 'HUMIRA', 'kept', 'room', 'temperature', 'longer', '14', 'day', 'HUMIRA', 'stored', '77°F', '(', '25°C', ')', '.'], 'stemmed': ['•', 'humira', 'kept', 'room', 'temperatur', 'longer', '14', 'day', 'humira', 'store', '77°f', '(', '25°c', ')', '.'], 'dependencies': [('•', 'nummod'), ('humira', 'nsubj'), ('kept', 'ROOT'), ('room', 'compound'), ('temperatur', 'advmod'), ('longer', 'advmod'), ('14', 'nummod'), ('day', 'compound'), ('humira', 'compound'), ('store', 'conj'), ('77', 'nummod'), ('°', 'npadvmod'), ('f', 'prep'), ('(', 'punct'), ('25', 'nummod'), ('°', 'appos'), ('c', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'See the “How should I store HUMIRA?” section at the end of this Instructions for Use.', 'tokens': ['See', '“', 'store', 'HUMIRA', '?', '”', 'section', 'end', 'Instructions', 'Use', '.'], 'lemmatized': ['See', '“', 'store', 'HUMIRA', '?', '”', 'section', 'end', 'Instructions', 'Use', '.'], 'stemmed': ['see', '“', 'store', 'humira', '?', '”', 'section', 'end', 'instruct', 'use', '.'], 'dependencies': [('see', 'ROOT'), ('“', 'punct'), ('store', 'compound'), ('humira', 'dobj'), ('?', 'punct'), ('”', 'punct'), ('section', 'compound'), ('end', 'nsubj'), ('instruct', 'ROOT'), ('use', 'dobj'), ('.', 'punct')]}, {'original_sentence': '3.', 'tokens': ['3', '.'], 'lemmatized': ['3', '.'], 'stemmed': ['3', '.'], 'dependencies': [('3', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Hold the Pen with the gray cap (Cap # 1) pointed down.', 'tokens': ['Hold', 'Pen', 'gray', 'cap', '(', 'Cap', '#', '1', ')', 'pointed', '.'], 'lemmatized': ['Hold', 'Pen', 'gray', 'cap', '(', 'Cap', '#', '1', ')', 'pointed', '.'], 'stemmed': ['hold', 'pen', 'gray', 'cap', '(', 'cap', '#', '1', ')', 'point', '.'], 'dependencies': [('hold', 'ROOT'), ('pen', 'compound'), ('gray', 'amod'), ('cap', 'dobj'), ('(', 'punct'), ('cap', 'dep'), ('#', 'nmod'), ('1', 'nummod'), (')', 'punct'), ('point', 'appos'), ('.', 'punct')]}, {'original_sentence': '4.', 'tokens': ['4', '.'], 'lemmatized': ['4', '.'], 'stemmed': ['4', '.'], 'dependencies': [('4', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Make sure the amount of liquid in the Pen is at the fill line or close to the fill line seen through \\nthe window.', 'tokens': ['Make', 'sure', 'amount', 'liquid', 'Pen', 'fill', 'line', 'close', 'fill', 'line', 'seen', 'window', '.'], 'lemmatized': ['Make', 'sure', 'amount', 'liquid', 'Pen', 'fill', 'line', 'close', 'fill', 'line', 'seen', 'window', '.'], 'stemmed': ['make', 'sure', 'amount', 'liquid', 'pen', 'fill', 'line', 'close', 'fill', 'line', 'seen', 'window', '.'], 'dependencies': [('make', 'ROOT'), ('sure', 'amod'), ('amount', 'nmod'), ('liquid', 'amod'), ('pen', 'compound'), ('fill', 'compound'), ('line', 'nmod'), ('close', 'amod'), ('fill', 'compound'), ('line', 'nsubj'), ('seen', 'amod'), ('window', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'This is the full dose of HUMIRA that you will inject.', 'tokens': ['full', 'dose', 'HUMIRA', 'inject', '.'], 'lemmatized': ['full', 'dose', 'HUMIRA', 'inject', '.'], 'stemmed': ['full', 'dose', 'humira', 'inject', '.'], 'dependencies': [('full', 'compound'), ('dose', 'compound'), ('humira', 'compound'), ('inject', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'See Figure B.', 'tokens': ['See', 'Figure', 'B', '.'], 'lemmatized': ['See', 'Figure', 'B', '.'], 'stemmed': ['see', 'figur', 'b', '.'], 'dependencies': [('see', 'ROOT'), ('figur', 'compound'), ('b', 'dobj'), ('.', 'punct')]}, {'original_sentence': '5.', 'tokens': ['5', '.'], 'lemmatized': ['5', '.'], 'stemmed': ['5', '.'], 'dependencies': [('5', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'If the Pen does not have the full amount of liquid, do not use that Pen.', 'tokens': ['Pen', 'full', 'amount', 'liquid', ',', 'use', 'Pen', '.'], 'lemmatized': ['Pen', 'full', 'amount', 'liquid', ',', 'use', 'Pen', '.'], 'stemmed': ['pen', 'full', 'amount', 'liquid', ',', 'use', 'pen', '.'], 'dependencies': [('pen', 'nmod'), ('full', 'amod'), ('amount', 'compound'), ('liquid', 'ROOT'), (',', 'punct'), ('use', 'conj'), ('pen', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Call your pharmacist.', 'tokens': ['Call', 'pharmacist', '.'], 'lemmatized': ['Call', 'pharmacist', '.'], 'stemmed': ['call', 'pharmacist', '.'], 'dependencies': [('call', 'ROOT'), ('pharmacist', 'dobj'), ('.', 'punct')]}], 'text': 'If you do not have all the supplies you need to give yourself an injection, go to a pharmacy or \\ncall your pharmacist. The figure below shows what the HUMIRA Pen looks like. See Figure A.  \\nFigure A \\n \\nCheck the carton, dose tray, and HUMIRA Pen.  \\n1. Make sure the name HUMIRA appears on the carton, dose tray, and HUMIRA Pen label.  \\n2. Do not use and do call your doctor or pharmacist if:  \\n• you drop or crush your HUMIRA Pen. \\n• the seals on the top or bottom of the carton are broken or missing. \\n• the expiration date on the carton, dose tray, and Pen has passed. \\n• the HUMIRA Pen has been frozen or left in direct sunlight.  \\n• HUMIRA has been kept at room temperature for longer than 14 days or HUMIRA has been \\nstored above 77°F (25°C).  \\n  \\nSee the “How should I store HUMIRA?” section at the end of this Instructions for Use.  \\n3. Hold the Pen with the gray cap (Cap # 1) pointed down.  \\n4. Make sure the amount of liquid in the Pen is at the fill line or close to the fill line seen through \\nthe window. This is the full dose of HUMIRA that you will inject. See Figure B.  \\n5. If the Pen does not have the full amount of liquid, do not use that Pen. Call your pharmacist.  \\n'}, 'page_char_count': 1188, 'page_word_count': 231, 'sentences': ['If you do not have all the supplies you need to give yourself an injection, go to a pharmacy or \\ncall your pharmacist.', 'The figure below shows what the HUMIRA Pen looks like.', 'See Figure A.  \\nFigure A \\n \\nCheck the carton, dose tray, and HUMIRA Pen.', ' \\n1.', 'Make sure the name HUMIRA appears on the carton, dose tray, and HUMIRA Pen label.', ' \\n2.', 'Do not use and do call your doctor or pharmacist if:  \\n• you drop or crush your HUMIRA Pen.', '\\n• the seals on the top or bottom of the carton are broken or missing.', '\\n• the expiration date on the carton, dose tray, and Pen has passed.', '\\n• the HUMIRA Pen has been frozen or left in direct sunlight.', ' \\n• HUMIRA has been kept at room temperature for longer than 14 days or HUMIRA has been \\nstored above 77°F (25°C).', ' \\n  \\nSee the “How should I store HUMIRA?”', 'section at the end of this Instructions for Use.', ' \\n3.', 'Hold the Pen with the gray cap (Cap # 1) pointed down.', ' \\n4.', 'Make sure the amount of liquid in the Pen is at the fill line or close to the fill line seen through \\nthe window.', 'This is the full dose of HUMIRA that you will inject.', 'See Figure B.  \\n5.', 'If the Pen does not have the full amount of liquid, do not use that Pen.', 'Call your pharmacist.', ' \\n'], 'page_sentence_count_spacy': 22}\n",
            "{'page_number': 67, 'text': 'Figure B \\n \\n6. Turn the Pen over and hold the Pen with the gray cap (Cap # 1) pointed up. See Figure C.  \\n7. Check the solution through the windows on the side of the Pen to make sure the liquid is \\nclear and colorless. Do not use your HUMIRA Pen if the liquid is cloudy, discolored, or if it has \\nflakes or particles in it. Call your pharmacist. It is normal to see one or more bubbles in the \\nwindow.  \\n', 'processed_text': {'sentences': [{'original_sentence': 'Figure B \\n \\n6.', 'tokens': ['Figure', 'B', '6', '.'], 'lemmatized': ['Figure', 'B', '6', '.'], 'stemmed': ['figur', 'b', '6', '.'], 'dependencies': [('figur', 'compound'), ('b', 'ROOT'), ('6', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Turn the Pen over and hold the Pen with the gray cap (Cap # 1) pointed up.', 'tokens': ['Turn', 'Pen', 'hold', 'Pen', 'gray', 'cap', '(', 'Cap', '#', '1', ')', 'pointed', '.'], 'lemmatized': ['Turn', 'Pen', 'hold', 'Pen', 'gray', 'cap', '(', 'Cap', '#', '1', ')', 'pointed', '.'], 'stemmed': ['turn', 'pen', 'hold', 'pen', 'gray', 'cap', '(', 'cap', '#', '1', ')', 'point', '.'], 'dependencies': [('turn', 'ROOT'), ('pen', 'dobj'), ('hold', 'dep'), ('pen', 'npadvmod'), ('gray', 'amod'), ('cap', 'dobj'), ('(', 'punct'), ('cap', 'dep'), ('#', 'nmod'), ('1', 'nummod'), (')', 'punct'), ('point', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'See Figure C.  \\n7.', 'tokens': ['See', 'Figure', 'C.', '7', '.'], 'lemmatized': ['See', 'Figure', 'C.', '7', '.'], 'stemmed': ['see', 'figur', 'c.', '7', '.'], 'dependencies': [('see', 'ROOT'), ('figur', 'compound'), ('c.', 'dobj'), ('7', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Check the solution through the windows on the side of the Pen to make sure the liquid is \\nclear and colorless.', 'tokens': ['Check', 'solution', 'windows', 'side', 'Pen', 'make', 'sure', 'liquid', 'clear', 'colorless', '.'], 'lemmatized': ['Check', 'solution', 'window', 'side', 'Pen', 'make', 'sure', 'liquid', 'clear', 'colorless', '.'], 'stemmed': ['check', 'solut', 'window', 'side', 'pen', 'make', 'sure', 'liquid', 'clear', 'colorless', '.'], 'dependencies': [('check', 'ROOT'), ('solut', 'amod'), ('window', 'compound'), ('side', 'compound'), ('pen', 'dobj'), ('make', 'conj'), ('sure', 'amod'), ('liquid', 'amod'), ('clear', 'amod'), ('colorless', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Do not use your HUMIRA Pen if the liquid is cloudy, discolored, or if it has \\nflakes or particles in it.', 'tokens': ['use', 'HUMIRA', 'Pen', 'liquid', 'cloudy', ',', 'discolored', ',', 'flakes', 'particles', '.'], 'lemmatized': ['use', 'HUMIRA', 'Pen', 'liquid', 'cloudy', ',', 'discolored', ',', 'flake', 'particle', '.'], 'stemmed': ['use', 'humira', 'pen', 'liquid', 'cloudi', ',', 'discolor', ',', 'flake', 'particl', '.'], 'dependencies': [('use', 'ROOT'), ('humira', 'compound'), ('pen', 'compound'), ('liquid', 'compound'), ('cloudi', 'dobj'), (',', 'punct'), ('discolor', 'nmod'), (',', 'punct'), ('flake', 'compound'), ('particl', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Call your pharmacist.', 'tokens': ['Call', 'pharmacist', '.'], 'lemmatized': ['Call', 'pharmacist', '.'], 'stemmed': ['call', 'pharmacist', '.'], 'dependencies': [('call', 'ROOT'), ('pharmacist', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'It is normal to see one or more bubbles in the \\nwindow.', 'tokens': ['normal', 'see', 'one', 'bubbles', 'window', '.'], 'lemmatized': ['normal', 'see', 'one', 'bubble', 'window', '.'], 'stemmed': ['normal', 'see', 'one', 'bubbl', 'window', '.'], 'dependencies': [('normal', 'nsubj'), ('see', 'ROOT'), ('one', 'nummod'), ('bubbl', 'compound'), ('window', 'dobj'), ('.', 'punct')]}], 'text': 'Figure B \\n \\n6. Turn the Pen over and hold the Pen with the gray cap (Cap # 1) pointed up. See Figure C.  \\n7. Check the solution through the windows on the side of the Pen to make sure the liquid is \\nclear and colorless. Do not use your HUMIRA Pen if the liquid is cloudy, discolored, or if it has \\nflakes or particles in it. Call your pharmacist. It is normal to see one or more bubbles in the \\nwindow.  \\n'}, 'page_char_count': 405, 'page_word_count': 81, 'sentences': ['Figure B \\n \\n6.', 'Turn the Pen over and hold the Pen with the gray cap (Cap # 1) pointed up.', 'See Figure C.  \\n7.', 'Check the solution through the windows on the side of the Pen to make sure the liquid is \\nclear and colorless.', 'Do not use your HUMIRA Pen if the liquid is cloudy, discolored, or if it has \\nflakes or particles in it.', 'Call your pharmacist.', 'It is normal to see one or more bubbles in the \\nwindow.', ' \\n'], 'page_sentence_count_spacy': 8}\n",
            "{'page_number': 68, 'text': 'Figure C \\n \\nChoose the Injection Site \\n8. Wash and dry your hands well.  \\n9. Choose an injection site on:  \\n• the front of your thighs or \\n• your lower abdomen (belly). If you choose your abdomen, do not use the area 2 inches \\naround your belly button (navel). See Figure D.  \\n', 'processed_text': {'sentences': [{'original_sentence': 'Figure C \\n \\nChoose the Injection Site \\n8.', 'tokens': ['Figure', 'C', 'Choose', 'Injection', 'Site', '8', '.'], 'lemmatized': ['Figure', 'C', 'Choose', 'Injection', 'Site', '8', '.'], 'stemmed': ['figur', 'c', 'choos', 'inject', 'site', '8', '.'], 'dependencies': [('figur', 'compound'), ('c', 'compound'), ('choos', 'compound'), ('inject', 'compound'), ('site', 'ROOT'), ('8', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Wash and dry your hands well.', 'tokens': ['Wash', 'dry', 'hands', 'well', '.'], 'lemmatized': ['Wash', 'dry', 'hand', 'well', '.'], 'stemmed': ['wash', 'dri', 'hand', 'well', '.'], 'dependencies': [('wash', 'ROOT'), ('dri', 'compound'), ('hand', 'dobj'), ('well', 'advmod'), ('.', 'punct')]}, {'original_sentence': '9.', 'tokens': ['9', '.'], 'lemmatized': ['9', '.'], 'stemmed': ['9', '.'], 'dependencies': [('9', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Choose an injection site on:  \\n• the front of your thighs or \\n• your lower abdomen (belly).', 'tokens': ['Choose', 'injection', 'site', ':', '•', 'front', 'thighs', '•', 'lower', 'abdomen', '(', 'belly', ')', '.'], 'lemmatized': ['Choose', 'injection', 'site', ':', '•', 'front', 'thigh', '•', 'lower', 'abdomen', '(', 'belly', ')', '.'], 'stemmed': ['choos', 'inject', 'site', ':', '•', 'front', 'thigh', '•', 'lower', 'abdomen', '(', 'belli', ')', '.'], 'dependencies': [('choos', 'compound'), ('inject', 'compound'), ('site', 'ROOT'), (':', 'punct'), ('•', 'nummod'), ('front', 'amod'), ('thigh', 'appos'), ('•', 'cc'), ('lower', 'amod'), ('abdomen', 'conj'), ('(', 'punct'), ('belli', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'If you choose your abdomen, do not use the area 2 inches \\naround your belly button (navel).', 'tokens': ['choose', 'abdomen', ',', 'use', 'area', '2', 'inches', 'around', 'belly', 'button', '(', 'navel', ')', '.'], 'lemmatized': ['choose', 'abdomen', ',', 'use', 'area', '2', 'inch', 'around', 'belly', 'button', '(', 'navel', ')', '.'], 'stemmed': ['choos', 'abdomen', ',', 'use', 'area', '2', 'inch', 'around', 'belli', 'button', '(', 'navel', ')', '.'], 'dependencies': [('choos', 'compound'), ('abdomen', 'nsubj'), (',', 'punct'), ('use', 'ROOT'), ('area', 'dobj'), ('2', 'nummod'), ('inch', 'npadvmod'), ('around', 'prep'), ('belli', 'compound'), ('button', 'pobj'), ('(', 'punct'), ('navel', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'See Figure D.', 'tokens': ['See', 'Figure', '.'], 'lemmatized': ['See', 'Figure', '.'], 'stemmed': ['see', 'figur', '.'], 'dependencies': [('see', 'ROOT'), ('figur', 'dobj'), ('.', 'punct')]}], 'text': 'Figure C \\n \\nChoose the Injection Site \\n8. Wash and dry your hands well.  \\n9. Choose an injection site on:  \\n• the front of your thighs or \\n• your lower abdomen (belly). If you choose your abdomen, do not use the area 2 inches \\naround your belly button (navel). See Figure D.  \\n'}, 'page_char_count': 277, 'page_word_count': 51, 'sentences': ['Figure C \\n \\nChoose the Injection Site \\n8.', 'Wash and dry your hands well.', ' \\n9.', 'Choose an injection site on:  \\n• the front of your thighs or \\n• your lower abdomen (belly).', 'If you choose your abdomen, do not use the area 2 inches \\naround your belly button (navel).', 'See Figure D.  \\n'], 'page_sentence_count_spacy': 6}\n",
            "{'page_number': 69, 'text': ' \\nFigure D \\n \\n• Choose a different site each time you give yourself an injection. Each new injection should \\nbe given at least one inch from a site you used before.  \\n• Do not inject HUMIRA into skin that is: \\n• sore (tender) \\n• bruised \\n• red \\n• hard \\n• scarred or where you have stretch marks \\n• If you have psoriasis, do not inject directly into any raised, thick, red or scaly skin patches or \\nlesions on your skin.  \\n• Do not inject through your clothes. \\n  \\nPrepare the Injection Site \\n10. Wipe the injection site with an alcohol prep (swab) using a circular motion.  \\n• Do not touch this area again before giving the injection. Allow the skin to dry before \\ninjecting. Do not fan or blow on the clean area.  \\n  \\nPreparing the HUMIRA Pen \\n11. Do not remove the gray cap (Cap # 1) or the plum-colored cap (Cap # 2) until right \\nbefore your injection. \\n', 'processed_text': {'sentences': [{'original_sentence': ' \\nFigure D \\n \\n• Choose a different site each time you give yourself an injection.', 'tokens': ['Figure', '•', 'Choose', 'different', 'site', 'time', 'give', 'injection', '.'], 'lemmatized': ['Figure', '•', 'Choose', 'different', 'site', 'time', 'give', 'injection', '.'], 'stemmed': ['figur', '•', 'choos', 'differ', 'site', 'time', 'give', 'inject', '.'], 'dependencies': [('figur', 'nmod'), ('•', 'nummod'), ('choos', 'nsubj'), ('differ', 'ROOT'), ('site', 'compound'), ('time', 'npadvmod'), ('give', 'advcl'), ('inject', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Each new injection should \\nbe given at least one inch from a site you used before.', 'tokens': ['new', 'injection', 'given', 'least', 'one', 'inch', 'site', 'used', '.'], 'lemmatized': ['new', 'injection', 'given', 'least', 'one', 'inch', 'site', 'used', '.'], 'stemmed': ['new', 'inject', 'given', 'least', 'one', 'inch', 'site', 'use', '.'], 'dependencies': [('new', 'amod'), ('inject', 'nsubj'), ('given', 'ROOT'), ('least', 'advmod'), ('one', 'nummod'), ('inch', 'compound'), ('site', 'compound'), ('use', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• Do not inject HUMIRA into skin that is: \\n• sore (tender) \\n• bruised \\n• red \\n• hard \\n• scarred or where you have stretch marks \\n• If you have psoriasis, do not inject directly into any raised, thick, red or scaly skin patches or \\nlesions on your skin.', 'tokens': ['•', 'inject', 'HUMIRA', 'skin', ':', '•', 'sore', '(', 'tender', ')', '•', 'bruised', '•', 'red', '•', 'hard', '•', 'scarred', 'stretch', 'marks', '•', 'psoriasis', ',', 'inject', 'directly', 'raised', ',', 'thick', ',', 'red', 'scaly', 'skin', 'patches', 'lesions', 'skin', '.'], 'lemmatized': ['•', 'inject', 'HUMIRA', 'skin', ':', '•', 'sore', '(', 'tender', ')', '•', 'bruised', '•', 'red', '•', 'hard', '•', 'scarred', 'stretch', 'mark', '•', 'psoriasis', ',', 'inject', 'directly', 'raised', ',', 'thick', ',', 'red', 'scaly', 'skin', 'patch', 'lesion', 'skin', '.'], 'stemmed': ['•', 'inject', 'humira', 'skin', ':', '•', 'sore', '(', 'tender', ')', '•', 'bruis', '•', 'red', '•', 'hard', '•', 'scar', 'stretch', 'mark', '•', 'psoriasi', ',', 'inject', 'directli', 'rais', ',', 'thick', ',', 'red', 'scali', 'skin', 'patch', 'lesion', 'skin', '.'], 'dependencies': [('•', 'nummod'), ('inject', 'amod'), ('humira', 'compound'), ('skin', 'ROOT'), (':', 'punct'), ('•', 'appos'), ('sore', 'amod'), ('(', 'punct'), ('tender', 'nmod'), (')', 'punct'), ('•', 'nummod'), ('bruis', 'nmod'), ('•', 'nummod'), ('red', 'amod'), ('•', 'punct'), ('hard', 'amod'), ('•', 'npadvmod'), ('scar', 'compound'), ('stretch', 'compound'), ('mark', 'nmod'), ('•', 'nummod'), ('psoriasi', 'appos'), (',', 'punct'), ('inject', 'compound'), ('directli', 'compound'), ('rais', 'conj'), (',', 'punct'), ('thick', 'amod'), (',', 'punct'), ('red', 'amod'), ('scali', 'amod'), ('skin', 'compound'), ('patch', 'compound'), ('lesion', 'compound'), ('skin', 'appos'), ('.', 'punct')]}, {'original_sentence': '• Do not inject through your clothes.', 'tokens': ['•', 'inject', 'clothes', '.'], 'lemmatized': ['•', 'inject', 'clothes', '.'], 'stemmed': ['•', 'inject', 'cloth', '.'], 'dependencies': [('•', 'nummod'), ('inject', 'amod'), ('cloth', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Prepare the Injection Site \\n10.', 'tokens': ['Prepare', 'Injection', 'Site', '10', '.'], 'lemmatized': ['Prepare', 'Injection', 'Site', '10', '.'], 'stemmed': ['prepar', 'inject', 'site', '10', '.'], 'dependencies': [('prepar', 'compound'), ('inject', 'compound'), ('site', 'ROOT'), ('10', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Wipe the injection site with an alcohol prep (swab) using a circular motion.', 'tokens': ['Wipe', 'injection', 'site', 'alcohol', 'prep', '(', 'swab', ')', 'using', 'circular', 'motion', '.'], 'lemmatized': ['Wipe', 'injection', 'site', 'alcohol', 'prep', '(', 'swab', ')', 'using', 'circular', 'motion', '.'], 'stemmed': ['wipe', 'inject', 'site', 'alcohol', 'prep', '(', 'swab', ')', 'use', 'circular', 'motion', '.'], 'dependencies': [('wipe', 'ROOT'), ('inject', 'compound'), ('site', 'compound'), ('alcohol', 'compound'), ('prep', 'dobj'), ('(', 'punct'), ('swab', 'appos'), (')', 'punct'), ('use', 'conj'), ('circular', 'amod'), ('motion', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• Do not touch this area again before giving the injection.', 'tokens': ['•', 'touch', 'area', 'giving', 'injection', '.'], 'lemmatized': ['•', 'touch', 'area', 'giving', 'injection', '.'], 'stemmed': ['•', 'touch', 'area', 'give', 'inject', '.'], 'dependencies': [('•', 'nummod'), ('touch', 'compound'), ('area', 'nsubj'), ('give', 'ROOT'), ('inject', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Allow the skin to dry before \\ninjecting.', 'tokens': ['Allow', 'skin', 'dry', 'injecting', '.'], 'lemmatized': ['Allow', 'skin', 'dry', 'injecting', '.'], 'stemmed': ['allow', 'skin', 'dri', 'inject', '.'], 'dependencies': [('allow', 'ROOT'), ('skin', 'compound'), ('dri', 'compound'), ('inject', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Do not fan or blow on the clean area.', 'tokens': ['fan', 'blow', 'clean', 'area', '.'], 'lemmatized': ['fan', 'blow', 'clean', 'area', '.'], 'stemmed': ['fan', 'blow', 'clean', 'area', '.'], 'dependencies': [('fan', 'nmod'), ('blow', 'nmod'), ('clean', 'amod'), ('area', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Preparing the HUMIRA Pen \\n11.', 'tokens': ['Preparing', 'HUMIRA', 'Pen', '11', '.'], 'lemmatized': ['Preparing', 'HUMIRA', 'Pen', '11', '.'], 'stemmed': ['prepar', 'humira', 'pen', '11', '.'], 'dependencies': [('prepar', 'compound'), ('humira', 'compound'), ('pen', 'ROOT'), ('11', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Do not remove the gray cap (Cap # 1) or the plum-colored cap (Cap # 2) until right \\nbefore your injection.', 'tokens': ['remove', 'gray', 'cap', '(', 'Cap', '#', '1', ')', 'plum-colored', 'cap', '(', 'Cap', '#', '2', ')', 'right', 'injection', '.'], 'lemmatized': ['remove', 'gray', 'cap', '(', 'Cap', '#', '1', ')', 'plum-colored', 'cap', '(', 'Cap', '#', '2', ')', 'right', 'injection', '.'], 'stemmed': ['remov', 'gray', 'cap', '(', 'cap', '#', '1', ')', 'plum-color', 'cap', '(', 'cap', '#', '2', ')', 'right', 'inject', '.'], 'dependencies': [('remov', 'amod'), ('gray', 'amod'), ('cap', 'ROOT'), ('(', 'punct'), ('cap', 'parataxis'), ('#', 'npadvmod'), ('1', 'nummod'), (')', 'punct'), ('plum', 'compound'), ('-', 'punct'), ('color', 'compound'), ('cap', 'appos'), ('(', 'punct'), ('cap', 'parataxis'), ('#', 'nmod'), ('2', 'nummod'), (')', 'punct'), ('right', 'advmod'), ('inject', 'appos'), ('.', 'punct')]}], 'text': ' \\nFigure D \\n \\n• Choose a different site each time you give yourself an injection. Each new injection should \\nbe given at least one inch from a site you used before.  \\n• Do not inject HUMIRA into skin that is: \\n• sore (tender) \\n• bruised \\n• red \\n• hard \\n• scarred or where you have stretch marks \\n• If you have psoriasis, do not inject directly into any raised, thick, red or scaly skin patches or \\nlesions on your skin.  \\n• Do not inject through your clothes. \\n  \\nPrepare the Injection Site \\n10. Wipe the injection site with an alcohol prep (swab) using a circular motion.  \\n• Do not touch this area again before giving the injection. Allow the skin to dry before \\ninjecting. Do not fan or blow on the clean area.  \\n  \\nPreparing the HUMIRA Pen \\n11. Do not remove the gray cap (Cap # 1) or the plum-colored cap (Cap # 2) until right \\nbefore your injection. \\n'}, 'page_char_count': 857, 'page_word_count': 157, 'sentences': [' \\nFigure D \\n \\n• Choose a different site each time you give yourself an injection.', 'Each new injection should \\nbe given at least one inch from a site you used before.', ' \\n• Do not inject HUMIRA into skin that is: \\n• sore (tender) \\n• bruised \\n• red \\n• hard \\n• scarred or where you have stretch marks \\n• If you have psoriasis, do not inject directly into any raised, thick, red or scaly skin patches or \\nlesions on your skin.', ' \\n• Do not inject through your clothes.', '\\n  \\nPrepare the Injection Site \\n10.', 'Wipe the injection site with an alcohol prep (swab) using a circular motion.', ' \\n• Do not touch this area again before giving the injection.', 'Allow the skin to dry before \\ninjecting.', 'Do not fan or blow on the clean area.', ' \\n  \\nPreparing the HUMIRA Pen \\n11.', 'Do not remove the gray cap (Cap # 1) or the plum-colored cap (Cap # 2) until right \\nbefore your injection.', '\\n'], 'page_sentence_count_spacy': 12}\n",
            "{'page_number': 70, 'text': '12. Hold the middle of the Pen (gray body) with one hand so that you are not touching the gray \\ncap (Cap # 1) or the plum-colored cap (Cap # 2). Turn the Pen so that the gray cap (Cap # 1) is \\npointing up. See Figure E.  \\nFigure E \\n \\n13. With your other hand, pull the gray cap (Cap # 1) straight off (do not twist the cap). Make \\nsure the small needle cover of the syringe has come off with the gray cap (Cap # 1). See Figure \\nF.  \\n14. Throw away the gray cap (Cap # 1).  \\n', 'processed_text': {'sentences': [{'original_sentence': '12.', 'tokens': ['12', '.'], 'lemmatized': ['12', '.'], 'stemmed': ['12', '.'], 'dependencies': [('12', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Hold the middle of the Pen (gray body) with one hand so that you are not touching the gray \\ncap (Cap # 1) or the plum-colored cap (Cap # 2).', 'tokens': ['Hold', 'middle', 'Pen', '(', 'gray', 'body', ')', 'one', 'hand', 'touching', 'gray', 'cap', '(', 'Cap', '#', '1', ')', 'plum-colored', 'cap', '(', 'Cap', '#', '2', ')', '.'], 'lemmatized': ['Hold', 'middle', 'Pen', '(', 'gray', 'body', ')', 'one', 'hand', 'touching', 'gray', 'cap', '(', 'Cap', '#', '1', ')', 'plum-colored', 'cap', '(', 'Cap', '#', '2', ')', '.'], 'stemmed': ['hold', 'middl', 'pen', '(', 'gray', 'bodi', ')', 'one', 'hand', 'touch', 'gray', 'cap', '(', 'cap', '#', '1', ')', 'plum-color', 'cap', '(', 'cap', '#', '2', ')', '.'], 'dependencies': [('hold', 'ROOT'), ('middl', 'amod'), ('pen', 'dobj'), ('(', 'punct'), ('gray', 'amod'), ('bodi', 'appos'), (')', 'punct'), ('one', 'nummod'), ('hand', 'npadvmod'), ('touch', 'nmod'), ('gray', 'amod'), ('cap', 'dobj'), ('(', 'punct'), ('cap', 'parataxis'), ('#', 'npadvmod'), ('1', 'nummod'), (')', 'punct'), ('plum', 'compound'), ('-', 'punct'), ('color', 'compound'), ('cap', 'appos'), ('(', 'punct'), ('cap', 'parataxis'), ('#', 'npadvmod'), ('2', 'nummod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Turn the Pen so that the gray cap (Cap # 1) is \\npointing up.', 'tokens': ['Turn', 'Pen', 'gray', 'cap', '(', 'Cap', '#', '1', ')', 'pointing', '.'], 'lemmatized': ['Turn', 'Pen', 'gray', 'cap', '(', 'Cap', '#', '1', ')', 'pointing', '.'], 'stemmed': ['turn', 'pen', 'gray', 'cap', '(', 'cap', '#', '1', ')', 'point', '.'], 'dependencies': [('turn', 'ROOT'), ('pen', 'npadvmod'), ('gray', 'amod'), ('cap', 'dobj'), ('(', 'punct'), ('cap', 'dep'), ('#', 'nmod'), ('1', 'nummod'), (')', 'punct'), ('point', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'See Figure E.  \\nFigure E \\n \\n13.', 'tokens': ['See', 'Figure', 'E.', 'Figure', 'E', '13', '.'], 'lemmatized': ['See', 'Figure', 'E.', 'Figure', 'E', '13', '.'], 'stemmed': ['see', 'figur', 'e.', 'figur', 'e', '13', '.'], 'dependencies': [('see', 'ROOT'), ('figur', 'compound'), ('e.', 'compound'), ('figur', 'compound'), ('e', 'dobj'), ('13', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'With your other hand, pull the gray cap (Cap # 1) straight off (do not twist the cap).', 'tokens': ['hand', ',', 'pull', 'gray', 'cap', '(', 'Cap', '#', '1', ')', 'straight', '(', 'twist', 'cap', ')', '.'], 'lemmatized': ['hand', ',', 'pull', 'gray', 'cap', '(', 'Cap', '#', '1', ')', 'straight', '(', 'twist', 'cap', ')', '.'], 'stemmed': ['hand', ',', 'pull', 'gray', 'cap', '(', 'cap', '#', '1', ')', 'straight', '(', 'twist', 'cap', ')', '.'], 'dependencies': [('hand', 'npadvmod'), (',', 'punct'), ('pull', 'ROOT'), ('gray', 'amod'), ('cap', 'dobj'), ('(', 'punct'), ('cap', 'parataxis'), ('#', 'nmod'), ('1', 'nummod'), (')', 'punct'), ('straight', 'amod'), ('(', 'punct'), ('twist', 'amod'), ('cap', 'npadvmod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Make \\nsure the small needle cover of the syringe has come off with the gray cap (Cap # 1).', 'tokens': ['Make', 'sure', 'small', 'needle', 'cover', 'syringe', 'come', 'gray', 'cap', '(', 'Cap', '#', '1', ')', '.'], 'lemmatized': ['Make', 'sure', 'small', 'needle', 'cover', 'syringe', 'come', 'gray', 'cap', '(', 'Cap', '#', '1', ')', '.'], 'stemmed': ['make', 'sure', 'small', 'needl', 'cover', 'syring', 'come', 'gray', 'cap', '(', 'cap', '#', '1', ')', '.'], 'dependencies': [('make', 'ROOT'), ('sure', 'ccomp'), ('small', 'amod'), ('needl', 'nsubj'), ('cover', 'ccomp'), ('syring', 'amod'), ('come', 'amod'), ('gray', 'amod'), ('cap', 'dobj'), ('(', 'punct'), ('cap', 'parataxis'), ('#', 'npadvmod'), ('1', 'nummod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'See Figure \\nF.  \\n14.', 'tokens': ['See', 'Figure', 'F.', '14', '.'], 'lemmatized': ['See', 'Figure', 'F.', '14', '.'], 'stemmed': ['see', 'figur', 'f.', '14', '.'], 'dependencies': [('see', 'ROOT'), ('figur', 'dobj'), ('f.', 'npadvmod'), ('14', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Throw away the gray cap (Cap # 1).', 'tokens': ['Throw', 'away', 'gray', 'cap', '(', 'Cap', '#', '1', ')', '.'], 'lemmatized': ['Throw', 'away', 'gray', 'cap', '(', 'Cap', '#', '1', ')', '.'], 'stemmed': ['throw', 'away', 'gray', 'cap', '(', 'cap', '#', '1', ')', '.'], 'dependencies': [('throw', 'ROOT'), ('away', 'advmod'), ('gray', 'amod'), ('cap', 'dobj'), ('(', 'punct'), ('cap', 'parataxis'), ('#', 'npadvmod'), ('1', 'nummod'), (')', 'punct'), ('.', 'punct')]}], 'text': '12. Hold the middle of the Pen (gray body) with one hand so that you are not touching the gray \\ncap (Cap # 1) or the plum-colored cap (Cap # 2). Turn the Pen so that the gray cap (Cap # 1) is \\npointing up. See Figure E.  \\nFigure E \\n \\n13. With your other hand, pull the gray cap (Cap # 1) straight off (do not twist the cap). Make \\nsure the small needle cover of the syringe has come off with the gray cap (Cap # 1). See Figure \\nF.  \\n14. Throw away the gray cap (Cap # 1).  \\n'}, 'page_char_count': 474, 'page_word_count': 100, 'sentences': ['12.', 'Hold the middle of the Pen (gray body) with one hand so that you are not touching the gray \\ncap (Cap # 1) or the plum-colored cap (Cap # 2).', 'Turn the Pen so that the gray cap (Cap # 1) is \\npointing up.', 'See Figure E.  \\nFigure E \\n \\n13.', 'With your other hand, pull the gray cap (Cap # 1) straight off (do not twist the cap).', 'Make \\nsure the small needle cover of the syringe has come off with the gray cap (Cap # 1).', 'See Figure \\nF.  \\n14.', 'Throw away the gray cap (Cap # 1).', ' \\n'], 'page_sentence_count_spacy': 9}\n",
            "{'page_number': 71, 'text': 'Figure F \\n \\n• Do not put the gray cap (Cap # 1) back on the Pen. Putting the gray cap (Cap # 1) back on \\nmay damage the needle.  \\n• The white needle sleeve, which covers the needle, can now be seen.  \\n• Do not touch the needle with your fingers or let the needle touch anything.  \\n• You may see a few drops of liquid come out of the needle. This is normal. \\n  \\n15. Remove the plum-colored cap (Cap # 2) from the bottom of the Pen by pulling it straight off \\n(do not twist the cap). The Pen is now activated. Throw away the plum-colored cap (Cap # 2).  \\n• Do not put the plum-colored cap (Cap # 2) back on the Pen because it could cause \\nmedicine to come out of the syringe. \\n  \\nThe plum-colored activator button: \\n• Turn the Pen so the plum-colored activator button is pointed up. See Figure G. \\n  \\n', 'processed_text': {'sentences': [{'original_sentence': 'Figure F \\n \\n• Do not put the gray cap (Cap # 1) back on the Pen.', 'tokens': ['Figure', 'F', '•', 'put', 'gray', 'cap', '(', 'Cap', '#', '1', ')', 'back', 'Pen', '.'], 'lemmatized': ['Figure', 'F', '•', 'put', 'gray', 'cap', '(', 'Cap', '#', '1', ')', 'back', 'Pen', '.'], 'stemmed': ['figur', 'f', '•', 'put', 'gray', 'cap', '(', 'cap', '#', '1', ')', 'back', 'pen', '.'], 'dependencies': [('figur', 'npadvmod'), ('f', 'nsubj'), ('•', 'npadvmod'), ('put', 'ROOT'), ('gray', 'amod'), ('cap', 'dobj'), ('(', 'punct'), ('cap', 'parataxis'), ('#', 'npadvmod'), ('1', 'nummod'), (')', 'punct'), ('back', 'amod'), ('pen', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Putting the gray cap (Cap # 1) back on \\nmay damage the needle.', 'tokens': ['Putting', 'gray', 'cap', '(', 'Cap', '#', '1', ')', 'back', 'may', 'damage', 'needle', '.'], 'lemmatized': ['Putting', 'gray', 'cap', '(', 'Cap', '#', '1', ')', 'back', 'may', 'damage', 'needle', '.'], 'stemmed': ['put', 'gray', 'cap', '(', 'cap', '#', '1', ')', 'back', 'may', 'damag', 'needl', '.'], 'dependencies': [('put', 'ROOT'), ('gray', 'amod'), ('cap', 'dobj'), ('(', 'punct'), ('cap', 'parataxis'), ('#', 'npadvmod'), ('1', 'nummod'), (')', 'punct'), ('back', 'advmod'), ('may', 'aux'), ('damag', 'advcl'), ('needl', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• The white needle sleeve, which covers the needle, can now be seen.', 'tokens': ['•', 'white', 'needle', 'sleeve', ',', 'covers', 'needle', ',', 'seen', '.'], 'lemmatized': ['•', 'white', 'needle', 'sleeve', ',', 'cover', 'needle', ',', 'seen', '.'], 'stemmed': ['•', 'white', 'needl', 'sleev', ',', 'cover', 'needl', ',', 'seen', '.'], 'dependencies': [('•', 'nummod'), ('white', 'amod'), ('needl', 'compound'), ('sleev', 'nsubj'), (',', 'punct'), ('cover', 'ROOT'), ('needl', 'dobj'), (',', 'punct'), ('seen', 'acl'), ('.', 'punct')]}, {'original_sentence': '• Do not touch the needle with your fingers or let the needle touch anything.', 'tokens': ['•', 'touch', 'needle', 'fingers', 'let', 'needle', 'touch', 'anything', '.'], 'lemmatized': ['•', 'touch', 'needle', 'finger', 'let', 'needle', 'touch', 'anything', '.'], 'stemmed': ['•', 'touch', 'needl', 'finger', 'let', 'needl', 'touch', 'anyth', '.'], 'dependencies': [('•', 'nummod'), ('touch', 'compound'), ('needl', 'compound'), ('finger', 'nsubj'), ('let', 'ROOT'), ('needl', 'nsubj'), ('touch', 'ccomp'), ('anyth', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• You may see a few drops of liquid come out of the needle.', 'tokens': ['•', 'may', 'see', 'drops', 'liquid', 'come', 'needle', '.'], 'lemmatized': ['•', 'may', 'see', 'drop', 'liquid', 'come', 'needle', '.'], 'stemmed': ['•', 'may', 'see', 'drop', 'liquid', 'come', 'needl', '.'], 'dependencies': [('•', 'nsubj'), ('may', 'aux'), ('see', 'ROOT'), ('drop', 'compound'), ('liquid', 'nsubj'), ('come', 'compound'), ('needl', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'This is normal.', 'tokens': ['normal', '.'], 'lemmatized': ['normal', '.'], 'stemmed': ['normal', '.'], 'dependencies': [('normal', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '15.', 'tokens': ['15', '.'], 'lemmatized': ['15', '.'], 'stemmed': ['15', '.'], 'dependencies': [('15', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Remove the plum-colored cap (Cap # 2) from the bottom of the Pen by pulling it straight off \\n(do not twist the cap).', 'tokens': ['Remove', 'plum-colored', 'cap', '(', 'Cap', '#', '2', ')', 'bottom', 'Pen', 'pulling', 'straight', '(', 'twist', 'cap', ')', '.'], 'lemmatized': ['Remove', 'plum-colored', 'cap', '(', 'Cap', '#', '2', ')', 'bottom', 'Pen', 'pulling', 'straight', '(', 'twist', 'cap', ')', '.'], 'stemmed': ['remov', 'plum-color', 'cap', '(', 'cap', '#', '2', ')', 'bottom', 'pen', 'pull', 'straight', '(', 'twist', 'cap', ')', '.'], 'dependencies': [('remov', 'compound'), ('plum', 'compound'), ('-', 'punct'), ('color', 'compound'), ('cap', 'nsubj'), ('(', 'punct'), ('cap', 'parataxis'), ('#', 'nmod'), ('2', 'nummod'), (')', 'punct'), ('bottom', 'compound'), ('pen', 'nsubj'), ('pull', 'ROOT'), ('straight', 'amod'), ('(', 'punct'), ('twist', 'amod'), ('cap', 'dobj'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'The Pen is now activated.', 'tokens': ['Pen', 'activated', '.'], 'lemmatized': ['Pen', 'activated', '.'], 'stemmed': ['pen', 'activ', '.'], 'dependencies': [('pen', 'ROOT'), ('activ', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Throw away the plum-colored cap (Cap # 2).', 'tokens': ['Throw', 'away', 'plum-colored', 'cap', '(', 'Cap', '#', '2', ')', '.'], 'lemmatized': ['Throw', 'away', 'plum-colored', 'cap', '(', 'Cap', '#', '2', ')', '.'], 'stemmed': ['throw', 'away', 'plum-color', 'cap', '(', 'cap', '#', '2', ')', '.'], 'dependencies': [('throw', 'ROOT'), ('away', 'advmod'), ('plum', 'compound'), ('-', 'punct'), ('color', 'compound'), ('cap', 'dobj'), ('(', 'punct'), ('cap', 'parataxis'), ('#', 'npadvmod'), ('2', 'nummod'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': '• Do not put the plum-colored cap (Cap # 2) back on the Pen because it could cause \\nmedicine to come out of the syringe.', 'tokens': ['•', 'put', 'plum-colored', 'cap', '(', 'Cap', '#', '2', ')', 'back', 'Pen', 'could', 'cause', 'medicine', 'come', 'syringe', '.'], 'lemmatized': ['•', 'put', 'plum-colored', 'cap', '(', 'Cap', '#', '2', ')', 'back', 'Pen', 'could', 'cause', 'medicine', 'come', 'syringe', '.'], 'stemmed': ['•', 'put', 'plum-color', 'cap', '(', 'cap', '#', '2', ')', 'back', 'pen', 'could', 'caus', 'medicin', 'come', 'syring', '.'], 'dependencies': [('•', 'npadvmod'), ('put', 'ROOT'), ('plum', 'compound'), ('-', 'punct'), ('color', 'compound'), ('cap', 'dobj'), ('(', 'punct'), ('cap', 'parataxis'), ('#', 'nmod'), ('2', 'nummod'), (')', 'punct'), ('back', 'amod'), ('pen', 'dobj'), ('could', 'aux'), ('caus', 'conj'), ('medicin', 'dobj'), ('come', 'conj'), ('syring', 'acomp'), ('.', 'punct')]}, {'original_sentence': 'The plum-colored activator button: \\n• Turn the Pen so the plum-colored activator button is pointed up.', 'tokens': ['plum-colored', 'activator', 'button', ':', '•', 'Turn', 'Pen', 'plum-colored', 'activator', 'button', 'pointed', '.'], 'lemmatized': ['plum-colored', 'activator', 'button', ':', '•', 'Turn', 'Pen', 'plum-colored', 'activator', 'button', 'pointed', '.'], 'stemmed': ['plum-color', 'activ', 'button', ':', '•', 'turn', 'pen', 'plum-color', 'activ', 'button', 'point', '.'], 'dependencies': [('plum', 'compound'), ('-', 'punct'), ('color', 'compound'), ('activ', 'compound'), ('button', 'nsubj'), (':', 'punct'), ('•', 'appos'), ('turn', 'ROOT'), ('pen', 'nmod'), ('plum', 'compound'), ('-', 'punct'), ('color', 'compound'), ('activ', 'compound'), ('button', 'compound'), ('point', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'See Figure G.', 'tokens': ['See', 'Figure', 'G', '.'], 'lemmatized': ['See', 'Figure', 'G', '.'], 'stemmed': ['see', 'figur', 'g', '.'], 'dependencies': [('see', 'ROOT'), ('figur', 'compound'), ('g', 'dobj'), ('.', 'punct')]}], 'text': 'Figure F \\n \\n• Do not put the gray cap (Cap # 1) back on the Pen. Putting the gray cap (Cap # 1) back on \\nmay damage the needle.  \\n• The white needle sleeve, which covers the needle, can now be seen.  \\n• Do not touch the needle with your fingers or let the needle touch anything.  \\n• You may see a few drops of liquid come out of the needle. This is normal. \\n  \\n15. Remove the plum-colored cap (Cap # 2) from the bottom of the Pen by pulling it straight off \\n(do not twist the cap). The Pen is now activated. Throw away the plum-colored cap (Cap # 2).  \\n• Do not put the plum-colored cap (Cap # 2) back on the Pen because it could cause \\nmedicine to come out of the syringe. \\n  \\nThe plum-colored activator button: \\n• Turn the Pen so the plum-colored activator button is pointed up. See Figure G. \\n  \\n'}, 'page_char_count': 799, 'page_word_count': 155, 'sentences': ['Figure F \\n \\n• Do not put the gray cap (Cap # 1) back on the Pen.', 'Putting the gray cap (Cap # 1) back on \\nmay damage the needle.', ' \\n• The white needle sleeve, which covers the needle, can now be seen.', ' \\n• Do not touch the needle with your fingers or let the needle touch anything.', ' \\n• You may see a few drops of liquid come out of the needle.', 'This is normal.', '\\n  \\n15.', 'Remove the plum-colored cap (Cap # 2) from the bottom of the Pen by pulling it straight off \\n(do not twist the cap).', 'The Pen is now activated.', 'Throw away the plum-colored cap (Cap # 2).', ' \\n• Do not put the plum-colored cap (Cap # 2) back on the Pen because it could cause \\nmedicine to come out of the syringe.', '\\n  \\nThe plum-colored activator button: \\n• Turn the Pen so the plum-colored activator button is pointed up.', 'See Figure G. \\n  \\n'], 'page_sentence_count_spacy': 13}\n",
            "{'page_number': 72, 'text': 'Figure G \\n \\n• Do not press the plum-colored activator button until you are ready to inject HUMIRA. \\nPressing the plum-colored activator button will release the medicine from the Pen.  \\n• Hold the Pen so that you can see the window. See Figure H. It is normal to see one or more \\nbubbles in the window.  \\n  \\n', 'processed_text': {'sentences': [{'original_sentence': 'Figure G \\n \\n• Do not press the plum-colored activator button until you are ready to inject HUMIRA.', 'tokens': ['Figure', 'G', '•', 'press', 'plum-colored', 'activator', 'button', 'ready', 'inject', 'HUMIRA', '.'], 'lemmatized': ['Figure', 'G', '•', 'press', 'plum-colored', 'activator', 'button', 'ready', 'inject', 'HUMIRA', '.'], 'stemmed': ['figur', 'g', '•', 'press', 'plum-color', 'activ', 'button', 'readi', 'inject', 'humira', '.'], 'dependencies': [('figur', 'compound'), ('g', 'compound'), ('•', 'nummod'), ('press', 'compound'), ('plum', 'compound'), ('-', 'punct'), ('color', 'compound'), ('activ', 'compound'), ('button', 'compound'), ('readi', 'compound'), ('inject', 'compound'), ('humira', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Pressing the plum-colored activator button will release the medicine from the Pen.', 'tokens': ['Pressing', 'plum-colored', 'activator', 'button', 'release', 'medicine', 'Pen', '.'], 'lemmatized': ['Pressing', 'plum-colored', 'activator', 'button', 'release', 'medicine', 'Pen', '.'], 'stemmed': ['press', 'plum-color', 'activ', 'button', 'releas', 'medicin', 'pen', '.'], 'dependencies': [('press', 'compound'), ('plum', 'compound'), ('-', 'punct'), ('color', 'compound'), ('activ', 'compound'), ('button', 'compound'), ('releas', 'compound'), ('medicin', 'compound'), ('pen', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• Hold the Pen so that you can see the window.', 'tokens': ['•', 'Hold', 'Pen', 'see', 'window', '.'], 'lemmatized': ['•', 'Hold', 'Pen', 'see', 'window', '.'], 'stemmed': ['•', 'hold', 'pen', 'see', 'window', '.'], 'dependencies': [('•', 'npadvmod'), ('hold', 'ROOT'), ('pen', 'nsubj'), ('see', 'ccomp'), ('window', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'See Figure H. It is normal to see one or more \\nbubbles in the window.', 'tokens': ['See', 'Figure', 'H.', 'normal', 'see', 'one', 'bubbles', 'window', '.'], 'lemmatized': ['See', 'Figure', 'H.', 'normal', 'see', 'one', 'bubble', 'window', '.'], 'stemmed': ['see', 'figur', 'h.', 'normal', 'see', 'one', 'bubbl', 'window', '.'], 'dependencies': [('see', 'ROOT'), ('figur', 'compound'), ('h.', 'compound'), ('normal', 'nsubj'), ('see', 'ccomp'), ('one', 'nummod'), ('bubbl', 'compound'), ('window', 'dobj'), ('.', 'punct')]}], 'text': 'Figure G \\n \\n• Do not press the plum-colored activator button until you are ready to inject HUMIRA. \\nPressing the plum-colored activator button will release the medicine from the Pen.  \\n• Hold the Pen so that you can see the window. See Figure H. It is normal to see one or more \\nbubbles in the window.  \\n  \\n'}, 'page_char_count': 307, 'page_word_count': 55, 'sentences': ['Figure G \\n \\n• Do not press the plum-colored activator button until you are ready to inject HUMIRA.', '\\nPressing the plum-colored activator button will release the medicine from the Pen.', ' \\n• Hold the Pen so that you can see the window.', 'See Figure H. It is normal to see one or more \\nbubbles in the window.', ' \\n  \\n'], 'page_sentence_count_spacy': 5}\n",
            "{'page_number': 73, 'text': 'Figure H \\n \\nPosition the Pen and Inject HUMIRA \\n16. Position the Pen:  \\n• Squeeze the area of the cleaned skin and hold it firmly until the injection is complete. See \\nFigure I. You will inject into this raised area of skin.  \\n  \\n', 'processed_text': {'sentences': [{'original_sentence': 'Figure H \\n \\nPosition the Pen and Inject HUMIRA \\n16.', 'tokens': ['Figure', 'H', 'Position', 'Pen', 'Inject', 'HUMIRA', '16', '.'], 'lemmatized': ['Figure', 'H', 'Position', 'Pen', 'Inject', 'HUMIRA', '16', '.'], 'stemmed': ['figur', 'h', 'posit', 'pen', 'inject', 'humira', '16', '.'], 'dependencies': [('figur', 'compound'), ('h', 'compound'), ('posit', 'compound'), ('pen', 'compound'), ('inject', 'compound'), ('humira', 'ROOT'), ('16', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Position the Pen:  \\n• Squeeze the area of the cleaned skin and hold it firmly until the injection is complete.', 'tokens': ['Position', 'Pen', ':', '•', 'Squeeze', 'area', 'cleaned', 'skin', 'hold', 'firmly', 'injection', 'complete', '.'], 'lemmatized': ['Position', 'Pen', ':', '•', 'Squeeze', 'area', 'cleaned', 'skin', 'hold', 'firmly', 'injection', 'complete', '.'], 'stemmed': ['posit', 'pen', ':', '•', 'squeez', 'area', 'clean', 'skin', 'hold', 'firmli', 'inject', 'complet', '.'], 'dependencies': [('posit', 'compound'), ('pen', 'dep'), (':', 'punct'), ('•', 'nummod'), ('squeez', 'compound'), ('area', 'nmod'), ('clean', 'amod'), ('skin', 'nsubj'), ('hold', 'ROOT'), ('firmli', 'compound'), ('inject', 'compound'), ('complet', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'See \\nFigure I.', 'tokens': ['See', 'Figure', '.'], 'lemmatized': ['See', 'Figure', '.'], 'stemmed': ['see', 'figur', '.'], 'dependencies': [('see', 'ROOT'), ('figur', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'You will inject into this raised area of skin.', 'tokens': ['inject', 'raised', 'area', 'skin', '.'], 'lemmatized': ['inject', 'raised', 'area', 'skin', '.'], 'stemmed': ['inject', 'rais', 'area', 'skin', '.'], 'dependencies': [('inject', 'compound'), ('rais', 'compound'), ('area', 'compound'), ('skin', 'ROOT'), ('.', 'punct')]}], 'text': 'Figure H \\n \\nPosition the Pen and Inject HUMIRA \\n16. Position the Pen:  \\n• Squeeze the area of the cleaned skin and hold it firmly until the injection is complete. See \\nFigure I. You will inject into this raised area of skin.  \\n  \\n'}, 'page_char_count': 230, 'page_word_count': 41, 'sentences': ['Figure H \\n \\nPosition the Pen and Inject HUMIRA \\n16.', 'Position the Pen:  \\n• Squeeze the area of the cleaned skin and hold it firmly until the injection is complete.', 'See \\nFigure I. You will inject into this raised area of skin.', ' \\n  \\n'], 'page_sentence_count_spacy': 4}\n",
            "{'page_number': 74, 'text': 'Figure I \\n \\n17. Place the white end of the Pen straight (at a 90º angle) and flat against the raised area of \\nyour skin that you are squeezing. Place the Pen so that it will not inject the needle into your \\nfingers that are holding the raised skin. See Figure J.  \\n', 'processed_text': {'sentences': [{'original_sentence': 'Figure I \\n \\n17.', 'tokens': ['Figure', '17', '.'], 'lemmatized': ['Figure', '17', '.'], 'stemmed': ['figur', '17', '.'], 'dependencies': [('figur', 'ROOT'), ('17', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Place the white end of the Pen straight (at a 90º angle) and flat against the raised area of \\nyour skin that you are squeezing.', 'tokens': ['Place', 'white', 'end', 'Pen', 'straight', '(', '90º', 'angle', ')', 'flat', 'raised', 'area', 'skin', 'squeezing', '.'], 'lemmatized': ['Place', 'white', 'end', 'Pen', 'straight', '(', '90º', 'angle', ')', 'flat', 'raised', 'area', 'skin', 'squeezing', '.'], 'stemmed': ['place', 'white', 'end', 'pen', 'straight', '(', '90º', 'angl', ')', 'flat', 'rais', 'area', 'skin', 'squeez', '.'], 'dependencies': [('place', 'ROOT'), ('white', 'amod'), ('end', 'compound'), ('pen', 'appos'), ('straight', 'amod'), ('(', 'punct'), ('90º', 'npadvmod'), ('angl', 'amod'), (')', 'punct'), ('flat', 'amod'), ('rais', 'compound'), ('area', 'compound'), ('skin', 'compound'), ('squeez', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Place the Pen so that it will not inject the needle into your \\nfingers that are holding the raised skin.', 'tokens': ['Place', 'Pen', 'inject', 'needle', 'fingers', 'holding', 'raised', 'skin', '.'], 'lemmatized': ['Place', 'Pen', 'inject', 'needle', 'finger', 'holding', 'raised', 'skin', '.'], 'stemmed': ['place', 'pen', 'inject', 'needl', 'finger', 'hold', 'rais', 'skin', '.'], 'dependencies': [('place', 'compound'), ('pen', 'compound'), ('inject', 'nsubj'), ('needl', 'nsubj'), ('finger', 'dobj'), ('hold', 'ROOT'), ('rais', 'compound'), ('skin', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'See Figure J.', 'tokens': ['See', 'Figure', 'J', '.'], 'lemmatized': ['See', 'Figure', 'J', '.'], 'stemmed': ['see', 'figur', 'j', '.'], 'dependencies': [('see', 'ROOT'), ('figur', 'compound'), ('j', 'dobj'), ('.', 'punct')]}], 'text': 'Figure I \\n \\n17. Place the white end of the Pen straight (at a 90º angle) and flat against the raised area of \\nyour skin that you are squeezing. Place the Pen so that it will not inject the needle into your \\nfingers that are holding the raised skin. See Figure J.  \\n'}, 'page_char_count': 265, 'page_word_count': 51, 'sentences': ['Figure I \\n \\n17.', 'Place the white end of the Pen straight (at a 90º angle) and flat against the raised area of \\nyour skin that you are squeezing.', 'Place the Pen so that it will not inject the needle into your \\nfingers that are holding the raised skin.', 'See Figure J.  \\n'], 'page_sentence_count_spacy': 4}\n",
            "{'page_number': 75, 'text': 'Figure J \\n \\n18. Inject HUMIRA  \\n• It is important that you firmly push the Pen down all the way against the injection site \\nbefore starting the injection.  \\n• Keep pushing down to prevent the Pen from moving away from the skin during the \\ninjection.  \\n• Press the plum-colored activator button with your thumb to begin the injection. Try not to \\ncover the window. See Figure K.  \\n', 'processed_text': {'sentences': [{'original_sentence': 'Figure J \\n \\n18.', 'tokens': ['Figure', 'J', '18', '.'], 'lemmatized': ['Figure', 'J', '18', '.'], 'stemmed': ['figur', 'j', '18', '.'], 'dependencies': [('figur', 'ROOT'), ('j', 'npadvmod'), ('18', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Inject HUMIRA  \\n• It is important that you firmly push the Pen down all the way against the injection site \\nbefore starting the injection.', 'tokens': ['Inject', 'HUMIRA', '•', 'important', 'firmly', 'push', 'Pen', 'way', 'injection', 'site', 'starting', 'injection', '.'], 'lemmatized': ['Inject', 'HUMIRA', '•', 'important', 'firmly', 'push', 'Pen', 'way', 'injection', 'site', 'starting', 'injection', '.'], 'stemmed': ['inject', 'humira', '•', 'import', 'firmli', 'push', 'pen', 'way', 'inject', 'site', 'start', 'inject', '.'], 'dependencies': [('inject', 'compound'), ('humira', 'nmod'), ('•', 'nummod'), ('import', 'compound'), ('firmli', 'compound'), ('push', 'compound'), ('pen', 'compound'), ('way', 'npadvmod'), ('inject', 'compound'), ('site', 'nsubj'), ('start', 'ROOT'), ('inject', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• Keep pushing down to prevent the Pen from moving away from the skin during the \\ninjection.', 'tokens': ['•', 'Keep', 'pushing', 'prevent', 'Pen', 'moving', 'away', 'skin', 'injection', '.'], 'lemmatized': ['•', 'Keep', 'pushing', 'prevent', 'Pen', 'moving', 'away', 'skin', 'injection', '.'], 'stemmed': ['•', 'keep', 'push', 'prevent', 'pen', 'move', 'away', 'skin', 'inject', '.'], 'dependencies': [('•', 'meta'), ('keep', 'ROOT'), ('push', 'compound'), ('prevent', 'compound'), ('pen', 'compound'), ('move', 'xcomp'), ('away', 'advmod'), ('skin', 'compound'), ('inject', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• Press the plum-colored activator button with your thumb to begin the injection.', 'tokens': ['•', 'Press', 'plum-colored', 'activator', 'button', 'thumb', 'begin', 'injection', '.'], 'lemmatized': ['•', 'Press', 'plum-colored', 'activator', 'button', 'thumb', 'begin', 'injection', '.'], 'stemmed': ['•', 'press', 'plum-color', 'activ', 'button', 'thumb', 'begin', 'inject', '.'], 'dependencies': [('•', 'nummod'), ('press', 'compound'), ('plum', 'compound'), ('-', 'punct'), ('color', 'compound'), ('activ', 'compound'), ('button', 'compound'), ('thumb', 'nsubj'), ('begin', 'ROOT'), ('inject', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Try not to \\ncover the window.', 'tokens': ['Try', 'cover', 'window', '.'], 'lemmatized': ['Try', 'cover', 'window', '.'], 'stemmed': ['tri', 'cover', 'window', '.'], 'dependencies': [('tri', 'amod'), ('cover', 'compound'), ('window', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'See Figure K.', 'tokens': ['See', 'Figure', 'K', '.'], 'lemmatized': ['See', 'Figure', 'K', '.'], 'stemmed': ['see', 'figur', 'k', '.'], 'dependencies': [('see', 'ROOT'), ('figur', 'compound'), ('k', 'dobj'), ('.', 'punct')]}], 'text': 'Figure J \\n \\n18. Inject HUMIRA  \\n• It is important that you firmly push the Pen down all the way against the injection site \\nbefore starting the injection.  \\n• Keep pushing down to prevent the Pen from moving away from the skin during the \\ninjection.  \\n• Press the plum-colored activator button with your thumb to begin the injection. Try not to \\ncover the window. See Figure K.  \\n'}, 'page_char_count': 380, 'page_word_count': 66, 'sentences': ['Figure J \\n \\n18.', 'Inject HUMIRA  \\n• It is important that you firmly push the Pen down all the way against the injection site \\nbefore starting the injection.', ' \\n• Keep pushing down to prevent the Pen from moving away from the skin during the \\ninjection.', ' \\n• Press the plum-colored activator button with your thumb to begin the injection.', 'Try not to \\ncover the window.', 'See Figure K.  \\n'], 'page_sentence_count_spacy': 6}\n",
            "{'page_number': 76, 'text': ' \\nFigure K \\n \\n• You will hear a loud ‘click’ when you press the plum-colored activator button. The loud click \\nmeans the start of the injection. \\n• Keep pressing the plum-colored activator button and continue to push the Pen against your \\nsqueezed, raised skin until all the medicine is injected. This can take up to 10 seconds, so \\ncount slowly to ten. Keep pushing the Pen against the squeezed, raised skin of your \\ninjection site for the whole time so you get the full dose of medicine.  \\n• You will know that the injection has finished when the yellow indicator fully appears in the \\nwindow view and stops moving. See Figure L.  \\n  \\n', 'processed_text': {'sentences': [{'original_sentence': ' \\nFigure K \\n \\n• You will hear a loud ‘click’ when you press the plum-colored activator button.', 'tokens': ['Figure', 'K', '•', 'hear', 'loud', '‘', 'click', '’', 'press', 'plum-colored', 'activator', 'button', '.'], 'lemmatized': ['Figure', 'K', '•', 'hear', 'loud', '‘', 'click', '’', 'press', 'plum-colored', 'activator', 'button', '.'], 'stemmed': ['figur', 'k', '•', 'hear', 'loud', '‘', 'click', '’', 'press', 'plum-color', 'activ', 'button', '.'], 'dependencies': [('figur', 'npadvmod'), ('k', 'compound'), ('•', 'appos'), ('hear', 'ROOT'), ('loud', 'advmod'), ('‘', 'punct'), ('click', 'xcomp'), ('’', 'punct'), ('press', 'compound'), ('plum', 'compound'), ('-', 'punct'), ('color', 'compound'), ('activ', 'compound'), ('button', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The loud click \\nmeans the start of the injection.', 'tokens': ['loud', 'click', 'means', 'start', 'injection', '.'], 'lemmatized': ['loud', 'click', 'mean', 'start', 'injection', '.'], 'stemmed': ['loud', 'click', 'mean', 'start', 'inject', '.'], 'dependencies': [('loud', 'advmod'), ('click', 'ROOT'), ('mean', 'advmod'), ('start', 'dep'), ('inject', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• Keep pressing the plum-colored activator button and continue to push the Pen against your \\nsqueezed, raised skin until all the medicine is injected.', 'tokens': ['•', 'Keep', 'pressing', 'plum-colored', 'activator', 'button', 'continue', 'push', 'Pen', 'squeezed', ',', 'raised', 'skin', 'medicine', 'injected', '.'], 'lemmatized': ['•', 'Keep', 'pressing', 'plum-colored', 'activator', 'button', 'continue', 'push', 'Pen', 'squeezed', ',', 'raised', 'skin', 'medicine', 'injected', '.'], 'stemmed': ['•', 'keep', 'press', 'plum-color', 'activ', 'button', 'continu', 'push', 'pen', 'squeez', ',', 'rais', 'skin', 'medicin', 'inject', '.'], 'dependencies': [('•', 'meta'), ('keep', 'ccomp'), ('press', 'compound'), ('plum', 'compound'), ('-', 'punct'), ('color', 'compound'), ('activ', 'compound'), ('button', 'compound'), ('continu', 'compound'), ('push', 'compound'), ('pen', 'compound'), ('squeez', 'dobj'), (',', 'punct'), ('rais', 'compound'), ('skin', 'compound'), ('medicin', 'compound'), ('inject', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'This can take up to 10 seconds, so \\ncount slowly to ten.', 'tokens': ['take', '10', 'seconds', ',', 'count', 'slowly', 'ten', '.'], 'lemmatized': ['take', '10', 'second', ',', 'count', 'slowly', 'ten', '.'], 'stemmed': ['take', '10', 'second', ',', 'count', 'slowli', 'ten', '.'], 'dependencies': [('take', 'ROOT'), ('10', 'nummod'), ('second', 'dobj'), (',', 'punct'), ('count', 'compound'), ('slowli', 'npadvmod'), ('ten', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Keep pushing the Pen against the squeezed, raised skin of your \\ninjection site for the whole time so you get the full dose of medicine.', 'tokens': ['Keep', 'pushing', 'Pen', 'squeezed', ',', 'raised', 'skin', 'injection', 'site', 'whole', 'time', 'get', 'full', 'dose', 'medicine', '.'], 'lemmatized': ['Keep', 'pushing', 'Pen', 'squeezed', ',', 'raised', 'skin', 'injection', 'site', 'whole', 'time', 'get', 'full', 'dose', 'medicine', '.'], 'stemmed': ['keep', 'push', 'pen', 'squeez', ',', 'rais', 'skin', 'inject', 'site', 'whole', 'time', 'get', 'full', 'dose', 'medicin', '.'], 'dependencies': [('keep', 'ROOT'), ('push', 'amod'), ('pen', 'compound'), ('squeez', 'dobj'), (',', 'punct'), ('rais', 'compound'), ('skin', 'compound'), ('inject', 'compound'), ('site', 'nmod'), ('whole', 'amod'), ('time', 'npadvmod'), ('get', 'ccomp'), ('full', 'amod'), ('dose', 'compound'), ('medicin', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• You will know that the injection has finished when the yellow indicator fully appears in the \\nwindow view and stops moving.', 'tokens': ['•', 'know', 'injection', 'finished', 'yellow', 'indicator', 'fully', 'appears', 'window', 'view', 'stops', 'moving', '.'], 'lemmatized': ['•', 'know', 'injection', 'finished', 'yellow', 'indicator', 'fully', 'appears', 'window', 'view', 'stop', 'moving', '.'], 'stemmed': ['•', 'know', 'inject', 'finish', 'yellow', 'indic', 'fulli', 'appear', 'window', 'view', 'stop', 'move', '.'], 'dependencies': [('•', 'meta'), ('know', 'parataxis'), ('inject', 'nsubj'), ('finish', 'ccomp'), ('yellow', 'amod'), ('indic', 'amod'), ('fulli', 'appos'), ('appear', 'ROOT'), ('window', 'compound'), ('view', 'compound'), ('stop', 'ccomp'), ('move', 'xcomp'), ('.', 'punct')]}, {'original_sentence': 'See Figure L.', 'tokens': ['See', 'Figure', 'L', '.'], 'lemmatized': ['See', 'Figure', 'L', '.'], 'stemmed': ['see', 'figur', 'l', '.'], 'dependencies': [('see', 'ROOT'), ('figur', 'compound'), ('l', 'dobj'), ('.', 'punct')]}], 'text': ' \\nFigure K \\n \\n• You will hear a loud ‘click’ when you press the plum-colored activator button. The loud click \\nmeans the start of the injection. \\n• Keep pressing the plum-colored activator button and continue to push the Pen against your \\nsqueezed, raised skin until all the medicine is injected. This can take up to 10 seconds, so \\ncount slowly to ten. Keep pushing the Pen against the squeezed, raised skin of your \\ninjection site for the whole time so you get the full dose of medicine.  \\n• You will know that the injection has finished when the yellow indicator fully appears in the \\nwindow view and stops moving. See Figure L.  \\n  \\n'}, 'page_char_count': 637, 'page_word_count': 111, 'sentences': [' \\nFigure K \\n \\n• You will hear a loud ‘click’ when you press the plum-colored activator button.', 'The loud click \\nmeans the start of the injection.', '\\n• Keep pressing the plum-colored activator button and continue to push the Pen against your \\nsqueezed, raised skin until all the medicine is injected.', 'This can take up to 10 seconds, so \\ncount slowly to ten.', 'Keep pushing the Pen against the squeezed, raised skin of your \\ninjection site for the whole time so you get the full dose of medicine.', ' \\n• You will know that the injection has finished when the yellow indicator fully appears in the \\nwindow view and stops moving.', 'See Figure L.  \\n  \\n'], 'page_sentence_count_spacy': 7}\n",
            "{'page_number': 77, 'text': 'Figure L \\n \\n19. When the injection is finished, slowly pull the Pen from your skin. The white needle sleeve \\nwill move to cover the needle tip. See Figure M.  \\n• Do not touch the needle. The white needle sleeve is there to prevent you from touching the \\nneedle.  \\n', 'processed_text': {'sentences': [{'original_sentence': 'Figure L \\n \\n19.', 'tokens': ['Figure', 'L', '19', '.'], 'lemmatized': ['Figure', 'L', '19', '.'], 'stemmed': ['figur', 'l', '19', '.'], 'dependencies': [('figur', 'ROOT'), ('l', 'npadvmod'), ('19', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'When the injection is finished, slowly pull the Pen from your skin.', 'tokens': ['injection', 'finished', ',', 'slowly', 'pull', 'Pen', 'skin', '.'], 'lemmatized': ['injection', 'finished', ',', 'slowly', 'pull', 'Pen', 'skin', '.'], 'stemmed': ['inject', 'finish', ',', 'slowli', 'pull', 'pen', 'skin', '.'], 'dependencies': [('inject', 'compound'), ('finish', 'ROOT'), (',', 'punct'), ('slowli', 'amod'), ('pull', 'amod'), ('pen', 'compound'), ('skin', 'appos'), ('.', 'punct')]}, {'original_sentence': 'The white needle sleeve \\nwill move to cover the needle tip.', 'tokens': ['white', 'needle', 'sleeve', 'move', 'cover', 'needle', 'tip', '.'], 'lemmatized': ['white', 'needle', 'sleeve', 'move', 'cover', 'needle', 'tip', '.'], 'stemmed': ['white', 'needl', 'sleev', 'move', 'cover', 'needl', 'tip', '.'], 'dependencies': [('white', 'nsubj'), ('needl', 'compound'), ('sleev', 'nsubj'), ('move', 'ROOT'), ('cover', 'dobj'), ('needl', 'compound'), ('tip', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'See Figure M.  \\n• Do not touch the needle.', 'tokens': ['See', 'Figure', 'M.', '•', 'touch', 'needle', '.'], 'lemmatized': ['See', 'Figure', 'M.', '•', 'touch', 'needle', '.'], 'stemmed': ['see', 'figur', 'm.', '•', 'touch', 'needl', '.'], 'dependencies': [('see', 'ROOT'), ('figur', 'compound'), ('m.', 'nmod'), ('•', 'nummod'), ('touch', 'compound'), ('needl', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The white needle sleeve is there to prevent you from touching the \\nneedle.', 'tokens': ['white', 'needle', 'sleeve', 'prevent', 'touching', 'needle', '.'], 'lemmatized': ['white', 'needle', 'sleeve', 'prevent', 'touching', 'needle', '.'], 'stemmed': ['white', 'needl', 'sleev', 'prevent', 'touch', 'needl', '.'], 'dependencies': [('white', 'compound'), ('needl', 'nsubj'), ('sleev', 'nsubj'), ('prevent', 'ROOT'), ('touch', 'compound'), ('needl', 'dobj'), ('.', 'punct')]}], 'text': 'Figure L \\n \\n19. When the injection is finished, slowly pull the Pen from your skin. The white needle sleeve \\nwill move to cover the needle tip. See Figure M.  \\n• Do not touch the needle. The white needle sleeve is there to prevent you from touching the \\nneedle.  \\n'}, 'page_char_count': 264, 'page_word_count': 48, 'sentences': ['Figure L \\n \\n19.', 'When the injection is finished, slowly pull the Pen from your skin.', 'The white needle sleeve \\nwill move to cover the needle tip.', 'See Figure M.  \\n• Do not touch the needle.', 'The white needle sleeve is there to prevent you from touching the \\nneedle.', ' \\n'], 'page_sentence_count_spacy': 6}\n",
            "{'page_number': 78, 'text': ' \\nFigure M \\n \\n• There may be a small amount of liquid on the injection site. This is normal. \\n• Press a cotton ball or gauze pad over the injection site and hold it for 10 seconds. Do not \\nrub the injection site. You may have slight bleeding. This is normal.  \\n  \\n20. Throw away (dispose of) your used HUMIRA Pen in a sharps disposal container right away \\nafter use. See the section “How should I dispose of the used HUMIRA Pen?” \\n21. Keep a record of the dates and location of your injection sites. To help you remember when \\nto take HUMIRA, you can mark your calendar ahead of time.  \\nHow should I throw away (dispose of) the used HUMIRA Pen? \\n• Put your Pen in a FDA-cleared sharps disposal container right away after use. See Figure \\nN. Do not throw away the Pen in your household trash.  \\n• Do not try to touch the needle. The white needle sleeve is there to prevent you from \\ntouching the needle. \\n \\n', 'processed_text': {'sentences': [{'original_sentence': ' \\nFigure M \\n \\n• There may be a small amount of liquid on the injection site.', 'tokens': ['Figure', '•', 'may', 'small', 'amount', 'liquid', 'injection', 'site', '.'], 'lemmatized': ['Figure', '•', 'may', 'small', 'amount', 'liquid', 'injection', 'site', '.'], 'stemmed': ['figur', '•', 'may', 'small', 'amount', 'liquid', 'inject', 'site', '.'], 'dependencies': [('figur', 'nsubj'), ('•', 'nummod'), ('may', 'ROOT'), ('small', 'amod'), ('amount', 'nmod'), ('liquid', 'amod'), ('inject', 'compound'), ('site', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'This is normal.', 'tokens': ['normal', '.'], 'lemmatized': ['normal', '.'], 'stemmed': ['normal', '.'], 'dependencies': [('normal', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• Press a cotton ball or gauze pad over the injection site and hold it for 10 seconds.', 'tokens': ['•', 'Press', 'cotton', 'ball', 'gauze', 'pad', 'injection', 'site', 'hold', '10', 'seconds', '.'], 'lemmatized': ['•', 'Press', 'cotton', 'ball', 'gauze', 'pad', 'injection', 'site', 'hold', '10', 'second', '.'], 'stemmed': ['•', 'press', 'cotton', 'ball', 'gauz', 'pad', 'inject', 'site', 'hold', '10', 'second', '.'], 'dependencies': [('•', 'nummod'), ('press', 'compound'), ('cotton', 'compound'), ('ball', 'compound'), ('gauz', 'compound'), ('pad', 'compound'), ('inject', 'compound'), ('site', 'nsubj'), ('hold', 'ROOT'), ('10', 'nummod'), ('second', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Do not \\nrub the injection site.', 'tokens': ['rub', 'injection', 'site', '.'], 'lemmatized': ['rub', 'injection', 'site', '.'], 'stemmed': ['rub', 'inject', 'site', '.'], 'dependencies': [('rub', 'ROOT'), ('inject', 'compound'), ('site', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'You may have slight bleeding.', 'tokens': ['may', 'slight', 'bleeding', '.'], 'lemmatized': ['may', 'slight', 'bleeding', '.'], 'stemmed': ['may', 'slight', 'bleed', '.'], 'dependencies': [('may', 'aux'), ('slight', 'amod'), ('bleed', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'This is normal.', 'tokens': ['normal', '.'], 'lemmatized': ['normal', '.'], 'stemmed': ['normal', '.'], 'dependencies': [('normal', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '20.', 'tokens': ['20', '.'], 'lemmatized': ['20', '.'], 'stemmed': ['20', '.'], 'dependencies': [('20', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Throw away (dispose of) your used HUMIRA Pen in a sharps disposal container right away \\nafter use.', 'tokens': ['Throw', 'away', '(', 'dispose', ')', 'used', 'HUMIRA', 'Pen', 'sharps', 'disposal', 'container', 'right', 'away', 'use', '.'], 'lemmatized': ['Throw', 'away', '(', 'dispose', ')', 'used', 'HUMIRA', 'Pen', 'sharp', 'disposal', 'container', 'right', 'away', 'use', '.'], 'stemmed': ['throw', 'away', '(', 'dispos', ')', 'use', 'humira', 'pen', 'sharp', 'dispos', 'contain', 'right', 'away', 'use', '.'], 'dependencies': [('throw', 'ROOT'), ('away', 'advmod'), ('(', 'punct'), ('dispos', 'npadvmod'), (')', 'punct'), ('use', 'conj'), ('humira', 'compound'), ('pen', 'compound'), ('sharp', 'amod'), ('dispos', 'dobj'), ('contain', 'xcomp'), ('right', 'advmod'), ('away', 'advmod'), ('use', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'See the section “How should I dispose of the used HUMIRA Pen?” \\n21.', 'tokens': ['See', 'section', '“', 'dispose', 'used', 'HUMIRA', 'Pen', '?', '”', '21', '.'], 'lemmatized': ['See', 'section', '“', 'dispose', 'used', 'HUMIRA', 'Pen', '?', '”', '21', '.'], 'stemmed': ['see', 'section', '“', 'dispos', 'use', 'humira', 'pen', '?', '”', '21', '.'], 'dependencies': [('see', 'ROOT'), ('section', 'dobj'), ('“', 'punct'), ('dispos', 'nsubj'), ('use', 'relcl'), ('humira', 'compound'), ('pen', 'dobj'), ('?', 'punct'), ('”', 'punct'), ('21', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Keep a record of the dates and location of your injection sites.', 'tokens': ['Keep', 'record', 'dates', 'location', 'injection', 'sites', '.'], 'lemmatized': ['Keep', 'record', 'date', 'location', 'injection', 'site', '.'], 'stemmed': ['keep', 'record', 'date', 'locat', 'inject', 'site', '.'], 'dependencies': [('keep', 'ROOT'), ('record', 'compound'), ('date', 'compound'), ('locat', 'compound'), ('inject', 'compound'), ('site', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'To help you remember when \\nto take HUMIRA, you can mark your calendar ahead of time.', 'tokens': ['help', 'remember', 'take', 'HUMIRA', ',', 'mark', 'calendar', 'ahead', 'time', '.'], 'lemmatized': ['help', 'remember', 'take', 'HUMIRA', ',', 'mark', 'calendar', 'ahead', 'time', '.'], 'stemmed': ['help', 'rememb', 'take', 'humira', ',', 'mark', 'calendar', 'ahead', 'time', '.'], 'dependencies': [('help', 'advcl'), ('rememb', 'amod'), ('take', 'compound'), ('humira', 'dobj'), (',', 'punct'), ('mark', 'compound'), ('calendar', 'ROOT'), ('ahead', 'amod'), ('time', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'How should I throw away (dispose of) the used HUMIRA Pen?', 'tokens': ['throw', 'away', '(', 'dispose', ')', 'used', 'HUMIRA', 'Pen', '?'], 'lemmatized': ['throw', 'away', '(', 'dispose', ')', 'used', 'HUMIRA', 'Pen', '?'], 'stemmed': ['throw', 'away', '(', 'dispos', ')', 'use', 'humira', 'pen', '?'], 'dependencies': [('throw', 'ROOT'), ('away', 'advmod'), ('(', 'punct'), ('dispos', 'npadvmod'), (')', 'punct'), ('use', 'conj'), ('humira', 'compound'), ('pen', 'dobj'), ('?', 'punct')]}, {'original_sentence': '• Put your Pen in a FDA-cleared sharps disposal container right away after use.', 'tokens': ['•', 'Put', 'Pen', 'FDA-cleared', 'sharps', 'disposal', 'container', 'right', 'away', 'use', '.'], 'lemmatized': ['•', 'Put', 'Pen', 'FDA-cleared', 'sharp', 'disposal', 'container', 'right', 'away', 'use', '.'], 'stemmed': ['•', 'put', 'pen', 'fda-clear', 'sharp', 'dispos', 'contain', 'right', 'away', 'use', '.'], 'dependencies': [('•', 'npadvmod'), ('put', 'ROOT'), ('pen', 'compound'), ('fda', 'compound'), ('-', 'punct'), ('clear', 'amod'), ('sharp', 'amod'), ('dispos', 'dobj'), ('contain', 'ccomp'), ('right', 'advmod'), ('away', 'advmod'), ('use', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'See Figure \\nN. Do not throw away the Pen in your household trash.', 'tokens': ['See', 'Figure', 'N.', 'throw', 'away', 'Pen', 'household', 'trash', '.'], 'lemmatized': ['See', 'Figure', 'N.', 'throw', 'away', 'Pen', 'household', 'trash', '.'], 'stemmed': ['see', 'figur', 'n.', 'throw', 'away', 'pen', 'household', 'trash', '.'], 'dependencies': [('see', 'ROOT'), ('figur', 'compound'), ('n.', 'nsubj'), ('throw', 'ccomp'), ('away', 'advmod'), ('pen', 'compound'), ('household', 'compound'), ('trash', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• Do not try to touch the needle.', 'tokens': ['•', 'try', 'touch', 'needle', '.'], 'lemmatized': ['•', 'try', 'touch', 'needle', '.'], 'stemmed': ['•', 'tri', 'touch', 'needl', '.'], 'dependencies': [('•', 'nmod'), ('tri', 'amod'), ('touch', 'compound'), ('needl', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'The white needle sleeve is there to prevent you from \\ntouching the needle.', 'tokens': ['white', 'needle', 'sleeve', 'prevent', 'touching', 'needle', '.'], 'lemmatized': ['white', 'needle', 'sleeve', 'prevent', 'touching', 'needle', '.'], 'stemmed': ['white', 'needl', 'sleev', 'prevent', 'touch', 'needl', '.'], 'dependencies': [('white', 'compound'), ('needl', 'nsubj'), ('sleev', 'nsubj'), ('prevent', 'ROOT'), ('touch', 'compound'), ('needl', 'dobj'), ('.', 'punct')]}], 'text': ' \\nFigure M \\n \\n• There may be a small amount of liquid on the injection site. This is normal. \\n• Press a cotton ball or gauze pad over the injection site and hold it for 10 seconds. Do not \\nrub the injection site. You may have slight bleeding. This is normal.  \\n  \\n20. Throw away (dispose of) your used HUMIRA Pen in a sharps disposal container right away \\nafter use. See the section “How should I dispose of the used HUMIRA Pen?” \\n21. Keep a record of the dates and location of your injection sites. To help you remember when \\nto take HUMIRA, you can mark your calendar ahead of time.  \\nHow should I throw away (dispose of) the used HUMIRA Pen? \\n• Put your Pen in a FDA-cleared sharps disposal container right away after use. See Figure \\nN. Do not throw away the Pen in your household trash.  \\n• Do not try to touch the needle. The white needle sleeve is there to prevent you from \\ntouching the needle. \\n \\n'}, 'page_char_count': 906, 'page_word_count': 168, 'sentences': [' \\nFigure M \\n \\n• There may be a small amount of liquid on the injection site.', 'This is normal.', '\\n• Press a cotton ball or gauze pad over the injection site and hold it for 10 seconds.', 'Do not \\nrub the injection site.', 'You may have slight bleeding.', 'This is normal.', ' \\n  \\n20.', 'Throw away (dispose of) your used HUMIRA Pen in a sharps disposal container right away \\nafter use.', 'See the section “How should I dispose of the used HUMIRA Pen?”', '\\n21.', 'Keep a record of the dates and location of your injection sites.', 'To help you remember when \\nto take HUMIRA, you can mark your calendar ahead of time.', ' \\nHow should I throw away (dispose of) the used HUMIRA Pen?', '\\n• Put your Pen in a FDA-cleared sharps disposal container right away after use.', 'See Figure \\nN. Do not throw away the Pen in your household trash.', ' \\n• Do not try to touch the needle.', 'The white needle sleeve is there to prevent you from \\ntouching the needle.', '\\n \\n'], 'page_sentence_count_spacy': 18}\n",
            "{'page_number': 79, 'text': ' \\nFigure N \\n \\n• If you do not have a FDA-cleared sharps disposal container, you may use a household \\ncontainer that is:  \\n◦ made of a heavy-duty plastic,  \\n◦ can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to \\ncome out, \\n◦ upright and stable during use,  \\n◦ leak-resistant, and \\n◦ properly labeled to warn of hazardous waste inside the container. \\n• When your sharps disposal container is almost full, you will need to follow your community \\nguidelines for the right way to dispose of your sharps disposal container. There may be state \\nor local laws about how you should throw away used needles and syringes. For more \\ninformation about safe sharps disposal, and for specific information about sharps disposal in \\nthe state that you live in, go to the FDA’s website at: http://www.fda.gov/safesharpsdisposal.  \\n• For the safety and health of you and others, never re-use your HUMIRA Pens. \\n• The used alcohol pads, cotton balls, dose trays and packaging may be placed in your \\nhousehold trash. \\n• Do not dispose of your used sharps disposal container in your household trash \\nunless your community guidelines permit this. Do not recycle your used sharps \\ndisposal container.  \\n• Always keep the sharps container out of the reach of children. \\n  \\nHow should I store HUMIRA? \\n• Store HUMIRA in the refrigerator between 36ºF to 46ºF (2ºC to 8ºC). Store HUMIRA in the \\noriginal carton until use to protect it from light.  \\n', 'processed_text': {'sentences': [{'original_sentence': ' \\nFigure N \\n \\n• If you do not have a FDA-cleared sharps disposal container, you may use a household \\ncontainer that is:  \\n◦ made of a heavy-duty plastic,  \\n◦ can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to \\ncome out, \\n◦ upright and stable during use,  \\n◦ leak-resistant, and \\n◦ properly labeled to warn of hazardous waste inside the container.', 'tokens': ['Figure', 'N', '•', 'FDA-cleared', 'sharps', 'disposal', 'container', ',', 'may', 'use', 'household', 'container', ':', '◦', 'made', 'heavy-duty', 'plastic', ',', '◦', 'closed', 'tight-fitting', ',', 'puncture-resistant', 'lid', ',', 'without', 'sharps', 'able', 'come', ',', '◦', 'upright', 'stable', 'use', ',', '◦', 'leak-resistant', ',', '◦', 'properly', 'labeled', 'warn', 'hazardous', 'waste', 'inside', 'container', '.'], 'lemmatized': ['Figure', 'N', '•', 'FDA-cleared', 'sharp', 'disposal', 'container', ',', 'may', 'use', 'household', 'container', ':', '◦', 'made', 'heavy-duty', 'plastic', ',', '◦', 'closed', 'tight-fitting', ',', 'puncture-resistant', 'lid', ',', 'without', 'sharp', 'able', 'come', ',', '◦', 'upright', 'stable', 'use', ',', '◦', 'leak-resistant', ',', '◦', 'properly', 'labeled', 'warn', 'hazardous', 'waste', 'inside', 'container', '.'], 'stemmed': ['figur', 'n', '•', 'fda-clear', 'sharp', 'dispos', 'contain', ',', 'may', 'use', 'household', 'contain', ':', '◦', 'made', 'heavy-duti', 'plastic', ',', '◦', 'close', 'tight-fit', ',', 'puncture-resist', 'lid', ',', 'without', 'sharp', 'abl', 'come', ',', '◦', 'upright', 'stabl', 'use', ',', '◦', 'leak-resist', ',', '◦', 'properli', 'label', 'warn', 'hazard', 'wast', 'insid', 'contain', '.'], 'dependencies': [('figur', 'npadvmod'), ('n', 'cc'), ('•', 'nummod'), ('fda', 'amod'), ('-', 'punct'), ('clear', 'amod'), ('sharp', 'amod'), ('dispos', 'nsubj'), ('contain', 'ccomp'), (',', 'punct'), ('may', 'aux'), ('use', 'ROOT'), ('household', 'compound'), ('contain', 'dobj'), (':', 'punct'), ('◦', 'nsubj'), ('made', 'xcomp'), ('heavy', 'amod'), ('-', 'punct'), ('duti', 'compound'), ('plastic', 'dobj'), (',', 'punct'), ('◦', 'advcl'), ('close', 'amod'), ('tight', 'amod'), ('-', 'punct'), ('fit', 'amod'), (',', 'punct'), ('puncture', 'amod'), ('-', 'punct'), ('resist', 'compound'), ('lid', 'dobj'), (',', 'punct'), ('without', 'prep'), ('sharp', 'amod'), ('abl', 'nsubj'), ('come', 'pobj'), (',', 'punct'), ('◦', 'dep'), ('upright', 'amod'), ('stabl', 'amod'), ('use', 'dobj'), (',', 'punct'), ('◦', 'compound'), ('leak', 'compound'), ('-', 'punct'), ('resist', 'nsubj'), (',', 'punct'), ('◦', 'conj'), ('properli', 'compound'), ('label', 'nsubj'), ('warn', 'conj'), ('hazard', 'compound'), ('wast', 'nsubj'), ('insid', 'amod'), ('contain', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• When your sharps disposal container is almost full, you will need to follow your community \\nguidelines for the right way to dispose of your sharps disposal container.', 'tokens': ['•', 'sharps', 'disposal', 'container', 'almost', 'full', ',', 'need', 'follow', 'community', 'guidelines', 'right', 'way', 'dispose', 'sharps', 'disposal', 'container', '.'], 'lemmatized': ['•', 'sharp', 'disposal', 'container', 'almost', 'full', ',', 'need', 'follow', 'community', 'guideline', 'right', 'way', 'dispose', 'sharp', 'disposal', 'container', '.'], 'stemmed': ['•', 'sharp', 'dispos', 'contain', 'almost', 'full', ',', 'need', 'follow', 'commun', 'guidelin', 'right', 'way', 'dispos', 'sharp', 'dispos', 'contain', '.'], 'dependencies': [('•', 'nummod'), ('sharp', 'amod'), ('dispos', 'nsubj'), ('contain', 'ROOT'), ('almost', 'advmod'), ('full', 'advmod'), (',', 'punct'), ('need', 'conj'), ('follow', 'dobj'), ('commun', 'amod'), ('guidelin', 'dobj'), ('right', 'amod'), ('way', 'npadvmod'), ('dispos', 'nsubj'), ('sharp', 'amod'), ('dispos', 'nsubj'), ('contain', 'ccomp'), ('.', 'punct')]}, {'original_sentence': 'There may be state \\nor local laws about how you should throw away used needles and syringes.', 'tokens': ['may', 'state', 'local', 'laws', 'throw', 'away', 'used', 'needles', 'syringes', '.'], 'lemmatized': ['may', 'state', 'local', 'law', 'throw', 'away', 'used', 'needle', 'syrinx', '.'], 'stemmed': ['may', 'state', 'local', 'law', 'throw', 'away', 'use', 'needl', 'syrinx', '.'], 'dependencies': [('may', 'aux'), ('state', 'ROOT'), ('local', 'amod'), ('law', 'dobj'), ('throw', 'ccomp'), ('away', 'advmod'), ('use', 'dobj'), ('needl', 'conj'), ('syrinx', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'For more \\ninformation about safe sharps disposal, and for specific information about sharps disposal in \\nthe state that you live in, go to the FDA’s website at: http://www.fda.gov/safesharpsdisposal.', 'tokens': ['information', 'safe', 'sharps', 'disposal', ',', 'specific', 'information', 'sharps', 'disposal', 'state', 'live', ',', 'go', 'FDA', '’', 'website', ':', 'http', ':', '//www.fda.gov/safesharpsdisposal', '.'], 'lemmatized': ['information', 'safe', 'sharp', 'disposal', ',', 'specific', 'information', 'sharp', 'disposal', 'state', 'live', ',', 'go', 'FDA', '’', 'website', ':', 'http', ':', '//www.fda.gov/safesharpsdisposal', '.'], 'stemmed': ['inform', 'safe', 'sharp', 'dispos', ',', 'specif', 'inform', 'sharp', 'dispos', 'state', 'live', ',', 'go', 'fda', '’', 'websit', ':', 'http', ':', '//www.fda.gov/safesharpsdispos', '.'], 'dependencies': [('inform', 'advcl'), ('safe', 'amod'), ('sharp', 'amod'), ('dispos', 'dobj'), (',', 'punct'), ('specif', 'nsubj'), ('inform', 'ROOT'), ('sharp', 'amod'), ('dispos', 'compound'), ('state', 'dobj'), ('live', 'advmod'), (',', 'punct'), ('go', 'conj'), ('fda', 'nmod'), ('’', 'punct'), ('websit', 'dobj'), (':', 'punct'), ('http', 'appos'), (':', 'punct'), ('//www.fda.gov', 'nmod'), ('/', 'punct'), ('safesharpsdispos', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': '• For the safety and health of you and others, never re-use your HUMIRA Pens.', 'tokens': ['•', 'safety', 'health', 'others', ',', 'never', 're-use', 'HUMIRA', 'Pens', '.'], 'lemmatized': ['•', 'safety', 'health', 'others', ',', 'never', 're-use', 'HUMIRA', 'Pens', '.'], 'stemmed': ['•', 'safeti', 'health', 'other', ',', 'never', 're-us', 'humira', 'pen', '.'], 'dependencies': [('•', 'nummod'), ('safeti', 'compound'), ('health', 'compound'), ('other', 'ROOT'), (',', 'punct'), ('never', 'neg'), ('re', 'conj'), ('-', 'amod'), ('us', 'dep'), ('humira', 'compound'), ('pen', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• The used alcohol pads, cotton balls, dose trays and packaging may be placed in your \\nhousehold trash.', 'tokens': ['•', 'used', 'alcohol', 'pads', ',', 'cotton', 'balls', ',', 'dose', 'trays', 'packaging', 'may', 'placed', 'household', 'trash', '.'], 'lemmatized': ['•', 'used', 'alcohol', 'pad', ',', 'cotton', 'ball', ',', 'dose', 'tray', 'packaging', 'may', 'placed', 'household', 'trash', '.'], 'stemmed': ['•', 'use', 'alcohol', 'pad', ',', 'cotton', 'ball', ',', 'dose', 'tray', 'packag', 'may', 'place', 'household', 'trash', '.'], 'dependencies': [('•', 'meta'), ('use', 'nsubj'), ('alcohol', 'compound'), ('pad', 'dobj'), (',', 'punct'), ('cotton', 'compound'), ('ball', 'conj'), (',', 'punct'), ('dose', 'conj'), ('tray', 'compound'), ('packag', 'dobj'), ('may', 'aux'), ('place', 'ROOT'), ('household', 'compound'), ('trash', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• Do not dispose of your used sharps disposal container in your household trash \\nunless your community guidelines permit this.', 'tokens': ['•', 'dispose', 'used', 'sharps', 'disposal', 'container', 'household', 'trash', 'unless', 'community', 'guidelines', 'permit', '.'], 'lemmatized': ['•', 'dispose', 'used', 'sharp', 'disposal', 'container', 'household', 'trash', 'unless', 'community', 'guideline', 'permit', '.'], 'stemmed': ['•', 'dispos', 'use', 'sharp', 'dispos', 'contain', 'household', 'trash', 'unless', 'commun', 'guidelin', 'permit', '.'], 'dependencies': [('•', 'nummod'), ('dispos', 'nsubj'), ('use', 'ROOT'), ('sharp', 'amod'), ('dispos', 'dobj'), ('contain', 'xcomp'), ('household', 'compound'), ('trash', 'dobj'), ('unless', 'mark'), ('commun', 'amod'), ('guidelin', 'compound'), ('permit', 'advcl'), ('.', 'punct')]}, {'original_sentence': 'Do not recycle your used sharps \\ndisposal container.', 'tokens': ['recycle', 'used', 'sharps', 'disposal', 'container', '.'], 'lemmatized': ['recycle', 'used', 'sharp', 'disposal', 'container', '.'], 'stemmed': ['recycl', 'use', 'sharp', 'dispos', 'contain', '.'], 'dependencies': [('recycl', 'nsubj'), ('use', 'ROOT'), ('sharp', 'amod'), ('dispos', 'dobj'), ('contain', 'xcomp'), ('.', 'punct')]}, {'original_sentence': '• Always keep the sharps container out of the reach of children.', 'tokens': ['•', 'Always', 'keep', 'sharps', 'container', 'reach', 'children', '.'], 'lemmatized': ['•', 'Always', 'keep', 'sharp', 'container', 'reach', 'child', '.'], 'stemmed': ['•', 'alway', 'keep', 'sharp', 'contain', 'reach', 'child', '.'], 'dependencies': [('•', 'nsubj'), ('alway', 'advmod'), ('keep', 'ROOT'), ('sharp', 'amod'), ('contain', 'nsubj'), ('reach', 'xcomp'), ('child', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'How should I store HUMIRA?', 'tokens': ['store', 'HUMIRA', '?'], 'lemmatized': ['store', 'HUMIRA', '?'], 'stemmed': ['store', 'humira', '?'], 'dependencies': [('store', 'compound'), ('humira', 'ROOT'), ('?', 'punct')]}, {'original_sentence': '• Store HUMIRA in the refrigerator between 36ºF to 46ºF (2ºC to 8ºC).', 'tokens': ['•', 'Store', 'HUMIRA', 'refrigerator', '36ºF', '46ºF', '(', '2ºC', '8ºC', ')', '.'], 'lemmatized': ['•', 'Store', 'HUMIRA', 'refrigerator', '36ºF', '46ºF', '(', '2ºC', '8ºC', ')', '.'], 'stemmed': ['•', 'store', 'humira', 'refriger', '36ºf', '46ºf', '(', '2ºc', '8ºc', ')', '.'], 'dependencies': [('•', 'nummod'), ('store', 'nmod'), ('humira', 'compound'), ('refriger', 'compound'), ('36ºf', 'compound'), ('46ºf', 'ROOT'), ('(', 'punct'), ('2ºc', 'amod'), ('8ºc', 'parataxis'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Store HUMIRA in the \\noriginal carton until use to protect it from light.', 'tokens': ['Store', 'HUMIRA', 'original', 'carton', 'use', 'protect', 'light', '.'], 'lemmatized': ['Store', 'HUMIRA', 'original', 'carton', 'use', 'protect', 'light', '.'], 'stemmed': ['store', 'humira', 'origin', 'carton', 'use', 'protect', 'light', '.'], 'dependencies': [('store', 'compound'), ('humira', 'compound'), ('origin', 'compound'), ('carton', 'compound'), ('use', 'compound'), ('protect', 'compound'), ('light', 'ROOT'), ('.', 'punct')]}], 'text': ' \\nFigure N \\n \\n• If you do not have a FDA-cleared sharps disposal container, you may use a household \\ncontainer that is:  \\n◦ made of a heavy-duty plastic,  \\n◦ can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to \\ncome out, \\n◦ upright and stable during use,  \\n◦ leak-resistant, and \\n◦ properly labeled to warn of hazardous waste inside the container. \\n• When your sharps disposal container is almost full, you will need to follow your community \\nguidelines for the right way to dispose of your sharps disposal container. There may be state \\nor local laws about how you should throw away used needles and syringes. For more \\ninformation about safe sharps disposal, and for specific information about sharps disposal in \\nthe state that you live in, go to the FDA’s website at: http://www.fda.gov/safesharpsdisposal.  \\n• For the safety and health of you and others, never re-use your HUMIRA Pens. \\n• The used alcohol pads, cotton balls, dose trays and packaging may be placed in your \\nhousehold trash. \\n• Do not dispose of your used sharps disposal container in your household trash \\nunless your community guidelines permit this. Do not recycle your used sharps \\ndisposal container.  \\n• Always keep the sharps container out of the reach of children. \\n  \\nHow should I store HUMIRA? \\n• Store HUMIRA in the refrigerator between 36ºF to 46ºF (2ºC to 8ºC). Store HUMIRA in the \\noriginal carton until use to protect it from light.  \\n'}, 'page_char_count': 1458, 'page_word_count': 240, 'sentences': [' \\nFigure N \\n \\n• If you do not have a FDA-cleared sharps disposal container, you may use a household \\ncontainer that is:  \\n◦ made of a heavy-duty plastic,  \\n◦ can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to \\ncome out, \\n◦ upright and stable during use,  \\n◦ leak-resistant, and \\n◦ properly labeled to warn of hazardous waste inside the container.', '\\n• When your sharps disposal container is almost full, you will need to follow your community \\nguidelines for the right way to dispose of your sharps disposal container.', 'There may be state \\nor local laws about how you should throw away used needles and syringes.', 'For more \\ninformation about safe sharps disposal, and for specific information about sharps disposal in \\nthe state that you live in, go to the FDA’s website at: http://www.fda.gov/safesharpsdisposal.', ' \\n• For the safety and health of you and others, never re-use your HUMIRA Pens.', '\\n• The used alcohol pads, cotton balls, dose trays and packaging may be placed in your \\nhousehold trash.', '\\n• Do not dispose of your used sharps disposal container in your household trash \\nunless your community guidelines permit this.', 'Do not recycle your used sharps \\ndisposal container.', ' \\n• Always keep the sharps container out of the reach of children.', '\\n  \\nHow should I store HUMIRA?', '\\n• Store HUMIRA in the refrigerator between 36ºF to 46ºF (2ºC to 8ºC).', 'Store HUMIRA in the \\noriginal carton until use to protect it from light.', ' \\n'], 'page_sentence_count_spacy': 13}\n",
            "{'page_number': 80, 'text': '• Do not freeze HUMIRA. Do not use HUMIRA if frozen, even if it has been thawed.  \\n• Refrigerated HUMIRA may be used until the expiration date printed on the HUMIRA carton, \\ndose tray or Pen. Do not use HUMIRA after the expiration date.  \\n• If needed, for example when you are traveling, you may also store HUMIRA at room \\ntemperature up to 77°F (25°C) for up to 14 days. Store HUMIRA in the original carton until \\nuse to protect it from light.  \\n• Throw away HUMIRA if it has been kept at room temperature and not been used within 14 \\ndays.  \\n• Record the date you first remove HUMIRA from the refrigerator in the spaces provided on \\nthe carton and dose tray. \\n• Do not store HUMIRA in extreme heat or cold. \\n• Do not use a Pen if the liquid is cloudy, discolored, or has flakes or particles in it. \\n• Do not drop or crush HUMIRA. \\n• Keep HUMIRA, injection supplies, and all other medicines out of the reach of children. \\n  \\nThis Instructions for Use has been approved by the U.S. Food and Drug Administration.  \\nManufactured by:  \\nAbbVie Inc.  \\nNorth Chicago, IL 60064, U.S.A.  \\nUS License Number 1889  \\n20066944 \\nRevised: 02/2021  \\n \\n \\n \\n  \\nINSTRUCTIONS FOR USE \\nHUMIRA® (Hu-MARE-ah) \\n(adalimumab) \\n40 mg/0.4 mL \\nSingle-Dose Pen \\nBefore Injecting: Your healthcare provider should show you how to use HUMIRA before you \\nuse it for the first time. Call your healthcare provider or 1-800-4HUMIRA (1-800-448-6472) if \\nyou need help. \\n', 'processed_text': {'sentences': [{'original_sentence': '• Do not freeze HUMIRA.', 'tokens': ['•', 'freeze', 'HUMIRA', '.'], 'lemmatized': ['•', 'freeze', 'HUMIRA', '.'], 'stemmed': ['•', 'freez', 'humira', '.'], 'dependencies': [('•', 'nummod'), ('freez', 'compound'), ('humira', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Do not use HUMIRA if frozen, even if it has been thawed.', 'tokens': ['use', 'HUMIRA', 'frozen', ',', 'even', 'thawed', '.'], 'lemmatized': ['use', 'HUMIRA', 'frozen', ',', 'even', 'thawed', '.'], 'stemmed': ['use', 'humira', 'frozen', ',', 'even', 'thaw', '.'], 'dependencies': [('use', 'ROOT'), ('humira', 'npadvmod'), ('frozen', 'amod'), (',', 'punct'), ('even', 'advmod'), ('thaw', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• Refrigerated HUMIRA may be used until the expiration date printed on the HUMIRA carton, \\ndose tray or Pen.', 'tokens': ['•', 'Refrigerated', 'HUMIRA', 'may', 'used', 'expiration', 'date', 'printed', 'HUMIRA', 'carton', ',', 'dose', 'tray', 'Pen', '.'], 'lemmatized': ['•', 'Refrigerated', 'HUMIRA', 'may', 'used', 'expiration', 'date', 'printed', 'HUMIRA', 'carton', ',', 'dose', 'tray', 'Pen', '.'], 'stemmed': ['•', 'refriger', 'humira', 'may', 'use', 'expir', 'date', 'print', 'humira', 'carton', ',', 'dose', 'tray', 'pen', '.'], 'dependencies': [('•', 'nummod'), ('refriger', 'compound'), ('humira', 'nsubj'), ('may', 'aux'), ('use', 'ROOT'), ('expir', 'compound'), ('date', 'compound'), ('print', 'compound'), ('humira', 'compound'), ('carton', 'dobj'), (',', 'punct'), ('dose', 'xcomp'), ('tray', 'compound'), ('pen', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Do not use HUMIRA after the expiration date.', 'tokens': ['use', 'HUMIRA', 'expiration', 'date', '.'], 'lemmatized': ['use', 'HUMIRA', 'expiration', 'date', '.'], 'stemmed': ['use', 'humira', 'expir', 'date', '.'], 'dependencies': [('use', 'ROOT'), ('humira', 'compound'), ('expir', 'compound'), ('date', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• If needed, for example when you are traveling, you may also store HUMIRA at room \\ntemperature up to 77°F (25°C) for up to 14 days.', 'tokens': ['•', 'needed', ',', 'example', 'traveling', ',', 'may', 'also', 'store', 'HUMIRA', 'room', 'temperature', '77°F', '(', '25°C', ')', '14', 'days', '.'], 'lemmatized': ['•', 'needed', ',', 'example', 'traveling', ',', 'may', 'also', 'store', 'HUMIRA', 'room', 'temperature', '77°F', '(', '25°C', ')', '14', 'day', '.'], 'stemmed': ['•', 'need', ',', 'exampl', 'travel', ',', 'may', 'also', 'store', 'humira', 'room', 'temperatur', '77°f', '(', '25°c', ')', '14', 'day', '.'], 'dependencies': [('•', 'nummod'), ('need', 'advcl'), (',', 'punct'), ('exampl', 'nsubj'), ('travel', 'meta'), (',', 'punct'), ('may', 'aux'), ('also', 'advmod'), ('store', 'ROOT'), ('humira', 'compound'), ('room', 'dobj'), ('temperatur', 'nmod'), ('77', 'nummod'), ('°', 'npadvmod'), ('f', 'dobj'), ('(', 'punct'), ('25', 'nummod'), ('°', 'appos'), ('c', 'punct'), (')', 'punct'), ('14', 'nummod'), ('day', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Store HUMIRA in the original carton until \\nuse to protect it from light.', 'tokens': ['Store', 'HUMIRA', 'original', 'carton', 'use', 'protect', 'light', '.'], 'lemmatized': ['Store', 'HUMIRA', 'original', 'carton', 'use', 'protect', 'light', '.'], 'stemmed': ['store', 'humira', 'origin', 'carton', 'use', 'protect', 'light', '.'], 'dependencies': [('store', 'compound'), ('humira', 'compound'), ('origin', 'compound'), ('carton', 'compound'), ('use', 'compound'), ('protect', 'compound'), ('light', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• Throw away HUMIRA if it has been kept at room temperature and not been used within 14 \\ndays.', 'tokens': ['•', 'Throw', 'away', 'HUMIRA', 'kept', 'room', 'temperature', 'used', 'within', '14', 'days', '.'], 'lemmatized': ['•', 'Throw', 'away', 'HUMIRA', 'kept', 'room', 'temperature', 'used', 'within', '14', 'day', '.'], 'stemmed': ['•', 'throw', 'away', 'humira', 'kept', 'room', 'temperatur', 'use', 'within', '14', 'day', '.'], 'dependencies': [('•', 'npadvmod'), ('throw', 'csubj'), ('away', 'prt'), ('humira', 'dobj'), ('kept', 'ROOT'), ('room', 'compound'), ('temperatur', 'compound'), ('use', 'dobj'), ('within', 'prep'), ('14', 'nummod'), ('day', 'pobj'), ('.', 'punct')]}, {'original_sentence': '• Record the date you first remove HUMIRA from the refrigerator in the spaces provided on \\nthe carton and dose tray.', 'tokens': ['•', 'Record', 'date', 'first', 'remove', 'HUMIRA', 'refrigerator', 'spaces', 'provided', 'carton', 'dose', 'tray', '.'], 'lemmatized': ['•', 'Record', 'date', 'first', 'remove', 'HUMIRA', 'refrigerator', 'space', 'provided', 'carton', 'dose', 'tray', '.'], 'stemmed': ['•', 'record', 'date', 'first', 'remov', 'humira', 'refriger', 'space', 'provid', 'carton', 'dose', 'tray', '.'], 'dependencies': [('•', 'nummod'), ('record', 'compound'), ('date', 'compound'), ('first', 'amod'), ('remov', 'compound'), ('humira', 'compound'), ('refriger', 'compound'), ('space', 'compound'), ('provid', 'compound'), ('carton', 'compound'), ('dose', 'compound'), ('tray', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• Do not store HUMIRA in extreme heat or cold.', 'tokens': ['•', 'store', 'HUMIRA', 'extreme', 'heat', 'cold', '.'], 'lemmatized': ['•', 'store', 'HUMIRA', 'extreme', 'heat', 'cold', '.'], 'stemmed': ['•', 'store', 'humira', 'extrem', 'heat', 'cold', '.'], 'dependencies': [('•', 'nummod'), ('store', 'compound'), ('humira', 'compound'), ('extrem', 'compound'), ('heat', 'compound'), ('cold', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• Do not use a Pen if the liquid is cloudy, discolored, or has flakes or particles in it.', 'tokens': ['•', 'use', 'Pen', 'liquid', 'cloudy', ',', 'discolored', ',', 'flakes', 'particles', '.'], 'lemmatized': ['•', 'use', 'Pen', 'liquid', 'cloudy', ',', 'discolored', ',', 'flake', 'particle', '.'], 'stemmed': ['•', 'use', 'pen', 'liquid', 'cloudi', ',', 'discolor', ',', 'flake', 'particl', '.'], 'dependencies': [('•', 'meta'), ('use', 'ROOT'), ('pen', 'compound'), ('liquid', 'compound'), ('cloudi', 'dobj'), (',', 'punct'), ('discolor', 'nmod'), (',', 'punct'), ('flake', 'compound'), ('particl', 'appos'), ('.', 'punct')]}, {'original_sentence': '• Do not drop or crush HUMIRA.', 'tokens': ['•', 'drop', 'crush', 'HUMIRA', '.'], 'lemmatized': ['•', 'drop', 'crush', 'HUMIRA', '.'], 'stemmed': ['•', 'drop', 'crush', 'humira', '.'], 'dependencies': [('•', 'nummod'), ('drop', 'compound'), ('crush', 'compound'), ('humira', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• Keep HUMIRA, injection supplies, and all other medicines out of the reach of children.', 'tokens': ['•', 'Keep', 'HUMIRA', ',', 'injection', 'supplies', ',', 'medicines', 'reach', 'children', '.'], 'lemmatized': ['•', 'Keep', 'HUMIRA', ',', 'injection', 'supply', ',', 'medicine', 'reach', 'child', '.'], 'stemmed': ['•', 'keep', 'humira', ',', 'inject', 'suppli', ',', 'medicin', 'reach', 'child', '.'], 'dependencies': [('•', 'meta'), ('keep', 'advcl'), ('humira', 'dobj'), (',', 'punct'), ('inject', 'compound'), ('suppli', 'conj'), (',', 'punct'), ('medicin', 'nsubj'), ('reach', 'ROOT'), ('child', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'This Instructions for Use has been approved by the U.S. Food and Drug Administration.', 'tokens': ['Instructions', 'Use', 'approved', 'U.S.', 'Food', 'Drug', 'Administration', '.'], 'lemmatized': ['Instructions', 'Use', 'approved', 'U.S.', 'Food', 'Drug', 'Administration', '.'], 'stemmed': ['instruct', 'use', 'approv', 'u.s.', 'food', 'drug', 'administr', '.'], 'dependencies': [('instruct', 'ROOT'), ('use', 'dobj'), ('approv', 'compound'), ('u.s', 'compound'), ('.', 'compound'), ('food', 'compound'), ('drug', 'compound'), ('administr', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Manufactured by:  \\nAbbVie Inc.  \\nNorth Chicago, IL 60064, U.S.A.', 'tokens': ['Manufactured', ':', 'AbbVie', 'Inc.', 'North', 'Chicago', ',', 'IL', '60064', ',', 'U.S.A', '.'], 'lemmatized': ['Manufactured', ':', 'AbbVie', 'Inc.', 'North', 'Chicago', ',', 'IL', '60064', ',', 'U.S.A', '.'], 'stemmed': ['manufactur', ':', 'abbvi', 'inc.', 'north', 'chicago', ',', 'il', '60064', ',', 'u.s.a', '.'], 'dependencies': [('manufactur', 'dep'), (':', 'punct'), ('abbvi', 'ROOT'), ('inc', 'compound'), ('.', 'compound'), ('north', 'compound'), ('chicago', 'npadvmod'), (',', 'punct'), ('il', 'npadvmod'), ('60064', 'nummod'), (',', 'punct'), ('u.s.a', 'intj'), ('.', 'punct')]}, {'original_sentence': 'US License Number 1889  \\n20066944 \\nRevised: 02/2021  \\n \\n \\n \\n  \\nINSTRUCTIONS FOR USE \\nHUMIRA® (Hu-MARE-ah) \\n(adalimumab) \\n40 mg/0.4 mL \\nSingle-Dose Pen \\nBefore Injecting: Your healthcare provider should show you how to use HUMIRA before you \\nuse it for the first time.', 'tokens': ['US', 'License', 'Number', '1889', '20066944', 'Revised', ':', '02/2021', 'INSTRUCTIONS', 'USE', 'HUMIRA®', '(', 'Hu-MARE-ah', ')', '(', 'adalimumab', ')', '40', 'mg/0.4', 'mL', 'Single-Dose', 'Pen', 'Injecting', ':', 'healthcare', 'provider', 'show', 'use', 'HUMIRA', 'use', 'first', 'time', '.'], 'lemmatized': ['US', 'License', 'Number', '1889', '20066944', 'Revised', ':', '02/2021', 'INSTRUCTIONS', 'USE', 'HUMIRA®', '(', 'Hu-MARE-ah', ')', '(', 'adalimumab', ')', '40', 'mg/0.4', 'mL', 'Single-Dose', 'Pen', 'Injecting', ':', 'healthcare', 'provider', 'show', 'use', 'HUMIRA', 'use', 'first', 'time', '.'], 'stemmed': ['us', 'licens', 'number', '1889', '20066944', 'revis', ':', '02/2021', 'instruct', 'use', 'humira®', '(', 'hu-mare-ah', ')', '(', 'adalimumab', ')', '40', 'mg/0.4', 'ml', 'single-dos', 'pen', 'inject', ':', 'healthcar', 'provid', 'show', 'use', 'humira', 'use', 'first', 'time', '.'], 'dependencies': [('us', 'compound'), ('licens', 'compound'), ('number', 'dep'), ('1889', 'nummod'), ('20066944', 'nummod'), ('revis', 'nummod'), (':', 'punct'), ('02/2021', 'compound'), ('instruct', 'nsubj'), ('use', 'ROOT'), ('humira', 'compound'), ('®', 'dobj'), ('(', 'punct'), ('hu', 'appos'), ('-', 'punct'), ('mare', 'npadvmod'), ('-', 'punct'), ('ah', 'intj'), (')', 'punct'), ('(', 'punct'), ('adalimumab', 'ROOT'), (')', 'punct'), ('40', 'nummod'), ('mg/0.4', 'punct'), ('ml', 'nmod'), ('single', 'amod'), ('-', 'punct'), ('dos', 'compound'), ('pen', 'compound'), ('inject', 'dep'), (':', 'punct'), ('healthcar', 'compound'), ('provid', 'compound'), ('show', 'nsubj'), ('use', 'ROOT'), ('humira', 'dobj'), ('use', 'dobj'), ('first', 'amod'), ('time', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Call your healthcare provider or 1-800-4HUMIRA (1-800-448-6472) if \\nyou need help.', 'tokens': ['Call', 'healthcare', 'provider', '1-800-4HUMIRA', '(', '1-800-448-6472', ')', 'need', 'help', '.'], 'lemmatized': ['Call', 'healthcare', 'provider', '1-800-4HUMIRA', '(', '1-800-448-6472', ')', 'need', 'help', '.'], 'stemmed': ['call', 'healthcar', 'provid', '1-800-4humira', '(', '1-800-448-6472', ')', 'need', 'help', '.'], 'dependencies': [('call', 'ROOT'), ('healthcar', 'compound'), ('provid', 'dobj'), ('1', 'npadvmod'), ('-', 'punct'), ('800', 'dobj'), ('-', 'punct'), ('4humira', 'dobj'), ('(', 'punct'), ('1', 'appos'), ('-', 'punct'), ('800', 'prep'), ('-', 'punct'), ('448', 'nummod'), ('-', 'punct'), ('6472', 'appos'), (')', 'punct'), ('need', 'conj'), ('help', 'dobj'), ('.', 'punct')]}], 'text': '• Do not freeze HUMIRA. Do not use HUMIRA if frozen, even if it has been thawed.  \\n• Refrigerated HUMIRA may be used until the expiration date printed on the HUMIRA carton, \\ndose tray or Pen. Do not use HUMIRA after the expiration date.  \\n• If needed, for example when you are traveling, you may also store HUMIRA at room \\ntemperature up to 77°F (25°C) for up to 14 days. Store HUMIRA in the original carton until \\nuse to protect it from light.  \\n• Throw away HUMIRA if it has been kept at room temperature and not been used within 14 \\ndays.  \\n• Record the date you first remove HUMIRA from the refrigerator in the spaces provided on \\nthe carton and dose tray. \\n• Do not store HUMIRA in extreme heat or cold. \\n• Do not use a Pen if the liquid is cloudy, discolored, or has flakes or particles in it. \\n• Do not drop or crush HUMIRA. \\n• Keep HUMIRA, injection supplies, and all other medicines out of the reach of children. \\n  \\nThis Instructions for Use has been approved by the U.S. Food and Drug Administration.  \\nManufactured by:  \\nAbbVie Inc.  \\nNorth Chicago, IL 60064, U.S.A.  \\nUS License Number 1889  \\n20066944 \\nRevised: 02/2021  \\n \\n \\n \\n  \\nINSTRUCTIONS FOR USE \\nHUMIRA® (Hu-MARE-ah) \\n(adalimumab) \\n40 mg/0.4 mL \\nSingle-Dose Pen \\nBefore Injecting: Your healthcare provider should show you how to use HUMIRA before you \\nuse it for the first time. Call your healthcare provider or 1-800-4HUMIRA (1-800-448-6472) if \\nyou need help. \\n'}, 'page_char_count': 1433, 'page_word_count': 246, 'sentences': ['• Do not freeze HUMIRA.', 'Do not use HUMIRA if frozen, even if it has been thawed.', ' \\n• Refrigerated HUMIRA may be used until the expiration date printed on the HUMIRA carton, \\ndose tray or Pen.', 'Do not use HUMIRA after the expiration date.', ' \\n• If needed, for example when you are traveling, you may also store HUMIRA at room \\ntemperature up to 77°F (25°C) for up to 14 days.', 'Store HUMIRA in the original carton until \\nuse to protect it from light.', ' \\n• Throw away HUMIRA if it has been kept at room temperature and not been used within 14 \\ndays.', ' \\n• Record the date you first remove HUMIRA from the refrigerator in the spaces provided on \\nthe carton and dose tray.', '\\n• Do not store HUMIRA in extreme heat or cold.', '\\n• Do not use a Pen if the liquid is cloudy, discolored, or has flakes or particles in it.', '\\n• Do not drop or crush HUMIRA.', '\\n• Keep HUMIRA, injection supplies, and all other medicines out of the reach of children.', '\\n  \\nThis Instructions for Use has been approved by the U.S. Food and Drug Administration.', ' \\nManufactured by:  \\nAbbVie Inc.  \\nNorth Chicago, IL 60064, U.S.A.  \\nUS License Number 1889  \\n20066944 \\nRevised: 02/2021  \\n \\n \\n \\n  \\nINSTRUCTIONS FOR USE \\nHUMIRA® (Hu-MARE-ah) \\n(adalimumab) \\n40 mg/0.4 mL \\nSingle-Dose Pen \\nBefore Injecting: Your healthcare provider should show you how to use HUMIRA before you \\nuse it for the first time.', 'Call your healthcare provider or 1-800-4HUMIRA (1-800-448-6472) if \\nyou need help.', '\\n'], 'page_sentence_count_spacy': 16}\n",
            "{'page_number': 81, 'text': 'Important Information You Need to Know Before Injecting HUMIRA \\nDo not use the Pen and call your healthcare provider or pharmacist if:  \\n• Liquid is cloudy, discolored, or has flakes \\nor particles in it \\n• Expiration date has passed \\n• Liquid has been frozen (even if thawed) or \\nleft in direct sunlight \\n• The Pen has been dropped or crushed \\nKeep the caps on until right before your injection. \\nHow should I store HUMIRA? \\n• Store HUMIRA in the refrigerator between \\n36°F to 46°F (2°C to 8°C). \\n• Store HUMIRA in the original carton until \\nuse to protect it from light. \\n• Do not freeze \\n• Refrigerated HUMIRA may be used until \\nthe expiration date printed on the HUMIRA \\ncarton, dose tray or Pen. \\n• If needed, for example when you are \\ntraveling, you may also store HUMIRA at \\nroom temperature up to 77°F (25°C) for up \\nto 14 days.  \\n• Throw away HUMIRA if it has been kept at \\nroom temperature and not used within 14 \\ndays.  \\n• Record the date you first remove HUMIRA \\nfrom the refrigerator in the spaces provided \\non the carton and dose tray. \\n• Do not store HUMIRA in extreme heat or \\ncold.  \\n \\nKeep HUMIRA, injection supplies, and all other medicines out of reach of children. \\n \\nRead Instructions on All Pages Before Using the HUMIRA Pen \\n', 'processed_text': {'sentences': [{'original_sentence': 'Important Information You Need to Know Before Injecting HUMIRA \\nDo not use the Pen and call your healthcare provider or pharmacist if:  \\n• Liquid is cloudy, discolored, or has flakes \\nor particles in it \\n• Expiration date has passed \\n• Liquid has been frozen (even if thawed) or \\nleft in direct sunlight \\n• The Pen has been dropped or crushed \\nKeep the caps on until right before your injection.', 'tokens': ['Important', 'Information', 'Need', 'Know', 'Injecting', 'HUMIRA', 'use', 'Pen', 'call', 'healthcare', 'provider', 'pharmacist', ':', '•', 'Liquid', 'cloudy', ',', 'discolored', ',', 'flakes', 'particles', '•', 'Expiration', 'date', 'passed', '•', 'Liquid', 'frozen', '(', 'even', 'thawed', ')', 'left', 'direct', 'sunlight', '•', 'Pen', 'dropped', 'crushed', 'Keep', 'caps', 'right', 'injection', '.'], 'lemmatized': ['Important', 'Information', 'Need', 'Know', 'Injecting', 'HUMIRA', 'use', 'Pen', 'call', 'healthcare', 'provider', 'pharmacist', ':', '•', 'Liquid', 'cloudy', ',', 'discolored', ',', 'flake', 'particle', '•', 'Expiration', 'date', 'passed', '•', 'Liquid', 'frozen', '(', 'even', 'thawed', ')', 'left', 'direct', 'sunlight', '•', 'Pen', 'dropped', 'crushed', 'Keep', 'cap', 'right', 'injection', '.'], 'stemmed': ['import', 'inform', 'need', 'know', 'inject', 'humira', 'use', 'pen', 'call', 'healthcar', 'provid', 'pharmacist', ':', '•', 'liquid', 'cloudi', ',', 'discolor', ',', 'flake', 'particl', '•', 'expir', 'date', 'pass', '•', 'liquid', 'frozen', '(', 'even', 'thaw', ')', 'left', 'direct', 'sunlight', '•', 'pen', 'drop', 'crush', 'keep', 'cap', 'right', 'inject', '.'], 'dependencies': [('import', 'compound'), ('inform', 'nsubj'), ('need', 'nsubj'), ('know', 'parataxis'), ('inject', 'compound'), ('humira', 'nsubj'), ('use', 'dep'), ('pen', 'compound'), ('call', 'compound'), ('healthcar', 'compound'), ('provid', 'compound'), ('pharmacist', 'dobj'), (':', 'punct'), ('•', 'nummod'), ('liquid', 'compound'), ('cloudi', 'nmod'), (',', 'punct'), ('discolor', 'conj'), (',', 'punct'), ('flake', 'compound'), ('particl', 'conj'), ('•', 'punct'), ('expir', 'compound'), ('date', 'nsubj'), ('pass', 'ROOT'), ('•', 'punct'), ('liquid', 'amod'), ('frozen', 'amod'), ('(', 'punct'), ('even', 'advmod'), ('thaw', 'dobj'), (')', 'punct'), ('left', 'ROOT'), ('direct', 'amod'), ('sunlight', 'dobj'), ('•', 'npadvmod'), ('pen', 'compound'), ('drop', 'compound'), ('crush', 'nsubj'), ('keep', 'conj'), ('cap', 'dobj'), ('right', 'advmod'), ('inject', 'oprd'), ('.', 'punct')]}, {'original_sentence': 'How should I store HUMIRA?', 'tokens': ['store', 'HUMIRA', '?'], 'lemmatized': ['store', 'HUMIRA', '?'], 'stemmed': ['store', 'humira', '?'], 'dependencies': [('store', 'compound'), ('humira', 'ROOT'), ('?', 'punct')]}, {'original_sentence': '• Store HUMIRA in the refrigerator between \\n36°F to 46°F (2°C to 8°C).', 'tokens': ['•', 'Store', 'HUMIRA', 'refrigerator', '36°F', '46°F', '(', '2°C', '8°C', ')', '.'], 'lemmatized': ['•', 'Store', 'HUMIRA', 'refrigerator', '36°F', '46°F', '(', '2°C', '8°C', ')', '.'], 'stemmed': ['•', 'store', 'humira', 'refriger', '36°f', '46°f', '(', '2°c', '8°c', ')', '.'], 'dependencies': [('•', 'nummod'), ('store', 'compound'), ('humira', 'compound'), ('refriger', 'ROOT'), ('36', 'nummod'), ('°', 'npadvmod'), ('f', 'npadvmod'), ('46', 'nummod'), ('°', 'npadvmod'), ('f', 'npadvmod'), ('(', 'punct'), ('2', 'appos'), ('°', 'cc'), ('c', 'npadvmod'), ('8', 'npadvmod'), ('°', 'nummod'), ('c', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': '• Store HUMIRA in the original carton until \\nuse to protect it from light.', 'tokens': ['•', 'Store', 'HUMIRA', 'original', 'carton', 'use', 'protect', 'light', '.'], 'lemmatized': ['•', 'Store', 'HUMIRA', 'original', 'carton', 'use', 'protect', 'light', '.'], 'stemmed': ['•', 'store', 'humira', 'origin', 'carton', 'use', 'protect', 'light', '.'], 'dependencies': [('•', 'nummod'), ('store', 'compound'), ('humira', 'compound'), ('origin', 'compound'), ('carton', 'compound'), ('use', 'compound'), ('protect', 'compound'), ('light', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• Do not freeze \\n• Refrigerated HUMIRA may be used until \\nthe expiration date printed on the HUMIRA \\ncarton, dose tray or Pen.', 'tokens': ['•', 'freeze', '•', 'Refrigerated', 'HUMIRA', 'may', 'used', 'expiration', 'date', 'printed', 'HUMIRA', 'carton', ',', 'dose', 'tray', 'Pen', '.'], 'lemmatized': ['•', 'freeze', '•', 'Refrigerated', 'HUMIRA', 'may', 'used', 'expiration', 'date', 'printed', 'HUMIRA', 'carton', ',', 'dose', 'tray', 'Pen', '.'], 'stemmed': ['•', 'freez', '•', 'refriger', 'humira', 'may', 'use', 'expir', 'date', 'print', 'humira', 'carton', ',', 'dose', 'tray', 'pen', '.'], 'dependencies': [('•', 'meta'), ('freez', 'compound'), ('•', 'nummod'), ('refriger', 'amod'), ('humira', 'nsubj'), ('may', 'aux'), ('use', 'ROOT'), ('expir', 'compound'), ('date', 'compound'), ('print', 'compound'), ('humira', 'compound'), ('carton', 'dobj'), (',', 'punct'), ('dose', 'xcomp'), ('tray', 'compound'), ('pen', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• If needed, for example when you are \\ntraveling, you may also store HUMIRA at \\nroom temperature up to 77°F (25°C) for up \\nto 14 days.', 'tokens': ['•', 'needed', ',', 'example', 'traveling', ',', 'may', 'also', 'store', 'HUMIRA', 'room', 'temperature', '77°F', '(', '25°C', ')', '14', 'days', '.'], 'lemmatized': ['•', 'needed', ',', 'example', 'traveling', ',', 'may', 'also', 'store', 'HUMIRA', 'room', 'temperature', '77°F', '(', '25°C', ')', '14', 'day', '.'], 'stemmed': ['•', 'need', ',', 'exampl', 'travel', ',', 'may', 'also', 'store', 'humira', 'room', 'temperatur', '77°f', '(', '25°c', ')', '14', 'day', '.'], 'dependencies': [('•', 'nummod'), ('need', 'advcl'), (',', 'punct'), ('exampl', 'nsubj'), ('travel', 'meta'), (',', 'punct'), ('may', 'aux'), ('also', 'advmod'), ('store', 'ROOT'), ('humira', 'compound'), ('room', 'dobj'), ('temperatur', 'nmod'), ('77', 'nummod'), ('°', 'npadvmod'), ('f', 'dobj'), ('(', 'punct'), ('25', 'nummod'), ('°', 'appos'), ('c', 'punct'), (')', 'punct'), ('14', 'nummod'), ('day', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': '• Throw away HUMIRA if it has been kept at \\nroom temperature and not used within 14 \\ndays.', 'tokens': ['•', 'Throw', 'away', 'HUMIRA', 'kept', 'room', 'temperature', 'used', 'within', '14', 'days', '.'], 'lemmatized': ['•', 'Throw', 'away', 'HUMIRA', 'kept', 'room', 'temperature', 'used', 'within', '14', 'day', '.'], 'stemmed': ['•', 'throw', 'away', 'humira', 'kept', 'room', 'temperatur', 'use', 'within', '14', 'day', '.'], 'dependencies': [('•', 'npadvmod'), ('throw', 'csubj'), ('away', 'prt'), ('humira', 'dobj'), ('kept', 'ROOT'), ('room', 'compound'), ('temperatur', 'compound'), ('use', 'dobj'), ('within', 'prep'), ('14', 'nummod'), ('day', 'pobj'), ('.', 'punct')]}, {'original_sentence': '• Record the date you first remove HUMIRA \\nfrom the refrigerator in the spaces provided \\non the carton and dose tray.', 'tokens': ['•', 'Record', 'date', 'first', 'remove', 'HUMIRA', 'refrigerator', 'spaces', 'provided', 'carton', 'dose', 'tray', '.'], 'lemmatized': ['•', 'Record', 'date', 'first', 'remove', 'HUMIRA', 'refrigerator', 'space', 'provided', 'carton', 'dose', 'tray', '.'], 'stemmed': ['•', 'record', 'date', 'first', 'remov', 'humira', 'refriger', 'space', 'provid', 'carton', 'dose', 'tray', '.'], 'dependencies': [('•', 'nummod'), ('record', 'compound'), ('date', 'compound'), ('first', 'amod'), ('remov', 'compound'), ('humira', 'compound'), ('refriger', 'compound'), ('space', 'compound'), ('provid', 'compound'), ('carton', 'compound'), ('dose', 'compound'), ('tray', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• Do not store HUMIRA in extreme heat or \\ncold.', 'tokens': ['•', 'store', 'HUMIRA', 'extreme', 'heat', 'cold', '.'], 'lemmatized': ['•', 'store', 'HUMIRA', 'extreme', 'heat', 'cold', '.'], 'stemmed': ['•', 'store', 'humira', 'extrem', 'heat', 'cold', '.'], 'dependencies': [('•', 'nummod'), ('store', 'compound'), ('humira', 'compound'), ('extrem', 'compound'), ('heat', 'compound'), ('cold', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Keep HUMIRA, injection supplies, and all other medicines out of reach of children.', 'tokens': ['Keep', 'HUMIRA', ',', 'injection', 'supplies', ',', 'medicines', 'reach', 'children', '.'], 'lemmatized': ['Keep', 'HUMIRA', ',', 'injection', 'supply', ',', 'medicine', 'reach', 'child', '.'], 'stemmed': ['keep', 'humira', ',', 'inject', 'suppli', ',', 'medicin', 'reach', 'child', '.'], 'dependencies': [('keep', 'advcl'), ('humira', 'dobj'), (',', 'punct'), ('inject', 'compound'), ('suppli', 'conj'), (',', 'punct'), ('medicin', 'nsubj'), ('reach', 'ROOT'), ('child', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Read Instructions on All Pages Before Using the HUMIRA Pen', 'tokens': ['Read', 'Instructions', 'Pages', 'Using', 'HUMIRA', 'Pen'], 'lemmatized': ['Read', 'Instructions', 'Pages', 'Using', 'HUMIRA', 'Pen'], 'stemmed': ['read', 'instruct', 'page', 'use', 'humira', 'pen'], 'dependencies': [('read', 'ROOT'), ('instruct', 'compound'), ('page', 'compound'), ('use', 'ccomp'), ('humira', 'compound'), ('pen', 'dobj')]}], 'text': 'Important Information You Need to Know Before Injecting HUMIRA \\nDo not use the Pen and call your healthcare provider or pharmacist if:  \\n• Liquid is cloudy, discolored, or has flakes \\nor particles in it \\n• Expiration date has passed \\n• Liquid has been frozen (even if thawed) or \\nleft in direct sunlight \\n• The Pen has been dropped or crushed \\nKeep the caps on until right before your injection. \\nHow should I store HUMIRA? \\n• Store HUMIRA in the refrigerator between \\n36°F to 46°F (2°C to 8°C). \\n• Store HUMIRA in the original carton until \\nuse to protect it from light. \\n• Do not freeze \\n• Refrigerated HUMIRA may be used until \\nthe expiration date printed on the HUMIRA \\ncarton, dose tray or Pen. \\n• If needed, for example when you are \\ntraveling, you may also store HUMIRA at \\nroom temperature up to 77°F (25°C) for up \\nto 14 days.  \\n• Throw away HUMIRA if it has been kept at \\nroom temperature and not used within 14 \\ndays.  \\n• Record the date you first remove HUMIRA \\nfrom the refrigerator in the spaces provided \\non the carton and dose tray. \\n• Do not store HUMIRA in extreme heat or \\ncold.  \\n \\nKeep HUMIRA, injection supplies, and all other medicines out of reach of children. \\n \\nRead Instructions on All Pages Before Using the HUMIRA Pen \\n'}, 'page_char_count': 1248, 'page_word_count': 222, 'sentences': ['Important Information You Need to Know Before Injecting HUMIRA \\nDo not use the Pen and call your healthcare provider or pharmacist if:  \\n• Liquid is cloudy, discolored, or has flakes \\nor particles in it \\n• Expiration date has passed \\n• Liquid has been frozen (even if thawed) or \\nleft in direct sunlight \\n• The Pen has been dropped or crushed \\nKeep the caps on until right before your injection.', '\\nHow should I store HUMIRA?', '\\n• Store HUMIRA in the refrigerator between \\n36°F to 46°F (2°C to 8°C).', '\\n• Store HUMIRA in the original carton until \\nuse to protect it from light.', '\\n• Do not freeze \\n• Refrigerated HUMIRA may be used until \\nthe expiration date printed on the HUMIRA \\ncarton, dose tray or Pen.', '\\n• If needed, for example when you are \\ntraveling, you may also store HUMIRA at \\nroom temperature up to 77°F (25°C) for up \\nto 14 days.', ' \\n• Throw away HUMIRA if it has been kept at \\nroom temperature and not used within 14 \\ndays.', ' \\n• Record the date you first remove HUMIRA \\nfrom the refrigerator in the spaces provided \\non the carton and dose tray.', '\\n• Do not store HUMIRA in extreme heat or \\ncold.', ' \\n \\nKeep HUMIRA, injection supplies, and all other medicines out of reach of children.', '\\n \\nRead Instructions on All Pages Before Using the HUMIRA Pen \\n'], 'page_sentence_count_spacy': 11}\n",
            "{'page_number': 82, 'text': ' \\n   \\n \\nTake HUMIRA out of the refrigerator.  \\nLeave HUMIRA at room temperature for 15 to \\n30 minutes before injecting.  \\n• Do not remove the Gray Cap (Cap #1) or \\nPlum-colored Cap (Cap #2) while allowing \\nHUMIRA to reach room temperature  \\n• Do not warm HUMIRA in any other way. For \\nexample, do not warm it in a microwave or \\nin hot water.  \\n• Do not use the Pen if liquid has been frozen \\n(even if thawed)  \\n \\n   \\n \\nCheck expiration date on the Pen label. Do not \\nuse the Pen if expiration date has passed.  \\nPlace the following on a clean, flat surface:  \\n• 1 single-dose Pen and alcohol swab \\n• 1 cotton ball or gauze pad (not included) \\n• Puncture-resistant sharps disposal container \\n(not included). See Step 9 at the end of this \\nInstructions for Use for instructions on how \\nto throw away (dispose of) your HUMIRA \\nPen  \\nWash and dry your hands.  \\n \\n   \\n \\nChoose an injection site:  \\n• On the front of your thighs or \\n• Your abdomen (belly) at least 2 inches from \\nyour navel (belly button)  \\n• Different from your last injection site \\nWipe the injection site in a circular motion with \\nthe alcohol swab.  \\n• Do not inject through clothes  \\n• Do not inject into skin that is sore, bruised, \\nred, hard, scarred, has stretch marks, or \\nareas with psoriasis plaques  \\n', 'processed_text': {'sentences': [{'original_sentence': ' \\n   \\n \\nTake HUMIRA out of the refrigerator.', 'tokens': ['Take', 'HUMIRA', 'refrigerator', '.'], 'lemmatized': ['Take', 'HUMIRA', 'refrigerator', '.'], 'stemmed': ['take', 'humira', 'refriger', '.'], 'dependencies': [('take', 'ROOT'), ('humira', 'compound'), ('refriger', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Leave HUMIRA at room temperature for 15 to \\n30 minutes before injecting.', 'tokens': ['Leave', 'HUMIRA', 'room', 'temperature', '15', '30', 'minutes', 'injecting', '.'], 'lemmatized': ['Leave', 'HUMIRA', 'room', 'temperature', '15', '30', 'minute', 'injecting', '.'], 'stemmed': ['leav', 'humira', 'room', 'temperatur', '15', '30', 'minut', 'inject', '.'], 'dependencies': [('leav', 'amod'), ('humira', 'compound'), ('room', 'compound'), ('temperatur', 'ROOT'), ('15', 'nummod'), ('30', 'nummod'), ('minut', 'compound'), ('inject', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• Do not remove the Gray Cap (Cap #1) or \\nPlum-colored Cap (Cap #2) while allowing \\nHUMIRA to reach room temperature  \\n• Do not warm HUMIRA in any other way.', 'tokens': ['•', 'remove', 'Gray', 'Cap', '(', 'Cap', '#', '1', ')', 'Plum-colored', 'Cap', '(', 'Cap', '#', '2', ')', 'allowing', 'HUMIRA', 'reach', 'room', 'temperature', '•', 'warm', 'HUMIRA', 'way', '.'], 'lemmatized': ['•', 'remove', 'Gray', 'Cap', '(', 'Cap', '#', '1', ')', 'Plum-colored', 'Cap', '(', 'Cap', '#', '2', ')', 'allowing', 'HUMIRA', 'reach', 'room', 'temperature', '•', 'warm', 'HUMIRA', 'way', '.'], 'stemmed': ['•', 'remov', 'gray', 'cap', '(', 'cap', '#', '1', ')', 'plum-color', 'cap', '(', 'cap', '#', '2', ')', 'allow', 'humira', 'reach', 'room', 'temperatur', '•', 'warm', 'humira', 'way', '.'], 'dependencies': [('•', 'nummod'), ('remov', 'amod'), ('gray', 'amod'), ('cap', 'nsubj'), ('(', 'punct'), ('cap', 'parataxis'), ('#', 'npadvmod'), ('1', 'nummod'), (')', 'punct'), ('plum', 'compound'), ('-', 'punct'), ('color', 'compound'), ('cap', 'appos'), ('(', 'punct'), ('cap', 'parataxis'), ('#', 'nmod'), ('2', 'nummod'), (')', 'punct'), ('allow', 'ROOT'), ('humira', 'nsubj'), ('reach', 'ccomp'), ('room', 'dobj'), ('temperatur', 'advmod'), ('•', 'appos'), ('warm', 'amod'), ('humira', 'compound'), ('way', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'For \\nexample, do not warm it in a microwave or \\nin hot water.', 'tokens': ['example', ',', 'warm', 'microwave', 'hot', 'water', '.'], 'lemmatized': ['example', ',', 'warm', 'microwave', 'hot', 'water', '.'], 'stemmed': ['exampl', ',', 'warm', 'microwav', 'hot', 'water', '.'], 'dependencies': [('exampl', 'ROOT'), (',', 'punct'), ('warm', 'amod'), ('microwav', 'amod'), ('hot', 'amod'), ('water', 'appos'), ('.', 'punct')]}, {'original_sentence': '• Do not use the Pen if liquid has been frozen \\n(even if thawed)  \\n \\n   \\n \\nCheck expiration date on the Pen label.', 'tokens': ['•', 'use', 'Pen', 'liquid', 'frozen', '(', 'even', 'thawed', ')', 'Check', 'expiration', 'date', 'Pen', 'label', '.'], 'lemmatized': ['•', 'use', 'Pen', 'liquid', 'frozen', '(', 'even', 'thawed', ')', 'Check', 'expiration', 'date', 'Pen', 'label', '.'], 'stemmed': ['•', 'use', 'pen', 'liquid', 'frozen', '(', 'even', 'thaw', ')', 'check', 'expir', 'date', 'pen', 'label', '.'], 'dependencies': [('•', 'meta'), ('use', 'ROOT'), ('pen', 'compound'), ('liquid', 'dobj'), ('frozen', 'amod'), ('(', 'punct'), ('even', 'advmod'), ('thaw', 'npadvmod'), (')', 'punct'), ('check', 'ROOT'), ('expir', 'compound'), ('date', 'compound'), ('pen', 'compound'), ('label', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Do not \\nuse the Pen if expiration date has passed.', 'tokens': ['use', 'Pen', 'expiration', 'date', 'passed', '.'], 'lemmatized': ['use', 'Pen', 'expiration', 'date', 'passed', '.'], 'stemmed': ['use', 'pen', 'expir', 'date', 'pass', '.'], 'dependencies': [('use', 'ROOT'), ('pen', 'compound'), ('expir', 'compound'), ('date', 'compound'), ('pass', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Place the following on a clean, flat surface:  \\n• 1 single-dose Pen and alcohol swab \\n• 1 cotton ball or gauze pad (not included) \\n• Puncture-resistant sharps disposal container \\n(not included).', 'tokens': ['Place', 'following', 'clean', ',', 'flat', 'surface', ':', '•', '1', 'single-dose', 'Pen', 'alcohol', 'swab', '•', '1', 'cotton', 'ball', 'gauze', 'pad', '(', 'included', ')', '•', 'Puncture-resistant', 'sharps', 'disposal', 'container', '(', 'included', ')', '.'], 'lemmatized': ['Place', 'following', 'clean', ',', 'flat', 'surface', ':', '•', '1', 'single-dose', 'Pen', 'alcohol', 'swab', '•', '1', 'cotton', 'ball', 'gauze', 'pad', '(', 'included', ')', '•', 'Puncture-resistant', 'sharp', 'disposal', 'container', '(', 'included', ')', '.'], 'stemmed': ['place', 'follow', 'clean', ',', 'flat', 'surfac', ':', '•', '1', 'single-dos', 'pen', 'alcohol', 'swab', '•', '1', 'cotton', 'ball', 'gauz', 'pad', '(', 'includ', ')', '•', 'puncture-resist', 'sharp', 'dispos', 'contain', '(', 'includ', ')', '.'], 'dependencies': [('place', 'nsubj'), ('follow', 'ROOT'), ('clean', 'amod'), (',', 'punct'), ('flat', 'amod'), ('surfac', 'dobj'), (':', 'punct'), ('•', 'nummod'), ('1', 'nummod'), ('single', 'amod'), ('-', 'punct'), ('dos', 'compound'), ('pen', 'compound'), ('alcohol', 'compound'), ('swab', 'nmod'), ('•', 'case'), ('1', 'nummod'), ('cotton', 'compound'), ('ball', 'compound'), ('gauz', 'compound'), ('pad', 'nsubj'), ('(', 'punct'), ('includ', 'nmod'), (')', 'punct'), ('•', 'appos'), ('puncture', 'amod'), ('-', 'punct'), ('resist', 'acl'), ('sharp', 'amod'), ('dispos', 'dobj'), ('contain', 'conj'), ('(', 'punct'), ('includ', 'dobj'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'See Step 9 at the end of this \\nInstructions for Use for instructions on how \\nto throw away (dispose of) your HUMIRA \\nPen  \\nWash and dry your hands.', 'tokens': ['See', 'Step', '9', 'end', 'Instructions', 'Use', 'instructions', 'throw', 'away', '(', 'dispose', ')', 'HUMIRA', 'Pen', 'Wash', 'dry', 'hands', '.'], 'lemmatized': ['See', 'Step', '9', 'end', 'Instructions', 'Use', 'instruction', 'throw', 'away', '(', 'dispose', ')', 'HUMIRA', 'Pen', 'Wash', 'dry', 'hand', '.'], 'stemmed': ['see', 'step', '9', 'end', 'instruct', 'use', 'instruct', 'throw', 'away', '(', 'dispos', ')', 'humira', 'pen', 'wash', 'dri', 'hand', '.'], 'dependencies': [('see', 'ROOT'), ('step', 'nmod'), ('9', 'nummod'), ('end', 'compound'), ('instruct', 'compound'), ('use', 'compound'), ('instruct', 'nsubj'), ('throw', 'xcomp'), ('away', 'advmod'), ('(', 'punct'), ('dispos', 'dep'), (')', 'punct'), ('humira', 'compound'), ('pen', 'nsubj'), ('wash', 'ccomp'), ('dri', 'compound'), ('hand', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Choose an injection site:  \\n• On the front of your thighs or \\n• Your abdomen (belly) at least 2 inches from \\nyour navel (belly button)  \\n• Different from your last injection site \\nWipe the injection site in a circular motion with \\nthe alcohol swab.', 'tokens': ['Choose', 'injection', 'site', ':', '•', 'front', 'thighs', '•', 'abdomen', '(', 'belly', ')', 'least', '2', 'inches', 'navel', '(', 'belly', 'button', ')', '•', 'Different', 'last', 'injection', 'site', 'Wipe', 'injection', 'site', 'circular', 'motion', 'alcohol', 'swab', '.'], 'lemmatized': ['Choose', 'injection', 'site', ':', '•', 'front', 'thigh', '•', 'abdomen', '(', 'belly', ')', 'least', '2', 'inch', 'navel', '(', 'belly', 'button', ')', '•', 'Different', 'last', 'injection', 'site', 'Wipe', 'injection', 'site', 'circular', 'motion', 'alcohol', 'swab', '.'], 'stemmed': ['choos', 'inject', 'site', ':', '•', 'front', 'thigh', '•', 'abdomen', '(', 'belli', ')', 'least', '2', 'inch', 'navel', '(', 'belli', 'button', ')', '•', 'differ', 'last', 'inject', 'site', 'wipe', 'inject', 'site', 'circular', 'motion', 'alcohol', 'swab', '.'], 'dependencies': [('choos', 'compound'), ('inject', 'compound'), ('site', 'nsubj'), (':', 'punct'), ('•', 'nummod'), ('front', 'amod'), ('thigh', 'compound'), ('•', 'nummod'), ('abdomen', 'appos'), ('(', 'punct'), ('belli', 'appos'), (')', 'punct'), ('least', 'advmod'), ('2', 'nummod'), ('inch', 'compound'), ('navel', 'conj'), ('(', 'punct'), ('belli', 'compound'), ('button', 'appos'), (')', 'punct'), ('•', 'nummod'), ('differ', 'ROOT'), ('last', 'amod'), ('inject', 'compound'), ('site', 'nmod'), ('wipe', 'nmod'), ('inject', 'nmod'), ('site', 'compound'), ('circular', 'amod'), ('motion', 'compound'), ('alcohol', 'compound'), ('swab', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• Do not inject through clothes  \\n• Do not inject into skin that is sore, bruised, \\nred, hard, scarred, has stretch marks, or \\nareas with psoriasis plaques', 'tokens': ['•', 'inject', 'clothes', '•', 'inject', 'skin', 'sore', ',', 'bruised', ',', 'red', ',', 'hard', ',', 'scarred', ',', 'stretch', 'marks', ',', 'areas', 'psoriasis', 'plaques'], 'lemmatized': ['•', 'inject', 'clothes', '•', 'inject', 'skin', 'sore', ',', 'bruised', ',', 'red', ',', 'hard', ',', 'scarred', ',', 'stretch', 'mark', ',', 'area', 'psoriasis', 'plaque'], 'stemmed': ['•', 'inject', 'cloth', '•', 'inject', 'skin', 'sore', ',', 'bruis', ',', 'red', ',', 'hard', ',', 'scar', ',', 'stretch', 'mark', ',', 'area', 'psoriasi', 'plaqu'], 'dependencies': [('•', 'nummod'), ('inject', 'compound'), ('cloth', 'nmod'), ('•', 'appos'), ('inject', 'amod'), ('skin', 'ROOT'), ('sore', 'amod'), (',', 'punct'), ('bruis', 'conj'), (',', 'punct'), ('red', 'conj'), (',', 'punct'), ('hard', 'conj'), (',', 'punct'), ('scar', 'conj'), (',', 'punct'), ('stretch', 'compound'), ('mark', 'conj'), (',', 'punct'), ('area', 'compound'), ('psoriasi', 'compound'), ('plaqu', 'appos')]}], 'text': ' \\n   \\n \\nTake HUMIRA out of the refrigerator.  \\nLeave HUMIRA at room temperature for 15 to \\n30 minutes before injecting.  \\n• Do not remove the Gray Cap (Cap #1) or \\nPlum-colored Cap (Cap #2) while allowing \\nHUMIRA to reach room temperature  \\n• Do not warm HUMIRA in any other way. For \\nexample, do not warm it in a microwave or \\nin hot water.  \\n• Do not use the Pen if liquid has been frozen \\n(even if thawed)  \\n \\n   \\n \\nCheck expiration date on the Pen label. Do not \\nuse the Pen if expiration date has passed.  \\nPlace the following on a clean, flat surface:  \\n• 1 single-dose Pen and alcohol swab \\n• 1 cotton ball or gauze pad (not included) \\n• Puncture-resistant sharps disposal container \\n(not included). See Step 9 at the end of this \\nInstructions for Use for instructions on how \\nto throw away (dispose of) your HUMIRA \\nPen  \\nWash and dry your hands.  \\n \\n   \\n \\nChoose an injection site:  \\n• On the front of your thighs or \\n• Your abdomen (belly) at least 2 inches from \\nyour navel (belly button)  \\n• Different from your last injection site \\nWipe the injection site in a circular motion with \\nthe alcohol swab.  \\n• Do not inject through clothes  \\n• Do not inject into skin that is sore, bruised, \\nred, hard, scarred, has stretch marks, or \\nareas with psoriasis plaques  \\n'}, 'page_char_count': 1274, 'page_word_count': 222, 'sentences': [' \\n   \\n \\nTake HUMIRA out of the refrigerator.', ' \\nLeave HUMIRA at room temperature for 15 to \\n30 minutes before injecting.', ' \\n• Do not remove the Gray Cap (Cap #1) or \\nPlum-colored Cap (Cap #2) while allowing \\nHUMIRA to reach room temperature  \\n• Do not warm HUMIRA in any other way.', 'For \\nexample, do not warm it in a microwave or \\nin hot water.', ' \\n• Do not use the Pen if liquid has been frozen \\n(even if thawed)  \\n \\n   \\n \\nCheck expiration date on the Pen label.', 'Do not \\nuse the Pen if expiration date has passed.', ' \\nPlace the following on a clean, flat surface:  \\n• 1 single-dose Pen and alcohol swab \\n• 1 cotton ball or gauze pad (not included) \\n• Puncture-resistant sharps disposal container \\n(not included).', 'See Step 9 at the end of this \\nInstructions for Use for instructions on how \\nto throw away (dispose of) your HUMIRA \\nPen  \\nWash and dry your hands.', ' \\n \\n   \\n \\nChoose an injection site:  \\n• On the front of your thighs or \\n• Your abdomen (belly) at least 2 inches from \\nyour navel (belly button)  \\n• Different from your last injection site \\nWipe the injection site in a circular motion with \\nthe alcohol swab.', ' \\n• Do not inject through clothes  \\n• Do not inject into skin that is sore, bruised, \\nred, hard, scarred, has stretch marks, or \\nareas with psoriasis plaques  \\n'], 'page_sentence_count_spacy': 10}\n",
            "{'page_number': 83, 'text': ' \\n   \\n \\nHold the Pen with the Gray Cap #1 facing up. \\nCheck the window.  \\n• It is normal to see 1 or more bubbles in the \\nwindow  \\n• Make sure the liquid is clear and colorless \\n• Do not use the Pen if the liquid is cloudy, \\ndiscolored, or has flakes or particles in it  \\n• Do not use the Pen if it has been dropped or \\ncrushed  \\n \\n   \\n \\nPull the Gray Cap #1 straight off.  \\nThrow the cap away.  \\n• It is normal to see a few drops of liquid come \\nout of the needle  \\nPull the Plum-colored Cap #2 straight off.  \\nThrow the cap away.  \\nTurn the Pen so that the white arrow points \\ntoward the injection site.  \\n \\n   \\n \\nSqueeze the skin at your injection site to make \\na raised area and hold it firmly until the injection \\nis complete.  \\nPoint the white arrow toward the injection site.  \\nPlace the white needle sleeve straight (90° \\nangle) against the injection site.  \\nHold the Pen so that you can see the inspection \\nwindow.  \\nDo not press the plum activator button until you \\nare ready to inject.  \\n', 'processed_text': {'sentences': [{'original_sentence': ' \\n   \\n \\nHold the Pen with the Gray Cap #1 facing up.', 'tokens': ['Hold', 'Pen', 'Gray', 'Cap', '#', '1', 'facing', '.'], 'lemmatized': ['Hold', 'Pen', 'Gray', 'Cap', '#', '1', 'facing', '.'], 'stemmed': ['hold', 'pen', 'gray', 'cap', '#', '1', 'face', '.'], 'dependencies': [('hold', 'ROOT'), ('pen', 'compound'), ('gray', 'amod'), ('cap', 'compound'), ('#', 'nmod'), ('1', 'nummod'), ('face', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Check the window.', 'tokens': ['Check', 'window', '.'], 'lemmatized': ['Check', 'window', '.'], 'stemmed': ['check', 'window', '.'], 'dependencies': [('check', 'ROOT'), ('window', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• It is normal to see 1 or more bubbles in the \\nwindow  \\n• Make sure the liquid is clear and colorless \\n• Do not use the Pen if the liquid is cloudy, \\ndiscolored, or has flakes or particles in it  \\n• Do not use the Pen if it has been dropped or \\ncrushed  \\n \\n   \\n \\nPull the Gray Cap #1 straight off.', 'tokens': ['•', 'normal', 'see', '1', 'bubbles', 'window', '•', 'Make', 'sure', 'liquid', 'clear', 'colorless', '•', 'use', 'Pen', 'liquid', 'cloudy', ',', 'discolored', ',', 'flakes', 'particles', '•', 'use', 'Pen', 'dropped', 'crushed', 'Pull', 'Gray', 'Cap', '#', '1', 'straight', '.'], 'lemmatized': ['•', 'normal', 'see', '1', 'bubble', 'window', '•', 'Make', 'sure', 'liquid', 'clear', 'colorless', '•', 'use', 'Pen', 'liquid', 'cloudy', ',', 'discolored', ',', 'flake', 'particle', '•', 'use', 'Pen', 'dropped', 'crushed', 'Pull', 'Gray', 'Cap', '#', '1', 'straight', '.'], 'stemmed': ['•', 'normal', 'see', '1', 'bubbl', 'window', '•', 'make', 'sure', 'liquid', 'clear', 'colorless', '•', 'use', 'pen', 'liquid', 'cloudi', ',', 'discolor', ',', 'flake', 'particl', '•', 'use', 'pen', 'drop', 'crush', 'pull', 'gray', 'cap', '#', '1', 'straight', '.'], 'dependencies': [('•', 'nummod'), ('normal', 'amod'), ('see', 'dep'), ('1', 'nummod'), ('bubbl', 'compound'), ('window', 'nsubj'), ('•', 'appos'), ('make', 'ROOT'), ('sure', 'amod'), ('liquid', 'amod'), ('clear', 'amod'), ('colorless', 'dobj'), ('•', 'punct'), ('use', 'ccomp'), ('pen', 'compound'), ('liquid', 'compound'), ('cloudi', 'dobj'), (',', 'punct'), ('discolor', 'conj'), (',', 'punct'), ('flake', 'compound'), ('particl', 'conj'), ('•', 'punct'), ('use', 'compound'), ('pen', 'compound'), ('drop', 'compound'), ('crush', 'nsubj'), ('pull', 'ccomp'), ('gray', 'amod'), ('cap', 'dobj'), ('#', 'npadvmod'), ('1', 'nummod'), ('straight', 'advmod'), ('.', 'punct')]}, {'original_sentence': 'Throw the cap away.', 'tokens': ['Throw', 'cap', 'away', '.'], 'lemmatized': ['Throw', 'cap', 'away', '.'], 'stemmed': ['throw', 'cap', 'away', '.'], 'dependencies': [('throw', 'ROOT'), ('cap', 'dobj'), ('away', 'advmod'), ('.', 'punct')]}, {'original_sentence': '• It is normal to see a few drops of liquid come \\nout of the needle  \\nPull the Plum-colored Cap #2 straight off.', 'tokens': ['•', 'normal', 'see', 'drops', 'liquid', 'come', 'needle', 'Pull', 'Plum-colored', 'Cap', '#', '2', 'straight', '.'], 'lemmatized': ['•', 'normal', 'see', 'drop', 'liquid', 'come', 'needle', 'Pull', 'Plum-colored', 'Cap', '#', '2', 'straight', '.'], 'stemmed': ['•', 'normal', 'see', 'drop', 'liquid', 'come', 'needl', 'pull', 'plum-color', 'cap', '#', '2', 'straight', '.'], 'dependencies': [('•', 'nummod'), ('normal', 'amod'), ('see', 'compound'), ('drop', 'compound'), ('liquid', 'compound'), ('come', 'nsubj'), ('needl', 'ROOT'), ('pull', 'xcomp'), ('plum', 'compound'), ('-', 'punct'), ('color', 'compound'), ('cap', 'compound'), ('#', 'npadvmod'), ('2', 'nummod'), ('straight', 'advmod'), ('.', 'punct')]}, {'original_sentence': 'Throw the cap away.', 'tokens': ['Throw', 'cap', 'away', '.'], 'lemmatized': ['Throw', 'cap', 'away', '.'], 'stemmed': ['throw', 'cap', 'away', '.'], 'dependencies': [('throw', 'ROOT'), ('cap', 'dobj'), ('away', 'advmod'), ('.', 'punct')]}, {'original_sentence': 'Turn the Pen so that the white arrow points \\ntoward the injection site.', 'tokens': ['Turn', 'Pen', 'white', 'arrow', 'points', 'toward', 'injection', 'site', '.'], 'lemmatized': ['Turn', 'Pen', 'white', 'arrow', 'point', 'toward', 'injection', 'site', '.'], 'stemmed': ['turn', 'pen', 'white', 'arrow', 'point', 'toward', 'inject', 'site', '.'], 'dependencies': [('turn', 'ROOT'), ('pen', 'dobj'), ('white', 'amod'), ('arrow', 'compound'), ('point', 'npadvmod'), ('toward', 'prep'), ('inject', 'compound'), ('site', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'Squeeze the skin at your injection site to make \\na raised area and hold it firmly until the injection \\nis complete.', 'tokens': ['Squeeze', 'skin', 'injection', 'site', 'make', 'raised', 'area', 'hold', 'firmly', 'injection', 'complete', '.'], 'lemmatized': ['Squeeze', 'skin', 'injection', 'site', 'make', 'raised', 'area', 'hold', 'firmly', 'injection', 'complete', '.'], 'stemmed': ['squeez', 'skin', 'inject', 'site', 'make', 'rais', 'area', 'hold', 'firmli', 'inject', 'complet', '.'], 'dependencies': [('squeez', 'compound'), ('skin', 'compound'), ('inject', 'compound'), ('site', 'nsubj'), ('make', 'ROOT'), ('rais', 'compound'), ('area', 'nsubj'), ('hold', 'ccomp'), ('firmli', 'compound'), ('inject', 'compound'), ('complet', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Point the white arrow toward the injection site.', 'tokens': ['Point', 'white', 'arrow', 'toward', 'injection', 'site', '.'], 'lemmatized': ['Point', 'white', 'arrow', 'toward', 'injection', 'site', '.'], 'stemmed': ['point', 'white', 'arrow', 'toward', 'inject', 'site', '.'], 'dependencies': [('point', 'ROOT'), ('white', 'amod'), ('arrow', 'dobj'), ('toward', 'prep'), ('inject', 'compound'), ('site', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'Place the white needle sleeve straight (90° \\nangle) against the injection site.', 'tokens': ['Place', 'white', 'needle', 'sleeve', 'straight', '(', '90°', 'angle', ')', 'injection', 'site', '.'], 'lemmatized': ['Place', 'white', 'needle', 'sleeve', 'straight', '(', '90°', 'angle', ')', 'injection', 'site', '.'], 'stemmed': ['place', 'white', 'needl', 'sleev', 'straight', '(', '90°', 'angl', ')', 'inject', 'site', '.'], 'dependencies': [('place', 'nsubj'), ('white', 'amod'), ('needl', 'ROOT'), ('sleev', 'dobj'), ('straight', 'advmod'), ('(', 'punct'), ('90', 'nummod'), ('°', 'npadvmod'), ('angl', 'conj'), (')', 'punct'), ('inject', 'compound'), ('site', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Hold the Pen so that you can see the inspection \\nwindow.', 'tokens': ['Hold', 'Pen', 'see', 'inspection', 'window', '.'], 'lemmatized': ['Hold', 'Pen', 'see', 'inspection', 'window', '.'], 'stemmed': ['hold', 'pen', 'see', 'inspect', 'window', '.'], 'dependencies': [('hold', 'ROOT'), ('pen', 'nsubj'), ('see', 'ccomp'), ('inspect', 'amod'), ('window', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Do not press the plum activator button until you \\nare ready to inject.', 'tokens': ['press', 'plum', 'activator', 'button', 'ready', 'inject', '.'], 'lemmatized': ['press', 'plum', 'activator', 'button', 'ready', 'inject', '.'], 'stemmed': ['press', 'plum', 'activ', 'button', 'readi', 'inject', '.'], 'dependencies': [('press', 'compound'), ('plum', 'compound'), ('activ', 'compound'), ('button', 'compound'), ('readi', 'compound'), ('inject', 'ROOT'), ('.', 'punct')]}], 'text': ' \\n   \\n \\nHold the Pen with the Gray Cap #1 facing up. \\nCheck the window.  \\n• It is normal to see 1 or more bubbles in the \\nwindow  \\n• Make sure the liquid is clear and colorless \\n• Do not use the Pen if the liquid is cloudy, \\ndiscolored, or has flakes or particles in it  \\n• Do not use the Pen if it has been dropped or \\ncrushed  \\n \\n   \\n \\nPull the Gray Cap #1 straight off.  \\nThrow the cap away.  \\n• It is normal to see a few drops of liquid come \\nout of the needle  \\nPull the Plum-colored Cap #2 straight off.  \\nThrow the cap away.  \\nTurn the Pen so that the white arrow points \\ntoward the injection site.  \\n \\n   \\n \\nSqueeze the skin at your injection site to make \\na raised area and hold it firmly until the injection \\nis complete.  \\nPoint the white arrow toward the injection site.  \\nPlace the white needle sleeve straight (90° \\nangle) against the injection site.  \\nHold the Pen so that you can see the inspection \\nwindow.  \\nDo not press the plum activator button until you \\nare ready to inject.  \\n'}, 'page_char_count': 999, 'page_word_count': 183, 'sentences': [' \\n   \\n \\nHold the Pen with the Gray Cap #1 facing up.', '\\nCheck the window.', ' \\n• It is normal to see 1 or more bubbles in the \\nwindow  \\n• Make sure the liquid is clear and colorless \\n• Do not use the Pen if the liquid is cloudy, \\ndiscolored, or has flakes or particles in it  \\n• Do not use the Pen if it has been dropped or \\ncrushed  \\n \\n   \\n \\nPull the Gray Cap #1 straight off.', ' \\nThrow the cap away.', ' \\n• It is normal to see a few drops of liquid come \\nout of the needle  \\nPull the Plum-colored Cap #2 straight off.', ' \\nThrow the cap away.', ' \\nTurn the Pen so that the white arrow points \\ntoward the injection site.', ' \\n \\n   \\n \\nSqueeze the skin at your injection site to make \\na raised area and hold it firmly until the injection \\nis complete.', ' \\nPoint the white arrow toward the injection site.', ' \\nPlace the white needle sleeve straight (90° \\nangle) against the injection site.', ' \\nHold the Pen so that you can see the inspection \\nwindow.', ' \\nDo not press the plum activator button until you \\nare ready to inject.', ' \\n'], 'page_sentence_count_spacy': 13}\n",
            "{'page_number': 84, 'text': ' \\n   \\n \\nIt is important that you firmly push the Pen \\ndown all the way against the injection site \\nbefore starting the injection.  \\nKeep pushing down to prevent the Pen from \\nmoving away from the skin during the injection.  \\nPress the plum activator button and count \\nslowly for 10 seconds.  \\n• A loud “click” will signal the start of the \\ninjection  \\n• Keep pushing the Pen down firmly against \\nthe injection site until the injection is \\ncomplete  \\n• Injection is complete when the yellow \\nindicator has stopped moving \\n \\n   \\n \\nWhen the injection is completed, slowly pull the \\nPen from the skin. The white needle sleeve will \\ncover the needle tip.  \\n• A small amount of liquid on the injection site \\nis normal \\nIf there are more than a few drops of liquid on \\nthe injection site, call 1-800-4HUMIRA (1-800-\\n448-6472) for help.  \\nAfter completing the injection, place a cotton ball \\nor gauze pad on the skin of the injection site.  \\n• Do not rub  \\n• Slight bleeding at the injection site is normal \\n', 'processed_text': {'sentences': [{'original_sentence': ' \\n   \\n \\nIt is important that you firmly push the Pen \\ndown all the way against the injection site \\nbefore starting the injection.', 'tokens': ['important', 'firmly', 'push', 'Pen', 'way', 'injection', 'site', 'starting', 'injection', '.'], 'lemmatized': ['important', 'firmly', 'push', 'Pen', 'way', 'injection', 'site', 'starting', 'injection', '.'], 'stemmed': ['import', 'firmli', 'push', 'pen', 'way', 'inject', 'site', 'start', 'inject', '.'], 'dependencies': [('import', 'nsubj'), ('firmli', 'amod'), ('push', 'ccomp'), ('pen', 'dobj'), ('way', 'npadvmod'), ('inject', 'compound'), ('site', 'nsubj'), ('start', 'ROOT'), ('inject', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Keep pushing down to prevent the Pen from \\nmoving away from the skin during the injection.', 'tokens': ['Keep', 'pushing', 'prevent', 'Pen', 'moving', 'away', 'skin', 'injection', '.'], 'lemmatized': ['Keep', 'pushing', 'prevent', 'Pen', 'moving', 'away', 'skin', 'injection', '.'], 'stemmed': ['keep', 'push', 'prevent', 'pen', 'move', 'away', 'skin', 'inject', '.'], 'dependencies': [('keep', 'ROOT'), ('push', 'amod'), ('prevent', 'compound'), ('pen', 'compound'), ('move', 'dobj'), ('away', 'advmod'), ('skin', 'compound'), ('inject', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Press the plum activator button and count \\nslowly for 10 seconds.', 'tokens': ['Press', 'plum', 'activator', 'button', 'count', 'slowly', '10', 'seconds', '.'], 'lemmatized': ['Press', 'plum', 'activator', 'button', 'count', 'slowly', '10', 'second', '.'], 'stemmed': ['press', 'plum', 'activ', 'button', 'count', 'slowli', '10', 'second', '.'], 'dependencies': [('press', 'compound'), ('plum', 'compound'), ('activ', 'compound'), ('button', 'compound'), ('count', 'nsubj'), ('slowli', 'ROOT'), ('10', 'nummod'), ('second', 'advmod'), ('.', 'punct')]}, {'original_sentence': '• A loud “click” will signal the start of the \\ninjection  \\n• Keep pushing the Pen down firmly against \\nthe injection site until the injection is \\ncomplete  \\n• Injection is complete when the yellow \\nindicator has stopped moving \\n \\n   \\n \\nWhen the injection is completed, slowly pull the \\nPen from the skin.', 'tokens': ['•', 'loud', '“', 'click', '”', 'signal', 'start', 'injection', '•', 'Keep', 'pushing', 'Pen', 'firmly', 'injection', 'site', 'injection', 'complete', '•', 'Injection', 'complete', 'yellow', 'indicator', 'stopped', 'moving', 'injection', 'completed', ',', 'slowly', 'pull', 'Pen', 'skin', '.'], 'lemmatized': ['•', 'loud', '“', 'click', '”', 'signal', 'start', 'injection', '•', 'Keep', 'pushing', 'Pen', 'firmly', 'injection', 'site', 'injection', 'complete', '•', 'Injection', 'complete', 'yellow', 'indicator', 'stopped', 'moving', 'injection', 'completed', ',', 'slowly', 'pull', 'Pen', 'skin', '.'], 'stemmed': ['•', 'loud', '“', 'click', '”', 'signal', 'start', 'inject', '•', 'keep', 'push', 'pen', 'firmli', 'inject', 'site', 'inject', 'complet', '•', 'inject', 'complet', 'yellow', 'indic', 'stop', 'move', 'inject', 'complet', ',', 'slowli', 'pull', 'pen', 'skin', '.'], 'dependencies': [('•', 'meta'), ('loud', 'advmod'), ('“', 'punct'), ('click', 'amod'), ('”', 'punct'), ('signal', 'compound'), ('start', 'compound'), ('inject', 'nsubj'), ('•', 'nummod'), ('keep', 'ROOT'), ('push', 'compound'), ('pen', 'compound'), ('firmli', 'npadvmod'), ('inject', 'compound'), ('site', 'compound'), ('inject', 'compound'), ('complet', 'dep'), ('•', 'npadvmod'), ('inject', 'nmod'), ('complet', 'npadvmod'), ('yellow', 'amod'), ('indic', 'amod'), ('stop', 'nsubj'), ('move', 'ccomp'), ('inject', 'compound'), ('complet', 'dobj'), (',', 'punct'), ('slowli', 'amod'), ('pull', 'compound'), ('pen', 'compound'), ('skin', 'appos'), ('.', 'punct')]}, {'original_sentence': 'The white needle sleeve will \\ncover the needle tip.', 'tokens': ['white', 'needle', 'sleeve', 'cover', 'needle', 'tip', '.'], 'lemmatized': ['white', 'needle', 'sleeve', 'cover', 'needle', 'tip', '.'], 'stemmed': ['white', 'needl', 'sleev', 'cover', 'needl', 'tip', '.'], 'dependencies': [('white', 'nsubj'), ('needl', 'compound'), ('sleev', 'compound'), ('cover', 'ROOT'), ('needl', 'compound'), ('tip', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• A small amount of liquid on the injection site \\nis normal \\nIf there are more than a few drops of liquid on \\nthe injection site, call 1-800-4HUMIRA (1-800-\\n448-6472) for help.', 'tokens': ['•', 'small', 'amount', 'liquid', 'injection', 'site', 'normal', 'drops', 'liquid', 'injection', 'site', ',', 'call', '1-800-4HUMIRA', '(', '1-800-', '448-6472', ')', 'help', '.'], 'lemmatized': ['•', 'small', 'amount', 'liquid', 'injection', 'site', 'normal', 'drop', 'liquid', 'injection', 'site', ',', 'call', '1-800-4HUMIRA', '(', '1-800-', '448-6472', ')', 'help', '.'], 'stemmed': ['•', 'small', 'amount', 'liquid', 'inject', 'site', 'normal', 'drop', 'liquid', 'inject', 'site', ',', 'call', '1-800-4humira', '(', '1-800-', '448-6472', ')', 'help', '.'], 'dependencies': [('•', 'nummod'), ('small', 'amod'), ('amount', 'nmod'), ('liquid', 'nmod'), ('inject', 'nmod'), ('site', 'nmod'), ('normal', 'amod'), ('drop', 'nmod'), ('liquid', 'amod'), ('inject', 'compound'), ('site', 'npadvmod'), (',', 'punct'), ('call', 'nmod'), ('1', 'npadvmod'), ('-', 'punct'), ('800', 'dobj'), ('-', 'punct'), ('4humira', 'quantmod'), ('(', 'punct'), ('1', 'appos'), ('-', 'punct'), ('800-', 'compound'), ('448', 'dobj'), ('-', 'punct'), ('6472', 'prep'), (')', 'punct'), ('help', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'After completing the injection, place a cotton ball \\nor gauze pad on the skin of the injection site.', 'tokens': ['completing', 'injection', ',', 'place', 'cotton', 'ball', 'gauze', 'pad', 'skin', 'injection', 'site', '.'], 'lemmatized': ['completing', 'injection', ',', 'place', 'cotton', 'ball', 'gauze', 'pad', 'skin', 'injection', 'site', '.'], 'stemmed': ['complet', 'inject', ',', 'place', 'cotton', 'ball', 'gauz', 'pad', 'skin', 'inject', 'site', '.'], 'dependencies': [('complet', 'compound'), ('inject', 'ROOT'), (',', 'punct'), ('place', 'compound'), ('cotton', 'compound'), ('ball', 'compound'), ('gauz', 'compound'), ('pad', 'compound'), ('skin', 'compound'), ('inject', 'compound'), ('site', 'appos'), ('.', 'punct')]}, {'original_sentence': '• Do not rub  \\n• Slight bleeding at the injection site is normal', 'tokens': ['•', 'rub', '•', 'Slight', 'bleeding', 'injection', 'site', 'normal'], 'lemmatized': ['•', 'rub', '•', 'Slight', 'bleeding', 'injection', 'site', 'normal'], 'stemmed': ['•', 'rub', '•', 'slight', 'bleed', 'inject', 'site', 'normal'], 'dependencies': [('•', 'meta'), ('rub', 'ROOT'), ('•', 'preconj'), ('slight', 'amod'), ('bleed', 'compound'), ('inject', 'compound'), ('site', 'dobj'), ('normal', 'amod')]}], 'text': ' \\n   \\n \\nIt is important that you firmly push the Pen \\ndown all the way against the injection site \\nbefore starting the injection.  \\nKeep pushing down to prevent the Pen from \\nmoving away from the skin during the injection.  \\nPress the plum activator button and count \\nslowly for 10 seconds.  \\n• A loud “click” will signal the start of the \\ninjection  \\n• Keep pushing the Pen down firmly against \\nthe injection site until the injection is \\ncomplete  \\n• Injection is complete when the yellow \\nindicator has stopped moving \\n \\n   \\n \\nWhen the injection is completed, slowly pull the \\nPen from the skin. The white needle sleeve will \\ncover the needle tip.  \\n• A small amount of liquid on the injection site \\nis normal \\nIf there are more than a few drops of liquid on \\nthe injection site, call 1-800-4HUMIRA (1-800-\\n448-6472) for help.  \\nAfter completing the injection, place a cotton ball \\nor gauze pad on the skin of the injection site.  \\n• Do not rub  \\n• Slight bleeding at the injection site is normal \\n'}, 'page_char_count': 1000, 'page_word_count': 170, 'sentences': [' \\n   \\n \\nIt is important that you firmly push the Pen \\ndown all the way against the injection site \\nbefore starting the injection.', ' \\nKeep pushing down to prevent the Pen from \\nmoving away from the skin during the injection.', ' \\nPress the plum activator button and count \\nslowly for 10 seconds.', ' \\n• A loud “click” will signal the start of the \\ninjection  \\n• Keep pushing the Pen down firmly against \\nthe injection site until the injection is \\ncomplete  \\n• Injection is complete when the yellow \\nindicator has stopped moving \\n \\n   \\n \\nWhen the injection is completed, slowly pull the \\nPen from the skin.', 'The white needle sleeve will \\ncover the needle tip.', ' \\n• A small amount of liquid on the injection site \\nis normal \\nIf there are more than a few drops of liquid on \\nthe injection site, call 1-800-4HUMIRA (1-800-\\n448-6472) for help.', ' \\nAfter completing the injection, place a cotton ball \\nor gauze pad on the skin of the injection site.', ' \\n• Do not rub  \\n• Slight bleeding at the injection site is normal \\n'], 'page_sentence_count_spacy': 8}\n",
            "{'page_number': 85, 'text': ' \\n   \\nHow should I dispose of the used HUMIRA \\nPen? \\n• Put your used needles, Pens, and sharps in \\na FDA cleared sharps disposal container \\nright away after use. Do not throw away \\n(dispose of) loose needles, syringes, and \\nthe Pen in the household trash.  \\n• If you do not have a FDA cleared sharps \\ndisposal container, you may use a \\nhousehold container that is:  \\n◦ made of a heavy-duty plastic, \\n◦ can be closed with a tight-fitting, \\npuncture-resistant lid, without sharps \\nbeing able to come out,  \\n◦ upright and stable during use, \\n◦ leak-resistant, and  \\n◦ properly labeled to warn of hazardous \\nwaste inside the container. \\n• When your sharps disposal container is \\nalmost full, you will need to follow your \\ncommunity guidelines for the right way to \\ndispose of your sharps disposal container. \\nThere may be state or local laws about how \\nyou should throw away used needles and \\nsyringes. For more information about safe \\nsharps disposal, and for specific information \\nabout sharps disposal in the state that you \\nlive in, go to the FDA’s website at: \\nhttp://www.fda.gov/safesharpsdisposal.  \\n• Do not dispose of your used sharps disposal \\ncontainer in your household trash unless \\nyour community guidelines permit this. Do \\nnot recycle your used sharps disposal \\ncontainer.  \\nThe Pen caps, alcohol swab, cotton ball or gauze pad, dose tray, and packaging may be placed \\nin your household trash.  \\n', 'processed_text': {'sentences': [{'original_sentence': ' \\n   \\nHow should I dispose of the used HUMIRA \\nPen?', 'tokens': ['dispose', 'used', 'HUMIRA', 'Pen', '?'], 'lemmatized': ['dispose', 'used', 'HUMIRA', 'Pen', '?'], 'stemmed': ['dispos', 'use', 'humira', 'pen', '?'], 'dependencies': [('dispos', 'nsubj'), ('use', 'ROOT'), ('humira', 'compound'), ('pen', 'dobj'), ('?', 'punct')]}, {'original_sentence': '• Put your used needles, Pens, and sharps in \\na FDA cleared sharps disposal container \\nright away after use.', 'tokens': ['•', 'Put', 'used', 'needles', ',', 'Pens', ',', 'sharps', 'FDA', 'cleared', 'sharps', 'disposal', 'container', 'right', 'away', 'use', '.'], 'lemmatized': ['•', 'Put', 'used', 'needle', ',', 'Pens', ',', 'sharp', 'FDA', 'cleared', 'sharp', 'disposal', 'container', 'right', 'away', 'use', '.'], 'stemmed': ['•', 'put', 'use', 'needl', ',', 'pen', ',', 'sharp', 'fda', 'clear', 'sharp', 'dispos', 'contain', 'right', 'away', 'use', '.'], 'dependencies': [('•', 'npadvmod'), ('put', 'ROOT'), ('use', 'compound'), ('needl', 'dobj'), (',', 'punct'), ('pen', 'nmod'), (',', 'punct'), ('sharp', 'amod'), ('fda', 'nmod'), ('clear', 'amod'), ('sharp', 'amod'), ('dispos', 'nsubj'), ('contain', 'conj'), ('right', 'advmod'), ('away', 'advmod'), ('use', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Do not throw away \\n(dispose of) loose needles, syringes, and \\nthe Pen in the household trash.', 'tokens': ['throw', 'away', '(', 'dispose', ')', 'loose', 'needles', ',', 'syringes', ',', 'Pen', 'household', 'trash', '.'], 'lemmatized': ['throw', 'away', '(', 'dispose', ')', 'loose', 'needle', ',', 'syrinx', ',', 'Pen', 'household', 'trash', '.'], 'stemmed': ['throw', 'away', '(', 'dispos', ')', 'loos', 'needl', ',', 'syrinx', ',', 'pen', 'household', 'trash', '.'], 'dependencies': [('throw', 'ROOT'), ('away', 'advmod'), ('(', 'punct'), ('dispos', 'dobj'), (')', 'punct'), ('loos', 'compound'), ('needl', 'dobj'), (',', 'punct'), ('syrinx', 'conj'), (',', 'punct'), ('pen', 'compound'), ('household', 'compound'), ('trash', 'conj'), ('.', 'punct')]}, {'original_sentence': '• If you do not have a FDA cleared sharps \\ndisposal container, you may use a \\nhousehold container that is:  \\n◦ made of a heavy-duty plastic, \\n◦ can be closed with a tight-fitting, \\npuncture-resistant lid, without sharps \\nbeing able to come out,  \\n◦ upright and stable during use, \\n◦ leak-resistant, and  \\n◦ properly labeled to warn of hazardous \\nwaste inside the container.', 'tokens': ['•', 'FDA', 'cleared', 'sharps', 'disposal', 'container', ',', 'may', 'use', 'household', 'container', ':', '◦', 'made', 'heavy-duty', 'plastic', ',', '◦', 'closed', 'tight-fitting', ',', 'puncture-resistant', 'lid', ',', 'without', 'sharps', 'able', 'come', ',', '◦', 'upright', 'stable', 'use', ',', '◦', 'leak-resistant', ',', '◦', 'properly', 'labeled', 'warn', 'hazardous', 'waste', 'inside', 'container', '.'], 'lemmatized': ['•', 'FDA', 'cleared', 'sharp', 'disposal', 'container', ',', 'may', 'use', 'household', 'container', ':', '◦', 'made', 'heavy-duty', 'plastic', ',', '◦', 'closed', 'tight-fitting', ',', 'puncture-resistant', 'lid', ',', 'without', 'sharp', 'able', 'come', ',', '◦', 'upright', 'stable', 'use', ',', '◦', 'leak-resistant', ',', '◦', 'properly', 'labeled', 'warn', 'hazardous', 'waste', 'inside', 'container', '.'], 'stemmed': ['•', 'fda', 'clear', 'sharp', 'dispos', 'contain', ',', 'may', 'use', 'household', 'contain', ':', '◦', 'made', 'heavy-duti', 'plastic', ',', '◦', 'close', 'tight-fit', ',', 'puncture-resist', 'lid', ',', 'without', 'sharp', 'abl', 'come', ',', '◦', 'upright', 'stabl', 'use', ',', '◦', 'leak-resist', ',', '◦', 'properli', 'label', 'warn', 'hazard', 'wast', 'insid', 'contain', '.'], 'dependencies': [('•', 'dep'), ('fda', 'nsubj'), ('clear', 'amod'), ('sharp', 'amod'), ('dispos', 'nsubj'), ('contain', 'advcl'), (',', 'punct'), ('may', 'aux'), ('use', 'ROOT'), ('household', 'compound'), ('contain', 'dobj'), (':', 'punct'), ('◦', 'nsubj'), ('made', 'xcomp'), ('heavy', 'amod'), ('-', 'punct'), ('duti', 'compound'), ('plastic', 'dobj'), (',', 'punct'), ('◦', 'advcl'), ('close', 'amod'), ('tight', 'amod'), ('-', 'punct'), ('fit', 'amod'), (',', 'punct'), ('puncture', 'amod'), ('-', 'punct'), ('resist', 'compound'), ('lid', 'dobj'), (',', 'punct'), ('without', 'prep'), ('sharp', 'amod'), ('abl', 'nsubj'), ('come', 'pobj'), (',', 'punct'), ('◦', 'dep'), ('upright', 'amod'), ('stabl', 'amod'), ('use', 'dobj'), (',', 'punct'), ('◦', 'compound'), ('leak', 'compound'), ('-', 'punct'), ('resist', 'nsubj'), (',', 'punct'), ('◦', 'conj'), ('properli', 'compound'), ('label', 'nsubj'), ('warn', 'conj'), ('hazard', 'compound'), ('wast', 'nsubj'), ('insid', 'amod'), ('contain', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• When your sharps disposal container is \\nalmost full, you will need to follow your \\ncommunity guidelines for the right way to \\ndispose of your sharps disposal container.', 'tokens': ['•', 'sharps', 'disposal', 'container', 'almost', 'full', ',', 'need', 'follow', 'community', 'guidelines', 'right', 'way', 'dispose', 'sharps', 'disposal', 'container', '.'], 'lemmatized': ['•', 'sharp', 'disposal', 'container', 'almost', 'full', ',', 'need', 'follow', 'community', 'guideline', 'right', 'way', 'dispose', 'sharp', 'disposal', 'container', '.'], 'stemmed': ['•', 'sharp', 'dispos', 'contain', 'almost', 'full', ',', 'need', 'follow', 'commun', 'guidelin', 'right', 'way', 'dispos', 'sharp', 'dispos', 'contain', '.'], 'dependencies': [('•', 'nummod'), ('sharp', 'amod'), ('dispos', 'nsubj'), ('contain', 'ROOT'), ('almost', 'advmod'), ('full', 'advmod'), (',', 'punct'), ('need', 'conj'), ('follow', 'dobj'), ('commun', 'amod'), ('guidelin', 'dobj'), ('right', 'amod'), ('way', 'npadvmod'), ('dispos', 'nsubj'), ('sharp', 'amod'), ('dispos', 'nsubj'), ('contain', 'ccomp'), ('.', 'punct')]}, {'original_sentence': 'There may be state or local laws about how \\nyou should throw away used needles and \\nsyringes.', 'tokens': ['may', 'state', 'local', 'laws', 'throw', 'away', 'used', 'needles', 'syringes', '.'], 'lemmatized': ['may', 'state', 'local', 'law', 'throw', 'away', 'used', 'needle', 'syrinx', '.'], 'stemmed': ['may', 'state', 'local', 'law', 'throw', 'away', 'use', 'needl', 'syrinx', '.'], 'dependencies': [('may', 'aux'), ('state', 'ROOT'), ('local', 'amod'), ('law', 'dobj'), ('throw', 'ccomp'), ('away', 'advmod'), ('use', 'dobj'), ('needl', 'conj'), ('syrinx', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'For more information about safe \\nsharps disposal, and for specific information \\nabout sharps disposal in the state that you \\nlive in, go to the FDA’s website at: \\nhttp://www.fda.gov/safesharpsdisposal.', 'tokens': ['information', 'safe', 'sharps', 'disposal', ',', 'specific', 'information', 'sharps', 'disposal', 'state', 'live', ',', 'go', 'FDA', '’', 'website', ':', 'http', ':', '//www.fda.gov/safesharpsdisposal', '.'], 'lemmatized': ['information', 'safe', 'sharp', 'disposal', ',', 'specific', 'information', 'sharp', 'disposal', 'state', 'live', ',', 'go', 'FDA', '’', 'website', ':', 'http', ':', '//www.fda.gov/safesharpsdisposal', '.'], 'stemmed': ['inform', 'safe', 'sharp', 'dispos', ',', 'specif', 'inform', 'sharp', 'dispos', 'state', 'live', ',', 'go', 'fda', '’', 'websit', ':', 'http', ':', '//www.fda.gov/safesharpsdispos', '.'], 'dependencies': [('inform', 'advcl'), ('safe', 'amod'), ('sharp', 'amod'), ('dispos', 'dobj'), (',', 'punct'), ('specif', 'nsubj'), ('inform', 'ROOT'), ('sharp', 'amod'), ('dispos', 'compound'), ('state', 'dobj'), ('live', 'advmod'), (',', 'punct'), ('go', 'conj'), ('fda', 'nmod'), ('’', 'punct'), ('websit', 'dobj'), (':', 'punct'), ('http', 'appos'), (':', 'punct'), ('//www.fda.gov', 'nmod'), ('/', 'punct'), ('safesharpsdispos', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': '• Do not dispose of your used sharps disposal \\ncontainer in your household trash unless \\nyour community guidelines permit this.', 'tokens': ['•', 'dispose', 'used', 'sharps', 'disposal', 'container', 'household', 'trash', 'unless', 'community', 'guidelines', 'permit', '.'], 'lemmatized': ['•', 'dispose', 'used', 'sharp', 'disposal', 'container', 'household', 'trash', 'unless', 'community', 'guideline', 'permit', '.'], 'stemmed': ['•', 'dispos', 'use', 'sharp', 'dispos', 'contain', 'household', 'trash', 'unless', 'commun', 'guidelin', 'permit', '.'], 'dependencies': [('•', 'nummod'), ('dispos', 'nsubj'), ('use', 'ROOT'), ('sharp', 'amod'), ('dispos', 'dobj'), ('contain', 'xcomp'), ('household', 'compound'), ('trash', 'dobj'), ('unless', 'mark'), ('commun', 'amod'), ('guidelin', 'compound'), ('permit', 'advcl'), ('.', 'punct')]}, {'original_sentence': 'Do \\nnot recycle your used sharps disposal \\ncontainer.', 'tokens': ['recycle', 'used', 'sharps', 'disposal', 'container', '.'], 'lemmatized': ['recycle', 'used', 'sharp', 'disposal', 'container', '.'], 'stemmed': ['recycl', 'use', 'sharp', 'dispos', 'contain', '.'], 'dependencies': [('recycl', 'nsubj'), ('use', 'ROOT'), ('sharp', 'amod'), ('dispos', 'dobj'), ('contain', 'xcomp'), ('.', 'punct')]}, {'original_sentence': 'The Pen caps, alcohol swab, cotton ball or gauze pad, dose tray, and packaging may be placed \\nin your household trash.', 'tokens': ['Pen', 'caps', ',', 'alcohol', 'swab', ',', 'cotton', 'ball', 'gauze', 'pad', ',', 'dose', 'tray', ',', 'packaging', 'may', 'placed', 'household', 'trash', '.'], 'lemmatized': ['Pen', 'cap', ',', 'alcohol', 'swab', ',', 'cotton', 'ball', 'gauze', 'pad', ',', 'dose', 'tray', ',', 'packaging', 'may', 'placed', 'household', 'trash', '.'], 'stemmed': ['pen', 'cap', ',', 'alcohol', 'swab', ',', 'cotton', 'ball', 'gauz', 'pad', ',', 'dose', 'tray', ',', 'packag', 'may', 'place', 'household', 'trash', '.'], 'dependencies': [('pen', 'compound'), ('cap', 'dep'), (',', 'punct'), ('alcohol', 'compound'), ('swab', 'conj'), (',', 'punct'), ('cotton', 'compound'), ('ball', 'compound'), ('gauz', 'compound'), ('pad', 'conj'), (',', 'punct'), ('dose', 'compound'), ('tray', 'appos'), (',', 'punct'), ('packag', 'nsubj'), ('may', 'aux'), ('place', 'ROOT'), ('household', 'compound'), ('trash', 'dobj'), ('.', 'punct')]}], 'text': ' \\n   \\nHow should I dispose of the used HUMIRA \\nPen? \\n• Put your used needles, Pens, and sharps in \\na FDA cleared sharps disposal container \\nright away after use. Do not throw away \\n(dispose of) loose needles, syringes, and \\nthe Pen in the household trash.  \\n• If you do not have a FDA cleared sharps \\ndisposal container, you may use a \\nhousehold container that is:  \\n◦ made of a heavy-duty plastic, \\n◦ can be closed with a tight-fitting, \\npuncture-resistant lid, without sharps \\nbeing able to come out,  \\n◦ upright and stable during use, \\n◦ leak-resistant, and  \\n◦ properly labeled to warn of hazardous \\nwaste inside the container. \\n• When your sharps disposal container is \\nalmost full, you will need to follow your \\ncommunity guidelines for the right way to \\ndispose of your sharps disposal container. \\nThere may be state or local laws about how \\nyou should throw away used needles and \\nsyringes. For more information about safe \\nsharps disposal, and for specific information \\nabout sharps disposal in the state that you \\nlive in, go to the FDA’s website at: \\nhttp://www.fda.gov/safesharpsdisposal.  \\n• Do not dispose of your used sharps disposal \\ncontainer in your household trash unless \\nyour community guidelines permit this. Do \\nnot recycle your used sharps disposal \\ncontainer.  \\nThe Pen caps, alcohol swab, cotton ball or gauze pad, dose tray, and packaging may be placed \\nin your household trash.  \\n'}, 'page_char_count': 1408, 'page_word_count': 228, 'sentences': [' \\n   \\nHow should I dispose of the used HUMIRA \\nPen?', '\\n• Put your used needles, Pens, and sharps in \\na FDA cleared sharps disposal container \\nright away after use.', 'Do not throw away \\n(dispose of) loose needles, syringes, and \\nthe Pen in the household trash.', ' \\n• If you do not have a FDA cleared sharps \\ndisposal container, you may use a \\nhousehold container that is:  \\n◦ made of a heavy-duty plastic, \\n◦ can be closed with a tight-fitting, \\npuncture-resistant lid, without sharps \\nbeing able to come out,  \\n◦ upright and stable during use, \\n◦ leak-resistant, and  \\n◦ properly labeled to warn of hazardous \\nwaste inside the container.', '\\n• When your sharps disposal container is \\nalmost full, you will need to follow your \\ncommunity guidelines for the right way to \\ndispose of your sharps disposal container.', '\\nThere may be state or local laws about how \\nyou should throw away used needles and \\nsyringes.', 'For more information about safe \\nsharps disposal, and for specific information \\nabout sharps disposal in the state that you \\nlive in, go to the FDA’s website at: \\nhttp://www.fda.gov/safesharpsdisposal.', ' \\n• Do not dispose of your used sharps disposal \\ncontainer in your household trash unless \\nyour community guidelines permit this.', 'Do \\nnot recycle your used sharps disposal \\ncontainer.', ' \\nThe Pen caps, alcohol swab, cotton ball or gauze pad, dose tray, and packaging may be placed \\nin your household trash.', ' \\n'], 'page_sentence_count_spacy': 11}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "100%|██████████| 111/111 [00:01<00:00, 84.96it/s] "
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "{'page_number': 86, 'text': 'Questions About Using the HUMIRA Pen \\n \\nWhat if I have not received in person training from a healthcare provider? \\n• Call your healthcare provider or 1-800-4HUMIRA (1-800-448-6472) or visit \\nwww.HUMIRA.com if you need help  \\nHow do I know when the injection is complete? \\n• The yellow indicator has stopped moving. This takes up to 10 seconds.  \\nWhat should I do if there are more than a few drops of liquid on the injection site? \\n• Call 1-800-4HUMIRA (1-800-448-6472) for help  \\nWhat if I do not have an FDA-cleared sharps disposal container or proper household \\ncontainer? \\n• Call 1-800-4HUMIRA (1-800-448-6472) for a free FDA-cleared sharps disposal container  \\n  \\nAlways keep the Pen and the sharps disposal \\ncontainer out of reach of children.  \\n \\n   \\nKeep a record of the dates and locations of your \\ninjections. To help remember when to take \\nHUMIRA, mark your calendar ahead of time.  \\n \\n   \\nThis Instructions for Use has been approved \\nby the U.S. Food and Drug Administration. \\nRevised 02/2021 \\nManufactured by AbbVie Inc. North Chicago, IL 60064 U.S.A. \\nUS License Number 1889  20066945  \\n \\n  \\n \\n \\n', 'processed_text': {'sentences': [{'original_sentence': 'Questions About Using the HUMIRA Pen \\n \\nWhat if I have not received in person training from a healthcare provider?', 'tokens': ['Questions', 'Using', 'HUMIRA', 'Pen', 'received', 'person', 'training', 'healthcare', 'provider', '?'], 'lemmatized': ['Questions', 'Using', 'HUMIRA', 'Pen', 'received', 'person', 'training', 'healthcare', 'provider', '?'], 'stemmed': ['question', 'use', 'humira', 'pen', 'receiv', 'person', 'train', 'healthcar', 'provid', '?'], 'dependencies': [('question', 'compound'), ('use', 'ROOT'), ('humira', 'compound'), ('pen', 'compound'), ('receiv', 'compound'), ('person', 'nsubj'), ('train', 'ccomp'), ('healthcar', 'compound'), ('provid', 'dobj'), ('?', 'punct')]}, {'original_sentence': '• Call your healthcare provider or 1-800-4HUMIRA (1-800-448-6472) or visit \\nwww.HUMIRA.com if you need help  \\nHow do I know when the injection is complete?', 'tokens': ['•', 'Call', 'healthcare', 'provider', '1-800-4HUMIRA', '(', '1-800-448-6472', ')', 'visit', 'www.HUMIRA.com', 'need', 'help', 'know', 'injection', 'complete', '?'], 'lemmatized': ['•', 'Call', 'healthcare', 'provider', '1-800-4HUMIRA', '(', '1-800-448-6472', ')', 'visit', 'www.HUMIRA.com', 'need', 'help', 'know', 'injection', 'complete', '?'], 'stemmed': ['•', 'call', 'healthcar', 'provid', '1-800-4humira', '(', '1-800-448-6472', ')', 'visit', 'www.humira.com', 'need', 'help', 'know', 'inject', 'complet', '?'], 'dependencies': [('•', 'nummod'), ('call', 'npadvmod'), ('healthcar', 'compound'), ('provid', 'dobj'), ('1', 'nummod'), ('-', 'punct'), ('800', 'npadvmod'), ('-', 'punct'), ('4humira', 'prep'), ('(', 'punct'), ('1', 'npadvmod'), ('-', 'punct'), ('800', 'appos'), ('-', 'punct'), ('448', 'nummod'), ('-', 'punct'), ('6472', 'prep'), (')', 'punct'), ('visit', 'ROOT'), ('www.humira.com', 'dobj'), ('need', 'dobj'), ('help', 'aux'), ('know', 'advcl'), ('inject', 'compound'), ('complet', 'dobj'), ('?', 'punct')]}, {'original_sentence': '• The yellow indicator has stopped moving.', 'tokens': ['•', 'yellow', 'indicator', 'stopped', 'moving', '.'], 'lemmatized': ['•', 'yellow', 'indicator', 'stopped', 'moving', '.'], 'stemmed': ['•', 'yellow', 'indic', 'stop', 'move', '.'], 'dependencies': [('•', 'nummod'), ('yellow', 'amod'), ('indic', 'amod'), ('stop', 'compound'), ('move', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'This takes up to 10 seconds.', 'tokens': ['takes', '10', 'seconds', '.'], 'lemmatized': ['take', '10', 'second', '.'], 'stemmed': ['take', '10', 'second', '.'], 'dependencies': [('take', 'ROOT'), ('10', 'nummod'), ('second', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'What should I do if there are more than a few drops of liquid on the injection site?', 'tokens': ['drops', 'liquid', 'injection', 'site', '?'], 'lemmatized': ['drop', 'liquid', 'injection', 'site', '?'], 'stemmed': ['drop', 'liquid', 'inject', 'site', '?'], 'dependencies': [('drop', 'ROOT'), ('liquid', 'amod'), ('inject', 'compound'), ('site', 'dobj'), ('?', 'punct')]}, {'original_sentence': '• Call 1-800-4HUMIRA (1-800-448-6472) for help  \\nWhat if I do not have an FDA-cleared sharps disposal container or proper household \\ncontainer?', 'tokens': ['•', 'Call', '1-800-4HUMIRA', '(', '1-800-448-6472', ')', 'help', 'FDA-cleared', 'sharps', 'disposal', 'container', 'proper', 'household', 'container', '?'], 'lemmatized': ['•', 'Call', '1-800-4HUMIRA', '(', '1-800-448-6472', ')', 'help', 'FDA-cleared', 'sharp', 'disposal', 'container', 'proper', 'household', 'container', '?'], 'stemmed': ['•', 'call', '1-800-4humira', '(', '1-800-448-6472', ')', 'help', 'fda-clear', 'sharp', 'dispos', 'contain', 'proper', 'household', 'contain', '?'], 'dependencies': [('•', 'nummod'), ('call', 'dep'), ('1', 'npadvmod'), ('-', 'punct'), ('800', 'prep'), ('-', 'punct'), ('4humira', 'prep'), ('(', 'punct'), ('1', 'npadvmod'), ('-', 'punct'), ('800', 'prep'), ('-', 'punct'), ('448', 'nummod'), ('-', 'punct'), ('6472', 'appos'), (')', 'punct'), ('help', 'ROOT'), ('fda', 'compound'), ('-', 'punct'), ('clear', 'amod'), ('sharp', 'amod'), ('dispos', 'nsubj'), ('contain', 'ccomp'), ('proper', 'amod'), ('household', 'compound'), ('contain', 'dobj'), ('?', 'punct')]}, {'original_sentence': '• Call 1-800-4HUMIRA (1-800-448-6472) for a free FDA-cleared sharps disposal container  \\n  \\nAlways keep the Pen and the sharps disposal \\ncontainer out of reach of children.', 'tokens': ['•', 'Call', '1-800-4HUMIRA', '(', '1-800-448-6472', ')', 'free', 'FDA-cleared', 'sharps', 'disposal', 'container', 'Always', 'keep', 'Pen', 'sharps', 'disposal', 'container', 'reach', 'children', '.'], 'lemmatized': ['•', 'Call', '1-800-4HUMIRA', '(', '1-800-448-6472', ')', 'free', 'FDA-cleared', 'sharp', 'disposal', 'container', 'Always', 'keep', 'Pen', 'sharp', 'disposal', 'container', 'reach', 'child', '.'], 'stemmed': ['•', 'call', '1-800-4humira', '(', '1-800-448-6472', ')', 'free', 'fda-clear', 'sharp', 'dispos', 'contain', 'alway', 'keep', 'pen', 'sharp', 'dispos', 'contain', 'reach', 'child', '.'], 'dependencies': [('•', 'nummod'), ('call', 'npadvmod'), ('1', 'npadvmod'), ('-', 'punct'), ('800', 'prep'), ('-', 'punct'), ('4humira', 'prep'), ('(', 'punct'), ('1', 'npadvmod'), ('-', 'punct'), ('800', 'prep'), ('-', 'punct'), ('448', 'nummod'), ('-', 'punct'), ('6472', 'prep'), (')', 'punct'), ('free', 'amod'), ('fda', 'compound'), ('-', 'punct'), ('clear', 'amod'), ('sharp', 'amod'), ('dispos', 'nsubj'), ('contain', 'ROOT'), ('alway', 'advmod'), ('keep', 'advcl'), ('pen', 'nmod'), ('sharp', 'amod'), ('dispos', 'dobj'), ('contain', 'xcomp'), ('reach', 'conj'), ('child', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Keep a record of the dates and locations of your \\ninjections.', 'tokens': ['Keep', 'record', 'dates', 'locations', 'injections', '.'], 'lemmatized': ['Keep', 'record', 'date', 'location', 'injection', '.'], 'stemmed': ['keep', 'record', 'date', 'locat', 'inject', '.'], 'dependencies': [('keep', 'ROOT'), ('record', 'compound'), ('date', 'compound'), ('locat', 'compound'), ('inject', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'To help remember when to take \\nHUMIRA, mark your calendar ahead of time.', 'tokens': ['help', 'remember', 'take', 'HUMIRA', ',', 'mark', 'calendar', 'ahead', 'time', '.'], 'lemmatized': ['help', 'remember', 'take', 'HUMIRA', ',', 'mark', 'calendar', 'ahead', 'time', '.'], 'stemmed': ['help', 'rememb', 'take', 'humira', ',', 'mark', 'calendar', 'ahead', 'time', '.'], 'dependencies': [('help', 'advcl'), ('rememb', 'amod'), ('take', 'compound'), ('humira', 'dobj'), (',', 'punct'), ('mark', 'compound'), ('calendar', 'ROOT'), ('ahead', 'amod'), ('time', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'This Instructions for Use has been approved \\nby the U.S. Food and Drug Administration.', 'tokens': ['Instructions', 'Use', 'approved', 'U.S.', 'Food', 'Drug', 'Administration', '.'], 'lemmatized': ['Instructions', 'Use', 'approved', 'U.S.', 'Food', 'Drug', 'Administration', '.'], 'stemmed': ['instruct', 'use', 'approv', 'u.s.', 'food', 'drug', 'administr', '.'], 'dependencies': [('instruct', 'ROOT'), ('use', 'dobj'), ('approv', 'compound'), ('u.s', 'compound'), ('.', 'compound'), ('food', 'compound'), ('drug', 'compound'), ('administr', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Revised 02/2021 \\nManufactured by AbbVie Inc. North Chicago, IL 60064 U.S.A.', 'tokens': ['Revised', '02/2021', 'Manufactured', 'AbbVie', 'Inc.', 'North', 'Chicago', ',', 'IL', '60064', 'U.S.A', '.'], 'lemmatized': ['Revised', '02/2021', 'Manufactured', 'AbbVie', 'Inc.', 'North', 'Chicago', ',', 'IL', '60064', 'U.S.A', '.'], 'stemmed': ['revis', '02/2021', 'manufactur', 'abbvi', 'inc.', 'north', 'chicago', ',', 'il', '60064', 'u.s.a', '.'], 'dependencies': [('revis', 'compound'), ('02/2021', 'compound'), ('manufactur', 'nsubj'), ('abbvi', 'compound'), ('inc', 'compound'), ('.', 'compound'), ('north', 'compound'), ('chicago', 'dep'), (',', 'punct'), ('il', 'nmod'), ('60064', 'nummod'), ('u.s.a', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'US License Number 1889  20066945', 'tokens': ['US', 'License', 'Number', '1889', '20066945'], 'lemmatized': ['US', 'License', 'Number', '1889', '20066945'], 'stemmed': ['us', 'licens', 'number', '1889', '20066945'], 'dependencies': [('us', 'compound'), ('licens', 'compound'), ('number', 'ROOT'), ('1889', 'nummod'), ('20066945', 'nummod')]}], 'text': 'Questions About Using the HUMIRA Pen \\n \\nWhat if I have not received in person training from a healthcare provider? \\n• Call your healthcare provider or 1-800-4HUMIRA (1-800-448-6472) or visit \\nwww.HUMIRA.com if you need help  \\nHow do I know when the injection is complete? \\n• The yellow indicator has stopped moving. This takes up to 10 seconds.  \\nWhat should I do if there are more than a few drops of liquid on the injection site? \\n• Call 1-800-4HUMIRA (1-800-448-6472) for help  \\nWhat if I do not have an FDA-cleared sharps disposal container or proper household \\ncontainer? \\n• Call 1-800-4HUMIRA (1-800-448-6472) for a free FDA-cleared sharps disposal container  \\n  \\nAlways keep the Pen and the sharps disposal \\ncontainer out of reach of children.  \\n \\n   \\nKeep a record of the dates and locations of your \\ninjections. To help remember when to take \\nHUMIRA, mark your calendar ahead of time.  \\n \\n   \\nThis Instructions for Use has been approved \\nby the U.S. Food and Drug Administration. \\nRevised 02/2021 \\nManufactured by AbbVie Inc. North Chicago, IL 60064 U.S.A. \\nUS License Number 1889  20066945  \\n \\n  \\n \\n \\n'}, 'page_char_count': 1111, 'page_word_count': 174, 'sentences': ['Questions About Using the HUMIRA Pen \\n \\nWhat if I have not received in person training from a healthcare provider?', '\\n• Call your healthcare provider or 1-800-4HUMIRA (1-800-448-6472) or visit \\nwww.HUMIRA.com if you need help  \\nHow do I know when the injection is complete?', '\\n• The yellow indicator has stopped moving.', 'This takes up to 10 seconds.', ' \\nWhat should I do if there are more than a few drops of liquid on the injection site?', '\\n• Call 1-800-4HUMIRA (1-800-448-6472) for help  \\nWhat if I do not have an FDA-cleared sharps disposal container or proper household \\ncontainer?', '\\n• Call 1-800-4HUMIRA (1-800-448-6472) for a free FDA-cleared sharps disposal container  \\n  \\nAlways keep the Pen and the sharps disposal \\ncontainer out of reach of children.', ' \\n \\n   \\nKeep a record of the dates and locations of your \\ninjections.', 'To help remember when to take \\nHUMIRA, mark your calendar ahead of time.', ' \\n \\n   \\nThis Instructions for Use has been approved \\nby the U.S. Food and Drug Administration.', '\\nRevised 02/2021 \\nManufactured by AbbVie Inc. North Chicago, IL 60064 U.S.A. \\nUS License Number 1889  20066945  \\n \\n  \\n \\n \\n'], 'page_sentence_count_spacy': 11}\n",
            "{'page_number': 87, 'text': ' \\n \\n \\n  \\nINSTRUCTIONS FOR USE \\nHUMIRA® (Hu-MARE-ah)  \\n(adalimumab) \\nPackages containing 80 mg/0.8 mL \\nSingle-Dose Pen \\nBefore Injecting: Your healthcare provider should show you how to use HUMIRA before you \\nuse it for the first time. Call your healthcare provider or 1-800-4HUMIRA (1-800-448-6472) if \\nyou need help. \\n Important Information You Need to Know Before Injecting HUMIRA \\nDo not use the Pen and call your healthcare provider or pharmacist if:  \\n• Liquid is cloudy, discolored, or has flakes or \\nparticles in it \\n• Expiration date has passed \\n• Liquid has been frozen (even if thawed) or \\nleft in direct sunlight \\n• The Pen has been dropped or crushed \\nKeep the caps on until right before your injection.  \\n \\nHow should I store HUMIRA? \\n', 'processed_text': {'sentences': [{'original_sentence': ' \\n \\n \\n  \\nINSTRUCTIONS FOR USE \\nHUMIRA® (Hu-MARE-ah)  \\n(adalimumab) \\nPackages containing 80 mg/0.8 mL \\nSingle-Dose Pen \\nBefore Injecting: Your healthcare provider should show you how to use HUMIRA before you \\nuse it for the first time.', 'tokens': ['INSTRUCTIONS', 'USE', 'HUMIRA®', '(', 'Hu-MARE-ah', ')', '(', 'adalimumab', ')', 'Packages', 'containing', '80', 'mg/0.8', 'mL', 'Single-Dose', 'Pen', 'Injecting', ':', 'healthcare', 'provider', 'show', 'use', 'HUMIRA', 'use', 'first', 'time', '.'], 'lemmatized': ['INSTRUCTIONS', 'USE', 'HUMIRA®', '(', 'Hu-MARE-ah', ')', '(', 'adalimumab', ')', 'Packages', 'containing', '80', 'mg/0.8', 'mL', 'Single-Dose', 'Pen', 'Injecting', ':', 'healthcare', 'provider', 'show', 'use', 'HUMIRA', 'use', 'first', 'time', '.'], 'stemmed': ['instruct', 'use', 'humira®', '(', 'hu-mare-ah', ')', '(', 'adalimumab', ')', 'packag', 'contain', '80', 'mg/0.8', 'ml', 'single-dos', 'pen', 'inject', ':', 'healthcar', 'provid', 'show', 'use', 'humira', 'use', 'first', 'time', '.'], 'dependencies': [('instruct', 'aux'), ('use', 'ROOT'), ('humira', 'compound'), ('®', 'nmod'), ('(', 'punct'), ('hu', 'appos'), ('-', 'punct'), ('mare', 'npadvmod'), ('-', 'punct'), ('ah', 'intj'), (')', 'punct'), ('(', 'punct'), ('adalimumab', 'nmod'), (')', 'punct'), ('packag', 'nsubj'), ('contain', 'xcomp'), ('80', 'nummod'), ('mg/0.8', 'dobj'), ('ml', 'nmod'), ('single', 'amod'), ('-', 'punct'), ('dos', 'compound'), ('pen', 'compound'), ('inject', 'dobj'), (':', 'punct'), ('healthcar', 'compound'), ('provid', 'compound'), ('show', 'compound'), ('use', 'conj'), ('humira', 'dobj'), ('use', 'dobj'), ('first', 'amod'), ('time', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Call your healthcare provider or 1-800-4HUMIRA (1-800-448-6472) if \\nyou need help.', 'tokens': ['Call', 'healthcare', 'provider', '1-800-4HUMIRA', '(', '1-800-448-6472', ')', 'need', 'help', '.'], 'lemmatized': ['Call', 'healthcare', 'provider', '1-800-4HUMIRA', '(', '1-800-448-6472', ')', 'need', 'help', '.'], 'stemmed': ['call', 'healthcar', 'provid', '1-800-4humira', '(', '1-800-448-6472', ')', 'need', 'help', '.'], 'dependencies': [('call', 'ROOT'), ('healthcar', 'compound'), ('provid', 'dobj'), ('1', 'npadvmod'), ('-', 'punct'), ('800', 'dobj'), ('-', 'punct'), ('4humira', 'dobj'), ('(', 'punct'), ('1', 'appos'), ('-', 'punct'), ('800', 'prep'), ('-', 'punct'), ('448', 'nummod'), ('-', 'punct'), ('6472', 'appos'), (')', 'punct'), ('need', 'conj'), ('help', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Important Information You Need to Know Before Injecting HUMIRA \\nDo not use the Pen and call your healthcare provider or pharmacist if:  \\n• Liquid is cloudy, discolored, or has flakes or \\nparticles in it \\n• Expiration date has passed \\n• Liquid has been frozen (even if thawed) or \\nleft in direct sunlight \\n• The Pen has been dropped or crushed \\nKeep the caps on until right before your injection.', 'tokens': ['Important', 'Information', 'Need', 'Know', 'Injecting', 'HUMIRA', 'use', 'Pen', 'call', 'healthcare', 'provider', 'pharmacist', ':', '•', 'Liquid', 'cloudy', ',', 'discolored', ',', 'flakes', 'particles', '•', 'Expiration', 'date', 'passed', '•', 'Liquid', 'frozen', '(', 'even', 'thawed', ')', 'left', 'direct', 'sunlight', '•', 'Pen', 'dropped', 'crushed', 'Keep', 'caps', 'right', 'injection', '.'], 'lemmatized': ['Important', 'Information', 'Need', 'Know', 'Injecting', 'HUMIRA', 'use', 'Pen', 'call', 'healthcare', 'provider', 'pharmacist', ':', '•', 'Liquid', 'cloudy', ',', 'discolored', ',', 'flake', 'particle', '•', 'Expiration', 'date', 'passed', '•', 'Liquid', 'frozen', '(', 'even', 'thawed', ')', 'left', 'direct', 'sunlight', '•', 'Pen', 'dropped', 'crushed', 'Keep', 'cap', 'right', 'injection', '.'], 'stemmed': ['import', 'inform', 'need', 'know', 'inject', 'humira', 'use', 'pen', 'call', 'healthcar', 'provid', 'pharmacist', ':', '•', 'liquid', 'cloudi', ',', 'discolor', ',', 'flake', 'particl', '•', 'expir', 'date', 'pass', '•', 'liquid', 'frozen', '(', 'even', 'thaw', ')', 'left', 'direct', 'sunlight', '•', 'pen', 'drop', 'crush', 'keep', 'cap', 'right', 'inject', '.'], 'dependencies': [('import', 'compound'), ('inform', 'nsubj'), ('need', 'nsubj'), ('know', 'parataxis'), ('inject', 'compound'), ('humira', 'nsubj'), ('use', 'dep'), ('pen', 'compound'), ('call', 'compound'), ('healthcar', 'compound'), ('provid', 'compound'), ('pharmacist', 'dobj'), (':', 'punct'), ('•', 'nummod'), ('liquid', 'compound'), ('cloudi', 'nmod'), (',', 'punct'), ('discolor', 'conj'), (',', 'punct'), ('flake', 'compound'), ('particl', 'conj'), ('•', 'punct'), ('expir', 'compound'), ('date', 'nsubj'), ('pass', 'ROOT'), ('•', 'punct'), ('liquid', 'amod'), ('frozen', 'amod'), ('(', 'punct'), ('even', 'advmod'), ('thaw', 'dobj'), (')', 'punct'), ('left', 'ROOT'), ('direct', 'amod'), ('sunlight', 'dobj'), ('•', 'npadvmod'), ('pen', 'compound'), ('drop', 'compound'), ('crush', 'nsubj'), ('keep', 'conj'), ('cap', 'dobj'), ('right', 'advmod'), ('inject', 'oprd'), ('.', 'punct')]}, {'original_sentence': 'How should I store HUMIRA?', 'tokens': ['store', 'HUMIRA', '?'], 'lemmatized': ['store', 'HUMIRA', '?'], 'stemmed': ['store', 'humira', '?'], 'dependencies': [('store', 'compound'), ('humira', 'ROOT'), ('?', 'punct')]}], 'text': ' \\n \\n \\n  \\nINSTRUCTIONS FOR USE \\nHUMIRA® (Hu-MARE-ah)  \\n(adalimumab) \\nPackages containing 80 mg/0.8 mL \\nSingle-Dose Pen \\nBefore Injecting: Your healthcare provider should show you how to use HUMIRA before you \\nuse it for the first time. Call your healthcare provider or 1-800-4HUMIRA (1-800-448-6472) if \\nyou need help. \\n Important Information You Need to Know Before Injecting HUMIRA \\nDo not use the Pen and call your healthcare provider or pharmacist if:  \\n• Liquid is cloudy, discolored, or has flakes or \\nparticles in it \\n• Expiration date has passed \\n• Liquid has been frozen (even if thawed) or \\nleft in direct sunlight \\n• The Pen has been dropped or crushed \\nKeep the caps on until right before your injection.  \\n \\nHow should I store HUMIRA? \\n'}, 'page_char_count': 748, 'page_word_count': 118, 'sentences': [' \\n \\n \\n  \\nINSTRUCTIONS FOR USE \\nHUMIRA® (Hu-MARE-ah)  \\n(adalimumab) \\nPackages containing 80 mg/0.8 mL \\nSingle-Dose Pen \\nBefore Injecting: Your healthcare provider should show you how to use HUMIRA before you \\nuse it for the first time.', 'Call your healthcare provider or 1-800-4HUMIRA (1-800-448-6472) if \\nyou need help.', '\\n Important Information You Need to Know Before Injecting HUMIRA \\nDo not use the Pen and call your healthcare provider or pharmacist if:  \\n• Liquid is cloudy, discolored, or has flakes or \\nparticles in it \\n• Expiration date has passed \\n• Liquid has been frozen (even if thawed) or \\nleft in direct sunlight \\n• The Pen has been dropped or crushed \\nKeep the caps on until right before your injection.', ' \\n \\nHow should I store HUMIRA?', '\\n'], 'page_sentence_count_spacy': 5}\n",
            "{'page_number': 88, 'text': '• Store HUMIRA in the refrigerator between \\n36°F to 46°F (2°C to 8°C). \\n• Store HUMIRA in the original carton until \\nuse to protect it from light. \\n• Do not freeze \\n• Refrigerated HUMIRA may be used until \\nthe expiration date printed on the HUMIRA \\ncarton, dose tray or Pen. \\n• If needed, for example when you are \\ntraveling, you may also store HUMIRA at \\nroom temperature up to 77°F (25°C) for up \\nto 14 days.  \\n• Throw away HUMIRA if it has been kept at \\nroom temperature and not used within 14 \\ndays.  \\n• Record the date you first remove HUMIRA \\nfrom the refrigerator in the spaces provided \\non the carton and dose tray. \\n• Do not store HUMIRA in extreme heat or \\ncold. \\n \\nKeep HUMIRA, injection supplies, and all other medicines out of reach of children. \\n \\nRead Instructions on All Pages Before Using the HUMIRA Pen \\n \\n   \\n \\nTake HUMIRA out of the refrigerator.  \\nLeave HUMIRA at room temperature for 15 to \\n30 minutes before injecting.  \\n• Do not remove the Gray Cap (Cap #1) or \\nPlum-colored Cap (Cap #2) while allowing \\nHUMIRA to reach room temperature  \\n• Do not warm HUMIRA in any other way. \\nFor example, do not warm it in a \\nmicrowave or in hot water  \\n• Do not use the Pen if liquid has been \\nfrozen (even if thawed)  \\n', 'processed_text': {'sentences': [{'original_sentence': '• Store HUMIRA in the refrigerator between \\n36°F to 46°F (2°C to 8°C).', 'tokens': ['•', 'Store', 'HUMIRA', 'refrigerator', '36°F', '46°F', '(', '2°C', '8°C', ')', '.'], 'lemmatized': ['•', 'Store', 'HUMIRA', 'refrigerator', '36°F', '46°F', '(', '2°C', '8°C', ')', '.'], 'stemmed': ['•', 'store', 'humira', 'refriger', '36°f', '46°f', '(', '2°c', '8°c', ')', '.'], 'dependencies': [('•', 'nummod'), ('store', 'compound'), ('humira', 'compound'), ('refriger', 'ROOT'), ('36', 'nummod'), ('°', 'npadvmod'), ('f', 'npadvmod'), ('46', 'nummod'), ('°', 'npadvmod'), ('f', 'npadvmod'), ('(', 'punct'), ('2', 'appos'), ('°', 'cc'), ('c', 'npadvmod'), ('8', 'npadvmod'), ('°', 'nummod'), ('c', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': '• Store HUMIRA in the original carton until \\nuse to protect it from light.', 'tokens': ['•', 'Store', 'HUMIRA', 'original', 'carton', 'use', 'protect', 'light', '.'], 'lemmatized': ['•', 'Store', 'HUMIRA', 'original', 'carton', 'use', 'protect', 'light', '.'], 'stemmed': ['•', 'store', 'humira', 'origin', 'carton', 'use', 'protect', 'light', '.'], 'dependencies': [('•', 'nummod'), ('store', 'compound'), ('humira', 'compound'), ('origin', 'compound'), ('carton', 'compound'), ('use', 'compound'), ('protect', 'compound'), ('light', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• Do not freeze \\n• Refrigerated HUMIRA may be used until \\nthe expiration date printed on the HUMIRA \\ncarton, dose tray or Pen.', 'tokens': ['•', 'freeze', '•', 'Refrigerated', 'HUMIRA', 'may', 'used', 'expiration', 'date', 'printed', 'HUMIRA', 'carton', ',', 'dose', 'tray', 'Pen', '.'], 'lemmatized': ['•', 'freeze', '•', 'Refrigerated', 'HUMIRA', 'may', 'used', 'expiration', 'date', 'printed', 'HUMIRA', 'carton', ',', 'dose', 'tray', 'Pen', '.'], 'stemmed': ['•', 'freez', '•', 'refriger', 'humira', 'may', 'use', 'expir', 'date', 'print', 'humira', 'carton', ',', 'dose', 'tray', 'pen', '.'], 'dependencies': [('•', 'meta'), ('freez', 'compound'), ('•', 'nummod'), ('refriger', 'amod'), ('humira', 'nsubj'), ('may', 'aux'), ('use', 'ROOT'), ('expir', 'compound'), ('date', 'compound'), ('print', 'compound'), ('humira', 'compound'), ('carton', 'dobj'), (',', 'punct'), ('dose', 'xcomp'), ('tray', 'compound'), ('pen', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• If needed, for example when you are \\ntraveling, you may also store HUMIRA at \\nroom temperature up to 77°F (25°C) for up \\nto 14 days.', 'tokens': ['•', 'needed', ',', 'example', 'traveling', ',', 'may', 'also', 'store', 'HUMIRA', 'room', 'temperature', '77°F', '(', '25°C', ')', '14', 'days', '.'], 'lemmatized': ['•', 'needed', ',', 'example', 'traveling', ',', 'may', 'also', 'store', 'HUMIRA', 'room', 'temperature', '77°F', '(', '25°C', ')', '14', 'day', '.'], 'stemmed': ['•', 'need', ',', 'exampl', 'travel', ',', 'may', 'also', 'store', 'humira', 'room', 'temperatur', '77°f', '(', '25°c', ')', '14', 'day', '.'], 'dependencies': [('•', 'nummod'), ('need', 'advcl'), (',', 'punct'), ('exampl', 'nsubj'), ('travel', 'meta'), (',', 'punct'), ('may', 'aux'), ('also', 'advmod'), ('store', 'ROOT'), ('humira', 'compound'), ('room', 'dobj'), ('temperatur', 'nmod'), ('77', 'nummod'), ('°', 'npadvmod'), ('f', 'dobj'), ('(', 'punct'), ('25', 'nummod'), ('°', 'appos'), ('c', 'punct'), (')', 'punct'), ('14', 'nummod'), ('day', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': '• Throw away HUMIRA if it has been kept at \\nroom temperature and not used within 14 \\ndays.', 'tokens': ['•', 'Throw', 'away', 'HUMIRA', 'kept', 'room', 'temperature', 'used', 'within', '14', 'days', '.'], 'lemmatized': ['•', 'Throw', 'away', 'HUMIRA', 'kept', 'room', 'temperature', 'used', 'within', '14', 'day', '.'], 'stemmed': ['•', 'throw', 'away', 'humira', 'kept', 'room', 'temperatur', 'use', 'within', '14', 'day', '.'], 'dependencies': [('•', 'npadvmod'), ('throw', 'csubj'), ('away', 'prt'), ('humira', 'dobj'), ('kept', 'ROOT'), ('room', 'compound'), ('temperatur', 'compound'), ('use', 'dobj'), ('within', 'prep'), ('14', 'nummod'), ('day', 'pobj'), ('.', 'punct')]}, {'original_sentence': '• Record the date you first remove HUMIRA \\nfrom the refrigerator in the spaces provided \\non the carton and dose tray.', 'tokens': ['•', 'Record', 'date', 'first', 'remove', 'HUMIRA', 'refrigerator', 'spaces', 'provided', 'carton', 'dose', 'tray', '.'], 'lemmatized': ['•', 'Record', 'date', 'first', 'remove', 'HUMIRA', 'refrigerator', 'space', 'provided', 'carton', 'dose', 'tray', '.'], 'stemmed': ['•', 'record', 'date', 'first', 'remov', 'humira', 'refriger', 'space', 'provid', 'carton', 'dose', 'tray', '.'], 'dependencies': [('•', 'nummod'), ('record', 'compound'), ('date', 'compound'), ('first', 'amod'), ('remov', 'compound'), ('humira', 'compound'), ('refriger', 'compound'), ('space', 'compound'), ('provid', 'compound'), ('carton', 'compound'), ('dose', 'compound'), ('tray', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• Do not store HUMIRA in extreme heat or \\ncold.', 'tokens': ['•', 'store', 'HUMIRA', 'extreme', 'heat', 'cold', '.'], 'lemmatized': ['•', 'store', 'HUMIRA', 'extreme', 'heat', 'cold', '.'], 'stemmed': ['•', 'store', 'humira', 'extrem', 'heat', 'cold', '.'], 'dependencies': [('•', 'nummod'), ('store', 'compound'), ('humira', 'compound'), ('extrem', 'compound'), ('heat', 'compound'), ('cold', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Keep HUMIRA, injection supplies, and all other medicines out of reach of children.', 'tokens': ['Keep', 'HUMIRA', ',', 'injection', 'supplies', ',', 'medicines', 'reach', 'children', '.'], 'lemmatized': ['Keep', 'HUMIRA', ',', 'injection', 'supply', ',', 'medicine', 'reach', 'child', '.'], 'stemmed': ['keep', 'humira', ',', 'inject', 'suppli', ',', 'medicin', 'reach', 'child', '.'], 'dependencies': [('keep', 'advcl'), ('humira', 'dobj'), (',', 'punct'), ('inject', 'compound'), ('suppli', 'conj'), (',', 'punct'), ('medicin', 'nsubj'), ('reach', 'ROOT'), ('child', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Read Instructions on All Pages Before Using the HUMIRA Pen \\n \\n   \\n \\nTake HUMIRA out of the refrigerator.', 'tokens': ['Read', 'Instructions', 'Pages', 'Using', 'HUMIRA', 'Pen', 'Take', 'HUMIRA', 'refrigerator', '.'], 'lemmatized': ['Read', 'Instructions', 'Pages', 'Using', 'HUMIRA', 'Pen', 'Take', 'HUMIRA', 'refrigerator', '.'], 'stemmed': ['read', 'instruct', 'page', 'use', 'humira', 'pen', 'take', 'humira', 'refriger', '.'], 'dependencies': [('read', 'advcl'), ('instruct', 'compound'), ('page', 'compound'), ('use', 'compound'), ('humira', 'compound'), ('pen', 'nsubj'), ('take', 'ROOT'), ('humira', 'compound'), ('refriger', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Leave HUMIRA at room temperature for 15 to \\n30 minutes before injecting.', 'tokens': ['Leave', 'HUMIRA', 'room', 'temperature', '15', '30', 'minutes', 'injecting', '.'], 'lemmatized': ['Leave', 'HUMIRA', 'room', 'temperature', '15', '30', 'minute', 'injecting', '.'], 'stemmed': ['leav', 'humira', 'room', 'temperatur', '15', '30', 'minut', 'inject', '.'], 'dependencies': [('leav', 'amod'), ('humira', 'compound'), ('room', 'compound'), ('temperatur', 'ROOT'), ('15', 'nummod'), ('30', 'nummod'), ('minut', 'compound'), ('inject', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• Do not remove the Gray Cap (Cap #1) or \\nPlum-colored Cap (Cap #2) while allowing \\nHUMIRA to reach room temperature  \\n• Do not warm HUMIRA in any other way.', 'tokens': ['•', 'remove', 'Gray', 'Cap', '(', 'Cap', '#', '1', ')', 'Plum-colored', 'Cap', '(', 'Cap', '#', '2', ')', 'allowing', 'HUMIRA', 'reach', 'room', 'temperature', '•', 'warm', 'HUMIRA', 'way', '.'], 'lemmatized': ['•', 'remove', 'Gray', 'Cap', '(', 'Cap', '#', '1', ')', 'Plum-colored', 'Cap', '(', 'Cap', '#', '2', ')', 'allowing', 'HUMIRA', 'reach', 'room', 'temperature', '•', 'warm', 'HUMIRA', 'way', '.'], 'stemmed': ['•', 'remov', 'gray', 'cap', '(', 'cap', '#', '1', ')', 'plum-color', 'cap', '(', 'cap', '#', '2', ')', 'allow', 'humira', 'reach', 'room', 'temperatur', '•', 'warm', 'humira', 'way', '.'], 'dependencies': [('•', 'nummod'), ('remov', 'amod'), ('gray', 'amod'), ('cap', 'nsubj'), ('(', 'punct'), ('cap', 'parataxis'), ('#', 'npadvmod'), ('1', 'nummod'), (')', 'punct'), ('plum', 'compound'), ('-', 'punct'), ('color', 'compound'), ('cap', 'appos'), ('(', 'punct'), ('cap', 'parataxis'), ('#', 'nmod'), ('2', 'nummod'), (')', 'punct'), ('allow', 'ROOT'), ('humira', 'nsubj'), ('reach', 'ccomp'), ('room', 'dobj'), ('temperatur', 'advmod'), ('•', 'appos'), ('warm', 'amod'), ('humira', 'compound'), ('way', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'For example, do not warm it in a \\nmicrowave or in hot water  \\n• Do not use the Pen if liquid has been \\nfrozen (even if thawed)', 'tokens': ['example', ',', 'warm', 'microwave', 'hot', 'water', '•', 'use', 'Pen', 'liquid', 'frozen', '(', 'even', 'thawed', ')'], 'lemmatized': ['example', ',', 'warm', 'microwave', 'hot', 'water', '•', 'use', 'Pen', 'liquid', 'frozen', '(', 'even', 'thawed', ')'], 'stemmed': ['exampl', ',', 'warm', 'microwav', 'hot', 'water', '•', 'use', 'pen', 'liquid', 'frozen', '(', 'even', 'thaw', ')'], 'dependencies': [('exampl', 'ROOT'), (',', 'punct'), ('warm', 'amod'), ('microwav', 'nmod'), ('hot', 'amod'), ('water', 'nmod'), ('•', 'nummod'), ('use', 'compound'), ('pen', 'compound'), ('liquid', 'appos'), ('frozen', 'amod'), ('(', 'punct'), ('even', 'advmod'), ('thaw', 'appos'), (')', 'punct')]}], 'text': '• Store HUMIRA in the refrigerator between \\n36°F to 46°F (2°C to 8°C). \\n• Store HUMIRA in the original carton until \\nuse to protect it from light. \\n• Do not freeze \\n• Refrigerated HUMIRA may be used until \\nthe expiration date printed on the HUMIRA \\ncarton, dose tray or Pen. \\n• If needed, for example when you are \\ntraveling, you may also store HUMIRA at \\nroom temperature up to 77°F (25°C) for up \\nto 14 days.  \\n• Throw away HUMIRA if it has been kept at \\nroom temperature and not used within 14 \\ndays.  \\n• Record the date you first remove HUMIRA \\nfrom the refrigerator in the spaces provided \\non the carton and dose tray. \\n• Do not store HUMIRA in extreme heat or \\ncold. \\n \\nKeep HUMIRA, injection supplies, and all other medicines out of reach of children. \\n \\nRead Instructions on All Pages Before Using the HUMIRA Pen \\n \\n   \\n \\nTake HUMIRA out of the refrigerator.  \\nLeave HUMIRA at room temperature for 15 to \\n30 minutes before injecting.  \\n• Do not remove the Gray Cap (Cap #1) or \\nPlum-colored Cap (Cap #2) while allowing \\nHUMIRA to reach room temperature  \\n• Do not warm HUMIRA in any other way. \\nFor example, do not warm it in a \\nmicrowave or in hot water  \\n• Do not use the Pen if liquid has been \\nfrozen (even if thawed)  \\n'}, 'page_char_count': 1232, 'page_word_count': 223, 'sentences': ['• Store HUMIRA in the refrigerator between \\n36°F to 46°F (2°C to 8°C).', '\\n• Store HUMIRA in the original carton until \\nuse to protect it from light.', '\\n• Do not freeze \\n• Refrigerated HUMIRA may be used until \\nthe expiration date printed on the HUMIRA \\ncarton, dose tray or Pen.', '\\n• If needed, for example when you are \\ntraveling, you may also store HUMIRA at \\nroom temperature up to 77°F (25°C) for up \\nto 14 days.', ' \\n• Throw away HUMIRA if it has been kept at \\nroom temperature and not used within 14 \\ndays.', ' \\n• Record the date you first remove HUMIRA \\nfrom the refrigerator in the spaces provided \\non the carton and dose tray.', '\\n• Do not store HUMIRA in extreme heat or \\ncold.', '\\n \\nKeep HUMIRA, injection supplies, and all other medicines out of reach of children.', '\\n \\nRead Instructions on All Pages Before Using the HUMIRA Pen \\n \\n   \\n \\nTake HUMIRA out of the refrigerator.', ' \\nLeave HUMIRA at room temperature for 15 to \\n30 minutes before injecting.', ' \\n• Do not remove the Gray Cap (Cap #1) or \\nPlum-colored Cap (Cap #2) while allowing \\nHUMIRA to reach room temperature  \\n• Do not warm HUMIRA in any other way.', '\\nFor example, do not warm it in a \\nmicrowave or in hot water  \\n• Do not use the Pen if liquid has been \\nfrozen (even if thawed)  \\n'], 'page_sentence_count_spacy': 12}\n",
            "{'page_number': 89, 'text': ' \\n   \\n \\nCheck expiration date on the Pen label. Do not \\nuse the Pen if expiration date has passed.  \\nPlace the following on a clean, flat surface:  \\n• 1 single-dose Pen and alcohol swab \\n• 1 cotton ball or gauze pad (not included) \\n• Puncture-resistant sharps disposal \\ncontainer (not included). See Step 9 at the \\nend of this Instructions for Use for \\ninstructions on how to throw away (dispose \\nof) your HUMIRA Pen  \\nWash and dry your hands.  \\n \\n   \\n \\nChoose an injection site:  \\n• On the front of your thighs or \\n• Your abdomen (belly) at least 2 inches from \\nyour navel (belly button)  \\n• Different from your last injection site \\nWipe the injection site in a circular motion with \\nthe alcohol swab.  \\n• Do not inject through clothes  \\n• Do not inject into skin that is sore, bruised, \\nred, hard, scarred, has stretch marks, or \\nareas with psoriasis plaques  \\n \\n   \\n \\nHold the Pen with the Gray Cap #1 facing up. \\nCheck the window.  \\n• It is normal to see 1 or more bubbles in the \\nwindow  \\n• Make sure the liquid is clear and colorless \\n• Do not use the Pen if the liquid is cloudy, \\ndiscolored, or has flakes or particles in it  \\n• Do not use the Pen if it has been dropped \\nor crushed  \\n', 'processed_text': {'sentences': [{'original_sentence': ' \\n   \\n \\nCheck expiration date on the Pen label.', 'tokens': ['Check', 'expiration', 'date', 'Pen', 'label', '.'], 'lemmatized': ['Check', 'expiration', 'date', 'Pen', 'label', '.'], 'stemmed': ['check', 'expir', 'date', 'pen', 'label', '.'], 'dependencies': [('check', 'ROOT'), ('expir', 'compound'), ('date', 'compound'), ('pen', 'compound'), ('label', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Do not \\nuse the Pen if expiration date has passed.', 'tokens': ['use', 'Pen', 'expiration', 'date', 'passed', '.'], 'lemmatized': ['use', 'Pen', 'expiration', 'date', 'passed', '.'], 'stemmed': ['use', 'pen', 'expir', 'date', 'pass', '.'], 'dependencies': [('use', 'ROOT'), ('pen', 'compound'), ('expir', 'compound'), ('date', 'compound'), ('pass', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Place the following on a clean, flat surface:  \\n• 1 single-dose Pen and alcohol swab \\n• 1 cotton ball or gauze pad (not included) \\n• Puncture-resistant sharps disposal \\ncontainer (not included).', 'tokens': ['Place', 'following', 'clean', ',', 'flat', 'surface', ':', '•', '1', 'single-dose', 'Pen', 'alcohol', 'swab', '•', '1', 'cotton', 'ball', 'gauze', 'pad', '(', 'included', ')', '•', 'Puncture-resistant', 'sharps', 'disposal', 'container', '(', 'included', ')', '.'], 'lemmatized': ['Place', 'following', 'clean', ',', 'flat', 'surface', ':', '•', '1', 'single-dose', 'Pen', 'alcohol', 'swab', '•', '1', 'cotton', 'ball', 'gauze', 'pad', '(', 'included', ')', '•', 'Puncture-resistant', 'sharp', 'disposal', 'container', '(', 'included', ')', '.'], 'stemmed': ['place', 'follow', 'clean', ',', 'flat', 'surfac', ':', '•', '1', 'single-dos', 'pen', 'alcohol', 'swab', '•', '1', 'cotton', 'ball', 'gauz', 'pad', '(', 'includ', ')', '•', 'puncture-resist', 'sharp', 'dispos', 'contain', '(', 'includ', ')', '.'], 'dependencies': [('place', 'nsubj'), ('follow', 'ROOT'), ('clean', 'amod'), (',', 'punct'), ('flat', 'amod'), ('surfac', 'dobj'), (':', 'punct'), ('•', 'nummod'), ('1', 'nummod'), ('single', 'amod'), ('-', 'punct'), ('dos', 'compound'), ('pen', 'compound'), ('alcohol', 'compound'), ('swab', 'nmod'), ('•', 'case'), ('1', 'nummod'), ('cotton', 'compound'), ('ball', 'compound'), ('gauz', 'compound'), ('pad', 'nsubj'), ('(', 'punct'), ('includ', 'nmod'), (')', 'punct'), ('•', 'appos'), ('puncture', 'amod'), ('-', 'punct'), ('resist', 'acl'), ('sharp', 'amod'), ('dispos', 'dobj'), ('contain', 'conj'), ('(', 'punct'), ('includ', 'dobj'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'See Step 9 at the \\nend of this Instructions for Use for \\ninstructions on how to throw away (dispose \\nof) your HUMIRA Pen  \\nWash and dry your hands.', 'tokens': ['See', 'Step', '9', 'end', 'Instructions', 'Use', 'instructions', 'throw', 'away', '(', 'dispose', ')', 'HUMIRA', 'Pen', 'Wash', 'dry', 'hands', '.'], 'lemmatized': ['See', 'Step', '9', 'end', 'Instructions', 'Use', 'instruction', 'throw', 'away', '(', 'dispose', ')', 'HUMIRA', 'Pen', 'Wash', 'dry', 'hand', '.'], 'stemmed': ['see', 'step', '9', 'end', 'instruct', 'use', 'instruct', 'throw', 'away', '(', 'dispos', ')', 'humira', 'pen', 'wash', 'dri', 'hand', '.'], 'dependencies': [('see', 'ROOT'), ('step', 'nmod'), ('9', 'nummod'), ('end', 'compound'), ('instruct', 'compound'), ('use', 'compound'), ('instruct', 'nsubj'), ('throw', 'xcomp'), ('away', 'advmod'), ('(', 'punct'), ('dispos', 'dep'), (')', 'punct'), ('humira', 'compound'), ('pen', 'nsubj'), ('wash', 'ccomp'), ('dri', 'compound'), ('hand', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Choose an injection site:  \\n• On the front of your thighs or \\n• Your abdomen (belly) at least 2 inches from \\nyour navel (belly button)  \\n• Different from your last injection site \\nWipe the injection site in a circular motion with \\nthe alcohol swab.', 'tokens': ['Choose', 'injection', 'site', ':', '•', 'front', 'thighs', '•', 'abdomen', '(', 'belly', ')', 'least', '2', 'inches', 'navel', '(', 'belly', 'button', ')', '•', 'Different', 'last', 'injection', 'site', 'Wipe', 'injection', 'site', 'circular', 'motion', 'alcohol', 'swab', '.'], 'lemmatized': ['Choose', 'injection', 'site', ':', '•', 'front', 'thigh', '•', 'abdomen', '(', 'belly', ')', 'least', '2', 'inch', 'navel', '(', 'belly', 'button', ')', '•', 'Different', 'last', 'injection', 'site', 'Wipe', 'injection', 'site', 'circular', 'motion', 'alcohol', 'swab', '.'], 'stemmed': ['choos', 'inject', 'site', ':', '•', 'front', 'thigh', '•', 'abdomen', '(', 'belli', ')', 'least', '2', 'inch', 'navel', '(', 'belli', 'button', ')', '•', 'differ', 'last', 'inject', 'site', 'wipe', 'inject', 'site', 'circular', 'motion', 'alcohol', 'swab', '.'], 'dependencies': [('choos', 'compound'), ('inject', 'compound'), ('site', 'nsubj'), (':', 'punct'), ('•', 'nummod'), ('front', 'amod'), ('thigh', 'compound'), ('•', 'nummod'), ('abdomen', 'appos'), ('(', 'punct'), ('belli', 'appos'), (')', 'punct'), ('least', 'advmod'), ('2', 'nummod'), ('inch', 'compound'), ('navel', 'conj'), ('(', 'punct'), ('belli', 'compound'), ('button', 'appos'), (')', 'punct'), ('•', 'nummod'), ('differ', 'ROOT'), ('last', 'amod'), ('inject', 'compound'), ('site', 'nmod'), ('wipe', 'nmod'), ('inject', 'nmod'), ('site', 'compound'), ('circular', 'amod'), ('motion', 'compound'), ('alcohol', 'compound'), ('swab', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• Do not inject through clothes  \\n• Do not inject into skin that is sore, bruised, \\nred, hard, scarred, has stretch marks, or \\nareas with psoriasis plaques  \\n \\n   \\n \\nHold the Pen with the Gray Cap #1 facing up.', 'tokens': ['•', 'inject', 'clothes', '•', 'inject', 'skin', 'sore', ',', 'bruised', ',', 'red', ',', 'hard', ',', 'scarred', ',', 'stretch', 'marks', ',', 'areas', 'psoriasis', 'plaques', 'Hold', 'Pen', 'Gray', 'Cap', '#', '1', 'facing', '.'], 'lemmatized': ['•', 'inject', 'clothes', '•', 'inject', 'skin', 'sore', ',', 'bruised', ',', 'red', ',', 'hard', ',', 'scarred', ',', 'stretch', 'mark', ',', 'area', 'psoriasis', 'plaque', 'Hold', 'Pen', 'Gray', 'Cap', '#', '1', 'facing', '.'], 'stemmed': ['•', 'inject', 'cloth', '•', 'inject', 'skin', 'sore', ',', 'bruis', ',', 'red', ',', 'hard', ',', 'scar', ',', 'stretch', 'mark', ',', 'area', 'psoriasi', 'plaqu', 'hold', 'pen', 'gray', 'cap', '#', '1', 'face', '.'], 'dependencies': [('•', 'nummod'), ('inject', 'compound'), ('cloth', 'nmod'), ('•', 'appos'), ('inject', 'amod'), ('skin', 'dep'), ('sore', 'amod'), (',', 'punct'), ('bruis', 'conj'), (',', 'punct'), ('red', 'conj'), (',', 'punct'), ('hard', 'conj'), (',', 'punct'), ('scar', 'conj'), (',', 'punct'), ('stretch', 'compound'), ('mark', 'conj'), (',', 'punct'), ('area', 'compound'), ('psoriasi', 'compound'), ('plaqu', 'nsubj'), ('hold', 'ROOT'), ('pen', 'compound'), ('gray', 'amod'), ('cap', 'compound'), ('#', 'nmod'), ('1', 'nummod'), ('face', 'ccomp'), ('.', 'punct')]}, {'original_sentence': 'Check the window.', 'tokens': ['Check', 'window', '.'], 'lemmatized': ['Check', 'window', '.'], 'stemmed': ['check', 'window', '.'], 'dependencies': [('check', 'ROOT'), ('window', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• It is normal to see 1 or more bubbles in the \\nwindow  \\n• Make sure the liquid is clear and colorless \\n• Do not use the Pen if the liquid is cloudy, \\ndiscolored, or has flakes or particles in it  \\n• Do not use the Pen if it has been dropped \\nor crushed', 'tokens': ['•', 'normal', 'see', '1', 'bubbles', 'window', '•', 'Make', 'sure', 'liquid', 'clear', 'colorless', '•', 'use', 'Pen', 'liquid', 'cloudy', ',', 'discolored', ',', 'flakes', 'particles', '•', 'use', 'Pen', 'dropped', 'crushed'], 'lemmatized': ['•', 'normal', 'see', '1', 'bubble', 'window', '•', 'Make', 'sure', 'liquid', 'clear', 'colorless', '•', 'use', 'Pen', 'liquid', 'cloudy', ',', 'discolored', ',', 'flake', 'particle', '•', 'use', 'Pen', 'dropped', 'crushed'], 'stemmed': ['•', 'normal', 'see', '1', 'bubbl', 'window', '•', 'make', 'sure', 'liquid', 'clear', 'colorless', '•', 'use', 'pen', 'liquid', 'cloudi', ',', 'discolor', ',', 'flake', 'particl', '•', 'use', 'pen', 'drop', 'crush'], 'dependencies': [('•', 'nummod'), ('normal', 'amod'), ('see', 'dep'), ('1', 'nummod'), ('bubbl', 'compound'), ('window', 'nsubj'), ('•', 'appos'), ('make', 'ROOT'), ('sure', 'amod'), ('liquid', 'amod'), ('clear', 'amod'), ('colorless', 'dobj'), ('•', 'punct'), ('use', 'ccomp'), ('pen', 'compound'), ('liquid', 'compound'), ('cloudi', 'dobj'), (',', 'punct'), ('discolor', 'conj'), (',', 'punct'), ('flake', 'compound'), ('particl', 'conj'), ('•', 'punct'), ('use', 'compound'), ('pen', 'compound'), ('drop', 'compound'), ('crush', 'dobj')]}], 'text': ' \\n   \\n \\nCheck expiration date on the Pen label. Do not \\nuse the Pen if expiration date has passed.  \\nPlace the following on a clean, flat surface:  \\n• 1 single-dose Pen and alcohol swab \\n• 1 cotton ball or gauze pad (not included) \\n• Puncture-resistant sharps disposal \\ncontainer (not included). See Step 9 at the \\nend of this Instructions for Use for \\ninstructions on how to throw away (dispose \\nof) your HUMIRA Pen  \\nWash and dry your hands.  \\n \\n   \\n \\nChoose an injection site:  \\n• On the front of your thighs or \\n• Your abdomen (belly) at least 2 inches from \\nyour navel (belly button)  \\n• Different from your last injection site \\nWipe the injection site in a circular motion with \\nthe alcohol swab.  \\n• Do not inject through clothes  \\n• Do not inject into skin that is sore, bruised, \\nred, hard, scarred, has stretch marks, or \\nareas with psoriasis plaques  \\n \\n   \\n \\nHold the Pen with the Gray Cap #1 facing up. \\nCheck the window.  \\n• It is normal to see 1 or more bubbles in the \\nwindow  \\n• Make sure the liquid is clear and colorless \\n• Do not use the Pen if the liquid is cloudy, \\ndiscolored, or has flakes or particles in it  \\n• Do not use the Pen if it has been dropped \\nor crushed  \\n'}, 'page_char_count': 1193, 'page_word_count': 214, 'sentences': [' \\n   \\n \\nCheck expiration date on the Pen label.', 'Do not \\nuse the Pen if expiration date has passed.', ' \\nPlace the following on a clean, flat surface:  \\n• 1 single-dose Pen and alcohol swab \\n• 1 cotton ball or gauze pad (not included) \\n• Puncture-resistant sharps disposal \\ncontainer (not included).', 'See Step 9 at the \\nend of this Instructions for Use for \\ninstructions on how to throw away (dispose \\nof) your HUMIRA Pen  \\nWash and dry your hands.', ' \\n \\n   \\n \\nChoose an injection site:  \\n• On the front of your thighs or \\n• Your abdomen (belly) at least 2 inches from \\nyour navel (belly button)  \\n• Different from your last injection site \\nWipe the injection site in a circular motion with \\nthe alcohol swab.', ' \\n• Do not inject through clothes  \\n• Do not inject into skin that is sore, bruised, \\nred, hard, scarred, has stretch marks, or \\nareas with psoriasis plaques  \\n \\n   \\n \\nHold the Pen with the Gray Cap #1 facing up.', '\\nCheck the window.', ' \\n• It is normal to see 1 or more bubbles in the \\nwindow  \\n• Make sure the liquid is clear and colorless \\n• Do not use the Pen if the liquid is cloudy, \\ndiscolored, or has flakes or particles in it  \\n• Do not use the Pen if it has been dropped \\nor crushed  \\n'], 'page_sentence_count_spacy': 8}\n",
            "{'page_number': 90, 'text': ' \\n   \\n \\nPull the Gray Cap #1 straight off.  \\nThrow the cap away.  \\n• It is normal to see a few drops of liquid \\ncome out of the needle  \\nPull the Plum-colored Cap #2 straight off.  \\nThrow the cap away.  \\nTurn the Pen so that the white arrow points \\ntoward the injection site.  \\n \\n   \\n \\nSqueeze the skin at your injection site to make \\na raised area and hold it firmly until the \\ninjection is complete.  \\nPoint the white arrow toward the injection site.  \\nPlace the white needle sleeve straight (90° \\nangle) against the injection site.  \\nHold the Pen so that you can see the \\ninspection window.  \\n \\nDo not press the plum activator button until \\nyou are ready to inject.  \\n \\n   \\n \\nIt is important that you firmly push the Pen \\ndown all the way against the injection site \\nbefore starting the injection.  \\nPress the plum activator button and count \\nslowly for 15 seconds.  \\n• A loud “click” will signal the start of the \\ninjection  \\n• Keep pushing the Pen down firmly \\nagainst the injection site until the injection is \\ncomplete  \\n• Injection is complete when the yellow \\nindicator has stopped moving \\n', 'processed_text': {'sentences': [{'original_sentence': ' \\n   \\n \\nPull the Gray Cap #1 straight off.', 'tokens': ['Pull', 'Gray', 'Cap', '#', '1', 'straight', '.'], 'lemmatized': ['Pull', 'Gray', 'Cap', '#', '1', 'straight', '.'], 'stemmed': ['pull', 'gray', 'cap', '#', '1', 'straight', '.'], 'dependencies': [('pull', 'ROOT'), ('gray', 'amod'), ('cap', 'dobj'), ('#', 'npadvmod'), ('1', 'nummod'), ('straight', 'advmod'), ('.', 'punct')]}, {'original_sentence': 'Throw the cap away.', 'tokens': ['Throw', 'cap', 'away', '.'], 'lemmatized': ['Throw', 'cap', 'away', '.'], 'stemmed': ['throw', 'cap', 'away', '.'], 'dependencies': [('throw', 'ROOT'), ('cap', 'dobj'), ('away', 'advmod'), ('.', 'punct')]}, {'original_sentence': '• It is normal to see a few drops of liquid \\ncome out of the needle  \\nPull the Plum-colored Cap #2 straight off.', 'tokens': ['•', 'normal', 'see', 'drops', 'liquid', 'come', 'needle', 'Pull', 'Plum-colored', 'Cap', '#', '2', 'straight', '.'], 'lemmatized': ['•', 'normal', 'see', 'drop', 'liquid', 'come', 'needle', 'Pull', 'Plum-colored', 'Cap', '#', '2', 'straight', '.'], 'stemmed': ['•', 'normal', 'see', 'drop', 'liquid', 'come', 'needl', 'pull', 'plum-color', 'cap', '#', '2', 'straight', '.'], 'dependencies': [('•', 'nummod'), ('normal', 'amod'), ('see', 'compound'), ('drop', 'compound'), ('liquid', 'compound'), ('come', 'nsubj'), ('needl', 'ROOT'), ('pull', 'xcomp'), ('plum', 'compound'), ('-', 'punct'), ('color', 'compound'), ('cap', 'compound'), ('#', 'npadvmod'), ('2', 'nummod'), ('straight', 'advmod'), ('.', 'punct')]}, {'original_sentence': 'Throw the cap away.', 'tokens': ['Throw', 'cap', 'away', '.'], 'lemmatized': ['Throw', 'cap', 'away', '.'], 'stemmed': ['throw', 'cap', 'away', '.'], 'dependencies': [('throw', 'ROOT'), ('cap', 'dobj'), ('away', 'advmod'), ('.', 'punct')]}, {'original_sentence': 'Turn the Pen so that the white arrow points \\ntoward the injection site.', 'tokens': ['Turn', 'Pen', 'white', 'arrow', 'points', 'toward', 'injection', 'site', '.'], 'lemmatized': ['Turn', 'Pen', 'white', 'arrow', 'point', 'toward', 'injection', 'site', '.'], 'stemmed': ['turn', 'pen', 'white', 'arrow', 'point', 'toward', 'inject', 'site', '.'], 'dependencies': [('turn', 'ROOT'), ('pen', 'dobj'), ('white', 'amod'), ('arrow', 'compound'), ('point', 'npadvmod'), ('toward', 'prep'), ('inject', 'compound'), ('site', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'Squeeze the skin at your injection site to make \\na raised area and hold it firmly until the \\ninjection is complete.', 'tokens': ['Squeeze', 'skin', 'injection', 'site', 'make', 'raised', 'area', 'hold', 'firmly', 'injection', 'complete', '.'], 'lemmatized': ['Squeeze', 'skin', 'injection', 'site', 'make', 'raised', 'area', 'hold', 'firmly', 'injection', 'complete', '.'], 'stemmed': ['squeez', 'skin', 'inject', 'site', 'make', 'rais', 'area', 'hold', 'firmli', 'inject', 'complet', '.'], 'dependencies': [('squeez', 'compound'), ('skin', 'compound'), ('inject', 'compound'), ('site', 'nsubj'), ('make', 'ROOT'), ('rais', 'compound'), ('area', 'nsubj'), ('hold', 'ccomp'), ('firmli', 'compound'), ('inject', 'compound'), ('complet', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Point the white arrow toward the injection site.', 'tokens': ['Point', 'white', 'arrow', 'toward', 'injection', 'site', '.'], 'lemmatized': ['Point', 'white', 'arrow', 'toward', 'injection', 'site', '.'], 'stemmed': ['point', 'white', 'arrow', 'toward', 'inject', 'site', '.'], 'dependencies': [('point', 'ROOT'), ('white', 'amod'), ('arrow', 'dobj'), ('toward', 'prep'), ('inject', 'compound'), ('site', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'Place the white needle sleeve straight (90° \\nangle) against the injection site.', 'tokens': ['Place', 'white', 'needle', 'sleeve', 'straight', '(', '90°', 'angle', ')', 'injection', 'site', '.'], 'lemmatized': ['Place', 'white', 'needle', 'sleeve', 'straight', '(', '90°', 'angle', ')', 'injection', 'site', '.'], 'stemmed': ['place', 'white', 'needl', 'sleev', 'straight', '(', '90°', 'angl', ')', 'inject', 'site', '.'], 'dependencies': [('place', 'nsubj'), ('white', 'amod'), ('needl', 'ROOT'), ('sleev', 'dobj'), ('straight', 'advmod'), ('(', 'punct'), ('90', 'nummod'), ('°', 'npadvmod'), ('angl', 'conj'), (')', 'punct'), ('inject', 'compound'), ('site', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Hold the Pen so that you can see the \\ninspection window.', 'tokens': ['Hold', 'Pen', 'see', 'inspection', 'window', '.'], 'lemmatized': ['Hold', 'Pen', 'see', 'inspection', 'window', '.'], 'stemmed': ['hold', 'pen', 'see', 'inspect', 'window', '.'], 'dependencies': [('hold', 'ROOT'), ('pen', 'nsubj'), ('see', 'ccomp'), ('inspect', 'amod'), ('window', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Do not press the plum activator button until \\nyou are ready to inject.', 'tokens': ['press', 'plum', 'activator', 'button', 'ready', 'inject', '.'], 'lemmatized': ['press', 'plum', 'activator', 'button', 'ready', 'inject', '.'], 'stemmed': ['press', 'plum', 'activ', 'button', 'readi', 'inject', '.'], 'dependencies': [('press', 'compound'), ('plum', 'compound'), ('activ', 'compound'), ('button', 'compound'), ('readi', 'compound'), ('inject', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'It is important that you firmly push the Pen \\ndown all the way against the injection site \\nbefore starting the injection.', 'tokens': ['important', 'firmly', 'push', 'Pen', 'way', 'injection', 'site', 'starting', 'injection', '.'], 'lemmatized': ['important', 'firmly', 'push', 'Pen', 'way', 'injection', 'site', 'starting', 'injection', '.'], 'stemmed': ['import', 'firmli', 'push', 'pen', 'way', 'inject', 'site', 'start', 'inject', '.'], 'dependencies': [('import', 'nsubj'), ('firmli', 'amod'), ('push', 'ccomp'), ('pen', 'dobj'), ('way', 'npadvmod'), ('inject', 'compound'), ('site', 'nsubj'), ('start', 'ROOT'), ('inject', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Press the plum activator button and count \\nslowly for 15 seconds.', 'tokens': ['Press', 'plum', 'activator', 'button', 'count', 'slowly', '15', 'seconds', '.'], 'lemmatized': ['Press', 'plum', 'activator', 'button', 'count', 'slowly', '15', 'second', '.'], 'stemmed': ['press', 'plum', 'activ', 'button', 'count', 'slowli', '15', 'second', '.'], 'dependencies': [('press', 'compound'), ('plum', 'compound'), ('activ', 'compound'), ('button', 'compound'), ('count', 'nsubj'), ('slowli', 'ROOT'), ('15', 'nummod'), ('second', 'advmod'), ('.', 'punct')]}, {'original_sentence': '• A loud “click” will signal the start of the \\ninjection  \\n• Keep pushing the Pen down firmly \\nagainst the injection site until the injection is \\ncomplete  \\n• Injection is complete when the yellow \\nindicator has stopped moving', 'tokens': ['•', 'loud', '“', 'click', '”', 'signal', 'start', 'injection', '•', 'Keep', 'pushing', 'Pen', 'firmly', 'injection', 'site', 'injection', 'complete', '•', 'Injection', 'complete', 'yellow', 'indicator', 'stopped', 'moving'], 'lemmatized': ['•', 'loud', '“', 'click', '”', 'signal', 'start', 'injection', '•', 'Keep', 'pushing', 'Pen', 'firmly', 'injection', 'site', 'injection', 'complete', '•', 'Injection', 'complete', 'yellow', 'indicator', 'stopped', 'moving'], 'stemmed': ['•', 'loud', '“', 'click', '”', 'signal', 'start', 'inject', '•', 'keep', 'push', 'pen', 'firmli', 'inject', 'site', 'inject', 'complet', '•', 'inject', 'complet', 'yellow', 'indic', 'stop', 'move'], 'dependencies': [('•', 'meta'), ('loud', 'advmod'), ('“', 'punct'), ('click', 'amod'), ('”', 'punct'), ('signal', 'compound'), ('start', 'compound'), ('inject', 'nsubj'), ('•', 'nummod'), ('keep', 'ROOT'), ('push', 'compound'), ('pen', 'compound'), ('firmli', 'npadvmod'), ('inject', 'compound'), ('site', 'compound'), ('inject', 'compound'), ('complet', 'dep'), ('•', 'dep'), ('inject', 'amod'), ('complet', 'npadvmod'), ('yellow', 'amod'), ('indic', 'amod'), ('stop', 'compound'), ('move', 'xcomp')]}], 'text': ' \\n   \\n \\nPull the Gray Cap #1 straight off.  \\nThrow the cap away.  \\n• It is normal to see a few drops of liquid \\ncome out of the needle  \\nPull the Plum-colored Cap #2 straight off.  \\nThrow the cap away.  \\nTurn the Pen so that the white arrow points \\ntoward the injection site.  \\n \\n   \\n \\nSqueeze the skin at your injection site to make \\na raised area and hold it firmly until the \\ninjection is complete.  \\nPoint the white arrow toward the injection site.  \\nPlace the white needle sleeve straight (90° \\nangle) against the injection site.  \\nHold the Pen so that you can see the \\ninspection window.  \\n \\nDo not press the plum activator button until \\nyou are ready to inject.  \\n \\n   \\n \\nIt is important that you firmly push the Pen \\ndown all the way against the injection site \\nbefore starting the injection.  \\nPress the plum activator button and count \\nslowly for 15 seconds.  \\n• A loud “click” will signal the start of the \\ninjection  \\n• Keep pushing the Pen down firmly \\nagainst the injection site until the injection is \\ncomplete  \\n• Injection is complete when the yellow \\nindicator has stopped moving \\n'}, 'page_char_count': 1099, 'page_word_count': 186, 'sentences': [' \\n   \\n \\nPull the Gray Cap #1 straight off.', ' \\nThrow the cap away.', ' \\n• It is normal to see a few drops of liquid \\ncome out of the needle  \\nPull the Plum-colored Cap #2 straight off.', ' \\nThrow the cap away.', ' \\nTurn the Pen so that the white arrow points \\ntoward the injection site.', ' \\n \\n   \\n \\nSqueeze the skin at your injection site to make \\na raised area and hold it firmly until the \\ninjection is complete.', ' \\nPoint the white arrow toward the injection site.', ' \\nPlace the white needle sleeve straight (90° \\nangle) against the injection site.', ' \\nHold the Pen so that you can see the \\ninspection window.', ' \\n \\nDo not press the plum activator button until \\nyou are ready to inject.', ' \\n \\n   \\n \\nIt is important that you firmly push the Pen \\ndown all the way against the injection site \\nbefore starting the injection.', ' \\nPress the plum activator button and count \\nslowly for 15 seconds.', ' \\n• A loud “click” will signal the start of the \\ninjection  \\n• Keep pushing the Pen down firmly \\nagainst the injection site until the injection is \\ncomplete  \\n• Injection is complete when the yellow \\nindicator has stopped moving \\n'], 'page_sentence_count_spacy': 13}\n",
            "{'page_number': 91, 'text': ' \\n   \\n \\nWhen the injection is completed, slowly pull the \\nPen from the skin. The white needle sleeve will \\ncover the needle tip.  \\n• A small amount of liquid on the injection site \\nis normal  \\nIf there are more than a few drops of liquid on \\nthe injection site, call 1-800-4HUMIRA (1-800-\\n448-6472) for help.  \\nAfter completing the injection, place a cotton \\nball or gauze pad on the skin of the injection \\nsite.  \\n• Do not rub  \\n• Slight bleeding at the injection site is normal \\n', 'processed_text': {'sentences': [{'original_sentence': ' \\n   \\n \\nWhen the injection is completed, slowly pull the \\nPen from the skin.', 'tokens': ['injection', 'completed', ',', 'slowly', 'pull', 'Pen', 'skin', '.'], 'lemmatized': ['injection', 'completed', ',', 'slowly', 'pull', 'Pen', 'skin', '.'], 'stemmed': ['inject', 'complet', ',', 'slowli', 'pull', 'pen', 'skin', '.'], 'dependencies': [('inject', 'compound'), ('complet', 'ROOT'), (',', 'punct'), ('slowli', 'amod'), ('pull', 'amod'), ('pen', 'compound'), ('skin', 'appos'), ('.', 'punct')]}, {'original_sentence': 'The white needle sleeve will \\ncover the needle tip.', 'tokens': ['white', 'needle', 'sleeve', 'cover', 'needle', 'tip', '.'], 'lemmatized': ['white', 'needle', 'sleeve', 'cover', 'needle', 'tip', '.'], 'stemmed': ['white', 'needl', 'sleev', 'cover', 'needl', 'tip', '.'], 'dependencies': [('white', 'nsubj'), ('needl', 'compound'), ('sleev', 'compound'), ('cover', 'ROOT'), ('needl', 'compound'), ('tip', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• A small amount of liquid on the injection site \\nis normal  \\nIf there are more than a few drops of liquid on \\nthe injection site, call 1-800-4HUMIRA (1-800-\\n448-6472) for help.', 'tokens': ['•', 'small', 'amount', 'liquid', 'injection', 'site', 'normal', 'drops', 'liquid', 'injection', 'site', ',', 'call', '1-800-4HUMIRA', '(', '1-800-', '448-6472', ')', 'help', '.'], 'lemmatized': ['•', 'small', 'amount', 'liquid', 'injection', 'site', 'normal', 'drop', 'liquid', 'injection', 'site', ',', 'call', '1-800-4HUMIRA', '(', '1-800-', '448-6472', ')', 'help', '.'], 'stemmed': ['•', 'small', 'amount', 'liquid', 'inject', 'site', 'normal', 'drop', 'liquid', 'inject', 'site', ',', 'call', '1-800-4humira', '(', '1-800-', '448-6472', ')', 'help', '.'], 'dependencies': [('•', 'nummod'), ('small', 'amod'), ('amount', 'nmod'), ('liquid', 'nmod'), ('inject', 'nmod'), ('site', 'nmod'), ('normal', 'amod'), ('drop', 'nmod'), ('liquid', 'amod'), ('inject', 'compound'), ('site', 'npadvmod'), (',', 'punct'), ('call', 'nmod'), ('1', 'npadvmod'), ('-', 'punct'), ('800', 'dobj'), ('-', 'punct'), ('4humira', 'quantmod'), ('(', 'punct'), ('1', 'appos'), ('-', 'punct'), ('800-', 'compound'), ('448', 'dobj'), ('-', 'punct'), ('6472', 'prep'), (')', 'punct'), ('help', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'After completing the injection, place a cotton \\nball or gauze pad on the skin of the injection \\nsite.', 'tokens': ['completing', 'injection', ',', 'place', 'cotton', 'ball', 'gauze', 'pad', 'skin', 'injection', 'site', '.'], 'lemmatized': ['completing', 'injection', ',', 'place', 'cotton', 'ball', 'gauze', 'pad', 'skin', 'injection', 'site', '.'], 'stemmed': ['complet', 'inject', ',', 'place', 'cotton', 'ball', 'gauz', 'pad', 'skin', 'inject', 'site', '.'], 'dependencies': [('complet', 'compound'), ('inject', 'ROOT'), (',', 'punct'), ('place', 'compound'), ('cotton', 'compound'), ('ball', 'compound'), ('gauz', 'compound'), ('pad', 'compound'), ('skin', 'compound'), ('inject', 'compound'), ('site', 'appos'), ('.', 'punct')]}, {'original_sentence': '• Do not rub  \\n• Slight bleeding at the injection site is normal', 'tokens': ['•', 'rub', '•', 'Slight', 'bleeding', 'injection', 'site', 'normal'], 'lemmatized': ['•', 'rub', '•', 'Slight', 'bleeding', 'injection', 'site', 'normal'], 'stemmed': ['•', 'rub', '•', 'slight', 'bleed', 'inject', 'site', 'normal'], 'dependencies': [('•', 'meta'), ('rub', 'ROOT'), ('•', 'preconj'), ('slight', 'amod'), ('bleed', 'compound'), ('inject', 'compound'), ('site', 'dobj'), ('normal', 'amod')]}], 'text': ' \\n   \\n \\nWhen the injection is completed, slowly pull the \\nPen from the skin. The white needle sleeve will \\ncover the needle tip.  \\n• A small amount of liquid on the injection site \\nis normal  \\nIf there are more than a few drops of liquid on \\nthe injection site, call 1-800-4HUMIRA (1-800-\\n448-6472) for help.  \\nAfter completing the injection, place a cotton \\nball or gauze pad on the skin of the injection \\nsite.  \\n• Do not rub  \\n• Slight bleeding at the injection site is normal \\n'}, 'page_char_count': 481, 'page_word_count': 84, 'sentences': [' \\n   \\n \\nWhen the injection is completed, slowly pull the \\nPen from the skin.', 'The white needle sleeve will \\ncover the needle tip.', ' \\n• A small amount of liquid on the injection site \\nis normal  \\nIf there are more than a few drops of liquid on \\nthe injection site, call 1-800-4HUMIRA (1-800-\\n448-6472) for help.', ' \\nAfter completing the injection, place a cotton \\nball or gauze pad on the skin of the injection \\nsite.', ' \\n• Do not rub  \\n• Slight bleeding at the injection site is normal \\n'], 'page_sentence_count_spacy': 5}\n",
            "{'page_number': 92, 'text': ' \\n   \\nHow should I dispose of the used HUMIRA \\nPen? \\n• Put your used needles, Pens, and sharps in \\na FDA cleared sharps disposal container \\nright away after use. Do not throw away \\n(dispose of) loose needles, syringes, \\nand the Pen in the household trash.  \\n• If you do not have a FDA-cleared sharps \\ndisposal container, you may use a \\nhousehold container that is:  \\n◦ made of a heavy-duty plastic, \\n◦ can be closed with a tight-fitting, \\npuncture-resistant lid, without sharps \\nbeing able to come out,  \\n◦ upright and stable during use, \\n◦ leak-resistant, and  \\n◦ properly labeled to warn of hazardous \\nwaste inside the container. \\n• When your sharps disposal container is \\nalmost full, you will need to follow your \\ncommunity guidelines for the right way to \\ndispose of your sharps disposal container. \\nThere may be state or local laws about how \\nyou should throw away used needles and \\nsyringes. For more information about safe \\nsharps disposal, and for specific information \\nabout sharps disposal in the state that you \\nlive in, go to the FDA’s website at: \\nhttp://www.fda.gov/safesharpsdisposal.  \\n• Do not dispose of your used sharps \\ndisposal container in your household trash \\nunless your community guidelines permit \\nthis. Do not recycle your used sharps \\ndisposal container.  \\nThe Pen caps, alcohol swab, cotton ball or gauze pad, dose tray, and packaging may be placed \\nin your household trash.  \\n', 'processed_text': {'sentences': [{'original_sentence': ' \\n   \\nHow should I dispose of the used HUMIRA \\nPen?', 'tokens': ['dispose', 'used', 'HUMIRA', 'Pen', '?'], 'lemmatized': ['dispose', 'used', 'HUMIRA', 'Pen', '?'], 'stemmed': ['dispos', 'use', 'humira', 'pen', '?'], 'dependencies': [('dispos', 'nsubj'), ('use', 'ROOT'), ('humira', 'compound'), ('pen', 'dobj'), ('?', 'punct')]}, {'original_sentence': '• Put your used needles, Pens, and sharps in \\na FDA cleared sharps disposal container \\nright away after use.', 'tokens': ['•', 'Put', 'used', 'needles', ',', 'Pens', ',', 'sharps', 'FDA', 'cleared', 'sharps', 'disposal', 'container', 'right', 'away', 'use', '.'], 'lemmatized': ['•', 'Put', 'used', 'needle', ',', 'Pens', ',', 'sharp', 'FDA', 'cleared', 'sharp', 'disposal', 'container', 'right', 'away', 'use', '.'], 'stemmed': ['•', 'put', 'use', 'needl', ',', 'pen', ',', 'sharp', 'fda', 'clear', 'sharp', 'dispos', 'contain', 'right', 'away', 'use', '.'], 'dependencies': [('•', 'npadvmod'), ('put', 'ROOT'), ('use', 'compound'), ('needl', 'dobj'), (',', 'punct'), ('pen', 'nmod'), (',', 'punct'), ('sharp', 'amod'), ('fda', 'nmod'), ('clear', 'amod'), ('sharp', 'amod'), ('dispos', 'nsubj'), ('contain', 'conj'), ('right', 'advmod'), ('away', 'advmod'), ('use', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Do not throw away \\n(dispose of) loose needles, syringes, \\nand the Pen in the household trash.', 'tokens': ['throw', 'away', '(', 'dispose', ')', 'loose', 'needles', ',', 'syringes', ',', 'Pen', 'household', 'trash', '.'], 'lemmatized': ['throw', 'away', '(', 'dispose', ')', 'loose', 'needle', ',', 'syrinx', ',', 'Pen', 'household', 'trash', '.'], 'stemmed': ['throw', 'away', '(', 'dispos', ')', 'loos', 'needl', ',', 'syrinx', ',', 'pen', 'household', 'trash', '.'], 'dependencies': [('throw', 'ROOT'), ('away', 'advmod'), ('(', 'punct'), ('dispos', 'dobj'), (')', 'punct'), ('loos', 'compound'), ('needl', 'dobj'), (',', 'punct'), ('syrinx', 'conj'), (',', 'punct'), ('pen', 'compound'), ('household', 'compound'), ('trash', 'conj'), ('.', 'punct')]}, {'original_sentence': '• If you do not have a FDA-cleared sharps \\ndisposal container, you may use a \\nhousehold container that is:  \\n◦ made of a heavy-duty plastic, \\n◦ can be closed with a tight-fitting, \\npuncture-resistant lid, without sharps \\nbeing able to come out,  \\n◦ upright and stable during use, \\n◦ leak-resistant, and  \\n◦ properly labeled to warn of hazardous \\nwaste inside the container.', 'tokens': ['•', 'FDA-cleared', 'sharps', 'disposal', 'container', ',', 'may', 'use', 'household', 'container', ':', '◦', 'made', 'heavy-duty', 'plastic', ',', '◦', 'closed', 'tight-fitting', ',', 'puncture-resistant', 'lid', ',', 'without', 'sharps', 'able', 'come', ',', '◦', 'upright', 'stable', 'use', ',', '◦', 'leak-resistant', ',', '◦', 'properly', 'labeled', 'warn', 'hazardous', 'waste', 'inside', 'container', '.'], 'lemmatized': ['•', 'FDA-cleared', 'sharp', 'disposal', 'container', ',', 'may', 'use', 'household', 'container', ':', '◦', 'made', 'heavy-duty', 'plastic', ',', '◦', 'closed', 'tight-fitting', ',', 'puncture-resistant', 'lid', ',', 'without', 'sharp', 'able', 'come', ',', '◦', 'upright', 'stable', 'use', ',', '◦', 'leak-resistant', ',', '◦', 'properly', 'labeled', 'warn', 'hazardous', 'waste', 'inside', 'container', '.'], 'stemmed': ['•', 'fda-clear', 'sharp', 'dispos', 'contain', ',', 'may', 'use', 'household', 'contain', ':', '◦', 'made', 'heavy-duti', 'plastic', ',', '◦', 'close', 'tight-fit', ',', 'puncture-resist', 'lid', ',', 'without', 'sharp', 'abl', 'come', ',', '◦', 'upright', 'stabl', 'use', ',', '◦', 'leak-resist', ',', '◦', 'properli', 'label', 'warn', 'hazard', 'wast', 'insid', 'contain', '.'], 'dependencies': [('•', 'advmod'), ('fda', 'amod'), ('-', 'punct'), ('clear', 'amod'), ('sharp', 'amod'), ('dispos', 'nsubj'), ('contain', 'advcl'), (',', 'punct'), ('may', 'aux'), ('use', 'ROOT'), ('household', 'compound'), ('contain', 'dobj'), (':', 'punct'), ('◦', 'nsubj'), ('made', 'xcomp'), ('heavy', 'amod'), ('-', 'punct'), ('duti', 'compound'), ('plastic', 'dobj'), (',', 'punct'), ('◦', 'advcl'), ('close', 'amod'), ('tight', 'amod'), ('-', 'punct'), ('fit', 'amod'), (',', 'punct'), ('puncture', 'amod'), ('-', 'punct'), ('resist', 'compound'), ('lid', 'dobj'), (',', 'punct'), ('without', 'prep'), ('sharp', 'amod'), ('abl', 'nsubj'), ('come', 'pobj'), (',', 'punct'), ('◦', 'dep'), ('upright', 'amod'), ('stabl', 'amod'), ('use', 'dobj'), (',', 'punct'), ('◦', 'compound'), ('leak', 'compound'), ('-', 'punct'), ('resist', 'nsubj'), (',', 'punct'), ('◦', 'conj'), ('properli', 'compound'), ('label', 'nsubj'), ('warn', 'conj'), ('hazard', 'compound'), ('wast', 'nsubj'), ('insid', 'amod'), ('contain', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• When your sharps disposal container is \\nalmost full, you will need to follow your \\ncommunity guidelines for the right way to \\ndispose of your sharps disposal container.', 'tokens': ['•', 'sharps', 'disposal', 'container', 'almost', 'full', ',', 'need', 'follow', 'community', 'guidelines', 'right', 'way', 'dispose', 'sharps', 'disposal', 'container', '.'], 'lemmatized': ['•', 'sharp', 'disposal', 'container', 'almost', 'full', ',', 'need', 'follow', 'community', 'guideline', 'right', 'way', 'dispose', 'sharp', 'disposal', 'container', '.'], 'stemmed': ['•', 'sharp', 'dispos', 'contain', 'almost', 'full', ',', 'need', 'follow', 'commun', 'guidelin', 'right', 'way', 'dispos', 'sharp', 'dispos', 'contain', '.'], 'dependencies': [('•', 'nummod'), ('sharp', 'amod'), ('dispos', 'nsubj'), ('contain', 'ROOT'), ('almost', 'advmod'), ('full', 'advmod'), (',', 'punct'), ('need', 'conj'), ('follow', 'dobj'), ('commun', 'amod'), ('guidelin', 'dobj'), ('right', 'amod'), ('way', 'npadvmod'), ('dispos', 'nsubj'), ('sharp', 'amod'), ('dispos', 'nsubj'), ('contain', 'ccomp'), ('.', 'punct')]}, {'original_sentence': 'There may be state or local laws about how \\nyou should throw away used needles and \\nsyringes.', 'tokens': ['may', 'state', 'local', 'laws', 'throw', 'away', 'used', 'needles', 'syringes', '.'], 'lemmatized': ['may', 'state', 'local', 'law', 'throw', 'away', 'used', 'needle', 'syrinx', '.'], 'stemmed': ['may', 'state', 'local', 'law', 'throw', 'away', 'use', 'needl', 'syrinx', '.'], 'dependencies': [('may', 'aux'), ('state', 'ROOT'), ('local', 'amod'), ('law', 'dobj'), ('throw', 'ccomp'), ('away', 'advmod'), ('use', 'dobj'), ('needl', 'conj'), ('syrinx', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'For more information about safe \\nsharps disposal, and for specific information \\nabout sharps disposal in the state that you \\nlive in, go to the FDA’s website at: \\nhttp://www.fda.gov/safesharpsdisposal.', 'tokens': ['information', 'safe', 'sharps', 'disposal', ',', 'specific', 'information', 'sharps', 'disposal', 'state', 'live', ',', 'go', 'FDA', '’', 'website', ':', 'http', ':', '//www.fda.gov/safesharpsdisposal', '.'], 'lemmatized': ['information', 'safe', 'sharp', 'disposal', ',', 'specific', 'information', 'sharp', 'disposal', 'state', 'live', ',', 'go', 'FDA', '’', 'website', ':', 'http', ':', '//www.fda.gov/safesharpsdisposal', '.'], 'stemmed': ['inform', 'safe', 'sharp', 'dispos', ',', 'specif', 'inform', 'sharp', 'dispos', 'state', 'live', ',', 'go', 'fda', '’', 'websit', ':', 'http', ':', '//www.fda.gov/safesharpsdispos', '.'], 'dependencies': [('inform', 'advcl'), ('safe', 'amod'), ('sharp', 'amod'), ('dispos', 'dobj'), (',', 'punct'), ('specif', 'nsubj'), ('inform', 'ROOT'), ('sharp', 'amod'), ('dispos', 'compound'), ('state', 'dobj'), ('live', 'advmod'), (',', 'punct'), ('go', 'conj'), ('fda', 'nmod'), ('’', 'punct'), ('websit', 'dobj'), (':', 'punct'), ('http', 'appos'), (':', 'punct'), ('//www.fda.gov', 'nmod'), ('/', 'punct'), ('safesharpsdispos', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': '• Do not dispose of your used sharps \\ndisposal container in your household trash \\nunless your community guidelines permit \\nthis.', 'tokens': ['•', 'dispose', 'used', 'sharps', 'disposal', 'container', 'household', 'trash', 'unless', 'community', 'guidelines', 'permit', '.'], 'lemmatized': ['•', 'dispose', 'used', 'sharp', 'disposal', 'container', 'household', 'trash', 'unless', 'community', 'guideline', 'permit', '.'], 'stemmed': ['•', 'dispos', 'use', 'sharp', 'dispos', 'contain', 'household', 'trash', 'unless', 'commun', 'guidelin', 'permit', '.'], 'dependencies': [('•', 'nummod'), ('dispos', 'nsubj'), ('use', 'ROOT'), ('sharp', 'amod'), ('dispos', 'dobj'), ('contain', 'xcomp'), ('household', 'compound'), ('trash', 'dobj'), ('unless', 'mark'), ('commun', 'amod'), ('guidelin', 'compound'), ('permit', 'advcl'), ('.', 'punct')]}, {'original_sentence': 'Do not recycle your used sharps \\ndisposal container.', 'tokens': ['recycle', 'used', 'sharps', 'disposal', 'container', '.'], 'lemmatized': ['recycle', 'used', 'sharp', 'disposal', 'container', '.'], 'stemmed': ['recycl', 'use', 'sharp', 'dispos', 'contain', '.'], 'dependencies': [('recycl', 'nsubj'), ('use', 'ROOT'), ('sharp', 'amod'), ('dispos', 'dobj'), ('contain', 'xcomp'), ('.', 'punct')]}, {'original_sentence': 'The Pen caps, alcohol swab, cotton ball or gauze pad, dose tray, and packaging may be placed \\nin your household trash.', 'tokens': ['Pen', 'caps', ',', 'alcohol', 'swab', ',', 'cotton', 'ball', 'gauze', 'pad', ',', 'dose', 'tray', ',', 'packaging', 'may', 'placed', 'household', 'trash', '.'], 'lemmatized': ['Pen', 'cap', ',', 'alcohol', 'swab', ',', 'cotton', 'ball', 'gauze', 'pad', ',', 'dose', 'tray', ',', 'packaging', 'may', 'placed', 'household', 'trash', '.'], 'stemmed': ['pen', 'cap', ',', 'alcohol', 'swab', ',', 'cotton', 'ball', 'gauz', 'pad', ',', 'dose', 'tray', ',', 'packag', 'may', 'place', 'household', 'trash', '.'], 'dependencies': [('pen', 'compound'), ('cap', 'dep'), (',', 'punct'), ('alcohol', 'compound'), ('swab', 'conj'), (',', 'punct'), ('cotton', 'compound'), ('ball', 'compound'), ('gauz', 'compound'), ('pad', 'conj'), (',', 'punct'), ('dose', 'compound'), ('tray', 'appos'), (',', 'punct'), ('packag', 'nsubj'), ('may', 'aux'), ('place', 'ROOT'), ('household', 'compound'), ('trash', 'dobj'), ('.', 'punct')]}], 'text': ' \\n   \\nHow should I dispose of the used HUMIRA \\nPen? \\n• Put your used needles, Pens, and sharps in \\na FDA cleared sharps disposal container \\nright away after use. Do not throw away \\n(dispose of) loose needles, syringes, \\nand the Pen in the household trash.  \\n• If you do not have a FDA-cleared sharps \\ndisposal container, you may use a \\nhousehold container that is:  \\n◦ made of a heavy-duty plastic, \\n◦ can be closed with a tight-fitting, \\npuncture-resistant lid, without sharps \\nbeing able to come out,  \\n◦ upright and stable during use, \\n◦ leak-resistant, and  \\n◦ properly labeled to warn of hazardous \\nwaste inside the container. \\n• When your sharps disposal container is \\nalmost full, you will need to follow your \\ncommunity guidelines for the right way to \\ndispose of your sharps disposal container. \\nThere may be state or local laws about how \\nyou should throw away used needles and \\nsyringes. For more information about safe \\nsharps disposal, and for specific information \\nabout sharps disposal in the state that you \\nlive in, go to the FDA’s website at: \\nhttp://www.fda.gov/safesharpsdisposal.  \\n• Do not dispose of your used sharps \\ndisposal container in your household trash \\nunless your community guidelines permit \\nthis. Do not recycle your used sharps \\ndisposal container.  \\nThe Pen caps, alcohol swab, cotton ball or gauze pad, dose tray, and packaging may be placed \\nin your household trash.  \\n'}, 'page_char_count': 1408, 'page_word_count': 227, 'sentences': [' \\n   \\nHow should I dispose of the used HUMIRA \\nPen?', '\\n• Put your used needles, Pens, and sharps in \\na FDA cleared sharps disposal container \\nright away after use.', 'Do not throw away \\n(dispose of) loose needles, syringes, \\nand the Pen in the household trash.', ' \\n• If you do not have a FDA-cleared sharps \\ndisposal container, you may use a \\nhousehold container that is:  \\n◦ made of a heavy-duty plastic, \\n◦ can be closed with a tight-fitting, \\npuncture-resistant lid, without sharps \\nbeing able to come out,  \\n◦ upright and stable during use, \\n◦ leak-resistant, and  \\n◦ properly labeled to warn of hazardous \\nwaste inside the container.', '\\n• When your sharps disposal container is \\nalmost full, you will need to follow your \\ncommunity guidelines for the right way to \\ndispose of your sharps disposal container.', '\\nThere may be state or local laws about how \\nyou should throw away used needles and \\nsyringes.', 'For more information about safe \\nsharps disposal, and for specific information \\nabout sharps disposal in the state that you \\nlive in, go to the FDA’s website at: \\nhttp://www.fda.gov/safesharpsdisposal.', ' \\n• Do not dispose of your used sharps \\ndisposal container in your household trash \\nunless your community guidelines permit \\nthis.', 'Do not recycle your used sharps \\ndisposal container.', ' \\nThe Pen caps, alcohol swab, cotton ball or gauze pad, dose tray, and packaging may be placed \\nin your household trash.', ' \\n'], 'page_sentence_count_spacy': 11}\n",
            "{'page_number': 93, 'text': 'Questions About Using the HUMIRA Pen \\n \\nWhat if I have not received in-person training from a healthcare provider? \\n• Call your healthcare provider or 1-800-4HUMIRA (1-800-448-6472) or visit \\nwww.HUMIRA.com if you need help  \\nHow do I know when the injection is complete? \\n• The yellow indicator has stopped moving. This takes up to 15 seconds.  \\nWhat should I do if there are more than a few drops of liquid on the injection site? \\n• Call 1-800-4HUMIRA (1-800-448-6472) for help  \\nWhat if I do not have an FDA-cleared sharps disposal container or proper household \\ncontainer? \\n• Call 1-800-4HUMIRA (1-800-448-6472) for a free FDA-cleared sharps disposal container  \\n  \\nAlways keep the Pen and the sharps disposal \\ncontainer out of reach of children.  \\n \\n   \\nKeep a record of the dates and locations of \\nyour injections. To help remember when to take \\nHUMIRA, mark your calendar ahead of time.  \\n \\n   \\nThis Instructions for Use has been approved by \\nthe U.S. Food and Drug Administration. \\nRevised 02/2021 \\nManufactured by AbbVie Inc. North Chicago, IL 60064 U.S.A. \\nUS License Number 1889  20066946  \\n \\n  \\nINSTRUCTIONS FOR USE \\nHUMIRA® (Hu-MARE-ah) \\n(adalimumab) \\n40 MG/0.8 ML, 20 MG/0.4 ML AND 10 MG/0.2 ML \\nSINGLE-DOSE PREFILLED SYRINGE \\nDo not try to inject HUMIRA yourself until you have been shown the right way to give the \\ninjections and have read and understand this Instructions for Use. If your doctor decides that \\nyou or a caregiver may be able to give your injections of HUMIRA at home, you should receive \\ntraining on the right way to prepare and inject HUMIRA. It is important that you read, \\n', 'processed_text': {'sentences': [{'original_sentence': 'Questions About Using the HUMIRA Pen \\n \\nWhat if I have not received in-person training from a healthcare provider?', 'tokens': ['Questions', 'Using', 'HUMIRA', 'Pen', 'received', 'in-person', 'training', 'healthcare', 'provider', '?'], 'lemmatized': ['Questions', 'Using', 'HUMIRA', 'Pen', 'received', 'in-person', 'training', 'healthcare', 'provider', '?'], 'stemmed': ['question', 'use', 'humira', 'pen', 'receiv', 'in-person', 'train', 'healthcar', 'provid', '?'], 'dependencies': [('question', 'compound'), ('use', 'ROOT'), ('humira', 'compound'), ('pen', 'compound'), ('receiv', 'appos'), ('in', 'nmod'), ('-', 'punct'), ('person', 'pobj'), ('train', 'compound'), ('healthcar', 'compound'), ('provid', 'appos'), ('?', 'punct')]}, {'original_sentence': '• Call your healthcare provider or 1-800-4HUMIRA (1-800-448-6472) or visit \\nwww.HUMIRA.com if you need help  \\nHow do I know when the injection is complete?', 'tokens': ['•', 'Call', 'healthcare', 'provider', '1-800-4HUMIRA', '(', '1-800-448-6472', ')', 'visit', 'www.HUMIRA.com', 'need', 'help', 'know', 'injection', 'complete', '?'], 'lemmatized': ['•', 'Call', 'healthcare', 'provider', '1-800-4HUMIRA', '(', '1-800-448-6472', ')', 'visit', 'www.HUMIRA.com', 'need', 'help', 'know', 'injection', 'complete', '?'], 'stemmed': ['•', 'call', 'healthcar', 'provid', '1-800-4humira', '(', '1-800-448-6472', ')', 'visit', 'www.humira.com', 'need', 'help', 'know', 'inject', 'complet', '?'], 'dependencies': [('•', 'nummod'), ('call', 'npadvmod'), ('healthcar', 'compound'), ('provid', 'dobj'), ('1', 'nummod'), ('-', 'punct'), ('800', 'npadvmod'), ('-', 'punct'), ('4humira', 'prep'), ('(', 'punct'), ('1', 'npadvmod'), ('-', 'punct'), ('800', 'appos'), ('-', 'punct'), ('448', 'nummod'), ('-', 'punct'), ('6472', 'prep'), (')', 'punct'), ('visit', 'ROOT'), ('www.humira.com', 'dobj'), ('need', 'dobj'), ('help', 'aux'), ('know', 'advcl'), ('inject', 'compound'), ('complet', 'dobj'), ('?', 'punct')]}, {'original_sentence': '• The yellow indicator has stopped moving.', 'tokens': ['•', 'yellow', 'indicator', 'stopped', 'moving', '.'], 'lemmatized': ['•', 'yellow', 'indicator', 'stopped', 'moving', '.'], 'stemmed': ['•', 'yellow', 'indic', 'stop', 'move', '.'], 'dependencies': [('•', 'nummod'), ('yellow', 'amod'), ('indic', 'amod'), ('stop', 'compound'), ('move', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'This takes up to 15 seconds.', 'tokens': ['takes', '15', 'seconds', '.'], 'lemmatized': ['take', '15', 'second', '.'], 'stemmed': ['take', '15', 'second', '.'], 'dependencies': [('take', 'ROOT'), ('15', 'nummod'), ('second', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'What should I do if there are more than a few drops of liquid on the injection site?', 'tokens': ['drops', 'liquid', 'injection', 'site', '?'], 'lemmatized': ['drop', 'liquid', 'injection', 'site', '?'], 'stemmed': ['drop', 'liquid', 'inject', 'site', '?'], 'dependencies': [('drop', 'ROOT'), ('liquid', 'amod'), ('inject', 'compound'), ('site', 'dobj'), ('?', 'punct')]}, {'original_sentence': '• Call 1-800-4HUMIRA (1-800-448-6472) for help  \\nWhat if I do not have an FDA-cleared sharps disposal container or proper household \\ncontainer?', 'tokens': ['•', 'Call', '1-800-4HUMIRA', '(', '1-800-448-6472', ')', 'help', 'FDA-cleared', 'sharps', 'disposal', 'container', 'proper', 'household', 'container', '?'], 'lemmatized': ['•', 'Call', '1-800-4HUMIRA', '(', '1-800-448-6472', ')', 'help', 'FDA-cleared', 'sharp', 'disposal', 'container', 'proper', 'household', 'container', '?'], 'stemmed': ['•', 'call', '1-800-4humira', '(', '1-800-448-6472', ')', 'help', 'fda-clear', 'sharp', 'dispos', 'contain', 'proper', 'household', 'contain', '?'], 'dependencies': [('•', 'nummod'), ('call', 'dep'), ('1', 'npadvmod'), ('-', 'punct'), ('800', 'prep'), ('-', 'punct'), ('4humira', 'prep'), ('(', 'punct'), ('1', 'npadvmod'), ('-', 'punct'), ('800', 'prep'), ('-', 'punct'), ('448', 'nummod'), ('-', 'punct'), ('6472', 'appos'), (')', 'punct'), ('help', 'ROOT'), ('fda', 'compound'), ('-', 'punct'), ('clear', 'amod'), ('sharp', 'amod'), ('dispos', 'nsubj'), ('contain', 'ccomp'), ('proper', 'amod'), ('household', 'compound'), ('contain', 'dobj'), ('?', 'punct')]}, {'original_sentence': '• Call 1-800-4HUMIRA (1-800-448-6472) for a free FDA-cleared sharps disposal container  \\n  \\nAlways keep the Pen and the sharps disposal \\ncontainer out of reach of children.', 'tokens': ['•', 'Call', '1-800-4HUMIRA', '(', '1-800-448-6472', ')', 'free', 'FDA-cleared', 'sharps', 'disposal', 'container', 'Always', 'keep', 'Pen', 'sharps', 'disposal', 'container', 'reach', 'children', '.'], 'lemmatized': ['•', 'Call', '1-800-4HUMIRA', '(', '1-800-448-6472', ')', 'free', 'FDA-cleared', 'sharp', 'disposal', 'container', 'Always', 'keep', 'Pen', 'sharp', 'disposal', 'container', 'reach', 'child', '.'], 'stemmed': ['•', 'call', '1-800-4humira', '(', '1-800-448-6472', ')', 'free', 'fda-clear', 'sharp', 'dispos', 'contain', 'alway', 'keep', 'pen', 'sharp', 'dispos', 'contain', 'reach', 'child', '.'], 'dependencies': [('•', 'nummod'), ('call', 'npadvmod'), ('1', 'npadvmod'), ('-', 'punct'), ('800', 'prep'), ('-', 'punct'), ('4humira', 'prep'), ('(', 'punct'), ('1', 'npadvmod'), ('-', 'punct'), ('800', 'prep'), ('-', 'punct'), ('448', 'nummod'), ('-', 'punct'), ('6472', 'prep'), (')', 'punct'), ('free', 'amod'), ('fda', 'compound'), ('-', 'punct'), ('clear', 'amod'), ('sharp', 'amod'), ('dispos', 'nsubj'), ('contain', 'ROOT'), ('alway', 'advmod'), ('keep', 'advcl'), ('pen', 'nmod'), ('sharp', 'amod'), ('dispos', 'dobj'), ('contain', 'xcomp'), ('reach', 'conj'), ('child', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Keep a record of the dates and locations of \\nyour injections.', 'tokens': ['Keep', 'record', 'dates', 'locations', 'injections', '.'], 'lemmatized': ['Keep', 'record', 'date', 'location', 'injection', '.'], 'stemmed': ['keep', 'record', 'date', 'locat', 'inject', '.'], 'dependencies': [('keep', 'ROOT'), ('record', 'compound'), ('date', 'compound'), ('locat', 'compound'), ('inject', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'To help remember when to take \\nHUMIRA, mark your calendar ahead of time.', 'tokens': ['help', 'remember', 'take', 'HUMIRA', ',', 'mark', 'calendar', 'ahead', 'time', '.'], 'lemmatized': ['help', 'remember', 'take', 'HUMIRA', ',', 'mark', 'calendar', 'ahead', 'time', '.'], 'stemmed': ['help', 'rememb', 'take', 'humira', ',', 'mark', 'calendar', 'ahead', 'time', '.'], 'dependencies': [('help', 'advcl'), ('rememb', 'amod'), ('take', 'compound'), ('humira', 'dobj'), (',', 'punct'), ('mark', 'compound'), ('calendar', 'ROOT'), ('ahead', 'amod'), ('time', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'This Instructions for Use has been approved by \\nthe U.S. Food and Drug Administration.', 'tokens': ['Instructions', 'Use', 'approved', 'U.S.', 'Food', 'Drug', 'Administration', '.'], 'lemmatized': ['Instructions', 'Use', 'approved', 'U.S.', 'Food', 'Drug', 'Administration', '.'], 'stemmed': ['instruct', 'use', 'approv', 'u.s.', 'food', 'drug', 'administr', '.'], 'dependencies': [('instruct', 'ROOT'), ('use', 'dobj'), ('approv', 'compound'), ('u.s', 'compound'), ('.', 'compound'), ('food', 'compound'), ('drug', 'compound'), ('administr', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Revised 02/2021 \\nManufactured by AbbVie Inc. North Chicago, IL 60064 U.S.A.', 'tokens': ['Revised', '02/2021', 'Manufactured', 'AbbVie', 'Inc.', 'North', 'Chicago', ',', 'IL', '60064', 'U.S.A', '.'], 'lemmatized': ['Revised', '02/2021', 'Manufactured', 'AbbVie', 'Inc.', 'North', 'Chicago', ',', 'IL', '60064', 'U.S.A', '.'], 'stemmed': ['revis', '02/2021', 'manufactur', 'abbvi', 'inc.', 'north', 'chicago', ',', 'il', '60064', 'u.s.a', '.'], 'dependencies': [('revis', 'compound'), ('02/2021', 'compound'), ('manufactur', 'nsubj'), ('abbvi', 'compound'), ('inc', 'compound'), ('.', 'compound'), ('north', 'compound'), ('chicago', 'dep'), (',', 'punct'), ('il', 'nmod'), ('60064', 'nummod'), ('u.s.a', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'US License Number 1889  20066946  \\n \\n  \\nINSTRUCTIONS FOR USE \\nHUMIRA® (Hu-MARE-ah) \\n(adalimumab) \\n40 MG/0.8 ML, 20 MG/0.4 ML AND 10 MG/0.2 ML \\nSINGLE-DOSE PREFILLED SYRINGE \\nDo not try to inject HUMIRA yourself until you have been shown the right way to give the \\ninjections and have read and understand this Instructions for Use.', 'tokens': ['US', 'License', 'Number', '1889', '20066946', 'INSTRUCTIONS', 'USE', 'HUMIRA®', '(', 'Hu-MARE-ah', ')', '(', 'adalimumab', ')', '40', 'MG/0.8', 'ML', ',', '20', 'MG/0.4', 'ML', '10', 'MG/0.2', 'ML', 'SINGLE-DOSE', 'PREFILLED', 'SYRINGE', 'try', 'inject', 'HUMIRA', 'shown', 'right', 'way', 'give', 'injections', 'read', 'understand', 'Instructions', 'Use', '.'], 'lemmatized': ['US', 'License', 'Number', '1889', '20066946', 'INSTRUCTIONS', 'USE', 'HUMIRA®', '(', 'Hu-MARE-ah', ')', '(', 'adalimumab', ')', '40', 'MG/0.8', 'ML', ',', '20', 'MG/0.4', 'ML', '10', 'MG/0.2', 'ML', 'SINGLE-DOSE', 'PREFILLED', 'SYRINGE', 'try', 'inject', 'HUMIRA', 'shown', 'right', 'way', 'give', 'injection', 'read', 'understand', 'Instructions', 'Use', '.'], 'stemmed': ['us', 'licens', 'number', '1889', '20066946', 'instruct', 'use', 'humira®', '(', 'hu-mare-ah', ')', '(', 'adalimumab', ')', '40', 'mg/0.8', 'ml', ',', '20', 'mg/0.4', 'ml', '10', 'mg/0.2', 'ml', 'single-dos', 'prefil', 'syring', 'tri', 'inject', 'humira', 'shown', 'right', 'way', 'give', 'inject', 'read', 'understand', 'instruct', 'use', '.'], 'dependencies': [('us', 'compound'), ('licens', 'nsubj'), ('number', 'nsubj'), ('1889', 'nummod'), ('20066946', 'nummod'), ('instruct', 'ROOT'), ('use', 'dobj'), ('humira', 'compound'), ('®', 'dobj'), ('(', 'punct'), ('hu', 'appos'), ('-', 'punct'), ('mare', 'npadvmod'), ('-', 'punct'), ('ah', 'intj'), (')', 'punct'), ('(', 'punct'), ('adalimumab', 'compound'), (')', 'punct'), ('40', 'nummod'), ('mg/0.8', 'punct'), ('ml', 'dep'), (',', 'punct'), ('20', 'nummod'), ('mg/0.4', 'punct'), ('ml', 'parataxis'), ('10', 'nummod'), ('mg/0.2', 'npadvmod'), ('ml', 'nmod'), ('single', 'amod'), ('-', 'punct'), ('dos', 'compound'), ('prefil', 'nsubj'), ('syring', 'acl'), ('tri', 'compound'), ('inject', 'compound'), ('humira', 'dobj'), ('shown', 'ROOT'), ('right', 'amod'), ('way', 'dobj'), ('give', 'xcomp'), ('inject', 'dative'), ('read', 'compound'), ('understand', 'compound'), ('instruct', 'ccomp'), ('use', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'If your doctor decides that \\nyou or a caregiver may be able to give your injections of HUMIRA at home, you should receive \\ntraining on the right way to prepare and inject HUMIRA.', 'tokens': ['doctor', 'decides', 'caregiver', 'may', 'able', 'give', 'injections', 'HUMIRA', 'home', ',', 'receive', 'training', 'right', 'way', 'prepare', 'inject', 'HUMIRA', '.'], 'lemmatized': ['doctor', 'decides', 'caregiver', 'may', 'able', 'give', 'injection', 'HUMIRA', 'home', ',', 'receive', 'training', 'right', 'way', 'prepare', 'inject', 'HUMIRA', '.'], 'stemmed': ['doctor', 'decid', 'caregiv', 'may', 'abl', 'give', 'inject', 'humira', 'home', ',', 'receiv', 'train', 'right', 'way', 'prepar', 'inject', 'humira', '.'], 'dependencies': [('doctor', 'compound'), ('decid', 'compound'), ('caregiv', 'nsubj'), ('may', 'aux'), ('abl', 'advmod'), ('give', 'ccomp'), ('inject', 'compound'), ('humira', 'compound'), ('home', 'dobj'), (',', 'punct'), ('receiv', 'compound'), ('train', 'ROOT'), ('right', 'amod'), ('way', 'npadvmod'), ('prepar', 'compound'), ('inject', 'compound'), ('humira', 'appos'), ('.', 'punct')]}, {'original_sentence': 'It is important that you read,', 'tokens': ['important', 'read', ','], 'lemmatized': ['important', 'read', ','], 'stemmed': ['import', 'read', ','], 'dependencies': [('import', 'compound'), ('read', 'ROOT'), (',', 'punct')]}], 'text': 'Questions About Using the HUMIRA Pen \\n \\nWhat if I have not received in-person training from a healthcare provider? \\n• Call your healthcare provider or 1-800-4HUMIRA (1-800-448-6472) or visit \\nwww.HUMIRA.com if you need help  \\nHow do I know when the injection is complete? \\n• The yellow indicator has stopped moving. This takes up to 15 seconds.  \\nWhat should I do if there are more than a few drops of liquid on the injection site? \\n• Call 1-800-4HUMIRA (1-800-448-6472) for help  \\nWhat if I do not have an FDA-cleared sharps disposal container or proper household \\ncontainer? \\n• Call 1-800-4HUMIRA (1-800-448-6472) for a free FDA-cleared sharps disposal container  \\n  \\nAlways keep the Pen and the sharps disposal \\ncontainer out of reach of children.  \\n \\n   \\nKeep a record of the dates and locations of \\nyour injections. To help remember when to take \\nHUMIRA, mark your calendar ahead of time.  \\n \\n   \\nThis Instructions for Use has been approved by \\nthe U.S. Food and Drug Administration. \\nRevised 02/2021 \\nManufactured by AbbVie Inc. North Chicago, IL 60064 U.S.A. \\nUS License Number 1889  20066946  \\n \\n  \\nINSTRUCTIONS FOR USE \\nHUMIRA® (Hu-MARE-ah) \\n(adalimumab) \\n40 MG/0.8 ML, 20 MG/0.4 ML AND 10 MG/0.2 ML \\nSINGLE-DOSE PREFILLED SYRINGE \\nDo not try to inject HUMIRA yourself until you have been shown the right way to give the \\ninjections and have read and understand this Instructions for Use. If your doctor decides that \\nyou or a caregiver may be able to give your injections of HUMIRA at home, you should receive \\ntraining on the right way to prepare and inject HUMIRA. It is important that you read, \\n'}, 'page_char_count': 1609, 'page_word_count': 259, 'sentences': ['Questions About Using the HUMIRA Pen \\n \\nWhat if I have not received in-person training from a healthcare provider?', '\\n• Call your healthcare provider or 1-800-4HUMIRA (1-800-448-6472) or visit \\nwww.HUMIRA.com if you need help  \\nHow do I know when the injection is complete?', '\\n• The yellow indicator has stopped moving.', 'This takes up to 15 seconds.', ' \\nWhat should I do if there are more than a few drops of liquid on the injection site?', '\\n• Call 1-800-4HUMIRA (1-800-448-6472) for help  \\nWhat if I do not have an FDA-cleared sharps disposal container or proper household \\ncontainer?', '\\n• Call 1-800-4HUMIRA (1-800-448-6472) for a free FDA-cleared sharps disposal container  \\n  \\nAlways keep the Pen and the sharps disposal \\ncontainer out of reach of children.', ' \\n \\n   \\nKeep a record of the dates and locations of \\nyour injections.', 'To help remember when to take \\nHUMIRA, mark your calendar ahead of time.', ' \\n \\n   \\nThis Instructions for Use has been approved by \\nthe U.S. Food and Drug Administration.', '\\nRevised 02/2021 \\nManufactured by AbbVie Inc. North Chicago, IL 60064 U.S.A. \\nUS License Number 1889  20066946  \\n \\n  \\nINSTRUCTIONS FOR USE \\nHUMIRA® (Hu-MARE-ah) \\n(adalimumab) \\n40 MG/0.8 ML, 20 MG/0.4 ML AND 10 MG/0.2 ML \\nSINGLE-DOSE PREFILLED SYRINGE \\nDo not try to inject HUMIRA yourself until you have been shown the right way to give the \\ninjections and have read and understand this Instructions for Use.', 'If your doctor decides that \\nyou or a caregiver may be able to give your injections of HUMIRA at home, you should receive \\ntraining on the right way to prepare and inject HUMIRA.', 'It is important that you read, \\n'], 'page_sentence_count_spacy': 13}\n",
            "{'page_number': 94, 'text': 'understand, and follow these instructions so that you inject HUMIRA the right way. It is also \\nimportant to talk to your doctor to be sure you understand your HUMIRA dosing instructions. To \\nhelp you remember when to inject HUMIRA, you can mark your calendar ahead of time. Call \\nyour healthcare provider if you or your caregiver have any questions about the right way to \\ninject HUMIRA.  \\nGather the Supplies for Your Injection \\n• You will need the following supplies for each injection of HUMIRA. \\nFind a clean, flat surface to place the supplies on. \\n• 1 alcohol swab \\n• 1 cotton ball or gauze pad (not included in your HUMIRA carton) \\n• 1 HUMIRA prefilled syringe (See Figure A) \\n• Puncture-resistant sharps disposal container for HUMIRA prefilled syringe disposal (not \\nincluded in your HUMIRA carton). See the “How should I throw away (dispose of) the \\nused prefilled syringes and needles?” section at the end of this Instructions for Use.  \\n  \\nIf more comfortable, take your HUMIRA prefilled syringe out of the refrigerator 15 to 30 minutes \\nbefore injecting to allow the liquid to reach room temperature. Do not remove the needle cover \\nwhile allowing it to reach room temperature. Do not warm HUMIRA in any other way (for \\nexample, do not warm it in a microwave or in hot water).  \\nIf you do not have all the supplies you need to give yourself an injection, go to a pharmacy or \\ncall your pharmacist.  \\nThe figure below shows what a prefilled syringe looks like. See Figure A.  \\nFigure A \\n \\n', 'processed_text': {'sentences': [{'original_sentence': 'understand, and follow these instructions so that you inject HUMIRA the right way.', 'tokens': ['understand', ',', 'follow', 'instructions', 'inject', 'HUMIRA', 'right', 'way', '.'], 'lemmatized': ['understand', ',', 'follow', 'instruction', 'inject', 'HUMIRA', 'right', 'way', '.'], 'stemmed': ['understand', ',', 'follow', 'instruct', 'inject', 'humira', 'right', 'way', '.'], 'dependencies': [('understand', 'ROOT'), (',', 'punct'), ('follow', 'conj'), ('instruct', 'dobj'), ('inject', 'compound'), ('humira', 'dobj'), ('right', 'amod'), ('way', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'It is also \\nimportant to talk to your doctor to be sure you understand your HUMIRA dosing instructions.', 'tokens': ['also', 'important', 'talk', 'doctor', 'sure', 'understand', 'HUMIRA', 'dosing', 'instructions', '.'], 'lemmatized': ['also', 'important', 'talk', 'doctor', 'sure', 'understand', 'HUMIRA', 'dosing', 'instruction', '.'], 'stemmed': ['also', 'import', 'talk', 'doctor', 'sure', 'understand', 'humira', 'dose', 'instruct', '.'], 'dependencies': [('also', 'advmod'), ('import', 'ROOT'), ('talk', 'compound'), ('doctor', 'nsubj'), ('sure', 'advmod'), ('understand', 'ccomp'), ('humira', 'compound'), ('dose', 'compound'), ('instruct', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'To \\nhelp you remember when to inject HUMIRA, you can mark your calendar ahead of time.', 'tokens': ['help', 'remember', 'inject', 'HUMIRA', ',', 'mark', 'calendar', 'ahead', 'time', '.'], 'lemmatized': ['help', 'remember', 'inject', 'HUMIRA', ',', 'mark', 'calendar', 'ahead', 'time', '.'], 'stemmed': ['help', 'rememb', 'inject', 'humira', ',', 'mark', 'calendar', 'ahead', 'time', '.'], 'dependencies': [('help', 'advcl'), ('rememb', 'amod'), ('inject', 'compound'), ('humira', 'dobj'), (',', 'punct'), ('mark', 'compound'), ('calendar', 'ROOT'), ('ahead', 'amod'), ('time', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Call \\nyour healthcare provider if you or your caregiver have any questions about the right way to \\ninject HUMIRA.', 'tokens': ['Call', 'healthcare', 'provider', 'caregiver', 'questions', 'right', 'way', 'inject', 'HUMIRA', '.'], 'lemmatized': ['Call', 'healthcare', 'provider', 'caregiver', 'question', 'right', 'way', 'inject', 'HUMIRA', '.'], 'stemmed': ['call', 'healthcar', 'provid', 'caregiv', 'question', 'right', 'way', 'inject', 'humira', '.'], 'dependencies': [('call', 'ROOT'), ('healthcar', 'compound'), ('provid', 'compound'), ('caregiv', 'dobj'), ('question', 'dobj'), ('right', 'amod'), ('way', 'npadvmod'), ('inject', 'compound'), ('humira', 'oprd'), ('.', 'punct')]}, {'original_sentence': 'Gather the Supplies for Your Injection \\n• You will need the following supplies for each injection of HUMIRA.', 'tokens': ['Gather', 'Supplies', 'Injection', '•', 'need', 'following', 'supplies', 'injection', 'HUMIRA', '.'], 'lemmatized': ['Gather', 'Supplies', 'Injection', '•', 'need', 'following', 'supply', 'injection', 'HUMIRA', '.'], 'stemmed': ['gather', 'suppli', 'inject', '•', 'need', 'follow', 'suppli', 'inject', 'humira', '.'], 'dependencies': [('gather', 'ROOT'), ('suppli', 'nsubj'), ('inject', 'ccomp'), ('•', 'punct'), ('need', 'dobj'), ('follow', 'compound'), ('suppli', 'compound'), ('inject', 'compound'), ('humira', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Find a clean, flat surface to place the supplies on.', 'tokens': ['Find', 'clean', ',', 'flat', 'surface', 'place', 'supplies', '.'], 'lemmatized': ['Find', 'clean', ',', 'flat', 'surface', 'place', 'supply', '.'], 'stemmed': ['find', 'clean', ',', 'flat', 'surfac', 'place', 'suppli', '.'], 'dependencies': [('find', 'ROOT'), ('clean', 'amod'), (',', 'punct'), ('flat', 'amod'), ('surfac', 'compound'), ('place', 'compound'), ('suppli', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• 1 alcohol swab \\n• 1 cotton ball or gauze pad (not included in your HUMIRA carton) \\n• 1 HUMIRA prefilled syringe (See Figure A) \\n• Puncture-resistant sharps disposal container for HUMIRA prefilled syringe disposal (not \\nincluded in your HUMIRA carton).', 'tokens': ['•', '1', 'alcohol', 'swab', '•', '1', 'cotton', 'ball', 'gauze', 'pad', '(', 'included', 'HUMIRA', 'carton', ')', '•', '1', 'HUMIRA', 'prefilled', 'syringe', '(', 'See', 'Figure', ')', '•', 'Puncture-resistant', 'sharps', 'disposal', 'container', 'HUMIRA', 'prefilled', 'syringe', 'disposal', '(', 'included', 'HUMIRA', 'carton', ')', '.'], 'lemmatized': ['•', '1', 'alcohol', 'swab', '•', '1', 'cotton', 'ball', 'gauze', 'pad', '(', 'included', 'HUMIRA', 'carton', ')', '•', '1', 'HUMIRA', 'prefilled', 'syringe', '(', 'See', 'Figure', ')', '•', 'Puncture-resistant', 'sharp', 'disposal', 'container', 'HUMIRA', 'prefilled', 'syringe', 'disposal', '(', 'included', 'HUMIRA', 'carton', ')', '.'], 'stemmed': ['•', '1', 'alcohol', 'swab', '•', '1', 'cotton', 'ball', 'gauz', 'pad', '(', 'includ', 'humira', 'carton', ')', '•', '1', 'humira', 'prefil', 'syring', '(', 'see', 'figur', ')', '•', 'puncture-resist', 'sharp', 'dispos', 'contain', 'humira', 'prefil', 'syring', 'dispos', '(', 'includ', 'humira', 'carton', ')', '.'], 'dependencies': [('•', 'nmod'), ('1', 'nummod'), ('alcohol', 'compound'), ('swab', 'compound'), ('•', 'nummod'), ('1', 'nummod'), ('cotton', 'compound'), ('ball', 'compound'), ('gauz', 'compound'), ('pad', 'nsubj'), ('(', 'punct'), ('includ', 'compound'), ('humira', 'compound'), ('carton', 'appos'), (')', 'punct'), ('•', 'nummod'), ('1', 'nummod'), ('humira', 'compound'), ('prefil', 'compound'), ('syring', 'ROOT'), ('(', 'punct'), ('see', 'parataxis'), ('figur', 'dobj'), (')', 'punct'), ('•', 'meta'), ('puncture', 'npadvmod'), ('-', 'punct'), ('resist', 'amod'), ('sharp', 'amod'), ('dispos', 'nsubj'), ('contain', 'ROOT'), ('humira', 'compound'), ('prefil', 'compound'), ('syring', 'compound'), ('dispos', 'dobj'), ('(', 'punct'), ('includ', 'compound'), ('humira', 'compound'), ('carton', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'See the “How should I throw away (dispose of) the \\nused prefilled syringes and needles?” section at the end of this Instructions for Use.', 'tokens': ['See', '“', 'throw', 'away', '(', 'dispose', ')', 'used', 'prefilled', 'syringes', 'needles', '?', '”', 'section', 'end', 'Instructions', 'Use', '.'], 'lemmatized': ['See', '“', 'throw', 'away', '(', 'dispose', ')', 'used', 'prefilled', 'syrinx', 'needle', '?', '”', 'section', 'end', 'Instructions', 'Use', '.'], 'stemmed': ['see', '“', 'throw', 'away', '(', 'dispos', ')', 'use', 'prefil', 'syrinx', 'needl', '?', '”', 'section', 'end', 'instruct', 'use', '.'], 'dependencies': [('see', 'ROOT'), ('“', 'punct'), ('throw', 'xcomp'), ('away', 'advmod'), ('(', 'punct'), ('dispos', 'npadvmod'), (')', 'punct'), ('use', 'conj'), ('prefil', 'compound'), ('syrinx', 'compound'), ('needl', 'dobj'), ('?', 'punct'), ('”', 'punct'), ('section', 'compound'), ('end', 'nsubj'), ('instruct', 'ROOT'), ('use', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'If more comfortable, take your HUMIRA prefilled syringe out of the refrigerator 15 to 30 minutes \\nbefore injecting to allow the liquid to reach room temperature.', 'tokens': ['comfortable', ',', 'take', 'HUMIRA', 'prefilled', 'syringe', 'refrigerator', '15', '30', 'minutes', 'injecting', 'allow', 'liquid', 'reach', 'room', 'temperature', '.'], 'lemmatized': ['comfortable', ',', 'take', 'HUMIRA', 'prefilled', 'syringe', 'refrigerator', '15', '30', 'minute', 'injecting', 'allow', 'liquid', 'reach', 'room', 'temperature', '.'], 'stemmed': ['comfort', ',', 'take', 'humira', 'prefil', 'syring', 'refriger', '15', '30', 'minut', 'inject', 'allow', 'liquid', 'reach', 'room', 'temperatur', '.'], 'dependencies': [('comfort', 'npadvmod'), (',', 'punct'), ('take', 'ROOT'), ('humira', 'compound'), ('prefil', 'compound'), ('syring', 'compound'), ('refriger', 'dobj'), ('15', 'compound'), ('30', 'nummod'), ('minut', 'compound'), ('inject', 'nsubj'), ('allow', 'conj'), ('liquid', 'compound'), ('reach', 'compound'), ('room', 'compound'), ('temperatur', 'ccomp'), ('.', 'punct')]}, {'original_sentence': 'Do not remove the needle cover \\nwhile allowing it to reach room temperature.', 'tokens': ['remove', 'needle', 'cover', 'allowing', 'reach', 'room', 'temperature', '.'], 'lemmatized': ['remove', 'needle', 'cover', 'allowing', 'reach', 'room', 'temperature', '.'], 'stemmed': ['remov', 'needl', 'cover', 'allow', 'reach', 'room', 'temperatur', '.'], 'dependencies': [('remov', 'compound'), ('needl', 'compound'), ('cover', 'nsubj'), ('allow', 'ROOT'), ('reach', 'compound'), ('room', 'compound'), ('temperatur', 'ccomp'), ('.', 'punct')]}, {'original_sentence': 'Do not warm HUMIRA in any other way (for \\nexample, do not warm it in a microwave or in hot water).', 'tokens': ['warm', 'HUMIRA', 'way', '(', 'example', ',', 'warm', 'microwave', 'hot', 'water', ')', '.'], 'lemmatized': ['warm', 'HUMIRA', 'way', '(', 'example', ',', 'warm', 'microwave', 'hot', 'water', ')', '.'], 'stemmed': ['warm', 'humira', 'way', '(', 'exampl', ',', 'warm', 'microwav', 'hot', 'water', ')', '.'], 'dependencies': [('warm', 'amod'), ('humira', 'compound'), ('way', 'ROOT'), ('(', 'punct'), ('exampl', 'appos'), (',', 'punct'), ('warm', 'amod'), ('microwav', 'amod'), ('hot', 'amod'), ('water', 'conj'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'If you do not have all the supplies you need to give yourself an injection, go to a pharmacy or \\ncall your pharmacist.', 'tokens': ['supplies', 'need', 'give', 'injection', ',', 'go', 'pharmacy', 'call', 'pharmacist', '.'], 'lemmatized': ['supply', 'need', 'give', 'injection', ',', 'go', 'pharmacy', 'call', 'pharmacist', '.'], 'stemmed': ['suppli', 'need', 'give', 'inject', ',', 'go', 'pharmaci', 'call', 'pharmacist', '.'], 'dependencies': [('suppli', 'nsubj'), ('need', 'ccomp'), ('give', 'xcomp'), ('inject', 'dobj'), (',', 'punct'), ('go', 'ROOT'), ('pharmaci', 'compound'), ('call', 'compound'), ('pharmacist', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'The figure below shows what a prefilled syringe looks like.', 'tokens': ['figure', 'shows', 'prefilled', 'syringe', 'looks', 'like', '.'], 'lemmatized': ['figure', 'show', 'prefilled', 'syringe', 'look', 'like', '.'], 'stemmed': ['figur', 'show', 'prefil', 'syring', 'look', 'like', '.'], 'dependencies': [('figur', 'nsubj'), ('show', 'ROOT'), ('prefil', 'compound'), ('syring', 'dobj'), ('look', 'ccomp'), ('like', 'prep'), ('.', 'punct')]}, {'original_sentence': 'See Figure A.', 'tokens': ['See', 'Figure', '.'], 'lemmatized': ['See', 'Figure', '.'], 'stemmed': ['see', 'figur', '.'], 'dependencies': [('see', 'ROOT'), ('figur', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Figure A', 'tokens': ['Figure'], 'lemmatized': ['Figure'], 'stemmed': ['figur'], 'dependencies': [('figur', 'ROOT')]}], 'text': 'understand, and follow these instructions so that you inject HUMIRA the right way. It is also \\nimportant to talk to your doctor to be sure you understand your HUMIRA dosing instructions. To \\nhelp you remember when to inject HUMIRA, you can mark your calendar ahead of time. Call \\nyour healthcare provider if you or your caregiver have any questions about the right way to \\ninject HUMIRA.  \\nGather the Supplies for Your Injection \\n• You will need the following supplies for each injection of HUMIRA. \\nFind a clean, flat surface to place the supplies on. \\n• 1 alcohol swab \\n• 1 cotton ball or gauze pad (not included in your HUMIRA carton) \\n• 1 HUMIRA prefilled syringe (See Figure A) \\n• Puncture-resistant sharps disposal container for HUMIRA prefilled syringe disposal (not \\nincluded in your HUMIRA carton). See the “How should I throw away (dispose of) the \\nused prefilled syringes and needles?” section at the end of this Instructions for Use.  \\n  \\nIf more comfortable, take your HUMIRA prefilled syringe out of the refrigerator 15 to 30 minutes \\nbefore injecting to allow the liquid to reach room temperature. Do not remove the needle cover \\nwhile allowing it to reach room temperature. Do not warm HUMIRA in any other way (for \\nexample, do not warm it in a microwave or in hot water).  \\nIf you do not have all the supplies you need to give yourself an injection, go to a pharmacy or \\ncall your pharmacist.  \\nThe figure below shows what a prefilled syringe looks like. See Figure A.  \\nFigure A \\n \\n'}, 'page_char_count': 1500, 'page_word_count': 257, 'sentences': ['understand, and follow these instructions so that you inject HUMIRA the right way.', 'It is also \\nimportant to talk to your doctor to be sure you understand your HUMIRA dosing instructions.', 'To \\nhelp you remember when to inject HUMIRA, you can mark your calendar ahead of time.', 'Call \\nyour healthcare provider if you or your caregiver have any questions about the right way to \\ninject HUMIRA.', ' \\nGather the Supplies for Your Injection \\n• You will need the following supplies for each injection of HUMIRA.', '\\nFind a clean, flat surface to place the supplies on.', '\\n• 1 alcohol swab \\n• 1 cotton ball or gauze pad (not included in your HUMIRA carton) \\n• 1 HUMIRA prefilled syringe (See Figure A) \\n• Puncture-resistant sharps disposal container for HUMIRA prefilled syringe disposal (not \\nincluded in your HUMIRA carton).', 'See the “How should I throw away (dispose of) the \\nused prefilled syringes and needles?”', 'section at the end of this Instructions for Use.', ' \\n  \\nIf more comfortable, take your HUMIRA prefilled syringe out of the refrigerator 15 to 30 minutes \\nbefore injecting to allow the liquid to reach room temperature.', 'Do not remove the needle cover \\nwhile allowing it to reach room temperature.', 'Do not warm HUMIRA in any other way (for \\nexample, do not warm it in a microwave or in hot water).', ' \\nIf you do not have all the supplies you need to give yourself an injection, go to a pharmacy or \\ncall your pharmacist.', ' \\nThe figure below shows what a prefilled syringe looks like.', 'See Figure A.  \\nFigure A \\n \\n'], 'page_sentence_count_spacy': 15}\n",
            "{'page_number': 95, 'text': 'Check the carton, dose tray, and prefilled syringe \\n1. Make sure the name HUMIRA appears on the dose tray and prefilled syringe label.  \\n2. Do not use and do call your doctor or pharmacist if:  \\n• the seals on top or bottom of the carton are broken or missing. \\n• the HUMIRA labeling has an expired date. Check the expiration date on your HUMIRA \\ncarton and do not use if the date has passed.  \\n• the prefilled syringe has been frozen or left in direct sunlight.  \\n• HUMIRA has been kept at room temperature for longer than 14 days or HUMIRA has been \\nstored above 77°F (25°C).  \\n• the liquid in the prefilled syringe is cloudy, discolored or has flakes or particles in it. Make \\nsure the liquid is clear and colorless.  \\n  \\nSee the “How should I store HUMIRA?” section at the end of this Instructions for Use.  \\nChoose the Injection Site \\n3. Wash and dry your hands well.  \\n4. Choose an injection site on:  \\n• the front of your thighs or \\n• your lower abdomen (belly). If you choose your abdomen, do not use the area 2 inches \\naround your belly button (navel). See Figure B.  \\n \\nFigure B \\n \\n• Choose a different site each time you give yourself an injection. Each new injection should \\nbe given at least one inch from a site you used before.  \\n• Do not inject into skin that is: \\n', 'processed_text': {'sentences': [{'original_sentence': 'Check the carton, dose tray, and prefilled syringe \\n1.', 'tokens': ['Check', 'carton', ',', 'dose', 'tray', ',', 'prefilled', 'syringe', '1', '.'], 'lemmatized': ['Check', 'carton', ',', 'dose', 'tray', ',', 'prefilled', 'syringe', '1', '.'], 'stemmed': ['check', 'carton', ',', 'dose', 'tray', ',', 'prefil', 'syring', '1', '.'], 'dependencies': [('check', 'advcl'), ('carton', 'dobj'), (',', 'punct'), ('dose', 'compound'), ('tray', 'conj'), (',', 'punct'), ('prefil', 'nsubj'), ('syring', 'ROOT'), ('1', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Make sure the name HUMIRA appears on the dose tray and prefilled syringe label.', 'tokens': ['Make', 'sure', 'name', 'HUMIRA', 'appears', 'dose', 'tray', 'prefilled', 'syringe', 'label', '.'], 'lemmatized': ['Make', 'sure', 'name', 'HUMIRA', 'appears', 'dose', 'tray', 'prefilled', 'syringe', 'label', '.'], 'stemmed': ['make', 'sure', 'name', 'humira', 'appear', 'dose', 'tray', 'prefil', 'syring', 'label', '.'], 'dependencies': [('make', 'ROOT'), ('sure', 'ccomp'), ('name', 'compound'), ('humira', 'nsubj'), ('appear', 'ccomp'), ('dose', 'oprd'), ('tray', 'compound'), ('prefil', 'compound'), ('syring', 'compound'), ('label', 'dobj'), ('.', 'punct')]}, {'original_sentence': '2.', 'tokens': ['2', '.'], 'lemmatized': ['2', '.'], 'stemmed': ['2', '.'], 'dependencies': [('2', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Do not use and do call your doctor or pharmacist if:  \\n• the seals on top or bottom of the carton are broken or missing.', 'tokens': ['use', 'call', 'doctor', 'pharmacist', ':', '•', 'seals', 'top', 'bottom', 'carton', 'broken', 'missing', '.'], 'lemmatized': ['use', 'call', 'doctor', 'pharmacist', ':', '•', 'seal', 'top', 'bottom', 'carton', 'broken', 'missing', '.'], 'stemmed': ['use', 'call', 'doctor', 'pharmacist', ':', '•', 'seal', 'top', 'bottom', 'carton', 'broken', 'miss', '.'], 'dependencies': [('use', 'ROOT'), ('call', 'compound'), ('doctor', 'compound'), ('pharmacist', 'dobj'), (':', 'punct'), ('•', 'appos'), ('seal', 'dobj'), ('top', 'amod'), ('bottom', 'compound'), ('carton', 'compound'), ('broken', 'compound'), ('miss', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• the HUMIRA labeling has an expired date.', 'tokens': ['•', 'HUMIRA', 'labeling', 'expired', 'date', '.'], 'lemmatized': ['•', 'HUMIRA', 'labeling', 'expired', 'date', '.'], 'stemmed': ['•', 'humira', 'label', 'expir', 'date', '.'], 'dependencies': [('•', 'meta'), ('humira', 'compound'), ('label', 'compound'), ('expir', 'compound'), ('date', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Check the expiration date on your HUMIRA \\ncarton and do not use if the date has passed.', 'tokens': ['Check', 'expiration', 'date', 'HUMIRA', 'carton', 'use', 'date', 'passed', '.'], 'lemmatized': ['Check', 'expiration', 'date', 'HUMIRA', 'carton', 'use', 'date', 'passed', '.'], 'stemmed': ['check', 'expir', 'date', 'humira', 'carton', 'use', 'date', 'pass', '.'], 'dependencies': [('check', 'ROOT'), ('expir', 'compound'), ('date', 'compound'), ('humira', 'compound'), ('carton', 'compound'), ('use', 'compound'), ('date', 'compound'), ('pass', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• the prefilled syringe has been frozen or left in direct sunlight.', 'tokens': ['•', 'prefilled', 'syringe', 'frozen', 'left', 'direct', 'sunlight', '.'], 'lemmatized': ['•', 'prefilled', 'syringe', 'frozen', 'left', 'direct', 'sunlight', '.'], 'stemmed': ['•', 'prefil', 'syring', 'frozen', 'left', 'direct', 'sunlight', '.'], 'dependencies': [('•', 'nummod'), ('prefil', 'npadvmod'), ('syring', 'advmod'), ('frozen', 'nsubj'), ('left', 'amod'), ('direct', 'amod'), ('sunlight', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• HUMIRA has been kept at room temperature for longer than 14 days or HUMIRA has been \\nstored above 77°F (25°C).', 'tokens': ['•', 'HUMIRA', 'kept', 'room', 'temperature', 'longer', '14', 'days', 'HUMIRA', 'stored', '77°F', '(', '25°C', ')', '.'], 'lemmatized': ['•', 'HUMIRA', 'kept', 'room', 'temperature', 'longer', '14', 'day', 'HUMIRA', 'stored', '77°F', '(', '25°C', ')', '.'], 'stemmed': ['•', 'humira', 'kept', 'room', 'temperatur', 'longer', '14', 'day', 'humira', 'store', '77°f', '(', '25°c', ')', '.'], 'dependencies': [('•', 'nummod'), ('humira', 'nsubj'), ('kept', 'ROOT'), ('room', 'compound'), ('temperatur', 'advmod'), ('longer', 'advmod'), ('14', 'nummod'), ('day', 'compound'), ('humira', 'compound'), ('store', 'conj'), ('77', 'nummod'), ('°', 'npadvmod'), ('f', 'prep'), ('(', 'punct'), ('25', 'nummod'), ('°', 'appos'), ('c', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': '• the liquid in the prefilled syringe is cloudy, discolored or has flakes or particles in it.', 'tokens': ['•', 'liquid', 'prefilled', 'syringe', 'cloudy', ',', 'discolored', 'flakes', 'particles', '.'], 'lemmatized': ['•', 'liquid', 'prefilled', 'syringe', 'cloudy', ',', 'discolored', 'flake', 'particle', '.'], 'stemmed': ['•', 'liquid', 'prefil', 'syring', 'cloudi', ',', 'discolor', 'flake', 'particl', '.'], 'dependencies': [('•', 'nummod'), ('liquid', 'amod'), ('prefil', 'compound'), ('syring', 'compound'), ('cloudi', 'ROOT'), (',', 'punct'), ('discolor', 'compound'), ('flake', 'compound'), ('particl', 'appos'), ('.', 'punct')]}, {'original_sentence': 'Make \\nsure the liquid is clear and colorless.', 'tokens': ['Make', 'sure', 'liquid', 'clear', 'colorless', '.'], 'lemmatized': ['Make', 'sure', 'liquid', 'clear', 'colorless', '.'], 'stemmed': ['make', 'sure', 'liquid', 'clear', 'colorless', '.'], 'dependencies': [('make', 'ROOT'), ('sure', 'amod'), ('liquid', 'amod'), ('clear', 'amod'), ('colorless', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'See the “How should I store HUMIRA?” section at the end of this Instructions for Use.', 'tokens': ['See', '“', 'store', 'HUMIRA', '?', '”', 'section', 'end', 'Instructions', 'Use', '.'], 'lemmatized': ['See', '“', 'store', 'HUMIRA', '?', '”', 'section', 'end', 'Instructions', 'Use', '.'], 'stemmed': ['see', '“', 'store', 'humira', '?', '”', 'section', 'end', 'instruct', 'use', '.'], 'dependencies': [('see', 'ROOT'), ('“', 'punct'), ('store', 'compound'), ('humira', 'dobj'), ('?', 'punct'), ('”', 'punct'), ('section', 'compound'), ('end', 'nsubj'), ('instruct', 'ROOT'), ('use', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Choose the Injection Site \\n3.', 'tokens': ['Choose', 'Injection', 'Site', '3', '.'], 'lemmatized': ['Choose', 'Injection', 'Site', '3', '.'], 'stemmed': ['choos', 'inject', 'site', '3', '.'], 'dependencies': [('choos', 'compound'), ('inject', 'compound'), ('site', 'ROOT'), ('3', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Wash and dry your hands well.', 'tokens': ['Wash', 'dry', 'hands', 'well', '.'], 'lemmatized': ['Wash', 'dry', 'hand', 'well', '.'], 'stemmed': ['wash', 'dri', 'hand', 'well', '.'], 'dependencies': [('wash', 'ROOT'), ('dri', 'compound'), ('hand', 'dobj'), ('well', 'advmod'), ('.', 'punct')]}, {'original_sentence': '4.', 'tokens': ['4', '.'], 'lemmatized': ['4', '.'], 'stemmed': ['4', '.'], 'dependencies': [('4', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Choose an injection site on:  \\n• the front of your thighs or \\n• your lower abdomen (belly).', 'tokens': ['Choose', 'injection', 'site', ':', '•', 'front', 'thighs', '•', 'lower', 'abdomen', '(', 'belly', ')', '.'], 'lemmatized': ['Choose', 'injection', 'site', ':', '•', 'front', 'thigh', '•', 'lower', 'abdomen', '(', 'belly', ')', '.'], 'stemmed': ['choos', 'inject', 'site', ':', '•', 'front', 'thigh', '•', 'lower', 'abdomen', '(', 'belli', ')', '.'], 'dependencies': [('choos', 'compound'), ('inject', 'compound'), ('site', 'ROOT'), (':', 'punct'), ('•', 'nummod'), ('front', 'amod'), ('thigh', 'appos'), ('•', 'cc'), ('lower', 'amod'), ('abdomen', 'conj'), ('(', 'punct'), ('belli', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'If you choose your abdomen, do not use the area 2 inches \\naround your belly button (navel).', 'tokens': ['choose', 'abdomen', ',', 'use', 'area', '2', 'inches', 'around', 'belly', 'button', '(', 'navel', ')', '.'], 'lemmatized': ['choose', 'abdomen', ',', 'use', 'area', '2', 'inch', 'around', 'belly', 'button', '(', 'navel', ')', '.'], 'stemmed': ['choos', 'abdomen', ',', 'use', 'area', '2', 'inch', 'around', 'belli', 'button', '(', 'navel', ')', '.'], 'dependencies': [('choos', 'compound'), ('abdomen', 'nsubj'), (',', 'punct'), ('use', 'ROOT'), ('area', 'dobj'), ('2', 'nummod'), ('inch', 'npadvmod'), ('around', 'prep'), ('belli', 'compound'), ('button', 'pobj'), ('(', 'punct'), ('navel', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'See Figure B.', 'tokens': ['See', 'Figure', 'B', '.'], 'lemmatized': ['See', 'Figure', 'B', '.'], 'stemmed': ['see', 'figur', 'b', '.'], 'dependencies': [('see', 'ROOT'), ('figur', 'compound'), ('b', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Figure B \\n \\n• Choose a different site each time you give yourself an injection.', 'tokens': ['Figure', 'B', '•', 'Choose', 'different', 'site', 'time', 'give', 'injection', '.'], 'lemmatized': ['Figure', 'B', '•', 'Choose', 'different', 'site', 'time', 'give', 'injection', '.'], 'stemmed': ['figur', 'b', '•', 'choos', 'differ', 'site', 'time', 'give', 'inject', '.'], 'dependencies': [('figur', 'nmod'), ('b', 'npadvmod'), ('•', 'nummod'), ('choos', 'nsubj'), ('differ', 'ROOT'), ('site', 'compound'), ('time', 'npadvmod'), ('give', 'advcl'), ('inject', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Each new injection should \\nbe given at least one inch from a site you used before.', 'tokens': ['new', 'injection', 'given', 'least', 'one', 'inch', 'site', 'used', '.'], 'lemmatized': ['new', 'injection', 'given', 'least', 'one', 'inch', 'site', 'used', '.'], 'stemmed': ['new', 'inject', 'given', 'least', 'one', 'inch', 'site', 'use', '.'], 'dependencies': [('new', 'amod'), ('inject', 'nsubj'), ('given', 'ROOT'), ('least', 'advmod'), ('one', 'nummod'), ('inch', 'compound'), ('site', 'compound'), ('use', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• Do not inject into skin that is:', 'tokens': ['•', 'inject', 'skin', ':'], 'lemmatized': ['•', 'inject', 'skin', ':'], 'stemmed': ['•', 'inject', 'skin', ':'], 'dependencies': [('•', 'nummod'), ('inject', 'amod'), ('skin', 'ROOT'), (':', 'punct')]}], 'text': 'Check the carton, dose tray, and prefilled syringe \\n1. Make sure the name HUMIRA appears on the dose tray and prefilled syringe label.  \\n2. Do not use and do call your doctor or pharmacist if:  \\n• the seals on top or bottom of the carton are broken or missing. \\n• the HUMIRA labeling has an expired date. Check the expiration date on your HUMIRA \\ncarton and do not use if the date has passed.  \\n• the prefilled syringe has been frozen or left in direct sunlight.  \\n• HUMIRA has been kept at room temperature for longer than 14 days or HUMIRA has been \\nstored above 77°F (25°C).  \\n• the liquid in the prefilled syringe is cloudy, discolored or has flakes or particles in it. Make \\nsure the liquid is clear and colorless.  \\n  \\nSee the “How should I store HUMIRA?” section at the end of this Instructions for Use.  \\nChoose the Injection Site \\n3. Wash and dry your hands well.  \\n4. Choose an injection site on:  \\n• the front of your thighs or \\n• your lower abdomen (belly). If you choose your abdomen, do not use the area 2 inches \\naround your belly button (navel). See Figure B.  \\n \\nFigure B \\n \\n• Choose a different site each time you give yourself an injection. Each new injection should \\nbe given at least one inch from a site you used before.  \\n• Do not inject into skin that is: \\n'}, 'page_char_count': 1281, 'page_word_count': 235, 'sentences': ['Check the carton, dose tray, and prefilled syringe \\n1.', 'Make sure the name HUMIRA appears on the dose tray and prefilled syringe label.', ' \\n2.', 'Do not use and do call your doctor or pharmacist if:  \\n• the seals on top or bottom of the carton are broken or missing.', '\\n• the HUMIRA labeling has an expired date.', 'Check the expiration date on your HUMIRA \\ncarton and do not use if the date has passed.', ' \\n• the prefilled syringe has been frozen or left in direct sunlight.', ' \\n• HUMIRA has been kept at room temperature for longer than 14 days or HUMIRA has been \\nstored above 77°F (25°C).', ' \\n• the liquid in the prefilled syringe is cloudy, discolored or has flakes or particles in it.', 'Make \\nsure the liquid is clear and colorless.', ' \\n  \\nSee the “How should I store HUMIRA?”', 'section at the end of this Instructions for Use.', ' \\nChoose the Injection Site \\n3.', 'Wash and dry your hands well.', ' \\n4.', 'Choose an injection site on:  \\n• the front of your thighs or \\n• your lower abdomen (belly).', 'If you choose your abdomen, do not use the area 2 inches \\naround your belly button (navel).', 'See Figure B.  \\n \\nFigure B \\n \\n• Choose a different site each time you give yourself an injection.', 'Each new injection should \\nbe given at least one inch from a site you used before.', ' \\n• Do not inject into skin that is: \\n'], 'page_sentence_count_spacy': 20}\n",
            "{'page_number': 96, 'text': '• sore (tender) \\n• bruised \\n• red \\n• hard \\n• scarred or where you have stretch marks \\n• If you have psoriasis, do not inject directly into any raised, thick, red or scaly skin patches or \\nlesions on your skin. \\n• Do not inject through your clothes. \\n  \\nPrepare the Injection Site \\n5. Wipe the injection site with an alcohol prep (swab) using a circular motion.  \\n6. Do not touch this area again before giving the injection. Allow the skin to dry before injecting. \\nDo not fan or blow on the clean area.  \\nPrepare the Syringe and Needle \\n7. Check the fluid level in the syringe:  \\n• Hold the syringe with the covered needle pointing down. See Figure C.  \\n \\nFigure C \\n \\n  \\n• Hold the syringe at eye level. Look closely to make sure that the amount of liquid in the \\nsyringe is the same or close to the: \\n• 0.8 mL line for the 40 mg prefilled syringe. See Figure D. \\n• 0.4 mL line for the 20 mg prefilled syringe. See Figure D. \\n• 0.2 mL line for the 10 mg prefilled syringe. See Figure D. \\n', 'processed_text': {'sentences': [{'original_sentence': '• sore (tender) \\n• bruised \\n• red \\n• hard \\n• scarred or where you have stretch marks \\n• If you have psoriasis, do not inject directly into any raised, thick, red or scaly skin patches or \\nlesions on your skin.', 'tokens': ['•', 'sore', '(', 'tender', ')', '•', 'bruised', '•', 'red', '•', 'hard', '•', 'scarred', 'stretch', 'marks', '•', 'psoriasis', ',', 'inject', 'directly', 'raised', ',', 'thick', ',', 'red', 'scaly', 'skin', 'patches', 'lesions', 'skin', '.'], 'lemmatized': ['•', 'sore', '(', 'tender', ')', '•', 'bruised', '•', 'red', '•', 'hard', '•', 'scarred', 'stretch', 'mark', '•', 'psoriasis', ',', 'inject', 'directly', 'raised', ',', 'thick', ',', 'red', 'scaly', 'skin', 'patch', 'lesion', 'skin', '.'], 'stemmed': ['•', 'sore', '(', 'tender', ')', '•', 'bruis', '•', 'red', '•', 'hard', '•', 'scar', 'stretch', 'mark', '•', 'psoriasi', ',', 'inject', 'directli', 'rais', ',', 'thick', ',', 'red', 'scali', 'skin', 'patch', 'lesion', 'skin', '.'], 'dependencies': [('•', 'npadvmod'), ('sore', 'amod'), ('(', 'punct'), ('tender', 'nmod'), (')', 'punct'), ('•', 'nummod'), ('bruis', 'nmod'), ('•', 'nummod'), ('red', 'amod'), ('•', 'punct'), ('hard', 'amod'), ('•', 'npadvmod'), ('scar', 'compound'), ('stretch', 'compound'), ('mark', 'ROOT'), ('•', 'nummod'), ('psoriasi', 'dobj'), (',', 'punct'), ('inject', 'compound'), ('directli', 'compound'), ('rais', 'conj'), (',', 'punct'), ('thick', 'amod'), (',', 'punct'), ('red', 'amod'), ('scali', 'amod'), ('skin', 'compound'), ('patch', 'compound'), ('lesion', 'compound'), ('skin', 'appos'), ('.', 'punct')]}, {'original_sentence': '• Do not inject through your clothes.', 'tokens': ['•', 'inject', 'clothes', '.'], 'lemmatized': ['•', 'inject', 'clothes', '.'], 'stemmed': ['•', 'inject', 'cloth', '.'], 'dependencies': [('•', 'nummod'), ('inject', 'amod'), ('cloth', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Prepare the Injection Site \\n5.', 'tokens': ['Prepare', 'Injection', 'Site', '5', '.'], 'lemmatized': ['Prepare', 'Injection', 'Site', '5', '.'], 'stemmed': ['prepar', 'inject', 'site', '5', '.'], 'dependencies': [('prepar', 'compound'), ('inject', 'compound'), ('site', 'ROOT'), ('5', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Wipe the injection site with an alcohol prep (swab) using a circular motion.', 'tokens': ['Wipe', 'injection', 'site', 'alcohol', 'prep', '(', 'swab', ')', 'using', 'circular', 'motion', '.'], 'lemmatized': ['Wipe', 'injection', 'site', 'alcohol', 'prep', '(', 'swab', ')', 'using', 'circular', 'motion', '.'], 'stemmed': ['wipe', 'inject', 'site', 'alcohol', 'prep', '(', 'swab', ')', 'use', 'circular', 'motion', '.'], 'dependencies': [('wipe', 'ROOT'), ('inject', 'compound'), ('site', 'compound'), ('alcohol', 'compound'), ('prep', 'dobj'), ('(', 'punct'), ('swab', 'appos'), (')', 'punct'), ('use', 'conj'), ('circular', 'amod'), ('motion', 'dobj'), ('.', 'punct')]}, {'original_sentence': '6.', 'tokens': ['6', '.'], 'lemmatized': ['6', '.'], 'stemmed': ['6', '.'], 'dependencies': [('6', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Do not touch this area again before giving the injection.', 'tokens': ['touch', 'area', 'giving', 'injection', '.'], 'lemmatized': ['touch', 'area', 'giving', 'injection', '.'], 'stemmed': ['touch', 'area', 'give', 'inject', '.'], 'dependencies': [('touch', 'compound'), ('area', 'nsubj'), ('give', 'ROOT'), ('inject', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Allow the skin to dry before injecting.', 'tokens': ['Allow', 'skin', 'dry', 'injecting', '.'], 'lemmatized': ['Allow', 'skin', 'dry', 'injecting', '.'], 'stemmed': ['allow', 'skin', 'dri', 'inject', '.'], 'dependencies': [('allow', 'ROOT'), ('skin', 'compound'), ('dri', 'compound'), ('inject', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Do not fan or blow on the clean area.', 'tokens': ['fan', 'blow', 'clean', 'area', '.'], 'lemmatized': ['fan', 'blow', 'clean', 'area', '.'], 'stemmed': ['fan', 'blow', 'clean', 'area', '.'], 'dependencies': [('fan', 'nmod'), ('blow', 'nmod'), ('clean', 'amod'), ('area', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Prepare the Syringe and Needle \\n7.', 'tokens': ['Prepare', 'Syringe', 'Needle', '7', '.'], 'lemmatized': ['Prepare', 'Syringe', 'Needle', '7', '.'], 'stemmed': ['prepar', 'syring', 'needl', '7', '.'], 'dependencies': [('prepar', 'compound'), ('syring', 'nsubj'), ('needl', 'ROOT'), ('7', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Check the fluid level in the syringe:  \\n• Hold the syringe with the covered needle pointing down.', 'tokens': ['Check', 'fluid', 'level', 'syringe', ':', '•', 'Hold', 'syringe', 'covered', 'needle', 'pointing', '.'], 'lemmatized': ['Check', 'fluid', 'level', 'syringe', ':', '•', 'Hold', 'syringe', 'covered', 'needle', 'pointing', '.'], 'stemmed': ['check', 'fluid', 'level', 'syring', ':', '•', 'hold', 'syring', 'cover', 'needl', 'point', '.'], 'dependencies': [('check', 'ROOT'), ('fluid', 'amod'), ('level', 'compound'), ('syring', 'dobj'), (':', 'punct'), ('•', 'nsubj'), ('hold', 'acl'), ('syring', 'compound'), ('cover', 'compound'), ('needl', 'compound'), ('point', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'See Figure C.  \\n \\nFigure C \\n \\n  \\n• Hold the syringe at eye level.', 'tokens': ['See', 'Figure', 'C.', 'Figure', 'C', '•', 'Hold', 'syringe', 'eye', 'level', '.'], 'lemmatized': ['See', 'Figure', 'C.', 'Figure', 'C', '•', 'Hold', 'syringe', 'eye', 'level', '.'], 'stemmed': ['see', 'figur', 'c.', 'figur', 'c', '•', 'hold', 'syring', 'eye', 'level', '.'], 'dependencies': [('see', 'ROOT'), ('figur', 'compound'), ('c.', 'compound'), ('figur', 'compound'), ('c', 'dobj'), ('•', 'nummod'), ('hold', 'ccomp'), ('syring', 'amod'), ('eye', 'compound'), ('level', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Look closely to make sure that the amount of liquid in the \\nsyringe is the same or close to the: \\n• 0.8 mL line for the 40 mg prefilled syringe.', 'tokens': ['Look', 'closely', 'make', 'sure', 'amount', 'liquid', 'syringe', 'close', ':', '•', '0.8', 'mL', 'line', '40', 'mg', 'prefilled', 'syringe', '.'], 'lemmatized': ['Look', 'closely', 'make', 'sure', 'amount', 'liquid', 'syringe', 'close', ':', '•', '0.8', 'mL', 'line', '40', 'mg', 'prefilled', 'syringe', '.'], 'stemmed': ['look', 'close', 'make', 'sure', 'amount', 'liquid', 'syring', 'close', ':', '•', '0.8', 'ml', 'line', '40', 'mg', 'prefil', 'syring', '.'], 'dependencies': [('look', 'ROOT'), ('close', 'acomp'), ('make', 'dep'), ('sure', 'amod'), ('amount', 'nsubj'), ('liquid', 'nsubj'), ('syring', 'ccomp'), ('close', 'advmod'), (':', 'punct'), ('•', 'appos'), ('0.8', 'nummod'), ('ml', 'nsubj'), ('line', 'npadvmod'), ('40', 'nummod'), ('mg', 'prep'), ('prefil', 'compound'), ('syring', 'advcl'), ('.', 'punct')]}, {'original_sentence': 'See Figure D. \\n• 0.4 mL line for the 20 mg prefilled syringe.', 'tokens': ['See', 'Figure', 'D.', '•', '0.4', 'mL', 'line', '20', 'mg', 'prefilled', 'syringe', '.'], 'lemmatized': ['See', 'Figure', 'D.', '•', '0.4', 'mL', 'line', '20', 'mg', 'prefilled', 'syringe', '.'], 'stemmed': ['see', 'figur', 'd.', '•', '0.4', 'ml', 'line', '20', 'mg', 'prefil', 'syring', '.'], 'dependencies': [('see', 'ROOT'), ('figur', 'compound'), ('d.', 'dobj'), ('•', 'nummod'), ('0.4', 'nummod'), ('ml', 'nsubj'), ('line', 'ccomp'), ('20', 'nummod'), ('mg', 'prep'), ('prefil', 'nsubj'), ('syring', 'ccomp'), ('.', 'punct')]}, {'original_sentence': 'See Figure D. \\n• 0.2 mL line for the 10 mg prefilled syringe.', 'tokens': ['See', 'Figure', 'D.', '•', '0.2', 'mL', 'line', '10', 'mg', 'prefilled', 'syringe', '.'], 'lemmatized': ['See', 'Figure', 'D.', '•', '0.2', 'mL', 'line', '10', 'mg', 'prefilled', 'syringe', '.'], 'stemmed': ['see', 'figur', 'd.', '•', '0.2', 'ml', 'line', '10', 'mg', 'prefil', 'syring', '.'], 'dependencies': [('see', 'ROOT'), ('figur', 'compound'), ('d.', 'nsubj'), ('•', 'nummod'), ('0.2', 'nummod'), ('ml', 'nsubj'), ('line', 'ccomp'), ('10', 'nummod'), ('mg', 'prep'), ('prefil', 'compound'), ('syring', 'advcl'), ('.', 'punct')]}, {'original_sentence': 'See Figure D.', 'tokens': ['See', 'Figure', '.'], 'lemmatized': ['See', 'Figure', '.'], 'stemmed': ['see', 'figur', '.'], 'dependencies': [('see', 'ROOT'), ('figur', 'dobj'), ('.', 'punct')]}], 'text': '• sore (tender) \\n• bruised \\n• red \\n• hard \\n• scarred or where you have stretch marks \\n• If you have psoriasis, do not inject directly into any raised, thick, red or scaly skin patches or \\nlesions on your skin. \\n• Do not inject through your clothes. \\n  \\nPrepare the Injection Site \\n5. Wipe the injection site with an alcohol prep (swab) using a circular motion.  \\n6. Do not touch this area again before giving the injection. Allow the skin to dry before injecting. \\nDo not fan or blow on the clean area.  \\nPrepare the Syringe and Needle \\n7. Check the fluid level in the syringe:  \\n• Hold the syringe with the covered needle pointing down. See Figure C.  \\n \\nFigure C \\n \\n  \\n• Hold the syringe at eye level. Look closely to make sure that the amount of liquid in the \\nsyringe is the same or close to the: \\n• 0.8 mL line for the 40 mg prefilled syringe. See Figure D. \\n• 0.4 mL line for the 20 mg prefilled syringe. See Figure D. \\n• 0.2 mL line for the 10 mg prefilled syringe. See Figure D. \\n'}, 'page_char_count': 988, 'page_word_count': 186, 'sentences': ['• sore (tender) \\n• bruised \\n• red \\n• hard \\n• scarred or where you have stretch marks \\n• If you have psoriasis, do not inject directly into any raised, thick, red or scaly skin patches or \\nlesions on your skin.', '\\n• Do not inject through your clothes.', '\\n  \\nPrepare the Injection Site \\n5.', 'Wipe the injection site with an alcohol prep (swab) using a circular motion.', ' \\n6.', 'Do not touch this area again before giving the injection.', 'Allow the skin to dry before injecting.', '\\nDo not fan or blow on the clean area.', ' \\nPrepare the Syringe and Needle \\n7.', 'Check the fluid level in the syringe:  \\n• Hold the syringe with the covered needle pointing down.', 'See Figure C.  \\n \\nFigure C \\n \\n  \\n• Hold the syringe at eye level.', 'Look closely to make sure that the amount of liquid in the \\nsyringe is the same or close to the: \\n• 0.8 mL line for the 40 mg prefilled syringe.', 'See Figure D. \\n• 0.4 mL line for the 20 mg prefilled syringe.', 'See Figure D. \\n• 0.2 mL line for the 10 mg prefilled syringe.', 'See Figure D. \\n'], 'page_sentence_count_spacy': 15}\n",
            "{'page_number': 97, 'text': '  \\nFigure D \\n \\n8. The top of the liquid may be curved. If the syringe does not have the correct amount of liquid, \\ndo not use that syringe. Call your pharmacist.  \\n9. Remove the needle cover:  \\n• Hold the syringe in one hand. With the other hand gently remove the needle cover. See \\nFigure E. \\n• Throw away the needle cover.  \\n', 'processed_text': {'sentences': [{'original_sentence': '  \\nFigure D \\n \\n8.', 'tokens': ['Figure', '8', '.'], 'lemmatized': ['Figure', '8', '.'], 'stemmed': ['figur', '8', '.'], 'dependencies': [('figur', 'ROOT'), ('8', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'The top of the liquid may be curved.', 'tokens': ['top', 'liquid', 'may', 'curved', '.'], 'lemmatized': ['top', 'liquid', 'may', 'curved', '.'], 'stemmed': ['top', 'liquid', 'may', 'curv', '.'], 'dependencies': [('top', 'amod'), ('liquid', 'nsubj'), ('may', 'aux'), ('curv', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'If the syringe does not have the correct amount of liquid, \\ndo not use that syringe.', 'tokens': ['syringe', 'correct', 'amount', 'liquid', ',', 'use', 'syringe', '.'], 'lemmatized': ['syringe', 'correct', 'amount', 'liquid', ',', 'use', 'syringe', '.'], 'stemmed': ['syring', 'correct', 'amount', 'liquid', ',', 'use', 'syring', '.'], 'dependencies': [('syring', 'amod'), ('correct', 'amod'), ('amount', 'compound'), ('liquid', 'nsubj'), (',', 'punct'), ('use', 'ROOT'), ('syring', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Call your pharmacist.', 'tokens': ['Call', 'pharmacist', '.'], 'lemmatized': ['Call', 'pharmacist', '.'], 'stemmed': ['call', 'pharmacist', '.'], 'dependencies': [('call', 'ROOT'), ('pharmacist', 'dobj'), ('.', 'punct')]}, {'original_sentence': '9.', 'tokens': ['9', '.'], 'lemmatized': ['9', '.'], 'stemmed': ['9', '.'], 'dependencies': [('9', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Remove the needle cover:  \\n• Hold the syringe in one hand.', 'tokens': ['Remove', 'needle', 'cover', ':', '•', 'Hold', 'syringe', 'one', 'hand', '.'], 'lemmatized': ['Remove', 'needle', 'cover', ':', '•', 'Hold', 'syringe', 'one', 'hand', '.'], 'stemmed': ['remov', 'needl', 'cover', ':', '•', 'hold', 'syring', 'one', 'hand', '.'], 'dependencies': [('remov', 'compound'), ('needl', 'nsubj'), ('cover', 'ROOT'), (':', 'punct'), ('•', 'nsubj'), ('hold', 'ccomp'), ('syring', 'advmod'), ('one', 'nummod'), ('hand', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'With the other hand gently remove the needle cover.', 'tokens': ['hand', 'gently', 'remove', 'needle', 'cover', '.'], 'lemmatized': ['hand', 'gently', 'remove', 'needle', 'cover', '.'], 'stemmed': ['hand', 'gentli', 'remov', 'needl', 'cover', '.'], 'dependencies': [('hand', 'compound'), ('gentli', 'compound'), ('remov', 'nsubj'), ('needl', 'compound'), ('cover', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'See \\nFigure E. \\n• Throw away the needle cover.', 'tokens': ['See', 'Figure', 'E.', '•', 'Throw', 'away', 'needle', 'cover', '.'], 'lemmatized': ['See', 'Figure', 'E.', '•', 'Throw', 'away', 'needle', 'cover', '.'], 'stemmed': ['see', 'figur', 'e.', '•', 'throw', 'away', 'needl', 'cover', '.'], 'dependencies': [('see', 'ROOT'), ('figur', 'compound'), ('e.', 'compound'), ('•', 'punct'), ('throw', 'ccomp'), ('away', 'prt'), ('needl', 'compound'), ('cover', 'dobj'), ('.', 'punct')]}], 'text': '  \\nFigure D \\n \\n8. The top of the liquid may be curved. If the syringe does not have the correct amount of liquid, \\ndo not use that syringe. Call your pharmacist.  \\n9. Remove the needle cover:  \\n• Hold the syringe in one hand. With the other hand gently remove the needle cover. See \\nFigure E. \\n• Throw away the needle cover.  \\n'}, 'page_char_count': 327, 'page_word_count': 60, 'sentences': ['  \\nFigure D \\n \\n8.', 'The top of the liquid may be curved.', 'If the syringe does not have the correct amount of liquid, \\ndo not use that syringe.', 'Call your pharmacist.', ' \\n9.', 'Remove the needle cover:  \\n• Hold the syringe in one hand.', 'With the other hand gently remove the needle cover.', 'See \\nFigure E. \\n• Throw away the needle cover.', ' \\n'], 'page_sentence_count_spacy': 9}\n",
            "{'page_number': 98, 'text': ' \\nFigure E \\n \\n• Do not touch the needle with your fingers or let the needle touch anything. \\n  \\n10. Turn the syringe so the needle is facing up and hold the syringe at eye level with one hand \\nso you can see the air in the syringe. Using your other hand, slowly push the plunger in to push \\nthe air out through the needle. See Figure F.  \\n', 'processed_text': {'sentences': [{'original_sentence': ' \\nFigure E \\n \\n• Do not touch the needle with your fingers or let the needle touch anything.', 'tokens': ['Figure', 'E', '•', 'touch', 'needle', 'fingers', 'let', 'needle', 'touch', 'anything', '.'], 'lemmatized': ['Figure', 'E', '•', 'touch', 'needle', 'finger', 'let', 'needle', 'touch', 'anything', '.'], 'stemmed': ['figur', 'e', '•', 'touch', 'needl', 'finger', 'let', 'needl', 'touch', 'anyth', '.'], 'dependencies': [('figur', 'compound'), ('e', 'compound'), ('•', 'nummod'), ('touch', 'nsubj'), ('needl', 'compound'), ('finger', 'nsubj'), ('let', 'ROOT'), ('needl', 'nsubj'), ('touch', 'ccomp'), ('anyth', 'dobj'), ('.', 'punct')]}, {'original_sentence': '10.', 'tokens': ['10', '.'], 'lemmatized': ['10', '.'], 'stemmed': ['10', '.'], 'dependencies': [('10', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Turn the syringe so the needle is facing up and hold the syringe at eye level with one hand \\nso you can see the air in the syringe.', 'tokens': ['Turn', 'syringe', 'needle', 'facing', 'hold', 'syringe', 'eye', 'level', 'one', 'hand', 'see', 'air', 'syringe', '.'], 'lemmatized': ['Turn', 'syringe', 'needle', 'facing', 'hold', 'syringe', 'eye', 'level', 'one', 'hand', 'see', 'air', 'syringe', '.'], 'stemmed': ['turn', 'syring', 'needl', 'face', 'hold', 'syring', 'eye', 'level', 'one', 'hand', 'see', 'air', 'syring', '.'], 'dependencies': [('turn', 'ROOT'), ('syring', 'dobj'), ('needl', 'dobj'), ('face', 'nsubj'), ('hold', 'ccomp'), ('syring', 'amod'), ('eye', 'compound'), ('level', 'nmod'), ('one', 'nummod'), ('hand', 'nsubj'), ('see', 'ccomp'), ('air', 'compound'), ('syring', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Using your other hand, slowly push the plunger in to push \\nthe air out through the needle.', 'tokens': ['Using', 'hand', ',', 'slowly', 'push', 'plunger', 'push', 'air', 'needle', '.'], 'lemmatized': ['Using', 'hand', ',', 'slowly', 'push', 'plunger', 'push', 'air', 'needle', '.'], 'stemmed': ['use', 'hand', ',', 'slowli', 'push', 'plunger', 'push', 'air', 'needl', '.'], 'dependencies': [('use', 'ROOT'), ('hand', 'dobj'), (',', 'punct'), ('slowli', 'amod'), ('push', 'compound'), ('plunger', 'compound'), ('push', 'compound'), ('air', 'compound'), ('needl', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'See Figure F.', 'tokens': ['See', 'Figure', 'F', '.'], 'lemmatized': ['See', 'Figure', 'F', '.'], 'stemmed': ['see', 'figur', 'f', '.'], 'dependencies': [('see', 'ROOT'), ('figur', 'compound'), ('f', 'dobj'), ('.', 'punct')]}], 'text': ' \\nFigure E \\n \\n• Do not touch the needle with your fingers or let the needle touch anything. \\n  \\n10. Turn the syringe so the needle is facing up and hold the syringe at eye level with one hand \\nso you can see the air in the syringe. Using your other hand, slowly push the plunger in to push \\nthe air out through the needle. See Figure F.  \\n'}, 'page_char_count': 339, 'page_word_count': 66, 'sentences': [' \\nFigure E \\n \\n• Do not touch the needle with your fingers or let the needle touch anything.', '\\n  \\n10.', 'Turn the syringe so the needle is facing up and hold the syringe at eye level with one hand \\nso you can see the air in the syringe.', 'Using your other hand, slowly push the plunger in to push \\nthe air out through the needle.', 'See Figure F.  \\n'], 'page_sentence_count_spacy': 5}\n",
            "{'page_number': 99, 'text': 'Figure F \\n \\n• You may see a drop of liquid at the end of the needle. This is normal. \\n  \\nPosition the Prefilled Syringe and Inject HUMIRA \\nPosition the Syringe \\n11. Hold the body of the prefilled syringe in one hand between the thumb and index finger. Hold \\nthe syringe in your hand like a pencil. See Figure G.  \\n', 'processed_text': {'sentences': [{'original_sentence': 'Figure F \\n \\n• You may see a drop of liquid at the end of the needle.', 'tokens': ['Figure', 'F', '•', 'may', 'see', 'drop', 'liquid', 'end', 'needle', '.'], 'lemmatized': ['Figure', 'F', '•', 'may', 'see', 'drop', 'liquid', 'end', 'needle', '.'], 'stemmed': ['figur', 'f', '•', 'may', 'see', 'drop', 'liquid', 'end', 'needl', '.'], 'dependencies': [('figur', 'compound'), ('f', 'nsubj'), ('•', 'npadvmod'), ('may', 'aux'), ('see', 'ROOT'), ('drop', 'compound'), ('liquid', 'amod'), ('end', 'compound'), ('needl', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'This is normal.', 'tokens': ['normal', '.'], 'lemmatized': ['normal', '.'], 'stemmed': ['normal', '.'], 'dependencies': [('normal', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Position the Prefilled Syringe and Inject HUMIRA \\nPosition the Syringe \\n11.', 'tokens': ['Position', 'Prefilled', 'Syringe', 'Inject', 'HUMIRA', 'Position', 'Syringe', '11', '.'], 'lemmatized': ['Position', 'Prefilled', 'Syringe', 'Inject', 'HUMIRA', 'Position', 'Syringe', '11', '.'], 'stemmed': ['posit', 'prefil', 'syring', 'inject', 'humira', 'posit', 'syring', '11', '.'], 'dependencies': [('posit', 'compound'), ('prefil', 'compound'), ('syring', 'compound'), ('inject', 'compound'), ('humira', 'compound'), ('posit', 'compound'), ('syring', 'ROOT'), ('11', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Hold the body of the prefilled syringe in one hand between the thumb and index finger.', 'tokens': ['Hold', 'body', 'prefilled', 'syringe', 'one', 'hand', 'thumb', 'index', 'finger', '.'], 'lemmatized': ['Hold', 'body', 'prefilled', 'syringe', 'one', 'hand', 'thumb', 'index', 'finger', '.'], 'stemmed': ['hold', 'bodi', 'prefil', 'syring', 'one', 'hand', 'thumb', 'index', 'finger', '.'], 'dependencies': [('hold', 'ROOT'), ('bodi', 'compound'), ('prefil', 'nsubj'), ('syring', 'ccomp'), ('one', 'nummod'), ('hand', 'compound'), ('thumb', 'compound'), ('index', 'compound'), ('finger', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Hold \\nthe syringe in your hand like a pencil.', 'tokens': ['Hold', 'syringe', 'hand', 'like', 'pencil', '.'], 'lemmatized': ['Hold', 'syringe', 'hand', 'like', 'pencil', '.'], 'stemmed': ['hold', 'syring', 'hand', 'like', 'pencil', '.'], 'dependencies': [('hold', 'ROOT'), ('syring', 'amod'), ('hand', 'dobj'), ('like', 'prep'), ('pencil', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'See Figure G.', 'tokens': ['See', 'Figure', 'G', '.'], 'lemmatized': ['See', 'Figure', 'G', '.'], 'stemmed': ['see', 'figur', 'g', '.'], 'dependencies': [('see', 'ROOT'), ('figur', 'compound'), ('g', 'dobj'), ('.', 'punct')]}], 'text': 'Figure F \\n \\n• You may see a drop of liquid at the end of the needle. This is normal. \\n  \\nPosition the Prefilled Syringe and Inject HUMIRA \\nPosition the Syringe \\n11. Hold the body of the prefilled syringe in one hand between the thumb and index finger. Hold \\nthe syringe in your hand like a pencil. See Figure G.  \\n'}, 'page_char_count': 314, 'page_word_count': 58, 'sentences': ['Figure F \\n \\n• You may see a drop of liquid at the end of the needle.', 'This is normal.', '\\n  \\nPosition the Prefilled Syringe and Inject HUMIRA \\nPosition the Syringe \\n11.', 'Hold the body of the prefilled syringe in one hand between the thumb and index finger.', 'Hold \\nthe syringe in your hand like a pencil.', 'See Figure G.  \\n'], 'page_sentence_count_spacy': 6}\n",
            "{'page_number': 100, 'text': 'Figure G \\n \\n• Do not pull back on the plunger at any time.  \\n• With your other hand, gently squeeze the area of the cleaned skin and hold it firmly. See \\nFigure H. \\n  \\n', 'processed_text': {'sentences': [{'original_sentence': 'Figure G \\n \\n• Do not pull back on the plunger at any time.', 'tokens': ['Figure', 'G', '•', 'pull', 'back', 'plunger', 'time', '.'], 'lemmatized': ['Figure', 'G', '•', 'pull', 'back', 'plunger', 'time', '.'], 'stemmed': ['figur', 'g', '•', 'pull', 'back', 'plunger', 'time', '.'], 'dependencies': [('figur', 'compound'), ('g', 'nsubj'), ('•', 'nummod'), ('pull', 'ROOT'), ('back', 'advmod'), ('plunger', 'compound'), ('time', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• With your other hand, gently squeeze the area of the cleaned skin and hold it firmly.', 'tokens': ['•', 'hand', ',', 'gently', 'squeeze', 'area', 'cleaned', 'skin', 'hold', 'firmly', '.'], 'lemmatized': ['•', 'hand', ',', 'gently', 'squeeze', 'area', 'cleaned', 'skin', 'hold', 'firmly', '.'], 'stemmed': ['•', 'hand', ',', 'gentli', 'squeez', 'area', 'clean', 'skin', 'hold', 'firmli', '.'], 'dependencies': [('•', 'nummod'), ('hand', 'dep'), (',', 'punct'), ('gentli', 'nmod'), ('squeez', 'compound'), ('area', 'nsubj'), ('clean', 'amod'), ('skin', 'appos'), ('hold', 'ROOT'), ('firmli', 'oprd'), ('.', 'punct')]}, {'original_sentence': 'See \\nFigure H.', 'tokens': ['See', 'Figure', 'H', '.'], 'lemmatized': ['See', 'Figure', 'H', '.'], 'stemmed': ['see', 'figur', 'h', '.'], 'dependencies': [('see', 'ROOT'), ('figur', 'compound'), ('h', 'dobj'), ('.', 'punct')]}], 'text': 'Figure G \\n \\n• Do not pull back on the plunger at any time.  \\n• With your other hand, gently squeeze the area of the cleaned skin and hold it firmly. See \\nFigure H. \\n  \\n'}, 'page_char_count': 168, 'page_word_count': 33, 'sentences': ['Figure G \\n \\n• Do not pull back on the plunger at any time.', ' \\n• With your other hand, gently squeeze the area of the cleaned skin and hold it firmly.', 'See \\nFigure H. \\n  \\n'], 'page_sentence_count_spacy': 3}\n",
            "{'page_number': 101, 'text': 'Figure H \\n \\nInject HUMIRA \\n12. Using a quick, dart-like motion, insert the needle into the squeezed skin at about a 45-\\ndegree angle. See Figure I.  \\n', 'processed_text': {'sentences': [{'original_sentence': 'Figure H \\n \\nInject HUMIRA \\n12.', 'tokens': ['Figure', 'H', 'Inject', 'HUMIRA', '12', '.'], 'lemmatized': ['Figure', 'H', 'Inject', 'HUMIRA', '12', '.'], 'stemmed': ['figur', 'h', 'inject', 'humira', '12', '.'], 'dependencies': [('figur', 'compound'), ('h', 'compound'), ('inject', 'compound'), ('humira', 'ROOT'), ('12', 'nummod'), ('.', 'punct')]}, {'original_sentence': 'Using a quick, dart-like motion, insert the needle into the squeezed skin at about a 45-\\ndegree angle.', 'tokens': ['Using', 'quick', ',', 'dart-like', 'motion', ',', 'insert', 'needle', 'squeezed', 'skin', '45-', 'degree', 'angle', '.'], 'lemmatized': ['Using', 'quick', ',', 'dart-like', 'motion', ',', 'insert', 'needle', 'squeezed', 'skin', '45-', 'degree', 'angle', '.'], 'stemmed': ['use', 'quick', ',', 'dart-lik', 'motion', ',', 'insert', 'needl', 'squeez', 'skin', '45-', 'degre', 'angl', '.'], 'dependencies': [('use', 'ROOT'), ('quick', 'amod'), (',', 'punct'), ('dart', 'compound'), ('-', 'punct'), ('lik', 'compound'), ('motion', 'dobj'), (',', 'punct'), ('insert', 'nsubj'), ('needl', 'conj'), ('squeez', 'compound'), ('skin', 'dobj'), ('45-', 'meta'), ('degre', 'npadvmod'), ('angl', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'See Figure I.', 'tokens': ['See', 'Figure', '.'], 'lemmatized': ['See', 'Figure', '.'], 'stemmed': ['see', 'figur', '.'], 'dependencies': [('see', 'ROOT'), ('figur', 'dobj'), ('.', 'punct')]}], 'text': 'Figure H \\n \\nInject HUMIRA \\n12. Using a quick, dart-like motion, insert the needle into the squeezed skin at about a 45-\\ndegree angle. See Figure I.  \\n'}, 'page_char_count': 150, 'page_word_count': 26, 'sentences': ['Figure H \\n \\nInject HUMIRA \\n12.', 'Using a quick, dart-like motion, insert the needle into the squeezed skin at about a 45-\\ndegree angle.', 'See Figure I.  \\n'], 'page_sentence_count_spacy': 3}\n",
            "{'page_number': 102, 'text': 'Figure I \\n \\n• After the needle is in, let go of the skin. Pull back gently on the plunger. \\n  \\nIf blood appears in the syringe: \\n• It means that you have entered a blood vessel. \\n• Do not inject HUMIRA. \\n• Pull the needle out of the skin while keeping the syringe at the same angle. \\n• Press a cotton ball or gauze pad over the injection site and hold it for 10 seconds. See \\nFigure J.  \\n', 'processed_text': {'sentences': [{'original_sentence': 'Figure I \\n \\n• After the needle is in, let go of the skin.', 'tokens': ['Figure', '•', 'needle', ',', 'let', 'go', 'skin', '.'], 'lemmatized': ['Figure', '•', 'needle', ',', 'let', 'go', 'skin', '.'], 'stemmed': ['figur', '•', 'needl', ',', 'let', 'go', 'skin', '.'], 'dependencies': [('figur', 'nsubj'), ('•', 'nummod'), ('needl', 'ROOT'), (',', 'punct'), ('let', 'conj'), ('go', 'xcomp'), ('skin', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Pull back gently on the plunger.', 'tokens': ['Pull', 'back', 'gently', 'plunger', '.'], 'lemmatized': ['Pull', 'back', 'gently', 'plunger', '.'], 'stemmed': ['pull', 'back', 'gentli', 'plunger', '.'], 'dependencies': [('pull', 'ROOT'), ('back', 'advmod'), ('gentli', 'compound'), ('plunger', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'If blood appears in the syringe: \\n• It means that you have entered a blood vessel.', 'tokens': ['blood', 'appears', 'syringe', ':', '•', 'means', 'entered', 'blood', 'vessel', '.'], 'lemmatized': ['blood', 'appears', 'syringe', ':', '•', 'mean', 'entered', 'blood', 'vessel', '.'], 'stemmed': ['blood', 'appear', 'syring', ':', '•', 'mean', 'enter', 'blood', 'vessel', '.'], 'dependencies': [('blood', 'nsubj'), ('appear', 'ROOT'), ('syring', 'oprd'), (':', 'punct'), ('•', 'nummod'), ('mean', 'parataxis'), ('enter', 'ccomp'), ('blood', 'compound'), ('vessel', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• Do not inject HUMIRA.', 'tokens': ['•', 'inject', 'HUMIRA', '.'], 'lemmatized': ['•', 'inject', 'HUMIRA', '.'], 'stemmed': ['•', 'inject', 'humira', '.'], 'dependencies': [('•', 'nummod'), ('inject', 'compound'), ('humira', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• Pull the needle out of the skin while keeping the syringe at the same angle.', 'tokens': ['•', 'Pull', 'needle', 'skin', 'keeping', 'syringe', 'angle', '.'], 'lemmatized': ['•', 'Pull', 'needle', 'skin', 'keeping', 'syringe', 'angle', '.'], 'stemmed': ['•', 'pull', 'needl', 'skin', 'keep', 'syring', 'angl', '.'], 'dependencies': [('•', 'npadvmod'), ('pull', 'csubj'), ('needl', 'dobj'), ('skin', 'npadvmod'), ('keep', 'ROOT'), ('syring', 'xcomp'), ('angl', 'oprd'), ('.', 'punct')]}, {'original_sentence': '• Press a cotton ball or gauze pad over the injection site and hold it for 10 seconds.', 'tokens': ['•', 'Press', 'cotton', 'ball', 'gauze', 'pad', 'injection', 'site', 'hold', '10', 'seconds', '.'], 'lemmatized': ['•', 'Press', 'cotton', 'ball', 'gauze', 'pad', 'injection', 'site', 'hold', '10', 'second', '.'], 'stemmed': ['•', 'press', 'cotton', 'ball', 'gauz', 'pad', 'inject', 'site', 'hold', '10', 'second', '.'], 'dependencies': [('•', 'nummod'), ('press', 'compound'), ('cotton', 'compound'), ('ball', 'compound'), ('gauz', 'compound'), ('pad', 'compound'), ('inject', 'compound'), ('site', 'nsubj'), ('hold', 'ROOT'), ('10', 'nummod'), ('second', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'See \\nFigure J.', 'tokens': ['See', 'Figure', 'J', '.'], 'lemmatized': ['See', 'Figure', 'J', '.'], 'stemmed': ['see', 'figur', 'j', '.'], 'dependencies': [('see', 'ROOT'), ('figur', 'compound'), ('j', 'dobj'), ('.', 'punct')]}], 'text': 'Figure I \\n \\n• After the needle is in, let go of the skin. Pull back gently on the plunger. \\n  \\nIf blood appears in the syringe: \\n• It means that you have entered a blood vessel. \\n• Do not inject HUMIRA. \\n• Pull the needle out of the skin while keeping the syringe at the same angle. \\n• Press a cotton ball or gauze pad over the injection site and hold it for 10 seconds. See \\nFigure J.  \\n'}, 'page_char_count': 388, 'page_word_count': 77, 'sentences': ['Figure I \\n \\n• After the needle is in, let go of the skin.', 'Pull back gently on the plunger.', '\\n  \\nIf blood appears in the syringe: \\n• It means that you have entered a blood vessel.', '\\n• Do not inject HUMIRA.', '\\n• Pull the needle out of the skin while keeping the syringe at the same angle.', '\\n• Press a cotton ball or gauze pad over the injection site and hold it for 10 seconds.', 'See \\nFigure J.  \\n'], 'page_sentence_count_spacy': 7}\n",
            "{'page_number': 103, 'text': ' \\nFigure J \\n \\n• Do not use the same syringe and needle again. Throw away the needle and syringe in your \\nsharps container.  \\n• Do not rub the injection site. You may have slight bleeding. This is normal.  \\n• Repeat Steps 1 through 12 with a new prefilled syringe. \\n  \\nIf no blood appears in the syringe: \\n• Slowly push the plunger all the way in until all the liquid is injected and the syringe is empty. \\n• Pull the needle out of the skin while keeping the syringe at the same angle. \\n• Press a cotton ball or gauze pad over the injection site and hold it for 10 seconds. Do not \\nrub the injection site. You may have slight bleeding. This is normal.  \\n  \\n13. Throw away the used prefilled syringe and needle in a sharps disposal container right away \\nafter use. See “How should I throw away (dispose of) used prefilled syringes and \\nneedles?” \\n14. Keep a record of the dates and location of your injection sites. To help you remember when \\nto take HUMIRA, you can mark your calendar ahead of time.  \\nHow should I throw away (dispose of) used prefilled syringes and needles? \\n• Put your used needles and syringes in a FDA-cleared sharps disposal container right \\naway after use. See Figure K. Do not throw away (dispose of) loose needles and \\nsyringes in your household trash.  \\n• Do not try to touch the needle.  \\n', 'processed_text': {'sentences': [{'original_sentence': ' \\nFigure J \\n \\n• Do not use the same syringe and needle again.', 'tokens': ['Figure', 'J', '•', 'use', 'syringe', 'needle', '.'], 'lemmatized': ['Figure', 'J', '•', 'use', 'syringe', 'needle', '.'], 'stemmed': ['figur', 'j', '•', 'use', 'syring', 'needl', '.'], 'dependencies': [('figur', 'npadvmod'), ('j', 'compound'), ('•', 'appos'), ('use', 'ROOT'), ('syring', 'compound'), ('needl', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Throw away the needle and syringe in your \\nsharps container.', 'tokens': ['Throw', 'away', 'needle', 'syringe', 'sharps', 'container', '.'], 'lemmatized': ['Throw', 'away', 'needle', 'syringe', 'sharp', 'container', '.'], 'stemmed': ['throw', 'away', 'needl', 'syring', 'sharp', 'contain', '.'], 'dependencies': [('throw', 'ROOT'), ('away', 'advmod'), ('needl', 'dobj'), ('syring', 'amod'), ('sharp', 'amod'), ('contain', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• Do not rub the injection site.', 'tokens': ['•', 'rub', 'injection', 'site', '.'], 'lemmatized': ['•', 'rub', 'injection', 'site', '.'], 'stemmed': ['•', 'rub', 'inject', 'site', '.'], 'dependencies': [('•', 'meta'), ('rub', 'ROOT'), ('inject', 'compound'), ('site', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'You may have slight bleeding.', 'tokens': ['may', 'slight', 'bleeding', '.'], 'lemmatized': ['may', 'slight', 'bleeding', '.'], 'stemmed': ['may', 'slight', 'bleed', '.'], 'dependencies': [('may', 'aux'), ('slight', 'amod'), ('bleed', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'This is normal.', 'tokens': ['normal', '.'], 'lemmatized': ['normal', '.'], 'stemmed': ['normal', '.'], 'dependencies': [('normal', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• Repeat Steps 1 through 12 with a new prefilled syringe.', 'tokens': ['•', 'Repeat', 'Steps', '1', '12', 'new', 'prefilled', 'syringe', '.'], 'lemmatized': ['•', 'Repeat', 'Steps', '1', '12', 'new', 'prefilled', 'syringe', '.'], 'stemmed': ['•', 'repeat', 'step', '1', '12', 'new', 'prefil', 'syring', '.'], 'dependencies': [('•', 'nummod'), ('repeat', 'compound'), ('step', 'npadvmod'), ('1', 'compound'), ('12', 'nummod'), ('new', 'amod'), ('prefil', 'nsubj'), ('syring', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'If no blood appears in the syringe: \\n• Slowly push the plunger all the way in until all the liquid is injected and the syringe is empty.', 'tokens': ['blood', 'appears', 'syringe', ':', '•', 'Slowly', 'push', 'plunger', 'way', 'liquid', 'injected', 'syringe', 'empty', '.'], 'lemmatized': ['blood', 'appears', 'syringe', ':', '•', 'Slowly', 'push', 'plunger', 'way', 'liquid', 'injected', 'syringe', 'empty', '.'], 'stemmed': ['blood', 'appear', 'syring', ':', '•', 'slowli', 'push', 'plunger', 'way', 'liquid', 'inject', 'syring', 'empti', '.'], 'dependencies': [('blood', 'nsubj'), ('appear', 'ROOT'), ('syring', 'oprd'), (':', 'punct'), ('•', 'nummod'), ('slowli', 'amod'), ('push', 'compound'), ('plunger', 'compound'), ('way', 'nmod'), ('liquid', 'amod'), ('inject', 'compound'), ('syring', 'nsubj'), ('empti', 'oprd'), ('.', 'punct')]}, {'original_sentence': '• Pull the needle out of the skin while keeping the syringe at the same angle.', 'tokens': ['•', 'Pull', 'needle', 'skin', 'keeping', 'syringe', 'angle', '.'], 'lemmatized': ['•', 'Pull', 'needle', 'skin', 'keeping', 'syringe', 'angle', '.'], 'stemmed': ['•', 'pull', 'needl', 'skin', 'keep', 'syring', 'angl', '.'], 'dependencies': [('•', 'npadvmod'), ('pull', 'csubj'), ('needl', 'dobj'), ('skin', 'npadvmod'), ('keep', 'ROOT'), ('syring', 'xcomp'), ('angl', 'oprd'), ('.', 'punct')]}, {'original_sentence': '• Press a cotton ball or gauze pad over the injection site and hold it for 10 seconds.', 'tokens': ['•', 'Press', 'cotton', 'ball', 'gauze', 'pad', 'injection', 'site', 'hold', '10', 'seconds', '.'], 'lemmatized': ['•', 'Press', 'cotton', 'ball', 'gauze', 'pad', 'injection', 'site', 'hold', '10', 'second', '.'], 'stemmed': ['•', 'press', 'cotton', 'ball', 'gauz', 'pad', 'inject', 'site', 'hold', '10', 'second', '.'], 'dependencies': [('•', 'nummod'), ('press', 'compound'), ('cotton', 'compound'), ('ball', 'compound'), ('gauz', 'compound'), ('pad', 'compound'), ('inject', 'compound'), ('site', 'nsubj'), ('hold', 'ROOT'), ('10', 'nummod'), ('second', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Do not \\nrub the injection site.', 'tokens': ['rub', 'injection', 'site', '.'], 'lemmatized': ['rub', 'injection', 'site', '.'], 'stemmed': ['rub', 'inject', 'site', '.'], 'dependencies': [('rub', 'ROOT'), ('inject', 'compound'), ('site', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'You may have slight bleeding.', 'tokens': ['may', 'slight', 'bleeding', '.'], 'lemmatized': ['may', 'slight', 'bleeding', '.'], 'stemmed': ['may', 'slight', 'bleed', '.'], 'dependencies': [('may', 'aux'), ('slight', 'amod'), ('bleed', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'This is normal.', 'tokens': ['normal', '.'], 'lemmatized': ['normal', '.'], 'stemmed': ['normal', '.'], 'dependencies': [('normal', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '13.', 'tokens': ['13', '.'], 'lemmatized': ['13', '.'], 'stemmed': ['13', '.'], 'dependencies': [('13', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Throw away the used prefilled syringe and needle in a sharps disposal container right away \\nafter use.', 'tokens': ['Throw', 'away', 'used', 'prefilled', 'syringe', 'needle', 'sharps', 'disposal', 'container', 'right', 'away', 'use', '.'], 'lemmatized': ['Throw', 'away', 'used', 'prefilled', 'syringe', 'needle', 'sharp', 'disposal', 'container', 'right', 'away', 'use', '.'], 'stemmed': ['throw', 'away', 'use', 'prefil', 'syring', 'needl', 'sharp', 'dispos', 'contain', 'right', 'away', 'use', '.'], 'dependencies': [('throw', 'advcl'), ('away', 'advmod'), ('use', 'compound'), ('prefil', 'compound'), ('syring', 'nsubj'), ('needl', 'ROOT'), ('sharp', 'amod'), ('dispos', 'dobj'), ('contain', 'conj'), ('right', 'advmod'), ('away', 'advmod'), ('use', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'See “How should I throw away (dispose of) used prefilled syringes and \\nneedles?” \\n14.', 'tokens': ['See', '“', 'throw', 'away', '(', 'dispose', ')', 'used', 'prefilled', 'syringes', 'needles', '?', '”', '14', '.'], 'lemmatized': ['See', '“', 'throw', 'away', '(', 'dispose', ')', 'used', 'prefilled', 'syrinx', 'needle', '?', '”', '14', '.'], 'stemmed': ['see', '“', 'throw', 'away', '(', 'dispos', ')', 'use', 'prefil', 'syrinx', 'needl', '?', '”', '14', '.'], 'dependencies': [('see', 'ROOT'), ('“', 'punct'), ('throw', 'xcomp'), ('away', 'advmod'), ('(', 'punct'), ('dispos', 'npadvmod'), (')', 'punct'), ('use', 'conj'), ('prefil', 'compound'), ('syrinx', 'compound'), ('needl', 'dobj'), ('?', 'punct'), ('”', 'punct'), ('14', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Keep a record of the dates and location of your injection sites.', 'tokens': ['Keep', 'record', 'dates', 'location', 'injection', 'sites', '.'], 'lemmatized': ['Keep', 'record', 'date', 'location', 'injection', 'site', '.'], 'stemmed': ['keep', 'record', 'date', 'locat', 'inject', 'site', '.'], 'dependencies': [('keep', 'ROOT'), ('record', 'compound'), ('date', 'compound'), ('locat', 'compound'), ('inject', 'compound'), ('site', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'To help you remember when \\nto take HUMIRA, you can mark your calendar ahead of time.', 'tokens': ['help', 'remember', 'take', 'HUMIRA', ',', 'mark', 'calendar', 'ahead', 'time', '.'], 'lemmatized': ['help', 'remember', 'take', 'HUMIRA', ',', 'mark', 'calendar', 'ahead', 'time', '.'], 'stemmed': ['help', 'rememb', 'take', 'humira', ',', 'mark', 'calendar', 'ahead', 'time', '.'], 'dependencies': [('help', 'advcl'), ('rememb', 'amod'), ('take', 'compound'), ('humira', 'dobj'), (',', 'punct'), ('mark', 'compound'), ('calendar', 'ROOT'), ('ahead', 'amod'), ('time', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'How should I throw away (dispose of) used prefilled syringes and needles?', 'tokens': ['throw', 'away', '(', 'dispose', ')', 'used', 'prefilled', 'syringes', 'needles', '?'], 'lemmatized': ['throw', 'away', '(', 'dispose', ')', 'used', 'prefilled', 'syrinx', 'needle', '?'], 'stemmed': ['throw', 'away', '(', 'dispos', ')', 'use', 'prefil', 'syrinx', 'needl', '?'], 'dependencies': [('throw', 'ROOT'), ('away', 'advmod'), ('(', 'punct'), ('dispos', 'dobj'), (')', 'punct'), ('use', 'conj'), ('prefil', 'compound'), ('syrinx', 'compound'), ('needl', 'dobj'), ('?', 'punct')]}, {'original_sentence': '• Put your used needles and syringes in a FDA-cleared sharps disposal container right \\naway after use.', 'tokens': ['•', 'Put', 'used', 'needles', 'syringes', 'FDA-cleared', 'sharps', 'disposal', 'container', 'right', 'away', 'use', '.'], 'lemmatized': ['•', 'Put', 'used', 'needle', 'syrinx', 'FDA-cleared', 'sharp', 'disposal', 'container', 'right', 'away', 'use', '.'], 'stemmed': ['•', 'put', 'use', 'needl', 'syrinx', 'fda-clear', 'sharp', 'dispos', 'contain', 'right', 'away', 'use', '.'], 'dependencies': [('•', 'npadvmod'), ('put', 'csubj'), ('use', 'dobj'), ('needl', 'ROOT'), ('syrinx', 'dobj'), ('fda', 'nmod'), ('-', 'punct'), ('clear', 'amod'), ('sharp', 'amod'), ('dispos', 'nsubj'), ('contain', 'ccomp'), ('right', 'advmod'), ('away', 'advmod'), ('use', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'See Figure K. Do not throw away (dispose of) loose needles and \\nsyringes in your household trash.', 'tokens': ['See', 'Figure', 'K.', 'throw', 'away', '(', 'dispose', ')', 'loose', 'needles', 'syringes', 'household', 'trash', '.'], 'lemmatized': ['See', 'Figure', 'K.', 'throw', 'away', '(', 'dispose', ')', 'loose', 'needle', 'syrinx', 'household', 'trash', '.'], 'stemmed': ['see', 'figur', 'k.', 'throw', 'away', '(', 'dispos', ')', 'loos', 'needl', 'syrinx', 'household', 'trash', '.'], 'dependencies': [('see', 'ROOT'), ('figur', 'compound'), ('k.', 'nsubj'), ('throw', 'ccomp'), ('away', 'advmod'), ('(', 'punct'), ('dispos', 'parataxis'), (')', 'punct'), ('loos', 'nsubj'), ('needl', 'ccomp'), ('syrinx', 'amod'), ('household', 'compound'), ('trash', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• Do not try to touch the needle.', 'tokens': ['•', 'try', 'touch', 'needle', '.'], 'lemmatized': ['•', 'try', 'touch', 'needle', '.'], 'stemmed': ['•', 'tri', 'touch', 'needl', '.'], 'dependencies': [('•', 'nmod'), ('tri', 'amod'), ('touch', 'compound'), ('needl', 'ROOT'), ('.', 'punct')]}], 'text': ' \\nFigure J \\n \\n• Do not use the same syringe and needle again. Throw away the needle and syringe in your \\nsharps container.  \\n• Do not rub the injection site. You may have slight bleeding. This is normal.  \\n• Repeat Steps 1 through 12 with a new prefilled syringe. \\n  \\nIf no blood appears in the syringe: \\n• Slowly push the plunger all the way in until all the liquid is injected and the syringe is empty. \\n• Pull the needle out of the skin while keeping the syringe at the same angle. \\n• Press a cotton ball or gauze pad over the injection site and hold it for 10 seconds. Do not \\nrub the injection site. You may have slight bleeding. This is normal.  \\n  \\n13. Throw away the used prefilled syringe and needle in a sharps disposal container right away \\nafter use. See “How should I throw away (dispose of) used prefilled syringes and \\nneedles?” \\n14. Keep a record of the dates and location of your injection sites. To help you remember when \\nto take HUMIRA, you can mark your calendar ahead of time.  \\nHow should I throw away (dispose of) used prefilled syringes and needles? \\n• Put your used needles and syringes in a FDA-cleared sharps disposal container right \\naway after use. See Figure K. Do not throw away (dispose of) loose needles and \\nsyringes in your household trash.  \\n• Do not try to touch the needle.  \\n'}, 'page_char_count': 1315, 'page_word_count': 237, 'sentences': [' \\nFigure J \\n \\n• Do not use the same syringe and needle again.', 'Throw away the needle and syringe in your \\nsharps container.', ' \\n• Do not rub the injection site.', 'You may have slight bleeding.', 'This is normal.', ' \\n• Repeat Steps 1 through 12 with a new prefilled syringe.', '\\n  \\nIf no blood appears in the syringe: \\n• Slowly push the plunger all the way in until all the liquid is injected and the syringe is empty.', '\\n• Pull the needle out of the skin while keeping the syringe at the same angle.', '\\n• Press a cotton ball or gauze pad over the injection site and hold it for 10 seconds.', 'Do not \\nrub the injection site.', 'You may have slight bleeding.', 'This is normal.', ' \\n  \\n13.', 'Throw away the used prefilled syringe and needle in a sharps disposal container right away \\nafter use.', 'See “How should I throw away (dispose of) used prefilled syringes and \\nneedles?”', '\\n14.', 'Keep a record of the dates and location of your injection sites.', 'To help you remember when \\nto take HUMIRA, you can mark your calendar ahead of time.', ' \\nHow should I throw away (dispose of) used prefilled syringes and needles?', '\\n• Put your used needles and syringes in a FDA-cleared sharps disposal container right \\naway after use.', 'See Figure K. Do not throw away (dispose of) loose needles and \\nsyringes in your household trash.', ' \\n• Do not try to touch the needle.', ' \\n'], 'page_sentence_count_spacy': 23}\n",
            "{'page_number': 104, 'text': ' \\nFigure K \\n \\n• If you do not have a FDA-cleared sharps disposal container, you may use a household \\ncontainer that is:  \\n◦ made of a heavy-duty plastic,  \\n◦ can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to \\ncome out,  \\n◦ upright and stable during use, \\n◦ leak-resistant, and  \\n◦ properly labeled to warn of hazardous waste inside the container. \\n• When your sharps disposal container is almost full, you will need to follow your community \\nguidelines for the right way to dispose of your sharps disposal container. There may be state \\nor local laws about how you should throw away used needles and syringes. For more \\ninformation about safe sharps disposal, and for specific information about sharps disposal in \\nthe state that you live in, go to the FDA’s website at: http://www.fda.gov/safesharpsdisposal.  \\n• For the safety and health of you and others, needles and used syringes must never be re-\\nused.  \\n• The used alcohol pads, cotton balls, dose trays and packaging may be placed in your \\nhousehold trash. \\n• Do not dispose of your used sharps disposal container in your household trash \\nunless your community guidelines permit this. Do not recycle your used sharps \\ndisposal container. \\n• Always keep the sharps container out of the reach of children. \\n  \\nHow should I store HUMIRA? \\n', 'processed_text': {'sentences': [{'original_sentence': ' \\nFigure K \\n \\n• If you do not have a FDA-cleared sharps disposal container, you may use a household \\ncontainer that is:  \\n◦ made of a heavy-duty plastic,  \\n◦ can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to \\ncome out,  \\n◦ upright and stable during use, \\n◦ leak-resistant, and  \\n◦ properly labeled to warn of hazardous waste inside the container.', 'tokens': ['Figure', 'K', '•', 'FDA-cleared', 'sharps', 'disposal', 'container', ',', 'may', 'use', 'household', 'container', ':', '◦', 'made', 'heavy-duty', 'plastic', ',', '◦', 'closed', 'tight-fitting', ',', 'puncture-resistant', 'lid', ',', 'without', 'sharps', 'able', 'come', ',', '◦', 'upright', 'stable', 'use', ',', '◦', 'leak-resistant', ',', '◦', 'properly', 'labeled', 'warn', 'hazardous', 'waste', 'inside', 'container', '.'], 'lemmatized': ['Figure', 'K', '•', 'FDA-cleared', 'sharp', 'disposal', 'container', ',', 'may', 'use', 'household', 'container', ':', '◦', 'made', 'heavy-duty', 'plastic', ',', '◦', 'closed', 'tight-fitting', ',', 'puncture-resistant', 'lid', ',', 'without', 'sharp', 'able', 'come', ',', '◦', 'upright', 'stable', 'use', ',', '◦', 'leak-resistant', ',', '◦', 'properly', 'labeled', 'warn', 'hazardous', 'waste', 'inside', 'container', '.'], 'stemmed': ['figur', 'k', '•', 'fda-clear', 'sharp', 'dispos', 'contain', ',', 'may', 'use', 'household', 'contain', ':', '◦', 'made', 'heavy-duti', 'plastic', ',', '◦', 'close', 'tight-fit', ',', 'puncture-resist', 'lid', ',', 'without', 'sharp', 'abl', 'come', ',', '◦', 'upright', 'stabl', 'use', ',', '◦', 'leak-resist', ',', '◦', 'properli', 'label', 'warn', 'hazard', 'wast', 'insid', 'contain', '.'], 'dependencies': [('figur', 'nsubj'), ('k', 'nmod'), ('•', 'nummod'), ('fda', 'npadvmod'), ('-', 'punct'), ('clear', 'amod'), ('sharp', 'amod'), ('dispos', 'nsubj'), ('contain', 'ccomp'), (',', 'punct'), ('may', 'aux'), ('use', 'ROOT'), ('household', 'compound'), ('contain', 'dobj'), (':', 'punct'), ('◦', 'nsubj'), ('made', 'dep'), ('heavy', 'amod'), ('-', 'punct'), ('duti', 'compound'), ('plastic', 'dobj'), (',', 'punct'), ('◦', 'advcl'), ('close', 'amod'), ('tight', 'amod'), ('-', 'punct'), ('fit', 'amod'), (',', 'punct'), ('puncture', 'amod'), ('-', 'punct'), ('resist', 'compound'), ('lid', 'dobj'), (',', 'punct'), ('without', 'prep'), ('sharp', 'amod'), ('abl', 'nsubj'), ('come', 'pobj'), (',', 'punct'), ('◦', 'dep'), ('upright', 'amod'), ('stabl', 'amod'), ('use', 'dobj'), (',', 'punct'), ('◦', 'compound'), ('leak', 'compound'), ('-', 'punct'), ('resist', 'nsubj'), (',', 'punct'), ('◦', 'conj'), ('properli', 'compound'), ('label', 'nsubj'), ('warn', 'conj'), ('hazard', 'compound'), ('wast', 'nsubj'), ('insid', 'amod'), ('contain', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• When your sharps disposal container is almost full, you will need to follow your community \\nguidelines for the right way to dispose of your sharps disposal container.', 'tokens': ['•', 'sharps', 'disposal', 'container', 'almost', 'full', ',', 'need', 'follow', 'community', 'guidelines', 'right', 'way', 'dispose', 'sharps', 'disposal', 'container', '.'], 'lemmatized': ['•', 'sharp', 'disposal', 'container', 'almost', 'full', ',', 'need', 'follow', 'community', 'guideline', 'right', 'way', 'dispose', 'sharp', 'disposal', 'container', '.'], 'stemmed': ['•', 'sharp', 'dispos', 'contain', 'almost', 'full', ',', 'need', 'follow', 'commun', 'guidelin', 'right', 'way', 'dispos', 'sharp', 'dispos', 'contain', '.'], 'dependencies': [('•', 'nummod'), ('sharp', 'amod'), ('dispos', 'nsubj'), ('contain', 'ROOT'), ('almost', 'advmod'), ('full', 'advmod'), (',', 'punct'), ('need', 'conj'), ('follow', 'dobj'), ('commun', 'amod'), ('guidelin', 'dobj'), ('right', 'amod'), ('way', 'npadvmod'), ('dispos', 'nsubj'), ('sharp', 'amod'), ('dispos', 'nsubj'), ('contain', 'ccomp'), ('.', 'punct')]}, {'original_sentence': 'There may be state \\nor local laws about how you should throw away used needles and syringes.', 'tokens': ['may', 'state', 'local', 'laws', 'throw', 'away', 'used', 'needles', 'syringes', '.'], 'lemmatized': ['may', 'state', 'local', 'law', 'throw', 'away', 'used', 'needle', 'syrinx', '.'], 'stemmed': ['may', 'state', 'local', 'law', 'throw', 'away', 'use', 'needl', 'syrinx', '.'], 'dependencies': [('may', 'aux'), ('state', 'ROOT'), ('local', 'amod'), ('law', 'dobj'), ('throw', 'ccomp'), ('away', 'advmod'), ('use', 'dobj'), ('needl', 'conj'), ('syrinx', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'For more \\ninformation about safe sharps disposal, and for specific information about sharps disposal in \\nthe state that you live in, go to the FDA’s website at: http://www.fda.gov/safesharpsdisposal.', 'tokens': ['information', 'safe', 'sharps', 'disposal', ',', 'specific', 'information', 'sharps', 'disposal', 'state', 'live', ',', 'go', 'FDA', '’', 'website', ':', 'http', ':', '//www.fda.gov/safesharpsdisposal', '.'], 'lemmatized': ['information', 'safe', 'sharp', 'disposal', ',', 'specific', 'information', 'sharp', 'disposal', 'state', 'live', ',', 'go', 'FDA', '’', 'website', ':', 'http', ':', '//www.fda.gov/safesharpsdisposal', '.'], 'stemmed': ['inform', 'safe', 'sharp', 'dispos', ',', 'specif', 'inform', 'sharp', 'dispos', 'state', 'live', ',', 'go', 'fda', '’', 'websit', ':', 'http', ':', '//www.fda.gov/safesharpsdispos', '.'], 'dependencies': [('inform', 'advcl'), ('safe', 'amod'), ('sharp', 'amod'), ('dispos', 'dobj'), (',', 'punct'), ('specif', 'nsubj'), ('inform', 'ROOT'), ('sharp', 'amod'), ('dispos', 'compound'), ('state', 'dobj'), ('live', 'advmod'), (',', 'punct'), ('go', 'conj'), ('fda', 'nmod'), ('’', 'punct'), ('websit', 'dobj'), (':', 'punct'), ('http', 'appos'), (':', 'punct'), ('//www.fda.gov', 'nmod'), ('/', 'punct'), ('safesharpsdispos', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': '• For the safety and health of you and others, needles and used syringes must never be re-\\nused.', 'tokens': ['•', 'safety', 'health', 'others', ',', 'needles', 'used', 'syringes', 'must', 'never', 're-', 'used', '.'], 'lemmatized': ['•', 'safety', 'health', 'others', ',', 'needle', 'used', 'syrinx', 'must', 'never', 're-', 'used', '.'], 'stemmed': ['•', 'safeti', 'health', 'other', ',', 'needl', 'use', 'syrinx', 'must', 'never', 're-', 'use', '.'], 'dependencies': [('•', 'nummod'), ('safeti', 'compound'), ('health', 'compound'), ('other', 'nsubj'), (',', 'punct'), ('needl', 'ROOT'), ('use', 'compound'), ('syrinx', 'dobj'), ('must', 'aux'), ('never', 'neg'), ('re-', 'amod'), ('use', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• The used alcohol pads, cotton balls, dose trays and packaging may be placed in your \\nhousehold trash.', 'tokens': ['•', 'used', 'alcohol', 'pads', ',', 'cotton', 'balls', ',', 'dose', 'trays', 'packaging', 'may', 'placed', 'household', 'trash', '.'], 'lemmatized': ['•', 'used', 'alcohol', 'pad', ',', 'cotton', 'ball', ',', 'dose', 'tray', 'packaging', 'may', 'placed', 'household', 'trash', '.'], 'stemmed': ['•', 'use', 'alcohol', 'pad', ',', 'cotton', 'ball', ',', 'dose', 'tray', 'packag', 'may', 'place', 'household', 'trash', '.'], 'dependencies': [('•', 'meta'), ('use', 'nsubj'), ('alcohol', 'compound'), ('pad', 'dobj'), (',', 'punct'), ('cotton', 'compound'), ('ball', 'conj'), (',', 'punct'), ('dose', 'conj'), ('tray', 'compound'), ('packag', 'dobj'), ('may', 'aux'), ('place', 'ROOT'), ('household', 'compound'), ('trash', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• Do not dispose of your used sharps disposal container in your household trash \\nunless your community guidelines permit this.', 'tokens': ['•', 'dispose', 'used', 'sharps', 'disposal', 'container', 'household', 'trash', 'unless', 'community', 'guidelines', 'permit', '.'], 'lemmatized': ['•', 'dispose', 'used', 'sharp', 'disposal', 'container', 'household', 'trash', 'unless', 'community', 'guideline', 'permit', '.'], 'stemmed': ['•', 'dispos', 'use', 'sharp', 'dispos', 'contain', 'household', 'trash', 'unless', 'commun', 'guidelin', 'permit', '.'], 'dependencies': [('•', 'nummod'), ('dispos', 'nsubj'), ('use', 'ROOT'), ('sharp', 'amod'), ('dispos', 'dobj'), ('contain', 'xcomp'), ('household', 'compound'), ('trash', 'dobj'), ('unless', 'mark'), ('commun', 'amod'), ('guidelin', 'compound'), ('permit', 'advcl'), ('.', 'punct')]}, {'original_sentence': 'Do not recycle your used sharps \\ndisposal container.', 'tokens': ['recycle', 'used', 'sharps', 'disposal', 'container', '.'], 'lemmatized': ['recycle', 'used', 'sharp', 'disposal', 'container', '.'], 'stemmed': ['recycl', 'use', 'sharp', 'dispos', 'contain', '.'], 'dependencies': [('recycl', 'nsubj'), ('use', 'ROOT'), ('sharp', 'amod'), ('dispos', 'dobj'), ('contain', 'xcomp'), ('.', 'punct')]}, {'original_sentence': '• Always keep the sharps container out of the reach of children.', 'tokens': ['•', 'Always', 'keep', 'sharps', 'container', 'reach', 'children', '.'], 'lemmatized': ['•', 'Always', 'keep', 'sharp', 'container', 'reach', 'child', '.'], 'stemmed': ['•', 'alway', 'keep', 'sharp', 'contain', 'reach', 'child', '.'], 'dependencies': [('•', 'nsubj'), ('alway', 'advmod'), ('keep', 'ROOT'), ('sharp', 'amod'), ('contain', 'nsubj'), ('reach', 'xcomp'), ('child', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'How should I store HUMIRA?', 'tokens': ['store', 'HUMIRA', '?'], 'lemmatized': ['store', 'HUMIRA', '?'], 'stemmed': ['store', 'humira', '?'], 'dependencies': [('store', 'compound'), ('humira', 'ROOT'), ('?', 'punct')]}], 'text': ' \\nFigure K \\n \\n• If you do not have a FDA-cleared sharps disposal container, you may use a household \\ncontainer that is:  \\n◦ made of a heavy-duty plastic,  \\n◦ can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to \\ncome out,  \\n◦ upright and stable during use, \\n◦ leak-resistant, and  \\n◦ properly labeled to warn of hazardous waste inside the container. \\n• When your sharps disposal container is almost full, you will need to follow your community \\nguidelines for the right way to dispose of your sharps disposal container. There may be state \\nor local laws about how you should throw away used needles and syringes. For more \\ninformation about safe sharps disposal, and for specific information about sharps disposal in \\nthe state that you live in, go to the FDA’s website at: http://www.fda.gov/safesharpsdisposal.  \\n• For the safety and health of you and others, needles and used syringes must never be re-\\nused.  \\n• The used alcohol pads, cotton balls, dose trays and packaging may be placed in your \\nhousehold trash. \\n• Do not dispose of your used sharps disposal container in your household trash \\nunless your community guidelines permit this. Do not recycle your used sharps \\ndisposal container. \\n• Always keep the sharps container out of the reach of children. \\n  \\nHow should I store HUMIRA? \\n'}, 'page_char_count': 1333, 'page_word_count': 218, 'sentences': [' \\nFigure K \\n \\n• If you do not have a FDA-cleared sharps disposal container, you may use a household \\ncontainer that is:  \\n◦ made of a heavy-duty plastic,  \\n◦ can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to \\ncome out,  \\n◦ upright and stable during use, \\n◦ leak-resistant, and  \\n◦ properly labeled to warn of hazardous waste inside the container.', '\\n• When your sharps disposal container is almost full, you will need to follow your community \\nguidelines for the right way to dispose of your sharps disposal container.', 'There may be state \\nor local laws about how you should throw away used needles and syringes.', 'For more \\ninformation about safe sharps disposal, and for specific information about sharps disposal in \\nthe state that you live in, go to the FDA’s website at: http://www.fda.gov/safesharpsdisposal.', ' \\n• For the safety and health of you and others, needles and used syringes must never be re-\\nused.', ' \\n• The used alcohol pads, cotton balls, dose trays and packaging may be placed in your \\nhousehold trash.', '\\n• Do not dispose of your used sharps disposal container in your household trash \\nunless your community guidelines permit this.', 'Do not recycle your used sharps \\ndisposal container.', '\\n• Always keep the sharps container out of the reach of children.', '\\n  \\nHow should I store HUMIRA?', '\\n'], 'page_sentence_count_spacy': 11}\n",
            "{'page_number': 105, 'text': '• Store HUMIRA in the refrigerator between 36ºF to 46ºF (2ºC to 8ºC). Store HUMIRA in the \\noriginal carton until use to protect it from light.  \\n• Do not freeze HUMIRA. Do not use HUMIRA if frozen, even if it has been thawed.  \\n• Refrigerated HUMIRA may be used until the expiration date printed on the HUMIRA carton, \\ndose tray or prefilled syringe. Do not use HUMIRA after the expiration date.  \\n• If needed, for example when you are traveling, you may also store HUMIRA at room \\ntemperature up to 77°F (25°C) for up to 14 days. Store HUMIRA in the original carton until \\nuse to protect it from light.  \\n• Throw away HUMIRA if it has been kept at room temperature and not been used within 14 \\ndays.  \\n• Record the date you first remove HUMIRA from the refrigerator in the spaces provided on \\nthe carton and dose tray. \\n• Do not store HUMIRA in extreme heat or cold. \\n• Do not use a prefilled syringe if the liquid is cloudy, discolored, or has flakes or particles in it. \\n• Do not drop or crush HUMIRA. The prefilled syringe is glass. \\n• Keep HUMIRA, injection supplies, and all other medicines out of the reach of children. \\n  \\n \\nThis Instructions for Use has been approved by the U.S. Food and Drug Administration.  \\nManufactured by:  \\nAbbVie Inc.  \\nNorth Chicago, IL 60064, U.S.A.  \\nUS License Number 1889  \\n20066947 \\nRevised: 02/2021  \\n \\n \\n', 'processed_text': {'sentences': [{'original_sentence': '• Store HUMIRA in the refrigerator between 36ºF to 46ºF (2ºC to 8ºC).', 'tokens': ['•', 'Store', 'HUMIRA', 'refrigerator', '36ºF', '46ºF', '(', '2ºC', '8ºC', ')', '.'], 'lemmatized': ['•', 'Store', 'HUMIRA', 'refrigerator', '36ºF', '46ºF', '(', '2ºC', '8ºC', ')', '.'], 'stemmed': ['•', 'store', 'humira', 'refriger', '36ºf', '46ºf', '(', '2ºc', '8ºc', ')', '.'], 'dependencies': [('•', 'nummod'), ('store', 'nmod'), ('humira', 'compound'), ('refriger', 'compound'), ('36ºf', 'compound'), ('46ºf', 'ROOT'), ('(', 'punct'), ('2ºc', 'amod'), ('8ºc', 'parataxis'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'Store HUMIRA in the \\noriginal carton until use to protect it from light.', 'tokens': ['Store', 'HUMIRA', 'original', 'carton', 'use', 'protect', 'light', '.'], 'lemmatized': ['Store', 'HUMIRA', 'original', 'carton', 'use', 'protect', 'light', '.'], 'stemmed': ['store', 'humira', 'origin', 'carton', 'use', 'protect', 'light', '.'], 'dependencies': [('store', 'compound'), ('humira', 'compound'), ('origin', 'compound'), ('carton', 'compound'), ('use', 'compound'), ('protect', 'compound'), ('light', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• Do not freeze HUMIRA.', 'tokens': ['•', 'freeze', 'HUMIRA', '.'], 'lemmatized': ['•', 'freeze', 'HUMIRA', '.'], 'stemmed': ['•', 'freez', 'humira', '.'], 'dependencies': [('•', 'nummod'), ('freez', 'compound'), ('humira', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Do not use HUMIRA if frozen, even if it has been thawed.', 'tokens': ['use', 'HUMIRA', 'frozen', ',', 'even', 'thawed', '.'], 'lemmatized': ['use', 'HUMIRA', 'frozen', ',', 'even', 'thawed', '.'], 'stemmed': ['use', 'humira', 'frozen', ',', 'even', 'thaw', '.'], 'dependencies': [('use', 'ROOT'), ('humira', 'npadvmod'), ('frozen', 'amod'), (',', 'punct'), ('even', 'advmod'), ('thaw', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• Refrigerated HUMIRA may be used until the expiration date printed on the HUMIRA carton, \\ndose tray or prefilled syringe.', 'tokens': ['•', 'Refrigerated', 'HUMIRA', 'may', 'used', 'expiration', 'date', 'printed', 'HUMIRA', 'carton', ',', 'dose', 'tray', 'prefilled', 'syringe', '.'], 'lemmatized': ['•', 'Refrigerated', 'HUMIRA', 'may', 'used', 'expiration', 'date', 'printed', 'HUMIRA', 'carton', ',', 'dose', 'tray', 'prefilled', 'syringe', '.'], 'stemmed': ['•', 'refriger', 'humira', 'may', 'use', 'expir', 'date', 'print', 'humira', 'carton', ',', 'dose', 'tray', 'prefil', 'syring', '.'], 'dependencies': [('•', 'nummod'), ('refriger', 'compound'), ('humira', 'nsubj'), ('may', 'aux'), ('use', 'ROOT'), ('expir', 'compound'), ('date', 'compound'), ('print', 'compound'), ('humira', 'compound'), ('carton', 'dobj'), (',', 'punct'), ('dose', 'xcomp'), ('tray', 'compound'), ('prefil', 'dobj'), ('syring', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Do not use HUMIRA after the expiration date.', 'tokens': ['use', 'HUMIRA', 'expiration', 'date', '.'], 'lemmatized': ['use', 'HUMIRA', 'expiration', 'date', '.'], 'stemmed': ['use', 'humira', 'expir', 'date', '.'], 'dependencies': [('use', 'ROOT'), ('humira', 'compound'), ('expir', 'compound'), ('date', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• If needed, for example when you are traveling, you may also store HUMIRA at room \\ntemperature up to 77°F (25°C) for up to 14 days.', 'tokens': ['•', 'needed', ',', 'example', 'traveling', ',', 'may', 'also', 'store', 'HUMIRA', 'room', 'temperature', '77°F', '(', '25°C', ')', '14', 'days', '.'], 'lemmatized': ['•', 'needed', ',', 'example', 'traveling', ',', 'may', 'also', 'store', 'HUMIRA', 'room', 'temperature', '77°F', '(', '25°C', ')', '14', 'day', '.'], 'stemmed': ['•', 'need', ',', 'exampl', 'travel', ',', 'may', 'also', 'store', 'humira', 'room', 'temperatur', '77°f', '(', '25°c', ')', '14', 'day', '.'], 'dependencies': [('•', 'nummod'), ('need', 'advcl'), (',', 'punct'), ('exampl', 'nsubj'), ('travel', 'meta'), (',', 'punct'), ('may', 'aux'), ('also', 'advmod'), ('store', 'ROOT'), ('humira', 'compound'), ('room', 'dobj'), ('temperatur', 'nmod'), ('77', 'nummod'), ('°', 'npadvmod'), ('f', 'dobj'), ('(', 'punct'), ('25', 'nummod'), ('°', 'appos'), ('c', 'punct'), (')', 'punct'), ('14', 'nummod'), ('day', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Store HUMIRA in the original carton until \\nuse to protect it from light.', 'tokens': ['Store', 'HUMIRA', 'original', 'carton', 'use', 'protect', 'light', '.'], 'lemmatized': ['Store', 'HUMIRA', 'original', 'carton', 'use', 'protect', 'light', '.'], 'stemmed': ['store', 'humira', 'origin', 'carton', 'use', 'protect', 'light', '.'], 'dependencies': [('store', 'compound'), ('humira', 'compound'), ('origin', 'compound'), ('carton', 'compound'), ('use', 'compound'), ('protect', 'compound'), ('light', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• Throw away HUMIRA if it has been kept at room temperature and not been used within 14 \\ndays.', 'tokens': ['•', 'Throw', 'away', 'HUMIRA', 'kept', 'room', 'temperature', 'used', 'within', '14', 'days', '.'], 'lemmatized': ['•', 'Throw', 'away', 'HUMIRA', 'kept', 'room', 'temperature', 'used', 'within', '14', 'day', '.'], 'stemmed': ['•', 'throw', 'away', 'humira', 'kept', 'room', 'temperatur', 'use', 'within', '14', 'day', '.'], 'dependencies': [('•', 'npadvmod'), ('throw', 'csubj'), ('away', 'prt'), ('humira', 'dobj'), ('kept', 'ROOT'), ('room', 'compound'), ('temperatur', 'compound'), ('use', 'dobj'), ('within', 'prep'), ('14', 'nummod'), ('day', 'pobj'), ('.', 'punct')]}, {'original_sentence': '• Record the date you first remove HUMIRA from the refrigerator in the spaces provided on \\nthe carton and dose tray.', 'tokens': ['•', 'Record', 'date', 'first', 'remove', 'HUMIRA', 'refrigerator', 'spaces', 'provided', 'carton', 'dose', 'tray', '.'], 'lemmatized': ['•', 'Record', 'date', 'first', 'remove', 'HUMIRA', 'refrigerator', 'space', 'provided', 'carton', 'dose', 'tray', '.'], 'stemmed': ['•', 'record', 'date', 'first', 'remov', 'humira', 'refriger', 'space', 'provid', 'carton', 'dose', 'tray', '.'], 'dependencies': [('•', 'nummod'), ('record', 'compound'), ('date', 'compound'), ('first', 'amod'), ('remov', 'compound'), ('humira', 'compound'), ('refriger', 'compound'), ('space', 'compound'), ('provid', 'compound'), ('carton', 'compound'), ('dose', 'compound'), ('tray', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• Do not store HUMIRA in extreme heat or cold.', 'tokens': ['•', 'store', 'HUMIRA', 'extreme', 'heat', 'cold', '.'], 'lemmatized': ['•', 'store', 'HUMIRA', 'extreme', 'heat', 'cold', '.'], 'stemmed': ['•', 'store', 'humira', 'extrem', 'heat', 'cold', '.'], 'dependencies': [('•', 'nummod'), ('store', 'compound'), ('humira', 'compound'), ('extrem', 'compound'), ('heat', 'compound'), ('cold', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• Do not use a prefilled syringe if the liquid is cloudy, discolored, or has flakes or particles in it.', 'tokens': ['•', 'use', 'prefilled', 'syringe', 'liquid', 'cloudy', ',', 'discolored', ',', 'flakes', 'particles', '.'], 'lemmatized': ['•', 'use', 'prefilled', 'syringe', 'liquid', 'cloudy', ',', 'discolored', ',', 'flake', 'particle', '.'], 'stemmed': ['•', 'use', 'prefil', 'syring', 'liquid', 'cloudi', ',', 'discolor', ',', 'flake', 'particl', '.'], 'dependencies': [('•', 'meta'), ('use', 'ROOT'), ('prefil', 'dobj'), ('syring', 'amod'), ('liquid', 'compound'), ('cloudi', 'dobj'), (',', 'punct'), ('discolor', 'nmod'), (',', 'punct'), ('flake', 'compound'), ('particl', 'appos'), ('.', 'punct')]}, {'original_sentence': '• Do not drop or crush HUMIRA.', 'tokens': ['•', 'drop', 'crush', 'HUMIRA', '.'], 'lemmatized': ['•', 'drop', 'crush', 'HUMIRA', '.'], 'stemmed': ['•', 'drop', 'crush', 'humira', '.'], 'dependencies': [('•', 'nummod'), ('drop', 'compound'), ('crush', 'compound'), ('humira', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'The prefilled syringe is glass.', 'tokens': ['prefilled', 'syringe', 'glass', '.'], 'lemmatized': ['prefilled', 'syringe', 'glass', '.'], 'stemmed': ['prefil', 'syring', 'glass', '.'], 'dependencies': [('prefil', 'compound'), ('syring', 'compound'), ('glass', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• Keep HUMIRA, injection supplies, and all other medicines out of the reach of children.', 'tokens': ['•', 'Keep', 'HUMIRA', ',', 'injection', 'supplies', ',', 'medicines', 'reach', 'children', '.'], 'lemmatized': ['•', 'Keep', 'HUMIRA', ',', 'injection', 'supply', ',', 'medicine', 'reach', 'child', '.'], 'stemmed': ['•', 'keep', 'humira', ',', 'inject', 'suppli', ',', 'medicin', 'reach', 'child', '.'], 'dependencies': [('•', 'meta'), ('keep', 'advcl'), ('humira', 'dobj'), (',', 'punct'), ('inject', 'compound'), ('suppli', 'conj'), (',', 'punct'), ('medicin', 'nsubj'), ('reach', 'ROOT'), ('child', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'This Instructions for Use has been approved by the U.S. Food and Drug Administration.', 'tokens': ['Instructions', 'Use', 'approved', 'U.S.', 'Food', 'Drug', 'Administration', '.'], 'lemmatized': ['Instructions', 'Use', 'approved', 'U.S.', 'Food', 'Drug', 'Administration', '.'], 'stemmed': ['instruct', 'use', 'approv', 'u.s.', 'food', 'drug', 'administr', '.'], 'dependencies': [('instruct', 'ROOT'), ('use', 'dobj'), ('approv', 'compound'), ('u.s', 'compound'), ('.', 'compound'), ('food', 'compound'), ('drug', 'compound'), ('administr', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Manufactured by:  \\nAbbVie Inc.  \\nNorth Chicago, IL 60064, U.S.A.', 'tokens': ['Manufactured', ':', 'AbbVie', 'Inc.', 'North', 'Chicago', ',', 'IL', '60064', ',', 'U.S.A', '.'], 'lemmatized': ['Manufactured', ':', 'AbbVie', 'Inc.', 'North', 'Chicago', ',', 'IL', '60064', ',', 'U.S.A', '.'], 'stemmed': ['manufactur', ':', 'abbvi', 'inc.', 'north', 'chicago', ',', 'il', '60064', ',', 'u.s.a', '.'], 'dependencies': [('manufactur', 'dep'), (':', 'punct'), ('abbvi', 'ROOT'), ('inc', 'compound'), ('.', 'compound'), ('north', 'compound'), ('chicago', 'npadvmod'), (',', 'punct'), ('il', 'npadvmod'), ('60064', 'nummod'), (',', 'punct'), ('u.s.a', 'intj'), ('.', 'punct')]}, {'original_sentence': 'US License Number 1889  \\n20066947 \\nRevised: 02/2021', 'tokens': ['US', 'License', 'Number', '1889', '20066947', 'Revised', ':', '02/2021'], 'lemmatized': ['US', 'License', 'Number', '1889', '20066947', 'Revised', ':', '02/2021'], 'stemmed': ['us', 'licens', 'number', '1889', '20066947', 'revis', ':', '02/2021'], 'dependencies': [('us', 'compound'), ('licens', 'compound'), ('number', 'ROOT'), ('1889', 'nummod'), ('20066947', 'npadvmod'), ('revis', 'advmod'), (':', 'punct'), ('02/2021', 'appos')]}], 'text': '• Store HUMIRA in the refrigerator between 36ºF to 46ºF (2ºC to 8ºC). Store HUMIRA in the \\noriginal carton until use to protect it from light.  \\n• Do not freeze HUMIRA. Do not use HUMIRA if frozen, even if it has been thawed.  \\n• Refrigerated HUMIRA may be used until the expiration date printed on the HUMIRA carton, \\ndose tray or prefilled syringe. Do not use HUMIRA after the expiration date.  \\n• If needed, for example when you are traveling, you may also store HUMIRA at room \\ntemperature up to 77°F (25°C) for up to 14 days. Store HUMIRA in the original carton until \\nuse to protect it from light.  \\n• Throw away HUMIRA if it has been kept at room temperature and not been used within 14 \\ndays.  \\n• Record the date you first remove HUMIRA from the refrigerator in the spaces provided on \\nthe carton and dose tray. \\n• Do not store HUMIRA in extreme heat or cold. \\n• Do not use a prefilled syringe if the liquid is cloudy, discolored, or has flakes or particles in it. \\n• Do not drop or crush HUMIRA. The prefilled syringe is glass. \\n• Keep HUMIRA, injection supplies, and all other medicines out of the reach of children. \\n  \\n \\nThis Instructions for Use has been approved by the U.S. Food and Drug Administration.  \\nManufactured by:  \\nAbbVie Inc.  \\nNorth Chicago, IL 60064, U.S.A.  \\nUS License Number 1889  \\n20066947 \\nRevised: 02/2021  \\n \\n \\n'}, 'page_char_count': 1346, 'page_word_count': 237, 'sentences': ['• Store HUMIRA in the refrigerator between 36ºF to 46ºF (2ºC to 8ºC).', 'Store HUMIRA in the \\noriginal carton until use to protect it from light.', ' \\n• Do not freeze HUMIRA.', 'Do not use HUMIRA if frozen, even if it has been thawed.', ' \\n• Refrigerated HUMIRA may be used until the expiration date printed on the HUMIRA carton, \\ndose tray or prefilled syringe.', 'Do not use HUMIRA after the expiration date.', ' \\n• If needed, for example when you are traveling, you may also store HUMIRA at room \\ntemperature up to 77°F (25°C) for up to 14 days.', 'Store HUMIRA in the original carton until \\nuse to protect it from light.', ' \\n• Throw away HUMIRA if it has been kept at room temperature and not been used within 14 \\ndays.', ' \\n• Record the date you first remove HUMIRA from the refrigerator in the spaces provided on \\nthe carton and dose tray.', '\\n• Do not store HUMIRA in extreme heat or cold.', '\\n• Do not use a prefilled syringe if the liquid is cloudy, discolored, or has flakes or particles in it.', '\\n• Do not drop or crush HUMIRA.', 'The prefilled syringe is glass.', '\\n• Keep HUMIRA, injection supplies, and all other medicines out of the reach of children.', '\\n  \\n \\nThis Instructions for Use has been approved by the U.S. Food and Drug Administration.', ' \\nManufactured by:  \\nAbbVie Inc.  \\nNorth Chicago, IL 60064, U.S.A.  \\nUS License Number 1889  \\n20066947 \\nRevised: 02/2021  \\n \\n \\n'], 'page_sentence_count_spacy': 17}\n",
            "{'page_number': 106, 'text': ' \\n \\nINSTRUCTIONS FOR USE \\n \\nHUMIRA® (Hu-MARE-ah)  \\n(adalimumab) \\n80 mg/0.8 mL, 40 mg/0.4 mL, 20 mg/0.2 mL and 10 mg/0.1 mL \\nSingle-Dose Prefilled Syringe \\nBefore Injecting: Your healthcare provider should show you how to use HUMIRA before you \\nuse it for the first time. Call your healthcare provider or 1-800-4HUMIRA (1-800-448-6472) if \\nyou need help. \\nImportant Information You Need to Know Before Injecting HUMIRA   \\nDo not use the prefilled syringe and call your healthcare provider or pharmacist if:  \\n• Liquid is cloudy, discolored, or has flakes \\nor particles in it \\n• Expiration date has passed \\n• Liquid has been frozen (even if thawed) or \\nleft in direct sunlight \\n• The prefilled syringe has been dropped or \\ncrushed \\nKeep the needle cover on until right before your injection. \\nHow should I store HUMIRA? \\n• Store HUMIRA in the refrigerator between \\n36°F to 46°F (2°C to 8°C). \\n• Store HUMIRA in the original carton until \\nuse to protect it from light. \\n• Do not freeze \\n• Refrigerated HUMIRA may be used until \\nthe expiration date printed on the HUMIRA \\ncarton, dose tray or prefilled syringe. \\n• If needed, for example when you are \\ntraveling, you may also store HUMIRA at \\nroom temperature up to 77°F (25°C) for up \\nto 14 days.  \\n• Throw away HUMIRA if it has been kept at \\nroom temperature and not used within 14 \\ndays.  \\n• Record the date you first remove HUMIRA \\nfrom the refrigerator in the spaces provided \\non the carton and dose tray. \\n• Do not store HUMIRA in extreme heat or \\ncold.  \\n \\nKeep HUMIRA, injection supplies, and all other medicines out of reach of children. \\nRead Instructions on All Pages Before Using the HUMIRA Single-Dose Prefilled Syringe \\n', 'processed_text': {'sentences': [{'original_sentence': ' \\n \\nINSTRUCTIONS FOR USE \\n \\nHUMIRA® (Hu-MARE-ah)  \\n(adalimumab) \\n80 mg/0.8 mL, 40 mg/0.4 mL, 20 mg/0.2 mL and 10 mg/0.1 mL \\nSingle-Dose Prefilled Syringe \\nBefore Injecting: Your healthcare provider should show you how to use HUMIRA before you \\nuse it for the first time.', 'tokens': ['INSTRUCTIONS', 'USE', 'HUMIRA®', '(', 'Hu-MARE-ah', ')', '(', 'adalimumab', ')', '80', 'mg/0.8', 'mL', ',', '40', 'mg/0.4', 'mL', ',', '20', 'mg/0.2', 'mL', '10', 'mg/0.1', 'mL', 'Single-Dose', 'Prefilled', 'Syringe', 'Injecting', ':', 'healthcare', 'provider', 'show', 'use', 'HUMIRA', 'use', 'first', 'time', '.'], 'lemmatized': ['INSTRUCTIONS', 'USE', 'HUMIRA®', '(', 'Hu-MARE-ah', ')', '(', 'adalimumab', ')', '80', 'mg/0.8', 'mL', ',', '40', 'mg/0.4', 'mL', ',', '20', 'mg/0.2', 'mL', '10', 'mg/0.1', 'mL', 'Single-Dose', 'Prefilled', 'Syringe', 'Injecting', ':', 'healthcare', 'provider', 'show', 'use', 'HUMIRA', 'use', 'first', 'time', '.'], 'stemmed': ['instruct', 'use', 'humira®', '(', 'hu-mare-ah', ')', '(', 'adalimumab', ')', '80', 'mg/0.8', 'ml', ',', '40', 'mg/0.4', 'ml', ',', '20', 'mg/0.2', 'ml', '10', 'mg/0.1', 'ml', 'single-dos', 'prefil', 'syring', 'inject', ':', 'healthcar', 'provid', 'show', 'use', 'humira', 'use', 'first', 'time', '.'], 'dependencies': [('instruct', 'aux'), ('use', 'ccomp'), ('humira', 'compound'), ('®', 'dobj'), ('(', 'punct'), ('hu', 'appos'), ('-', 'punct'), ('mare', 'npadvmod'), ('-', 'punct'), ('ah', 'intj'), (')', 'punct'), ('(', 'punct'), ('adalimumab', 'appos'), (')', 'punct'), ('80', 'nummod'), ('mg/0.8', 'quantmod'), ('ml', 'appos'), (',', 'punct'), ('40', 'nummod'), ('mg/0.4', 'dep'), ('ml', 'appos'), (',', 'punct'), ('20', 'nummod'), ('mg/0.2', 'conj'), ('ml', 'appos'), ('10', 'nummod'), ('mg/0.1', 'dobj'), ('ml', 'nmod'), ('single', 'amod'), ('-', 'punct'), ('dos', 'compound'), ('prefil', 'compound'), ('syring', 'compound'), ('inject', 'dobj'), (':', 'punct'), ('healthcar', 'compound'), ('provid', 'compound'), ('show', 'compound'), ('use', 'ROOT'), ('humira', 'dobj'), ('use', 'dobj'), ('first', 'amod'), ('time', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Call your healthcare provider or 1-800-4HUMIRA (1-800-448-6472) if \\nyou need help.', 'tokens': ['Call', 'healthcare', 'provider', '1-800-4HUMIRA', '(', '1-800-448-6472', ')', 'need', 'help', '.'], 'lemmatized': ['Call', 'healthcare', 'provider', '1-800-4HUMIRA', '(', '1-800-448-6472', ')', 'need', 'help', '.'], 'stemmed': ['call', 'healthcar', 'provid', '1-800-4humira', '(', '1-800-448-6472', ')', 'need', 'help', '.'], 'dependencies': [('call', 'ROOT'), ('healthcar', 'compound'), ('provid', 'dobj'), ('1', 'npadvmod'), ('-', 'punct'), ('800', 'dobj'), ('-', 'punct'), ('4humira', 'dobj'), ('(', 'punct'), ('1', 'appos'), ('-', 'punct'), ('800', 'prep'), ('-', 'punct'), ('448', 'nummod'), ('-', 'punct'), ('6472', 'appos'), (')', 'punct'), ('need', 'conj'), ('help', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Important Information You Need to Know Before Injecting HUMIRA   \\nDo not use the prefilled syringe and call your healthcare provider or pharmacist if:  \\n• Liquid is cloudy, discolored, or has flakes \\nor particles in it \\n• Expiration date has passed \\n• Liquid has been frozen (even if thawed) or \\nleft in direct sunlight \\n• The prefilled syringe has been dropped or \\ncrushed \\nKeep the needle cover on until right before your injection.', 'tokens': ['Important', 'Information', 'Need', 'Know', 'Injecting', 'HUMIRA', 'use', 'prefilled', 'syringe', 'call', 'healthcare', 'provider', 'pharmacist', ':', '•', 'Liquid', 'cloudy', ',', 'discolored', ',', 'flakes', 'particles', '•', 'Expiration', 'date', 'passed', '•', 'Liquid', 'frozen', '(', 'even', 'thawed', ')', 'left', 'direct', 'sunlight', '•', 'prefilled', 'syringe', 'dropped', 'crushed', 'Keep', 'needle', 'cover', 'right', 'injection', '.'], 'lemmatized': ['Important', 'Information', 'Need', 'Know', 'Injecting', 'HUMIRA', 'use', 'prefilled', 'syringe', 'call', 'healthcare', 'provider', 'pharmacist', ':', '•', 'Liquid', 'cloudy', ',', 'discolored', ',', 'flake', 'particle', '•', 'Expiration', 'date', 'passed', '•', 'Liquid', 'frozen', '(', 'even', 'thawed', ')', 'left', 'direct', 'sunlight', '•', 'prefilled', 'syringe', 'dropped', 'crushed', 'Keep', 'needle', 'cover', 'right', 'injection', '.'], 'stemmed': ['import', 'inform', 'need', 'know', 'inject', 'humira', 'use', 'prefil', 'syring', 'call', 'healthcar', 'provid', 'pharmacist', ':', '•', 'liquid', 'cloudi', ',', 'discolor', ',', 'flake', 'particl', '•', 'expir', 'date', 'pass', '•', 'liquid', 'frozen', '(', 'even', 'thaw', ')', 'left', 'direct', 'sunlight', '•', 'prefil', 'syring', 'drop', 'crush', 'keep', 'needl', 'cover', 'right', 'inject', '.'], 'dependencies': [('import', 'compound'), ('inform', 'nsubj'), ('need', 'nsubj'), ('know', 'parataxis'), ('inject', 'compound'), ('humira', 'nsubj'), ('use', 'ccomp'), ('prefil', 'nmod'), ('syring', 'compound'), ('call', 'compound'), ('healthcar', 'compound'), ('provid', 'compound'), ('pharmacist', 'dobj'), (':', 'punct'), ('•', 'nummod'), ('liquid', 'compound'), ('cloudi', 'nmod'), (',', 'punct'), ('discolor', 'conj'), (',', 'punct'), ('flake', 'compound'), ('particl', 'conj'), ('•', 'punct'), ('expir', 'compound'), ('date', 'nsubj'), ('pass', 'ROOT'), ('•', 'punct'), ('liquid', 'amod'), ('frozen', 'amod'), ('(', 'punct'), ('even', 'advmod'), ('thaw', 'dobj'), (')', 'punct'), ('left', 'conj'), ('direct', 'amod'), ('sunlight', 'dobj'), ('•', 'punct'), ('prefil', 'nmod'), ('syring', 'amod'), ('drop', 'compound'), ('crush', 'nsubj'), ('keep', 'conj'), ('needl', 'nsubj'), ('cover', 'ccomp'), ('right', 'amod'), ('inject', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'How should I store HUMIRA?', 'tokens': ['store', 'HUMIRA', '?'], 'lemmatized': ['store', 'HUMIRA', '?'], 'stemmed': ['store', 'humira', '?'], 'dependencies': [('store', 'compound'), ('humira', 'ROOT'), ('?', 'punct')]}, {'original_sentence': '• Store HUMIRA in the refrigerator between \\n36°F to 46°F (2°C to 8°C).', 'tokens': ['•', 'Store', 'HUMIRA', 'refrigerator', '36°F', '46°F', '(', '2°C', '8°C', ')', '.'], 'lemmatized': ['•', 'Store', 'HUMIRA', 'refrigerator', '36°F', '46°F', '(', '2°C', '8°C', ')', '.'], 'stemmed': ['•', 'store', 'humira', 'refriger', '36°f', '46°f', '(', '2°c', '8°c', ')', '.'], 'dependencies': [('•', 'nummod'), ('store', 'compound'), ('humira', 'compound'), ('refriger', 'ROOT'), ('36', 'nummod'), ('°', 'npadvmod'), ('f', 'npadvmod'), ('46', 'nummod'), ('°', 'npadvmod'), ('f', 'npadvmod'), ('(', 'punct'), ('2', 'appos'), ('°', 'cc'), ('c', 'npadvmod'), ('8', 'npadvmod'), ('°', 'nummod'), ('c', 'appos'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': '• Store HUMIRA in the original carton until \\nuse to protect it from light.', 'tokens': ['•', 'Store', 'HUMIRA', 'original', 'carton', 'use', 'protect', 'light', '.'], 'lemmatized': ['•', 'Store', 'HUMIRA', 'original', 'carton', 'use', 'protect', 'light', '.'], 'stemmed': ['•', 'store', 'humira', 'origin', 'carton', 'use', 'protect', 'light', '.'], 'dependencies': [('•', 'nummod'), ('store', 'compound'), ('humira', 'compound'), ('origin', 'compound'), ('carton', 'compound'), ('use', 'compound'), ('protect', 'compound'), ('light', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• Do not freeze \\n• Refrigerated HUMIRA may be used until \\nthe expiration date printed on the HUMIRA \\ncarton, dose tray or prefilled syringe.', 'tokens': ['•', 'freeze', '•', 'Refrigerated', 'HUMIRA', 'may', 'used', 'expiration', 'date', 'printed', 'HUMIRA', 'carton', ',', 'dose', 'tray', 'prefilled', 'syringe', '.'], 'lemmatized': ['•', 'freeze', '•', 'Refrigerated', 'HUMIRA', 'may', 'used', 'expiration', 'date', 'printed', 'HUMIRA', 'carton', ',', 'dose', 'tray', 'prefilled', 'syringe', '.'], 'stemmed': ['•', 'freez', '•', 'refriger', 'humira', 'may', 'use', 'expir', 'date', 'print', 'humira', 'carton', ',', 'dose', 'tray', 'prefil', 'syring', '.'], 'dependencies': [('•', 'meta'), ('freez', 'compound'), ('•', 'nummod'), ('refriger', 'amod'), ('humira', 'nsubj'), ('may', 'aux'), ('use', 'ROOT'), ('expir', 'compound'), ('date', 'compound'), ('print', 'compound'), ('humira', 'compound'), ('carton', 'dobj'), (',', 'punct'), ('dose', 'xcomp'), ('tray', 'compound'), ('prefil', 'dobj'), ('syring', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• If needed, for example when you are \\ntraveling, you may also store HUMIRA at \\nroom temperature up to 77°F (25°C) for up \\nto 14 days.', 'tokens': ['•', 'needed', ',', 'example', 'traveling', ',', 'may', 'also', 'store', 'HUMIRA', 'room', 'temperature', '77°F', '(', '25°C', ')', '14', 'days', '.'], 'lemmatized': ['•', 'needed', ',', 'example', 'traveling', ',', 'may', 'also', 'store', 'HUMIRA', 'room', 'temperature', '77°F', '(', '25°C', ')', '14', 'day', '.'], 'stemmed': ['•', 'need', ',', 'exampl', 'travel', ',', 'may', 'also', 'store', 'humira', 'room', 'temperatur', '77°f', '(', '25°c', ')', '14', 'day', '.'], 'dependencies': [('•', 'nummod'), ('need', 'advcl'), (',', 'punct'), ('exampl', 'nsubj'), ('travel', 'meta'), (',', 'punct'), ('may', 'aux'), ('also', 'advmod'), ('store', 'ROOT'), ('humira', 'compound'), ('room', 'dobj'), ('temperatur', 'nmod'), ('77', 'nummod'), ('°', 'npadvmod'), ('f', 'dobj'), ('(', 'punct'), ('25', 'nummod'), ('°', 'appos'), ('c', 'punct'), (')', 'punct'), ('14', 'nummod'), ('day', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': '• Throw away HUMIRA if it has been kept at \\nroom temperature and not used within 14 \\ndays.', 'tokens': ['•', 'Throw', 'away', 'HUMIRA', 'kept', 'room', 'temperature', 'used', 'within', '14', 'days', '.'], 'lemmatized': ['•', 'Throw', 'away', 'HUMIRA', 'kept', 'room', 'temperature', 'used', 'within', '14', 'day', '.'], 'stemmed': ['•', 'throw', 'away', 'humira', 'kept', 'room', 'temperatur', 'use', 'within', '14', 'day', '.'], 'dependencies': [('•', 'npadvmod'), ('throw', 'csubj'), ('away', 'prt'), ('humira', 'dobj'), ('kept', 'ROOT'), ('room', 'compound'), ('temperatur', 'compound'), ('use', 'dobj'), ('within', 'prep'), ('14', 'nummod'), ('day', 'pobj'), ('.', 'punct')]}, {'original_sentence': '• Record the date you first remove HUMIRA \\nfrom the refrigerator in the spaces provided \\non the carton and dose tray.', 'tokens': ['•', 'Record', 'date', 'first', 'remove', 'HUMIRA', 'refrigerator', 'spaces', 'provided', 'carton', 'dose', 'tray', '.'], 'lemmatized': ['•', 'Record', 'date', 'first', 'remove', 'HUMIRA', 'refrigerator', 'space', 'provided', 'carton', 'dose', 'tray', '.'], 'stemmed': ['•', 'record', 'date', 'first', 'remov', 'humira', 'refriger', 'space', 'provid', 'carton', 'dose', 'tray', '.'], 'dependencies': [('•', 'nummod'), ('record', 'compound'), ('date', 'compound'), ('first', 'amod'), ('remov', 'compound'), ('humira', 'compound'), ('refriger', 'compound'), ('space', 'compound'), ('provid', 'compound'), ('carton', 'compound'), ('dose', 'compound'), ('tray', 'ROOT'), ('.', 'punct')]}, {'original_sentence': '• Do not store HUMIRA in extreme heat or \\ncold.', 'tokens': ['•', 'store', 'HUMIRA', 'extreme', 'heat', 'cold', '.'], 'lemmatized': ['•', 'store', 'HUMIRA', 'extreme', 'heat', 'cold', '.'], 'stemmed': ['•', 'store', 'humira', 'extrem', 'heat', 'cold', '.'], 'dependencies': [('•', 'nummod'), ('store', 'compound'), ('humira', 'compound'), ('extrem', 'compound'), ('heat', 'compound'), ('cold', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Keep HUMIRA, injection supplies, and all other medicines out of reach of children.', 'tokens': ['Keep', 'HUMIRA', ',', 'injection', 'supplies', ',', 'medicines', 'reach', 'children', '.'], 'lemmatized': ['Keep', 'HUMIRA', ',', 'injection', 'supply', ',', 'medicine', 'reach', 'child', '.'], 'stemmed': ['keep', 'humira', ',', 'inject', 'suppli', ',', 'medicin', 'reach', 'child', '.'], 'dependencies': [('keep', 'advcl'), ('humira', 'dobj'), (',', 'punct'), ('inject', 'compound'), ('suppli', 'conj'), (',', 'punct'), ('medicin', 'nsubj'), ('reach', 'ROOT'), ('child', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Read Instructions on All Pages Before Using the HUMIRA Single-Dose Prefilled Syringe', 'tokens': ['Read', 'Instructions', 'Pages', 'Using', 'HUMIRA', 'Single-Dose', 'Prefilled', 'Syringe'], 'lemmatized': ['Read', 'Instructions', 'Pages', 'Using', 'HUMIRA', 'Single-Dose', 'Prefilled', 'Syringe'], 'stemmed': ['read', 'instruct', 'page', 'use', 'humira', 'single-dos', 'prefil', 'syring'], 'dependencies': [('read', 'ROOT'), ('instruct', 'compound'), ('page', 'compound'), ('use', 'ccomp'), ('humira', 'nmod'), ('single', 'amod'), ('-', 'punct'), ('dos', 'compound'), ('prefil', 'dobj'), ('syring', 'ccomp')]}], 'text': ' \\n \\nINSTRUCTIONS FOR USE \\n \\nHUMIRA® (Hu-MARE-ah)  \\n(adalimumab) \\n80 mg/0.8 mL, 40 mg/0.4 mL, 20 mg/0.2 mL and 10 mg/0.1 mL \\nSingle-Dose Prefilled Syringe \\nBefore Injecting: Your healthcare provider should show you how to use HUMIRA before you \\nuse it for the first time. Call your healthcare provider or 1-800-4HUMIRA (1-800-448-6472) if \\nyou need help. \\nImportant Information You Need to Know Before Injecting HUMIRA   \\nDo not use the prefilled syringe and call your healthcare provider or pharmacist if:  \\n• Liquid is cloudy, discolored, or has flakes \\nor particles in it \\n• Expiration date has passed \\n• Liquid has been frozen (even if thawed) or \\nleft in direct sunlight \\n• The prefilled syringe has been dropped or \\ncrushed \\nKeep the needle cover on until right before your injection. \\nHow should I store HUMIRA? \\n• Store HUMIRA in the refrigerator between \\n36°F to 46°F (2°C to 8°C). \\n• Store HUMIRA in the original carton until \\nuse to protect it from light. \\n• Do not freeze \\n• Refrigerated HUMIRA may be used until \\nthe expiration date printed on the HUMIRA \\ncarton, dose tray or prefilled syringe. \\n• If needed, for example when you are \\ntraveling, you may also store HUMIRA at \\nroom temperature up to 77°F (25°C) for up \\nto 14 days.  \\n• Throw away HUMIRA if it has been kept at \\nroom temperature and not used within 14 \\ndays.  \\n• Record the date you first remove HUMIRA \\nfrom the refrigerator in the spaces provided \\non the carton and dose tray. \\n• Do not store HUMIRA in extreme heat or \\ncold.  \\n \\nKeep HUMIRA, injection supplies, and all other medicines out of reach of children. \\nRead Instructions on All Pages Before Using the HUMIRA Single-Dose Prefilled Syringe \\n'}, 'page_char_count': 1680, 'page_word_count': 281, 'sentences': [' \\n \\nINSTRUCTIONS FOR USE \\n \\nHUMIRA® (Hu-MARE-ah)  \\n(adalimumab) \\n80 mg/0.8 mL, 40 mg/0.4 mL, 20 mg/0.2 mL and 10 mg/0.1 mL \\nSingle-Dose Prefilled Syringe \\nBefore Injecting: Your healthcare provider should show you how to use HUMIRA before you \\nuse it for the first time.', 'Call your healthcare provider or 1-800-4HUMIRA (1-800-448-6472) if \\nyou need help.', '\\nImportant Information You Need to Know Before Injecting HUMIRA   \\nDo not use the prefilled syringe and call your healthcare provider or pharmacist if:  \\n• Liquid is cloudy, discolored, or has flakes \\nor particles in it \\n• Expiration date has passed \\n• Liquid has been frozen (even if thawed) or \\nleft in direct sunlight \\n• The prefilled syringe has been dropped or \\ncrushed \\nKeep the needle cover on until right before your injection.', '\\nHow should I store HUMIRA?', '\\n• Store HUMIRA in the refrigerator between \\n36°F to 46°F (2°C to 8°C).', '\\n• Store HUMIRA in the original carton until \\nuse to protect it from light.', '\\n• Do not freeze \\n• Refrigerated HUMIRA may be used until \\nthe expiration date printed on the HUMIRA \\ncarton, dose tray or prefilled syringe.', '\\n• If needed, for example when you are \\ntraveling, you may also store HUMIRA at \\nroom temperature up to 77°F (25°C) for up \\nto 14 days.', ' \\n• Throw away HUMIRA if it has been kept at \\nroom temperature and not used within 14 \\ndays.', ' \\n• Record the date you first remove HUMIRA \\nfrom the refrigerator in the spaces provided \\non the carton and dose tray.', '\\n• Do not store HUMIRA in extreme heat or \\ncold.', ' \\n \\nKeep HUMIRA, injection supplies, and all other medicines out of reach of children.', '\\nRead Instructions on All Pages Before Using the HUMIRA Single-Dose Prefilled Syringe \\n'], 'page_sentence_count_spacy': 13}\n",
            "{'page_number': 107, 'text': ' \\n   \\n \\nTake HUMIRA out of the refrigerator.  \\nLeave HUMIRA at room temperature for 15 to \\n30 minutes before injecting.  \\n• Do not remove the needle cover while \\nallowing HUMIRA to reach room \\ntemperature  \\n• Do not warm HUMIRA in any other way. For \\nexample, do not warm it in a microwave or \\nin hot water.  \\n• Do not use the prefilled syringe if liquid has \\nbeen frozen (even if thawed)  \\n \\n   \\n \\nCheck expiration date on the prefilled syringe \\nlabel. Do not use the prefilled syringe if \\nexpiration date has passed.  \\nPlace the following on a clean, flat surface:  \\n• 1 single-dose prefilled syringe and alcohol \\nswab \\n• 1 cotton ball or gauze pad (not included) \\n• Puncture-resistant sharps disposal container \\n(not included). See Step 9 at the end of this \\nInstructions for Use for instructions on how \\nto throw away (dispose of) your prefilled \\nsyringe  \\nWash and dry your hands.  \\n \\n   \\n \\nChoose an injection site:  \\n• On the front of your thighs or \\n• Your abdomen (belly) at least 2 inches from \\nyour navel (belly button)  \\n• Different from your last injection site \\nWipe the injection site in a circular motion with \\nthe alcohol swab.  \\n• Do not inject through clothes  \\n• Do not inject into skin that is sore, bruised, \\nred, hard, scarred, has stretch marks, or \\nareas with psoriasis plaques  \\n', 'processed_text': {'sentences': [{'original_sentence': ' \\n   \\n \\nTake HUMIRA out of the refrigerator.', 'tokens': ['Take', 'HUMIRA', 'refrigerator', '.'], 'lemmatized': ['Take', 'HUMIRA', 'refrigerator', '.'], 'stemmed': ['take', 'humira', 'refriger', '.'], 'dependencies': [('take', 'ROOT'), ('humira', 'compound'), ('refriger', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Leave HUMIRA at room temperature for 15 to \\n30 minutes before injecting.', 'tokens': ['Leave', 'HUMIRA', 'room', 'temperature', '15', '30', 'minutes', 'injecting', '.'], 'lemmatized': ['Leave', 'HUMIRA', 'room', 'temperature', '15', '30', 'minute', 'injecting', '.'], 'stemmed': ['leav', 'humira', 'room', 'temperatur', '15', '30', 'minut', 'inject', '.'], 'dependencies': [('leav', 'amod'), ('humira', 'compound'), ('room', 'compound'), ('temperatur', 'ROOT'), ('15', 'nummod'), ('30', 'nummod'), ('minut', 'compound'), ('inject', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• Do not remove the needle cover while \\nallowing HUMIRA to reach room \\ntemperature  \\n• Do not warm HUMIRA in any other way.', 'tokens': ['•', 'remove', 'needle', 'cover', 'allowing', 'HUMIRA', 'reach', 'room', 'temperature', '•', 'warm', 'HUMIRA', 'way', '.'], 'lemmatized': ['•', 'remove', 'needle', 'cover', 'allowing', 'HUMIRA', 'reach', 'room', 'temperature', '•', 'warm', 'HUMIRA', 'way', '.'], 'stemmed': ['•', 'remov', 'needl', 'cover', 'allow', 'humira', 'reach', 'room', 'temperatur', '•', 'warm', 'humira', 'way', '.'], 'dependencies': [('•', 'nummod'), ('remov', 'compound'), ('needl', 'compound'), ('cover', 'nsubj'), ('allow', 'ROOT'), ('humira', 'nsubj'), ('reach', 'ccomp'), ('room', 'dobj'), ('temperatur', 'advmod'), ('•', 'appos'), ('warm', 'amod'), ('humira', 'compound'), ('way', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'For \\nexample, do not warm it in a microwave or \\nin hot water.', 'tokens': ['example', ',', 'warm', 'microwave', 'hot', 'water', '.'], 'lemmatized': ['example', ',', 'warm', 'microwave', 'hot', 'water', '.'], 'stemmed': ['exampl', ',', 'warm', 'microwav', 'hot', 'water', '.'], 'dependencies': [('exampl', 'ROOT'), (',', 'punct'), ('warm', 'amod'), ('microwav', 'amod'), ('hot', 'amod'), ('water', 'appos'), ('.', 'punct')]}, {'original_sentence': '• Do not use the prefilled syringe if liquid has \\nbeen frozen (even if thawed)  \\n \\n   \\n \\nCheck expiration date on the prefilled syringe \\nlabel.', 'tokens': ['•', 'use', 'prefilled', 'syringe', 'liquid', 'frozen', '(', 'even', 'thawed', ')', 'Check', 'expiration', 'date', 'prefilled', 'syringe', 'label', '.'], 'lemmatized': ['•', 'use', 'prefilled', 'syringe', 'liquid', 'frozen', '(', 'even', 'thawed', ')', 'Check', 'expiration', 'date', 'prefilled', 'syringe', 'label', '.'], 'stemmed': ['•', 'use', 'prefil', 'syring', 'liquid', 'frozen', '(', 'even', 'thaw', ')', 'check', 'expir', 'date', 'prefil', 'syring', 'label', '.'], 'dependencies': [('•', 'meta'), ('use', 'ROOT'), ('prefil', 'dobj'), ('syring', 'amod'), ('liquid', 'amod'), ('frozen', 'amod'), ('(', 'punct'), ('even', 'advmod'), ('thaw', 'dobj'), (')', 'punct'), ('check', 'ROOT'), ('expir', 'compound'), ('date', 'compound'), ('prefil', 'compound'), ('syring', 'compound'), ('label', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Do not use the prefilled syringe if \\nexpiration date has passed.', 'tokens': ['use', 'prefilled', 'syringe', 'expiration', 'date', 'passed', '.'], 'lemmatized': ['use', 'prefilled', 'syringe', 'expiration', 'date', 'passed', '.'], 'stemmed': ['use', 'prefil', 'syring', 'expir', 'date', 'pass', '.'], 'dependencies': [('use', 'ROOT'), ('prefil', 'dobj'), ('syring', 'xcomp'), ('expir', 'compound'), ('date', 'compound'), ('pass', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Place the following on a clean, flat surface:  \\n• 1 single-dose prefilled syringe and alcohol \\nswab \\n• 1 cotton ball or gauze pad (not included) \\n• Puncture-resistant sharps disposal container \\n(not included).', 'tokens': ['Place', 'following', 'clean', ',', 'flat', 'surface', ':', '•', '1', 'single-dose', 'prefilled', 'syringe', 'alcohol', 'swab', '•', '1', 'cotton', 'ball', 'gauze', 'pad', '(', 'included', ')', '•', 'Puncture-resistant', 'sharps', 'disposal', 'container', '(', 'included', ')', '.'], 'lemmatized': ['Place', 'following', 'clean', ',', 'flat', 'surface', ':', '•', '1', 'single-dose', 'prefilled', 'syringe', 'alcohol', 'swab', '•', '1', 'cotton', 'ball', 'gauze', 'pad', '(', 'included', ')', '•', 'Puncture-resistant', 'sharp', 'disposal', 'container', '(', 'included', ')', '.'], 'stemmed': ['place', 'follow', 'clean', ',', 'flat', 'surfac', ':', '•', '1', 'single-dos', 'prefil', 'syring', 'alcohol', 'swab', '•', '1', 'cotton', 'ball', 'gauz', 'pad', '(', 'includ', ')', '•', 'puncture-resist', 'sharp', 'dispos', 'contain', '(', 'includ', ')', '.'], 'dependencies': [('place', 'nsubj'), ('follow', 'ROOT'), ('clean', 'amod'), (',', 'punct'), ('flat', 'amod'), ('surfac', 'dobj'), (':', 'punct'), ('•', 'nummod'), ('1', 'nummod'), ('single', 'amod'), ('-', 'punct'), ('dos', 'compound'), ('prefil', 'nmod'), ('syring', 'compound'), ('alcohol', 'compound'), ('swab', 'nmod'), ('•', 'case'), ('1', 'nummod'), ('cotton', 'compound'), ('ball', 'compound'), ('gauz', 'compound'), ('pad', 'nsubj'), ('(', 'punct'), ('includ', 'nmod'), (')', 'punct'), ('•', 'appos'), ('puncture', 'amod'), ('-', 'punct'), ('resist', 'acl'), ('sharp', 'amod'), ('dispos', 'dobj'), ('contain', 'conj'), ('(', 'punct'), ('includ', 'dobj'), (')', 'punct'), ('.', 'punct')]}, {'original_sentence': 'See Step 9 at the end of this \\nInstructions for Use for instructions on how \\nto throw away (dispose of) your prefilled \\nsyringe  \\nWash and dry your hands.', 'tokens': ['See', 'Step', '9', 'end', 'Instructions', 'Use', 'instructions', 'throw', 'away', '(', 'dispose', ')', 'prefilled', 'syringe', 'Wash', 'dry', 'hands', '.'], 'lemmatized': ['See', 'Step', '9', 'end', 'Instructions', 'Use', 'instruction', 'throw', 'away', '(', 'dispose', ')', 'prefilled', 'syringe', 'Wash', 'dry', 'hand', '.'], 'stemmed': ['see', 'step', '9', 'end', 'instruct', 'use', 'instruct', 'throw', 'away', '(', 'dispos', ')', 'prefil', 'syring', 'wash', 'dri', 'hand', '.'], 'dependencies': [('see', 'ROOT'), ('step', 'nmod'), ('9', 'nummod'), ('end', 'compound'), ('instruct', 'compound'), ('use', 'compound'), ('instruct', 'ccomp'), ('throw', 'xcomp'), ('away', 'advmod'), ('(', 'punct'), ('dispos', 'dep'), (')', 'punct'), ('prefil', 'compound'), ('syring', 'nsubj'), ('wash', 'ccomp'), ('dri', 'compound'), ('hand', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Choose an injection site:  \\n• On the front of your thighs or \\n• Your abdomen (belly) at least 2 inches from \\nyour navel (belly button)  \\n• Different from your last injection site \\nWipe the injection site in a circular motion with \\nthe alcohol swab.', 'tokens': ['Choose', 'injection', 'site', ':', '•', 'front', 'thighs', '•', 'abdomen', '(', 'belly', ')', 'least', '2', 'inches', 'navel', '(', 'belly', 'button', ')', '•', 'Different', 'last', 'injection', 'site', 'Wipe', 'injection', 'site', 'circular', 'motion', 'alcohol', 'swab', '.'], 'lemmatized': ['Choose', 'injection', 'site', ':', '•', 'front', 'thigh', '•', 'abdomen', '(', 'belly', ')', 'least', '2', 'inch', 'navel', '(', 'belly', 'button', ')', '•', 'Different', 'last', 'injection', 'site', 'Wipe', 'injection', 'site', 'circular', 'motion', 'alcohol', 'swab', '.'], 'stemmed': ['choos', 'inject', 'site', ':', '•', 'front', 'thigh', '•', 'abdomen', '(', 'belli', ')', 'least', '2', 'inch', 'navel', '(', 'belli', 'button', ')', '•', 'differ', 'last', 'inject', 'site', 'wipe', 'inject', 'site', 'circular', 'motion', 'alcohol', 'swab', '.'], 'dependencies': [('choos', 'compound'), ('inject', 'compound'), ('site', 'nsubj'), (':', 'punct'), ('•', 'nummod'), ('front', 'amod'), ('thigh', 'compound'), ('•', 'nummod'), ('abdomen', 'appos'), ('(', 'punct'), ('belli', 'appos'), (')', 'punct'), ('least', 'advmod'), ('2', 'nummod'), ('inch', 'compound'), ('navel', 'conj'), ('(', 'punct'), ('belli', 'compound'), ('button', 'appos'), (')', 'punct'), ('•', 'nummod'), ('differ', 'ROOT'), ('last', 'amod'), ('inject', 'compound'), ('site', 'nmod'), ('wipe', 'nmod'), ('inject', 'nmod'), ('site', 'compound'), ('circular', 'amod'), ('motion', 'compound'), ('alcohol', 'compound'), ('swab', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• Do not inject through clothes  \\n• Do not inject into skin that is sore, bruised, \\nred, hard, scarred, has stretch marks, or \\nareas with psoriasis plaques', 'tokens': ['•', 'inject', 'clothes', '•', 'inject', 'skin', 'sore', ',', 'bruised', ',', 'red', ',', 'hard', ',', 'scarred', ',', 'stretch', 'marks', ',', 'areas', 'psoriasis', 'plaques'], 'lemmatized': ['•', 'inject', 'clothes', '•', 'inject', 'skin', 'sore', ',', 'bruised', ',', 'red', ',', 'hard', ',', 'scarred', ',', 'stretch', 'mark', ',', 'area', 'psoriasis', 'plaque'], 'stemmed': ['•', 'inject', 'cloth', '•', 'inject', 'skin', 'sore', ',', 'bruis', ',', 'red', ',', 'hard', ',', 'scar', ',', 'stretch', 'mark', ',', 'area', 'psoriasi', 'plaqu'], 'dependencies': [('•', 'nummod'), ('inject', 'compound'), ('cloth', 'nmod'), ('•', 'appos'), ('inject', 'amod'), ('skin', 'ROOT'), ('sore', 'amod'), (',', 'punct'), ('bruis', 'conj'), (',', 'punct'), ('red', 'conj'), (',', 'punct'), ('hard', 'conj'), (',', 'punct'), ('scar', 'conj'), (',', 'punct'), ('stretch', 'compound'), ('mark', 'conj'), (',', 'punct'), ('area', 'compound'), ('psoriasi', 'compound'), ('plaqu', 'appos')]}], 'text': ' \\n   \\n \\nTake HUMIRA out of the refrigerator.  \\nLeave HUMIRA at room temperature for 15 to \\n30 minutes before injecting.  \\n• Do not remove the needle cover while \\nallowing HUMIRA to reach room \\ntemperature  \\n• Do not warm HUMIRA in any other way. For \\nexample, do not warm it in a microwave or \\nin hot water.  \\n• Do not use the prefilled syringe if liquid has \\nbeen frozen (even if thawed)  \\n \\n   \\n \\nCheck expiration date on the prefilled syringe \\nlabel. Do not use the prefilled syringe if \\nexpiration date has passed.  \\nPlace the following on a clean, flat surface:  \\n• 1 single-dose prefilled syringe and alcohol \\nswab \\n• 1 cotton ball or gauze pad (not included) \\n• Puncture-resistant sharps disposal container \\n(not included). See Step 9 at the end of this \\nInstructions for Use for instructions on how \\nto throw away (dispose of) your prefilled \\nsyringe  \\nWash and dry your hands.  \\n \\n   \\n \\nChoose an injection site:  \\n• On the front of your thighs or \\n• Your abdomen (belly) at least 2 inches from \\nyour navel (belly button)  \\n• Different from your last injection site \\nWipe the injection site in a circular motion with \\nthe alcohol swab.  \\n• Do not inject through clothes  \\n• Do not inject into skin that is sore, bruised, \\nred, hard, scarred, has stretch marks, or \\nareas with psoriasis plaques  \\n'}, 'page_char_count': 1305, 'page_word_count': 219, 'sentences': [' \\n   \\n \\nTake HUMIRA out of the refrigerator.', ' \\nLeave HUMIRA at room temperature for 15 to \\n30 minutes before injecting.', ' \\n• Do not remove the needle cover while \\nallowing HUMIRA to reach room \\ntemperature  \\n• Do not warm HUMIRA in any other way.', 'For \\nexample, do not warm it in a microwave or \\nin hot water.', ' \\n• Do not use the prefilled syringe if liquid has \\nbeen frozen (even if thawed)  \\n \\n   \\n \\nCheck expiration date on the prefilled syringe \\nlabel.', 'Do not use the prefilled syringe if \\nexpiration date has passed.', ' \\nPlace the following on a clean, flat surface:  \\n• 1 single-dose prefilled syringe and alcohol \\nswab \\n• 1 cotton ball or gauze pad (not included) \\n• Puncture-resistant sharps disposal container \\n(not included).', 'See Step 9 at the end of this \\nInstructions for Use for instructions on how \\nto throw away (dispose of) your prefilled \\nsyringe  \\nWash and dry your hands.', ' \\n \\n   \\n \\nChoose an injection site:  \\n• On the front of your thighs or \\n• Your abdomen (belly) at least 2 inches from \\nyour navel (belly button)  \\n• Different from your last injection site \\nWipe the injection site in a circular motion with \\nthe alcohol swab.', ' \\n• Do not inject through clothes  \\n• Do not inject into skin that is sore, bruised, \\nred, hard, scarred, has stretch marks, or \\nareas with psoriasis plaques  \\n'], 'page_sentence_count_spacy': 10}\n",
            "{'page_number': 108, 'text': ' \\n   \\n \\nHold the prefilled syringe in one hand.  \\nGently pull the needle cover straight off with the \\nother hand.  \\n• Throw the needle cover away \\n• Do not touch the needle with your fingers or \\nlet the needle touch anything  \\n \\n   \\n \\nHold the prefilled syringe with the needle facing \\nup.  \\n• Hold the prefilled syringe at eye level with \\none hand so you can see the air in the \\nprefilled syringe  \\n• Using your other hand, slowly push the \\nplunger in to push the air out through the \\nneedle.  \\n• You may see a drop of liquid at the end of \\nthe needle. This is normal. \\n \\n   \\n \\nHold the body of the prefilled syringe in one \\nhand between the thumb and index fingers. Hold \\nthe prefilled syringe in your hand like a pencil. \\nDo not pull back on the plunger at any time.  \\n', 'processed_text': {'sentences': [{'original_sentence': ' \\n   \\n \\nHold the prefilled syringe in one hand.', 'tokens': ['Hold', 'prefilled', 'syringe', 'one', 'hand', '.'], 'lemmatized': ['Hold', 'prefilled', 'syringe', 'one', 'hand', '.'], 'stemmed': ['hold', 'prefil', 'syring', 'one', 'hand', '.'], 'dependencies': [('hold', 'ROOT'), ('prefil', 'nsubj'), ('syring', 'ccomp'), ('one', 'nummod'), ('hand', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Gently pull the needle cover straight off with the \\nother hand.', 'tokens': ['Gently', 'pull', 'needle', 'cover', 'straight', 'hand', '.'], 'lemmatized': ['Gently', 'pull', 'needle', 'cover', 'straight', 'hand', '.'], 'stemmed': ['gentli', 'pull', 'needl', 'cover', 'straight', 'hand', '.'], 'dependencies': [('gentli', 'nsubj'), ('pull', 'ROOT'), ('needl', 'nsubj'), ('cover', 'ccomp'), ('straight', 'amod'), ('hand', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• Throw the needle cover away \\n• Do not touch the needle with your fingers or \\nlet the needle touch anything  \\n \\n   \\n \\nHold the prefilled syringe with the needle facing \\nup.', 'tokens': ['•', 'Throw', 'needle', 'cover', 'away', '•', 'touch', 'needle', 'fingers', 'let', 'needle', 'touch', 'anything', 'Hold', 'prefilled', 'syringe', 'needle', 'facing', '.'], 'lemmatized': ['•', 'Throw', 'needle', 'cover', 'away', '•', 'touch', 'needle', 'finger', 'let', 'needle', 'touch', 'anything', 'Hold', 'prefilled', 'syringe', 'needle', 'facing', '.'], 'stemmed': ['•', 'throw', 'needl', 'cover', 'away', '•', 'touch', 'needl', 'finger', 'let', 'needl', 'touch', 'anyth', 'hold', 'prefil', 'syring', 'needl', 'face', '.'], 'dependencies': [('•', 'npadvmod'), ('throw', 'compound'), ('needl', 'nsubj'), ('cover', 'advcl'), ('away', 'advmod'), ('•', 'nummod'), ('touch', 'compound'), ('needl', 'compound'), ('finger', 'nsubj'), ('let', 'ROOT'), ('needl', 'nsubj'), ('touch', 'nsubj'), ('anyth', 'nsubj'), ('hold', 'ccomp'), ('prefil', 'compound'), ('syring', 'nsubj'), ('needl', 'ccomp'), ('face', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• Hold the prefilled syringe at eye level with \\none hand so you can see the air in the \\nprefilled syringe  \\n• Using your other hand, slowly push the \\nplunger in to push the air out through the \\nneedle.', 'tokens': ['•', 'Hold', 'prefilled', 'syringe', 'eye', 'level', 'one', 'hand', 'see', 'air', 'prefilled', 'syringe', '•', 'Using', 'hand', ',', 'slowly', 'push', 'plunger', 'push', 'air', 'needle', '.'], 'lemmatized': ['•', 'Hold', 'prefilled', 'syringe', 'eye', 'level', 'one', 'hand', 'see', 'air', 'prefilled', 'syringe', '•', 'Using', 'hand', ',', 'slowly', 'push', 'plunger', 'push', 'air', 'needle', '.'], 'stemmed': ['•', 'hold', 'prefil', 'syring', 'eye', 'level', 'one', 'hand', 'see', 'air', 'prefil', 'syring', '•', 'use', 'hand', ',', 'slowli', 'push', 'plunger', 'push', 'air', 'needl', '.'], 'dependencies': [('•', 'npadvmod'), ('hold', 'ROOT'), ('prefil', 'nmod'), ('syring', 'amod'), ('eye', 'compound'), ('level', 'nsubj'), ('one', 'nummod'), ('hand', 'nsubj'), ('see', 'ccomp'), ('air', 'compound'), ('prefil', 'nsubj'), ('syring', 'nmod'), ('•', 'nummod'), ('use', 'compound'), ('hand', 'npadvmod'), (',', 'punct'), ('slowli', 'amod'), ('push', 'compound'), ('plunger', 'compound'), ('push', 'compound'), ('air', 'compound'), ('needl', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• You may see a drop of liquid at the end of \\nthe needle.', 'tokens': ['•', 'may', 'see', 'drop', 'liquid', 'end', 'needle', '.'], 'lemmatized': ['•', 'may', 'see', 'drop', 'liquid', 'end', 'needle', '.'], 'stemmed': ['•', 'may', 'see', 'drop', 'liquid', 'end', 'needl', '.'], 'dependencies': [('•', 'nsubj'), ('may', 'aux'), ('see', 'ROOT'), ('drop', 'compound'), ('liquid', 'amod'), ('end', 'compound'), ('needl', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'This is normal.', 'tokens': ['normal', '.'], 'lemmatized': ['normal', '.'], 'stemmed': ['normal', '.'], 'dependencies': [('normal', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Hold the body of the prefilled syringe in one \\nhand between the thumb and index fingers.', 'tokens': ['Hold', 'body', 'prefilled', 'syringe', 'one', 'hand', 'thumb', 'index', 'fingers', '.'], 'lemmatized': ['Hold', 'body', 'prefilled', 'syringe', 'one', 'hand', 'thumb', 'index', 'finger', '.'], 'stemmed': ['hold', 'bodi', 'prefil', 'syring', 'one', 'hand', 'thumb', 'index', 'finger', '.'], 'dependencies': [('hold', 'ROOT'), ('bodi', 'compound'), ('prefil', 'nsubj'), ('syring', 'ccomp'), ('one', 'nummod'), ('hand', 'compound'), ('thumb', 'compound'), ('index', 'compound'), ('finger', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Hold \\nthe prefilled syringe in your hand like a pencil.', 'tokens': ['Hold', 'prefilled', 'syringe', 'hand', 'like', 'pencil', '.'], 'lemmatized': ['Hold', 'prefilled', 'syringe', 'hand', 'like', 'pencil', '.'], 'stemmed': ['hold', 'prefil', 'syring', 'hand', 'like', 'pencil', '.'], 'dependencies': [('hold', 'ROOT'), ('prefil', 'dobj'), ('syring', 'amod'), ('hand', 'npadvmod'), ('like', 'prep'), ('pencil', 'pobj'), ('.', 'punct')]}, {'original_sentence': 'Do not pull back on the plunger at any time.', 'tokens': ['pull', 'back', 'plunger', 'time', '.'], 'lemmatized': ['pull', 'back', 'plunger', 'time', '.'], 'stemmed': ['pull', 'back', 'plunger', 'time', '.'], 'dependencies': [('pull', 'ROOT'), ('back', 'advmod'), ('plunger', 'compound'), ('time', 'dobj'), ('.', 'punct')]}], 'text': ' \\n   \\n \\nHold the prefilled syringe in one hand.  \\nGently pull the needle cover straight off with the \\nother hand.  \\n• Throw the needle cover away \\n• Do not touch the needle with your fingers or \\nlet the needle touch anything  \\n \\n   \\n \\nHold the prefilled syringe with the needle facing \\nup.  \\n• Hold the prefilled syringe at eye level with \\none hand so you can see the air in the \\nprefilled syringe  \\n• Using your other hand, slowly push the \\nplunger in to push the air out through the \\nneedle.  \\n• You may see a drop of liquid at the end of \\nthe needle. This is normal. \\n \\n   \\n \\nHold the body of the prefilled syringe in one \\nhand between the thumb and index fingers. Hold \\nthe prefilled syringe in your hand like a pencil. \\nDo not pull back on the plunger at any time.  \\n'}, 'page_char_count': 772, 'page_word_count': 140, 'sentences': [' \\n   \\n \\nHold the prefilled syringe in one hand.', ' \\nGently pull the needle cover straight off with the \\nother hand.', ' \\n• Throw the needle cover away \\n• Do not touch the needle with your fingers or \\nlet the needle touch anything  \\n \\n   \\n \\nHold the prefilled syringe with the needle facing \\nup.', ' \\n• Hold the prefilled syringe at eye level with \\none hand so you can see the air in the \\nprefilled syringe  \\n• Using your other hand, slowly push the \\nplunger in to push the air out through the \\nneedle.', ' \\n• You may see a drop of liquid at the end of \\nthe needle.', 'This is normal.', '\\n \\n   \\n \\nHold the body of the prefilled syringe in one \\nhand between the thumb and index fingers.', 'Hold \\nthe prefilled syringe in your hand like a pencil.', '\\nDo not pull back on the plunger at any time.', ' \\n'], 'page_sentence_count_spacy': 10}\n",
            "{'page_number': 109, 'text': ' \\n   \\n \\nGently squeeze the area of cleaned skin at \\nyour injection site with your other hand. Hold the \\nskin firmly.  \\n \\nInsert the needle into the skin at about a 45-\\ndegree angle using a quick, dart-like motion. \\n• After the needle is in, let go of the skin. \\n \\nSlowly push the plunger all the way in until all \\nof the liquid is injected and the prefilled syringe \\nis empty.  \\n \\n   \\n \\nWhen the injection is completed, slowly pull the \\nneedle out of the skin while keeping the prefilled \\nsyringe at the same angle.  \\nAfter completing the injection, place a cotton ball \\nor gauze pad on the skin of the injection site.  \\n• Do not rub  \\n• Slight bleeding at the injection site is normal \\n', 'processed_text': {'sentences': [{'original_sentence': ' \\n   \\n \\nGently squeeze the area of cleaned skin at \\nyour injection site with your other hand.', 'tokens': ['Gently', 'squeeze', 'area', 'cleaned', 'skin', 'injection', 'site', 'hand', '.'], 'lemmatized': ['Gently', 'squeeze', 'area', 'cleaned', 'skin', 'injection', 'site', 'hand', '.'], 'stemmed': ['gentli', 'squeez', 'area', 'clean', 'skin', 'inject', 'site', 'hand', '.'], 'dependencies': [('gentli', 'compound'), ('squeez', 'compound'), ('area', 'compound'), ('clean', 'amod'), ('skin', 'compound'), ('inject', 'compound'), ('site', 'compound'), ('hand', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'Hold the \\nskin firmly.', 'tokens': ['Hold', 'skin', 'firmly', '.'], 'lemmatized': ['Hold', 'skin', 'firmly', '.'], 'stemmed': ['hold', 'skin', 'firmli', '.'], 'dependencies': [('hold', 'ROOT'), ('skin', 'compound'), ('firmli', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Insert the needle into the skin at about a 45-\\ndegree angle using a quick, dart-like motion.', 'tokens': ['Insert', 'needle', 'skin', '45-', 'degree', 'angle', 'using', 'quick', ',', 'dart-like', 'motion', '.'], 'lemmatized': ['Insert', 'needle', 'skin', '45-', 'degree', 'angle', 'using', 'quick', ',', 'dart-like', 'motion', '.'], 'stemmed': ['insert', 'needl', 'skin', '45-', 'degre', 'angl', 'use', 'quick', ',', 'dart-lik', 'motion', '.'], 'dependencies': [('insert', 'nsubj'), ('needl', 'ROOT'), ('skin', 'dobj'), ('45-', 'cc'), ('degre', 'conj'), ('angl', 'amod'), ('use', 'dobj'), ('quick', 'amod'), (',', 'punct'), ('dart', 'compound'), ('-', 'punct'), ('lik', 'compound'), ('motion', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• After the needle is in, let go of the skin.', 'tokens': ['•', 'needle', ',', 'let', 'go', 'skin', '.'], 'lemmatized': ['•', 'needle', ',', 'let', 'go', 'skin', '.'], 'stemmed': ['•', 'needl', ',', 'let', 'go', 'skin', '.'], 'dependencies': [('•', 'nummod'), ('needl', 'ROOT'), (',', 'punct'), ('let', 'xcomp'), ('go', 'xcomp'), ('skin', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'Slowly push the plunger all the way in until all \\nof the liquid is injected and the prefilled syringe \\nis empty.', 'tokens': ['Slowly', 'push', 'plunger', 'way', 'liquid', 'injected', 'prefilled', 'syringe', 'empty', '.'], 'lemmatized': ['Slowly', 'push', 'plunger', 'way', 'liquid', 'injected', 'prefilled', 'syringe', 'empty', '.'], 'stemmed': ['slowli', 'push', 'plunger', 'way', 'liquid', 'inject', 'prefil', 'syring', 'empti', '.'], 'dependencies': [('slowli', 'amod'), ('push', 'compound'), ('plunger', 'compound'), ('way', 'npadvmod'), ('liquid', 'amod'), ('inject', 'compound'), ('prefil', 'compound'), ('syring', 'nsubj'), ('empti', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'When the injection is completed, slowly pull the \\nneedle out of the skin while keeping the prefilled \\nsyringe at the same angle.', 'tokens': ['injection', 'completed', ',', 'slowly', 'pull', 'needle', 'skin', 'keeping', 'prefilled', 'syringe', 'angle', '.'], 'lemmatized': ['injection', 'completed', ',', 'slowly', 'pull', 'needle', 'skin', 'keeping', 'prefilled', 'syringe', 'angle', '.'], 'stemmed': ['inject', 'complet', ',', 'slowli', 'pull', 'needl', 'skin', 'keep', 'prefil', 'syring', 'angl', '.'], 'dependencies': [('inject', 'compound'), ('complet', 'nsubj'), (',', 'punct'), ('slowli', 'amod'), ('pull', 'compound'), ('needl', 'compound'), ('skin', 'appos'), ('keep', 'ROOT'), ('prefil', 'nsubj'), ('syring', 'ccomp'), ('angl', 'oprd'), ('.', 'punct')]}, {'original_sentence': 'After completing the injection, place a cotton ball \\nor gauze pad on the skin of the injection site.', 'tokens': ['completing', 'injection', ',', 'place', 'cotton', 'ball', 'gauze', 'pad', 'skin', 'injection', 'site', '.'], 'lemmatized': ['completing', 'injection', ',', 'place', 'cotton', 'ball', 'gauze', 'pad', 'skin', 'injection', 'site', '.'], 'stemmed': ['complet', 'inject', ',', 'place', 'cotton', 'ball', 'gauz', 'pad', 'skin', 'inject', 'site', '.'], 'dependencies': [('complet', 'compound'), ('inject', 'ROOT'), (',', 'punct'), ('place', 'compound'), ('cotton', 'compound'), ('ball', 'compound'), ('gauz', 'compound'), ('pad', 'compound'), ('skin', 'compound'), ('inject', 'compound'), ('site', 'appos'), ('.', 'punct')]}, {'original_sentence': '• Do not rub  \\n• Slight bleeding at the injection site is normal', 'tokens': ['•', 'rub', '•', 'Slight', 'bleeding', 'injection', 'site', 'normal'], 'lemmatized': ['•', 'rub', '•', 'Slight', 'bleeding', 'injection', 'site', 'normal'], 'stemmed': ['•', 'rub', '•', 'slight', 'bleed', 'inject', 'site', 'normal'], 'dependencies': [('•', 'meta'), ('rub', 'ROOT'), ('•', 'preconj'), ('slight', 'amod'), ('bleed', 'compound'), ('inject', 'compound'), ('site', 'dobj'), ('normal', 'amod')]}], 'text': ' \\n   \\n \\nGently squeeze the area of cleaned skin at \\nyour injection site with your other hand. Hold the \\nskin firmly.  \\n \\nInsert the needle into the skin at about a 45-\\ndegree angle using a quick, dart-like motion. \\n• After the needle is in, let go of the skin. \\n \\nSlowly push the plunger all the way in until all \\nof the liquid is injected and the prefilled syringe \\nis empty.  \\n \\n   \\n \\nWhen the injection is completed, slowly pull the \\nneedle out of the skin while keeping the prefilled \\nsyringe at the same angle.  \\nAfter completing the injection, place a cotton ball \\nor gauze pad on the skin of the injection site.  \\n• Do not rub  \\n• Slight bleeding at the injection site is normal \\n'}, 'page_char_count': 687, 'page_word_count': 121, 'sentences': [' \\n   \\n \\nGently squeeze the area of cleaned skin at \\nyour injection site with your other hand.', 'Hold the \\nskin firmly.', ' \\n \\nInsert the needle into the skin at about a 45-\\ndegree angle using a quick, dart-like motion.', '\\n• After the needle is in, let go of the skin.', '\\n \\nSlowly push the plunger all the way in until all \\nof the liquid is injected and the prefilled syringe \\nis empty.', ' \\n \\n   \\n \\nWhen the injection is completed, slowly pull the \\nneedle out of the skin while keeping the prefilled \\nsyringe at the same angle.', ' \\nAfter completing the injection, place a cotton ball \\nor gauze pad on the skin of the injection site.', ' \\n• Do not rub  \\n• Slight bleeding at the injection site is normal \\n'], 'page_sentence_count_spacy': 8}\n",
            "{'page_number': 110, 'text': ' \\n   \\nHow should I dispose of the used HUMIRA \\nprefilled syringe? \\n• Put your used needles, syringes, and sharps \\nin a FDA-cleared sharps disposal container \\nright away after use. Do not throw away \\n(dispose of) loose needles and syringes \\nin the household trash.  \\n• If you do not have a FDA-cleared sharps \\ndisposal container, you may use a \\nhousehold container that is:  \\n◦ made of a heavy-duty plastic, \\n◦ can be closed with a tight-fitting, \\npuncture-resistant lid, without sharps \\nbeing able to come out,  \\n◦ upright and stable during use, \\n◦ leak-resistant, and  \\n◦ properly labeled to warn of hazardous \\nwaste inside the container. \\n• When your sharps disposal container is \\nalmost full, you will need to follow your \\ncommunity guidelines for the right way to \\ndispose of your sharps disposal container. \\nThere may be state or local laws about how \\nyou should throw away used needles and \\nsyringes. For more information about safe \\nsharps disposal, and for specific information \\nabout sharps disposal in the state that you \\nlive in, go to the FDA’s website at: \\nhttp://www.fda.gov/safesharpsdisposal.  \\n• Do not dispose of your used sharps disposal \\ncontainer in your household trash unless \\nyour community guidelines permit this. Do \\nnot recycle your used sharps disposal \\ncontainer.  \\nThe needle cover, alcohol swab, cotton ball or gauze pad, dose tray, and packaging may be \\nplaced in your household trash.  \\n \\nQuestions About Using the HUMIRA Single-Dose Prefilled Syringe \\n \\nWhat if I have not received in-person training from a healthcare provider? \\n• Call your healthcare provider or 1-800-4HUMIRA (1-800-448-6472) or visit \\nwww.HUMIRA.com if you need help  \\nWhat if I do not have an FDA-cleared sharps disposal container or proper household \\ncontainer? \\n• Call 1-800-4HUMIRA (1-800-448-6472) for a free FDA-cleared sharps disposal container  \\n', 'processed_text': {'sentences': [{'original_sentence': ' \\n   \\nHow should I dispose of the used HUMIRA \\nprefilled syringe?', 'tokens': ['dispose', 'used', 'HUMIRA', 'prefilled', 'syringe', '?'], 'lemmatized': ['dispose', 'used', 'HUMIRA', 'prefilled', 'syringe', '?'], 'stemmed': ['dispos', 'use', 'humira', 'prefil', 'syring', '?'], 'dependencies': [('dispos', 'nsubj'), ('use', 'ROOT'), ('humira', 'compound'), ('prefil', 'dobj'), ('syring', 'dobj'), ('?', 'punct')]}, {'original_sentence': '• Put your used needles, syringes, and sharps \\nin a FDA-cleared sharps disposal container \\nright away after use.', 'tokens': ['•', 'Put', 'used', 'needles', ',', 'syringes', ',', 'sharps', 'FDA-cleared', 'sharps', 'disposal', 'container', 'right', 'away', 'use', '.'], 'lemmatized': ['•', 'Put', 'used', 'needle', ',', 'syrinx', ',', 'sharp', 'FDA-cleared', 'sharp', 'disposal', 'container', 'right', 'away', 'use', '.'], 'stemmed': ['•', 'put', 'use', 'needl', ',', 'syrinx', ',', 'sharp', 'fda-clear', 'sharp', 'dispos', 'contain', 'right', 'away', 'use', '.'], 'dependencies': [('•', 'npadvmod'), ('put', 'ROOT'), ('use', 'compound'), ('needl', 'dobj'), (',', 'punct'), ('syrinx', 'nmod'), (',', 'punct'), ('sharp', 'amod'), ('fda', 'amod'), ('-', 'punct'), ('clear', 'amod'), ('sharp', 'amod'), ('dispos', 'nsubj'), ('contain', 'conj'), ('right', 'advmod'), ('away', 'advmod'), ('use', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Do not throw away \\n(dispose of) loose needles and syringes \\nin the household trash.', 'tokens': ['throw', 'away', '(', 'dispose', ')', 'loose', 'needles', 'syringes', 'household', 'trash', '.'], 'lemmatized': ['throw', 'away', '(', 'dispose', ')', 'loose', 'needle', 'syrinx', 'household', 'trash', '.'], 'stemmed': ['throw', 'away', '(', 'dispos', ')', 'loos', 'needl', 'syrinx', 'household', 'trash', '.'], 'dependencies': [('throw', 'nmod'), ('away', 'advmod'), ('(', 'punct'), ('dispos', 'npadvmod'), (')', 'punct'), ('loos', 'nsubj'), ('needl', 'ROOT'), ('syrinx', 'amod'), ('household', 'compound'), ('trash', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• If you do not have a FDA-cleared sharps \\ndisposal container, you may use a \\nhousehold container that is:  \\n◦ made of a heavy-duty plastic, \\n◦ can be closed with a tight-fitting, \\npuncture-resistant lid, without sharps \\nbeing able to come out,  \\n◦ upright and stable during use, \\n◦ leak-resistant, and  \\n◦ properly labeled to warn of hazardous \\nwaste inside the container.', 'tokens': ['•', 'FDA-cleared', 'sharps', 'disposal', 'container', ',', 'may', 'use', 'household', 'container', ':', '◦', 'made', 'heavy-duty', 'plastic', ',', '◦', 'closed', 'tight-fitting', ',', 'puncture-resistant', 'lid', ',', 'without', 'sharps', 'able', 'come', ',', '◦', 'upright', 'stable', 'use', ',', '◦', 'leak-resistant', ',', '◦', 'properly', 'labeled', 'warn', 'hazardous', 'waste', 'inside', 'container', '.'], 'lemmatized': ['•', 'FDA-cleared', 'sharp', 'disposal', 'container', ',', 'may', 'use', 'household', 'container', ':', '◦', 'made', 'heavy-duty', 'plastic', ',', '◦', 'closed', 'tight-fitting', ',', 'puncture-resistant', 'lid', ',', 'without', 'sharp', 'able', 'come', ',', '◦', 'upright', 'stable', 'use', ',', '◦', 'leak-resistant', ',', '◦', 'properly', 'labeled', 'warn', 'hazardous', 'waste', 'inside', 'container', '.'], 'stemmed': ['•', 'fda-clear', 'sharp', 'dispos', 'contain', ',', 'may', 'use', 'household', 'contain', ':', '◦', 'made', 'heavy-duti', 'plastic', ',', '◦', 'close', 'tight-fit', ',', 'puncture-resist', 'lid', ',', 'without', 'sharp', 'abl', 'come', ',', '◦', 'upright', 'stabl', 'use', ',', '◦', 'leak-resist', ',', '◦', 'properli', 'label', 'warn', 'hazard', 'wast', 'insid', 'contain', '.'], 'dependencies': [('•', 'advmod'), ('fda', 'amod'), ('-', 'punct'), ('clear', 'amod'), ('sharp', 'amod'), ('dispos', 'nsubj'), ('contain', 'advcl'), (',', 'punct'), ('may', 'aux'), ('use', 'ROOT'), ('household', 'compound'), ('contain', 'dobj'), (':', 'punct'), ('◦', 'nsubj'), ('made', 'xcomp'), ('heavy', 'amod'), ('-', 'punct'), ('duti', 'compound'), ('plastic', 'dobj'), (',', 'punct'), ('◦', 'advcl'), ('close', 'amod'), ('tight', 'amod'), ('-', 'punct'), ('fit', 'amod'), (',', 'punct'), ('puncture', 'amod'), ('-', 'punct'), ('resist', 'compound'), ('lid', 'dobj'), (',', 'punct'), ('without', 'prep'), ('sharp', 'amod'), ('abl', 'nsubj'), ('come', 'pobj'), (',', 'punct'), ('◦', 'dep'), ('upright', 'amod'), ('stabl', 'amod'), ('use', 'dobj'), (',', 'punct'), ('◦', 'compound'), ('leak', 'compound'), ('-', 'punct'), ('resist', 'nsubj'), (',', 'punct'), ('◦', 'conj'), ('properli', 'compound'), ('label', 'nsubj'), ('warn', 'conj'), ('hazard', 'compound'), ('wast', 'nsubj'), ('insid', 'amod'), ('contain', 'dobj'), ('.', 'punct')]}, {'original_sentence': '• When your sharps disposal container is \\nalmost full, you will need to follow your \\ncommunity guidelines for the right way to \\ndispose of your sharps disposal container.', 'tokens': ['•', 'sharps', 'disposal', 'container', 'almost', 'full', ',', 'need', 'follow', 'community', 'guidelines', 'right', 'way', 'dispose', 'sharps', 'disposal', 'container', '.'], 'lemmatized': ['•', 'sharp', 'disposal', 'container', 'almost', 'full', ',', 'need', 'follow', 'community', 'guideline', 'right', 'way', 'dispose', 'sharp', 'disposal', 'container', '.'], 'stemmed': ['•', 'sharp', 'dispos', 'contain', 'almost', 'full', ',', 'need', 'follow', 'commun', 'guidelin', 'right', 'way', 'dispos', 'sharp', 'dispos', 'contain', '.'], 'dependencies': [('•', 'nummod'), ('sharp', 'amod'), ('dispos', 'nsubj'), ('contain', 'ROOT'), ('almost', 'advmod'), ('full', 'advmod'), (',', 'punct'), ('need', 'conj'), ('follow', 'dobj'), ('commun', 'amod'), ('guidelin', 'dobj'), ('right', 'amod'), ('way', 'npadvmod'), ('dispos', 'nsubj'), ('sharp', 'amod'), ('dispos', 'nsubj'), ('contain', 'ccomp'), ('.', 'punct')]}, {'original_sentence': 'There may be state or local laws about how \\nyou should throw away used needles and \\nsyringes.', 'tokens': ['may', 'state', 'local', 'laws', 'throw', 'away', 'used', 'needles', 'syringes', '.'], 'lemmatized': ['may', 'state', 'local', 'law', 'throw', 'away', 'used', 'needle', 'syrinx', '.'], 'stemmed': ['may', 'state', 'local', 'law', 'throw', 'away', 'use', 'needl', 'syrinx', '.'], 'dependencies': [('may', 'aux'), ('state', 'ROOT'), ('local', 'amod'), ('law', 'dobj'), ('throw', 'ccomp'), ('away', 'advmod'), ('use', 'dobj'), ('needl', 'conj'), ('syrinx', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'For more information about safe \\nsharps disposal, and for specific information \\nabout sharps disposal in the state that you \\nlive in, go to the FDA’s website at: \\nhttp://www.fda.gov/safesharpsdisposal.', 'tokens': ['information', 'safe', 'sharps', 'disposal', ',', 'specific', 'information', 'sharps', 'disposal', 'state', 'live', ',', 'go', 'FDA', '’', 'website', ':', 'http', ':', '//www.fda.gov/safesharpsdisposal', '.'], 'lemmatized': ['information', 'safe', 'sharp', 'disposal', ',', 'specific', 'information', 'sharp', 'disposal', 'state', 'live', ',', 'go', 'FDA', '’', 'website', ':', 'http', ':', '//www.fda.gov/safesharpsdisposal', '.'], 'stemmed': ['inform', 'safe', 'sharp', 'dispos', ',', 'specif', 'inform', 'sharp', 'dispos', 'state', 'live', ',', 'go', 'fda', '’', 'websit', ':', 'http', ':', '//www.fda.gov/safesharpsdispos', '.'], 'dependencies': [('inform', 'advcl'), ('safe', 'amod'), ('sharp', 'amod'), ('dispos', 'dobj'), (',', 'punct'), ('specif', 'nsubj'), ('inform', 'ROOT'), ('sharp', 'amod'), ('dispos', 'compound'), ('state', 'dobj'), ('live', 'advmod'), (',', 'punct'), ('go', 'conj'), ('fda', 'nmod'), ('’', 'punct'), ('websit', 'dobj'), (':', 'punct'), ('http', 'appos'), (':', 'punct'), ('//www.fda.gov', 'nmod'), ('/', 'punct'), ('safesharpsdispos', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': '• Do not dispose of your used sharps disposal \\ncontainer in your household trash unless \\nyour community guidelines permit this.', 'tokens': ['•', 'dispose', 'used', 'sharps', 'disposal', 'container', 'household', 'trash', 'unless', 'community', 'guidelines', 'permit', '.'], 'lemmatized': ['•', 'dispose', 'used', 'sharp', 'disposal', 'container', 'household', 'trash', 'unless', 'community', 'guideline', 'permit', '.'], 'stemmed': ['•', 'dispos', 'use', 'sharp', 'dispos', 'contain', 'household', 'trash', 'unless', 'commun', 'guidelin', 'permit', '.'], 'dependencies': [('•', 'nummod'), ('dispos', 'nsubj'), ('use', 'ROOT'), ('sharp', 'amod'), ('dispos', 'dobj'), ('contain', 'xcomp'), ('household', 'compound'), ('trash', 'dobj'), ('unless', 'mark'), ('commun', 'amod'), ('guidelin', 'compound'), ('permit', 'advcl'), ('.', 'punct')]}, {'original_sentence': 'Do \\nnot recycle your used sharps disposal \\ncontainer.', 'tokens': ['recycle', 'used', 'sharps', 'disposal', 'container', '.'], 'lemmatized': ['recycle', 'used', 'sharp', 'disposal', 'container', '.'], 'stemmed': ['recycl', 'use', 'sharp', 'dispos', 'contain', '.'], 'dependencies': [('recycl', 'nsubj'), ('use', 'ROOT'), ('sharp', 'amod'), ('dispos', 'dobj'), ('contain', 'xcomp'), ('.', 'punct')]}, {'original_sentence': 'The needle cover, alcohol swab, cotton ball or gauze pad, dose tray, and packaging may be \\nplaced in your household trash.', 'tokens': ['needle', 'cover', ',', 'alcohol', 'swab', ',', 'cotton', 'ball', 'gauze', 'pad', ',', 'dose', 'tray', ',', 'packaging', 'may', 'placed', 'household', 'trash', '.'], 'lemmatized': ['needle', 'cover', ',', 'alcohol', 'swab', ',', 'cotton', 'ball', 'gauze', 'pad', ',', 'dose', 'tray', ',', 'packaging', 'may', 'placed', 'household', 'trash', '.'], 'stemmed': ['needl', 'cover', ',', 'alcohol', 'swab', ',', 'cotton', 'ball', 'gauz', 'pad', ',', 'dose', 'tray', ',', 'packag', 'may', 'place', 'household', 'trash', '.'], 'dependencies': [('needl', 'advcl'), ('cover', 'dobj'), (',', 'punct'), ('alcohol', 'compound'), ('swab', 'npadvmod'), (',', 'punct'), ('cotton', 'compound'), ('ball', 'compound'), ('gauz', 'compound'), ('pad', 'conj'), (',', 'punct'), ('dose', 'compound'), ('tray', 'conj'), (',', 'punct'), ('packag', 'nsubj'), ('may', 'aux'), ('place', 'ROOT'), ('household', 'compound'), ('trash', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Questions About Using the HUMIRA Single-Dose Prefilled Syringe \\n \\nWhat if I have not received in-person training from a healthcare provider?', 'tokens': ['Questions', 'Using', 'HUMIRA', 'Single-Dose', 'Prefilled', 'Syringe', 'received', 'in-person', 'training', 'healthcare', 'provider', '?'], 'lemmatized': ['Questions', 'Using', 'HUMIRA', 'Single-Dose', 'Prefilled', 'Syringe', 'received', 'in-person', 'training', 'healthcare', 'provider', '?'], 'stemmed': ['question', 'use', 'humira', 'single-dos', 'prefil', 'syring', 'receiv', 'in-person', 'train', 'healthcar', 'provid', '?'], 'dependencies': [('question', 'compound'), ('use', 'ROOT'), ('humira', 'nmod'), ('single', 'amod'), ('-', 'punct'), ('dos', 'compound'), ('prefil', 'nmod'), ('syring', 'compound'), ('receiv', 'nmod'), ('in', 'nmod'), ('-', 'punct'), ('person', 'pobj'), ('train', 'compound'), ('healthcar', 'compound'), ('provid', 'dobj'), ('?', 'punct')]}, {'original_sentence': '• Call your healthcare provider or 1-800-4HUMIRA (1-800-448-6472) or visit \\nwww.HUMIRA.com if you need help  \\nWhat if I do not have an FDA-cleared sharps disposal container or proper household \\ncontainer?', 'tokens': ['•', 'Call', 'healthcare', 'provider', '1-800-4HUMIRA', '(', '1-800-448-6472', ')', 'visit', 'www.HUMIRA.com', 'need', 'help', 'FDA-cleared', 'sharps', 'disposal', 'container', 'proper', 'household', 'container', '?'], 'lemmatized': ['•', 'Call', 'healthcare', 'provider', '1-800-4HUMIRA', '(', '1-800-448-6472', ')', 'visit', 'www.HUMIRA.com', 'need', 'help', 'FDA-cleared', 'sharp', 'disposal', 'container', 'proper', 'household', 'container', '?'], 'stemmed': ['•', 'call', 'healthcar', 'provid', '1-800-4humira', '(', '1-800-448-6472', ')', 'visit', 'www.humira.com', 'need', 'help', 'fda-clear', 'sharp', 'dispos', 'contain', 'proper', 'household', 'contain', '?'], 'dependencies': [('•', 'nummod'), ('call', 'npadvmod'), ('healthcar', 'compound'), ('provid', 'dobj'), ('1', 'nummod'), ('-', 'punct'), ('800', 'npadvmod'), ('-', 'punct'), ('4humira', 'prep'), ('(', 'punct'), ('1', 'npadvmod'), ('-', 'punct'), ('800', 'appos'), ('-', 'punct'), ('448', 'nummod'), ('-', 'punct'), ('6472', 'prep'), (')', 'punct'), ('visit', 'ROOT'), ('www.humira.com', 'dobj'), ('need', 'dobj'), ('help', 'dobj'), ('fda', 'compound'), ('-', 'punct'), ('clear', 'amod'), ('sharp', 'amod'), ('dispos', 'nsubj'), ('contain', 'conj'), ('proper', 'amod'), ('household', 'compound'), ('contain', 'dobj'), ('?', 'punct')]}, {'original_sentence': '• Call 1-800-4HUMIRA (1-800-448-6472) for a free FDA-cleared sharps disposal container', 'tokens': ['•', 'Call', '1-800-4HUMIRA', '(', '1-800-448-6472', ')', 'free', 'FDA-cleared', 'sharps', 'disposal', 'container'], 'lemmatized': ['•', 'Call', '1-800-4HUMIRA', '(', '1-800-448-6472', ')', 'free', 'FDA-cleared', 'sharp', 'disposal', 'container'], 'stemmed': ['•', 'call', '1-800-4humira', '(', '1-800-448-6472', ')', 'free', 'fda-clear', 'sharp', 'dispos', 'contain'], 'dependencies': [('•', 'nummod'), ('call', 'npadvmod'), ('1', 'npadvmod'), ('-', 'punct'), ('800', 'prep'), ('-', 'punct'), ('4humira', 'prep'), ('(', 'punct'), ('1', 'npadvmod'), ('-', 'punct'), ('800', 'prep'), ('-', 'punct'), ('448', 'nummod'), ('-', 'punct'), ('6472', 'prep'), (')', 'punct'), ('free', 'amod'), ('fda', 'compound'), ('-', 'punct'), ('clear', 'amod'), ('sharp', 'amod'), ('dispos', 'nsubj'), ('contain', 'ROOT')]}], 'text': ' \\n   \\nHow should I dispose of the used HUMIRA \\nprefilled syringe? \\n• Put your used needles, syringes, and sharps \\nin a FDA-cleared sharps disposal container \\nright away after use. Do not throw away \\n(dispose of) loose needles and syringes \\nin the household trash.  \\n• If you do not have a FDA-cleared sharps \\ndisposal container, you may use a \\nhousehold container that is:  \\n◦ made of a heavy-duty plastic, \\n◦ can be closed with a tight-fitting, \\npuncture-resistant lid, without sharps \\nbeing able to come out,  \\n◦ upright and stable during use, \\n◦ leak-resistant, and  \\n◦ properly labeled to warn of hazardous \\nwaste inside the container. \\n• When your sharps disposal container is \\nalmost full, you will need to follow your \\ncommunity guidelines for the right way to \\ndispose of your sharps disposal container. \\nThere may be state or local laws about how \\nyou should throw away used needles and \\nsyringes. For more information about safe \\nsharps disposal, and for specific information \\nabout sharps disposal in the state that you \\nlive in, go to the FDA’s website at: \\nhttp://www.fda.gov/safesharpsdisposal.  \\n• Do not dispose of your used sharps disposal \\ncontainer in your household trash unless \\nyour community guidelines permit this. Do \\nnot recycle your used sharps disposal \\ncontainer.  \\nThe needle cover, alcohol swab, cotton ball or gauze pad, dose tray, and packaging may be \\nplaced in your household trash.  \\n \\nQuestions About Using the HUMIRA Single-Dose Prefilled Syringe \\n \\nWhat if I have not received in-person training from a healthcare provider? \\n• Call your healthcare provider or 1-800-4HUMIRA (1-800-448-6472) or visit \\nwww.HUMIRA.com if you need help  \\nWhat if I do not have an FDA-cleared sharps disposal container or proper household \\ncontainer? \\n• Call 1-800-4HUMIRA (1-800-448-6472) for a free FDA-cleared sharps disposal container  \\n'}, 'page_char_count': 1859, 'page_word_count': 286, 'sentences': [' \\n   \\nHow should I dispose of the used HUMIRA \\nprefilled syringe?', '\\n• Put your used needles, syringes, and sharps \\nin a FDA-cleared sharps disposal container \\nright away after use.', 'Do not throw away \\n(dispose of) loose needles and syringes \\nin the household trash.', ' \\n• If you do not have a FDA-cleared sharps \\ndisposal container, you may use a \\nhousehold container that is:  \\n◦ made of a heavy-duty plastic, \\n◦ can be closed with a tight-fitting, \\npuncture-resistant lid, without sharps \\nbeing able to come out,  \\n◦ upright and stable during use, \\n◦ leak-resistant, and  \\n◦ properly labeled to warn of hazardous \\nwaste inside the container.', '\\n• When your sharps disposal container is \\nalmost full, you will need to follow your \\ncommunity guidelines for the right way to \\ndispose of your sharps disposal container.', '\\nThere may be state or local laws about how \\nyou should throw away used needles and \\nsyringes.', 'For more information about safe \\nsharps disposal, and for specific information \\nabout sharps disposal in the state that you \\nlive in, go to the FDA’s website at: \\nhttp://www.fda.gov/safesharpsdisposal.', ' \\n• Do not dispose of your used sharps disposal \\ncontainer in your household trash unless \\nyour community guidelines permit this.', 'Do \\nnot recycle your used sharps disposal \\ncontainer.', ' \\nThe needle cover, alcohol swab, cotton ball or gauze pad, dose tray, and packaging may be \\nplaced in your household trash.', ' \\n \\nQuestions About Using the HUMIRA Single-Dose Prefilled Syringe \\n \\nWhat if I have not received in-person training from a healthcare provider?', '\\n• Call your healthcare provider or 1-800-4HUMIRA (1-800-448-6472) or visit \\nwww.HUMIRA.com if you need help  \\nWhat if I do not have an FDA-cleared sharps disposal container or proper household \\ncontainer?', '\\n• Call 1-800-4HUMIRA (1-800-448-6472) for a free FDA-cleared sharps disposal container  \\n'], 'page_sentence_count_spacy': 13}\n",
            "{'page_number': 111, 'text': '  \\nAlways keep the prefilled syringe and the \\nsharps disposal container out of the reach of \\nchildren.  \\n \\n   \\n \\nKeep a record of the dates and locations of your \\ninjections. To help remember when to take \\nHUMIRA, mark your calendar ahead of time.  \\n \\n   \\nThis Instructions for Use has been approved \\nby the U.S. Food and Drug Administration. \\nRevised 02/2021 \\nManufactured by AbbVie Inc. North Chicago, IL 60064 U.S.A. \\nUS License Number 1889  20069914     \\n \\n  \\n', 'processed_text': {'sentences': [{'original_sentence': '  \\nAlways keep the prefilled syringe and the \\nsharps disposal container out of the reach of \\nchildren.', 'tokens': ['Always', 'keep', 'prefilled', 'syringe', 'sharps', 'disposal', 'container', 'reach', 'children', '.'], 'lemmatized': ['Always', 'keep', 'prefilled', 'syringe', 'sharp', 'disposal', 'container', 'reach', 'child', '.'], 'stemmed': ['alway', 'keep', 'prefil', 'syring', 'sharp', 'dispos', 'contain', 'reach', 'child', '.'], 'dependencies': [('alway', 'advmod'), ('keep', 'ROOT'), ('prefil', 'nsubj'), ('syring', 'ccomp'), ('sharp', 'amod'), ('dispos', 'dobj'), ('contain', 'ccomp'), ('reach', 'conj'), ('child', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Keep a record of the dates and locations of your \\ninjections.', 'tokens': ['Keep', 'record', 'dates', 'locations', 'injections', '.'], 'lemmatized': ['Keep', 'record', 'date', 'location', 'injection', '.'], 'stemmed': ['keep', 'record', 'date', 'locat', 'inject', '.'], 'dependencies': [('keep', 'ROOT'), ('record', 'compound'), ('date', 'compound'), ('locat', 'compound'), ('inject', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'To help remember when to take \\nHUMIRA, mark your calendar ahead of time.', 'tokens': ['help', 'remember', 'take', 'HUMIRA', ',', 'mark', 'calendar', 'ahead', 'time', '.'], 'lemmatized': ['help', 'remember', 'take', 'HUMIRA', ',', 'mark', 'calendar', 'ahead', 'time', '.'], 'stemmed': ['help', 'rememb', 'take', 'humira', ',', 'mark', 'calendar', 'ahead', 'time', '.'], 'dependencies': [('help', 'advcl'), ('rememb', 'amod'), ('take', 'compound'), ('humira', 'dobj'), (',', 'punct'), ('mark', 'compound'), ('calendar', 'ROOT'), ('ahead', 'amod'), ('time', 'npadvmod'), ('.', 'punct')]}, {'original_sentence': 'This Instructions for Use has been approved \\nby the U.S. Food and Drug Administration.', 'tokens': ['Instructions', 'Use', 'approved', 'U.S.', 'Food', 'Drug', 'Administration', '.'], 'lemmatized': ['Instructions', 'Use', 'approved', 'U.S.', 'Food', 'Drug', 'Administration', '.'], 'stemmed': ['instruct', 'use', 'approv', 'u.s.', 'food', 'drug', 'administr', '.'], 'dependencies': [('instruct', 'ROOT'), ('use', 'dobj'), ('approv', 'compound'), ('u.s', 'compound'), ('.', 'compound'), ('food', 'compound'), ('drug', 'compound'), ('administr', 'dobj'), ('.', 'punct')]}, {'original_sentence': 'Revised 02/2021 \\nManufactured by AbbVie Inc. North Chicago, IL 60064 U.S.A.', 'tokens': ['Revised', '02/2021', 'Manufactured', 'AbbVie', 'Inc.', 'North', 'Chicago', ',', 'IL', '60064', 'U.S.A', '.'], 'lemmatized': ['Revised', '02/2021', 'Manufactured', 'AbbVie', 'Inc.', 'North', 'Chicago', ',', 'IL', '60064', 'U.S.A', '.'], 'stemmed': ['revis', '02/2021', 'manufactur', 'abbvi', 'inc.', 'north', 'chicago', ',', 'il', '60064', 'u.s.a', '.'], 'dependencies': [('revis', 'compound'), ('02/2021', 'compound'), ('manufactur', 'nsubj'), ('abbvi', 'compound'), ('inc', 'compound'), ('.', 'compound'), ('north', 'compound'), ('chicago', 'dep'), (',', 'punct'), ('il', 'nmod'), ('60064', 'nummod'), ('u.s.a', 'ROOT'), ('.', 'punct')]}, {'original_sentence': 'US License Number 1889  20069914', 'tokens': ['US', 'License', 'Number', '1889', '20069914'], 'lemmatized': ['US', 'License', 'Number', '1889', '20069914'], 'stemmed': ['us', 'licens', 'number', '1889', '20069914'], 'dependencies': [('us', 'compound'), ('licens', 'compound'), ('number', 'ROOT'), ('1889', 'nummod'), ('20069914', 'nummod')]}], 'text': '  \\nAlways keep the prefilled syringe and the \\nsharps disposal container out of the reach of \\nchildren.  \\n \\n   \\n \\nKeep a record of the dates and locations of your \\ninjections. To help remember when to take \\nHUMIRA, mark your calendar ahead of time.  \\n \\n   \\nThis Instructions for Use has been approved \\nby the U.S. Food and Drug Administration. \\nRevised 02/2021 \\nManufactured by AbbVie Inc. North Chicago, IL 60064 U.S.A. \\nUS License Number 1889  20069914     \\n \\n  \\n'}, 'page_char_count': 464, 'page_word_count': 70, 'sentences': ['  \\nAlways keep the prefilled syringe and the \\nsharps disposal container out of the reach of \\nchildren.', ' \\n \\n   \\n \\nKeep a record of the dates and locations of your \\ninjections.', 'To help remember when to take \\nHUMIRA, mark your calendar ahead of time.', ' \\n \\n   \\nThis Instructions for Use has been approved \\nby the U.S. Food and Drug Administration.', '\\nRevised 02/2021 \\nManufactured by AbbVie Inc. North Chicago, IL 60064 U.S.A. \\nUS License Number 1889  20069914     \\n \\n  \\n'], 'page_sentence_count_spacy': 5}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "\n"
          ]
        }
      ],
      "source": [
        "for item in tqdm(pages_and_texts):\n",
        "    item[\"sentences\"] = list(nlp(item[\"text\"]).sents)\n",
        "\n",
        "    # Make sure all sentences are strings (the default type is a spaCy datatype)\n",
        "    item[\"sentences\"] = [str(sentence) for sentence in item[\"sentences\"]]\n",
        "\n",
        "    # Count the sentences\n",
        "    item[\"page_sentence_count_spacy\"] = len(item[\"sentences\"])\n",
        "    print(item)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "bFNkUr_tg2yK",
        "outputId": "c3177ae0-7c49-43da-b272-79092193ce51"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[{'page_number': 91,\n",
              "  'text': ' \\n   \\n \\nWhen the injection is completed, slowly pull the \\nPen from the skin. The white needle sleeve will \\ncover the needle tip.  \\n• A small amount of liquid on the injection site \\nis normal  \\nIf there are more than a few drops of liquid on \\nthe injection site, call 1-800-4HUMIRA (1-800-\\n448-6472) for help.  \\nAfter completing the injection, place a cotton \\nball or gauze pad on the skin of the injection \\nsite.  \\n• Do not rub  \\n• Slight bleeding at the injection site is normal \\n',\n",
              "  'processed_text': {'sentences': [{'original_sentence': ' \\n   \\n \\nWhen the injection is completed, slowly pull the \\nPen from the skin.',\n",
              "     'tokens': ['injection',\n",
              "      'completed',\n",
              "      ',',\n",
              "      'slowly',\n",
              "      'pull',\n",
              "      'Pen',\n",
              "      'skin',\n",
              "      '.'],\n",
              "     'lemmatized': ['injection',\n",
              "      'completed',\n",
              "      ',',\n",
              "      'slowly',\n",
              "      'pull',\n",
              "      'Pen',\n",
              "      'skin',\n",
              "      '.'],\n",
              "     'stemmed': ['inject',\n",
              "      'complet',\n",
              "      ',',\n",
              "      'slowli',\n",
              "      'pull',\n",
              "      'pen',\n",
              "      'skin',\n",
              "      '.'],\n",
              "     'dependencies': [('inject', 'compound'),\n",
              "      ('complet', 'ROOT'),\n",
              "      (',', 'punct'),\n",
              "      ('slowli', 'amod'),\n",
              "      ('pull', 'amod'),\n",
              "      ('pen', 'compound'),\n",
              "      ('skin', 'appos'),\n",
              "      ('.', 'punct')]},\n",
              "    {'original_sentence': 'The white needle sleeve will \\ncover the needle tip.',\n",
              "     'tokens': ['white', 'needle', 'sleeve', 'cover', 'needle', 'tip', '.'],\n",
              "     'lemmatized': ['white',\n",
              "      'needle',\n",
              "      'sleeve',\n",
              "      'cover',\n",
              "      'needle',\n",
              "      'tip',\n",
              "      '.'],\n",
              "     'stemmed': ['white', 'needl', 'sleev', 'cover', 'needl', 'tip', '.'],\n",
              "     'dependencies': [('white', 'nsubj'),\n",
              "      ('needl', 'compound'),\n",
              "      ('sleev', 'compound'),\n",
              "      ('cover', 'ROOT'),\n",
              "      ('needl', 'compound'),\n",
              "      ('tip', 'dobj'),\n",
              "      ('.', 'punct')]},\n",
              "    {'original_sentence': '• A small amount of liquid on the injection site \\nis normal  \\nIf there are more than a few drops of liquid on \\nthe injection site, call 1-800-4HUMIRA (1-800-\\n448-6472) for help.',\n",
              "     'tokens': ['•',\n",
              "      'small',\n",
              "      'amount',\n",
              "      'liquid',\n",
              "      'injection',\n",
              "      'site',\n",
              "      'normal',\n",
              "      'drops',\n",
              "      'liquid',\n",
              "      'injection',\n",
              "      'site',\n",
              "      ',',\n",
              "      'call',\n",
              "      '1-800-4HUMIRA',\n",
              "      '(',\n",
              "      '1-800-',\n",
              "      '448-6472',\n",
              "      ')',\n",
              "      'help',\n",
              "      '.'],\n",
              "     'lemmatized': ['•',\n",
              "      'small',\n",
              "      'amount',\n",
              "      'liquid',\n",
              "      'injection',\n",
              "      'site',\n",
              "      'normal',\n",
              "      'drop',\n",
              "      'liquid',\n",
              "      'injection',\n",
              "      'site',\n",
              "      ',',\n",
              "      'call',\n",
              "      '1-800-4HUMIRA',\n",
              "      '(',\n",
              "      '1-800-',\n",
              "      '448-6472',\n",
              "      ')',\n",
              "      'help',\n",
              "      '.'],\n",
              "     'stemmed': ['•',\n",
              "      'small',\n",
              "      'amount',\n",
              "      'liquid',\n",
              "      'inject',\n",
              "      'site',\n",
              "      'normal',\n",
              "      'drop',\n",
              "      'liquid',\n",
              "      'inject',\n",
              "      'site',\n",
              "      ',',\n",
              "      'call',\n",
              "      '1-800-4humira',\n",
              "      '(',\n",
              "      '1-800-',\n",
              "      '448-6472',\n",
              "      ')',\n",
              "      'help',\n",
              "      '.'],\n",
              "     'dependencies': [('•', 'nummod'),\n",
              "      ('small', 'amod'),\n",
              "      ('amount', 'nmod'),\n",
              "      ('liquid', 'nmod'),\n",
              "      ('inject', 'nmod'),\n",
              "      ('site', 'nmod'),\n",
              "      ('normal', 'amod'),\n",
              "      ('drop', 'nmod'),\n",
              "      ('liquid', 'amod'),\n",
              "      ('inject', 'compound'),\n",
              "      ('site', 'npadvmod'),\n",
              "      (',', 'punct'),\n",
              "      ('call', 'nmod'),\n",
              "      ('1', 'npadvmod'),\n",
              "      ('-', 'punct'),\n",
              "      ('800', 'dobj'),\n",
              "      ('-', 'punct'),\n",
              "      ('4humira', 'quantmod'),\n",
              "      ('(', 'punct'),\n",
              "      ('1', 'appos'),\n",
              "      ('-', 'punct'),\n",
              "      ('800-', 'compound'),\n",
              "      ('448', 'dobj'),\n",
              "      ('-', 'punct'),\n",
              "      ('6472', 'prep'),\n",
              "      (')', 'punct'),\n",
              "      ('help', 'ROOT'),\n",
              "      ('.', 'punct')]},\n",
              "    {'original_sentence': 'After completing the injection, place a cotton \\nball or gauze pad on the skin of the injection \\nsite.',\n",
              "     'tokens': ['completing',\n",
              "      'injection',\n",
              "      ',',\n",
              "      'place',\n",
              "      'cotton',\n",
              "      'ball',\n",
              "      'gauze',\n",
              "      'pad',\n",
              "      'skin',\n",
              "      'injection',\n",
              "      'site',\n",
              "      '.'],\n",
              "     'lemmatized': ['completing',\n",
              "      'injection',\n",
              "      ',',\n",
              "      'place',\n",
              "      'cotton',\n",
              "      'ball',\n",
              "      'gauze',\n",
              "      'pad',\n",
              "      'skin',\n",
              "      'injection',\n",
              "      'site',\n",
              "      '.'],\n",
              "     'stemmed': ['complet',\n",
              "      'inject',\n",
              "      ',',\n",
              "      'place',\n",
              "      'cotton',\n",
              "      'ball',\n",
              "      'gauz',\n",
              "      'pad',\n",
              "      'skin',\n",
              "      'inject',\n",
              "      'site',\n",
              "      '.'],\n",
              "     'dependencies': [('complet', 'compound'),\n",
              "      ('inject', 'ROOT'),\n",
              "      (',', 'punct'),\n",
              "      ('place', 'compound'),\n",
              "      ('cotton', 'compound'),\n",
              "      ('ball', 'compound'),\n",
              "      ('gauz', 'compound'),\n",
              "      ('pad', 'compound'),\n",
              "      ('skin', 'compound'),\n",
              "      ('inject', 'compound'),\n",
              "      ('site', 'appos'),\n",
              "      ('.', 'punct')]},\n",
              "    {'original_sentence': '• Do not rub  \\n• Slight bleeding at the injection site is normal',\n",
              "     'tokens': ['•',\n",
              "      'rub',\n",
              "      '•',\n",
              "      'Slight',\n",
              "      'bleeding',\n",
              "      'injection',\n",
              "      'site',\n",
              "      'normal'],\n",
              "     'lemmatized': ['•',\n",
              "      'rub',\n",
              "      '•',\n",
              "      'Slight',\n",
              "      'bleeding',\n",
              "      'injection',\n",
              "      'site',\n",
              "      'normal'],\n",
              "     'stemmed': ['•',\n",
              "      'rub',\n",
              "      '•',\n",
              "      'slight',\n",
              "      'bleed',\n",
              "      'inject',\n",
              "      'site',\n",
              "      'normal'],\n",
              "     'dependencies': [('•', 'meta'),\n",
              "      ('rub', 'ROOT'),\n",
              "      ('•', 'preconj'),\n",
              "      ('slight', 'amod'),\n",
              "      ('bleed', 'compound'),\n",
              "      ('inject', 'compound'),\n",
              "      ('site', 'dobj'),\n",
              "      ('normal', 'amod')]}],\n",
              "   'text': ' \\n   \\n \\nWhen the injection is completed, slowly pull the \\nPen from the skin. The white needle sleeve will \\ncover the needle tip.  \\n• A small amount of liquid on the injection site \\nis normal  \\nIf there are more than a few drops of liquid on \\nthe injection site, call 1-800-4HUMIRA (1-800-\\n448-6472) for help.  \\nAfter completing the injection, place a cotton \\nball or gauze pad on the skin of the injection \\nsite.  \\n• Do not rub  \\n• Slight bleeding at the injection site is normal \\n'},\n",
              "  'page_char_count': 481,\n",
              "  'page_word_count': 84,\n",
              "  'sentences': [' \\n   \\n \\nWhen the injection is completed, slowly pull the \\nPen from the skin.',\n",
              "   'The white needle sleeve will \\ncover the needle tip.',\n",
              "   ' \\n• A small amount of liquid on the injection site \\nis normal  \\nIf there are more than a few drops of liquid on \\nthe injection site, call 1-800-4HUMIRA (1-800-\\n448-6472) for help.',\n",
              "   ' \\nAfter completing the injection, place a cotton \\nball or gauze pad on the skin of the injection \\nsite.',\n",
              "   ' \\n• Do not rub  \\n• Slight bleeding at the injection site is normal \\n'],\n",
              "  'page_sentence_count_spacy': 5}]"
            ]
          },
          "metadata": {},
          "execution_count": 42
        }
      ],
      "source": [
        "import random # import the random module to access its functions\n",
        "\n",
        "random.sample(pages_and_texts, k=1) # Now you can use random.sample"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 300
        },
        "id": "-isP3ouShGKK",
        "outputId": "1fc1e570-a611-4299-be62-90de7b346cea"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "       page_number  page_char_count  page_word_count  \\\n",
              "count       111.00           111.00           111.00   \n",
              "mean         56.00          1964.23           310.74   \n",
              "std          32.19          1139.53           173.75   \n",
              "min           1.00           150.00            26.00   \n",
              "25%          28.50          1072.50           184.50   \n",
              "50%          56.00          1957.00           291.00   \n",
              "75%          83.50          2889.00           454.00   \n",
              "max         111.00          6260.00          1017.00   \n",
              "\n",
              "       page_sentence_count_spacy  \n",
              "count                     111.00  \n",
              "mean                       14.16  \n",
              "std                         7.36  \n",
              "min                         2.00  \n",
              "25%                        10.00  \n",
              "50%                        13.00  \n",
              "75%                        19.00  \n",
              "max                        39.00  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-572bcade-0b9b-4bc3-9d55-a362d8659818\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>page_number</th>\n",
              "      <th>page_char_count</th>\n",
              "      <th>page_word_count</th>\n",
              "      <th>page_sentence_count_spacy</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>count</th>\n",
              "      <td>111.00</td>\n",
              "      <td>111.00</td>\n",
              "      <td>111.00</td>\n",
              "      <td>111.00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>mean</th>\n",
              "      <td>56.00</td>\n",
              "      <td>1964.23</td>\n",
              "      <td>310.74</td>\n",
              "      <td>14.16</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>std</th>\n",
              "      <td>32.19</td>\n",
              "      <td>1139.53</td>\n",
              "      <td>173.75</td>\n",
              "      <td>7.36</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>min</th>\n",
              "      <td>1.00</td>\n",
              "      <td>150.00</td>\n",
              "      <td>26.00</td>\n",
              "      <td>2.00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>25%</th>\n",
              "      <td>28.50</td>\n",
              "      <td>1072.50</td>\n",
              "      <td>184.50</td>\n",
              "      <td>10.00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>50%</th>\n",
              "      <td>56.00</td>\n",
              "      <td>1957.00</td>\n",
              "      <td>291.00</td>\n",
              "      <td>13.00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>75%</th>\n",
              "      <td>83.50</td>\n",
              "      <td>2889.00</td>\n",
              "      <td>454.00</td>\n",
              "      <td>19.00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>max</th>\n",
              "      <td>111.00</td>\n",
              "      <td>6260.00</td>\n",
              "      <td>1017.00</td>\n",
              "      <td>39.00</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-572bcade-0b9b-4bc3-9d55-a362d8659818')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-572bcade-0b9b-4bc3-9d55-a362d8659818 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-572bcade-0b9b-4bc3-9d55-a362d8659818');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-d987fae4-9890-4aa1-b741-7b3f29210a21\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-d987fae4-9890-4aa1-b741-7b3f29210a21')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-d987fae4-9890-4aa1-b741-7b3f29210a21 button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "summary": "{\n  \"name\": \"df\",\n  \"rows\": 8,\n  \"fields\": [\n    {\n      \"column\": \"page_number\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 39.70033121038521,\n        \"min\": 1.0,\n        \"max\": 111.0,\n        \"num_unique_values\": 6,\n        \"samples\": [\n          111.0,\n          56.0,\n          83.5\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"page_char_count\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 1982.2951681375375,\n        \"min\": 111.0,\n        \"max\": 6260.0,\n        \"num_unique_values\": 8,\n        \"samples\": [\n          1964.23,\n          1957.0,\n          111.0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"page_word_count\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 310.4259930407844,\n        \"min\": 26.0,\n        \"max\": 1017.0,\n        \"num_unique_values\": 8,\n        \"samples\": [\n          310.74,\n          291.0,\n          111.0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"page_sentence_count_spacy\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 35.70627475868712,\n        \"min\": 2.0,\n        \"max\": 111.0,\n        \"num_unique_values\": 8,\n        \"samples\": [\n          14.16,\n          13.0,\n          111.0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 43
        }
      ],
      "source": [
        "df = pd.DataFrame(pages_and_texts)\n",
        "df.describe().round(2)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "MHRoWhJahFzX",
        "outputId": "fc1544cf-1120-48a7-e8da-ba4252b7fa09"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[[0, 1, 2, 3, 4, 5, 6, 7, 8, 9],\n",
              " [10, 11, 12, 13, 14, 15, 16, 17, 18, 19],\n",
              " [20, 21, 22, 23, 24]]"
            ]
          },
          "metadata": {},
          "execution_count": 44
        }
      ],
      "source": [
        "# Define split size to turn groups of sentences into chunks\n",
        "num_sentence_chunk_size = 10\n",
        "\n",
        "# Create a function to split lists of texts recursively into chunk size\n",
        "# e.g. [20] -> [10, 10] or [25] -> [10, 10, 5]\n",
        "def split_list(input_list: list[str],\n",
        "               slice_size: int=num_sentence_chunk_size) -> list[list[str]]:\n",
        "    return [input_list[i:i+slice_size] for i in range(0, len(input_list), slice_size)]\n",
        "\n",
        "test_list = list(range(25))\n",
        "split_list(test_list)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "GPl4w0AphEtf",
        "outputId": "33acde7d-6bb0-479f-cf93-8b5a8904fdff"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "100%|██████████| 111/111 [00:00<00:00, 56929.29it/s]\n"
          ]
        }
      ],
      "source": [
        "# Loop through pages and texts and split sentences into chunks\n",
        "for item in tqdm(pages_and_texts):\n",
        "    item[\"sentence_chunks\"] = split_list(input_list=item[\"sentences\"],\n",
        "                                         slice_size=num_sentence_chunk_size)\n",
        "    item[\"num_chunks\"] = len(item[\"sentence_chunks\"])"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "_WS7AJjohMr6",
        "outputId": "320c8fe8-b7a5-4dba-a6c6-a58868605a78"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[{'page_number': 31,\n",
              "  'text': \"Anti-Drug Antibody Effects on Pharmacokinetics  \\nRheumatoid Arthritis: A trend toward higher apparent clearance of adalimumab in the presence \\nof anti-adalimumab antibodies was identified.  \\nPediatric Ulcerative Colitis: Antibodies to adalimumab by ECL assay were associated with \\nreduced serum adalimumab concentrations in pediatric patients with moderately to severely \\nactive ulcerative colitis. \\nHidradenitis Suppurativa: In subjects with moderate to severe HS, antibodies to adalimumab \\nwere associated with reduced serum adalimumab concentrations. In general, the extent of \\nreduction in serum adalimumab concentrations is greater with increasing titers of antibodies to \\nadalimumab.  \\nSpecific Populations \\nGeriatric Patients: A lower clearance with increasing age was observed in patients with RA aged \\n40 to >75 years. \\nPediatric Patients: \\nJuvenile Idiopathic Arthritis:  \\n• 4 years to 17 years of age: The adalimumab mean steady-state trough concentrations were \\n6.8 mcg/mL and 10.9 mcg/mL in patients weighing <30 kg receiving 20 mg HUMIRA \\nsubcutaneously every other week as monotherapy or with concomitant MTX, respectively. \\nThe adalimumab mean steady-state trough concentrations were 6.6 mcg/mL and 8.1 \\nmcg/mL in patients weighing ≥30 kg receiving 40 mg HUMIRA subcutaneously every \\nother week as monotherapy or with MTX concomitant treatment, respectively.  \\n• 2 years to <4 years of age or 4 years of age and older weighing <15 kg: The adalimumab \\nmean steady-state trough adalimumab concentrations were 6.0 mcg/mL and 7.9 mcg/mL in \\npatients receiving HUMIRA subcutaneously every other week as monotherapy or with \\nMTX concomitant treatment, respectively. \\nPediatric Hidradenitis Suppurativa: Adalimumab concentrations in adolescent patients with HS \\nreceiving the recommended dosage regimens are predicted to be similar to those observed in \\nadult subjects with HS based on population pharmacokinetic modeling and simulation. \\nPediatric Crohn's Disease: Adalimumab mean ± SD concentrations were 15.7±6.5 mcg/mL at \\nWeek 4 following 160 mg at Week 0 and 80 mg at Week 2, and 10.5±6.0 mcg/mL at Week 52 \\nfollowing 40 mg every other week dosing in patients weighing ≥ 40 kg. Adalimumab mean ± SD \\nconcentrations were 10.6±6.1 mcg/mL at Week 4 following dosing 80 mg at Week 0 and 40 mg \\nat Week 2, and 6.9±3.6 mcg/mL at Week 52 following 20 mg every other week dosing in \\npatients weighing < 40 kg. \\nPediatric Ulcerative Colitis: The adalimumab mean steady-state trough concentration was \\n5.0±3.3 mcg/mL at Week 52 following subcutaneous administration of 0.6 mg/kg (maximum of \\n40 mg) every other week in pediatric UC patients 5 years to 17 years of age. In patients who \\nreceived 0.6 mg/kg (maximum of 40 mg) every week, the mean steady-state trough \\nconcentration was 15.7±5.6 mcg/mL at Week 52 in pediatric UC patients 5 years to 17 years of \\nage. \\n\",\n",
              "  'processed_text': {'sentences': [{'original_sentence': 'Anti-Drug Antibody Effects on Pharmacokinetics  \\nRheumatoid Arthritis: A trend toward higher apparent clearance of adalimumab in the presence \\nof anti-adalimumab antibodies was identified.',\n",
              "     'tokens': ['Anti-Drug',\n",
              "      'Antibody',\n",
              "      'Effects',\n",
              "      'Pharmacokinetics',\n",
              "      'Rheumatoid',\n",
              "      'Arthritis',\n",
              "      ':',\n",
              "      'trend',\n",
              "      'toward',\n",
              "      'higher',\n",
              "      'apparent',\n",
              "      'clearance',\n",
              "      'adalimumab',\n",
              "      'presence',\n",
              "      'anti-adalimumab',\n",
              "      'antibodies',\n",
              "      'identified',\n",
              "      '.'],\n",
              "     'lemmatized': ['Anti-Drug',\n",
              "      'Antibody',\n",
              "      'Effects',\n",
              "      'Pharmacokinetics',\n",
              "      'Rheumatoid',\n",
              "      'Arthritis',\n",
              "      ':',\n",
              "      'trend',\n",
              "      'toward',\n",
              "      'higher',\n",
              "      'apparent',\n",
              "      'clearance',\n",
              "      'adalimumab',\n",
              "      'presence',\n",
              "      'anti-adalimumab',\n",
              "      'antibody',\n",
              "      'identified',\n",
              "      '.'],\n",
              "     'stemmed': ['anti-drug',\n",
              "      'antibodi',\n",
              "      'effect',\n",
              "      'pharmacokinet',\n",
              "      'rheumatoid',\n",
              "      'arthriti',\n",
              "      ':',\n",
              "      'trend',\n",
              "      'toward',\n",
              "      'higher',\n",
              "      'appar',\n",
              "      'clearanc',\n",
              "      'adalimumab',\n",
              "      'presenc',\n",
              "      'anti-adalimumab',\n",
              "      'antibodi',\n",
              "      'identifi',\n",
              "      '.'],\n",
              "     'dependencies': [('anti', 'amod'),\n",
              "      ('-', 'amod'),\n",
              "      ('drug', 'amod'),\n",
              "      ('antibodi', 'amod'),\n",
              "      ('effect', 'compound'),\n",
              "      ('pharmacokinet', 'compound'),\n",
              "      ('rheumatoid', 'compound'),\n",
              "      ('arthriti', 'dep'),\n",
              "      (':', 'punct'),\n",
              "      ('trend', 'ROOT'),\n",
              "      ('toward', 'prep'),\n",
              "      ('higher', 'amod'),\n",
              "      ('appar', 'compound'),\n",
              "      ('clearanc', 'compound'),\n",
              "      ('adalimumab', 'compound'),\n",
              "      ('presenc', 'amod'),\n",
              "      ('anti', 'amod'),\n",
              "      ('-', 'amod'),\n",
              "      ('adalimumab', 'amod'),\n",
              "      ('antibodi', 'amod'),\n",
              "      ('identifi', 'pobj'),\n",
              "      ('.', 'punct')]},\n",
              "    {'original_sentence': 'Pediatric Ulcerative Colitis: Antibodies to adalimumab by ECL assay were associated with \\nreduced serum adalimumab concentrations in pediatric patients with moderately to severely \\nactive ulcerative colitis.',\n",
              "     'tokens': ['Pediatric',\n",
              "      'Ulcerative',\n",
              "      'Colitis',\n",
              "      ':',\n",
              "      'Antibodies',\n",
              "      'adalimumab',\n",
              "      'ECL',\n",
              "      'assay',\n",
              "      'associated',\n",
              "      'reduced',\n",
              "      'serum',\n",
              "      'adalimumab',\n",
              "      'concentrations',\n",
              "      'pediatric',\n",
              "      'patients',\n",
              "      'moderately',\n",
              "      'severely',\n",
              "      'active',\n",
              "      'ulcerative',\n",
              "      'colitis',\n",
              "      '.'],\n",
              "     'lemmatized': ['Pediatric',\n",
              "      'Ulcerative',\n",
              "      'Colitis',\n",
              "      ':',\n",
              "      'Antibodies',\n",
              "      'adalimumab',\n",
              "      'ECL',\n",
              "      'assay',\n",
              "      'associated',\n",
              "      'reduced',\n",
              "      'serum',\n",
              "      'adalimumab',\n",
              "      'concentration',\n",
              "      'pediatric',\n",
              "      'patient',\n",
              "      'moderately',\n",
              "      'severely',\n",
              "      'active',\n",
              "      'ulcerative',\n",
              "      'colitis',\n",
              "      '.'],\n",
              "     'stemmed': ['pediatr',\n",
              "      'ulcer',\n",
              "      'coliti',\n",
              "      ':',\n",
              "      'antibodi',\n",
              "      'adalimumab',\n",
              "      'ecl',\n",
              "      'assay',\n",
              "      'associ',\n",
              "      'reduc',\n",
              "      'serum',\n",
              "      'adalimumab',\n",
              "      'concentr',\n",
              "      'pediatr',\n",
              "      'patient',\n",
              "      'moder',\n",
              "      'sever',\n",
              "      'activ',\n",
              "      'ulcer',\n",
              "      'coliti',\n",
              "      '.'],\n",
              "     'dependencies': [('pediatr', 'amod'),\n",
              "      ('ulcer', 'compound'),\n",
              "      ('coliti', 'dep'),\n",
              "      (':', 'punct'),\n",
              "      ('antibodi', 'amod'),\n",
              "      ('adalimumab', 'compound'),\n",
              "      ('ecl', 'compound'),\n",
              "      ('assay', 'compound'),\n",
              "      ('associ', 'compound'),\n",
              "      ('reduc', 'compound'),\n",
              "      ('serum', 'nmod'),\n",
              "      ('adalimumab', 'compound'),\n",
              "      ('concentr', 'appos'),\n",
              "      ('pediatr', 'amod'),\n",
              "      ('patient', 'compound'),\n",
              "      ('moder', 'nsubj'),\n",
              "      ('sever', 'ROOT'),\n",
              "      ('activ', 'compound'),\n",
              "      ('ulcer', 'compound'),\n",
              "      ('coliti', 'dobj'),\n",
              "      ('.', 'punct')]},\n",
              "    {'original_sentence': 'Hidradenitis Suppurativa: In subjects with moderate to severe HS, antibodies to adalimumab \\nwere associated with reduced serum adalimumab concentrations.',\n",
              "     'tokens': ['Hidradenitis',\n",
              "      'Suppurativa',\n",
              "      ':',\n",
              "      'subjects',\n",
              "      'moderate',\n",
              "      'severe',\n",
              "      'HS',\n",
              "      ',',\n",
              "      'antibodies',\n",
              "      'adalimumab',\n",
              "      'associated',\n",
              "      'reduced',\n",
              "      'serum',\n",
              "      'adalimumab',\n",
              "      'concentrations',\n",
              "      '.'],\n",
              "     'lemmatized': ['Hidradenitis',\n",
              "      'Suppurativa',\n",
              "      ':',\n",
              "      'subject',\n",
              "      'moderate',\n",
              "      'severe',\n",
              "      'HS',\n",
              "      ',',\n",
              "      'antibody',\n",
              "      'adalimumab',\n",
              "      'associated',\n",
              "      'reduced',\n",
              "      'serum',\n",
              "      'adalimumab',\n",
              "      'concentration',\n",
              "      '.'],\n",
              "     'stemmed': ['hidraden',\n",
              "      'suppurativa',\n",
              "      ':',\n",
              "      'subject',\n",
              "      'moder',\n",
              "      'sever',\n",
              "      'hs',\n",
              "      ',',\n",
              "      'antibodi',\n",
              "      'adalimumab',\n",
              "      'associ',\n",
              "      'reduc',\n",
              "      'serum',\n",
              "      'adalimumab',\n",
              "      'concentr',\n",
              "      '.'],\n",
              "     'dependencies': [('hidraden', 'compound'),\n",
              "      ('suppurativa', 'dep'),\n",
              "      (':', 'punct'),\n",
              "      ('subject', 'compound'),\n",
              "      ('moder', 'nsubj'),\n",
              "      ('sever', 'parataxis'),\n",
              "      ('hs', 'dobj'),\n",
              "      (',', 'punct'),\n",
              "      ('antibodi', 'amod'),\n",
              "      ('adalimumab', 'compound'),\n",
              "      ('associ', 'nsubj'),\n",
              "      ('reduc', 'ROOT'),\n",
              "      ('serum', 'compound'),\n",
              "      ('adalimumab', 'compound'),\n",
              "      ('concentr', 'dobj'),\n",
              "      ('.', 'punct')]},\n",
              "    {'original_sentence': 'In general, the extent of \\nreduction in serum adalimumab concentrations is greater with increasing titers of antibodies to \\nadalimumab.',\n",
              "     'tokens': ['general',\n",
              "      ',',\n",
              "      'extent',\n",
              "      'reduction',\n",
              "      'serum',\n",
              "      'adalimumab',\n",
              "      'concentrations',\n",
              "      'greater',\n",
              "      'increasing',\n",
              "      'titers',\n",
              "      'antibodies',\n",
              "      'adalimumab',\n",
              "      '.'],\n",
              "     'lemmatized': ['general',\n",
              "      ',',\n",
              "      'extent',\n",
              "      'reduction',\n",
              "      'serum',\n",
              "      'adalimumab',\n",
              "      'concentration',\n",
              "      'greater',\n",
              "      'increasing',\n",
              "      'titer',\n",
              "      'antibody',\n",
              "      'adalimumab',\n",
              "      '.'],\n",
              "     'stemmed': ['gener',\n",
              "      ',',\n",
              "      'extent',\n",
              "      'reduct',\n",
              "      'serum',\n",
              "      'adalimumab',\n",
              "      'concentr',\n",
              "      'greater',\n",
              "      'increas',\n",
              "      'titer',\n",
              "      'antibodi',\n",
              "      'adalimumab',\n",
              "      '.'],\n",
              "     'dependencies': [('gener', 'dep'),\n",
              "      (',', 'punct'),\n",
              "      ('extent', 'compound'),\n",
              "      ('reduct', 'compound'),\n",
              "      ('serum', 'compound'),\n",
              "      ('adalimumab', 'nsubj'),\n",
              "      ('concentr', 'ROOT'),\n",
              "      ('greater', 'amod'),\n",
              "      ('increas', 'compound'),\n",
              "      ('titer', 'compound'),\n",
              "      ('antibodi', 'compound'),\n",
              "      ('adalimumab', 'npadvmod'),\n",
              "      ('.', 'punct')]},\n",
              "    {'original_sentence': 'Specific Populations \\nGeriatric Patients: A lower clearance with increasing age was observed in patients with RA aged \\n40 to >75 years.',\n",
              "     'tokens': ['Specific',\n",
              "      'Populations',\n",
              "      'Geriatric',\n",
              "      'Patients',\n",
              "      ':',\n",
              "      'lower',\n",
              "      'clearance',\n",
              "      'increasing',\n",
              "      'age',\n",
              "      'observed',\n",
              "      'patients',\n",
              "      'RA',\n",
              "      'aged',\n",
              "      '40',\n",
              "      '>',\n",
              "      '75',\n",
              "      'years',\n",
              "      '.'],\n",
              "     'lemmatized': ['Specific',\n",
              "      'Populations',\n",
              "      'Geriatric',\n",
              "      'Patients',\n",
              "      ':',\n",
              "      'lower',\n",
              "      'clearance',\n",
              "      'increasing',\n",
              "      'age',\n",
              "      'observed',\n",
              "      'patient',\n",
              "      'RA',\n",
              "      'aged',\n",
              "      '40',\n",
              "      '>',\n",
              "      '75',\n",
              "      'year',\n",
              "      '.'],\n",
              "     'stemmed': ['specif',\n",
              "      'popul',\n",
              "      'geriatr',\n",
              "      'patient',\n",
              "      ':',\n",
              "      'lower',\n",
              "      'clearanc',\n",
              "      'increas',\n",
              "      'age',\n",
              "      'observ',\n",
              "      'patient',\n",
              "      'ra',\n",
              "      'age',\n",
              "      '40',\n",
              "      '>',\n",
              "      '75',\n",
              "      'year',\n",
              "      '.'],\n",
              "     'dependencies': [('specif', 'compound'),\n",
              "      ('popul', 'nsubj'),\n",
              "      ('geriatr', 'compound'),\n",
              "      ('patient', 'ROOT'),\n",
              "      (':', 'punct'),\n",
              "      ('lower', 'amod'),\n",
              "      ('clearanc', 'compound'),\n",
              "      ('increas', 'compound'),\n",
              "      ('age', 'compound'),\n",
              "      ('observ', 'compound'),\n",
              "      ('patient', 'compound'),\n",
              "      ('ra', 'compound'),\n",
              "      ('age', 'appos'),\n",
              "      ('40', 'nummod'),\n",
              "      ('>', 'punct'),\n",
              "      ('75', 'nummod'),\n",
              "      ('year', 'npadvmod'),\n",
              "      ('.', 'punct')]},\n",
              "    {'original_sentence': 'Pediatric Patients: \\nJuvenile Idiopathic Arthritis:  \\n• 4 years to 17 years of age: The adalimumab mean steady-state trough concentrations were \\n6.8 mcg/mL and 10.9 mcg/mL in patients weighing <30 kg receiving 20 mg HUMIRA \\nsubcutaneously every other week as monotherapy or with concomitant MTX, respectively.',\n",
              "     'tokens': ['Pediatric',\n",
              "      'Patients',\n",
              "      ':',\n",
              "      'Juvenile',\n",
              "      'Idiopathic',\n",
              "      'Arthritis',\n",
              "      ':',\n",
              "      '•',\n",
              "      '4',\n",
              "      'years',\n",
              "      '17',\n",
              "      'years',\n",
              "      'age',\n",
              "      ':',\n",
              "      'adalimumab',\n",
              "      'mean',\n",
              "      'steady-state',\n",
              "      'trough',\n",
              "      'concentrations',\n",
              "      '6.8',\n",
              "      'mcg/mL',\n",
              "      '10.9',\n",
              "      'mcg/mL',\n",
              "      'patients',\n",
              "      'weighing',\n",
              "      '<',\n",
              "      '30',\n",
              "      'kg',\n",
              "      'receiving',\n",
              "      '20',\n",
              "      'mg',\n",
              "      'HUMIRA',\n",
              "      'subcutaneously',\n",
              "      'every',\n",
              "      'week',\n",
              "      'monotherapy',\n",
              "      'concomitant',\n",
              "      'MTX',\n",
              "      ',',\n",
              "      'respectively',\n",
              "      '.'],\n",
              "     'lemmatized': ['Pediatric',\n",
              "      'Patients',\n",
              "      ':',\n",
              "      'Juvenile',\n",
              "      'Idiopathic',\n",
              "      'Arthritis',\n",
              "      ':',\n",
              "      '•',\n",
              "      '4',\n",
              "      'year',\n",
              "      '17',\n",
              "      'year',\n",
              "      'age',\n",
              "      ':',\n",
              "      'adalimumab',\n",
              "      'mean',\n",
              "      'steady-state',\n",
              "      'trough',\n",
              "      'concentration',\n",
              "      '6.8',\n",
              "      'mcg/mL',\n",
              "      '10.9',\n",
              "      'mcg/mL',\n",
              "      'patient',\n",
              "      'weighing',\n",
              "      '<',\n",
              "      '30',\n",
              "      'kg',\n",
              "      'receiving',\n",
              "      '20',\n",
              "      'mg',\n",
              "      'HUMIRA',\n",
              "      'subcutaneously',\n",
              "      'every',\n",
              "      'week',\n",
              "      'monotherapy',\n",
              "      'concomitant',\n",
              "      'MTX',\n",
              "      ',',\n",
              "      'respectively',\n",
              "      '.'],\n",
              "     'stemmed': ['pediatr',\n",
              "      'patient',\n",
              "      ':',\n",
              "      'juvenil',\n",
              "      'idiopath',\n",
              "      'arthriti',\n",
              "      ':',\n",
              "      '•',\n",
              "      '4',\n",
              "      'year',\n",
              "      '17',\n",
              "      'year',\n",
              "      'age',\n",
              "      ':',\n",
              "      'adalimumab',\n",
              "      'mean',\n",
              "      'steady-st',\n",
              "      'trough',\n",
              "      'concentr',\n",
              "      '6.8',\n",
              "      'mcg/ml',\n",
              "      '10.9',\n",
              "      'mcg/ml',\n",
              "      'patient',\n",
              "      'weigh',\n",
              "      '<',\n",
              "      '30',\n",
              "      'kg',\n",
              "      'receiv',\n",
              "      '20',\n",
              "      'mg',\n",
              "      'humira',\n",
              "      'subcutan',\n",
              "      'everi',\n",
              "      'week',\n",
              "      'monotherapi',\n",
              "      'concomit',\n",
              "      'mtx',\n",
              "      ',',\n",
              "      'respect',\n",
              "      '.'],\n",
              "     'dependencies': [('pediatr', 'amod'),\n",
              "      ('patient', 'dep'),\n",
              "      (':', 'punct'),\n",
              "      ('juvenil', 'amod'),\n",
              "      ('idiopath', 'compound'),\n",
              "      ('arthriti', 'dep'),\n",
              "      (':', 'punct'),\n",
              "      ('•', 'appos'),\n",
              "      ('4', 'nummod'),\n",
              "      ('year', 'npadvmod'),\n",
              "      ('17', 'nummod'),\n",
              "      ('year', 'compound'),\n",
              "      ('age', 'appos'),\n",
              "      (':', 'punct'),\n",
              "      ('adalimumab', 'nsubj'),\n",
              "      ('mean', 'parataxis'),\n",
              "      ('steady', 'amod'),\n",
              "      ('-', 'punct'),\n",
              "      ('st', 'compound'),\n",
              "      ('trough', 'nsubj'),\n",
              "      ('concentr', 'ROOT'),\n",
              "      ('6.8', 'nummod'),\n",
              "      ('mcg', 'nmod'),\n",
              "      ('/', 'punct'),\n",
              "      ('ml', 'nmod'),\n",
              "      ('10.9', 'nummod'),\n",
              "      ('mcg', 'nmod'),\n",
              "      ('/', 'punct'),\n",
              "      ('ml', 'nmod'),\n",
              "      ('patient', 'compound'),\n",
              "      ('weigh', 'nmod'),\n",
              "      ('<', 'dep'),\n",
              "      ('30', 'nummod'),\n",
              "      ('kg', 'compound'),\n",
              "      ('receiv', 'dobj'),\n",
              "      ('20', 'nummod'),\n",
              "      ('mg', 'prep'),\n",
              "      ('humira', 'nsubj'),\n",
              "      ('subcutan', 'conj'),\n",
              "      ('everi', 'compound'),\n",
              "      ('week', 'compound'),\n",
              "      ('monotherapi', 'compound'),\n",
              "      ('concomit', 'compound'),\n",
              "      ('mtx', 'dobj'),\n",
              "      (',', 'punct'),\n",
              "      ('respect', 'appos'),\n",
              "      ('.', 'punct')]},\n",
              "    {'original_sentence': 'The adalimumab mean steady-state trough concentrations were 6.6 mcg/mL and 8.1 \\nmcg/mL in patients weighing ≥30 kg receiving 40 mg HUMIRA subcutaneously every \\nother week as monotherapy or with MTX concomitant treatment, respectively.',\n",
              "     'tokens': ['adalimumab',\n",
              "      'mean',\n",
              "      'steady-state',\n",
              "      'trough',\n",
              "      'concentrations',\n",
              "      '6.6',\n",
              "      'mcg/mL',\n",
              "      '8.1',\n",
              "      'mcg/mL',\n",
              "      'patients',\n",
              "      'weighing',\n",
              "      '≥30',\n",
              "      'kg',\n",
              "      'receiving',\n",
              "      '40',\n",
              "      'mg',\n",
              "      'HUMIRA',\n",
              "      'subcutaneously',\n",
              "      'every',\n",
              "      'week',\n",
              "      'monotherapy',\n",
              "      'MTX',\n",
              "      'concomitant',\n",
              "      'treatment',\n",
              "      ',',\n",
              "      'respectively',\n",
              "      '.'],\n",
              "     'lemmatized': ['adalimumab',\n",
              "      'mean',\n",
              "      'steady-state',\n",
              "      'trough',\n",
              "      'concentration',\n",
              "      '6.6',\n",
              "      'mcg/mL',\n",
              "      '8.1',\n",
              "      'mcg/mL',\n",
              "      'patient',\n",
              "      'weighing',\n",
              "      '≥30',\n",
              "      'kg',\n",
              "      'receiving',\n",
              "      '40',\n",
              "      'mg',\n",
              "      'HUMIRA',\n",
              "      'subcutaneously',\n",
              "      'every',\n",
              "      'week',\n",
              "      'monotherapy',\n",
              "      'MTX',\n",
              "      'concomitant',\n",
              "      'treatment',\n",
              "      ',',\n",
              "      'respectively',\n",
              "      '.'],\n",
              "     'stemmed': ['adalimumab',\n",
              "      'mean',\n",
              "      'steady-st',\n",
              "      'trough',\n",
              "      'concentr',\n",
              "      '6.6',\n",
              "      'mcg/ml',\n",
              "      '8.1',\n",
              "      'mcg/ml',\n",
              "      'patient',\n",
              "      'weigh',\n",
              "      '≥30',\n",
              "      'kg',\n",
              "      'receiv',\n",
              "      '40',\n",
              "      'mg',\n",
              "      'humira',\n",
              "      'subcutan',\n",
              "      'everi',\n",
              "      'week',\n",
              "      'monotherapi',\n",
              "      'mtx',\n",
              "      'concomit',\n",
              "      'treatment',\n",
              "      ',',\n",
              "      'respect',\n",
              "      '.'],\n",
              "     'dependencies': [('adalimumab', 'nsubj'),\n",
              "      ('mean', 'parataxis'),\n",
              "      ('steady', 'amod'),\n",
              "      ('-', 'punct'),\n",
              "      ('st', 'compound'),\n",
              "      ('trough', 'nsubj'),\n",
              "      ('concentr', 'ROOT'),\n",
              "      ('6.6', 'nummod'),\n",
              "      ('mcg', 'nmod'),\n",
              "      ('/', 'punct'),\n",
              "      ('ml', 'npadvmod'),\n",
              "      ('8.1', 'nummod'),\n",
              "      ('mcg', 'nmod'),\n",
              "      ('/', 'punct'),\n",
              "      ('ml', 'nmod'),\n",
              "      ('patient', 'compound'),\n",
              "      ('weigh', 'punct'),\n",
              "      ('≥30', 'punct'),\n",
              "      ('kg', 'compound'),\n",
              "      ('receiv', 'dep'),\n",
              "      ('40', 'nummod'),\n",
              "      ('mg', 'prep'),\n",
              "      ('humira', 'nsubj'),\n",
              "      ('subcutan', 'ROOT'),\n",
              "      ('everi', 'compound'),\n",
              "      ('week', 'compound'),\n",
              "      ('monotherapi', 'compound'),\n",
              "      ('mtx', 'compound'),\n",
              "      ('concomit', 'compound'),\n",
              "      ('treatment', 'dobj'),\n",
              "      (',', 'punct'),\n",
              "      ('respect', 'appos'),\n",
              "      ('.', 'punct')]},\n",
              "    {'original_sentence': '• 2 years to <4 years of age or 4 years of age and older weighing <15 kg: The adalimumab \\nmean steady-state trough adalimumab concentrations were 6.0 mcg/mL and 7.9 mcg/mL in \\npatients receiving HUMIRA subcutaneously every other week as monotherapy or with \\nMTX concomitant treatment, respectively.',\n",
              "     'tokens': ['•',\n",
              "      '2',\n",
              "      'years',\n",
              "      '<',\n",
              "      '4',\n",
              "      'years',\n",
              "      'age',\n",
              "      '4',\n",
              "      'years',\n",
              "      'age',\n",
              "      'older',\n",
              "      'weighing',\n",
              "      '<',\n",
              "      '15',\n",
              "      'kg',\n",
              "      ':',\n",
              "      'adalimumab',\n",
              "      'mean',\n",
              "      'steady-state',\n",
              "      'trough',\n",
              "      'adalimumab',\n",
              "      'concentrations',\n",
              "      '6.0',\n",
              "      'mcg/mL',\n",
              "      '7.9',\n",
              "      'mcg/mL',\n",
              "      'patients',\n",
              "      'receiving',\n",
              "      'HUMIRA',\n",
              "      'subcutaneously',\n",
              "      'every',\n",
              "      'week',\n",
              "      'monotherapy',\n",
              "      'MTX',\n",
              "      'concomitant',\n",
              "      'treatment',\n",
              "      ',',\n",
              "      'respectively',\n",
              "      '.'],\n",
              "     'lemmatized': ['•',\n",
              "      '2',\n",
              "      'year',\n",
              "      '<',\n",
              "      '4',\n",
              "      'year',\n",
              "      'age',\n",
              "      '4',\n",
              "      'year',\n",
              "      'age',\n",
              "      'older',\n",
              "      'weighing',\n",
              "      '<',\n",
              "      '15',\n",
              "      'kg',\n",
              "      ':',\n",
              "      'adalimumab',\n",
              "      'mean',\n",
              "      'steady-state',\n",
              "      'trough',\n",
              "      'adalimumab',\n",
              "      'concentration',\n",
              "      '6.0',\n",
              "      'mcg/mL',\n",
              "      '7.9',\n",
              "      'mcg/mL',\n",
              "      'patient',\n",
              "      'receiving',\n",
              "      'HUMIRA',\n",
              "      'subcutaneously',\n",
              "      'every',\n",
              "      'week',\n",
              "      'monotherapy',\n",
              "      'MTX',\n",
              "      'concomitant',\n",
              "      'treatment',\n",
              "      ',',\n",
              "      'respectively',\n",
              "      '.'],\n",
              "     'stemmed': ['•',\n",
              "      '2',\n",
              "      'year',\n",
              "      '<',\n",
              "      '4',\n",
              "      'year',\n",
              "      'age',\n",
              "      '4',\n",
              "      'year',\n",
              "      'age',\n",
              "      'older',\n",
              "      'weigh',\n",
              "      '<',\n",
              "      '15',\n",
              "      'kg',\n",
              "      ':',\n",
              "      'adalimumab',\n",
              "      'mean',\n",
              "      'steady-st',\n",
              "      'trough',\n",
              "      'adalimumab',\n",
              "      'concentr',\n",
              "      '6.0',\n",
              "      'mcg/ml',\n",
              "      '7.9',\n",
              "      'mcg/ml',\n",
              "      'patient',\n",
              "      'receiv',\n",
              "      'humira',\n",
              "      'subcutan',\n",
              "      'everi',\n",
              "      'week',\n",
              "      'monotherapi',\n",
              "      'mtx',\n",
              "      'concomit',\n",
              "      'treatment',\n",
              "      ',',\n",
              "      'respect',\n",
              "      '.'],\n",
              "     'dependencies': [('•', 'nummod'),\n",
              "      ('2', 'nummod'),\n",
              "      ('year', 'npadvmod'),\n",
              "      ('<', 'dep'),\n",
              "      ('4', 'nummod'),\n",
              "      ('year', 'compound'),\n",
              "      ('age', 'nmod'),\n",
              "      ('4', 'nummod'),\n",
              "      ('year', 'compound'),\n",
              "      ('age', 'dep'),\n",
              "      ('older', 'amod'),\n",
              "      ('weigh', 'npadvmod'),\n",
              "      ('<', 'dep'),\n",
              "      ('15', 'nummod'),\n",
              "      ('kg', 'appos'),\n",
              "      (':', 'punct'),\n",
              "      ('adalimumab', 'nsubj'),\n",
              "      ('mean', 'parataxis'),\n",
              "      ('steady', 'amod'),\n",
              "      ('-', 'punct'),\n",
              "      ('st', 'compound'),\n",
              "      ('trough', 'compound'),\n",
              "      ('adalimumab', 'nsubj'),\n",
              "      ('concentr', 'dative'),\n",
              "      ('6.0', 'nummod'),\n",
              "      ('mcg', 'nmod'),\n",
              "      ('/', 'punct'),\n",
              "      ('ml', 'nmod'),\n",
              "      ('7.9', 'nummod'),\n",
              "      ('mcg', 'nmod'),\n",
              "      ('/', 'punct'),\n",
              "      ('ml', 'nmod'),\n",
              "      ('patient', 'compound'),\n",
              "      ('receiv', 'compound'),\n",
              "      ('humira', 'nsubj'),\n",
              "      ('subcutan', 'ROOT'),\n",
              "      ('everi', 'compound'),\n",
              "      ('week', 'compound'),\n",
              "      ('monotherapi', 'compound'),\n",
              "      ('mtx', 'compound'),\n",
              "      ('concomit', 'compound'),\n",
              "      ('treatment', 'dobj'),\n",
              "      (',', 'punct'),\n",
              "      ('respect', 'appos'),\n",
              "      ('.', 'punct')]},\n",
              "    {'original_sentence': 'Pediatric Hidradenitis Suppurativa: Adalimumab concentrations in adolescent patients with HS \\nreceiving the recommended dosage regimens are predicted to be similar to those observed in \\nadult subjects with HS based on population pharmacokinetic modeling and simulation.',\n",
              "     'tokens': ['Pediatric',\n",
              "      'Hidradenitis',\n",
              "      'Suppurativa',\n",
              "      ':',\n",
              "      'Adalimumab',\n",
              "      'concentrations',\n",
              "      'adolescent',\n",
              "      'patients',\n",
              "      'HS',\n",
              "      'receiving',\n",
              "      'recommended',\n",
              "      'dosage',\n",
              "      'regimens',\n",
              "      'predicted',\n",
              "      'similar',\n",
              "      'observed',\n",
              "      'adult',\n",
              "      'subjects',\n",
              "      'HS',\n",
              "      'based',\n",
              "      'population',\n",
              "      'pharmacokinetic',\n",
              "      'modeling',\n",
              "      'simulation',\n",
              "      '.'],\n",
              "     'lemmatized': ['Pediatric',\n",
              "      'Hidradenitis',\n",
              "      'Suppurativa',\n",
              "      ':',\n",
              "      'Adalimumab',\n",
              "      'concentration',\n",
              "      'adolescent',\n",
              "      'patient',\n",
              "      'HS',\n",
              "      'receiving',\n",
              "      'recommended',\n",
              "      'dosage',\n",
              "      'regimen',\n",
              "      'predicted',\n",
              "      'similar',\n",
              "      'observed',\n",
              "      'adult',\n",
              "      'subject',\n",
              "      'HS',\n",
              "      'based',\n",
              "      'population',\n",
              "      'pharmacokinetic',\n",
              "      'modeling',\n",
              "      'simulation',\n",
              "      '.'],\n",
              "     'stemmed': ['pediatr',\n",
              "      'hidraden',\n",
              "      'suppurativa',\n",
              "      ':',\n",
              "      'adalimumab',\n",
              "      'concentr',\n",
              "      'adolesc',\n",
              "      'patient',\n",
              "      'hs',\n",
              "      'receiv',\n",
              "      'recommend',\n",
              "      'dosag',\n",
              "      'regimen',\n",
              "      'predict',\n",
              "      'similar',\n",
              "      'observ',\n",
              "      'adult',\n",
              "      'subject',\n",
              "      'hs',\n",
              "      'base',\n",
              "      'popul',\n",
              "      'pharmacokinet',\n",
              "      'model',\n",
              "      'simul',\n",
              "      '.'],\n",
              "     'dependencies': [('pediatr', 'compound'),\n",
              "      ('hidraden', 'compound'),\n",
              "      ('suppurativa', 'dep'),\n",
              "      (':', 'punct'),\n",
              "      ('adalimumab', 'compound'),\n",
              "      ('concentr', 'compound'),\n",
              "      ('adolesc', 'advmod'),\n",
              "      ('patient', 'compound'),\n",
              "      ('hs', 'compound'),\n",
              "      ('receiv', 'nsubj'),\n",
              "      ('recommend', 'ROOT'),\n",
              "      ('dosag', 'compound'),\n",
              "      ('regimen', 'dobj'),\n",
              "      ('predict', 'ccomp'),\n",
              "      ('similar', 'amod'),\n",
              "      ('observ', 'compound'),\n",
              "      ('adult', 'nmod'),\n",
              "      ('subject', 'amod'),\n",
              "      ('hs', 'nmod'),\n",
              "      ('base', 'compound'),\n",
              "      ('popul', 'compound'),\n",
              "      ('pharmacokinet', 'compound'),\n",
              "      ('model', 'nsubj'),\n",
              "      ('simul', 'ccomp'),\n",
              "      ('.', 'punct')]},\n",
              "    {'original_sentence': \"Pediatric Crohn's Disease: Adalimumab mean ± SD concentrations were 15.7±6.5 mcg/mL at \\nWeek 4 following 160 mg at Week 0 and 80 mg at Week 2, and 10.5±6.0 mcg/mL at Week 52 \\nfollowing 40 mg every other week dosing in patients weighing ≥ 40 kg.\",\n",
              "     'tokens': ['Pediatric',\n",
              "      'Crohn',\n",
              "      \"'s\",\n",
              "      'Disease',\n",
              "      ':',\n",
              "      'Adalimumab',\n",
              "      'mean',\n",
              "      '±',\n",
              "      'SD',\n",
              "      'concentrations',\n",
              "      '15.7±6.5',\n",
              "      'mcg/mL',\n",
              "      'Week',\n",
              "      '4',\n",
              "      'following',\n",
              "      '160',\n",
              "      'mg',\n",
              "      'Week',\n",
              "      '0',\n",
              "      '80',\n",
              "      'mg',\n",
              "      'Week',\n",
              "      '2',\n",
              "      ',',\n",
              "      '10.5±6.0',\n",
              "      'mcg/mL',\n",
              "      'Week',\n",
              "      '52',\n",
              "      'following',\n",
              "      '40',\n",
              "      'mg',\n",
              "      'every',\n",
              "      'week',\n",
              "      'dosing',\n",
              "      'patients',\n",
              "      'weighing',\n",
              "      '≥',\n",
              "      '40',\n",
              "      'kg',\n",
              "      '.'],\n",
              "     'lemmatized': ['Pediatric',\n",
              "      'Crohn',\n",
              "      \"'s\",\n",
              "      'Disease',\n",
              "      ':',\n",
              "      'Adalimumab',\n",
              "      'mean',\n",
              "      '±',\n",
              "      'SD',\n",
              "      'concentration',\n",
              "      '15.7±6.5',\n",
              "      'mcg/mL',\n",
              "      'Week',\n",
              "      '4',\n",
              "      'following',\n",
              "      '160',\n",
              "      'mg',\n",
              "      'Week',\n",
              "      '0',\n",
              "      '80',\n",
              "      'mg',\n",
              "      'Week',\n",
              "      '2',\n",
              "      ',',\n",
              "      '10.5±6.0',\n",
              "      'mcg/mL',\n",
              "      'Week',\n",
              "      '52',\n",
              "      'following',\n",
              "      '40',\n",
              "      'mg',\n",
              "      'every',\n",
              "      'week',\n",
              "      'dosing',\n",
              "      'patient',\n",
              "      'weighing',\n",
              "      '≥',\n",
              "      '40',\n",
              "      'kg',\n",
              "      '.'],\n",
              "     'stemmed': ['pediatr',\n",
              "      'crohn',\n",
              "      \"'s\",\n",
              "      'diseas',\n",
              "      ':',\n",
              "      'adalimumab',\n",
              "      'mean',\n",
              "      '±',\n",
              "      'sd',\n",
              "      'concentr',\n",
              "      '15.7±6.5',\n",
              "      'mcg/ml',\n",
              "      'week',\n",
              "      '4',\n",
              "      'follow',\n",
              "      '160',\n",
              "      'mg',\n",
              "      'week',\n",
              "      '0',\n",
              "      '80',\n",
              "      'mg',\n",
              "      'week',\n",
              "      '2',\n",
              "      ',',\n",
              "      '10.5±6.0',\n",
              "      'mcg/ml',\n",
              "      'week',\n",
              "      '52',\n",
              "      'follow',\n",
              "      '40',\n",
              "      'mg',\n",
              "      'everi',\n",
              "      'week',\n",
              "      'dose',\n",
              "      'patient',\n",
              "      'weigh',\n",
              "      '≥',\n",
              "      '40',\n",
              "      'kg',\n",
              "      '.'],\n",
              "     'dependencies': [('pediatr', 'amod'),\n",
              "      ('crohn', 'poss'),\n",
              "      (\"'s\", 'case'),\n",
              "      ('diseas', 'dep'),\n",
              "      (':', 'punct'),\n",
              "      ('adalimumab', 'compound'),\n",
              "      ('mean', 'npadvmod'),\n",
              "      ('±', 'compound'),\n",
              "      ('sd', 'nsubj'),\n",
              "      ('concentr', 'ROOT'),\n",
              "      ('15.7±6.5', 'nummod'),\n",
              "      ('mcg', 'nmod'),\n",
              "      ('/', 'punct'),\n",
              "      ('ml', 'dobj'),\n",
              "      ('week', 'npadvmod'),\n",
              "      ('4', 'nummod'),\n",
              "      ('follow', 'conj'),\n",
              "      ('160', 'nummod'),\n",
              "      ('mg', 'prep'),\n",
              "      ('week', 'pobj'),\n",
              "      ('0', 'nummod'),\n",
              "      ('80', 'nummod'),\n",
              "      ('mg', 'prep'),\n",
              "      ('week', 'pobj'),\n",
              "      ('2', 'nummod'),\n",
              "      (',', 'punct'),\n",
              "      ('10.5±6.0', 'nummod'),\n",
              "      ('mcg', 'nmod'),\n",
              "      ('/', 'punct'),\n",
              "      ('ml', 'compound'),\n",
              "      ('week', 'npadvmod'),\n",
              "      ('52', 'nummod'),\n",
              "      ('follow', 'appos'),\n",
              "      ('40', 'nummod'),\n",
              "      ('mg', 'nmod'),\n",
              "      ('everi', 'amod'),\n",
              "      ('week', 'npadvmod'),\n",
              "      ('dose', 'compound'),\n",
              "      ('patient', 'compound'),\n",
              "      ('weigh', 'compound'),\n",
              "      ('≥', 'appos'),\n",
              "      ('40', 'nummod'),\n",
              "      ('kg', 'appos'),\n",
              "      ('.', 'punct')]},\n",
              "    {'original_sentence': 'Adalimumab mean ± SD \\nconcentrations were 10.6±6.1 mcg/mL at Week 4 following dosing 80 mg at Week 0 and 40 mg \\nat Week 2, and 6.9±3.6 mcg/mL at Week 52 following 20 mg every other week dosing in \\npatients weighing < 40 kg.',\n",
              "     'tokens': ['Adalimumab',\n",
              "      'mean',\n",
              "      '±',\n",
              "      'SD',\n",
              "      'concentrations',\n",
              "      '10.6±6.1',\n",
              "      'mcg/mL',\n",
              "      'Week',\n",
              "      '4',\n",
              "      'following',\n",
              "      'dosing',\n",
              "      '80',\n",
              "      'mg',\n",
              "      'Week',\n",
              "      '0',\n",
              "      '40',\n",
              "      'mg',\n",
              "      'Week',\n",
              "      '2',\n",
              "      ',',\n",
              "      '6.9±3.6',\n",
              "      'mcg/mL',\n",
              "      'Week',\n",
              "      '52',\n",
              "      'following',\n",
              "      '20',\n",
              "      'mg',\n",
              "      'every',\n",
              "      'week',\n",
              "      'dosing',\n",
              "      'patients',\n",
              "      'weighing',\n",
              "      '<',\n",
              "      '40',\n",
              "      'kg',\n",
              "      '.'],\n",
              "     'lemmatized': ['Adalimumab',\n",
              "      'mean',\n",
              "      '±',\n",
              "      'SD',\n",
              "      'concentration',\n",
              "      '10.6±6.1',\n",
              "      'mcg/mL',\n",
              "      'Week',\n",
              "      '4',\n",
              "      'following',\n",
              "      'dosing',\n",
              "      '80',\n",
              "      'mg',\n",
              "      'Week',\n",
              "      '0',\n",
              "      '40',\n",
              "      'mg',\n",
              "      'Week',\n",
              "      '2',\n",
              "      ',',\n",
              "      '6.9±3.6',\n",
              "      'mcg/mL',\n",
              "      'Week',\n",
              "      '52',\n",
              "      'following',\n",
              "      '20',\n",
              "      'mg',\n",
              "      'every',\n",
              "      'week',\n",
              "      'dosing',\n",
              "      'patient',\n",
              "      'weighing',\n",
              "      '<',\n",
              "      '40',\n",
              "      'kg',\n",
              "      '.'],\n",
              "     'stemmed': ['adalimumab',\n",
              "      'mean',\n",
              "      '±',\n",
              "      'sd',\n",
              "      'concentr',\n",
              "      '10.6±6.1',\n",
              "      'mcg/ml',\n",
              "      'week',\n",
              "      '4',\n",
              "      'follow',\n",
              "      'dose',\n",
              "      '80',\n",
              "      'mg',\n",
              "      'week',\n",
              "      '0',\n",
              "      '40',\n",
              "      'mg',\n",
              "      'week',\n",
              "      '2',\n",
              "      ',',\n",
              "      '6.9±3.6',\n",
              "      'mcg/ml',\n",
              "      'week',\n",
              "      '52',\n",
              "      'follow',\n",
              "      '20',\n",
              "      'mg',\n",
              "      'everi',\n",
              "      'week',\n",
              "      'dose',\n",
              "      'patient',\n",
              "      'weigh',\n",
              "      '<',\n",
              "      '40',\n",
              "      'kg',\n",
              "      '.'],\n",
              "     'dependencies': [('adalimumab', 'compound'),\n",
              "      ('mean', 'npadvmod'),\n",
              "      ('±', 'compound'),\n",
              "      ('sd', 'nsubj'),\n",
              "      ('concentr', 'ROOT'),\n",
              "      ('10.6±6.1', 'nummod'),\n",
              "      ('mcg', 'nmod'),\n",
              "      ('/', 'punct'),\n",
              "      ('ml', 'compound'),\n",
              "      ('week', 'npadvmod'),\n",
              "      ('4', 'nummod'),\n",
              "      ('follow', 'compound'),\n",
              "      ('dose', 'appos'),\n",
              "      ('80', 'nummod'),\n",
              "      ('mg', 'compound'),\n",
              "      ('week', 'pobj'),\n",
              "      ('0', 'nummod'),\n",
              "      ('40', 'nummod'),\n",
              "      ('mg', 'prep'),\n",
              "      ('week', 'pobj'),\n",
              "      ('2', 'nummod'),\n",
              "      (',', 'punct'),\n",
              "      ('6.9±3.6', 'nummod'),\n",
              "      ('mcg', 'nmod'),\n",
              "      ('/', 'punct'),\n",
              "      ('ml', 'compound'),\n",
              "      ('week', 'npadvmod'),\n",
              "      ('52', 'nummod'),\n",
              "      ('follow', 'appos'),\n",
              "      ('20', 'nummod'),\n",
              "      ('mg', 'nmod'),\n",
              "      ('everi', 'amod'),\n",
              "      ('week', 'compound'),\n",
              "      ('dose', 'compound'),\n",
              "      ('patient', 'compound'),\n",
              "      ('weigh', 'npadvmod'),\n",
              "      ('<', 'dep'),\n",
              "      ('40', 'nummod'),\n",
              "      ('kg', 'npadvmod'),\n",
              "      ('.', 'punct')]},\n",
              "    {'original_sentence': 'Pediatric Ulcerative Colitis: The adalimumab mean steady-state trough concentration was \\n5.0±3.3 mcg/mL at Week 52 following subcutaneous administration of 0.6 mg/kg (maximum of \\n40 mg) every other week in pediatric UC patients 5 years to 17 years of age.',\n",
              "     'tokens': ['Pediatric',\n",
              "      'Ulcerative',\n",
              "      'Colitis',\n",
              "      ':',\n",
              "      'adalimumab',\n",
              "      'mean',\n",
              "      'steady-state',\n",
              "      'trough',\n",
              "      'concentration',\n",
              "      '5.0±3.3',\n",
              "      'mcg/mL',\n",
              "      'Week',\n",
              "      '52',\n",
              "      'following',\n",
              "      'subcutaneous',\n",
              "      'administration',\n",
              "      '0.6',\n",
              "      'mg/kg',\n",
              "      '(',\n",
              "      'maximum',\n",
              "      '40',\n",
              "      'mg',\n",
              "      ')',\n",
              "      'every',\n",
              "      'week',\n",
              "      'pediatric',\n",
              "      'UC',\n",
              "      'patients',\n",
              "      '5',\n",
              "      'years',\n",
              "      '17',\n",
              "      'years',\n",
              "      'age',\n",
              "      '.'],\n",
              "     'lemmatized': ['Pediatric',\n",
              "      'Ulcerative',\n",
              "      'Colitis',\n",
              "      ':',\n",
              "      'adalimumab',\n",
              "      'mean',\n",
              "      'steady-state',\n",
              "      'trough',\n",
              "      'concentration',\n",
              "      '5.0±3.3',\n",
              "      'mcg/mL',\n",
              "      'Week',\n",
              "      '52',\n",
              "      'following',\n",
              "      'subcutaneous',\n",
              "      'administration',\n",
              "      '0.6',\n",
              "      'mg/kg',\n",
              "      '(',\n",
              "      'maximum',\n",
              "      '40',\n",
              "      'mg',\n",
              "      ')',\n",
              "      'every',\n",
              "      'week',\n",
              "      'pediatric',\n",
              "      'UC',\n",
              "      'patient',\n",
              "      '5',\n",
              "      'year',\n",
              "      '17',\n",
              "      'year',\n",
              "      'age',\n",
              "      '.'],\n",
              "     'stemmed': ['pediatr',\n",
              "      'ulcer',\n",
              "      'coliti',\n",
              "      ':',\n",
              "      'adalimumab',\n",
              "      'mean',\n",
              "      'steady-st',\n",
              "      'trough',\n",
              "      'concentr',\n",
              "      '5.0±3.3',\n",
              "      'mcg/ml',\n",
              "      'week',\n",
              "      '52',\n",
              "      'follow',\n",
              "      'subcutan',\n",
              "      'administr',\n",
              "      '0.6',\n",
              "      'mg/kg',\n",
              "      '(',\n",
              "      'maximum',\n",
              "      '40',\n",
              "      'mg',\n",
              "      ')',\n",
              "      'everi',\n",
              "      'week',\n",
              "      'pediatr',\n",
              "      'uc',\n",
              "      'patient',\n",
              "      '5',\n",
              "      'year',\n",
              "      '17',\n",
              "      'year',\n",
              "      'age',\n",
              "      '.'],\n",
              "     'dependencies': [('pediatr', 'amod'),\n",
              "      ('ulcer', 'compound'),\n",
              "      ('coliti', 'dep'),\n",
              "      (':', 'punct'),\n",
              "      ('adalimumab', 'nsubj'),\n",
              "      ('mean', 'parataxis'),\n",
              "      ('steady', 'amod'),\n",
              "      ('-', 'punct'),\n",
              "      ('st', 'compound'),\n",
              "      ('trough', 'nsubj'),\n",
              "      ('concentr', 'dep'),\n",
              "      ('5.0±3.3', 'dobj'),\n",
              "      ('mcg', 'nmod'),\n",
              "      ('/', 'punct'),\n",
              "      ('ml', 'compound'),\n",
              "      ('week', 'npadvmod'),\n",
              "      ('52', 'nummod'),\n",
              "      ('follow', 'ROOT'),\n",
              "      ('subcutan', 'compound'),\n",
              "      ('administr', 'dobj'),\n",
              "      ('0.6', 'nummod'),\n",
              "      ('mg', 'nmod'),\n",
              "      ('/', 'punct'),\n",
              "      ('kg', 'npadvmod'),\n",
              "      ('(', 'punct'),\n",
              "      ('maximum', 'parataxis'),\n",
              "      ('40', 'nummod'),\n",
              "      ('mg', 'prep'),\n",
              "      (')', 'punct'),\n",
              "      ('everi', 'amod'),\n",
              "      ('week', 'compound'),\n",
              "      ('pediatr', 'ROOT'),\n",
              "      ('uc', 'advmod'),\n",
              "      ('patient', 'amod'),\n",
              "      ('5', 'nummod'),\n",
              "      ('year', 'nmod'),\n",
              "      ('17', 'nummod'),\n",
              "      ('year', 'compound'),\n",
              "      ('age', 'npadvmod'),\n",
              "      ('.', 'punct')]},\n",
              "    {'original_sentence': 'In patients who \\nreceived 0.6 mg/kg (maximum of 40 mg) every week, the mean steady-state trough \\nconcentration was 15.7±5.6 mcg/mL at Week 52 in pediatric UC patients 5 years to 17 years of \\nage.',\n",
              "     'tokens': ['patients',\n",
              "      'received',\n",
              "      '0.6',\n",
              "      'mg/kg',\n",
              "      '(',\n",
              "      'maximum',\n",
              "      '40',\n",
              "      'mg',\n",
              "      ')',\n",
              "      'every',\n",
              "      'week',\n",
              "      ',',\n",
              "      'mean',\n",
              "      'steady-state',\n",
              "      'trough',\n",
              "      'concentration',\n",
              "      '15.7±5.6',\n",
              "      'mcg/mL',\n",
              "      'Week',\n",
              "      '52',\n",
              "      'pediatric',\n",
              "      'UC',\n",
              "      'patients',\n",
              "      '5',\n",
              "      'years',\n",
              "      '17',\n",
              "      'years',\n",
              "      'age',\n",
              "      '.'],\n",
              "     'lemmatized': ['patient',\n",
              "      'received',\n",
              "      '0.6',\n",
              "      'mg/kg',\n",
              "      '(',\n",
              "      'maximum',\n",
              "      '40',\n",
              "      'mg',\n",
              "      ')',\n",
              "      'every',\n",
              "      'week',\n",
              "      ',',\n",
              "      'mean',\n",
              "      'steady-state',\n",
              "      'trough',\n",
              "      'concentration',\n",
              "      '15.7±5.6',\n",
              "      'mcg/mL',\n",
              "      'Week',\n",
              "      '52',\n",
              "      'pediatric',\n",
              "      'UC',\n",
              "      'patient',\n",
              "      '5',\n",
              "      'year',\n",
              "      '17',\n",
              "      'year',\n",
              "      'age',\n",
              "      '.'],\n",
              "     'stemmed': ['patient',\n",
              "      'receiv',\n",
              "      '0.6',\n",
              "      'mg/kg',\n",
              "      '(',\n",
              "      'maximum',\n",
              "      '40',\n",
              "      'mg',\n",
              "      ')',\n",
              "      'everi',\n",
              "      'week',\n",
              "      ',',\n",
              "      'mean',\n",
              "      'steady-st',\n",
              "      'trough',\n",
              "      'concentr',\n",
              "      '15.7±5.6',\n",
              "      'mcg/ml',\n",
              "      'week',\n",
              "      '52',\n",
              "      'pediatr',\n",
              "      'uc',\n",
              "      'patient',\n",
              "      '5',\n",
              "      'year',\n",
              "      '17',\n",
              "      'year',\n",
              "      'age',\n",
              "      '.'],\n",
              "     'dependencies': [('patient', 'compound'),\n",
              "      ('receiv', 'ROOT'),\n",
              "      ('0.6', 'nummod'),\n",
              "      ('mg', 'nmod'),\n",
              "      ('/', 'punct'),\n",
              "      ('kg', 'appos'),\n",
              "      ('(', 'punct'),\n",
              "      ('maximum', 'amod'),\n",
              "      ('40', 'nummod'),\n",
              "      ('mg', 'appos'),\n",
              "      (')', 'punct'),\n",
              "      ('everi', 'amod'),\n",
              "      ('week', 'npadvmod'),\n",
              "      (',', 'punct'),\n",
              "      ('mean', 'amod'),\n",
              "      ('steady', 'amod'),\n",
              "      ('-', 'punct'),\n",
              "      ('st', 'compound'),\n",
              "      ('trough', 'compound'),\n",
              "      ('concentr', 'conj'),\n",
              "      ('15.7±5.6', 'compound'),\n",
              "      ('mcg', 'nmod'),\n",
              "      ('/', 'punct'),\n",
              "      ('ml', 'compound'),\n",
              "      ('week', 'pobj'),\n",
              "      ('52', 'nummod'),\n",
              "      ('pediatr', 'amod'),\n",
              "      ('uc', 'advmod'),\n",
              "      ('patient', 'appos'),\n",
              "      ('5', 'nummod'),\n",
              "      ('year', 'ROOT'),\n",
              "      ('17', 'nummod'),\n",
              "      ('year', 'compound'),\n",
              "      ('age', 'npadvmod'),\n",
              "      ('.', 'punct')]}],\n",
              "   'text': \"Anti-Drug Antibody Effects on Pharmacokinetics  \\nRheumatoid Arthritis: A trend toward higher apparent clearance of adalimumab in the presence \\nof anti-adalimumab antibodies was identified.  \\nPediatric Ulcerative Colitis: Antibodies to adalimumab by ECL assay were associated with \\nreduced serum adalimumab concentrations in pediatric patients with moderately to severely \\nactive ulcerative colitis. \\nHidradenitis Suppurativa: In subjects with moderate to severe HS, antibodies to adalimumab \\nwere associated with reduced serum adalimumab concentrations. In general, the extent of \\nreduction in serum adalimumab concentrations is greater with increasing titers of antibodies to \\nadalimumab.  \\nSpecific Populations \\nGeriatric Patients: A lower clearance with increasing age was observed in patients with RA aged \\n40 to >75 years. \\nPediatric Patients: \\nJuvenile Idiopathic Arthritis:  \\n• 4 years to 17 years of age: The adalimumab mean steady-state trough concentrations were \\n6.8 mcg/mL and 10.9 mcg/mL in patients weighing <30 kg receiving 20 mg HUMIRA \\nsubcutaneously every other week as monotherapy or with concomitant MTX, respectively. \\nThe adalimumab mean steady-state trough concentrations were 6.6 mcg/mL and 8.1 \\nmcg/mL in patients weighing ≥30 kg receiving 40 mg HUMIRA subcutaneously every \\nother week as monotherapy or with MTX concomitant treatment, respectively.  \\n• 2 years to <4 years of age or 4 years of age and older weighing <15 kg: The adalimumab \\nmean steady-state trough adalimumab concentrations were 6.0 mcg/mL and 7.9 mcg/mL in \\npatients receiving HUMIRA subcutaneously every other week as monotherapy or with \\nMTX concomitant treatment, respectively. \\nPediatric Hidradenitis Suppurativa: Adalimumab concentrations in adolescent patients with HS \\nreceiving the recommended dosage regimens are predicted to be similar to those observed in \\nadult subjects with HS based on population pharmacokinetic modeling and simulation. \\nPediatric Crohn's Disease: Adalimumab mean ± SD concentrations were 15.7±6.5 mcg/mL at \\nWeek 4 following 160 mg at Week 0 and 80 mg at Week 2, and 10.5±6.0 mcg/mL at Week 52 \\nfollowing 40 mg every other week dosing in patients weighing ≥ 40 kg. Adalimumab mean ± SD \\nconcentrations were 10.6±6.1 mcg/mL at Week 4 following dosing 80 mg at Week 0 and 40 mg \\nat Week 2, and 6.9±3.6 mcg/mL at Week 52 following 20 mg every other week dosing in \\npatients weighing < 40 kg. \\nPediatric Ulcerative Colitis: The adalimumab mean steady-state trough concentration was \\n5.0±3.3 mcg/mL at Week 52 following subcutaneous administration of 0.6 mg/kg (maximum of \\n40 mg) every other week in pediatric UC patients 5 years to 17 years of age. In patients who \\nreceived 0.6 mg/kg (maximum of 40 mg) every week, the mean steady-state trough \\nconcentration was 15.7±5.6 mcg/mL at Week 52 in pediatric UC patients 5 years to 17 years of \\nage. \\n\"},\n",
              "  'page_char_count': 2871,\n",
              "  'page_word_count': 429,\n",
              "  'sentences': ['Anti-Drug Antibody Effects on Pharmacokinetics  \\nRheumatoid Arthritis: A trend toward higher apparent clearance of adalimumab in the presence \\nof anti-adalimumab antibodies was identified.',\n",
              "   ' \\nPediatric Ulcerative Colitis: Antibodies to adalimumab by ECL assay were associated with \\nreduced serum adalimumab concentrations in pediatric patients with moderately to severely \\nactive ulcerative colitis.',\n",
              "   '\\nHidradenitis Suppurativa: In subjects with moderate to severe HS, antibodies to adalimumab \\nwere associated with reduced serum adalimumab concentrations.',\n",
              "   'In general, the extent of \\nreduction in serum adalimumab concentrations is greater with increasing titers of antibodies to \\nadalimumab.',\n",
              "   ' \\nSpecific Populations \\nGeriatric Patients: A lower clearance with increasing age was observed in patients with RA aged \\n40 to >75 years.',\n",
              "   '\\nPediatric Patients: \\nJuvenile Idiopathic Arthritis:  \\n• 4 years to 17 years of age: The adalimumab mean steady-state trough concentrations were \\n6.8 mcg/mL and 10.9 mcg/mL in patients weighing <30 kg receiving 20 mg HUMIRA \\nsubcutaneously every other week as monotherapy or with concomitant MTX, respectively.',\n",
              "   '\\nThe adalimumab mean steady-state trough concentrations were 6.6 mcg/mL and 8.1 \\nmcg/mL in patients weighing ≥30 kg receiving 40 mg HUMIRA subcutaneously every \\nother week as monotherapy or with MTX concomitant treatment, respectively.',\n",
              "   ' \\n• 2 years to <4 years of age or 4 years of age and older weighing <15 kg: The adalimumab \\nmean steady-state trough adalimumab concentrations were 6.0 mcg/mL and 7.9 mcg/mL in \\npatients receiving HUMIRA subcutaneously every other week as monotherapy or with \\nMTX concomitant treatment, respectively.',\n",
              "   '\\nPediatric Hidradenitis Suppurativa: Adalimumab concentrations in adolescent patients with HS \\nreceiving the recommended dosage regimens are predicted to be similar to those observed in \\nadult subjects with HS based on population pharmacokinetic modeling and simulation.',\n",
              "   \"\\nPediatric Crohn's Disease: Adalimumab mean ± SD concentrations were 15.7±6.5 mcg/mL at \\nWeek 4 following 160 mg at Week 0 and 80 mg at Week 2, and 10.5±6.0 mcg/mL at Week 52 \\nfollowing 40 mg every other week dosing in patients weighing ≥ 40 kg.\",\n",
              "   'Adalimumab mean ± SD \\nconcentrations were 10.6±6.1 mcg/mL at Week 4 following dosing 80 mg at Week 0 and 40 mg \\nat Week 2, and 6.9±3.6 mcg/mL at Week 52 following 20 mg every other week dosing in \\npatients weighing < 40 kg.',\n",
              "   '\\nPediatric Ulcerative Colitis: The adalimumab mean steady-state trough concentration was \\n5.0±3.3 mcg/mL at Week 52 following subcutaneous administration of 0.6 mg/kg (maximum of \\n40 mg) every other week in pediatric UC patients 5 years to 17 years of age.',\n",
              "   'In patients who \\nreceived 0.6 mg/kg (maximum of 40 mg) every week, the mean steady-state trough \\nconcentration was 15.7±5.6 mcg/mL at Week 52 in pediatric UC patients 5 years to 17 years of \\nage.',\n",
              "   '\\n'],\n",
              "  'page_sentence_count_spacy': 14,\n",
              "  'sentence_chunks': [['Anti-Drug Antibody Effects on Pharmacokinetics  \\nRheumatoid Arthritis: A trend toward higher apparent clearance of adalimumab in the presence \\nof anti-adalimumab antibodies was identified.',\n",
              "    ' \\nPediatric Ulcerative Colitis: Antibodies to adalimumab by ECL assay were associated with \\nreduced serum adalimumab concentrations in pediatric patients with moderately to severely \\nactive ulcerative colitis.',\n",
              "    '\\nHidradenitis Suppurativa: In subjects with moderate to severe HS, antibodies to adalimumab \\nwere associated with reduced serum adalimumab concentrations.',\n",
              "    'In general, the extent of \\nreduction in serum adalimumab concentrations is greater with increasing titers of antibodies to \\nadalimumab.',\n",
              "    ' \\nSpecific Populations \\nGeriatric Patients: A lower clearance with increasing age was observed in patients with RA aged \\n40 to >75 years.',\n",
              "    '\\nPediatric Patients: \\nJuvenile Idiopathic Arthritis:  \\n• 4 years to 17 years of age: The adalimumab mean steady-state trough concentrations were \\n6.8 mcg/mL and 10.9 mcg/mL in patients weighing <30 kg receiving 20 mg HUMIRA \\nsubcutaneously every other week as monotherapy or with concomitant MTX, respectively.',\n",
              "    '\\nThe adalimumab mean steady-state trough concentrations were 6.6 mcg/mL and 8.1 \\nmcg/mL in patients weighing ≥30 kg receiving 40 mg HUMIRA subcutaneously every \\nother week as monotherapy or with MTX concomitant treatment, respectively.',\n",
              "    ' \\n• 2 years to <4 years of age or 4 years of age and older weighing <15 kg: The adalimumab \\nmean steady-state trough adalimumab concentrations were 6.0 mcg/mL and 7.9 mcg/mL in \\npatients receiving HUMIRA subcutaneously every other week as monotherapy or with \\nMTX concomitant treatment, respectively.',\n",
              "    '\\nPediatric Hidradenitis Suppurativa: Adalimumab concentrations in adolescent patients with HS \\nreceiving the recommended dosage regimens are predicted to be similar to those observed in \\nadult subjects with HS based on population pharmacokinetic modeling and simulation.',\n",
              "    \"\\nPediatric Crohn's Disease: Adalimumab mean ± SD concentrations were 15.7±6.5 mcg/mL at \\nWeek 4 following 160 mg at Week 0 and 80 mg at Week 2, and 10.5±6.0 mcg/mL at Week 52 \\nfollowing 40 mg every other week dosing in patients weighing ≥ 40 kg.\"],\n",
              "   ['Adalimumab mean ± SD \\nconcentrations were 10.6±6.1 mcg/mL at Week 4 following dosing 80 mg at Week 0 and 40 mg \\nat Week 2, and 6.9±3.6 mcg/mL at Week 52 following 20 mg every other week dosing in \\npatients weighing < 40 kg.',\n",
              "    '\\nPediatric Ulcerative Colitis: The adalimumab mean steady-state trough concentration was \\n5.0±3.3 mcg/mL at Week 52 following subcutaneous administration of 0.6 mg/kg (maximum of \\n40 mg) every other week in pediatric UC patients 5 years to 17 years of age.',\n",
              "    'In patients who \\nreceived 0.6 mg/kg (maximum of 40 mg) every week, the mean steady-state trough \\nconcentration was 15.7±5.6 mcg/mL at Week 52 in pediatric UC patients 5 years to 17 years of \\nage.',\n",
              "    '\\n']],\n",
              "  'num_chunks': 2}]"
            ]
          },
          "metadata": {},
          "execution_count": 46
        }
      ],
      "source": [
        "random.sample(pages_and_texts, k=1)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 300
        },
        "id": "OQMYBjrohPDe",
        "outputId": "73a7a581-8989-4d84-a9bc-11b4a9d7f3fa"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "       page_number  page_char_count  page_word_count  \\\n",
              "count       111.00           111.00           111.00   \n",
              "mean         56.00          1964.23           310.74   \n",
              "std          32.19          1139.53           173.75   \n",
              "min           1.00           150.00            26.00   \n",
              "25%          28.50          1072.50           184.50   \n",
              "50%          56.00          1957.00           291.00   \n",
              "75%          83.50          2889.00           454.00   \n",
              "max         111.00          6260.00          1017.00   \n",
              "\n",
              "       page_sentence_count_spacy  num_chunks  \n",
              "count                     111.00      111.00  \n",
              "mean                       14.16        1.89  \n",
              "std                         7.36        0.75  \n",
              "min                         2.00        1.00  \n",
              "25%                        10.00        1.00  \n",
              "50%                        13.00        2.00  \n",
              "75%                        19.00        2.00  \n",
              "max                        39.00        4.00  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-94a6864f-7b98-4aa9-99f8-62737314677d\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>page_number</th>\n",
              "      <th>page_char_count</th>\n",
              "      <th>page_word_count</th>\n",
              "      <th>page_sentence_count_spacy</th>\n",
              "      <th>num_chunks</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>count</th>\n",
              "      <td>111.00</td>\n",
              "      <td>111.00</td>\n",
              "      <td>111.00</td>\n",
              "      <td>111.00</td>\n",
              "      <td>111.00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>mean</th>\n",
              "      <td>56.00</td>\n",
              "      <td>1964.23</td>\n",
              "      <td>310.74</td>\n",
              "      <td>14.16</td>\n",
              "      <td>1.89</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>std</th>\n",
              "      <td>32.19</td>\n",
              "      <td>1139.53</td>\n",
              "      <td>173.75</td>\n",
              "      <td>7.36</td>\n",
              "      <td>0.75</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>min</th>\n",
              "      <td>1.00</td>\n",
              "      <td>150.00</td>\n",
              "      <td>26.00</td>\n",
              "      <td>2.00</td>\n",
              "      <td>1.00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>25%</th>\n",
              "      <td>28.50</td>\n",
              "      <td>1072.50</td>\n",
              "      <td>184.50</td>\n",
              "      <td>10.00</td>\n",
              "      <td>1.00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>50%</th>\n",
              "      <td>56.00</td>\n",
              "      <td>1957.00</td>\n",
              "      <td>291.00</td>\n",
              "      <td>13.00</td>\n",
              "      <td>2.00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>75%</th>\n",
              "      <td>83.50</td>\n",
              "      <td>2889.00</td>\n",
              "      <td>454.00</td>\n",
              "      <td>19.00</td>\n",
              "      <td>2.00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>max</th>\n",
              "      <td>111.00</td>\n",
              "      <td>6260.00</td>\n",
              "      <td>1017.00</td>\n",
              "      <td>39.00</td>\n",
              "      <td>4.00</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-94a6864f-7b98-4aa9-99f8-62737314677d')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-94a6864f-7b98-4aa9-99f8-62737314677d button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-94a6864f-7b98-4aa9-99f8-62737314677d');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-f7780643-7052-4928-87d6-0b1609e2924b\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-f7780643-7052-4928-87d6-0b1609e2924b')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-f7780643-7052-4928-87d6-0b1609e2924b button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "summary": "{\n  \"name\": \"df\",\n  \"rows\": 8,\n  \"fields\": [\n    {\n      \"column\": \"page_number\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 39.70033121038521,\n        \"min\": 1.0,\n        \"max\": 111.0,\n        \"num_unique_values\": 6,\n        \"samples\": [\n          111.0,\n          56.0,\n          83.5\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"page_char_count\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 1982.2951681375375,\n        \"min\": 111.0,\n        \"max\": 6260.0,\n        \"num_unique_values\": 8,\n        \"samples\": [\n          1964.23,\n          1957.0,\n          111.0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"page_word_count\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 310.4259930407844,\n        \"min\": 26.0,\n        \"max\": 1017.0,\n        \"num_unique_values\": 8,\n        \"samples\": [\n          310.74,\n          291.0,\n          111.0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"page_sentence_count_spacy\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 35.70627475868712,\n        \"min\": 2.0,\n        \"max\": 111.0,\n        \"num_unique_values\": 8,\n        \"samples\": [\n          14.16,\n          13.0,\n          111.0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"num_chunks\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 38.61953317761807,\n        \"min\": 0.75,\n        \"max\": 111.0,\n        \"num_unique_values\": 6,\n        \"samples\": [\n          111.0,\n          1.89,\n          4.0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 47
        }
      ],
      "source": [
        "df = pd.DataFrame(pages_and_texts)\n",
        "df.describe().round(2)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "0mTCvim3hRxM",
        "outputId": "2cc9aa9c-f775-4ec9-ad65-3be392e773e0"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "100%|██████████| 111/111 [00:00<00:00, 7578.59it/s]\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "210"
            ]
          },
          "metadata": {},
          "execution_count": 48
        }
      ],
      "source": [
        "import re\n",
        "\n",
        "# Split each chunk into its own item\n",
        "pages_and_chunks = []\n",
        "for item in tqdm(pages_and_texts):\n",
        "    for sentence_chunk in item[\"sentence_chunks\"]:\n",
        "        chunk_dict = {}\n",
        "        chunk_dict[\"page_number\"] = item[\"page_number\"]\n",
        "\n",
        "        # Join the sentences together into a paragraph-like structure, aka join the list of sentences into one paragraph\n",
        "        joined_sentence_chunk = \"\".join(sentence_chunk).replace(\"  \", \" \").strip()\n",
        "        joined_sentence_chunk = re.sub(r'\\.([A-Z])', r'. \\1', joined_sentence_chunk) # \".A\" => \". A\" (will work for any captial letter)\n",
        "\n",
        "        chunk_dict[\"sentence_chunk\"] = joined_sentence_chunk\n",
        "\n",
        "        # Get some stats on our chunks\n",
        "        chunk_dict[\"chunk_char_count\"] = len(joined_sentence_chunk)\n",
        "        chunk_dict[\"chunk_word_count\"] = len([word for word in joined_sentence_chunk.split(\" \")])\n",
        "        chunk_dict[\"chunk_token_count\"] = len(joined_sentence_chunk) / 4 # 1 token = ~4 chars\n",
        "\n",
        "        pages_and_chunks.append(chunk_dict)\n",
        "\n",
        "len(pages_and_chunks)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "lBK8j4B5hU-X",
        "outputId": "78331d74-2733-4b0c-fedf-fd7b781aa5ec"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[{'page_number': 37,\n",
              "  'sentence_chunk': 'All patients had to show signs of active moderate or severe disease despite \\nprevious treatment with NSAIDs, analgesics, corticosteroids, or DMARDS. Patients who \\nreceived prior treatment with any biologic DMARDS were excluded from the study. \\nThe study included four phases: an open-label lead in phase (OL-LI; 16 weeks), a double-blind \\nrandomized withdrawal phase (DB; 32 weeks), an open-label extension phase (OLE-BSA; up to \\n136 weeks), and an open-label fixed dose phase (OLE-FD; 16 weeks). In the first three phases of \\nthe study, HUMIRA was administered based on body surface area at a dose of 24 mg/m2 up to a \\nmaximum total body dose of 40 mg subcutaneously (SC) every other week. In the OLE-FD \\nphase, the patients were treated with 20 mg of HUMIRA SC every other week if their weight \\nwas less than 30 kg and with 40 mg of HUMIRA SC every other week if their weight was 30 kg \\nor greater. Patients remained on stable doses of NSAIDs and or prednisone (≤0.2 mg/kg/day or \\n10 mg/day maximum).',\n",
              "  'chunk_char_count': 1002,\n",
              "  'chunk_word_count': 170,\n",
              "  'chunk_token_count': 250.5}]"
            ]
          },
          "metadata": {},
          "execution_count": 49
        }
      ],
      "source": [
        "random.sample(pages_and_chunks, k=1)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 300
        },
        "id": "hzLVbDgFhbFl",
        "outputId": "39b2bf41-fc82-4dee-ba37-7e3e842e1a29"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "       page_number  chunk_char_count  chunk_word_count  chunk_token_count\n",
              "count       210.00            210.00            210.00             210.00\n",
              "mean         52.68           1028.97            165.35             257.24\n",
              "std          31.08            715.01            110.27             178.75\n",
              "min           1.00              0.00              1.00               0.00\n",
              "25%          26.25            440.75             75.25             110.19\n",
              "50%          54.00            911.50            151.50             227.88\n",
              "75%          78.00           1526.25            229.25             381.56\n",
              "max         111.00           3039.00            535.00             759.75"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-57ace00d-709a-4c78-85b3-c237f4f7ee4d\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>page_number</th>\n",
              "      <th>chunk_char_count</th>\n",
              "      <th>chunk_word_count</th>\n",
              "      <th>chunk_token_count</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>count</th>\n",
              "      <td>210.00</td>\n",
              "      <td>210.00</td>\n",
              "      <td>210.00</td>\n",
              "      <td>210.00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>mean</th>\n",
              "      <td>52.68</td>\n",
              "      <td>1028.97</td>\n",
              "      <td>165.35</td>\n",
              "      <td>257.24</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>std</th>\n",
              "      <td>31.08</td>\n",
              "      <td>715.01</td>\n",
              "      <td>110.27</td>\n",
              "      <td>178.75</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>min</th>\n",
              "      <td>1.00</td>\n",
              "      <td>0.00</td>\n",
              "      <td>1.00</td>\n",
              "      <td>0.00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>25%</th>\n",
              "      <td>26.25</td>\n",
              "      <td>440.75</td>\n",
              "      <td>75.25</td>\n",
              "      <td>110.19</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>50%</th>\n",
              "      <td>54.00</td>\n",
              "      <td>911.50</td>\n",
              "      <td>151.50</td>\n",
              "      <td>227.88</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>75%</th>\n",
              "      <td>78.00</td>\n",
              "      <td>1526.25</td>\n",
              "      <td>229.25</td>\n",
              "      <td>381.56</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>max</th>\n",
              "      <td>111.00</td>\n",
              "      <td>3039.00</td>\n",
              "      <td>535.00</td>\n",
              "      <td>759.75</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-57ace00d-709a-4c78-85b3-c237f4f7ee4d')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-57ace00d-709a-4c78-85b3-c237f4f7ee4d button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-57ace00d-709a-4c78-85b3-c237f4f7ee4d');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-e443f296-3af5-4ed4-ae4b-4d85363528cd\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-e443f296-3af5-4ed4-ae4b-4d85363528cd')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-e443f296-3af5-4ed4-ae4b-4d85363528cd button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "summary": "{\n  \"name\": \"df\",\n  \"rows\": 8,\n  \"fields\": [\n    {\n      \"column\": \"page_number\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 65.56218562501232,\n        \"min\": 1.0,\n        \"max\": 210.0,\n        \"num_unique_values\": 8,\n        \"samples\": [\n          52.68,\n          54.0,\n          210.0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"chunk_char_count\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 960.5910949737444,\n        \"min\": 0.0,\n        \"max\": 3039.0,\n        \"num_unique_values\": 8,\n        \"samples\": [\n          1028.97,\n          911.5,\n          210.0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"chunk_word_count\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 159.4975872410435,\n        \"min\": 1.0,\n        \"max\": 535.0,\n        \"num_unique_values\": 8,\n        \"samples\": [\n          165.35,\n          151.5,\n          210.0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"chunk_token_count\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 228.17709353153748,\n        \"min\": 0.0,\n        \"max\": 759.75,\n        \"num_unique_values\": 8,\n        \"samples\": [\n          257.24,\n          227.88,\n          210.0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 50
        }
      ],
      "source": [
        "df = pd.DataFrame(pages_and_chunks)\n",
        "df.describe().round(2)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 206
        },
        "id": "JO6-dksxhcdG",
        "outputId": "b2785c30-00c9-4f6a-87fe-9b7fd2e21e78"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "   page_number                                     sentence_chunk  \\\n",
              "0            1  HIGHLIGHTS OF PRESCRIBING INFORMATION \\nThese ...   \n",
              "1            1  • Juvenile Idiopathic Arthritis (JIA) (1.2): r...   \n",
              "2            1  Juvenile Idiopathic Arthritis or Pediatric Uve...   \n",
              "3            2  WARNINGS AND PRECAUTIONS \\n• Serious infection...   \n",
              "4            2  6.1) \\n \\nTo report SUSPECTED ADVERSE REACTION...   \n",
              "\n",
              "   chunk_char_count  chunk_word_count  chunk_token_count  \n",
              "0              1643               226             410.75  \n",
              "1              1733               258             433.25  \n",
              "2              2787               535             696.75  \n",
              "3              1232               174             308.00  \n",
              "4              2619               340             654.75  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-e4e3b741-e694-4b9e-8c9e-e68962ee1a92\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>page_number</th>\n",
              "      <th>sentence_chunk</th>\n",
              "      <th>chunk_char_count</th>\n",
              "      <th>chunk_word_count</th>\n",
              "      <th>chunk_token_count</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>1</td>\n",
              "      <td>HIGHLIGHTS OF PRESCRIBING INFORMATION \\nThese ...</td>\n",
              "      <td>1643</td>\n",
              "      <td>226</td>\n",
              "      <td>410.75</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>1</td>\n",
              "      <td>• Juvenile Idiopathic Arthritis (JIA) (1.2): r...</td>\n",
              "      <td>1733</td>\n",
              "      <td>258</td>\n",
              "      <td>433.25</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>1</td>\n",
              "      <td>Juvenile Idiopathic Arthritis or Pediatric Uve...</td>\n",
              "      <td>2787</td>\n",
              "      <td>535</td>\n",
              "      <td>696.75</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>2</td>\n",
              "      <td>WARNINGS AND PRECAUTIONS \\n• Serious infection...</td>\n",
              "      <td>1232</td>\n",
              "      <td>174</td>\n",
              "      <td>308.00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>2</td>\n",
              "      <td>6.1) \\n \\nTo report SUSPECTED ADVERSE REACTION...</td>\n",
              "      <td>2619</td>\n",
              "      <td>340</td>\n",
              "      <td>654.75</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-e4e3b741-e694-4b9e-8c9e-e68962ee1a92')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-e4e3b741-e694-4b9e-8c9e-e68962ee1a92 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-e4e3b741-e694-4b9e-8c9e-e68962ee1a92');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-e66b19c4-4701-45a7-b3fb-a320b10c4ae2\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-e66b19c4-4701-45a7-b3fb-a320b10c4ae2')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-e66b19c4-4701-45a7-b3fb-a320b10c4ae2 button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "df",
              "summary": "{\n  \"name\": \"df\",\n  \"rows\": 210,\n  \"fields\": [\n    {\n      \"column\": \"page_number\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 31,\n        \"min\": 1,\n        \"max\": 111,\n        \"num_unique_values\": 111,\n        \"samples\": [\n          79,\n          11,\n          5\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"sentence_chunk\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 203,\n        \"samples\": [\n          \"The vial does not contain preservatives; therefore, \\ndiscard unused portions. \\n3 DOSAGE FORMS AND STRENGTHS \\nHUMIRA is a clear and colorless solution available as: \\n\\u2022 Pen (HUMIRA Pen) \\nInjection: 80 mg/0.8 mL in a single-dose pen.\\nInjection: 40 mg/0.8 mL in a single-dose pen. \\nInjection: 40 mg/0.4 mL in a single-dose pen. \\n \\n\\u2022 Prefilled Syringe \\nInjection: 80 mg/0.8 mL in a single-dose prefilled glass syringe.\\nInjection: 40 mg/0.8 mL in a single-dose prefilled glass syringe.\\nInjection: 40 mg/0.4 mL in a single-dose prefilled glass syringe.\\nInjection: 20 mg/0.4 mL in a single-dose prefilled glass syringe.\\nInjection: 20 mg/0.2 mL in a single-dose prefilled glass syringe.\\nInjection: 10 mg/0.2 mL in a single-dose prefilled glass syringe.\",\n          \"will be closely monitored and have regular follow-up visits with a physician [see Warnings and \\nPrecautions (5)]. \\n1.8 Hidradenitis Suppurativa \\nHUMIRA is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients \\n12 years of age and older. \\n1.9 Uveitis \\nHUMIRA is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis \\nin adults and pediatric patients 2 years of age and older. \\n2 DOSAGE AND ADMINISTRATION \\n2.1 Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis \\nThe recommended subcutaneous dosage of HUMIRA for adult patients with rheumatoid arthritis \\n(RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) is 40 mg administered every other \\nweek. Methotrexate (MTX), other non-biologic DMARDS, glucocorticoids, nonsteroidal anti-\\ninflammatory drugs (NSAIDs), and/or analgesics may be continued during treatment with \\nHUMIRA. In the treatment of RA, some patients not taking concomitant MTX may derive \\nadditional benefit from increasing the dosage of HUMIRA to 40 mg every week or 80 mg every \\nother week. \\n2.2 Juvenile Idiopathic Arthritis or Pediatric Uveitis \\nThe recommended subcutaneous dosage of HUMIRA for patients 2 years of age and older with \\npolyarticular juvenile idiopathic arthritis (JIA) or pediatric uveitis is based on weight as shown \\nbelow. MTX, glucocorticoids, NSAIDs, and/or analgesics may be continued during treatment \\nwith HUMIRA. \\n \\n \\nPediatric Weight \\n(2 Years of Age and older) \\nRecommended Dosage \\n10 kg (22 lbs) to less than 15 kg (33 lbs) \\n10 mg every other week \\n15 kg (33 lbs) to less than 30 kg (66 lbs) \\n20 mg every other week \\n30 kg (66 lbs) and greater \\n40 mg every other week \\n \\n \\nHUMIRA has not been studied in patients with polyarticular JIA or pediatric uveitis less than 2 \\nyears of age or in patients with a weight below 10 kg. \\n2.3 Crohn\\u2019s Disease \\nAdults \\nThe recommended subcutaneous dosage of HUMIRA for adult patients with Crohn\\u2019s disease \\n(CD) is 160 mg initially on Day 1 (given in one day or split over two consecutive days), \\nfollowed by 80 mg two weeks later (Day 15).\",\n          \"\\u2022 Your doctor should check you closely for signs and symptoms of TB during treatment with \\nHUMIRA.\\nYou should not start taking HUMIRA if you have any kind of infection unless your doctor says it \\nis okay. \\nBefore starting HUMIRA, tell your doctor if you: \\n\\u2022 think you have an infection or have symptoms of an infection such as: \\n \\n\\u25e6 fever, sweats, or chills \\n\\u25e6 muscle aches \\n\\u25e6 cough \\n\\u25e6 shortness of breath \\n\\u25e6 blood in phlegm \\n\\u25e6 warm, red, or painful skin or sores on \\nyour body \\n\\u25e6 diarrhea or stomach pain \\n\\u25e6 burning when you urinate or urinate \\nmore often than normal \\n\\u25e6 feel very tired \\n\\u25e6 weight loss \\n\\u2022 are being treated for an infection.\\n\\u2022 get a lot of infections or have infections that keep coming back.\\n\\u2022 have diabetes.\\n\\u2022 have TB, or have been in close contact with someone with TB.\\n\\u2022 were born in, lived in, or traveled to countries where there is more risk for getting TB. Ask \\nyour doctor if you are not sure.\\n\\u2022 live or have lived in certain parts of the country (such as the Ohio and Mississippi River \\nvalleys) where there is an increased risk for getting certain kinds of fungal infections \\n(histoplasmosis, coccidioidomycosis, or blastomycosis). These infections may happen or \\nbecome more severe if you use HUMIRA.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"chunk_char_count\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 715,\n        \"min\": 0,\n        \"max\": 3039,\n        \"num_unique_values\": 193,\n        \"samples\": [\n          2315,\n          469,\n          1236\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"chunk_word_count\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 110,\n        \"min\": 1,\n        \"max\": 535,\n        \"num_unique_values\": 164,\n        \"samples\": [\n          230,\n          120,\n          150\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"chunk_token_count\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 178.7519738963742,\n        \"min\": 0.0,\n        \"max\": 759.75,\n        \"num_unique_values\": 193,\n        \"samples\": [\n          578.75,\n          117.25,\n          309.0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 51
        }
      ],
      "source": [
        "df.head()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "hONe-cF7hfBO",
        "outputId": "d4feca8e-b3a9-4f53-e7d9-c266e9419a79"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Chunk token count: 0.5 | Text: In\n",
            "Chunk token count: 27.5 | Text: Revised 02/2021 \n",
            "Manufactured by AbbVie Inc. North Chicago, IL 60064 U. S. A. \n",
            "US License Number 1889 20066945\n",
            "Chunk token count: 0.0 | Text: \n",
            "Chunk token count: 0.0 | Text: \n",
            "Chunk token count: 12.0 | Text: Two weeks later (Day 29) begin a dosage of 40 mg\n"
          ]
        }
      ],
      "source": [
        "# Show random chunks with under 30 tokens in length\n",
        "min_token_length = 30\n",
        "for row in df[df[\"chunk_token_count\"] <= min_token_length].sample(5).iterrows():\n",
        "    print(f'Chunk token count: {row[1][\"chunk_token_count\"]} | Text: {row[1][\"sentence_chunk\"]}')"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "mjWJdVHfhhkQ",
        "outputId": "a48622c3-997d-474b-a8bc-e42a191ebddf"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[{'page_number': 1,\n",
              "  'sentence_chunk': 'HIGHLIGHTS OF PRESCRIBING INFORMATION \\nThese highlights do not include all the information needed to use \\nHUMIRA safely and effectively. See full prescribing information for \\nHUMIRA.\\n \\nHUMIRA® (adalimumab) injection, for subcutaneous use \\nInitial U. S. Approval: 2002 \\n \\nWARNING: SERIOUS INFECTIONS AND MALIGNANCY \\nSee full prescribing information for complete boxed warning.\\nSERIOUS INFECTIONS (5.1, 6.1): \\n• Increased risk of serious infections leading to hospitalization or \\ndeath, including tuberculosis (TB), bacterial sepsis, invasive \\nfungal infections (such as histoplasmosis), and infections due to \\nother opportunistic pathogens.\\n• Discontinue HUMIRA if a patient develops a serious infection or \\nsepsis during treatment.\\n• Perform test for latent TB; if positive, start treatment for TB \\nprior to starting HUMIRA.\\n• Monitor all patients for active TB during treatment, even if initial \\nlatent TB test is negative. \\nMALIGNANCY (5.2): \\n• Lymphoma and other malignancies, some fatal, have been \\nreported in children and adolescent patients treated with TNF \\nblockers including HUMIRA.\\n• Post-marketing cases of hepatosplenic T-cell lymphoma \\n(HSTCL), a rare type of T-cell lymphoma, have occurred in \\nadolescent and young adults with inflammatory bowel disease \\ntreated with TNF blockers including HUMIRA. \\n \\n INDICATIONS AND USAGE \\nHUMIRA is a tumor necrosis factor (TNF) blocker indicated for: \\n• Rheumatoid Arthritis (RA) (1.1): reducing signs and symptoms, inducing \\nmajor clinical response, inhibiting the progression of structural damage, and \\nimproving physical function in adult patients with moderately to severely \\nactive RA.',\n",
              "  'chunk_char_count': 1643,\n",
              "  'chunk_word_count': 226,\n",
              "  'chunk_token_count': 410.75},\n",
              " {'page_number': 1,\n",
              "  'sentence_chunk': '• Juvenile Idiopathic Arthritis (JIA) (1.2): reducing signs and symptoms of \\nmoderately to severely active polyarticular JIA in patients 2 years of age \\nand older. \\n• Psoriatic Arthritis (PsA) (1.3): reducing signs and symptoms, inhibiting \\nthe progression of structural damage, and improving physical function in \\nadult patients with active PsA. \\n• Ankylosing Spondylitis (AS) (1.4): reducing signs and symptoms in adult \\npatients with active AS. \\n• Crohn’s Disease (CD) (1.5): treatment of moderately to severely active \\nCrohn’s disease in adults and pediatric patients 6 years of age and older. \\n• Ulcerative Colitis (UC) (1.6): treatment of moderately to severely active \\nulcerative colitis in adults and pediatric patients 5 years of age and older. \\nLimitations of Use: Effectiveness has not been established in patients who \\nhave lost response to or were intolerant to TNF blockers.\\n• Plaque Psoriasis (Ps) (1.7): treatment of adult patients with moderate to \\nsevere chronic plaque psoriasis who are candidates for systemic therapy or \\nphototherapy, and when other systemic therapies are medically less \\nappropriate. \\n• Hidradenitis Suppurativa (HS) (1.8): treatment of moderate to severe \\nhidradenitis suppurativa in patients 12 years of age and older. \\n• Uveitis (UV) (1.9): treatment of non-infectious intermediate, posterior, and \\npanuveitis in adults and pediatric patients 2 years of age and older. \\n \\n DOSAGE AND ADMINISTRATION \\n• Administer by subcutaneous injection (2) \\nRheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis (2.1): \\n• Adults: 40 mg every other week. \\n• Some patients with RA not receiving methotrexate may benefit from \\nincreasing the dosage to 40 mg every week or 80 mg every other \\nweek.',\n",
              "  'chunk_char_count': 1733,\n",
              "  'chunk_word_count': 258,\n",
              "  'chunk_token_count': 433.25}]"
            ]
          },
          "metadata": {},
          "execution_count": 53
        }
      ],
      "source": [
        "# Filter our DataFrame for rows with under 30 tokens\n",
        "pages_and_chunks_over_min_token_len = df[df[\"chunk_token_count\"] > min_token_length].to_dict(orient=\"records\")\n",
        "pages_and_chunks_over_min_token_len[:2]"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "pqNNSoI0hkVq",
        "outputId": "b538a432-c1ec-4cde-8ffa-8d63cf45c06c"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[{'page_number': 106,\n",
              "  'sentence_chunk': '• Do not store HUMIRA in extreme heat or \\ncold. \\n \\nKeep HUMIRA, injection supplies, and all other medicines out of reach of children.\\nRead Instructions on All Pages Before Using the HUMIRA Single-Dose Prefilled Syringe',\n",
              "  'chunk_char_count': 218,\n",
              "  'chunk_word_count': 35,\n",
              "  'chunk_token_count': 54.5}]"
            ]
          },
          "metadata": {},
          "execution_count": 54
        }
      ],
      "source": [
        "random.sample(pages_and_chunks_over_min_token_len, k=1)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "In_7SBBHhm5C",
        "outputId": "7344c2d1-fd38-495b-be60-6747196e9da6"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: sentence_transformers in /usr/local/lib/python3.11/dist-packages (3.4.1)\n",
            "Requirement already satisfied: transformers<5.0.0,>=4.41.0 in /usr/local/lib/python3.11/dist-packages (from sentence_transformers) (4.48.3)\n",
            "Requirement already satisfied: tqdm in /usr/local/lib/python3.11/dist-packages (from sentence_transformers) (4.67.1)\n",
            "Requirement already satisfied: torch>=1.11.0 in /usr/local/lib/python3.11/dist-packages (from sentence_transformers) (2.5.1+cu124)\n",
            "Requirement already satisfied: scikit-learn in /usr/local/lib/python3.11/dist-packages (from sentence_transformers) (1.6.1)\n",
            "Requirement already satisfied: scipy in /usr/local/lib/python3.11/dist-packages (from sentence_transformers) (1.13.1)\n",
            "Requirement already satisfied: huggingface-hub>=0.20.0 in /usr/local/lib/python3.11/dist-packages (from sentence_transformers) (0.28.1)\n",
            "Requirement already satisfied: Pillow in /usr/local/lib/python3.11/dist-packages (from sentence_transformers) (11.1.0)\n",
            "Requirement already satisfied: filelock in /usr/local/lib/python3.11/dist-packages (from huggingface-hub>=0.20.0->sentence_transformers) (3.17.0)\n",
            "Requirement already satisfied: fsspec>=2023.5.0 in /usr/local/lib/python3.11/dist-packages (from huggingface-hub>=0.20.0->sentence_transformers) (2024.10.0)\n",
            "Requirement already satisfied: packaging>=20.9 in /usr/local/lib/python3.11/dist-packages (from huggingface-hub>=0.20.0->sentence_transformers) (24.2)\n",
            "Requirement already satisfied: pyyaml>=5.1 in /usr/local/lib/python3.11/dist-packages (from huggingface-hub>=0.20.0->sentence_transformers) (6.0.2)\n",
            "Requirement already satisfied: requests in /usr/local/lib/python3.11/dist-packages (from huggingface-hub>=0.20.0->sentence_transformers) (2.32.3)\n",
            "Requirement already satisfied: typing-extensions>=3.7.4.3 in /usr/local/lib/python3.11/dist-packages (from huggingface-hub>=0.20.0->sentence_transformers) (4.12.2)\n",
            "Requirement already satisfied: networkx in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence_transformers) (3.4.2)\n",
            "Requirement already satisfied: jinja2 in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence_transformers) (3.1.5)\n",
            "Requirement already satisfied: nvidia-cuda-nvrtc-cu12==12.4.127 in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence_transformers) (12.4.127)\n",
            "Requirement already satisfied: nvidia-cuda-runtime-cu12==12.4.127 in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence_transformers) (12.4.127)\n",
            "Requirement already satisfied: nvidia-cuda-cupti-cu12==12.4.127 in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence_transformers) (12.4.127)\n",
            "Requirement already satisfied: nvidia-cudnn-cu12==9.1.0.70 in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence_transformers) (9.1.0.70)\n",
            "Requirement already satisfied: nvidia-cublas-cu12==12.4.5.8 in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence_transformers) (12.4.5.8)\n",
            "Requirement already satisfied: nvidia-cufft-cu12==11.2.1.3 in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence_transformers) (11.2.1.3)\n",
            "Requirement already satisfied: nvidia-curand-cu12==10.3.5.147 in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence_transformers) (10.3.5.147)\n",
            "Requirement already satisfied: nvidia-cusolver-cu12==11.6.1.9 in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence_transformers) (11.6.1.9)\n",
            "Requirement already satisfied: nvidia-cusparse-cu12==12.3.1.170 in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence_transformers) (12.3.1.170)\n",
            "Requirement already satisfied: nvidia-nccl-cu12==2.21.5 in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence_transformers) (2.21.5)\n",
            "Requirement already satisfied: nvidia-nvtx-cu12==12.4.127 in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence_transformers) (12.4.127)\n",
            "Requirement already satisfied: nvidia-nvjitlink-cu12==12.4.127 in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence_transformers) (12.4.127)\n",
            "Requirement already satisfied: triton==3.1.0 in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence_transformers) (3.1.0)\n",
            "Requirement already satisfied: sympy==1.13.1 in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence_transformers) (1.13.1)\n",
            "Requirement already satisfied: mpmath<1.4,>=1.1.0 in /usr/local/lib/python3.11/dist-packages (from sympy==1.13.1->torch>=1.11.0->sentence_transformers) (1.3.0)\n",
            "Requirement already satisfied: numpy>=1.17 in /usr/local/lib/python3.11/dist-packages (from transformers<5.0.0,>=4.41.0->sentence_transformers) (1.26.4)\n",
            "Requirement already satisfied: regex!=2019.12.17 in /usr/local/lib/python3.11/dist-packages (from transformers<5.0.0,>=4.41.0->sentence_transformers) (2024.11.6)\n",
            "Requirement already satisfied: tokenizers<0.22,>=0.21 in /usr/local/lib/python3.11/dist-packages (from transformers<5.0.0,>=4.41.0->sentence_transformers) (0.21.0)\n",
            "Requirement already satisfied: safetensors>=0.4.1 in /usr/local/lib/python3.11/dist-packages (from transformers<5.0.0,>=4.41.0->sentence_transformers) (0.5.2)\n",
            "Requirement already satisfied: joblib>=1.2.0 in /usr/local/lib/python3.11/dist-packages (from scikit-learn->sentence_transformers) (1.4.2)\n",
            "Requirement already satisfied: threadpoolctl>=3.1.0 in /usr/local/lib/python3.11/dist-packages (from scikit-learn->sentence_transformers) (3.5.0)\n",
            "Requirement already satisfied: MarkupSafe>=2.0 in /usr/local/lib/python3.11/dist-packages (from jinja2->torch>=1.11.0->sentence_transformers) (3.0.2)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.11/dist-packages (from requests->huggingface-hub>=0.20.0->sentence_transformers) (3.4.1)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.11/dist-packages (from requests->huggingface-hub>=0.20.0->sentence_transformers) (3.10)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.11/dist-packages (from requests->huggingface-hub>=0.20.0->sentence_transformers) (2.3.0)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.11/dist-packages (from requests->huggingface-hub>=0.20.0->sentence_transformers) (2025.1.31)\n",
            "Sentence: how to use humira in prefilled syrings\n",
            "Embedding: [-2.55657360e-03 -3.05669494e-02  1.68988910e-02 -2.96754912e-02\n",
            " -1.66612566e-02  9.60313901e-03  1.43177938e-02 -3.77670862e-02\n",
            "  3.58540602e-02  2.64036446e-03  1.21128629e-03  1.99122466e-02\n",
            "  3.50778587e-02 -2.32466473e-03  1.27488775e-02  3.42038646e-02\n",
            " -8.02902877e-03 -1.69258267e-02 -4.48584184e-02  1.57773383e-02\n",
            "  1.12181874e-02  2.03912705e-02  9.65969078e-03  1.26845622e-02\n",
            " -1.25365248e-02 -5.23258746e-03 -2.48183068e-02  2.23946646e-02\n",
            "  3.44104730e-02 -8.29056501e-02  5.25778718e-02  5.34655079e-02\n",
            " -2.33757542e-03 -6.65309727e-02  1.15697310e-06 -1.62118152e-02\n",
            "  3.70060951e-02  3.35713699e-02 -4.20633852e-02 -1.22700231e-02\n",
            "  9.90527496e-02 -6.59296336e-03  3.34362909e-02  1.93425249e-02\n",
            " -4.73867096e-02 -4.98499488e-04 -2.27467529e-02 -3.90525982e-02\n",
            "  5.03813401e-02  1.30595434e-02 -1.30070178e-02 -2.48651691e-02\n",
            "  3.84113751e-02  1.53268836e-02 -9.37011675e-04 -6.21402822e-02\n",
            "  1.79286208e-02 -2.30749827e-02  7.35682994e-03  1.20835258e-02\n",
            " -1.82346385e-02  2.70948727e-02 -2.91032065e-03 -1.79735124e-02\n",
            "  2.72254646e-02 -1.92824975e-02 -1.50127569e-02 -4.65501286e-02\n",
            " -1.04927467e-02 -1.52659398e-02 -8.59449990e-03 -3.47537063e-02\n",
            "  2.22030585e-03  4.08209488e-02 -4.82972376e-02 -4.49566729e-02\n",
            " -3.29794176e-02 -3.32444981e-02  3.55586293e-03  2.87275929e-02\n",
            "  8.16478282e-02  2.05620639e-02 -3.37231979e-02  1.74058415e-02\n",
            " -2.08680127e-02 -2.93448605e-02  1.93779990e-02 -1.11615483e-03\n",
            "  4.90683541e-02 -2.02539712e-02 -9.01636574e-03 -5.02625667e-02\n",
            " -2.99880672e-02 -1.98916369e-03  9.98311117e-03  1.09062493e-02\n",
            "  9.97557584e-03 -2.78005423e-03  6.65941834e-02  1.37816425e-02\n",
            " -1.71181783e-02  6.33704290e-02  3.94523814e-02 -8.50007229e-04\n",
            "  1.58241540e-02 -5.29305488e-02  5.57598658e-02  5.83418272e-02\n",
            "  1.90119892e-02  2.11747251e-02 -8.17830116e-03  1.28880432e-02\n",
            " -5.27082104e-03 -2.96118222e-02  1.28661073e-03 -1.93307661e-02\n",
            " -4.67832386e-02 -2.40316242e-02 -4.21599895e-02 -2.50379331e-02\n",
            "  4.39393893e-02 -7.61654833e-03 -2.05454752e-02  2.27230359e-02\n",
            " -1.54258152e-02  1.59093086e-02  3.67351398e-02  4.39601280e-02\n",
            " -3.26535963e-02 -2.20559984e-02 -5.89218596e-03  7.48452730e-03\n",
            " -1.06166722e-02 -2.00972683e-03  2.06323322e-02 -3.84220146e-02\n",
            "  4.09418046e-02  1.15790265e-03 -3.97439487e-02  5.16219363e-02\n",
            "  7.60225654e-02  5.39118098e-03  9.26522166e-03  7.77540654e-02\n",
            "  8.22257530e-03 -2.40658969e-02 -4.36445372e-03  4.11212817e-02\n",
            " -3.58424075e-02  4.71926704e-02 -3.84295546e-02  2.53575910e-02\n",
            " -4.17956151e-02  1.95768885e-02  7.61223910e-03 -2.58718953e-02\n",
            "  5.80512313e-03 -2.98099872e-02 -2.27324497e-02  3.20230983e-02\n",
            " -4.93907407e-02  3.19551043e-02  2.49176584e-02 -5.24741001e-02\n",
            "  2.84967590e-02  2.12417711e-02 -1.65358577e-02  8.82754922e-02\n",
            " -7.69174984e-03 -4.78213616e-02  3.71141499e-03  3.39496396e-02\n",
            "  1.26488227e-02  3.72976586e-02 -3.63932438e-02  4.07744804e-03\n",
            "  1.55200139e-02 -1.04364783e-01  3.48398127e-02 -4.00642678e-02\n",
            "  4.79533225e-02  4.27667238e-03 -7.24799857e-02 -5.40809035e-02\n",
            "  1.32397367e-02  4.11271155e-02  8.00348446e-02  2.29421537e-02\n",
            " -9.40713845e-03 -2.24003233e-02 -1.03165591e-02 -3.86048891e-02\n",
            " -3.61495614e-02  8.41648225e-03  2.00871169e-03  7.23686665e-02\n",
            "  1.11771831e-02 -6.69016968e-03  5.58037609e-02 -4.08430817e-03\n",
            "  4.85972315e-02 -8.40382874e-02 -2.83120703e-02  2.51579322e-02\n",
            " -1.25377625e-02 -1.84132196e-02 -4.48437296e-02 -3.08278911e-02\n",
            " -6.09630160e-02 -1.85624249e-02 -9.35877413e-02 -1.61159802e-02\n",
            " -3.78973298e-02 -7.35340714e-02  3.42522073e-03  6.22892976e-02\n",
            "  1.41953733e-02 -2.41555087e-02  3.82043719e-02  5.78295663e-02\n",
            " -2.89821364e-02  3.57349142e-02  1.29057914e-01  1.30741531e-02\n",
            " -3.28290723e-02 -1.47513812e-02 -2.89013572e-02 -1.38457464e-02\n",
            "  4.81902957e-02 -2.23052129e-03  8.00154172e-03 -1.28100412e-02\n",
            "  5.37665747e-02  3.42330746e-02  5.82159422e-02 -3.71149629e-02\n",
            "  3.63902152e-02 -1.96583513e-02  7.55627034e-03  1.50526483e-02\n",
            " -5.53795509e-03 -2.83305701e-02 -1.25368722e-02  2.09299307e-02\n",
            "  3.38000507e-04  5.40594533e-02  3.97400297e-02 -3.85922682e-03\n",
            "  1.15528260e-03  6.47623045e-03 -8.07553902e-03 -4.58720699e-02\n",
            " -5.26033007e-02  6.96832407e-03 -6.52100220e-02  4.32240553e-02\n",
            " -4.38911989e-02 -2.73252726e-02  3.37269194e-02  8.80508311e-03\n",
            "  1.06417695e-02  2.41006054e-02  8.82864837e-03 -2.83140279e-02\n",
            "  1.28033888e-02  2.46292260e-03 -1.97640229e-02 -1.30849317e-01\n",
            " -2.66459845e-02  4.39647622e-02  2.84815487e-02 -2.77552474e-02\n",
            "  6.85854489e-03 -2.39449623e-03 -2.96826288e-02  2.66597694e-04\n",
            " -1.59906913e-02  1.56078469e-02 -6.79764599e-02 -1.69348158e-02\n",
            "  4.64162938e-02  1.90080106e-02  8.34474433e-03 -1.68504827e-02\n",
            " -2.03549745e-03  3.40198539e-02 -4.14575040e-02  1.44266598e-02\n",
            " -2.31103543e-02 -6.30766079e-02  3.53841595e-02  3.46220247e-02\n",
            "  1.12688337e-02 -2.62305024e-03  2.52818856e-02 -2.54941508e-02\n",
            "  4.43890207e-02  3.13730054e-02 -2.62193028e-02  8.47958960e-03\n",
            " -4.38251235e-02  4.95278239e-02  2.61365473e-02  2.02756058e-02\n",
            "  9.60970577e-03  2.01447550e-02  3.65126207e-02 -8.28805193e-03\n",
            " -1.86653715e-02  1.46015268e-02 -3.36460397e-02 -8.98613967e-03\n",
            " -2.06660642e-03  5.12410663e-02 -2.65573673e-02 -1.39514741e-03\n",
            "  6.54006451e-02 -3.19547877e-02  2.67204065e-02  1.46820359e-02\n",
            "  3.63012776e-02 -4.60587628e-02  1.04911532e-02  2.33264044e-02\n",
            " -3.70938927e-02 -4.84147966e-02 -5.91428811e-03 -4.67310250e-02\n",
            " -1.01115972e-01  1.33338962e-02 -3.61474627e-03 -2.20342465e-02\n",
            " -1.54286372e-02 -4.21039341e-03 -5.68586476e-02 -4.23026085e-02\n",
            "  1.89801138e-02 -6.03196733e-02  1.56631563e-02  1.85955763e-02\n",
            "  9.82525293e-03 -2.71258503e-02 -1.43795377e-02 -6.49272427e-02\n",
            " -3.48959141e-03 -2.44669095e-02  4.98382412e-02  5.41902557e-02\n",
            "  9.41224396e-03  3.88450362e-02 -5.04872613e-02  1.63818020e-02\n",
            "  8.52682907e-03 -2.28888392e-02 -5.65179391e-03 -3.73535044e-02\n",
            "  7.08818668e-03 -7.40534067e-02  1.25824483e-02  2.08005160e-02\n",
            "  1.07102860e-02 -5.43680601e-02  4.00848314e-02 -2.41051912e-02\n",
            "  4.96140623e-04  8.86210278e-02 -1.67794377e-02  2.18105712e-03\n",
            "  3.68071022e-03  3.70883830e-02 -5.95109574e-02  5.89117929e-02\n",
            "  6.48543015e-02  1.08030383e-02  4.94024940e-02 -1.26894098e-04\n",
            " -2.40714364e-02 -9.07937065e-03 -4.65457663e-02 -1.77147482e-02\n",
            " -9.80905630e-03 -6.08719438e-02  1.55170483e-03  7.28165405e-03\n",
            " -2.92210709e-02  3.26496959e-02  2.38426588e-02 -4.26304191e-02\n",
            " -2.88963248e-03  1.80999730e-02 -1.03286123e-02 -4.06476520e-02\n",
            " -1.74416397e-02 -4.82528424e-03  1.98495928e-02 -2.19002664e-02\n",
            "  5.50876372e-02  3.33882449e-03  1.25923846e-02  5.96351363e-02\n",
            "  1.93980336e-02  2.07147542e-02 -6.58342391e-02 -5.27859740e-02\n",
            "  5.40645942e-02 -2.16582101e-02 -4.27834056e-02  7.90787116e-03\n",
            "  6.37263656e-02  1.10840145e-02 -6.31644204e-02  2.56156679e-02\n",
            " -6.11782260e-02 -3.26621495e-02  1.13367112e-02 -1.46988258e-02\n",
            "  5.00757073e-04  4.65982407e-02 -7.96766486e-03 -6.49608672e-02\n",
            " -7.69675672e-02 -1.96940787e-02 -4.22635861e-02  5.70873208e-02\n",
            "  5.27698398e-02 -3.89559567e-02  5.77102229e-02  2.05545295e-02\n",
            " -9.03222337e-03 -5.85485308e-04  4.58992571e-02  6.55626878e-02\n",
            "  4.49916795e-02  9.00345221e-02  8.26560929e-02  9.20587406e-03\n",
            " -1.24033224e-02 -1.46961426e-02  1.05414458e-01  1.29251713e-02\n",
            " -1.05742048e-02  9.03175399e-03  4.97438349e-02  1.32221412e-02\n",
            " -1.24296239e-02 -7.13275094e-03  2.13843957e-02  2.65611522e-02\n",
            "  6.95613795e-04 -2.19042264e-02 -2.24881154e-02 -5.33376522e-02\n",
            " -1.41575588e-02 -6.12788834e-03  8.02536309e-03  1.05579942e-03\n",
            "  6.81938380e-02 -3.29896212e-02 -1.03623271e-02  6.19368181e-02\n",
            " -2.02669837e-02  2.79707834e-02  5.81506966e-03  1.78599693e-02\n",
            "  2.25076489e-02  3.63615565e-02 -7.25356787e-02 -2.72268411e-02\n",
            " -2.74884626e-02 -4.25601341e-02  4.23738221e-03  1.46086449e-02\n",
            " -1.08049102e-02  4.73023765e-02 -2.16977447e-02  9.84886661e-03\n",
            " -2.17280127e-02  1.73595417e-02 -4.59546000e-02 -3.81159484e-02\n",
            " -5.94172813e-03 -5.67797385e-03 -3.11632156e-02  4.91219983e-02\n",
            " -1.00451512e-02  4.32030968e-02  4.99936789e-02 -4.36255559e-02\n",
            " -7.09703751e-03 -1.45254768e-02 -1.02861170e-02  4.04434763e-02\n",
            " -1.92282163e-02 -2.62072962e-02 -1.89369805e-02 -3.24402340e-02\n",
            "  8.72052163e-02 -7.92487711e-02  3.17830928e-02 -2.34137736e-02\n",
            "  2.85623353e-02  6.02085553e-02  1.60638820e-02 -5.54457046e-02\n",
            " -4.16126015e-04  1.87675541e-04 -5.84128909e-02  2.36735810e-02\n",
            " -7.21133873e-02 -2.17874590e-02  5.90827167e-02  3.50213088e-02\n",
            " -3.42918001e-02 -2.45738085e-02  2.12012548e-02  5.68138696e-02\n",
            " -2.06035767e-02 -6.89054057e-02 -2.70585250e-02  4.19372655e-02\n",
            "  1.46028372e-02  2.07485296e-02  3.83267808e-03 -1.97239481e-02\n",
            "  8.44966248e-02 -5.41250072e-02  9.54534509e-04 -1.55347623e-02\n",
            " -3.97599638e-02  1.19543048e-02  1.63229089e-02 -1.94927342e-02\n",
            " -3.15782963e-03  1.75652932e-02 -1.32753775e-02 -2.70123295e-02\n",
            "  1.01467341e-01 -4.26574872e-04 -1.09856268e-02 -3.68286949e-03\n",
            " -2.32572667e-02 -3.85777578e-02  2.38475315e-02 -2.53186468e-02\n",
            " -2.24495903e-02  4.47653122e-02 -3.28055322e-02 -5.02556970e-04\n",
            "  2.63595562e-02 -5.29014273e-03  3.37410048e-02  6.26102313e-02\n",
            "  3.32809836e-02 -2.34934259e-02  5.42988144e-02 -4.50241005e-33\n",
            " -3.26938257e-02  2.21001059e-02 -2.60974672e-02 -1.18924364e-01\n",
            "  5.09369671e-02  8.90975147e-02  1.17390566e-02 -4.33014296e-02\n",
            "  2.55781710e-02  5.95044084e-02 -1.31415473e-02 -6.73586084e-03\n",
            "  2.55628731e-02  3.06189544e-02 -7.71320313e-02  4.56485478e-03\n",
            " -2.39443891e-02  2.82136612e-02  1.35297570e-02  2.66606174e-02\n",
            " -2.53982805e-02  8.32934305e-03 -2.29319725e-02  7.49580190e-02\n",
            "  7.98557047e-03 -4.34960537e-02  4.09794673e-02  2.16260273e-02\n",
            " -3.51847224e-02  5.55618182e-02  1.91340894e-02 -6.60711229e-02\n",
            " -6.84013590e-03  5.68677597e-02 -4.41910923e-02  8.96224752e-02\n",
            " -1.51653169e-02 -2.23130379e-02  6.58225315e-03 -9.85248294e-03\n",
            " -4.19704840e-02 -4.68106911e-04 -3.81701402e-02 -2.80460063e-02\n",
            " -1.04004806e-02  5.02623543e-02 -1.45903165e-02  5.16729355e-02\n",
            "  5.20349815e-02 -3.14972550e-02 -5.42756841e-02 -3.90292332e-03\n",
            "  4.58430089e-02 -6.91954345e-02  1.03055220e-02 -1.53480843e-02\n",
            "  2.06547696e-02  1.83443185e-02  7.29785711e-02  4.06160997e-03\n",
            " -1.19366776e-02  3.30224400e-03 -1.59140620e-02 -9.96386353e-03\n",
            " -2.79717408e-02 -3.53131704e-02 -6.83458000e-02 -4.17703092e-02\n",
            "  2.91722640e-02 -1.62355732e-02 -1.45016098e-02 -8.56072009e-02\n",
            "  2.82158460e-02 -1.60166714e-02  3.39258499e-02  3.55897322e-02\n",
            " -1.74373798e-02 -2.49549467e-02 -4.05061319e-02  4.03973535e-02\n",
            " -3.10286898e-02  7.92993605e-03 -5.50615322e-03 -3.75691392e-02\n",
            " -1.34343635e-02 -3.75444517e-02 -1.92309022e-02  1.27094407e-02\n",
            "  1.82892401e-02 -8.22935440e-03 -6.75323140e-03  3.29575837e-02\n",
            "  1.59073927e-04  2.12073587e-02  2.64710560e-02  2.57989783e-02\n",
            "  2.10447572e-02  4.40196280e-04  1.73328929e-02 -4.22881451e-03\n",
            "  1.54258450e-02  5.87627338e-03  6.98389411e-02 -4.25233208e-02\n",
            "  1.41784630e-03  9.78694647e-04 -8.36111046e-03  1.61859971e-02\n",
            " -7.77194602e-03  2.08477695e-02  1.56658385e-02  4.84130308e-02\n",
            "  5.67630976e-02  1.68959685e-02 -1.42771313e-02  4.73404713e-02\n",
            "  9.39982478e-03 -1.93755142e-02 -1.71938855e-02 -6.35038242e-02\n",
            "  2.39672344e-02 -5.99474646e-04  4.89438418e-03  2.86679324e-02\n",
            " -1.75313409e-02 -9.71434230e-04 -3.77270090e-03  2.96802409e-02\n",
            " -1.44672198e-02 -3.15688066e-02  1.24881119e-02 -1.38221812e-02\n",
            "  1.84362435e-07  5.46362698e-02  1.74535792e-02 -1.69853978e-02\n",
            " -1.18176229e-02 -3.29028256e-02 -4.44402769e-02 -2.29400769e-02\n",
            "  2.34848782e-02 -5.17066941e-02 -4.46461774e-02  2.89505180e-02\n",
            "  2.68761013e-02 -1.61829814e-02  4.32371115e-03 -7.39906505e-02\n",
            " -1.04286604e-01  5.24429716e-02 -5.29379845e-02 -1.42999773e-03\n",
            "  1.83665100e-02  4.84963180e-03  3.61525454e-02  6.56017847e-03\n",
            " -4.16396521e-02 -1.40528344e-02 -1.80730224e-02 -6.52910676e-03\n",
            " -1.77130923e-02 -2.81070247e-02  3.71378399e-02 -2.74845008e-02\n",
            " -1.46065634e-02 -1.08834095e-02  5.35309091e-02 -1.72265363e-03\n",
            " -1.80505570e-02  3.26934271e-02  1.97045580e-02 -5.64956851e-02\n",
            " -9.77016985e-03  1.89207308e-02 -1.57887340e-02 -1.75045971e-02\n",
            " -3.82914431e-02 -3.80468108e-02  1.62402373e-02 -1.56831574e-02\n",
            " -5.45527600e-02  2.14207564e-02  5.73862297e-03  6.22281395e-02\n",
            " -2.58309506e-02 -4.67613637e-02  3.34249139e-02  1.14515265e-02\n",
            "  2.95781735e-02 -1.61474515e-02 -2.78288573e-02  4.47660461e-02\n",
            " -4.83029336e-02 -2.68453397e-02 -4.35828529e-02  6.49095327e-02\n",
            " -1.28426785e-02  8.94417614e-03 -3.55164334e-02  2.34643072e-02\n",
            "  1.57013157e-34  1.98987499e-02 -3.89866754e-02  9.92443413e-03\n",
            "  3.44942845e-02  6.71714693e-02 -1.05735101e-02  2.80259876e-03\n",
            "  4.05523516e-02  3.26818489e-02 -7.56511763e-02  5.58791682e-03]\n",
            "\n"
          ]
        }
      ],
      "source": [
        "!pip install sentence_transformers\n",
        "from sentence_transformers import SentenceTransformer\n",
        "embedding_model = SentenceTransformer(model_name_or_path=\"all-mpnet-base-v2\",\n",
        "                                      device=\"cpu\")\n",
        "\n",
        "# Create a list of sentences\n",
        "sentences = [\"how to use humira in prefilled syrings\"]\n",
        "\n",
        "# Sentences are encoded/embedded by calling model.encode()\n",
        "embeddings = embedding_model.encode(sentences)\n",
        "embeddings_dict = dict(zip(sentences, embeddings))\n",
        "\n",
        "# See the embeddings\n",
        "for sentence, embedding in embeddings_dict.items():\n",
        "    print(f\"Sentence: {sentence}\")\n",
        "    print(f\"Embedding: {embedding}\")\n",
        "    print(\"\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "ixR6KFS8irpF",
        "outputId": "07146379-de43-4b26-a398-b5f3c0cddc49"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: sentence_transformers in /usr/local/lib/python3.11/dist-packages (3.4.1)\n",
            "Requirement already satisfied: transformers<5.0.0,>=4.41.0 in /usr/local/lib/python3.11/dist-packages (from sentence_transformers) (4.48.3)\n",
            "Requirement already satisfied: tqdm in /usr/local/lib/python3.11/dist-packages (from sentence_transformers) (4.67.1)\n",
            "Requirement already satisfied: torch>=1.11.0 in /usr/local/lib/python3.11/dist-packages (from sentence_transformers) (2.5.1+cu124)\n",
            "Requirement already satisfied: scikit-learn in /usr/local/lib/python3.11/dist-packages (from sentence_transformers) (1.6.1)\n",
            "Requirement already satisfied: scipy in /usr/local/lib/python3.11/dist-packages (from sentence_transformers) (1.13.1)\n",
            "Requirement already satisfied: huggingface-hub>=0.20.0 in /usr/local/lib/python3.11/dist-packages (from sentence_transformers) (0.28.1)\n",
            "Requirement already satisfied: Pillow in /usr/local/lib/python3.11/dist-packages (from sentence_transformers) (11.1.0)\n",
            "Requirement already satisfied: filelock in /usr/local/lib/python3.11/dist-packages (from huggingface-hub>=0.20.0->sentence_transformers) (3.17.0)\n",
            "Requirement already satisfied: fsspec>=2023.5.0 in /usr/local/lib/python3.11/dist-packages (from huggingface-hub>=0.20.0->sentence_transformers) (2024.10.0)\n",
            "Requirement already satisfied: packaging>=20.9 in /usr/local/lib/python3.11/dist-packages (from huggingface-hub>=0.20.0->sentence_transformers) (24.2)\n",
            "Requirement already satisfied: pyyaml>=5.1 in /usr/local/lib/python3.11/dist-packages (from huggingface-hub>=0.20.0->sentence_transformers) (6.0.2)\n",
            "Requirement already satisfied: requests in /usr/local/lib/python3.11/dist-packages (from huggingface-hub>=0.20.0->sentence_transformers) (2.32.3)\n",
            "Requirement already satisfied: typing-extensions>=3.7.4.3 in /usr/local/lib/python3.11/dist-packages (from huggingface-hub>=0.20.0->sentence_transformers) (4.12.2)\n",
            "Requirement already satisfied: networkx in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence_transformers) (3.4.2)\n",
            "Requirement already satisfied: jinja2 in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence_transformers) (3.1.5)\n",
            "Requirement already satisfied: nvidia-cuda-nvrtc-cu12==12.4.127 in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence_transformers) (12.4.127)\n",
            "Requirement already satisfied: nvidia-cuda-runtime-cu12==12.4.127 in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence_transformers) (12.4.127)\n",
            "Requirement already satisfied: nvidia-cuda-cupti-cu12==12.4.127 in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence_transformers) (12.4.127)\n",
            "Requirement already satisfied: nvidia-cudnn-cu12==9.1.0.70 in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence_transformers) (9.1.0.70)\n",
            "Requirement already satisfied: nvidia-cublas-cu12==12.4.5.8 in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence_transformers) (12.4.5.8)\n",
            "Requirement already satisfied: nvidia-cufft-cu12==11.2.1.3 in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence_transformers) (11.2.1.3)\n",
            "Requirement already satisfied: nvidia-curand-cu12==10.3.5.147 in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence_transformers) (10.3.5.147)\n",
            "Requirement already satisfied: nvidia-cusolver-cu12==11.6.1.9 in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence_transformers) (11.6.1.9)\n",
            "Requirement already satisfied: nvidia-cusparse-cu12==12.3.1.170 in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence_transformers) (12.3.1.170)\n",
            "Requirement already satisfied: nvidia-nccl-cu12==2.21.5 in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence_transformers) (2.21.5)\n",
            "Requirement already satisfied: nvidia-nvtx-cu12==12.4.127 in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence_transformers) (12.4.127)\n",
            "Requirement already satisfied: nvidia-nvjitlink-cu12==12.4.127 in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence_transformers) (12.4.127)\n",
            "Requirement already satisfied: triton==3.1.0 in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence_transformers) (3.1.0)\n",
            "Requirement already satisfied: sympy==1.13.1 in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence_transformers) (1.13.1)\n",
            "Requirement already satisfied: mpmath<1.4,>=1.1.0 in /usr/local/lib/python3.11/dist-packages (from sympy==1.13.1->torch>=1.11.0->sentence_transformers) (1.3.0)\n",
            "Requirement already satisfied: numpy>=1.17 in /usr/local/lib/python3.11/dist-packages (from transformers<5.0.0,>=4.41.0->sentence_transformers) (1.26.4)\n",
            "Requirement already satisfied: regex!=2019.12.17 in /usr/local/lib/python3.11/dist-packages (from transformers<5.0.0,>=4.41.0->sentence_transformers) (2024.11.6)\n",
            "Requirement already satisfied: tokenizers<0.22,>=0.21 in /usr/local/lib/python3.11/dist-packages (from transformers<5.0.0,>=4.41.0->sentence_transformers) (0.21.0)\n",
            "Requirement already satisfied: safetensors>=0.4.1 in /usr/local/lib/python3.11/dist-packages (from transformers<5.0.0,>=4.41.0->sentence_transformers) (0.5.2)\n",
            "Requirement already satisfied: joblib>=1.2.0 in /usr/local/lib/python3.11/dist-packages (from scikit-learn->sentence_transformers) (1.4.2)\n",
            "Requirement already satisfied: threadpoolctl>=3.1.0 in /usr/local/lib/python3.11/dist-packages (from scikit-learn->sentence_transformers) (3.5.0)\n",
            "Requirement already satisfied: MarkupSafe>=2.0 in /usr/local/lib/python3.11/dist-packages (from jinja2->torch>=1.11.0->sentence_transformers) (3.0.2)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.11/dist-packages (from requests->huggingface-hub>=0.20.0->sentence_transformers) (3.4.1)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.11/dist-packages (from requests->huggingface-hub>=0.20.0->sentence_transformers) (3.10)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.11/dist-packages (from requests->huggingface-hub>=0.20.0->sentence_transformers) (2.3.0)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.11/dist-packages (from requests->huggingface-hub>=0.20.0->sentence_transformers) (2025.1.31)\n",
            "Sentence: Yo! How cool are embeddings?\n",
            "Embedding:\n",
            "[-1.97448116e-02 -4.51077055e-03 -4.98486962e-03  6.55444860e-02\n",
            " -9.87674389e-03  2.72836108e-02  3.66426110e-02 -3.30219767e-03\n",
            "  8.50078650e-03  8.24952498e-03 -2.28497703e-02  4.02430147e-02\n",
            " -5.75200692e-02  6.33691847e-02  4.43207137e-02 -4.49506715e-02\n",
            "  1.25284614e-02 -2.52011847e-02 -3.55293006e-02  1.29559003e-02\n",
            "  8.67021922e-03 -1.92917790e-02  3.55635840e-03  1.89505480e-02\n",
            " -1.47128161e-02 -9.39848833e-03  7.64175924e-03  9.62184742e-03\n",
            " -5.98920882e-03 -3.90168726e-02 -5.47824651e-02 -5.67456335e-03\n",
            "  1.11644426e-02  4.08067517e-02  1.76319088e-06  9.15305596e-03\n",
            " -8.77257995e-03  2.39382870e-02 -2.32784245e-02  8.04999843e-02\n",
            "  3.19176875e-02  5.12598455e-03 -1.47708450e-02 -1.62525177e-02\n",
            " -6.03213124e-02 -4.35689688e-02  4.51211594e-02 -1.79053694e-02\n",
            "  2.63366792e-02 -3.47866528e-02 -8.89172778e-03 -5.47675341e-02\n",
            " -1.24372439e-02 -2.38606706e-02  8.33496898e-02  5.71241677e-02\n",
            "  1.13328267e-02 -1.49595067e-02  9.20377970e-02  2.72710025e-02\n",
            " -1.42185586e-02  1.91208981e-02  1.49963303e-02 -3.12198866e-02\n",
            "  8.99579152e-02  4.51188162e-02  2.58020535e-02 -5.51739102e-03\n",
            "  1.15909716e-02  4.72100899e-02 -1.51019190e-02  1.70818325e-02\n",
            " -7.22596981e-03  3.45763564e-02 -8.76465999e-03  5.22016846e-02\n",
            " -6.49008900e-02 -4.31378335e-02  6.36964813e-02  4.02881242e-02\n",
            " -1.99042782e-02  5.39059704e-03  1.28820529e-02 -4.81255502e-02\n",
            "  4.58800681e-02 -2.17094608e-02  1.89203694e-02 -3.46344374e-02\n",
            " -1.66456699e-02  7.65162846e-03 -2.26693675e-02 -1.96454227e-02\n",
            "  1.87632181e-02  1.01383040e-02  6.85412809e-02 -5.39850304e-03\n",
            " -3.38225579e-03  4.08412963e-02  4.98623997e-02 -1.16485534e-02\n",
            "  8.91738907e-02  4.02785838e-02 -3.64719215e-03  4.37758975e-02\n",
            " -2.96080597e-02 -5.53753832e-03 -2.00208891e-02 -2.01982595e-02\n",
            "  4.59849164e-02  2.29337290e-02 -5.37306331e-02 -3.19279172e-02\n",
            "  1.37536845e-03  6.25036359e-02 -2.18308680e-02 -6.43255934e-02\n",
            " -2.24791840e-02  3.31955217e-02 -3.12837772e-02  5.17936423e-02\n",
            " -2.84003261e-02  2.55067777e-02  3.36493775e-02  7.50668272e-02\n",
            " -4.46472317e-03 -4.87705469e-02 -7.35218897e-02 -5.46353199e-02\n",
            "  8.88524856e-03  2.95797866e-02 -9.95699130e-03 -6.32761279e-03\n",
            "  4.46259752e-02 -1.58483982e-02 -1.71330497e-02  3.36603001e-02\n",
            " -1.57665915e-03 -5.45971878e-02  2.91160922e-02 -2.80596036e-02\n",
            "  2.96793506e-02  5.12153134e-02  1.48765966e-02 -4.76487912e-02\n",
            "  1.26052313e-02  1.49851339e-03  1.33206481e-02 -2.82469429e-02\n",
            " -3.29254642e-02 -8.53569247e-03 -5.27607873e-02  7.29350299e-02\n",
            " -6.41821176e-02 -2.51785177e-03 -9.02637839e-03 -1.10469048e-03\n",
            "  1.57514382e-02  4.30823267e-02  1.12269474e-02 -3.54585350e-02\n",
            "  4.95163240e-02  1.21270753e-02  1.66343944e-03 -5.06922835e-03\n",
            " -1.11001981e-02 -8.66925716e-03 -3.26440036e-02 -3.98021601e-02\n",
            " -2.05970593e-02  1.09074460e-02 -6.62528276e-02  3.71707082e-02\n",
            " -3.74916568e-02 -3.24730650e-02  5.85900694e-02  8.48081112e-02\n",
            "  3.92413139e-02  3.15815173e-02  3.78386192e-02 -1.35472463e-02\n",
            "  5.95062524e-02  2.58904770e-02 -1.31900040e-02  6.30589649e-02\n",
            "  3.27136293e-02  6.92142686e-03 -1.42607335e-02  7.76676536e-02\n",
            " -1.16102919e-02 -3.66428010e-02 -2.83837840e-02  2.72279773e-02\n",
            "  2.49364488e-02 -4.22296487e-03 -3.63100693e-02 -2.04887725e-02\n",
            "  3.98861170e-02 -2.64726747e-02  4.41380590e-03 -5.19635379e-02\n",
            "  1.71031425e-05  4.81284857e-02  2.04450656e-02  9.84970033e-02\n",
            "  3.68267260e-02  1.53404567e-02  7.50978128e-04 -3.38638499e-02\n",
            " -2.69872826e-02  4.72444631e-02  4.56701554e-02 -3.49246487e-02\n",
            " -1.18770609e-02  3.45576694e-03 -6.32300740e-03 -4.78412546e-02\n",
            "  1.84098631e-02 -2.23157462e-02 -3.70727777e-02  5.87339625e-02\n",
            "  6.22731261e-03 -1.46716302e-02  7.29222819e-02  2.21960037e-03\n",
            " -6.53120056e-02  3.51679660e-02 -1.54901426e-02  6.01420999e-02\n",
            " -9.41001624e-03  2.81196851e-02 -1.12652015e-02  5.24159812e-04\n",
            "  1.01888627e-01 -5.69957457e-02 -3.52360681e-02 -5.20478189e-03\n",
            " -8.46638530e-03  1.39209256e-02  1.80780459e-02 -1.10493951e-01\n",
            "  5.13116606e-02 -4.36432101e-02  2.84142829e-02  9.55936499e-03\n",
            "  4.28096876e-02 -3.95833775e-02  5.25829196e-02  1.92814786e-02\n",
            "  3.44885583e-03 -1.76871512e-02  3.85699905e-02  6.92503573e-03\n",
            " -3.59440297e-02 -2.63612997e-02 -4.96697752e-03  4.24525589e-02\n",
            " -4.22464013e-02  3.45900049e-03  3.55866738e-02 -1.68201923e-02\n",
            "  3.54331844e-02  4.52805730e-03  6.46290975e-03 -2.17710938e-02\n",
            " -2.50032954e-02  1.41418697e-02  1.51257757e-02 -2.99570095e-02\n",
            " -3.94227579e-02  1.87821817e-02 -1.68784207e-03 -9.83500038e-04\n",
            " -3.26322019e-02  5.06563019e-03 -8.90461728e-03 -1.55095393e-02\n",
            "  1.87758375e-02 -4.52473201e-02 -1.72957368e-02  3.50973345e-02\n",
            "  1.33018205e-02  1.00633139e-02 -4.36593257e-02 -1.68618988e-02\n",
            " -1.91048421e-02  6.35489821e-02  8.08325410e-03 -1.02532730e-02\n",
            " -4.53626877e-03 -4.60835695e-02 -1.64704248e-02 -6.24686107e-03\n",
            "  2.58868579e-02 -6.39063939e-02 -7.82401394e-03 -2.36076415e-02\n",
            "  2.74617691e-02  5.80534860e-02 -3.40748765e-02  6.46012202e-02\n",
            "  2.00062506e-02 -2.14934926e-02  1.69361029e-02 -5.54070575e-03\n",
            " -2.40397546e-02  3.09444238e-02 -2.34439666e-03  3.02589443e-02\n",
            " -4.57217321e-02  2.00641155e-02 -2.57117227e-02 -1.13377406e-03\n",
            " -3.57524604e-02  6.92953467e-02  2.80848774e-03  3.58742177e-02\n",
            " -1.52722159e-02 -3.41523737e-02  1.80923473e-02  1.65400244e-02\n",
            "  1.31705850e-02 -6.36670925e-03  5.49302921e-02  8.47313832e-03\n",
            " -4.26077433e-02  2.17084587e-02 -4.89023477e-02  1.18851785e-04\n",
            "  5.16287647e-02  7.59220857e-04  1.59222875e-02 -1.61299706e-02\n",
            "  1.44981248e-02  2.19509210e-02  3.02651562e-02 -3.44151333e-02\n",
            " -4.80380096e-02 -3.71689945e-02  4.68194932e-02 -3.46219353e-02\n",
            "  4.74861532e-04 -4.34820950e-02 -1.80125143e-02 -6.44844398e-02\n",
            " -2.66967565e-02  3.63660902e-02 -3.76219675e-02 -1.64600983e-02\n",
            "  2.20248327e-02  2.16080312e-04  3.64510454e-02 -2.76135765e-02\n",
            " -5.87056717e-03  6.97318371e-03 -1.25863450e-03  2.12774165e-02\n",
            "  6.21470995e-03 -3.57214659e-02 -5.09366281e-02  2.85553224e-02\n",
            "  6.48822486e-02  3.45731415e-02 -2.57281270e-02  4.52561444e-03\n",
            " -4.63605747e-02  3.32225338e-02  1.69973925e-03 -1.29355500e-02\n",
            " -3.03734131e-02  1.23608978e-02 -3.17957747e-04  1.66231990e-02\n",
            "  1.04892189e-02  1.71540752e-02  1.88860409e-02 -3.62256467e-02\n",
            "  4.65737768e-02  2.17128210e-02  4.97535989e-02  3.03067546e-02\n",
            "  1.59914012e-03 -6.30024746e-02 -6.34594914e-03  1.07304622e-04\n",
            " -5.56749525e-03  2.37264968e-02 -8.38230271e-03  5.38897254e-02\n",
            " -9.08977017e-02 -1.37359872e-02  1.18454583e-02  3.37257539e-03\n",
            " -2.81855483e-02  1.56333228e-03  2.22415458e-02  6.21023960e-02\n",
            " -8.68119821e-02 -4.40635020e-03 -1.63995549e-02  1.69665273e-02\n",
            " -1.34548452e-02  3.00696120e-03 -2.14618240e-02 -2.09503789e-02\n",
            " -1.39877591e-02 -1.23850694e-02  5.39979152e-02  6.03614561e-02\n",
            "  2.52982210e-02 -1.29661456e-01 -1.08081467e-01 -4.15774900e-03\n",
            " -7.20272539e-03  2.75885276e-02  4.87622321e-02 -2.95970980e-02\n",
            " -4.32555042e-02  2.75215656e-02  1.35718873e-02  3.87699716e-02\n",
            "  2.42039673e-02 -2.70842165e-02  8.59166235e-02 -1.98402982e-02\n",
            " -2.26344205e-02 -6.24927804e-02 -1.56845022e-02  4.11566831e-02\n",
            "  1.66952405e-02  7.97291845e-02 -3.24839242e-02  1.46561884e-03\n",
            " -3.27906273e-02  6.44815490e-02  2.09739413e-02 -7.56986067e-02\n",
            " -1.31789874e-03  2.24045897e-03 -6.60841586e-03 -6.84251785e-02\n",
            " -5.36860572e-03  6.55136183e-02  5.45558985e-03  1.58993863e-02\n",
            " -2.18052231e-02  2.16424419e-03  4.72954288e-03 -7.25655705e-02\n",
            " -1.59349740e-02 -1.05623305e-02  2.70786788e-02  1.93766574e-03\n",
            " -4.45123315e-02  2.89783385e-02  2.43084226e-02 -1.73885785e-02\n",
            " -3.80669758e-02 -3.06799151e-02 -3.24778259e-02 -4.33339184e-04\n",
            "  2.55846083e-02  2.70478483e-02 -1.72519751e-04 -4.93688567e-04\n",
            " -7.12094754e-02  5.69768772e-02  6.61400855e-02 -3.87268104e-02\n",
            " -1.30683519e-02  1.00663211e-02 -2.17740331e-02  1.92212239e-02\n",
            "  7.66691146e-03 -3.86652574e-02 -1.66108645e-02 -3.41467746e-02\n",
            " -1.04185315e-02  1.75906308e-02 -1.23776542e-02 -1.68433841e-02\n",
            " -2.40113102e-02  4.70198505e-03  4.88461461e-03  4.73663509e-02\n",
            "  4.34111953e-02 -8.08343571e-03 -2.48272233e-02 -1.93978269e-02\n",
            " -3.16525102e-02 -1.56419035e-02 -7.79948430e-03  1.28888441e-02\n",
            "  2.61943396e-02  3.65819340e-03  5.79228774e-02  5.43151647e-02\n",
            " -5.05586788e-02  1.78927090e-03 -2.45471150e-02 -2.47595999e-02\n",
            "  3.60356877e-03  1.94152240e-02 -4.23822924e-02 -1.86907277e-02\n",
            "  2.32945494e-02 -3.17982435e-02 -2.60645691e-02 -5.40362298e-03\n",
            " -3.82069871e-02  2.21719909e-02  1.33360280e-02  5.58054484e-02\n",
            " -3.57716866e-02 -3.54791656e-02  1.27723301e-02  6.80177063e-02\n",
            "  5.37152812e-02  2.54151784e-02 -1.16638504e-02 -1.07512977e-02\n",
            " -9.74432100e-03  7.20507465e-03  9.21899080e-03 -4.73684780e-02\n",
            " -3.89389903e-03  3.11453529e-02  3.62331979e-02 -1.65902935e-02\n",
            " -3.63394991e-02  1.95634607e-02 -2.15058494e-02 -7.04767322e-03\n",
            "  9.13175754e-03 -4.05358896e-02 -3.67076248e-02  1.16995938e-01\n",
            "  1.17913887e-01  8.00502896e-02 -1.61983129e-02 -2.00733747e-02\n",
            " -5.54062016e-02 -7.22410306e-02  2.14558002e-02 -4.46405145e-04\n",
            " -1.42903179e-02  8.35540146e-03  3.34207676e-02  1.42891202e-02\n",
            "  4.62512635e-02 -3.53420191e-02  1.68673266e-02 -2.99732201e-03\n",
            " -5.44997007e-02 -4.80719730e-02  9.47561057e-04 -6.29721507e-33\n",
            " -2.30286438e-02 -2.51128357e-02 -5.35218976e-02 -2.09470019e-02\n",
            " -6.79717492e-03 -4.64015529e-02 -4.49633691e-03  1.65114887e-02\n",
            " -1.12677794e-02  1.33013809e-02 -1.72552820e-02 -1.96653586e-02\n",
            "  5.53236343e-03  1.02775376e-02  9.47373686e-04 -2.24022288e-02\n",
            "  5.30364849e-02  7.77775934e-03 -9.48474091e-03  2.25515869e-02\n",
            " -4.34495928e-03  2.25208756e-02  1.98086575e-02 -7.57428482e-02\n",
            " -4.36680904e-03  2.50829905e-02  2.59393696e-02 -3.07077561e-02\n",
            "  7.04764351e-02  8.63500684e-02 -7.75880739e-02  1.59991533e-02\n",
            " -5.04692420e-02  4.88355197e-02  3.74992355e-03 -6.12926669e-04\n",
            " -3.87277901e-02 -2.32235119e-02 -3.63983437e-02 -5.07016154e-03\n",
            "  1.10517768e-02 -3.26515660e-02  3.68386693e-02 -4.54948992e-02\n",
            " -1.18526642e-03  1.92688184e-03  2.18783580e-02  2.71092802e-02\n",
            " -4.06264216e-02  6.99159801e-02 -7.33282045e-02 -8.15295149e-03\n",
            " -1.42555609e-02  3.78038781e-03  1.20974362e-01 -6.68213218e-02\n",
            "  3.05051152e-02  1.24480613e-02 -4.59293984e-02  1.03873098e-02\n",
            " -3.97978052e-02 -1.33042196e-02 -1.59402415e-02 -4.29347157e-02\n",
            "  4.05275710e-02  7.07073808e-02 -4.50928546e-02 -3.62474471e-02\n",
            " -1.87588781e-02  1.60928648e-02  2.12657135e-02  6.70025423e-02\n",
            "  3.25864181e-02  1.51125938e-02  3.20371501e-02 -1.35436170e-02\n",
            "  2.31779981e-02 -1.13125844e-02  1.23795634e-02 -3.73516977e-02\n",
            "  1.55545224e-03  2.15824582e-02 -3.49442437e-02 -2.97690742e-02\n",
            "  2.32397411e-02 -1.25703337e-02 -1.09432973e-02 -8.87968689e-02\n",
            " -2.20183991e-02 -1.18423048e-02 -5.71083613e-02  3.91810127e-02\n",
            " -1.98827125e-02 -5.59270494e-02  7.60342227e-03  2.23641824e-02\n",
            " -1.86267253e-02  3.79805267e-02 -8.79652449e-04 -5.26199490e-02\n",
            "  2.05068011e-03  1.72814839e-02 -4.84028980e-02 -1.87740419e-02\n",
            "  1.91171608e-07  2.06594449e-02  3.03575210e-02  5.71851479e-03\n",
            " -5.33938222e-02 -2.46520881e-02  1.80340782e-02 -3.39978002e-02\n",
            "  3.46113593e-05 -6.40035793e-02  2.50049569e-02 -2.04111841e-02\n",
            " -2.72037974e-03 -3.55961695e-02  2.71923114e-02  6.48940206e-02\n",
            "  9.83432983e-04 -4.38490510e-02 -4.45297174e-02 -7.44889490e-03\n",
            "  1.15205254e-02 -2.91254069e-03 -2.15494987e-02  2.84254062e-03\n",
            "  4.29398939e-02 -6.09041229e-02 -7.86320306e-03 -3.90126230e-03\n",
            "  2.47718305e-07  7.75886059e-04  7.47737065e-02  1.99318118e-03\n",
            " -6.07220875e-03  3.69210728e-02  2.78421324e-02 -5.64900041e-02\n",
            "  1.61058903e-02 -9.50827170e-03 -2.60848785e-03 -2.45737229e-02\n",
            "  1.91390775e-02  5.08195609e-02  2.61258744e-02 -1.03838101e-01\n",
            " -3.05815265e-02 -3.53345163e-02 -4.07038108e-02 -2.19843015e-02\n",
            " -2.24092193e-02  5.05567454e-02  7.22607598e-02  5.54789975e-02\n",
            "  4.89434041e-02  3.37949395e-03 -6.84760064e-02  7.10320659e-03\n",
            "  3.15671461e-03  4.78091799e-02 -7.19795078e-02 -3.30301970e-02\n",
            "  3.19158584e-02  1.76431192e-03 -4.62790132e-02 -1.96378492e-02\n",
            "  1.67493820e-02  4.73603830e-02 -2.09441632e-02  7.10244663e-03\n",
            "  4.53146063e-02 -4.76523638e-02 -4.74881381e-02  1.00799864e-02\n",
            " -8.39594007e-02  3.36930230e-02 -3.72189060e-02  1.19432965e-02\n",
            " -3.16896290e-02 -1.29724119e-03 -1.55541236e-02  1.81727745e-02\n",
            " -1.49368513e-02 -1.70671456e-02 -4.19716686e-02  3.94660467e-03\n",
            " -2.24302057e-02  2.07292736e-02 -4.61415686e-02  8.50217510e-03\n",
            " -2.56864522e-02 -1.65337678e-02 -1.51846372e-02 -1.00041572e-02\n",
            "  2.19642837e-02  2.61104815e-02  7.31359124e-02 -1.83709543e-02\n",
            "  1.93979481e-34 -7.27934530e-03  5.96488127e-03  4.44310270e-02\n",
            "  4.14822660e-02  1.12916902e-02 -1.93217508e-02  4.41879369e-02\n",
            " -8.93792044e-03  3.61120030e-02 -5.52125759e-02 -2.89572161e-02]\n",
            "Embedding size: (768,)\n"
          ]
        }
      ],
      "source": [
        "!pip install sentence_transformers\n",
        "from sentence_transformers import SentenceTransformer\n",
        "embedding_model = SentenceTransformer(model_name_or_path=\"all-mpnet-base-v2\",\n",
        "                                      device=\"cpu\")\n",
        "single_sentence = \"Yo! How cool are embeddings?\"\n",
        "single_embedding = embedding_model.encode(single_sentence)\n",
        "print(f\"Sentence: {single_sentence}\")\n",
        "print(f\"Embedding:\\n{single_embedding}\")\n",
        "print(f\"Embedding size: {single_embedding.shape}\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "vdk8jp8okB8L",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "e53e28fa-0c09-4dc9-8838-64e3117e7ed7"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "100%|██████████| 191/191 [00:04<00:00, 45.02it/s]\n"
          ]
        }
      ],
      "source": [
        "# Send the model to the GPU\n",
        "embedding_model.to(\"cuda\") # requires a GPU installed, for reference on my local machine, I'm using a NVIDIA RTX 4090\n",
        "\n",
        "# Create embeddings one by one on the GPU\n",
        "for item in tqdm(pages_and_chunks_over_min_token_len):\n",
        "    item[\"embedding\"] = embedding_model.encode(item[\"sentence_chunk\"])"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "0IUON6fdkJeg",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "f8e2eee1-90ec-4258-b00e-c22c13e6b57a"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "CPU times: user 3.25 s, sys: 5.77 ms, total: 3.26 s\n",
            "Wall time: 3.16 s\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "tensor([[ 0.0424,  0.0066,  0.0097,  ...,  0.0243, -0.0777, -0.0570],\n",
              "        [ 0.0476, -0.0372,  0.0139,  ...,  0.0442, -0.0236, -0.0444],\n",
              "        [ 0.0317, -0.0542,  0.0144,  ...,  0.0267, -0.0563, -0.0359],\n",
              "        ...,\n",
              "        [ 0.0439,  0.0070,  0.0333,  ...,  0.0116, -0.0492,  0.0160],\n",
              "        [ 0.0417, -0.0117,  0.0101,  ...,  0.0018, -0.0262, -0.0109],\n",
              "        [ 0.0386,  0.0226, -0.0127,  ...,  0.0080, -0.0246, -0.0384]],\n",
              "       device='cuda:0')"
            ]
          },
          "metadata": {},
          "execution_count": 58
        }
      ],
      "source": [
        "%%time\n",
        "text_chunks = [item[\"sentence_chunk\"] for item in pages_and_chunks_over_min_token_len]\n",
        "# Embed all texts in batches\n",
        "text_chunk_embeddings = embedding_model.encode(text_chunks,\n",
        "                                               batch_size=32, # you can use different batch sizes here for speed/performance, I found 32 works well for this use case\n",
        "                                               convert_to_tensor=True) # optional to return embeddings as tensor instead of array\n",
        "\n",
        "text_chunk_embeddings"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "TsxyZn9EkM2-"
      },
      "outputs": [],
      "source": [
        "# Save embeddings to file\n",
        "text_chunks_and_embeddings_df = pd.DataFrame(pages_and_chunks_over_min_token_len)\n",
        "embeddings_df_save_path = \"text_chunks_and_embeddings_df.csv\"\n",
        "text_chunks_and_embeddings_df.to_csv(embeddings_df_save_path, index=False)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "95MhD7KrkP_Q",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 206
        },
        "outputId": "f330718d-bf0b-469b-c857-18aae616d074"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "   page_number                                     sentence_chunk  \\\n",
              "0            1  HIGHLIGHTS OF PRESCRIBING INFORMATION \\nThese ...   \n",
              "1            1  • Juvenile Idiopathic Arthritis (JIA) (1.2): r...   \n",
              "2            1  Juvenile Idiopathic Arthritis or Pediatric Uve...   \n",
              "3            2  WARNINGS AND PRECAUTIONS \\n• Serious infection...   \n",
              "4            2  6.1) \\n \\nTo report SUSPECTED ADVERSE REACTION...   \n",
              "\n",
              "   chunk_char_count  chunk_word_count  chunk_token_count  \\\n",
              "0              1643               226             410.75   \n",
              "1              1733               258             433.25   \n",
              "2              2787               535             696.75   \n",
              "3              1232               174             308.00   \n",
              "4              2619               340             654.75   \n",
              "\n",
              "                                           embedding  \n",
              "0  [ 4.24278118e-02  6.55023102e-03  9.72411223e-...  \n",
              "1  [ 4.75581251e-02 -3.71793509e-02  1.38818892e-...  \n",
              "2  [ 3.17343101e-02 -5.42078987e-02  1.43824583e-...  \n",
              "3  [ 1.90991834e-02 -1.51055853e-03  2.92231571e-...  \n",
              "4  [ 1.33229289e-02 -2.21084952e-02  1.62922137e-...  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-7af4fc41-a8db-425e-b884-db7db907a055\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>page_number</th>\n",
              "      <th>sentence_chunk</th>\n",
              "      <th>chunk_char_count</th>\n",
              "      <th>chunk_word_count</th>\n",
              "      <th>chunk_token_count</th>\n",
              "      <th>embedding</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>1</td>\n",
              "      <td>HIGHLIGHTS OF PRESCRIBING INFORMATION \\nThese ...</td>\n",
              "      <td>1643</td>\n",
              "      <td>226</td>\n",
              "      <td>410.75</td>\n",
              "      <td>[ 4.24278118e-02  6.55023102e-03  9.72411223e-...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>1</td>\n",
              "      <td>• Juvenile Idiopathic Arthritis (JIA) (1.2): r...</td>\n",
              "      <td>1733</td>\n",
              "      <td>258</td>\n",
              "      <td>433.25</td>\n",
              "      <td>[ 4.75581251e-02 -3.71793509e-02  1.38818892e-...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>1</td>\n",
              "      <td>Juvenile Idiopathic Arthritis or Pediatric Uve...</td>\n",
              "      <td>2787</td>\n",
              "      <td>535</td>\n",
              "      <td>696.75</td>\n",
              "      <td>[ 3.17343101e-02 -5.42078987e-02  1.43824583e-...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>2</td>\n",
              "      <td>WARNINGS AND PRECAUTIONS \\n• Serious infection...</td>\n",
              "      <td>1232</td>\n",
              "      <td>174</td>\n",
              "      <td>308.00</td>\n",
              "      <td>[ 1.90991834e-02 -1.51055853e-03  2.92231571e-...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>2</td>\n",
              "      <td>6.1) \\n \\nTo report SUSPECTED ADVERSE REACTION...</td>\n",
              "      <td>2619</td>\n",
              "      <td>340</td>\n",
              "      <td>654.75</td>\n",
              "      <td>[ 1.33229289e-02 -2.21084952e-02  1.62922137e-...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-7af4fc41-a8db-425e-b884-db7db907a055')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-7af4fc41-a8db-425e-b884-db7db907a055 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-7af4fc41-a8db-425e-b884-db7db907a055');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-77c3c360-c71d-4694-865c-1d0920827fbe\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-77c3c360-c71d-4694-865c-1d0920827fbe')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-77c3c360-c71d-4694-865c-1d0920827fbe button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "text_chunks_and_embedding_df_load",
              "summary": "{\n  \"name\": \"text_chunks_and_embedding_df_load\",\n  \"rows\": 191,\n  \"fields\": [\n    {\n      \"column\": \"page_number\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 31,\n        \"min\": 1,\n        \"max\": 111,\n        \"num_unique_values\": 111,\n        \"samples\": [\n          79,\n          11,\n          5\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"sentence_chunk\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 191,\n        \"samples\": [\n          \"It is important that you firmly push the Pen \\ndown all the way against the injection site \\nbefore starting the injection. \\nKeep pushing down to prevent the Pen from \\nmoving away from the skin during the injection. \\nPress the plum activator button and count \\nslowly for 10 seconds. \\n\\u2022 A loud \\u201cclick\\u201d will signal the start of the \\ninjection \\n\\u2022 Keep pushing the Pen down firmly against \\nthe injection site until the injection is \\ncomplete \\n\\u2022 Injection is complete when the yellow \\nindicator has stopped moving \\n \\n  \\n \\nWhen the injection is completed, slowly pull the \\nPen from the skin. The white needle sleeve will \\ncover the needle tip. \\n\\u2022 A small amount of liquid on the injection site \\nis normal \\nIf there are more than a few drops of liquid on \\nthe injection site, call 1-800-4HUMIRA (1-800-\\n448-6472) for help. \\nAfter completing the injection, place a cotton ball \\nor gauze pad on the skin of the injection site. \\n\\u2022 Do not rub \\n\\u2022 Slight bleeding at the injection site is normal\",\n          \"Lumbar flexion (cm) \\n4.1 \\n4.0 \\n4.2 \\n4.4 \\n   Cervical rotation (degrees) \\n42.2 \\n42.1 \\n48.4 \\n51.6 \\n   Lumbar side flexion (cm) \\n8.9 \\n9.0 \\n9.7 \\n11.7 \\n   Intermalleolar distance (cm) \\n92.9 \\n94.0 \\n93.5 \\n100.8 \\nCRPf* \\n2.2 \\n2.0 \\n1.8 \\n0.6 \\na Percent of subjects with at least a 20% and 10-unit improvement measured on a Visual \\nAnalog Scale (VAS) with 0 = \\u201cnone\\u201d and 100 = \\u201csevere\\u201d \\nb mean of questions 5 and 6 of BASDAI (defined in \\u2018d\\u2019) \\nc Bath Ankylosing Spondylitis Functional Index \\nd Bath Ankylosing Spondylitis Disease Activity Index \\ne Bath Ankylosing Spondylitis Metrology Index \\nf C-Reactive Protein (mg/dL) \\n* statistically significant for comparisons between HUMIRA and placebo at Week 24 \\n \\n \\nA second randomized, multicenter, double-blind, placebo-controlled study of 82 patients with \\nankylosing spondylitis showed similar results. \\nPatients treated with HUMIRA achieved improvement from baseline in the Ankylosing \\nSpondylitis Quality of Life Questionnaire (ASQoL) score (-3.6 vs. -1.1) and in the Short Form \\nHealth Survey (SF-36) Physical Component Summary (PCS) score (7.4 vs. 1.9) compared to \\nplacebo-treated patients at Week 24. \\n14.5 Adult Crohn\\u2019s Disease \\nThe safety and efficacy of multiple doses of HUMIRA were assessed in adult patients with \\nmoderately to severely active Crohn\\u2019s disease, CD, (Crohn\\u2019s Disease Activity Index (CDAI) \\u2265 \\n220 and \\u2264 450) in randomized, double-blind, placebo-controlled studies. Concomitant stable \\ndoses of aminosalicylates, corticosteroids, and/or immunomodulatory agents were permitted, and \\n79% of patients continued to receive at least one of these medications. \\nInduction of clinical remission (defined as CDAI < 150) was evaluated in two studies. In Study \\nCD-I, 299 TNF-blocker na\\u00efve patients were randomized to one of four treatment groups: the \\nplacebo group received placebo at Weeks 0 and 2, the 160/80 group received 160 mg HUMIRA \\nat Week 0 and 80 mg at Week 2, the 80/40 group received 80 mg at Week 0 and 40 mg at Week \\n2, and the 40/20 group received 40 mg at Week 0 and 20 mg at Week 2. Clinical results were \\nassessed at Week 4. \\nIn the second induction study, Study CD-II, 325 patients who had lost response to, or were \\nintolerant to, previous infliximab therapy were randomized to receive either 160 mg HUMIRA at \\nWeek 0 and 80 mg at Week 2, or placebo at Weeks 0 and 2. Clinical results were assessed at \\nWeek 4. \\nMaintenance of clinical remission was evaluated in Study CD-III.\",\n          \"Check expiration date on the Pen label. Do not \\nuse the Pen if expiration date has passed. \\nPlace the following on a clean, flat surface: \\n\\u2022 1 single-dose Pen and alcohol swab \\n\\u2022 1 cotton ball or gauze pad (not included) \\n\\u2022 Puncture-resistant sharps disposal \\ncontainer (not included). See Step 9 at the \\nend of this Instructions for Use for \\ninstructions on how to throw away (dispose \\nof) your HUMIRA Pen \\nWash and dry your hands. \\n \\n  \\n \\nChoose an injection site: \\n\\u2022 On the front of your thighs or \\n\\u2022 Your abdomen (belly) at least 2 inches from \\nyour navel (belly button) \\n\\u2022 Different from your last injection site \\nWipe the injection site in a circular motion with \\nthe alcohol swab. \\n\\u2022 Do not inject through clothes \\n\\u2022 Do not inject into skin that is sore, bruised, \\nred, hard, scarred, has stretch marks, or \\nareas with psoriasis plaques \\n \\n  \\n \\nHold the Pen with the Gray Cap #1 facing up.\\nCheck the window. \\n\\u2022 It is normal to see 1 or more bubbles in the \\nwindow \\n\\u2022 Make sure the liquid is clear and colorless \\n\\u2022 Do not use the Pen if the liquid is cloudy, \\ndiscolored, or has flakes or particles in it \\n\\u2022 Do not use the Pen if it has been dropped \\nor crushed\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"chunk_char_count\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 674,\n        \"min\": 128,\n        \"max\": 3039,\n        \"num_unique_values\": 181,\n        \"samples\": [\n          2821,\n          1988,\n          649\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"chunk_word_count\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 103,\n        \"min\": 24,\n        \"max\": 535,\n        \"num_unique_values\": 154,\n        \"samples\": [\n          129,\n          116,\n          222\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"chunk_token_count\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 168.627081775278,\n        \"min\": 32.0,\n        \"max\": 759.75,\n        \"num_unique_values\": 181,\n        \"samples\": [\n          705.25,\n          497.0,\n          162.25\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"embedding\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 191,\n        \"samples\": [\n          \"[ 1.49745261e-02 -5.63175566e-02  1.51777826e-02 -2.54074652e-02\\n -4.60726675e-03  3.89141240e-03  2.29955986e-02 -3.51872742e-02\\n  5.37096057e-03  4.99691702e-02  2.13944912e-02  3.33943665e-02\\n  5.66491522e-02  2.81450152e-02 -2.42673233e-02  7.16634244e-02\\n -4.46091592e-02  1.95769910e-02 -3.58984508e-02 -1.14383660e-02\\n  1.23514635e-02  1.89411975e-02 -3.86537649e-02  4.37193885e-02\\n  9.86952800e-03 -3.10327858e-03 -3.20884325e-02  4.51272689e-02\\n  4.58516516e-02 -7.40813091e-02  1.51917562e-02  5.16445898e-02\\n  9.33631230e-03  1.12565421e-02  1.46944876e-06 -4.72026318e-02\\n  4.29870039e-02  4.04071696e-02 -7.19504282e-02 -6.42497540e-02\\n  3.73262540e-03 -1.23047456e-01  3.73451710e-02 -7.65404804e-03\\n  5.01623377e-03  5.62475361e-02  3.23962048e-02 -2.43204236e-02\\n  3.36513743e-02  1.84816234e-02 -6.80492120e-03  2.36193393e-03\\n  8.70342106e-02 -9.99856833e-03  8.90315790e-03 -5.56315966e-02\\n -1.58037823e-02  2.21724785e-03  5.09722196e-02  6.11705370e-02\\n -7.76062440e-03  1.47568888e-03  1.17843803e-02  8.72870348e-03\\n -3.54059809e-03  1.75771897e-03  3.80149335e-02 -8.01121294e-02\\n -7.65876891e-03 -2.29063798e-02  3.00300810e-02  5.61928609e-03\\n -1.54207795e-04  2.59719491e-02 -4.75139879e-02 -6.40994236e-02\\n -2.47905832e-02 -3.24995816e-02  2.07069814e-02 -1.44221606e-02\\n  3.07154879e-02  1.32590029e-02 -1.86927915e-02 -9.71901789e-03\\n  3.55890580e-02 -3.76488008e-02  2.41991170e-02  1.37071572e-02\\n  1.64358541e-02  3.42902727e-03  7.86590502e-02 -1.35656749e-03\\n -1.27725545e-02  1.23226065e-02 -2.34882981e-02  1.11305853e-02\\n -2.35509966e-02 -5.73754171e-03  3.26222070e-02 -4.02616784e-02\\n  9.16558802e-02  2.49200463e-02  6.32358640e-02  5.25965691e-02\\n  5.66996112e-02 -2.32789945e-02  3.02983280e-02  1.24338437e-02\\n  2.63791978e-02  3.24899368e-02  2.87142023e-02 -1.69047676e-02\\n  1.65555874e-04 -6.25781566e-02  3.12373191e-02  1.72843821e-02\\n -2.49688402e-02 -3.25402096e-02 -6.23860024e-03  3.40315998e-02\\n  2.87295994e-03 -5.52589493e-03  1.56297488e-03 -5.49625047e-02\\n -2.64842771e-02  3.30872126e-02  4.19311151e-02  2.90320236e-02\\n -5.83265014e-02 -4.05457839e-02 -1.88827571e-02 -1.10158464e-02\\n -2.74267867e-02 -5.43959476e-02  7.49154203e-03 -1.01990588e-02\\n  3.91299184e-03  1.49673242e-02 -4.30270396e-02  3.12779844e-02\\n  4.33474034e-02 -3.04988865e-02  4.03906703e-02  3.99819575e-02\\n  1.94411054e-02 -1.19946850e-02  1.79955047e-02 -2.58373376e-02\\n -1.74813159e-02 -1.08767103e-03 -3.56290564e-02 -1.04644801e-02\\n -7.02811331e-02  5.50707476e-03  4.24843021e-02  5.42835973e-04\\n -2.20100004e-02 -4.02050689e-02 -2.43516499e-03  2.33440995e-02\\n  4.00617224e-04 -9.64913808e-04  1.46412235e-02 -3.83326262e-02\\n  5.09549454e-02  4.10509557e-02 -3.67248394e-02  6.99107572e-02\\n -7.74908403e-04 -2.69809049e-02  4.16175835e-02  6.02894370e-03\\n  2.89359652e-02  4.92267199e-02 -2.79248953e-02 -1.33909900e-02\\n  3.57673466e-02 -1.01668604e-01  2.88413130e-02 -5.77537939e-02\\n  1.42991897e-02 -3.34614515e-02 -7.09437951e-02 -3.73161919e-02\\n -4.60609887e-03  4.63345498e-02  5.55855501e-03 -7.70946359e-03\\n -3.80096287e-02 -8.41144565e-03 -7.42605235e-03 -2.29874216e-02\\n -4.94149141e-02 -2.55434997e-02  1.50946602e-02  2.28220988e-02\\n  3.83034386e-02  1.59156173e-02  3.94644476e-02  4.91370074e-02\\n  8.86663701e-03 -7.39183500e-02  2.15938897e-04  4.85463254e-02\\n -4.16784883e-02 -2.48000380e-02  9.48621426e-03 -1.40142255e-02\\n -2.46623363e-02 -1.40137048e-02 -8.30922648e-02 -1.32946623e-02\\n -2.19408125e-02 -5.52534088e-02 -8.11443664e-03  3.29241715e-02\\n  2.22380366e-03 -5.17739682e-03  5.46489954e-02  3.37394550e-02\\n -4.56664572e-03  3.92965488e-02  9.03569385e-02  3.84908058e-02\\n -1.23438872e-01 -1.73128396e-02 -2.49417070e-02 -1.22875208e-02\\n  1.12377349e-02  1.31998947e-02  4.68372405e-02  6.72630360e-03\\n  4.67103198e-02  2.20817905e-02  3.81411426e-02 -4.81610335e-02\\n  1.07470388e-02 -2.40887664e-02  3.84491868e-03  1.91631000e-02\\n  6.15954108e-04  7.74130039e-03 -6.68271165e-03  6.90194825e-03\\n -2.33757161e-02 -6.90627983e-03 -1.18821627e-02  1.05432253e-02\\n  2.38005500e-02  2.74722502e-02 -2.99422909e-02 -2.63128951e-02\\n -5.67372367e-02  1.21260034e-02  1.31975105e-02  2.85527483e-02\\n -1.35166021e-02 -4.41700034e-02 -3.53483334e-02 -1.19093187e-04\\n -1.27217826e-02 -1.14982687e-02  4.82839309e-02 -4.88656349e-02\\n  3.12575698e-02  1.16333496e-02  9.17201303e-03 -3.80511060e-02\\n -1.78813301e-02  4.41878214e-02  8.58161971e-03 -3.08320094e-02\\n  2.92945802e-02  1.75034273e-02 -2.95271557e-02  1.22538405e-02\\n -1.68852452e-02 -1.17164133e-02 -2.86295209e-02 -3.20795700e-02\\n  2.69530378e-02  6.71043098e-02 -2.11536512e-02 -2.63006594e-02\\n  3.09986938e-02  4.07646922e-03 -2.89893206e-02  6.44868985e-03\\n  5.43632079e-03 -2.85667647e-02  5.94603419e-02 -5.74137550e-04\\n -2.91845743e-02 -4.12895158e-02  3.58144380e-02  9.25435405e-03\\n -3.83310728e-02  2.23053899e-02 -1.72142312e-02  3.79073918e-02\\n  1.82515848e-02  9.48955119e-02  3.15834209e-02 -6.81187259e-03\\n -1.90280005e-02  5.87248132e-02  4.86372560e-02 -1.25279219e-03\\n -1.28856432e-02  5.00197113e-02 -1.35178340e-03 -1.86354853e-02\\n  6.39516162e-03  3.01221404e-02  2.37887483e-02  8.49625003e-03\\n  7.72278234e-02 -4.57919873e-02  8.23347736e-03 -2.94302367e-02\\n -2.63537746e-03 -1.30066080e-02  5.89244068e-03  6.23830734e-03\\n -3.82365026e-02 -3.40375714e-02 -5.60849812e-03 -8.58735107e-03\\n -2.12684926e-02 -2.11119689e-02 -1.94494356e-03 -4.03774269e-02\\n -3.10437828e-02  4.59147505e-02  8.04859027e-03 -4.58727032e-02\\n  2.92772092e-02 -4.41858843e-02  2.61845738e-02  8.93598795e-03\\n -1.35127818e-02 -6.44543096e-02 -2.61058901e-02 -5.71482778e-02\\n -7.77069852e-02 -1.25685083e-02  3.89205664e-02  3.14837322e-02\\n  4.53260466e-02  6.72628218e-03 -4.11396706e-03  3.20676900e-02\\n  2.56342459e-02  6.03103312e-03  8.37399450e-04 -4.79067042e-02\\n -3.69435921e-02 -1.93808582e-02  1.06712375e-02  5.89264184e-02\\n  6.33343235e-02 -1.57800205e-02 -5.49320206e-02  2.15392485e-02\\n -4.28580679e-02  5.01420274e-02 -2.81416476e-02 -5.23078106e-02\\n -1.67754237e-02 -2.18805093e-02 -3.25954445e-02  2.87094302e-02\\n -2.02529808e-03 -5.64451050e-03  2.98885014e-02 -3.67997251e-02\\n  8.43664352e-03 -9.36815701e-03 -6.40483126e-02 -2.66464557e-02\\n -4.30166386e-02 -6.31281957e-02 -1.28593408e-02 -1.25727225e-02\\n -1.02811409e-02  1.53811378e-02  5.26910424e-02 -3.42696942e-02\\n -3.14631127e-02  2.85404511e-02 -3.11963330e-03 -6.34478927e-02\\n -3.36664356e-03 -3.94835770e-02  5.41375428e-02 -1.89054366e-02\\n  2.02504620e-02 -2.44522374e-03  1.50884502e-02  4.12085839e-02\\n -1.57242343e-02  5.08770868e-02 -1.07680097e-01 -3.28023024e-02\\n  2.70511191e-02 -3.00375521e-02 -4.95154709e-02 -8.38635303e-03\\n  3.84221077e-02  9.89272743e-02  5.51972724e-02 -4.76447456e-02\\n -3.68724354e-02 -2.89534521e-03  4.84838486e-02  3.33276275e-03\\n  1.54693658e-03  4.07028683e-02 -2.89745117e-03 -6.93534762e-02\\n -5.18929213e-02 -1.42329163e-03 -6.63996041e-02  3.17576937e-02\\n  3.61248180e-02 -1.35352518e-02  5.89686744e-02  5.59081323e-03\\n  7.88812933e-04  1.48370322e-02  3.05693364e-04  8.72585475e-02\\n  2.02559810e-02  9.81976539e-02  5.72462454e-02  4.20899084e-03\\n  1.38110472e-02 -1.43534411e-02 -3.40593942e-02  1.11189000e-02\\n -1.27841933e-02  1.76828988e-02  5.86744808e-02  3.59332673e-02\\n -1.08360890e-02  4.33475710e-02  3.19345258e-02  6.04863018e-02\\n  1.15208775e-02  7.14916037e-03  2.45978255e-02 -9.37616173e-03\\n -5.70448674e-03 -8.25115852e-03  1.15636243e-02 -3.47093605e-02\\n  6.02279119e-02 -1.52526861e-02  1.09181844e-03  4.16759066e-02\\n -5.19334059e-03  3.40915248e-02  3.57829034e-03 -3.29908654e-02\\n  7.04474794e-03 -4.46275733e-02 -1.76539887e-02 -5.44095272e-03\\n -2.89613809e-02 -5.41432649e-02  3.09346933e-02  3.44277243e-03\\n -3.41292731e-02  2.69362032e-02 -3.83270252e-03 -1.41018694e-02\\n  3.14481147e-02 -8.36960748e-02 -7.67390504e-02 -4.96219173e-02\\n  1.38700940e-02  7.28898740e-04 -4.72953320e-02  7.50485733e-02\\n -2.32816376e-02  4.64161560e-02  3.99884880e-02 -2.69630961e-02\\n -1.93219036e-02  2.40264144e-02 -2.89397705e-02 -2.33479291e-02\\n -1.62477177e-02 -1.49260387e-01 -1.18563138e-03 -3.56478952e-02\\n -8.99395999e-03 -7.30166435e-02  1.14718117e-01  2.05037165e-02\\n  4.43384163e-02  6.38088360e-02 -1.70243103e-02  2.98670363e-02\\n -2.86425464e-02 -1.62521261e-03 -4.23874073e-02  2.88509671e-02\\n -4.80979346e-02 -4.72865961e-02  1.49891516e-02  4.70499396e-02\\n -8.24822579e-03  3.24778408e-02  3.02412584e-02  4.73768115e-02\\n -2.53430102e-02 -1.32797835e-02 -1.02853719e-02  6.41119480e-02\\n -1.08839078e-02 -4.09788499e-03  3.83165292e-03 -2.44167410e-02\\n  5.14795855e-02 -1.86616909e-02  1.56749994e-03 -5.25088608e-03\\n -4.34727520e-02 -2.42009829e-03  7.03189801e-03 -1.21210888e-02\\n  5.65020880e-03 -2.58922167e-02 -1.51794055e-03  9.49981064e-03\\n  1.01818152e-01  9.79270600e-03 -2.81111188e-02 -1.32494960e-02\\n  1.13205230e-02 -4.32575904e-02 -1.31147970e-02 -3.18619213e-03\\n -7.87486508e-03  3.72076444e-02 -1.22177303e-02 -1.78491659e-02\\n -2.03480907e-02  3.03888344e-03  2.63141422e-03  6.32364079e-02\\n  1.64113902e-02 -1.63196251e-02  3.35123055e-02 -4.72499652e-33\\n  1.43341850e-02  3.36102839e-03 -5.58599047e-02 -5.63498400e-02\\n  2.01891046e-02  4.79362383e-02 -1.08506519e-03  3.43840905e-02\\n  1.81479938e-02  4.76594716e-02  1.03460671e-02 -1.77774318e-02\\n  3.40626538e-02  2.27353219e-02 -9.83678922e-03  2.14454960e-02\\n  6.10582624e-03  1.89325865e-02 -2.63562594e-02  4.07332852e-02\\n -1.76456552e-02 -2.03315988e-02  8.63479823e-03  5.88186979e-02\\n  3.50094847e-02 -3.68616991e-02  1.87478866e-02  5.66947553e-03\\n  7.17443787e-03  5.30450605e-02  1.06910744e-03 -5.57320490e-02\\n  1.53364288e-02  4.70642336e-02 -1.65932178e-02  4.76131663e-02\\n -5.79282194e-02 -3.21837179e-02 -2.65351720e-02 -7.89552089e-03\\n -8.27390775e-02 -3.39423195e-02  4.42543486e-03 -4.29958738e-02\\n  6.67661056e-03 -1.90588497e-02 -5.42177446e-03  3.59370895e-02\\n -3.22218775e-03 -4.00652625e-02 -2.32654773e-02  2.76212441e-03\\n  2.52180006e-02 -1.13344394e-01  2.01764610e-03 -4.05970253e-02\\n  1.23390565e-02 -1.66220814e-02 -3.98349855e-03  8.96874908e-03\\n -6.69755638e-02 -4.39052619e-02 -5.51779605e-02 -1.56847984e-02\\n -5.84753528e-02 -5.66279478e-02 -8.50308910e-02  7.71302870e-03\\n -1.82040129e-03  2.40587480e-02  3.72091238e-03 -8.05373937e-02\\n -9.08139511e-04 -3.55921350e-02  3.35693881e-02  6.77928030e-02\\n -1.73400249e-02 -1.51407113e-02 -2.68535130e-02  2.48496141e-02\\n -1.56953838e-02 -8.33612122e-03 -3.26746181e-02 -3.74982730e-02\\n -1.15263211e-02 -7.77183026e-02  1.06406650e-02 -1.88347250e-02\\n -1.72669161e-03  2.50957496e-02 -6.68443320e-03 -4.23569605e-03\\n  1.22549967e-03 -1.20844701e-02  2.29853578e-02 -3.36065218e-02\\n  1.18841957e-02  3.69131640e-02  1.03455046e-02 -4.66510840e-02\\n -1.88384410e-02  3.09822019e-02  1.51121218e-04  3.37466039e-02\\n  1.25544406e-02  1.71543229e-02 -4.91205975e-02  9.74428281e-03\\n  3.76708061e-02  1.87410489e-02  8.23925994e-03  3.58824432e-02\\n -3.26422951e-03  3.42263915e-02 -1.97394732e-02  1.43015571e-02\\n  2.00976860e-02  2.37997863e-02  1.19383447e-04  2.00960860e-02\\n  3.12347151e-02  8.69453140e-03  1.02886930e-02  3.95811684e-02\\n -1.66979320e-02  3.80561978e-04  1.28404397e-04  5.65241426e-02\\n -4.34644185e-02  1.25407921e-02  4.04405035e-02 -3.09575330e-02\\n  2.14735280e-07 -3.92896263e-03  1.12743480e-02  2.86075361e-02\\n  5.53601906e-02 -9.71911475e-03 -3.19167711e-02 -4.89754751e-02\\n -2.75451820e-02 -3.66679057e-02 -7.45111108e-02  5.94660342e-02\\n -6.38227444e-03  3.60504934e-03 -1.92828639e-03 -9.65068936e-02\\n -6.77858591e-02  3.86221632e-02  3.35573591e-02 -7.61700375e-03\\n -2.03129034e-02 -1.74891744e-02 -2.24007037e-03  1.71451513e-02\\n -4.48183194e-02 -4.66342606e-02 -3.30260932e-03  1.15613071e-02\\n  1.89204849e-02 -2.11428246e-03 -1.66705996e-02  1.97722800e-02\\n  4.20963615e-02  1.54979760e-02  9.57656465e-03 -3.20314430e-02\\n  3.35081131e-03  4.28361632e-02  5.07741198e-02 -6.70205578e-02\\n  2.24789139e-02  3.66386436e-02 -3.01463660e-02  7.53919547e-03\\n -7.35809729e-02 -1.18527403e-02  1.51110012e-02 -4.59017436e-04\\n -8.14143661e-03  4.76487204e-02  1.03232274e-02  1.00682072e-01\\n -1.88208669e-02 -4.21281233e-02  2.75119562e-02 -4.40392736e-03\\n  8.03843886e-03  1.45930992e-02  1.26520330e-02  5.82990684e-02\\n  1.26398494e-02  2.43110000e-03 -8.04947391e-02  8.01944360e-02\\n -3.76700563e-03 -3.56815122e-02 -4.74887565e-02 -2.19864380e-02\\n  1.54227970e-34  2.07583001e-03 -3.15732509e-02  3.52566242e-02\\n  7.55601330e-03  1.60926189e-02 -8.58805794e-03  8.14851299e-02\\n  4.87839207e-02  3.18301953e-02 -5.70554100e-02  2.17608474e-02]\",\n          \"[ 3.66375335e-02  2.30626133e-03 -2.21605320e-02  3.02405171e-02\\n -2.45429035e-02  3.96712869e-02  1.92884263e-02  7.23213926e-02\\n  8.55077282e-02  3.91872860e-02 -1.05917314e-02  5.77749833e-02\\n  2.73554567e-02 -2.78169531e-02 -1.67829785e-02  4.25703563e-02\\n -5.75888604e-02  1.97716057e-02  6.47317758e-03 -1.11434171e-02\\n -2.94992235e-02 -1.32845831e-03 -4.67871018e-02  1.14080240e-03\\n  1.61907282e-02 -2.43543163e-02  6.79558292e-02 -3.73113528e-02\\n  1.25724245e-02 -6.64999858e-02  1.22134965e-02  2.04167329e-02\\n  1.18119689e-02 -2.94575412e-02  2.52197333e-06 -3.74851227e-02\\n  7.23379711e-03  2.87587121e-02  2.60830466e-02 -3.45101170e-02\\n  4.57443036e-02 -7.97488075e-03  8.32148734e-03  6.13825023e-03\\n -1.90756470e-02 -1.86997261e-02 -6.01303205e-03  2.03219522e-03\\n -9.06346366e-02  1.12724872e-02 -7.61175109e-03 -1.53305707e-02\\n -5.28243668e-02  9.07177757e-03  2.87135271e-03 -7.47668464e-03\\n -2.06125733e-02  1.66656803e-02  1.40030906e-02 -9.76016223e-02\\n -2.93293931e-02  6.51206763e-04 -2.55497126e-03  1.24223055e-02\\n -2.33404990e-02  4.81450818e-02  3.62972878e-02 -4.27910350e-02\\n  3.86904590e-02  1.78735759e-02  4.09268066e-02  4.00325796e-03\\n  2.55414401e-03  2.15225182e-02  1.49743659e-02 -6.13401383e-02\\n -1.67392436e-02 -3.44310068e-02  7.10128294e-03 -2.34310385e-02\\n  7.83365890e-02  5.07516563e-02 -8.77375249e-03 -1.09113818e-02\\n  4.62468974e-02  3.80391348e-03  5.27534215e-03  3.62024605e-02\\n  2.43577659e-02 -1.69879496e-02  7.06352890e-02  2.34181397e-02\\n  2.16219332e-02  1.75590999e-02 -2.97910701e-02  1.67860873e-02\\n  9.34451818e-02 -5.54312300e-03  6.99437857e-02  2.25744536e-03\\n  3.26186642e-02  3.95667702e-02  5.81222773e-02 -6.03485219e-02\\n  2.54889484e-02  3.73087414e-02  3.34771834e-02 -1.60676707e-02\\n -1.80594865e-02  6.08722493e-02  2.57629603e-02  2.79371627e-04\\n -1.16047552e-02 -2.03378852e-02 -9.30335373e-03 -3.24467421e-02\\n -6.36781752e-02  1.19823283e-02  8.56613088e-03  2.34280527e-02\\n  4.56090756e-02  7.06570735e-03  1.55313294e-02  5.24897985e-02\\n  6.63765846e-03  7.43959695e-02  4.47650962e-02  3.88366580e-02\\n  4.36366610e-02 -5.83777577e-02  5.18114455e-02 -5.77119961e-02\\n -3.44400145e-02  1.13897612e-02  1.10224951e-02 -3.25697362e-02\\n  2.35320088e-02 -3.12034395e-02  6.76441491e-02  4.65834253e-02\\n -3.17760706e-02 -2.40096115e-02 -3.02144140e-02 -9.04947927e-04\\n  4.14263047e-02  2.47243866e-02  6.77033048e-03  2.20180489e-02\\n -5.26011363e-02  8.43282416e-03  2.37728353e-03 -1.71352527e-03\\n -7.01231956e-02  4.83982861e-02  5.43642342e-02 -4.21645818e-03\\n -2.71436814e-02 -4.98976186e-02  7.70489732e-03  1.84927844e-02\\n  1.83805916e-02  6.50418922e-03 -2.95301881e-02 -1.38691049e-02\\n -5.17707765e-02  5.37576303e-02  2.86475513e-02  1.05678678e-01\\n -3.80810164e-02  1.64880697e-02 -1.10194251e-01  1.29452329e-02\\n -1.32484147e-02  7.37720132e-02  3.04329116e-02 -3.06704976e-02\\n -8.79296288e-03 -1.15580307e-02 -4.96923886e-02 -7.19072148e-02\\n  4.19665463e-02 -9.98758804e-03  2.02732775e-02  5.93132921e-04\\n  9.77778248e-03  2.71052402e-02  2.08078232e-02  2.89506000e-02\\n  3.54128634e-03 -2.45740023e-02 -3.72083262e-02 -7.08510401e-03\\n -2.74470635e-02  6.39178697e-03 -3.56862284e-02  1.57378074e-02\\n -2.64538750e-02 -3.83262672e-02  3.60052511e-02 -3.78741622e-02\\n  3.11435293e-02 -1.39962686e-02  8.32537748e-03  2.23873034e-02\\n -1.15454076e-02  9.27409995e-03  1.25328805e-02  5.58677781e-03\\n -6.57569915e-02 -2.91552376e-02 -1.67231467e-02 -1.14338538e-02\\n  3.67336418e-03 -2.18657684e-02  4.31006588e-02  6.07391773e-03\\n  4.12697531e-02 -1.81066412e-02  1.01053556e-02 -9.14783310e-03\\n -2.22142451e-02  1.01672662e-02 -6.07722998e-03 -3.03523825e-03\\n  2.02234015e-02  5.10931239e-02  3.57196517e-02 -2.72826441e-02\\n  2.61856560e-02 -7.71522801e-03  3.25987265e-02  3.17990631e-02\\n  3.74854878e-02  2.35621817e-02  4.44227643e-03 -9.00383946e-03\\n  1.84339397e-02 -5.41498810e-02 -3.92036140e-02  3.37716900e-02\\n  3.95864202e-03  2.02124771e-02 -4.20554914e-02  1.01744523e-02\\n  4.62199980e-03 -4.59750630e-02 -2.47314349e-02  2.61705909e-02\\n -8.21479317e-03  5.95653318e-02 -4.14456148e-03 -2.12141848e-03\\n -5.76317608e-02  3.42212319e-02 -4.56239283e-02  1.27345631e-02\\n -8.47555101e-02 -1.52215753e-02 -5.69004305e-02 -3.86912152e-02\\n  2.58291010e-02 -2.14005131e-02  5.27213851e-04 -1.17133548e-02\\n -1.61043666e-02 -3.49268094e-02 -5.06054163e-02 -7.46094286e-02\\n  5.33215096e-03  2.02029496e-02 -1.07922470e-02 -1.84471067e-02\\n -1.12491772e-02 -6.01683836e-03 -4.11028042e-02 -1.92844681e-02\\n -1.57557558e-02  4.23184149e-02 -2.49787886e-02  4.61405329e-02\\n -5.23240957e-03  6.82014180e-03 -4.32530008e-02  8.35652370e-03\\n  4.19717357e-02 -3.08986586e-02  1.77643988e-02 -4.32744622e-02\\n  6.81626722e-02 -8.58423561e-02  3.87662686e-02  1.68224759e-02\\n  3.99340270e-03 -8.29966553e-03  5.56023931e-03  4.38956656e-02\\n  1.50824152e-02  4.51646820e-02  1.09329325e-04 -5.52496780e-03\\n  1.35055324e-02  4.53571416e-02 -2.84391060e-03  1.63280964e-02\\n -3.80691104e-02  3.03160977e-02  4.85147350e-03 -3.78318727e-02\\n  1.56180356e-02  3.15223038e-02  3.67107452e-03 -6.29478926e-03\\n -1.12714628e-02 -5.81419840e-02  2.12840829e-02 -1.40806204e-02\\n  8.09102952e-02  1.04479687e-02 -2.30973549e-02 -3.73117104e-02\\n  1.01686176e-02 -2.09330097e-02 -2.71457359e-02  1.85835883e-02\\n -8.97346064e-03 -4.92851771e-02  7.96792954e-02 -1.98409036e-02\\n -3.50830108e-02 -1.33137470e-02 -1.55474190e-02 -4.02740017e-02\\n  5.59540726e-02  6.51451647e-02 -3.26307267e-02  1.39414519e-02\\n  1.46810729e-02  1.43189344e-03 -2.32343581e-02  2.30420455e-02\\n -2.73454692e-02 -2.40969155e-02  2.00979318e-03  1.06309757e-01\\n -4.80370335e-02 -1.64871104e-02 -1.59823410e-02  2.70829853e-02\\n  2.34833863e-02 -2.65412126e-02 -3.47109437e-02  4.79415804e-02\\n -4.73557636e-02  5.34970127e-02  8.13532248e-03 -1.21328637e-01\\n  2.47643702e-02  9.01637971e-03 -2.18203478e-02  4.08098698e-02\\n -2.56814603e-02  8.37056781e-04 -7.50878975e-02 -1.65712833e-02\\n  3.86731438e-02  4.58139293e-02 -1.92183740e-02 -3.55553888e-02\\n -4.94566280e-03  2.44585536e-02 -7.91016817e-02 -6.39002712e-04\\n  7.10439123e-03  3.42868492e-02  2.68183816e-02 -2.15084292e-02\\n -2.28081327e-02 -5.58046205e-03 -3.54118049e-02  4.17130621e-04\\n -2.14078091e-02  2.88922992e-02 -2.93593872e-02 -4.43375632e-02\\n  2.87615899e-02  2.45134067e-02  2.26363428e-02 -7.09728850e-03\\n  4.41561043e-02 -4.83537652e-02 -2.55982596e-02 -7.02673476e-03\\n -6.34077564e-02  8.03067442e-03  7.83207826e-03  1.59024987e-02\\n  3.12867686e-02  2.98917536e-02  4.69511822e-02  3.63986343e-02\\n  4.99440692e-02 -6.86464310e-02 -1.81746129e-02  1.97191145e-02\\n  6.03221878e-02 -2.33229809e-02 -4.09867838e-02  2.88761500e-02\\n  7.97183514e-02 -8.62637311e-02 -5.70264868e-02  6.41475022e-02\\n -1.32150259e-02 -4.05035876e-02  9.02200341e-02  8.23641475e-03\\n  3.68166231e-02 -3.24256122e-02 -7.19952723e-03 -3.85442525e-02\\n  5.66862412e-02 -4.74811904e-02 -4.14198115e-02  2.08587516e-02\\n -2.93457299e-03  2.48775212e-03  1.06438911e-02  1.12209255e-02\\n -3.41628119e-02  3.20925601e-02  7.48839676e-02  1.81700997e-02\\n  4.81467061e-02  4.42506522e-02 -3.15412171e-02  6.89919442e-02\\n -8.82827397e-03 -9.38906521e-02  8.06891918e-03 -3.09819896e-02\\n -1.78832503e-03  1.59754492e-02  5.91935450e-03 -2.46862993e-02\\n  4.05776091e-02 -3.70092168e-02  4.76095313e-03 -1.39698312e-02\\n -6.48485124e-02  5.20020463e-02  3.37624177e-02  1.95414778e-02\\n -2.17131637e-02  3.53918560e-02  2.41274405e-02  6.81706099e-03\\n -5.40681668e-02  3.62581834e-02  3.75535674e-02  2.51110941e-02\\n  1.43604930e-02 -5.58671635e-03 -1.54325217e-02 -1.08434623e-02\\n  3.22664529e-02  1.55385258e-03 -3.06803118e-02 -8.11754435e-04\\n -2.44262815e-02 -3.00169969e-03  2.42919363e-02  3.78629332e-03\\n  8.22761469e-03 -4.08793567e-03 -3.42377014e-02 -3.62432450e-02\\n  3.29493918e-02  1.08434428e-02 -2.88164429e-02  4.10762578e-02\\n  3.82405240e-03 -1.52549818e-02 -2.13355217e-02  3.19246091e-02\\n -1.84686370e-02  2.08536740e-02  1.10979965e-02 -2.56908592e-02\\n -1.29836602e-02 -1.87393278e-02  4.12652083e-02 -6.66097319e-03\\n -2.04735491e-02  1.01134285e-01 -5.30572943e-02  4.55758013e-02\\n  2.85144802e-02 -3.99077544e-03  5.53475320e-02 -8.17216584e-04\\n  9.04428307e-03  3.87692754e-03 -4.50160392e-02 -2.24999748e-02\\n  3.10280211e-02 -2.33339821e-03 -3.35792662e-03  1.69492681e-02\\n -3.91574576e-02 -1.91827752e-02  5.97504787e-02  4.04988155e-02\\n  8.23443234e-02  4.39683907e-02  2.90329996e-02 -2.12142598e-02\\n  2.91113183e-02  3.42650972e-02  5.79067767e-02  2.54184138e-02\\n -6.08712493e-04 -3.18209119e-02 -6.56415075e-02  8.46485514e-03\\n  2.57543735e-02  9.97569319e-03 -4.69294749e-02  8.78551044e-03\\n -2.43584216e-02  7.81208230e-03 -2.18442529e-02 -7.92021453e-02\\n  1.15417577e-02 -4.49005030e-02 -2.19435822e-02 -6.52334094e-02\\n  5.90308756e-02 -5.92014864e-02 -8.49356577e-02  1.19993591e-03\\n -3.39241773e-02 -5.95490374e-02 -1.23514561e-02 -3.63073836e-04\\n  6.10843226e-02 -8.50652624e-03 -2.87866984e-02  2.99133430e-03\\n  2.55648866e-02 -3.60966697e-02 -4.73379754e-02  9.63603426e-03\\n  2.11234670e-03 -1.99826844e-02  5.28120175e-02 -6.43617908e-33\\n  1.86864994e-02  4.47787606e-04  1.26983933e-02 -8.65057185e-02\\n  2.93316673e-02  5.52286766e-02 -3.00090890e-02 -2.45880615e-02\\n -2.65350332e-03  5.56020252e-02 -1.68169737e-02 -4.40467149e-02\\n  8.78127292e-03  3.09620108e-02 -4.74977121e-02  1.53376127e-03\\n -3.79511230e-02  7.20831100e-03  1.90570597e-02 -2.63244305e-02\\n -3.60646658e-02 -3.49220298e-02  3.37189697e-02 -2.08236817e-02\\n  4.48451601e-02  1.65060069e-02  3.92002128e-02 -6.52321726e-02\\n -4.76480313e-02  2.67774537e-02  2.57781483e-02 -2.24169996e-03\\n  2.81375330e-02  4.14071083e-02 -2.32342836e-02 -3.63033004e-02\\n -4.08957489e-02  4.31649275e-02  1.34358099e-02  1.78613532e-02\\n  1.19581474e-02  2.78197844e-02 -5.07869087e-02  1.85669065e-02\\n -2.28583533e-02  3.32982489e-03 -5.33690527e-02 -4.63969521e-02\\n  2.27779560e-02 -8.15622956e-02 -1.17873223e-02  2.68059224e-03\\n  8.70211236e-03  3.85871134e-03 -3.59095447e-02 -3.55758592e-02\\n -2.66312677e-02  2.12247297e-02  7.30964690e-02 -2.28786822e-02\\n  5.43283001e-02  1.53398840e-02  9.99375805e-03 -2.36221682e-02\\n -2.02866201e-03 -4.11664769e-02 -4.64580283e-02 -2.49091499e-02\\n -1.52998948e-02 -1.70534663e-02 -1.29348869e-02 -4.66900058e-02\\n  5.27980663e-02  5.25752418e-02  4.56923572e-03 -7.70719256e-03\\n -2.63751391e-02  1.36600826e-02 -8.25489592e-03  2.46492326e-02\\n  4.72553819e-02  3.58609781e-02 -1.73556190e-02  5.75277302e-03\\n -5.14771789e-02 -1.81430634e-02 -1.32615212e-03  5.71767800e-03\\n -6.47366513e-03  1.70788094e-02  1.47866243e-02 -2.10099760e-02\\n  1.04241641e-02 -1.60101391e-02  2.28101052e-02 -8.46876577e-02\\n -2.11824663e-02 -4.93031600e-03  1.59056019e-02 -2.85559818e-02\\n  9.62231494e-03  4.83240820e-02  3.09244022e-02  1.24232480e-02\\n -2.27076858e-02 -2.01490112e-02  3.58497463e-02 -3.55920084e-02\\n  5.65687642e-02  3.72236893e-02 -4.16203402e-02  9.32495017e-03\\n  6.85421526e-02  3.04906964e-02 -7.07274601e-02  3.61701697e-02\\n -5.96552622e-04  5.83872460e-02  1.19187264e-02  3.35147716e-02\\n -3.90589945e-02 -2.04642452e-02 -3.43928523e-02 -2.38088262e-03\\n -4.83522676e-02 -3.27028409e-02  1.62321944e-02  8.94081220e-02\\n -1.14299301e-02 -2.83069946e-02  3.76419947e-02  7.40437908e-03\\n  3.10278011e-07 -1.53089492e-02  4.25652526e-02 -2.80970223e-02\\n -7.80854002e-02  5.15842177e-02  6.08903775e-03 -3.55249681e-02\\n  2.52125524e-02  5.45251835e-03  4.07448560e-02  3.55997756e-02\\n -1.12809679e-02 -1.61308646e-02 -4.31656055e-02  1.00681679e-02\\n -9.89896432e-02 -5.10319285e-02 -1.99799929e-02  5.94098261e-03\\n  1.28147881e-02 -2.92406790e-02  2.26267967e-02 -1.05325626e-02\\n -5.55093475e-02  4.01014200e-04  2.67393123e-02 -2.67889705e-02\\n -6.06697351e-02 -8.80681816e-03 -1.10742077e-03  4.97755297e-02\\n -7.05116987e-02  2.99270637e-03 -3.10198721e-02 -3.05688158e-02\\n -5.71925417e-02  5.99765498e-03  3.46733369e-02 -3.99563871e-02\\n -3.11788581e-02  3.87356710e-03 -5.87482788e-02  5.00930026e-02\\n -4.82329242e-02 -4.24717367e-02  1.04448227e-02  5.02780138e-04\\n  5.76382279e-02 -4.58839759e-02 -4.96311113e-03  5.19337319e-02\\n -2.37546284e-02 -3.63669209e-02 -4.78976266e-03  1.83021296e-02\\n  7.10323872e-03 -4.80840495e-03  2.00407542e-02  4.29737419e-02\\n -8.71343613e-02 -5.42956293e-02 -3.18113230e-02  3.12273614e-02\\n -3.57195549e-02 -3.43526676e-02  2.50639338e-02 -2.69909091e-02\\n  2.68034592e-34  2.70275399e-02  1.04091018e-02  5.75770903e-03\\n -6.54166713e-02  5.15171587e-02 -2.14639902e-02 -7.41311908e-03\\n  2.86113489e-02  3.72669287e-02 -4.61808257e-02 -6.56750053e-02]\",\n          \"[ 5.60845919e-02 -1.58231482e-02  2.20260322e-02 -2.66746385e-03\\n  1.04471222e-02  7.64649687e-03 -4.93153511e-03 -9.05555859e-03\\n  2.63210796e-02  4.00849432e-02  1.36337793e-02  5.85746281e-02\\n  6.08286858e-02 -2.05766410e-02 -3.18662785e-02  4.42622192e-02\\n -4.30173166e-02 -1.31543335e-02  2.16655969e-03  1.98355075e-02\\n  4.55166912e-03  1.68144275e-02  2.99979607e-03  3.83535363e-02\\n  1.19148511e-02 -3.36743519e-02 -3.55562344e-02  2.91697122e-02\\n  4.04403135e-02 -1.12431034e-01  7.45905144e-03  4.24826778e-02\\n  4.01974954e-02 -5.26388437e-02  1.42349688e-06  1.00718243e-02\\n  4.76763397e-02  1.68119799e-02 -4.85809669e-02 -3.32059972e-02\\n  7.63236061e-02 -2.49236058e-02  3.01093273e-02  2.37814635e-02\\n -2.72663170e-03 -5.91126941e-02 -5.68934251e-04 -3.84012908e-02\\n  5.63086085e-02  6.70709973e-03 -1.76465586e-02 -1.67990848e-02\\n  7.37282261e-02  1.10129789e-02  9.00328159e-03 -8.02382007e-02\\n  3.71714029e-03 -1.06518706e-02  1.42763741e-02 -4.22873441e-03\\n  4.08828771e-03  3.68950292e-02  9.61281732e-03  5.44141978e-03\\n  2.98168585e-02  8.50615557e-03  2.24162750e-02  1.44843776e-02\\n -1.74105335e-02 -3.67997363e-02  5.60163334e-02 -1.71884056e-02\\n  3.36191151e-03  4.85024117e-02 -4.86918800e-02 -5.78213446e-02\\n -2.00933442e-02 -5.06848767e-02  4.70682792e-02  2.23177131e-02\\n  2.63681766e-02  2.30236556e-02 -1.29150609e-02  8.97248369e-03\\n  7.83359781e-02 -1.68015379e-02 -1.51066645e-03  1.85159389e-02\\n  2.21044924e-02  1.41370185e-02  8.99300873e-02  2.03499962e-02\\n -2.06011459e-02  1.11938166e-02  7.10707977e-02 -6.69803889e-03\\n  1.07745603e-02 -3.21731828e-02  3.96245494e-02  2.11641397e-02\\n  9.61099714e-02  1.67703684e-02  6.34012893e-02  3.89155671e-02\\n  3.54373902e-02 -4.51623052e-02  4.48946394e-02 -1.73410831e-03\\n  2.46273237e-03 -8.87290481e-03  5.95204532e-03 -5.09224944e-02\\n  3.87087953e-03 -3.64736207e-02  1.07713342e-01  4.25296165e-02\\n -2.37501860e-02 -4.04204205e-02  6.16013724e-03  7.60869682e-03\\n -3.17495479e-03 -1.43461190e-02  1.74508300e-02 -1.93601884e-02\\n -3.92695926e-02  3.87685150e-02  1.88316442e-02  1.25665925e-02\\n  3.87739553e-03 -3.80403958e-02 -6.01585675e-03 -5.86358970e-03\\n -3.34031284e-02 -4.07358855e-02  1.10174704e-03 -1.37494374e-02\\n -1.68837013e-03 -4.92230942e-03 -1.03820160e-01  3.00057381e-02\\n  2.40230206e-02 -4.53935526e-02  3.98963615e-02  5.66696115e-02\\n  2.08878797e-02 -6.82100561e-03 -2.00935472e-02 -2.67512305e-03\\n -6.16883412e-02  8.23995285e-03 -7.75558501e-03 -1.41546945e-03\\n -5.40945977e-02  2.37740632e-02  3.64843309e-02 -6.42780028e-03\\n -5.08990362e-02 -2.47058105e-02  2.92815529e-02  3.88981774e-02\\n -4.23222594e-02  9.89782903e-03  6.16462482e-03 -5.08992970e-02\\n  2.13637892e-02  6.40281141e-02 -4.73957285e-02  4.90445122e-02\\n -3.70457908e-03 -5.66762015e-02 -2.67806873e-02  1.72751937e-02\\n  1.87902078e-02  5.49491681e-02 -3.41763385e-02 -3.23581323e-02\\n -2.69558448e-02 -9.74411368e-02 -3.66215757e-03 -3.49790826e-02\\n  2.46068481e-02 -5.13181500e-02 -6.95142597e-02 -2.61032637e-02\\n -1.33940876e-02  3.23464982e-02 -9.62098036e-03  3.12336590e-02\\n -1.11490944e-02 -1.26097840e-03 -3.81437130e-02 -2.28332747e-02\\n  8.78650043e-03 -1.41312396e-02 -6.06494443e-03  2.77385185e-03\\n  4.28103469e-02  2.98675103e-03 -6.80537941e-03  3.79965678e-02\\n  1.57392882e-02 -6.17102906e-02  2.50944421e-02  9.89983007e-02\\n -5.44179790e-02 -6.87220320e-03 -3.14373560e-02 -1.63378883e-02\\n -2.81022210e-02 -4.03026901e-02 -6.63842186e-02 -3.36660147e-02\\n -3.24892960e-02 -8.27857926e-02 -2.52766591e-02  6.94066361e-02\\n  1.69732496e-02 -1.48551855e-02  5.78907244e-02  7.36075491e-02\\n -1.97304171e-02 -1.41997896e-02  8.62344354e-02  2.64263563e-02\\n -3.41035016e-02 -2.10465714e-02 -2.99256966e-02 -4.52027016e-04\\n  3.62987258e-02  3.56760155e-03  5.97925261e-02  1.55991884e-02\\n  4.40867431e-02  1.99342053e-02  6.64194394e-03 -4.34580408e-02\\n  1.50812957e-02 -8.24243296e-03  1.64347515e-02  1.07429065e-02\\n -2.74025258e-02  2.81650592e-02  2.70411605e-03  1.49410134e-02\\n -5.93014359e-02  2.57604364e-02  3.40832025e-02 -2.70108506e-02\\n  1.25050908e-02  1.58902071e-02 -4.34382372e-02 -3.76509391e-02\\n -3.73132862e-02 -1.46910371e-02 -3.97765078e-02  5.30173145e-02\\n -5.40155210e-02 -1.29483929e-02 -3.26981861e-03  2.42799800e-02\\n -2.66122557e-02  2.06420869e-02  3.33962068e-02 -7.21786544e-02\\n  1.83631890e-02  2.70387791e-02 -2.21860632e-02 -4.36874405e-02\\n -1.02263717e-02  1.78567395e-02  1.80481020e-02 -4.19988781e-02\\n -1.29998036e-04  3.28065199e-03 -5.69725484e-02  4.05030102e-02\\n -2.45558005e-02 -9.16287303e-03 -2.35255472e-02 -1.37507834e-03\\n  3.95461731e-02  3.68651822e-02  3.19558084e-02 -1.22044338e-02\\n  2.43909862e-02  2.31930912e-02 -6.94215968e-02 -5.33474386e-02\\n -2.56378986e-02 -6.55311672e-03  4.54214811e-02  1.30921518e-02\\n -2.87127886e-02 -1.24391615e-02  2.72374414e-02 -2.84713861e-02\\n  1.87719446e-02  8.64359550e-03 -2.43690144e-02  2.33293232e-02\\n  9.19816736e-03  7.45362639e-02  6.14873655e-02 -1.30204707e-02\\n  5.39090820e-02  7.24692717e-02  5.65082543e-02 -2.21911483e-02\\n -2.76601017e-02 -6.43975288e-03 -4.81942343e-03 -5.06582437e-03\\n  3.99240153e-03  5.83145283e-02 -2.27736235e-02 -1.46550378e-02\\n  9.06050429e-02  4.46183933e-03  2.02656444e-02 -5.71800582e-02\\n -3.85446195e-03 -2.83470023e-02 -4.75151278e-03  2.57061366e-02\\n -4.13708016e-02 -1.58537813e-02  1.51968980e-02 -3.78367491e-02\\n -3.05274054e-02 -2.66130790e-02 -2.12090481e-02 -1.78958997e-02\\n -2.28524785e-02  2.09524091e-02 -5.29180840e-02 -2.49452740e-02\\n  1.47524746e-02 -3.13438177e-02  2.42983596e-03  2.29695886e-02\\n -9.04136151e-03 -1.15601011e-02  1.93396937e-02 -4.65337075e-02\\n -7.01316074e-02  1.69336721e-02 -2.79583577e-02  7.64603838e-02\\n  2.52934247e-02  1.29304156e-02  6.18696678e-03  1.94736558e-03\\n  1.78706683e-02 -7.76176574e-03  1.57044921e-02 -5.32416254e-02\\n  3.32392775e-03 -5.98439239e-02 -5.20947110e-03  3.62690128e-02\\n -2.58571710e-02  1.57733764e-02 -2.75355461e-03 -1.30780619e-02\\n -3.65092754e-02  2.21837275e-02 -2.84589585e-02  3.11599928e-03\\n -1.67489736e-04  2.11708918e-02 -3.34909149e-02  1.64200310e-02\\n  7.14868158e-02 -1.98596083e-02  1.38819860e-02 -2.20937710e-02\\n  9.63194855e-03  3.77850384e-02 -5.35637103e-02 -3.29221301e-02\\n -1.73354354e-02 -1.29200462e-02 -3.11240950e-03  6.28859224e-03\\n -2.17062123e-02  3.90547663e-02  3.38499993e-02 -3.63741256e-02\\n -1.07354885e-02  1.19814994e-02 -1.28312409e-02 -4.54165488e-02\\n -4.93926508e-03  5.08421585e-02  5.82321770e-02 -2.10456736e-02\\n  2.51997616e-02  1.19827865e-02  6.81676716e-03  2.91979741e-02\\n -1.05050148e-03  9.48101934e-03 -3.37707885e-02 -4.43530902e-02\\n  5.03413640e-02 -1.51198739e-02 -7.56443888e-02 -2.92745251e-02\\n  6.15549348e-02  1.90236010e-02 -3.65049727e-02 -1.36943366e-02\\n -7.76714832e-03 -2.55671646e-02  1.71257537e-02  4.62791957e-02\\n  9.96394549e-03  4.59079485e-04  1.02964388e-02 -9.46367532e-02\\n -6.37282059e-02  1.68846175e-02 -1.74550321e-02  2.29010079e-02\\n  5.35652786e-03 -2.63558105e-02  1.67905930e-02 -3.61551866e-02\\n -1.24927834e-02  2.52808742e-02  4.24037240e-02  4.24594320e-02\\n  3.82589386e-03  1.01440735e-01 -1.53613286e-02  3.25361937e-02\\n -3.36948410e-02 -3.42691205e-02  4.91799153e-02  1.48344571e-02\\n  4.62673418e-03 -7.79725146e-03  4.85603437e-02  2.72512492e-02\\n -4.95577743e-03  1.93645004e-02  1.92844830e-02  1.78322196e-02\\n  7.71211600e-03  2.56897602e-03 -2.83054840e-02  6.80943532e-03\\n -4.68078330e-02  1.16200848e-02  3.32747698e-02 -1.44310417e-02\\n  6.41677901e-02 -3.52437422e-02 -2.81524118e-02  4.73642796e-02\\n -2.64991373e-02  1.09843360e-02 -2.49176975e-02 -1.93159245e-02\\n  2.75797546e-02  1.29798558e-02 -5.73082976e-02  3.30512295e-04\\n -3.01632341e-02 -4.28894535e-02  7.40953605e-04  1.88207142e-02\\n -1.49330636e-02  2.77599841e-02 -3.42949331e-02 -2.87032337e-03\\n  5.41256927e-03 -4.56084795e-02 -5.22344038e-02 -5.46820350e-02\\n -2.78644096e-02 -4.61084098e-02 -3.92441228e-02  9.06686485e-03\\n -1.42158577e-02  3.81718427e-02  7.96498880e-02 -4.18970138e-02\\n  5.26857469e-03 -1.84791011e-03 -2.01096628e-02 -3.00419219e-02\\n -3.40663642e-02 -4.50120829e-02  2.34250966e-02 -3.19486521e-02\\n  5.40280342e-02 -8.10540766e-02  6.85295537e-02 -1.71275493e-02\\n  3.23184952e-02  9.03388262e-02 -2.27077063e-02  4.46551070e-02\\n -3.94926108e-02 -6.03977069e-02 -6.56539723e-02  3.16655599e-02\\n -4.11945544e-02 -9.16215312e-03  8.88594836e-02  8.91174451e-02\\n  1.17489994e-02  5.96018787e-03  1.85694955e-02  4.10213023e-02\\n -3.14235426e-02 -5.02974354e-03 -6.11551339e-03  6.57859370e-02\\n  1.20045394e-02 -1.04208046e-03  3.68602499e-02 -4.02353853e-02\\n  3.00637614e-02 -7.61159584e-02  9.76395793e-03 -2.27281079e-02\\n -2.83924025e-02  1.22464867e-03  2.85028107e-02 -1.83784664e-02\\n  1.28287943e-02  1.55625856e-02 -9.76360589e-03 -3.38726584e-03\\n  1.41108632e-02 -4.52441573e-02  5.72707038e-03 -4.74718958e-02\\n  2.05890629e-02 -9.44684520e-02  4.87891771e-02 -5.26512647e-03\\n -1.89776812e-02  4.39490043e-02 -2.81499270e-02 -1.11315874e-02\\n -1.94108172e-03 -4.26159538e-02 -1.30289234e-02  1.09245352e-01\\n  3.70044671e-02 -1.06829312e-02  1.64619274e-02 -4.61238416e-33\\n  1.66776795e-02 -2.15832312e-02 -1.37652997e-02 -8.96824524e-02\\n  3.16366106e-02  5.21235615e-02 -1.11113712e-02  8.62884428e-03\\n  2.20898371e-02  5.75844757e-02 -9.37526274e-05 -2.34108809e-02\\n  4.06718962e-02  6.35718089e-03 -2.63582561e-02 -1.87103115e-02\\n -3.39417532e-02  2.77115162e-02 -7.53994239e-03  1.47688929e-02\\n  3.92504706e-04  1.68965422e-02  3.84522788e-02  2.78159901e-02\\n -1.32500222e-02 -2.56914608e-02  3.88426110e-02  6.17960840e-03\\n -1.59770474e-02  7.62011409e-02  2.56929127e-03 -8.05306435e-02\\n  5.63674718e-02  8.09180290e-02 -1.14439838e-02  3.92547026e-02\\n -5.91815487e-02  7.54820835e-03 -2.47916244e-02 -1.23364534e-02\\n -2.49633752e-02 -7.02114329e-02 -3.71192098e-02 -5.71915619e-02\\n -2.44524740e-02  1.55926086e-02 -9.92838200e-03  2.46910471e-02\\n  1.09968858e-03 -1.17493151e-02  1.71151180e-02 -1.69038232e-02\\n  4.43363488e-02 -7.41764754e-02 -9.65279248e-03 -3.16583477e-02\\n  3.19313183e-02  1.52341733e-02  1.66541375e-02  2.26210291e-03\\n -1.47890467e-02 -1.16368430e-02 -3.69641669e-02 -1.03989936e-04\\n -2.60801800e-03 -5.64862601e-03 -1.43086672e-01  2.49298587e-02\\n  1.02477372e-02 -3.94565612e-02  4.26902585e-02 -1.14835277e-01\\n -2.06513572e-02 -3.62108722e-02  5.45411892e-02  5.02543934e-02\\n  2.47405563e-02 -2.13541426e-02  6.49414724e-03  8.06867052e-03\\n -2.50845253e-02  1.09364511e-02 -2.98406165e-02 -4.42065559e-02\\n  3.78016126e-03 -3.21948379e-02  2.34052539e-02 -6.04684232e-03\\n  3.31430435e-02  1.28118163e-02 -5.89814708e-02 -5.46132214e-03\\n  7.66099105e-03 -1.27357347e-02  4.46997117e-03 -2.72814054e-02\\n  3.59809101e-02  3.88475507e-02  2.55447123e-02 -3.45607027e-02\\n  3.02894413e-02  2.36878376e-02 -1.36228083e-02  8.81332811e-03\\n -1.12252058e-02 -2.58606318e-02 -6.13095891e-03  2.54040938e-02\\n  2.82427259e-02 -5.17628901e-03  1.52806928e-02  5.93042970e-02\\n  2.82451287e-02  3.13354097e-02 -3.49820592e-02  4.16277014e-02\\n  2.11710818e-02  3.93869616e-02 -4.57869290e-04  3.52030881e-02\\n  8.04041885e-03  4.38883482e-03  2.85207331e-02  1.00963414e-02\\n  1.01891141e-02  3.21708317e-03  6.99047185e-03  3.05519011e-02\\n -1.71159822e-02 -2.01491942e-03  1.47171849e-02 -7.53491651e-03\\n  2.06983231e-07  5.65006100e-02  1.50131881e-02  6.30602390e-02\\n  3.25639844e-02 -3.17726433e-02 -3.00003197e-02 -7.73194805e-02\\n -1.54096019e-02 -7.51582384e-02 -4.09045368e-02  2.62133218e-03\\n  3.32137905e-02 -7.92239886e-03  1.61866122e-03 -1.08941980e-01\\n -8.74174759e-02  2.92194411e-02 -1.79080665e-02 -2.38208799e-03\\n  1.02196205e-02 -4.47899848e-02 -1.73798800e-02  2.41321605e-02\\n -4.64516617e-02 -4.75164726e-02  3.02362745e-03  2.20007598e-02\\n  1.48038156e-02 -3.51164043e-02 -8.79282411e-03  1.32546779e-02\\n -1.10181440e-02 -9.62806959e-03 -2.37005483e-02  1.83956530e-02\\n -6.51854575e-02  2.09132824e-02  7.86301494e-02 -2.36314218e-02\\n -3.26895784e-03  3.86872999e-02 -2.72785351e-02 -3.61026190e-02\\n  2.49712542e-02  8.91345646e-03  7.15485364e-02 -8.19907244e-03\\n -9.60032269e-03  2.93240994e-02  1.98074989e-02  4.45320085e-02\\n -2.50106286e-02 -4.87843044e-02  9.90562234e-03 -9.46578290e-03\\n -5.12170093e-03  1.86807178e-02  2.36720201e-02  4.59281057e-02\\n -3.22470330e-02 -1.91602763e-02 -1.23480493e-02  5.94779290e-02\\n -2.29577143e-02 -1.13245584e-02 -6.64489195e-02  9.86787491e-03\\n  1.36834797e-34 -6.38109865e-03 -5.03508672e-02 -2.10447535e-02\\n -5.66393277e-03  6.06152089e-03  2.34318078e-02  7.62389302e-02\\n  1.52882086e-02  2.82171927e-02 -4.76469547e-02  1.41833639e-02]\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 60
        }
      ],
      "source": [
        "# Import saved file and view\n",
        "text_chunks_and_embedding_df_load = pd.read_csv(embeddings_df_save_path)\n",
        "text_chunks_and_embedding_df_load.head()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Qka7XZHckS4n",
        "outputId": "4ef2baf6-9ecd-4e6d-f409-f9f6f227a435"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "torch.Size([191, 768])"
            ]
          },
          "metadata": {},
          "execution_count": 61
        }
      ],
      "source": [
        "import random\n",
        "\n",
        "import torch\n",
        "import numpy as np\n",
        "import pandas as pd\n",
        "from sentence_transformers import util\n",
        "device = \"cuda\" if torch.cuda.is_available() else \"cpu\"\n",
        "\n",
        "# Import texts and embedding df\n",
        "text_chunks_and_embedding_df = pd.read_csv(\"text_chunks_and_embeddings_df.csv\")\n",
        "\n",
        "# Convert embedding column back to np.array (it got converted to string when it got saved to CSV)\n",
        "text_chunks_and_embedding_df[\"embedding\"] = text_chunks_and_embedding_df[\"embedding\"].apply(lambda x: np.fromstring(x.strip(\"[]\"), sep=\" \"))\n",
        "\n",
        "# Convert texts and embedding df to list of dicts\n",
        "pages_and_chunks = text_chunks_and_embedding_df.to_dict(orient=\"records\")\n",
        "\n",
        "# Convert embeddings to torch tensor and send to device (note: NumPy arrays are float64, torch tensors are float32 by default)\n",
        "embeddings = torch.tensor(np.array(text_chunks_and_embedding_df[\"embedding\"].tolist()), dtype=torch.float32).to(device)\n",
        "embeddings.shape"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 206
        },
        "id": "9xsVV3q6kVqF",
        "outputId": "78ee39c3-54f2-46e3-a5bd-711bd7cc0671"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "   page_number                                     sentence_chunk  \\\n",
              "0            1  HIGHLIGHTS OF PRESCRIBING INFORMATION \\nThese ...   \n",
              "1            1  • Juvenile Idiopathic Arthritis (JIA) (1.2): r...   \n",
              "2            1  Juvenile Idiopathic Arthritis or Pediatric Uve...   \n",
              "3            2  WARNINGS AND PRECAUTIONS \\n• Serious infection...   \n",
              "4            2  6.1) \\n \\nTo report SUSPECTED ADVERSE REACTION...   \n",
              "\n",
              "   chunk_char_count  chunk_word_count  chunk_token_count  \\\n",
              "0              1643               226             410.75   \n",
              "1              1733               258             433.25   \n",
              "2              2787               535             696.75   \n",
              "3              1232               174             308.00   \n",
              "4              2619               340             654.75   \n",
              "\n",
              "                                           embedding  \n",
              "0  [0.0424278118, 0.00655023102, 0.00972411223, -...  \n",
              "1  [0.0475581251, -0.0371793509, 0.0138818892, -0...  \n",
              "2  [0.0317343101, -0.0542078987, 0.0143824583, -0...  \n",
              "3  [0.0190991834, -0.00151055853, 0.0292231571, -...  \n",
              "4  [0.0133229289, -0.0221084952, 0.000162922137, ...  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-fb627227-4d5e-41a4-a4c5-a47c06eeaf67\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>page_number</th>\n",
              "      <th>sentence_chunk</th>\n",
              "      <th>chunk_char_count</th>\n",
              "      <th>chunk_word_count</th>\n",
              "      <th>chunk_token_count</th>\n",
              "      <th>embedding</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>1</td>\n",
              "      <td>HIGHLIGHTS OF PRESCRIBING INFORMATION \\nThese ...</td>\n",
              "      <td>1643</td>\n",
              "      <td>226</td>\n",
              "      <td>410.75</td>\n",
              "      <td>[0.0424278118, 0.00655023102, 0.00972411223, -...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>1</td>\n",
              "      <td>• Juvenile Idiopathic Arthritis (JIA) (1.2): r...</td>\n",
              "      <td>1733</td>\n",
              "      <td>258</td>\n",
              "      <td>433.25</td>\n",
              "      <td>[0.0475581251, -0.0371793509, 0.0138818892, -0...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>1</td>\n",
              "      <td>Juvenile Idiopathic Arthritis or Pediatric Uve...</td>\n",
              "      <td>2787</td>\n",
              "      <td>535</td>\n",
              "      <td>696.75</td>\n",
              "      <td>[0.0317343101, -0.0542078987, 0.0143824583, -0...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>2</td>\n",
              "      <td>WARNINGS AND PRECAUTIONS \\n• Serious infection...</td>\n",
              "      <td>1232</td>\n",
              "      <td>174</td>\n",
              "      <td>308.00</td>\n",
              "      <td>[0.0190991834, -0.00151055853, 0.0292231571, -...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>2</td>\n",
              "      <td>6.1) \\n \\nTo report SUSPECTED ADVERSE REACTION...</td>\n",
              "      <td>2619</td>\n",
              "      <td>340</td>\n",
              "      <td>654.75</td>\n",
              "      <td>[0.0133229289, -0.0221084952, 0.000162922137, ...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-fb627227-4d5e-41a4-a4c5-a47c06eeaf67')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-fb627227-4d5e-41a4-a4c5-a47c06eeaf67 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-fb627227-4d5e-41a4-a4c5-a47c06eeaf67');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-afca0860-693b-4d92-afb2-7fea551db1cf\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-afca0860-693b-4d92-afb2-7fea551db1cf')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-afca0860-693b-4d92-afb2-7fea551db1cf button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "text_chunks_and_embedding_df",
              "summary": "{\n  \"name\": \"text_chunks_and_embedding_df\",\n  \"rows\": 191,\n  \"fields\": [\n    {\n      \"column\": \"page_number\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 31,\n        \"min\": 1,\n        \"max\": 111,\n        \"num_unique_values\": 111,\n        \"samples\": [\n          79,\n          11,\n          5\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"sentence_chunk\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 191,\n        \"samples\": [\n          \"It is important that you firmly push the Pen \\ndown all the way against the injection site \\nbefore starting the injection. \\nKeep pushing down to prevent the Pen from \\nmoving away from the skin during the injection. \\nPress the plum activator button and count \\nslowly for 10 seconds. \\n\\u2022 A loud \\u201cclick\\u201d will signal the start of the \\ninjection \\n\\u2022 Keep pushing the Pen down firmly against \\nthe injection site until the injection is \\ncomplete \\n\\u2022 Injection is complete when the yellow \\nindicator has stopped moving \\n \\n  \\n \\nWhen the injection is completed, slowly pull the \\nPen from the skin. The white needle sleeve will \\ncover the needle tip. \\n\\u2022 A small amount of liquid on the injection site \\nis normal \\nIf there are more than a few drops of liquid on \\nthe injection site, call 1-800-4HUMIRA (1-800-\\n448-6472) for help. \\nAfter completing the injection, place a cotton ball \\nor gauze pad on the skin of the injection site. \\n\\u2022 Do not rub \\n\\u2022 Slight bleeding at the injection site is normal\",\n          \"Lumbar flexion (cm) \\n4.1 \\n4.0 \\n4.2 \\n4.4 \\n   Cervical rotation (degrees) \\n42.2 \\n42.1 \\n48.4 \\n51.6 \\n   Lumbar side flexion (cm) \\n8.9 \\n9.0 \\n9.7 \\n11.7 \\n   Intermalleolar distance (cm) \\n92.9 \\n94.0 \\n93.5 \\n100.8 \\nCRPf* \\n2.2 \\n2.0 \\n1.8 \\n0.6 \\na Percent of subjects with at least a 20% and 10-unit improvement measured on a Visual \\nAnalog Scale (VAS) with 0 = \\u201cnone\\u201d and 100 = \\u201csevere\\u201d \\nb mean of questions 5 and 6 of BASDAI (defined in \\u2018d\\u2019) \\nc Bath Ankylosing Spondylitis Functional Index \\nd Bath Ankylosing Spondylitis Disease Activity Index \\ne Bath Ankylosing Spondylitis Metrology Index \\nf C-Reactive Protein (mg/dL) \\n* statistically significant for comparisons between HUMIRA and placebo at Week 24 \\n \\n \\nA second randomized, multicenter, double-blind, placebo-controlled study of 82 patients with \\nankylosing spondylitis showed similar results. \\nPatients treated with HUMIRA achieved improvement from baseline in the Ankylosing \\nSpondylitis Quality of Life Questionnaire (ASQoL) score (-3.6 vs. -1.1) and in the Short Form \\nHealth Survey (SF-36) Physical Component Summary (PCS) score (7.4 vs. 1.9) compared to \\nplacebo-treated patients at Week 24. \\n14.5 Adult Crohn\\u2019s Disease \\nThe safety and efficacy of multiple doses of HUMIRA were assessed in adult patients with \\nmoderately to severely active Crohn\\u2019s disease, CD, (Crohn\\u2019s Disease Activity Index (CDAI) \\u2265 \\n220 and \\u2264 450) in randomized, double-blind, placebo-controlled studies. Concomitant stable \\ndoses of aminosalicylates, corticosteroids, and/or immunomodulatory agents were permitted, and \\n79% of patients continued to receive at least one of these medications. \\nInduction of clinical remission (defined as CDAI < 150) was evaluated in two studies. In Study \\nCD-I, 299 TNF-blocker na\\u00efve patients were randomized to one of four treatment groups: the \\nplacebo group received placebo at Weeks 0 and 2, the 160/80 group received 160 mg HUMIRA \\nat Week 0 and 80 mg at Week 2, the 80/40 group received 80 mg at Week 0 and 40 mg at Week \\n2, and the 40/20 group received 40 mg at Week 0 and 20 mg at Week 2. Clinical results were \\nassessed at Week 4. \\nIn the second induction study, Study CD-II, 325 patients who had lost response to, or were \\nintolerant to, previous infliximab therapy were randomized to receive either 160 mg HUMIRA at \\nWeek 0 and 80 mg at Week 2, or placebo at Weeks 0 and 2. Clinical results were assessed at \\nWeek 4. \\nMaintenance of clinical remission was evaluated in Study CD-III.\",\n          \"Check expiration date on the Pen label. Do not \\nuse the Pen if expiration date has passed. \\nPlace the following on a clean, flat surface: \\n\\u2022 1 single-dose Pen and alcohol swab \\n\\u2022 1 cotton ball or gauze pad (not included) \\n\\u2022 Puncture-resistant sharps disposal \\ncontainer (not included). See Step 9 at the \\nend of this Instructions for Use for \\ninstructions on how to throw away (dispose \\nof) your HUMIRA Pen \\nWash and dry your hands. \\n \\n  \\n \\nChoose an injection site: \\n\\u2022 On the front of your thighs or \\n\\u2022 Your abdomen (belly) at least 2 inches from \\nyour navel (belly button) \\n\\u2022 Different from your last injection site \\nWipe the injection site in a circular motion with \\nthe alcohol swab. \\n\\u2022 Do not inject through clothes \\n\\u2022 Do not inject into skin that is sore, bruised, \\nred, hard, scarred, has stretch marks, or \\nareas with psoriasis plaques \\n \\n  \\n \\nHold the Pen with the Gray Cap #1 facing up.\\nCheck the window. \\n\\u2022 It is normal to see 1 or more bubbles in the \\nwindow \\n\\u2022 Make sure the liquid is clear and colorless \\n\\u2022 Do not use the Pen if the liquid is cloudy, \\ndiscolored, or has flakes or particles in it \\n\\u2022 Do not use the Pen if it has been dropped \\nor crushed\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"chunk_char_count\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 674,\n        \"min\": 128,\n        \"max\": 3039,\n        \"num_unique_values\": 181,\n        \"samples\": [\n          2821,\n          1988,\n          649\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"chunk_word_count\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 103,\n        \"min\": 24,\n        \"max\": 535,\n        \"num_unique_values\": 154,\n        \"samples\": [\n          129,\n          116,\n          222\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"chunk_token_count\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 168.627081775278,\n        \"min\": 32.0,\n        \"max\": 759.75,\n        \"num_unique_values\": 181,\n        \"samples\": [\n          705.25,\n          497.0,\n          162.25\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"embedding\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 62
        }
      ],
      "source": [
        "text_chunks_and_embedding_df.head()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "OEfKZ1rrkYRU",
        "outputId": "6c114085-a2f8-438c-fcdc-898aa416db3a"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "tensor([ 4.2428e-02,  6.5502e-03,  9.7241e-03, -2.0206e-02, -3.2781e-03,\n",
              "         9.6387e-03,  1.2219e-02, -5.0598e-03,  1.0083e-01,  5.3754e-03,\n",
              "        -1.8179e-02, -4.3153e-03, -2.5794e-02, -1.4473e-02, -1.0110e-02,\n",
              "         6.5214e-02, -5.6035e-02, -1.8901e-02, -6.9506e-02,  9.5313e-03,\n",
              "        -1.0532e-02,  2.5006e-02, -5.9097e-03,  3.1038e-02,  2.7805e-02,\n",
              "        -1.9371e-02,  3.1472e-02, -2.6991e-02,  2.6361e-02, -7.6127e-02,\n",
              "         3.6059e-02,  4.5474e-03, -1.4479e-03, -4.6773e-02,  2.1800e-06,\n",
              "         9.7448e-03,  1.9914e-02, -3.9382e-03,  7.3059e-03, -5.8833e-02,\n",
              "         6.9018e-02,  1.6042e-02,  1.6726e-02,  8.5298e-03, -5.1108e-02,\n",
              "         1.3062e-05, -2.5384e-02, -5.1245e-03, -6.0193e-02,  3.2813e-03,\n",
              "         1.6903e-02, -8.1258e-03, -2.6136e-02,  4.9436e-02,  3.8884e-02,\n",
              "        -3.5986e-02, -2.3926e-02, -6.4114e-03,  2.1932e-02, -2.4682e-02,\n",
              "        -7.4504e-03,  1.2406e-02, -3.3399e-02, -1.2727e-02, -4.9850e-03,\n",
              "         6.2220e-03,  1.6255e-02, -3.6751e-02,  2.3976e-02,  4.1447e-02,\n",
              "         4.4291e-02, -4.1248e-02,  3.4364e-02,  5.4208e-02, -9.9208e-03,\n",
              "        -5.5022e-02, -2.1072e-03, -1.6781e-02,  3.6314e-04,  1.1047e-02,\n",
              "         8.9085e-02,  3.4014e-02, -1.3249e-02,  1.3093e-02,  3.5416e-02,\n",
              "         6.3809e-03, -9.1775e-03,  1.6261e-02, -2.4715e-02, -3.6071e-02,\n",
              "         6.9678e-02, -7.2166e-02,  1.3001e-02,  3.5017e-02, -2.0004e-02,\n",
              "        -3.3620e-03, -3.9558e-03, -2.6937e-02,  5.0770e-02, -9.1245e-03,\n",
              "        -3.7372e-02,  1.5679e-02,  8.0415e-03,  3.7769e-04,  7.6054e-03,\n",
              "         7.1058e-04,  7.5567e-03,  5.6627e-03,  2.4735e-02,  3.6358e-02,\n",
              "         1.2609e-02,  4.5425e-02, -1.3986e-02,  2.4001e-02,  4.4656e-02,\n",
              "        -1.4914e-02, -6.9095e-02,  3.5304e-02, -1.6595e-02,  1.8926e-04,\n",
              "         3.3518e-02, -1.8039e-02,  1.7220e-02,  2.5465e-02,  3.5848e-02,\n",
              "        -9.1966e-03,  5.3092e-02, -3.6497e-03,  2.7760e-03, -5.3050e-02,\n",
              "         3.0482e-02, -7.2155e-02, -6.3431e-03, -7.1363e-03,  8.4443e-03,\n",
              "        -1.0094e-02,  2.2808e-02, -1.0501e-02,  2.0760e-02,  6.8614e-02,\n",
              "         5.7742e-03, -6.5345e-02, -1.3784e-02,  4.8138e-02,  2.6474e-03,\n",
              "         2.0213e-02,  3.8071e-03, -6.9632e-03, -3.2102e-02,  3.1255e-02,\n",
              "        -4.3591e-02,  2.3634e-02, -3.7497e-02,  5.6982e-03,  1.5572e-03,\n",
              "        -1.8387e-02, -6.8772e-02, -5.0659e-02, -1.6747e-02, -2.9820e-05,\n",
              "        -1.9818e-02,  3.1472e-02, -4.9984e-03, -3.0520e-02, -1.9325e-03,\n",
              "         4.2027e-02, -1.1774e-02,  7.2055e-02, -4.4483e-02, -3.2653e-02,\n",
              "        -8.9121e-02,  6.2845e-02,  3.7540e-03,  5.6572e-02,  6.0375e-03,\n",
              "        -3.4910e-02, -4.7365e-02, -2.8061e-02, -3.7899e-02, -1.8879e-02,\n",
              "         2.8521e-02, -5.0173e-03, -1.4748e-02, -3.2816e-03, -4.4820e-02,\n",
              "         2.8267e-03,  4.5461e-02, -9.7520e-03, -3.2181e-03, -1.2054e-03,\n",
              "         1.1390e-03, -1.7305e-02, -6.7664e-03,  2.1894e-02, -1.8631e-02,\n",
              "         2.8359e-02, -3.7497e-02, -4.2248e-02,  2.9639e-02,  8.9798e-03,\n",
              "        -1.6709e-02, -7.6818e-02, -2.5641e-02,  5.7850e-02, -3.2886e-02,\n",
              "         2.2484e-02, -4.4189e-02, -2.6007e-02, -5.1885e-02, -2.8544e-02,\n",
              "        -6.3767e-02, -2.0713e-02, -1.9620e-02, -4.0264e-02,  4.0794e-02,\n",
              "         3.6333e-02,  2.8726e-02, -4.7891e-02,  1.9354e-02,  1.5575e-02,\n",
              "        -4.7575e-02, -1.9264e-02,  2.5683e-02, -7.8466e-05,  9.6404e-03,\n",
              "         1.2739e-02,  1.9648e-02,  2.1925e-02,  1.4856e-02, -5.1117e-03,\n",
              "         2.0753e-02,  8.5732e-03,  3.9726e-02,  5.1716e-02, -2.2003e-03,\n",
              "         8.4402e-03,  2.9656e-02, -6.7640e-02, -1.0005e-02,  5.4856e-02,\n",
              "        -1.8852e-02,  3.7386e-02, -1.6988e-02,  2.0704e-03,  6.5866e-02,\n",
              "        -2.9380e-02, -3.7340e-02,  2.0734e-02,  6.8906e-03,  3.7470e-02,\n",
              "        -4.1492e-02, -7.8204e-03, -4.9511e-02,  4.1270e-02, -8.3607e-02,\n",
              "         7.0057e-02, -1.2744e-01, -1.5953e-02,  1.5702e-02, -1.3313e-02,\n",
              "         2.2570e-02, -1.1743e-02,  5.0418e-02, -1.2829e-02, -3.5504e-02,\n",
              "         1.0747e-02, -1.6801e-02, -6.9235e-02,  2.8367e-02,  3.7984e-02,\n",
              "        -5.6632e-04,  2.6145e-03, -1.8723e-02,  7.2156e-03, -6.8547e-02,\n",
              "        -3.3712e-02, -4.6703e-02,  3.4227e-02, -5.9450e-02,  7.9627e-04,\n",
              "         2.6638e-02, -7.7099e-03,  9.1716e-03,  2.7681e-02,  1.5404e-02,\n",
              "         6.2566e-04, -5.3065e-02, -8.0660e-02,  5.7258e-02, -4.7868e-02,\n",
              "         4.5862e-02,  5.7957e-02, -2.4613e-02,  2.2202e-02, -6.6190e-03,\n",
              "        -2.6096e-02, -5.2684e-03,  4.2904e-02, -4.5120e-02,  4.1115e-02,\n",
              "         9.9538e-04,  5.4737e-02, -1.9887e-02,  3.7357e-02,  3.1749e-02,\n",
              "        -5.1308e-02,  3.8351e-02, -3.2291e-02, -4.3407e-02,  5.9607e-02,\n",
              "        -1.5305e-02, -1.9972e-02, -1.8997e-02, -4.9465e-02, -1.6950e-02,\n",
              "        -2.5402e-02,  4.2959e-02,  1.0216e-03,  1.5397e-02, -4.4907e-02,\n",
              "         2.0409e-02, -5.5109e-02, -9.0697e-03,  1.6623e-02, -2.1417e-02,\n",
              "        -5.5459e-02,  2.2044e-02, -1.6049e-02, -6.4489e-02, -8.9626e-03,\n",
              "        -1.7630e-02,  3.8811e-02,  3.9954e-03,  8.1732e-02, -2.1378e-02,\n",
              "        -4.6813e-02,  9.2280e-03,  5.6707e-02, -2.2209e-02,  3.3563e-02,\n",
              "        -2.3756e-03, -1.0145e-02,  4.3280e-02,  2.9259e-02, -4.0931e-02,\n",
              "        -2.8774e-02,  1.9152e-02,  5.7251e-02, -5.1622e-02, -1.6397e-02,\n",
              "        -8.2632e-02,  3.5380e-02, -6.0025e-02,  6.6586e-03, -3.0763e-03,\n",
              "        -7.0830e-02,  3.4126e-02, -7.3466e-02, -3.5525e-02,  3.6461e-02,\n",
              "         1.7593e-02, -3.0598e-03, -9.0020e-03, -3.0692e-02, -2.1024e-02,\n",
              "         7.9765e-02, -3.2255e-03, -2.3497e-02, -1.7670e-02,  4.7011e-02,\n",
              "         1.5726e-02, -2.7054e-02,  2.0524e-02,  5.4551e-02, -9.8599e-03,\n",
              "         1.8729e-02, -9.5322e-03,  1.0870e-02, -1.5248e-02, -3.8496e-02,\n",
              "        -1.9737e-02, -4.3062e-02, -3.6008e-02, -4.3872e-03, -1.6247e-02,\n",
              "         1.8309e-02, -2.2220e-03, -2.6399e-02,  8.6110e-02, -2.5954e-02,\n",
              "         1.2656e-02, -3.5615e-02, -1.8522e-02,  3.0603e-02, -1.9991e-02,\n",
              "         3.3521e-02,  1.5290e-02,  2.3268e-04,  1.5910e-02,  5.1733e-02,\n",
              "         7.7534e-02, -3.5983e-02, -6.0338e-02,  1.7154e-02,  4.0365e-02,\n",
              "        -5.8269e-03, -8.3169e-02,  1.2834e-02,  6.5462e-02,  2.8270e-02,\n",
              "        -8.5287e-02,  8.8870e-02, -1.5542e-02,  5.7314e-03,  5.6863e-02,\n",
              "        -3.7554e-02,  1.5661e-02, -4.6658e-02, -3.5450e-02, -9.5923e-02,\n",
              "         2.4569e-02, -3.2725e-02,  2.0427e-02, -8.7770e-03,  7.6401e-03,\n",
              "         5.7954e-03,  3.9342e-02, -1.2713e-03, -2.0987e-02,  1.6430e-02,\n",
              "         4.1000e-02,  3.0315e-02,  3.9465e-02,  2.3043e-02, -6.8304e-02,\n",
              "         4.0888e-02, -5.0775e-03, -4.1588e-02,  1.0344e-01,  3.2683e-02,\n",
              "        -4.2104e-02,  2.6055e-02, -3.8998e-02,  1.7679e-03,  4.1484e-02,\n",
              "        -5.2139e-02, -5.2433e-03, -5.8891e-03, -1.2149e-02,  6.7706e-03,\n",
              "        -1.7759e-02, -2.2711e-03, -3.1043e-02,  7.6338e-03, -1.5687e-02,\n",
              "         1.8944e-02,  7.4018e-02, -4.4928e-03,  1.4284e-02, -4.1944e-03,\n",
              "        -3.0909e-02,  5.2851e-03, -1.1764e-02,  2.1538e-02,  3.5636e-02,\n",
              "        -1.8582e-02, -5.0085e-02,  3.1871e-02, -5.4804e-02, -1.6208e-02,\n",
              "        -2.0931e-02,  2.3919e-02,  1.1094e-02, -2.2566e-02, -7.3368e-03,\n",
              "        -2.9327e-04,  2.1566e-02,  2.1863e-02,  1.1982e-03,  3.8223e-02,\n",
              "        -1.9171e-02, -2.7265e-02, -5.7145e-02, -2.4419e-02, -2.2801e-02,\n",
              "         1.6869e-02,  4.5155e-02, -3.9923e-04, -4.1506e-02,  1.1747e-03,\n",
              "         1.5203e-02, -2.1099e-02, -3.8674e-02,  3.7984e-02, -6.8666e-02,\n",
              "         3.4341e-02,  6.3548e-02, -5.5771e-03,  4.0872e-03,  1.0980e-02,\n",
              "         6.2357e-02,  4.0403e-02,  1.0314e-02, -3.7815e-02,  4.3315e-02,\n",
              "        -4.0697e-02, -2.1261e-03,  4.0023e-02, -2.7171e-02, -1.8550e-02,\n",
              "         6.3242e-02,  8.7058e-02,  1.1247e-02,  4.3099e-02,  2.1539e-02,\n",
              "        -2.2935e-02,  3.1660e-02,  2.4041e-02,  5.0425e-02,  8.3248e-03,\n",
              "         2.9465e-02, -3.2125e-02,  5.0978e-04,  2.8640e-02,  6.0610e-02,\n",
              "         7.2231e-03, -2.8368e-03, -3.6556e-02, -3.0570e-02,  2.1354e-02,\n",
              "         8.3398e-02, -4.0334e-02,  8.5404e-03,  1.0790e-02, -3.1877e-02,\n",
              "        -1.6651e-02,  5.6618e-02, -1.9449e-02, -4.7054e-02, -2.7112e-02,\n",
              "        -1.4053e-02, -1.8799e-02,  2.5190e-02, -6.1999e-02,  2.5557e-02,\n",
              "        -1.3025e-02, -2.0947e-02,  1.9529e-03,  3.3891e-02, -4.9917e-02,\n",
              "        -4.0901e-02,  5.4156e-02,  3.8612e-02,  2.7399e-02,  1.1879e-02,\n",
              "        -5.8477e-33,  9.2323e-03, -1.8211e-03,  2.0221e-03, -1.1250e-01,\n",
              "         5.5608e-02,  9.6013e-02, -2.3575e-02, -4.1424e-02, -9.7765e-03,\n",
              "         4.3573e-02, -1.1029e-02, -2.4789e-02,  1.0256e-02,  5.7491e-02,\n",
              "        -4.0515e-02, -3.1114e-04, -1.1685e-02, -3.6249e-03,  1.6262e-02,\n",
              "         2.2647e-02, -2.8428e-02, -1.4012e-02,  3.7086e-02,  3.4808e-02,\n",
              "         1.6770e-02, -1.6257e-02,  6.0210e-02, -1.6500e-02, -4.7490e-02,\n",
              "         9.8836e-02,  1.5609e-02,  3.2980e-04,  2.0881e-02,  2.4738e-02,\n",
              "        -2.4853e-02,  4.8587e-02, -5.2912e-02,  5.2046e-02,  6.6209e-04,\n",
              "         2.1549e-02, -3.8034e-02, -3.2919e-02, -1.4711e-02, -9.9439e-04,\n",
              "        -3.7559e-02,  7.6506e-03, -4.4924e-02,  4.3768e-03,  1.6265e-03,\n",
              "        -5.6513e-02, -2.5850e-02,  4.0436e-02,  2.8654e-02, -3.3030e-02,\n",
              "        -1.9295e-02,  5.2030e-04,  2.7112e-03,  6.9418e-02,  1.9993e-02,\n",
              "         4.7694e-03,  2.9463e-02, -2.5884e-02,  3.7418e-03, -5.0733e-02,\n",
              "        -6.1183e-02, -2.1379e-02, -4.5761e-02, -1.0068e-02, -7.6179e-03,\n",
              "        -8.4737e-02, -4.7507e-02, -3.6107e-02, -3.8665e-02, -3.2165e-02,\n",
              "         2.5736e-02,  4.5024e-02,  3.3935e-03, -2.3902e-03, -2.1141e-02,\n",
              "         3.9135e-02,  1.6801e-02,  4.0351e-02, -3.8017e-02, -3.0015e-03,\n",
              "        -6.4303e-02, -1.9621e-02,  4.7780e-03, -1.6022e-02,  1.9297e-02,\n",
              "         1.8048e-02,  5.1749e-02,  2.7487e-02,  8.1345e-03, -8.7508e-04,\n",
              "         3.3927e-02, -2.8808e-02,  1.6300e-02,  1.6259e-02,  4.0673e-03,\n",
              "         1.9491e-02,  4.8838e-02,  1.4566e-02,  6.9508e-02, -3.4738e-02,\n",
              "        -3.5295e-02,  1.1061e-02,  6.8780e-03, -6.8326e-03, -2.0172e-02,\n",
              "         4.1244e-02, -2.5625e-02,  4.3218e-02,  4.3420e-02,  5.2604e-02,\n",
              "         4.2791e-02, -1.1425e-02,  4.3207e-02,  4.1547e-02,  1.7931e-02,\n",
              "        -1.4555e-02,  6.1716e-03,  3.7461e-02, -4.2548e-02,  5.5267e-03,\n",
              "        -1.4371e-03,  1.5532e-02, -6.5980e-03,  7.0745e-02, -4.1751e-02,\n",
              "        -9.1712e-02,  2.2966e-02, -9.0514e-03,  2.9394e-07, -1.8974e-03,\n",
              "         6.8124e-02, -3.4872e-02, -4.0413e-02,  4.3495e-02,  1.4033e-02,\n",
              "        -6.5348e-02,  2.7015e-02, -2.8204e-02,  1.9958e-02,  3.3806e-02,\n",
              "         1.8272e-03, -1.7632e-02, -3.9212e-02, -1.4951e-02, -9.3596e-02,\n",
              "        -3.5929e-02, -2.0368e-02,  2.5601e-02, -3.6743e-03, -2.1230e-03,\n",
              "         2.7067e-03, -2.7199e-03, -3.4406e-02,  4.2146e-02, -8.9088e-03,\n",
              "        -2.1466e-02, -2.4808e-02, -4.9630e-02,  2.0235e-02,  3.2571e-02,\n",
              "        -7.8328e-02,  3.7020e-03,  4.8261e-02, -2.7561e-02, -1.6922e-02,\n",
              "         1.3762e-02,  5.7048e-02, -4.8799e-02, -4.9556e-02,  1.3804e-02,\n",
              "        -7.2446e-02,  2.2522e-02, -5.5127e-02, -1.7948e-02,  7.0741e-02,\n",
              "        -2.3434e-02,  2.6414e-02,  1.0631e-02,  3.6083e-03,  2.6114e-02,\n",
              "         2.8534e-02, -6.2801e-02,  2.1650e-02,  6.0342e-03,  3.5118e-02,\n",
              "        -2.7832e-02,  2.4276e-02,  7.7202e-02, -8.2477e-02, -4.3261e-02,\n",
              "        -3.4854e-02,  3.7589e-02, -1.2556e-02, -2.2017e-02,  9.6226e-03,\n",
              "         1.2045e-02,  2.5389e-34,  3.9845e-02, -1.7510e-02,  3.6505e-02,\n",
              "        -3.3208e-02,  6.3647e-02, -3.2151e-03,  1.6964e-02,  2.8346e-02,\n",
              "         2.4283e-02, -7.7662e-02, -5.7029e-02], device='cuda:0')"
            ]
          },
          "metadata": {},
          "execution_count": 63
        }
      ],
      "source": [
        "embeddings[0]"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "RR8L8K9Oka6Y",
        "outputId": "7b65fca1-32b5-4a44-daf7-bbe4c1165863"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Query: how to use humira in prefilled syringe \n",
            "Time take to get scores on 191 embeddings: 0.00016 seconds.\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "torch.return_types.topk(\n",
              "values=tensor([0.8660, 0.8305, 0.8215, 0.7908, 0.7700], device='cuda:0'),\n",
              "indices=tensor([173, 165, 185,  12, 166], device='cuda:0'))"
            ]
          },
          "metadata": {},
          "execution_count": 64
        }
      ],
      "source": [
        "# 1. Define the query\n",
        "# Note: This could be anything. But since we're working with a nutrition textbook, we'll stick with nutrition-based queries.\n",
        "query = \"how to use humira in prefilled syringe \"\n",
        "print(f\"Query: {query}\")\n",
        "\n",
        "# 2. Embed the query to the same numerical space as the text examples\n",
        "# Note: It's important to embed your query with the same model you embedded your examples with.\n",
        "query_embedding = embedding_model.encode(query, convert_to_tensor=True)\n",
        "\n",
        "# 3. Get similarity scores with the dot product (we'll time this for fun)\n",
        "from time import perf_counter as timer\n",
        "\n",
        "start_time = timer()\n",
        "dot_scores = util.dot_score(a=query_embedding, b=embeddings)[0]\n",
        "end_time = timer()\n",
        "\n",
        "print(f\"Time take to get scores on {len(embeddings)} embeddings: {end_time-start_time:.5f} seconds.\")\n",
        "\n",
        "# 4. Get the top-k results (we'll keep this to 5)\n",
        "top_results_dot_product = torch.topk(dot_scores, k=5)\n",
        "top_results_dot_product"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "ZKDTvq6ckd9o",
        "outputId": "753f2d56-bf10-49b7-a96b-64e0627a6f15"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Embeddings shape: torch.Size([19100, 768])\n",
            "Time take to get scores on 19100 embeddings: 0.00058 seconds.\n"
          ]
        }
      ],
      "source": [
        "larger_embeddings = torch.randn(100*embeddings.shape[0], 768).to(device)\n",
        "print(f\"Embeddings shape: {larger_embeddings.shape}\")\n",
        "\n",
        "# Perform dot product across 168,000 embeddings\n",
        "start_time = timer()\n",
        "dot_scores = util.dot_score(a=query_embedding, b=larger_embeddings)[0]\n",
        "end_time = timer()\n",
        "\n",
        "print(f\"Time take to get scores on {len(larger_embeddings)} embeddings: {end_time-start_time:.5f} seconds.\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "KQGUyiTDkhAk"
      },
      "outputs": [],
      "source": [
        "# Define helper function to print wrapped text\n",
        "import textwrap\n",
        "\n",
        "def print_wrapped(text, wrap_length=80):\n",
        "    wrapped_text = textwrap.fill(text, wrap_length)\n",
        "    print(wrapped_text)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "PDQ4k611kjkM",
        "outputId": "174a5aca-aec1-4612-d57d-35a970ef819c"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Query: 'how to use humira in prefilled syringe '\n",
            "\n",
            "Results:\n",
            "Score: 0.8660\n",
            "Text:\n",
            "Figure F    • You may see a drop of liquid at the end of the needle. This is\n",
            "normal.   Position the Prefilled Syringe and Inject HUMIRA  Position the Syringe\n",
            "11. Hold the body of the prefilled syringe in one hand between the thumb and\n",
            "index finger. Hold  the syringe in your hand like a pencil. See Figure G.\n",
            "Page number: 99\n",
            "\n",
            "\n",
            "Score: 0.8305\n",
            "Text:\n",
            "understand, and follow these instructions so that you inject HUMIRA the right\n",
            "way. It is also  important to talk to your doctor to be sure you understand your\n",
            "HUMIRA dosing instructions. To  help you remember when to inject HUMIRA, you can\n",
            "mark your calendar ahead of time. Call  your healthcare provider if you or your\n",
            "caregiver have any questions about the right way to  inject HUMIRA.  Gather the\n",
            "Supplies for Your Injection  • You will need the following supplies for each\n",
            "injection of HUMIRA. Find a clean, flat surface to place the supplies on. • 1\n",
            "alcohol swab  • 1 cotton ball or gauze pad (not included in your HUMIRA carton)\n",
            "• 1 HUMIRA prefilled syringe (See Figure A)  • Puncture-resistant sharps\n",
            "disposal container for HUMIRA prefilled syringe disposal (not  included in your\n",
            "HUMIRA carton). See the “How should I throw away (dispose of) the  used\n",
            "prefilled syringes and needles?”section at the end of this Instructions for Use.\n",
            "If more comfortable, take your HUMIRA prefilled syringe out of the refrigerator\n",
            "15 to 30 minutes  before injecting to allow the liquid to reach room\n",
            "temperature.\n",
            "Page number: 94\n",
            "\n",
            "\n",
            "Score: 0.8215\n",
            "Text:\n",
            "Take HUMIRA out of the refrigerator.  Leave HUMIRA at room temperature for 15 to\n",
            "30 minutes before injecting.  • Do not remove the needle cover while  allowing\n",
            "HUMIRA to reach room  temperature  • Do not warm HUMIRA in any other way. For\n",
            "example, do not warm it in a microwave or  in hot water.  • Do not use the\n",
            "prefilled syringe if liquid has  been frozen (even if thawed)         Check\n",
            "expiration date on the prefilled syringe  label. Do not use the prefilled\n",
            "syringe if  expiration date has passed.  Place the following on a clean, flat\n",
            "surface:  • 1 single-dose prefilled syringe and alcohol  swab  • 1 cotton ball\n",
            "or gauze pad (not included)  • Puncture-resistant sharps disposal container\n",
            "(not included). See Step 9 at the end of this  Instructions for Use for\n",
            "instructions on how  to throw away (dispose of) your prefilled  syringe  Wash\n",
            "and dry your hands.         Choose an injection site:  • On the front of your\n",
            "thighs or  • Your abdomen (belly) at least 2 inches from  your navel (belly\n",
            "button)  • Different from your last injection site  Wipe the injection site in a\n",
            "circular motion with  the alcohol swab.  • Do not inject through clothes  • Do\n",
            "not inject into skin that is sore, bruised,  red, hard, scarred, has stretch\n",
            "marks, or  areas with psoriasis plaques\n",
            "Page number: 107\n",
            "\n",
            "\n",
            "Score: 0.7908\n",
            "Text:\n",
            "does not contain preservatives; therefore, discard unused portions of drug\n",
            "remaining from the  syringe. NOTE: Instruct patients sensitive to latex not to\n",
            "handle the needle cover of the  HUMIRA 40 mg/0.8 mL Pen and 40 mg/0.8 mL, 20\n",
            "mg/0.4 mL and 10 mg/0.2 mL prefilled  syringe because it may contain natural\n",
            "rubber latex [see How Supplied/Storage and Handling  (16)].  Instruct patients\n",
            "using the HUMIRA Pen or prefilled syringe to inject the full amount in the\n",
            "syringe, according to the directions provided in the Instructions for Use [see\n",
            "Instructions for  Use].  Injections should occur at separate sites in the thigh\n",
            "or abdomen. Rotate injection sites and do  not give injections into areas where\n",
            "the skin is tender, bruised, red or hard.  If a dose is missed, administer the\n",
            "dose as soon as possible. Thereafter, resume dosing at the  regular scheduled\n",
            "time. The HUMIRA single-dose institutional use vial is for administration within\n",
            "an institutional  setting only, such as a hospital, physician’s office or\n",
            "clinic. Withdraw the dose using a sterile  needle and syringe and administer\n",
            "promptly by a healthcare provider within an institutional  setting. Only\n",
            "administer one dose per vial.\n",
            "Page number: 8\n",
            "\n",
            "\n",
            "Score: 0.7700\n",
            "Text:\n",
            "Do not remove the needle cover  while allowing it to reach room temperature. Do\n",
            "not warm HUMIRA in any other way (for  example, do not warm it in a microwave or\n",
            "in hot water).  If you do not have all the supplies you need to give yourself an\n",
            "injection, go to a pharmacy or  call your pharmacist.  The figure below shows\n",
            "what a prefilled syringe looks like. See Figure A.  Figure A\n",
            "Page number: 94\n",
            "\n",
            "\n"
          ]
        }
      ],
      "source": [
        "print(f\"Query: '{query}'\\n\")\n",
        "print(\"Results:\")\n",
        "# Loop through zipped together scores and indicies from torch.topk\n",
        "for score, idx in zip(top_results_dot_product[0], top_results_dot_product[1]):\n",
        "    print(f\"Score: {score:.4f}\")\n",
        "    # Print relevant sentence chunk (since the scores are in descending order, the most relevant chunk will be first)\n",
        "    print(\"Text:\")\n",
        "    print_wrapped(pages_and_chunks[idx][\"sentence_chunk\"])\n",
        "    # Print the page number too so we can reference the textbook further (and check the results)\n",
        "    print(f\"Page number: {pages_and_chunks[idx]['page_number']}\")\n",
        "    print(\"\\n\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "yo18w0E_knD4",
        "outputId": "64cd8da3-ef9b-4cbe-a4f4-01db2590f8c0"
      },
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 1300x1000 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ],
      "source": [
        "import fitz\n",
        "\n",
        "# Open PDF and load target page\n",
        "pdf_path = \"humira (1).pdf\" # requires PDF to be downloaded\n",
        "doc = fitz.open(pdf_path)\n",
        "page = doc.load_page(5 + 41) # number of page (our doc starts page numbers on page 41)\n",
        "\n",
        "# Get the image of the page\n",
        "img = page.get_pixmap(dpi=300)\n",
        "\n",
        "# Optional: save the image\n",
        "#img.save(\"output_filename.png\")\n",
        "doc.close()\n",
        "\n",
        "# Convert the Pixmap to a numpy array\n",
        "img_array = np.frombuffer(img.samples_mv,\n",
        "                          dtype=np.uint8).reshape((img.h, img.w, img.n))\n",
        "\n",
        "# Display the image using Matplotlib\n",
        "import matplotlib.pyplot as plt\n",
        "plt.figure(figsize=(13, 10))\n",
        "plt.imshow(img_array)\n",
        "plt.title(f\"Query: '{query}' | Most relevant page:\")\n",
        "plt.axis('off') # Turn off axis\n",
        "plt.show()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "gXM8XLOnkocY"
      },
      "outputs": [],
      "source": []
    }
  ],
  "metadata": {
    "accelerator": "GPU",
    "colab": {
      "gpuType": "T4",
      "provenance": []
    },
    "kernelspec": {
      "display_name": "Python 3",
      "name": "python3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "nbformat": 4,
  "nbformat_minor": 0
}